

WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND MUSCULOSKELETAL DISEASES

WCO
IOF-ESCEO

2019 PARIS

April 4-7, 2019
Palais des Congrès
www.WCO-IOF-ESCEO.org



Congress Organizer
Sinklar Congress Management B.V.

Congress Secretariat
www.humacom.com

#OsteoCongress

WORLD'S LEADING CLINICAL CONFERENCE ON BONE, JOINT AND MUSCLE HEALTH

AbstractBook

BROKEN BONES TOOK AWAY HIS INDEPENDENCE



That's osteoporosis

Robert is 65 years old, he discovered he had osteoporosis after having severe vertebral fractures



Our vision is a world without fragility fracture in which healthy mobility is a reality for all

WorldOsteoporosisDay
October20

About ESCEO and IOF	5
Message from the Congress Presidents	7
Congress Organization	8
Congress Information	10
Venue Map - Level 1	12
Venue Map - Level 3	13
Final Programme – Thursday April 4	15
Final Programme – Friday April 5	16
Final Programme – Saturday April 6	23
Final Programme – Sunday April 7	28
Final Programme – Sponsored Symposia	31
Special Lectures Abstracts	33
Plenary Lectures Abstracts	37
Oral Communications Abstracts	43
ESCEO Symposia Abstracts	67
ESCEO-WHO CC Symposium Abstracts	73
ESCEO-IOF-WHO CC Symposium Abstracts	76
ESCEO-IOF USA Symposium Abstracts	78
EUGMS-ESCEO-IOF Symposium Abstracts	80
ESPRM-ESCEO-IOF Symposium Abstracts	82
ESCEO-IOF-SFR-GRIO Symposium Abstracts	85
Meet-the-Experts Abstracts	88
Committee of National Societies Abstracts	96
Non-Sponsored Symposia Abstracts	103
Poster Abstracts	133
Satellite Symposia Abstracts	683
Author Index	693

Pagination in this file will differ from the version of record
(Osteoporosis International vol. 30 supplement 1) that will be found on link.springer.com

This supplement will not be sponsored by outside commercial interests; it is entirely funded by the society's own resources




CAPTURE *the* FRACTURE[®]

A GLOBAL PROGRAMME FACILITATING THE IMPLEMENTATION OF FRACTURE LIAISON SERVICES (FLS) FOR SECONDARY FRACTURE PREVENTION

MORE THAN
330 FLS
AROUND THE WORLD!

GET MAPPED

Submit your service and be part of an internationally recognized FLS network



ABOUT ESCEO

The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) is a not-for-profit organization, dedicated to a close interaction between clinical scientists dealing with bone, joint and muscle disorder, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policy makers, to integrate the management of Osteoporosis and Osteoarthritis within the comprehensive perspective of health resources utilization.

The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception. – www.esceo.org



ABOUT IOF

The International Osteoporosis Foundation (IOF) is a non-profit, non-governmental organization dedicated to the worldwide fight against osteoporosis, the disease known as “the silent epidemic”. IOF's members – committees of scientific researchers, patient, medical and research societies and industry representatives from around the world – share a common vision of a world without osteoporotic fractures. IOF now represents 240 societies in 99 locations around the world. – www.iofbonehealth.org

Mission


- | Increase awareness and understanding of osteoporosis.
- | Motivate people to take action to prevent, diagnose and treat osteoporosis.
- | Support national osteoporosis societies in order to maximize their effectiveness



Keep up with the latest research and advances in the field

LEADING JOURNALS with impact

IOF offers an extensive publication portfolio of leading scientific journals in the field of osteoporosis and bone health.



Osteoporosis International

Editors-in-Chief: John A. Kanis and Felicia Cosman
Highly cited, journal of choice for the latest clinical research
in the musculoskeletal field

Archives of Osteoporosis

Editors-in-Chief: John A. Kanis and Felicia Cosman
With an impressive first impact factor, a key forum for
regional research and guidelines

Calcified Tissue International & Musculoskeletal Research

Editors-in-Chief: Stuart H. Ralston and René Rizzoli
Cutting edge preclinical and translational research in the bone and muscle field



*Our vision is a world without
fragility fractures, in which
healthy mobility is a reality for all.*

www.iofbonehealth.org

DEAR COLLEAGUES,

It is with great pleasure that we welcome you to Paris and the 2019 IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.

The Congress' scientific programme has been developed by a team comprising members of the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) and the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). We would like to thank the respective Scientific Chairs, Professors Cyrus Cooper and René Rizzoli, for taking the lead in setting up an exciting and comprehensive programme that brings together the world's best in the field of musculoskeletal health and disease and takes advantage of the synergies and combined expertise of our two organisations.

We are all meeting in Paris with a common aim - to gather new knowledge, skills and tools in the prevention and treatment of osteoporosis and osteoarthritis, the two most disabling conditions in elderly people. An important addition is a focus on sarcopenia because of its intimate relation to bone and joint disease. It is our hope that this Congress will move the field one step forward on all fronts; from new understanding of bone metabolism and pathology, to new strategies and options in prevention, diagnosis and treatment.

The core scientific programme consists of **10** plenary lectures by renowned speakers and **49** oral communications selected from the very best of hundreds of submitted abstracts, and **19** oral presentations of selected posters. In addition, participants can choose among **14** different

Meet-The-Expert sessions and **15** special sessions and symposia on issues of clinical importance. We also encourage you to attend many of the scheduled poster sessions. **8** industry sponsored satellite symposia and to visit the large commercial exhibition presented by the leading companies in the bone field.

The city of Paris offers an outstanding setting for international congresses. We hope that you will also take the opportunity to explore its many attractions, or simply savour 'la bonne vie' in this truly wonderful city!

Thank you for your participation. We will do our best to ensure that this meeting is a memorable, enriching experience for all.



Jean-Yves Reginster

John A. Kanis

EVENT

WCO-IOF-ESCEO**April 4-7, 2019**

WORLD CONGRESS ON OSTEOPOROSIS, OSTEOARTHRITIS AND MUSCULOSKELETAL DISEASES

CONGRESS CHAIRMEN

Jean-Yves REGINSTER

ESCEO President

John A. KANIS

IOF Honorary President

PROGRAMME COMMITTEE

Cyrus COOPER

IOF President

René RIZZOLIChair, ESCEO Scientific Advisory Board
(SAB)**John A. KANIS**

IOF Honorary President

Jean-Yves REGINSTER

ESCEO President

HONORARY LOCAL

ORGANIZING COMMITTEE

B. AVOUAC	E. LEGRAND
F. BERENBAUM	E. LESPESSAILLES
H. BLAIN	E. MAHEU
V. BREUIL	C. MARCELLI
K. BRIOT	P. MIOSSEC
N. BURLET	P. ORCEL
D. CHAPPARD	J. PACCOU
M. COHEN-SOLAL	F. RANNOU
B. CORTET	Y. ROLLAND
V. COXAM	C. ROUX
P. FARDELLONE	P. SZULC
J.-M. FERON	F. TRÉMOLLIÈRES
L. GRANGÉ	B. VELLAS
F. GUILLEMIN	L. VICO
M.-H. LAFAGE- PROUST	S. WALRAND
	G. WERYHA

SCIENTIFIC ADVISORY BOARD AND ABSTRACTS

REVIEWERS

D. AGNUSDEI	H. JOHANSSON
K. AKESSON	J. A. KANIS
N. ARDEN	J.-M. KAUFMAN
J. BAUER	F. LANDI
I. BAUTMANS	P. LIPS
C. BEAUDART	R. LORENC
E. BIVER	G. LYRITIS
J.-J. BODY	S. MAGGI
A. BORG	J. MARTEL-PELLETIER
M. BOUXSEIN	E. McCLOSKEY
M.-L. BRANDI	X. NOGUES
O. BRUYÈRE	J. PACCOU
F. BUCKINX	S. PAPAPOULOS
N. BURLET	K. PAVELKA
V. CASTRONOVO	J.-P. PELLETIER
E. CAVALIER	D. PINTO
M. CESARI	D. PRIETO-ALHAMBRA
R. CHAPURLAT	J.-Y. REGINSTER
A. CHERUBINI	J. RINGE
T. CHEVALLEY	R. RIZZOLI
J. COMPSTON	Y. ROLLAND
C. COOPER	C. ROUX
B. CORTET	C. SIEBER
A. CRUZ-JENTOFT	P. SZULC
E. CZERWINSKI	T. THOMAS
B. DAWSON-HUGHES	B. VELLAS
E. DENNISON	
J.-P. DEVOGELAER	
H. P. DIMAI	
R. FIELDING	
S. FERRARI	
A. GASPARIK	
N. HARVEY	
M. HILIGSMANN	

CONGRESS ORGANIZER

Sinklar Conference Management B.V.
 Pietersbergweg, 283
 1105 BM Amsterdam, The Netherlands
 secretariat@sinklarcm.org

CONGRESS SECRETARIAT

Humacom
 Rue Renier, 9
 4800 Verviers, Belgium
 Tel: +32 87 852 652
 info@humacom.com
 www.humacom.com

REGISTRATION

Pacific World

World Trade Center, North Building, 8th Floor
 Moll de Barcelona s/n
 08039 Barcelona, Spain
 Tel: +34 96 352 81 61
 registration-wco-iof-esceo@pacificworld.com

HOTEL BOOKING

Pacific World

World Trade Center, North Building, 8th Floor
 Moll de Barcelona s/n
 08039 Barcelona, Spain
 Tel: +34 96 352 81 61
 accommodation@wco-iof-esceo.org

SPONSORSHIP OPPORTUNITIES / EXHIBITION

Humacom

leisten@humacom.com
 Rue Renier, 9
 4800 Verviers, Belgium
 Phone: +32 87 852 652

CONGRESS WEBSITE

www.wco-iof-esceo.org

SPONSORS AND EXHIBITORS LIST

DIAMOND SPONSOR



GOLD SPONSOR



GENERAL SPONSORS

OPENING CEREMONY VENUE (APRIL 4)

Palais des Congrès de Paris
Place de la Porte Maillot, 2
75017 Paris

CONGRESS VENUE (APRIL 5-7)

Palais des Congrès de Paris
Place de la Porte Maillot, 2
75017 Paris
www.viparis.com

OPERATING DATES AND HOURS**Congress Opening Hours**

Thursday April 4, 2019	14.30-20.00
Friday April 5, 2019	07.30-18.30
Saturday April 6, 2019	07.30-17.00
Sunday April 7, 2019	07.30-13.00

Registration Desks Opening Hours

Palais des Congrès de Paris	
Friday April 5, 2019	07.30-19.00
Saturday April 6, 2019	07.30-17.30
Sunday April 7, 2019	07.30-13.00

Congress Exhibition Hours

Palais des Congrès de Paris	
Friday April 5, 2019	07.30-18.30
Saturday April 6, 2019	07.30-17.00
Sunday April 7, 2019	07.30-13.00

POSTER VIEWING**Poster Viewing Session I (P101-P500)**

Friday April 5, 2019	14.00-15.00
----------------------	-------------

Poster Viewing Session II (P501-P900)

Saturday April 6, 2019	14.00-15.00
------------------------	-------------

Poster Viewing Session III (P901 and above)

Sunday April 7, 2019	09.00-10.00
----------------------	-------------

Oral Presentation of Selected Posters

Friday April 5, 2019	14.00-15.10
Saturday April 6, 2019	14.00-15.03

ACCREDITATIONS**European**

The WCO-IOF-ESCEO 2019 Paris Congress has been granted 20 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME).

American

EACCME credits can be converted to AMA credits for American delegates.

Belgian

In Process

BADGES**Courtesy of UCB**

For registered participants, personalized badges will be requested for entry to all scientific programmes and to access the exhibition and posters areas. Blank badges are prohibited.

Lost badges: 65 euros fee/badge

CERTIFICATE OF ATTENDANCE

A certificate of attendance may be printed at the self-printing stations available in the Registration Area on Saturday April 6, 2019 (afternoon). This system will issue your certificate with date from the barcode printed on your badge.

Please ensure that you have your badge with you.

CLOAKROOM

A cloakroom service for clothing and reasonably sized items is available during the opening hours of the Congress. It is located inside the exhibition area. Items of value should not be left in the cloakroom. Please make sure to collect all belongings at the end of each day.

HOTEL INFORMATION DESK

The Hotel Desk is located in the Registration Area during Registration opening hours.

INTERNET ACCESS**Courtesy of ESCEO**

A free Wireless internet connexion is available in the Congress Center.

LUNCHES, COFFEE AND REFRESHMENTS

In order to comply with international compliance rules, no official lunches or coffee breaks will be provided. Coffee, beverages and snacks can be purchased from the cafeteria located in the exhibition area and opened during Congress hours.

MEDIA

The WCO-IOF-ESCEO 2019 Congress will not provide any Media Center.

NOTE PADS AND PENS**Courtesy of Medimaps****POCKET GUIDE****Courtesy of Theramex****TOURIST INFORMATION**

www.parisinfo.com

GENERAL EMERGENCY NUMBER

European Telephone Number: 112

WELCOME COCKTAIL**Courtesy of Mylan**

All WCO-IOF-ESCEO 2019 participants are invited to the Welcome Cocktail on Thursday April 4, 2019

Venue

Palais des Congrès de Paris
Place de la Porte Maillot, 2
75017 Paris

FUTURE MEETINGS

2020 – WORLD CONGRESS ON
OSTEOPOROSIS, OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES

WCO-IOF-ESCEO 2020

Barcelona – Spain
April 2 - 5, 2020


LANGUAGE

English will be the official language of the Congress. No translation is provided.

Auditorium A



- | | | |
|------------------|---------------------------------|---------------------|
| 1&2. Hologic | 15. Eugms | 27&28. Medi |
| 3. Edimark | 16. Expanscience | 29a. Kyowa Kirin |
| 4. Time Research | 17. TRB Chemedica International | 29b. Gedeon Richter |
| 5. Roche | 18. Fidia | 29c. Zebra |
| 6. Thuasne | 19→21. Abiogen & EFRX | 30. Wisepress |
| 7. Eli Lilly | 22. Galgo Medical | 31. IOF |
| 8. Theramex | 23. Pierre Fabre | 32. UCB |
| 9. Medimaps | 24. Straxcorp | 33. Echolight |
| 10&11. Mylan | 25. Bindex | 34. WCO |
| 13. Agnovos | 26. GE Healthcare | 35. ESCEO |
| 14. Amgen | | 36. SarQoL |



Poster Area

Friday, April 5 P101-500

Saturday, April 6 P501-900

Sunday, April 7 P901 and above

WORLD CONGRESS
ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL
DISEASES



WCO
IOF-ESCEO

2020 BARCELONA

April 2-5, 2020

Barcelona | Spain
CCIB Congress Center



WORLD'S LEADING CLINICAL CONFERENCE ON BONE, JOINT AND MUSCLE HEALTH
Congress Organizer Sinklar Congress Management B.V. | Congress Secretariat www.humacom.com

www.WCO-IOF-ESCEO.org

14.30 - 17.00

Auditorium A

Actualités et controverses sur l'arthrose et l'ostéoporose

Symposium conjointement organisé par la Société Française de Rhumatologie (SFR), le Groupe de Recherche et d'Informations sur les Ostéoporoses (GRIO), l'International Osteoporosis Foundation (IOF) et l'European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

Chairpersons: Leith Zakraoui, Bernard Cortet, Thierry Thomas

- 14h30 : *Produits laitiers fermentés et santé osseuse* Emmanuel Biver
- 14h55 : *L'arthrose, une histoire d'alimentation ?* Jérémie Sellam
- 15h20 : *L'arthrose, une maladie inflammatoire ?* Florent Eymard
- 15h45 : *Vitamine D, arthrose et ostéoporose* Etienne Cavalier
- 16h10 : *L'arthrose rachidienne existe-t-elle ?* François Rannou
- 16h35 : *La place de la vertébroplastie, les données sont-elles solides ?* Bernard Cortet
- 17h00 : *Conclusion* Thierry Thomas

Symposium organisé en langue française.

17.45 - 20.00

Auditorium A

WCO-IOF-ESCEO - OPENING CEREMONY

Chairpersons: John A. Kanis, Jean-Yves Reginster

17.45

Auditorium A

Best clinical papers published in 2018

- René Rizzoli

18.30

Auditorium A

Beyond nutrients: health effects of the dairy matrix

- Arne Astrup

19.00

Auditorium A

2018 update of the European guidelines for the diagnosis and management of osteoporosis (ESCEO-IOF)

- René Rizzoli

19.15

Auditorium A

Plenary Lecture: Disease in Art Painting

- Davide Lazzeri

19.45

Auditorium A

Opening of the meeting

- Cyrus Cooper (IOF President, ESCEO Vice-President)

19.50

Auditorium A

Presentation of the 2019 ESCEO Medal of Excellence

- Jean-Yves Reginster

19.50

Auditorium A

Presentation of the IOF Olof Johnell Science Award

- Cyrus Cooper

20.00 - 21.00

INDUSTRY-SPONSORED WELCOME COCKTAIL

See detailed programme on [page 31](#)

08.00 - 09.00

Auditorium A

INDUSTRY BREAKFAST SYMPOSIUMSee detailed programme on [page 31](#)

08.00 - 09.00

SYMPOSIA

Meeting Room 342A

Patients' preferences for anti-osteoarthritis treatment: A cross-European Discrete Choice Experiment: outcomes of an experts consensus meeting organized under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

Chairpersons: Mickaël Hiligsmann, Elaine M. Dennison

- ▶ 08:00: *Welcome and introduction* Mickaël Hiligsmann
- ▶ 08:05: *Identification prioritization of important attributes of OA treatment* Elaine M. Dennison
- ▶ 08:20: *Results from the cross-European discrete choice experiment* Mickaël Hiligsmann
- ▶ 08:35: *Discussion* Elaine M. Dennison
- ▶ 08:55: *Conclusion* Mickaël Hiligsmann

Meeting Room 351

Osteosarcopenic obesity: enough evidence for a distinct entity: outcomes of an ESCEO experts consensus meeting organized under the auspices of the World Health Organization Collaborating Center for Public Health Aspects of Musculo-skeletal Health and Ageing

Chairpersons: Islene Araujo de Carvalho, Roger Fielding

- ▶ 08:00: *Introduction* Stefania Maggi
- ▶ 08:05: *Osteosarcopenic obesity: Facts and evidence supporting a distinct entity* Jürgen Bauer
- ▶ 08:20: *Osteosarcopenic obesity: Lack of evidence supporting a distinct entity* Alfonso Cruz Jentoft
- ▶ 08:35: *Discussion* Jürgen Bauer
- ▶ 08:55: *Conclusion* Roger Fielding

Panel: Islene Araujo de Carvalho, Jürgen Bauer, Olivier Bruyère, Roland D. Chapurlat, Cyrus Cooper, Alfonso Cruz Jentoft, Elaine M. Dennison, Roger Fielding, John A. Kanis, Jean-Marc Kaufman, Francesco Landi, Andrea Laslop, Médéa Locquet, Stefania Maggi, Eugene McCloskey, Simone Perna, Jean-Yves Reginster, René Rizzoli, Yves Rolland, Pawel Szulc

08.00 - 09.00

NON-SPONSORED SYMPOSIA

Meeting Room 352A

Real World Evidence in Metabolic Bone Disease

Chairperson: Daniel Prieto-Alhambra

- ▶ *Real world data for assessing the use, risks, and benefits of anti-osteoporosis therapies in actual practice conditions* Daniel Prieto-Alhambra
- ▶ *Routinely collected data for the study of the epidemiology of fractures, and for characterising imminent fracture risk* Bo Abrahamsen
- ▶ *Health economics using real world data: an introduction* Rafael Pinedo-Villanueva
- ▶ *Real world data for the study of orthopaedics and hip fracture care* Alma Pedersen

Meeting Room 341

What's new in tendinopathies?

Chairperson: Jean-François Kaux

- ▶ *Introduction* Olivier Bruyère
- ▶ *Tendon physiopathology and imagery... What's new ?* Stijn Bogaerts
- ▶ *Rehabilitation: eccentric or not eccentric? Which physiotherapy?* Jean-Louis Croisier
- ▶ *Which efficacy for the new treatments ?* Jean-François Kaux

Meeting Room 353

Emerging Biomarkers in Vitamin D Metabolism

Chairperson: Shaun Sabico

- ▶ *Biomarker Discovery* Nasser Al-Daghri
- ▶ *Vitamin D Biomarker Discovery* Majed Alokail
- ▶ *Validation* Yousef Al-Saleh

Meeting Room 343

Sarcopenia in older people: actual perspectives

Chairpersons: Nicola Veronese, Charlotte Beaudart

- ▶ *The radiological evaluation of muscle mass in older people* Giuseppe Guglielmi
- ▶ *Physical performance in older people: actual evidence* Olivier Bruyère
- ▶ *The diagnosis of sarcopenia in older people: between research and clinical practice* Nicola Veronese

08.00 - 09.00

Meeting Room 342B

Female Bone Health: a gynecological approach through routine assistance

Chairperson: Adriana Orcesi Pedro

- ▶ *Opening: Women’s Hospital - CAISM - University of Campinas message for bone health*
Adriana Orcesi Pedro
- ▶ *Bone mass and fracture risk during pregnancy and lactation*
Anna V. Gueldini de Moraes, Fernanda Garanhani de Castro Surita
- ▶ *Update on management of osteoporosis in young women - special clinical situations*
Adriana Orcesi Pedro, Gabriela Pravatta Rezende
- ▶ *Evaluation and management of osteopenia and osteoporosis in breast cancer survivors*
Adriana Orcesi Pedro, Cesar Cabello dos Santos
- ▶ *Question & Answers with audience*

09.00 - 10.30

Auditorium A

SCIENTIFIC SESSION I

Chairpersons: Jean-Yves Reginster, John A. Kanis

09.00

Auditorium A

Plenary Lecture 1

When and why use a bone forming agent?

- ▶ Eugene McCloskey

09.30

Auditorium A

Oral communication selected from abstracts

09.30

Auditorium A

OC1

HORMONE THERAPY REDUCES THE RISK OF FRACTURE IN FALLERS AND IN NON-FALLERS: RESULTS FROM THE WOMEN’S HEALTH INITIATIVE HORMONE THERAPY TRIALS

Presenting author: ▶ M. Lorentzon

Authors: H. Johansson, N. C. Harvey, E. Liu, J. Crandall, E. V. McCloskey, J. A. Kanis

09.40

Auditorium A

OC2

ROMOSUZUMAB EFFICACY ON FRACTURE OUTCOMES IS GREATER IN PATIENTS AT HIGH BASELINE FRACTURE RISK: A POST HOC ANALYSIS OF THE FRAME STUDY

Presenting author: ▶ E. V. McCloskey

Authors: M. Lorentzon, H. Johansson, N. C. Harvey, J. A. Kanis

09.50

Auditorium A

OC3

ROMOSUZUMAB ENHANCES 3D VERTEBRAL STRUCTURE IN WOMEN WITH LOW BONE DENSITY: MAPPING BONE GAINS AT ONE YEAR COMPARED WITH TERIPARATIDE OR PLACEBO

Presenting author: ▶ K. E. S. Poole

Authors: G. M. Treece, R. A. Pearson, A. H. Gee, M. A. Bolognese, J. P. Brown, S. Goemaere, A. Grauer, D. A. Hanley, C. Mautalen, C. Recknor, Y. C. Yang, C. Libanati, T. Whitmarsh

10.00

Auditorium A

OC4

EFFECT OF ABALOPARATIDE ON BONE MINERAL DENSITY AND FRACTURE INCIDENCE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND OSTEOARTHRITIS

Presenting author: ▶ N. E. Lane

Authors: B. Mitlak, R. Weiss, Y. Wang, G. J. Valenzuela, J. P. Bilezikian

10.10

Auditorium A

OC5

BUROSUMAB IMPROVES THE BIOCHEMICAL, SKELETAL, AND CLINICAL SYMPTOMS OF TUMOR-INDUCED OSTEOMALACIA (TIO) SYNDROME

Presenting author: ▶ S. Jan de Beur

Authors: P. Miller, T. Weber, M. Peacock, K. Insogna, R. Kumar, D. Luca, T. Cimms, K. Lampl, J. San Martin, T. Carpenter

10.20

Auditorium A

Presentation of the ESCEO-AgNovos Healthcare Young Investigator Awards

- ▶ Jean-Yves Reginster

10.30 - 12.10

Auditorium A

SCIENTIFIC SESSION II

Chairpersons: René Rizzoli, Cyrus Cooper

10.30

Auditorium A

Presentation of the ESCEO-IOF Herbert Fleisch Medal

- ▶ René Rizzoli

10.40

Auditorium A

Plenary Lecture 2

Bone fragility and its treatment in chronic renal failure

- ▶ Peter R. Ebeling

11.10

Auditorium A

Presentation of the IOF President's Award

► Cyrus Cooper

11.20

Auditorium A

Oral communication selected from abstracts

11.20

Auditorium A

OC6

IMMINENT (1- AND 2-YEAR) FRACTURE RISK FOLLOWING A FIRST (SENTINEL) FRACTURE: A MULTINATIONAL EUROPEAN COHORT STUDY INCLUDING OVER 700,000 PARTICIPANTS FROM DENMARK, SPAIN, AND THE UK

Presenting author: ► D. Prieto-Alhambra

Authors: S. Khalid, M. Thomsen Ernst, M. K. Javaid, C. Libanati, C. Cooper, A. Delmestri, D. Martinez-Laguna, E. Toth, B. Abrahamsen

11.30

Auditorium A

OC7

ADJUSTING FRAX FOR IMMINENT RISK

Presenting author: ► H. Johansson

Authors: K. Siggeirsdottir, N. C. Harvey, E. V. McCloskey, V. Gudnason, G. Sigurdsson, M. Lorentzon, E. Liu, J. A. Kanis

11.40

Auditorium A

OC8

AGE AT HIP FRACTURE: TIME TRENDS OVER TWO DECADES IN A NATIONAL HOSPITAL DISCHARGE REGISTER

Presenting author: ► B. Abrahamsen

Authors: H. V. B. Laursen, M. K. Skjødt, M. H. Jensen, P. Vestergaard

11.50

Auditorium A

OC9

T-SCORE AS AN INDICATOR OF FRACTURE RISK ON THERAPY: EVIDENCE FROM ROMOSUZUMAB VS. ALENDRONATE TREATMENT IN THE ACTIVE-CONTROLLED FRACTURE STUDY IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK TRIAL

Presenting author: ► S. Ferrari

Authors: F. Cosman, E. M. Lewiecki, P. R. Ebeling, E. Hesse, N. Napoli, D. B. Crittenden, M. Rojeski, W. Yang, C. Libanati

12.00

Auditorium A

OC10

FRACTURE INCIDENCE AFTER DENOSUMAB DISCONTINUATION: REAL-WORLD DATA FROM A LARGE HEALTHCARE PROVIDER

Presenting author: ► L. Tripto-Shkolnik

Authors: N. Fund, V. Rouach, G. Chodick, V. Shalev, I. Goldshtein

12.15 - 13.45

Auditorium A

INDUSTRY SATELLITE LUNCH SYMPOSIUM

See detailed programme on [page 31](#)

12.15 - 13.45

Auditorium B

INDUSTRY SATELLITE LUNCH SYMPOSIUM

See detailed programme on [page 31](#)

13.45 - 14.00

Podium

IOF Calcium Academy Awards ceremony

► Bess Dawson-Hughes

14.00 - 15.00

MEET-THE-EXPERT SESSIONS

Meeting Room 341

► *How to assess frailty in daily practice ?*

► Evelien Gielen

Meeting Room 352A

► *Local therapies in osteoarthritis management*

► François Rannou

Meeting Room 342B

► *New algorithm for the management of bone fragility in diabetes*

► Serge Ferrari

Meeting Room 353

► *Pre- and postnatal influences on bone and muscle health in children*

► Nicholas Harvey

Meeting Room 343

► *Strengths of recommendations for GIOP management*

► Jonathan Adachi

14.00 - 15.00

Poster Area

Poster Viewing Session I

14.00 - 15.10

Podium

Oral presentation of selected posters

Chairperson: Tara Brennan-Speranza

14.00

Podium

P893

IDENTIFICATION OF PATIENTS AT HIGH RISK FOR OSTEOPOROTIC FRACTURES THROUGH RADIOFREQUENCY ECHOGRAPHIC MULTI SPECTROMETRY (REMS): RESULTS OF A 5-YEAR FOLLOW-UP STUDY

Presenting author: ► C. Caffarelli

Authors: S. Gonnelli, G. Bianchi, M. L. Brandi, S. Casciaro, L. Cavalli, L. Cianferotti, F. Conversano, A. Fassio, G. Girasole, A. Grimaldi, F. A. Lombardi, M. Muratore, P. Pisani, L. Quarta, D. Gatti

14.07

Podium

P927

PATIENT AND SERVICE-LEVEL PREDICTORS OF BONE TREATMENT RECOMMENDATION POST-FRACTURE: RESULTS FROM THE UK NATIONAL FRACTURE LIAISON SERVICE (FLS) DATABASE

Presenting author: ▶ M. K. Javaid

Authors: S. Hawley, N. Vasilakis, B. Wiles, C. L. Gregson, N. Gittoes, G. Clunie, C. Cockill, I. Price, A. Judge, A. Smith

14.14

Podium

P363

FRAILTY IN OLDER COMMUNITY DWELLING ADULTS: A COMPARATIVE STUDY OF THE UK AND JAPAN

Presenting author: ▶ N. Yoshimura

Authors: E. M. Dennison, K. A. Jameson, S. Tanaka, T. Iidaka, C. Cooper

14.21

Podium

P154

EWGSOP 2 VERSUS EWGSOP 1: IMPACT ON THE PREVALENCE OF SARCOPENIA AND ITS OUTCOMES

Presenting author: ▶ M. Loquet

Authors: C. Beaudart, J. Petermans, O. Bruyère

14.28

Podium

P639

DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS IS A NEW RISK FACTOR FOR VERTEBRAL FRACTURE IN OLDER MEN – THE PROSPECTIVE MINOS STUDY

Presenting author: ▶ P. Szulc

Authors: A. Guiot, R. D. Chapurlat

14.35

Podium

P837

FOR ALL PRACTITIONERS AND RESEARCHERS TO ASSESS HAND DYSFUNCTION IN HAND OSTEOARTHRITIS (OA): THE QUICK, FRIENDLY AND AVAILABLE FOR FREE FUNCTIONAL INDEX FOR HAND OA WEBSITE FHOA.NET

Presenting author: ▶ E. Maheu

Author: R.-L. Dreiser

14.42

Podium

P586

IMMINENT FRACTURE RISK AMONGST NEW USERS OF ORAL BISPHOSPHONATES IN ACTUAL PRACTICE SETTINGS: A MULTI-NATIONAL EUROPEAN COHORT STUDY FROM DENMARK, SPAIN, AND THE UK

Presenting author: ▶ D. Prieto-Alhambra

Authors: S. Khalid, M. Thomsen Ernst, M. K. Javaid, C. Libanati, C. Cooper, A. Delmestri, D. Martinez-Laguna, E. Toth, B. Abrahamsen

14.49

Podium

P701

RISK OF HAND OSTEOARTHRITIS IN NEW USERS OF HORMONE REPLACEMENT THERAPY: A NESTED CASE-CONTROL ANALYSIS

Presenting author: ▶ T. Burkard

Authors: M. Rauch, J. Spoendlin, D. Prieto-Alhambra, S. S. Jick, C. R. Meier

14.56

Podium

P1041

CAN WE AVOID THE LOSS OF BONE MINERAL DENSITY ONE YEAR AFTER DENOSUMAB DISCONTINUATION? THE REOLAUS BONE PROJECT

Presenting author: ▶ B. Aubry-Rozier

Authors: G. Liebich, D. Stoll, E. Gonzalez-Rodriguez, D. Hans, O. Lamy

15.03

Podium

P698

MAJOR OSTEOPOROTIC FRACTURE RISK FOLLOWING BARIATRIC SURGERY: A SELF-CONTROLLED CASE SERIES INCLUDING 5,492 PEOPLE FROM THE UK CPRD AND LINKED HES DATABASES

Presenting author: ▶ D. E. Robinson

Authors: I. Douglas, G. D. Tan, C. Cooper, A. Delmestri, M. K. Javaid, A. Judge, V. Y. Strauss, D. Prieto-Alhambra

14.00 - 15.00

SYMPOSIA

Meeting Room 342A

Reassessment of the safety of anti-osteoarthritis medications: outcomes of an experts consensus meeting organized under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

Chairpersons: Olivier Bruyère, Elaine M. Dennison

▶ 14:00: *Welcome and scope of the problem*

Cyrus Cooper

▶ 14:05: *Methodology of the ESCEO Working Group*

Cyrus Cooper

▶ 14:15: *Safety of analgesics, non-steroidal anti-inflammatory drugs and opioids* Nicholas R. Fuggle▶ 14:30: *Safety of SYSADOAs, intraarticular Hyaluronic Acid and intraarticular corticosteroids*

Tim McAlindon

▶ 14:45: *Discussion* Nigel K. Arden▶ 14:55: *Wrap-up and conclusions* Nigel K. Arden

14.00 - 15.00

Meeting Room 351

Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: outcomes of an ESCEO-IOF experts consensus meeting organized under the auspices of the WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging

Chairpersons: Adolfo Diez-Perez, Stefania Maggi

- ▶ 14:00: *Welcome and scope of the problem*

Maria Luisa Brandi

- ▶ 14:05: *Determinants of non-adherence to anti-osteoporosis medications* Bernard Vrijens
- ▶ 14:20: *Recommendations to improve adherence to anti-osteoporosis medications* Mickaël Hiligsmann
- ▶ 14:35: *Recommendations for additional research needed to improve adherence to anti-osteoporosis medications* Bo Abrahamsen
- ▶ 14:45: *Discussion* (Leader : Sansin Tuzun)
- ▶ 15:00: *Closure of the meeting* Adolfo Diez-Perez

15.00 - 17.00

Auditorium A

SCIENTIFIC SESSION III

Chairpersons: Charlotte Beaudart, Bess Dawson-Hughes

15.00

Auditorium A

Plenary Lecture 3*Early treatment of osteoarthritis*

- ▶ Nigel K. Arden

15.30

Auditorium A

Oral communication selected from abstracts

15.30

Auditorium A

OC11

CARDIOVASCULAR COMORBIDITIES HAS A DELETERIOUS INFLUENCE ON KNEE OA PROGNOSIS AT 5 YEARS: DATA FROM THE PROSPECTIVE KHOALA COHORT

Presenting author: ▶ C. Roubille

Authors: J. Joel, S. Sellam, A. C. Rat, F. Guillemin, C. Roux

15.40

Auditorium A

OC12

PREVALENCE OF SARCOPENIA ACCORDING TO THE REVISED EWGSOP DEFINITION AND ITS ASSOCIATIONS WITH BONE STRUCTURE AND INCIDENT FALLS IN SWEDISH OLDER ADULTS

Presenting author: ▶ D. Scott

Authors: J. Johansson, L. Mcmillan, P. R. Ebeling, P. Nordstrom, A. Nordstrom

15.50

Auditorium A

OC13

STRENGTH AND PERFORMANCE-BASED OPERATIONAL MEASURES OF SARCOPENIA: PREVALENCE AND ASSOCIATIONS WITH SOCIAL FACTORS AND PHYSICAL DISABILITY IN 10,461 ADULTS AGED 65 YEARS AND OVER FROM SIX LOWER- AND MIDDLE-INCOME COUNTRIES

Presenting author: ▶ S. L. Brennan-Olsen

Authors: S. J. Bowe, P. Kowal, J. Gaskin, N. Naidoo, J. Snodgrass, T. Quashie, S. Agrawal, G. Eick, C. D'Este

16.00

Auditorium A

OC14

WHICH MUSCLE PARAMETERS ARE LONGITUDINALLY ASSOCIATED WITH FUTURE KNEE OSTEOARTHRITIS OUTCOMES? FINDINGS FROM THE HERTFORDSHIRE COHORT STUDY

Presenting author: ▶ N. R. Fuggle

Authors: L. D. Westbury, K. A. Jameson, H. E. Syddall, M. H. Edwards, K. A. Ward, E. M. Dennison, C. Cooper

16.10

Auditorium A

OC15

PATIENT ENGAGEMENT IN CLINICAL GUIDELINES DEVELOPMENT: INPUT FROM >1000 MEMBERS OF THE CANADIAN OSTEOPOROSIS PATIENT NETWORK

Presenting author: ▶ L. Funnell

Authors: M. Djekic-Ivankovic, R. Chepesiuk, L. Giangregorio, I. Braganca Rodrigues, R. Ridout, S. Feldman, S. Kim, H. McDonald-Blumer, G. Kline, W. E. Ward, N. Santesso, W. D. Leslie, S. N. Morin

16.20

Auditorium A

OC16

RISK OF MAJOR OSTEOPOROTIC FRACTURE AFTER BARIATRIC SURGERY IN FRANCE: POPULATION BASED, RETROSPECTIVE COHORT STUDY

Presenting author: ▶ J. Paccou

Authors: N. Martignène, E. Lespessailles, G. Babykina, B. Cortet, G. Ficheur

16.30

Auditorium A

Plenary Lecture 4*Guidelines for the management of osteoarthritis*

► Jean-Yves Reginster

15.00 - 16.45

Meeting Room 351

**COMMITTEE OF NATIONAL SOCIETIES
SPECIAL PLENARY SESSION***Clinical, social, ethical and economic burden of osteoporosis and fragility fractures*

Chairpersons: Jean-Yves Reginster, Famida Jiwa, Philippe Halbout

15.03

Meeting Room 351

OCs1*DETERMINANTS AND HEALTH CONSEQUENCES OF A RAPID MUSCLE HEALTH DECLINE IN OLDER ADULTS FROM THE SARCOPHAGE STUDY*

Presenting author: ► M. Locquet

Authors: C. Beaudart, J.-L. Croisier, J.-Y. Reginster, O. Bruyère

15.11

Meeting Room 351

OCs2*THE ASSOCIATION BETWEEN RESTING METABOLIC RATE (RMR) AND SARCOPENIC OBESITY (SO) IN OVERWEIGHT AND OBESE ADULT WOMEN*

Presenting author: ► K. Mirzaei

Authors: N. Rasaei, S. F. Sajjadi, S. A. Keshavarz

15.19

Meeting Room 351

OCs3*WILL THERE BE A FRACTURE IN THEIR FUTURE? BONE MINERAL DENSITY FINDINGS IN YOUNG SOUTH EAST ASIAN WOMEN WITH ANOREXIA NERVOSA*

Presenting author: ► M. Chandran

Author: Y. Hao

15.27

Meeting Room 351

OCs4*THE BENEFITS OF REGULAR WEIGHT BEARING ACTIVITY THROUGHOUT THE LIFE-COURSE: DO MEN AND WOMEN REAP THE SAME REWARDS?*

Presenting author: ► J. Zhang

Authors: M. A. Clynes, K. A. Jameson, C. Cooper, E. M. Dennison

15.35

Meeting Room 351

OCs5*ASSOCIATION OF 25-HYDROXY VITAMIN D WITH BONE TURNOVER MARKERS AND BONE MINERAL DENSITY IN AN IRANIAN ELDERLY POPULATION: BUSHEHR ELDERLY HEALTH (BEH) PROGRAM*

Presenting author: ► S. Gharibzadeh

Authors: N. Fahimfar, G. Shafiee, R. Heshmat, N. Mehrdad, F. Razi, P. Khashayar, A. Raiesi, I. Nabipour, B. Larijani, A. Ostovar

15.45

Meeting Room 351

Presentation of the IOF Committee of National Societies Medal

► Jean-Yves Reginster

15.55

Meeting Room 351

OCs6*SERUM VITAMIN D LEVEL ASSOCIATED WITH COGNITIVE AND PHYSICAL FUNCTIONING OF POSTMENOPAUSAL WOMEN*

Presenting author: ► A. A. Popov

Authors: N. V. Izmozherova, E. A. Safianik, A. A. Vikhareva, V. M. Bakhtin, M. A. Shambatov

16.03

Meeting Room 351

OCs7*POSTPARTUM OSTEOPOROSIS ASSOCIATED WITH VERTEBRAL FRACTURES*

Presenting author: ► N. Temelkova

Authors: A. Gerganova, K. Temelkova, K. Sirakova, P. Popivanov

16.11

Meeting Room 351

OCs8*VALIDATION OF THE FRACTURE RISK ASSESSMENT TOOL (FRAX) CALCULATOR IN TAIWAN-TWO COHORTS STUDY*

Presenting author: ► C. H. Wu

Authors: F. W. Liang, I. T. Liu, Y. F. Chang, L. C. Ou, C. S. Chang, T. H. Lu

16.19

Meeting Room 351

OCs9*PREVALENCE OF SARCOPENIA IN INDIAN MEN AND WOMEN VARIES ACCORDING TO THE DEFINITION USED*

Presenting author: ► A. Zengin

Authors: B. Kulkarni, A. V. Khadilkar, V. Ekbote, N. Kajale, N. Tandon, S. K. Bhargava, H. P. S. Sachdev, S. Sinha, C. H. D. Fall, P. R. Ebeling

16.27

Meeting Room 351

OCs10

VERTEBRAL PAIN AND PHYSICAL PERFORMANCE INDICES IN POSTMENOPAUSAL WOMEN WITH VERTEBRAL FRACTURES DEPENDING ON BONE MINERAL DENSITY PARAMETERS

Presenting author: ▶ N. Grygorieva

Authors: V. Povoroznyuk, O. Rybina

16.35

Meeting Room 351

OCs11

FAMILY HISTORY INFLUENCES FRACTURE RISK BMD- INDEPENDENTLY

Presenting author: ▶ A. I. Gasparik

Authors: M. L. Cevei, D. Stoicanescu, T. Szocs

17.00 - 18.30

Auditorium A

INDUSTRY SATELLITE SYMPOSIUMSee detailed programme on [page 31](#)

17.00 - 18.30

Auditorium B

INDUSTRY SATELLITE SYMPOSIUMSee detailed programme on [page 31](#)

08.00 - 09.00

Meeting Room 101-102-103

SPONSORED BREAKFAST SESSIONSee detailed programme on [page 31](#)

08.00 - 09.00

NON-SPONSORED SYMPOSIA

Meeting Room 341

Vitamin D: as viewed by the laboratory

Chairperson: Etienne Cavalier

- ▶ *Vitamin D: Optimal levels* Harjit Pal Bhattoa
- ▶ *Vitamin D metabolites: Now and Beyond*
Etienne Cavalier

Meeting Room 352A

FLS in the UK 2014-2018: implementation, standards, quality improvement and benefits

Chairperson: Bo Abrahamsen

- ▶ *FLS Implementation: An innovative service support model for secondary fracture prevention in the UK*
Will Carr
- ▶ *Securing funding for service implementation and improvement - demonstrating the benefits and effectiveness of fracture liaison services*
Tim Jones
- ▶ *Vertebral Fracture Identification – meeting the challenge of FLS standards*
Jill Griffin

Meeting Room 353

Non-pharmacological treatment of low back pain

Chairperson: Alexander Barulin

- ▶ *Cognitive-behavioral therapy in the treatment of chronic back pain*
Olga Kurushina
- ▶ *Biomechanical aspects for understanding of non-specific low-back pain*
Alexander Barulin
- ▶ *Kinesiotaping in the correction of myofascial back pain*
Bogdan Kalinchenko
- ▶ *New approaches to the correction of pain in patients with peripheral paralysis*
Olga Agarkova

Meeting Room 343

Learning on Common Diseases by Understanding the Rare Disorders: The Case of Bone Fragility

Chairperson: Maria Luisa Brandi

- ▶ *Taxonomy of Metabolic Bone Diseases*
Laura Masi
- ▶ *FD-MAS Guidelines*
Naveen Hamdy
- ▶ *Hypophosphatasia in the adults*
Christian Roux
- ▶ *Phosphate wasting disorders in the adults*
Kassim Javaid

Meeting Room 342B

Are current treatment recommendations for Osteoarthritis adapted to old/very old patients ?

Chairpersons: Emmanuel Maheu, Odile Levy-Raynaud

- ▶ *How to manage NSAID in the Elderly in knee, hip or hand osteoarthritis treatment?*
Christian Cadet
- ▶ *Are guidelines for the management of osteoarthritis adapted to very old patients: how to manage opioids in the Elderly in knee, hip or hand osteoarthritis?*
Agnès Portier
- ▶ *Exercise and weight loss in the management of knee/hip OA in very old patients: current data and how to prescribe*
Jean-Laurent Le Quintrec
- ▶ *Total joint replacement of knee or hip in osteoarthritis management of very old patients, is it possible: current evidence and how to proceed?*
Emmanuel Maheu

Auditorium B

Osteosarcopenia: Elucidating bone, muscle and fat interactions

Chairperson: Gustavo Duque

- ▶ *Osteosarcopenia: Where bone, muscle and fat collide*
Gustavo Duque
- ▶ *Diagnostic approach to osteosarcopenia*
Alexandra Papaioannou
- ▶ *Osteosarcopenia: Potential Therapeutic Interventions*
Liang-Kung Chen

08.00 - 09.00

SYMPOSIUM

Meeting Room 342A

Recommendations for the conduct of the economic evaluation in osteoporosis: outcomes of an experts consensus meeting organized under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF) USA branch

Chairpersons: Stuart Silverman, Mickaël Hiligsmann

- ▶ 08:00: *Welcome and scope of the problem*
Stuart Silverman
- ▶ 08:05: *Recommendations for the conduct of economic evaluations in osteoporosis: a summary from an ESCEO-IOF USA Working Group*
Mickaël Hiligsmann
- ▶ 08:25: *Challenges, uncertainties and future research agenda for the conduct of economic evaluations in osteoporosis: a summary from an ESCEO-IOF USA Working Group* Stuart Silverman
- ▶ 08:40: *Discussion Panel*
- ▶ 08:55: *Conclusion* Mickaël Hiligsmann
Panel: Susan Bukata, Philippe Halbout, Mickaël Hiligsmann, Famida Jiwa, Mike Lewiecki, Daniel Pinto, Jean-Yves Reginster, Kenneth Saag, Stuart Silverman, Anna N. A. Tosteson

08.00 - 09.00

Meeting Room 351

EUGMS-ESCEO-IOF Symposium**SARCOPENIA COMES OF AGE**

Chairperson: Stefania Maggi

- ▶ *What is new in the definition of sarcopenia?*
Alfonso Cruz Jentoft
- ▶ *Diagnosing sarcopenia in clinical practice* Yves Rolland
- ▶ *Diet and exercise to treat sarcopenia* Jürgen Bauer

09.00 - 10.30

Auditorium A

SCIENTIFIC SESSION IV

Chairpersons: Thierry Thomas, Stefania Maggi

09.00

Auditorium A

Plenary Lecture 5

What spaceflight has taught us regarding bone and muscle

- ▶ Laurence Vico

09.30

Auditorium A

Oral communication selected from abstracts

09.30

Auditorium A

OC17

A MULTICENTER, RANDOMIZED, RATER-BLINDED, PARALLEL-GROUP, PHASE 3 STUDY TO COMPARE THE EFFICACY, SAFETY, AND IMMUNOGENICITY OF BIOSIMILAR RGB-10 AND REFERENCE ONCE-DAILY TERIPARATIDE IN PATIENTS WITH PRIMARY OSTEOPOROSIS

Presenting author: ▶ H. Hagino

Authors: R. Narita, Y. Yokoyama, M. Watanabe, M. Tomomitsu

09.40

Auditorium A

OC18

SKELETAL BENEFIT/RISK OF LONG-TERM DENOSUMAB (DMAB) THERAPY: A VIRTUAL TWIN ANALYSIS OF FRACTURES (FX) PREVENTED TO SKELETAL SAFETY EVENTS OBSERVED

Presenting author: ▶ S. Ferrari

Authors: E. M. Lewiecki, P. W. Butler, D. L. Kendler, N. Napoli, S. Huang, D. B. Crittenden, N. Pannaciuilli, E. Siris, N. Binkley

09.50

Auditorium A

OC19

THE EFFECT OF COMBINED TERIPARATIDE AND WHOLEBODY VIBRATION EXERCISE IN POSTMENOPAUSAL OSTEOPOROSIS: A RANDOMIZED CONTROLLED TRIAL

Presenting author: ▶ D. B. Jepsen

Authors: J. Ryg, S. Hansen, J. Gram, N. R. Jørgensen, T. Masud

10.00

Auditorium A

OC20

EFFECTS OF A MULTINUTRIENT FORTIFIED DAIRY PRODUCT COMBINED WITH EXERCISE ON FUNCTIONAL MUSCLE PERFORMANCE, BODY COMPOSITION AND INFLAMMATION IN SEDENTARY MIDDLE AGED WOMEN: A 4-MONTH DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED TRIAL

Presenting author: ▶ R. Daly

Authors: J. Gianoudis, B. De Ross, S. O'Connell, L. Schollum, C. Gunn

10.10

Auditorium A

OC21

EFFECT OF ORAL CHONDROITIN SULFATE ON PAIN IN PATIENTS WITH KNEE OSTEOARTHRITIS: OUTCOMES OF A COMPREHENSIVE META-ANALYSIS EXPLORING INCONSISTENCIES IN RANDOMISED, PLACEBO-CONTROLLED TRIALS

Presenting author: ▶ G. Honvo

Authors: O. Bruyère, A. Geerinck, N. Veronese, J.-Y. Reginster

10.20

Auditorium A

Presentation of the ESCEO-IOF Pierre Meunier Young Scientist Award

▶ Jean-Yves Reginster

10.30 - 12.10

Auditorium A

SCIENTIFIC SESSION V

Chairpersons: Bernard Cortet, Elaine M. Dennison

10.30

Auditorium A

Presentation of the IOF Medal of Achievement

▶ Serge Ferrari

10.40

Auditorium A

Plenary Lecture 6

Pharmacological agents for the treatment of sarcopenia

▶ Roger Fielding

11.10

Auditorium A

Oral communication selected from abstracts

11.10

Auditorium A

OC22

DXA-BASED 3D ANALYSIS OF PROXIMAL FEMUR CORTICAL AND TRABECULAR BONE FOR FRACTURE RISK ASSESSMENT: A PROSPECTIVE STUDY IN POSTMENOPAUSAL WOMEN

Presenting author: ▶ E. Biver

Authors: M. Hars, R. Winzenrieth, R. Rizzoli, S. Ferrari

11.20

Auditorium A

OC23

SARCOPENIA DEFINITIONS AS PREDICTORS OF FRACTURE RISK INDEPENDENT OF FRAX, FALLS AND BMD IN THE OSTEOPOROTIC FRACTURES IN MEN (MROS) STUDY: A META-ANALYSIS

Presenting author: ▶ N. C. Harvey

Authors: A. Odén, E. Orwoll, T. Kwok, M. K. Karlsson, B. E. Rosengren, E. Ribom, P. M. Cawthon, K. Ensrud, C. Cooper, J. A. Kanis, M. Lorentzon, C. Ohlsson, D. Mellström, H. Johansson, E. V. McCloskey

11.30

Auditorium A

OC24

RELATIONSHIP BETWEEN THE CHANGES OVER TIME OF BONE AND MUSCLE HEALTH IN CHILDREN AND ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Presenting author: ▶ M. Locquet

Authors: C. Beaudart, N. Durieux, J.-Y. Reginster, O. Bruyère

11.40

Auditorium A

OC25

BIRTHWEIGHT, LIMB MUSCLE MASS AND GRIP STRENGTH IN MIDDLE AGE: FINDINGS FROM THE UK BIOBANK IMAGING ENHANCEMENT

Presenting author: ▶ E. M. Curtis

Authors: J. K. H. Liu, K. A. Ward, K. A. Jameson, Z. Raisi-Estabragh, J. Bell, S. E. Petersen, C. Cooper, N. C. Harvey

11.50

Auditorium A

OC26

INTRINSIC CAPACITY AND ITS ASSOCIATION WITH MORTALITY OVER THREE YEARS IN NURSING HOMES: RESULTS OF THE SENIOR COHORT

Presenting author: ▶ A. Charles

Authors: F. Buckinx, M. Locquet, J.-Y. Reginster, J. Petermans, B. Gruslin, O. Bruyère

12.00

Auditorium A

OC27

DEVELOPMENT AND EXTERNAL VALIDATION OF A PATIENT-LEVEL PREDICTION MODEL FOR 60-DAY MORTALITY FOLLOWING TOTAL KNEE ARTHROPLASTY: A MULTINATIONAL COHORT STUDY

Presenting author: ▶ D. Prieto-Alhambra

Authors: A. Bourke, T. Burkard, E. Burn, R. E. Costello, D. J. Culliford, A. Delmestri, T. Duarte-Salles, Y. He, L. H. John, S. Kolovos, D. R. Morales, C. O'Leary, R. Pinedo-Villanueva, A. Prats-Urbe, J. Reps, D. Robinson, A. G. Sena, W. Sproviero, V. Y. Strauss, R. D. Williams, B. B. Yimer, D. Yu, P. Ryan

12.15 - 13.45

Auditorium A

INDUSTRY SATELLITE LUNCH SYMPOSIUM

See detailed programme on [page 31](#)

12.15 - 13.45

Auditorium B

INDUSTRY SATELLITE LUNCH SYMPOSIUM

See detailed programme on [page 31](#)

14.00 - 15.00

MEET-THE-EXPERT SESSIONS

Meeting Room 341

- ▶ *Vitamin D and osteoarthritis*
- ▶ Tim McAlindon

Meeting Room 342B

- ▶ *Local Bone Treatment in Osteoporosis (supported by an Unrestricted Educational Grant from Agnovos Healthcare)*
- ▶ Andreas Kurth

Meeting Room 352A

- ▶ *Disorders of phosphate homeostasis*
- ▶ Maria Luisa Brandi

Meeting Room 353

- ▶ *Fracture Liaison Services: models and fracture risk reduction*
- ▶ Kassim Javaid

14.00 - 15.00

SYMPOSIUM

Meeting Room 342A

Diabetes and Osteoarthritis: outcomes of an ESCEO experts consensus meeting organized under the auspices of the World Health Organization Collaborating Center for Public Health Aspects of Musculo-skeletal Health and Ageing

Chairpersons: Elaine M. Dennison, Marc Hochberg

- ▶ *14:00: Introduction* Roland D. Chapurlat
 - ▶ *14:05: Impact of diabetes mellitus on osteoarthritis incidence and progression* Nicola Veronese
 - ▶ *14:20 Management of osteoarthritis in diabetic patients* Daniel Uebelhart
 - ▶ *14:35 Discussion* André Scheen, Islene Araujo de Carvalho
 - ▶ *14:55 Conclusion* Elaine M. Dennison
- Panel: Jaime Branco, Olivier Bruyère, Roland D. Chapurlat, Cyrus Cooper, Elaine M. Dennison, Gabriel Herrero-Beaumont, Marc Hochberg, Andrea Laslop, Emmanuel Maheu, Jean-Yves Reginster, René Rizzoli, Roland Roth, Lucio C. Rovati, André Scheen, Daniel Uebelhart, Nicola Veronese

14.00 - 15.00

Meeting Room 343

Effects of biologics on bone in chronic arthritis

- ▶ Osvaldo D. Messina

14.00 - 15.00

Poster Area

Poster Viewing Session II

14.00 - 15.03

Podium

Oral presentation of selected posters

Chairperson: Tara Brennan-Speranza

14.00

Podium

P433

INFANT FEEDING AND BONE HEALTH IN LATER LIFE: EVIDENCE FROM THE HERTFORDSHIRE COHORT STUDY

Presenting author: ▶ S. Carter

Authors: C. Parsons, S. Robinson, E. M. Dennison, C. Cooper

14.07

Podium

P170

DISSCO STUDY: AN INTERNATIONAL, MULTICENTRE, DOUBLE-BLIND, RANDOMISED STUDY ON THE EFFECT OF DIACEREIN VERSUS CELECOXIB ON SYMPTOMS IN KNEE OSTEOARTHRITIS PATIENTS

Presenting author: ▶ J.-P. Pelletier

Authors: J.-P. Raynaud, P. Paiement, J. Martel-Pelletier

14.14

Podium

P542

DEVELOPMENT OF A FRAILTY SPECIFIC PATIENT REPORTED OUTCOME (PRO): THE FRAILQOL

Presenting author: ▶ F. Buckinx

Authors: C. Beaudart, J.-Y. Reginster, Y. Rolland, M. Cesari, R. Rizzoli, J. Petermans, O. Bruyère

14.21

Podium

P671

BONE MICROINDENTATION AND TRABECULAR BONE SCORE IDENTIFY PRIOR FRACTURE IN MEN WITH AND WITHOUT CHRONIC KIDNEY DISEASE

Presenting author: ▶ K. L. Holloway-Kew

Authors: P. G. Rufus-Membere, K. B. Anderson, M. A. Kotowicz, A. Diez-Perez, N. Hyde, J. A. Pasco

14.28

Podium

P193

EFFECT OF BISPHOSPHONATE VERSUS MENOPAUSAL HORMONE THERAPY ON FRACTURE RECURRENCE AND MORTALITY AFTER HIP FRACTURE SURGERY IN POSTMENOPAUSAL KOREAN WOMEN: A RANDOMIZED, OPEN-LABEL TRIAL

Presenting author: ▶ S.-J. Lim

Authors: C.-W. Park, Y.-S. Park, S.-H. Choi, Y.-K. Min, B.-K. Yoon

14.35

Podium

P466

USING ARTIFICIAL INTELLIGENCE TECHNOLOGY TO IMPROVE CASE FINDING FOR VERTEBRAL FRACTURES IN THE FRACTURE LIAISON SERVICE (FLS) SETTING

Presenting author: ▶ R. Eckert

Authors: S. Connacher, R. Mansour, M. K. Javaid

14.42

Podium

P525

EFFECT OF NUTRITIONAL SUPPLEMENTATIONS ON PHYSICAL PERFORMANCE AND MUSCLE STRENGTH PARAMETERS IN OLDER PEOPLE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Presenting author: ▶ N. Veronese

Authors: P. Soysal, S. Maggi

14.49

Podium

P458

MEDICAL MANAGEMENT OF ATYPICAL FEMUR FRACTURES: A SYSTEMATIC LITERATURE REVIEW

Presenting author: ▶ D. M. van de Laarschot

Authors: M. J. McKenna, C. Zillikens

14.56

Podium

P319

IMPACT OF POPULATION-BASED OR TARGETED INTERVENTIONS ON FRACTURE INCIDENCE

Presenting author: ▶ N. C. Harvey

Authors: J. A. Kanis, E. Liu, M. Lorentzon, E. V. McCloskey, H. Johansson

15.00 - 17.10

Auditorium A

SCIENTIFIC SESSION VI

Chairpersons: Radmila Matijevic, Fanny Buckinx

15.00

Auditorium A

Plenary Lecture 7*Tools for estimating fracture probability*

▶ John A. Kanis

15.40

Auditorium A

Oral communication selected from abstracts

15.40

Auditorium A

OC28

COMPARISON OF THE PSYCHOMETRIC PROPERTIES OF THE SARQOL® QUESTIONNAIRE WITH THE EWGSOP AND EWGSOP2 CRITERIA FOR SARCOPENIA

Presenting author: ▶ A. Geerinck

Authors: C. Beaudart, J.-Y. Reginster, O. Bruyère

15.50

Auditorium A

OC29

A POOLED ANALYSIS OF FALL INCIDENCE FROM PLACEBO-CONTROLLED TRIALS OF DENOSUMAB

Presenting author: ▶ E. V. McCloskey

Authors: R. Eastell, M. R. McClung, N. Pannacciulli, C. Wang, S. Yue, S. R. Cummings

16.00

Auditorium A

OC30

IS LOW IMPACT PHYSICAL ACTIVITY ASSOCIATED WITH LOWER LIMB BONE DENSITY AND STRENGTH? RESULTS FROM THE HERTFORDSHIRE COHORT STUDY

Presenting author: ▶ C. Parsons

Authors: E. M. Dennison, J. Tobias, C. Cooper, K. A. Ward

16.10

Auditorium A

OC31

DIETARY PROTEIN INTAKE AND FALLS IN OLDER PEOPLE: A LONGITUDINAL COHORT STUDY

Presenting author: ▶ N. Veronese

Authors: P. Soysal, S. Maggi, L. Smith

16.20

Auditorium A

OC32

LONGITUDINAL ASSOCIATIONS BETWEEN DIETARY INFLAMMATORY INDEX AND MUSCULOSKELETAL HEALTH IN COMMUNITY-DWELLING OLDER ADULTS

Presenting author: ▶ M. M. Cervo

Authors: N. Shivappa, J. Hebert, W. Oddy, T. Winzenberg, S. Balogun, F. T. Wu, P. R. Ebeling, D. Aitken, G. Jones, D. Scott

16.30

Auditorium A

OC33

COST-EFFECTIVENESS ASSESSMENT OF DIFFERENT GLUCOSAMINES IN PATIENTS WITH KNEE OSTEOARTHRITIS: A SIMULATION MODEL ADAPTED TO GERMANY

Presenting author: ▶ O. Bruyère

Authors: J. Detilleux, J.-Y. Reginster

16.40

Auditorium A

Plenary Lecture 8*Osteoporosis screening and fracture risk reduction*

▶ Cyrus Cooper

08.00 - 09.00

NON-SPONSORED SYMPOSIA

Meeting Room 352A

Bone structure in chronic arthritides

Chairpersons: Osvaldo D. Messina, Cristiano A. F. Zerbinì

- ▶ *Biologic agents and bone loss in rheumatoid arthritis* Willem Lems
- ▶ *Non invasive measurement of erosive disease with QCT and MRI in rheumatoid arthritis* Jonathan D. Adachi
- ▶ *Value and limitations in HRpQCT imaging in chronic arthritides. Current status and future directions* Klaus Engelke

Meeting Room 353

IOF-FFN Joint symposium - Moving from treatment to prevention of new fractures

Chairpersons: Kristina Åkesson, Matt Costa

- ▶ *Getting the stars on the map* Thierry Thomas
- ▶ *What are the potential uncertainties for trauma surgeons - e.g. fracture healing* Andy Gray
- ▶ *The future of surgical fixation in fragile bone* Matt Costa
- ▶ *Monitoring patients and tools for getting better* Kassim Javaid
- ▶ *Capture the Fracture mentorship programme* Donncha O'Gradaigh

Meeting Room 343

Regenerative Medicine in degenerative joint diseases

Chairperson: George Skarpas

- ▶ *Regenerative Medicine definitions, techniques and joint applications. Where do we stand now?* George Skarpas
- ▶ *Guidelines, Theories, Practice and Regulatory mechanisms for Stem Cell Therapy* George Samoutis
- ▶ *The role of regenerative medicine in degenerative conditions of the spine. Is there really a role for it?* Elias Papadopoulos
- ▶ *Regenerative medicine techniques need specially designed and individualized rehabilitation protocols for optimal results* Eirini Kontopoulou

Meeting Room 341

Women's special issues: osteoporosis

Chairperson: Adriana Orcesi Pedro

- ▶ *Risk factors for osteoporosis: Frax-based intervention and assessment thresholds in Brazil* Ben-Hur Albergaria
- ▶ *Osteoporosis prevention and treatment on special situations during women's reproductive period* Adriana Orcesi Pedro
- ▶ *Update on efficacy and safety of post-menopause hormone therapy and fracture prevention* Bruno Muzzi Camargos
- ▶ *Question & Answers with audience*

08.00 - 09.00

SYMPOSIA

Meeting Room 342A

New insights in the management of Osteoarthritis: an update of the ESCEO algorithm for the management of the Osteoarthritis

Chairpersons: François Rannou, Cyrus Cooper

- ▶ *08:00 Welcome* Cyrus Cooper
- ▶ *08:05 The 2014-2016 ESCEO Algorithm for the management of the Osteoarthritis* Olivier Bruyère
- ▶ *08:15 New insights in the management of Osteoarthritis* Cyrus Cooper
- ▶ *08:30 The updated ESCEO algorithm for the management of knee Osteoarthritis : Assessment of the various treatment modalities by GRADE* Nicola Veronese
- ▶ *8:55 Discussion* Roland Roth

Meeting Room 351

Selection of relevant outcomes in sarcopenia: a Discrete Choice Experiment. Outcomes of an ESCEO consensus meeting

Chairpersons: Charlotte Beaudart, Mickaël Hiligsmann

- ▶ *08:00: Welcome and introduction* Mickaël Hiligsmann
 - ▶ *08:05: Identification and prioritization of important outcomes for patients in sarcopenia* Charlotte Beaudart
 - ▶ *08:20: A cross-european discrete choice experiment to assess patients' preferences for sarcopenia outcomes* Mickaël Hiligsmann
 - ▶ *08:40: Discussion* Alfonso Cruz Jentoft, Islene Araujo de Carvalho
 - ▶ *08:55: Conclusion* Charlotte Beaudart
- Panel: Jürgen Bauer, Charlotte Beaudart, Olivier Bruyère, Cyrus Cooper, Alfonso Cruz Jentoft, Mickaël Hiligsmann, Francesco Landi, Stefania Maggi, Jean-Yves Reginster, René Rizzoli, Yves Rolland

08.00 - 09.00

Meeting Room 342B

ESPRM-ESCEO-IOF Joint Session

WIN - What is new in Physical and Rehabilitation Medicine on Osteoarthritis

Chairpersons: Fitnat Dincer, Michael Quittan

- ▶ *W.I.N. - What is new in Hand Osteoarthritis? Update in Physical and Rehabilitation Medicine on Hand Osteoarthritis* Fitnat Dincer
- ▶ *W.I.N. - What is new in Knee Osteoarthritis? Update in Physical and Rehabilitation Medicine on Knee Osteoarthritis* Michael Quittan
- ▶ *W.I.N. - What is New in Hip Osteoarthritis? Update in Physical and Rehabilitation Medicine on Hip Osteoarthritis* Raquel Valero

09.00 - 10.00

MEET-THE-EXPERT SESSIONS

Meeting Room 342B

- ▶ *Obesity, bone and muscle*
- ▶ Roland D. Chapurlat

Meeting Room 341

- ▶ *Androgens: a role in bone and muscle disorders management?*
- ▶ Jean-Marc Kaufman

Meeting Room 352A

- ▶ *Atypical femoral fracture: stage in 2019*
- ▶ Emmanuel Biver

Meeting Room 353

- ▶ *Pitfalls in identification of vertebral fracture*
- ▶ Christian Roux

Meeting Room 343

- ▶ *Muscle strength/power assessment and outcomes*
- ▶ Olivier Bruyère, ▶ Charlotte Beaudart, ▶ Mylène Aubertin-Leheudre

09.00 - 10.00

Poster Area

Poster Viewing Session III

10.00 - 12.00

Auditorium B

SCIENTIFIC SESSION VII

Chairpersons: Şansın Tüzün, Famida Jiwa

10.00

Auditorium B

Plenary Lecture 9

Vitamin D: how much is too much?

- ▶ Bess Dawson-Hughes

10.40

Auditorium B

Oral communication selected from abstracts

10.40

Auditorium B

OC34

COST-EFFECTIVENESS OF GASTRO-RESISTANT RISEDRONATE TABLETS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN FRANCE

Presenting author: ▶ M. Hilgsmann

Author: J.-Y. Reginster

10.50

Auditorium B

OC35

LOCAL OSTEO-ENHANCEMENT PROCEDURE FOR OSTEOPOROTIC BONE LOSS INCREASES RAW TRABECULAR BONE SCORE (R-TBS) IN PROXIMAL FEMURS AT 5-7 YEARS FOLLOW-UP

Presenting author: ▶ R. Hill

Authors: J. Stroncek, J. Howe, B. Huber, C. Lelong, D. Hans

11.00

Auditorium B

OC36

EFFECTS OF MUSIC-BASED MULTITASK EXERCISE (JAQUES-DALCROZE EURHYTHMICS) VERSUS MULTICOMPONENT EXERCISE ON PHYSICAL FUNCTION, FALLS AND BRAIN PLASTICITY IN OLDER ADULTS: A RANDOMIZED CONTROLLED TRIAL

Presenting author: ▶ A. Trombetti

Authors: M. Hars, N. Fernandez, F. Herrmann, R. Rizzoli, G. Gold, P. Vuilleumier

11.10

Auditorium B

OC37

RESULTS FROM A PHASE 2B TRIAL OF SM04690, A NOVEL INTRA-ARTICULAR WNT PATHWAY INHIBITOR FOR THE TREATMENT OF KNEE OSTEOARTHRITIS

Presenting author: ▶ J. Tambiah

Authors: Y. Yazici, T. McAlindon, A. Gibofsky, N. Lane, C. Lattermann, N. Skrepnik, C. Swearingen, A. Difrancesco, M. Hochberg

11.20

Auditorium B

OC38

LONG TERM RATES OF CHANGE IN MUSCULOSKELETAL AGING: FINDINGS FROM THE HEALTH, AGING AND BODY COMPOSITION STUDY

Presenting author: ▶ L. D. Westbury

Authors: H. E. Syddall, E. M. Dennison, J. Cauley, T. B. Harris, E. J. Shiroma, B. H. Goodpaster, A. B. Newman, C. Cooper

11.30

Auditorium B

Plenary Lecture 10

Dietary protein, dairy and bone: devils or angels?

- ▶ René Rizzoli

12.00 - 13.00

NON-SPONSORED SYMPOSIA

Meeting Room 343

Osteoarthritis and vascular aging

Chairperson: Sekib Sokolovic

- ▶ *Introduction* Sekib Sokolovic
- ▶ *The impact of osteoarthritis on aging* Sansin Tüzün
- ▶ *The crosstalk between vessels, bone and cartilage: does it exist* Marius Miglinas
- ▶ *Osteoarthritis and vascular aging* Sekib Sokolovic

Meeting Room 341

Approach to Osteoporotic Hip Fractures

Chairpersons: Berrin Durmaz, Sema Oncel

- ▶ *Osteoporotic Hip Fractures: Are we able to prevent?* Yesim Kirazli
- ▶ *Pharmacological Treatment after Hip Fractures: When and How?* Ozlem El
- ▶ *Adherence to Pharmacological Treatment of Osteoporosis* Yesim Gokce Kutsal
- ▶ *Rehabilitation after Hip Fractures* Funda Calis
- ▶ *Prevention of Complications Following Hip Fractures* Ozlen Peker

Meeting Room 352A

Osteonecrosis of the jaw management in the clinical setting

Chairperson: Bruno Muzzi Camargos

- ▶ *Pathophysiology and Risk Factors* Oscar Rosero Olarte
- ▶ *Biochemical markers and Imaging use on ONJ* Bruno Muzzi Camargos
- ▶ *Osteoporosis Therapies and ONJ.* Adriana Medina Orjuella
- ▶ *Clinical scenarios #1: Oral invasive procedures pre-op patients* Monique Chalem
- ▶ *Clinical scenarios #2: Oral invasive procedures pre-op patients* Ana Karina Sarmiento Lievano

Meeting Room 342B

Exercise with or without nutrition as countermeasures of dynapenia in older adults

Chairpersons: Bertrand Fougère, Fanny Buckinx, Mylène Aubertin-Leheudre

- ▶ *How to maintain muscle quality: the secret of a successful aging* Bertrand Fougère
- ▶ *Exercise to prevent muscle function in dynapenic or non-dynapenic older adults: one fits for all?* Mylène Aubertin-Leheudre
- ▶ *Impact of nutrition during exercise intervention on muscle adaptation in older adults* Fanny Buckinx

THURSDAY, APRIL 4

20.00 - 21.00

**INDUSTRY-SPONSORED WELCOME
COCKTAIL**

Courtesy of Mylan

FRIDAY, APRIL 5

08.00 - 09.00

Auditorium A

**ABIOTEN BREAKFAST SYMPOSIUM -
VITAMIN D FOR MUSCLE-SKELETAL HEALTH**

Chairperson: Maria Luisa Brandi

- ▶ *Vitamin D for Bone Health* René Rizzoli
- ▶ *Vitamin D for Muscle Health* Bess Dawson-Hughes

12.15 - 13.45

Auditorium A

**MYLAN SATELLITE LUNCH SYMPOSIUM -
CRYSTALLINE GLUCOSAMINE SULFATE:
EXPLORING THE EFFICACY FOR POTENTIAL
NEW INDICATIONS**

Chairpersons: Alberto Migliore, Jean-Yves Reginster

- ▶ *ESCEO recommendations for clinical trials for hand OA* Jean-Yves Reginster
- ▶ *Hand osteoarthritis: specificities and similarities with knee OA - a short overview* Emmanuel Maheu
- ▶ *A new opportunity to treat hand Osteoarthritis: the role of crystalline glucosamine sulfate* Sandro Tenti
- ▶ *The challenge of early symptomatic knee osteoarthritis (ESKOA)* Alberto Migliore
- ▶ *Serum kinetics of cartilage biological markers in response to immobilization and physical exercise, and the potential role of CGS in this context* Anna-Maria Liphardt
- ▶ *Opening of discussion* Jean-Yves Reginster
- ▶ *Conclusion*

12.15 - 13.45

Auditorium B

**UCB SATELLITE LUNCH SYMPOSIUM -
TREATING TO TARGET – A REALITY ON THE
HORIZON?**

Chairperson: Kassim Javaid

- ▶ *Why do we need to change our approach for patients with fragility fractures?* Kassim Javaid
- ▶ *What can we learn from other therapy areas?* Clifford J. Bailey, Serge Ferrari
- ▶ *What could we be targeting for patients with fragility fractures?* Serge Ferrari
- ▶ *How do we apply the evidence when all patients are different?* Including audience exercise
Bente Langdahl facilitated by Kassim Javaid
- ▶ *Where have we landed?* Kassim Javaid, Serge Ferrari, Bente Langdahl

17.00 - 18.30

Auditorium A

**KYOWA KIRIN SATELLITE SYMPOSIUM - THE
MANY FACES OF RARE BONE DISEASE**

Chairpersons: Cyrus Cooper, Christian Roux

- ▶ *Welcome and introductions* Cyrus Cooper, Christian Roux
- ▶ *Phosphate wasting disorders in adults: a clinical overview* Maria Luisa Brandi
- ▶ *Case report 1: Unexplained fractures in a previously healthy young adult* Salvatore Minisola
- ▶ *Case report 2: How to find the needle in the haystack?* Lars Rejnmark
- ▶ *Case report 3: A case of mistaken identity: spondyloarthritis or not?* Karine Briot
- ▶ *Q&A* Christian Roux
- ▶ *Summary and close* Cyrus Cooper

FRIDAY, APRIL 5

17.00 - 18.30

Auditorium B

**IBSA SATELLITE SYMPOSIUM -
DIFFERENCES IN THE EFFICACY OF VARIOUS
CHONDROITIN SULFATE PREPARATIONS:
FACTS OR FANTASY?**

Chairperson: Jean-Yves Reginster

- ▶ *Welcome and introduction* Jean-Yves Reginster
- ▶ *Efficacy and tolerance of pharmaceutical-grade Chondroitin Sulfate: What does evidence-based medicine say?* Jean-Yves Reginster
- ▶ *Is there a responder profile to pharmaceutical-grade Chondroitin Sulfate? An analysis of the CONCEPT study* Olivier Bruyère
- ▶ *CS pharmaceutical grade and CS nutraceuticals how far are they?* Chiara Schiraldi
- ▶ *Discussion and conclusion* Jean-Yves Reginster

SATURDAY, APRIL 6

08.00 - 09.00

Meeting Room 101-102-103

**AGNOVOS BREAKFAST SESSION - ESCEO –
AGNOVOS YOUNG INVESTIGATOR AWARD
BREAKFAST EVENT**

- ▶ *Introduction and welcome* James Howe
- ▶ *Keynote* Andreas Kurth
- ▶ *Award winners speech*

12.15 - 13.45

Auditorium A

**AMGEN SATELLITE LUNCH SYMPOSIUM -
IMPROVING OSTEOPOROSIS CARE - GETTING
CLOSER TO THE PATIENT**

Chairpersons: Eugene McCloskey, Christian Roux

- ▶ *Welcome and introduction*
Eugene McCloskey, Christian Roux
- ▶ *Estimating the treatment gap in elderly women – a cross-sectional primary care study* Socrates Papapoulos
- ▶ *Utility of fracture risk assessment in primary care; identifying the right patient* Eugene McCloskey
- ▶ *Managing osteoporosis treatment – challenges and opportunities for primary care physicians*
Liesbeth Borgermans
- ▶ *Q&A session and meeting close*
Eugene McCloskey, Christian Roux

12.15 - 13.45

Auditorium B

**ELI LILLY SATELLITE LUNCH SYMPOSIUM -
17 YEARS OF TERIPARATIDE: NEW INSIGHTS
IN THE TREATMENT OF SEVERE
OSTEOPOROSIS**

Chairperson: Thierry Thomas

- ▶ *Welcome and Introduction* Thierry Thomas
- ▶ *New Insights on the Mechanism of Action of Teriparatide* Erik Fink Eriksen
- ▶ *New Results of Teriparatide in the Treatment of Severe Osteoporosis* Adolfo Diez-Perez
- ▶ *Question and Answers and Close All*



2019 PARIS

**WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES**

PARIS, France | 2019

Abstract Book

Special Lectures Abstracts

SL1 BEYOND NUTRIENTS: HEALTH EFFECTS OF THE DAIRY MATRIX

A. Astrup¹

¹Department Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark

Nutrition recommendations have historically focused on nutrients, and are typically constructed to ensure that diet meets requirements for individual nutrients. Translation of nutritional requirements to dietary guidance has typically resulted in advice such as “reduce intake of cholesterol and saturated fat”. However, people consume foods not nutrients, and translation from individual nutrients to foods has proven problematic.

Recent research has shown that saturated fat (SAT) does not exert the adverse effect on cardiovascular disease (CVD) previously thought, and that the various saturated fatty acids exert very different biological effects, which are substantially modified by the food matrix. One example is cheese, which might be expected to increase CVD risk due to high content of SAT and sodium, but studies indicate the opposite, with a reduction in blood pressure, and reduced risk of CVD and particularly of stroke. The evidence for reducing sodium is also challenged, as the lowering of blood pressure achieved by reducing salt intake is modest, even in hypertensives.

Another example is from two large observational studies from Harvard, which found that each serving of milk per day was associated with an 8% lower risk of hip fracture (RR = 0.92). It is interesting that the effect could not be explained by the intake of calcium, vitamin D and protein from dairy, as adjustment for these nutrients did not weaken the association. This observation supports that other nutrients, or interactions within the dairy matrix, are responsible for the effect on skeletal health.

It makes good sense to base dietary guidelines on foods, but these prove impossible to formulate at a global or even a regional level. Genetically, racially, ethnically, and culturally different people, living in different geographical areas, eat different foods due to tradition and differences in availability. The nutrient content of any particular food may vary dramatically depending on the composition of the cultivars involved. Some of these differences may have consequences for nutrition guidelines for local populations, for harmonizing guidelines across countries, and for the health maintenance/disease prevention outcomes of the guidelines. Thus, the impact of the food matrix on health complicates the definition of dietary advice.

Potential conflicts of interest

AA is co-chair of the Expert Workshop on the Dairy Matrix in Relation to Musculoskeletal Health 2019, supported by an unrestricted grant from the European Milk Forum. In the past 24 months he has acted as consultant for Nestlé Research Center, Switzerland. He is recipient of travel grants and honoraria as speaker for a wide range of Danish and international concerns. AA is co-inventor of a number of patents owned by UCPH, in accordance with Danish law. AA is not advocate or activist for specific diets, and is

not strongly committed to any specific diet, e.g. veganism, Atkins diet, gluten-free diet, high animal protein diet, or dietary supplements.

SL2 EUROPEAN GUIDANCE FOR THE DIAGNOSIS AND MANAGEMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

J. A. Kanis^{1,2}, C. Cooper^{3,4}, R. Rizzoli⁵, J.-Y. Reginster^{6,7}, on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF)

¹Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom, ²Mary McKillop Health Institute, Australian Catholic University, Melbourne, Australia, ³MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁴Institute of Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁵Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland, ⁶Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ⁷Chair for Biomarkers and Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia

Introduction The International Osteoporosis Foundation and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis published guidance for the diagnosis and management of patients with osteoporosis in 2013. The present 2018 guidance updates the previous one in a European setting.

Methods Updated systematic reviews.

Results This document reviews the role of BMD measurement for the diagnosis of osteoporosis and assessment of fracture risk; general and pharmacological management of patients with osteoporosis; monitoring of treatment; assessment of fracture risk; case finding strategies; investigation of patients; and health economics of treatment. The update includes new information on the evaluation of bone microstructure in fracture risk assessment, the role of FRAX® and Fracture Liaison Services in secondary fracture prevention, long-term effects on fracture risk of dietary intakes, and increased fracture risk on stopping drug treatment.

Conclusions This document provides a platform on which specific guidelines can be developed for national use.

SL3 CHRONIC ARTHRITIDES AND BONE INTEGRITY. THE POTENTIAL PROTECTIVE EFFECTS OF BIOLOGIC AGENTS

O. D. Messina¹

¹Rheumatology Service, Cosme Argerich Hospital and IRO Clinical Research Center, Buenos Aires, Argentina

Chronic arthritides are common systemic autoimmune disease . Rheumatoid arthritis (RA) is characterized by chronic , symmetric and progressive inflammatory polyarthritis. One of the most deleterious effects induced by the chronic inflammation of RA is bone loss. There is an inverse relationship between proinflammatory cytokines , Wnt antagonists and the level of inflammation . Anabolic Wnt agonists and erosion repair increase as soon as inflammation , pro inflammatory cytokines and Wnt antagonists decrease(E Gravallesse . Figure 1) (1). This process occurs in chronic inflammatory diseases and can be diagnosed in RA , ankylosing spondylitis , chronic bowel diseases , systemic lupus erythematosus and psoriatic arthritis among others.(2)

Causes of bone damage include several cytokines released from chronic synovitis that activate osteoclastic activity mainly TNF alpha , IL 1 , IL6 , anorexia , malnutrition , impaired mobility , lack of exercises associated with joint pain , chronic corticosteroids (CS) administration and vitamin D deficiency (2) The use of CS during RA treatment , even as a small dose of prednisone 5 mg/ day or equivalent for more than 3 months is associated with a fast and persistent loss of bone. One study showed that continuous treatment with prednisone 10 mg/day during 90 days or more increased by 17- fold the risk of vertebral fractures and by 7-fold the risk of hip fractures (3)

Three different forms of skeletal involvement can be seen in patients with RA and they are associated with a common pathophysiological mechanism related to alteration in bone remodeling as a result of increased bone resorption. The first is a peri articular bone loss of "juxta articular osteoporosis ". A second form is related to marginal bone erosions and the third is a generalized osteoporosis involving the skeleton as a whole . Patients with RA mainly those with high disease activity have a twofold risk of developing osteoporosis compared to the general population and almost the double risk for hip and vertebral fractures independent of the adverse effects of CS therapy on bone mass . Risk factors for fractures in patients with RA include high CRP , the presence of bone erosions , long disease duration and the presence of ACPA antibodies which enhance by several mechanisms osteoclasts activation .(4) Kocijan showed that patients with seropositive RA have greater alterations of trabecular bone than those with seronegative RA. Those patients who are serum positive for rheumatoid factors and /or ACPAs had significant decreases in total trabecular density and inner trabecular density as evaluated by HRpQCT.(5)

In patients with RA synovitis express RANK L which is enhanced by pro inflammatory cytokines being the most potent TNF alpha exceeding the OPG levels . Besides TNF - alpha is a potent inducer of the protein Dkk-1 , an inhibitor of the Wnt signal found

in high serum levels of RA patients . This elevated production of Dkk-1 induced by TNF-alpha reduces the Wnt- induced production of OPG , which results in an increase in the RANKL/OPG ratio and an acceleration of osteoclast resorption leading to bone loss.

During the last 19 years potent inhibitors of the inflammatory cytokines have been developed and were classified as biological drug modifying anti rheumatic drugs (DMARDs) . These drugs are very effective in the inhibition of inflammation but there are few studies regarding their role in bone protection . Most of published data are related to the effects of etanercept , infliximab , adalimumab , tocilizumab , rituximab and denosumab , the RANKL blocker . Sites of action are shown on figure 2 designed by C Zerbini (5) .

Studies with TNF blocking agents show preservation or increase in spine and hip BMD and also a better profile of bone markers . Only three studies analysed the effect on fractures after anti TNF blocking agent's treatment. IL-6 blocking agents also showed improvement in localized bone loss not seen with anti -TNF agents. Hand BMD improved with adalimumab and this effect is not linear with the control of inflammatory activity. However there are still unmet needs for studies regarding their actions on the risk of bone fractures

Figure 1





Fig 2 Cytokine network and biological treatment blockade



References

- Gravallesse E . Advances in Rheumatology , Harvard Medical School , Sept , 2018

- Bultink IE, Vis M, van der Horst-Bruinsma IE, Lems W (2012) Inflammatory rheumatic disorders and bone. *Curr Rheumatol Rep* 14:224-230.
- Buckley L, Guyyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, et al

2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. *Arthritis Rheumatol* 2017, Aug;69(8) 1521-1537.

- Harre U et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. *The Jour of clin Invest* Vol 122, N 5, May 2012.
- Zerbin CA, Clark PE, Mendez-Sanchez L, Pereira RMR, Messina OD, Una CR, Adachi JD, Lems W, Cooper C, Lane NE on behalf of the IOF Chronic Inflammation and bone Structure (CIBS) working group.

Osteoporosis Int, pub on line October 31, 2016.



2019 PARIS

WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES

PARIS, France | 2019

Abstract Book

Plenary Lectures Abstracts

PL1

WHEN AND WHY USE A BONE-FORMING AGENT?

E. V. McCloskey¹¹Department of Oncology & Metabolism, University of Sheffield, Sheffield, United Kingdom

The last few years have seen exciting advances in our knowledge of musculoskeletal biology and the comparative efficacy of established and novel bone-forming agents in clinical trials. Of the two questions raised here, the reason why to use bone-forming agents is the easiest to address. The natural experiments that led to the discovery of sclerostin deficiency, and its impact on bone mass and strength, has enabled the pharmacological development of sclerostin-targeted monoclonal antibodies, one of which (romosozumab) is now entering clinical practice. In a large placebo-controlled study, and more importantly in a head-to-head trial with the most widely used treatment for osteoporosis, alendronic acid, romosozumab has shown superior increases in bone density at all skeletal sites, with a consequent greater and more rapid decrease in fracture rates. Furthermore, teriparatide, which has been available for the treatment of osteoporosis for approximately 16 years, has also recently shown superior antifracture efficacy in a head-to-head trial with oral risedronate across a wide range of vertebral and clinical fracture outcomes. Thus, the reason why to use bone-forming agents is straightforward; they have a different mechanism of action to antiresorptives which leads to more marked improvements in skeletal mass and/or structure with a consequent greater efficacy in reducing fracture risk.

When to use a bone-forming agent? The clinician's choice is often impacted by external influences, a common one being the presence of a steep cost gradient across the available treatment options. It is easily concluded that more expensive agents, such as bone-forming treatments, will be of greatest merit and utility when targeted to patients at high risk of fracture, where the greater absolute risk reduction will benefit the patient and address some of the concerns around cost-effectiveness. Indeed, this high risk population was reflected in the inclusion criteria for the two recent head-to-head studies. There is therefore a need to characterise high risk. While this has frequently been achieved by providing clinical exemplars of high risk (e.g. identification of subgroups with very low BMD T-scores, previous multiple fractures or a combination of clinical risk factors), the availability of risk assessment tools such as FRAX are likely to be of use in this setting. Indeed, several authorities, most notably the National Institute for Health and Care Excellence (NICE) in the UK, now incorporate such tools into health economic analyses that underpin clinical guideline development. This and other strategies will be explored in this plenary lecture.

Disclosures: Grants/research support from Amgen, ARUK, AstraZeneca, Consilient Healthcare, GSK, Hologic, I3 Innovus, Internis, IOF, Lilly, Merck, MRC, Novartis, Pfizer, Roche, Sanofi-Aventis, UCB, Unilever. Consultant for Amgen, Consilient Healthcare, Fresenius Kabi, GSK, Synexus, and UCB. Speaking fees from Agnovos, Amgen, AstraZeneca, Consilient Healthcare, GSK, Hologic, Internis, Lilly, Pfizer, Roche, Servier, and UCB.

PL2

BONE FRAGILITY AND ITS TREATMENT IN CHRONIC RENAL FAILURE

P. R. Ebeling¹¹Bone and Muscle Health Research Group, Department of Medicine, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia

Chronic kidney disease (CKD) is commonly associated with ageing. The majority has stage 1, 2 or 3 CKD with estimated glomerular filtration rates (eGFR) of ³90 mLs/min, 60-89 mLs/min, and 30-59 mLs/min, respectively. However, many have stage 4 CKD (15-29 mLs/min) and stage 5 CKD (<15 mLs/min) or are on dialysis. CKD is associated with excess morbidity, including fractures, and mortality. CKD-Metabolic Bone Disorder (MBD) occurs in stage 4 and 5 CKD, and is characterized by bone (renal osteodystrophy), soft tissue (calcifications), and mineral (phosphate, calcium, fibroblast growth factor-23, calcitriol, sclerostin, Dickkopf-1) abnormalities. Its pathological end-points are increased cardiovascular risk, mortality and fractures.

Hip fracture incidence is increased at every age for patients with Stage 3b, 4 and 5 CKD. Mortality after any fracture is also increased in patients with CKD, being highest in patients with Stage 5 CKD. It is unclear whether conventional anti-osteoporosis drugs are either appropriate, or effective, in patients with CKD. Prior reluctance to measure bone mineral density (BMD) using dual energy absorptiometry (DXA) in CKD was based on a poorer predictive value for fractures in patients with CKD. A reluctance to use anti-resorptive drugs, relates to the possibility of underlying adynamic bone disease and theoretical worsening of skeletal fragility. In adynamic bone disease, turnover is low, mineralization is normal, and volume is low, while in hyperparathyroidism, turnover is high, mineralization is normal, and volume is low. By contrast, in osteomalacia, turnover is low, mineralization is low, and volume is normal.

New 2017 KDIGO guidelines state that the optimal PTH level is not known. Instead, they emphasise a renewed focus on assessment of both fracture risk, using DXA, and bone turnover in individual patients with CKD Stage 3a-G5D, if these results will impact treatment decisions. In patients with high turnover bone disease, an anti-resorptive drug +/- vitamin D should be used, while in patients with low turnover bone disease, an anabolic drug +/- vitamin D should be used instead. The use of calcitriol or other active vitamin D analogs is reserved for patients with CKD stages 4-5 with severe and progressive hyperparathyroidism. Both risedronate and denosumab have been shown to reduce vertebral fractures in patients with milder CKD (stage 2-4 CKD for risedronate, and stage 2-3 CKD for denosumab). However, it should be noted that denosumab use can be associated with hypocalcaemia in stage 4 CKD patients and may probably best be avoided in stage 5D CKD.

Alternative 2017 European guidelines from ECTS and ERANDT recommend the combination of PTH levels with the bone formation marker, bone specific alkaline phosphatase (BSAP), which is not affected by renal function, remain the best non-invasive way

to divide patients into high or low bone turnover. However, in cases with either low PTH, or low or intermediate levels of BSAP, a bone biopsy may be required to exclude causes of low turnover renal osteodystrophy (adynamic bone disease and osteomalacia).

In conclusion, it is critical that an individual and tailored approach to managing bone disease is taken in patients with CKD.

PL3

EARLY TREATMENT OF OSTEOARTHRITIS

N. Arden¹

¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, United Kingdom

Osteoarthritis (OA) is one of the leading causes of pain and disability incurring substantial health sector costs, largely in the treatment of end stage OA, including joint replacement surgery. Currently, most healthcare resources is focused on the treatment of established knee OA, i.e. patients with chronic knee pain and evident radiographic changes of osteoarthritis. Classification criteria and clinical management guidance have been issued for such patients, attempting to decrease pain and maintain function and reduce the need for joint replacement. To date, few treatments have large, or even moderate effect sizes for the reduction of pain and increase in function. However, patients fulfilling the criteria for knee OA already have significant joint damage, involving several tissues such as cartilage, meniscus, underlying bone and synovium, often with substantial secondary biomechanical dysfunction. This makes it imperative to intervene earlier in the course of osteoarthritis, well before it becomes a multi-tissue disease and before an adverse biomechanical environment is produced.

In order to enable change from our current reactive approach of managing established osteoarthritis into a proactive one, with an emphasis on secondary prevention, and early intervention, we need to identify risk factors and diagnose OA early. Indeed, as demonstrated for rheumatoid arthritis and in animal models of osteoarthritis, there may be a window of opportunity in the early phase of the disease process to restore joint homeostasis. To achieve this, there is a clear need to more accurately define early OA, and come to validated classification criteria and relevant outcomes. This talk will discuss these issues in more detail.

PL4

MANAGEMENT OF KNEE OSTEOARTHRITIS IN 2019: AN UPDATED ALGORITHM FROM THE EUROPEAN SOCIETY FOR CLINICAL AND ECONOMIC ASPECTS OF OSTEOPOROSIS, OSTEOARTHRITIS AND MUSCULOSKELETAL DISEASES (ESCEO)

J.-Y. Reginster, on behalf of the ESCEO Working Group on knee osteoarthritis ^{1,2}

¹University of Liège, Liège, Belgium, ²Chair for Biomarkers and Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia

Osteoarthritis (OA) is the most common form of arthritis, and is characterized by joint pain and stiffness leading to functional decline and loss in quality of life. In 2014, ESCEO published recommendations for the management of knee OA in the form of a treatment algorithm that provides practical guidance for the prioritization of interventions and guides physicians through progressive logical steps. Since the publication of the ESCEO algorithm, considerable new evidence has been published, particularly regarding the safety of many medications commonly used to treat OA. Therefore, ESCEO revisited its treatment algorithm recommendations in the light of the new evidence and developed new recommendations based upon systematic literature review and application of the GRADE process. The combination of treatment modalities including non-pharmacological and pharmacological intervention remains key to the management of knee OA. As step 1 pharmacological treatment, ESCEO advocates the use of background therapy with chronic SYSADOAs, specifically pharmaceutical-grade prescription Crystalline Glucosamine Sulfate and Chondroitin Sulfate, for which the evidence is unequivocal. Recent concern over the safety profile of Paracetamol raises questions over its routine, chronic use, due to increasing evidence of adverse events. Topical NSAIDs may be added to step 1 background therapy or used in preference to oral NSAIDs, particularly in OA patients aged > 75 years and those with co-morbidities or at increased risk of systemic AES. If step 1 treatments show inadequate efficacy, or in patients presenting with moderate-severe pain, benefit may be obtained with advanced pharmacological treatments, such as oral NSAIDs. Oral NSAIDs selection should be based on the patients risk profile. Intra-articular Hyaluronic Acid may be a good alternative to NSAIDs for knee OA, with a better safety profile. Last pharmacological options for the severely symptomatic patients are represented by short-term weak opioids, such as Tramadol. Eventually, total knee replacement surgery is appropriate when all previous modalities have failed, or if the patients are severely symptomatic and they present significant loss in quality of life.

Participants to the ESCEO Working Group on knee osteoarthritis: Olivier Bruyère, PhD, Germain Honvo, MPh, Nicola Veronese, MD, Nigel K. Arden, MD, Jaime Branco, MD, PhD, Elizabeth Curtis, MD, Nasser M. Al-Daghri, MD, PhD, Gabriel Herrero-Beaumont, MD, Marc C. Hochberg, MD, PhD, Johanne Martel-Pelletier, PhD, Jean-

Pierre Pelletier, MD, PhD, François Rannou, MD, PhD, René Rizzoli, MD, Roland Roth, MD, Daniel Uebelhart, MD, Cyrus Cooper, FMed-Sci, Jean-Yves Reginster, MD, PhD

PL5

WHAT SPACEFLIGHT HAS TAUGHT US REGARDING BONE AND MUSCLE?

L. Vico¹

¹INSERM, U1059 Sainbiose, Université de Lyon, Saint-Etienne, France

Space sojourns are challenging for life. The ability of the human body to adapt to these extreme conditions has been noted since the beginning of human space travel. Musculoskeletal alterations that occur in crewmembers during spaceflight are now better understood, and murine models help researchers to understand cellular and matrix changes that occur in bone and that are difficult to measure in humans. It is thus established that spaceflight induces bone fragility at weight-bearing skeletal sites and increases bone resorption. Muscle volume is also lost, particularly in muscles such as the soleus, which is involved in maintaining posture against the force of gravity, despite extensive use of exercise countermeasures. Bone that is lost during space sojourns is not fully regained, and bone mass in the less weight bearing segments of the skeleton progressively deteriorates after landing. In mice, we demonstrated that spaceflight induces osteocyte death, which may trigger bone resorption and result in bone mass and microstructural deterioration. Muscle strength and endurance seem to recover after spaceflights. Cartilaginous tissues, such as intervertebral discs, lose structure and function in space and require effective countermeasures to facilitate readaptation to gravity upon landing.

Besides, questions remain with regard to interactions of the skeleton with fluid shifts towards the head and with the vascular system. Further investigations into the relationships between the musculoskeletal system, energy metabolism and sensory motor acclimatisation are needed.

Although space is a unique environment, clear parallels exist between the effects of spaceflight, periods of immobilization and ageing, with possibly irreversible features. Space travel offers an opportunity to establish integrated deconditioning and ageing interventions that combine nutritional, physical and pharmaceutical strategies.

PL6

PHARMACOLOGIC AGENTS FOR THE TREATMENT OF SARCOPENIA

R. Fielding¹

¹Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, United States

The age-related loss of skeletal muscle mass and function, sarcopenia, is associated with well-characterized functional limitations, physical disability, and distal clinically relevant outcomes such as falls, fractures, and death. Underlying these age-related changes are physiological changes in the force/power generating

capacity of skeletal muscle that appear to be driven by changes in skeletal contractile protein function, metabolic derangements and alterations in neuromuscular activation. Biologically-relevant age-associated changes in skeletal muscle biology include alterations in gene transcription, mitochondrial stability, anabolic capacity, and metabolic flexibility. Underlying molecular targets have been identified in skeletal muscle that are potential sites for the development of therapeutic interventions. In my presentation, I will provide a state of the art update on key therapeutics targets for components of the sarcopenia syndrome. Two major classes of therapies, selective androgen receptor activation (SARM) and inhibition of myostatin signaling (Anti-myostat), have emerged as leading targets for treatment of sarcopenia. However, more recently, additional relevant novel pathways have been uncovered that show promise. These include approaches that target skeletal muscle excitation-contraction coupling (E-C coupling) such as the selective activation of skeletal muscle troponin proteins, and targets that stimulate biogenesis or stability of mitochondria and their upstream activators (eg: sirtuins). I will summarize the available clinical trials data on these emerging novel pathways and discuss the barriers towards regulatory approval for these indications which include the development of an international consensus definition of sarcopenia and establishment of treatment guidelines.

PL7

TOOLS FOR ESTIMATING FRACTURE PROBABILITY

J. A. Kanis^{1,2}

¹Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, United Kingdom, ²Mary McKillop Health Institute, Australian Catholic University, Melbourne, Australia

A major objective of fracture risk assessment is to enable the targeting of interventions to those at need and avoid unnecessary treatment in those at low risk of fracture. Historically, fracture risk assessment was largely based on the measurement of bone mineral density (BMD), since osteoporosis is defined operationally in terms of bone mass. Whereas BMD forms a central component in the assessment of risk, the accuracy of risk prediction is improved by taking into account other readily measured indices, particularly those that add information to that provided by BMD. Several risk prediction models have been developed, but the most widely used is FRAX®. QFracture® in the UK and the Garvan instrument in Australia provide estimates of age- and sex-specific risk of fracture for their respective countries rather a fracture probability. Probability of fracture depends not only on the risk of fracture but also on the risk of death.

FRAX® (<http://www.shef.ac.uk/FRAX>) calculates the 10-year probability of a major fracture (hip, clinical spine, humerus or wrist fracture) and the 10-year probability of hip fracture alone. Probability is calculated from age, body mass index and well validated dichotomized risk factors. Femoral neck BMD can be optionally input to enhance fracture risk prediction. The first 8 models were launched in 2008 and there are currently 68 models in 63 countries covering more than 80% of the world population. With

the increasing geographic representation of FRAX, uptake has risen progressively and there are upwards of 3 million calculations undertaken each year on the web site and many more on bone densitometers, i-phones and hand-held calculators.

A major use of FRAX has been its incorporation into treatment and assessment guidelines. Since its release, FRAX has been integrated into more than 80 guidelines worldwide. The setting of universal intervention thresholds is problematic from an international perspective since the risk of fracture, the cost of fracture, the cost of treatment, reimbursement and willingness to pay, all differ by country. Thus, probability-based guidelines variously use an age-dependent fracture probability, or a fixed probability threshold applied to all relevant ages. In European guidelines, age-dependent fracture probabilities equivalent to women with a prior fragility fracture are recommended as intervention thresholds.

Whereas FRAX has traditionally been used for opportunistic case finding, the publication of the MRC/Arthritis Research UK SCOOP trial (SCreening of Older wOMen for the Prevention of fractures) provides strong support for a screening strategy. This seven-centre pragmatic randomised controlled trial with 5-year follow-up, included 12,483 women aged 70-85 years, who were randomised to receive a care algorithm including FRAX and drug targeting (n=6,233) or usual primary care for osteoporosis based on opportunistic case-finding (n=6,250). Women were recruited from 100 UK general practices, and the principal outcome measures were major osteoporotic, hip and all fractures. Screening reduced the incidence of hip fractures (HR=0.72, 95%CI=0.59-0.89, p=0.002). The effect on hip fracture increased significantly with baseline FRAX hip fracture probability; for example, at the 10th percentile of baseline FRAX hip probability (2.6%), hip fractures were not significantly reduced (HR 0.93, 0.71 to 1.23) but at the 90th percentile (16.6%), there was a 33% reduction (HR 0.67, 0.53 to 0.84). The screening algorithm resulted in a pronounced increase in the use of anti-osteoporosis medication, and greater compliance with therapy, over the period of follow-up and was shown to be cost effective. In conclusion, FRAX is well established as the globally most widely used risk assessment tool. The findings of the SCOOP trial strongly support an alteration of the current policy in many countries from that of opportunistic case finding to a FRAX-based systematic, community-based focused screening programme of fracture risk in older women. In addition, the strategy appears to be cost-effective.

PL8

OSTEOPOROSIS SCREENING AND FRACTURE RISK REDUCTION

C. Cooper^{1,2}

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ²Institute of Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

Osteoporosis constitutes a major public health problem through its association with age related fractures. These fractures typically occur at the hip, spine and distal forearm. It has been estimated from incidence rates derived in North America that the

lifetime risk of a hip fracture in Caucasian women is 17.5%, with a comparable risk in men of 6%. Age and sex-adjusted hip fracture rates are generally higher in Caucasian than in Asian populations. Furthermore, the pronounced female preponderance in fracture incidence observed in white populations is not seen amongst blacks or Asians in whom age-adjusted female to male incidence ratios approximate unity. Life expectancy is increasing around the globe and the number of elderly individuals is rising in every geographic region. Assuming constant age-specific incidence rates for fracture, the number of hip fractures occurring worldwide among people aged 65 years and over will rise from 1.66 million in 1990 to 6.26 million in 2050. Studies performed in the United States, Scandinavia, and the United Kingdom, between 1930 and the late 1980s, consistently reported increases in the age-adjusted incidence of hip fractures among men and women. This increase appears to have levelled off, in the northern regions of the United States, as well as more recently in Europe. Rates in Asian populations continue to show substantial rises between the 1960s and the present time. In 2008, following a major systematic review of the literature, a fracture risk assessment tool was constructed (FRAX). This is now utilised to derive 10-year absolute risks of hip and major osteoporotic fractures. Application of this risk stratification system has been shown capable of reducing hip fracture risk by 24% in a large UK population-based randomised controlled trial (SCOOP). Further modification of this tool and development of preventive strategies against first and subsequent fractures will offer scope for even greater reductions in incidence: an enticing prospect.

PL9

VITAMIN D – HOW MUCH IS TOO MUCH?

B. Dawson-Hughes¹

¹Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, United States

Muscle weakness is a classical feature of vitamin D deficiency but evidence is accumulating that over-replacement with large doses of vitamin D can adversely affect muscle function and increase the risk of falls and fractures. An initial report that supplementation with 300,000 IU of vitamin D₂ given intramuscularly annually for 3 years to older adults significantly increased the risk of hip fracture was followed by another report in which high annual dosing with vitamin D significantly increased the number of falls and fractures in women age 70 years and older. Increased risk of falling has subsequently been observed in a trial that employed monthly dosing with 60,000 IU of vitamin D₃. The comparator group in this trial received 24,000 IU per month. Two trials have tested the effect of 100,000 IU of vitamin D per month on fall risk, one in community-dwelling elders and the other in nursing home residents. This dose had no effect on fall risk in the community-dwelling elders but it doubled risk of falling in the nursing home residents. Supplemental vitamin D is variably reported to be mildly favorable, null, and mildly harmful in its effect on muscle mass, strength and function in older adults. In conclusion, high intermittent doses of vitamin D have significant potential to increase risk of falls and fractures in older adults. Vitamin D supplementation

of deficient patients is appropriate and important but excess vitamin D, particularly in high intermittent doses, is counterproductive and should be avoided.

PL10

DIETARY PROTEIN, DAIRY AND BONE: DEVILS OR ANGELS ?

R. Rizzoli¹

¹Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

Several nutritional insufficiencies contribute to bone mass loss and bone structure alterations, and a loss in muscle mass and function. Adequate supplies of dietary protein are required for optimal bone growth and for maintaining the integrity and function of bone and skeletal muscles. In the elderly, protein undernutrition can favour the occurrence of hip fracture by increasing the propensity to fall, by affecting protective mechanisms, such as reaction time or muscle strength, and/or by decreasing bone mass. In adults, bone mineral density (BMD) is positively correlated to dietary protein intakes. Variation in protein intakes within the 'normal' range accounts for 2–4% of BMD variance. Regarding bone microstructure, which is another important determinant of bone strength not captured by BMD, estimated from microstructure bone strength, trabecular and cortical microstructure are positively correlated with total protein intakes. Mainly animal proteins, especially dairy proteins, are correlated with bone strength. In older people with osteoporosis, higher protein intake (≥ 0.8 g/kg body weight/day, ie above the current RDA) is associated with a slower rate of bone loss, and reduced risk of hip fracture, provided that dietary calcium intakes are adequate. Intervention with dietary protein supplements attenuate age-related BMD decrease, and reduce bone turnover markers levels, together with an increase in IGF-I and a decrease in PTH. In a balanced western diet, dairy products are responsible for about 50 to 70% of total dietary calcium intakes and 20-28% of total protein intakes in adults. By providing calcium and protein, dairy products may help to maintain bone health during aging. Dairies have been shown to be a cost-effective way of reducing fracture risk. Within a usual protein diet, there is no evidence that diet-derived acid load is deleterious for bone health. Thus, insufficient dietary protein intakes may be a more severe problem than protein excess in the elderly.



2019 PARIS

**WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES**

PARIS, France | 2019

Abstract Book

**Oral Communications
Abstracts**

OC1

HORMONE THERAPY REDUCES THE RISK OF FRACTURE IN FALLERS AND IN NON-FALLERS: RESULTS FROM THE WOMEN'S HEALTH INITIATIVE HORMONE THERAPY TRIALS

M. Lorentzon¹, H. Johansson², N. C. Harvey³, E. Liu⁴, J. Crandall⁵, E. V. McCloskey⁶, J. A. Kanis⁷

¹Geriatric Medicine, University of Gothenburg and Sahlgrenska University Hospital, Mölndal, Sweden, ²Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Centre for Metabolic Bone Diseases, University of Sheffield and Mary McKillop Health Institute, Australian Catholic University, Melbourne, Australia, ³MRC Lifecourse Epidemiology Unit, University of Southampton and NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK, ⁴Mary McKillop Health Institute, Australian Catholic University, Melbourne, Australia, ⁵David Geffen School of Medicine at the University of California, Los Angeles, USA, ⁶Mellanby Centre for bone research, Department of Oncology and Metabolism and Centre for Integrated research in Musculoskeletal Ageing (CIMA), Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK, ⁷Centre for Metabolic Bone Diseases, University of Sheffield and Mary McKillop Health Institute, Australian Catholic University, Melbourne, Australia

Objective: To determine if the anti-fracture efficacy of hormone therapy (HT) was dependent on falls risk in a combined analysis of the two WHI HT trials.

Methods: 27 347 postmenopausal women aged 50-79 y were enrolled, comprising 16 608 women with, and 10 739 women without, an intact uterus. At baseline, information regarding falls was recorded in 25 389 women using questionnaires, and fallers were defined as those reporting ≥1 fall in the last 12 months. Incident clinical fractures, other than fractures of the fingers, toes, ribs, sternum, skull, face and cervical vertebrae, were verified using medical records. An extension of Poisson regression was used to investigate the relationship between treatment and fractures in fallers and non-fallers and an interaction term for previous falls and treatment.

Results: In the two trials combined, 13 816 women were randomized to 0.625 mg daily conjugated equine estrogen with or without 2.5 mg daily medroxyprogesterone acetate and 13 531 women to placebo. Over 8.1±1.4 y, treatment significantly reduced the risk of any fracture (hazard ratio [HR] 0.77 [95%CI, 0.72-0.82]), major osteoporotic fracture (HR 0.71 [95%CI, 0.65-0.78]) and hip fracture (0.78 [95%CI, 0.63-0.95]). Treatment was similarly effective in both fallers and in non-fallers (Table) and there was no interaction between treatment effect and falls risk (p>0.30). Statistical adjustment for randomization status in the calcium/vitamin D and low-fat diet WHI trials, did not affect these results.

Table. Treatment effect in fallers and in non-fallers, adjusted for age and time since baseline

Fracture type	Effect of hormone therapy	
	Within Non-fallers (n=16 868)	Within Fallers (n=8521)
Any	0.75 (0.69, 0.82)	0.79 (0.71, 0.88)
Major osteoporotic Hip	0.72 (0.64, 0.81)	0.70 (0.61, 0.81)
	0.77 (0.59, 1.01)	0.79 (0.58, 1.08)

Conclusions: Our results indicate that falls risk does not affect HT's ability to reduce the risk of fracture in postmenopausal women.

Acknowledgement: The National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. WHI project:3572

OC2

ROMOSUZUMAB EFFICACY ON FRACTURE OUTCOMES IS GREATER IN PATIENTS AT HIGH BASELINE FRACTURE RISK: A POST HOC ANALYSIS OF THE FRAME STUDY

E. V. McCloskey¹, M. Lorentzon², H. Johansson³, N. C. Harvey⁴, J. A. Kanis⁵

¹Department of Oncology & Metabolism, University of Sheffield, Sheffield, UK, ²Geriatric Medicine, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK, ⁵Mary McKillop Health Institute, Australian Catholic University, Melbourne, Australia

Post hoc analyses of placebo-controlled studies of several osteoporosis treatments have shown significantly greater reductions of fracture incidence in patients at higher fracture risk. We aimed to determine the interaction, if any, between baseline FRAX fracture probability and the efficacy of romosozumab (Romo) in the placebo-controlled first year of the FRAME study.

Using an ITT approach, we used an extension of Poisson regression analysis to study the relationship between treatment/placebo, FRAX 10-year probability of major osteoporotic fracture (MOF, calculated without BMD) and the risk of first incident fracture, adjusting for age and follow-up time. Treatment interactions considered the following fracture outcomes: all clinical fractures, osteoporotic fractures, MOF, clinical vertebral fractures and morphometric vertebral fractures. Two-sided p-value of <0.1 for the interaction between treatment and FRAX was considered significant.

Compared to placebo, Romo reduced the incidence of all fracture outcomes in the first year, ranging from a 32% reduction in MOF (p=0.07) to an 80% reduction in clinical vertebral fractures (p=0.038). Significant interactions were observed between efficacy and baseline FRAX probability, for the outcomes of clinical

fractures, osteoporotic fractures, and MOF ($p=0.064-0.084$), but not for vertebral fractures ($p>0.3$). For example, Romo decreased clinical fractures by 22% at the 25th centile of FRAX probability but the reduction was 41% at the 75th centile; in contrast, vertebral fractures were reduced by a similar extent regardless of baseline risk. An analysis of the nonvertebral components of each of the fracture outcomes showed even stronger interactions with baseline FRAX probability ($p=0.036-0.046$).

We conclude that the efficacy of romosozumab on clinical fracture, osteoporotic fracture and major osteoporotic fracture is significantly greater in patients at high baseline fracture risk, when compared to placebo.

OC3

ROMOSUZUMAB ENHANCES 3D VERTEBRAL STRUCTURE IN WOMEN WITH LOW BONE DENSITY: MAPPING BONE GAINS AT ONE YEAR COMPARED WITH TERIPARATIDE OR PLACEBO

K. E. S. Poole¹, G. M. Treece¹, R. A. Pearson², A. H. Gee¹, M. A. Bolognese³, J. P. Brown⁴, S. Goemaere⁵, A. Grauer⁶, D. A. Hanley⁷, C. Mautalan⁸, C. Recknor⁹, Y. C. Yang⁶, C. Libanati¹⁰, T. Whitmarsh¹

¹University of Cambridge, Cambridge, UK, ²University of Canterbury, Canterbury, UK, ³Bethesda Health Research Center, Bethesda, USA, ⁴CHU de Québec Research Centre and Laval University, Quebec, Canada, ⁵Ghent University Hospital, Ghent, Belgium, ⁶Amgen, Thousand Oaks, USA, ⁷University of Calgary, Calgary, Canada, ⁸Centro de Osteopatias Medicas, Buenos Aires, Argentina, ⁹United Osteoporosis Centers, Gainesville, USA, ¹⁰UCB, Brussels, Belgium

The magnitude and location of vertebral bone accrual by romosozumab, teriparatide and placebo is of great interest. Romosozumab monoclonal antibody treatment for osteoporosis prevented vertebral fractures in recent trials by binding sclerostin and causing rapid stimulation of bone formation while decreasing bone resorption. During 12 consecutive, monthly romosozumab injections, women sustained 73% fewer vertebral fractures vs. placebo.

Baseline and one-year computed tomography scans were performed in a phase 2 randomised clinical trial in postmenopausal women with low BMD. Scans were done at enrolment and 12 months post-treatment with romosozumab (210 mg SC QM, $n=17$), placebo (SC QM, $n=20$) or open-label daily teriparatide (TPTD, 20 ug, $n=19$). Maps of the cortical and cancellous bone changes in lumbar vertebrae were statistically analysed, then visualised on the bone surface in 3D. The cortical and endocortical thickness was determined using the method of Pearson & Treece (MIA 2017). Cortical thickness (CtTh), endocortical thickness (EcTh), and cancellous BMD (CnBMD) were measured over each L1 vertebral surface.

Treatment groups were balanced at baseline. By one-year, romosozumab treatment had resulted in a mean vertebral CTh increase of +10.3% (95%CI (7.8, 12.8) vs. TPTD +4.3% (2.6, 5.9); $p=0.000099$), a CnBMD increase of +22.7% (19.0, 26.4) vs. TPTD

+16.9% (11.7, 22.1; $p=0.035$), and an EcTh increase of +37.2% (27.7, 46.7) vs. TPTD +12.3% (6.9, 17.7), $p=0.000081$. Cortical maps showed the precise topographical locations of the increase in bone compared with placebo; in fracture-prone areas of the vertebral shell, walls and endplates. The only significant change in the placebo group was a decrease in CnBMD of -3.4% (-1.2, -5.6).

Treatment with romosozumab was associated with large improvements in bone structural parameters of lumbar vertebrae, including the cortex. At 12 months (the mid-point of a typical teriparatide course) structural improvements with daily teriparatide injections were also substantial, but statistically significantly lower than with romosozumab injected monthly. This study confirms widespread vertebral bone accrual with anabolic treatments and provides new insights into how the rapid prevention of vertebral fractures is achieved in women with osteoporosis.

Acknowledgment: Funding by Amgen and NIHR Cambridge Biomedical Research Centre.

OC4

EFFECT OF ABALOPARATIDE ON BONE MINERAL DENSITY AND FRACTURE INCIDENCE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND OSTEOARTHRITIS

N. E. Lane¹, B. Mitlak², R. Weiss², Y. Wang², G. J. Valenzuela³, J. P. Bilezikian⁴

¹University of California at Davis, School of Medicine, Sacramento, USA, ²Radius Health, Inc., Waltham, USA, ³Integral Rheumatology & Immunology Specialists, Plantation, USA, ⁴Columbia University College of Physicians and Surgeons, New York, USA

Objective: To evaluate the efficacy and safety of abaloparatide (ABL) in patients with osteoarthritis (OA) enrolled in ACTIVE.

Methods: In ACTIVE, 2463 postmenopausal women with osteoporosis (OP) were randomized 1:1:1 to double-blind daily ABL 80 µg or placebo (PBO), or open-label teriparatide (TPTD) 20 µg, SC for 18 months. Patients were identified as those with medical history of ongoing "osteoarthritis", "spinal osteoarthritis", "nodal osteoarthritis", or "intervertebral disc degeneration." New vertebral fracture (VF) incidence was evaluated using the modified intent-to-treat (mITT) population, other efficacy endpoints were evaluated using the ITT population. The percent mean changes in BMD from baseline to 18 months were calculated.

Results: A total of 888 patients with ongoing OA were identified in three treatment groups; ABL ($n=291$), PBO ($n=303$), and TPTD ($n=294$) [overall median age: 70 y; range: 50-85 y; mean femoral neck T-score: -2.10]. Most common sites of OA were the spine ($n=336$, 38%) and knee ($n=328$, 37%). At baseline, 196 (22%) patients had a prevalent VF, 208 (23%) reported ≥ 1 prior nonvertebral fractures (NVF) within the last 5 y, and 369 (42%) had no prior fractures. Percent experiencing any new VF were 0%, 5.1%, and 0.4% in ABL, PBO, and TPTD, respectively (ABL vs. PBO, $P<0.001$). Kaplan-Meier estimated cumulative incidence for other fracture endpoints was similar across treatment groups. At 18 months, significant BMD increases ($P<0.0001$) from baseline were ob-

served for ABL vs. PBO at the total hip (mean change 3.17% vs. -0.35%), femoral neck (2.81% vs. -0.36%), and lumbar spine (8.78% vs. 0.86%), consistent with the overall ACTIVE population. Most common TEAEs were hypercalciuria (11% vs. 10.2%), dizziness (10.7% vs. 6.6%), increased creatinine clearance (8.9% vs. 10.6%), upper respiratory tract infection (8.6% vs. 6.9%), and back pain (7.9% vs. 11.6%) for ABL vs. PBO groups, respectively.

Conclusions: Among postmenopausal women with OP in ACTIVE, in a subpopulation with prevalent OA, ABL resulted in significant reduction in risk of new VF as well as significant improvements in BMD, vs. PBO. Results suggest ABL may be useful in the treatment of women with postmenopausal OP and concurrent OA, at high risk for fracture.

OC5 BUROSUMAB IMPROVES THE BIOCHEMICAL, SKELETAL, AND CLINICAL SYMPTOMS OF TUMOR-INDUCED OSTEOMALACIA (TIO) SYNDROME

S. Jan de Beur¹, P. Miller², T. Weber³, M. Peacock³, K. Insogna⁴, R. Kumar⁵, D. Luca⁶, T. Cimms⁶, K. Lampl⁶, J. San Martin⁶, T. Carpenter⁴


¹Johns Hopkins University School of Medicine, Baltimore, ²Colorado Center for Bone Research, Lakewood, ³Duke University, Durham, ⁴Yale University School of Medicine, New Haven, ⁵Mayo Clinic College of Medicine, Rochester, ⁶Ultranexy Pharmaceutical Inc., Novato, USA

Objective: Evaluate the efficacy and safety of burosumab, a fully human monoclonal antibody to FGF23, in adults with TIO and epidermal nevus syndrome with osteomalacia (ENS).

Methods: In an open-label Phase 2 study (NCT02304367), 17 adults with TIO (16) and ENS (1) received burosumab. Key endpoints were changes in serum phosphorus and osteomalacia as assessed from transiliac crest bone biopsies. The per protocol (PP) analysis set included 14/17 subjects who received 0.3-2.0 mg/kg burosumab every 4 weeks (W). Three subjects were excluded: 1 received subthreshold dosing (0.3 mg/kg at Day 0 and 0.15 mg/kg at W8, W32, and W72); 2 were diagnosed with X-linked hypophosphatemia post-enrollment.

Results: In the PP analysis set, mean (SD) serum phosphorus was 0.49 (0.09) mmol/L at baseline and 0.85 (0.25) mmol/L when averaged across the midpoint of the dose interval through W24; this increase was maintained through W72 when measurements occurred only at the end of the dose interval. Ten subjects in the PP analysis set completed paired bone biopsies at baseline and W48. At baseline 2/10 subjects had no osteomalacia, 2/10 subjects had mild or moderate osteomalacia, and 6/10 subjects had severe osteomalacia. Histomorphometric measures improved in the 8/10 subjects with TIO who showed osteomalacia at baseline (**Figure**). Mean (SD) global fatigue score decreased from 5.3 (2.8) at baseline to 3.6 (2.9) at W48 (p=0.020) and to 3.3 (2.7) at W72 (p=0.004). The SF-36 mean (SD) physical component summary score increased from 34 (11) at baseline to 39 (10) at W48 (p=0.059) and to 42 (10) at W72 (p=0.003). By W72, all 17 subjects had at least 1 adverse event (AE). Thirteen serious AEs

occurred in 6 subjects, none were drug-related. Tumor progression occurred only in subjects with a prestudy history of tumor progression. One subject discontinued treatment prior to W48 to treat tumor progression. There was 1 death, considered unrelated to treatment.



X indicates mean; Imputed results are used for Mineralization Lag Time (Baseline 5/7 subjects, Week 48 2/8 subjects); ^aRecker et al. *J Bone Miner Res.* 1988;3(2):133-44; ^bP-valued based on mean change from baseline, except for mineralization lag time, which is based on median change from baseline

Conclusion: In adults with TIO Syndrome, burosumab was associated with improvements in serum phosphorus, osteomalacia, physical functioning and reductions in fatigue.

OC6

IMMINENT (1- AND 2-YEAR) FRACTURE RISK FOLLOWING A FIRST (SENTINEL) FRACTURE: A MULTINATIONAL EUROPEAN COHORT STUDY INCLUDING OVER 700,000 PARTICIPANTS FROM DENMARK, SPAIN, AND THE UK

S. Khalid¹, M. T. Ernst², M. A. Javaid¹, C. Libanati³, C. Cooper¹, A. Delmestri¹, D. Martinez-Laguna⁴, E. Toth⁵, B. Abrahamsen², D. Prieto-Alhambra¹

¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, ²Odense Patient Data Explorative Network OPEN, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark, ³UCB Biopharma Sprl, Brussels, Belgium, ⁴GREMPAL Research Group, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain, ⁵UCB Biopharma Sprl, Allée de la Recherche, Brussels, Belgium

Objective: There is inconsistent data on the magnitude of short-term fracture risk following a first fracture. We aimed to estimate imminent (1- and 2-y) fracture risk in real world cohorts of fractured patients from Denmark (DK), Spain (ES), and the UK (UK).

Methods: Patients aged 50+ with a first incident fracture (6-month wash-out), were identified in three routinely collected data from the UK (CPRD GOLD), Spain (SIDIAP), and DK registries. CPRD and SIDIAP are primary care records linked to hospital inpatient, whilst the latter accounts for hospital contacts (including outpatient). Participants were followed from first fracture to another fracture, death, transfer, or end of study (1 or 2 y after index). Incidence rates and 95% CIs of fracture were calculated overall and stratified by sentinel fracture site and age.

Results: In total, 593,503 (DK), 55,304 (ES), and 83,514 UK patients were included. Average age and % of gender ranged from 70.2 (Spain) to 78.9 (UK) years old, and from 69% (Denmark) to 77.8% (UK) women. Imminent (1-y) rates of new fracture (/1000 person-years) were 24.1 [95CI 23.7 – 24.6], 8.8 [95CI 8.0 – 9.6], and 18.1 [95CI 17.1 – 19.1] for new hip fracture/s in Denmark, Spain, and the UK respectively; 3.7 [95CI 3.5 – 3.9], 8.9 [95CI 8.1 – 9.7], and 2.8 [95CI 2.4 – 3.2] for clinical spine; and 54.4 [95CI 53.7 – 55.1], 68.0 [95CI 65.7 – 70.3], and 80.3 [95CI 78.1 – 82.4] for non-hip non-spine fractures. Rates in the second year were similar if slightly lower. Risk increased with age, and was higher for those with a sentinel hip or clinical spine fracture.

Conclusion: Overall, annual imminent fracture risk is around 10% in the first year following a first fracture, and higher in older patients and after a hip or clinical spine fracture. Rates were similarly high in all three countries, highlighting the need for immediate secondary prevention measures following a sentinel fracture.

Disclosures: DPA's institution has received research grants, speaker, and advisory board fees from Amgen, research grants from Servier Laboratoires and UCB Pharma, and consultancy fees from UCB; CC reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB; MKJ reports personal fees from

Amgen outside the submitted work; DML reports personal fees from Amgen, Lilly, Novartis, Ferrer and RUBIÓ outside the submitted work; BA reports research support from Novartis and UCB and advisory board and consulting fees from UCB; CL and ET are employees and own stock of UCB.

OC7

ADJUSTING FRAX FOR IMMINENT RISK

H. Johansson¹, K. Siggeirsdottir², N. C. Harvey³, E. V. McCloskey⁴, V. Gudnason², G. Sigurdsson², M. Lorentzon⁵, E. Liu¹, J. A. Kanis¹

¹McKillop Health Institute, Australian Catholic University, Melbourne, Australia, Melbourne, Australia, ²Icelandic Heart Association, Kopavogur, Iceland, Kopavogur, Iceland, ³MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK, ⁴Center for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK, ⁵Geriatric Medicine, Sahlgrenska University Hospital, Mölndal, Sweden

Objectives: The impact of fracture on subsequent fracture risk appears greatest in the early years after fracture (imminent risk). We wished to compare the 10-y probability of a major osteoporotic fracture (MOF) in women in the 2 y after an incident ('sentinel') clinical vertebral fracture to that in women with any previous fracture in adult life.

Methods: The analysis was conducted within an Icelandic population-based cohort of 18,873 men and women born between 1907-1935 (mean age 53 y), with incident fractures documented over 510,265 person-years of follow-up. The 10-y empirical (i.e. not FRAX) probability of a subsequent MOF was calculated for the subcohort of women experiencing a sentinel clinical vertebral fracture up to 2 y previously. This was compared to probabilities calculated with the Iceland FRAX model for age-matched women with any previous fracture, using a simulated population with a prevalence and distribution of FRAX risk factors similar to the cohorts used to develop FRAX.

Results: Sentinel clinical vertebral fractures occurred in 1003 women. The empirical 10-y probability of MOF was consistently higher in this subgroup than the FRAX probability in the population of the same age with any previous fracture, but the relative risk (observed/expected probability) varied by age. For example, the relative risk at the age of 50 y for a woman with a clinical vertebral fracture within the previous 2 y was 2.5; for the age of 80 y, the ratio was 1.2 (Table).

Conclusions: 10-y FRAX probabilities can be adjusted in the presence of a recent fracture and are likely to be useful in treatment decision-making. The impact is age-dependent.

Table. 10-y probability of MOF for Icelandic women at different ages, categorized by previous fracture (see text)

Age	10 year probability of MOF		Ratio
	Cohort with clinical vertebral fracture 0-2 years ago	Cohort with any previous fracture in adult life	
50	29.0	11.7	2.47
60	36.1	19.4	1.86
70	41.9	27.6	1.52
80	42.5	34.2	1.24
90	34.7	33.3	1.04

OC8

AGE AT HIP FRACTURE: TIME TRENDS OVER TWO DECADES IN A NATIONAL HOSPITAL DISCHARGE REGISTER

B. Abrahamsen¹, H. V. B. Laursen², M. K. Skjødt³, M. H. Jensen⁴, P. Vestergaard⁴


¹Odense Patient Data Explorative Network, University of Southern Denmark, Odense ²Department of Health Science and Technology, Aalborg University, Aalborg, ³Holbæk Hospital, Department of Medicine, Holbæk, ⁴Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark

Objective: Recent years have seen an improvement in the overall health of the oldest old in Western Europe and a significant decline in hip fracture rates. We speculated that better health and more widespread initiatives to treat osteoporosis and prevent falls would have led to a delay in hip fractures and hence an increasing mean age of the hip fracture population.

Methods: National information in the Danish Hospital Discharge Register was obtained (access granted by Statistics Denmark under ref 703382) for a calculation of the age distribution of femoral neck fractures and intratrochanteric fractures, allowing only the first fracture at each of these two sites to contribute to the analysis in each calendar year. Only primary diagnoses were considered in this analysis.

Results: Over the period 1996-2017, the mean age at the time of femoral neck fracture was 77.0 year and for intratrochanteric fractures 78.9 years. For both types of fracture (Fig 1), we noted a very slow increase in mean age over the two decades, corresponding to an increment in the mean age of femoral neck fracture patients of 8.4 days per calendar year and for intratrochanteric fractures of 5.3 days per calendar year.

Age at fracture



Conclusions: Despite reports of improved health in the oldest old, we did not observe a clinically significant change in the mean age of the hip fracture populations in Denmark from 1996 to 2017.

OC9

T-SCORE AS AN INDICATOR OF FRACTURE RISK ON THERAPY: EVIDENCE FROM ROMOSUZUMAB VS. ALENDRONATE TREATMENT IN THE ACTIVE-CONTROLLED FRACTURE STUDY IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK TRIAL

F. Cosman¹, E. M. Lewiecki², P. R. Ebeling³, E. Hesse⁴, N. Napoli⁵, D. B. Crittenden⁶, M. Rojeski⁶, W. Yang⁶, C. Libanati⁷, S. L. Ferrari⁸

¹Columbia University, New York, USA, ²New Mexico Clinical Research & Osteoporosis Center, Albuquerque, USA, ³Monash University, Melbourne, Australia, ⁴University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁵Campus Bio-Medico University of Rome, Rome, Italy, ⁶Amgen Inc., Thousand Oaks, USA, ⁷UCB Pharma, Brussels, Belgium, ⁸Geneva University Hospital, Geneva, Switzerland


Objective: BMD achieved on treatment may reflect fracture (fx) risk; thus, T-scores are being considered as a target to guide osteoporosis treatment. In the ARCH trial (NCT01631214), romosozumab (Romo), an investigational bone-forming agent with a dual effect of increasing bone formation and decreasing bone resorption, followed by alendronate (ALN) had greater efficacy in fx

risk reduction and BMD gains vs. ALN alone (Saag NEJM 2017). Here we explored the relationship between T-scores achieved on-study after 1 y with Romo or ALN and subsequent fx risk.

Methods: Postmenopausal women with osteoporosis and prior fragility fx were randomized 1:1 to receive Romo 210 mg SC QM or ALN 70 mg PO QW for 12 months, followed by open-label (OL) ALN 70 mg PO QW for ≥ 12 months, with an event-driven primary analysis. We examined change from baseline in BMD and T-scores at 12 months and the relationship between total hip T-scores at month 12 and subsequent nonvertebral (NVT) fx rates. We also compared fx rates in the OL period, including new vertebral (VT) fx in year 2 (based on month 24 spine radiographs) and clinical, NVT, and hip fx between arms in the full OL period.

Results: ARCH enrolled 4093 patients (2046 Romo, 2047 ALN); mean baseline T-scores were -2.96 at the lumbar spine and -2.80 at the total hip. 3465 patients (1739 Romo, 1726 ALN) received ≥ 1 OL ALN dose in the OL period (median 1.9 years follow-up). Mean total hip BMD increased by 6.2% for Romo and 2.8% for ALN in the first year, with increases in T-score of 0.31 and 0.15, respectively. At month 12, the achieved total hip T-score was associated with the 1-year NVT fx rate observed in the OL period (Figure) and the relationship was independent of the drug received in the first year. During the OL period, when all patients were on ALN, patients who received Romo first had a 75% lower relative risk of new VT fx ($P < 0.001$), and had reductions in clinical (32%, $P = 0.001$), NVT (19%, $P = 0.120$), and hip (40%, $P = 0.041$) fx vs. patients who received ALN first.

Figure. Month 12 Total Hip T-score and Nonvertebral Fracture Rate During the Open-label Period.



The dashed lines indicate upper and lower 95% confidence intervals. Likelihood ratio test $P < 0.001$.

Conclusions: Higher absolute total hip T-scores achieved on therapy at month 12 resulted in subsequent lower fx risk regardless of the treatment received, with ongoing benefits from building a BMD foundation. These data support the concept of a T-score target to improve outcomes in osteoporosis treatment.

Disclosures: This study was sponsored by Amgen Inc., Astellas, and UCB Pharma. F. Cosman has grant/research support from Amgen and Eli Lilly and consultant/speaker's bureau/advisory activities with Amgen, Merck, Radius, Tarsa, and Eli Lilly; EM Lewiecki has grant/research support and consultant/speaker's bureau/advisory activities with Amgen and Radius; PR Ebeling has grant/

research support from Amgen and Eli Lilly and consultant/speaker's bureau/advisory activities with Amgen, Alexion, and Eli Lilly; E Hesse has consultant/speaker's bureau/advisory activities with AgNovos, Amgen, and Eli Lilly; N Napoli has consultant/speaker's bureau/advisory activities with Amgen, Eli Lilly and UCB Pharma; DB Crittenden, M Rojas, and W Yang are company employees and have stock ownership or royalties with Amgen; C Libanati is a company employee and has stock ownership or royalties with UCB Pharma; and S L Ferrari has grant/research support with Amgen, UCB Pharma, and MSD and consultant/speaker's bureau/advisory activities with Amgen, UCB Pharms, Labatec, AgNovos, and Eli Lilly.

OC10

FRACTURE INCIDENCE AFTER DENOSUMAB DISCONTINUATION: REAL-WORLD DATA FROM A LARGE HEALTHCARE PROVIDER

L. Tripto-Shkolnik¹, N. Fund², V. Rouach³, G. Chodick⁴, V. Shalev⁵, I. Goldshtein⁶

¹Division of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, ²Institute of Research and Innovation, Maccabi Healthcare Services, Tel Aviv, ³Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center, Tel Aviv, ⁴Institute of Research and Innovation, Maccabi Healthcare Services, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, ⁵Institute of Research and Innovation, Maccabi Healthcare Services and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, ⁶Institute of Research and Innovation, Macabi Healthcare Services, Tel Aviv, Israel

Objective: Vertebral fractures (VF) upon denosumab discontinuation were first described as a distinct phenomenon in 2015, yet the magnitude of this event is still to be determined. **Our aim was to estimate the incidence of fractures after denosumab discontinuation, in a real-world setting.**

Methods: The computerized database of Maccabi Healthcare Services comprising over 2 million individuals, was retrospectively studied. Patients with at least two denosumab dispenses were included. Treatment discontinuation was defined as a gap of 3 months or more after an anticipated denosumab dose. Fractures were identified by coded diagnoses and adjudicated by an electronic medical record review. Fractures occurring within a year from discontinuation among denosumab discontinuers (DD) and from the first year of treatment onwards for persistent users (PU) were included. Fracture incidence rate was analyzed per 100 patient-years of follow-up (100PYFU).

Results: A total of 1500 DD and 1610 PU were identified (91.8% vs. 90.7% women, age 71.8 ± 9.5 vs. 71.7 ± 8.8). The groups did not differ in the percentage of patients with previous fractures (39.9 vs. 39), prevalent VF (16.9 vs. 16.8), bisphosphonate exposure (30.3 vs. 27.9), current smoking (6.5 vs. 5.2) and rheumatoid arthritis (6.4 vs. 6), for DD and PU, respectively. T-score was lower in the PU (-2.67 ± 0.76 vs. -2.53 ± 0.78 , $p < 0.001$). Among DD, 12 patients (0.8%) suffered from multiple VF, vs. 2 (0.1%) in the PU group ($p < 0.05$). The overall rate of fractures per 100PYFU was significantly higher in DD than PU (5.12(3.31-7.84) vs. 1.59 (0.96-

2.63)). The rate of all VF per 100PYFU was higher in the DD group (1.99(1.15-3.43) vs. 0.43(0.02-0.91)), as was the rate of multiple VF (1.14(0.55-2.34) vs. 0.08(0.02-0.4)).

Conclusions: VF, including multiple VF occur more often in patients who discontinue denosumab treatment, yet the overall incidence is low. Doctors, patients and healthcare organizations need to be aware of this phenomenon and measures must be taken to prevent unscheduled treatment discontinuation.

Acknowledgement: This is an investigator-initiated study, supported by Amgen

OC11

CARDIOVASCULAR COMORBIDITIES HAS A DELETERIOUS INFLUENCE ON KNEE OA PROGNOSIS AT 5 YEARS: DATA FROM THE PROSPECTIVE KHOALA COHORT

C. Roubille¹, J. Joel², S. Sellam³, A. C. Rat⁴, F. Guillemin⁴, C. Roux⁵

¹Internal Medicine and Hypertension Department, Lapeyronie Hospital, Montpellier University, Montpellier, ²Biostatistics and Epidemiology Unit, Hôtel Dieu Hospital, Paris, Nice, ³Department of Rheumatology, Assistance Publique - Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, Paris, ⁴EA 4360 APEMAC, Université de Lorraine, Nancy, ⁵University Cote d'Azur, Lamhess, IBV, Chu de Nice, Nice, France

Objectives: The long-term effect of comorbidities on progression of structural changes in osteoarthritis (OA) remains poorly understood. Patients with knee OA have been reported to be at increased risk of several comorbidities including cardiovascular diseases (CVD). Nevertheless, the impact of all comorbidities on structural progression and on arthroplasty, not only in knee but also in hip OA, should be further defined. The objective of our study was to explore the relationship between comorbidities and the progression of structural changes in symptomatic knee and/or hip OA patients over 5 y.

Methods: The KHOALA (Knee and Hip OsteoArthritis Long-term Assessment) cohort is a French prospective multicenter observational cohort that included 878 subjects, aged 40-75 y, with symptomatic hip and/or knee OA at baseline (Kellgren-Lawrence (KL) ≥ 2). The structural progression was defined by the increase of one point of KL ($\Delta KL \geq 1$) or incidence of total knee or hip replacement at 5 years. Various comorbidities were analyzed: cardiovascular diseases excluding hypertension (coronary artery disease, heart failure, stroke, lower limb arteriopathy), hypertension, diabetes, smoking, dyslipidemia, metabolic syndrome, osteoporosis, neurological (e.g., Parkinson's disease, dementia), digestive (e.g., gastroesophageal reflux disease, ulcer), pulmonary (e.g., asthma, COPD), and psychiatric (depression, anxiety) diseases. Multivariate analysis was performed separately in hip and knee OA adjusted on age, sex and BMI. Subjects with a BMI >30 kg/m² were excluded from the analysis given the close relationship between obesity and the different comorbidities analyzed. Subjects with KL=4 at the time of inclusion were also excluded from the analysis.

Results: Data from 631 nonobese subjects (BMI <30 kg/m²) were analyzed. At 5 y, CVDs were significantly associated with the 5-y KL change in knee OA (OR=2.6 [1.13-5.76], $p=0.02$) and with knee arthroplasty (OR=3.4 [1.1-11.2], $p=0.04$). Such associations were not found at the hip. Other comorbidities had no significant impact on knee OA structural progression. No significant relationship was found between any type of comorbidities and hip OA structural progression.

Conclusion: This 5-y data analysis of the KHOALA cohort revealed a significant association between cardiovascular comorbidities and structural progression of knee OA in subjects without obesity (BMI <30 kg/m²). Other types of comorbidities do not appear to influence the structural prognosis of OA. These results argue for an integrated management of cardiovascular comorbidities in knee OA patients and highlight the differences between hip and knee OA.

OC12

PREVALENCE OF SARCOPENIA ACCORDING TO THE REVISED EWGSOP DEFINITION AND ITS ASSOCIATIONS WITH BONE STRUCTURE AND INCIDENT FALLS IN SWEDISH OLDER ADULTS

D. Scott¹, J. Johansson², L. McMillan¹, P. Ebeling¹, P. Nordstrom³, A. Nordstrom⁴

¹School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia, ²Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway, ³Department of Community Medicine and Rehabilitation, Umeå University, Umeå, Sweden, ⁴Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden

Objectives: In 2018, the European Working Group on Sarcopenia in Older People (EWGSOP) revised its consensus definition of sarcopenia (EWGSOP2). We aimed to compare bone structure and likelihood of 12-month falls across EWGSOP2 sarcopenia categories in Swedish older adults.


Methods: 3334 community-dwelling 70-year-olds residing in Umea, Sweden, were included in this analysis. Appendicular lean mass (normalised to height (m²); ALMht), lumbar spine and total hip areal BMD (aBMD) were estimated by DXA. Trabecular and cortical volumetric BMD (vBMD) and architecture at the distal and proximal tibia and radius were estimated by peripheral quantitative computed tomography. Hand grip strength (HGS) was assessed by dynamometry and timed up-and-go (TUG) tests were performed. Sarcopenia categories were: "probable sarcopenia" (low HGS), "confirmed sarcopenia" (low HGS and low ALMht), and "severe sarcopenia" (low HGS, low ALMht and slow TUG). Incident falls were self-reported at 6 and 12 months after baseline.

Results: Only 0.8% and 1.0% of participants had probable and confirmed sarcopenia, respectively, and none had severe sarcopenia (Fig. 1). Almost one-third of participants with confirmed sarcopenia reported incident falls, compared with 20% for probable sarcopenia and 14% without sarcopenia ($P=0.025$). Compared with participants without sarcopenia, those with confirmed sarcopenia generally had poorer values for bone parameters (all $P<0.05$ ex-

cept for proximal radius and tibia endosteal circumferences, both $P > 0.05$), while those with probable sarcopenia only had lower cortical area at the proximal radius ($B = -5.9$; 95%CI $-11.7, -0.1 \text{ mm}^2$) and periosteal and endosteal circumferences at the proximal tibia (-3.3 ; $-6.4, -0.3$ and -3.8 ; $-7.5, -0.05 \text{ mm}^2$, respectively). Compared with probable sarcopenia, confirmed sarcopenic participants also had significantly lower lumbar spine and total hip aBMD, distal radius and tibia total vBMD, and proximal radius and tibia cortical vBMD, area and thickness (all $P < 0.05$).

Conclusions: Prevalence of sarcopenia according to the EWG-SOP2 definition was low in Swedish community-dwelling 70-year-olds. Nevertheless, confirmed sarcopenia was associated with poorer aBMD, vBMD and bone architecture compared with probable and no sarcopenia, and also with increased likelihood of 12-month incident falls.

Fig. 1. Numbers of participants meeting EWGSOP2 criteria for sarcopenia categories and components.



OC13

STRENGTH AND PERFORMANCE-BASED OPERATIONAL MEASURES OF SARCOPIENIA: PREVALENCE AND ASSOCIATIONS WITH SOCIAL FACTORS AND PHYSICAL DISABILITY IN 10,461 ADULTS AGED 65 YEARS AND OVER FROM SIX LOWER- AND MIDDLE-INCOME COUNTRIES

S. J. Bowe¹, S. L. Brennan-Olsen², P. Kowal³, J. Gaskin⁴, N. Naidoo⁵, J. Snodgrass⁶, T. Quashie⁷, S. Agrawal⁸, G. Eick⁶, C. D'Este⁹

¹Deakin University, Deakin Biostatistics Unit, Geelong, Australia, ²University of Melbourne, Department of Medicine, St Albans, Australia, ³University of Newcastle, Research Centre for Generational Health and Ageing, Newcastle, Australia, ⁴Deakin University, Faculty of Health, Geelong, Australia, ⁵WHO (SAGE), Geneva, Switzerland, ⁶University of Oregon, Department of Anthropology, Eugene, USA, ⁷Chulalongkorn University, Bangkok, Thailand, ⁸Public Health Foundation of India, New Delhi, India, ⁹Australian National University, National Centre for Epidemiology and Population Health, Canberra, Australia

Objectives: To study the prevalence of operational sarcopenia (low handgrip strength and gait speed) and its association with physical disability, accounting for socioeconomic factors, among adults aged ≥ 65 yrs in low- and middle-income countries (LMICs). Material and Methods: Nationally representative cross-sectional data from the WHO Study on global AGEing and adult health (WHO-SAGE Wave 1, 2007-10) for adults aged ≥ 65 yrs living in China (C), Mexico (M), Ghana (G), India (I), Russia (R) and South Africa (SA) was used ($n=10,461$; 52% women). We calculated country-specific prevalence of operational sarcopenia using a combination of slow gait speed ($< 0.8 \text{ m/sec}$) and low handgrip strength (men $< 30 \text{ kg}$, women $< 20 \text{ kg}$ [M, G, R, SA]; men $< 26 \text{ kg}$, women $< 18 \text{ kg}$ [C, I]). Using multivariable negative binomial regression, we assessed associations between individual and combined operational measures of sarcopenia with disability (WHODAS 2.0), adjusting for education and household wealth. Results: Prevalence of operational sarcopenia was highest in M (42%) and lowest in C (18%). Those with operational sarcopenia had a 1.2 to 1.5-fold worse disability score compared to those without. Low education (none or completed some/all primary school) was independently associated with worse disability scores in C, I, R and SA, whilst low household wealth was associated in C, M, G and I. Conclusions: Operational sarcopenia and its individual components were associated with worse disability amongst adults in LMICs, indicating the global relevance of this preventable morbidity, and foreseeable trajectories towards frailty. Acknowledgements: SB-O: supported by Career Development Fellowship from NHMRC, Australia. SAGE: supported by WHO and the Division of Behavioral and Social Research, US NIA, through interagency Agreements with WHO. Governments of Shanghai, China and South Africa provided financial/other support for their national study. J Zanker and S Phu provided expert comment.

OC14

WHICH MUSCLE PARAMETERS ARE LONGITUDINALLY ASSOCIATED WITH FUTURE KNEE OSTEOARTHRITIS OUTCOMES? FINDINGS FROM THE HERTFORDSHIRE COHORT STUDY

N. R. Fuggle¹, L. D. Westbury¹, K. A. Jameson¹, H. E. Syddall¹, M. H. Edwards¹, K. A. Ward¹, E. M. Dennison¹, C. Cooper¹

¹MRC Lifecourse Epidemiology Unit, Southampton, UK

Objectives: Osteoarthritis (OA) is the most common joint condition and sarcopenia is defined according to age-related deterioration in muscle parameters. Longitudinal studies examining the relationship between these two conditions are lacking. Thus, we investigated whether longitudinal muscle strength and cross-sectional body composition was associated with knee pain or radiographic knee OA in the Hertfordshire Cohort Study (comprised of UK community-dwelling older adults).

Methods: We recruited 443 older adults (222 males and 221 females). At baseline grip strength was assessed using JAMAR dynamometry. At follow-up, grip strength was reassessed; whole-body DXA was used to derive body composition; knee pain was defined as a WOMAC Index knee pain score of ≥ 1 ; and radiographic OA defined as a Kellgren-Lawrence score ≥ 2 . Logistic regression was used to assess the relationship between muscle and body composition parameters and knee pain and/or radiographic OA in models adjusted for anthropometric and lifestyle factors.

Results: The mean age of participants was approximately at baseline and follow-up was 6.5 y. There were no significant sex differences in the prevalence of radiographic OA (males 101 (50.2%), females 118 (58.7%)) or knee pain (males 68 (31.2%), women 82 (37.4%)).

In fully-adjusted analyses, we observed that baseline grip strength (OR 0.56 (0.37, 0.86) z-score $p < 0.01$) and conditional change in grip strength (OR 0.69 (0.54, 0.87) per SD lower decline, $p < 0.01$) were associated with knee pain at follow-up. Total fat mass was associated with radiographic OA (OR 1.36 (1.03, 1.80) z-score $p < 0.03$). Combined knee pain and radiographic OA at follow-up was predicted by baseline grip strength (OR 0.51 (0.28, 0.95) z-score $p < 0.04$) but also total fat mass (OR 2.02 (1.28, 3.20) z-score $p < 0.01$) and percentage lean mass (OR 0.44 (0.25, 0.78) z-score $p < 0.01$).

Conclusions: We observed that muscle mass and body composition were associated with the future development of knee pain and radiographic OA. If our results are replicated elsewhere, individuals with poor grip strength and body composition could be targeted in order to reduce the risk of future knee pain and radiographic OA.

OC15

PATIENT ENGAGEMENT IN CLINICAL GUIDELINES DEVELOPMENT: INPUT FROM >1000 MEMBERS OF THE CANADIAN OSTEOPOROSIS PATIENT NETWORK

L. Funnell¹, M. Djekic-Ivankovic², R. Chepesiuk¹, L. Giangregorio³, I. Braganca Rodrigues³, R. Ridout⁴, S. Feldman⁴, S. Kim⁴, H. McDonald-Blumer⁴, G. Kline⁵, W. E. Ward⁶, N. Santesso⁷, W. D. Leslie⁸, S. N. Morin⁹

¹Osteoporosis Canada, Toronto, ²Research Institute of the McGill University Health Center, Montreal, ³University of Waterloo, Waterloo, ⁴University of Toronto, Toronto, ⁵University of Calgary, Calgary, ⁶Brock University, St. Catharines, ⁷McMaster University, Hamilton, ⁸University of Manitoba, Winnipeg, ⁹McGill University, Montreal, Canada

Objectives: Osteoporosis Canada (OC) is updating its national clinical practice guidelines using the GRADE approach and is ensuring active patient involvement throughout the entire process.

Methods: Using electronic mail, we contacted 6937 members of the Canadian Osteoporosis Patient Network to provide input in the selection of clinical questions and relevant outcomes via a self-administered online survey developed by an interdisciplinary group of clinicians, patients and researchers. Closed-ended questions were analyzed using descriptive statistics. Content analysis was conducted for the open-ended questions.

Results: A total of 1108 individuals (16% participation rate) completed the survey (96% were women, 85% stated they lived with osteoporosis and most reported they were knowledgeable [61%] or very knowledgeable [24%] about osteoporosis). Most considered it to be very important to have recommendations on exercise (74%), nutrition (68%), fall prevention (68%), and how to discuss risks and benefits of medications (65%). Respondents stated that preventing fractures, preserving quality of life and ability to perform daily activities, preventing admission to long term care and fracture-related death and avoiding serious harms from medications were very important outcomes to consider (average scores ≥ 4.7 on a 5-point Likert scale). Key issues that emerged from the content analysis of the open-ended question (498 respondents with 960 references): "Provide up to three questions you would like to see addressed in the next Guidelines" included: pharmacotherapy, screening, monitoring, nutrition, education, exercise as well as pain management following fractures and alternative therapies. Safety, effectiveness and benefits of exercise were identified as key themes in response to a question specific to the performance of exercise and physical activities (661 references).

Conclusion: This survey has identified issues important to people living with osteoporosis that will inform the search strategy for knowledge syntheses and the development of OC clinical guidelines recommendations.

OC16

RISK OF MAJOR OSTEOPOROTIC FRACTURE AFTER BARIATRIC SURGERY IN FRANCE: POPULATION BASED, RETROSPECTIVE COHORT STUDY

J. Paccou¹, N. Martignère¹, E. Lespessailles², G. Babykina¹, B. Cortet¹, G. Ficheur¹

¹Lille University Hospital, Lille, ²University of Orléans, Orléans, France

Objectives: To investigate the major osteoporotic fracture (MOF - hip, proximal humerus, wrist and distal forearm, and clinical spine) risk in patients aged 40-65 undergoing bariatric surgery vs. matched controls.

Methods: Design: population based, exposed/unexposed cohort study. Setting: records from the French National Inpatient database from 2008-2017. Participants: bariatric surgery patients, aged 40-65, morbid obesity (BMI ≥ 40 kg/m²), hospitalized between January 1, 2010 and June 30, 2012 were matched to up to three controls by age, sex, Charlson comorbidity index and class of obesity (40-49.9 vs. ≥ 50 kg/m²). Patients were followed 5 y. Main outcome measure: we conducted three conditional logistic regressions to assess the association between the risk of any MOF-related hospitalization, and respectively (i) bariatric surgery yes/no, (ii) type of surgery malabsorptive/restrictive, and (iii) type of surgery procedure (gastric bypass, biliopancreatic diversion, gastric banding, vertical banded gastroplasty, sleeve gastrectomy and no surgery).

Results: 64 595 patients were included (19 104 bariatric surgery group and 45 591 matched controls). There were 216 MOF in the surgical group (2.28 cases per 1000 PY) and 459 MOF in the matched controls (2.04 cases per 1000 PY). The risk of MOF in the surgical group was significantly increased (odds ratio (OR) [95%CI]=1.25 [1.06 to 1.48]). Compared with the control group, the risk of MOF was significantly increased for the malabsorptive bariatric surgery (OR=1.81 (1.47 to 2.22)) whereas no association was found regarding restrictive surgery (OR=0.91 (0.73 to 1.13)). Regarding the analysis by type of procedure, we did observe an increased risk of MOF only for gastric bypass (OR=1.83, (1.48-2.25)) compared with the matched controls.

Conclusions: In patients aged 40-65; bariatric surgery was significantly associated with an increased risk of MOF, mainly with malabsorptive procedures, in particular gastric bypass.

OC17

A MULTICENTER, RANDOMIZED, RATER-BLINDED, PARALLEL-GROUP, PHASE 3 STUDY TO COMPARE THE EFFICACY, SAFETY, AND IMMUNOGENICITY OF BIOSIMILAR RGB-10 AND REFERENCE ONCE-DAILY TERIPARATIDE IN PATIENTS WITH PRIMARY OSTEOPOROSIS

H. Hagino¹, R. Narita², Y. Yokoyama², M. Watanabe², M. Tomomitsu²

¹Tottori University, Yonago, ²Mochida Pharmaceutical Co. Ltd., Tokyo, Japan

Objective: RGB-10 is the first biosimilar teriparatide authorized in the European Union. This multicenter, randomized, rater-blinded, parallel-group phase 3 study evaluated equivalence in efficacy and compared safety between RGB-10 and reference teriparatide in patients with primary osteoporosis at high risk of fracture for registration in Japan.

Methods: Patients were ambulatory men and postmenopausal women (≥ 55 y of age) with primary osteoporosis at high risk of fracture. Patients were randomized 1:1 to receive either RGB-10 or reference teriparatide 20 μ g once-daily via subcutaneous self-injection for 52 weeks. The primary efficacy endpoint was the percent change from baseline to 52 weeks in lumbar spine (L2-L4) BMD. Safety outcomes and immunogenicity were also assessed.

Results: In total, 250 patients (125 for each group) were randomized. The percent changes from baseline to 52 weeks in lumbar spine (L2-L4) BMD (mean \pm SD) were 8.94 \pm 6.19% in the RGB-10 group and 9.65 \pm 6.22% in the reference teriparatide group. The estimated between-group difference (95%CI) was -0.65% (-2.17% to -0.87%) within the prespecified equivalence margin ($\pm 2.8\%$), which indicates equivalence in efficacy between the two groups. Change in BMD at lumbar spine (L1-L4), femoral neck, and total hip, and serum procollagen type I N-terminal propeptide were also similar between groups. Safety, including immunogenicity, profiles were comparable.

Conclusions: The therapeutic equivalence of RGB-10 to reference teriparatide was demonstrated. RGB-10 had comparable safety profile to that of reference teriparatide.

OC18

SKELETAL BENEFIT/RISK OF LONG-TERM DENOSUMAB (DMAB) THERAPY: A VIRTUAL TWIN ANALYSIS OF FRACTURES (FX) PREVENTED TO SKELETAL SAFETY EVENTS OBSERVED

S. L. Ferrari¹, E. M. Lewiecki², P. W. Butler³, D. L. Kendler⁴, N. Napoli⁵, S. Huang³, D. B. Crittenden³, N. Pannacciulli³, E. Siris⁶, N. Binkley⁷

¹Geneva University Hospital, Geneva, Switzerland, ²New Mexico Clinical Research & Osteoporosis Center, Albuquerque, USA, ³Amgen Inc., Thousand Oaks, USA, ⁴University of British Columbia, Vancouver, Canada, ⁵Universita Campus Bio-medical di Roma, Rome, Italy, ⁶Columbia University Medical Center, New York, USA, ⁷University of Wisconsin-Madison, Madison, USA

Objective: Calculate the ratio of fractures prevented per skeletal adverse event (AE) observed in the FREEDOM Extension (Ext) study using a hypothetical group of untreated patients (virtual twins [VT]).

Methods: Exposure-adjusted subject incidence per 100,000 subject-years of clinical, major osteoporotic, vertebral, nonvertebral, and hip fractures was calculated for long-term (LT) subjects ran-

domized to DMAB in the 3-y FREEDOM trial and enrolled in the 7-y Ext (follow-up on DMAB, 3-10 y). In the absence of a LT placebo (PBO) group, fracture rates in a hypothetical cohort of 10-y PBO controls (VT) were estimated: A regression model was generated using data from subjects randomized to PBO during FREEDOM and then enrolled in the Ext; a VT with identical baseline characteristics to each LT subject was derived; and fracture rates predicted for the untreated VT group using the regression model. The number of fractures prevented per 100,000 subject-years was calculated as (VT rate – LT rate). AFF and ONJ incidences on DMAB were based on observed cases in the LT group; the VT group was assumed to have no AFF or ONJ. A skeletal benefit/risk ratio was calculated from fractures prevented per AFF or ONJ observed.

Results: Fracture rates and skeletal benefit/risk ratios are shown below. There was 1 case of AFF and 7 ONJ (mild and moderate; 5 AFF and 35 ONJ per 100,000 subject-years), with 281 and 40 clinical fractures prevented per AFF and ONJ observed, respectively.

Conclusions: As long-term PBO-controlled fracture outcome studies in postmenopausal OP are unethical, the virtual twin model provides a reasonable estimate of untreated fracture rates. Using this model, long-term DMAB therapy has a highly favorable benefit/risk profile when comparing fractures prevented per skeletal AE observed.

		Exposure-adjusted subject incidence per 100,00 subject-years				
		Clinical fractures	Major osteoporotic fractures ^a	Vertebral fractures	Non-vertebral fractures	Hip fractures
		N=2343	N=2343	N=2116 ^b	N=2343	N=2343
		Exp=18295	Exp=18772	Exp=18385	Exp = 18451	Exp=19742
Long-term		1777	1525	901	1528	149
Twin		3180	2699	1879	2924	297
Ratio ^c		0.56	0.57	0.48	0.53	0.54
Fractures prevented		1403	1174	978	1396	148
Ratio of fractures prevented per AE observed ^d	AFF (5) ^e	280.6	234.8	195.6	279.2	29.6
	ONJ (35) ^{e, f}	40.1	33.5	27.9	39.9	4.2

Based on LT DMAB subjects. All results are based on 5000 bootstrap samples. N = number of LT subjects who had fracture outcome data; Exp = exposure time in subject years indicating the time from FREEDOM baseline to the onset of first event (for subjects who had a fracture event), or end of study or last assessment date, whichever was greater (for subjects who did not have a fracture event)
^a Major osteoporotic fractures were defined as clinical spine, forearm, hip, or shoulder fracture
^b 227 LT subjects had missing vertebral fracture outcome data during FREEDOM and/or its Ext
^c Calculated as (LT rate) / (VT rate)
^d Calculated as (VT rate – LT rate) / AE rate
^e The number in parentheses indicates the AE subject incidence rate per 100,000 subject-years in LT subjects
^f There were 2 mild, 5 moderate, and no severe cases of ONJ in the LT group
 AE: Adverse event; AFF: atypical femoral fracture; ONJ: osteonecrosis of the jaw

Disclosures: Amgen Inc. sponsored this study and provided medical writing assistance for this abstract. S L Ferrari: Research support from UCB and MSD; Consultant for Amgen, UCB, Labatec, and Agnovos. EM Lewiecki: Research support from and consultant for Amgen and Radius; Speaker’s Bureau for Radius. PW Butler, S Huang, DB Crittenden, and N Pannacciulli: Employee of and stock in Amgen. DL Kendler: Research support from Eli Lilly, Amgen, and AstraZeneca; Consultant for Eli Lilly, Amgen, and Pfizer; Speaker’s Bureau for Eli Lilly and Amgen. N Napoli: Consultant for Amgen and Eli Lilly. E Siris: none. N Binkley: Research support from Novartis and Viking; Consultant for Amgen and Viking.

OC19

THE EFFECT OF COMBINED TERIPARATIDE AND WHOLEBODY VIBRATION EXERCISE IN POSTMENOPAUSAL OSTEOPOROSIS: A RANDOMIZED CONTROLLED TRIAL

D. B. Jepsen¹, J. Ryg¹, S. Hansen², J. Gram³, N. R. Jørgensen⁴, T. Masud⁵

¹Department of Geriatric Medicine, Odense University Hospital/Institute of Clinical Research, University of Southern Denmark, Odense, Denmark, ²Department of Endocrinology, Odense University Hospital, Odense, Denmark, ³Department of Endocrinology, Hospital of Southwest Jutland, Esbjerg, Denmark, ⁴Department of Clinical Biochemistry, Rigshospitalet/OPEN-Odense Patient data Explorative Network, Department of Clinical Research, Odense University Hospital/ University of Southern Denmark, Glostrup, Denmark, ⁵Department of Geriatric Medicine, Nottingham University Hospitals Trust NHS, Nottingham, UK

Objectives: Parathyroid hormone teriparatide (PTH) is an effective but expensive anabolic treatment for osteoporosis. Whole-body vibration exercise (WBV) has been found to stimulate muscles and bones. Animal studies demonstrate a beneficial effect on bone when combining PTH with mechanical loading. A combined treatment with PTH and loading in the form of WBV might have beneficial effects.

Methods: PaVOS is a randomized controlled trial. Postmenopausal women (n=35) starting PTH 20 µg/d were randomized to PTH+WBV, or PTH alone. WBV consisted of three sessions a week (12-min, including 1:1 ratio of exercise: rest). Primary outcome was BMD at 12 months of follow-up. Secondary outcomes were microarchitecture, bone turnover makers, and sclerostin. Data were analyzed using a mixed linear regression model with adjustment for baseline values or robust cluster regression in an intention to treat analysis (ITT).

Results: At 12 months, both groups increased significantly in BMD at lumbar spine. The PTH+WBV increased by (mean±SD) 8.90%±5.47 and the PTH by 6.65%±5.51. The adjusted mixed effect model found a significant overall difference in treatment effect between groups of 2.95% (95%CI (0.14- 5.77), p=0.04) (ANCOVA). Markers of bone turnover increased significantly in both groups at three and six months with no significant difference between groups. No other treatment effects were observed in hip BMD, the microarchitecture parameters, or sclerostin in either group.

Conclusion: Twelve months of WBV and PTH had a significant clinically relevant treatment effect in total lumbar spine compared to PTH alone in postmenopausal osteoporotic women.

Acknowledgement: ClinicalTrials.gov ID: NCT02563353

OC20

EFFECTS OF A MULTINUTRIENT FORTIFIED DAIRY PRODUCT COMBINED WITH EXERCISE ON FUNCTIONAL MUSCLE PERFORMANCE, BODY COMPOSITION AND INFLAMMATION IN SEDENTARY MIDDLE AGED WOMEN: A 4-MONTH DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED TRIAL

R. M. Daly¹, J. Gianoudis¹, B. De Ross¹, S. O'Connell¹, L. Schollum², C. Gunn²

¹Deakin University, Institute for Physical Activity and Nutrition, Melbourne, Australia, ²Fonterra Co-operative Group Ltd, Palmerston North, New Zealand

Objective: To evaluate whether a multinutrient fortified dairy product (FDP) containing added protein, calcium, vitamin D and other micronutrients could augment the effects of exercise on functional muscle performance, body composition and markers of inflammation in sedentary middle-aged women.

Methods: In this 4-month double-blind, placebo RCT, 244 sedentary women aged 45-65 y participated in a multicomponent exercise (Ex) program including high-velocity resistance and challenging balance training 3 d/week with random allocation to twice daily FDP (2x150 ml) or an energy matched placebo. Outcomes included: functional muscle power (primary outcome) [stair climb, vertical jump height (VJH), 5 sit-to-stand (STS)], DXA lean mass (LM) and fat mass (FM), pQCT 50% femur and 66% tibia muscle CSA and muscle adiposity, muscle strength (leg press, ankle dorsiflexion), mobility [gait speed, four-square step test (FSST), timed-up-and-go (TUG)], flexibility (sit-and-reach), single leg balance (SLB) eyes open/closed and inflammation (serum IL-6, IL-10, TNFα).

Results: 216 women (89%) completed the study. Adherence was 90-92% for FDP and placebo and 78-79% for Ex. After 4-months there was a 0.09 s (P<0.05) and 0.07 s (P=0.08) greater improvement in stair descent and ascent time in FDP vs. placebo. FDP also had greater net gains in VJH (0.5 cm, P<0.05), SLB eyes closed (P<0.01), flexibility (1.4 cm, P<0.05), LM (0.3 kg, P<0.05), muscle CSA (femur 1.8%; tibia 0.9%, P<0.01), and a greater reduction in FM (-0.6 kg, P<0.01). Femur and tibia muscle adiposity decreased in FDP only (P<0.01). Both groups had similar significant improvements in STS, gait speed, FSST, TUG and muscle strength, with no significant difference between the groups on inflammatory markers.

Conclusion: In sedentary middle-aged women, daily consumption of a multinutrient fortified dairy product enhanced the effects of exercise on measure of functional muscle power, lean mass, muscle size, flexibility and balance.

Disclosures: L.S. and C.G. are employees of Fonterra Co-operative Group Ltd. This study was funded by a Primary Growth Partnership grant via the Ministry of Primary Industries in New Zealand with Fonterra Co-operative Group Ltd.

OC21

EFFECT OF ORAL CHONDROITIN SULFATE ON PAIN IN PATIENTS WITH KNEE OSTEOARTHRITIS: OUTCOMES OF A COMPREHENSIVE META-ANALYSIS EXPLORING INCONSISTENCIES IN RANDOMISED, PLACEBO-CONTROLLED TRIALS

G. Honvo¹, O. Bruyère¹, A. Geerinck¹, N. Veronese², J.-Y. Reginster³

¹Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium; WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liège, Belgium, ²National Research Council, Neuroscience Institute, Aging Branch, Padova, Italy, ³WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liège, Belgium; Chair for Biomarkers of Chronic Diseases, Department of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia

Objective: To determine whether chondroitin sulfate (CS) is effective at alleviating pain in patients with knee osteoarthritis (OA) and to assess whether brand of CS, risk of bias, dose of CS and duration of study explain inconsistencies in trials using CS for the symptomatic management of OA.

Methods: A systematic review of randomised, placebo-controlled trials was conducted, searching the Medline, CENTRAL and Scopus databases. Random-effects meta-analysis was performed, using Tau² and I² statistics to assess heterogeneity. The effect size for pain was expressed as standardised mean difference (SMD), with 95%CI. Heterogeneity was explored by stratifying the analysis, according to pre-specified study-level characteristics, and assessing the sources of funnel plot asymmetry. For sensitivity analyses, the fixed-effect model was applied.

Results: The inclusion criteria yielded 18 trials. Compared to placebo, CS significantly but inconsistently reduced pain (SMD: -0.63; 95%CI: -0.91, -0.35; I²=94%). When limiting the analysis to studies with a low risk of bias, the pharmaceutical-grade CS of IBSA origin showed a greater reduction in pain (SMD: -0.25; 95%CI: -0.34, -0.16; I²=75%), compared to the other preparations (SMD: -0.08; 95%CI: -0.19, +0.02; I²=20%). Assessing funnel plots asymmetry in the studies with a low risk of bias, we found a strong correlation between the treatment effect and study size ($r_s=0.93$, $p<0.05$). Overall, there was no residual heterogeneity in the CS effect on pain when the smallest studies were removed from the analyses.

Conclusion: This new meta-analysis suggests that CS provides a moderate benefit on pain in patients with knee OA, however, with substantial heterogeneity. Our analyses showed that the risk of bias, brand and study size were the factors explaining inconsistency among the clinical trials results. The pharmaceutical-grade preparation with CS of IBSA origin generated greater effect on pain than the other CS in the studies with a low risk of bias.

Acknowledgement: This study was funded by an Unrestricted Educational Grant from the IBSA (Institut Biochimique SA). However, preparation of the study protocol, data analysis, and writing and submission of this abstract were under the sole responsibility of the authors.

OC22

DXA-BASED 3D ANALYSIS OF PROXIMAL FEMUR CORTICAL AND TRABECULAR BONE FOR FRACTURE RISK ASSESSMENT: A PROSPECTIVE STUDY IN POSTMENOPAUSAL WOMEN

E. Biver¹, M. Hars¹, R. Winzenrieth², R. Rizzoli¹, S. L. Ferrari¹

¹Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland, ²Musculoskeletal Unit, Galgo Medical, Barcelona, Spain

Objective: DXA-based 3D modeling approaches, using statistical shape and appearance models, provide a 3D analysis of the trabecular (Tb) and cortical (Ct) compartments from proximal femur DXA scans. They have been developed as complements to standard femur DXA examination to assess bone compartments alterations in various conditions associated with bone fragility and to selectively monitor osteoporosis treatment effects. However, whether DXA-based 3D modeling approaches are able to predict incident fractures has not been investigated.

Methods: In this population-based study from the Geneva Retirees Cohort (ISRCTN registry 11865958), 796 postmenopausal women (age 65.1±1.5 y) (mean±SD) were prospectively evaluated over 5.7±1.5 y for the occurrence of low-trauma fractures. A software algorithm (3D-SHAPER, version 2.9, Galgo Medical, Barcelona, Spain) was used to derive 3D models from baseline proximal femur DXA scans and compute total (Tt), Tb and Ct volumetric BMD (vBMD), Ct thickness (Ct.th), and Ct surface BMD (Ct.sBMD) at the total hip, femoral neck, trochanter and femoral shaft.

Results: 100 women (13%) sustained a low-trauma fracture after a follow-up of 3.6±2 y (mean±SD), including 44 with a major osteoporotic fracture (MOF). Tt and Tb vBMD, most Ct parameters, as well as standard (2D) areal BMD, were significantly associated with incident fractures (fracture risk increased by 23-40% and major osteoporotic fracture (MOF) risk by 36-63% for each standard deviation decrease in the independent variable) (Table). Using stepwise multivariate Cox regressions including all the 3D parameters and 2D areal BMD, the strongest and unique predictors of MOF were Tb vBMD at the total hip, femoral neck and trochanter (hazard ratio (HR), 1.59, $p=0.002$; 1.48, $p=0.007$; and 1.63, $p=0.004$, respectively), and Tt vBMD at the proximal femoral shaft (HR 1.53, $p=0.006$). The corresponding HR for 2D-derived areal BMD were 1.49 ($p=0.010$), 1.46 ($p=0.017$), 1.53 ($p=0.009$) and 1.47 ($p=0.011$), respectively.

Conclusion: DXA-based 3D modeling data predict all types and major osteoporotic fractures, in a way similar to classic 2D measurements. By selectively distinguishing the predictive value of the

various bone compartments, the associations of Tb vBMD with fractures were of greater magnitude than those of the Ct parameters.

Table: Associations between 2D and 3D hip DXA parameters and the risk of incident major osteoporotic fractures in women

	Total hip		Femoral neck		Trochanter		Proximal femoral shaft	
	HR (95%CI)	P-value	HR (95%CI)	P-value	HR (95%CI)	P-value	HR (95%CI)	P-value
2D aBMD	1.49 (1.10, 2.01)	0.010	1.46 (1.07, 2.00)	0.017	1.53 (1.11, 2.10)	0.009	1.47 (1.09, 1.97)	0.011
3D Tt.vBMD	1.58 (1.15, 2.15)	0.004	1.46 (1.10, 1.93)	0.009	1.53 (1.13, 2.07)	0.005	1.53 (1.13, 2.07)	0.006
3D Tb.vBMD	1.59 (1.18, 2.14)	0.002	1.48 (1.11, 1.96)	0.007	1.63 (1.17, 2.26)	0.004	1.49 (1.12, 1.98)	0.007
3D Ct.vBMD	1.25 (0.92, 1.68)	0.152	1.30 (0.96, 1.75)	0.086	1.27 (0.94, 1.71)	0.120	1.23 (0.91, 1.67)	0.170
3D Ct.sBMD	1.43 (1.05, 1.93)	0.021	1.36 (1.01, 1.82)	0.042	1.39 (1.03, 1.89)	0.033	1.38 (1.01, 1.89)	0.041
3D Ct.Th	1.51 (1.12, 2.05)	0.007	1.21 (0.91, 1.60)	0.183	1.33 (0.99, 1.80)	0.058	1.42 (1.04, 1.93)	0.026

Data are hazard ratio associated with one standard deviation impairment of each parameter, obtained from Cox's proportional hazard models.

OC23
SARCOPENIA DEFINITIONS AS PREDICTORS OF FRACTURE RISK INDEPENDENT OF FRAX, FALLS AND BMD IN THE OSTEOPOROTIC FRACTURES IN MEN (MROS) STUDY: A META-ANALYSIS

N. C. Harvey¹, A. Odén², E. Orwoll³, T. Kwok⁴, M. K. Karlsson⁵, B. E. Rosengren⁵, E. Ribom⁶, P. M. Cawthon⁷, K. Ensrud⁸, C. Cooper¹, J. A. Kanis⁹, M. Lorentzon¹⁰, C. Ohlsson², D. Mellström², H. Johansson¹¹, E. V. McCloskey¹¹

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK, ²Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Oregon Health and Science University, Portland, Oregon, USA, ⁴The Chinese University of Hong Kong, Hong Kong, China, ⁵Clinical and Molecular Osteoporosis Research Unit, Lund University and Department of Orthopedics, Skane University, Malmo, Sweden, ⁶Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden, ⁷Research Institute, California Pacific Medical Center, San Francisco, California, USA, ⁸Medicine and Epidemiology & Community Health, University of Minnesota, Minnesota, USA, ⁹Centre of Metabolic Bone Diseases, University of Sheffield, Sheffield, UK, ¹⁰Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ¹¹Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK

Objective: We investigated the predictive value of sarcopenia definitions for incident fracture, independent of BMD, FRAX 10-y fracture probability and prior falls.

Methods: In US, Sweden and Hong Kong(HK) MrOS cohorts, we used an extension of Poisson regression to investigate relationships between sarcopenia(y/n) and incident major osteoporotic fracture(MOF: clinical vertebral, hip, wrist, proximal humerus). Sarcopenia definitions were as published by Baumgartner, Field-

ing, Cruz-Jentoft, Morley, Chen, Delmonico, Studenski. Associations were adjusted for age and follow-up time, reported as hazard ratio (HR) for first incident MOF. Further analyses adjusted additionally for FRAX MOF probability, prior falls (y/n) or femoral neck (FN) BMD T-score. Results were synthesized by meta-analysis.

Results: We studied 5660 men in USA, 2764 in Sweden and 1987 in HK; (mean ages 73.5, 75.4 and 72.4 y). Sarcopenia status, except by Studenski, was associated with incident MOF (HR:1.39 to 1.76), e.g., Cruz-Jentoft (HR:1.76; 95%CI:1.38,2.26); Fielding (HR:1.60; 5%CI:1.27,2.01); Morley (HR:1.74; 95%CI:1.29,2.36). Associations were robust to adjustment for prior falls or FRAX probability. Adjustment for FNBMD T-score alone led to marked attenuation to below or borderline statistical significance, e.g., Cruz-Jentoft (HR:1.34; 95%CI:1.04, 1.73); Fielding (HR:1.24; 95%CI:0.98,1.56); Morley (HR:1.24; 95%CI:0.91,1.69).

Conclusions: The predictive value for fracture of sarcopenia definitions is reduced by inclusion of FNBMD T-score, suggesting limited additional value in fracture risk assessment over current approaches. Investigation of alternative methods of muscle assessment, e.g., peripheral quantitative computed tomography or creatine dilution is warranted.

Acknowledgement: HJ and EM are joint senior author

OC24

RELATIONSHIP BETWEEN THE CHANGES OVER TIME OF BONE AND MUSCLE HEALTH IN CHILDREN AND ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS

M. Locquet¹, C. Beaudart¹, N. Durieux², J.-Y. Reginster¹, O. Bruyère¹

¹Public Health, Epidemiology & Health Economics, University of Liège, ²ULiège Library, University of Liège, Liège, Belgium

Objective: Various cross-sectional studies provide an abundance of evidence to show a relationship between bone quantity and muscle health. However, one aspect remains that is less often studied: is their development - or decline - associated? The aim of the research was to conduct a systematic review and meta-analysis to summarize the studies exploring the association between changes in BMD and changes in muscle parameters (registration CRD42018093813).

Methods: We searched for prospective studies, both in children and adults, by consulting electronic databases (Ovid-MEDLINE, Ovid-AMED, Scopus). Each review steps were performed by two independent reviewers. For outcomes reported by less of 3 studies, we synthesized the results narratively. In other cases, a meta-analysis was performed, giving an overall r coefficient and its 95%CI.

Results: Fifteen papers were included. In connection with the evolution of BMD, 10 studies concerned the parallel evolution of muscle mass, 4 were about grip strength, and 1 was about physical performance. Children were the population of interest for 5 studies, while the aging population was the focus of the other studies. The correlation between hip BMD and muscle mass was significant, with an overall coefficient $r=0.37$ (95%CI 0.23-0.49). High heterogeneity was observed between studies but the length of follow-up, sex and study quality did not seem to significantly influence results. The systematic review allowed some other highlights: a significant link between changes in BMD and changes in muscle strength was observed (p -value <0.05 in the 4 studies), in addition to changes in performance (1 study, $r=0.21$, p -value=0.004).

Conclusion: Despite the heterogeneity between studies, we highlighted a significant association between the evolution of BMD and the evolution of various muscle parameters, thus proposing the use of preventive and therapeutic strategies that are based on a single entity: the 'muscle-bone unit'.

OC25

BIRTHWEIGHT, LIMB MUSCLE MASS AND GRIP STRENGTH IN MIDDLE AGE: FINDINGS FROM THE UK BIOBANK IMAGING ENHANCEMENT

E. M. Curtis¹, J. K. H. Liu¹, K. A. Ward¹, K. Jameson¹, Z. Raisi-Estabragh², J. Bell³, S. Petersen², C. Cooper¹, N. C. Harvey¹

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, ²NIHR Advanced Imaging, NIHR Barts Biomedical Research Centre (BRC), Queen Mary University of London, London, ³Research Centre for Optimal Health, Department of Life Sciences, University of Westminster, London, UK

Objective: Low birthweight has been associated with poorer musculoskeletal health in later life. We investigated relationships between birthweight, and grip strength or MRI measures of muscle volume in UK Biobank.

Methods: UK Biobank is a large prospective cohort of men and women aged 40-69 y, including a detailed baseline assessment in which birthweight was collected by self-report. A subset underwent MRI examination with the dual-echo Dixon Vibe protocol, from neck to knees. Automated analysis was performed using the AMRA Profiler™ system, to segment and quantify total thigh muscle volume. Grip strength was assessed using a Jamar hydraulic hand dynamometer. Associations between birthweight, and thigh muscle volume or grip strength (expressed as Fisher-Yates z-scores) were investigated using multivariate linear regression analysis. This study was conducted under generic ethics approval (NRES:11/NW/0382).

Results: 3699 participants [1513 men, mean (SD) age 61.0 (7.6) y and 2186 women, age 60.1 (7.4) y] were able to recall their birthweight and had their grip strength assessed or underwent MRI body composition analysis. In both men and women, higher birthweight was associated with greater thigh muscle volume (adjusted for age and BMI): men, β (95%CI): 0.229(0.156,0.301) SD/kg, $p<0.001$; women, β (95%CI): 0.284(0.221,0.346) SD/kg, $p<0.001$. Higher birthweight was also associated with higher grip strength (adjusted for age and height); men, β (95%CI): 0.123(0.051,0.195) SD/kg, $p=0.001$; women, β (95%CI): 0.070(0.007,0.134) SD/kg, $p=0.031$. Apart from the association with grip strength in women, these associations persisted after additional adjustment for current smoking and physical activity.

Conclusions: These findings provide novel evidence of associations between birthweight and volumetric measures of muscle size and grip strength, and support the developmental programming hypothesis. Interventions to improve obstetric health and optimise birthweight may help to prevent sarcopenia and reduce the risk of falls in future generations.

OC26

INTRINSIC CAPACITY AND ITS ASSOCIATION WITH MORTALITY OVER THREE YEARS IN NURSING HOMES: RESULTS OF THE SENIOR COHORT

A. Charles¹, F. Buckinx¹, M. Locquet¹, J.-Y. Reginster^{1,2}, J. Petermans³, B. Gruslin¹, O. Bruyère^{1,4}

¹WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Ageing, Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ²Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia, ³Department of Geriatrics, University of Liège, Liège, Belgium, ⁴Department of Sport and Rehabilitation Sciences, University of Liège, Liège, Belgium

Objective: Recently, in order to evaluate functional ability of older people, the WHO proposed a model containing 5 domains of intrinsic capacity (i.e., cognition, locomotion, sensory, vitality and psychosocial), divided in 13 subdomains. The predictive value of these subdomains on mortality has not yet been investigated in nursing home setting. The aim of this study was to evaluate the predictive value of the 13 proposed subdomains of intrinsic capacity on the 3-year mortality of nursing home residents.

Methods: At baseline, clinical data (i.e. age, sex, comorbidities, medication and education) from an initial cohort of 662 subjects living in 28 Belgian nursing homes, were collected. For the Cognition subdomains, time orientation and memory were assessed using the Mini-Mental State Examination. For Locomotion, balance, gait speed and chair stand performance were evaluated with the Short Physical Performance Battery (SPPB). Sensory was measured using the self-reported Strawbridge questionnaire for audition and vision. For Vitality, abdominal circumference, BMI, nutritional status (by Mini Nutritional Assessment [MNA]) and handgrip strength (by a hand-dynamometer) were assessed. For the Psychosocial subdomains, depression was evaluated by the EuroQol-5D and fatigue by the CES-D scale. Multiple imputations were applied to handle missing data. Cox proportional hazard models were performed to evaluate the association between subdomains of intrinsic capacity and the occurrence of death during the 3-year follow-up.

Results: Out of the initial 662 subjects, 604 (aged 82.9±9 y, 72.5% of women) were included in this study. Indeed, 2 nursing homes with 58 residents dropped out. After 3 y, 38.2% of the study population deceased and the mean survival was 2.6 y. The residents who died were significantly older compared to the alive subjects (p=0.01), but no other clinical characteristics were significantly different. In the multivariate model adjusted for age, sex and the 10 intrinsic capacity subdomains associated with mortality in univariate analyses, a one-unit increase in balance performance of the SPPB and in the nutrition score of the MNA decreased the probability of death within 3 y by 12% (hazard ratio (HR) 0.88; 95%CI 0.78-0.99) and 4% (HR 0.96; 95%CI 0.93-0.99), respectively.

Conclusion: Balance capacity and nutrition, belonging respectively to the general domains of locomotion and vitality proposed by the WHO, are independently associated with the 3-y mortality among nursing home residents.

OC27

DEVELOPMENT AND EXTERNAL VALIDATION OF A PATIENT-LEVEL PREDICTION MODEL FOR 60-DAY MORTALITY FOLLOWING TOTAL KNEE ARTHROPLASTY: A MULTINATIONAL COHORT STUDY

D. Prieto-Alhambra¹, A. Bourke², T. S. Burkard³, E. Burn⁴, R. E. Costello⁵, D. J. Culliford⁶, A. Delmestri⁴, T. Duarte-Salles⁷, Y. He⁴, L. H. John⁸, S. Kolovos⁴, D. R. Morales⁹, C. O'Leary¹⁰, R. Pinedo-Villanueva⁴, A. Prats-Urbe⁴, J. Rejs¹¹, D. Robinson⁴, A. G. Sena¹¹, W. Sproviero¹², V. Y. Strauss⁴, R. D. Williams⁸, B. B. Yimer⁵, D. Yu¹³, P. Ryan¹¹

¹CSM, NDORMS, University of Oxford, Oxford, UK, ²Center for Advanced Evidence Generation, IQVIA Real-World & Analytics Solutions, London, UK, ³University Hospital Basel, Basel, Switzerland, ⁴NDORMS, University of Oxford, Oxford, UK, ⁵Arthritis Research UK Centre for Epidemiology, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK, ⁶NIHR CLAHRC Wessex, University of Southampton, Southampton, UK, ⁷Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain, ⁸Erasmus University Medical Center, Rotterdam, The Netherlands, ⁹University of Dundee, Dundee, UK, ¹⁰NEMEA Centre of Excellence for Retrospective Studies, IQVIA, London, UK, ¹¹Janssen Research and Development, Titusville, USA, ¹²Department of Psychiatry, University of Oxford, Oxford, UK, ¹³Arthritis Research UK Primary Care Centre, Research Institute for Primary Care & Health Sciences, Keele University, Keele, UK

Objective: Total knee replacement (TKR) is the most effective intervention available for the treatment of severe knee osteoarthritis. A small proportion of patients undergoing TKR are at risk of postoperative complications. We aimed to develop and externally validate algorithms for the prediction of post-operative mortality.

Methods: We conducted a multinational, multidatabase cohort analysis using claims data from the USA (Optum® de-identified Clinformatics® Datamart, Extended - Date of Death (Optum)) and The Health Improvement Network (THIN) UK primary care database. Both data sources were mapped to the Observational Medical Outcomes Partnership (OMOP) common data model, and processed using the same analytical platform developed by the Observational Health Data Sciences and Informatics (OHDSI) initiative. All subjects undergoing a primary TKR, aged 40 years or older and registered in any of the contributing data sources for at least one year before surgery were included. Study outcome was postoperative (60-d) all-cause mortality. Lasso logistic regression models were fitted with predictors with prevalence 0.1% using Optum, assessing discrimination and calibration and externally validated in THIN. Model performance was assessed using area under curve, AUC and calibration plot.

Results: A total of 152,665 US and 40,950 UK participants were included, with 353 (0.23%) and 81 (0.20%) deaths identified in the 60 days post-TKR respectively. A total of 121/89,031 potential variables were included in the final model. 102 predictors covering morbidity, process of care, and prescription medicine codes were included in the final model. Discrimination performance of the model developed on the OPTUM database was AUC 0.78 in the internal, and 0.69 in the external validation. Calibration was acceptable based on visual assessment.

Conclusions: TKR is a common procedure with low (1/500) mortality in the 60 d following surgery. We have developed and externally validated a prediction tool for the identification of subjects at high risk of postoperative mortality. More research is needed to understand the impact of its use in clinical practice.

Acknowledgements: This activity under the European Health Data & Evidence Network (EHDEN) has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 806968. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. The sponsor of the study did not have any involvement in the writing of the manuscript or the decision to submit it for publication. This study was approved by THIN's Scientific Review Committee (reference number: 18THIN100).

Disclosures: AGS, JR, and PR are full-time employees of Janssen Research & Development, a pharmaceutical company of Johnson & Johnson, and shareholders in Johnson & Johnson. The Johnson & Johnson family of companies also includes DePuy Synthes, which is the maker of medical devices for joint reconstruction. DPA reports research grants from AMGEN, UCB Biopharma and Les Laboratoires Servier. APU reports grants from MRC - DTP Funding. AB and COL are employees of IQVIA.

OC28

COMPARISON OF THE PSYCHOMETRIC PROPERTIES OF THE SARQOL® QUESTIONNAIRE WITH THE EWGSOP AND EWGSOP2 CRITERIA FOR SARCOPENIA

A. Geerinck¹, C. Beaudart¹, J.-Y. Reginster¹, O. Bruyère¹

¹Department of Public Health, Epidemiology and Health Economics, University of Liège, WHO Collaborating Center for Public Health Aspects of Musculoskeletal Health and Ageing, Liège, Belgium

Objective: Recently, the European Working Group on Sarcopenia in Older People (EWGSOP) published its revised consensus statement on the definition and diagnosis of sarcopenia. In light of this, we aim to investigate the psychometric properties of the Sarcopenia Quality of Life (SarQoL) questionnaire when using the EWGSOP2 criteria, and to compare the results to those obtained with the original EWGSOP criteria.

Methods: Data from the SarcoPhAge study, previously used to validate the SarQoL questionnaire, were re-analyzed with the EWGSOP2 criteria. We evaluated discriminative power, construct validity, test-retest reliability, and floor and ceiling effects.

Results: Initially, 43 subjects (14.5%) out of the 296 participants included in the SarcoPhAge study were diagnosed as sarcopenic, using the EWGSOP criteria. This number dropped to 19 subjects (6.4%) with the EWGSOP2 criteria. The SarQoL questionnaire was able to discriminate between sarcopenic and nonsarcopenic subjects for all 7 domains and the Overall score, irrespective of the diagnostic criteria used to establish sarcopenia. For the EWGSOP criteria, non-sarcopenic subjects scored 67.80 (57.17-79.09) points on the Overall score vs. 54.71 (45.87-66.34) for sarcopenic subjects ($p < 0.001$). For the EWGSOP2 criteria, this became 66.59 (56.37-78.37) points vs. 47.45 (38.89-66.34) with $p < 0.001$. For both sets of diagnostic criteria, the convergent construct validity is confirmed by strong correlations between the SarQoL Overall score and similar domains of the SF-36 and EQ-5D questionnaires. However, we also find moderate to strong correlations where weak ones were expected, which means we cannot confirm the divergent validity. The questionnaire has good test-retest reliability for both diagnostic criteria, with an ICC of 0.91 (0.82-0.95) for the EWGSOP criteria and an ICC of 0.90 (0.47-0.98) for EWGSOP2. Finally, no sarcopenic subject, both for the EWGSOP and EWGSOP2 criteria, obtained the highest or lowest score for the overall SarQoL score, confirming the absence of floor and ceiling effects.

Conclusions: The SarQoL questionnaire demonstrates adequate psychometric properties when using the revised EWGSOP2 diagnostic criteria for sarcopenia.

Disclosures: CB, OB & J-YR are shareholders of SarQoL sprl.

OC29

A POOLED ANALYSIS OF FALL INCIDENCE FROM PLACEBO-CONTROLLED TRIALS OF DENOSUMAB

E. V. McCloskey¹, R. Eastell¹, M. McClung², N. Pannacciulli³, C. Wang³, S. Yue³, S. R. Cummings⁴

¹The University of Sheffield, Sheffield, UK, ²Oregon Osteoporosis Center, Portland, USA, ³Amgen Inc., Thousand Oaks, USA, ⁴San Francisco Coordinating Center, San Francisco, USA


Objective: In the pivotal fracture trial of denosumab (DMAb) in postmenopausal women with osteoporosis (FREEDOM), treatment with DMAb, a RANK ligand (RANKL) inhibitor, resulted in a lower subject incidence of falls not associated with fracture (log rank P value=0.02) compared with placebo (Pbo) [1]. In addition to its role in osteoporosis, the RANK/RANKL pathway has also been shown to play a role in muscle strength in a murine model [2]. In an ad hoc exploratory analysis, we pooled data from additional Pbo-controlled trials of DMAb to determine the consistency across trials of the reduction in the incidence of falls.

Materials and Methods: The five Pbo-controlled trials that contributed data to the FDA approval of DMAb for the bone loss indication were analyzed. These trials included study populations with low bone mass/osteoporosis and those receiving hormone ablation therapy. Trials in postmenopausal women with osteoporosis (FREEDOM, Trial 1, NCT00089791, [1]) and low bone mass (Trial 2, NCT00091793, [3]), in men with osteoporosis (Trial 3, NCT00980174, [4]), in women receiving adjuvant aromatase in-

hibitors for breast cancer (Trial 4, NCT00089661, [5]), and in men receiving androgen deprivation therapy for prostate cancer (Trial 5, NCT00089674, [6]) were analyzed. The analysis was stratified by trial and only included data from the Pbo-controlled period of each trial. A time-to-event analysis of first fall and exposure-adjusted subject incidence rates of falls (data not shown) were analyzed. Falls were reported as adverse events and not prospectively collected.

Results: Kaplan-Meier estimates showed an occurrence of falls in 6.5% of subjects in the Pbo groups (N=5006) compared with 5.2% in DMAB-treated subjects (N=5030), with an HR (95%CI) of 0.78 (0.66, 0.93), *P*-value=0.0053. The forest plot of time-to-first occurrence of fall is shown for both the individual studies and overall (Figure), and exposure-adjusted subject incidence rates of falls showed similar results. Heterogeneity in study designs did not permit overall assessment of association with fracture outcomes.

Figure. Time-to-first Occurrence of Fall Adverse Event



N = Number of subjects who received at least 1 dose of investigational product in Trial 1 (placebo-controlled 36 months), Trial 2 (placebo-controlled first 24 months), Trial 3 (placebo-controlled first 12 months), Trial 4 (placebo-controlled first 24 months), and Trial 5 (placebo-controlled first 36 months).

REFERENCES:

- [1] Cummings S, et al. *N Engl J Med.* 2009;361:756-765.
- [2] Dufresne S, et al. *Receptors Clin Investig.* 2016;3(2):e1323-1–e1323-6.
- [3] Bone HG, et al. *J Clin Endocrinol Metab.* 2008;93(6):2149-2157.
- [4] Langdahl BL, et al. *J Clin Endocrinol Metab.* 2015;100(4):1335-1342.
- [5] Ellis GK, et al. *J Clin Oncol.* 2008;26(30):4875-4882.
- [6] Smith MR, et al. *N Engl J Med.* 2009;361(8):745-755.

Conclusion: DMAb may reduce the risk of falls in postmenopausal women with osteoporosis, in addition to the established fracture risk reduction in these patients.

Disclosures: This study was sponsored by Amgen Inc. Eugene McCloskey–Grants/Research support from ActiveSignal, Amgen, AR UK, AstraZeneca, Consilient Healthcare, GSK, Hologic, I3 Innovus, Internis, IOF, Lilly, Medtronic, Merck, MRC, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Synexus, Tethys, UCB, Unilever, and Warner Chilcott; Consultant for ActiveSignal, Amgen, Consilient Healthcare, Fresenius Kabi, GSK, Synexus, and UCB; Speaking fees from AgNovos, Amgen, AstraZeneca, Consilient

Healthcare, GSK, Hologic, Internis, Lilly, Pfizer, Roche, Servier, and UCB. Richard Eastell–Grants from Alexion, Amgen, Immunodiagnostic Systems, Roche, and Ultragenyx; Consultancy fees from Alexion, Amgen, D-Star, Immunodiagnostic Systems, Roche, and Sandoz; Speaker fees from Amgen; Travel expenses from Radius. Michael McClung–Consultant and Speakers’ Bureau for Amgen and Radius Health. Nicola Pannacchiulli, Christine Wang, and Susan Yue–Employees and Stockholders of Amgen Inc. Steven R. Cummings–Consultant for Amgen and Radius.

OC30

IS LOW IMPACT PHYSICAL ACTIVITY ASSOCIATED WITH LOWER LIMB BONE DENSITY AND STRENGTH? RESULTS FROM THE HERTFORDSHIRE COHORT STUDY

C. M. Parsons¹, E. M. Dennison¹, J. Tobias², C. Cooper¹, K. Ward¹

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, ²Musculoskeletal Research Unit, University of Bristol, Bristol, UK

Objectives: Medium and high impact physical activity (PA) are positively associated with bone mass. However, several studies have shown PA of low impact is the predominant form of activity in later life. In this study we examined relationships between low impact PA, lower limb bone strength and muscle power in community dwelling older adults.

Methods: This study was based in participants of the Hertfordshire Cohort Study, men and women born in 1931-9. Participants underwent a pQCT scan of the tibia (4%, 14%, 38% sites) (Stratec 2000); and maximum jump power and velocity were assessed using a two-footed countermovement jump on a Leonardo Mechanography Ground Reaction Force Platform (Leonardo software version 4.2; Novotec Medical GmbH). Over a 7-d period participants wore triaxial accelerometers which enabled counts of low (0.5-1.0 g) impact activity to be calculated. Linear regression was used to quantify the association between bone parameters, muscle power, velocity and PA (defined as log-transformed low impact activity counts). Results are presented B (95%CI).

Results: 105 participants, mean(SD) age 76.1(2.7) y, wore accelerometers; jumping mechanography (JM) was available for 78 participants (65.4% male). PA was positively associated with maximum velocity (m/s) (1.82(0.92, 2.72), and maximum relative power (w/kg) (0.09 (0.04, 0.13)), with relationships remaining after adjustment for age and sex. Significant positive associations were found between total area (mm²) at 4% and 14% slice and activity counts ((38.7(11.8, 65.7)) (14.5 (2.3, 26.7))). Cortical mass (g/cm), cortical area (mm²) and polar strength strain index (mm³) were also positively associated with PA at 14% slice ((8.5 (1.6, 15.5)) (7.2 (1.4, 13.0)) (97.2 (42.3, 152.0)) and 38% slice ((10.5 (2.4, 18.6)) (60.4 (1.4, 119.5))). After adjusting for age, sex and BMI the relationship with tibia total area 4%, tibia total area 14% and polar strength strain index at 38% were attenuated.

Conclusions: On unadjusted analyses, low impact PA was associated with increased total area, cortical mass and area and strength of the tibia. Maximum velocity and relative power were also positively associated with low levels of loading, after adjustment for age and sex

OC31

DIETARY PROTEIN INTAKE AND FALLS IN OLDER PEOPLE: A LONGITUDINAL COHORT STUDY

N. Veronese¹, P. Soysal², S. Maggi¹, L. Smith³

¹Consiglio Nazionale delle Ricerche, Padova, Italy, ²Department of Geriatric Medicine, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey, ³The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK

Objective: Literature regarding dietary protein intake and risk of falls is limited to a few studies with relatively small sample sizes and short follow-ups, which have reported contrasting findings. Thus, we investigated whether dietary protein intake is associated with risk of falls in a large cohort of North American adults.

Methods: Data were drawn from the Osteoarthritis Initiative, a cohort study of community-dwelling adults with knee osteoarthritis or at high risk for this condition with 8 y of follow-up. Dietary protein intake was recorded using the Block Brief 2000 food frequency questionnaire and categorized using gender-specific quartiles (Q). Falls were self-reported in response to the question "Did you fall during the past year?" and categorized as yes vs. no during the 8 y of follow-up. Results are reported as relative risks (RRs) with their 95%CIs, using a multivariable Poisson regression.

Results: The final sample consisted of 4450 adults (mean age 61.2 y, females=59.6%). Higher dietary protein intake was significantly associated with higher frequency of falls during the previous year at baseline and prospectively over 8-y follow-up. After adjusting for 17 potential confounders, people with the greatest amount of protein intake (Q4) had a significantly higher risk of falling over the 8-year follow-up period (RR=1.112; 95%CI: 1.027-1.211; p=0.009) than those with the lowest protein intake (Q1).

Conclusion: High dietary protein intake may increase the risk of falls in older people, but further research is needed to confirm or refute these findings.

OC32

LONGITUDINAL ASSOCIATIONS BETWEEN DIETARY INFLAMMATORY INDEX AND MUSCULOSKELETAL HEALTH IN COMMUNITY-DWELLING OLDER ADULTS

M. M. Cervo¹, N. Shivappa², J. Hebert², W. Oddy³, T. Winzenberg³, S. Balogun³, F. Wu³, P. R. Ebeling¹, D. Aitken³, G. Jones³, D. Scott¹

¹Department of Medicine, Monash University, Clayton, Australia, ²Arnold School of Public Health, University of South Carolina, Columbia, SC, USA, South Carolina, USA, ³Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia

Objective: This study was designed to determine prospective associations between dietary inflammatory index (DII[®]) scores and bone health, sarcopenia-related outcomes, falls risk and incident fractures in community-dwelling Australian older adults.

Methods: A total of 1098 [51% male; age (mean±SD) 63.0±7.5 years] noninstitutionalized older adults who participated in the Tasmanian Older Adult Cohort Study (TASOAC) at baseline, 768

at 5 y, and 566 at 10 y follow-up were included in this analysis. Baseline energy-adjusted DII (E-DII) scores were calculated using a validated food frequency questionnaire. Changes in BMD and appendicular lean mass (ALM) were measured over ten years using DXA. 10-y changes in hand grip, knee extensor and whole lower-limb muscle strength and quality were assessed by dynamometers and change in falls risk score using the physical profile assessment (PPA). Incident fractures at any site and non-vertebral fractures over 10 y were self-reported.

Results: The E-DII range was -3.48 to +3.23 in men and -3.80 to +2.74 in women. Higher E-DII score (indicating a more pro-inflammatory diet) was associated with lower total hip (B: -0.009; 95%CI: -0.017, 0.000) and lumbar spine BMD (B: -0.013; 95%CI: -0.024, -0.002), and higher falls risk score (B: 0.040; 95%CI: 0.002, 0.078) over 10 y in men. Women with higher E-DII scores had higher whole lower-limb muscle quality over 10 y (B: 0.109; 95%CI: 0.002, 0.215). For every unit increase in E-DII score, incident fracture rates increased by 9.0% in men (IRR: 1.090; 95%CI: 1.011, 1.175) and decreased by 12.2% in women (IRR: 0.878; 95%CI: 0.800, 0.964) in a fully adjusted model.

Conclusion: Higher E-DII scores were associated with lower bone density, higher falls risk, and increased incidence of fractures in community-dwelling older men, but decreased fracture incidence in women, over 10 y. This suggests pro-inflammatory diets may be more detrimental to musculoskeletal health in older men than in women. Additional studies are warranted to elucidate these sex differences.

OC33 COST-EFFECTIVENESS ASSESSMENT OF DIFFERENT GLUCOSAMINES IN PATIENTS WITH KNEE OSTEOARTHRITIS: A SIMULATION MODEL ADAPTED TO GERMANY

O. Bruyère¹, J. Detilleux², J.-Y. Reginster^{1,3}

¹Department of Public Health, Epidemiology and Health Economics, WHO Collaborating Centre for Public Health, Aspects of Musculo-Skeletal Health and Ageing, University of Liège, Liège, Belgium, ²Department of Veterinary Management of Animal Resources, University of Liège, Liège, Belgium, ³Chair for Biomarkers and Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia

Introduction: The use of symptomatic slow-acting drugs for osteoarthritis (e.g. glucosamine, chondroitin) is largely debated in the scientific literature. Indeed, multiple formulations of these agents are available, both as prescription-grade products and nutritional supplements but, while all preparations may claim to deliver a therapeutic effect, not all are supported by clinical evidence. Moreover, few data are available regarding the cost-effectiveness of all these formulations. The economic evaluation of treatments usually requires access to individual patient data, which is difficult to obtain. We previously developed a model to simulate individual health utility scores from aggregated data obtained in published trials (Bruyère et al., Aging Clin Exp Res.

2019). In the present study, we investigated, using our new simulation model, the cost-effectiveness of different glucosamines used in Germany.

Methods: We used our validated model to simulate the utility scores of 10 published trials that used different glucosamine preparations. The utility estimates were used to calculate the quality-adjusted life year (QALY) using the area-under-the-curve method. We used the 2018 public costs of glucosamine products available in Germany. The incremental cost/effectiveness ratio (ICER) was then calculated. We separated the analyses for pharmaceutical grade crystalline glucosamine sulfate and other formulations of glucosamine. A costeffectiveness cut-off of 30.000 €/QALY was considered.

Results: From 10 studies where utility was simulated, four used crystalline glucosamine sulfate, and six used other formulations. The ICER revealed that compared to placebo, crystalline glucosamine sulfate was costeffective with an ICER of 4583 €/QALY at month 3, 4121 €/QALY at month 6 and 9889 €/QALY at year 3. The use of other formulations was not cost-effective at any of the time points considered.

Conclusion: Using a new model to simulate individual health utility scores of patients, we showed that, in the German context, the use of crystalline glucosamine sulfate is cost-effective, while other formulations are not. These results confirm the importance of the formulation of glucosamine products.

OC34 COST-EFFECTIVENESS OF GASTRO-RESISTANT RISEDRONATE TABLETS FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS IN FRANCE

M. Hiligsmann¹, J.-Y. Reginster²

¹Maastricht University, Maastricht, The Netherlands, ²University of Liège, Liège, Belgium

Objective: Gastro-resistant (GR) risedronate tablets are associated with improved persistence compared to common oral bisphosphonates, but are slightly more expensive. This study assessed its cost-effectiveness compared to weekly alendronate, generic risedronate and no treatment for the treatment of postmenopausal women with osteoporosis in France.

Methods: A previously validated Markov microsimulation model was used to estimate the lifetime costs (expressed in €2017) per quality-adjusted life-years (QALY) of GR risedronate compared with weekly alendronate, generic risedronate and no treatment. Pooled efficacy data for bisphosphonates derived from a previous meta-analysis were used for all treatment options and persistence data (up to 3 years) were obtained from a large Australian longitudinal study. Evaluation was done for high-risk women 60-80 years of age, with a BMD T-score \leq -2.5 and/or prevalent vertebral fractures. One-way and probabilistic sensitivity analyses were performed to test the robustness and uncertainty of the model results.

Results: In all of the simulated populations, GR risedronate was cost-effective compared to alendronate, generic risedronate and no treatment at a threshold of €60,000 per QALY gained. In women with a BMD T-score ≤ -2.5 and prevalent vertebral fractures, the cost per QALY gained of GR risedronate compared to alendronate, generic risedronate and no treatment fall below €20,000 per QALY gained. In women aged 75 years and older, GR risedronate was even shown to be dominant (more QALYs, less costs) compared to alendronate, generic risedronate and no treatment. Sensitivity analyses suggest that results are most sensitive to the incremental difference in persistence between GR risedronate and the active comparators

Conclusion: This study provides the first economic results about GR risedronate, suggesting that it represents a cost-effective strategy compared with weekly alendronate, generic risedronate and no treatment for the treatment of postmenopausal women with osteoporosis in France.

Disclosure: This study was funded by Teva and Theramex.

OC35

LOCAL OSTEO-ENHANCEMENT PROCEDURE FOR OSTEOPOROTIC BONE LOSS INCREASES RAW TRABECULAR BONE SCORE (R-TBS) IN PROXIMAL FEMURS AT 5-7 YEARS FOLLOW-UP

R. Hill¹, J. Stroncek¹, J. Howe¹, B. Huber², C. Lelong³, D. Hans³

¹AgNovos Healthcare, Rockville, USA, ²Copley Hospital, Morrisville, USA, ³Medimap Group, Plan-les-Quates, Switzerland

Objectives: This study evaluated the long-term effects of a novel local osteo-enhancement procedure (LOEP) on bone microarchitecture in the hip.

Methods: Osteoporosis is characterized by deteriorating bone microarchitecture leading to increased fracture risk. Trabecular bone score (TBS) is correlated with changes in bone microarchitecture and is independent of BMD¹. AGN1 LOEP is a minimally invasive treatment for local osteoporotic bone loss. The treatment involves injecting a triphasic calcium sulfate/calcium phosphate implant material (AGN1) into a surgically prepared site in the proximal femur. AGN1 is then resorbed and replaced with bone. An IRB-approved clinical study enrolled 12 postmenopausal osteoporotic women (age range: 59-86). The left proximal femur was treated with AGN1 LOEP; the right was an untreated control. Ten patients were available for imaging at 5-7 year follow-up. TRIP software v1.0 (Medimaps) was used to analyze the texture of AP DXAs and compute a raw TBS (rTBS). The region of interest included trabecular space from the lateral subtrochanteric region to the femoral neck.

Results: There was no significant difference at baseline between treated and control femoral neck aBMD or rTBS. At 5-7 y, AGN1 was completely resorbed and femoral neck aBMD had increased 57.4% in treated compared to control femurs (0.828±0.125 vs. 0.526±0.039 g/cm²; p<0.001). Similarly, rTBS was 55.3% greater in treated vs. control femurs (1.376±0.033 vs. 0.886±0.112; p<0.001). In addition, for all treated femurs rTBS increased;

whereas for all control femurs, rTBS decreased from baseline. AGN1 LOEP improved femoral neck aBMD with a concomitant increase in femoral rTBS suggesting improved proximal femur trabecular microarchitecture.

Conclusions: Differences between treated and control femurs suggest that AGN1 LOEP treatment results in bone less prone to fracture, supporting further analyses during clinical use of AGN1 LOEP.

References: 1. Silva BC et al. *J Bone Miner Res* 2014;29:518

OC36

EFFECTS OF MUSIC-BASED MULTITASK EXERCISE (JAQUES-DALCROZE EURHYTHMICS) VERSUS MULTICOMPONENT EXERCISE ON PHYSICAL FUNCTION, FALLS AND BRAIN PLASTICITY IN OLDER ADULTS: A RANDOMIZED CONTROLLED TRIAL

M. Hars¹, N. Fernandez², F. Herrmann³, R. Rizzoli¹, G. Gold³, P. Vuilleumier², A. Trombetti¹

¹Division of Bone Diseases, Department of Medicine, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland, ²Laboratory for Behavioural Neurology and Imaging of Cognition, Campus Biotech, University of Geneva, Geneva, Switzerland, ³Division of Geriatrics, Department of Readaptation and Geriatrics, Geneva University Hospitals and Faculty of Medicine, Thônex, Switzerland

Objectives: Currently, no robust evidence exists to support one exercise type over another for prevention of physical decline and falls among older adults, primarily because of the lack of comparative trials. The music-based multitask program Jaques-Dalcroze Eurhythmics (JDE) has been shown to increase physical performances and reduce falls [1], but also to improve executive functions, which play a crucial role in falls risk. In the EPHYCOS study, we aimed to i) determine the effectiveness of a JDE exercise intervention compared with a multicomponent (MULTI) exercise intervention –an evidence-based fall prevention program– on physical function and falls, and ii) explore to which extent these interventions are associated with changes in brain structure and brain activity.

Material and Methods: We conducted a prospective, randomized, single blind comparative effectiveness trial involving 142 community-dwelling older adults (130 women; 74.3±6.5 years) at high risk for falls. Participants were randomized to i) a JDE exercise program (once weekly, group-based) or ii) a MULTI exercise program (twice weekly, mix of group- and home-based) that included balance, gait, and strength training activities, for 12 months. Physical and falls outcomes were assessed over 12 months. In an exploratory sub-study (n=34), brain structure and function were also assessed through magnetic resonance imaging (MRI).

Results: At 12 months, physical performances improved in both groups, but the JDE group improved more than the MULTI group in gait and balance tests (e.g., Timed up & Go and Tinetti tests: p for interaction= 0.013 and 0.030, respectively). The JDE program reduced falls as compared with the MULTI program (adjusted haz-

ard ratio, 0.50 [95%CI, 0.29-0.87]). Exercise-related changes in functional brain MRI showed a decreased activation in the executive network in the JDE group, while an over-recruitment of motor and salience networks was observed in the MULTI group. Finally, an increase of grey matter density across several brain areas was observed in the structural analysis for the JDE group only.

Conclusion: In conclusion, JDE exercise results in greater benefits compared with MULTI exercise for a variety of physical outcomes and for falls reduction in older adults. The JDE exercise-related improvements are associated with brain plasticity, including both functional and structural changes in regions related to executive functions.

References [1] Trombetti et al. Arch Intern Med 2011.




FIGURE 1. ILLUSTRATION OF THE BRAIN AREAS ASSOCIATED WITH CONFLICT RESOLUTION (BASED ON A MODIFIED ERIKSEN FLANKER TASK)
 a) In blue, the brain areas reduced after the intervention (i.e. activated at baseline but no more activated at 12-month).
 b) In red, the brain areas increased after the training (i.e. not activated at baseline and recruited at 12-month).
 All the clusters presented are significant at the peak-level at $p < 0.001$, uncorrected for multiple comparisons, with a minimum cluster size of 50.

OC37

RESULTS FROM A PHASE 2B TRIAL OF SM04690, A NOVEL INTRA-ARTICULAR WNT PATHWAY INHIBITOR FOR THE TREATMENT OF KNEE OSTEOARTHRITIS

Y. Yazici¹, T. McAlindon², A. Gibofsky³, N. Lane⁴, C. Lattermann⁵, N. Skrepnik⁶, C. Swearingen¹, A. Difrancesco¹, J. Tambiah¹, M. Hochberg⁷

¹Samumed, LLC, San Diego, ²Tufts Medical Center, Boston, USA, ³Weill Cornell Medical College and Hospital for Special Surgery, New York, ⁴UC Davis Medical Center, Davis, ⁵Brigham and Women's Hospital, Harvard University, Cambridge, ⁶Tucson Orthopedic Institute, Tucson, ⁷University of Maryland School of Medicine, Baltimore, USA


Objective: A phase 2a study of SM04690 demonstrated improvements in knee pain, physical function, and medial joint space width (mJSW) at 52 weeks in key subgroups of subjects with knee osteoarthritis (OA) compared to placebo (PBO).¹ A 24-week phase 2b study was conducted to refine patient reported outcomes (PROs), target population, dose, and to assess safety. PRO results (Weeks 12 and 24) are presented.

Methods: Subjects with knee OA, Kellgren-Lawrence (KL) grade 2 or 3, and Pain Numeric Rating Scale (NRS) scores ≥ 4 and ≤ 8 in the target knee (< 4 in nontarget knee) were given a single 2 mL IA injection of SM04690 (0.03, 0.07, 0.15, 0.23 mg), vehicle PBO, or sham (dry needle only) on Day 0. PROs included change from baseline in weekly average of daily pain in target knee (NRS) [0-10], WOMAC Pain [0-100], WOMAC Physical Function [0-100], and Patient Global Assessment (PtGA)-VAS [0-100].

Results: 635 subjects (91.4%) completed the study. No safety signals were observed.

Significant improvements from baseline compared to PBO were observed in pain NRS for 0.07 mg and 0.23 mg groups at Weeks 12 and 24 (Figure). Similar improvements were observed in WOMAC Pain, WOMAC Physical Function, and PTGA for 0.07 mg (Week 12) and 0.23 mg (Weeks 12 and 24) dose groups.

Figure. Actual observations over time and ladder plots depicting mean improvement ($\pm 95\%CI$) of SM04690 compared to baseline-adjusted PBO for Pain NRS



Conclusion: SM04690, in development as a potential disease-modifying OA drug, showed in this Phase 2b study statistically significant improvements from baseline compared to PBO for PROs in pain, function, and PTGA. Phase 3 studies are planned.

Reference: 1. Yazici Y et al. *Arthritis Rheum* 2017;69(suppl 10).

Disclosures: All authors are employees or consultants of Samumed, LLC


OC38 LONG TERM RATES OF CHANGE IN MUSCULOSKELETAL AGING: FINDINGS FROM THE HEALTH, AGING AND BODY COMPOSITION STUDY

L. D. Westbury¹, H. E. Syddall¹, E. M. Dennison¹, J. A. Cauley², T. B. Harris³, E. J. Shiroma⁴, B. H. Goodpaster⁵, A. B. Newman², C. Cooper¹

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK, ²Department of Epidemiology, University of Pittsburgh, Pittsburgh, USA, ³Laboratory of Epidemiology and Population Sciences, Intramural Research Program, National Institute on Aging, Bethesda, USA, ⁴Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, USA, ⁵Translational Research Institute for Metabolism and Diabetes, Florida Hospital, Orlando, USA

Objective: To describe change in grip strength, walking speed, lean mass and hip BMD among older people participating in a population-based US cohort study.

Methods: Analyses were based on 3075 older men and women (aged 70-79 y at baseline) from the Health, Aging and Body Composition Study. Total hip BMD and whole body lean mass were ascertained using DXA; muscle strength by grip dynamometry; and customary walking speed was measured as a marker of muscle function. Each measure was assessed at least 5 times during a



median 9 year follow-up period. Mean annual percentage change was compared between characteristics. Measures of conditional change (independent of baseline) were derived for each characteristic and their interrelationships were examined using Pearson correlations. For each characteristic, the mean trajectory in relation to age was estimated using linear mixed models with random intercepts and slopes.

Results: Mean (SD) age at baseline was 74.1 (2.9) y. Mean annual percentage declines for walking speed and grip strength were 2.1% and 1.5%, respectively; declines were smaller for hip BMD (0.6%) and lean mass (0.5%). Mean trajectories for grip strength, walking speed and hip BMD were quadratic; declines accelerated with advancing age. Decline in lean mass was linear. All conditional change measures were significantly (p<0.05) and positively correlated, suggesting that declines in these characteristics co-occur. Conditional changes in hip BMD and lean mass were most strongly correlated (r=0.42, p<0.001); 0.08<r<0.24 for correlations between other conditional change measures.

Conclusions: These analyses provide unique insights into the life-course trajectory of body composition, muscle strength and physical performance. The indices of body composition (BMD and lean mass) clearly cluster together; furthermore, baseline values explain around 80% of the variance in these markers some 9 years later. In marked contrast, grip strength and walking speed may be much more susceptible to alterations in their loss rate, with only around 50% of the variance in later measurement explained by baseline values. Finally, declines in grip strength and walking speed accelerate with advancing age and are considerably greater than those observed for lean mass and BMD.



2019 PARIS

WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES

PARIS, France | 2019

Abstract Book

ESCEO Symposia Abstracts

ESCEO1

IDENTIFICATION PRIORITIZATION OF IMPORTANT ATTRIBUTES OF OA TREATMENT

E. M. Dennison¹, on behalf of the ESCEO Working Group on patients' preferences for anti-osteoarthritis treatment: a cross-European Discrete Choice Experiment

¹MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom

In recent years, there has been a growing interest in obtaining patients' preferences for healthcare treatments that are deemed 'preference sensitive'. In particular, the use of stated-preference studies, including discrete-choice experiments (DCE), has markedly increased. Preference sensitive treatments are those in which there are trade-offs between health benefits and risks. Previous studies of this kind that have focused on osteoarthritis (OA) treatment have suggested that OA patients are most concerned about efficacy and risks of therapy. Further insights into the preferences of patients will be useful to optimize policy and clinical decision making through healthcare decision making that better reflects patients' preferences.

An important step in the conduct of a DCE is the identification and selection of attributes. We therefore followed a four-step process. First a literature review was undertaken by 2 researchers to identify potential outcomes that might be important to OA patients. Second, individual interviews with OA patients and experts were made to identify further outcomes. Third, based on the list of 26 identified outcomes, a survey was conducted with 56 OA patients from seven European countries to ask them to identify and prioritize the most important characteristics regarding OA treatment. Finally, the final list of outcomes was agreed at an expert meeting (n=11), held in March 2018. The expert group agreed on seven attributes to be included in the DCE: improvement in pain, improvement in walking, ability to manage domestic activities (such as cooking, cleaning, gardening), ability to manage social activities (such as playing games, belonging to social groups, or traveling), improvement in overall energy and well-being, risk of moderate/severe side effects and impact on disease progression.

ESCEO2

A CROSS-EUROPEAN DISCRETE CHOICE EXPERIMENT TO ELICIT PATIENTS' PREFERENCES FOR OSTEOARTHRITIS TREATMENT

M. Hilgsmann¹, on behalf of the ESCEO Working Group on patients' preferences for anti-osteoarthritis treatment: a cross-European Discrete Choice Experiment

¹Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands

This study aims to evaluate the preferences of patients for anti-osteoarthritis treatment by establishing how they trade between the seven previously identified outcomes using a discrete-choice experiment (DCE). In the DCE survey, patients were repetitively asked to choose which one of two treatment options (Treatment A and Treatment B) they would prefer. The two treatment differs

in seven attributes, i.e. improvement in pain, improvement in walking, ability to manage domestic activities (such as cooking, cleaning, gardening), ability to manage social activities (such as playing games, belonging to social groups, or traveling), improvement in overall energy and well-being, risk of moderate/severe side effects and impact on disease progression. An efficient experimental design was used to construct the 12 choice sets and the self-completed paper questionnaire was pilot tested with about 20 osteoarthritis patients to check interpretation problems and face validity. The DCE is thereafter conducted in about 250 patients with knee and/or hip osteoarthritis recruited in UK, France, Belgium, Italy, Netherlands, Portugal and Spain. A mixed logit panel data model was used to estimate patients' preferences and a latent class model was conducted to identify profiles of responses. Results of the DCE will be presented during the symposium and reveal the most important treatment outcomes for patients with osteoarthritis, as well as potential patients' profiles and differences between European countries.

ESCEO3

METHODOLOGY OF THE ESCEO WORKING GROUP

C. Cooper^{1,2}

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ²Institute of Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) sought to revisit the 2014 algorithm recommendations for knee osteoarthritis (OA), in light of recent efficacy and safety evidence, in order to develop an updated stepwise algorithm that provides practical guidance for the prescribing physician that is applicable in Europe and internationally.

Using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) process, a summary of evidence document for each intervention in OA was provided to all members of an ESCEO working group, who were required to evaluate and vote on the strength of recommendation for each intervention. Based on the evidence collected, and on the strength of recommendations afforded by consensus of the working group, the final algorithm was constructed.

An algorithm for management of knee OA comprising a stepwise approach and incorporating consensus on 15 treatment recommendations was prepared by the ESCEO working group. Both "strong" and "weak" recommendations were afforded to different interventions. The algorithm highlights the continued importance of non-pharmacological interventions throughout the management of OA. Benefits and limitations of different pharmacological treatments are explored in this article, with particular emphasis on safety issues highlighted by recent literature analyses.

Conclusions: The updated ESCEO stepwise algorithm, developed by consensus from clinical experts in OA and informed by available evidence for the benefits and harms of various treatments, provides practical, current guidance that will enable clinicians to deliver patient-centric care in OA practice.

ESCEO4

SAFETY OF ANALGESICS, NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND OPIOIDS

N. R. Fuggle¹, E. M. Curtis¹, S. Shaw¹, L. Spooner², O. Bruyère^{3,4}, G. Ntani¹, C. Parsons¹, P. G. Conaghan⁵, N. Corp⁶, G. Honvo^{3,4}, S. Maggi⁷, D. Uebelhart⁸, J. Baird¹, E. M. Dennison¹, J.-Y. Reginster^{3,4,9}, C. Cooper^{1,4,10}

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, United Kingdom, ²University Hospitals Southampton NHS Trust, Southampton, United Kingdom, ³Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ⁴WHO Collaborating Centre for Public Health Aspects of Musculo-Skeletal Health and Aging, Liège, Belgium, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Arthritis Research UK Primary Care Centre, Institute for Primary Care & Health Sciences, Keele University, Keele, United Kingdom, ⁷National Research Council, Neuroscience Institute, Aging Branch, Padua, Italy, ⁸Division of Musculoskeletal, Internal Medicine and Oncological Rehabilitation, Department of Orthopaedics and Traumatology, Hôpital du Valais (HVS), Centre Hospitalier du Valais Romand (CHVR), CVP, Crans-Montana, Switzerland, ⁹Chair for Biomarkers and Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia, ¹⁰National Institute for Health Research (NIHR) Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom

Objectives: To assess the safety of opioids and COX-2 inhibitors in the management of osteoarthritis (OA) in a systematic review and meta-analysis of randomized, placebo-controlled trials.

Materials and methods: A comprehensive literature search was undertaken in the databases MEDLINE, Cochrane Central Register of Controlled Trials (Ovid CENTRAL), and Scopus. Randomized, double-blind, placebo-controlled, parallel-group trials that assessed adverse events (AEs) with opioids or COX-2 inhibitors in patients with OA were eligible for inclusion. The primary outcomes were severe and serious AEs, as well as MedDRA System Organ Class (SOC)-related AEs: gastrointestinal (GI) disorders, cardiac disorders, vascular disorders, nervous system disorders, and dermatologic disorders.

Results: For opioids, database searches identified 2189 records from which, after exclusions, 17 papers were included in the meta-analysis. More disorders of the lower gastrointestinal (GI) tract (constipation, fecaloma) were reported with both immediate-release (IR) and extended-release (ER) formulations of opioids versus placebo: IR opioids (relative risk [RR] = 5.20, 95% confidence interval [CI] 3.42, 7.89); ER opioids (RR = 4.22, 95% CI 3.44, 5.17).

The risk of risk of nausea, vomiting or loss of appetite increased 4 to 5-fold with both IR (RR = 3.39, 95% CI 2.22, 5.18) and ER opioids (RR = 4.03, 95% CI 3.37, 4.83). An increased risk of dermatologic AEs (rash and pruritis) (IR opioids: RR = 3.60, 95% CI 1.74, 7.43; ER opioids: RR = 7.87, 95% CI, 5.20, 11.89).

For COX-2 inhibitors, database searches identified 2149 records from which, after exclusions, 40 trials were included in the meta-analysis. The use of COX-2 inhibitors in OA was associated with a significantly increased risk of drug-related AEs compared with placebo (relative risk [RR] = 1.26, 95% CI 1.09, 1.46; I² = 24%). The risk of upper gastrointestinal complications (including dyspepsia, gastritis, and heartburn) was significantly increased with COX-2 inhibitors versus placebo (RR = 1.19, 95% CI 1.03, 1.38; I² = 0%). The risk of heart failure and edema was increased by nearly 70% with COX-2 inhibitors versus placebo (RR = 1.68, 95% CI 1.22, 2.31; 0%).

Conclusions: Our results confirm the concerns regarding safety and tolerability surrounding the use of opioids and COX-2 inhibitors in OA.

ESCEO5

SAFETY OF SYSADOAS, INTRAARTICULAR HYALURONIC ACID AND INTRAARTICULAR CORTICOSTEROIDS

T. McAlindon¹, M. Osani¹

¹Tufts Medical Center, Boston, United States

Objectives: In the absence of any treatments clearly established to modify the progression of OA, a number of products have been tested and/or promulgated for potential chondroprotective effects while providing symptom relief. These treatments could theoretically be preferable to traditional analgesic regimens through lower risk of toxicity. We comprehensively assessed the safety profiles of agents in this broad category in patients with knee and/or hip OA.

Material and Methods: We searched Medline and the Cochrane Databases from inception through December 2017. We included randomized controlled trials (RCTs) of knee / hip OA that tested avocado soybean unsaponifiables (ASU), glucosamine (GC), chondroitin (CS), risedronate, calcitonin, diacerein strontium ranelate (SR), intra-articular hyaluronic acid (IAHA), intra-articular corticosteroids (IACS). Reference screening and extraction of adverse event data were undertaken by two independent reviewers. We calculated risk ratios and 95% confidence intervals using a random effects model. Data from knee OA, hip OA, and mixed knee/hip OA populations were analyzed separately.

Results: We identified 118 eligible RCTs involving 22,994 knee OA patients, 18 RCTs involving 1,877 hip OA patients, and 2 RCTs involving 468 patients with knee and/or hip OA. In these RCTs, there were no significant increase in risk for adverse events compared to placebo for ASU, GC, CS, risedronate, or SR. Evidence of toxicity was evident in RCTs of calcitonin (more withdrawals, GI AEs, flushes); diacerein (diarrhea, withdrawals), IAHA (AEs, SAEs, and local reactions). There was no significant difference in safety outcomes observed between IACS and IA placebo in studies of

up to 2 years, although one of these detected an increased rate of cartilage damage of uncertain clinical significance. Quality of toxicity reporting was generally low and in one instance inconsistent with post-marketing surveillance (SR).

Conclusions: Evaluation of toxicity profiles based on RCTs can be limited by methodologic problems, inconsistent reporting, small numbers of events (especially serious events) and issues of generalizability. However, no safety signals emerged for nutritional products promulgated for OA.

ESCEO6

THE 2014-2016 ESCEO ALGORITHM FOR THE MANAGEMENT OF KNEE OSTEOARTHRITIS

O. Bruyère¹

¹Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) published a treatment algorithm for the management of knee osteoarthritis (OA) in 2014, which provides practical guidance for the prioritization of interventions. Basic principles consist of the need for a combined pharmacological and non-pharmacological treatment with a core set of initial measures, including information access/education, weight loss if overweight, and an appropriate exercise program. Four multimodal steps are then established. Step 1 consists of background therapy, either non-pharmacological (referral to a physical therapist for re-alignment treatment if needed and sequential introduction of further physical interventions initially and at any time thereafter) or pharmacological. The latter consists of chronic Symptomatic Slow-Acting Drugs for OA (e.g., prescription glucosamine sulfate and/or chondroitin sulfate) with paracetamol at-need; topical NSAIDs are added in the still symptomatic patient. Step 2 consists of the advanced pharmacological management in the persistent symptomatic patient and is centred on the use of oral COX-2 selective or non-selective NSAIDs, chosen based on concomitant risk factors, with intra-articular corticosteroids or hyaluronate for further symptom relief if insufficient. In Step 3, the last pharmacological attempts before surgery are represented by weak opioids and other central analgesics. Finally, Step 4 consists of end-stage disease management and surgery, with classical opioids as a difficult-to-manage alternative when surgery is contraindicated. Further analysis of real-world data for OA, published in 2016, provided additional evidence in support of pharmacological interventions, in terms of management of OA pain and function, avoidance of adverse events, disease-modifying effects and long-term outcomes, e.g., delay of total joint replacement surgery, and pharmacoeconomic factors such as reduction in healthcare resource utilization. Since 2014, these guidance documents have received international endorsement, with translation, adaptation to the local context, and publication in China, Russia, and South-East Asia.

ESCEO7

NEW INSIGHTS IN THE MANAGEMENT OF OSTEOARTHRITIS

C. Cooper^{1,2}

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ²Institute of Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

Knee osteoarthritis (OA) affects around 4% of people worldwide and accounts for 17.1 million years of life lived with disability. It is expected to become the fourth leading cause of functional impairment by 2020, placing a huge burden on health services. Recommendations for the management of knee OA have been issued by several international and national bodies, including the European League Against Rheumatism (EULAR); the American Society for Rheumatology (ACR); and the Osteoarthritis Research Society (OARSI). These have recently been systematically evaluated by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), to construct a treatment algorithm that might enhance OA management throughout Europe and worldwide. The initiative advanced existing practice guidelines, which typically evaluate interventions individually, by prioritising these into a well-ordered series of practical steps which can be undertaken by physicians. The algorithm was constructed by an international taskforce experienced in the performance, analysis and interpretation of clinical trial evidence in OA. The core set of measures, which are applicable to all patients with knee OA include: (a) Access to information about the disease and education about the disorder; (b) Weight loss if adipose; and provision of (c) an exercise programme. The consequent treatment algorithm consists of four multimodal steps. Step 1 consists of background therapy, either non-pharmacological (referral to a physical therapist for realignment treatment if needed and sequential introduction of further physical interventions) or pharmacological. The latter consists of chronic symptomatic slow-acting drugs for OA (eg prescription of glucosamine sulphate with chondroitin sulphate) with paracetamol if required; topical NSAIDs are added in the still symptomatic patient. Step 2 consists of the advanced pharmacological management in the persistently symptomatic patient. It centres on the use of oral COX-2 selective or non-selective NSAIDs, chosen based on concomitant risk factors, with intra-articular glucocorticoids or hyaluronic acid derivatives for further symptom relief. Step 3 incorporates the remaining pre-surgical pharmacological measures including weak opioids and other central analgesics such as duloxetine; Step 4 progresses to surgical intervention, or classical opioids where surgery is contraindicated. This treatment algorithm represents a new framework for the development of future guidelines for OA management, which are more easily accessible to primary and secondary care physicians.

ESCEO8

THE UPDATED ESCEO ALGORITHM FOR THE MANAGEMENT OF KNEE OSTEOARTHRITIS: ASSESSMENT OF THE VARIOUS TREATMENT MODALITIES BY GRADE

N. Veronese¹

¹consiglio nazionale delle ricerche, Padova, Italy

Objective: The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) decided to revisit the 2014 algorithm recommendations for knee osteoarthritis (OA), using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) process.

Material and methods: A Summary of Evidence document for each intervention was provided to all members of a dedicated working group and consisted of: a) 2014 Status; b) 2014-2018 Literature Search Results; c) GRADE Evidence Profiles: these tables included the summary of findings and quality assessment by a judgment of factors that determine the quality of evidence (certainty assessment) and the magnitude of effect for each outcome. The derived questions were subject to the GRADE Grid, rating evidence from weak to strong recommendations within the algorithm.

Results: Regarding non-pharmacological interventions, the ESCEO working group affords a strong recommendation for the core set consisting of education, weight loss and exercise programs. Regarding pharmacological interventions, in the first step (background treatment), the group gives a weak recommendation not to use paracetamol, a strong recommendation for prescription crystalline glucosamine sulfate (pCGS) or chondroitin sulfate, a weak recommendation for the use of other SYSADOAs and against glucosamine-chondroitin combinations. Topical NSAIDs have a strong recommendation as cyclic add-on analgesics in step 1. In step 2 (advanced pharmacological treatment), the ESCEO working group affords a strong recommendation for cyclic use of oral NSAIDs based on the patient risk profile, whilst the use of intra-articular medications (hyaluronate and corticosteroids) reaches only a weak recommendation. In step 3 (last pharmacological treatment), short-term weak opioids or duloxetine have a weak recommendation. In step 4 (most severe forms), the ESCEO working group gives a strong recommendation for total knee replacement and a weak recommendation to the use of classical oral/transdermal opioids for patients in whom surgery is contraindicated.

Conclusion: The GRADE assessment gives a solid evidence regarding the strength of the recommendations for interventions in the treatment of knee OA in the revised ESCEO algorithm guidelines. ESCEO9

IDENTIFICATION AND PRIORITIZATION OF IMPORTANT OUTCOMES FOR PATIENTS IN SARCOPENIA

C. Beaudart^{1,2}, O. Bruyère^{1,2}, J.-Y. Reginster^{1,2}, J. Bauer³, C. Cooper^{4,5}, A. J. Cruz-Jentoft⁶, C. Dupuy⁷, F. Landi⁸, M. Locquet^{1,2}, S. Maggi⁹, R. René¹⁰, Y. Rolland⁷, N. Vaquero⁶, M. Hiligsmann¹¹

¹Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ²WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liège, Belgium, ³Center for Geriatric Medicine, University of Heidelberg, Heidelberg, Germany, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁵NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁶Servicio de Geriatria, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain, ⁷Gérontopôle de Toulouse, University of Toulouse III, CHU Purpan, Toulouse, France, ⁸Department of Geriatrics, Neurosciences and Orthopedics, Catholic University of the Sacred Heart Rome, Milano, Italy, ⁹National Research Council, Neuroscience Institute, Aging Branch, Padua, Italy, ¹⁰Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland, ¹¹Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands

Objectives: Sarcopenia, defined by a progressive loss of muscle mass and function, has been shown to be associated with several individual and public health outcomes. Identifying hard clinical outcomes of patients with sarcopenia is an important step in designing valid and useful clinical trials and outcome studies. This study aims first to identify which outcomes are important for patients with sarcopenia and second to assess the most importance ones.

Material and methods: The identification and prioritization of outcomes for patients with sarcopenia was conducted following a 4-step procedure: 1) a literature review to generate an initial list of outcomes of sarcopenia; 2) an expert consultation (n=11) to restructure initial outcomes and validate them; 3) three focus groups with participants suffering from sarcopenia (2 in Belgium, 1 in Spain) to validate these outcomes, to generate additional ones and to rank the most important outcomes; 4) an expert meeting (n=11) to identify the 5 most important outcomes of sarcopenia based on the results of the focus groups.

Results: In the first step, the initial list of outcomes comprised 6 different outcomes: mortality, functional decline, hospitalisation, falls, fracture and length of hospitalisation. With the second step, the list was extended to 9 outcomes including mortality, hospitalisation, falls, fractures, institutionalisation, quality of life, difficulties in self-care, difficulties in moving and difficulties in domestic duties. In the third step, the focus groups with sarcopenic subjects (n=19, 6 men and 13 women, mean age 78 years) identified a large number of additional outcomes such as fatigue, affected mood, physical and mental slowness, loss of balance, fear of walking, etc; and each patient ranked the five most important

ones. Based on the ranking of all the outcomes during the focus groups, experts agreed on the 5 most important outcomes: “quality of life”, “mobility”, “domestic activities”, “fatigue” and “falls”.

Conclusion: This study identified and prioritized important outcomes for sarcopenia. The five important outcomes were used, during a next step, in a discrete-choice experiment to further elicit the relative importance of these outcomes in a larger group of patients and experts.

ESCEO10

A CROSS-EUROPEAN DISCRETE CHOICE EXPERIMENT TO ASSESS PATIENTS' PREFERENCES FOR SARCOPEZIA OUTCOMES

M. Hiligsmann¹, C. Beudart^{2,3}, O. Bruyère^{2,3}, E. Biver⁴, J. Bauer⁵, A. J. Cruz-Jentoft⁶, A. Gesmundo⁷, S. Goisser⁵, F. Landi⁸, M. Locquet^{2,3}, S. Maggi⁹, R. Rizzoli¹⁰, Y. Rolland¹¹, N. Vaqueró⁶, J.-Y. Reginster^{2,3}

¹Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands, ²Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ³WHO Collaborating Centre for Public Health Aspects of Musculo-Skeletal Health and Aging, Liège, Belgium, ⁴Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland, ⁵Center for Geriatric Medicine, University of Heidelberg, Heidelberg, Germany, ⁶Servicio de Geriátria, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain, ⁷Department of Medicine, University of Padua, Padua, Italy, ⁸Department of Geriatrics, Neurosciences and Orthopedics, Catholic University of the Sacred Heart Rome, Milano, Italy, ⁹National Research Council, Neuroscience Institute, Aging Branch, Padua, Italy, ¹⁰Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland, ¹¹Gérontopôle de Toulouse, University of Toulouse III, CHU Purpan, Toulouse, France

Objectives: To evaluate the preferences of patients for sarcopenia outcomes by establishing how they trade between the five previously identified outcomes using a discrete-choice experiment (DCE).

Methods: In the DCE survey, patients were repetitively asked to choose which one of two patients (Patient A and Patient B) suffering from sarcopenia who were eligible to receive a drug treatment deserves the most a treatment. The two patients presented different levels of risk for the five outcomes previously identified, i.e. quality of life, mobility, domestic activities, fatigue and falls. An efficient experimental design was used to construct the 12 choice sets. The questionnaire was pilot tested with 10 experts of sarcopenia and 20 sarcopenic subjects to check interpretation problems and face validity. The DCE was thereafter conducted in subjects of 65 years and older suffering from sarcopenia recruited in Belgium, France, Switzerland, Germany, Spain and Italy. A mixed logit panel data model was used to estimate patients' preferences and a latent class model was conducted to identify profiles of responses.

Results: A total of 202 sarcopenic subjects were included for the analysis (68% of women; mean age of 78 years). All five sarcopenia outcomes were shown to be significant and thus important for patients. Overall, the most important sarcopenia outcome was mobility (29%) followed by the ability to manage domestic activity (23%), the risk of falls (18%), fatigue (17%) and quality of life (12%). Significance variations in preferences between patients were observed for mobility and domestic activity. The latent class model identified two classes of respondents with class probabilities of 56% and 44%, respectively. In the first class, patients valued the most the mobility (42%) followed by ability to manage domestic activity (24%) and risk of falls (17%). In the second class, fatigue was the most important outcome (27%) followed by mobility (19%), domestic activity (19%), risk of falls (18%) and quality of life (17%)

Conclusion: This study suggests that all five sarcopenia outcomes were important for patients. Overall, the most important outcomes were mobility and ability to manage domestic activity although variations in preferences were observed between respondents.



2019 PARIS

**WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES**

PARIS, France | 2019

Abstract Book

**ESCEO-WHO Collaborating Centre for
Public Health Aspects of Musculoskeletal
Health and Aging Symposium Abstracts
(ESCEO-WHO CC)**

ESCEO-WHOCC1

OSTEOSARCOPENIC OBESITY: FACTS AND EVIDENCE SUPPORTING A DISTINCT ENTITY

J. Bauer^{1,2}

¹Center for Geriatric Medicine, University of Heidelberg, Heidelberg, Germany, ²Agaplesion Bethanien Krankenhaus Heidelberg, Heidelberg, Germany

The co-existence of impaired bone health (osteopenia/osteoporosis), reduced muscle mass and strength (sarcopenia), and increased adiposity (obesity) in middle-aged and older people has been identified in recent studies, leading to a proposal for the existence of “osteosarcopenic obesity” (OSO) as a distinct entity. At present OSO is described as the most advanced stage in a conceptual model of bone, muscle, and fat tissue change resulting from aging and individual comorbidities. A prevalence of 12–19% of OSO has been reported in women aged over 50 years in several studies. In the majority of them it was associated with poor physical performance and frailty. Recent evidence suggests a potential interconnection between osteoporosis, sarcopenia, and obesity on the basis of a shared pathophysiology. An increase in total and/or abdominal adipose tissue causes an increase in pro-inflammatory cytokines, as well as hormonal disturbances leading to losses of both muscle and bone tissues through a variety of mechanisms which ultimately affect clinical outcomes, such as a higher risk for falls and fractures. Mechanisms responsible for the development of OSO components are complex and may include multiple factors: endocrine versus local regulation, threshold effects, hormonal implications of comorbidities, and cross-talk between endocrine-immune-neurologic factors. However, at the moment evidence for the clinical relevance of OSA coming from carefully designed prospective studies is still scarce. Additional studies are therefore eagerly warranted.

ESCEO-WHOCC2

OSTEOSARCOPENIC OBESITY: ENOUGH EVIDENCE FOR A DISTINCT ENTITY?

J. Bauer¹, A. J. Cruz-Jentoft², on behalf of the ESCEO Working Group on osteosarcopenic obesity

¹Center for Geriatric Medicine, University of Heidelberg; AGAPLESION Bethanien Krankenhaus, Heidelberg, Germany, ²Servicio de Geriátría, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain

The co-existence of impaired bone health (osteopenia/osteoporosis), beyond the risks associated with the sum of the component parts remains to be proven and is a question of research interest. In this article we review evidence for the current operational definition of OSO, prevalence, pathophysiology, outcomes and exploratory approaches to the management of OSO components. To expand knowledge and understanding in this area, there is a need for consensus on a definition of OSO which will allow for identification, further epidemiological studies and comparisons between studies. Additionally, studies should assess whether the clinical outcomes associated with OSO are worse than the mere addition of those linked with its components. This will help to de-

termine whether defining a person as having this condition will eventually result in a more effective treatment than addressing each of the three conditions separately.

Authors: Jürgen M. Bauer MD, PhD, Alfonso J. Cruz-Jentoft MD, PhD, Roger A. Fielding PhD, John A. Kanis MD, Jean-Yves Reginster MD, PhD, Olivier Bruyère PhD, Matteo Cesari MD, PhD, Roland Chapurlat MD, PhD, Nasser Al-Daghri PhD, Elaine Dennison MB BChir, PhD, Jean-Marc Kaufman MD, PhD, Francesco Landi MD, PhD, Andrea Laslop MD, Médéa Locquet MSc, MPH, Stefania Maggi MD, PhD, Eugene McCloskey MD, Simone Perna PhD, René Rizzoli MD, PhD, Yves Rolland MD, PhD, Mariangela Rondanelli, MD, PhD, Pawel Szulc MD, PhD, Bruno Vellas MD, Mila Vlaskovska MD, Cyrus Cooper FMedSci

ESCEO-WHOCC3

IMPACT OF DIABETES MELLITUS ON OSTEOARTHRITIS INCIDENCE AND PROGRESSION

N. Veronese¹

¹consiglio nazionale delle ricerche, Padova, Italy

Objective: Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are common diseases that frequently co-exist, along with overweight/obesity. While the mechanical impact of excess body weight on joints may explain lower limb OA, we sought to explore whether T2DM is linked to OA outside of excess weight and whether T2DM may play a role in OA pathophysiology.

Material and methods: We conducted a critical review of the literature to explore the association between T2DM and OA, whether any association is site-specific for OA, and whether the presence of T2DM impacts on OA outcomes.

Results: T2DM has a pathogenic effect on OA through two major pathways involving oxidative stress and low-grade chronic inflammation resulting from chronic hyperglycemia and insulin resistance. T2DM is a risk factor for OA progression and has a negative impact on arthroplasty outcomes.

Conclusion: Our work suggested that T2DM is highly involved in the pathogenesis of knee OA, but future research is needed to better understand whether diabetes control and prevention can modulate OA occurrence and progression.

ESCEO-WHOCC4

MANAGEMENT OF OSTEOARTHRITIS IN DIABETIC PATIENTS

D. Uebelhart¹ on behalf of the ESCEO Working Group on diabetes and osteoarthritis

¹Division of Musculoskeletal, Internal Medicine and Oncological Rehabilitation, Department of Orthopaedics and Traumatology, Hôpital du Valais (HVS), Centre Hospitalier du Valais Romand (CHVR), CVP, Crans-Montana, Switzerland

The overall and targeted management of osteoarthritis (OA) in usual patients without diabetes is well defined and was addressed in various papers of the ESCEO Working Group on Osteoarthritis (see Olivier Bruyère et al.). The therapeutic tree which is proposed was built up as a progressive and continuous process

to take into account the various gradations and severities of the disease, beginning with a non pharmacological approach, basic supportive techniques, preventive approaches, health education, then moving to pharmacologic approaches including oral substances, then injectable drugs and at the end referring the patient to the orthopaedic surgeon to perform an arthroplasty..

The question to be asked and to be solved is to know if the management of the diabetic osteoarthritic patient significantly differs from the usual OA patient without diabetes? Even if the epidemiological association between osteoarthritis and type 2 diabetes seems to be robust beyond the common association with other risk factors. Based on the available literature, the answer appears mainly to be negative which means that the recommendations for the management of the OA diabetic patient looks globally the same as for the non diabetic patient.

The only point to underline is certainly the major importance of optimal dietetic measures as well as the regular physical activity and exercise in those patients with diabetes in order to prevent different complications such as bone fractures and osteoarthritis.

Participants to the ESCEO Working Group on diabetes and osteoarthritis: Jaime Branco, Olivier Bruyère, Roland D. Chapurlat, Cyrus Cooper, Elaine M. Dennison, Gabriel HerreroBeaumont, Marc Hochberg, Andrea Laslop, Emmanuel Maheu, JeanYves Reginster, René Rizzoli, Roland Roth, Lucio C. Rovati, André Scheen, Daniel Uebelhart, Nicola Veronese, Mila Vlaskovska



2019 PARIS

**WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES**

PARIS, France | 2019

Abstract Book

**ESCEO-IOF - WHO Collaborating
Centre for Public Health Aspects of
Musculoskeletal Health and Aging
Symposium Abstracts
(ESCEO-IOF-WHO CC)**

ESCEO-IOF-WHOCC1 POOR ADHERENCE TO ANTI- OSTEOPOROSIS TREATMENT: DETERMINANTS, RECOMMENDATIONS FOR PRACTICE AND FOR RESEARCH

M. Hiligsmann¹, B. Vrijens², B. Abrahamsen³, on behalf of the ESCEO Working Group on adherence to anti-osteoporosis medications

¹Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands, ²AARDEX group, Liège, Belgium, ³Holbæk Hospital, Holbæk, Denmark; University of Southern Denmark, Odense, Denmark

Poor adherence to medications remains a major challenge in the treatment of osteoporosis (OP). Medication non-adherence is associated with increased risk of fractures, leading to a substantial decrease in the clinical and economic benefits of drug therapy. It is therefore extremely important to identify potential solutions to manage patient's adherence to therapy. A working group was therefore convened by IOF and ESCEO to review determinants and potential adherence-management interventions, and to make recommendations for medical practice and for further research. A systematic review and a face-to-face meeting in Geneva in January 2019 (including 21 experts) were conducted. During this IOF-ESCEO symposium, three presentations will be made to highlight the findings and recommendations of the working group, and more specifically, (1) to review the determinants of non-adherence to (OP) medications, (2) to provide recommendations for practice how to manage OP medication adherence and (3) to make recommendations for further research. These recommendations are intended for clinicians to manage adherence of their patients, and to researchers and policy makers to design, facilitate and appropriately use adherence-management interventions.

Acknowledgement: ESCEO Working Group composed of Bo Abrahamsen, Emmanuel Biver, Maria Luisa Brandi, Cyrus Cooper, Dennis Cornelissen, Bernard Cortet, Elaine Dennison, Adolfo Diez-Perez, Andrea Gasparik, Alda Grosso (patient), Peyman Hadji, Philippe Halbout, Mickaël Hiligsmann, John Kanis, Jean-Marc Kaufman, Stefania Maggi, Jean-Yves Reginster, René Rizzoli, Thierry Thomas, Sansin Tuzun, Bernard Vrijens, Nasser Al-Daghri, Olivier Bruyère, Nansa Burlet, Andrea Laslop, Mila Vlaskovska



2019 PARIS

WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES

PARIS, France | 2019

Abstract Book

ESCEO-IOF USA Symposium
Abstracts

ESCEO-IOFUSA1 RECOMMENDATIONS FOR THE CONDUCT OF ECONOMIC EVALUATIONS IN OSTEOPOROSIS: A SUMMARY FROM AN ESCEO-IOF USA WORKING GROUP

M. Hiligsmann¹

¹Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands

Objective: To provide recommendations for the conduct of economic evaluations in osteoporosis in order to improve their transparency, comparability, and methodologic standards.

Material and Methods: An ESCEO-IOF USA working group (including 23 experts) was convened to make recommendations for the design, conduct, and reporting of economic evaluations in osteoporosis, and to define an osteoporosis-specific reference case to serve a minimum standard for all economic analyses in osteoporosis. A literature review, a face-to-face meeting in New York City (including 11 experts), and a review/approval by a larger group of experts worldwide (including 23 experts in total) were conducted.

Results: Recommendations on the type of economic evaluation, methods for economic evaluation, modeling aspects, base-case analysis and population, excess mortality, fracture costs and disutility, treatment characteristics, and model validation were provided. Recommendations for reporting economic evaluations in osteoporosis were also made and an osteoporosis-specific checklist was designed that includes items to report when performing an economic evaluation in osteoporosis. Further, 12 minimum criteria for economic evaluations in osteoporosis were identified.

Conclusion: These recommendations are intended to supplement general and national guidelines for economic evaluations, improve transparency, quality, and comparability of economic evaluations in osteoporosis, and maintain methodologic standards to increase their use by decision-makers.

ESCEO-IOFUSA2 CHALLENGES, UNCERTAINTIES AND FUTURE RESEARCH AGENDA FOR THE CONDUCT OF ECONOMIC EVALUATIONS IN OSTEOPOROSIS: A SUMMARY FROM AN ESCEO-IOF USA WORKING GROUP

S. Silverman¹

¹Cedars-Sinai Medical Center, UCLA School of Medicine and the, OMC Clinical Research Center, Los Angeles, United States

Objective: To identify methodologic challenges, uncertainty and initiate a call for future research for the conduct of economic evaluation in osteoporosis.

Material and Methods: An ESCEO-IOF USA working group (including 23 experts) was convened to discuss methodologic challenges and initiate a call for research on economic evaluation in osteoporosis.

Results: Several methodologic challenges were identified and a call for future research was suggested in the following areas:

1. Modelling fracture risk after ten years;
2. Understanding the increased risk of fracture after a fracture;
3. Excess mortality after non-hip non-vert fracture;
4. Long term costs of care after hip fracture;
5. Understanding societal vs payor perspectives;
6. Modelling multiple fractures and their severity within the model;
7. Identifying appropriate comparators;
8. Absence of hip fracture data with some therapies;
9. Persistence of treatment effect after discontinuation;
10. Variations in response based on prior treatment exposure:
11. Treatment side effects;
12. Lack of sufficient data in males;
13. Cost effectiveness in subpopulations.

Conclusion: While the working group acknowledges challenges and the need for further research on economic evaluation in osteoporosis, this research may help increase the use of cost-effectiveness analyses by decision makers and to lead to a more effective allocation of health resources.



2019 PARIS

WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES

PARIS, France | 2019

Abstract Book

EUGMS-ESCEO-IOF
Symposium Abstracts

EUGMS-ESCEO-IOF1 WHAT IS NEW IN THE DEFINITION OF SARCOPENIA?

A. J. Cruz-Jentoft¹

¹Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain

In 2010/11 four definitions of sarcopenia incorporating adding reduced muscle function to low muscle mass were published, including the European Working Group on Sarcopenia in Older People (EWGSOP). Research focused on this definition, widely adopted worldwide, has advanced the field to a degree that an update was needed. In 2018, this group launched an updated definition of sarcopenia, named EWGSOP2, that reflects the new scientific and clinical evidence built over the last decade.

Sarcopenia is now considered a muscle disease (muscle failure) common among older adults that can also occur earlier in life. The new definition focuses on low muscle strength as a key characteristic of sarcopenia, uses detection of low muscle quantity and quality to confirm the sarcopenia diagnosis, and identifies poor physical performance as indicative of severe sarcopenia. Acute and chronic sarcopenia are defined, and a new algorithm that can be used for sarcopenia case-finding, diagnosis and confirmation intends to move sarcopenia from the academia to routine clinical practice. Also, clear and easy to remember cut-off points for measurements of variables are proposed.

EWGSOP2 intends that the new definition will increase awareness of sarcopenia and calls for healthcare professionals to promote early detection and treatment.

EUGMS-ESCEO-IOF2 DIAGNOSING SARCOPENIA IN CLINICAL PRACTICE

Y. Rolland¹

¹Gerontopole de Toulouse, CHU Toulouse, INSERM 1027, Toulouse, France

In 2016, sarcopenia was recognized as a disease with an established ICD-10-CM code. This achievement was a step toward for new treatments development and potential approval by regulatory agencies. Sarcopenia is now recognized as a condition strongly associated with adverse outcomes in older people including falls, fractures, institutionalization and mortality. Despite this progress, various barriers reduce the implementation of the diagnosis of sarcopenia in clinical practice. Many tools have been proposed to assess muscle strength, muscle mass and physical performances. However, these validated tests are poorly used and sarcopenia is still underdiagnosed by general practitioners in daily practice. In primary care, screening for sarcopenia could be performed using the SARC-F questionnaire. This approach has also some limitations. Various prediction equations have also been proposed. With the new updated consensus definition of sarcopenia proposed by the European Working Group on Sarcopenia in Older People (EWGSOP2), low muscle strength is highlighted as a key component for the operational definition of sarcopenia. The handgrip strength test, a validated, not time consuming, cheap,

and easy to apply in daily practice appears as a key test to diagnose a *probable sarcopenia*. The clinical algorithm proposed by the EWGSOP2 for sarcopenia case-finding, diagnosis and confirmation is also design to help healthcare professionals to perform an early detection and start the treatment. In the future, new pharmacological treatment to prescribe will probably contribute to implement the diagnosis of sarcopenia in clinical practice.

EUGMS-ESCEO-IOF3 DIET AND EXERCISE TO TREAT SARCOPENIA

J. Bauer^{1,2}

¹Center for Geriatric Medicine, University of Heidelberg, Heidelberg, Germany, ²Agaplesion Bethanien Krankenhaus Heidelberg, Heidelberg, Germany

At the moment, no pharmacologic or anabolic therapies can be recommended for the treatment of sarcopenia in older persons. Against this background exercise and nutritional interventions constitute the basic therapy for this geriatric syndrome. While numerous studies have shown that resistance training can increase muscle mass and muscle strength in older persons, a standard exercise program would always include components of endurance and balance training in this population as well. Only very few of the aforementioned studies focused on sarcopenic older persons. Results for muscle mass, muscle strength and balance were positive, but heterogeneity among studies was high. It is therefore still not clear, which exercise mode, duration and intensity would be indicated specifically in this population.

As malnutrition is a major etiologic factor in sarcopenia, it is essential that individual energy and protein requirements are met. Although this issue is still discussed in the literature, most experts currently agree that sarcopenic individuals benefit from higher protein intake. For sarcopenic individuals a daily protein intake of 1.2 – 1.4 gr / kg bodyweight is recommended. Experimental studies documented the catalyzing effect of leucine on muscle protein synthesis, while several clinical studies showed an increase in muscle mass and strength. Nevertheless, additional studies are warranted before leucine-enriched supplements can be recommended as a standard. Recently a positive effect of polyunsaturated fatty acids on muscle mass and muscle strength/function has been demonstrated. As a general principle populations of future therapeutic trials should be selected according to established sarcopenia criteria and approved thresholds for muscle mass and strength only as the effectiveness of exercise and nutritional interventions may otherwise vary significantly.



2019 PARIS

WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES

PARIS, France | 2019

Abstract Book

ESPRM-ESCEO-IOF
Symposium Abstracts

ESPRM-ESCEO-IOF1

W.I.N WHAT IS NEW IN HAND OSTEOARTHRITIS? UPDATE IN PHYSICAL AND REHABILITATION MEDICINE ON HAND OSTEOARTHRITISF. Dincer¹¹Hacettepe University Faculty of Medicine Dept of PRM, Ankara, Turkey

Objective(s): In this research ,especially the Management and PRM / Physical and Rehabilitation Medicine, of HOA is mentioned depending essentially on the recent Evidence Based Recommendations (EBR) and literature.

Material and Methods: EBR for the Diagnosis of HOA, according to; risk factors, clinical, subsets, differential diagnosis, images and laboratory tests is mentioned in details with Levels of Evidence.

Optimal Management of Hand OArequires a combination of Non-pharmacological& Pharmacologicaltreatment.

In Nonpharmacologicaltreatmentessentially and especially the applications of Physical Medicine and rehabilitation procedures play an important role.Education concerning,joint protection(how to avoid adverse mechanical factors) together with an exercise,both range of motion&strengthening exercises,are recommended for all patients with HOA.Local application of heat (eg paraffinwax, hotpack), Especially prior to: Exercise&ultrasound are beneficial treatments.

Also EBR for the Management of HOA developed through three Delphi rounds ,according to ; general, nonpharmacological, pharmacological, invasive , surgical, with Levels of evidence is given through the lecture.

Results: The results of 3 Delphi rounds ,for Diagnosis 108 , for Management of HOA 309 literature depending on Evidence Based Medicine and Hierarchy with Levels of Evidence is presented.

Conclusions:

- Pain relief , restoration of function remain the primary treatment objective.
- These are best achieved by a combination of pharmacological & nonpharmacological treatment especially by application of PRM
- Surgery remains the last resort for restoration of function if all else fails .

References:

- W Zhang,M Doherty,B F Leeb,L Alekseeva,N K Arden,J W BijlsmaF Dincer etal. EBR For Diagnosis Of AnnRheumDis 2009;68:8-17
- W Zhang, M Doherty, B F Leeb, L Alekseeva, N K Arden, J W Bijlsma, F Dinçer, etal. EBR For The Management of HOA . AnnRheumDis 2007;66:377-388

- Zhang , R. W. Moskowitz , et al. OARSI recommendations for the management of hip & knee OA, OARSI evidence-based, expert consensus Guidelines. Osteoarthritis and Cartilage 2008;16:137–62.
- Hochberg M,Altman R.et al.ACR 2012 Recommendations for Non and Pharmacologic Therapies in Hand,Hip,Knee OA. Arthritis Care & Research.2012; 64:465-474
- Kloppenburg M,Kroon FPB, Blanco FJ, et al.Ann Rheum Dis Epub ahead of print: doi:10.1136/ annrheumdis-2018-213826

ESPRM-ESCEO-IOF2

W.I.N. - WHAT IS NEW IN KNEE OSTEOARTHRITIS? UPDATE IN PHYSICAL AND REHABILITATION MEDICINE ON KNEE OSTEOARTHRITISM. Quittan¹¹Karl Landsteiner Institute of Remobilisation and Functional Health, Vienna, Austria

Osteoarthritis (OA) of the knee is the most common age related diseases and a major cause of chronic pain and disability. It affects in total about 23% of the population. Patients with radiologic verified knee-OA show a clearly increased risk of mortality in a twenty years follow up period.

This presentation highlights systematic reviews and metaanalysis of physical therapies in knee-OA. Physical exercise, both strength and endurance type, shows a significant favorable and clinically relevant effect on pain and physical function scores in the short term and midterm follow up. Aquatic exercise and Spa-Therapy also provide meaningful improvements of pain and physical function.

Nevertheless, dosage of exercise must be in accordance to established exercise guidelines. Improvements in pain and function seem to be dose dependent.

Lifestyle interventions like weight loss and education also contribute to improved functioning.

Supportive interventions are mind-body-exercises. Different methods of manual therapy contribute to relieving pain, stiffness and dysfunction of the knee joint. Physical treatment modalities like ultrasound, shortwave and electroceutical agents show in corresponding systematic reviews significant positive influences on pain and function.

Correction of biomechanical dysfunctions with insoles and orthoses improve pain and self-reported physical function. Acupuncture elicits small, clinically not relevant changes.

Most common scientific flaws are insufficiently powered and/or designed studies impairing the quality of evidence in some reviews.

To conclude, physical medicine provides tailored, patient-specific multimodal therapeutic and rehabilitative programs for patients with knee-OA, with various forms of guideline driven exercise therapy being the backbone of it.

ESPRM-ESCEO-IOF3

WHAT IS NEW IN HIP OSTEOARTHRITIS? UPDATE IN PHYSICAL AND REHABILITATION MEDICINER. Valero-Alcaide¹, S. Muñoz-Lasa¹¹University Complutense Madrid. Faculty Medicine. Dep. Physical Medicine and Rehabilitation, Madrid, Spain

Osteoarthritis (OA) is a painful and debilitating condition, patient report pain and difficulty with activities of daily living these may lead to a loss of functional independence and a profound reduction in quality of live. Optimally patiente shouls receive rehabilitation treatment

Purpose: To describe what is new in treatment in Hip Osteoarthritis (HOA) in Physical and Rehabilitation Medicine

Method: Systematic review from January 2010 to October 2018. Data Sources: Medline, DePedro, Cochrane, EMBASE and Evidence-Based Clinical Practice Guideline. EULAR

Results: Risk factors: Moderate evidence; Obesity, Age, Mental Healt disorder. Limited evidence: tobaco use

Pharmacological treatment: Strong evidence: NSAID,s, Intraarticular injectable. Moderate: Glucosamine sulfate

Rehabilitation treatment: Strong evidence: Exercise and physical therapy as conservative treatment

Scientific evidence of microbioma based medecine in OA

Conclusions: PRM physician is responsible for the diagnosis in these patients. There is a good level of evidence about the effectiveness of PRM interventions in the management on OA, high level evidence about low impact exercises, weight reduction and adjunct therapies

Promoting Physical activity should be an integral part of standard care throughout the course of disease in HOA. The mechanisms by which exercise reduces pain and improves function in cases of osteoarthritis may include the development of increased upper leg strength, the reduction of extension impairments, and the improvement of proprioception.

PRP injections are becoming more commonly performed as a treatment option for patients with osteoarthritis. PRP, which is derived from the patient's own blood, delivers a concentration of growth factors to the site of pathology.

New approaches in microbioma can change future treatments in OA.



2019 PARIS

WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES

PARIS, France | 2019

Abstract Book

ESCEO-IOF-SFR-GRIO
Symposium Abstracts

ESCEO-IOF-SFR-GRIO1 PRODUITS LAITIERS FERMENTÉS ET SANTÉ OSSEUSE

E. Biver¹

¹Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Switzerland, Geneva, Switzerland

Les produits laitiers fermentés, tels que le yogourt ou les fromages à pâte molle, constituent des sources alimentaires de calcium, phosphore et protéines, qui influencent la croissance osseuse chez les enfants et adolescents, mais aussi la fragilité osseuse liée à l'âge. Des études longitudinales suggèrent une association bénéfique entre la consommation de produits laitiers fermentés et la perte osseuse post-ménopausique ou le risque de fracture. Au-delà de ces nutriments, les produits laitiers fermentés contiennent des prébiotiques tels que l'inuline et des probiotiques capables de modifier l'absorption intestinale du calcium et possiblement la composition et le métabolisme du microbiote intestinal, qui interfèrent avec le métabolisme osseux. La consommation de produits laitiers fermentés pourrait également être un marqueur de mode de vie « sain » et d'un régime alimentaire équilibré favorisant la santé osseuse.

ESCEO-IOF-SFR-GRIO2 OSTEOARTHRITIS: A MATTER OF DIET?

J. Sellam¹

¹Service de rhumatologie, hôpital Saint-Antoine, AP-HP, Sorbonne Université, Paris, France

Osteoarthritis (OA) is the most common and frequent joint disease. To date, treatments are only symptomatic and we have no curative drugs. Thus, preventive approaches are crucial to limit OA occurrence

The 3 main risk factors of OA are aging, obesity and joint trauma. These 3 risk factors have been associated with OA in many studies. A recent study investigating knee OA on cadaveric skeletons from prehistoric, pre-industrial (1905-1940) and postindustrial (1976-2015) periods has shown that knee OA frequency has frankly increased during the postindustrial period. This increased risk of OA during the postindustrial versus pre industrial period was confirmed after adjustment on body mass index at death and sex (Wallace IJ, et al, PNAS 2018). Thus we have to accept that other factors are involved in the increase of OA prevalence since 40 years. We can suspect the role of environment and especially the role of diet, beyond obesity.

Research studies are mainly focused on omega 3 fatty acids and dietary fibers since their consumptions are usually below the recommendations. Data are encouraging about the biological and clinical effects of these nutrients but we need to have more data to recommend their consumption in the daily care to specifically improve OA symptoms and to prevent OA. Finally, beyond OA, it seems important that patients follow general recommendations about healthy diet and physical activity.

ESCEO-IOF-SFR-GRIO3 OSTEOARTHRITIS: AN INFLAMMATORY DISEASE?

F. Eymard^{1,2}

¹Department of rheumatology. AP-HP Henri Mondor Hospital. Créteil, Créteil, France, ²Cell Growth, Tissue Repair and Regeneration Laboratory (CRRET), UPEC EA 4397/ERL CNRS 9215, Créteil, France

Osteoarthritis (OA) is no longer considered as a simple degenerative "wear and tear" disease limited to the cartilage but as a complex disease affecting all joint tissues and involving a low-grade chronic inflammation.

Although some frequent clinical signs such as effusion, swelling or local warmth already suggested the involvement of an inflammatory process principally in the OA late stages, several MRI studies now attest to the presence of this inflammation also at early stages, especially in the subchondral bone and synovial membrane. The cytokine profile in OA synovial fluid has also confirmed the presence of this low-grade inflammation.

The remaining question is to know whether this inflammatory process is only a marker among others of a complex catabolic process or whether it can also initiate OA lesions. Indeed, although it seems logical to consider inflammation as one of the key actors in the occurrence of the so-called "metabolic OA" associated with obesity, this seems less obvious in the context of post-traumatic OA or in age-related OA.

From recent literature data, the presentation will focus on:

- the biological and radiological elements in favor of the participation of chronic inflammation in OA
- the pathophysiological mechanisms involving low grade chronic inflammation according to the OA phenotype (metabolic, elderly, post-traumatic or genetic OA)
- the effectiveness of anti-inflammatory therapy in OA.

ESCEO-IOF-SFR-GRIO4 VITAMIN D, OSTEOARTHRITIS AND OSTEOPOROSIS

E. Cavalier¹

¹Department of Clinical Chemistry, University of Liège, Belgium, Liège, Belgium

Osteoporosis (OP) and osteoarthritis (OA) are recognized as age-related disorders, but it has been considered for a long time that they did not occur in the same kind of patients. Indeed, OA is more frequently observed in high BMI patients whereas OP rather affects low BMI ones. It has even been postulated that "OA protects against hip fracture", even if such a statement had been made on lower quality studies. Evidence shows today that a significant percentage of OA patients present clinical features of OP. Epidemiological studies also suggest that both diseases are linked with low vitamin D (VTD) intakes or low 25(OH)-D levels. If it is well recognized that vitamin D (and calcium) supplementation is efficient in OP management, evidence is less convincing for OA. Yet, 3 mechanisms could potentially explain the role of VTD in OA: a positive role on subchondral bone, effects on inflam-

mation and cytokines and effects on muscle strength, particularly on quadriceps. Interventional studies have shown rather mitigated results on OA and the general feeling is that VTD deficiency does not seem a causal factor in OA. Nevertheless, OA patients should maintain 25(OH)D above at least 20 ng/mL to benefit from its action on muscle strength and, perhaps, pain reduction.

ESCEO-IOF-SFR-GRIO5 L'ARTHROSE RACHIDIENNE EXISTE-T-ELLE?

F. Rannou¹

¹Division of Physical Medicine and Rehabilitation, Department of Rheumatology, AP-HP Cochin Hospital, Université Paris Descartes Sorbonne Paris Cité, and INSERM U1124, Paris, France

A l'heure de la fake medicine et de la fake science qui envahissent quotidiennement le domaine de la lombalgie, cette lecture a pour but de remettre en perspective le rôle clé du diagnostic lésionnel et médical pour permettre une prise en charge médicale personnalisée.

ESCEO-IOF-SFR-GRIO6 LA PLACE DE LA VERTÉBROPLASTIE, LES DONNÉES SONT-ELLES SOLIDES ?

B. Cortet¹

¹Service de Rhumatologie & EA 4490, CHU Lille & Université de Lille, Lille, France

La vertébroplastie consiste à injecter dans une vertèbre fragilisée un ciment acrylique afin de la consolider. Cette technique a été développée par le Professeur Deramond, initialement dans la prise en charge d'angiomes vertébraux agressifs. Compte-tenu de son efficacité et de sa bonne tolérance, les indications se sont par la suite élargies tout d'abord aux affections malignes (métastases osseuses et myélome) puis depuis maintenant plusieurs années à l'ostéoporose. Les fractures vertébrales ostéoporotiques constituent en effet actuellement la principale indication de la vertébroplastie.

De nombreuses études ont été réalisées dont la méthodologie n'est pas toujours exempte de critiques. Les études rétrospectives et les études ouvertes ont clairement démontré que cette technique permettait de diminuer les douleurs en rapport avec une fracture vertébrale ostéoporotique. Des données suggèrent également que le taux de décès après vertébroplastie est moindre comparativement à des patients ayant une fracture vertébrale traitée médicalement. La plupart des études randomisées contre traitement conventionnel sont en faveur de l'intérêt de la vertébroplastie pour diminuer les douleurs. Depuis maintenant une dizaine d'années des études mieux conduites d'un point de vue méthodologique (vertébroplastie versus procédure factices) ont apporté des résultats contrastés quant à l'effet antalgique de cette technique. Malgré tout, l'efficacité, avec des études de bonne facture d'un point de vue méthodologique, a cependant été démontrée chez des sujets âgés hospitalisés pour une fracture vertébrale particulièrement algique. Dans un domaine très différent des résultats préliminaires ont montré l'intérêt de cette

technique chez des patients ayant une fracture vertébrale avec persistance d'un hypersignal en IRM sur les séquence pondérées T2 et dont la symptomatologie douloureuse perdure depuis au moins trois mois en dépit d'un traitement médical bien conduit. En ce qui concerne la tolérance, les données sont rassurantes et les complications sont rares. Les plus fréquentes sont marquées par des fuites de ciment en dehors du corps vertébral qui sont dans la plupart des cas asymptomatiques. Enfin l'augmentation du risque de fracture vertébrale au-dessus et en dessous de la vertèbre cimentée n'a pas été formellement démontrée.



2019 PARIS

WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES

PARIS, France | 2019

Abstract Book

Meet-the-Experts Abstracts

MTE1

**HOW TO ASSESS FRAILITY IN DAILY PRACTICE?
(MEET-THE-EXPERT SESSION, 5TH OF APRIL 2019)**E. Gielen¹¹Department of Geriatric Medicine & Centre for Metabolic Bone Diseases, UZ Leuven, Leuven, Belgium

Frailty is a geriatric syndrome characterized by an increased vulnerability and a decreased ability to maintain or regain homeostasis after a destabilizing stressor. It is the consequence of a cumulative decline in many physiological systems during lifetime. The prevalence of frailty increases with ageing, although not all elderly can be considered as frail. Frailty is associated with an increased risk of disability, falls, fractures, hospitalization, institutionalization and death. Therefore, in clinical practice, frailty screening is important to early identify individuals at high risk of these adverse outcomes. In this "Meet-the-Expert Session", the assessment of frailty in daily practice will be discussed. This will be done by providing an overview of the frailty tools that are most commonly used in clinical practice, together with their psychometric properties. In the discussion, a distinction will be made between tools suitable for screening and tools suitable for diagnosing frailty. The properties of the ideal tool to screen and/or diagnose frailty in clinical practice will be evaluated. The two methods that are currently most accepted to diagnose frailty are the frailty phenotype definition of Fried et al. and the frailty index definition of Rockwood et al. While the frailty phenotype definition focusses on musculoskeletal frailty, the frailty index definition is based on a comprehensive geriatric assessment which identifies accumulated deficits across multiple domains. In recent years, multiple frailty screenings tools have been developed, which are, to some extent, short versions of the frailty phenotype definition and the frailty index definition.

Up to date, there is no consensus on how to best assess frailty in clinical practice. Anyway, screening and diagnosis of frail elderly should only be undertaken if a positive screen with a subsequent diagnosis of frailty will influence the management of these elderly. In patients diagnosed with frailty, a multidisciplinary treatment plan tailored to the individual needs of the frail person should be initiated in order to prevent or at least slow down the occurrence of adverse events.

MTE2

**LOCAL THERAPIES IN OSTEOARTHRITIS
MANAGEMENT?**F. Rannou¹¹Division of Physical Medicine and Rehabilitation, Department of Rheumatology, AP-HP Cochin Hospital, Université Paris Descartes Sorbonne Paris Cité, and INSERM U1124, Paris, France

International guidelines including the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) recommend that the management of knee osteoarthritis (OA) combine both nonpharmacological and pharmacological interventions. These interventions can be divided in two main

categories including systemic and local therapies. In this lecture we will discuss using the last high level publications, the clinical interest and the safety profile for local therapies

- corticosteroids, hyaluronic acid, platelet-rich plasma and botulinum toxin used as intra articular therapies,
- NSAIDs used as topic,
- thermal agents, sleeves, braces, physical therapy used as local non pharmacological therapies

MTE3

**PRE- AND POSTNATAL INFLUENCES ON BONE
AND MUSCLE HEALTH IN CHILDREN**N. C. Harvey^{1,2}¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ²NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

Osteoporotic fractures are common, associated with immense morbidity, and reduced relative survival. The annual cost approaches €39 billion per year across Europe, and such events have a massive impact at the level of the individual, healthcare systems and societies as a whole. Whilst traditional approaches to preventing osteoporotic fracture have focused on assessment and treatment of those at highest risk, evidence is accumulating that risk of fracture accrues as a result of influences throughout life, even from as early as conception. Bone and muscle mass increase through early life and childhood to reach a peak in young adulthood. Mathematical modelling studies have demonstrated that the magnitude of peak bone mass is at least as important a predictor of later osteoporosis risk as is age-related bone loss. Bone and muscle accrual appear to track through growth and thus optimisation of accrual prior to peak mass may represent a successful public health approach to achieve a reduction in the burden of fractures in the population. Thus, work from Southampton and elsewhere has demonstrated that poor growth in early life is associated with reduced adult bone mass at peak and in old age, and also increased risk of hip fracture. Studies of fetal and postnatal growth have elucidated patterns of development associated with adverse bone mineralisation and geometry. The study of mother-offspring cohorts has permitted the documentation of specific risk factors during pregnancy and early postnatal life, such as maternal diet, lifestyle and physical activity, and postnatal body composition and exercise. Maternal vitamin D status is associated with offspring bone and muscle mass, and in the MAVIDOS randomised controlled trial, antenatal supplementation with vitamin D was associated with a marked increase in offspring bone mass, versus placebo, for deliveries in the winter months. In this session, I will summarise the evidence linking early pre- and postnatal development to musculoskeletal health in older age, together with potential mechanistic underpinnings, and key messages in relation to potential public health interventions.

MTE4 STRENGTHS OF RECOMMENDATIONS FOR GIOP MANAGEMENT

J. D. Adachi¹

¹McMaster University, Hamilton, Canada

Glucocorticoid-induced osteoporosis is the most common secondary cause of osteoporosis. As such, much research has been devoted towards learning about the epidemiology, pathophysiology and treatment of glucocorticoid bone loss and fractures. Based on this new knowledge, guidelines have been developed and revised to help in the management of glucocorticoid treated patients to prevent fractures.

We now know that fractures occur early in the use of glucocorticoids. Indeed, both epidemiologic studies and a meta-analysis of the placebo control groups from randomized controlled trials recognize this finding.

Most recommend fracture risk assessment within 6 months of commencing glucocorticoid therapy. Identification of those at risk for fractures is best accomplished through the use of FRAX with or without BMD. Adjustments made for prednisone dose is suggested. Most recommend therapy for those at moderate to high risk for fracture.

Very good randomized double-blind, placebo-controlled trials have shown that treatment in general results in greater increases in bone mass. In addition, head-to-head trials inform us of treatments that are superior in increasing bone mass. Fracture trials however have not been done and we assume that fractures are prevented based on trials in postmenopausal women.

One of the criticisms of the current guidelines lie in the complexity of the treatment algorithms making the application to clinical practice difficult. This often results in delays in treatment and is made worse by the lack of recognition of the need for early intervention. Treatment guidelines are often limited to RCT's when examining efficacy using the surrogate outcome BMD. However, evidence of the effectiveness of these therapies in day to day practice is limited. In particular poor adherence to therapy and patient preference are major factor that are not considered when treatment is contemplated. Further research addressing these limitations would be of benefit to the practicing clinician.

MTE5 DIAGNOSIS AND MANAGEMENT OF BONE FRAGILITY IN DIABETICS

S. L. Ferrari¹

¹Service and Laboratory of Bone diseases, Geneva University Hospital, Geneva, Switzerland

The risk of fragility fractures is increased up to 2fold in type 2 diabetes (T2D) and 5fold in type 1 (T1D). Diabetes-induced osteoporosis is characterized by a low bone turnover state with a prominent decrease in bone formation and alterations of bone microstructure as well as material properties of the bone matrix. Fracture prediction by FRAX and/or DXA is better in T1D than T2D, since FRAX allows to adjust for the increased risk of fractures as-

sociated with T1D ("secondary osteoporosis") in absence of BMD, and BMD, when available, is lower than average in T1D. In contrast in T2D, FRAX is currently not calibrated for the increased risk in diabetics and BMD is on average 5-10% higher than in non-diabetics, hence even with BMD fracture probability is underestimated by about 30%. Adjustments are therefore necessary, including for risk factors associated with diabetes itself, such as duration, severity (microvascular complications), and type of medication. Adequate vitamin D supplementation and falls prevention is important among diabetics as well as in standard patients with osteoporosis. Although some data support the use of osteoporosis drugs in diabetics with low BMD and/or fragility fractures, there is currently no evidence for fracture prevention with these drugs in diabetics without overt osteoporosis. A recent algorithm from the IOF working group of diabetes and bone regarding fracture risk evaluation and management in diabetics will be presented.

MTE6 DISORDERS OF PHOSPHATE HOMEOSTASIS

M. L. Brandi¹

¹Fondazione F.I.R.M.O., Florence, Italy

Phosphorus is a vital constituent of the bone mineral and cell membranes, it is essential for energy storage and metabolism and it is important for cell signaling and enzyme activation. The daily intake of phosphate is not a problem for humans, as the majority of foods contain phosphate in high concentrations. In healthy adults, the maintenance of phosphate homeostasis is regulated by the kidneys and to some extent by the gastrointestinal tract. In contrast with the regulation of calcium homeostasis, which has been extensively studied over the past several decades, much less is known about the regulation of phosphate homeostasis. Insights into the regulation of phosphate homeostasis were obtained from rare disorders characterized by either an excessive or a reduced level of serum phosphate.

Phosphatonins are the hormones that control tubular phosphate reabsorption at the kidney level. Among these fibroblast growth factor 23 (FGF23) is recognized part of a hormone bone-kidney axis. FGF23 secreted by osteocytes binds with high affinity to fibroblast growth factor receptor 1c in the presence of a co-receptor Klotho. It inhibits at the kidney level both reabsorption of phosphate and synthesis of calcitriol.

Acquired or inborn errors affecting this hormonal system can lead to abnormal phosphate homeostasis and tissue mineralization. This presentation will provide an update on the current knowledge of the phosphate physiology, the clinical presentation, diagnostic evaluation and therapy of the disorders of phosphate homeostasis and tissue mineralization.

MTE7

VITAMIN D AND OSTEOARTHRITIS

T. McAlindon¹, M. Osani¹¹Tufts Medical Center, Boston, United States

Objectives: It has been suggested that vitamin D might influence development and progression of OA through effects of periarticular bone and articular cartilage.

Material and Methods: We searched MEDLINE and the Cochrane databases from inception to January 2019 for observational studies and RCTs of Vitamin D and OA; and conducted meta-analysis of RCT data to test effects of Vitamin D on pain, function, and structural progression.

Results: We identified 21 eligible epidemiological studies testing relationships with knee / hip OA, including pain, physical function, radiographic incidence and prevalence and progression; and 4 clinical trials.

Five of 9 studies testing associations with OA *pain* found a greater level in those with Vitamin D deficiency but two of these were confounded by sex / ethnicity. In 4 of 5 studies of *physical function*, vitamin D sufficiency was associated with greater functional status. Among 11 studies of *incident* OA, 4 found a positive association with vitamin D deficiency. Six of the 10 studies assessing *structural progression* reported found a 'protective' effect of vitamin D.

Four eligible RCTs (N= 1,136 participants) tested Vitamin D for OA. Their methodologic quality ranged moderate to high according to the Cochrane Risk of Bias scale. One RCT was excluded due to heterogeneity. The pooled analysis showed small effects on pain reduction over 2 to 3 years (SMD: -0.14 [95% CI: -0.26, -0.02]). Similar results were observed for physical function (-0.19 [-0.32, -0.05]). There was no difference between Vitamin D and placebo with regard to structural progression outcomes. Vitamin D safety profile was not different from placebo. **Conclusions:**

There are discordances between observational and clinical trial results possibly due to biases in observational data (e.g. collider bias), selective reporting, confounding, differing observation periods and populations, and varying vitamin status. Overall, vitamin D demonstrated small, but significant, effects on pain and functional in individuals with OA. Though observational data suggested that Vitamin D might retard structural progression of OA, this is not confirmed by RCTs. There is insufficient evidence recommend vitamin D as a therapeutic option for OA.

MTE8

FRACTURE LIAISON SERVICES: MODELS AND FRACTURE RISK REDUCTION.

K. Javaid¹¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

Understanding the optimal model for a local healthcare setting is critically important when starting or improving and FLS. Despite the rationale for FLSs to reduce the local burden of fragility fractures, delivering an effective, efficient service with good patient experience remains a challenge. FLS service models vary widely depending on local healthcare systems and patient pathways. However, the outcomes for an effective FLS remain similar. During this session, we will explore the published data for FLSs and discuss the challenges in delivering specific models of FLSs from identification, investigation, treatment initiation and monitoring in different healthcare settings focusing on the characteristics of effective models that reduce fracture risk with good patient experience.

MTE9

IS THERE A ROLE FOR LOCAL BONE TREATMENT IN OSTEOPOROSIS?

A. A. Kurth^{1,2}¹Department of Orthopaedic and Trauma Surgery, Campus Kemperhof, Community Clinics Middle Rhine, Koblenz, Germany, ²Major Teaching Hospital of the University Medical Center Mainz, Mainz, Germany

Osteoporosis diminishes the quality and quantity of bone, resulting in compromised bone strength and increased fracture risk. In 2010, it was estimated that 22 million women and 5.5million men in the EU had osteoporosis using the diagnostic criterion of the WHO (Hertlind, Kanis, et al. 2013). **Fractures** in older adults are often the precursor of disability, loss of independence, and premature death. The number of new fractures in 2010 in the EU was estimated at 3.5 million, comprising approximately 610,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures and 1,800,000 other fractures. Hip fractures are the most devastating complication. They are associated with a 25% increase in mortality in the following year and a 4-fold increase of mortality risk in the first 3 months after fracture. The incidence of death from a hip fracture equals the breast cancer mortality rate.

Furthermore, patients with a recent hip fracture carry at least a 10% early risk of a contralateral fracture. Hence, osteoporosis is a severe and escalating socio-economic problem.

The prevention of osteoporotic fractures, especially hip fractures, remains a challenge. Currently available **pharmaceutical treatments** fail to address fracture risk during the early stages of therapy, taking up to 18 months to reduce fracture risk. Furthermore, efficacy is not 100% even with full compliance and compliance is,

at best, around 50% after 1 year. An estimated 20% increase in bone mineral density is required to prevent a hip from fracture in a simple fall.

Hence, complementary approaches to immediately prevent hip fractures in patients at very high risk are still an unmet clinical need.

The use of protective devices, such as hip pads or an energy absorbing floor, have been developed and investigated.

However, the compliance is low and effectiveness is still unclear. **Surgical approaches**, in order to augment the local bone have been proposed to strengthen fragile bone, particularly proximal femur, prior to subsequent fracture. Techniques are **prophylactic nailing**, **femoroplasty** with cement and **bone grafting** with osteoconductive or osteoinductive materials.

Prophylactic nailing: Prophylactic nailing to stabilize highly fragile osteoporotic hips is not currently performed in clinical practice. In a randomized controlled trial, contralateral hip fixation using a hydroxyapatite-coated titanium tubular screw was evaluated on the risk of recurrent fracture. Although the feasibility and safety of the procedure were confirmed, the results were not conclusive since no contralateral hip fracture occurred over the 16-month follow-up.

A device called YSTRUT[®], which is indicated for contralateral percutaneous internal fixation of proximal femur in patients with a low-energy pertrochanteric fracture. This device is implanted during the same anesthesia as for the fracture stabilization. The implant consists of two interlocking peek rods linked with surgical cement (polymethylmethacrylate (PMMA)). The loadings until failure of cadaver specimens with this implant showed increased both fracture load (+18%) and energy to fracture (+32%) as compared to contralateral femur. However, peri-prosthetic fracture risk should be taken into consideration in a careful benefit-risk and cost effectiveness analysis for any new local procedure aimed at preventing hip fractures. Indeed, prophylactic fixation with an intramedullary nail was not found to be cost-effective in elderly women with hip fracture. However, the case may differ in selected patients. **Bone Augmentation:** Several preclinical and clinical studies addressing the augmentation of bones by cement have been published over the last decades, investigating the augmentation of fractures of different locations, which have shown a better stability, stiffness and strength. For the hip, the augmentation of conventional osteosynthesis of femoral neck fractures and intertrochanteric fractures has been studied, as well as the effectiveness of different types of cements. In the spine, cement-augmentation of fractured or sintered vertebral bodies, well known as **Vertebroplasty** and **Kyphoplasty**, has been introduced in clinical use several years ago and has shown significant positive outcome with regard to pain reduction.

Prophylactic cement augmentation of the proximal femur ("**Femoroplasty**") may reduce fracture risk. This technique has only been evaluated to date in cadaver or animals. The results showed 30–80% improvement in bone strength, the results being volume dependent (cement augmentations of 20 to 40 ml) and location dependent. Despite the encouraging positive biomechanical ef-

fects of PMMA augmentation, this cement augmentation has not gained wide acceptance, as it cures with shrinkage in an exothermic reaction with possible associated bone necrosis, can compromise healing and is difficult to remove in revision surgery and the subsequent drilling and osteosynthesis with the cement left in situ might be difficult.

Furthermore, femoroplasty may be associated with the occurrence of sub-trochanteric fractures, fat embolism, circulatory damage and stress concentration. Thus, further clinical validation of the technique is mandatory. Bone grafts with osteoconductive or osteoinductive materials: Very promising results in preclinical and clinical studies have been published for bioactive cements. They cure with a non- or less-exothermic reaction and are considered to be osteoconductive, meaning that they can be resorbed gradually with time and replaced by host bone.

Synthetic bone grafts are mainly made of calcium-phosphate (e.g. hydroxyapatite and tricalcium phosphate), bioglass and calcium sulphate. Such materials can be used as carriers for growth factors (e.g. BMPs) as well to enhance bone graft efficacy, drugs (bisphosphonates) or ions (strontium) to promote osteoblast proliferation. In osteoporosis, the administration of osteoconductive or osteoinductive materials requires low viscosity material to avoid injection under high pressure in the trabecular bone network of the proximal femur.

One new approach for a local treatment of osteoporotic bone is AGN 1. The **AGN1 local osteo-enhancement procedure (LOEP)** is a novel minimally invasive approach intended to strengthen the hip by delivering a unique, resorbable, triphasic calcium sulfate/calcium phosphate implant material (AGN1) into the proximal femur. The implant material sets in situ and is designed to be resorbed and replaced with new bone. Preclinical studies demonstrate that the AGN1 fully resorbs and is replaced with host bone, suggesting that fracture protection may be sustained over time. Furthermore, AGN1 implantation provides an adjunctive treatment to deliver targeted immediate enhancement of strength of the proximal femur.

One preclinical study evaluated the immediate effect of AGN1 LOEP on the biomechanical properties of cadaveric femurs in a sideways fall configuration.

AGN1 LOEP delivered AGN1 without compromising the biomechanical properties of the proximal femur. In the treated group, no femurs fractured through the lateral cortical access portal. It immediately increased failure load and work to failure in osteopenic and osteoporotic femurs with the largest benefit in osteoporotic femurs. It was concluded that AGN1 LOEP is a biomechanically safe, minimally invasive procedure and a promising new surgical approach to treat patients at high risk of hip fracture.

Furthermore; a clinical study using AGN1 was conducted to evaluate the biomechanical performance of the injected proximal femurs of 12 post-menopausal osteoporotic women (age range 56–89; hip BMD T-scores: -3.0 ± 0.7). As a result, there appeared to be newly generated integrated load-bearing bone tissue within the original implant area through the 5–7 years follow up. These results suggest that local osteo-enhancement of the proximal

femur using AGN1 in osteoporotic women can substantially increase proximal femoral strength and that this benefit is apparent soon after treatment and persists for at least 5–7 years.

Conclusion: The prevention of hip fractures, the most devastating complication of osteoporosis, remains a challenge. Current medical treatment of osteoporosis, result in an increase in bone mass and reduction of fracture risk. However, there are non-responders, a lack of compliance and the effect of an antiresorptiv or osteoanabolic treatment may need a long time to achieve a sufficient gain of bone density and fracture risk reduction. Hence, complementary approaches, such as surgical procedures, to immediately prevent hip fractures in patients at very high risk are needed. Prophylactic osteosynthesis and PMMA augmentation of osteoporotic bone has been investigated pre-clinically and in clinical studies, but have not gained clinical acceptance over the years. Some new materials are currently being developed that are synthetic, resorbable, osteoconductive and osteoinductive materials, with the aim of an early local strengthening of fragile bone, e.g. hip, to fill an unmet clinical need in the management of elderly patients with an increased imminent risk of hip fracture. The most advanced local osteo-enhancement procedure is using AGN 1 as for the prevention of proximal femur fractures.

MTE10

OBESITY, BONE AND MUSCLE

R. Chapurlat¹

¹INSERM UMR 1033, Lyon, France

Bone, muscle and the adipose tissue have biological and biomechanical interactions. It has long been considered that obesity was a protective factor for fracture, but recent studies have shown that obese individuals were not protected. Muscle volume and strength tend to be protective factors for bone, so sarcopenia represents a risk factor for fracture. Obese patients may also have sarcopenia and low bone mass, placing them at high risk for fracture.

In this meet-the-expert session, we will address several clinical questions regarding the interactions of these three tissues, through typical clinical vignettes. Based on a first vignette, the epidemiology, pathophysiology and clinical management of fractures in obese

postmenopausal women will be discussed with particular focus on the site specificity of the effect of BMI on fracture, interactions between fat and bone and risk assessment and prevention of fractures. There is similarity in many respects between risk factors for fracture in obese and non obese women, although falls may play a particularly important role in the obese. In a second vignette, we will consider the effect of diet-induced weight loss on BMD, that tends to be negatively affected. Bariatric surgery will be addressed with regard to its negative effect on BMD and fracture incidence. In a third vignette, we will examine the effect on BMD and fracture of low muscle mass and strength, along with of poor physical performance in elderly. It has been observed in recent prospective studies that low muscle mass assessed by DXA is a predictor of fragility fracture. This is also the case of low muscle

strength. In a final vignette, the question of the relationships between the three together - obesity, bone and muscle - will be assessed. The concept of osteosarcopenic obesity has emerged in recent years, described as a combination of low bone mass, sarcopenia and obesity. While there is a biological rationale for this concept, more studies are needed to better define and describe this entity. The relationships between obesity, bone and muscle are important because of the increase in the prevalence of obesity, but also because these three factors have to be accounted for in the evaluation of the risk and prevention of fragility fracture.

MTE11

ANDROGENS: A ROLE IN BONE AND MUSCLE DISORDERS MANAGEMENT?

J.-M. Kaufman¹

¹Department of endocrinology, Ghent University Hospital, Ghent, Belgium

Androgens have an anabolic effect on skeletal muscle with dose-dependent increase of muscle mass (increase of type 1, slow twitch- and type 2, fast twitch muscle fibers) and consequent increases of muscle strength and power. Androgens are anabolic to muscle both in women and men and in older individuals as well as in the young. Androgens also have a role in bone health. Besides being the precursors for production of estrogens, the main sex steroid regulators of bone metabolism, they have androgen receptor-mediated direct beneficial effects on (trabecular) bone and indirect favorable effects on bone and fracture risk through extraskeletal action, in particular on muscle mass and propensity of falls. Whereas testosterone (T) effects on bone are largely dependent on its aromatization to estradiol (E2), anabolic action on muscle requires neither T aromatization nor 5-alpha-reduction to dihydrotestosterone. Both androgen levels and muscle mass and function decline with age. The latter may lead to a state of sarcopenia, which in turn often indicates presence or development of frailty, a more generally vulnerable health state. Sarcopenia is not uncommonly paralleled by- and contributing to increased skeletal fragility, occurrence of falls and risk of fracture. This has been referred to as 'osteosarcopenia'.

In observational studies in aging men T levels seem more related to (changes in) composite entities of physical performance such as sarcopenia or frailty than to direct muscle strength measurements. So, the decline in androgen exposure in aging men does not seem to fully account for their decreases in muscle strength and physical performance, and both processes may rather be related to the underlying processes of aging *per se*. Bone loss and increased fracture risk in aging men is associated with low E2 rather than low T, but the highest fracture risk is in men with both low E2 and T and with high SHBG. T therapy in older men with low to low-normal serum T is associated with increase or prevented decrease of skeletal muscle mass. The small, but consistent improvements in lean mass are associated with more variable effects on muscle strength and power with limited improvements or no effect depending on the considered study or muscle group and test. Findings on the impact of T-treatment on physical function have in turn been disappointing with both negative findings

besides positive findings with mostly small effect size and uncertain clinical significance. Higher dose, longer treatment duration, lower baseline T and presence of baseline functional capacity limitations are factors that may be associated with greater treatment responses. Although T-treatment in men with low T has (limited) positive effects on bone homeostasis, there is no documented effect on fracture risk and T supplementation in men should not be considered a treatment of osteoporosis. A major limitation for T treatment in older men is the lack of long term controlled data on (cardiovascular and prostate) safety.

Adrenal androgens (androstenedione, DHEA and DHEA-sulfate) and some residual ovarian T secretion are the only source of sex steroids in postmenopausal women and in particular of estrogens for which they are precursors. Lower androgen levels have been associated with poorer muscle functional status and skeletal health, Androgen can improve muscle mass and function but controlled data on (longer-term) efficacy and safety in women is presently very limited.

More recently, there has been considerable interest in the development of (non-steroidal) selective androgen receptor modulators for use in both women and men, aiming at improving the benefit-risk profile of androgen-based anabolic treatment. In conclusion, there is a potential for androgen treatment in the management of muscle and bone disorders, but presently its role is limited awaiting more data from randomized clinical trials.

MTE12

ATYPICAL FEMORAL FRACTURE: STAGE IN 2019

E. Biver¹

¹Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Switzerland, Geneva, Switzerland

Atypical femoral fractures (AFF) are characterized by specific radiographic and clinical features (prodromal pain, bilaterality) that resemble stress or insufficiency fractures of the subtrochanteric or diaphyseal part of the femur. They often occur in subjects with long-term antiresorptive therapies, but are also observed in antiresorptive drugs-naïve patients or in patients with monogenetic bone disorders, suggesting a genetic susceptibility. Other factors influence their pathogenesis, including some clinical risk factors (autoimmune disease and glucocorticoids use, Asian ethnicity), hip and lower limb geometry, and changes in bone material properties.

In this session, we will discuss:

- How to identify subtrochanteric or diaphyseal fractures of the femur which satisfy the case definition of AFF proposed by the ASBMR Task Force.
- The epidemiology of AFF in comparison to those of osteoporotic fractures prevented by antiresorptive therapy.
- How to monitor patients on long-term antiresorptive therapy for incomplete AFFs prior to fracture.

- The clinical management of patients who sustained an AFF, which is balanced by the risk of second AFF and the need to prevent future fragility fractures.
- Whether teriparatide may be of some benefit in accelerating AFF fracture healing.

MTE13

PITFALLS IN IDENTIFICATION OF VERTEBRAL FRACTURE

C. Roux¹, J. Fechtenbaum¹

¹Department of Rheumatology, Reference Center for Genetic Bone Diseases Cochin Hospital, Assistance Publique - Hôpitaux de Paris. Paris Descartes University, Paris, France

Vertebral fractures are the most common osteoporotic fractures, and their consequences in morbidity and mortality are well recognized. The diagnosis of vertebral fractures is based on spine X-rays, but under diagnosis has been reported by many studies. This is explained in part by the absence of gold standard for definition of fractures and by the high number of deformities of vertebral bodies, which are not of osteoporotic origin.

Computed tomography (CT) and magnetic resonance imaging (MRI) are very sensitive and specific but have high costs, and, in the case of CT, expose individuals to relatively high amounts of radiation. Densitometric vertebral fracture assessment (VFA) has the advantage of potentially reducing the impact of parallax effects on fracture identification with little expense and low radiation exposure.

Accurate identification of osteoporotic vertebral fractures and appropriate treatment are needed to reduce the impact of the disease on patients and on the health care system.

MTE14

MUSCLE STRENGTH/POWER ASSESSMENT AND OUTCOMES

O. Bruyère¹, C. Beaudart¹, M. Aubertin-Leheudre²

¹Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ²Université du Québec à Montréal (UQAM), Montréal, Canada

According to an ESCEO-EUGMS survey, 53.3% of clinicians assess muscle mass in daily practice, 54.5% muscle strength and 71.4% physical performance. However, the tools used are very different and no single tool is used by all clinicians. However, the tools and the cut-off values used by clinicians to diagnose various disorders such as sarcopenia are also heterogeneous. Interestingly, the relationship between muscle strength and physical function is influenced by level of muscle mass, the degree of obesity (e.g. BMI), age and physical activity. Therefore, these factors are to be taken into account in the evaluation of muscle strength. According to the revised European consensus on sarcopenia, muscle strength is the primary parameter of sarcopenia and is associated with adverse outcomes or physical limitation. However, it is necessary to have objective, reliable and sensitive tools to assess muscle strength, in different populations to detect and quantify

weakness, and to evaluate the effects of treatment. Handgrip strength measurement may be suitable for clinical practice while the measurement of knee flexors/extensors strength with both 1RM and dynamometers is more relevant but limited by the need for special equipment.



2019 PARIS

WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES

PARIS, France | 2019

Abstract Book

**Committee of National
Societies Abstracts**

OCs1

DETERMINANTS AND HEALTH CONSEQUENCES OF A RAPID MUSCLE HEALTH DECLINE IN OLDER ADULTS FROM THE SARCOPHAGE STUDY

M. Locquet¹, C. Beaudart¹, J.-L. Croisier², J.-Y. Reginster¹, O. Bruyère¹

¹Public Health, Epidemiology & Health Economics, University of Liège, ²Laboratory of Human Motion Analysis, University of Liège, Liège, Belgium

Objectives: To characterize the muscle health decline of older adults over 1 year and its association with adverse consequences over the 3 following years.

Methods: The SarcoPhAge cohort follows up 534 older adults to assess health consequences of sarcopenia. Subjects are seen annually and an assessment of muscle mass (DXA), muscle strength (handheld dynamometer) and physical performance (4-m gait speed) are performed. Outcomes are collected either during annual follow-up visits or by phone. Individual relevant decline of muscle mass, muscle strength and gait speed between baseline and the 1-year follow-up was evaluated using the Edwards-Nunnally index. The association between muscle decline and occurrence of outcomes was tested using logistic regressions. Missing data were handled using multiple imputations.

Results: 534 subjects were recruited (73.5±6.2 y, 60.5% women) but during the first year, 7 deaths occurred. Consequently, analyses were performed on 528 subjects. The prevalence of a rapid muscle mass decline was 41.5% (n=219). Subjects presenting a decline of muscle mass had no difference of their demographic or clinical characteristics compared to subjects without decline (all $p > 0.05$). The prevalence of a rapid decline of muscle strength was 47.3% (n=149). Subjects presenting a decline in muscle strength were more often women (21.2% of male vs. 66.0% of female, $p=0.02$) and had a lower cognitive status (27.6 points vs. 28.1 points at the MMSE, $p=0.02$). A significant decline in gait speed was observed in 28.2% (n=149) of the whole population. Subjects presenting decline of physical function were older (74.5 years vs. 73.0 y, $p=0.01$), had lower BMI and cognitive status (25.8 vs. 26.8, $p=0.03$ and 27.5 points vs. 28.0 points at the MMSE, $p=0.04$). Over the 3 following years, a rapid decline in muscle mass and strength did not predict the occurrence of falls, fractures and hospitalisations. A rapid decline in gait speed predicted the occurrence of self-reported physical disabilities (adjusted OR=1.87[1.18-2.96]) as well as deaths (adjusted OR=2.36 [1.17-4.73]).

Conclusion: A significant proportion of the older population showed a rapid decline in muscle health, associated with age, sex, BMI and cognitive status. A rapid decline of gait speed predicted the occurrence of 3-y death and disabilities, highlighting the importance of an assessment of gait speed in older subjects.

OCs2

THE ASSOCIATION BETWEEN RESTING METABOLIC RATE AND SARCOPENIC OBESITY IN OVERWEIGHT AND OBESE ADULT WOMEN

K. Mirzaei¹, N. Rasaei¹, S. F. Sajjadi¹, S. A. Keshavarz²

¹Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), ²Department of clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran

Objective: So far, no study has examined the contribution of resting metabolic rate (RMR) to sarcopenic obesity (SO) in obese and overweight people based on quintile of skeletal muscle mass (SMM) and fat mass (FM). This study was conducted to examine the association between RMR and SO.

Method: This cross-sectional study was conducted on 301 overweight and obese women aged 18-48 (BMI >25 kg/m²). Anthropometric measurements were assessed in all participants. Body composition was measured using body composition analyzer. Resting metabolic rate was measured by means of indirect calorimetry. The usual intake of food was evaluated over the past year by the use of questionnaire a valid and reliable semiquantitative food frequency containing 147 items.

Result: The prevalence of sarcopenia (who had two lower quintiles of SMM) and obesity (who had two highest quintiles of FM) was 19.6%, 20.4% respectively. The rate of SO among participants was 9.9%. Between SO and non-SO individuals there was statistically significant difference in height, BMI, Resting metabolic rate/kg, body fat%, SMM, FM, waist circumference, fat mass index, FBS and T-score ($P<0.05$). Binary logistic analysis showed that participants with lower RMR/kg had higher odds of SO (OR=0.87, 95%CI=0.78 to 0.98, $P=0.03$) and the risk of sarcopenia increased by 13%. After adjustment for weight, physical activity and total energy intake, the relationship between the RMR/kg and SO, was still significantly negative (OR=0.87, 95%CI=0.77 to 0.99, $P=0.04$) and participants with lower RMR/kg had higher odds of SO and the risk of sarcopenia reduced by 13% too.

Conclusion: The findings of this study suggest that there is a negative relationship between SO and RMR/kg, and increasing of RMR/kg, has a significant effect on reducing of incidence risk of SO.

OCs3

**WILL THERE BE A FRACTURE IN THEIR FUTURE?
BONE MINERAL DENSITY FINDINGS IN YOUNG
SOUTHEAST ASIAN WOMEN WITH ANOREXIA
NERVOSA**M. Chandran¹, Y. Hao²¹Osteoporosis and Bone Metabolism Unit, Singapore General Hospital, ²Health Services Research Unit, Singapore General Hospital, Singapore

Objective: Anorexia nervosa carries with it an increased risk of bone loss and fractures. No prior study has explored the bone density findings of Southeast Asian women with this condition and therefore that was the aim of our study.

Method: Case notes of 100 young women aged 20-30 with a history of anorexia nervosa and who were seen in the Endocrinology clinic of a large public hospital for evaluation of their bone health were retrospectively reviewed. 75 of them had DXA scans performed at the time of initial diagnosis and these scans were examined and these patients were analysed further.

Results: 49 (65%) had a diagnosis of restrictive type anorexia nervosa. The remaining carried a diagnosis of binge purge type. 97% of the women were Chinese, the remaining were Malay or Indian. The mean (SD) age and BMI at presentation was 18.5 (5.7) and 14.2 (2.0) respectively. The mean (SD) duration of amenorrhea in months at the time that the DXA scans were done was 16.5 (14). 19 of the 85 women had a Z-score ≤ -2 at the LS or neck of femur. Age at presentation (17.1 (5.3) vs. 22.1 (5.9); $p=0.005$), duration of untreated illness in years (1.51 (1.45) vs. 3.9 (3.1); $p=0.001$ and duration of amenorrhea in months (12.48(12.6) vs. 31.2 (30.9) were significantly associated with Z-score of ≤ -2 at either lumbar spine or neck of femur. None of the women had been started on any potential bone metabolism modifying agents including oral contraceptives at the time the DXA scans were done.

Conclusion: Early identification and treatment that will help to shorten the duration of illness and amenorrhea may help to ameliorate bone density losses in anorexia nervosa. This may potentially prevent complications such as fragility fractures in later life.

OCs4

**THE BENEFITS OF REGULAR WEIGHT BEARING
ACTIVITY THROUGHOUT THE LIFE-COURSE: DO
MEN AND WOMEN REAP THE SAME REWARDS?**J. Zhang¹, M. Clynes¹, K. Jameson¹, C. Cooper¹, E. M. Dennison¹¹MRC, Lifecourse Epidemiology Unit, Southampton, Southampton, UK

Objective: Higher levels of physical activity (PA) are thought to be beneficial for musculoskeletal health but few studies have considered relationships between reported PA levels at different stages of life, and musculoskeletal outcomes in late adulthood, particularly in men. We considered this in the Hertfordshire Cohort Study, a cohort of free living men and women born 1931-9.

Methods: The study population comprised 128 men and 130 women from the Hertfordshire Cohort Study. Participants completed a questionnaire that asked about participation in sports/leisure time exercise involving weight bearing activity up to age 18 y; aged 18-29 y; aged 30-49 y and since age 50 y. Responses were coded as none/ once a month/ once a week/ more than once a week. Current lifestyle and PA levels were recorded in the same questionnaire. Grip strength was assessed using a Jamar dynamometer. Bone densitometry was performed at the total femur (Hologic QDR 4500).

Results: The mean age of participants was 75.4 (SD 2.5) years in men and 75.7 (SD 2.6) years in women. Women were currently more physically active than men, recording a median activity time/d of 206 (IQR 146-277) min daily, vs. 194 (IQR 110-298) min daily in males. However, men tended to report higher levels of past PA through the life-course, with significant differences in weight bearing activity up to the age of 18 y ($p=0.006$) and also 18-29 y ($p<0.001$), when only 15.6% of women reported PA more than once a week, compared to 41.6% of men. In women, we observed greater BMD at the total hip in women who reported regular weight bearing PA at ages 18-29 y (β weekly exercise 0.72, $p=0.02$; β more than once a week exercise 0.83, $p=0.01$), and 30-49 y (β weekly exercise 0.52, $p=0.04$; β more than once a week exercise 0.78, $p=0.02$). compared with those who reported no weight bearing PA, even after adjustment for age, BMI, social class, smoker status, alcohol consumption, current physical activity and dietary calcium intake. No such relationships were apparent in men, before or after adjustment. No relationships were observed between past PA and grip strength in this sample.

Conclusions: Regular weight bearing activity around the time of peak bone mass acquisition was less common in women than men in this historical cohort. However, we observe higher hip BMD in those women participating in regular PA throughout the life-course, highlighting the need to promote exercise among young women.

OCs5

ASSOCIATION OF 25-HYDROXY VITAMIN D WITH BONE TURNOVER MARKERS AND BONE MINERAL DENSITY IN AN IRANIAN ELDERLY POPULATION: BUSHEHR ELDERLY HEALTH (BEH) PROGRAM

S. Gharibzadeh¹, N. Fahimfar², G. Shafiee³, R. Heshmat³, N. Mehrdad⁴, F. Razi⁵, P. Khashayar⁶, A. Raiesi⁷, I. Nabipour⁸, B. Larijani⁹, A. Ostovar²

¹Department of Epidemiology and Biostatistics, Pasteur Institute of Iran, Tehran, Iran, ²Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ³Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ⁴Elderly Health Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ⁵Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ⁶Center for Microsystems Technology, Imec and Ghent University, Ghent, Belgium, ⁷The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran, ⁸The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran, ⁹Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Objective: To investigate the associations between serum 25-hydroxyvitamin D (25-OH D), bone turnover markers, and BMD in an elderly population.

Methods: The present study was conducted within the framework of the Bushehr Elderly Health (BEH) programme, a population-based prospective cohort study being conducted in Bushehr, a southern province of Iran. In brief, 400 persons (186 men and 214 women) from participants of the second stage were selected; serum bone turnover markers (bone-specific alkaline phosphatase (bALP), amino-terminal procollagen propeptide of type I collagen (PINP), osteocalcin (OC), tartrate-resistant acid phosphatase isoenzyme 5b (TRAP)) and vitamin D were measured. Vitamin D deficiency and insufficiency were defined as serum 25-OHD below 50 ng/mL and between 50-75 ng/mL, respectively. Nonparametric Spearman's rho was used to assess the correlation between different measurements.

Results: Vitamin D deficiency and insufficiency were detected in 253(63.25%) and 71(17.75%) of participants, respectively. Vitamin D status was significantly different in men and women (chi-square=15.55, p=0.001). We found a significant inverse association between vitamin D levels and bALP in the total population (rho=-0.20, p<0.001). In vitamin D deficiency group, there were inverse correlations between vitamin D levels and both OC, and CTX (p<0.001) and direct correlation with BMD of all sites (p<0.001). We also found a significant reverse correlation between bALP and vitamin D levels among women (rho=-0.27, p<0.001)

Conclusions: Our findings suggest that in elderly participants with vitamin D deficiency, 25(OH) D levels were significantly and negatively related with serum CTX and serum OC and negatively associated with L1L4, femoral neck, and total hip BMD.

OCs6

SERUM VITAMIN D LEVEL ASSOCIATED WITH COGNITIVE AND PHYSICAL FUNCTIONING OF POSTMENOPAUSAL WOMEN

A. A. Popov¹, N. V. Izmozherova¹, E. A. Safianik¹, A. A. Vikhareva¹, V. M. Bakhtin¹, M. A. Shambatov¹

¹The Urals State Medical University, Ekaterinburg, Russia

Objective: Vitamin D insufficiency has been reported to be associated with increased risk of falls, low bone mineral mass, bone fractures and low quality of life in older adults [1]. Moreover, lack of vitamin D may be related to additional cardiovascular events, infections, several types of cancers and other causes of multimorbidity and premature death [2]. Our aim was to assess cognitive and physical functioning of postmenopausal women in relation with serum vitamin D level.

Methods: In a prospective cohort nested sample of 80 independently living postmenopausal women aged between 64-69 (median 67) serum 25OH-cholecalciferol level was assessed [1]. Mini Mental State Evaluation (MMSE) tool was used for cognitive impairment screening. Short Physical Performance Battery (SPPB) and grip strength were used to measure physical functioning.

Results: In this sampling menopause occurred at the age of 45-52 (median 50), 32 persons had low traumatic fractures, 9 women had traumatic fractures. Only 21 subjects had normal serum vitamin D level, 26 women had vitamin D insufficiency and 33 participants were vitamin D deficient. Low levels of serum vitamin D were associated with mild cognitive impairment (Spearman R=-0.36: P=0.001) and decrease of grip strength (Spearman R=-0.32: P=0.002). Low serum vitamin D group showed significantly higher occurrence of inability to perform SPPB tests (c2=7.27; P=0.02).

Conclusion: In a small but homogenous sampling of independently living postmenopausal women low level of serum vitamin D was associated with impairment of both cognitive and physical functioning.

References:

1. Holick M. Ann Epidemiol 2009;19:73
2. Dawson-Hughes B et al. Osteoporos Int 2010;21:1151
3. Celis-Morales CA et al. BMJ 2018;361:k1651

OCs7

POSTPARTUM OSTEOPOROSIS ASSOCIATED WITH VERTEBRAL FRACTURES

N. Temelkova¹, A. Gerganova¹, K. Temelkova², K. Sirakova³, P. Popivanov¹

¹Department of Clinical Densitometry, University Hospital "Alexandrovska", ²University Hospital for Children's Diseases "Ivan Mitev", ³Department of Imaging Diagnostics, Medical Faculty, Medical University, Sofia, Bulgaria

Osteoporosis in postpartum period is a very rare, but severe condition. Its etiology and pathogenesis are not well studied, but it is assumed that it could be due to genetic, hormonal or associated with calcium-phosphorus metabolism disorders.

Case report: We present a case of postpartum osteoporosis associated with multiple vertebral fractures. Two months after the delivery of twins a 35-year-old primipara patient experienced severe low back pain following minor physical activity. The subsequently performed MRI scan showed L1 compression fracture and multiple fractures on the upper vertebral end plates from Th8 to L5. The patient has undergone a couple of stimulations for in-vitro fertilization and during the last year she took intermittently 4 mg methylprednisolone for approximately 4 months. A DXA scan was performed on GE Lunar DPX, which revealed Z-score of - 4.2, height of 159 cm, and weight- 45 kg. The patient does not have family history of osteoporosis or any diseases that alter BMD. No pathological finding was observed from the lab results - 25(OH) vitamin D - 33 ng/ml, low rate of calciuria. The initialised treatment was calcium carbonate 600 mg, cholecalciferol 1500 IU and teriparatide 20 µg subcutaneous injection daily. Afterwards, L1 vertebroplasty was done. The ongoing therapy resulted in very good clinical outcome. 6 months after the beginning of the treatment patient's Z-score was - 2.4. The patient reported that she felt her spine more stable. Current lab results in reference range.

Conclusion: Postpartum osteoporosis is a rare condition, that has substantial health consequences. Currently no guideline regarding the treatment is established. At this juncture the therapy includes calcium and vitamin D supplementation and attempts with variable bisphosphonates regimens. Besides our data, many case reports in the literature support the concept of teriparatide-induced stimulation of trabecular bone growth as a promising opportunity to favourably influence this kind of patients.

OCs8

VALIDATION OF THE FRACTURE RISK ASSESSMENT TOOL (FRAX) CALCULATOR IN TAIWAN: TWO COHORTS STUDY

C. H. Wu¹, F. W. Liang², I. T. Liu³, Y. F. Chang¹, L. C. Ou⁴, C. S. Chang¹, T. H. Lu⁵

¹Department of Family Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, ²Department of Public Health, College of Health Science, Kaohsiung Medical University, Kaohsiung, ³Department of Family Medicine, E-Da Hospital/I-Shou University, Kaohsiung, ⁴College of Education, National Kaohsiung Normal University, Kaohsiung, ⁵Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Objectives: In 2030, the aging population will reach to 20% in Taiwan. The incidence of osteoporotic hip fracture in Taiwan was 9th ranking in Worldwide and top one ranking in Asia-Pacific regions. Taiwan FRAX® calculator was launched in 2010, but the appropriateness had never been validated by the long-term follow-up cohort.

Methods: The two cohorts including 776 (M/F=408/468) subjects aged 65 from Tianliao district in 2009-2010 and 1200 (M/F=524/676) subjects aged 40 and over from Douliou district in 2009-2010 were follow-up. The clinical risk factors (CRFs) for osteoporotic fracture were assessed along with DXA derived BMD to generate the baseline FRAX (with or without BMD) either major osteoporotic fracture (MOF) or hip fracture (HF) scores accordingly. We identified all claims records of outpatient clinic emergency room visits or hospital admissions of patients from 2009-2016 in the Taiwan National Health Insurance Research Database (NHIRD). The primary outcomes were the rate of major fractures (vertebral, hip, upper arm, or wrist), hip fracture and non-hip fracture according to ICD 9.0 code. Pathological fractures and high-energy fractures were excluded.

Results: Of the 1573 subjects with completed data, the fracture rate of major fracture is 1.843% (1843/100,000 population) during 2009-2016. Using the cutoffs by MOF FRAX score ≥20% or HF FRAX score ≥3%, the fracture rate were significantly higher in high score group (either with or without BMD, MOF or HF) (The ratio of fracture rate between high and low score group were shown in Table).

	FRAX HF Score (without BMD) At 3%	FRAX HF Score (with BMD) At 3%	FRAX MOF Score (without BMD) At 20%	FRAX MOF Score (with BMD) At 20%
Hip Fracture	15.94	15.42	9.51	4.99
Non-Hip Fracture	2.91	4.03	1.85	7.22
Major Fracture	4.02	5.18	4.26	6.91

Conclusions: The 2010 Taiwan FRAX is preliminarily validated and the cutoffs of MOF at 20% and HF at 3% are acceptable. However, the different cutoffs might be needed to provide better discrimination of high risk patients in advance.

OCs9

PREVALENCE OF SARCOPENIA IN INDIAN MEN AND WOMEN VARIES ACCORDING TO THE DEFINITION USED

A. Zengin¹, B. Kulkarni², A. V. Khadilkar³, V. Ekbote³, N. Kajale³, N. Tandon⁴, S. K. Bhargava⁵, H. P. S. Sachdev⁶, S. Sinha⁶, C. H. D. Fall⁷, P. R. Ebeling¹

¹Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia, ²Clinical Division, National Institute of Nutrition, Jamai Osmania PO, Hyderabad, India, ³Hirabai Cowasji Jehangir Medical Research Institute, Pune, India, ⁴Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India, ⁵Department of Paediatrics, Sunder Lal Jain Hospital, New Delhi, India, ⁶Department of Paediatrics and Clinical Epidemiology, Sitaram Bhatta Institute of Science and Research, New Delhi, India, ⁷MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK

Objective: India has over one third of the world’s population aged >60 , which is estimated to rise to over 38% by 2050 – equal to 494 million people. Prevention of sarcopenia is critical to ensure

healthy independent ageing in India. The prevalence of sarcopenia in India is unknown, as is whether the existing definitions, mainly developed in Caucasian populations (FNIH and EWGSOP2), are vigorous in this population. Our aim was to identify whether: (1) existing definitions are able to determine the prevalence of sarcopenia in India; (2) either the lowest 20th percentile of an older population, or 2SDs below a young Indian reference population is a more robust criterion for predicting sarcopenia in this population.

Methods: Cohort studies across different regions of India were used to compare appendicular lean mass index (ALMI, kg/m²), by DXA, and grip strength (GS, kg). The young Indian (YI) group (aged 20-35yrs) consisted of men (M) and women (W) (n=1070): from New Delhi Birth Cohort, Andhra Pradesh Children and Parents Study (APCAPS), Indian Migration Study (IMS) and the Pune Pregnancy Study; the older Indian (OI) population (>45 y) comprised 1764 participants from: APCAPS and IMS. Two SD below the mean of the YI, and the lowest 20th percentile of OI identified Indian specific cut-points for GS and ALMI. Receiver operating characteristic (ROC) analyses were used to determine the area under the curve, and sensitivity and specificity to discriminate between sarcopenic individuals who had low vs. normal GS across the 4 definitions.

Results:

Developed cut-points					Prevalence of sarcopenia			
		n	GS	ALMI	EWGSOP2	FNIH	YI	OI
Men	YI	602	15.4	6.0	35%	42%	8%	8%
	OI	1014	15.9	6.2				
Women	YI	468	9.9	4.5	28%	35%	1%	6%
	OI	750	11.3	5.2				

GS	MEN				WOMEN			
	Sensitivity (%)	Specificity (%)	AUC	OR (95%CI)	Sensitivity (%)	Specificity (%)	AUC	OR (95%CI)
EWGSOP 2	68	69.1	0.686	4.8 (3.7, 6.2)	78.6	47.5	0.630	3.3 (2.4, 4.7)
FNIH	84.2	51.1	0.676	5.6 (4.1, 7.5)	89.8	27.3	0.586	3.3 (2.1, 5.2)
Young Indian	28.3	93.2	0.607	5.4 (3.7, 7.9)	5.1	98	0.515	2.6 (0.8, 8.7)
Older Indian	43.4	86.9	0.651	5.1 (3.6, 7.2)	42.3	80.8	0.615	3.1 (2.0, 4.7)

Conclusion: EWGSOP2 was most robust at detecting low GS, more so in men than women. The variation in the prevalence of sarcopenia depends on the definition used and highlights the importance of measuring functional capability across ethnic populations.

OCs10

VERTEBRAL PAIN AND PHYSICAL PERFORMANCE INDICES IN POSTMENOPAUSAL WOMEN WITH VERTEBRAL FRACTURES DEPENDING ON BONE MINERAL DENSITY PARAMETERS

N. Grygorieva¹, V. Povoroznyuk¹, O. Rybina¹

¹Institute of Gerontology named after D. F. Chebotareva NAMS of Ukraine, Kyiv, Ukraine

Vertebral fractures (VFs) are amongst one of the most crucial osteoporotic fractures which manifest increased morbidity and mortality; however, their clinical features usually differ. BMD is one of the important parameters of bone strength and risk of osteoporotic fractures. The aim of the research was to study the indices of vertebral pain (VP) and physical performance (PP) in postmenopausal women with VFs depending on BMD parameters. We examined 89 females aged 50-89 years old with VFs in thoracic and/or lumbar spine which were divided into 3 groups: I – patients with osteoporosis (OP), according to WHO criteria for DXA, n=41; II – women with osteopenia (OPN), n=26; III – females with normal BMDs (NB), n=22. The parameters of VP in thoracic and/or lumbar spine were measured by 11-component visual analog scale (VAS), the indices of PP using static and dynamic functional tests (Thomayer, Schober tests, chest excursion, lateral trunk lean, 3-, 4-, 15-meter tests, “stand up from the chair”, static balancing). BMD was measured by DXA (Lunar, Prodigy). We have found the significantly lower parameters of weight and height in women with VFs and OP or OPN compared to females with NB. However, we did not establish any reliable differences of VP neither in thoracic nor in lumbar spine depending on BMD state. Also, we did not reveal the significant differences of most parameters of PP, except for the indices of chest excursion (mean parameter, of the inhalation and exhalation) which were reliably lower in patients with OP.

In conclusion, the indices of VP and PP do not differ in postmenopausal women depending on BMD parameters, except for chest excursion that should be taken into account in rehabilitation programs for females with VFs.

OCs11

FAMILY HISTORY INFLUENCES FRACTURE RISK BMD INDEPENDENTLY

A. Gasparik¹, M. Cevei², D. Stoicanescu³, T. Szocs¹

¹University of Medicine and Pharmacy (UMFST) Tirgu Mures, Tirgu Mures, ²University of Oradea, Oradea, ³University of Medicine and Pharmacy V. Babes, Timisoara, Romania

Osteoporosis, a major public health issue has been associated with a positive family history. We aimed to evaluate how family history of osteoporotic fractures influences: 1. fracture rate, 2.

BMD levels, 3 BMD levels when the fractures occurred compared to negative history. We included 541 patients, with an average age of 55 years. Our study confirms that a positive family history significantly increase fracture prevalence (37 vs. 17%, p<0.001), decreases BMD scores and: fractures occurred at higher (better) T and Z-scores. As a conclusion we can affirm that family history increases the probability of a fracture also independently of the BMD scores.



2019 PARIS

WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES

PARIS, France | 2019

Abstract Book

**Non-Sponsored Symposia
Abstracts**

NS1

ROUTINELY COLLECTED DATA FOR THE STUDY OF THE EPIDEMIOLOGY OF FRACTURES, AND FOR CHARACTERISING IMMINENT FRACTURE RISK**B. Abrahamsen¹**¹Holbæk Hospital, Holbæk, Denmark; University of Southern Denmark, Odense, Denmark

Prof Bo Abrahamsen will discuss the use of real world (routinely collected) data for the study of the epidemiology of metabolic bone disease, including osteoporosis, fracture/s, and osteonecrosis of the jaw.

He will start by introducing the audience briefly to a number of different data sources available around Europe, including Scandinavian registries and primary care and hospital electronic medical records.

Prof Abrahamsen will then cover his previous work on the epidemiology of fracture/s in Denmark, including both major osteoporotic and other fractures. He will also discuss previous work on the descriptive epidemiology of jaw osteonecrosis and subtrochanteric fracture/s, and their association with the use of oral bisphosphonates in actual practice conditions and patients.

NS2

REAL WORLD DATA FOR ASSESSING THE USE, RISKS, AND BENEFITS OF ANTI-OSTEOPOROSIS THERAPIES IN ACTUAL PRACTICE CONDITIONS**D. Prieto-Alhambra¹**¹University of Oxford, Oxford, United Kingdom

Prof Prieto-Alhambra will start with a brief presentation on the 'pros and cons' of the use of routinely collected data in post-marketing surveillance, with a focus on drug utilisation and safety studies in Europe.

Daniel will then discuss the use of routinely collected data from multiple data sources in Europe for the study of the conditions of use and prevalence/incidence of prescription/s of anti-osteoporosis treatments in different countries/regions, and the implications of such information for regulators and decision makers.

He will then discuss briefly methodological aspects for consideration when performing any analyses of association/s between the use of drugs and their potential side effects.

Prof Prieto-Alhambra will finish this presentation with a brief introduction to the concept of federated distributed data networks to enable multinational collaboration in the field.

NS3

HEALTH ECONOMICS USING REAL WORLD DATA: AN INTRODUCTION**R. Pinedo-Villanueva¹**¹University of Oxford, Oxford, United Kingdom

Dr Pinedo-Villanueva will start with a brief introduction to the concepts of costs as recorded in routinely collected data. He will discuss his experience with the use of such data for the research of the costs and benefits of a number of musculoskeletal treatments and conditions.

He will summarise the findings of his work on the health economics of hip and knee arthroplasty using a number of different real world data sources. He will then summarise his recent work on the costs of sarcopenia, to finish with a synopsis of his recent and current work on characterising the costs of musculoskeletal rare disease/s.

NS4

REAL WORLD DATA FOR THE STUDY OF ORTHOPAEDICS AND HIP FRACTURE CARE**A. Pedersen¹**¹Southern Denmark University, Odense, Denmark

Prof Pedersen will cover the use of real world data for the study of orthopaedics, with a focus on hip fracture epidemiology and care.

She will present her previous work on the analysis of the impact of hip fractures and hip fracture care quality on morbi-mortality using data from a number of different Danish data sources.

She will also discuss her recent publications on the secular trends of infections and antibiotic use associated with hip fracture surgery.

Prof Pedersen will finish by discussing her published data on the impact of painkillers use, patient characteristics and comorbidity on hip fracture care and complications.

NS5

TENDON PHYSIOPATHOLOGY AND IMAGERY... WHAT'S NEW ?**S. Bogaerts¹**¹Physical, rehabilitation and sports medicine - UZ Leuven, Leuven, Belgium

Tendinopathy remains a highly prevalent condition among recreational as well as high-level athletes. Despite an incomplete understanding of the multifactorial aetiology of tendinopathy, load management and mechanical loading exercises have become the gold standard in preventing and managing these injuries. However, exercises are often generic and prescribed in a "one-size-fits-all" principle, which might limit the success rates of current prevention and treatment regimens. In this symposium, new insights into local tendon mechanics will be highlighted by dr. Stijn Bogaerts, where the old idea of a tendon being one elastic band is put aside. He will reframe the concepts of multilevel (fibril-fibre-fascicle) sliding and gliding and their possible relationship

with tendinopathy. Also, the necessary paradigm shift towards dynamic-functional biomechanical evaluation of tendons will be discussed, as static-structural evaluation does not appear to be helpful in guiding prevention or treatment of tendinopathy.

NS6

REHABILITATION: ECCENTRIC OR NOT ECCENTRIC? WHICH PHYSIOTHERAPY?

J.-L. Croisier^{1,2,3}

¹Department of Sports and Rehabilitation Sciences, University of Liège, Liège, Belgium, ²FIFA Medical Centrer of Excellence, Liège, Belgium, ³IOC Research Center for Prevention of Injury and Protection of Athlete Health and FIMS collaborating Centre of Sports Medicine, Liège, Belgium

In the past, tendinopathy conservative treatment was mainly dedicated to pain relief, using « passive » techniques. Considering the possible weakness of tendon resistance properties, more « active » physiotherapy programmes were thereafter recommended in order to induce tendon structure adaptations.

Nowadays, eccentric exercises have strong evidence supporting its utility in various tendinopathy rehabilitation (patellar, achilles, epicondylar tendons for instance). Eccentric intervention is commonly based on low intensity and low speed muscle contractions excluding the maximal length of the muscle-tendon unit at the beginning. Modalities are progressively intensified yet the progression remains subordinated to pain free conditions.

Nevertheless, such treatment requires a great number of sessions (frequently more than 20). In the same time, some authors reckon that eccentric programmes should be less effective in athletes, especially during a competition season.

In the most recent studies, isometric and heavy slow resistance (HSR) exercises were suggested to be effective in pain reduction and functional improvement. For instance, a single bout of isometric contraction could have the potential of immediate patellar tendon pain relief for at least 45 minutes in athletes during competitive seasons.

Due to the varying localisation and severity of tendinopathies, treatment technique selection should be based on pain level, sports activities and specific responsiveness regarding the injury site.

Conservative management of tendinopathies should also include the correction different of modifiable factors contributing to the pathology occurrence (such as lack of muscle strength, flexibility,...).

NS7

WHICH EFFICACY FOR THE NEW TREATMENTS ?

J.-F. Kaux^{1,2,3,4}

¹Physical & rehabilitation medicine and Sports traumatology, Liège, Belgium, ²FIFA Medical Centrer of Excellence, Liège, Belgium, ³IOC Research Center for Prevention of Injury and Protection of Athlete Health and FIMS collaborating Centre of Sports Medicine, Liège, Belgium, ⁴University and University Hospital of Liège, Liège, Belgium

Tendinopathy is a major problem in medicine. It is due, inter alia, to mechanical overload. Painful and disabling, it frequently leads physical workers to impair their quality of life. It remains a challenge for the medical world, to the extent that its frequent resistance to conventional treatments rarely gives the patient a favourable outcome following therapeutic management. It is the reason why new treatments have been developed...

Platelet-rich plasma (PRP) is blood plasma with a high concentration of autologous platelets which constitute an immense reservoir of growth factors. The clinical use of PRP is widespread in various medical applications. Although highly popular with athletes, the use of PRP for the treatment of tendinopathies remains scientifically controversial, particularly due to the diversity of products that go by the name of 'PRP.'

Recently, the viscoelastic properties of hyaluronic acid (HA) on liquid connective tissue have been proposed for the treatment of tendinopathies. Some fundamental studies show encouraging results on hyaluronic acid's ability to promote tendon gliding and reduce adhesion as well as to improve tendon architectural organisation. Some observations also support its use in a clinical setting to improve pain and function.

NS8

BIOMARKER DISCOVERY

N. Al-Daghri¹

¹Dean of the College of Science, King Saud University, Director, Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia

The pleiotropic effects of vitamin D, specifically its extra-skeletal effects, remains controversial, despite an abundance of existing literature. Through biomarker discovery using 3D LC-nESI-FTMS quantitative proteomics, we revealed the different signature proteins activated by vitamin D that is influenced by sex and vitamin D status. The present study included vitamin D deficient Saudi adults recruited from several centers. The first phase is the biomarker discovery phase through profiling of pooled serum proteomes (males=31; females=28) and identified 2472 reproducible proteins, among which 248 exhibited significant modulation between men and women that mapped pathways associated with several key metabolic pathways including vitamin D function.

NS9

VITAMIN D BIOMARKER DISCOVERYM. Alokail¹

¹Vice-Dean for Development and Quality Affairs, Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia

The present study is the vitamin D biomarker discovery using the same depletion-free quantitative proteomics among vitamin D deficient subjects (males=26; females=24) that achieved vitamin D correction after 12-month vitamin D correction. The most significant biomarkers identified included those from the coagulation pathway, lipids, apolipoproteins, inflammatory markers, insulin growth factors and other proteins. Differentially expressed proteins were subjected to in silico bioinformatics assessment using principal component analysis, hierarchical clustering and Metacore™ pathway analysis. These identified proteins were also sexually-dimorphic. These sex-mediated effects should be factored in the design and interpretation of vitamin D observational/interventional studies testing cardiometabolic outcomes.

NS10

VALIDATIONY. Al-Saleh¹

¹Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia

The biomarker validation phase involved 35 most significantly modulated signature proteins using enzyme-linked immunosorbent assays from 259 vitamin D deficient participants stratified according to response to 6-month vitamin D supplementation [Responders: (25(OH)D >50nmol/l, N=162 (70 males; 92 females); Non-responders: 25(OH)D <50nmol/l, N=97 (27 males; 70 females)]. The last phase confirmed the associations of the identified biomarkers only among those whose vitamin D status responded to vitamin D status correction. Our series of studies confirm the importance of vitamin D in human metabolism at the proteomic level and the significant expression of major clinical biomarkers and their respective metabolic pathways depending on vitamin D supplementation response.

NS11

THE RADIOLOGICAL EVALUATION OF MUSCLE MASS IN OLDER PEOPLEG. Guglielmi¹

¹University of Foggia, Foggia, Italy

The loss of muscle mass in older people is one of the key mechanisms leading to sarcopenia. Therefore the evaluation of muscle mass is of remarkable importance in the evaluation of sarcopenic patient. In this presentation, we will discuss the importance to assess muscle mass in older people. In particular, we will deal with the most relevant tools used for assessing body composition in the diagnosis of sarcopenia including DXA, BIA, magnetic

resonance, echography and CT. A particular focus will be given to the pitfalls and the current issues in assessing muscle mass in the elderly.

NS12

PHYSICAL PERFORMANCE IN OLDER PEOPLE: ACTUAL EVIDENCEO. Bruyère¹

¹University of Liège, Department of Public Health, Epidemiology and Health Economics, Liège, Belgium

Together with the evaluation of the muscle mass, physical performance assessment is of extreme importance in the diagnosis of sarcopenia in older people. Recent guidelines of sarcopenia have modified the indications for assessing physical performance and muscle strength in older people. Moreover, some tests for evaluating physical performance (such as gait speed, TUG, SPPB) are of common use, whilst we have other new tests that are less known, but that seem to have an important prognostic value. In this presentation, we will discuss the use of these tests, with a focus of their use in older people and the actual issues and perspectives regarding this topic.

NS13

THE DIAGNOSIS OF SARCOPENIA IN OLDER PEOPLE: BETWEEN RESEARCH AND CLINICAL PRACTICEN. Veronese¹

¹National Research Council, Padova, Italy

Sarcopenia is becoming a new geriatric giant due to its high prevalence and to the negative outcomes associated with this condition. In these years, sarcopenia was introduced in the new classification of medical conditions, i.e. in the ICD 10 classification. However, sarcopenia is often assessed in academic centers, whilst its assessment in usual care is still limited. In this presentation, we will summarize the main findings of the two previous presentations and we will discuss how to improve the diagnosis of sarcopenia in older people, as standard evaluation, in daily practice.

NS14

BONE MASS AND FRACTURE RISK DURING PREGNANCY AND LACTATIONA. V. Gueldini de Moraes¹, F. Garanhan de Castro Surita²

¹Master's degree and Doctoral student of the Post-Graduation Course in Obstetrics and Gynecology, School of Medical Science, University of Campinas – UNICAMP, Campinas, Brazil, ²Associate Professor in Obstetrics and Gynecology Department, School of Medical Science, University of Campinas - UNICAMP, Campinas, Brazil

The prevalence of osteoporosis is less than 2% in women younger than 50 years, while between the ages of 20 and 40 years, the prevalence is only 1.2%. Physiological changes during puerperal-pregnancy cycle could lead to a rare disease: the pregnancy-

and lactation-associated osteoporosis (PLO). This rare disorder could affect young women during pregnancy, postpartum period, or while breastfeeding.

During pregnancy, major modifications of the calcium metabolism and bone mineral status of the mother occur, in order to meet the needs of the fetus for optimal growth of its skeleton and its mineralization. Fragility fractures have been described, but this occurs infrequently. It is possible that there is underdiagnosis as a result of the overlapping symptomatology with the frequent aches affecting normal pregnancies. Factors that may overlap maternal metabolic adaptations may have hormonal etiology, nutritional deficiency, mechanical changes, pharmacological association, renal disturbance, connective tissue disorders, other non-specified genetic disorders and idiopathic osteoporosis. Perhaps identification of this at-risk group may lead to effective interventions to reduce bone fracture risk in later life.

There are no established diagnostic criteria for PLO. However, a diagnosis can be easily obtained by an accurate medical interview, physical examination, imaging studies, and laboratory data, including bone mineral density measurement after delivery. This disease should be suspected when a woman presents with severe back pain in the late stages of pregnancy or the early postpartum period. An accurate and prompt diagnosis helps with appropriate treatment and prevents the progression of the disease.

There are no solid clinical practice guidelines for the management of this condition and treatment strategy remains controversial. Clinical judgment must be used to balance the potential benefit and risks of treatment that is being considered. The suggested treatment strategy includes optimize calcium and vitamin D intake, load reduction and analgesia. Cessation of lactation seems to be the major classical treatment in the reports. There is much uncertainty about whether pharmacological bone-specific therapy should be used for osteoporosis that presents during pregnancy or lactation. The temptation to prescribe anti-osteoporosis medications for pregnancy or lactation-induced osteoporosis needs to be tempered with the realization that BMD normally increases during the 6 to 12 months after weaning, with apparent recovery of the prior level of BMD and bone strength. Given the concerns about long-term safety, clinicians should carefully consider whether to commit a young woman to long-term treatment with these agents, especially since there is no clearly defined endpoint for treatment.

For avoiding post-pregnant osteoporosis and decrease in bone mass during pregnancy or lactation period, it is necessary to obtain sufficient bone mass before, during the growth period and maintain bone mass in adulthood. In addition to the prevention of post-pregnant osteoporosis, to avoid future osteoporosis and fragility fractures of older age, it is necessary to promote young women to take measures such as adequate nutrition intake and exercise habits, considering bone health.

NS15

UPDATE ON MANAGEMENT OF OSTEOPOROSIS IN YOUNG WOMEN

A. Orcesi Pedro^{1,2}

¹President of National Specialized Committee on Osteoporosis of FEBRASGO, Campinas, Brazil, ²Professor of Post-graduate Course of Obstetrics and Gynecology, School of Medical Science, University of Campinas- UNICAMP, Campinas, Brazil

Osteoporosis is less common in premenopausal women than in postmenopausal women. However, both fractures and low bone mineral density also occur in the premenopausal young women in special conditions that requires specialized clinical considerations.

The diagnosis of osteoporosis in a premenopausal woman is most secure when there is a history of low trauma fracture. Premenopausal fractures may be an important indicator of underlying poor bone quality and future fracture risk. There are few longitudinal prospective studies relating bone mineral density (BMD) by dual energy x-ray absorptiometry (DXA) to fracture risk in premenopausal women. Because of this, and because fracture rates are much lower in premenopausal than postmenopausal women the predictive relationship between BMD and short-term fracture incidence is unclear in premenopausal women. Therefore, BMD measurement is only recommended in young women with a history of low trauma fracture and in those with known causes of bone loss.

Special considerations required for management of low bone mass in premenopausal women:

- *Dynamics of Peak BMD Accrual – bone mass in premenopausal women depends primarily upon achievement of peak bone mass that occurs between the ages of 11-18 years. Illnesses or medications that negatively impact bone density accrual should be screened and adequate management should be initiated. This include amenorrhea (pituitary diseases, medications, exercise induced amenorrhea)*
- *Physiologic changes associated with pregnancy and lactation;*
- *Secondary Causes of Osteoporosis in Premenopausal Women: underlying disorder or medication exposure that has interfered with bone mass accrual during adolescence and/or has caused excessive bone loss after reaching peak bone mass. In general, the causes include estrogen deficiency, surgical premature menopause, glucocorticoids and other medication exposures.*

The main goal of the evaluation of a premenopausal woman with low-trauma fractures or low BMD is to identify any secondary cause, and to institute specific treatment for that cause if it is diagnosed. Correction or treatment of several of these conditions has been associated with measurable BMD improvement in some populations, although some have not been specifically studied in premenopausal women.

Treatment consideration: it is appropriate to recommend adequate weightbearing exercise, nutrition, calcium and vitamin D supplementation (when indicated), as well as lifestyle modifications such as smoking cessation and avoidance of excess alco-

hol. Hormone therapy with estrogen or estrogen plus progestogen, tibolone, SERM and teriparatide for bone mineral density in several types of premenopausal osteoporosis show evidence to be beneficial regarding fracture risk reduction. Gynecological has many opportunities to prevent osteoporosis during routine gynecological and obstetric assistance for women of all age groups. It is also important to increase patient education on modifiable disease factors and the goal should be to institute an appropriate intervention at a stage when bone quality is intact.

NS16

EVALUATION AND MANAGEMENT OF OSTEOPENIA AND OSTEOPOROSIS IN BREAST CANCER SURVIVORS

A. Orcesi Pedro^{1,2}, C. Cabello Santos^{3,4}

¹Professor of Post-graduate Course of Obstetrics and Gynecology, School of Medical Science, University of Campinas-UNICAMP, Campinas, Brazil, ²President of National Specialized Committee on Osteoporosis of FEBRASGO, Campinas, Brazil, ³Associate Professor of Obstetrics and Gynecology Department, School of Medical Science, University of Campinas- UNICAMP, Campinas, Brazil, ⁴Coordenator of Breast Cancer Program at Women's Health University Hospital (CAISM-UNICAMP), Campinas, Brazil

Breast cancer represents the most common female cancer, accounting for around 25% of all cancers. Osteopenia and osteoporosis, both systemic skeletal conditions associated with varying degrees of bone loss, are prevalent among breast cancer survivors, with prior reports of up to 68-80% experiencing bone loss.

Breast cancer-related risk factors for osteopenia and osteoporosis include both treatment and premature menopause. Aromatase inhibitors (AIs) increase the risk of osteoporosis by decreasing estrogen levels; this leads to increased bone resorption and a higher risk of fragility fractures compared to tamoxifen. Although tamoxifen, a selective ER modulator, is generally thought to be protective against bone loss in postmenopausal women, reports suggest that it may cause bone loss among premenopausal women due to premature menopause. Chemotherapy may also cause bone loss due to treatment-induced premature menopause in premenopausal women and may have direct toxic effects on bone formation cells. In addition, medications commonly prescribed along with chemotherapy (e.g., corticosteroids) have also been associated with bone loss. Therefore, it is biologically plausible that chemotherapy plus hormone therapy might have a combined deleterious effect on bone health early in treatment.

In the other hand, the increased bone resorption associated with osteoporosis may provide susceptibility for cancer growth and accelerate the development of bone metastases. These findings provide support for a baseline evaluation of bone density and fracture risk assessment close to breast cancer diagnosis, particularly among young survivors being treated with combined chemotherapy and hormone therapy, so that prevention strategies and appropriate monitoring can be implemented early.

Management of osteoporosis and other survivorship care is complex and a multi-disciplinary approach is advised. Assessment of risk factors for bone loss and osteoporosis and attention to optimizing bone health through lifestyle approaches and (when necessary) pharmacological intervention is recommended to prevent osteoporotic fracture. Treatment with bisphosphonates or denosumab must be recommended in women with BMD < -2.5 and/or prevalent fracture together with calcium and vitamin D supplementation. Bisphosphonate regimens, especially with regard to the frequency of IV zoledronic acid use indicate that their use at licensed anti-osteoporotic doses for the duration of the AI treatment period might be effective in preventing bone loss and subsequently reducing the risk of fracture. Bisphosphonates reduce skeletal complications from established bone metastases and prevent the recurrence of early breast cancer improving disease-free and overall survival. Adjuvant bisphosphonate led to a 28% reduction in bone metastasis and an 18% reduction in breast cancer deaths among postmenopausal women through alteration of hospitable bone microenvironment or through a direct antitumoral effect. However, pre- and perimenopausal patients had a higher incidence of visceral metastasis and shorter overall survival with zoledronic acid treatment (AZURE Study), but these results were not found in other studies.

Denosumab has been reported to not only decrease the time to first clinical fracture but also increase disease-free survival in postmenopausal adjuvant breast cancer patients treated with a nonsteroidal AI. Adjuvant denosumab 60 mg twice per year reduces the risk of clinical fractures in postmenopausal women with breast cancer receiving aromatase inhibitors, and can be administered without added toxicity.

This presentation will address the routine management algorithms for women experiencing a premature menopause and the other for postmenopausal women requiring adjuvant aromatase inhibitor therapy.

NS17

VITAMIN D: OPTIMAL LEVELS

H. P. Bhattoa¹

¹Department of Laboratory Medicine, University of Debrecen, Debrecen, Hungary

Low 25 hydroxyvitamin D (25OHD) levels are associated with poor skeletal and extra-skeletal health. Trials of vitamin D supplementation and the Institute of Medicine (IOM) systematic review advocate maintaining the serum 25OHD concentration between 50 and 100 nmol/L. Whereas the Endocrine Society, the National Osteoporosis Foundation, the International Osteoporosis Foundation and the American Geriatric Society suggest that a minimum level of 75 nmol/L is necessary in older adults to minimize the risk of falls and fracture. The optimal serum 25OHD concentrations for extra-skeletal health are evolving but appear to be above 75 nmol/L.

As such, development of robust healthcare policy to improve vitamin D sufficiency is critical and is primarily based on vitamin D data achieved from measurement of total 25OHD. Nonetheless,

vitamin D sufficiency is estimated by determining 25-hydroxyvitamin D concentrations and although there is abundance of data on vitamin D levels, standardization of 25OHD values is still a challenge. Lately, the Vitamin D standardization Program (VDSP) has delineated protocols for standardizing existing 25OHD data from national surveys around the world. In short, the VDSP suggests identifying a batch of samples from the sample pool used primarily to determine 25OHD in the given survey, get the vitamin D measurements done in the selected batch using the National Institute for Standards and Technology (NIST) and Ghent University reference measurement procedures and use the results attained, as such, to correct the originally measured 25OHD values of the sample pool.

The aim of the symposium would be to familiarize the participants with the cut-offs presently applicable to define Vitamin D sufficiency.

NS18

VITAMIN D METABOLITES: FROM NOW AND BEYOND

E. Cavalier¹

¹Department of Clinical Chemistry, University of Liège, Belgium, Liège, Belgium

Total 25-hydroxyvitamin D is currently considered as the most representative metabolite of vitamin D status. There are a multitude of challenges that still deserve to be addressed and despite recent technological advances its determination remains complicated. Standardization of 25(OH)D assays is ongoing under the auspices of the IFCC (International Federation of Clinical Chemistry) but remains a challenge, especially for immunoassays and in different categories of patients. Tandem mass spectrometry as the gold standard methodology in vitamin D testing shall be briefly introduced to the audience. LCMS/MS methods have allowed the determination of "new" metabolites, like 24,25(OH)₂D. Quantification of this metabolite is very interesting in patients presenting a mutation of the 24-hydroxylase. Last but not least, the concepts of 'free' and 'bioavailable' vitamin D along with the 'Vitamin D Metabolism Ratio' will be presented.

NS19

FLS IMPLEMENTATION: AN INNOVATIVE SERVICE SUPPORT MODEL FOR SECONDARY FRACTURE PREVENTION IN THE UK

W. Carr¹

¹Head of Service Delivery, Royal Osteoporosis Society, Bath, United Kingdom

An FLS systematically finds, assesses, treats and follows-up fragility fracture patients to prevent secondary fractures. Fracture prevention is cost-effective in terms of both social and healthcare budgets. Studies show that half of hip fractures occur after a prior fragility fracture, and 25% of hip fractures could be prevented with effective identification and treatment.

Since 2014 the NOS has led an innovative programme providing a 'top-down' (national influencing, policy agenda) and 'bottom-up' (operational health service delivery support) approach to developing FLS in the UK. To date, 29 new services have been set-up; providing FLS to an additional 10m people, potentially preventing over 3200 hip fractures and saving the local health economy £65m over 5 years. This session will share our extensive experience of promoting this model.

NS20

SECURING FUNDING FOR SERVICE IMPLEMENTATION AND IMPROVEMENT - DEMONSTRATING THE BENEFITS AND EFFECTIVENESS OF FRACTURE LIAISON SERVICES

T. Jones¹

¹Service Improvement Advisor, Royal Osteoporosis Society, Bath, United Kingdom

Using effectiveness data can strengthen the case for continued or additional investment in FLS. The NOS has been supporting sites since 2014 to demonstrate clinical and cost-effectiveness to payors, from business case to post-implementation evaluation. This session will include presentation of the tools developed by the NOS including the benefits calculator, and will describe our current work to investigate out-of-hospital secondary fracture prevention models.

The session will thoroughly explore the challenge of demonstrating clinical and cost effectiveness of FLS using the latest data in England, including:

- Real time run-charts from the national audit
- Economic analysis of data showing re-admissions to hospital
- Prescribing data showing impact of FLS on patients on treatment with bone sparing agents

NS21

VERTEBRAL FRACTURE IDENTIFICATION – MEETING THE CHALLENGE OF FLS STANDARDS

J. Griffin¹

¹Clinical Lead, Quality Improvement, Royal Osteoporosis Society, Bath, United Kingdom

This presentation will present published standards for FLS service delivery and examine the challenges met by services in identifying vertebral fractures. Using audit data from imaging departments the presentation will reveal common opportunities to improve the quality reporting of incidentally found vertebral fractures. The presentation will also explore the use of audit to drive quality improvements in vertebral fracture identification in collaboration with radiology departments.

NS22

COGNITIVE-BEHAVIORAL THERAPY IN THE TREATMENT OF CHRONIC BACK PAINO. Kurushina¹

¹Department of Neurology, Neurosurgery, Medical Genetics with the course of Neurology, Manual Therapy, Reflexotherapy of Volgograd State Medical University, Volgograd, Russia

Low back pain is one of the most striking examples of the role of psycho-emotional disorders in the formation of chronic pain syndromes. The report will present the main pathogenetic mechanisms of chronic myofascial pain syndromes, the role of social status and models of doctor-patient interaction. Approaches to the treatment and prevention of chronic back pain will be demonstrated using cognitive-behavioral psychotherapy.

NS23

BIOMECHANICAL ASPECTS FOR UNDERSTANDING OF NON-SPECIFIC LOW-BACK PAINA. Barulin¹

¹Department of Neurology, Neurosurgery, Medical Genetics with the course of Neurology, Manual Therapy, Reflexotherapy of Volgograd State Medical University, Volgograd, Russia

Non-specific low-back pain (LBP) definitely is a common problem in adult life. However, despite its high prevalence the nature of non-specific LBP are not yet well understanding. Its mechanism remains complex included biological, psychological and social factors. Some anatomical structures and their biomechanical characters are all suspects of forming the causes of the non-specific LBP. Researches are constantly attempting to search new approaches for understanding mechanism of LBP. Obviously, we need to exam the human biomechanical status deeply for create modern methods of treatment. This is specially important for patients with high risks (heavy physical work, static work postures and another).

NS24

KINESIOTAPING IN THE CORRECTION OF MYOFASCIAL BACK PAINB. Kalinchenko¹

¹Department of Neurology, Neurosurgery, Medical Genetics with the course of Neurology, Manual Therapy, Reflexotherapy of Volgograd State Medical University, Volgograd, Russia

Myofascial pain syndrome in the lower back is a disorder characterized by widespread muscle pain. Because of its high prevalence, many therapeutic approaches have been proposed with the aim of improving muscles function and reducing pain. Kinesiotaping is one of the effective methods of non-pharmacological treatment of patients with pain syndromes. The report will present the main features of the method, indications and contraindications of the use of kinesio taping in neurological patients. Clinical examples will be presented. In conclusion, the results of using kinesio tape for patients with neurological diseases will be summarized.

NS25

NEW APPROACHES TO THE CORRECTION OF PAIN IN PATIENTS WITH PERIPHERAL PARALYSISO. Agarkova¹

¹Department of Neurology, Neurosurgery, Medical Genetics with the course of Neurology, Manual Therapy, Reflexotherapy of Volgograd State Medical University, Volgograd, Russia

The pain and tension of the back muscles in patients with upper-peripheral paraparesis and monoparesis of various etiologies will be considered: post-traumatic, hereditary (Duschen's muscular dystrophy, Landusi-Jerin brachialo-muscular dystrophy etc.) on the background of therapy. As an additional non-pharmacological treatment, a device, developed in the Volgograd State University, exoskeleton «EXAR» was used. On the basis of the data obtained, the positive effect of the exoskeleton "EXAR" in the treatment and prevention of chronic pain syndrome in patients with peripheral paresis of the upper limbs in combination with background therapy will be shown.

NS26

TAXONOMY OF METABOLIC BONE DISEASESL. Masi¹

¹University Hospital of Florence, AOUC Largo Palagi,1, Florence, Italy

A disease or disorder is defined as rare or "orphan" when it affects less than 5 in 10,000 individuals or has a prevalence of <7.5/100,000. More than 6000 rare disorders have been described affecting approximately 30 million individuals in the USA and 27–36 million in the EU with almost half affecting children. Genetic disorders involving primarily the skeletal system represent a considerable portion of the recognized rare diseases. Accumulating evidence of the clinical and genetic heterogeneity of skeletal disorders has led to different classifications based on their clinical and radiological features and, subsequently, their molecular and embryological features. Nowadays, several websites, mainly focusing on genetics, are available and can be used as reference once a rare disease is identified.

The major advances in our understanding of the regulation of bone metabolism in recent years allow a different approach to the classification of rare skeletal diseases based on their metabolic pathogenesis. Such approach cannot only improve the recognition and diagnosis of affected patients but can also lead to identification of new targets for therapeutic interventions. In addition, it can provide bone specialists the background for the diagnostic evaluation of biochemical alterations in individual patients and can contribute to their better understanding of the etiology of the disease.

The members of the Skeletal Rare Diseases Working Group (SRD-WG) of the International Osteoporosis Foundation (IOF), classified genes encoding proteins involved in the activity of bone cells, bone matrix proteins, micro-environmental regulators essential for bone physiology, or response to calciotropic hormones. By this point of view, rare genetic metabolic bone disorders (RGMBDs) were classified in four major groups according to their primary

pathogenetic mechanism: 1. altered osteoblast, osteoclast, or osteocyte function; 2. bone matrix proteins; 3. altered bone micro-environmental regulators; and, 4. altered calciotropic hormonal activity. They reported 116 disease-related OMIM phenotypes with 86 affected genes, and we include genetic causes (germ line mutations, post zygotic somatic mutations, mitochondrial DNA) where known, as well as general and bone-specific features and biochemical alterations.

The metabolic framing of a rare skeletal disease is of paramount importance for therapeutics and can guide the clinician in the choice of the most appropriate pharmacological intervention.

NS27

ADDRESSING PITFALLS AND CHALLENGES IN THE EVALUATION AND MANAGEMENT OF BONE FRAGILITY IN FD/MAS

N. Hamdy¹

¹Department of Medicine, Division of Endocrinology and Centre for Bone Quality, Leiden University Medical Center, Leiden, The Netherlands

Objective: To address pitfalls and challenges encountered in the evaluation and management of bone fragility in FD/MAS.

Methods: Reviewing factors contributing to poor bone quality, decreased bone strength and increased bone fragility in FD/MAS and addressing difficulties and controversies faced by multidisciplinary teams of health care professionals engaged in its evaluation and management.

Results: Skeletal manifestations of FD/MAS are due to post-somatic activating *GNSa* mutations in cells of the osteogenic lineage, leading to replacement of normal bone by disorganised and poorly mineralized fibro-osseous tissue at one or more skeletal site. Local overexpression of RANK-L and IL-6 increases the number and activity of osteoclasts, FGF23-mediated renal phosphate wasting and hypophosphatemia further disturb mineralisation, and FD-associated endocrinopathies may worsen bone remodeling. All these factors may variably decrease bone strength by locally disrupting bone microarchitecture and mineralisation, leading to increased morbidity due to pain, deformities and fractures, curtailing patient autonomy and impairing quality of life. There are still controversies on how best to evaluate bone fragility in FD/MAS. The value of bone markers and of current imaging techniques in evaluating determinants of bone fragility such as FD activity, the relationship of these markers with pain, and their value in the evaluation of clinical outcome of treatment remain to be established. Whereas it is essential to correct vitamin deficiency, hypophosphatemia and hyperfunctioning endocrinopathies in all cases, a prerequisite before considering treatment with antiresorptives, opinions are still divided on the beneficial effects of bisphosphonates in FD/MAS and data about other antiresorptives are scarce in this disorder.

Conclusion: Identifying difficulties, controversies and remaining knowledge gaps in the complex evaluation and management of the patient with FD/MAS, has led our FD/MAS international consortium to develop consensus best clinical practice guidelines,

which are currently being finalised, aiming at informing and improving care for all patients with this complex and fascinating rare bone disease.

Acknowledgments: Members of the FD/MAS International consortium and involved PAGs

NS28

ADULT HYPOPHOSPHATASIA

C. Roux¹

¹Department of Rheumatology, Reference Center for Genetic Bone Diseases Cochin Hospital, Assistance Publique - Hôpitaux de Paris. Paris Descartes University, Paris, France

Hypophosphatasia (HPP) is a rare inherited metabolic disease, caused by mutations in the alkaline phosphatase liver type (ALPL) gene. Because of the implication of ALP in bone and joint metabolism, rheumatologic disorders can reveal the disease in young adults, apparently normal in their youth.

In adult form of HPP, the symptoms are related to osteomalacia and arthropathies. Non traumatic, recurrent fractures are a key issue of HPP in apparently healthy adults. The first complaint is typically foot pain, related to stress fractures of the metatarsals, with healing delay, and high risk of non-union. Thigh pain is related to femoral pseudofractures. Low bone mass can be observed, and wrongly diagnosed as "osteoporosis". Decrease in ALP activity in joints is responsible for calcium pyrophosphate crystals deposition, and HPP is a cause of chondrocalcinosis. In both genders low ALP increases the risk of having enthesopathies, diffuse idiopathic skeletal hyperostosis and calcific peri-arthritis. Dental abnormalities (early deciduous teeth loss, thin enamel, multiple extracted abnormal teeth) are observed.

The hallmark for HPP is a low serum total alkaline phosphatase level. Interestingly the primary clinical utility of ALP assessment in adult is the diagnosis of bone diseases with high bone turnover based on an increased ALP value, such as Paget's disease, or osteomalacia related to vitamin D deficiency. Less attention is paid to the low values of ALP. The main cause of low value of ALP in adult is the use of anti resorptive treatments, such as bisphosphonates and denosumab. It is of the utmost importance to assess ALP level before initiating such treatments. Cases of atypical femoral fractures have been reported during bisphosphonate treatment, which were given for an erroneous diagnosis of "osteoporosis" and finally related to an undiagnosed underlying HPP.

There is no established treatment for bone fragility related to HPP in adults. Clinical cases have been reported with treatment using an anabolic agent, either recombinant human parathyroid hormone, or teriparatide, with inconsistent results. Very encouraging data have been published with the use of a bone-targeted form of recombinant TNSALP in severe infantile forms of HPP.

Although very rare, HPP must be recognized to provide appropriate treatment of non-union fractures and chronic pain, and to avoid worsening bone disease by using potentially harmful drugs such as anti resorptive drugs to treat bone fragility.

NS29

LEARNING ON COMMON DISEASES BY UNDERSTANDING RARE DISORDERS: THE CASE OF BONE FRAGILITYK. Javaid¹¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

Monogenic rare bone disorders offer insights into the physiology and pathophysiology of common bone disorders. During this symposium, examples will be drawn from osteogenesis imperfecta, familial hypophosphataemic disorders, disorders of excessive mineralisation and hypophosphatasia for how understanding the basic metabolic and genetics components of these rare diseases has informed our understanding of osteoporosis and other common musculoskeletal diseases including their taxonomy.

NS30

HOW TO MANAGE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN THE ELDERLY IN KNEE, HIP OR HAND OSTEOARTHRITIS TREATMENT?C. Cadet¹, E. Maheu², A. Agrhum³¹Rheumatology office, Paris, France, ²Rheumatology dept. Hôpital Saint-Antoine, APHP, Paris, France, ³, Paris, France

Introduction: Treatment of osteoarthritis (OA) in elderly is a frequent challenge for health professionals in daily clinical practice. The objective of relieving pain in these frail people must be balanced by the iatrogenic risks. International guidelines for the management of osteoarthritis (OA) recommend NSAIDs use as second-line pharmacological treatment, but they make little or no mention of age.

Objectives: To clarify, based on recent data in the literature, the conditions of use of NSAIDs in elderly (>75 years of age) patients with OA.

Methods: Literature review of randomized controlled trials (RCTs), meta-analysis of RCTs and review articles on the treatment of NSAIDs in elderly with OA.

Results: Despite increased knowledge of the frequency and severity of their adverse side effects (AEs), NSAIDs, both over-the-counter and on prescription, are still widely used in the treatment of OA pain, even in old/very old patients who are at high risk of NSAID-induced AEs. Aging, with multiple co-morbidities, renal, cardiovascular and hepatic deficiencies, changes in body composition, modifies the pharmacokinetics and pharmacodynamics of drugs, increasing their toxicity. On the other hand, OA is a serious disease, often underestimated. Functional disability related to OA affects quality of life. OA is a factor of frailty and leads to a risk of excess mortality. Most OA patients are willing to accept an additional risk of stomach bleeding and/or heart attack or stroke to relieve their pain. International recommendations do not exclude the use of NSAIDs in elderly patients with OA if they do not have contraindications. They conclude that their prescription requires

caution, careful monitoring and, above all, the patient's consent after receiving full information on the benefit/risk ratio. Recent data suggest the possibility of providing patients with quantitative information on the rates of gastrointestinal and cardiovascular risks rates.

Conclusion: NSAIDs can be used in highly selected patients. They must be closely monitored for AEs. Risks and benefits should be assessed and discussed with the patient to allow shared decision-making with better-informed patients.

NS31

ARE GUIDELINES FOR THE MANAGEMENT OF OSTEOARTHRITIS ADAPTED TO VERY OLD PATIENTS: HOW TO MANAGE OPIOIDS IN THE ELDERLY IN OSTEOARTHRITIS?A. Portier¹, P. Breville¹, A. Groupe Agrhum²¹AGRUM Association Gériatrie-RHUMatologie, Paris, France,²AGRUM Association Gériatrie RHUMatologie, Paris, France

Introduction: International guidelines for the management of osteoarthritis (OA) recommend opioid use as second line treatment. Our aim was to assess whether this recommendation is appropriate to elderly, by reviewing what current literature says.

Objectives: To understand the management of opioids in elderly patients (> 75 years) with OA in the literature, in terms of efficiency and tolerance and to propose guidelines for use of opioids in this population in OA.

Methods: We performed a systematic literature review of randomized controlled trials (RCTs) concerning patients with OA aged more than 75 years, using Pubmed and Cochrane. Key words were "opioids", "analgesics", "old", "elderly", "painful osteoarthritis", used in combination. A manual research was then completed. Language had to be English or French.

Keywords were searched in Pubmed and Cochrane Library. Each study received a Jadad score, in 5 points. When this score was ≥ 3 , the study was considered of good quality, and was also included. A standardized form was used to extract data from each selected article that met the pre-specified eligibility criteria.

Results: We identified 1078 studies in Pubmed between 1985 and 2015 March. After reading all the titles, 76 studies were selected. After reading all the abstracts, 50 studies were identified, with only 28 studies having Jadad score ≥ 3 and also included. 3 other studies were included based on references after reading titles and abstracts and calculating Jadad score. We included 6 Cochrane reviews. Finally, 37 articles were included. Mean duration of RCTs was 3.5 months. Mean age of patients was 59.3 years. All the opioids were significantly more effective than placebo. Many and frequent adverse events were observed. but with mild to moderate intensity. No study was dedicated to elderly patients specifically. Chronic diseases were not always distinguished (osteoarthritis, lumbar pain...).

Conclusions: Data concerning opioids prescriptions remain unfrequent. Considering these results, it is not possible to propose guidelines for opioids prescriptions in the elderly. Other trials specifically addressed to elderly patients and with a longer trial duration are needed.

NS32

EXERCISE AND WEIGHT LOSS IN THE MANAGEMENT OF HIP AND KNEE OSTEOARTHRITIS IN VERY OLD PATIENTS: CURRENT DATA AND HOW TO PRESCRIBE?

J. L. Le Quintrec¹, A. Agrhum Working Group²

¹(1) Geriatric Department, Hôpital Sainte Perrine, APHP, Paris, France, ²AGRHum, Paris, France

Background and aim: Rheumatologic and geriatric international organisations have published recommendations for the management of hip and knee osteoarthritis (OA). They emphasize the usefulness of non-pharmacologic therapies, but are not scaled according to patient's age and physical condition. We decided to look at what literature says on non-pharmacological therapies in old/very old OA patients.

Methods: We conducted a systematic review of clinical trials on exercise and weight loss for hip/knee OA in very old patients, on PubMed.

Results: We identified 141 trials, of which 17 conducted in patients ≥ 70 years, and only 2 trials in patients ≥ 75 years. These trials mainly focused on knee OA in outpatients.

Among these 17 trials, 10 considered physical exercise, 5 aquatic exercise, and 2 weight loss. Physical exercise was effective on pain and function, with a persistent effect only for self-rehabilitation. Aquatic exercise was as effective as land-based exercise. Weight loss was effective on symptoms only when associated with exercise.

This review confirms that international recommendations on exercise for knee OA also apply to subjects aged 60-80 years, with long-term effectiveness requiring a maintenance strategy. Data on very old and/or polyarthritic patients are missing.

Specific trials on very old patients with various comorbidities are therefore mandatory, especially for land-based exercise. Aquatic exercise is potentially inadequate for very old patients with dementia or polyarthritic. Managing weight loss in overweight patients might be useful but should be very careful, to avoid sarcopenia worsening.

Conclusion: From now, our recommendation are to propose to old/very old OA patients regular land-based exercises sessions, in order to improve mobility and muscle strength. Patients should be proposed at least 20 to 60 minutes sessions 2 to 3 times a week, according to the type of exercise and their comorbidities, and walking every day, as far as they can.

NS33

TOTAL JOINT REPLACEMENT OF KNEE OR HIP IN OSTEOARTHRITIS IN OLD/VERY OLD PATIENTS, IS IT POSSIBLE? WHAT SAYS THE LITERATURE AND HOW TO PROCEED?

E. Maheu¹, B. Verlhac², A. Agrhum Working Group³

¹Rheumatology dept, Hôpital Saint-Antoine, APHP, Paris, France, ²Pole Aging, Rehabilitation and Guidance, Paul Brousse Hospital, APHP, Villejuif, France, ³AGRHum, Paris, France

Background and objective: International guidelines for the management of knee/hip osteoarthritis (OA) recommend surgery (i.e. total knee or hip replacement) in patients where the medical treatment has failed. However, age is never considered. Our objective was to review current literature data total knee or hip arthroplasty (TKA, THA) in very old patients (≥ 80 years old) with advanced knee or hip OA, and their risks and benefits.

Methods: A systematic electronic search was performed on PubMed using the following key-words : hip/knee osteoarthritis ; and arthroplasty ; and total replacement ; and elderly ; and 80 years and over ; in the literature published since 1996 up to 2017 ; selecting papers having an abstract available, in English and French languages. A further manual search was performed to identify additional articles in reference lists. Duplicate papers were eliminated.

Results: Among 1875 articles, we identified 59 studies conducted in subjects aged ≥ 80 . Papers published included patients having undergone total joint replacement between 80 and 101 years. Overall post-surgical 90-days mortality has decrease over the past 15 years, reaching 0.18% in 2014 versus 3.5% in 2002.

Postoperative medical complications were frequent (up to 41%): transient confusion (5-18%), urological (10-25%), cardiovascular (0.33-2.2%). Orthopedic complications rates (sepsis, prosthesis dislocation, prosthesis revisions) were similar whatever the age of patients.

Satisfaction rates, changes in pain and function were identical in very old (80+) and less old subjects (age ranges 65-74 years in studies). When the 2 knee or hip joints need to be operated, it seems safer to perform both replacements in the same procedure to minimize risks, according to most authors.

Conclusion: A total knee or hip replacement in old/very old knee or hip OA patients (≥ 80 years) is feasible and appears to offer the same benefits and have the same level of risks than in less old subjects.

NS34

FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS

W. Lems¹

¹Amsterdam UMC, location VUmc, Amsterdam, The Netherlands

It is well-known that active rheumatoid arthritis (RA) is associated with generalized bone loss and with fractures. This negative effect on bone particularly occurs in patients with suboptimally

treated RA, with persisting systemic inflammation (1); apart from that glucocorticoids (GC) might also have a negative effect on bone.

Earlier data, before the introduction of biologics, both vertebral and nonvertebral fracture risk are elevated, roughly doubled, in RA. With modern biologics, such as TNFblockers, the usually occurring bone loss can be prevented. Data on fractures during treatment with biologics are scarce.

Disclosures: Speakers fee/Consultancy: Eli Lilly, Merck, Servier, Amgen, Novartis, Pfizer, Abbvie

NS35

NON-INVASIVE MEASUREMENT OF EROSIVE DISEASE WITH QCT AND MRI IN RHEUMATOID ARTHRITIS

J. D. Adachi¹

¹McMaster University, Hamilton, Hamilton, Canada

Erosions in rheumatoid arthritis are associated with pain disability and decreases in quality of life. They reflect the destructive changes to bone that can be seen in rheumatoid arthritis. Standard radiography has typically been the method of detecting erosions however their appearance on x-rays is a late finding. More recently ultrasound has been used to detect early erosions and associated synovitis. Over the past 10 years investigators have examined the use of MRI and CT imaging to identify and quantify erosion size. What is evident from this research is that both MRI and CT scanning detect erosions earlier, are sensitive with good specificity and accuracy for the detection of erosions in rheumatoid arthritis. With the advent of faster computing and better edge detection algorithms, quantitation of erosion size is being explored. This may prove helpful in guiding patient care with progression of erosion size suggesting the need for more aggressive treatment and maintenance or decreases in erosion size indicating adequate or appropriate treatment. Ongoing research will help in determining the usefulness of these new non-invasive outcome measures.

NS36

VALUE AND LIMITATIONS IN HR-PQCT IMAGING IN CHRONIC ARTHRITIS. CURRENT STATUS AND FUTURE DIRECTIONS

K. Engelke¹, C. Figueiredo¹, A. Kleyer¹, D. Simon¹, G. Schett¹

¹University of Erlangen-Nürnberg, Univeristy Hospital, Dept of Medicine 3, Erlangen, Germany

HR-pQCT is a peripheral quantitative CT technique with an isotropic resolution of about 120 μm originally developed to quantify trabecular bone architecture of the distal radius and tibia. More recently it has also been applied to quantify erosions in the metacarpal and phalangeal joints in particular in patients with chronic arthritis. The high spatial resolution significantly improves accuracy of erosion size compared to standard x-ray or MRI measurements. The detection of small erosions obviously is of high importance for example, in the diagnosis of early rheumatoid ar-

thritis and to guide treatment decisions. However at the high spatial resolution of HR-pQCT it is also more difficult to differentiate erosions indicative for rheumatic disease from vascular channels as well as for other lesions. Thus while HR-pQCT is an excellent method to measure erosion size and also erosion shape, the identification of erosions remains challenging and automated algorithms result in a high number of false positive 'erosions'.

In addition to quantify erosions using a 3D technique and to measure changes of their size and shape over time and under treatment, HR-pQCT can also be used to determine the width and volume of the metacarpal joint space, bone mineral density and cortical thickness of metacarpals and phalanges. Moreover, finite element analysis of the metacarpal heads has been reported.

SPECTRA (Study group for xtrEme Computed Tomography in Rheumatoid Arthritis) is an international collaboration to advance and standardize this novel approach.

NS37

GETTING STARS ON THE MAP

T. Thomas¹

¹St Etienne, University of Lyon, Lyon, France

The International Capture the Fracture Map has enabled for the first time a global view on the delivery of secondary fracture prevention using these standards. A key aim of this project was to drive improvements in service effectiveness, efficiency and patient experience for secondary fracture prevention and led to 328 FLS in 41 countries now represented on our map. One of the priorities of this program is to disseminate best practice standards based on this collective experience. Our second priority is to engage with help clinical centres where fracture liaison services have not been considered a high local priority for healthcare investment and delivery. To facilitate this there are a number of tools and resources available for health care settings that a considering setting up fracture liaison services.

The aim of this talk is to present the process for getting your site on the Capture the Fracture map and describe the supporting materials available.

We will review the process to getting a site on the Capture the Fracture map including issues around completing the questionnaire, the review process within the IOF, the final adjudication for getting results on the map and the renewal process. In addition, we will describe the key online supporting materials such as the framework, implementation toolkit, webinars, slide sets as well as the different types of mentoring service available.

NS38

WHAT ARE THE POTENTIAL UNCERTAINTIES FOR TRAUMA SURGEONS - E.G. FRACTURE HEALING?

A. Gray¹

¹Royal Victoria Infirmary, Newcastle-upon-Tyne, United Kingdom

Fracture healing is a powerful process that is initiated immediately after the trauma. In the majority of cases a fracture will heal without problems, despite the complexity of the healing process.

Healing can be either direct or indirect, the latter being most common and meaning that the mineralized callus formation is preceded by a soft callus of chondrocytes.

Questions have been raised regarding both positive and negative effects from osteoporosis drugs on fracture healing. Positive effects are assumed from anabolic therapies but in the normal situation, evidence suggests that the gain in time may not be clinically meaningful. Additional research is needed in those with delayed healing. The effects on fracture from anti-resorptives is even less clear; there are indications of improved implant anchorage but there are also concerns of atypical fractures. Furthermore, the timing of initiating osteoporosis treatment after a fracture is also discussed.

NS39

THE FUTURE OF SURGICAL FIXATION IN FRAGILE BONE

M. Costa¹

¹University of Oxford, Oxford, United Kingdom

Despite the fact that fragility fractures are the most common fractures in many societies, surgical fracture repair of fragile bone is still a challenge. Bone quality is not measurable; hence, pre-operative planning relies on plain radiographs for the evaluation of fracture severity (location, type, comminution, dislocation etc). Equally important is the surgeons' experience. Over the past two decades, recognition of the particulars of fragility fractures had led to innovation and surgical implants that better match bone quality of the elderly. This includes special plates, screw and arthroplasties, while augmentation is still under development. A most obvious shift is the move from screw fixation of femoral neck fractures to a wider use of hemi- and total hip arthroplasty and as a consequence a reduction in secondary procedures and improved functioning. However, modern devices have also increased the likelihood of surgical repair of fractures in the elderly, while the benefit may not be proven and the outcome similar to conservative treatment. One of the current challenges is to determine when to operate on a fragility fracture and when not to. A number of randomized controlled trials are being reported or close to completion in order to provide us with better evidence for surgery (or not). Improvements in fracture management including surgical fixation is the foundation for best possible post-fracture functioning and therefore essential also for secondary fracture prevention.

NS40

MONITORING PATIENTS AND TOOLS FOR GETTING BETTER

K. Javaid¹

¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

For secondary fracture prevention to be effective, patients at high risk of a re-fracture need to adhere to anti-osteoporosis medications. The recognised poor adherence to certain anti-osteoporosis

medications in routine healthcare settings brings monitoring within the remit for an effective Fracture Liaison Services (FLSs). While the importance of monitoring is clear from the patient, clinician and healthcare systems perspective, who, when and what is monitored is not clearly defined. To address this, we used data from 328 FLSs registered with the Capture the Fracture programme and determined significant variability regarding who conducts the assessment, when it is completed, the content and method of the monitoring assessment. We identified common themes and recommendations for a minimum clinical dataset for monitoring as well highlight questions that remain for FLSs to improve their delivery of monitoring and increasing adherence to anti-osteoporosis therapies.

NS41

CAPTURE THE FRACTURE MENTORSHIP PROGRAMME

D. O'Gradaigh¹

¹University Hospital Waterford, Waterford, Ireland

"Capture the Fracture" (CtF) is a global programme for the prevention of secondary fractures by facilitating the implementation of Fracture Liaison Services (FLS). Among its aims is to provide support to teams seeking to establish and improve Fracture Liaison Services. A steering group of the International Osteoporosis Foundation drives this aim through a range of supports including the Best Practice Framework, webinars and teaching materials available to download. Here we describe our experience with a mentorship programme.

The mentorship programme offers two approaches. A single mentorship candidate may visit an FLS Champion's site for one day, supported by materials and travel costs. The second approach delivers a one-day workshop to a range of participants in their own country. Participants include any members of existing FLS teams, key leaders who intend to start a service, and others who wish to learn more about their potential roles. The programme is organised in close collaboration with a national osteoporosis society in the host country. The workshop is delivered by both local experts and by members of the CtF Steering Committee, blending local knowledge with the experience of many countries and expertise in developing, improving and sustaining FLS in a range of settings. Topics include prioritisation of FLS in the political landscape, exploring funding options, key steps to getting started, and advice on the quality improvement strategies necessary to improve and sustain the service. A vital element of the approach is to ensure local solutions are identified, that key leaders are supported in resolving barriers and identifying facilitators, and creating a local community which can drive and sustain service development. The mentorship programme encourages staged implementation, extending from a service focussed on identification, investigation and treatment initiation (a 3 i approach) in hip fracture cases, to then include other inpatient fractures and ultimately to cover all fragility fractures including vertebral fractures. The mentorship programme also encourages the key quality improvement aspect of monitoring patient adherence and adapting the FLS to optimise this vital element of effective fracture risk reduction.

The success of the CtF campaign and of its various support structures is the increase in the number of FLS registered globally, meeting the criteria of the Best Practice Framework. There are now 328 such FLS registered globally in 41 countries, with new services applying for recognition following each mentoring programme.

NS42

REGENERATIVE MEDICINE DEFINITIONS, TECHNIQUES AND JOINT APPLICATIONS. WHERE DO WE STAND NOW?

G. Skarpas^{1,2,3}

¹Consultant Orthopaedic Surgeon ., Nicosia, Cyprus, ²Head of Orthopaedic Dept., "EVGENIDEIO" University Clinic, Nicosia, Cyprus, ³Clinical Assistant Professor UNIVERSITY OF NICOSIA-CYPRUS, Nicosia, Cyprus

Stem cells are different than skin cells, muscle cells, liver cells, or any other human cells. What makes stem cells special is that they can:

1. Divide and duplicate themselves.
2. Develop into different types of cells. A stem cell itself does not serve a specific bodily function, but it can develop into a cell that does, such as a cartilage cell or a tendon cell.

Many physicians who use stem cell therapy hypothesize that, when placed into a certain environment, stem cells can transform to meet a certain need. For example, stem cells that are placed near damaged tendon are hypothesized to develop into healthy tendon cells.

The process of collecting stem cells is often called harvesting. Physicians usually harvest stem cells from the patient's fat, blood, or bone marrow.

- Fat. During surgery or liposuction a doctor can harvest adipose (fat) stem cells.
- Blood. A blood sample from the patient can be used to harvest peripheral blood stem cells, which are found in the bloodstream.
- Bone marrow. Doctors typically harvest bone marrow stem cells from the pelvic bone using a needle and syringe. The process is called bone marrow aspiration. Before a bone marrow aspiration, a patient is given a local anesthetic and may also be given a sedative.

All three types of stem cells listed above—adipose (fat), peripheral blood, and bone marrow—belong to a category of stem cells called mesenchymal stem cells. These stem cells, sometimes called adult stem cells, can be obtained from the patient's own body and are being increasingly used for treating degenerative joint disease.

Regenerative medicine treatments can be divided into three categories:

1. Cellular therapies facilitate healing by injecting or placing live cells into the patient. Examples of cellular therapy include PRP and stem cell therapies, which can be used to treat arthritis and other degenerative conditions.
2. Tissue engineering replaces or repairs damaged tissue with natural tissue, man-made tissue, or a combination of both. In regenerative medicine, tissue engineering techniques may be used to treat cartilage injuries.
3. Other therapies that attempt to trigger the body's natural ability to heal tissues without introducing new cells or tissues. Prolotherapy is an example of this type of therapy.

In degenerative joint disease, regenerative medicine treatments are typically used to repair or replace damaged cartilage, tendon, and ligament tissues by:

- Amplifying the body's natural healing abilities
- Encouraging the growth of new tendons, ligaments, or cartilage tissue

The goal is to reduce pain and improve function.

There are four types of Regenerative Medicine Treatments. All of these treatments are outpatient procedures and may not be covered by insurance, and more than one treatment session may be required before results are felt and, as with any treatment, results vary but the baseline is extremely encouraging.

1. Stem Cell Treatments

A stem cell does not serve a specific bodily function, but it can develop into a cell that does, such as a cartilage cell or a tendon cell. Physicians who use stem cell therapy believe that, when placed into a certain environment, stem cells can transform to meet a certain need. For example, stem cells that are placed near a damaged cartilage are hypothesized to develop into healthy cartilage cells.

2. Platelet Rich Plasma (PRP)

Many experts believe that the natural healing properties found in the blood's platelets and plasma can be used to facilitate the healing and repair of sports injuries. PRP can be injected or applied to the injured area during a surgery

To make PRP, blood is taken from the patient and then processed—often using a centrifuge—to create a concentrated solution of platelets and plasma (PRP).

All PRP is not the same and varies, depending on factors such as differences in patients' blood, the method of blood processing, and the use of other substances, such as anesthetics (e.g. lidocaine).

3. Prolotherapy

Inflammation increases blood flow and attracts cells—granulocytes, monocytes, macrophages and fibroblasts—that can repair and heal damaged tissues. Degenerative conditions usually cause inflammation, which persists during time and subsides occasionally. During prolotherapy, a physician injects an irritant into the injured area, which temporarily increases inflammation. The hope is that the additional inflammation will facilitate further healing.

Prolotherapy sometimes uses PRP as an irritant, but prolotherapy is not by definition a cellular therapy. In fact, the most commonly used irritant is dextrose, a simple sugar. Substances such as glycine or saline may also be used. Compared with other regenerative medicine treatments, such as stem cell and PRP injections, there is not a lot of clinical research regarding prolotherapy and its effectiveness.

4. Surgeries for Cartilage Regeneration

Because cartilage does not contain blood vessels, it does not have a reliable blood supply, which prevents damaged cartilage from healing well naturally. Different techniques may be used to try to repair cartilage, including but not limited to:

- Making microfractures, nanofractures or abrasions in the bone directly below the cartilage injury. The aim is that the blood from the damaged subchondral bone will facilitate new cartilage cell growth.
- Transplanting cartilage from another part of the patient's body, a donor, or animal.
- Implanting engineered tissue made from stem cells and an artificial scaffold—a sort of microscopic netting that holds the cells until they mature and grow.

These techniques are typically used to treat damaged articular cartilage, which covers bone at the joints, not other types of cartilage, such as the knee meniscus. They are all performed with minimally invasive procedures, mainly with arthroscopy and less with mini open joint techniques. The results of these procedures lead to promising combinations with proper rehabilitation protocols—always individualized.

Regenerative medicine is not a substitute for traditional nonsurgical treatments, such as rest, bracing, taping, and/or physical therapy to improve flexibility and strength. Regenerative medicine and traditional treatments can be used together to optimize healing. Regenerative medicine is not limited to treating degenerative musculoskeletal conditions. For example, tissue engineering allows skin tissue to be created for burn victims. Other applications, such as developing artificial organs, are being researched.

NS43

GUIDELINES, THEORIES, PRACTICE AND REGULATORY MECHANISMS FOR STEM CELL THERAPY

G. Samoutis¹

¹Associate Professor of Primary Care UNIVERSITY OF NICOSIA-CYPRUS and St. George's UNIVERSITY, London, United Kingdom

The biggest issue at the moment, is that there are no formal medical guidelines regarding who can receive stem cell therapy for degenerative joint disease. Whether or not to use stem cells for treatment is up to patients and their doctors. A lack of standardization further complicates the nature of treatment at one clinic versus another.

Some doctors have certain criteria for recommending stem cell therapy. For example, they only recommend it to patients who are healthy and younger (e.g. under 50). Other doctors make recommendations on a case-by-case basis. Medical doctors debate whether or not stem cells therapy is an effective treatment for these conditions. It is a controversial subject and research is ongoing.

The theories behind stem cell therapy are that:

- Develop into needed musculoskeletal cells, such as tendon, ligament, cartilage, or bone cells
- Facilitate better healing (e.g. encourage the growth of new blood vessels)
- Decrease or prevent inflammation that make conditions such as tendinopathy worse
- Release proteins (cytokines) that slow down tissue degeneration and/or decrease pain

The challenge facing researchers is that there is no standard “recipe” for stem cell therapy. The stem cell therapy in one study is not necessarily the same as the stem cell therapy in another study. The differences can include:

- How stem cells are separated and isolated from the harvested tissue
- The concentration of stem cells (how many cells per treatment)
- The health and age of patients
- How the stem cells are delivered to the injured area—For example, are they injected or applied during surgery?

Because of these differences, it is difficult for researchers to draw conclusions or make generalizations based on existing studies. Many physicians believe that PRP can make the most of the stem cells potential effects.

PRP is derived from a sample of the patient's blood. In the bloodstream, platelets secrete substances called growth factors and other proteins that:

- Regulate cell division
- Stimulate tissue regeneration
- Facilitate healing

PRP can be used alone to treat sports injuries, such as elbow tendinopathy.

While long-term studies are still needed, research does suggest stem cell therapy, when using a patient's own cells without any manipulation and performed in a single sitting, is generally considered safe. The most common side effects are temporary swelling and pain. Stem cell injections carry the same risks as any other therapeutic injection, such as a small risk of infection.

A patient is at a higher risk of an unwanted reaction if the stem cells are:

- Not the patient's—though uncommon, stem cell therapy can involve stem cells manufactured in a lab or harvested from another person or animal. In the majority of cases, stem cells are collected from the patient, minimizing the risk of an unwanted reaction.
- Cultured—taken from the patient and grown in the lab over time.
- Mixed with other chemicals—additives thought to enhance stem cells' therapeutic abilities may also add another risk factor.

Clinical research studies of regenerative medicine treatments have shown mixed results but are generally encouraging. Most studies have been relatively small. More large-scale, high-quality clinical studies are needed before scientists can know exactly if and how regenerative medicine treatments help heal degenerative joint disease such as arthritis.

In conclusion, interest in regenerative medicine has grown, particularly as some doctors and researchers look for a way to treat patients without NSAIDs, cortisone and metal implants. As time passes, individual doctors learn and share information, improving the application of these treatments. Until more is known, regenerative medicine treatments are not considered standard practice and insurance plans typically do not cover them but many patients are willing to pay out-of-pocket.

NS44

THE ROLE OF REGENERATIVE MEDICINE IN DEGENERATIVE CONDITIONS OF THE SPINE. IS THERE REALLY A ROLE FOR IT?

E. C. Papadopoulos^{1,2,3}

¹Consultant Spine Surgeon, Athens, Greece, ²Head of Spine Unit, "HYGEIA" General Clinic, Athens, Greece, ³Assistant Professor UNIVERSITY OF ATHENS, Athens, Greece

A great number of spine surgeons tend to embrace advanced biologic technologies in an attempt to achieve a better outcome in spine surgery. These new technologies include the contribution of different types of cells, that has not been definitively identified. The key stem cells used in spine surgery are the mesenchymal stem cells, the endothelial progenitor cells, and the hematopoietic stem cells.

Studies suggest that stem cell augmentation of spinal fusion surgery is somehow equivalent to the gold standard for iliac crest bone graft in posterolateral fusion models. Researchers showed promising results of safety and feasibility in the injectable treatments with autologous cell therapies that indicates a favorable outcome of mesenchymal cell concentration on discogenic pain reduction.

The use of adult stem cells is an innovation that promises fewer complications and improved function in patients who are demographically suitable for stem cell therapy. A large number of medical researchers are trying to introduce a new treatment for low back pain, by harvesting and then re-injecting the body's own bone marrow, which is rich in stem cells, and may repair worn-out

discs in the spine. In a small new study, the approach appeared to be safe -- and none of the patients reported that their pain got worse after the procedure. Surgeons who are testing the technique and other experts believe much more research is needed before they can say whether the treatment offers real relief.

Mechanical overloading of the intervertebral disc has been shown to induce catabolic activity associated with degeneration. On the other hand it has also been suggested that the routine cycle of disc deformation and recovery caused by normal activity could eventually lead to fatigue failure of the disc. Insufficient nutrition is significant in slowing matrix anabolism. The disc is avascular and needs to receive nutrients through diffusion. When nutrition of the disc is sufficiently impaired, disruption of matrix synthesis and cell death can occur.

It is well known that neither conservative nor surgical management addresses the underlying process of disc degeneration, and for many patients it is ineffective at relieving low back pain. Furthermore, fusion surgery has significant downsides; beyond the loss of flexibility between fused vertebrae, fusion can also increase stress and strain on adjacent discs and thus accelerate their degeneration, necessitating further surgical intervention.

In vivo studies have examined the use of stem cells to slow the process of disc degeneration and regenerate the matrix. This procedure was found to prevent histological and morphological disc degeneration when compared to a nontreated, degeneration-induced control. While small animal models have yielded universally positive results, the results of large animal studies have been mixed. A notable criticism of current studies involving in vivo implantation of stem cells is that they do not accurately replicate the environment of the human degenerate disc.

Based on current research, it is unclear whether repopulation without nutritional supplementation will lead to effective matrix anabolism. In the future, development of a standardized in vivo model that more accurately mimics disc degeneration in humans would allow for more meaningful study of all therapies targeting molecular and cellular components of degeneration. It is also important that the histological and morphological slowing and reversal of disc degeneration may not necessarily relieve low back pain. The clinical benefit of restoring matrix integrity must be further explored.

NS45

REGENERATIVE MEDICINE TECHNIQUES NEED SPECIALLY DESIGNED AND INDIVIDUALIZED REHABILITATION PROTOCOLS FOR OPTIMAL RESULTS

E. Kontopoulou^{1,2,3}

¹Consultant Rehabilitation and Physical Medicine, Athens, Greece, ²Head of Athens Municipal Outpatient Clinics, Athens, Greece, ³Sports Medicine and Accupuncture Specialist, Athens, Greece

All protocols are intended to provide a general guideline to treating degenerative joint disease after stem cells therapy. The progress is modified on an individual basis.

Firstly the modalities to control inflammation are engaged, then we evaluate and treat lumbar, sacral, and pelvic dysfunction. There is also evaluation for corrective orthotics and implementation of appropriate, selective stretching and apply appropriate mobilizations and strengthening, one very important factor is cardiovascular exercise and to initiate aquatic exercise and walking program at chest level water progressing to waist level as tolerated. This Phase I program could last for about 4-6 weeks.

In Phase II all the appropriate Phase I activities are continued, progressing as tolerated to advanced strengthening program with proprioception emphasis (duration 4-8 weeks).

Finally in Phase III the patient continues with consistent stretching and phase I/II exercise program, beginning gym strengthening as appropriate and advanced light weight bearing cardiovascular exercises (walking/elliptical trainer) with a mean duration of 3 months.

The main problem for patients with degenerative joint disease is the chronic pain associated with a lowered quality of life. In order to achieve improvement of the quality of life of these patients, comprehensive rehabilitation programs are applied, employing strategic approaches, with the inclusion of Tai Chi and Pilates, dictated by the program's goal. Before stem cell therapy and rehabilitation there occurs a lowered quality of life brought about chiefly by acute joint pain, which directly makes physical functioning difficult and indirectly influences those areas of quality of life linked to psychic and social functioning. As a result of implementing the stem cells combined with a comprehensive rehabilitation program there occurred an improvement in the quality of life. The results obtained were dependent on age, duration of the disease as well as the degree of joint degeneration.

In conclusion, applying a comprehensive rehabilitation program after regenerative therapy, improved the quality of life of the patients with degenerative joint disease. Selected Tai Chi and pilates exercises constitute a novel supplementation to a comprehensive rehabilitation program, influencing its effectiveness.

NS46

RISK FACTORS FOR OSTEOPOROSIS: FRAX-BASED INTERVENTION AND ASSESSMENT THRESHOLDS IN BRAZIL

B.-H. Albergaria^{1,2,3,4}

¹Professor of Clinical Epidemiology- Federal University of Espírito Santo – Brazil, Vitória, Brazil, ²Vice-President of National Osteoporosis Commission – FEBRASGO, Vitória, Brazil, ³Secretary of the Brazilian Association of Bone Evaluation and Osteometabolism – ABRASSO, Vitória, Brazil, ⁴Technical Director -CEDOES Diagnosis and Research of Osteoporosis, Vitória, Brazil

In recent years, efforts have been made to better understand the epidemiology of osteoporosis in Brazil, and to manage both direct and indirect costs to the Brazilian health care system. The reported prevalence of osteoporosis among postmenopausal women in Brazil varies from 15% to 33%, depending on the study methodology and the use of bone densitometry data or self-reporting by participants. A FRAX model for Brazil was released recently

and provides a country-specific algorithm for estimating individualized 10-year probability of hip and major osteoporotic fracture (hip, clinical spine, distal forearm, and proximal humerus). FRAX Brazil integrates the influence of several well validated risk factors for fracture with or without the use of BMD. Its use in fracture risk prediction creates new perspectives for patient assessment, and for the development of practice guidelines in our country.

In developing country, an important issue concerns is the reduced accessibility to densitometry. Thus, many clinical guidelines now recommend the use of FRAX to help primary care physicians identify women who may be candidates for treatment based on the level of fracture risk. These considerations suggest that bone mineral densitometry (BMD) should not be used as the sole gateway to risk assessment; rather, BMD should be used as an adjunct to assessment the fracture risk.

Regarding the intervention thresholds, the approach recommended by the National Osteoporosis Guideline Group (NOGG) in the UK was used in the Brazilian FRAX model. This methodology sets the intervention threshold at the age-specific fracture probability equivalent to women with a prior fragility fracture. Where access to BMD testing is limited, FRAX can be calculated using BMI and the use of BMD can be optimized by only testing those individuals in whom probabilities are close to the intervention threshold. In this way, testing is confined to individuals at high (or low) risk with reasonable likelihood to be reclassified at low (or high) risk on the basis of the BMD test. Following this approach, two assessment thresholds were calculated and applied to the intervention threshold described above: the threshold probability below which neither treatment nor a BMD test should be considered (lower assessment threshold) and the threshold probability above which treatment may be recommended without the need for BMD (upper assessment threshold). The results of this calculation are displayed in figures showing the fracture probabilities equivalent to women with a previous fragility fracture in the FRAX Brazil model.

This presentation describes the data used to develop the Brazilian FRAX® model and its future recalibration, illustrates its features, intervention thresholds and its incorporation to national guideline for management of osteoporosis.

NS47

OSTEOPOROSIS PREVENTION AND TREATMENT ON SPECIAL SITUATIONS DURING WOMEN'S REPRODUCTIVE PERIOD

A. Orcesi Pedro^{1,2,3}

¹Professor of post-graduate course of Obstetrics Gynecology – UNICAMP Medical School, Campinas, Brazil, ²President of National Committee on Osteoporosis of FEBRASGO, Campinas, Brazil, ³Counselor Member of the Brazilian Menopause Society (SOBRAC), Campinas, Brazil

To reduce the risk of osteoporosis, all women regardless age, should be encouraged to maintain a healthy lifestyle, regular physical activity and a balanced nutrition and knowledge about

risk factors for bone loss. Gynecological perspectives to prevent osteoporosis consist in primary care during routine gynecological and obstetric assistance for women of all age groups.

Many reproductive and menstrual factors like parity, breastfeeding, age at first pregnancy, age at menarche, type of contraceptives, age at menopause and time since menopause might influence the risk of osteoporosis.

Our aim is to present the correlation of these factors with bone health and to discuss strategies during gynecological and pre-natal care routine assistance. It will help in prevention of osteoporosis by assessing the need for early intervention.

It will be addressed special issues during routine gynecological and obstetrics assistance:

Puberty special issues: primary amenorrhea, gonadal dysgenesis and genetic diseases can contribute to suboptimal peak bone mass. It is important an early diagnosis and hormone treatment with estrogen dose similar to reproductive period in order to get a optimal peak bone peak. The goal should be to institute age appropriate interventions at a stage when bone quality is intact and future loss can be minimized.

Early or secondary menopause: primary ovarian insufficiency or premature surgical menopause due endometriosis or gynecological and breast cancer. Younger breast and gynecological cancer survivors are at higher risk for osteopenia and osteoporosis compared to cancer-free women. Breast cancer survivors had a 68% higher risk of osteopenia and osteoporosis compared to cancer-free women. The association was stronger among recent survivors after only 2 years of follow-up. A higher risk of osteopenia and osteoporosis was also observed among survivors aged ≤ 50 years, estrogen receptor-positive tumors, and those treated with aromatase inhibitors alone or chemotherapy plus any hormone therapy relative to cancer-free women.

Pregnancy and lactation: there are some hypotheses which support the contributory effect of pregnancy and lactation on osteoporosis later in life. High calcium demand during pregnancy and lactation and low estrogenic state support those hypotheses. Multiparity, duration of breastfeeding and BMD are associated to a detrimental effect on bone health. Lower educational level and limited knowledge of birth control methods are the major factors leading to multiparity in developing country. Moreover, prolonged lactation period, poor nutrition and lack of calcium supplementation during pregnancy and lactation lead to decreased BMD in multiparous females.

Women during reproductive period with some risk factors for low bone mass as multiparity, low BMI, short reproductive period, lack of use of oral contraceptives and prolonged breastfeeding should have special attention on gynecological and obstetric routine assistance. In addition to the prevention of post-pregnant osteoporosis, to avoid future osteoporosis and fragility fractures of older age, it is necessary to promote young women to take measures such as adequate nutrition intake and exercise habits and post-partum contraception.

Hormone therapy and combined oral contraceptives may be considered as a primary therapy for prevention of bone loss and fracture in women at elevated risk of osteoporosis or fractures during reproductive period.

However, it is important to consider individualization of treatment contraindications.

Long-term HRT in young women may be sufficient to prevent osteoporosis and fracture.

Conclusion: Health care practitioners also need to increase patient education on modifiable disease factors, including optimal nutrition from birth, age-appropriate regular weight bearing exercise, smoking cessation and minimization of environmental risk factors for fracture. The goal should be to institute an appropriate intervention at a stage when bone quality is intact and future loss can be minimized throughout aging process. This presentation addresses the most relevant situations where adequate medical assistance may interfere positively on the purpose of preserving bone health during women's lifespan.

NS48

UPDATE ON EFFICACY AND SAFETY OF POST-MENOPAUSE HORMONE THERAPY AND FRACTURE PREVENTION

B. Muzzi Camargos¹

¹Member of the IOF Committee of Scientific Advisors (CSA) Rede Materdei de Saúde – Densitometry Unit Coordinator Member of the National Committee on Osteoporosis of FEBRASGO, Belo Horizonte, Brazil

Hormone replacement therapy (HRT) at different types, doses and routes of administration rapidly normalizes bone turnover, preventing and/or treating osteoporosis. Estrogen replacement therapy was once the only approved osteoporosis medication, it is not as widely used today. Part of the reason for this is because the therapy has been associated to increased risks for breast cancer, stroke, ischemic heart disease and thrombosis. Despite these potential side effects, estrogen replacement therapy is effective at protecting post-menopausal women from bone loss, on dose and time-dependend basis. It is still not known how long, if at all, the protective effects of HRT on bone continue after HRT treatment ceases. For women over 60 who continue to have low bone density and who are still at risk of fracture, it is important that other treatments for osteoporosis should be commenced when HRT is stopped. The best timing for switch from HRT to other anti-reabsorptive agents remains uncertain. This session will discuss when to switch from an ongoing HRT to bisphosphonates or denosumab. Obstetricians and gynecologists also handle tibolone, raloxifene and all hormones therapy, like no other specialty does. It is also known that every single drug approved to treat osteoporosis was studied on post-menopausal women.

It is important to consider individualization of treatment taking in account additional secondary health benefits (treatment of vasomotor symptoms, genitourinary syndrome of menopause, sexual

dysfunction and quality of life on symptomatic hypoestrogenic women), side effects, contraindications, cost and likelihood of adherence.

Awareness on bone metabolism and osteoporosis is fundamental in order to promote bone health and prevent fractures on all phases of women's life span.

NS49

OSTEOARTRITIS AND AGEING

S. Tuzun¹

¹Istanbul University-Cerrahpasa, Physical Medicine&Rehabilitation Dept., Istanbul, Turkey

Osteoarthritis (OA) is a major cause of disability worldwide. The ageing of the population will compound the number of older adults disabled by this disease. That is why improved understanding of how ageing contributes to the development of OA is extremely important, and could lead to new therapies that slow or stop the progression of the disease, which would have a major impact on public health.

Many factors for the development of OA exist, including prior joint injury, obesity, genetics, sex, and anatomical factors related to joint shape and alignment; however, the most prominent risk factor is increasing age.

Ageing-associated changes that affect articular tissues promote the development of OA. Although ageing and OA are closely linked, they are independent processes. OA that occurs in young adults is most often caused by a prior joint injury, a process known as post-traumatic OA, whereas in older adults a number of factors related to ageing can contribute to the development of OA. These factors are; reduced muscle mass and increased fat mass, changes in extracellular matrix, including accumulation of advanced glycation end-products, reduced aggrecan size, reduced hydration, impairment in the function of subchondral bone due to reduced numbers of osteocytes, mitochondrial dysfunction, oxidative stress and reduced autophagy in chondrocytes.

The concept of hallmarks of ageing suggests that common mechanisms will drive dysfunction in various tissues and organ systems that are most affected by ageing. These hallmarks represent areas for further research into elucidating the connections between ageing and OA.

NS50

THE CROSSTALK BETWEEN VESSELS, BONE AND CARTILAGE: DOES IT EXIST?

M. Miglinas¹

¹Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania

Cardiovascular disease (CVD) risk in patients with inflammatory joint disorders (IJD) is substantially elevated compared with the general population. Recent EULAR task force recommendations suggest that the treating rheumatologist should ensure that CVD risk assessment and management in patients with inflammatory joint disorders is being performed regularly, make sure that the patient is aware of the need for regular risk assessment. In-

creasingly more data point that inflammatory mediators play a pivotal role in the perpetuation of the osteoarthritis (OA) as well. OA is considered to be a very complex disease with inflammatory substances released by cartilage, synovium and bone.

Locally produced inflammatory mediators may have an impact on the development of other age-related diseases. Numerous immune cells, pro-inflammatory cytokines, chemokines, growth factors, proteases, soluble and cell-expressed adhesion molecules and other mediators have been implicated in the development of inflammatory atherosclerosis associated with IJD. On the other hand, bone homeostasis disrupting skeletal disorders such as osteoporosis are closely related to atherosclerosis as well, corresponding to crosstalk between vessels and bones. Various substances are involved in bone homeostasis but also in vascular calcification.

Vascular calcification is a very complex: it may be affected by various inflammatory and metabolic factors. A peptide called osteoprotegerin (OPG) plays a very important role in the crosstalk between bone and vessels. In addition to its bone-specific effects, OPG is thought to inhibit vascular calcification through RANKL inhibition. Sclerostin and Dickkopf-1 (DKK-1) are TNF- α -mediated inhibitors of Wnt- and β -catenin-dependent bone formation. They play an important role in joint destruction. Both SOST and DKK-1 have been associated with the promotion of vascular calcification.

It remains to be shown if various circulating substances represent novel markers of vascular stress in patients with IJD and other skeletal disorders.

NS51

OSTEOARTRITIS AND VASCULAR AGING

S. Sokolovic¹

¹Clinic for heart, blood vessel and rheumatic diseases, University Clinical Center Sarajevo and Faculty of Medicine University of Sarajevo, Sarajevo, Bosnia-Herzegovina

Background: The aging and vascular tissue has not been well investigated in osteoarthritis (OA) especially specific the hemodynamic in vascular morphology changes. Arterial stiffness has not been studied in OA. This non-invasive technique is being used to detect central and peripheral blood pressure and real vascular age.

Objectives: To investigate whether Osteoarthritis has influence on the arterial stiffening and vascular aging.

Methods: The open ambulatory prospective parallel group study was designed. The arterial stiffness has been measured on Ageio apparatus on 73 RA patients and 52 controls. All OA patients did not suffer from arterial hypertension in order to obtain valid estimation. The central and peripheral blood pressure was measured as well as cardiac output, augmentation index, peripheral resistance, mean arterial pressure and pulse pressure. All patients were screened for cardiovascular risk factors, and for duration and stage of OA.

Results: The results obtained from this study showed that OA patients have vascular age approximately 3,4 years older than biological age. There was significant increase in the arterial stiffness.

Conclusions: According to this data, Osteoarthritis by disease itself does influence the blood vessel patomorphology changes, but not significantly and does not lead to premature cardiovascular events. This is also increased if the cardiovascular risk factors and risk profile are increased.

Disclosure of Interest: None declared

Keywords: Osteoarthritis, Vascular age.

NS52

OSTEOPOROTIC HIP FRACTURES: ARE WE ABLE TO PREVENT?

Y. Kirazli¹

¹Ege University Faculty of Medicine Department of Physical Medicine and Rehabilitation, Izmir, Turkey

Hip fractures are an important public health problem as 20-30% of the patients die within a year and only 1/3 of them regain their past functional level. Pharmacological agents have all been shown to reduce the risk of vertebral fracture. Some have also been shown to reduce the risk of non-vertebral fractures and, in some cases, agents have been shown specifically to decrease fracture risk at the hip. They reduce the risk of hip fractures by 30-51 %.

	Effect on vertebral fracture risk		Effect on non-vertebral fracture risk	
	Osteoporosis	Established osteoporosis ^a	Osteoporosis	Established osteoporosis ^a
Alendronate	+	+	NA	+(including hip)
Risedronate	+	+	NA	+(including hip)
Ibandronate	NA	+	NA	+ ^b
Zoledronic acid	+	+	NA	+ ^c
HRT	+	+	+	+(including hip)
Raloxifene	+	+	NA	NA
Teriparatide	NA	+	NA	+
Denosumab	+	+ ^c	+(including hip)	+ ^c

NA, no evidence available;

+, effective drug;

^awomen with a prior vertebral fracture;

^bin subsets of patients only (post-hoc analysis);

^cmixed group of patients with or without prevalent vertebral fractures

Table 1: Antifracture efficacy of the most frequently used treatments for postmenopausal osteoporosis when given with calcium and vitamin D, as derived from randomized controlled trials

It is recommended that patients should be reviewed after 3 years (IV) or 5 years (oral) treatment with bisphosphonate. The extension trials showed that alendronate continued to reduce the risk of clinical vertebral fractures up to ten years and zoledronic acid the risk of morphometric vertebral fractures up to six years, but not the hip fractures. The incidence of non-vertebral fractures was reduced by 20% and of hip fractures by 40% in the denosumab arm of the three-year study comparing denosumab with placebo. The study was extended to 10 years. The incidence of vertebral and non-vertebral fracture observed during the extension was similar to that observed in the denosumab group during the first 3 years.

Fracture liaison services (FLS), provide a system for the routine assessment and management of the patients who have sustained a fragility fracture. The Kaiser Permanente Healthy Bones Program which uses a systematic coordinator approach was associated with a 40 % reduction in hip fractures. Studies from the UK reported that the initiation of FLS reduced the 30-day and one-year mortality rates following hip fracture, led to a significant reduction in second fracture rate and increased the utilisation of anti-osteoporosis treatment by 15%.

Therefore, coordinator-based Fracture Liaison Services (FLS) should be used to systematically identify people with fragility fracture.

NS53

PHARMACOLOGIC TREATMENT AFTER HIP FRACTURE: WHEN AND HOW?

O. El¹

¹Dokuz Eylül University Faculty of Medicine Department of Physical Medicine and Rehabilitation, Izmir, Turkey

Osteoporotic hip fracture is associated with high morbidity, mortality, and economic burden worldwide. As 15 % to 25 % of patients experience a second fracture within 10 years. Proper management is vital to reduce the associated impact on quality of life and mortality and to prevent the risk of future fractures. But treatment rates in this population are reported to be low and decreasing over time.

Protein, calcium, and vitamin D supplementation is associated with increased hip BMD and a reduction in falls. Fall prevention, exercise, and balance training incorporated in a comprehensive rehabilitation program are essential to improve functional disability and survival. Exclusion of secondary causes of osteoporosis and treatment of coexistent medical conditions are also vital. Medical treatment of osteoporosis after hip fracture is also important. Despite the availability of a wide spectrum of anti-osteoporosis drugs, there is a significant paucity of evidence-based literature to guide treatment of this older patient population with hip fracture. Zoledronic acid appears to be the only agent that demonstrates both vertebral and non-vertebral fracture risk reduction as well as survival benefit in the fracture hip population. With regards general anti-fracture efficacy in the elderly, alendronate, ibandronate, risedronate, strontium ranelate, denosumab and teriparatide all provide evidence of early risk reduction of vertebral fracture.

Whether fracture healing is affected or not by anti-osteoporosis treatment is one of the most important concerns of the orthopedic surgeon, in particular with regard to bisphosphonates that suppress bone-turnover. There was no clinical evidence of impaired fracture healing with early administration of a potent bisphosphonate. The International Society for Fracture Repair recommended that secondary prevention should be implemented as soon as possible after a fragility fracture and at least prior to discharge from an acute fracture Service.

NS54

ADHERENCE TO PHARMACOLOGICAL TREATMENT OF OSTEOPOROSISY. Gokce Kutsal¹¹Hacettepe University Faculty of Medicine, Dept. of PMR and Hacettepe University Research Center of Geriatrics Sciences, Ankara, Turkey

Although affecting many people, similar to other chronic diseases, adherence to and persistence with osteoporosis treatment are low. Current estimates suggest that approximately half of the patients discontinue their osteoporosis medications within the first year of initiation and this suboptimal adherence leads to increased fracture risk, which results in increased morbidity and mortality especially in older people.

The reasons for these low adherence rates seem to be diverse: 1-There is an association with patients' apprehensions of medication side effects. The patients who have had adverse effects from previous medications are less adhere to treatment. 2-Appropriate communication and support of patients' families are significantly related to the adherence to treatment and facilitate following the recommendations of physicians. 3-High medication costs, lack of transportation, and poor understanding of directions are other reasons. 4-The time spent by the clinician with the patient may be insufficient to completely evaluate and understand the patients' drug intake behavior. 5-The lack of information about the patients' illnesses, lack of participation in the decision-making process and inadequacy of medical literacy, adversely affect patients' adherence to the treatment. 6-Some basic cultural differences between the patient and the clinician are important to provide the best health care. 7-There are various medication adherence problems because of the lack of adequate training of the geriatric patients. 8-The increasing number of drugs prescribed at hospital discharge is correlated with nonadherence. 9-One of the strongest reasons for the patient's treatment incompatibility is depression, which is associated with serious limitations in access to health care and daily functioning.

There is no single method to increase treatment compliance for all patients. Educational interventions is an effective way to increase compliance with treatment. It is also important for optimal communication between patient- physician to create an encouraging environment where patients are praised for achieving their treatment purposes and where permission is given to fairly ask questions about their treatment. Physicians should consider patients' cultural beliefs and attitudes in order to determine the most appropriate treatment options. Regulation and improvement of dosing programs is an important factor in following treatment plans and improving treatment outcomes. Reducing the dose frequency of drugs can be used to reduce drug abandonment rates. Poor health literacy affects health care negatively. Providing a shame-free environment is necessary for patients with poor health literacy. And when prescribing medications, the side effects should be considered. It is crucial for patients to keep their appointments, and some behavioral interventions can be used for reminding their appointments.

Simple but extremely relevant measures, such as providing appropriate information to patients regarding their health problems during the medical appointment, could improve adherence to treatment of osteoporosis. A good health system is essential to assess the adherence to treatment and to allow adequate time for each patient to receive personalized treatment.

NS55

REHABILITATION OF HIP FRACTURESF. Calis¹¹Ege University Faculty of Medicine Department of Physical Medicine and Rehabilitation, Izmir, Turkey

Hip fractures are primarily a disease of the elderly whose associated comorbidities can lead to postoperative complications and death. These fractures require surgery by osteosynthesis or—if there is a high risk of femoral head necrosis or underlying osteoarthritis—by a femoral head or total hip arthroplasty. In the osteosynthesis, fixation of the fracture can be treated by cannulated screw fixation, percutaneous pinning, sliding hip screw or intramedullary nail. The rehabilitation protocol after the surgery of hip fracture should be planned according to these surgery options. For example, weight-bearing should be limited to toe-touch if an osteotomy has been done. In the hemi-arthroplasty or total hip arthroplasty, weight-bearing restrictions varies according to cemented or cementless hip devices. It is essential that initial stability achieved with cement fixation is adequate to allow immediate full weight-bearing with a cane or walker. With a non-cemented hip prosthesis, maximal stability is probably not achieved for the first 6 weeks, toe-touch weight-bearing should be advocated. The postoperative instructions on motions, transfer instructions and exercises should be given for these patients in order to avoid prosthesis dislocations. If a gait fault occurs, they are corrected with observation and teaching.

NS56

PREVENTION OF COMPLICATIONS FOLLOWING HIP FRACTURESO. Peker¹¹Dokuz Eylül University Faculty of Medicine Department of Physical Medicine and Rehabilitation, Izmir, Turkey

Hip fractures are expected to increase worldwide due to an increase in life expectancy. Approximately 1.6 million hip fractures occur worldwide each year and this number can reach between 4.5 million and 6.3 million by 2050. Hip fractures are associated with increased mortality. Hip fractures also require long-term nursing home care.

Serious complications can occur after hip fractures. Pneumonia, heart failure, kidney failure, deep vein thrombosis, pulmonary embolism, electrolyte imbalance, hyperglycemia, mental deterioration, delirium, pressure sores, postoperative infection and muscle atrophy are among these complications. These problems increase the length of stay in hospital.

Osteoporotic hip fracture patients need specific clinical approach and treatment. Detailed assessment of metabolic disorders and co-morbid diseases before operation is important in order to improve the outcome. Post-operative management is also important in patients with hip fracture. Multidisciplinary team approach is recommended to take care of these patients.

NS57

PATHOPHYSIOLOGY AND RISK FACTORS

O. Rosero Olarte¹

¹Asociación Colombiana de Endocrinología. Asociación Colombiana de Osteoporosis y Metabolismo Mineral, Bogotá, Colombia

Osteonecrosis of the jaw associated with medication (MRONJ) is a rare condition that can occur after exposure to agents used to prevent bone complications, such as bisphosphonates or denosumab, or treatment with other agents, such as inhibitors of the angiogenesis.¹ In most cases, MRONJ manifests as exposed bone in the maxillofacial region, although MRONJ has also been recognized as unexposed.² Bisphosphonates are analogues of pyrophosphates, which bind to the hydroxyapatite crystals of bone in such a way that, when phagocytosed by the osteoclast, they inhibit the farnesyl pyrophosphate synthase enzyme responsible for converting mevalonate to cholesterol in the cell, causing osteoclast apoptosis.³ Denosumab is a monoclonal antibody that binds to the RANK ligand produced by osteoblasts so that it does not bind to the RANK receptor located in osteoclast precursor cells, and thus prevents the formation and maturation of osteoclasts and bone resorption, without that there is apoptosis.⁴

Bisphosphonates are small molecules that are incorporated into the bone matrix and remain in the skeleton for a long time, unlike denosumab, which is a monoclonal antibody whose action lasts only six months after which the antiresorptive effect is reversed.⁵

The pathophysiology of MRONJ is not clearly understood yet, but it is known that multiple factors contribute to it: oral mucosal lesions, inflammation, infection, inhibition of bone turnover, inhibition of angiogenesis, microtrauma, immunomodulation, antiresorptive potency, bisphosphonate toxicity on soft tissues, cancer and genetic predisposition.⁶

Normally, the bones are subject to continuous remodeling. The jaws, in particular, are subject to intense remodeling, especially in the dentoalveolar area. Consequently, the suppression of bone remodeling facilitates the accumulation of damage in the jaws, with the aggravating circumstance that this is a region associated with high levels of trauma due to the forces involved in masticatory activity.⁷

In addition, there is damage caused by bacterial accumulation in the gingival sulcus that causes chronic inflammation. Caries and periodontal disease are diseases of the oral cavity of bacterial origin that destroy the dental tissues and the support of the teeth, therefore, trauma and infection increase the demand for bone repair that the hypodynamic bone can not fulfill. This could result in osteonecrosis of the jaws.⁶⁻⁷

Although bisphosphonates have demonstrated an anti-angiogenic effect, this does not seem to be the fundamental cause, there are also other factors that produce additional antiangiogenic effects, which enhances the antiresorptive effect. Among these are: diabetes mellitus, cancer, the use of other agents with anti-angiogenic action such as glucocorticoids, thalidomide, proteasome inhibitors, bortezomib and cancer treatments such as sunitinib and bevacizumab. Smoking has negative effects, since it reduces angiogenesis and also contributes to a microenvironment that favors bacterial growth.⁸

There is also a genetic predisposition that would explain why not all people with similar comorbidities and typical management develop MRONJ.⁹

In general, the risk of MRONJ seems to increase with long-term antiresorptive therapy and a higher dose; for the presence of infectious foci in the oral cavity; due to smoking and the concomitant use of antiangiogenic drugs, including glucocorticoids.

References:

1. Khan A, Morrison A, Cheung A, et al. Os- teonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Os- teoporos Found USA. 2016; 27: 853-9.
2. Khan AA, Morrison A, Hanley DA, et al. Di- agnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res Off J Am Soc Bone Miner Res. 2015; 30: 3-23.
3. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Mönkkönen J, et al. Molecular mechanisms of action of bisphosphonates. Bone. 1999 (5 suppl):73S- 79S.
4. Lewiecki EM. Denosumab: an investigational drug for the management of postmenopausal osteoporosis. Biologics. 2008 Dec;2(4):645-53.
5. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011 Apr 1;48(4):677-92.
6. George EL, Lin YL, Saunders MM. Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective. Bone Rep. 2018;8:104-109.
7. Aghaloo T, Hazboun R, Tetradis S. Pathophysiology of Osteonecrosis of the Jaws. Oral Maxillofac Surg Clin North Am. 2015;27(4):489-96.
8. Japanese Allied Committee on Osteonecrosis of the Jaw; Yoneda T, Hagino H, et al. Anti- resorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017; 35: 6-19.
9. Marini F, Tonelli P, Cavalli L, et al. Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Front Biosci (Elite Ed) 2011; 3:364.

NS58

BIOCHEMICAL MARKERS AND IMAGING USE ON ONJ

B. Muzzi Camargos¹

¹Member of the IOF Committee of Scientific Advisors (CSA) Rede Materdei de Saúde – Densitometry Unit Coordinator Member of the National Committee on Osteoporosis of FEBRASGO, Belo Horizonte, Brazil

Bone Turnover Markers - Monitoring of bone turnover markers may help to avoid oversuppression of bone turnover and assist decisions to reduce the incidence of medication-associated osteonecrosis of the jaw with (MARONJ).¹

Serum bone turnover markers such as CTx and NTx are the most known and commonly used options and the evidence supports that the former may be more precise and, therefore, preferred.²

CTx is located at the terminal of type-1 collagen strands and reflects bone resorption. Different studies provided arguments in favour³⁻⁵ and against⁶⁻¹⁰. There are limitations for CTx use as predictor of MRONJ and an expert panel led by American Dental Association has documented against its routine use for such objectives.¹¹

The wide variability of sCTx within a 24-hour period and the wide range of reference values makes individual test results unreliable and difficult to extrapolate from different study populations.¹² More recently, a strategy proposed by an expert group advises that it would be reasonable to obtain a baseline sCTx level in patients prior to the use of antiresorptive therapies and compare it to another sample, obtained 90 days after its beginning. An expert Working Group led by IOF and ECTS proposed the measurement of CTx levels at baseline and after three months of initiating treatment. In those individuals where the decrease does not exceed the least significant change of about 38%, respectively assessment of adherence or investigation of secondary osteoporosis should be carried out.¹³

Imaging - The use of imaging technology to detect early changes predictable of MARONJ has been discussed. Imaging can help to determine the extent of the lesion and grade it, helping doctors to define which assessment would be mostly recommended. The use of imaging for diagnosing MARONJ on established pathology may be useful for evaluation of the extension rather than the diagnostic itself because the presence of exposed bone and associated symptoms (suppuration and soft tissue ulceration) can be clinically detected. The early identification of MARONJ is clearly important because it may influence prevention and care.¹⁴ Plain film panoramic radiographs (PR) are widely available, inexpensive and provide a good overview of the entire jaw. It is considered a first line documentation of the status of the jaw. Radiography is able to distinguish osteonecrosis from metastatic lesions, except if the lesion is an osteolytic one. When there are osteolytic and osteosclerotic lesions, radiography is particularly useful. Unfortunately, it is required to have at least a 30% loss of bone before detection is made.¹⁵ Computed Tomography (CT) detects differences between cortical and trabecular bone when MRONJ is suspected. Cone beam CT (CBCT) exposes the patient to a lower

radiation with higher spatial resolution than conventional CT. It provides better image quality besides a little limited for discrimination of soft tissue. Cone beam CT can provide detailed information about cortical thickness and integrity, marrow involvement, irregularities after tooth extraction and cancellous BMD.¹⁶ Magnetic Resonance Imaging (MRI) may be the method of choice for assessing MARONJ. It is sensitive for progressive cell death and host repair (edema). The general consensus is MRI is not sensitive to MARONJ alterations as it is for femur avascular necrosis (AVN).¹⁷ Besides that, the region of ischemia can be recognized as a nonenhanced area after the use of a contrast agent, such as gadolinium, especially in fat-suppressed T1 sequences. Available data on MRI findings of bisphosphonate-associated MARONJ are limited and suggest that this technique may be associated with a high percentage of false-positive diagnoses. Although it is considered an effective tool in the assessment of osteonecrosis of the jaw, clinical correlation and progression of lesions studied by MRI over time remains to be determined.^{18,19} In 2014, a literature review evaluated studies of modalities for evaluating MARONJ (CT, plain film radiographs, MRI, nuclear bone scanning). All of the selected studies showed a small number of patients and none of the selected studies have tested the accuracy of the imaging examination for evaluating BRONJ. They concluded that there is a scarcity of quantitative studies that analyzed the typical imaging findings related to BRONJ.²⁰ Despite the lacking of a formal grading system for imaging techniques, the sequestrum separation on panoramic radiography in patients with MRONJ was unclear in comparison to CT. Furthermore, characteristic CT findings of patients with MRONJ in the parenteral administration group were periosteal bone proliferation and spread of soft tissue inflammation to buccal and other spaces.²¹ Fluorescence-guided bone resection is a precisely described way of imaging in combination with surgery in MRONJ patients. Functional imaging is useful for detection of MRONJ at an early stage, especially if routine nuclear imaging is acquired for metastasis search or follow-up purposes, but also to capture lesions which are not obvious on anatomical imaging. The use of the VELscope® proved to be very helpful to detect the extent of the necrosis more precisely, and its use in the operation theatre is highly feasible and not time-consuming.²²

PET/CT Fluorodeoxyglucose (FDG) uptake, widely used to monitor and rule out recurrence and metastasis of head and neck carcinoma would be useful for detecting MARONJ. Functional imaging obtained by a tracer with oncotropic properties, like Tc99m-sestamibi, in comparison to a non-tumor-specific substance such as FDG-PET, can support the differential diagnosis. No sestamibi uptake was evident on jaw osteonecrosis, while FDG-PET/CT showed focal uptake. The combination usage of sestamibi scintigraphy and FDG-PET/CT could support the clinical diagnosis of oral osteonecrosis. Although this combination might seem promising, further studies on higher number of patients are necessary to validate these observations.²³⁻²⁴

References:

1. Khan A, Morrison A, Cheung A, Hashem W, Compston J (2016) Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. *Osteoporos Int* 27(3):853–859.

2. Chan CK, Mason A, Cooper C, Dennison E. Novel advances in the treatment of osteoporosis. *Br Med Bull.* 2016;119(1):129-42.
3. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. *J Oral Maxillofac Surg.* 2009;67:2-12.
4. Marx RE, Cillo JE, Jr., Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. *J Oral Maxillofac Surg.* 2007;65:2397-2410.
5. Lazarovici TS, Mesilaty-Gross S, Vered I, et al. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. *J Oral Maxillofac Surg.* 2010;68:2241-2247.
6. Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. *J Bone Miner Res.* 2009;24:561-574.
7. Avolio G, Brandao C, Marcucci M, Alonso G. Use of the plasma CTX for assessing the bone activity of the mandible among osteopenic and osteoporotic patients. *Braz Oral Res.* 2010;24:250-255.
8. Fleisher KE, Welch G, Kottal S, Craig RG, Saxena D, Glickman RS. Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* Oct 2010;110(4):509-516.
9. Lee CY, Suzuki JB. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Biological concepts with a review of the literature. *Implant Dent.* 2009;18:492-500.
10. Lee CY, Suzuki JB. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? A prospective clinical study. *Implant Dent.* 2010;19:29-38.
11. Hellstein JW, RA Adler, Edwards B, Jacobsen PL, Kalmar JR, Koka S, Migliorati CA, Ristic H. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. *JAmDentAssoc* 2011;142(11):1243-51.
12. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res.* 2007 Oct;22(10):1479-91.
13. Diez-Perez A, Naylor KE, Abrahamsen B, Agnusdei D, Brandi ML, Cooper C, Dennison E, Eriksen EF, Reginster J-Y, Rizzoli R, Silverman S, Eastell MR et al. Adherence Working Group of the International Osteoporosis Foundation and the European Calcified Tissue Society. *Osteoporos Int.* 2017; 28(3): 767-774.
14. Store G, Larheim T 1999 Mandibular osteoradionecrosis: A comparison of computed tomography with panoramic radiography. *Dentomaxillofac Radiol* 28:295-300.
15. Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova M, Lenarda R. 2006 Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. *Dentomaxillofac Radiol* 35:236-243.
16. Schulze D, Blessman M, Pohlenz P, Wagner KW, Heiland M. 2006 Diagnostic criteria for the detection of mandibular osteomyelitis using conebeam computed tomography. *Dentomaxillofac Radiol* 35:232-235.
17. Gabriel H, Fitzgerald SW, Myers MT, Donaldson JS, Posnanski AK. MR imaging of hip disorders. *Radiographics* 1994; 14:763-781.
18. García-Ferrer L, Bagán JV, Martínez-Sanjuan V, Hernandez-Bazan S, García R. Jiménez-Soriano Y, Vicente Hervas V. MRI of Mandibular Osteonecrosis Secondary to Bisphosphonates. *AJR* 2008; 190:949-955.
19. Morag Y, Morag-Hezroni M, Jamadar DA, Ward BB, Jacobson JA, Zwetckhenbaum SR, Helman J. *RadioGraphics* 2009; 29:1971-86.
20. Leite AF, Ogata Fdos S, de Melo NS, Figueiredo PT. Imaging findings of bisphosphonate-related osteonecrosis of the jaws: a critical review of the quantitative studies. *Int J Dent.* 2014;2014:2-11.
21. Ichiro Ogura, Yoshihiko Sasaki, Ayako Kameta, Mikiko Sue, Takaaki Oda. Characteristic Multimodal Imaging of Medication-Related Osteonecrosis of the Jaw: Comparison Between Oral and Parenteral Routes of Medication Administration. *Pol J Radiol*, 2017; 82: 551-560.
22. Berg BI, Mueller AA, Augello M, Berg S, Jaquiéry C. Imaging in Patients with Bisphosphonate-Associated Osteonecrosis of the Jaws (MRONJ). *Dent J (Basel).* 2016;4(3):29.
23. Akashi M, Wanifuchi S, Kusumoto J, et al. Potential role of post-treatment follow-up FDG-PET CT to detect mandibular osteoradionecrosis: A case report. *Mol Clin Oncol.* 2017;8(1):61-67.
24. Catalano L, Del Vecchio S, Petruzzello F, Fonti R, Salvatore B, Martorelli C, Califano C, Caparrotti G, Segreto S, Pace L, Rotoli B. *Ann Hematol* (2007) 86:415-423.

NS59

OSTEOSTEOPOROSIS THERAPIES AND ONJ

A. Medina Orjuela^{1,2,3}

¹Internal Medicine – Endocrinology. Fundación Universitaria De Ciencias De La Salud. Universidad Nacional de Colombia, Bogotá, Colombia, ²Asociación Colombiana de Osteometabolismo, Bogotá, Colombia, ³Asociación Colombiana de Endocrinología, Asociación Colombiana de Osteoporosis Y Metabolismo Mineral, Bogotá, Colombia

Antiresorptive are medications used in the context of osteoporosis and in patients with multiple myeloma or metastasis from solids tumors. The exposure to the medicine is different and, therefore, the incidence also varies in each scenario. Reports in the literature show that the impact of ONJ is 0.8-11% in patients treated with bisphosphonates (BP) in the context of underlying malignancies, while in patients with osteoporosis the reported incidence is between 0.01- 0.04%.¹

Until 2006, in post-marketing surveillance, Merck received reports of 170 cases of ONJ associated with alendronate among approximately 20 million patient-year (0.7 reports per 10,000 patient-year of exposure). Novartis also received reports of 352 cases of ONJ among 1.9 million patient-year treated with pamidronate and 1719 cases among 1.15 million patient-year treated with zoledronate.²

Antiresorptives are the group of drugs associated with the largest number of cases of ONJ. However, there are reports of other medications that, used in monotherapy or in combination with antiresorptives, have been associated with this complication, such as BP, RANKL inhibitors, antiangiogenic drugs and mTOR inhibitors.³ Some drugs for rheumatoid arthritis such as prednisone, methotrexate, etanercept, adalimumab and rituximab, may compromise healing and be associated with lesions in the mouth identical to those of the ONJ.⁴

Aminobisphosphonates, mainly intravenous (IV), are the drugs most involved in the development of ONJ. In oncological patients, potent antiresorptives are used with more frequent doses and higher accumulated doses, which means that the prevalence of ONJ is greater in oncologic patients than those with osteoporosis.⁵⁻⁸ The incidence of ONJ in patients with iv bisphosphonates for osteoporosis varies from 0 to 90 in 100,000 patients / year.⁹

In the pivotal study of zoledronic acid (HORIZON) involving 7765 patients who received 5 mg / year of zoledronic or placebo for 3 years, only one case of ONJ occurred in each treatment arm. These two patients had additional risk factors (prednisolone in the placebo arm and diabetes with dental abscess in the patient receiving zoledronate).¹⁰ Further studies on treatment with zoledronic acid were evaluated for possible cases of ONJ such as the HORIZON RFT,¹¹ the Glucocorticoid-Induced Osteoporosis Trial¹², the Male Osteoporosis Trial,¹³ and the Prevention of Osteoporosis Trial.¹⁴ In these studies, the incidence of adjudicated ONJ was <1 in 14200 patient / year in treatments with iv 5 mg zoledronic acid.¹⁵

In extension studies of denosumab, cases of ONJ have been found in patients prescribed with denosumab. The incidence range of ONJ is 0-30 (2 per 100,000 patient-year).¹⁶ In the pivotal study of denosumab (FREEDOM), with 7808 patients, there were no cases of ONJ in 3 years.¹⁷ In the study of Extension of FREEDOM, with denosumab in postmenopausal women with osteoporosis, there were 8 cases of ONJ in 4.550 participants.¹⁸

In the initial reports of ONJ associated with BP (2003), the great majority of cases (> 90%) occurred in cancer patients who received 6 to 10 times higher dose of BP than the used to treat osteoporosis.¹⁹

The risk of ONJ induced by BP increases when the duration of therapy exceeds 4 years.¹ Patients with osteoporosis with a longer duration and higher doses of these drugs are associated with an increased risk, although the correlation of ONJ and the accumulated dosage of BP remains a controversial issue.²⁰ However, after two years of exposure, the incidence of ONJ is 0.09% and 0.2% after 6 years.^{21,22}

It is estimated that the risk of ONJ in cancer patients exposed to zoledronic acid is 50 to 100 times higher compared to subjects with cancer in the placebo group,²³ while subjects with cancer exposed to denosumab, the risk of ONJ is between 0.7 and 1.7% .²⁴ and is 50 times higher compared to those with cancer in the placebo group.^{24,25}

The risk of ONJ is greater in oncologic patients who use antiresorptives combined with antiangiogenic drugs. In the case of concomitant use of zoledronic acid and bevacizumab, the risk is 0.9% (9 cases per 1000).²⁶ A study with oral ibandronic acid in women with breast cancer reported an incidence of 0.7%.²⁷ Among patients exposed to iv bisphosphonates for multiple myeloma or cancer, about 1% may develop ONJ after the first year of treatment, but the risk increases by 13% after the fourth year of use.²⁸

Conclusion: The incidence of ONJ in patients with osteoporosis is very low: between 0.15% to less than 0.001% people / year of exposure to BP or denosumab.¹⁶ But factors such as the duration of treatment of more than 4 years, and the use of powerful antiresorptives such as zoledronic acid and denosumab or high doses at higher frequencies, such as those used in oncological patients, are associated with an increased risk of this rare complication. There are other drugs such as angiogenic that can cause ONJ and should be taken into account when performing an invasive dental procedure.

References

1. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw 2009 update. Aust Endod J. 2009 Dec;35(3):119-30.
2. Silverman SL, Landesberg R. Osteonecrosis of the Jaw and the Role of Bisphosphonates: A Critical Review. Am J Med. 2009; 122:S33–S45.

3. Zhang X, Hamadeh IS, Song S, Katz J, Moreb JS, Langaee TY et al. Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). *J Bone Miner Res.* 2016 Feb;31(2):336-40.
4. Aghaloo TL, Tetradis S. Osteonecrosis of the jaw in the absence of antiresorptive or antiangiogenic exposure: a series of cases. *J Oral Maxillofac Surg* 2017; 75:129-142.
5. Thumbigere-Math V, Sabino MC, Gopalakrishnan R, et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. *J Oral Maxillofac Surg* 2009;67(9):1904-1913.
6. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a casecontrol study. *J Oral Maxillofac Surg* 2008;66(4):625-631.
7. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. *J Oral Maxillofac Surg* 2004;62(5):527-534.
8. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. *J Oral Maxillofac Surg* 2005;63(11):1567-1575.
9. Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY. Medication related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. *J Bone Metab.* 2015;22:151-165.
10. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. *N Engl J Med.* 2007 May 3;356(18):1809-22
11. Lyles KW, Col.n-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. *N Engl J Med.* 2007;357:1799-1809.
12. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. *Lancet.* 2009 Apr 11;373(9671):1253-63.
13. Orwoll ES1, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D et al. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. *J Bone Miner Res.* 2010 Oct;25(10):2239-50.
14. McClung M1, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. *Obstet Gynecol.* 2009 Nov;114(5):999-1007.
15. Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. *J Am Dent Assoc.* 2010 Nov;141(11):1365-70.
16. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res.* 2015 Jan;30(1):3-23.
17. Boonen S, Adachi JD, Man Z, Cummings SR, Lippuner K, T.rring O et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. *J Clin Endocrinol Metab.* 2011 Jun;96(6):1727-36.
18. Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. *Osteoporos Int.* 2015;26(12):2773-83.
19. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. *J Oral Maxillofac Surg.* 2003; 61: 1115-1118.
20. Barasch,1, J. Cunha-Cruz,2 F.A. Curro,3 P. Hujoel,2 A.H. Sung,4 D. Vena,5 A.E. Voinea-Griffin,1 and the CONDOR Collaborative Group†. Risk Factors for Osteonecrosis of the Jaws a Case-Control Study from the CONDOR Dental PBRN. *J Dent Res.* 2011 Apr; 90(4): 439-444.
21. Chan BH, Yee R, Puvanendran R, Ang SB. Medication-related osteonecrosis of the jaw in osteoporotic patients: prevention and management. *Singapore Med J.* 2018 Feb;59(2):70-75.
22. Bone HG, Chapurlat R, Brandi M-L, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension. *J Clin Endocrinol Metab* 2013;98:4483-92.
23. Ruggiero SL, Dodson TB, Fantasia J et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws 2014 update. *J Oral Maxillofac Surg.* 2014;72:1938-1956.
24. Kajizono M, Sada H, Sugiura Y, Soga Y, Kitamura Y, Matsuoka J, Sendo T. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study. *Biol Pharm Bull.* 2015;38(12):1850-5.
25. Dodson TB. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors. *Oral Maxillofac Surg Clin North Am.* 2015 Nov;27(4):509-16.
26. Christodoulou C, Pervena A, Klouvas G et al (2009) Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. *Oncology* 76:209-211.

27. Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. *Breast Cancer Res Treat* 2010;122:181.
28. Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. *Breast Cancer Res Treat* 2010;122:181.

NS60

CLINICAL SCENARIOS #1: PERSPECTIVE OF THE CLINICIAN

M. Chalem¹

¹Internal medicine and Rheumatology, Fundación Santafe de Bogotá. Past president ACOMM, Past President Asociación Colombiana de Reumatología, Bogotá, Colombia

It is common to see a deterioration of dental health in the elderly with the consequent need for invasive dental procedures such as extractions or placement of dental implants. We must evaluate the oral health of our patients and have an adequate communication with the dentist. Although the risk of osteonecrosis of the jaws associated with drugs (ONJ) is very low in the patient with osteoporosis, the dentist is afraid of performing dental procedures in patients receiving antiresorptives and requests our concept or authorization before carrying them out. Within dental procedures, the highest risk is related with dental extraction. In the case of dental implants, the evidence is controversial¹. In patients who have been exposed to oral bisphosphonates for the management of osteoporosis, it has been estimated that the risk of developing ONJ after a tooth extraction is 0.5% (1 per 200)². The risk of ONJ induced by bisphosphonates increases when the duration of therapy exceeds four years³.

The scenarios that we should consider are the following:

1. Patient with osteoporosis who has not started therapy and requires an invasive dental procedure. In this scenario, given the low risk of developing ONJ, invasive treatments can be performed in the oral cavity without delaying the initiation of antiresorptive treatment, especially in those patients with a high risk of fracture.
2. Patients who have already begun treatment for osteoporosis with antiresorptives have a low risk of developing ONJ after performing a dentoalveolar surgical procedure, provided that the treatment time is less than 4 years and the surgical technique and microbiological control of the oral cavity (use of antibacterial rinses and antibiotics) is done in the indicated manner. In this case, the medication should not be stopped⁴. In patients with more than four years of treatment, it is important to follow a special surgical protocol and a bacterial control that reduces the risk. This raises the question of whether or not to suspend the medication before the invasive procedure and there will be a difference between bisphosphonates and denosumab given the different mechanism of action.

It has been suggested that the levels of C-telopeptide (CTX) can be predictive of the risk of ONJ and that values below a certain level are associated with greater risk⁵. Although it is attractive and somewhat logical (low CTX values correlate with antiresorptive power) there is no consensus on this. However, many dentists and certain clinicians are guided by this parameter in order to choose the time to perform this type of intervention with less probability of risk. The very low incidence of ONJ in subjects with osteoporosis indicates that even very large studies are insufficient to answer this question⁶, or that there is definitely no association between the marker of resorption and the development of this complication.

References:

1. Aspenberg, P. Bisphosphonates and implants: an overview. *Acta Orthop*. 2009 Feb; 80(1):119-23.
2. Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. *J Int Soc Prev Community Dent*. 2016;6(2):97-104.
3. Ruggiero SL, Dodson TB, Assael LA, et al. Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. *Aust Endod J* 2009; 35:119-30.
4. Lo JC, O’Ryan FS, Gordon NP, et al: Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. *J Oral Maxillofac Surg*. 2010. 68:243.
5. Marx RE, Cillo JE, Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. *J Oral Maxillofac Surg* 2007;65:2397-410.
6. Grbic JT, Black DM, Lyles KW, et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. *J Am Dent Assoc*. 2010 Nov;141(11):1365-70.

NS61

CLINICAL SCENARIOS #2: INVASIVE PROCEDURES PRE-OP PATIENTS

A. K. Sarmiento Lievano¹

¹Dentist and Oral and Maxillofacial at Faculty of Dentistry - Universidad Nacional de Colombia. Professor at Medicine Faculty Universidad de Los Andes. Bone Fragility Group - Fundación Santa Fe de Bogota - Colombia, Bogotá, Colombia

In clinical practice, patients with high risk of fragility fracture who require medical treatment with antiresorptives are presented whose risk of developing osteonecrosis of the jaws depends on the coexistence of several factors, some of them controllable, among them: the presence of infection, inflammation and trauma in the oral cavity or the amount of bisphosphonates and microdamage accumulated in the bone.¹ The identification of these

factors in each patient allows to determine their individual risk at a specific time. This means that each patient has a sum of risk factors that vary over time, for example: the degree of suppression of bone turnover produced by denosumab at the time of its application is not the same as six months after it; the infectious and inflammatory stimulus in the dentoalveolar zone fluctuates according to the microbiological control that the patient has with the application of different oral hygiene techniques; the coexistence of other comorbidities such as diabetes and the effect of medications such as corticosteroids and antiangiogenics on bone increase the risk of developing the complication.² Although the incidence of osteonecrosis is low,³ when it occurs compromises the quality of life of patients affecting not only the aesthetic but the function and decreasing the possibilities of rehabilitation, and it has an impact on the treatment of any underlying disease. If the patient suspends the antiresorptive treatment and has a high risk of fractures, the result can be catastrophic. For this reason, the best clinical scenario is prevention, referring the patient who will benefit from antiresorptive treatment to the dentist in order to eliminate local inflammation and eliminate infectious foci in the mouth. These results must be maintained over time by teaching oral hygiene techniques and using adjuncts that vary in each patient.⁴ In the case of patients who are already in treatment with antiresorptives and require surgical procedures in the mouth, it is important to establish the cumulative time of treatment as the risk increases after the fourth year. The procedure must be performed by a maxillofacial surgeon, following measures that reduce the risk of non-healing or infection of the bone exposed to the oral environment during the intervention. These measures include the use of antibiotics, and the rotation and advancement of local mucoperiosteal flaps that lead to first intention healing. It is important to remember that in addition to reducing the risk of fragility fractures, the patient should also be given the opportunity to receive treatment for oral pathologies and the adequate rehabilitation of their masticatory function and aesthetics.⁴ The following clinical scenario is constituted by patients who present maxillary or non-odontogenic mandibular symptoms: dull pain, Vincent's sign, dental mobility and the presence of intraoral or extraoral fistulas. In stage 0 of osteonecrosis the most important thing is the differential diagnosis, a detailed clinical examination must be performed and the necessary images must be requested (x-rays, tomography, MRI) to rule out odontogenic processes and metastasis as the cause of the patient's signs and symptoms. The early identification of this symptomatology and the suspicion on the part of the attending physician of the first phases of an osteonecrosis will allow an opportune diagnosis and facilitate the control and management of the condition.⁵ Once the bone is exposed to the oral environment, the most important objective is to avoid the development of osteomyelitis, the bone must be covered by soft tissue, for which the contaminated bone must be removed and the remaining one covered with healthy mucosa.⁶ If the diagnosis of osteomyelitis exists, long-term treatment with specific antibiotics and the removal of more contaminated bone is necessary, which implies more complex surgical procedures and aesthetic and functional sequelae for the patient.³ We will present the case of a patient with grade 3 osteonecrosis of the

right hemi-mandible, and at risk of fragility fracture, who underwent antibiotic management for her osteomyelitis and, in parallel, treatment with teriparatide with resolution of osteonecrosis 4 months after initiation the treatment. In the context of the patient with osteoporosis, the option of anabolics such as teriparatide is shown as a promising alternative in reversing the damage of the jaws with osteonecrosis.⁷

References:

1. Schwartz HC. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update and CTX. *J Oral Maxillofac Surg.* 2015 Mar;73(3):377.
2. Chang J, Hakam AE, McCauley LK. Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw. *Curr Osteoporos Rep.* 2018 Oct;16(5):584-595.
3. Hauer L, Jambura J, Hrusak D, Chalupova M, Posta P, Rusnak S, Vyskocil V. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.* 2019 Jan 10. doi: 10.5507/bp.2018.081. [Epub ahead of print].
4. Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis of the jaw. *Cochrane Database Syst Rev.* 2017;10:CD012432.
5. Takaoka K, Kishimoto H. Current situation and future issues of antiresorptive agent-related osteonecrosis of the jaw. *Nihon Yakurigaku Zasshi.* 2019;153(1):22-27.
6. Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, Niepel D, Van den Wyngaert T. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2018;S2212-4403(18):31193-3.
7. Liu Y, Levack AE, Marty E, Or O, Samuels BP, Redko M, Lane JM. Anabolic agents: what is beyond osteoporosis? *Osteoporos Int.* 2018;29(5):1009-1022.

NS62

OSTEOSARCOPENIA: WHERE BONE, MUSCLE AND FAT COLLIDE

G. Duque¹

¹Professor and Chair of Medicine – Western Health, Director – Australian Institute for Musculoskeletal Science (AIMSS), The University of Melbourne and Western Health, Melbourne, Australia

Osteosarcopenia is a newly defined geriatric syndrome with serious consequences in the older population. Analysis of the pathophysiologic pathways of osteosarcopenia reveal major interactions between bone, muscle and fat. Typical features of osteosarcopenia include fat infiltration, local and systemic lipotoxicity, aging-related mechanisms, changes in stem cells differentiation and progressive loss of bone and muscle mass. Additionally, physical inactivity, vitamin D deficiency and poor nutrition

accelerate the progression of these conditions. In this session, we will discuss the pathogenesis of osteosarcopenia in the light of new discoveries on gerosciences and on the importance of local lipotoxicity induced by intramuscular and marrow fat. We will also discuss the current and possible future diagnostic and therapeutic methods for osteosarcopenia focusing on the identification and quantification of tissue-embedded fat.

NS63

DIAGNOSTIC APPROACH TO OSTEOSARCOPENIA

B. Buehring¹

¹Rheumazentrum Ruhrgebiet, Herne, Germany

Musculoskeletal health is a key factor for independent living and mobility. Impaired musculoskeletal health leads to fractures and falls which cause immobility, dependence, morbidity and mortality. Assessment of bone, muscle and fat are essential not only to diagnose common diseases such as adiposity and osteosarcopenia but also to monitor interventions to treat these entities. The aim of this presentation is to review current methods to assess "muscle and bone health" with an emphasis how they can be used for diagnosis and monitoring. These include established muscle and physical function tests as well as muscle and bone mass assessment methods currently used in diagnostic definitions but also approaches that are undergoing active investigation. Specifically, grip strength, components of the short physical performance battery and jumping power will be reviewed. Among muscle and bone mass assessment methods DXA, bioelectrical impedance analysis and spectroscopy, musculoskeletal ultrasound, cross-sectional imaging such as CT and MRI but also deuterated creatine will be discussed. Lastly, selected biomarkers which are involved in signalling between muscle, bone and adipose tissue will be at least briefly introduced.

NS64

OSTEOSARCOPENIA: POTENTIAL THERAPEUTIC INTERVENTIONS

L.-K. Chen¹

¹Director, Center for Geriatrics and Gerontology, Taipei Veterans General Hospital. Professor and Director, Aging and Health Research Center, National Yang Ming University. President, Taiwan Association of Integrated Care, Taiwan., Taipei, Taiwan

Osteosarcopenia, defined as the phenotype of combined osteoporosis and sarcopenia, lacks generally accepted operational definition yet. Currently, it is operationally defined as the concomitant presence of osteopenia and sarcopenia in older adults, which is associated with higher risk of falls and fractures in older adults. It has been proposed that age-related fat redistribution and infiltration may play an important role in the pathogenesis of osteosarcopenia. It has been reported that osteosarcopenia is associated with low serum Vit D level, as well as IGF-1 status. However, no available intervention study is available to evaluate the therapeutic potential. Currently, maintaining adequate nutritional intake is the foundation of osteosarcopenia management, especially protein, Calcium and Vit D. Besides, exercise is also essential to maintain musculoskeletal health. Until now, no specific pharma-

ceutical agents have been developed to treat osteosarcopenia. Nevertheless, myokines interact with bone, e.g. irisin, may be a potential therapeutic target. Exercise-induced secretion of irisin not only triggers the transformation of adipocytes, but also bone remodelling. Small, non-clinical studies suggested that inhibition of RANK pathway may be of beneficial effects to muscle mass. However, the beneficial effect was not noted in the sub-sample of FREEDOM trial. Currently, adequate nutritional intake and exercise remained to be the optimal non-pharmacological intervention for osteosarcopenia, but roles of irisin and RANK pathway deserve further investigation.

NS65

HOW TO MAINTAIN MUSCLE QUALITY :THE SECRET OF A SUCCESSFUL AGING

B. Fougère¹

¹Division of Geriatric Medicine, Tours University Hospital, Tours, France

Background: As consistently reported in the literature, muscle strength (MS) decreases at a higher rate than muscle mass (MM) during aging resulting in a decreased muscle quality (MQ). Loss of MQ has been associated with loss of mobility, falls, frailty and an increased risk of mortality. However, the degree of muscle declines is varying throughout the population leading to 3 states: successful, normal or pathological. It has been proposed that healthy life habits such as be physically active, having a healthy diet etc. could reduce the muscle aging decline. Thus, identifying if life habits could counteract or maintain muscle quality during successful aging is important to better characterize aging and to intervene more specifically.

Objective: The aim of the present study was to identify whether a physically active lifestyle could attenuate the effects of aging on MQ.

Methods: Active young were compared to active older men. To be considered active, young and older men need to practice voluntary physical activity at least 150min/week since 5yrs. Body composition (DXA; MRI) and maximum knee extension strength were measured. MQ was calculated as the ratio of MS to MM. Aerobic capacity (VO₂max; Moxus©) and muscle contractility (EMG) were also measured. Muscle biopsies were performed to determine fiber typing, size, intermuscular adipose tissue (IMAT) and intramyocellular lipid content (IMCL).

Results: Absolute MM ($p < 0.001$) and MS ($p = 0.005$) was greater in young participants compared to their older counterparts while MQ was similar between them. Even if total ($p = 0.04$) and type IIa ($p = 0.024$) fiber size were greater in YA than in OA, muscle fiber proportion, muscle contractility and lower limb fat mass (IMAT, IMCL) were similar between both groups ($p > 0.05$).

Conclusion: MQ was similar between younger and older physically active men suggesting that being physical activity may have mitigated the loss of MQ with aging and delayed some physiological age-related changes (muscle composition, contractility).

NS66

EXERCISE TO PREVENT MUSCLE FUNCTION IN DYNAPENIC OR NON-DYNAPENIC OLDER ADULTS: ONE FITS FOR ALL ?

M. Aubertin-Leheudre¹¹Université du Québec à Montréal (UQAM), Montréal, Canada

Background: Age-related muscle function decline could be counteracted through non-pharmacological interventions. First, resistance training is currently the most effective intervention. In addition, it has been shown that aerobic training is as beneficial as resistance training to maintain muscle quality and to mitigate the decline in functional capacities in older adults. However, the majority of older adults are sedentary and one of the main reported barriers is lack of time. Thus, high-intensity interval training (HIIT) with half of time is growing of interests in the field of aging. Indeed, intervening effectively in this process is essential because it will limit the long term needs of health resources, decreased the health care costs, and altogether improve or maintain the quality of life of the elderly. However, this task is not simple since older adults presented a various board of body profile (with or without dynapenia/obesity) which could influence their adaptations.

Objective: To compare muscle adaptation following different types (HIIT versus continuous versus power training) of exercises training in dynapenic-obese older adults.

Methods: A total of obese (fat mass: men>25%, women>35%) with or without dynapenia (grip strength/body weight: women<0.44, men<0.61) older adults were recruited and followed a 12-week exercise (HIIT or continuous or power training) interventions. Body composition; functional and aerobic capacities; absolute or relative upper and lower limbs muscle strength, muscle power; and energy balance were measured pre and post intervention.

Results: At baseline, OB-DY1 performed better than OB-DY2 in all functional tests ($p < 0.05$). Following the intervention, fat (ES = 0.21) and lean (ES = 0.32, $p < 0.001$) masses, functional performance (ES 0.11-0.54, $p < 0.05$), HS (ES = 0.10, $p < 0.05$) and lower limb muscle improved significantly. Regarding the second study, both groups were similar regarding age, BMI, body composition, muscle function, functional capacity, lifestyle habits and adherence. We observed that HIIT induced greater improvements in functional capacities (sit-to-stand, $p = .008$; 4-mWT, $p = .05$; TUG, $p < .001$; 6MWT, $p < .001$) than MICT following a 12-weeks intervention.

Conclusion: Seniors with obesity and severe dynapenia have poorer physical function than those in the early stage of dynapenia. Mixed power training induced beneficial effect in absence or presence of DYN although by slightly different pathway. In addition, although of a shorter duration, our results indicate also that HIIT is more efficient to improve functional capacities than MCIT in dynapenic-obese older adults. In conclusion, we showed that the presence or absence of dynapenia in older adults could influence the efficiency of interventions. Finally, even if mixed power training is considered as a gold standard intervention, HIIT could be a feasible and beneficial interventions in obese dynapenic older adults.

NS67

IMPACT OF NUTRITION DURING EXERCISE INTERVENTION ON MUSCLE ADAPTATION IN OLDER ADULTS

F. Buckinx¹¹University of Liège, Department of Public Health, Epidemiology and Health Economics, Liège, Belgium

Background: High-Intensity Interval Training (HIIT), due to its high effectiveness and short duration, is a promising avenue to prevent also muscle function decline and also metabolic disorders. Therefore, CIT may exert additional beneficial effects when combined with HIIT but their combined effects are unknown in obese older adults. In fact, citrulline (a non-proteinogenic amino acid) supplementation (CIT) was shown, in both rats and young human adults, to increase muscle protein synthesis and increase lipolysis in adipocytes. In addition, the quantity of dietary protein intake, an important factor to maintain physical performance in older adults, has been proposed to influence the muscle adaptation (i.e gains in muscle strength and quality) following an exercise training.

Objective: To examine the influence of initial protein intake during a HIIT intervention and the effects of CIT combined with HIIT on body composition (DXA) muscle function and physical performance adaptations in inactive obese older adults.

Methods: Sedentary obese (fat mass: men>27%; women>35%) older adults completed a 12-week elliptical HIIT program (cycle: 30sec at 85% and 90sec at 65% of maximal age-predicted heart rate; 3 x 30min/week). According to the first aim, subjects were matched and divided a-posteriori into 2 groups according to the amount of protein ingested at each meal: <20g in at least one meal (P20-, n=15, 66.8±3.7 years) and ≥20g in each meal (P20+, n=15, 68.1±4.1 years). To answer to our second question, participants took double-blinded a single and isocaloric 10g-dose of CIT or PLA every day. In addition, all obese subjects were dynapenic (grip strength/body weight: women<0.44, men<0.61). Body composition, functional capacity, muscle strength, muscle power, physical activity level and nutritional intake were measured pre and post-intervention.

Results: No difference was observed at baseline between groups. Following the HIIT intervention, we observed a significant decrease in waist and hip circumferences, an improvement in functional capacities and muscle function ($p < 0.05$). However, protein distribution induced no effect on these adaptations. Finally, and more importantly, HIIT+CIT demonstrated greater improvements in fast-pace Timed Up & Go ($p = 0.04$) and upper limbs muscle strength (absolute and relative) ($p = 0.05$) than HIIT+Placebo.

Conclusion: CIT supplementation when combined to HIIT seems to induce greater improvements in upper limbs muscle strength and walking speed in dynapenic-obese elderly. However, having at least 20g of proteins across meals does not further enhance muscle performance in response to HIIT intervention.



2019 PARIS

WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES

PARIS, France | 2019

Abstract Book

Poster Abstracts

P101

EFFECT OF ERAS ASSISTED MIPPO IN THE TREATMENT OF PROXIMAL HUMERAL FRACTURE

W. Ji¹, B. Weiguo¹

¹Department of Orthopaedics, The First Affiliated Hospital of Xi'an Jiaotong University, Xian, China

Objective: To investigate the effect of ERAS combined with MIPPO in the treatment of proximal humerus fracture.

Method: 32 patients with proximal humerus fractures were randomly divided into ERAS combined with MIPPO group and simple MIPPO group that have 16 cases each. These two kinds of groups have same operation, while the treatment before and after operation were very different. The VAS score, the incidence of complications, the average hospitalization days and cost, the time of beginning to walk postoperatively and functional exercise were compared between these two groups.

Results: Compared with MIPPO group, the VAS score of ERAS combined with MIPPO group was lower than that of MIPPO group. The incidence of nausea and vomiting was 12.5% vs. 43.75%. The average hospitalization day was 5.7±1.3 d vs. 8.2±1.4 d, the average hospitalization cost was 3.1±0.8 w vs. 3.9±0.6 w. The time of beginning to walk postoperatively was 6.2±0.8 h vs. 24.2±2.7 h while the time of beginning functional exercise after operation was 2.1±0.4 d vs. 7.2±1.2 d ($P<0.05$).

Conclusion: ERAS combined with MIPPO can alleviate postoperative pain, reduce postoperative complications, shorten average hospitalization days and cost, bring forward days of walking and functional exercise, which is better for patients' recovery and is worthy for clinical application.

P102

CLASSIFICATION ALGORITHMS FOR PREDICTING THE RISK OF OSTEOPOROTIC FRACTURE

H. Kim¹

¹Gachon University, Seoul, South Korea

Information technology may provide alternative approaches to osteoporosis disease diagnosis. This systematic review was performed to compare the diagnostic accuracy of vertebral fracture assessment. In this study, we examined the potential use of classification techniques on a massive volume of healthcare data, particularly in prediction of patients that may have osteoporosis through its risk factors. For this purpose, we proposed to develop a new solution approach based on random forest decision tree to identify the osteoporosis cases. There has been no research in using the aforementioned algorithm for osteoporosis patient prediction. The reduction of the attributes consisted to enumerate dynamically the optimal subsets of the reduced attributes of high interest by reducing the degree of complexity. A computer-aided system was developed for this purpose. The performance of the proposed model in this study was analyzed and evaluated based on set of benchmark techniques applied in this classification problem.

P103

L3 VERTEBRAL BODY COMPRESSION FRACTURE IN A PATIENT WITH TYPE 2 DIABETES MELLITUS AND VITAMIN B12 DEFICIENCY – RISK FACTORS ASSESSMENT AND THE ROLE OF DENOSUMAB IN ITS CONTROL: CLINICAL CASE PRESENTATION

A. Holub¹, J. Marante Fuertes²

¹Hospital of Jerez de la Frontera, La Granja First Care Center, ²Orthopaedic and Traumatology Department, Hospital of Jerez de la Frontera, Cadiz, Spain

Objectives: Vertebral compression fractures are very common especially in older adults and are usually caused by osteoporosis where mineral bone density became low. This kind of fractures is a growing public health problem with important socio-economic effects in the western countries. Osteoporotic fractures are those occurring from a fall from a standing height or less, without major trauma. They often occur at the midthoracic (T7-T8) spine and the thoracolumbar junction (T12-L1). Fractures may result in significant back pain, leading to inability to perform activities of daily living, and can lead to loss of independence, depression, and chronic pain. Osteoporotic fracture is an important risk factor for subsequent fracture. While the diagnosis can be suspected from history and physical examination, plain radiography, as well as occasional CT or MRI, are often helpful in accurate diagnosis and prognosis. Following the progressively ageing population the prevalence of osteoporosis is increasing and as a consequence, the incidence of spinal compression fractures. Denosumab, a specific inhibitor of RANKL, is a novel antiresorptive therapy for postmenopausal osteoporosis and effectively and quickly reduces the risk of important fractures related to osteoporosis, and that fracture protection persists as long as treatment is given.

Methods: We present a case of a 65-year-old patient with type 2 diabetes mellitus with poor glycemic control ($HbA1c \geq 7\%$), hypertension, and osteoporosis, following a spinal trauma secondary to a casual fall from a standing height. However the first radiological examinations did not show any changes an intense worsening pain of the lumbar spine and a restriction of motion lead to extended investigation. After 14 d from the traumatism, the patient returned to her first care doctor with worsening pain. The radiographs and CT scan showed collapse of the L3 vertebral body. Laboratory studies showed normal complete blood count and biochemistry confirmed *poor diabetic control* with $HbA1c$ value of 8.5% and vitamin B12 deficiency suggesting pernicious anemia. The patient was diagnosed osteoporosis on the basis of both his medical history and radiological and histological findings was diagnosed of L3 osteoporotic fracture and was treated with paracetamol and NSAIDs for the last 20 d.

Results: The patient was referred to the Traumatology consultation where conservative treatment were decided, including bracing with thoracolumbosacral orthosis (TLSO), pain medications (paracetamol, NSAIDs and opioids) and starts treatment with denosumab and B12 supplements with a great response and favorable evolution desestimating surgical treatment. During 2 y of follow-up the patient reestablished painless and full lumbar mo-

tion, did not present new compression fractures and the laboratory test shown HbA1c 5.8% and the deficiency of B12 was not detected.

Conclusion: It is necessary to keep all risk factors for osteoporotic fractures under control in order to prevent new events. Diabetes mellitus and B12 loss are being considered among the most important factors responsible for the increase of the risk of fracture especially in osteoporotic bones. New treatments like denosumab not only acts protecting bone from degradation but also seems to improve glycemic control in diabetic patients. It is also very important for the physicians to have a complete knowledge of the clinical, pathological and radiological characteristics osteoporotic fractures and its risk factors, as to follow a correct diagnostic course enabling to prepare the most suitable therapy.

P104

LOW BACK PAIN IN A 19-YEAR- OLD TEENAGER REVEALING CHONDROBLASTIC OSTEOSARCOMA: CLINICAL CASE REPORT

A. Holub¹, J. Marante Fuertes², A. Pérez Alcántara²

¹Hospital of Jerez de la Frontera, La Granja First Care Center, ²Orthopaedic and Traumatology Department, Hospital of Jerez de la Frontera, Cadiz, Spain

The purpose is to report a case of chondroblastic osteosarcoma in the region of the pelvis with 3 months of evolution. The term osteosarcoma refers to a heterogeneous group of malignancies with bone formation or mesenchymal tissue with histopathological evidence of osteogenic differentiation. The pattern of chondroblastic osteosarcoma represents 1/4 part of all reported cases of this neoplasm. Its histopathological diagnosis is based on the predominance of a chondroid matrix formed in the midst of neoplastic cells.

Case: A 19-year old male patient, presented in several occasions to his first care doctor and to the emergency room complaining of a dull ache in the lower back and thighs. No relevant clinical history. Plain X-ray was normal. The CT analysis exhibited a radiolucent pelvic mass with dispersed areas of radiopacity, with poorly defined and indistinct peripheral edges. The patient was subjected to incisional biopsy and histopathological examination showed the presence of a malignant neoplasm of mesenchymal origin characterized by the presence of irregular bone trabeculae dispersed among mildly atypical chondroblastic cells. The conventional or classical osteosarcoma is the most frequent variant, which develops within the medullary bone. This report illustrates the rapid evolution of one of the histological variants of osteosarcoma. The patient is referred to Oncology Department and resectional surgery is valorated and once rejected chemotherapy is used leaving the patient stable for months.

P105

ACCURACY OF DIGITAL TEMPLATING IN TOTAL HIP ARTHROPLASTY

L. A. Holzer¹, G. Scholler², J. Friesenbichler², W. Maurer-Ertl², A. Leithner²

¹AUVA Trauma Center Klagenfurt, Klagenfurt, ²Medical University of Graz, Graz, Austria

Objective: Preoperative planning is an essential part of total hip arthroplasty (THA). It facilitates the surgical procedure, helps to provide the correct implant size and aims at restoring biomechanical conditions. In recent times, surgeons rely increasingly on digital templating techniques. Although there are many positive effects associated with digital templating, problems remain that have to be taken into consideration. The core objective was to evaluate the impact of the planner's experience on the accuracy of predicting component size by digital preoperative templating. In addition the influence of overweight and obesity (according to WHO criteria), patient's sex and component design on the accuracy of preoperative planning have been analyzed.

Methods: This retrospective study included 632 patients who had primary THA. THAs were all planned with syngo – EndoMap® digital planning software (Siemens Medical Solutions AG). The accuracy of predicting component size has been evaluated by comparing preoperative planned sizes with definitely implanted sizes as documented by the surgeons. The planner's experience was tested by comparing the reliability of preoperative planning done by senior surgeons or residents. The influence of BMI on predicting component size has been tested by comparing the accuracy of digital templating between different groups of BMI according to WHO criteria. The same has been done for evaluating the impact of patient's sex and component design. Mann-Whitney U test and Kruskal-Wallis test have been used for statistical analysis.

Results: The implant size was predicted exactly in 42% for the femoral and in 37% for the acetabular component. 87% of the femoral components and 78% of the acetabular cups were accurate within one size. Digital templating of femoral implant size was significantly more reliable when done by a senior physician. No difference was found for the acetabular component sizes. The BMI also had an impact on estimating the correct femoral implant size. Overweight individuals were significantly harder to plan than normal weight people. Templating obese patients was not that accurate either but showed no significance. Again, the acetabular components were not affected. Furthermore, the design of the prostheses and the patient's sex had no influence on predicting component size.

Conclusion: Experience and overweight correlate with the accuracy of preoperative templating in femoral components. Acetabular components however seem to be independent of these factors.

P106

COMPLICATED TIBIAL PLATEAU FRACTURES IN YOUNG PATIENTS: FUNCTIONAL OUTCOME WITH DUAL PLATING VIA 2-INCISION TECHNIQUE EXPERIENCE OF TWO PUBLIC SECTOR HOSPITALS OF KARACHI, PAKISTAN

A. Q. Qadir¹¹Dow University of Health Sciences, Karachi, Pakistan

Objective: This prospective study was designed to evaluate the functional outcomes of dual plating via a 2-incisions technique for the fixation of tibial plateau fractures.

Method: This prospective study included 94 cases of type V and VI tibial plateau fractures of young patients age range from 15-45 y, operated between Jan 2014 and Dec 2016. Exclusion criteria include patients with multiple fracture on same side or same bone, age >45 y, open contaminated fracture, and patients with head injuries.

Results: Total 94 patients (45 single and 49 dual plating) were operated during the study period of 2 y. 38 (77%) patients in a double plating group regained full flexion (135°) and extension (0°) with a good alignment compared to single plating group, seen in 30 (66%) patients at follow-up.

Conclusion: Dual plating by 2-incision method resulted in better functional outcome in young patients.

P107

ROLE OF ALENDRONATE/TERIPARATIDE IN STEROID INDUCED OSTEOPOROSIS IN DEVELOPING COUNTRIES

A. Q. Qadir¹¹Dow University of Health Sciences, Karachi, Pakistan

Objective: Bisphosphonate therapy is the standard of care for the prevention and treatment of steroid-induced osteoporosis. Studies of anabolic therapy in patients who are taking long-term steroids and are at high risk for fracture are lacking.

Methods: This is double-blinded randomized controlled trial that was conducted in Civil Hospital Karachi from January 2015 to June 2017. In this study comparison of alendronate with teriparatide in 214 women and men with osteoporosis (ages, 22-65 y) who had received glucocorticoids for at least 3 months (prednisone equivalent, 5 mg daily or more). A total of 107 patients received 20 µg of teriparatide once daily, and 107 received 10 mg of alendronate once daily. The primary result was the change in BMD at the lumbar region. Secondary outcomes included changes in BMD at the total hip and in markers of bone turnover, the time to changes in BMD, the incidence of fractures, and safety.

Results: The mean (±SE) BMD at the lumbar spine had increased more in the teriparatide group than in the alendronate group (3.2±0.5% vs. 6.9±0.6%, P<0.001). A significant difference between the groups was reached by 6 months (P<0.001). At 12 months, BMD at the total hip had increased more in the teriparatide group. Fewer new vertebral fractures occurred in the teriparati-

de group than in the alendronate group (6.0% vs. 0.4%, P=0.004); the incidence of nonvertebral fractures was similar in the two groups (3.5% vs. 5.4%, P=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium.

Conclusion: Patients with osteoporosis who were at high risk for fracture, BMD increased more in patients receiving teriparatide than in those receiving alendronate.

P108

EARLY AND MIDTERM SURVIVALS OF UNCEMENTED BIPOLAR HEMIARTHROPLASTY IN ELDERLY OSTEOPOROTIC PATIENTS IN KARACHI, PAKISTAN

A. Q. Qadir¹¹Dow University of Health Sciences, Karachi, Pakistan

Objective: Treatment of unstable intertrochanteric fracture in elderly patients remains challenging. The purpose of this prospective study is to determine clinical and radiological results of cement less bipolar hemiarthroplasty using a fully porous-coated stem in osteoporotic elderly patients with unstable intertrochanteric fractures with follow-up over 1 y.

Methods: This retrospective study is conducted in 22 patients at Dept. of Orthopaedic Surgery Civil Hospital, DUHS Karachi. Exclusion criteria were the patients with age <40 y, with polytrauma and head injury. The patients with isolated neck of femur fractures either traumatic or osteoporotic having age >40 y were included in this study. The study duration is of 1 y from August 2017 to August 2018. All the patients were evaluated clinically as well as radiologically. The mean follow-up duration was 9 months.

Results: 13 cases (60%) showed no decrease in ambulation capacity postoperatively. Radiologically, there were 12 cases (57%) of fixation by bone ingrowth and 10 cases (43%) of stable fibrous fixation. There were no cases of osteolysis. 11 cases (27.5%) of new bone formation were found around the stem. All stems were stable without significant changes in alignment or progressive subsidence.

Conclusion: Cement less bipolar hemiarthroplasty using a fully porous-coated stem is a useful surgical treatment option for unstable intertrochanteric fracture in elderly patients with osteoporosis.

P109

GENDER, SKIN TYPE AND LIFESTYLE AND THE ELIGIBILITY FOR VITAMIN D SCREENING

H. M. Al Attia¹¹Private Practice, Abu Dhabi, United Arab Emirates

Background: It is becoming well known world-wise that low levels of vitamin D are associated with an elevated risk of chronic disorders including malignancies and metabolic disorders. Hypovitaminosis D is also common among the diverse population of the UAE despite the ample year-round sunshine. Many people however, tend to stay indoors avoiding the excessive heat during

the day time while others lead a predominantly an indoor life style because of their social status or the nature of occupation. Several studies in the past have attempted to identify the factors behind the vitamin inadequacy touching upon potential issues for the problem. None however, has addressed the issue of eligibility for vitamin D screening in certain groups of population at risk of deficiency and who will benefit the most from vitamin D correction. This work intends to pave the way for the above purpose and before a nation- wide task force can be initiated.

Methods: Over a period of 6 months , a cohort of 104 adult patients attended the clinic of (Internal Medicine & Rheumatology) for various medical reasons. They themselves requested the estimation of the level of vitamin D . None ,in this group was on vitamin supplementation nor indicated history of chronic renal or liver failure or malabsorption syndrome. Information of demographic characteristics , social and occupational history , daily activity whether (predominantly indoors or outdoor or of both) , skin scale type based on (Fitzpatrick scale) and the dressing style of females (fully concealing clothing ; as subgroup 1, concealing

clothing but with face and hands exposed : as subgroup 2,and others with western clothing style ; as subgroup 3), in addition to results of 25(OH) D assay were sought here.

Results: 91 (87.5%) had level of 25 (OH) D3 less than 30 ng/ml in G1 and 13 expressed normal values (>30ng/ml) in G2, P=0.0001. 65 (71.5%) & 10 (77%) were females in the two groups respectively, P=0.0001. Their age was from (15-72 years) and approximate mean of (41.4+/-12.4 and 44.5+/-13.7 yrs, P=0.47). 25(OH)D3 was significantly higher in G1 (mean of 18.8+/-5.72 vs. 40.8+/-ng/ml in G2) ,p=0.0001. In those with hypovitaminosis D ,the mean of 25(OH)D3 in both genders was equal though (18.6+/- 5.74 in females vs.19.1 +/- 5.76 ng/ml in males, p=0.75). Only 5 patients, ((4 females(6%) & 1 male (4%)) had deficiency levels of < 10 ng/ml (5%). 64 Arab nationals expressed mean of 19.5+/-5.83 vs . a mean of 17.7+/- 5.64 ng/ml in 22 Asian patients , P=0.22. In dress style perspectives, the majority of females 44 (68%) belonged to subgroups 1 & 2 ((8(12.5%) ,& 36 (55.5%)) respectively, vs. 21 as subgroup 3 (32%), p=0.0001. Surprisingly, the mean of 25(OH) D was not different between the three subgroups of dressing style, as all p values were non significant. The distribution of all patients based on Fitzpatrick skin scale is shown in Table 1.

3

Table 1

Patients with low 25 (OH)D (91) :Scale (%)	Patient with normal 25(OH)D (13):scale (%)	P
1 1 (1%)	1 (7.5%)	
2 16 (17.5%)	2 (15%)	1.000
3 52 (57%)	7 (54%)	1.000
4 16 (17.5%)	2 (15%)	1.000
5 5 (5.5%)	1 (7.5%)	0.56
6 1 (1%)	0	

4

The comparison between the mean of 25(OH)D (19.0 +/- in patients with skin scale 2 (the lightest) and each of that in patients with scale 3,4 and 5 did not reveal any statistical significance, P values (NS). The vast majority ((97 , (95.5%)) indicated a predominantly indoor daily activity and the remaining 4 patients (4.5%) indicated both of indoor and outdoor daily activity . The gross social & occupational categorization is shown in Table 2.

Table 2

Category	Number (%)
1.House wives & house maids 38 +2	40 (44%)
2.Various office work personnel including teachers	33 (36%)
3.Skillful (including medical professionals , engineers & technicians	10(11%)
4.Students	6 (6.5%)
5.Police force	2 (2%)

Discussion and Conclusion: Hypovitaminosis D appeared significantly common in this random group of patients who were interested in the estimation their 25(OH)D levels and the females appeared more concerned about that than the males. Nonetheless, the mean values o the 25(OH)D with regard to gender, skin scale type and dressing style in females were not discriminatory. Home or office-based individuals with minimal

5

access to sun exposure formed the bulk in this group hence they may represent the population with highest risk for vitamin D deficiency. These findings should be taken into consideration in future studies aiming at the eligibility for vitamin D screening.

P110

MULTIFOCAL BONE MARROW NECROSIS IN NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA: A CASE REPORT

A. Holub¹, J. Marante Fuertes², A. Pérez Alcántará²

¹Hospital of Jerez de la Frontera, La Granja First Care Center, ²Orthopaedic and Traumatology Department, Hospital of Jerez de la Frontera, Cadiz, Spain

Bone marrow necrosis (BMN) in acute leukemia is a rare histopathological entity at the time of initial diagnosis. However, it represents an important diagnostic and prognostic challenge. It is an uncommon, but not rare cytological and histological entity in both acute myeloid leukemia and acute lymphoblastic leukemia (ALL). The clinical symptoms could be very severe with fatigue, bone pains, fever and alterations as anemia, thrombocytopenia, leucopenia or leukocytosis, coagulopathy, high LDH level, and/or hypercalcemia. The diagnosis is made by bone marrow biopsy. The treatment is based on the associated pathology. The prognosis is generally poor, depending on age, patient clinical history

and severity of the initial pathology. The incidence of BMN seen across a wide range of malignant and nonmalignant hematological disorders. We present a case of 15-year-old boy diagnosed of ALL in February 2018 after presenting severe anemia, progressive fatigue and excessive sweating, hemoglobin concentration was 5.5 g/dl and the differential count indicated lymphocytosis and severe neutropenia. Under a treatment for pain control and chemotherapy ALL SEHOP - PETHEMA 2013 RI with acceptable control in the follow-up. BMN in ALL is a rare phenomenon, but the disease course and its underlying processes are of basis and clinical interest.

P111

METASTATIC MELANOMA IN THE FEMORAL NECK – A PATHOLOGIC FRACTURE IN A 53-YEAR-OLD MALE: A CASE REPORT WITH LITERATURE REVIEW

A. Holub¹, J. Marante Fuertes², A. Pérez Alcántara²

¹Hospital of Jerez de la Frontera, La Granja First Care Center,
²Orthopedic and Traumatology Department, Hospital of Jerez de la Frontera, Cadiz, Spain

Malignant melanoma is a neoplasm with malignant proliferation of melanocytes mainly in the skin, but also can occur in other organs like the esophagus, mucosas, the eyes and the meninges. Even though it represents only 3-5% of primary cutaneous malignancies, malignant melanoma remains the most aggressive one. The incidence of this type of cancer has increased a lot over the last decades. Nowadays, malignant melanoma is responsible for 50% of deaths from skin cancer. Metastatic melanoma or clinical stage 4 melanoma is described when the malignant melanocytes spread from the primary site to the regional or distant lymph nodes and to other organs. The metastatic behavior of malignant melanoma is uncommon because the sites of metastases are widespread compared to other tumors. Even if, in theory, any organ can be invaded by malignant cells, melanoma commonly spreads in certain organs more than in others. It will metastasise mainly in the following organs: skin (other areas), subcutaneous tissue and lymph nodes (50-75%), lungs and area between the lungs (70-87%), liver (54-77%), brain (36-54%), bone (23-49%), gastrointestinal tract (26-58%), heart (40-45%) adrenal glands (36-54%), kidneys (35-48%), spleen (30%), and others. The aim of this case report was to evaluate the histopathological characteristics on a patient with metastases in the femur from malignant melanoma. A review from the literature is also mentioned.

We present a case of metastatic malignant melanoma in the femur with known primary tumour in a 53-year-old male who presents in the Emergency Room complaining of severe pain and functional impotence in the right hip. Some pains in the left thigh and gluteal region were present for about a months, but at a lower intensity. Physical examination, during active and passive mobilisation attempts, reveals major pain in the hip and functional impotence were highlighted. The patient had been admitted with a diagnosis of proximal third right femur fracture on pathological bone, for specialised investigations and treatment. The wholebody scintigraphy examination realised on the third day of hospitalisation revealed a retention area with high intensity and heterogeneous

character in the proximal third of the left femur (trochanteric and shaft region). On SPECT/CT examination detected small areas of retention and heterogeneous character; it is also described the fracture trajectory marked on CT. Diagnosis was confirmed by histopathology. The patient undergoes a surgery with partial replacement of the left hip. In a follow-up presents correct recuperation from the surgery.

Malignant melanoma is a cancer that may metastasise in the skeleton. However most of bone metastases are found in the axial skeleton and they rarely involve the femur, as in our case. Only a few case reports are published in the literature. Clinicians must be aware of the varied clinical manifestations of disseminated malignant melanoma.

P112

ANALYSIS OF THE RISK OF BONE FRACTURES IN ELDERLY WOMEN THROUGH FRAX TOOL

C. Sousa¹, M. L. Oliveira¹

¹Catholic University of Brasilia, Brasília, Brazil

Objective: Evaluate the bone quality of women over 60 y of age through the application of the FRAX Tool.

Method: This is a descriptive, observational and cross-sectional study with quantitative approach and sampling of elderly individuals, consecutively included women, developed in a general gynecological clinic, which provides care to women from all regions of the Distrito Federal, in which a sociodemographic questionnaire and the FRAX tool were applied.

Results: A low risk of fractures in 10 y was observed in 93.2%. The risk of medium/high fractures of 6.8% was similar to other studies. In patients up to 79 y of age, the risk of medium/high fractures through FRAX is 3.7%, and in patients above 80 y, it rises to 45.5%. Another finding of this work is also about the low osteopenia/osteoporosis diagnosis of the study patients.

Conclusion: When comparing the elderly up to 79 years old with the elderly over 80 y, there is a greater variation in the percentage of risk of medium/high fractures, through FRAX. A high rate of falls is still observed in the patients.

P113

PERIPROSTHETIC BONE REMODELING AFTER IMPLANTATION A NEW ANATOMIC CEMENTLESS STEM: ONE YEAR DENSITOMETRIC FOLLOW-UP

J. Lopez Subias¹, M. Lillo Adan, J. J. Panisello Sebastia²

¹Hospital Royo Villanova, ²Hospital Miguel Servet, Zaragoza, Spain

Objective: In order to establish the pattern of bone remodeling caused by a cementless, anatomic implant, we intend to evaluate the changes in BMD observed after surgery in the Gruen zones.

Method: A controlled, prospective study was carried out, in which a group of 37 patients suffering from primary coxarthrosis were densitometrically analyzed over the 1-y period following the im-

plant of an Anato® stem (Stryker). The patient's healthy hip was taken as the control. Any differences in the remodeling pattern were compared according to age, BMI and implant size.

Results: Decreases in BMD were observed after 3 months in all of the zones studied. However, this BMD loss was recovered in all zones by the end of the study, except in zone 7 where a decrease of 7.2% in bone mass was observed. In zones 2 and 6, where more loads are transmitted, bone mass preservation, in accordance with Wolff's law, can be seen. No differences were found in the remodeling pattern in relation to age and BMI. Neither were there any differences related to stem size except in zones 1 and 7.

Conclusions: The Anato® stem achieves an efficient transmission of loads between the stem and the proximal femur, providing enough mechanical loads for bone preservation. It is only in zone 7 where significant bone atrophy can be observed, attributable to the damage that this area suffers during the surgical process and the subsequent stress-shielding caused by the implant design.

P114

MINIMALLY INVASIVE SURGICAL TREATMENT IN OSTEOPOROTIC VERTEBRAL FRACTURES

N. Pardina Lanuza¹, E. Gonzalez Buesa¹, I. Puyuelo Jarne¹, A. C. Laga Cuen¹, A. Aguirre Etxebarria¹

¹Hospital San Pedro, Logroño, Spain

The increase in life expectancy involves the raise of the incidence of osteoporosis. Likewise, the incidence of osteoporotic fractures also increases. Especially the vertebral fractures in osteoporotic postmenopausal women. This forces us to re-examine this subject once more. In some patients with painful vertebral compression fractures it is possible to obtain an analgesic effect by percutaneous vertebroplasty or by kyphoplasty.

In this area, we report the case of a 61-year-old postmenopausal woman with multiple osteoporotic vertebral fractures. Four months after suffering vertebral fractures of T10, T11 and T12, the patient did not show improvement of the dorsal pain, so it was decided to perform kyphoplasty of T10 and T12. At the post-surgical month it was reviewed in consultations, presenting an important pain improvement.

We consider kyphoplasty and vertebroplasty a good option for minimally invasive treatment for our osteoporotic patients with vertebral fractures and poor pain control.

P115

TAKING THE PLUNGE – BUILDING A CASE FOR A FRACTURE LIAISON SERVICE: EXPERIENCE OF A TERTIARY HEALTHCARE INSTITUTION IN SINGAPORE

Y. T. Chau¹, N. Nashi², S. C. Law³, K. H. Goh⁴, S. K. Seetharaman⁵

¹Department of Pharmacy/ Alexandra Hospital/ National University Hospital/ National University Health System, ²Department of Orthopaedic Surgery/ National University Hospital/ National University Health System, ³Department of Medicine/ Alexandra Hospital/ National University Health System, ⁴Department of Geriatric Medicine/ Sengkang General Hospital/ Singhealth, ⁵Department of Geriatric Medicine/ National University Hospital/ National University Health System, Singapore

Objective: To identify (i) the potential gap in osteoporosis treatment post-hip fracture, and (ii) compliance and persistence rate to therapy for justification of resources to set up a fracture liaison service.

Methods: A retrospective study of patients aged >50 admitted for surgical fixation of hip fractures from January 2014 to December 2016 at National University Hospital, Singapore was conducted. Of 532 patients enrolled, 347 had data sufficient for analysis. Key data collected were initiation of osteoporosis treatment (namely bisphosphonates, denosumab, teriparatide), calcium and/or vitamin D supplement, and compliance/persistence rate to therapy. Good compliance was defined as proportion of days covered (PDC) ≥ 0.8 . Persistence was defined as continuous treatment with <30-d permissible gap. Chi-square test, Mann-Whitney test and logistic regression were used, with significance level set at $p < 0.05$.

Results: Only 40.3% of patients were prescribed osteoporosis treatment within 1 year post-hip fracture. Independent treatment determinants include being female ($p=0.020$), screening of DXA scan ($p < 0.001$) and screening vitamin D levels ($p < 0.027$). In addition, only half of the patients (49.7%) were compliant with prescribed treatment. Elderly aged 70-79 ($p=0.026$) were shown to have poorer compliance. The mean PDC of oral bisphosphonates (0.66) was significantly lower than that of denosumab (0.83) ($p=0.032$). Persistence with therapy was also suboptimal (39.3%) especially among elderly aged 70-79 ($p=0.002$) and males ($p=0.017$).

Conclusion: Osteoporosis continues to be a suboptimally managed problem even in high risk patients with hip fracture. This study serves as a call to action for increasing awareness of osteoporosis and consideration of a fracture liaison service to improve treatment compliance especially among high risk individuals.

P116

DIAGNOSIS OF OSTEOPOROTIC CONDITIONS IN PATIENTS WITH COMBINED COURSE OF CHRONIC PANCREATITIS AND HYPERTENSIVE DISEASE BY DETERMINATION OF TARTRATE-RESISTANT ACID PHOSPHATASE

T. I. Viun¹

¹Department of General Practice - Family and Internal Medicine Kharkov National Medical University, Kharkiv, Ukraine

Objective: Disorders of calcium-phosphorus metabolism, which determines the composition and condition of bone tissue, lead not only to quantitative, but also qualitative changes. Population aging increase in patients with calcium-dependent diseases, their comorbidity, create conditions for the development of secondary osteoporosis. Among such diseases consider chronic pancreatitis (CP) and hypertensive disease (HD). Our aim was determination of the content of tartrate-resistant acid phosphatase (TRACP) in the blood serum of patients with combined course of CP and HD, as a bone resorption marker.

Methods: 110 patients were examined - 70 persons with CP and HD (main group) and a comparison group of 40 patients with isolated CP. The groups of those surveyed matched by age (39.4±5.2 and 38.2±4.1) and gender (men predominated - 53.4% and 54.3%). The duration of the history of HD was in the range of 2-10 y, CP 3-8 y. Diagnosis of structural and functional disorders of bone tissue was carried out by method of densitometry. In the study of TRACP used sets DAC - SpectroMed (Moldova) were used. Control results were obtained by examining 78 almost healthy people.

Results: A densitometric study showed that of 40 patients with isolated CP, changes in BMD were recorded in 16 cases (40%). When combined CP with HD - in 32 out of 70 (45.7%). At the same time, in the group with CP, the signs of osteopenia were confirmed in 9 persons (22.5% out of 40 examined), and osteoporosis in 6 (15%). In the group of CP and HD, 19 (27.1% of 70 individuals) and 13 (18.6%), respectively. When studying the TRACP, it was established that the mean increase in the group with isolated CP was 2.72±0.2 units, at the control 0.9±0.15 units. In patients with CP and HD, the level of TRACP was 3.14±0.2 units. At the same time, among patients with osteoporotic changes, in the groups the value of TRACP exceeded 3.12±0.3 units and 3.32±0.2 units, respectively. The level of TRACP tended to increase with an increase in the duration of the anamnesis of the combined pathology, and also slightly higher in female subjects.

Conclusion: The combined course of CP and HD can be the cause of the osteoporotic conditions formation. Anamnesis of the combined course, exceeding 5 y, is the basis for conducting research to identify changes in the structural and functional state of bone tissue.

P117

CORRELATES OF HAND ABNORMALITIES AND MEASURES OF HAND PAIN AND FUNCTION IN OLDER ADULTS

S. M. Mattap¹, L. Laslett¹, K. Squibb¹, K. Wills¹, P. Otahal¹, D. Aitken¹, F. Pan¹, H. Keen², T. Winzenberg¹, G. Jones¹

¹Menzies Institute for Medical Research, University of Tasmania, Hobart, ²University of Western Australia, Crawley, Australia

Objective: To describe associations of abnormal features seen on ultrasound (US) and clinical joint examination and hand osteoarthritis (HOA) reported symptoms.

Methods: Hand joints US and clinical features were assessed in a cohort of community-dwelling older adults (n=519). Hand pain, function, and stiffness were assessed using visual analogue scale (VAS) and Australian/Canadian hand osteoarthritis index (AUSCAN). Grip strength was assessed using dynamometer. Data was analysed using hurdle and linear models, adjusted for age, sex, BMI, and other clinical or US features.

Results: Participants with pain were more female and had more clinical and US features of HOA meet the ACR HOA criteria, had weaker grip strength than participants without pain. Osteophytes (OP) and grey-scale (GS) synovitis were ubiquitous, while power Doppler imaging (PDI) synovitis was common (33%). Number of tender joints was associated with greater pain (VAS, $\beta=1.57$ (95%CI; 1.11, 2.03); AUSCAN pain, $\beta=10.57$ (4.00, 17.13)) and AUSCAN function ($\beta=4.07$ (1.28, 6.86)) and poorer grip strength ($\beta=-0.07$ psi (-0.14, -0.005)); associations with functions were partially mediated by pain. PDI synovitis was associated with greater pain (VAS, $\beta=2.61$ (1.03, 4.19); AUSCAN pain, $\beta=13.07$ (3.82, 22.32)) but not function and stiffness. Joint deformity was associated with poorer function (AUSCAN function, $\beta=4.51$ (1.75, 7.26); grip strength, $\beta=-0.13$ (-0.23, -0.04)) but not pain and stiffness, whereas GS synovitis was independently associated with poorer grip strength ($\beta=-0.22$ (-0.41, -0.04)) but not pain. Nodules ($\beta=0.27$ (0.08, 0.46)) and OP ($\beta=0.51$ (0.03, 0.99)) were independently associated with stiffness. Further adjustment of US features for clinical features (and vice versa) did not change the associations, except for a significant reduction in the effect between nodules and stiffness when adjustments were made for OP.

Conclusion: Tender, deformed, nodulous joints and US-assessed PDI synovitis and GS synovitis were independently associated with hand pain, function or grip strength cross-sectionally. Associations with poor physical function were predominantly mediated through pain; however, tenderness and deformity affected function even after pain adjustment. Therefore, treating synovitis may improve hand pain, but preventing deformity as well as pain may be necessary for improving poor hand function.

P118

THE EFFECT OF COGNITIVE BEHAVIORAL THERAPY ON THE CIRCULATING PROINFLAMMATORY CYTOKINES OF FIBROMYALGIA PATIENTS: A CONTROLLED CLINICAL TRIAL

M. Zabihyeganeh¹, A. Mirzaei¹

¹Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran

Objective: There is no consensus regarding the effect of cognitive behavioral therapy (CBT) in the treatment of fibromyalgia (FM). This study aims to evaluate the effect of CBT on FM patients through the assessment of circulating proinflammatory cytokines.

Methods: A controlled, single-blind, parallel clinical trial was performed with 21 FM patients in each group. Sixteen FM patients in the intervention group (CBT) and 17 FM patients in the control group (waiting list) completed the study. For the intervention group, traditional face-to-face CBT was performed for groups of 10 and 11 patients in 20 sessions. Fibromyalgia impact questionnaire (FIQ), widespread pain index (WPI), circulating IL-6, IL-8, and TNF- α level were evaluated before and after the intervention, using enzyme-linked immunosorbent assay.

Results: Baseline measures were not significantly different between the two study groups. At the final evaluation, the mean FIQ, WPI, serum IL-6 level, and serum IL-8 level were significantly lower in the intervention group ($p=0.05$, $p=0.002$, $p=0.05$, $p=0.036$, respectively). The mean serum TNF- α level was not significantly different between the two study groups at the end of the study ($p=0.69$). No significant correlation was observed between FIQ and serum cytokine concentrations. A positive correlation was found between serum IL-8 level and WPI ($r=0.447$, $p=0.009$).

Conclusion: The circulating levels of IL-6 and IL-8 decreased following the CBT intervention, as well as FIQ and WPI. These results highlight the value of CBT as a safe and efficacious treatment for FM that improves both laboratory and subjective surrogates of FM patients.

P119

A MULTICENTER PROSPECTIVE STUDY ON THE EFFICACY AND SAFETY OF DENOSUMAB IN GASTROINTESTINAL CANCER PATIENTS RECEIVING SHORT-TERM PERIODIC STEROID PREMEDICATION FOR PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (ESPRESSO-02/HGCSG1602)

M. Nakamura¹, T. Muranaka², M. Yagisawa³, Y. Kawamoto², S. Yuki⁴, M. Dazai⁵, S. Sogabe⁶, K. Harada⁷, Y. Kobayashi⁷, T. Miyagishima⁷, N. Okamura⁸, Y. Tsuji⁸, Y. Komatsu²

¹Department of Gastroenterology, Sapporo City General Hospital, Sapporo, ²Department of Cancer Center, Hokkaido University Hospital, Sapporo, ³Department of Gastroenterology, National Cancer Center East, Kashiwa, ⁴Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, ⁵Department of Gastroenterology, Sapporo Medical Center NTT EC, Sapporo, ⁶Department of Medical Oncology, KKR Sapporo Medical Center, Sapporo, ⁷Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, ⁸Department of Medical Oncology, Tonan Hospital, Sapporo, Japan

Objective: We previously reported that short-term periodic premedication of glucocorticoids (GCs) used with chemotherapy for gastrointestinal cancer (GIC) caused the reduction of BMD (ESPRESSO-01 study; Oncologist 2017). Surprisingly, it seems that the BMD decreasing levels due to only the 16-week GC usage in GIC chemotherapy were comparable to that of the 12-month adjuvant aromatase inhibitor therapy for early stage breast cancer patients² or the 12-month androgen deprivation therapy for non-metastatic prostate cancer patients³. We conducted this study to evaluate the efficacy and safety of denosumab for prevention of chemotherapy-induced BMD decrease.

Methods: The eligibility criteria were as the follows: 1) Histologically confirmed GIC, including esophageal, gastric, pancreatic, and biliary cancer; 2) a schedule of periodical intravenous steroid administration as premedication that was weekly, biweekly, or triweekly, and in which >4-week steroid-free intervals were not allowed; 3) high-risk patient with steroid-induced secondary osteoporosis; 4) no prior treatment for osteoporosis. The dose of denosumab is 60 mg administered as a single subcutaneous injection within a week before the induction of chemotherapy. All participants should receive adequate calcium and vitamin D supplementation. The primary endpoint was to investigate the BMD change on lumbar spine between baseline and 16 weeks after induction of chemotherapy.

Results: From April 2017 to Feb 2018, 49 cases were enrolled. Two patients did not meet the inclusion criteria. One patient died before treatment and one patient refused just after enrollment. One case was not measured for BMD at baseline and four cases were not measured for BMD at 16 weeks, due to patient refusal, discontinuation of treatment, and death (42 cases were the full analysis set). In 30 cases (71.4% of FAS), the levels of BMD at 16w were significantly increased compared with baseline and the

average percent change of BMD of lumbar spine was +2.772% (n=42, 95%CI: 1.350% to 4.195%, p<0.0001). The lower limit of 95%CI of BMD variation rate was +1.350 and the primary endpoint was met. No one suffered any bone fracture in FAS population.

Conclusions: We found that denosumab administration could prevent the reduction of BMD and bone fracture.

P120

CIRCULATING ADIPOKINES IN POSTMENOPAUSAL WOMEN WITH AND WITHOUT HIP FRACTURES: BONE-FAT RELATIONSHIP

M. S. Shargorodsky¹

¹Wolfson Medical Center, Holon, Israel

Objective: Circulating adipokines, such as leptin and adiponectin have been considered as having a major role in the bone-fat relationship. The present study was designed to determine the possible impact of adiponectin, leptin and LAR on hip fracture prediction in postmenopausal women hospitalized for fragility fracture.

Method: This monocentric, prospective study consisted of 104 postmenopausal women divided into two groups: Group 1 consisted of 49 subjects hospitalized due to the diagnosis of non-traumatic hip fracture and Group 2 contained 55 postmenopausal women without history of hip fracture.

Results: Circulating adiponectin and leptin levels were significantly higher in Group 1 than in Group 2 (p=0.005 and p=0.044, respectively). LAR was significantly lower in postmenopausal women with hip fracture than women without fracture (2.1±2.2 vs. 4.0±4.5, p=0.011). In general linear model, there was no between-group difference in circulating leptin as well as adiponectin. Nevertheless, significant by-group differences in terms of LAR persisted even after adjustment (p=0.016).

Conclusions: We found that the LAR is an independent predictor of hip fracture in postmenopausal women. Our findings propose LAR as a preferential marker of hip fracture prediction compared to leptin and adiponectin alone. The present study emphasizes the potential role of adipokines in bone remodeling and justifies future studies to elucidate the clinical, genetic and molecular levels of adipokine-bone relationship.

P121

HERACLES STRAIGHT BLADE: A NEW CONCEPT FOR TROCHANTERIC FRACTURES

A. Aguilar¹, E. Corella¹, A. Gómez¹

¹Miguel Servet Hospital, Zaragoza, Spain

Objective: Trochanteric hip fractures are common and devastating injuries especially for the elderly. Surgical treatment is the optimal strategy for managing this kind of fractures as it allows early rehabilitation and functional recovery. Using cephalic blades instead of screws has shown a higher bone stock in femoral head and neck, but still there are complications as cut-out or femoral head displacement. Heracles straight blade has demonstrated a lower cut-out rate and femoral head displacement in comparison with other devices like spiral blades.

Methods: 38 patients with trochanteric fractures (31A1 and 31A2 AO fracture classification) were treated with Heracles proximal femoral nail using cephalic Heracles straight blade. In a follow-up between 3 and 6 months, no avascular necrosis or cut-out were noticed. Also none of them needed revision surgery; most of them recovering the independence level they had before trauma.

Results: Patients treated with Heracles straight blade show good recovery and none of the most frequent complications of trochanteric fracture surgery.

Conclusion: Although further studies are required, this cephalic devise appears as a good option of treatment with low complication level.

P122

QUALITY OF LIFE AFTER BILATERAL ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTIONS

M. Milankov¹, M. Obradović¹, M. Vranješ¹, M. Bjelobrk¹, M. Radomir¹

¹Department of Orthopaedic Surgery and Traumatology, Clinical Center Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia

Objective: To analyze the influence of bilateral anterior cruciate ligament reconstructions on life quality of patients and their return to sports activities.

Methods: 32 operated patients took part in this survey during the period of 10 y. There were 5 women and 27 men, their average age being 30.46 y (19-55). The participants answered a modified Knee Injury and Osteoarthritis Outcome Score questionnaire set and gave data about preoperative and postoperative periods.

Results: The participants' age and parameters of Lysol scale did not correlate significantly with the subjective level of physical activity after the second knee surgery. After the first anterior cruciate ligament reconstruction, 4 participants (12.5%) did not return to trainings, while 28 did (87.5%); 8 patients (25%) did not return to competitions and 24 of them (75%) achieved the competition level of sports activities. After the anterior cruciate ligament reconstruction of contralateral knee, 6 (18.8%) did not return to trainings, while 26 (81.3%) did; 15 patients (46.9%) did not return to competitions, while 17 (53.1%) continued to compete without restrictions. The average values of questionnaire scores were between 95.1-98.2 points.

Conclusion: Resuming the same or higher level of sports activities after the first reconstruction is one of the preconditions for the same injury of another knee. An athlete loses >2.5 y of competitions on average. Operations of additional meniscus ruptures do not play a crucial role in restitution of sports activities. Although we achieved good operative results, only every second athlete with bilateral injury has returned to sports activities without restrictions after the bilateral anterior cruciate reconstructions.

P123

IRISIN IN POSTMENOPAUSAL WOMEN WITH PRIMARY HYPERPARATHYROIDISM: AN INTERPLAY BETWEEN IRISIN AND PTH

A. Palermo¹, L. Sanesi², G. Colaianni², G. Tabacco¹, A. M. Naciu¹, R. Cesareo³, C. Pedone⁴, D. Lelli⁴, G. Brunetti⁵, G. Mori⁶, S. Colucci⁵, S. Manfrini¹, N. Napoli¹, M. Grano²

¹University Campus Bio-Medico, Unit of Endocrinology, Rome,

²University of Bari, Department of Emergency and Organ Transplantation, Bari, ³Santa Maria Goretti Hospital, Latina,

⁴University Campus Bio-Medico, Unit of Geriatric, Rome,

⁵University of Bari, Department of Basic Medical Sciences, Neuroscience and Sense Organs, Section of Human Anatomy and Histology, Bari, ⁶University of Foggia, Department of Clinical and Experimental Medicine, Foggia, Italy

Objective: Irisin is a myokine able to ameliorate bone status, muscle atrophy and it influences also glucose and energy homeostasis. PTH is hormone able to exert several metabolic effects that may interact with irisin's ones. No studies have investigated the biological relation between Irisin and PTH. Our aim was to test the hypothesis that irisin and PTH mutually affect their biological action, we evaluated the FNDC5 mRNA expression in myotubes treated with PTH (1-34) and PTH-R mRNA expression in osteoblast treated with recombinant irisin. To confirm the *in vivo* impact of PTH on irisin, we evaluated irisin serum concentration in postmenopausal women with primary hyperparathyroidism (PHPT) compared to age, sex and BMI matched control subjects with no impairment of calcium/phosphate metabolism.

Methods: C2C12 myotubes were treated with 100 nM of teriparatide for 3 and 8 h or with 100 nM of teriparatide for 6 d, refreshing medium every 48 h. MC3T3-E1 osteoblasts were treated with 100 ng/ml r-irisin for 8 h. Teriparatide-treated myotubes, irisin-treated osteoblasts and untreated controls were subjected to RNA extraction and qPCR analysis. In a cross-sectional, open-label trial, we enrolled 26 PHPT postmenopausal women and 31 age/BMI-matched control subjects with no impairment of calcium/phosphate metabolism.

Results: Both short ($p=0.036$) and continuous ($p=0.006$) teriparatide treatment on myotubes significantly decreased FNDC5 mRNA expression respect to untreated control. R-irisin led to a 50% downregulation of PTH-R mRNA expression compared to untreated cell ($p=0.029$).

Irisin was significantly lower in PHPT group compared to age/BMI-matched controls (4.5 ± 1.1 vs. 12 ± 5.2 $\mu\text{g/mL}$, $p<0.001$). No significant correlation between irisin and BMD or PTH was recorded in PHPT group.

Conclusion: For the first time, our preclinical findings suggest the existence of interplay between PTH and irisin metabolism that seems to be confirmed by the significant reduction of irisin concentration in postmenopausal women with PHPT.

P124

BONE MINERAL DENSITY CHANGES WITH LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM USAGES

M. H. Jung¹, Y. I. Ji²

¹Kyunghee University Hospital, ²Haeundae Paik Hospital, Busan, South Korea

Objective: To evaluate changes in BMD in patients using a levonorgestrel-releasing intrauterine system (LNG-IUS) or a TCu380A intrauterine device (IUD) after 2 y.

Methods: The medical records of all patients who underwent LNG-IUS or TCu380A IUD insertion were reviewed. The patients were 40-45 years old at the time of insertion, had undergone a BMD examination of the femur and lumbar spine before the loop insertion, and had also received a follow-up BMD examination 2 y later. Patients were excluded if risk factors known to affect BMD were noted in their medical records. The 2 groups of patients were compared with regard to age, parity, BMI, and levels of osteocalcin and pyridinoline. Changes in BMI, osteocalcin, and pyridinoline after 2 y were also compared.

Results: The LNG-IUS and TCu380A IUD groups showed no differences in mean age, mean parity, mean BMI, preinsertion or post-insertion BMD values of the femur or lumbar spine, changes after 2 y in the BMD of the femur or lumbar spine, or changes after 2 y in osteocalcin or pyridinoline level ($P>0.05$).

Conclusions: Women using the LNG-IUS for 2 y have changes in BMD and osteocalcin and pyridinoline levels similar to those of TCu380A IUD users. The use of the LNG-IUS for 2 y may have no adverse effect on BMD.

P125

PSORIATIC ARTHRITIS IN A PATIENT WITH EHLERS-DANLOS SYNDROME

N. Roganovic¹

¹Institute of Rheumatology, Belgrade, Serbia

Objective: Psoriatic arthritis (PsA) is a chronic disease which involves the inflammation of synovial tissue, entheses and skin. Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars, easy bruising, and generalized joint hypermobility. We report a case of a 39-year old woman with Ehlers-Danlos syndrome who developed PsA.

Results: Diagnosis of Ehlers-Danlos syndrome was made in early childhood of the patient. The onset of psoriasis occurred soon after that. During the year 2006, she developed joint symptoms and soon the diagnosis of PsA was made. For 3 y the patient was using salazopirin and pronison and then, on her own hand, stopped with the therapy. She felt good for a few years but then again experienced problems with her hand joints. Inflammatory markers were normal and she was anti-citrullinated protein antibody and rheumatoid factor negative. X-ray images of the hand have shown dysplastic changes on the skeleton (probably connected with

Ehlers-Danlos syndrome) and signs of chronic arthritis of both carpal regions. The ultrasound examination revealed the tenosynovitis of some extensor tendons in the right wrist region. The treatment with glucocorticoids and methotrexate was started and she responded very well on this therapy.

Conclusion: In the patient with Ehlers-Danlos syndrome, the development of PsA occurred. The most prominent problems, arthritis of both wrists and tenosynovitis of the right wrist, were completely withdrawn soon after the start of the treatment with glucocorticoids and methotrexate.

P126

PHARMACOKINETICS OF A NEW PHARMACEUTICAL FORM OF A VITAMIN D3 100 000 IU IN SOFT CAPSULE

P. Fardellone¹, J. C. Souberbielle², R. Mentaverri¹

¹CHU d'Amiens Picardie, Amiens, ²Vert le fraud, France

Objective: The bioequivalence, single-dose, open-label, parallel-group, randomized study compared a new developed vitamin D3 100 000 IU soft capsule (Group 1) and the reference drug vitamin D3 100 000 IU oral solution in ampoule (Group 2) in 53 healthy adults (mean age 26.9 y).

Methods: This pharmacokinetic study was conducted in the north of France between February to June 2014. There was no difference between groups for all baseline parameters. Before the treatment, a low serum 25-hydroxyvitamin D (25(OH)D) levels were observed in both groups (10.6 ng/ml in Group 1 and 9.0 ng/ml in Group 2).

Results: As the primary endpoint, the area under the curve (AUC) of serum 25(OH)D concentrations was 2499.4±463.8 nmol/ml (7.8±0.2 for LogAUC) for Group 1 and 2152.3±479.8 nmol/ml (7.6±0.2 for LogAUC) for Group 2 at Day 112. The bioequivalence of both treatments was not demonstrated. A superiority test concluded to a superiority of the soft capsule vs. ampoule using a nonparametric Wilcoxon test, with p=0.029 for AUC and p=0.03 for LogAUC.

Serum 25(OH)D concentration in Group 1 was higher than in Group 2 at all time points (significant at Day 1, Day 3, Day 7, Day 14, Day 90). Mean serum 25(OH)D concentration in Group 1 were between 20-30 ng/ml during the 4 months after administration, while they were under 20 ng/ml during all the study in Group 2, except at Day 112 (21.3 ng/ml). Mean C_{max} for Group 1 (28.5±5.0 ng/ml) was significantly higher (p=0.002) than mean C_{max} for Group 2 (23.9±4.3 ng/ml). Only 14 d were needed to reach T_{max} by more than half of subjects who received vitamin D3 100,000 IU soft capsule whereas 45 d were needed to reach T_{max} in Group 2. However T_{max} value distribution was not statistically different in the two groups (p=0.338).

Both treatments were well tolerated, with no severe or related adverse event reported throughout the study.

Conclusion: The pharmacokinetic profile of the new formulation of the soft capsule was superior to the solution in ampoule.

P127

CHILDHOOD OBESITY AND FRACTURE RISK: A REGION-WIDE LONGITUDINAL COHORT STUDY OF 466,000 CHILDREN AND UP TO 11 YEARS OF FOLLOW-UP

D. Martinez-Laguna¹, K. Butler², J. Poveda¹, C. Reyes¹, J. Lane³, J. De Bont¹, M. K. Javaid³, C. Cooper³, J. Logue⁴, T. Duarte-Salles¹, D. Furniss³, D. Prieto-Alhambra³

¹IDIAP Jordi Gol, Barcelona, Spain, ²Stoke Mandeville Hospital, Aylesbury, UK, ³University of Oxford, NIHR BRC, NDORMS, Oxford, UK, ⁴University of Glasgow, Institute of Cardiovascular and Medical Sciences, Glasgow, UK

Objectives: As childhood obesity increases, there is growing interest in the impact of BMI upon bone health. This study investigated if there is an association between childhood BMI and fracture risk.

Methods: A prospective cohort of children with a valid primary care BMI measurement in Catalonia, Spain at age 4 y (±6 months) between 1/1/2001 and 31/12/2013 were identified in SIDIAP database, and followed up until they turned 15, migrated, died, or until 31/12/2016. Fractures were defined using validated ICD10 codes recorded in primary care. Childhood cumulative incidence (age 4-15 y) was calculated by anatomical location and stratified by BMI category (WHO 2007 growth reference). Cox models were used to estimate hazard ratios (HR) according to BMI.

Results: Of 466,997 children, 9250 (2.0%) had obese range BMIs, 26526 (5.7%) overweight, and 540 (0.1%) underweight range BMIs. We identified 20878 incident fractures. The cumulative incidence of upper limb fracture for children with obese range BMIs was 76.1 per 10,000 (95%CI 58.4-81.1), compared to 62.1 (59.8-63.4) for normal BMI. Lower limb fracture cumulative incidence was 28.7 per 10,000 (18.0-34.1) in those with obese range BMIs and 15.1(13.9-15.7) in children with normal range BMI. Using BMI as a continuous variable, adjusted HR (95%CI) were 1.05 (1.03-1.06) per 1 SD increase for forearm fractures, 1.08 (1.05-1.12) for hand fractures, 1.14 (1.09-1.20) for ankle fractures and 1.15 (1.10-1.19) for foot fractures. Divided by WHO categories, compared to those with normal range BMI, children with obese range BMIs had an adjusted HR (95%CI) of 1.14 (1.0-1.29) for forearm fractures, 1.37 (1.14-1.66) for hand fractures, 1.66 (1.32-2.10) for foot fractures and 1.81 (1.37-2.37) for ankle fractures. Further adjustment for birthweight (available for 310,751 children) did not affect these estimates.

Conclusions: Childhood obesity is associated with a significantly increased risk of forearm, hand, ankle, and foot fractures. The effect of increased BMI upon fracture risk in adults appears to extend to the paediatric population

P128

TWO-YEAR PERSISTENCE WITH TERIPARATIDE IMPROVES SIGNIFICANTLY AFTER EXTENSION OF AN EDUCATIONAL AND MOTIVATIONAL SUPPORT PROGRAM

M. van Maren¹, C. E. Wyers², J. H. Driessen³, J. V. Visser⁴, K. van de Wijdeven⁴, S. Gevers⁴, F. De Vries⁵, W. F. Lems⁶, M. H. Emmelot-Vonk⁷, J. P. van den Bergh⁸

¹VieCuri Medical Center, Department of Internal Medicine, Venlo, ²VieCuri Medical Center, Department of Internal Medicine; Maastricht University, NUTRIM School for Nutrition and Translational Research in Metabolism, Department of Internal Medicine, Venlo, ³Maastricht University Medical Center (Maastricht UMC+), CAPHRI Care and Public Health Research Institute, NUTRIM School for Nutrition and Translational Research in Metabolism, Department of Clinical Pharmacy and Toxicology, Maastricht, ⁴ApotheekZorg, Bladel, ⁵Maastricht University Medical Center (Maastricht UMC+), Department of Clinical Pharmacy and Toxicology, Maastricht, ⁶VU Medical Centre, Amsterdam Rheumatology and Immunology Center, Amsterdam, ⁷University Medical Center Utrecht, Department of Geriatric Medicine, Utrecht, ⁸VieCuri Medical Center, Department of Internal Medicine; Maastricht University Medical Center (Maastricht UMC+), NUTRIM School for Nutrition and Translational Research in Metabolism, Department of Internal Medicine; Hasselt University, Venlo, The Netherlands

Objective: To determine whether an educational and motivational support program (EMSP) increases treatment persistence with teriparatide (TPTD).

Methods: In the Netherlands, one central pharmacy provides TPTD, enabling us to study persistence in all patients who were prescribed TPTD. TPTD was dispensed as a prefilled pen, intended to be used as daily subcutaneous injection of 20 µg TPTD for 28 consecutive days. From January 2013 - February 2014, patients were instructed and followed according to a basic support program (BSP) consisting of an intake, TPTD home delivery, educational home visit and phone calls by a trained nurse (1, 2.5 and 8 weeks after treatment initiation). Since May 2015, the BSP was extended with a medication adherence questionnaire, additional phone call (at 12 months) and motivational letters (at 9 and 14 months), the so called EMSP. The questionnaire was aimed at identifying potential nonpersistent patients and providing them an additional phone call or home visit to emphasize the importance of treatment completion. Patients with treatment initiation between March 2014 - April 2015, received the BSP including the motivational letters (BSP+letters). Patients were classified as persistent if 24-26 pens were delivered. The potential 24-month treatment course was evaluated using age and sex adjusted Cox proportional hazard analyses.

Results: TPTD treatment was initiated in 1573 patients: 649 patients received the BSP, 530 the BSP+letters, and 394 received the EMSP (88% vs. 89% vs. 85% women, mean age 72 y). Two-year persistence was 72% in BSP, 74% in BSP+letters and 78% in EMSP. Reasons for treatment discontinuation were comparable between

groups, except for discontinuation due to side effects, which was lower in the EMSP (8% vs. 15% BSP vs. 12% BSP+letters). Adjusted analyses showed a reduction of 28% for being nonpersistent for patients instructed and followed according to the EMSP compared to the BSP (HR:0.72; 95%CI:0.55-0.93).

Conclusion: Persistence with TPTD improved significantly if patients were instructed and followed by the EMSP including the medication adherence questionnaire. The adherence questionnaire was able to identify patients at risk of treatment discontinuation and allowed targeted interventions by a trained nurse resulting in a reduction of non-persistence during the 24-month treatment course.

P129

FAT MASS DOES NOT INCREASE THE PRECISION ERROR OF TRABECULAR BONE SCORE MEASUREMENTS

C. Messina¹, C. Buonomenna², D. Albano¹, S. Gitto², F. M. Olivieri³, L. M. Scofienza¹

¹Department of Diagnostic and Interventional Radiology, IRCCS Istituto Ortopedico Galeazzi, ²Postgraduation School in Radiodiagnostic, Università degli Studi di Milano, ³Bone Metabolic Unit, Nuclera Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy

Objective: Trabecular bone score (TBS) is a textural parameter that provides indirect information on trabecular microarchitecture, derived from lumbar spine DXA. Previous phantom study on TBS precision error showed no influence after increasing soft tissue thickness. We investigated the effect of progressive increase of BMI and waist circumference on TBS precision error on patients, in comparison to BMD.

Methods: We distributed a population of postmenopausal Caucasian women in 3 different BMI (normal, overweight, class I obesity), plus 2 further groups based on waist circumference diameter (≤ 88 cm and > 88 cm, respectively). In vivo precision error was calculated on 30 consecutive subjects that were scanned two times, with patient repositioning, using the Hologic QDR-Discovery W densitometer. The last available version of TBS (v 2.1) at the time of the study was used. Coefficient of variation, percent least significant change (LSC%) and reproducibility were calculated according to the ISCD guidelines.

Results: Ninety-five women aged 66 ± 10 (mean \pm SD) were included. No significant differences were found both for BMD and TBS precision errors, respectively, when comparing BMI groups and waist circumference groups. BMD reproducibility ranged from 95.9% (BMI > 30 kg/m²) to 97.5% (BMI < 25 kg/m²). TBS reproducibility ranged between 95.8% (BMI = 25-29.9 kg/m², waist circumference > 88 cm) and 96.6% (BMI < 25 kg/m²). With the exception of obese group, a significant difference was found between BMD and TBS reproducibility, being that of TBS slightly lower than BMD. A significant decrease of TBS values was found between normal and obese subjects, as well as between waist circumference groups; BMD variations between groups were not statistically significant.

Conclusions: TBS precision error is not affected by BMI and waist circumference differences. TBS reproducibility showed to be slightly lower than that of BMD, but this difference was mitigated in obese patients. A statistically significant negative association was found between the amount of fat mass and TBS mean values.

Disclosures: CM: travel grant from Abiogen, Sandoz and Bracco. LMS: travel grant from Abiogen, Fidia, Bracco.

P130

TOPICAL ATORVASTATIN AS A POTENTIAL CHONDROPROTECTIVE AGENT IN PATIENTS WITH KNEE OSTEOARTHRITIS

M. Elkasabi¹, A. Saleh¹

¹Mansoura University Hospitals, Mansoura, Egypt

Objective: Osteoarthritis (OA) is considered the leading cause of musculoskeletal disability in the elderly population worldwide. Several studies have shown a potential role of statins as an alternative treatment option for OA, beyond their cholesterol-lowering properties. Topical application of Atorvastatin had proved to induce more anti-inflammatory and hypocholesterolemic effect in rats with OA as compared to other used anti-inflammatory drugs such as Diclofenac. Therefore, Atorvastatin was prepared in a topical gel form to be compatible for human use.

Methods: The study was held at the Rheumatology and Rehabilitation Department in Mansoura University Hospitals in association with the Clinical Pharmacology Department. 60 patients with chronic knee OA were involved in a randomized controlled trial for a period of 12 months. Each patient underwent full history taking, full clinical examination, necessary laboratory investigations, and radiological investigations. The patients were divided equally into 3 groups of each receiving different drug regimen as follows: Group 1 was the control group receiving the ordinary regimen provided by the department staff members (piasclidine 300 mg tablet once/d + diclofenac sodium 75 mg tablet twice/d). Group 2 (Atorvastatin gel 5% + Diclofenac). Group 3 (Atorvastatin gel + Diclofenac + Glucosamine).

Results: All patients underwent a clinical assessment via WOMAC index twice during the whole period of study; pretreatment and 12 months post treatment. The collected data were coded, processed and analyzed using SPSS program. P values <0.05 were considered statistically significant. Group 1 showed a minimal stiffness reduction with an average score of 0.9 pretreatment down to 0.79 post treatment. Whereas Group 2 showed a significant reduction in the WOMAC index from 0.92 pretreatment to 0.44 post treatment. However, adding Glucosamine to Group 3 did not prove to improve the patients' scores as expected compared to results obtained from Group 2 with a reduction from 0.86 to only 0.53, which contributed to about 38.3% of stiffness reduction as compared to basal level. Whereas Group 2 showed a major improvement in the patients' WOMAC index in the form of approximately 52.1% stiffness reduction along the 12 months period of supervised drug regimen.

Conclusion: The results obtained by the use of topical Atorvastatin showed to super pass some commercially widely used chondroprotective agents. Topical Atorvastatin may be used safely and effectively for patients with knee OA.

P131

KNEE OSTEOARTHRITIS: INITIAL RADIOLOGICAL RESULTS IN TOTAL KNEE ARTHROPLASTY – COMPARISON BETWEEN CONVENTIONAL TECHNIQUE AND COMPUTER-ASSISTED SURGERY

A. C. Urgel¹, M. Ranera¹, M. Fadil¹, M. Royo¹, A. Rillo¹, J. García¹

¹Obispo Polanco, Teruel, Spain

Objectives: Many authors support the greater precision of computer-assisted surgery (CAS). The aim of this study is to analyse the differences in the femorotibial mechanical axis measured in telemetric radiographs when implanting a total knee arthroplasty comparing conventional surgery and CAS.

Methods: Retrospective observational study to evaluate the pre-operative radiological results and at 3 months of follow-up of the patients treated with Optetrak Logic® total knee arthroplasty between February 2016 and November 2017. We also analysed age, sex, operated knee, Ahlbäck classification, duration of the intervention and complications.

Results: There were 54 cases registered. Of the 28 patients operated by conventional surgery, 23 (82.1%) had a varus alignment, 3 (10.7%) normal alignment and 2 (7.1%) valgus alignment. Of the 26 patients operated on by CAS technique, 13 (50%) had a varus alignment, 6 (23.1%) normal alignment and 7 (26.9%) valgus alignment, with significant differences (p=0.039). The results for conventional surgery are 23 patients (82.1%) within±3° of varus/valgus and 5 patients (17.9%) out of range. All 26 patients (100%) treated by CAS were found within±3° of varus/valgus. These results were statistically significant (p=0.024). No differences were found between the different techniques and surgical time (p=0.98).

Conclusions: Numerous studies have shown that misalignment can lead to premature failure. They also seem to suggest that an alignment within±3° of the femorotibial angle in the frontal plane reduces this risk. Our results show that 100% of patients operated on by CAS were within the range of±3° of varus/valgus. In our environment, the CAS has proved to be a useful tool to improve the alignment without increasing the surgical time, which has made it currently our preferred technique.

P132

KNEE OSTEOARTHRITIS: ASSESSMENT OF SHORT-TERM FUNCTIONAL RESULTS AFTER UNICOMPARTMENTAL KNEE ARTHROPLASTY

A. C. Urgel¹, J. A. Blanco¹, M. Royo¹, A. Rillo¹, J. García¹, M. T. Espallargas¹

¹Obispo Polanco, Teruel, Spain

Objectives: Numerous studies indicate the advantages that the unicompartmental knee arthroplasty can provide reduction of postoperative morbidity, reduction of length of stay in hospitals, reduction of rehabilitation time and good cost-benefit ratio with a good long-term result. The aim of this study is to analyse the short-term functional results of the patients undergoing surgery through unicompartmental knee arthroplasty.

Methods: A retrospective observational study to evaluate the short-term functional results of patients undergoing Oxford® unicompartmental knee prosthesis between January 2012 and December 2017. Among the variables included: time to sitting and walking, length of stay, postsurgical flexion-extension, final flexion-extension and complications.

Results: 8 patients were included, with a mean age of 58.25 y (SD 10, 67). The average time until walking was 2, 12 d (SD 0.35). The hospital stay was of 3.38 d on average (SD 0.52). The patients received 9.38 sessions of physiotherapy average (SD 5.45), for a period of 47.88 d on average (SD 38). The average final flexion was 109, 38° with 1 SD (SD 7.76) and the mean final extension was -1.25 (SD 2.31). The mean total gain was 25, 63° of flexion (SD 6.23) and of 6.25° of extension (SD 6.4).

Conclusions: In general, these patients are discharged early and require less physical therapy, all associated with high survival rates. In our study we found an early sitting and ambulation, with a short hospital stay. As for the joint balance, the average total gain was 25, 63° of flexion (SD 6.23) and of 6.25° of extension (SD 6.4). We can conclude that this technique is satisfactory in the short term in our environment from the functional point of view, provided that strict inclusion criteria are followed.

P133

TERIPARATIDE AS COADJUVANT TREATMENT IN SEVERE OSTEOPENIA AFTER FAILURE OF MULTIPLE SURGERIES DUE TO FRACTURE OF THE DISTAL FEMUR

A. Rillo Lazaro¹, P. Muniesa Herrero¹, A. Urgel Granados¹, M. Royo Agustin¹, T. Espallargas Doñate¹, A. Castro Sauras¹

¹Hospital Obispo Polanco Traumatology, Teruel, Spain

Objective: To analyze the usefulness of teriparatide to increase bone formation and osseous consolidation in the specific case of a young patient with severe osteopenia who has undergone four surgical operations in four months due to their failure after a femur supracondylar fracture after a large fall.

Methods: We analyzed the radiographs and the clinical and functional evolution of our 54 years old patient who suffered a supracondylar fracture of the femur after a long fall. In the first moment damage control surgery was performed with an external fixator, two weeks later we performed closed reduction and internal fixation with a plate and screws, three months later this surgery failed and the fracture lost adequate reduction, factors that favored this failure are the great destruction of the distal femur, the loss of bone stock and the poor quality of it, which hindered the adequate consolidation. The fracture was immobilized provisionally with a new external fixator and later it was fixed by intramedullary nailing with a femur retrograde nail. The patient after leaving the hospital began the treatment with teriparatide (20 ng/24 h) in order to accelerate the consolidation of his fracture and increase the bone stock.

Results: In the control radiographs five months after the last surgery, a clear increase in bone density and formation of new bone was observed, and the patient is currently completing his rehabilitation satisfactorily. The consolidation of the fracture is satisfactory and the patient is clinically and functionally well.

Conclusion: In cases of severe fracture with a large loss of bone stock and poor bone quality, teriparatide can be an advantageous treatment to improve bone stock and accelerate the healing of a fracture during recovery even in nonelderly patients.

P134

USE OF TERIPARATIDE AS A COADJUVANT THERAPY IN THE TREATMENT OF SEVERE OSTEOPENIA AFTER THE FAILURE OF MULTIPLE INTERVENTIONS IN FRACTURE-LUXATION OF PROXIMAL HUMERUS

M. P. Muniesa Herrero¹, A. C. Urgel Granados¹, M. Royo Agustin¹, A. Rillo Lázaro¹, A. Castro Sauras¹

¹Hospital Obispo Polanco, Teruel, Spain

Objective: Osteoporosis and fracture of the proximal humerus in postmenopausal women is closely related. It is a challenge for the orthopedic surgeon that implies a decrease in the quality of life of the patient and the frequent need for numerous surgical interventions. All this entails an increased risk of complications and health costs.

Methods: A 66-year-old woman with a medical history of high blood pressure and dyslipidemia. Surgical intervention: amidectomy. In usual treatment with Indapamide 2.5 mg and Paroxetine 20 mg. After falling down stairs of his home, he presents fracture-dislocation of the right proximal humerus (13-09-14). During 2 y, 4 surgical procedures were performed. First intervention: failure of osteosynthesis attempt due to anesthetic problem (13-09-14). Second intervention: anatomical hemiarthroplasty (16-09-14). Third intervention: inverted shoulder prosthesis (07-22-16). Fourth intervention: Replace PIH + paresia radial nerve pro cement extravasation (19-12-16). One month after the last intervention, treatment begins with rehabilitation and treatment is started with teriparatide at a dose of 20 ng/d (after ruling out analytical alteration of the levels of calcemia, hepatic or renal alterations).

Results: In subsequent radiological controls an increase in bone density and formation of new bone is observed. In October of 2017, Rehabilitation consultations with dependency for basic activities of daily life are registered. Slight limitation 4/5 of the

Daniels scale, abduction of first finger and extension of fourth and fifth fingers. In September 2018, he was discharged from Traumatology clinics for clinical improvement and without radiological changes.



Conclusion: After the surgical failure on 4 occasions, it was decided to associate the peptide derived from the PTH subcutaneously, to increase the qualitative and quantitative properties of the bone tissue. (Dec.16 / Dec.18). Its anabolic effect is due to the stimulation of osteoblasts, which causes an increase in both cancellous and cortical bone, thus increasing bone strength.

P135
THREE SPINE OSTEOPOROTIC FRACTURES FOR 6 MONTHS IN AN ELDERLY MAN

M. Angulo Tabernero¹, A. Loste Ramos¹, E. Suñen Sanchez¹, D. Peña Jimenez¹, A. Tabuenca Sanchez¹, A. Charlez Marco¹, J. Rodriguez Vela¹

¹Hospital Universitario Miguel Servet, Zaragoza. Spain

The aging of the population, with a higher prevalence of osteoporosis, conditions an increase in the fragility and loss of resistance in the bone, which favors the appearance of fractures after minor traumatism. Osteoporotic spine fracture is one of the most prevalent osteoporotic fracture. It constitutes an epidemy that increases yearly. Osteoporosis is considered an elderly women disease but with increasing prevalence of osteoporosis we see fragility fractures in men.

We present the case of an octogenarian patient who, in <6 months, suffered three fractures without a traumatic history. The first one affected to L5. It was treated a kyphoplasty of the same. Two months later, the second fracture affected L4 causing lumbar pain and acute stenosis of the canal that required posterolateral lumbar arthrodesis and decompression. In the immediate postoperative period, he suffered a third thoracolumbar fracture treated with kyphoplasty of the fracture and prophylaxis vertebraloplasty of the adjacent vertebra because of the high risk of a new fracture. Currently the patient is under treatment for osteoporosis with calcium and vitamin D and teriparatide. The risk of suffering a vertebral fracture due to osteoporosis increases after the appearance of the first fracture. Kyphoplasty allows rapid clinical improvement and functional recovery of the patient.

P136
PANTERA PLATE IN THE TREATMENT OF OSTEOPOROTIC PROXIMAL HUMERUS FRACTURE

M. Lillo Adan¹, J. Lopez Subías¹

¹Hospital Rojo Villanova, Zaragoza, Spain

Objective: The “Pantera plate” is an alternative for the treatment of osteoporotic proximal humerus fractures. Proximal humerus fracture, is the third most common osteoporotic fracture in our area. 70% of cases affect women with osteoporosis. The aim of this study was to evaluate clinical and radiographic short-medium term results of the pantera plate in the treatment of osteoporotic proximal humerus fracture in 3 and 4 fragments.

Methods: A retrospective study was performed in our hospital, on 44 patients undergoing pantera plate from 2010-2012. The indications for surgical intervention were osteoporotic proximal humerus fracture in 3 and 4 fragments. Patient-oriented outcomes were obtained using the Constant score postoperatively at 3, 6, 12, 24 months. In addition, functional ranges of motion were measured in forward elevation and internal and external rotation. Preoperative and postoperative visual analog scale were recorded.

Results: The mean patient age was 78.6 y (range, 51-85 y). The mean follow-up was 4.3 y (range, 6 months - 6 y). 85% of the patients were women. 59% were right shoulders and 41% left shoulders. The average preoperative pain score was 7, with a range from 5-9. Preoperative constant score averaged 21,9, with a range from 16-29. Postoperatively, all scores improved with a mean pain score noted at 1, range 0-6; mean constant 40.5, with a range 23-55; mean abduction was 70, forward elevation was 80°, external rotation of 41°, internal rotation 43°. 25 patients were satisfied with the functional results of surgery while 13 were somewhat dissatisfied and 6 were dissatisfied. The overall incidence of complications was 12 cases, 2 cases of infection, 4 cases of avascular necrosis, 6 cases of nonunion.

Conclusions: Pantera plate is a therapeutic option for the treatment of proximal humerus fracture, providing good pain relief, but their long-term functional results are not entirely satisfactory than expected, design improvements are necessary in order to achieve better results.

P137

THE IMPACT OF PSORIATIC ARTHRITIS VS. PSORIASIS ON INCOME, EMPLOYMENT, HOUSING STATUS, RELATIONSHIPS, AND SOCIAL ACTIVITIES: AN OBSERVATIONAL STUDY

C. Gallaher¹, A. Kaul²

¹Emergency Department, St Helier Hospital, Carshalton,

²Department of Rheumatology, St George's Hospital, London, UK

Objective: Investigate if psoriatic arthritis (PsA) affected patients' ability to lead a 'normal' life compared to patients with psoriasis affecting the skin/nails only (PsO).

Methods: An observational study was undertaken at Royal Free Hospital, London, U.K. Adults attending rheumatology or dermatology outpatients were recruited using convenience sampling. In total, 94 (male=56; 60%) PsA patients and 34 (male=27; 79%) PsO patients consented.

Results: A greater proportion of PsA patients were not working (PsA: 39.4% vs. PsO: 14.7%; $P=0.009$), were more likely to describe themselves as "permanently sick or disabled" (PsA: 13.8% vs. PsO: 0%; $P=0.040$), and were more likely to be receiving state benefits (PsA: 28.7% vs. PsO: 2.9%; $P=0.002$). Of those in work, the median weekly hours worked was lower for PsA patients (PsA: 37.8 h vs. PsO: 40 h; $P=0.038$). A greater proportion of PsA patients lived in social housing (PsA: 26.6% vs. PsO: 8.8%; $P=0.002$), and reported that their physical health had at least moderately interfered with their normal social activities in the previous 4 weeks (PsA: 57.4% vs. PsO: 23.5%, $P=0.000$). There was no significant difference in median salary (PsA: £35,000/year vs. PsO: £40,000/year; $P=0.168$) between PsA and PsO patients. PsA patients did not report significantly greater difficulty in forming relationships as a result of their disease compared to PsO patients ($P=0.379$), or in the quality of their relationships as a result of their disease ($P=0.681$), nor was there a significant difference between the groups in the proportion of patients who were married or in civil partnerships ($P=0.927$).

Conclusion: PsA patients' ability to lead a 'normal' life is impaired compared to patients with PsO.

Acknowledgments: Dr Sandy McBride, Consultant Dermatologist, Royal Free Hospital; Dr Philip Sedgwick, Reader in Medical Statistics and Medical Education, St George's, University of London

P138

HEREDITARY MULTIPLE EXOSTOSES MISDIAGNOSED AS RHEUMATOID ARTHRITIS

H. M. Elhadary¹

¹Kasr Alaini Medical School, Cairo, Egypt

Making a diagnosis of rheumatoid arthritis (RA) is often tricky. With no single test that confirms or eliminates the disease, the diagnosis of RA is based on a physical exam, patient history, laboratory tests and often imaging. However, symptoms of RA, such as pain, swelling and fatigue, are not exclusive to the disease. And correct diagnosis is important in choosing an appropriate treatment plan. A number of diseases, such as lupus, fibromyalgia or Sjögren's syndrome, may easily be confused with RA, or coexist in a patient. Arthritis symptoms might develop following certain infections, such as Lyme disease, tuberculosis, gastrointestinal infection or sexually transmitted diseases. Patients with certain cancers, such as large granular lymphocyte leukemia, have an increased incidence of RA, an acute leukemia in children may even be misdiagnosed as idiopathic juvenile arthritis. In this case report a 25 years old male patient presented with arthralgia, fatigue, swelling of swelling of all MCPs, PIPs both wrists and knees, tender shoulders, Limited range of motion of right elbow, limitation of ROM of knees, severe cervical muscle spasm, was misdiagnosed as rheumatoid arthritis with 2ry Sjogren's syndrome with no response to treatment; imaging revealed multiple exostoses at distal end of Rt radius, ulna and distal femoral and tibial end.

P139

TOTAL KNEE ARTHROPLASTY IS A SAFETY PROCEDURE FOR OCTOGENARIAN PATIENTS

M. Royo Agustin¹, M. Osca Guadalajara², A. J. Urgel Granados¹, A. Rillo Lazaro¹

¹Hospital Obispo Polanco, Teruel, ²Hospital, Valencia, Spain

Objective: Nowadays, higher activity is demanded by octogenarian people as they preserve better quality of life than formerly. Therefore, the number of total knee arthroplasty (TKA) in these patients has been increased. Despite of this, its indication is still controversial as they are also supposed to present a higher risk of complications. Our aim was to determine if age is really a contraindication of performing TKA.

Methods: A retrospective study with 120 patients, operated on TKA in our hospital during 2010 and 2012, has been performed. It has been compared comorbidities, mortality, complications in-hospital and after the hospital discharge between group A (60 octogenarian patients) and group B (60 patients younger than 80).

Results: No statistical differences due to comorbidities, mortality, in-hospital stay or before hospital discharge complications or rehabilitation have been found. However, hospital stay and the need of transfusion have been greater for group A (octogenarians), with a relative risk (RR)=1,88 (IC 95% 1,1-3,1 $p>0,05$) for the last one.

Conclusion: Therefore, we can affirm that age is not a contraindication of TKA. However, we should try to decrease the need of transfusion and consider that more social resources may be needed after the hospital discharge in octogenarian patients.

P140

ASSESSMENT OF NUTRITIONAL STATUS AND BOWEL HABITS IN OSTEOPOROSIS: A CROSS-SECTIONAL, MULTICENTER STUDY OF TURKISH ELDERLY FEMALE POPULATION

A. Y. Karahan¹, S. Bagcaci², B. Ordahan³, B. Sevinc⁴, K. Ozkuk⁵, B. Kuran⁶, N. Sahin⁷, A. Karakoyun⁸, E. Salbas⁹, S. Ketenci¹⁰, P. Yildirim¹¹, B. Uysal¹², O. Sert², G. Gokmen¹³, E. Kaydok⁹, S. Savas¹⁴, M. Sahin¹⁵, B. Sarifakioglu¹⁶

¹Faculty of Medicine of University of Usak / Department of Physical Medicine and Rehabilitation, Usak, ²Faculty of Physical Therapy and Rehabilitation of KTO Karatay University / Department of Physical Medicine and Rehabilitation, Konya, ³Konya Training and Research Hospital of health Science University / Department of Physical Medicine and Rehabilitation, Konya, ⁴Faculty of Medicine of Usak University / Department of General Surgery, Usak, ⁵Faculty of Medicine of Usak University / Department of Medical Ecology and Hydroclimatology, Usak, ⁶University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital / Department of Physical Medicine and Rehabilitation, Istanbul, ⁷Faculty of Medicine of University of Balikesir / Department of Physical Medicine and Rehabilitation, Balikesir, ⁸Faculty of Medicine of Aksaray University / Department of Physical Medicine and Rehabilitation, Aksaray, ⁹Department of Physical Medicine and Rehabilitation, University of OHD Nigde, Nigde, ¹⁰University of Giresun/ Department of Rheumatology, Giresun, ¹¹Kocaeli Health Sciences University Derince Training And Research Hospital / Department of Physical Medicine and Rehabilitation, Kocaeli, ¹²Ababant Izzet Baysal University Izzet Baysal Physical Medicine and Rehabilitation Training and Research Hospital / Department of Physical Medicine and Rehabilitation, Bolu, ¹³Seferihisar Necat Hepkon State Hospital / Department of Physical Medicine and Rehabilitation, Izmir, ¹⁴Karapinar State Hospital / Department of Physical Medicine and Rehabilitation, Konya, ¹⁵Magnet Hospital / Department of Physical Medicine and Rehabilitation, Kayseri, ¹⁶Faculty of Medicine of Namik Kemal University, Tekirdag / Department of Physical Medicine and Rehabilitation, Tekirdag, Turkey

Objective: To investigate the differences in nutritional status and bowel habits between osteoporotic and nonosteoporotic elderly females

Methods: Design: A multicenter cross-sectional study. **Setting:** 12 different provinces of Turkey. **Subjects:** A total of 1224 elderly free-living postmenopausal Caucasian women (age>65). This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the University of Usak Human Research Ethics Committee (HREC) approval number HREC/2018/11. The study was conducted in outpatient clinic of 15 different physical medicine and rehabilitation clinics

from 12 different provinces. Participants were informed that the study aimed to determine the differences in nutritional status and bowel habits between osteoporotic and nonosteoporotic elderly females. Written informed consent was obtained from all participants. Inclusion criteria: elderly women (>65) who were performed DXA scans (lumbar spine and hip scan) within 1 month, volunteers for the study who had not received previous treatment for osteoporosis. Exclusion criteria: Chronic glucocorticoid use, malignancy, metabolic bone disease, neurogenic bladder, neurogenic bowel, other malnutrition diseases, use of drugs causing malabsorption, use of drugs causing constipation, nonambulatory status renal failure, and rheumatologic disease. Evaluated variables; Nutritional status as determined by the Mini-Nutritional Assessment (MNA). Bowel habits as assessed by gastrointestinal symptom rating scale (GSRS) and Bristol Stool Form Scale (BSFS). Measurements of BMD of the lumbar spine and left hip using DXA. BMD: DXA measurements were evaluated with the criteria of WHO. T-score between -1.0 and -2.5 accepted as osteopenia and -2.5 and below T-scores accepted as osteoporosis. The patients were divided into the nonosteoporotic group (NOP), osteopenic (OPN) and osteoporotic (OPR) groups. Statistical analysis: The SPSS for Windows 12.0 software package was used for the statistical evaluation of the data. All data were analyzed separately for women and men. Descriptive statistics were analyzed and reported as mean (with standard deviation), or as percentiles as appropriate. One-way ANOVA (analysis of variance) for comparing for three groups on each variable.

Results:

	NOP 586 (47.9%)	OPN 369 (30.1%)	OPR 269 (21.9%)	p
Age (years)	69.8± 5.5	71.4±6.3	74.4±7.8	< 0.05
BMI (kg/cm ²)	28.7±4.7	28.4±4.1	27.6±4.9	> 0.05
Vitamin D	14.47±7.9	15.78±8.8	10.32±8.8	< 0.05
Mid-arm C (cm)	29.1±4.6	28.8±4.1	27.4±4.6	> 0.05
Hemoglobin	12.75±2.36	11.95±2.48	11.24±1.97	> 0.05
Vitamin B12	345.48±87.15	359.51±101.4	284.97±115.78	> 0.05
IoL (glass/day)	10.2±6.8	9.8±7.4	8.7±7.1	< 0.05
MNA	25.4±4.2	24.2±4.1	23.1±5.3	< 0.05
BSFS	2.62±1.54	2.44±1.50	1.75±1.11	< 0.05
GSRS				
Reflux	3.86±1.12	3.80±1.18	3.88±1.23	> 0.05
Abdominal pain	3.0±1.45	3.16±1.53	3.26±1.69	> 0.05
Indigestion	3.34±1.14	3.31±1.26	3.59±1.73	> 0.05
Diarrhoea	1.85±0.45	1.16±0.29	0.98±0.18	> 0.05
Constipation	2.96±0.89	3.05±1.12	3.54±1.48	< 0.05

NOP: non-osteoporotic group, OPN: osteopenic group, OPR: osteoporotic group, MNA, Mini Nutritional Assessment Bristol Stool Form Scale (BSFS), GSRS; Gastrointestinal-symptom rating scale, Mid-arm C: Mid-arm circumference (cm), IoL: Intake of liquids (glass/day)

Conclusion: In general, the nutritional status was good in our study population. However, we found poorer status in nutrition and bowel habits in osteoporotic patients. While some similar results detected in four symptom clusters of GSRS (reflux, abdominal pain, indigestion, diarrhea), constipation was significantly more often in osteoporotic patients according to both GSRS and BSFS results. Healthcare professional should be careful to add the right amount of fiber to osteoporotic diets.

P141

MYOSTATIN AND INSULIN GROWTH FACTOR-1 ARE BIOMARKERS OF MUSCLE STRENGTH, MUSCLE MASS AND MORTALITY IN HEMODIALYSIS PATIENTS

P. Delanaye¹, S. Bataille², K. Quinonez¹, F. Buckinx³, X. Warling⁴, J.-M. Krzesinski¹, H. Pottel⁵, S. Burtey⁶, O. Bruyère³, E. Cavalier⁷

¹Department of Nephrology Dialysis and Transplantation, University of Liège, CHU Sart Tilman, Liège, Belgium, ²Centre de Néphrologie et Transplantation Rénale, Assistance Publique des Hôpitaux de Marseille, Marseille, France, ³Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart Tilman, Liège, Belgium, ⁴Department of Nephrology-Dialysis, Centre Hospitalier Régional (CHR) "La Citadelle", Liège, Belgium, ⁵Department of Public Health and Primary Care @ Kulak, University of Leuven, Kulak, Kortrijk, Belgium, ⁶Aix-Marseille University, INSERM, INRA, C2VN, Marseille, France, ⁷Department of Clinical Chemistry, University of Liège, CHU Sart Tilman, Liège, Belgium

Objective: Muscle strength is frequently altered in hemodialysis patients. In the present work, five potential muscle biomarkers have been studied in their ability to assess muscular strength, muscular mass and to predict mortality of hemodialysis patients: activin-A, procollagen III N-terminal peptide, follistatin, myostatin and insulin-like growth factor-1 (IGF-1).

Methods: In the current observational prospective study, three independent cohorts of prevalent hemodialysis patients (2 from Liège, Belgium and 1 from Marseille, France) were considered. The biomarkers were first measured in the Liège1 cohort. Two of them, myostatin and IGF-1, were then assessed in the whole population of patients (Liège1, Liège2 and Marseille). Muscle strength was assessed with handgrip strength (HGS) and muscle mass with bioimpedance analysis. One-year mortality predictive value of biomarkers was also studied in the Liège1 and Marseille cohorts.

Results: In the Liège1 cohort (n=67), HGS was only associated with concentrations of myostatin and IGF-1. These associations were confirmed in the whole population of 204 patients ($r=0.37$, $p<0.001$ and $r=0.46$, $p<0.001$, respectively) and remained significant ($p<0.05$) in multivariable models. The association between muscle mass and concentrations of myostatin and IGF-1 were also significant. The ability of myostatin, IGF-1 and serum creatinine to detect a low HGS compared by Receiver Operating Characteristic curves analysis were not significantly different. Both myostatin and IGF-1 had a significant and comparable area under the curve to predict one-year mortality: 0.73 (95%CI: 0.64 to 0.83) and 0.72 (95%CI: 0.61 to 0.82), respectively.

Conclusion: Our results suggest that myostatin and IGF-1 are two biomarkers of interest to assess muscle status of dialysis patients. Both biomarkers are associated with HGS, muscular mass, and one-year mortality.

P142

HIGH FORCE SHORT DURATION COMPRESSION FORCES ON BONE RESULTS IN SIGNIFICANT OSTEOBLASTIC ACTIVITY

J. Conviser¹, J. Koehler²

¹Ascend - Consultation in Healthcare, Chicago, Illinois, USA,

²Performance Health Systems, Northbrook, Illinois, USA

Objective: The relationship between bone geometry and mechanical influences on bone and suggests that when significant forces are applied to bone, the compression will stimulate an adaptive response, commonly known as Wolff's Law. While the American College of Sports Medicine recommends exercise as a treatment for those diagnosed with osteoporosis, traditional exercise has not been able to create the forces needed to stimulate bone growth in a safe and effective manner. A three year study conducted in multiple clinical locations with a novel apparatus allowed for significant compressive force to the level required to have an effect on the osteoblastic function offering high force production within a short duration, i.e. osteogenic loading (OL) was utilized. OL has been suggested as a non-pharmaceutical option to improve bone health. The purpose of this study was to examine if OL was 1) safe when generating forces required for osteoblastic function and 2) effective for individuals dealing with osteoporosis.

Methods: Twenty-six women ranging in age from 41-87 y from three independent clinical locations with a diagnosis of osteoporosis were selected to participate in a one-year study using an exercise device that allows the individual to create significant forces on the bone with four unique exercise movements. Since the study was conducted over a three year period, a subset of the 26 subjects (9 individuals) were followed for one additional year after the conclusion of the 48 sessions to determine if additional benefits could be obtained with additional exposure to higher forces on bone. All three centers had the same equipment, settings and protocol. Subjects completed a minimum of 48 sessions once a week over the year, each session lasting approximately 15 min. DXA scans were conducted at the same testing location for both pre-and post-assessments. Subjects self-reported their body weight, weekly minutes of traditional exercise, diet and prescription medications.

Results: Of the 26 subjects, 16 individuals demonstrated a significant reduction (improvement in bone) in their mean DXA score, 6 had no significant change and 4 individuals showed a further degradation in their bone density. Within the 4 movements (chest press, leg press, abdominal crunch and vertical lift), forces generated were 2x - 10x body weight with no injuries reported with any subject.

Conclusion: These data suggest that a nonpharmacologic exercise solution is available to individuals diagnosed with osteoporosis. Further study is required with larger sample sizes and more diverse demographics. Additional research is needed to validate OL as a viable and safe strategy for bone reformation.

P143

3-LEVEL DEGENERATIVE SPONDYLOLISTHESIS WITH SPINAL CANAL STENOSISM. Ing How¹¹Department of Orthopedic Surgery, Changi General Hospital, Singapore

Lumbar degenerative spondylolisthesis is a major cause of impaired quality of life and diminished functional capacity in the elderly. Degenerative spondylolisthesis often involves only one or two level and tend to present with one or two level spinal canal stenosis.

The authors describe an unusual case of degenerative spondylolisthesis involving 3 levels of the lumbar spine from L2 to L5. The patient was a 58-year-old woman who suffered chronic back pain and neurogenic claudication. Plain radiography revealed grade I degenerative spondylolisthesis at L2-L3, L3-L4 and L4-L5. Elevated pedicle-facet joint angles and W-type facet joints at the lumbar spine was observed. MRI showed L2-S1 spinal cord compression at the lumbar spine. Patient underwent L2-S1 decompression laminectomy and posterior lateral fusion of L2-S1 with posterior instrumentation and bone grafting. Symptoms improved significantly at 4 months follow-up.

Thorough evaluation for multilevel segmental involvement in degenerative spondylolisthesis is important because of the frequency of severe symptomatic spinal stenosis or foraminal encroachment. Good surgical outcome can be expected from decompression and stabilisation. The pathogenesis of multilevel lumbar degenerative spondylolisthesis can be complex and heterogeneous.

P144

CORONARY VASOSPASM IN INTRACTABLE AUTONOMIC DYSREFLEXIAM. Ing How¹¹Department of Orthopedic Surgery, Changi General Hospital, Singapore

Coronary vasospasm is a transient sudden vasoconstriction of one of the coronary arteries that can lead to myocardial ischaemia, myocardial infarction, fatal arrhythmia and sudden death. Most patients with coronary spasm have underlying cardiac pathology.

This paper presents a rare case of intractable autonomic dysreflexia in a 36-year-old patient with chronic C5 paraplegia with silent myocardial ischaemia secondary to coronary vasospasm in the absence of underlying cardiac pathology. The MRI perfusion study revealed normal left ventricular contractility and no evidence of coronary artery occlusion.

This case highlights the cardiac complications associated with paroxysmal heightened sympathetic nervous system and proposes that autonomic dysreflexia can predisposes to coronary vasospasm via uncontrolled sympathetic nervous system. The disruption of sensory input from the myocardium to the brain in patient with SCI predisposes them to asymptomatic myocardial

ischaemia. The challenges in the diagnosis and management of coronary vasospasm associated with autonomic dysreflexia are described.

P145

SIMILAR RADIOLOGICAL RESULTS WITH ACCELEROMETER-BASED NAVIGATION VS. CONVENTIONAL TECHNIQUE IN TOTAL KNEE ARTHROPLASTYM. Ing How¹¹Department of Orthopedic Surgery, Changi General Hospital, Singapore

Objective: The Zimmer iASSIST system is an accelerometer-based, portable navigation device for total knee arthroplasty that does not require the use of a large console for alignment feedback as required in computer-assisted surgery. The purpose of this study was to determine the accuracy of the accelerometer-based system in component positioning and overall mechanical alignment.

Methods: Two groups of 30 patients each with primary osteoarthritis underwent total knee arthroplasty using either conventional method or Zimmer iAssist navigation in 2013 was retrospectively studied. Patients were matched according to BMI, gender, and age. A senior arthroplasty surgeon performed all the operation using the same surgical approach. Perioperative and postoperative regimens were the same. All patients had standardised radiographs performed post-operatively to determine the lower limb mechanical alignment and component placement.

Results: There was no difference between the two groups for age, BMI, gender, side of operated knee and preoperative mechanical axis ($P > 0.05$). There was no difference in the proportion of outliers for mechanical axis ($P = 0.38$), coronal femoral angle ($P = 0.50$), coronal tibia angle ($P = 0.11$), sagittal femoral angle ($P = 0.28$) and sagittal tibia angle ($P = 0.33$). The duration of surgery, postoperative drop in hemoglobin level and transfusion incidence did not show statistically significant differences between the two groups ($P > 0.05$).

Conclusions: We showed that iAssist was safe and remains a useful tool to restore mechanical axis. However, our data demonstrated no difference in lower limb alignment and component placement between the total knee arthroplasty that used accelerometer-based system and those that underwent conventional method.

P146

COMPARISON OF THE PRESCRIBING PRACTICE OF INJECTION TREATMENTS FOR OSTEOPOROSIS IN FOUR HOSPITALS OF A HEALTH BOARD IN THE UK: A REAL WORLD STUDY

S. L. Hardie¹, H. Seymour¹, A. Gupta¹¹Glangwili Hospital, Swansea. UK

Objective: Injection treatments are approved second line treatment options for osteoporosis. National and international guidelines are available for use of these treatments. Hywel Dda University Health board has four hospitals which have equal access to these osteoporosis therapies. Our aim was to identify differences in antiosteoporotic drug prescribing between four hospitals within a health board.

Methods: Data was obtained from computerised dispensing pharmacy database. We identified all injectable osteoporosis prescriptions dispensed during the years 2016, 2017 and 2018 (up to September 2018).

Results: Across Hywel Dda Health board, denosumab was the commonest prescribed injectable antiosteoporotic drug (total of 502), followed by zoledronic acid (436) and teriparatide (192). Glangwili General Hospital was consistently the largest prescriber during 3 y. Issuing 40.2% of the denosumab prescriptions in Hywel Dda in 2016, 37.1% in 2017, and 31.3% in 2018.

Zoledronic acid had the largest prescriptions in Withybush Hospital throughout the 3 y (46.1% of the total zoledronic acid prescriptions). Bronglais Hospital had the lowest uptake of teriparatide (only 2.1% of the prescriptions) in Hywel Dda. Teriparatide had the lowest uptake within the whole health board. With none being prescribed in Prince Philip Hospital in the 3 y. Glangwili Hospital had 181 prescriptions across the 3 y (94.3% of the total).

Conclusion: The reasons and determinants of differential prescribing across different hospitals within a single health board need further study. Therapeutic decision making could depend on patient choice, physician choice and availability of interested local osteoporosis staff and services.

P147

CURRENT PRACTICE OF OSTEOPOROSIS DRUG PRESCRIBING ACROSS FOUR HOSPITALS OF A UK HEALTH BOARD

H. Seymour¹, S. L. Hardie¹, A. Gupta¹, D. Jagus¹¹Glangwili Hospital, Swansea. UK

Objective: We studied the pattern of osteoporosis oral and injectable treatment prescriptions in four hospitals in Wales covering a population of 384,000.

Methods: Setting: Four UK hospitals. Period: January 2016 up to September 2018. Information was collected from pharmacy electronic database for total prescriptions issued for alendronic acid, denosumab, teriparatide and zoledronic acid. We analysed comparative usage of different osteoporosis treatments.

Results: Over the years 2016, 2017 and 2018 the total number of oral bisphosphonate prescriptions was 4680 (GGH had 1797, PPH had 1703, WGH had 864 and Bronglais had 316). The total number of injectable denosumab prescriptions was 502 (GGH had 183, PPH had 87, WGH had 177, and Bronglais had 55). The total number of injectable zoledronic acid prescriptions was 436 (GGH had 68, PPH had 158, WGH had 201, and Bronglais had 9). The total number of teriparatide prescriptions was 192 (GGH had 181, PPH had 0, WGH had 4, and Bronglais had 7).

Conclusion: Results justify maximum usage of oral alendronic acid being cheap and effective medication for osteoporosis, but there was marked variation in prescribing practice of injection treatments across four hospitals. Similar large scale studies are needed in the future to gain more detailed information on possible variations in prescribing practice and trends across different hospitals of the UK, which provides uniform free national health-care.

P148

CLINICAL PROFILE OF PATIENTS ON DENOSUMAB AT A UK HOSPITAL IN 2017: REAL WORLD DATA

S. L. Hardie¹, H. Seymour¹, A. Gupta¹, D. Jagus¹¹Glangwili Hospital, Swansea. UK

Objective: National and international guidelines are available for use of denosumab, an injectable monoclonal antibody for the treatment of osteoporosis, as a second line drug. Our aim was to identify the clinical profile of patients prescribed injectable denosumab at a hospital in the UK.

Methods: We identified patients that were prescribed denosumab from Glangwili Hospital during 2017 from the pharmacy electronic database. We then accessed patients' medical records, information collected included age, gender, number and location of fracture, and latest DXA scan T-score. All patients had previous intolerance to oral bisphosphonates.

Results: Total 30 patients included in study. The average age of a denosumab user was 73.8 in 2017 (range 29-87), with 28 out of 30 recipients being female. On average patients had experienced 1.4 fragility fractures in the past (range 0-3). Site of fractures included vertebral (11), wrist (8), hip/femur (6), ankle (5), foot (5), ribs (3), hand (2) and elbow (1). DXA T-scores observed indicated that the spine had the lowest (-3.68). Scores observed for hip, femoral head and forearm were -2.01, -2.29, and -2.11, respectively. Data collected on vitamin D levels in patients prior to injection treatment showed that 76.7% were above 50 nmol (range 21-186 nmol/L, mean 81.4 nmol/L).

Conclusion: Our real world observational data show that an injection denosumab user is predominantly elderly female. Patients with osteopaenia and high fracture risk should not be denied denosumab. Further research is needed to determine reasons of low usage in male patients. The likely reason is denosumab was not approved for male osteoporosis until recently.

P149

TRENDS IN PRESCRIBING PRACTICE OF INJECTABLE OSTEOPOROSIS TREATMENTS AT 4 HOSPITALS OF A HEALTH BOARD IN THE UK

H. Seymour¹, S. L. Hardie¹, A. Gupta¹, D. Jagus¹

¹Glangwili Hospital, Swansea. UK

Objective: Injection treatments, including denosumab, zoledronic acid and teriparatide, are approved as second line treatment options for osteoporosis. National and international guidelines are available for the use of these injectable treatments. Our aim was to study the recent trends in the use of different injectable osteoporosis treatments across 4 hospitals within the same health board in Wales, UK.

Method: Using computerised dispensing pharmacy data we identified current users of inpatient and outpatient osteoporosis injectable treatments at Prince Philip Hospital (PPH), Withybush General Hospital (WGH), Glangwili General Hospital (GGH) and Bronglais hospital. Predicted values were calculated assuming that the same number of treatments would happen over the next 3 months.

Results: The total number of injectable prescriptions increased from 2016 to 2017 (405 to 412) and decreased during 2018 (actual 313 and predicted 12 month treatments is 376). Denosumab and zoledronic acid had maximum prescriptions in 2017. Teriparatide prescriptions declined from 2016 onwards.

Conclusion: The variable trends in prescribing practice of injection treatments for osteoporosis over three years need further analysis. Therapeutic decision-making could depend on patient choice, physician choice and availability of local osteoporosis service.

P150

NOVEL CLINICAL TOOL FOR ASSESSMENT OF RECOVERY AFTER ACHILLES TENDON RUPTURE

I. Dumić-Čule¹, G. Ivanac¹, D. Lemac², B. Brkljacic¹

¹Department of Diagnostic and Interventional Radiology,

²Department of Orthopaedics and Traumatology, Clinical Hospital Dubrava, Zagreb, Croatia

Objective: We aimed to develop a novel questionnaire tool in order to facilitate clinical assessment of patient's recovery after Achilles tendon surgical reconstruction. In addition, after the questionnaire validation process and final establishment, we evaluated whether its final score has a relationship with values obtained with shear-wave elastography (SWE).

Methods: The questionnaire was composed of 9 questions relying on widely used Achilles Tendon Total Rupture Score and American Orthopedic Foot and Ankle Society scoring system regarding assessment of capabilities and subjective feeling after Achilles tendon reconstruction. A total of 20 internationally recognized musculoskeletal radiologists (5), orthopedic surgeons (10) and physiatrists (5) were invited to participate in the questionnaire validation. Final multiple choice questions were developed by the researchers based on the domains that were answered as "very

important" by $\geq 70\%$ of first and second-round survey respondents. In parallel, 24 patients were analyzed by SWE to gain insight into objective recovery.

Results: Content experts (5 of them) review the relevance of each question on a 4-point Likert scale. Since 4/5 experts gave score 3 or 4, according to Content Validity index (I-CVI) suggested by Maruza in 1977 (1), the validity is calculated to be I-CVI=0.80. Our novel questionnaire showed a significant and strong propensity score match with SWE results (Spearman two-sided test).

Conclusion: Collectively, novel questionnaire positively correlated with quantifications obtained by SWE and is therefore appropriate for subjective assessment of functional recovery after Achilles tendon reconstruction.

P151

HIV INFECTION IS ASSOCIATED WITH WORSE BONE HEALTH AND INCREASED FRACTURE RISK: A META-ANALYSIS

C. Chang¹, T. Tai¹

¹Department of Orthopedics, National Cheng Kung University Hospital, College of Medicine, Tainan


Objective: Treatment of HIV infection was altered by the introduction of effective antiretroviral therapy and the life expectancy of HIV infected individuals are increased. Some studies had noted a decrease in BMD among HIV infected patients, while some other reports showed increased fracture risk in HIV population.

Methods: We performed a meta-analysis of case-control, cross-sectional and cohort studies to investigate whether fracture rates (fragility and overall) differs in individuals with and without HIV infection. A total of 34 articles were included in this meta-analysis, with 105,773 HIV infected patients and 228,792,927 non-HIV infected controls. Our objectives were to compare the BMD, risks of fragility fractures and overall fractures between these two groups.


Results: HIV-infected people showed lower lumbar spine BMD (0.85 to 1.25 g/cm²) than controls (0.92 to 1.31 g/cm²). HIV population also have significantly lower hip BMD than controls. ($p < 0.001$). HIV infected patients have higher prevalence of suffering from overall fracture injury (3.95% vs. 0.44%; RR, 1.99; 95%CI, 1.51-2.63; $P < 0.001$) and fragility fracture (2.62% vs. 2.19%; RR, 1.76; 95%CI, 1.47-2.11; $P < 0.001$) than non-HIV infected people. Subgroup analysis revealed that higher prevalence of vertebral fracture (1.26% vs. 0.37%; RR, 1.97; 95%CI, 1.22-3.2; $P < 0.05$), hip fracture (1.38% vs. 0.81%; RR, 1.88; 95%CI, 0.99-3.57; $P = 0.05$) and wrist fracture (1.38% vs. 1.29%; RR, 1.67; 95%CI, 1.13-2.45; $P < 0.05$) were noted in HIV infection groups when compared with healthy controls. Furthermore, the pooling data of fracture incidence showed that incident fracture rates per 100 person-year differed between HIV infected patients and healthy controls. (1.9 vs. 0.4 /100 person-year; RR, 1.39; 95%CI, 1.17-1.66; $P < 0.001$).

Conclusions: HIV infection had a negative impact on bone health and increase fracture risks. HIV-infected people had lower BMD and high prevalence of vertebral and wrist fractures. Targeted screening and management to maintain skeletal strength and reduce fragility are urgently needed for people who living with HIV.


A. Spine BMD




B. Hip BMD




A. All fractures



B. Fragility fractures



Incidence of all fractures



P152

**WHERE IS THE HEAD OF HUMERUS IN THIS CASE?
GORHAM'S DISEASE- LIKE IN A PATIENT WITH
DIABETES MELLITUS AND RHEUMATOID ARTHRITIS**


H. M. Al Attia¹

¹Private Practice, Abu Dhabi, United Arab Emirates

A 60 year old Arab female with history of RA for years. Also, she was suffering from T2 DM and hypertension for the last three years. Clinically, was found to have significant wasting of the shoulders most prominent in the right side (Figure 1).



The X-ray showed a total absence of the head of humerus (sharply demarcated) mimicking Gorham's disease, and diastrophic calcifications of the glenoid cavity (Figure 2).



The MRI image shows herniation of cerebellar tonsils in the foramen magnum and syringomyelia of (C2-C5) (Figure 3).



Together, these features were consistent with the diagnosis of Type 1 Arnold Chiari syndrome. So, the vanishing head of humerus was due to bone resorption secondary to an advanced and rather unusual neuropathic joint. Then, pursuing the diagnosis of Type 1 Arnold Chiari syndrome in this patient was clearly, worthwhile particularly. in presence of a coexisting DM which is capable of producing neuropathic joint. Rheumatoid arthritis on the other hand was also reported to cause Gorham's disease, though rarely.

Conclusion: The message derived from this report that in some clinical instances the real cause of the disorder can be overshadowed by another condition(s) that might lead to a similar presentation.

P153

**DETERMINANTS AND HEALTH CONSEQUENCES
OF A RAPID MUSCLE HEALTH DECLINE IN OLDER
ADULTS FROM THE SARCOPHAGE STUDY**

M. Locquet¹, C. Beaudart¹, J.-L. Croisier², J.-Y. Reginster¹, O. Bruyère¹

¹Public Health, Epidemiology & Health Economics, University of Liège, ²Laboratory of Human Motion Analysis, University of Liège, Liège, Belgium

Objectives: To characterize the muscle health decline of older adults over 1 year and its association with adverse consequences over the 3 following years.

Methods: The SarcoPhAge cohort follows up 534 older adults to assess health consequences of sarcopenia. Subjects are seen annually and an assessment of muscle mass (DXA), muscle strength (handheld dynamometer) and physical performance (4-m gait speed) are performed. Outcomes are collected either during annual follow-up visits or by phone. Individual relevant decline of muscle mass, muscle strength and gait speed between baseline and the 1-year follow-up was evaluated using the Edwards-Nun-

nally index. The association between muscle decline and occurrence of outcomes was tested using logistic regressions. Missing data were handled using multiple imputations.

Results: 534 subjects were recruited (73.5±6.2 y, 60.5% women) but during the first year, 7 deaths occurred. Consequently, analyses were performed on 528 subjects. The prevalence of a rapid muscle mass decline was 41.5% (n=219). Subjects presenting a decline of muscle mass had no difference of their demographic or clinical characteristics compared to subjects without decline (all $p > 0.05$). The prevalence of a rapid decline of muscle strength was 47.3% (n=149). Subjects presenting a decline in muscle strength were more often women (21.2% of male vs. 66.0% of female, $p=0.02$) and had a lower cognitive status (27.6 points vs. 28.1 points at the MMSE, $p=0.02$). A significant decline in gait speed was observed in 28.2% (n=149) of the whole population. Subjects presenting decline of physical function were older (74.5 years vs. 73.0 y, $p=0.01$), had lower BMI and cognitive status (25.8 vs. 26.8, $p=0.03$ and 27.5 points vs. 28.0 points at the MMSE, $p=0.04$). Over the 3 following years, a rapid decline in muscle mass and strength did not predict the occurrence of falls, fractures and hospitalisations. A rapid decline in gait speed predicted the occurrence of self-reported physical disabilities (adjusted OR=1.87[1.18-2.96]) as well as deaths (adjusted OR=2.36 [1.17-4.73]).

Conclusion: A significant proportion of the older population showed a rapid decline in muscle health, associated with age, sex, BMI and cognitive status. A rapid decline of gait speed predicted the occurrence of 3-y death and disabilities, highlighting the importance of an assessment of gait speed in older subjects.

P154

EWGSOP 2 VS. EWGSOP 1: IMPACT ON THE PREVALENCE OF SARCOPENIA AND ITS OUTCOMES

M. Locquet¹, C. Beaudart¹, J. Petermans², O. Bruyère¹

¹Public Health, Epidemiology & Health Economics, University of Liège, ²Geriatrics Department, CHU of Liège, Liège, Belgium

Objectives: In June 2018, we published a manuscript showing that sarcopenia, characterized by the EWGSOP definition (i.e., EWGSOP1), was associated with an increased risk of mortality (doi: 10.1016/j.jamda.2018.06.004). In October 2018, the EWGSOP proposed a new operational definition of sarcopenia (i.e., EWGSOP2). We sought to compare the prevalence of sarcopenia defined by EWGSOP1 and by EWGSOP2, and to determine the major outcomes associated with each of these definitions.

Methods: We used data available from the SarcoPhAge (for *Sarcopenia and Physical Impairment with Advancing Age*) cohort. To characterize sarcopenia, 3 main assessments were performed: the skeletal muscle mass index using DXA, the muscle strength using hand-dynamometer and the physical performance using SPPB test. According to EWGSOP1, sarcopenia is defined as a low muscle mass (i.e., ≤ 5.5 kg/m² for women, ≤ 7.26 kg/m² for men) plus a low grip strength (i.e., < 20 kg for women, < 30 kg for men) and/or low physical performance (i.e., ≤ 8 points/12). Ac-

cording to EWGSOP2, sarcopenia is characterized by a low grip strength (i.e., < 16 kg for women, < 26 kg for men) plus a low muscle mass (i.e., < 6 kg/m² for women, < 7 kg/m² for men). If low physical performance (i.e., ≤ 8 points/12) is also present, there is 'severe sarcopenia'. Outcomes were collected yearly during interview or by phone call. Association between sarcopenia and occurrence of outcomes was tested using Cox hazards model or logistic regression with adjustment for covariates known to potentially impact muscle health, including age, sex, BMI, number of comorbidities, number of coprescriptions, nutritional status, and cognitive status.

Results: 534 subjects were recruited (73.5±6.2 y, 60.5% female). After 3 y, 33 participants were lost to follow-up, so data were available for 501 subjects. According to EWGSOP1, the prevalence of sarcopenia reached 13.6% and, when using the EWGSOP2, 7.4%. Sarcopenia, defined by EWGSOP1, was associated with an increased risk of 3-year mortality (HR_{adjusted}=2.93 [1.17-7.35]). According to EWGSOP2, this association was no longer significant (HR_{adjusted}=2.74 [0.98-7.65]), but remained in the same range as observed for EWGSOP1. In the subgroup of subjects with severe sarcopenia, we observed a higher occurrence of death (HR_{adjusted}=4.50 [1.56-12.98]) and institutionalization (HR_{adjusted}=5.07 [1.02-25.27]) than in non-sarcopenic individuals.

Conclusion: The EWGSOP2 definition of sarcopenia appears to decrease its prevalence due to changes in the algorithm and/or the thresholds compared to EWGSOP1. Furthermore, the proposed severity index, based on physical performance assessment, seems to be a determinant of the occurrence of deaths and institutionalizations.

P155

PILOT STUDY ON A NEW INTERVENTION PROGRAM FOR GERIATRIC HIP FRACTURE PATIENT WITH SARCOPENIA

A. W. H. Ho¹, M. Y. Cheung¹, L. C. Man¹

¹Department of Orthopaedics and Traumatology, Caritas Medical Centre, Hong Kong, China

Objective: Sarcopenia and osteoporosis increase the risk of falls, resulting in fragility fracture. The prevalence of sarcopenia was found to be alarmingly high (73.6% in males and 67.7% in females) in geriatric hip fracture patients [1]. Intervention program on sarcopenic hip fracture was set up at our center.

Method: All patients age over or equal to 65 admitted to Caritas Medical Centre with operatively treated hip fracture and diagnosed sarcopenia were included. Interventions include inpatient nursing education, dietary advice, therapist assessment and structured 12-week geriatric day hospital (GDH) exercise program. Those not eligible for GDH training were classified as control group. Changes in relative skeletal muscle mass index (RASM), muscle strength, functional scores were measured.

Results: There were 9 intervention and 10 control patients. The mean age in intervention group was 81.8 and control group was 77.0. Female to male ratio in intervention group was 7:2 and control group was 8:2. All patients were noted to have increment

in RASM (intervention 0.316 mm/kg2, control 0.655 mm/kg2, $p < 0.05$), knee extension of good limb (intervention 1.32 kg, control 0.92 kg, $p < 0.05$) and injured limb (intervention 5.78 kg, control 3.49 kg, $p < 0.05$). All patients have improvement in functional scores ($p < 0.05$). Between groups analysis showed there was statistically significant improvement in muscle strength of both good and injured limbs. There was also statistically insignificant decrement in RASM, MFAC and BI in intervention program group compared with control group.

Conclusion: Generally, there were improvement in muscle mass, muscle strength and functional recovery in all patients. There was apparent improvement in muscle strength but reduction in muscle mass in intervention group compared with control group. The result shows that intervention program with exercise prescription in sarcopenic hip fracture patient can improve the lower limb muscle strength but not muscle mass. These patients may be too frail to benefit from traditional exercise treatment for sarcopenia. Hip fracture patients with sarcopenia may represent a special group of sarcopenic individuals that are resistant to traditional exercise treatment for sarcopenia. Further studies are needed to investigate the potential benefits of extension of rehabilitation training program for this group of frail patients on sarcopenia treatment.

Reference: 1. Ho AW et al. Hong Kong Med J 2016;22:23

P156

ANOREXIA NERVOSA AS RISK FACTOR OF OSTEOPOROSIS

S. Irina Alexandrovna¹, K. Shanmugaraj¹, B. Keerthanaa¹

¹Department of Public Health, V.I. Vernadsky Crimean Federal University, Simferopol, Russia

Objectives: Anorexia nervosa happens to be one of the threatened psychological conditions which affect mostly teenagers. Anorexia can affect people of all ages, genders, sexual orientations, races, and ethnicities. About 33-50% of anorexia patients have a mood disorder, such as depression. Anorexia nervosa imposes to be a threatened nature for future women also as it also causes osteoporosis. Our abstract describes the women who are at risk of osteoporosis due to anorexia nervosa.

Methods: Carried out a survey of 400 women who are in between 25±7 years old and from Europe, Asia, and Africa. Questionnaire consists of 30 questions. The questionnaire was shared among young women through social media platforms and we used variation statistics with the program Microsoft Excel 2013.

Results: Survey results include, students were 51%, employees were 26%, housewife were 23%. From the height and weight we obtained the respective BMI shows that women having BMI <17 were 11%, between 18-25 were 56.5%, 26-33 were 32.5%. The women who do sports were 37% and who do not were 63%. Women who were at stress are 66.5% and in this women in age of 18-20 y were 28.6%, 21-26 were 42.1%, 27-33 were 29.3% and the women who have maximum stress are at age group of 21-26 were 42.1%. The women who think by decreasing the food reduces their weight were 55.5%. Amenorrhea were seen in 50% of women and in this women in age of 18-20 years were 22%, 21-26 were 44%,

27-33 were 33% and the women who had amenorrhea in Europe were 47.6%, Asia were 23.8%, Africa were 28.6% and it is high among Russian women and in age group of 21-26. The women who were presented with pain (early symptom of osteoporosis) were 62% and in back pain was 58% and other joint pain was 42%.

Conclusion: Anorexia nervosa has long lasting effects causing osteoporosis and infertility, in order to stop the developing of the disorder proper nutrition rich in calcium, vitamin D, exercise and healthy lifestyle should be followed.

P157

RELATIONSHIP BETWEEN SERUM LEVEL OF RENALASE AND LUPUS NEPHRITIS ACTIVITY

Y. Gazar¹, K. Zaki¹, K. Nofal¹

¹Rheumatology department, Faculty of Medicine, Al-Azhar university, Cairo, Egypt

Objective: Lupus nephritis (LN) is a major risk for overall morbidity and mortality in systemic lupus erythromatosis (SLE), and despite potent anti-inflammatory and immunosuppressive therapies still ends in chronic kidney disease (CKD) or endstage renal disease (ESRD) for too many patients. Renalase is a novel, kidney secreted cytokine-like protein that promotes cell survival. Our aim was to study the relationship between level of human serum renalase (RNLS) with LN and its role in the disease activity and progression.

Methods: For The current cross-sectional study 23 healthy controls and 48 patients with LN were screened and 30 subjects were selected These patients were subdivided into two equal groups according to disease activity measured by SLE Disease Activity Index (SLEDAI). Human RNLS concentration was measured by a highly sensitive. commercial sandwich enzyme immunoassay which uses RNLS antibody to capture renalase from serum. Assessment before and after treatment was done for 17 patients who received prednisone and immunosuppressive therapy were recruited and followed up for three months to evaluate the serum renalase levels before and after treatment.

Results: The level of renalase was significantly higher in LN patients compared to healthy controls, ($P < 0.001$). Moreover, patients with active LN had higher serum renalase levels compared to patients with inactive LN ($P < 0.005$) Serum renalase levels were positively correlated with SLEDAI, 24-h urine protein excretion, ds-DNA and ESR and CRP but inversely correlated with serum C3 and the class (especially in proliferative type (class III, IV, more than class V). Renalase amounts decreased significantly after 3 months of standard therapy. Also we found there is insignificant difference of renalase level according to treatment by mycophenolate mofetil and cyclophosphamide during and after activity ($P = 0.655, 0.550$).

Conclusion: Serum renalase levels were correlated with disease activity in LN. Serum renalase might serve as a potential indicator for disease activity in LN.

P158
DETECTION OF SUBCLINICAL LV MYOCARDIAL DYSFUNCTION IN RHEUMATOID ARTHRITIS PATIENTS BY SPECKLE TRACKING

Y. Gazar¹, A. Abo Elmagd², A. I. Abdel Hamid², M. Nawara²

¹Rheumatology Department, ²Cardiology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

Objective: Patients with rheumatoid arthritis (RA) have shorter life expectancy and their risk of cardiovascular (CV) death is more than 50% higher than the rest of the population. Early myocardial dysfunction may be detectable more precisely and sooner using speckle tracking echocardiography. This study was designed to assess myocardial left ventricle (LV) systolic function by STE strain imaging in patients with RA without known CVD and to correlate the findings with characters of the disease.

Methods: Cross-sectional observational study enrolled 60 patients with RA (mean age 46.22±8.14 y) without known CVD, and 20 healthy controls. All subjects underwent a standard echocardiographic examination as well as the speckle tracking assessment of left ventricle strains.

Results: Speckle-tracking assessment of LV systolic function revealed decreased global longitudinal strain (GLS) among the patients group (-16.80% vs. -22.35%, P<0.001). There was a negative correlation between the duration of RA and the GLS (r=- 0.301).

Receiver operating characteristics curve was used to define the best cutoff value of GLS which was -20, with sensitivity of 76.7%, specificity of 80%, positive predictive value of 92%, negative predictive value of 63% with diagnostic accuracy of 83.9%.

Conclusion: The speckle tracking method for myocardial strain analysis showed unambiguously systolic impairment of longitudinal strain parameters. So, patients with RA should undergo a full comprehensive echocardiographic study for assessment of LV systolic function.

P159
“RELATIVE HYPOCALCEMIA” POST PARATHYROIDECTOMY: A NEGLECTED PHENOMENON?

C. V. Tong¹

¹Malacca General Hospital, Melaka, Malaysia

Objective: To describe a series of patients from Malacca Hospital, Malaysia, who developed symptoms of hypocalcemia post parathyroidectomy for primary hyperparathyroidism despite having normal serum calcium.

Method: The records of the above patients were retrieved and reviewed retrospectively.

Results: The following table summarizes the four patients we are describing:

Patient	Calcium Pre-surgery (2.18-2.6 mmol/l)	Parathyroid hormone levels (1.58-6.08 pmol/L)	Vitamin D levels (26-250 nmol/l)	Complications of hyperparathyroidism	Calcium post-surgery during review with symptoms (mmol/l)	Symptoms and Severity	Duration for symptoms to resolve post-surgery	Histopathology examination
Patient A 30 years old, female	2.92 – 3.1	50.2	15.93	Low Bone Mineral Density (BMD) Renal calculi	2.35	Severe cramps, Positive Chvostek’s sign unable to walk properly	7 weeks	Multifocal papillary thyroid carcinoma with right inferior parathyroid adenoma.
Patient B 45 years old, Female	3.08-3.32	50.4	Not available	Low BMD	2.36	Mild numbness over hands	12 weeks	Atypical parathyroid adenoma (tumor of uncertain malignant potential).
Patient C 65 years old, female	2.86 – 3.0	13.6	40.69	Osteoporosis	2.36	Mild numbness over hands	12 weeks	Parathyroid adenoma
Patient D 24 years old, male	2.7-2.9	17.7	45.02	Renal calculi	2.26	Mild numbness over hands	20 weeks	Parathyroid adenoma

Conclusion: As far as we know this is the first description of “relative hypocalcemia” post parathyroidectomy. From our experience, symptoms can range from mild to severely debilitating. It is crucial for clinicians reviewing these patients to look for symptoms despite patients having normal calcium levels.

P160

DOES KERATOTIC TISSUE OFFER A WINDOW INTO BONE HEALTH?M. Towler¹, R. Beattie²¹Ryerson University, Toronto, Canada, ²J Renwick Beattie Consulting, Ballycastle, UK

Objective: Using Raman spectroscopy to determine an association between collagen and keratin on exposure to systemic factors that influence bone health.

Methods: 12 weeks old Sprague Dawley rats were randomly assigned to 1 of 3 groups: Group 1 underwent a sham ovariectomy (n=11) and remained treatment naive while the other groups underwent either ovariectomy with no intervention (OVX, n=10), or ovariectomy with PTH (OVXP, n=12). All rats were sacrificed at 23 weeks and bone (right femur) and claw (right and left claw) samples were collected. Bone architecture was assessed using microcomputed tomography. Raman spectra were recorded on bone and claw samples using the Perkin Elmer Instrument, Raman Station.

Results: Raman signal signature successfully discriminated between ovariectomised rats and their sham controls for both bone (sensitivity 89%, specificity 91%) and claw (sensitivity 89%, specificity 82%). Compared to baseline, OVX reduced ordered α -helical conformation converting it to a random conformation. OVXP prevented 80% of the protein structure randomisation, but only prevented 50% of the demineralisation, suggesting that the interaction of this intervention with the collagen is stronger than with the mineral phase. The OVXP also showed significant changes from alpha to beta sheet content, suggesting that the intervention does not lead to protein disorganisation; its structure is instead reorganised. For both operation groups the changes in bone collagen and claw keratin were qualitatively equivalent, indicating a clear systemic modulation of both proteins.

Conclusions: Raman signatures revealed that systemic factors mediating bone health in ovariectomised rats exhibited recordable changes within claw tissue; specifically, a greater degree of structural flexibility within both collagen and keratin. It is likely that the less ordered collagen will impact on the elasticity of the collagen and also on mineral deposition and subsequently fracture risk. The fact that the same qualitative perturbations were observed in both tissues under both systemic perturbations opens the potential of using keratin as a surrogate marker for bone health.

P161

LOCATION OF ATYPICAL FEMORAL FRACTURES CAN BE DETERMINED BY THE MECHANICAL AXIS OF LOWER LIMB: CT- BASED FINITE ELEMENT ANALYSISJ. W. Kim¹, D. W. Hwang², Y. K. Lee³, J. Y. Yoon¹¹Asan Medical Center, University of Ulsan, Seoul, ²National Rehabilitation Center, Seoul, ³Korea Institute of Machinery & Materials, Daegu, South Korea


Objective: With increasing lateral bowing angle, the atypical femoral fracture (AFF) location was moved from the subtrochanteric area to the diaphyseal area. Besides of suppression of bone remodeling, the biomechanical factor including lower limb geometry would be considered as a cause of AFF. Although there has been reported about an early prediction of AFF, the method of early detection has not been established. We hypothesized that the lower limb axis would represent the patient-specific biomechanical factor of AFF. Thus, we developed a computed tomography (CT)-based finite element analysis (FEA) model that assesses possible fracture location to detect AFF early.

Methods: We retrospectively reviewed 18 patients with AFFs and gathered their CT image of the intact (contralateral) femur. We performed FEA analysis to find the maximal stress loading area of each patient and matched the location of AFF. In addition, we modified the mechanical axis as neutral, varus (5mm, 10mm, 15mm, 20mm, 25mm, 30mm) and valgus (5mm, 10mm, 15mm, 20mm, 25mm, 30mm), and analyzed the change of the maximal stress loading area according to lower limb alignment. Femoral lateral bowing was classified from 0(neutral)-3(varus).

Results: The average age of the participants was 77.3 y and all of them were female. There were 5 cases of subtrochanteric AFFs and 13 cases of diaphyseal AFFs. The average mechanical axis at the knee joint level was 24.5 mm (range, 0-70 mm) of varus. The grade of femoral bowing was 7 cases of grade 0, 2 cases of grade 1, 3 cases of grade 2, and 6 cases of grade 3. When the grade was 0 or 1, the maximal stress point was proximal femur, while the point was midshaft or distal 1/3 in grade 2 and 3. There were 6 patients with neutral axis had the same location of the maximal stress point in the contralateral femur and the location of AFF, but the other twelve patients did not show consistency. After the adjustment of varus axis of each patient with patient's whole lower bone x-ray, the maximal stress point was exactly consistent with the fracture site. CT/FEA model showed that the maximal stress location was changed according to the change of applied axis. Maximal stress location was changed distally and laterally relative to the varus degree, and the location was moved proximally and medially relative to the valgus angle. Peak maximal stress was increased according to the varus deformity of knee joint, while that was decreased correlated with the degree of the valgus deformity.

Conclusion: CT/FEA demonstrated that maximal stress location was consistent with the location of AFF, and the maximal stress location was determined by the lower limb axis, not only by the femoral bowing.

Fig. 1 The change of maximal stress location according to the varus deformity of the knee. (A) The maximal stress location in neutral position (B) The lower limb geometry of the patient. (C) The patients' incomplete atypical femur fracture. (D) The maximal stress location in the varus with 37mm medial translation.



P162
HYPOPARATHYROIDISM: INCIDENCE AND OPTIMAL TREATMENT BY A TERTIARY REFERRAL CENTER DATABASE

B. Szili¹, B. Bakos¹, B. Szabo¹, P. Lakatos¹, I. Takacs¹

¹Semmelweis University - 1st Dept. of Medicine, Budapest, Hungary

Introduction: hypoparathyroidism is a rare disorder, affects 24-37/100 000 persons. The most frequent cause is neck surgery complication, the autoimmune and developmental disorders are rare etiologies. For long time the only available treatment was calcium and vitamin D supplementation with activated D-hormone therapy. Since 2015 recombinant human parathyroid hormone is approved by FDA for the treatment of hypoparathyroidism.

Objective: the aim of our survey was to determine the frequency and the characteristics of patients with hypoparathyroidism in our tertiary referral university hospital. We aimed to investigate the medical therapy and its efficacy in our patient population.

Material and Methods: we performed a retrospective analysis of our patient database. We collected registered patients with hypoparathyroidism (at first visit both serum calcium and parathyroid hormone below reference range), presented in 2017 at Semmelweis University 1st Department of Medicine endocrinology outpatient clinic, a tertiary referral center. For descriptive statistics and database management we used SPSS 17. Data are presented as mean +/- SD.

Results: we could collect data of 14 females and 3 males. Hypoparathyroidism was postoperative in 13 cases, idiopathic in 4 patients and caused by DiGeorge syndrome in 1 case. The aver-

age at diagnosis was 44.5 years while the mean first measured serum calcium 1.62 mmol/l. Patients received 1608±620 mg elemental calcium, 2306±730 IU cholecalciferol and 0.6±0.3 µg activated D-hormone daily therapy in average. By this therapy the mean serum calcium level is 2.23±0.21 among our patients.

Conclusions: the typical presentation of hypoparathyroidism was paresthesia and muscle cramps after neck surgery, but in one case secondary Parkinsonism due to Fahr-disease was the presenting symptom. Serum calcium level usually could be maintained with cholecalciferol and calcium supplementation and activated vitamin D hormone analogue therapy. Currently the recombinant human PTH therapy is only available in clinical trials in our country.

P163 THE INFLUENCE OF BODY FAT CONTENT AND DISTRIBUTION ON BONE MASS THROUGHOUT ADULT LIFE: A POPULATION-BASED STUDY OF 18263 CASES

B. Chen¹, G. Liu¹, Y. Xu¹

¹Second Affiliated Hospital of Soochow University, Suzhou, China

Objectives: The aim of this cross-sectional study was to investigate the impact of body fat content and distribution on BMD in healthy males and females.

Methods: The study was consisted of 18263 subjects (8969 males and 9294 females) aged 20 y or older who had undergone routine health examinations at the Second Affiliated Hospital of Soochow University from 2008-2015 (Table 1). Percentage of local fat and BMD of lumbar spine (LS) and femoral neck (FN) were measured using DXA.

Results: As females age, their BMD decreased, while hip fat percentage (HF%) and waist fat percentage (WF%) increased. whereas in males, the LS BMD kept stable when WF% increasing (Fig 1). In the multiple linear regression models, BMI was the strongest predictor in the three models. HF% appeared to be a stronger predictor of LS BMD than of FN BMD in females, while WF% was stronger in determining FN BMD than LS BMD in males (Table 2). From the generalized additive models, the positive relationship between BMI and BMD were weaker at high BMI, particularly at the lumbar spine in females. As for fat percentages, a parabolic relationship with BMD was observed in female, whereas in males, the association between fat percentage and LS BMD appears weaker than FN BMD, particularly for the models with WF% as the predictor variable (Adjusted R²=0.058) (Fig 2). Females in the highest HF% quartile showed significantly faster bone loss in lumbar spine than in femoral neck while males in the highest WF% quartile showed significantly faster bone loss in femoral neck than in lumbar spine (Fig 3).

Conclusions: In males, the waist fat has more impact on LS BMD compared with hip fat, whereas in females, the hip fat exerts more influence on FN BMD compared with waist fat, which were due to some kind of cross-effect of fat on BMD in the two sites. The

low prevalence of osteoporotic fracture of lumbar spine in males could be attributed to the low hip fat percentage as well as the weak effect of waist fat on LS BMD.

Table 1 Descriptive statistics of study population

	Female (n=9294)	Male (n=8969)	P ^a
	Mean±SD	Mean±SD	
Age (yr)	52.59±14.27	48.34±13.40	<0.001
Anthropometric measures			
Height (cm)	158.6±5.4	170.7±5.8	<0.001
Weight (kg)	57.9±8.7	72.0±10.4	<0.001
BMI (kg/m ²)	23.01±3.27	24.70±3.14	<0.001
DXA measures			
FN BMD (mg/cm ²)	860.2±154.4	949.0±137.4	<0.001
FN T-score(SD)	-0.58±1.29	-0.22±1.06	<0.001
FN BMC(g/cm)	3.895±0.811	4.998±0.885	<0.001
LS BMD (mg/cm ²)	1061.1±198.7	1125.4±166.3	<0.001
LS T-score(SD)	-0.70±1.66	0.22±1.39	<0.001
LS BMC(g/cm)	29.840±7.101	37.049±7.140	<0.001
Waist fat to Hip fat Ratio	1.146±0.307	1.406±0.421	<0.001

Values are mean ± SD unless otherwise stated. To convert BMD from mg/cm² to BMD in g/cm², divide by 1000.

^aStudent's t-test.




Fig. 1 Changes of WF%/ HF% and LS BMD/ FN BMD over the lifespan of women and men.

Table.2 Regression coefficients of models with BMI (kg/m²),HF% or WF% as the predictor variable for lumbar spine and femoral neck BMD (mg/cm²)

	Female		Male	
	β	R _{adj} ²	β	R _{adj} ²
FN BMD				
BMI	0.319*	0.456	0.298*	0.232
HF%	-0.068*	0.459	-0.095*	0.238
WF%	-0.055*	0.458	-0.111*	0.238
LS BMD				
BMI	0.197*	0.366	0.165*	0.056
HF%	-0.179*	0.387	-0.138*	0.070
WF%	-0.039**	0.366	-0.033***	0.056


β : standard regression coefficient

* P<0.001 ** P<0.01 ***P<0.05 compared with the corresponding linear regression model.

Covariates adjusted in both linear regression and GAM include age, weight (for HF% and WF% only),height.

Linear regression analysis with BMD as dependent variable; BMI, HF% or WF% as the predictor variable.

(A)Female



(B)Male








Fig. 2. Graphic presentation of the dose-response relationship between BMI (Model 1) ,HF% (Model 2) or WF% (Model 3) in female (A) and male (B) obtained by generalized additive regression models. Models adjusted for age, weight (for the model 2 and 3 only) and height as covariates. Dotted lines represent 95% confidence intervals. The reference value for BMD is the value associated with the mean BMI, HF% or WF% for all subjects in each gender. The rug plot along the bottom of each graph depicts each observation.



(A) male FN BMD



(B) male LS BMD



(C) female FN BMD



(D) female LS BMD





Fig. 3. Risk of low BMD (T-score <-1.0) across quartiles of male HF%, male WF%, female HF%, and female WF%. (A) male FN BMD. (B) male LS BMD. (C) female FN BMD. (D) female LS BMD. ORs (95% CI) were calculated using multivariate logistic regression after adjusting for age, height and BMI; OR, odds ratio; CI, confidence interval.

P164

OSTEOPROTEGERIN EXPRESSION IN HUMAN BONE: RELATION TO MENOPAUSAL STATUS AND BONE ARCHITECTURE

N. Abaza¹, M. Hassab Elnaby¹, A. Elganzoury¹, H. Farouk¹, M. Hassan¹

¹Ain Shams University, Cairo, Egypt

Objective: In postmenopausal osteoporosis, bone density and architecture are greatly jeopardized. Estrogen masters a balance of anti and pro-osteoclastogenic factors production to guarantee normal bone remodeling. Estrogen deficiency is associated with accelerated bone resorption mainly due to increased osteoclast recruitment. Osteoprotegerin (OPG), the famous osteoclastogenesis inhibitory protein, is known to protect bone from the resorptive effect of RANK-RANKL interaction - a key step in osteoclast maturation - by preventing their binding. In vitro studies demonstrated estrogen stimulatory effect on OPG production; however, in vivo data relating this effect to bone structure and stages of menopause needs further investigations. Our aim was to detect OPG expression in human bone in relation to menopausal status (early & late) and its reflection on bone architecture highlighting its impact on quality osteoporosis treatment.

Methods: Bone specimens from iliac crest bone grafts from 34 female patients divided into three groups pre and postmenopausal (early 5 y & late >5 y after menopause) were studied for histomorphometric assessment (bone volume, trabecular thickness, trabecular separation, eroded surface, osteoblast surface, and osteoid surface) using image analysis system LeicaQ 500 MC. Serum estradiol levels (E2) and BMD were evaluated by chemiluminescence and DXA, respectively. Osteoporosis was diagnosed according to WHO criteria. Immunohistochemistry staining of OPG was performed measuring its expression percent and correlation with E2, BMD and histomorphometric measurements.

Results: Area percentage of OPG expression was significantly higher in premenopausal group (3.25±0.51%) in comparison to early (1.34±0.46%) and late postmenopausal (1.05±0.31%) groups (p<0.001) and in nonosteoporotic compared to osteoporotic postmenopausal patient (p<0.01). No statistically significant difference was detected between early and late postmenopausal groups. Our results also demonstrated a highly significant positive correlation between OPG expression and E2 (r=0.89, p<0.01), BMD (at forearm r=0.79, at lumbar spine r=0.65 and at femur r=0.73) (p<0.01), trabecular bone volume (r=0.89, p<0.01) and thickness (r=0.78, p<0.01) and inverse correlation with trabecular separation (r=-0.94, p<0.01).

Conclusions: OPG plays a pivotal role in pathogenesis of postmenopausal osteoporosis specially in the 1st five years. It is crucial for adequate BMD and better microarchitecture quality of trabecular bone. Restoring bone OPG level would be of great benefit in early postmenopausal phase of accelerated bone loss.

P165

FROM EFOS TO EXFOS, POST-TREATMENT PHASE: SIMILARITIES AND DIFFERENCES OF RESULTS IN THE GREEK COHORTS

K. Aloumanis¹, G. Gkouvas², S. Bintas³, S. Theocharatos¹, G. Kapetanios⁴, V. Drossinos¹

¹Department of Medical Research, Pharmaserve Lilly, Athens, ²Private office, Thessaloniki, ³Private office, Katerini, ⁴Papageorgiou General Hospital, 3rd Orthopedics University Clinic, Thessaloniki, Greece

Objective: Extended Forsteo Observational Study (ExFOS) is a multinational, prospective, observational study to evaluate fracture outcomes, back pain (BP), compliance and health-related quality of life in osteoporotic patients treated with teriparatide (TPTD) for up to 24 months with a follow-up of at least 18 months. Hellenic data of ExFOS follow-up period are juxtaposed to those of European Forsteo Observational Study (EFOS).

Methods: We have reported similarities and differences of the Hellenic EFOS and ExFOS cohort at baseline and during treatment1, 2. Post-treatment data (EFOS3 n=301 - ExFOS n=416) are juxtaposed. No statistical comparisons were performed.

Results: During follow-up, Greek patients in EFOS and ExFOS had a preservation of improvement in self-reported health quality parameters. In EFOS, significant improvement from baseline in BP during last month was reported by 77.0% at 18 months post treatment vs. 79.2% at treatment conclusion. In ExFOS significant improvement was seen by 42.4% and 37.2% respectively. Improvements in other parameters were numerically comparable (Table). After TPTD treatment 68.0% of EFOS patients received antiresorptives (vs. 81.7% at baseline)3. In ExFOS, 34.7% used bisphosphonates and 25.0% used other antiresorptives at 30 months (vs. 58.8% and 33.4% with prior use, respectively).

Conclusion: Improvements in both cohorts, sustained through follow-up, are shown. Lower antiresorptive use after TPTD treatment is recorded. Results should be interpreted in the context of observational studies.

Parameter Improvement	Hellenic EFOS cohort (N=301) ³		Hellenic ExFOS cohort (N=416)	
	18 months (treatment)	36 months	24 months (treatment)	42 months
BP during last month	79.2%	77.0%	37.2%	42.4%
Limitation due to BP	72.5%	70.9%	62.5%	62.2%
VAS-BP	-38.6	-42.0	-36.4	-36.0
EQ-5D-pain/discomfort	64.9%	59.4%	59.9%	57.4%
EQ-5D-mobility	48.0%	46.9%	45.5%	48.9%
EQ-5D-self-care	39.9%	39.1%	37.1%	38.0%
EQ-5D-usual activities	54.6%	48.4%	49.5%	54.8%
EQ-5D-anxiety/depression	45.8%	42.6%	41.7%	41.3%

EQ-5D: EuroQol health questionnaire VAS: visual analogue scale score

References:

1. BMC Musc Disord 2015;16:136
2. Endocrine Abstracts 2016;41:EP98
3. Arch Hell Med 2012;29:454

P166

DETRIMENTAL EFFECTS OF EMPAGLIFLOZIN ON BONE IN TYPE 2 DIABETIC RATS IS PREVENTED BY METFORMIN THROUGH AN INTERPLAY OF PTH, RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B AND PHOSPHORYLATION OF CREB

D. Vohora¹, P. Singh¹, D. Singh²

¹Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, ²Central Drugs Research Institute, Lucknow, India


Objectives: Type 2 diabetes mellitus (T2DM) is known to have a detrimental effect on skeletal health. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been reported to further deteriorate bone health. Clinically, SGLT2 inhibitors are used in combination with metformin, which has bone protective effects. Therefore, through this study, we evaluated the effect of empagliflozin, a relatively new SGLT2 inhibitor, alone and in combination with metformin on bone in high fat diet (HFD) and low dose streptozotocin (STZ)-induced T2DM in rats.

Methods: Male Wistar rats (6-8 weeks old) were made diabetic using HFD containing 60% fat for two weeks followed by an i.p. injection of low dose (35 mg/kg) of STZ. Empagliflozin (1 and 3 mg/kg), metformin (100 mg/kg) and their combination was administered orally for 8 weeks, following which rat femurs and tibia were isolated for studying bone microarchitecture using microCT and levels of alkaline phosphatase (ALP), acid phosphatase (TRAP),

PTH, pCREB were measured using commercially available kits while OPG:RANKL expression was studied using RT-PCR. Additionally, changes in serum calcium and PTH were also recorded.

Results: We show that accumulated levels of AGE in diabetic rats cause osteoblast apoptosis followed by an increase in level of RANKL which via stimulation of Ca-CaM pathway through the activation of PLC-γ increase the phosphorylation of CREB triggering osteoclast gene expression. Empagliflozin (3 mg/kg but not 1 mg/kg) adversely affected bone microarchitecture as indicated by trabecular bone volume, separation and thickness and also by enhanced serum calcium, reduced ALP, increased TRAP, reduced OPG:RANKL ratio, raised serum and bone PTH and increased pCREB. The adverse effects on bone were reverted by co-administration with metformin in diabetic rats possibly through an enhanced OPG/RANKL ratio and reversal of empagliflozin-induced phosphorylation of CREB.

Conclusions: The detrimental effect of empagliflozin on bone and its reversal by metformin is possibly mediated by an interplay between PTH, RANKL and pCREB (Figure 1). Future studies may target this pathway in diabetic individuals undergoing therapy with these drugs.



Acknowledgements: We are thankful to University Grants Commission Special Assistance Program for financial support to Department of Pharmacology at SPER, Jamia Hamdard.

P167
OBESITY AS AN INDEPENDENT RISK FACTOR FOR POSTOPERATIVE COMPLICATIONS, MORTALITY AND FUNCTIONAL OUTCOME AFTER TOTAL KNEE ARTHROPLASTY

D. Marín¹, P. Vicente¹, M. Sancho¹, S. Rebollo¹, M. Sanagustin¹, M. Molinedo¹
¹Hospital San Jorge, Huesca, Spain

Objective: To determine whether obesity is an independent risk factor for inpatient postoperative complications, mortality, and functional outcome in patients undergoing primary TKA.

Methods: We obtained our data from our hospital database of patients undergoing primary TKA between 2014-2017. The 285 patients obtained were divided according to their BMI: obese (≥ 30 kg/m²) and non-obese (< 30 kg/m²). To control for potential confounders and comorbidities, each obese patient was matched to a non-obese patient using age, sex, and other 16 comorbidities.

We evaluated in-hospital and later postoperative complications as well as mortality, length of stay and surgery duration. Functional outcome was evaluated using the Hospital for Special Surgery Score at 3, 6, 12 and 24 months after surgery.

Results: Our data showed that obese patients were more than twice as likely to have any postoperative complications (odds ratio (OR), 2.261; 95%CI, 1.279-4.015). Obese patients had a higher risk of postoperative in-hospital infection (OR, 5.609; 95%CI, 1.866–16.864; $p=0.0021$), wound dehiscence (OR, 2.697; 95%CI, 1.533–4.742; $p<0.001$) and in-hospital death after primary TKA (OR, 1.364; 95%CI, 1.173–1.719; $p=0.001$). There was no increase in the prevalence of cardiovascular or thromboembolic-related complications. Length of stay (6.3 vs. 5.8 d; $p=0.027$), and surgery duration (107.85 vs. 100.37 min; $p<0.001$), were also higher

in obese patients. There were no statistically significant differences in the functional outcome up to 24 months after the surgery (88.14 vs. 85.95 points; $p=0.46$).

Conclusions: Obesity appears to be independently associated with a higher risk for a small number of selected in-hospital postoperative complications and mortality after matching for comorbidities linked to obesity. However, the independent impact of obesity appears to be fairly modest, as it did not appear to be an independent risk factor for many systemic complications nor poor functional outcome. These findings lead to ask if it would be necessary to update the current pre and postoperative protocols in order to improve the results.

P168
CUTANEOUS METASTASES FROM PRIMARY EXTREMITY LEIOMYOSARCOMA: A CLINICAL REPORT

D. Marín¹, P. Vicente¹, M. Sancho¹, S. Rebollo¹, M. Sanagustin¹, M. Molinedo¹
¹Hospital San Jorge, Huesca, Spain

Objective: Report a case of a relatively rare tumor with an aggressive behavior leading to early skin and pulmonary metastases.

Methods: We report a case of an 86-year-old man with hypertension, COPD and gout referred to our trauma department with 3-month evolution ulcerative skin lesions in the right patella.

Results: Presumptive diagnosis was over infected tophi but the cultures were negative so further evaluation was necessary. Histological examination of the skin lesions showed a high grade leiomyosarcoma metastases. MRI revealed a heterogeneous 11x9x6 cm soft-tissue solid mass at the lateral aspect of the right leg. Extension study with thoracoabdominal CT scan was normal.

After multidisciplinary team meeting it is decided transfemoral amputation of the limb. Radiotherapy and chemotherapy were dismissed because of the patient comorbidities. One month after the surgery patient developed pulmonary symptoms and a new thoracic CT scan showed right pleural effusion and a 1 cm node in the lingula with PET-CT malignancy criteria.

Patient died one week after due to pulmonary dissemination.

Conclusions: Sarcomas are rare tumors that we should suspect in our primary care and hospital care consultations in presence of any soft tissue mass of suspicious characteristics and mainly located in lower extremities. $<0.25\%$ of patients with sarcomas develop cutaneous metastases although leiomyosarcoma is the most common primary to give rise to skin metastases. Cutaneous metastasis in these patients is usually a sign of very advanced disease, although it occasionally can be the first presenting sign of underlying malignancy. A misdiagnosis or a delay in its study can suppose an important deterioration in quality of life and survival of these patients. A multidisciplinary team for the management of these patients is needed, and it is also necessary to assess each case individually, trying to perform limb conservative surgery because no better survival results were obtained with radical surgery.

P169

PRIMARY HYPERPARATHYROIDISM PRESENTED WITH BROWN TUMORL. O. Ozsari¹, C. Y. Yidirim², A. Y. Yay³, F. D. Deniz³, A. Y. Yonem³¹University of Health Science, Department of Endocrinology,²University of Saglik Bilimleri/ Department of Orthopaedic³University of Saglik Bilimleri/ Department of Endocrinology/ Sultan Abdulhamid Han Hospital (GATA Haydarpasa), Istanbul, Turkey

Objective: We present a delayed parathyroid adenoma case that causes brown tumor. Even it has benign characteristics brown tumors can be confused with malign processes.

Methods: 27-year-old man admitted to the emergency department with right shoulder pain. The pain started four months ago and intensified by physical activity. A mass and dislocation were determined on direct x-ray graph. 7.5x5 cm cystic mass on the right humerus proximal epiphysis-metaphysis was reported on MRI. To understand the origin of this mass we scanned whole body and found multiple cystic lesions on the ribs and tibia. Biopsy was performed to a mass that is located at the right proximal humerus. Pathology reported aneurysmal cystic bone formation. After orthopedists realized serum calcium levels were high, the patient referred to the endocrinology clinic. Patient's medical history revealed nephrolithiasis operations. On physical examination, he had overweight appearance, BMI: 29 kg/m², right shoulder was stabilized with the bandage. No mass was palpated on neck examination. Vital findings were in normal range. Hypertension was not confirmed. Biochemical findings confirmed primary hyperparathyroidism with high serum PTH, high serum calcium, low serum phosphorous and normal vitamin D levels. A parathyroid adenoma with 21x29x7 mm diameter, hypoechoic appearance, located inferior side of right thyroid gland was suspected on neck ultrasound. Parathyroid scintigraphy (Tc-99m MIBI) was confirmed parathyroid adenoma on the right inferior thyroid gland location. After parathyroid adenectomy, calcium replacement was started against hungry bone disease. Pathology reported 3.6x3x0.9 cm parathyroid adenoma. After 6 months from surgery, he was on calcium carbonate 5000 mg/d, vitamin D3 3600 U/d and magnesium 365 mg/d. His PT level was low, calcium and phosphorus levels were normal. His right shoulder's movements were expanded near-normal by physical rehabilitation.

Result: Brown tumors are major problem in patients with secondary hyperparathyroidism, especially in chronic renal failure. Long lasting parathyroid adenomas, like our case, may cause multiple brown tumors.

Conclusion: Brown tumors may cause pathologic fractures which can mimic malign processes. Primary treatment is parathyroid adenectomy which regresses brown tumor.

P170

DISSCO STUDY: AN INTERNATIONAL, MULTICENTRE, DOUBLE-BLIND, RANDOMISED STUDY ON THE EFFECT OF DIACEREIN VS. CELECOXIB ON SYMPTOMS IN KNEE OSTEOARTHRITIS PATIENTSJ.-P. Pelletier¹, J.-P. Raynaud², P. Paiement³, J. Martel-Pelletier¹¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), ²Institut de Rhumatologie de Montréal, ³ArthroLab Inc., Montreal, Canada

Objective: To prove the noninferiority of diacerein vis-à-vis celecoxib on pain reduction (WOMAC A pain subscale) after 6 months treatment in symptomatic knee osteoarthritis (OA) patients.

Methods: A randomised double-blind multicentre trial conducted in Europe and Canada evaluating diacerein vs. celecoxib treatment in patients with KL grade 2-3 knee OA and moderate-to-severe pain (VAS₀₋₁₀₀ ≥ 40). Patients (n=380) diagnosed according to ACR criteria were randomised to 6 months treatment with diacerein 50 mg once daily for the first month and b.i.d. thereafter, or celecoxib 200 mg once daily. The primary outcome was change from baseline in WOMAC pain subscale (0-50) at 6 months. Secondary outcomes included WOMAC function and stiffness, VAS pain, and OMERACT-OARSI responders. The per protocol set (PPS) (primary analysis), intention-to-treat (ITT) (sensitivity analysis), and safety populations were analysed.

Results: In the PPS (n=288), the adjusted mean change in WOMAC pain was 11.14 (SEM, 0.91) with diacerein (n=140) and -11.82 (0.89) with celecoxib (n=148); the intergroup difference was 0.67 (95%CI -1.83 to 3.18; p=0.597), meeting the pre-specified noninferiority margin of <5. Sensitivity analysis (ITT population) showed similar results. All other outcomes showed no difference between treatment groups. The OMERACT-OARSI responder rate was similar in the diacerein (62.1%) and celecoxib (60.1%) groups. Incidence of adverse events related to drug treatment was low and balanced between groups. The exception, a greater incidence of GI side effects (diarrhoea) with diacerein (10.2% vs. 3.7%), led to 4.8% permanent discontinuation in the diacerein group vs. 1.6% in the celecoxib group. Diarrhoea was considered mild-to-moderate in all but one case with complete resolution.

Conclusion: In symptomatic knee OA patients, diacerein has comparable (noninferior) efficacy to celecoxib in reducing pain and stiffness and improving function after 6 months. Diacerein also demonstrated a good safety profile with positive benefit:risk ratio.

Disclosures: Study funded by TRB Chemedica International SA. JPP and JMP are consultants for TRB Chemedica and shareholders in ArthroLab Inc. JPR is a consultant for, and PP an employee of ArthroLab Inc.

P171

FAMILIAL PSEUDOHYPOPARATHYROIDISMM. Gurler¹, L. Ozsari²

¹Abant Izzet Baysal University, Faculty of Medicine, Department of Internal Medicine, Bolu, ²Health Science University, Sultanabulhamit Education and Research Hospital, Department of Endocrinology, Istanbul, Turkey

Pseudohypoparathyroidism (PHP) is a rare disorder characterized by target organ resistance to PTH, resulting in hypocalcemia and hyperphosphatemia. The subtypes are type 1a, 1b, 1c, 2 and PHP. Prevalence is 0.79/100.000. The 2 main subtypes PHP-1a and 1b, are caused by molecular alterations within or upstream of the imprinted GNAS gene, that encodes the G protein that activate cAMP-dependent pathways, due to a GNAS mutation on the maternal allele of the chromosome 20q13.3, with autosomal dominant (AD) inheritance. PHP-1a is characterized by the expression only of the paternal GNAS gene, with resistance to PTH and by the phenotype of Albright's hereditary osteodystrophy (AHO) with round facies, short stature, obesity, subcutaneous ossifications, brachydactyly, and in some cases mental retardation. To date, the genetic anomaly responsible for PHP-2 and 1c has not yet been identified, although in a few 1c patients, GNAS heterozygous mutations have been detected. It has been hypothesized that PHP-2 might be an acquired defect secondary to vitamin D deficiency. PHP can be sporadic or inherited AD with parental imprinting. We want to report patients with various clinical features of PHP in the same family. 23 y.o. F presented with numbness around lips and forgetfulness. In anamnesis wholebody numbness after a state of anxiety then severe hypocalcemia was found at the hospital 2 y ago. Family history was relevant to PHP, mother and brother. She had healthy appearance, height 165 cm, BMI 21.7 kg/m², BP 110/70 mmHg, and no Trousseau's sign. The physical findings were not compatible with AHO. PHP was confirmed by lab tests. Calcitriol (CCT) and calcium carbonate (CC) were started. She was fine without vitamin D or CC therapy last 3 months. 59 y.o. F was admitted to the hospital with cyanotic appearance, numbness around lips and hands in 4th decade of her life. After the finding of hypocalcemia, CCT and CC treatment was started. 2 of the 3 children were diagnosed with PHP. She had healthy appearance, height 158 cm, BMI 34.4kg/m², BP 120/70 mmHg and Trousseau's sign was observed. The physical findings were not compatible with AHO. She was fine with CCT and CC therapy. Genetic testing on GNAS1 gene was performed for the affected family members. Our patients do not show the features of AHO. According to clinical features of patients they are compatible with the type 1b.

P172

THE ASSOCIATION OF DIETARY PATTERNS WITH KNEE SYMPTOMS AND MRI DETECTED STRUCTURE IN PATIENTS WITH KNEE OSTEOARTHRITISS. Zheng¹, F. Wu¹, T. Winzenberg^{1,2}, A. Wluka³, F. Cicuttini³, D. Aitken¹, L. Blizzrad¹, G. Jones¹, C.-H. Ding^{1,3,4}

¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia, ²Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia ³Faculty of Health, University of Tasmania, Hobart, Tasmania, Australia ⁴Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Objective: To examine the cross-sectional and longitudinal associations of dietary patterns with knee symptoms and structures in knee OA patients.

Methods: Participants were selected from a randomised, placebo-controlled trial in Tasmania (N=261) and Victoria (N=152), who had symptomatic knee OA and vitamin D deficiency at baseline and received 50,000 IU vitamin D3 or placebo monthly for 24 months. Dietary was assessed by the Anti-Cancer Council of Victoria food frequency questionnaire. Exploratory factor analysis was used to identify dietary patterns. Each participant received a score for each dietary pattern, with a higher score indicating a great intake of food composing that pattern. At baseline and 24 months, knee symptoms were assessed using WOMAC and knee structures using MRI. Associations between dietary pattern scores and knee OA outcomes were examined using linear regressions with adjustment for covariates.

Results: Three dietary patterns "western pattern", "vegetable and meat pattern" and "healthy pattern" were identified in Tasmania, and two dietary patterns "meat and high fat pattern" and "vegetable pattern" were identified in Victoria. Participants with higher "healthy pattern" or "vegetable and meat pattern" scores had lower baseline dysfunction scores (b: -47.0, 95%CI: -88.4, -5.6; b: -45.01, 95%CI: -80.4, -9.8) and lower baseline total WOMAC scores (b: -59.2, 95%CI: -106.5, -11.9; b: -61.0, 95%CI: -116.5, -5.5). Participants who adhered to "western pattern" had significantly increased total WOMAC and dysfunction scores overtimes (b: 115.3, 95%CI: 33.5, 197.0; b: 94.1, 95%CI: 35.9, 152.3). Additionally, participants who adhered to "vegetable pattern" had significantly decreased knee symptoms impairment: pain (b: -25.4, 95%CI: -48.4, -2.5), dysfunction (b: -82.4, 95%CI: -151.7, -113.7), stiffness (b: -12.5, 95%CI: -23.5, -1.5); and effusion-synovitis volume (b: -0.95, 95%CI: -1.85, -0.05) over 24 months.

Conclusions: Our findings suggest that maintaining a healthy dietary pattern is associated with less knee function disability, whereas maintaining a western dietary pattern may contribute to increased functional disability over time. High intake of vegetables may be beneficial for joint symptom and effusion-synovitis. Our findings provide evidence for developing potential dietary strategies, such as keeping a healthy dietary, may improve joint symptoms and effusion-synovitis in OA patients.

P173

PSYCHOTROPIC MEDICATIONS AND PROTON PUMP INHIBITORS AND THE RISK OF FRACTURES IN THE TERIPARATIDE VS. RISEDRONATE “VERO” CLINICAL TRIAL

D. L. Kendler¹, F. Marin², P. Geusens³, E. Lespessailles⁴, P. López-Romero², J. -J. Body⁵, S. Minisola⁶

¹University of British Columbia, Vancouver, Canada, ²Lilly Research Center, Madrid, Spain, ³Maastricht University Medical Center, Maastricht, The Netherlands, ⁴Regional Hospital, University of Orleans, Orleans, France, ⁵CHU Brugmann, Université libre de Bruxelles, Brussels, Belgium, ⁶Sapienza Rome University, Rome, Italy

Objective: VERO is fracture endpoint study in women with established osteoporosis. The risks of new vertebral fractures (VFX) and clinical fractures in patients receiving teriparatide were reduced compared with risedronate¹. We analysed the effects of several concomitant medications associated with higher risk of low bone mass and fractures in the VERO cohort.

Methods: 1360 postmenopausal women with at least 2 moderate or 1 severe VFX and BMD T-score ≤-1.50 were randomized to SC daily teriparatide 20 µg or oral weekly risedronate (35 mg) in a double-blind, double-dummy 2-y trial. This *post hoc* analysis investigates the homogeneity of the treatment effect on the pri-

mary (new VFX) and key secondary fracture endpoints. Logistic and Cox proportional hazards regression models were used to analyse a potential treatment effect modification driven by the use of psychotropic drugs [hypnotics, benzodiazepines and antidepressants (selective serotonin- or norepinephrine-reuptake inhibitors: SSRIs and SNRIs)] and proton pump inhibitors (PPIs). A treatment-by-subgroup interaction p-value <0.1 was considered as evidence for the corresponding subgroup acting as an effect modifier. Additionally, we investigated whether these medications were associated with a higher risk of incident fractures during the VERO study.

Results: 406 (29.9%), 347 (25.5%) and 176 (12.9%) subjects were taking PPIs, benzodiazepines/hypnotics, and SSRIs/SNRIs at the randomization visit, respectively. For all fracture endpoints, the superior risk reduction of teriparatide vs. risedronate did not significantly differ in the categories of psychotropic drugs. In contrast, the risk reduction shown by teriparatide was statistically significantly higher in PPIs users vs. non-PPIs for clinical and nonvertebral fractures (NVFs) (Table). The risk of new VFX was higher in PPIs users vs. non-PPIs users (RR=1.70; p=0.0141) regardless of study treatments, but not for NVFs. Benzodiazepines/hypnotic drugs use increased the risk of clinical fractures (HR=1.79; p=0.0109) and NVFs (HR=2.12; p=0.0041). Similar increases in the risk of clinical fractures (HR=1.84; p=0.0232) and NVFs (HR=2.19; p=0.0089) were seen in SSRIs/SNRIs users.

	TPTD	RIS	HR (95% CI) TPTD vs RIS
Clinical fractures^a			
PPIs: Yes (n=406)	9 (4.1%)	27 (14.4%)	0.271 (0.127-0.576)
PPIs: No (n=954)	21 (4.6%)	34 (6.9%)	0.659 (0.383-1.136)
<i>Treatment-by-subgroup interaction p-value</i>			0.061
Non-vertebral fragility fractures			
PPIs: Yes (n=406)	7 (3.2%)	17 (9.1%)	0.344 (0.143-0.830)
PPIs: No (n=954)	18 (3.9%)	21 (4.3%)	0.924 (0.492-1.734)
<i>Treatment-by-subgroup interaction p-value</i>			0.074
Main non-vertebral fragility fractures			
PPIs: Yes (n=406)	5 (2.3%)	16 (8.6%)	0.262 (0.096-0.714)
PPIs: No (n=954)	13 (2.8%)	15 (3.0%)	0.935 (0.445-1.965)
<i>Treatment-by-subgroup interaction p-value</i>			0.046

^aclinical VFX plus non-vertebral fragility fractures

CI=confidence intervals; HR=hazard ratio; NVF=non-vertebral fractures; PPIs=proton pump inhibitors; RIS=risedronate; TPTD=teriparatide

Conclusion: In postmenopausal women with severe osteoporosis, the superior antifracture efficacy of teriparatide compared with risedronate was consistent in patients taking psychotropic drugs. PPI use was associated with a higher risk of fracture in subjects on risedronate compared with teriparatide.

Reference: 1Kendler DL et al. Lancet (2018)

Acknowledgement: Supported by Lilly

P174

OSTEOPOROSIS TREATMENT AFTER FRAGILITY FRACTURES OF THE HIP: EFFECTIVENESS OF A SECONDARY PREVENTION PROGRAM

G. Zinger¹, B. Bat-El¹, N. Sylvetsky², A. Peyser¹

¹Shaare Zedek Medical Center/Department of Orthopedics, ²Shaare Zedek Medical Center/Department of Endocrinology, Jerusalem, Israel

Objective: After a low-energy hip fracture, there is effective medication to treat the underlying osteoporosis but we need a better system to get patients on correct treatment. This study uses the fracture liaison (FLS) model to show that a successful program is possible in a national healthcare system.

Methods: At Shaare Zedek Medical Center, Jerusalem, Israel, we performed a prospective randomized study to show the effectiveness of an intervention program.

- Control group: At the time of discharge, patient were given a letter instructing them to discuss evaluation and treatment with their family physician.
- Intervention group: patients were given printed information on osteoporosis, DXA scan was performed during their initial hospitalization, patients were given a specific medication recommendation to give to their physician, and monthly phone calls were made by the FLS coordinator.

The primary outcome measure is whether the patient was on correct treatment at 4 months post-fracture. The study was powered assuming 20% of control would be on correct treatment vs. 50% of the intervention group. The secondary measure is mortality at one year.

Results: 18 months after starting the study, we treated 643 patients with hip fractures of which 305 were eligible. Of those, 200 patients (66%) were enrolled and randomized and we have 4-month data on 180 patients. Our secondary outcome is mortality rate at one year and we have data on 122 of those patients.

Intervention Efficacy:

- Control group - on correct treatment=5/84 (5.9%)
- Intervention group - on correct treatment=64/79 (81%)
- Intervention is significantly more effective, P<0.0001

Mortality Rate at one year: overall 16%

- On-treatment=2/52 (3.8%)
- Off-treatment=18/70 (26%)
- Being on treatment is associated with lower mortality, P<0.04 (t-test).

Age for the group on-medication was younger (76.0) compared to off-medication (81.3). However, with logistic regression analysis, the age was found to be not significant with regards to mortality (p=0.20) while treatment remained significant (p=0.013), ROC=0.74.

Conclusions: The most successful programs worldwide have a FLS coordinator that manages evaluation and guides treatment using a predetermined protocol. We show that in the setting of a national healthcare system, such a system is effective.

P175

MUSCULOSKELETAL DISORDERS AND PERCEIVED WORK DEMANDS AMONG FEMALE NURSES AT A TERTIARY CARE HOSPITAL IN INDIA

S. K. P. Katpattil¹

¹Mesams, Thrissur, India

Objective: Musculoskeletal disorders (MSD) are common among nurses and can affect patient outcomes. The study objective was to measure prevalence of MSD and their association with perceived work demands and sociodemographic variables among female nurses at a tertiary care hospital in South India.

Methods: A cross-sectional study was conducted starting June 2016 to May 2017 through interviewer administered questionnaires which comprised three parts: sociodemographic data, modified Nordic questionnaire, and perceived physical and psychological work demands.

Results: 296 nurses with a mean age of 30.4 y participated. Prevalence of any MSD in the last seven days was 60.5% with low back pain being the most common and elbow pain the least common. Occurrence of any MSD was associated with age, number of children, working hours at home, BMI, and total work experience. High perceived physical demands score was associated with lower back (OR: 3.06) and knee pain (OR: 7.73).

Conclusion: Prevalence of MSD was high and occurrence of lower back and knee MSD was associated with perceived physical demands. This information should be used as a benchmark and guiding tool for designing work place interventions to improve working conditions and health of nurses.

P176

MULTI- AND EXTENSIVELY-DRUG RESISTANT GRAM-NEGATIVE OSTEOMYELITIS: MICROBIOLOGICAL AND PATIENTS' CHARACTERISTICS

K. Raptis¹, C. Koutserimpas¹, A. Mari², S. Tournis², K. Alpantaki³

¹Department of Orthopaedics and Traumatology, 251 HAF - VA Hospital, Athens, ²Laboratory for the Research of the Musculoskeletal System, University of Athens, KAT Hospital, Athens, ³Department of Materials and Science University of Crete, Heraklion, Greece

Objective: Few series of osteomyelitis due to multidrug (MDR) or extensively drug resistant (XDR) gram-negative bacteria exist. A retrospective study of MDR and XDR gram-negative osteomyelitis cases was performed, aiming to investigate causative organisms, management and outcome.

Methods: All patients, treated at the University hospital of Crete between 2009-2018 for osteomyelitis, due to MDR or XDR gram-negative pathogens were evaluated.

Results: A total of 14 patients (8 males) were identified with a mean age of 50.6 y. Five *Acinetobacter baumannii* cases, 3 XDR and 2 MDR, were found. Furthermore, 3 MDR *Klebsiella pneumoniae* and 3 MDR *Enterobacter cloacae* isolates were identified. Additionally, 2 MDR *Escherichia coli*, as well as 2 *Pseudomonas aeruginosa*, 1 XDR and 1 MDR, were isolated. One case of *Roseomonas gilardii* was also identified. In 5 cases the same pathogen was also isolated from blood. Five out of the 14 patients were smokers, 6 were suffering severe injury, 4 had diabetes mellitus, 2 chronic renal disease and 2 were obese. Most causative organisms had hospital origin. All patients received first line empirical combination antimicrobial treatment, proven effective in 4.

Conclusions: The incidence of bacteremia observed was higher than that in similar studies. The study included mainly young individuals, most likely due to the high incidence of traffic accidents involving young adults in Crete. Emergence of resistant pathogenic bacteria has become a significant public health issue. Compliance with strict hygiene rules, as well as physicians' stewardship for appropriate antimicrobial use may contribute to successful management of these infections.

P177

DOES VITAMIN D LEVELS AFFECT CHANGES IN PQCT BONE DENSITY AND MICROARCHITECTURE IN POSTMENOPAUSAL WOMEN AFTER CONSERVATIVELY TREATED DISTAL RADIUS FRACTURES? AN EXPLORATORY STUDY

K. Raptis¹, A. Mari¹, C. Koutserimpas², K. Alpantaki³, S. Tournis¹

¹Laboratory for the Research of the Musculoskeletal System, University of Athens, KAT Hospital, Athens, ²Department of Orthopaedics and Traumatology, 251 HAF - VA Hospital, Athens, ³Department of Materials and Science University of Crete, Heraklion, Greece

Objective: Distal radial fractures (DRF) in postmenopausal women are among the most common types of low energy fractures and in most cases are associated with low serum VitD levels. The pivotal role of VitD deficiency in the pathogenesis of DRF fractures is generally accepted, but there still seems to be no sustainable consensus regarding VitD influence in early changes in vBMD and architecture of trabecular and cortical bone at radius after a DRF. The object of this experimental study was to obtain further information about the role of vitamin D on bone microarchitecture parameters during the first weeks of fracture healing period in postmenopausal women with distal radius fracture using pQCT scan.

Methods: The study group consisted of postmenopausal women with a DRF conservatively treated by cast immobilization. Patients were classified into 2 groups according to initial serum 25(OH)D level, Group A (25(OH)D \geq 15 ng/ml) and group B (25(OH)D <15 ng/ml). All patients were followed over a period of 12 weeks at

three outpatient visits: at 1 week (visit 1), at 6 weeks (visit 2) and at 12 weeks (visit 3) postfracture. PQCT measurements were performed at visit 1 in fractured and contralateral nonfractured distal radius (baseline), at visit 2 (6th week) and at visit 3 (12th week) on the fractured side.

Results: During a 19th month period we identified 57 women meeting the inclusion criteria, but only 39 women completed the protocol. The mean age was 66.69 \pm 10.12 (range: 51-88 y), 51.3% (n=20) of the fractures occurred at the right radius, while 51.3% (n=20) at the dominant side. Mean 25(OH)D levels were 15.60 \pm 7.35 ng/ml (3.5-41.7). At the peripheral trabecular site there was no interaction between baseline 25(OH)D levels and changes in trab BMC, vBMD and CSA. At the cortical site, cort BMC, cort vBMD and cort CSA progressively decreased (p<0.001) during the 12 weeks of the study, but there was no difference in cort BMC, vBMD and CSA at any of the three time points between group A vs. group B.

Conclusion: Our data indicate that vitamin D deficiency does not modulate the early post fracture response. Moreover we observed significant increase in trabecular BMC and vBMD at the fracture site, while there was deterioration in almost every pQCT derived parameter of cortical bone, independent of vitamin D levels, probably related to immobilization. Furthermore higher age and higher bone remodeling were associated.



P178

EARLY FRACTURE LIAISON SERVICE EXPERIENCE IN HONG KONG: ONE YEAR REVIEW

K. L. Tiu¹, S. M. Tam¹, C. K. J. Lau¹, K. H. T. Chui¹, K. B. Lee¹, W. Y. Li¹

¹Department of Orthopaedic & Traumatology, Queen Elizabeth Hospital, Hong Kong, China

Objective: The rapidly aging population of Hong Kong (HK) with increasing life expectancy poses high prevalence of osteoporosis. Among the 7000+ incidence a year, 98% of fragility hip fractures in HK were managed by the public hospitals system under Hospital Authority (HA) (Man, Ho & Wong, 2016). In 2017, HA has appointed 3 Fracture Liaison Nurses (FLN) to develop Fracture Liaison Service (FLS) in 3 different hospitals. Queen Elizabeth Hospital (QEH), a centrally located, largest hospital with 2000 acute beds, as a pilot center for the development of FLS. QEH FLS team was established in 2017, The 3 I protocol was advocated (Identification, Investigation & Initiation). We started a comprehensive secondary fracture prevention programme since 1/1/2018 to all patients admitted with fragility hip fractures. Our aim was to share and report the preliminary result of Early FLS experience in HK.



Methods: A retrospective reviews of all fragility hip fracture patients admitted to Queen Elizabeth Hospital from 1/1/2018 to 31/12/2018.

Results: Total of 800 patients was admitted and managed from 1/1/2018 to 31/12/2018 with a fragility hip fracture, (M/F: 1/2), Age 65-103, mean age of 84.5. 622 of them undergone operative managements (365 internal fixations and 257 hemiarthroplasties). All 800 patients (100%) were discharged with calcium and vitamin D supplements (22.9% in all hospital in 2012 HK, 69% in UK (Leung et al 2017)). Overall of 84.0% of patients (187) who are eligible and fitted for secondary prevention were treated with either intravenous zoledronate acid infusion or denosumab injection after FLN screening during the stay in acute hospital. (Figure 1) Although no evidence of decrease secondary fracture incidence in this first year report, all 157 patients received secondary osteoporosis treatment reported good compliances and no complication of treatment.

Service gap: Lack of systematic osteoporosis screening, education & treatment

2012	HK (%)	UK (%)
Discharge with bone protection medication (included Calcium and Vitamin D supplement)	22.9 <small>(orthopedic department of public hospitals)</small>	69 <small>(Leung et al., 2017)</small>

Low awareness on osteoporosis treatment!




Figure 1

Conclusions: Confusion over who is responsible for osteoporosis care after a fragility fracture is a major barrier to effective treatment (Miki et al. 2008). This is an introduction of FLS in HK, our model focused on secondary fracture prevention on patients after fragility hip fracture at the moment. We proved that is a feasible model with satisfactory result in one of the busiest hospital in HK which operated >750 hip fractures yearly (including younger hips and pathological fractures). As a pilot and an example, we hope the service can be extended to all fragility hip fracture cares in HK in the future.

References:

Ho AWH & Wong SH, Osteoporos Int 2015;26:396.
 Leung KS et al., Hong Kong Med J 2017;23(3).
 Miki RA et al., J Bone Joint Surg Am 2008;90:2346.

Acknowledgments: Thanks to the dedication, passion and trust to all members of the QEH FLS team.

P179

CROSS-SECTIONAL BETWEEN MRI AND CONVENTIONAL RADIOGRAPH OF ABNORMALITIES AND HAND SYMPTOMS IN OLDER ADULTS

S. M. Mattap¹, K. Wills¹, D. Aitken¹, A. Halliday², S.-N. Luong³, G. Jones¹, K. Squibb¹, L. Laslett¹

¹Menzies Institute for Medical Research, University of Tasmania, Hobart, ²Department of Medical Imaging, Royal Hobart Hospital, Hobart, ³University of New South Wales, Sydney, Australia

Objective: To describe associations between presence of MRI-detected effusion, bone marrow lesions, erosions, collateral ligaments (CL), osteophytes; radiograph-detected osteophytes and joint space narrowing (JSN) with joint symptoms and grip strength in older community-based adults.

Methods: Distal and proximal interphalangeal index finger joints (n=221, mean age=72, 44% females) were imaged using MRI, conventional radiographs (CR) and assessed using the Oslo hand osteoarthritis (HOA) score and OARSI atlas, respectively. Joints were assessed clinically for pain and tenderness. Hand pain, function, and stiffness were assessed using the Australian/Canadian HOA index (AUSCAN) questionnaire; grip strength was assessed using a dynamometer. Data was analysed using log binomial, ordinal logistic, and linear regression adjusted for age, sex, and other MRI or CR abnormalities.

Results: Participants with above average (worse) AUSCAN pain scores were more female (55%), meet ACR HOA criteria (92%) and have poorer grip strength (9psi) and quality of life (AQoL utility 0.66) than those with mild or no pain. Absent CLs on MRI (RR=3.33 (95% confidence interval; 1.45, 7.61)) and JSN on CR (RR=2.47 (1.06, 5.74)) had a higher risk of a painful joint after adjustment for other structures. Those with JSN had a higher risk of moving to a higher category of AUSCAN pain (OR=1.59 (1.08, 2.35)) while effusion, surprisingly, had a lower risk (OR=0.51 (0.28, 0.91)) of pain. JSN was also associated with lower grip strength independent of pain and other features (β =-0.95 (-1.74, -0.15)). No abnormalities were independently associated with tender joints, function limitation or stiffness.

Conclusion: Absence of CL and JSN were independently associated with painful joints; JSN was also associated with weak grip strength. Unexpectedly, effusions were associated with reduced odds of pain. This data does not support using MRI to identify potential targets for therapeutic interventions for hand pain.

P180

SAFETY OF INTRA-ARTICULAR HYALURONIC ACID INJECTIONS IN OSTEOARTHRITIS: OUTCOMES OF A SYSTEMATIC REVIEW AND META-ANALYSIS

G. Honvo¹, J.-Y. Reginster¹, F. Rannou², X. Rygaert¹, A. Geerinck¹, V. Rabenda¹, T. McAlindon³, A. Charles¹, N. R. Fuggle⁴, C. Cooper⁴, E. M. Curtis⁴, N. Arden⁵, B. Avouac¹, O. Bruyère¹

¹Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ²Division of Physical Medicine and Rehabilitation, Department of Rheumatology, AP-HP Cochin Hospital, Université Paris Descartes Sorbonne Paris Cité, and INSERM U1124, Paris, France, ³Division of Rheumatology, Tufts Medical Center, Boston, USA, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK, ⁵Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis, University of Oxford, Oxford, UK

Objective: To assess the safety of intra-articular hyaluronic acid (IAHA) in the management of osteoarthritis (OA) in a systematic review and meta-analysis of randomized, placebo-controlled trials.

Methods: A comprehensive literature search was undertaken in the databases MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and Scopus. Randomized, double-blind, placebo-controlled, parallel-group trials that assessed adverse events (AEs) with IAHA in patients with OA were eligible for inclusion. Authors and/or study sponsors were contacted to obtain the full report of AEs. The primary outcomes were overall severe and serious AEs, as well as the following MedDRA System Organ Class (SOC)-related AEs: gastrointestinal, cardiac, vascular, respiratory, nervous system, skin and subcutaneous tissue disorders, musculoskeletal, renal and urinary disorders, infections and infestations, and hypersensitivity reaction.

Results: Database searches initially identified 1481 records, from which, after exclusions, 22 were included in the qualitative synthesis, and 9 studies having adequate data were included in the meta-analysis. From the studies excluded according to the review protocol, 21 papers with other pharmacologic OA treatments permitted were included in a parallel qualitative synthesis, from which 8 studies were included in a parallel meta-analysis. No statistically significant difference in odds was found between IAHA and placebo for all types of SOC-related disorders, except for infections and infestations for which significantly lower odds was found with IAHA compared with placebo, both overall (odds ratio [OR]=0.61, 95% confidence interval [CI] 0.40, 0.93; I²=0%) and in studies without concomitant anti-OA treatment (OR=0.49, 95%CI 0.27, 0.89; I²=0%). There was significant increased odds of reporting serious AEs in the IAHA group both overall and with concomitant anti-OA treatment (OR=1.78, 95%CI 1.10, 2.89; I²=0%).

Conclusions: Using the available data on studies without any concomitant anti-OA treatment during clinical trials, IAHA appears not to be associated with any safety issue in the management of OA. A possible association with increased risk of serious AEs, particularly when used with concomitant OA medications, requires further investigation.

P181

COST-BENEFIT ANALYSIS TO THE MEDICAL SYSTEM FOR A FRACTURE LIAISON SYSTEM (FLS) FOR SECONDARY FRACTURE PREVENTION

G. Zinger¹, A. Davidson¹, B. Bat-El¹, A. Peyser¹

¹Shaare Zedek Medical Center/Department of Orthopedics, Jerusalem, Israel

Objective: To better understand the costs and benefits of an FLS system within a national healthcare network.

Methods: A prospective, randomized study was performed at Shaare Zedek Medical Center, Jerusalem, Israel to determine efficacy of a program for osteoporosis treatment. In parallel, a detailed cost analysis was made for each patient.

Results: 18 months after starting the study, we treated 643 patients with hip fractures of which 305 were eligible. Of those, 200 patients (66%) were enrolled and randomized and we have 4-month data on 180 patients. National Health Plan Perspective (Kupah): The average payment from the Kupah to the hospital was 32,800 NIS per hip fracture. Rehabilitation adds approximately 16,800 NIS bringing the total average cost per hip fracture to 50,055 NIS. Hospital Perspective: Despite income from the Kupah, the hospital lost an average of 17,810 NIS per hip fracture. Expected refractures based on Horizon study: Using our rates of effectiveness of our orthopedic department FLS program, and using the Horizon study2 reduction in new fractures per year (13.9% vs. 8.6%), we calculated the following (6000 fractures in Israel per year): The rate of refracture would be reduced by 3.94% or 236 less fractures per year. Loss per hip fracture is calculated at 67,865 NIS resulting in 16 million NIS savings. For comparison, with both primary and secondary prevention, Kaiser Permanente Southern California has achieved 40% reduction in fragility frac-

tures. Cost of Secondary Prevention Program: Using the Kaiser Permanente FLS program as a guide¹, we estimate 50 full-time personnel would be needed for a national secondary prevention program. Using local salary costs, we estimate a cost of 9.1 million NIS to save 16 million NIS. This cost savings does not include lives saved.

Conclusions: Everyone loses with low energy hip fractures: patients, hospitals and the national healthcare system. The solution is to invest. We show that compared to the salary of a FLS coordinator, investing in secondary fracture prevention is cost-effective.

References:

1. Dell RM et al. J Bone Joint Surg Am 2009;91 Suppl 6:79.
2. Lyles KW et al. NEJM 2007;357:1799

P182
IN VITRO EFFECTS OF INTERMITTENT PTH(1-34) ON HUMAN ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS DURING OSTEOGENIC DIFFERENTIATION AND MINERALIZATION

C. Romagnoli¹, G. Palmmini¹, F. Marini¹, G. Galli¹, R. Zonefrati¹, M. L. Brandi¹

¹Department of Surgery and Translational Medicine, University of Florence, Florence, Italy

Objective: PTH is a peptide of 84 amino acids, secreted by the parathyroid glands, which controls Ca²⁺ homeostasis by regulating intestinal absorption and renal secretion and playing an important role in bone metabolism. In hypoparathyroidism (HypoPT), there is a severe PTH deficiency, leading to persistent hypocalcemia and hyperphosphoremia, high urinary Ca²⁺ excretion and reduced levels of active vitamin D. Patients with HypoPT present a reduction in bone remodelling, with an increase in bone mass compared to healthy subjects. Therapy with PTH peptides makes possible to reduce Ca²⁺ and active vitamin D administration; however studies are necessary for a better understanding of how PTH acts on osteoprogenitor cells. We aim to analyze the *in vitro* effects of PTH (1-34) on osteogenic differentiation and mineralization of mesenchymal stem cells derived from human adipose tissue (hADMSCs).

Methods: hADMSCs were obtained by enzymatic digestion and mechanical dispersion, and cultured in growth medium. Multipotency was evaluated inducing hADMSCs towards different phenotypes. Cells were exposed to 10-8 M, 10-10 M, 10-12 M of PTH(1-34), for 6 h/d for 3 d. ALP activity and Ca²⁺ deposition were quantified by fluorometric assay up to 28 d of osteogenic induction. Statistical analysis was performed by ANOVA followed by Bonferroni's test.

Results: hADMSCs confirmed the ability to differentiate in 3 phenotypes. hADMSCs osteoinduction with PTH 10-10 M and 10-12 M showed significant increases (*p<0.05) in ALP activity vs. control after 7 d, and then it returned to values similar to the control.

Regarding the mineralization process, tested PTH at 10-10 M, 10-12 M resulted in significant increases (*p<0.05) in the deposition of Ca²⁺ + nodules vs. control, especially after 28 d.

Conclusion: The work aims to identify PTH (1-34) concentrations to which hADMSCs respond positively. Preliminary results have shown that the osteogenic activity and the mineralization of hADMSCs are increased using intermittent administration of PTH at 10-10 M and 10-12 M. Studies are in progress in order to evaluate OPG and RANKL genes.

Acknowledgment: This work is supported by FIRMO.

P183
IMPORTANT CLINICAL BENEFITS OF HAVING A SECONDARY FRACTURE PREVENTION PROGRAM

G. Zinger¹, N. Sylvetsky², A. Peyser¹, B. Bat-El¹

¹Shaare Zedek Medical Center/Department of Orthopedics,
²Shaare Zedek Medical Center/Department of Endocrinology, Jerusalem, Israel

Objective: Our orthopedic department started a secondary fracture prevention program using the successful fracture liaison service (FLS) model. The objectives of this study are to share the clinical benefits to the patients of having an FLS system and estimate the sensitivity of fracture prediction tools.

Methods: A prospective study was done evaluating patients with fragility fractures of the hip. Evaluation included the following labs: calcium level, albumin level, thyroid function, liver and kidney function and PTH level when indicated. During their hospitalization a DXA scan was performed and fracture risk assessment tool (FRAX) was calculated. The results of DXA and FRAX separately and together were analyzed to determine how well the fragility fracture could have been predicted.

Results:

155 patients are included in this analysis:

- 12 patients had labs that showed an underlying potentially treatable cause for their weak bone – 7 had high PTH levels and 5 had low TSH levels.
- 36 patients had labs that changed their treatment: 4 had low calcium levels that needed correction, 17 had elevated TSH levels and were started on thyroid supplement, and 15 had a new diagnosis of reduced kidney function.
- Overall 31% of patients had labs that were clinically important.

FRAX scores:

- Major osteoporotic fracture was correctly predicted in only 49%
- Hip fracture was predicted in 83%

DXA scores:

- Showed osteoporosis in only 46% of hips
- Showed osteoporosis in only 26% of spines

Taking the two most specific measures, hip FRAX and hip DXA:

- Requiring only one OR the other measure to be abnormal, would have predicted a fragility fracture 93% of the time.

Conclusions:

1. Laboratory evaluation in patients with a fragility fracture of the hip had significant benefit to 31% of the patients including identifying an underlying treatable cause or providing benefit to their overall health.
2. Hip FRAX was more predictive of a hip fracture than major osteoporotic prediction ($p < 0.0001$).
3. DXA showed osteoporosis more often in hip than in spine ($p < 0.023$).
4. The combination of FRAX hip score and DXA hip was the most sensitive in identifying the risk of a potential osteoporotic fracture.

P184

CLINICAL ASSESSMENT OF PATIENTS WITH ISOLATED HIP FRACTURES ASSOCIATED WITH AN UPPER LIMB FRACTURE

J. Gómez¹, S. González², E. Gil²

¹Clínica Universidad de Navarra, Pamplona, ²Hospital La Paz, Madrid, Spain

Objective: Some patients with a hip fracture also present a concomitant upper limb fracture. We want to know whether these patients have a worse functional level and whether they have any differences in various clinical parameters compared with patients with an isolated hip fracture.

Methods: We retrospectively reviewed 1061 discharge reports from the Orthogeriatrics Unit. We collected information on several clinical parameters of the fractures. Subsequently, we performed a statistical analysis of the data by comparing the associated fracture group with the isolated fracture group.

Results: We detected 44 patients with associated upper limb fracture, 90.9% were women (40) and the average age was 84.45 y. 81.8% of the upper limb fractures were distal radius or proximal humerus. Pertrochanteric fractures were the most common (none of them were subtrochanteric fractures). Surgical delay was 2.60 d and the average hospital stay was 12.30 d. 64.3% were nail surgery and 31% arthroplasty. The mean Barthel Index score was 84.88 ($P = .021$). 52.5% of the patients in the study group were referred to a functional support unit ($P = .03$). The in-hospital mortality rate was 4.2%, with no differences between groups.

Conclusions: Patients with an associated fracture have a higher previous functional capacity and they are more independent. Nevertheless, after the fracture they need more help from the health-care system for optimal functional recovery.

P185

OSTEONECROSIS OF THE JAW MANAGEMENT IN THE CLINICAL SETTING

B. Camargos¹

¹Densimeter / Rede Materdei, Belo Horizonte, Brazil

Osteonecrosis of the jaw (ONJ) is a pathological condition often attributed to antiosteoporotic therapy. Although it is low prevalence and incidence, the impact of ONJ over treatment discontinuation is clear. There are international consensus on the issue but ONJ remains a defying condition to manage in the clinical setting. This activity is aimed to provide the tools needed to manage patients considered for an oral invasive procedures (implants, extractions and bone grafts) at the same time that they are under anti-osteoporotic therapies. Examples will be provided for discussion.

Objectives:

- Provide background on the ONJ incidence and osteoporosis treatments
- Describe the mechanisms underlying increased risk of ONJ and most probable scenarios
- Give directions about ONJ risk evaluation
- Describe effects of bone pharmacological agents related to the ONJ
- Outline clinical guidance for management of ONJ

P186

CARDIOVASCULAR AUTONOMIC NEUROPATHY CAUSES AN IMPAIRMENT OF QUALITY OF LIFE IN SUBJECTS WITH CHRONIC HYPOPARATHYROIDISM

G. Tabacco¹, A. M. Naciu¹, D. Maggi¹, C. Pedone¹, D. Lelli¹, R. Cesareo², A. Santonati³, D. Bosco³, A. M. Di Tommaso¹, N. Napoli¹, P. Pozzilli¹, S. Manfrini¹, A. Palermo¹

¹Campus Biomedico University of Rome, Rome, ²UQS Malattie Metaboliche, Santa Maria Goretti Hospital, Latina, ³San Giovanni Addolorata Hospital, Rome, Italy

Objective: Patients with postsurgical hypoparathyroidism (hypopT) complain fatigue and seems to have an increased risk of mortality. Hypoparathyroid patients on conventional treatment with calcium and vitamin D supplementation show a reduction of Quality of life (QOL). Cardiovascular autonomic neuropathy (CAN) is an impairment of the cardiovascular autonomic system and it represents a cause of increased mortality and fatigability. Recently, we have demonstrated that patients with chronic post-surgical hypoparathyroidism show an increased risk of CAN. No previous studies have investigated the association between CAN and QoL in hypoparathyroidism. We tested the hypothesis that CAN would be associated with impaired QOL measures in subjects with chronic post-surgical hypoparathyroidism.

Methods: We included 49 postsurgical hypoparathyroid patients treated with calcium and calcitriol. Subjects completed the RAND 36-Item Short Form (SF-36) Health Survey, a measure of health-related QOL covering eight domains of physical and mental health. QOL has also been evaluated using Fatigue score (version 4). CAN was assessed by heart rate (HR) response to deep breathing, HR response to the lying-to-standing test, HR response to the Valsalva maneuver and blood pressure response to standing. Participants were considered to have "early CAN" (EC) if they had one abnormal result in the HR tests and "definite CAN" (DC) with two or more abnormal results.

Results: The prevalence of patients without CAN (WC) was 22% (n=11), the prevalence of EC was 39% (n=19), the prevalence of DC was 39% (n=19). Only DC subjects showed a statistically significant lower fatigue score compared to patient without CAN (35.1±5.8 vs. 44.4±4.6, P=0.004). These results have been confirmed after adjustment for age, calcium concentration, calcitriol and calcium supplementation (β :-9.31, P=0.004). No statistically significant differences between groups were found for mental and physical component summary scores. Role limitation due to physical problem represents the only domain that showed a significant reduction between groups (WC: 82.6±33.4, EC: 72.4±33.2, DC: 50±38.2, ANOVA P=0.044).

Conclusion: Patient with chronic postsurgical hypoparathyroidism and definite CAN show an impairment of QOL. The presence of cardiovascular autonomic neuropathy could explain the fatigue, a common complaint in patients with hypoparathyroidism.

P187

NONSPECIFIC INFLAMMATORY RESPONSE PARAMETERS IN THE PATHOGENESIS OF VASCULAR WALL AND BONE REMODELING IN POSTMENOPAUSAL FEMALE PATIENTS WITH ARTERIAL HYPERTENSION

T. Petelina¹, K. Avdeeva¹, S. Bycova¹, N. Musikhina¹, L. Gapon¹, E. Zueva¹

¹Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Tyumen, Russia

Objective: The searching study at the subclinical level of general pathogenetic mechanisms of atherosclerosis and osteoporosis in a steady ageing of the population is of considerable importance in prevention of development of complications. Our aim was to study the role of markers of vascular inflammation as a predictor of cardiovascular and degenerative bone complications in postmenopausal female patients with arterial hypertension (AH) and osteoporosis (OP).

Methods: 153 patients (mean age 57.45±6.16 y) were examined and divided into three groups. Gr.1 included 42 healthy individuals, Gr. 2 included 50 female patients with AH and Gr. 3 included 64 postmenopausal female patients with AH and OP. By age, patients in Gr. 2 and 3 were comparable. Patients had an average history of AH 12.31±8.91 y. All patients received optimal hypertensive therapy. The parameters of 24-h blood pressure (systolic

and diastolic BP) monitoring using ABMP-04 Meditex device; sphygmography by Vasera VS-1000 Fucuda (pulsewave velocity - PWV), osteodensitometry performed on the spiral computed tomography Siemens Somatom Emotion (calcium content CA-HA, standard deviation of the peak T-score); intima-media thickness (I/M) of carotid arteries; lipid profile parameters, inflammatory markers (hs-CRP, TNF- α homocysteine, interleukin (IL) 1 β , 6, 8); endothelial dysfunction markers (endothelin-1, nitrites); parameters of calcium metabolism (calcium, ionized calcium, vitamin D, calcitonin) and sex hormones like (estradiol, progesterone and testosterone) were measured.

Results: The levels of estradiol and progesterone were significantly higher in Gr. 1 (p=0.0001). The levels of total cholesterol, LDL cholesterol, APO-B, hs-CRP, homocysteine, IL6 and 8 and endothelin-1 have been above the reference value in Gr. 2 and 3. Additionally, in Gr. 3 statistically higher levels of office SAD and DAD, I/M, lower levels of sex hormones, vitamin D, total calcium, ionized calcium and peak T-score. Besides, in Gr. 3 there were registered negative correlations between peak T-score with ade, PWV, office SBP and DBP, duration of menopause, IL6, hs-CRP, homocysteine and between PWV with estradiol; positive correlations between T-score with progesterone and between PWV with IL6, LDL cholesterol, hs-CRP, TNF- α , endothelin-1, mean daytime systolic SBP, in day time SBP variability SBP and DBP variability (p<0.005 for all correlations).

Conclusions: The association of pulse wave velocity and T-score with nonspecific inflammatory response markers, the level of female sex hormones and parameters of calcium metabolism can be part of the pathogenesis combining the subclinical atherosclerosis with vascular stiffness and bone remodeling in postmenopausal women with hypertension.

P188

ASSOCIATION OF NEUTROPHIL-LYMPHOCYTE RATIO WITH THE SEVERITY OF PRIMARY KNEE OSTEOARTHRITIS IN A SAMPLE OF IRAQI PATIENTS

S. Salman¹, K. Jwad¹

¹Rheumatology Unit, College of Medicine, University of Baghdad, Baghdad, Iraq

Objective: Osteoarthritis is the most common form of arthritis. It is a leading musculoskeletal cause of disability in elderly persons all over the world and a major cause of physical limitations and reduced quality of life. Osteoarthritis is increasingly recognized as a disease with a significant inflammatory component. Blood neutrophil-lymphocyte ratio (NLR) is the ratio between the absolute neutrophil and lymphocyte counts. The systemic inflammation modulates the coagulation process, so NLR has emerged as a simple, cheap and useful tool that represents inflammation in many other systemic circumstances. Our aim was to evaluate the association between severity of knee osteoarthritis (KOA) and NLR levels.

Methods: This was a case-control study conducted at Baghdad Teaching Hospital, unit of Rheumatology during the period from September 2016 to June 2017. A total of 126 patients with KOA

diagnosed according to the ACR clinical criteria and 126 apparently healthy subjects, age and gender matched to the patients regarded as controls were recruited in this study after obtaining their consent. Patients with history of trauma, infection, malignancy, connective tissue diseases and very high ESR and CRP were excluded. Investigations that we did including: X-rays of both knee joints in anterior-posterior view in standing position and record the severity according to Kellgren-Lawrence grading system. Blood samples were collected under aseptic venipuncture and send for laboratories to complete investigations. This include CBC, WBC count, platelets count, neutrophil, lymphocyte, ESR and CRP. Blood NLR was calculated for every participant.

Results: KOA patients had higher NLR compared to healthy population. Higher NLR is weakly associated with severity of KOA. NLR is a poor predictor of severity of KOA. Age was a stronger predictor of severity of KOA than NLR.

Conclusions: NLR alone should not be depended on as a marker or predictor of severity of KOA. Further studies with larger sample size included other markers in order to generalize the results.

P189

PREVALENCE OF MAJOR DEPRESSIVE DISORDER AMONG POSTMENOPAUSAL IRAQI WOMEN WITH OSTEOPOROSIS

S. Salman¹, S. Qassem¹

¹Rheumatology Unit, College of Medicine, University of Baghdad, Baghdad, Iraq

Objective: Osteoporosis is a reduction in BMD that increases susceptibility to fractures. Major depressive disorder is one of the most prevalent psychiatric conditions characterized by depressive mood, anhedonia, and sleep abnormalities. They are chronic diseases that affect large population groups with great impact on morbidity, mortality and quality of life. In Iraq, the prevalence of osteoporosis in postmenopausal women was found to be 22.8% and the prevalence of major depressive disorder was 12% for age group 50-64 y and 13% for age group 65 y and above. Our aim was to find out the prevalence of major depressive disorder among postmenopausal Iraqi women with osteoporosis. To determine the association of major depressive disorder with osteoporotic vertebral fractures and history of other fragility fractures.

Methods: This was a cross-sectional study was conducted in Baghdad Teaching Hospital – Rheumatology Unit from October 2017 to April 2018. A total of 100 postmenopausal women were included in the study. They were diagnosed to have osteoporosis according to WHO criteria (T-score <-2.5). All women were screened for major depressive disorder by using the DSM5 diagnostic criteria of depression and severity of their depression was assessed by using the Arabic translation of Beck Depression Inventory scale. Thoracolumbar spine x-ray (lateral view) were performed for all women and osteoporotic vertebral fracture assessed by using the semiquantitative method. History of nonvertebral low trauma fractures were assessed by self-reports.

Results: The prevalence of major depressive disorder in postmenopausal Iraqi women with osteoporosis was 18%. Major depressive disorder was significantly higher among women who had vertebral fractures in comparison to women with history of others type of fragility fractures or no fracture. Major depressive disorder was insignificantly associated with sociodemographic data of osteoporotic women except for household crowding index where there was significant association.

Conclusions: A study with larger sample size over a long periods of time is needed to examine the causal relationship to determine which occurred first, prevalent vertebral fracture or major depressive disorder. Clinicians who manage osteoporosis should recognize the importance of checking for depressive symptom in their patients, and Clinicians who treat major depression should be alert to any evidence of fractures, bone loss, or osteoporosis.

P190

FIBRONECTIN ANTIBODIES IN IMMUNODIAGNOSIS OF OSTEOARTHRITIS

O. I. Emelyanova¹, I. P. Gontar¹, O. A. Rusanova¹, N. I. Emelyanov²

¹Federal State Budgetary Institution, Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky, ²Federal State Budgetary Educational Institution of Higher Education, Volgograd State Medical University of the Ministry of Healthcare of the Russian Federation, Volgograd, Russia

Objective: In the process of rheumatic inflammation fibronectin undergoes structural changes becoming immunogenic and starting to cause production of immune complexes that trigger cartilage deformation. The level of fibronectin antibodies indicates the activity of the pathological process. Detecting the antibodies using fibronectin-based high capacity immobilized magnetoccontrollable sorbents is an additional criterion of osteoarthritis (OA) activity. Our aim was to study the regularities of production of fibronectin antibodies by means of immobilized granulated antigen preparations with magnetic properties in patients with OA with reference to the stage and course of disease.

Methods: We observed 30 apparently healthy individuals and 121 patients with OA. Fibronectin antibodies were determined using indirect enzyme immunoassay with immobilized granulated antigen preparations. Immobilization was achieved by way of emulsion polymerization in a flow of gaseous nitrogen with inclusion of magnetic material in the structure of polyacrylamide gel.

Results: In healthy individuals the fibronectin level was 345.0±63.1 µg/ml, the level of fibronectin antibodies was 0.032±0.0028. The amount of fibronectin antibodies increased along with the increase in the number of affected joints. Elevated fibronectin antibodies were detected in patients with quickly progressing disease; their level was 0.112±0.011 absorbance units; the amount of fibronectin in patients' plasma was 554.5±56.0 µg/ml. The highest values of fibronectin antibodies were detected in patients with OA of stage II and III and multiple joint involvement, which

correlates with the extent of osteoarticular destruction (fibronectin level 561 ± 65.0 , fibronectin antibodies 0.124 ± 0.016 absorbance units).

Conclusion: By means of enzyme immunoassay using an immobilized magnetocontrollable sorbent we detected fibronectin antibodies whose level correlated with the stage and course of disease.

P191

IDENTIFICATION OF VERTEBRAL FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS USING BONE MINERAL DENSITY AND TRABECULAR BONE SCORE

M. Djennane¹, A. Tibiche¹

¹Department of Medicine, Tizi Ouzou, Algeria

Objective: Bone involvement is the main joint complication of rheumatoid arthritis (RA). Patients with RA have a greater risk of osteoporosis (OP) and of fracture than the general population. The prevalence of osteoporosis in RA is 20-30% in the spine and 7-26% in the hip. The diagnosis of OP is based on BMD. The main limit of the latter lies in the overlap of BMD values between fractured subjects and unfractured subjects. The trabecular bone score (TBS) is an indirect measurement of bone microarchitecture. Work has shown that a TBS low is correlated with the presence of fracture and this regardless of the outcome of the BMD. The aim of our work is to demonstrate the role of TBS in predicting fracture risk in patients with RA.

Methods: This is a retrospective type case study conducted at the level of at the level of the rheumatology department of the University Hospital of Tizi Ouzou concerning women with RA. 167 women with RA according to the ACR criteria were recruited at the BMD unit as part of the routine procedure. The questionnaire included a clinical assessment of demographic data (age, weight, height, BMI, duration of illness, corticosteroid dose, age of menopause). The activity of the disease by the DAS28, the health assessment question (HAQ) for the quality of life as well as the different basic and biological treatments taken. A radiological evaluation by the search for vertebral fracture (VF) using the VFA tool (vertebral fracture assessment) of T4-L4. The evaluation was performed qualitatively and semiquantitatively according to the Genant classification. BMD was measured by DXA (Hologic) at the lumbar and femoral spine. TBS was evaluated in the same measurement regions (L1-L4) as those used for BMD, using TBS iNsight® V1.0 (Med-Imaps).

Results: 25 patients with VF (case) were identified and 142 without VF (controls). Cases were older, had a higher DAS28, a more impaired HAQ and a duration of higher menopause than controls ($p < 0.001$). The BMD and the TBS were lower in cases vs. controls ($p < 0.001$). Comparing TBS coupled to BMD vs. BMD alone, according to a logistic regression model, it appears that the area under the curve (AUC) of the association lumbar BMD + TBS = 0.74 (0.65-0.83) vs. AUC of BMD alone = 0.61 (0.49-0.72) and that TBS + BMD femoral neck = 0.84 (0.77-0.90) vs. AUC of the TBS alone = 0.74 (0.65-0.84). The determination of the diagnostic

threshold value of TBS (corresponding to the TBS value having a better sensitivity and specificity) by the Youden index is 0.424 corresponding to a TBS value of 1.148 (with a sensitivity of 70% and a specificity of 72%).

Conclusion: TBS in RA, supplemented or not with BMD, has diagnostic value and this whatever the densitometric zone on patients matched or not for age and or at the DMO. Its use in clinical routine should be promoted to improve the care of our patients.

P192

PREVALENCE OF GENU VARUM/VALGUM IN ALGERIAN CHILDREN AND ADOLESCENTS WITH LOW VITAMIN D AND CALCIUM STATUS

M. Djennane¹, S. Lebbah², J. Souberbielle³

¹Department of Medicine, Tizi Ouzou, Algeria, ²Department of Biostatistics, Hospital Pitié Salpêtrière, Paris, ³Department Functional Explorations, Hospital Necker, Paris, France

Objective: The prevalence of lower extremity deformities is high in some areas of the world, often associated with low vitamin D status and low calcium intake. These bone deformities are physiological until the age of five. There is no published data on bone deformities in the lower limbs of healthy children living in North Africa.

Methods: We evaluated the prevalence of bone deformities and other clinical parameters, vitamin D status, calcium intake, calcium, phosphorus and alkaline phosphatase in 435 children aged 5-15 years old.

Results: There were bone deformities of the lower limbs in 72 children, a prevalence of 16.6%. Compared to the other 363 children without bone deformities, they have several potential risk factors for hypovitaminosis D. They also had lower 25OHD concentrations as well as elevated levels of PTH and alkaline phosphatase.

Conclusion: Low vitamin D status during winter associated with other potential risk factors such as low calcium intake, dark phototype, high BMI, poor living conditions are associated with increased risk of genu varum/valgum in healthy children and teenagers living in Algeria.

P193

EFFECT OF BISPHOSPHONATE VS. MENOPAUSAL HORMONE THERAPY ON FRACTURE RECURRENCE AND MORTALITY AFTER HIP FRACTURE SURGERY IN POSTMENOPAUSAL KOREAN WOMEN: A RANDOMIZED, OPEN-LABEL TRIAL

S.-J. Lim¹, C.-W. Park¹, Y.-S. Park¹, S.-H. Choi², Y.-K. Min³, B.-K. Yoon⁴

¹Department of Orthopaedic Surgery, ²Department of Radiology, ³Department of Medicine, ⁴Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Objective: Bisphosphonate reduces fracture recurrence and death in patients with hip fracture. Menopausal hormone therapy (MHT) prevents osteoporotic fractures in menopausal women. However, antifracture efficacy of MHT has not been studied yet in women with hip fracture.

Methods: We conducted a prospective, open-label, randomized trial to compare the effect of bisphosphonate vs. MHT in postmenopausal women. Among 1165 women 50 or older with acute and lower-energy trauma hip fracture, 317 were recruited after surgery. A total of 223 patients were randomly assigned to receive risedronate 35 mg weekly (n=114) or percutaneous 17 β -estradiol gel (0.1%, 1.5 g/d) plus oral micronized progesterone (100 mg/d) daily (n=109). Thoracic and lumbar spine X-ray examinations were undergone every six months. The primary endpoint was fracture recurrence over a period of 48 months.

Results: The overall new fracture rate including spinal deformity was 25.6% over the 48-month period. The dropout rates in the risedronate and MHT groups were 53.5% and 67.0%, respectively. The incidence of re-fracture per 100 person-years was 8.63 for the risedronate group and 12.86 for the MHT group. There was no difference between the two groups on survival analysis (*P* value by log rank test=0.180). The incidences of death per 100 person-years in participants receiving risedronate and MHT group were 3.58 and 4.40, respectively. Survival analysis did not demonstrate any difference between the two groups (*P* value by log rank test=0.503).

Conclusion: This randomized, open-label trial showed no significant difference in the rates of new fractures and death with risedronate vs. MHT following hip fracture surgery in postmenopausal women.

P194

OUTCOMES OF TOTAL HIP ARTHROPLASTY IN PATIENTS WITH STEROID-INDUCED OSTEONECROSIS OF THE FEMORAL HEAD FOLLOWING BRAIN TUMOR SURGERY

S.-J. Lim¹, C.-W. Park¹, S.-H. Park¹, S.-M. Yi¹, Y.-S. Park¹

¹Department of Orthopaedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Objective: Despite the extensive use of steroid therapy in brain tumor surgery, there is little information in the literature about total hip arthroplasty (THA) in brain tumor surgery patients. The aim of this study was to evaluate the results of THA in patients with steroid-induced osteonecrosis of the femoral head (ONFH) following brain tumor surgery and to compare the results with those for ONFH with no history of brain tumor surgery.

Methods: We retrospectively identified 32 THAs performed in 26 patients who have a history of brain tumor surgery in Samsung Medical Hospital and subsequent development of steroid-induced ONFH. Using the propensity score matching, the study group was matched to non-brain tumor surgery ONFH control group of 55 THAs in 52 Patients. All patients received cementless components with ceramic-on-ceramic bearing. Mean duration of follow-up for the study group was 6.39 y (range, 2–13.1 y). The medical record and radiographic data were retrospectively reviewed.

Results: No significant differences were found between the two groups with regard to mean operative time and intraoperative complications. In patients with steroid-induced ONFH following brain tumor surgery, mean Harris hip score improved from 45.0 points preoperatively to 79.3 points at the final follow-up and no hips were revised during the follow-up period. No significant differences were found between the two groups with respect to mean postoperative Harris hip scores and postoperative complication rates.

Conclusion: Our study showed encouraging clinical and radiographic results of THA in steroid-induced ONFH patients following brain tumor surgery without increased risk of adverse events compared to those in ONFH patients with no history of brain tumor surgery.

P195

PREVALENCE, RISK FACTORS AND PROGNOSTIC IMPLICATIONS OF DYSPHAGIA IN ELDERLY HIP FRACTURE PATIENTS

S.-J. Lim¹, S.-H. Park¹, S.-M. Yi¹, S.-E. Byun²

¹Department of Orthopaedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, ²Department of Orthopaedic Surgery, CHA Bundang Medical Center, CHA University, Seongnam, South Korea

Objectives: The influence of dysphagia on prognosis of elderly hip fracture patients has not been well studied. This study aimed to investigate (1) the prevalence of dysphagia with a protocol us-

ing clinical screening and VFSS, and (2) prognostic implications dysphagia, and (3) risk factors of dysphagia in elderly hip fracture patients aged 65 y and more.

Methods: A total of 393 female and 154 male hip fracture patients aged 65 y or more who underwent operation between 2015-2018 were retrospectively analyzed. Dysphagia was diagnosed by videofluoroscopic swallowing study (VFSS). VFSS was performed in patients who had history of aspiration pneumonia, complained of aspiration, or suspected dysphagia. To determine the prognostic implications of dysphagia, the incidence of pneumonia, hospital stay, frequency of the intensive care unit (ICU) admission, and in-hospital mortality rates were compared between patients with and without dysphagia.

Results: Dysphagia was found in 5.3% (29/546) of all hip fracture patients after VFSS. The mean age of patients with dysphagia was 82.3 y (range: 72-95 y) and that of patients without dysphagia was 80.1 y (range: 65-104, P=0.109). The percentage of male patients and patients with ASA classification more than 3 was higher in patients with dysphagia than those without dysphagia (P=0.012 and 0.005, respectively). Hip fracture patients with dysphagia showed higher rate of pneumonia, ICU admission, and six-month mortality, and longer hospital stay than those without dysphagia (P<0.001, 0.005, 0.026, 0.013, respectively). After logistic regression analysis, only albumin level <3.5 g/dL was found to be a risk factor for dysphagia.

Conclusion: Dysphagia was associated with longer hospital stay and higher rate of delirium, pneumonia, aspiration pneumonia and ICU admission. Serum albumin level lower than 3.5 g/dL was found to be a risk factor for dysphagia. Therefore, diagnostic test should be performed to detect dysphagia especially in patient with low albumin level and care should be taken to prevent post-operative complications in patients with dysphagia.

P196
SEROTONIN REUPTAKE INHIBITOR FLUOXETINE REDUCE BONE FORMATION AND INCREASE BONE RESORPTION POSSIBLY THROUGH A CENTRAL EFFECT

D. Vohora¹, R. Wadhwa¹

¹Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India

Objectives: Studies have reported that treatment with serotonin reuptake inhibitors (SSRIs) antidepressants may result in bone loss. Gut and brain derived serotonin are reported to have opposite effects on bone formation, therefore, carbidopa, blocking the peripheral serotonin synthesis, might help ascertain the role of brain serotonin, if any, in mediating the effects of SSRIs.

Methods: Male Wistar rats were administered fluoxetine and carbidopa for 40 d following which effects on bone formation markers viz alkaline phosphatase (ALP), sclerostin and dickkopf-1 (DKK-1), two Wnt signaling pathway inhibitors and markers of bone resorption including tartrate resistant acid phosphatase (TRAP5b) and RANKL were measured.

Results: Fluoxetine treatment resulted in elevated plasma sclerostin and DKK-1 and reduced ALP in femora bone. Further, its treatment caused elevated TRAP5b and RANKL levels. Blocking the peripheral synthesis of serotonin by carbidopa, a peripheral decarboxylase inhibitor, could not reverse the effects of fluoxetine on bone formation or resorption though carbidopa alone had a positive effect on bone formation markers.

Conclusion: Fluoxetine treatment may result in reduced bone formation and increased bone resorption. The effects of fluoxetine on bone formation may not be related to gut serotonin while brain serotonin is likely involved in its observed effects on bone resorption.

P197
TILLIE FRACTURE OF THE ADULT: A PURPOSE OF A CASE

M. P. Muniesa Herrero¹, A. C. Urgel Granados¹, M. Royo Agustin¹, A. Rillo Lázaro¹, J. Garcia Fuentes¹, A. Muniesa Herrero¹, A. Castro Sauras¹

¹Hospital Obispo Polanco, Teruel, Spain

The fracture of the anterolateral portion of the distal epiphysis of the tibia or Tillaux fracture is a rare lesion of the child-adolescent. The concurrence of two factors favors its appearance: the epiphyseal plate is weaker than the distal anterior tibiofibular ligament, and there is an asymmetry in the closure of the physis. Therefore, this fracture pattern is exceptional in adult patients, since these anatomopathological features are not present.

We present the case of a 61-year-old woman who, after a casual fall, had a right ankle injury, showing a fracture of the undisplaced peroneal malleolus and the anterolateral margin of the tibial pylon. The imaging study was completed by computerized axial tomography. The patient underwent surgery with open reduction and internal osteosynthesis, with the aim of restoring tibiotalar joint congruence.

The fracture of Tillaux is infrequent in the adult, being able to happen unnoticed or to be undervalued. Given the diagnostic suspicion, it is recommended to complete the study with a CT scan. The anatomical reconstruction of the joint surface is essential, recommending the surgical reduction of the fracture when the joint disruption is >2 mm to prevent degenerative changes and restore joint stability.

P198
WHEN WE FIX THE FRACTURE BUT NOT TREAT OSTEOPOROSIS

E. Romero Escribano¹, M. Montañez Ruiz¹, G. Garcia Melendez¹

¹Hospital Regional de Málaga, Málaga, Spain

Objective: To show the need for early diagnosis and treatment of osteoporotic disease from the point of view of traumatology, in order to avoid undesirable consequences for the elderly patient



Methods: We present the case of a 76-year-old woman who came to the clinic for a wrist fracture treated conservatively, as medical history included: arterial hypertension, atrial fibrillation, hysterectomy due to uterine prolapse and total left knee arthroplasty. After the fracture was followed up in consultation but was not prescribed any drug against osteoporosis. One year later, she went to the emergency room after a fall, presented a pertrochanteric fracture of her left hip, we performed osteosynthesis with a proximal femur nail. At hospital discharge, she was able to walk with a walker, but she also did not start taking any antiresorptive or osteoformative medicine. A few months later a bone densitometry showed osteopenia.

Results: After one year, she suffered another fall, presented a peri-implant fracture on her left femur and was performed an osteosynthesis with a plate. This type of fracture is much more complex to handle, without allowing the load to consolidate the fracture, and as a result the disability and deterioration of the patient

Conclusion: We must pay special attention to the osteoporotic fractures of the elderly patient or with risk factors, for multidisciplinary detection and treatment, to prevent new fractures of greater severity and thus the inability of our patients.



Results: A total of 93 patients were studied, from which 89% were women and 11% men. 66% presented sarcopenia by means of the gold standard test (DXA). The mean age was 66.39±9.70 [44-89]. The mean age for women was 66.4±9.8 and the average age of menopause was 46.97±5.61 and 63% were found to have sarcopenia. In men, the mean age was 66.7±9.2 and 43% had sarcopenia. Anthropometric measures were determined. The mean BMI was 26.54±4.69, which corresponds to ideal weight. Three tests were performed in addition to the gold standard (Fig 1). The average gait speed test was 0.92±1.25 s and 42% were positive for sarcopenia. The mean of the muscle strength test (dynamometer) was 19.99±9.90 and 61% had sarcopenia. The mean of the SARC-F screening questionnaire was 3.29±2.32 and 52% were positive for sarcopenia. According to the measurement of muscle mass by DXA, the mean appendicular skeletal muscle mass (ASMM) was 16.15±3.66, ASMM index 6.79±1.13 and the total skeletal muscle was 21.48±4.88. Men presented a higher muscle mass index compared to women [7.82±1.93 vs. 6.67±0.94]. When grouping patients by BMI, sarcopenia was present in 3% of the patients with low weight, 27% in the ideal weight group, 46% in the overweight group and 18% in the obesity group. A statistically significant relationship was found between sarcopenia and sex [0.01], weight and height [<0.001], gait test [0.04], muscle strength test [<0.001] and DXA [<0.001]. In addition, the sensitivity and specificity of the tests were determined (Fig 2). SARC-F had a 15% sensitivity and a 9% specificity, with a positive predictive value of 75% and a negative predictive value of 38%. The gait speed test 20% sensitivity and 39% specificity, with a positive predictive value of 53% and negative predictive value of 25%. The muscle strength test had a 93% sensitivity and 31% specificity, with a positive predictive value of 84% and negative predictive value of 84%.



P199

SARCOPENIA IN A RHEUMATOLOGY CENTER: DESCRIPTIVE STUDY

G. Maldonado¹, R. Guerrero¹, C. Rios²

¹Espiritu Santo University, ²Centro de Reumatología y Rehabilitación, Guayaquil, Ecuador

Objective: Sarcopenia is defined as an abnormal loss of muscle mass associated with aging. It has been validated that sarcopenia can predict functional deterioration. The purpose of this study is to determine the diagnosis of sarcopenia by conventional methods and gold standard.

Methods: Prospective observational study of patients attending a rheumatology center, to whom anthropometric and densitometric measurements were taken in order to determine sarcopenia.

Conclusion: This is the first study of determination of Sarcopenia in a Rheumatology Center in the city of Guayaquil. 66% of the studied population presented sarcopenia. It is evident that conventional methods may determine a diagnosis, however, a definitive diagnosis can be established by DXA. Because sarcopenia is a multidisciplinary entity, more studies are needed to determine the usefulness of the conventional methods.

P200

TRABECULAR BONE SCORE IS A USEFUL PARAMETER FOR THE PREDICTION OF VERTEBRAL FRACTURES IN PATIENTS WITH POLYMYALGIA RHEUMATICA

H. A. Kim¹, H. Y. Lee², J. Y. Jung¹, C. H. Suh¹, Y. S. Chung³, Y. J. Choi³

¹Department of Rheumatology, Ajou University School of Medicine, ²Clinical Trial Center, Ajou University Medical Center, ³Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea

Objectives: Polymyalgia rheumatica (PMR), a benign rheumatic disorder, requires long-term glucocorticoid therapy, which could be associated with osteoporosis. In the present study, we compared BMD, trabecular bone score (TBS), and frequencies of vertebral fracture (VF) between patients with PMR or rheumatoid arthritis (RA) and controls.

Methods: 53 postmenopausal women with PMR aged 50 y or older were eligible for inclusion in this study. Subjects with RA (n=106) and controls (n=106) were selected by propensity score matching, controlling for age, BMI, and the use of antiosteoporotic agents.

Results: The frequency of VF was significantly higher in patients with PMR (30.2%) than in patients with RA (13.2%) and controls (13.2%, P=0.017). The mean TBS was significantly lower in patients with PMR (1.317±0.092) than in patients with RA (1.336±0.089) and controls (1.373±0.073, P<0.001). In receiver operating characteristics analysis for VF in patients with PMR, the area under the curve was 0.759 (95%CI 0.601-0.918, P=0.003) for TBS and 0.618 (95%CI 0.445-0.791, P=0.175) for L-spine BMD. Multivariate analysis identified a lower TBS (OR: 0.000, 95%CI: 0.000-0.754, P=0.043) as a factor associated with VF in patients with PMR.

Conclusion: TBS could be a supplementary tool for discriminating osteoporotic fractures in postmenopausal patients with PMR.

P201

FRAGILITY FRACTURE RISK PREDICTION IN ELDERLY PEOPLE BASED ON A MICRORNA PANEL

A. Ladang¹, C. Beaudart², M. Locquet², J.-Y. Reginster^{3,4}, O. Bruyère⁴, E. Cavalier⁵

¹Clinical Chemistry / CHU de Liège, Liège, Belgium, ²Public Health, Epidemiology and Health Economics Department / ULiège, Liège, Belgium, ³Biomarkers of Chronic Diseases / Biochemistry Department / College of Science / King Saud University, Riyadh, Saudi Arabia, ⁴Public Health, Epidemiology and Health Economics Department / ULiège / Centre Académique de Recherche et d'Experimentation / CARES SPRL, Liège, Belgium, ⁵Clinical Chemistry / CHU de Liège / Centre Académique de Recherche et d'Expérimentation / CARES Sprl, Liège, Belgium

Objective: Often seen as promising targets for the establishment of new biomarkers, microRNAs (miRNAs) are short non coding RNA sequences implicated in translational repression. Study of miRNA can be easily achieved through biomolecular techniques. Regarding the diagnosis field, several advantages can be pointed out: miRNAs are highly stable and highly accessible through serum and plasma. Furthermore, miRNAs are often tissue-specific and can be used to design a disease signature. Fractures have a major impact on quality of life in elderly people. Comorbidities and loss of autonomy represent more than a trivial cost for our healthcare systems. Several studies show that risk-fracture prediction based on a simple blood test can be really cost-effective. Because several miRNAs have been implicated in bone homeostasis, we decided to evaluate the ability of the "osteomiR score" to predict the Fragility fracture risk.

Method: People selected for this study were implicated in a long term prospective study called the Sarcophage study. Serum was collected at the enrolment in the study. We selected 17 persons which developed a fracture within 3 y after entering the study. The control group is composed of 16 persons that did not fracture in the meantime. For those 2 groups, 19 miRNAs implicated in bone homeostasis (the so called "osteomiR panel") have been tested through qPCR technique (LighCycler 480 (Roche°)). Then, we calculated the "osteomiR score" as design by TamiRNA°.

Results: Separately, none of the 19 miRNAs harbored a statistically significant difference. Nonetheless, the "osteomiR score" based on the combination of the results obtained for 10 out of the 19 miRNAs showed a statistically significant increase in the fracture group compared to the control group. When a cutoff is defined at the median value of the osteomiR score, the predictive positive value is 68% with a sensitivity of 76%. Additionally, we compared "osteomiR" score specifications to IOF-FRAX algorithm and we observed a higher sensitivity for the "osteomiR" score on this cohort.

Conclusion: The osteomiR score seems a good predictive score in the establishment of the fragility fracture risk. The "osteomiR" score possesses a predictive value which appears to be in the same range as the one obtained from the IOF-FRAX algorithm.

It could be interesting to further assess whether the addition of osteomiR to the IOF-FRAX algorithm will improve the overall performance of FRAX, in terms of fragility fracture prediction.

P202

THE ROLE OF “D” HORMONE IN ANTIRESORPTIVE TREATMENT OF OSTEOPOROSIS: THE ROLE OF VITAMIN D IN ANTIRESORPTIVE TREATMENT PLANNING – OSTEOPOROSIS NATIONAL ASSOCIATION

L. Kilasonia¹, L. Lagvilava², N. Dolidze³, M. Kopaliani⁴, N. Kirvalidze¹, T. Rukhadze¹

¹Tbilisi Heart and Vascular Clinic/ Rheumatology Department, ²Multiprofile Clinic Consilium Medulla, ³National Institute of Endocrinology, ⁴Tbilisi State Medical University, Tbilisi, Georgia

Objective: There is a lot of talk about the pandemics of “D” hormone deficiency around the world. We all know, that supplementation with calcium and vitamin D3 is very important for the antiresorptive treatment of osteoporosis. Consequently, the question arises about how the concentration of vitamin D can influence the efficiency of the antiresorptive treatment, and is the recommended dosage of vitamin D supplement set in general guidelines is sufficient for successful treatment of narrow endemic population.

Methods: We have analyzed the results of 3 y treatment of 420 patients. 210 patients were treated with zoledronic acid (5mg – 1 IV transfusion annually); 95 patients were treated with ibandronic acid (150 mg monthly); 115 patients were treated with risedronate (35 mg weekly).

The concentration of vitamin D was measured in peripheral blood before start of treatment and at the end of each year of treatment.

Results: The results were devastating. 390 patients (93%) out of 420 showed insufficient concentration of vitamin D in their blood (< 30 ng/ml), 220 patients (55%) diagnosed to have deficiency of vitamin D (<20 ng/ml). During treatment all patients received calcium carbonate (500 mg) and cholecalciferol (800 IU daily).

Conclusions:

1. Majority of Georgian patients diagnosed with osteoporosis patients have vitamin D3 insufficiency and deficiency.
2. Concentration rise of vitamin D in the blood correlates to the effectiveness of antiresorptive treatment (i.e., with BMD). The lower the concentration of vitamin D3 in the blood, the lower is the BMD maintenance or increase after the treatment.
3. Therapeutic effectiveness of antiresorptive drugs is 50% higher in patients who have higher vitamin D concentration in blood (>30 ng/ml.).
4. It is recommended to optimize the dosage of vitamin D3 supplement, specifically for Georgian population in the process of antiresorptive treatment.

P203

MUSCULOSKELETAL INJURIES CAUSED BY YOGA IN OSTEOPENIA AND OSTEOPOROSIS: A RETROSPECTIVE ANALYSIS

M. Sinaki¹, M. Lee¹

¹Mayo Clinic, Rochester, USA

Objective: To analyze injuries that were directly associated with yoga practice and identify specific poses that should be avoided in patients with osteopenia or osteoporosis.

Methods: We retrospectively reviewed records of patients with injuries that were primarily caused by yoga. Patients were seen from January 1, 2006 through December 31, 2018. Injuries were categorized into 3 groups: 1) soft tissue injury, 2) axial no bony injury, and 3) bony injury. Patients underwent evaluation and were counseled on activity modification.

Results: 89 patients were included in the study. Within the soft tissue group, 66 (74.2%) had mechanical myofascial pain due to overuse. Rotator cuff injury was seen in 6 (6.7%), and trochanteric bursopathy was observed in 1 (1.1%). In the axial group, exacerbation of pain in degenerative joint disease (n=46 [51.7%]) and facet arthropathy (n=34 [38.2%]) were observed. Radiculopathy was seen in 5 (5.6%) patients. Within the bony injury category, kyphoscoliosis was seen on imaging in 15 (16.9%). Spondylolisthesis was present in 15 (16.9%) patients. Anterior wedging was seen in 16 (18%), and compression fractures were present in 13 (14.6%). The poses that were most commonly identified as causing the injuries involved hyperflexion and hyperextension of the spine.

Conclusion: To our knowledge, this report describes the largest case series of medically documented yoga-related injuries to date. Yoga potentially has many benefits, but care must be taken when performing positions with extreme spinal flexion and extension. Patients with osteopenia or osteoporosis may have higher risk of compression fractures or deformities and would benefit from avoiding extreme spinal flexion. As yoga gains popularity, prevalence of yoga-related injuries are also expected to increase. Physicians are encouraged to discuss such risks with their patients when asked about the safety of yoga, and appropriate exercise programs should be recommended on a case-by-case basis.

P204

VITAMIN D VALUES IN TWO COHORTS OF PATIENTS WITH RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS, WITHOUT VITAMIN D SUPPLEMENTATION

H. M. Al Attia¹

¹Private Practice, Abu Dhabi, United Arab Emirates

Objective: *The association between vitamin D deficiency and autoimmune diseases (AID) has been supported by epidemiological studies demonstrating higher prevalence of vitamin D deficiency among autoimmune patients, in comparison to the general population. Furthermore, with the increasing awareness of vitamin D's necessity to human health and its wide association with various*

medical conditions. It is becoming hard for researchers to identify many patients with AID and who are not receiving vitamin D supplementation. Hypovitaminosis D (insufficient and deficient) on the other hand is known to be high among the general population of UAE (between 78-90%) reaching up to 96% in some recent studies.

Methods: Data of 61 patients (35 and 26) adults with rheumatoid arthritis (RA) and systemic lupus erythematosus were sought. Their data were compared to those of other 77 individuals without AID who were also not on vitamin D supplementation (control group).

Results: The prevalence of hypovitaminosis D (25(OH)D3 <30 ng/ml) was not different between patients with RA 26 (74%) and 19 (73%) in SLE patients, $p=1.000$ but was significantly higher (71,92%) in the control group, than in the RA $p=0.0156$ and in SLE $p=0.0179$ patients respectively. The mean of 25 (OH)D3 in individuals with hypovitaminosis was also not different in RA and SLE patients (20.9±4.76 vs. 21.3±8.19 ng/ml) respectively, $p=0.87$ but significantly lower (18.0±5.77 ng/ml) in the control group, $p=0.021$ & $p=0.047$ towards rheumatoid and lupus patients respectively. Secondary hyperparathyroidism (PTH >65 ng/ml) was identified in 8/26 (30.5%) of RA and in 3/18 (16.5%) of SLE patients, $p=0.483$ compared to 29/71 (41%) in the control group ($p=0.482$ and $p=0.098$ towards the two groups) respectively.

Conclusions: RA and SLE patients exhibited comparable vitamin D values. The patients without AID, had significantly higher prevalence of hypovitaminosis D along with lower D values compared to each of the RA and SLE groups individually. These findings are in contrast to previous and widely spread reports suggesting the contrary. Nonetheless, before concluding further on the issue. larger number of patients need to be assessed in future studies.

P205

MALORHEOSTOSIS OF THE HAND

K. Tolis¹, K. Raptis¹, I. Triantafylopoulos¹, S. Tournis¹, N. Papoulidis¹

¹Laboratory for the Research of the Musculoskeletal System, University of Athens, KAT Hospital, Athens, Greece

Objective: Malorheostosis is a rare mesenchymal dysplasia which develops with sclerotomal distribution, usually affecting only one limb. On radiologic exam is characteristic the melting "candle wax" sign, which is the irregular cortical hyperostosis occurring in one side of the affected bone. We present 2 rare cases of malorheostosis of the hand.

Methods: The first case involves a 55 years old Greek woman presented with a malorheostosis of the left hand. The disease involved the lunate, the capitate, the metacarpal and the phalanges of the middle and index fingers. The patient complained for pain and dyskinesia between metacarpals, as well as the proximal and middle phalanges. Clinical examination revealed that flexion of MCP joint of index finger was 20° and of PIP joint 0°. To the patient proposed surgical intervention where under general anesthesia through a straight incision between 2nd – 3rd metacarpal extensive tenolysis of the extensor tendons was attempted. During the procedure removing the "murble" like bone spurs two saw

blades were destroyed, so any effort to continue stopped and a plaster cast was used for 2 weeks for protection and rest. The second case was involved a 36 years old Albanian woman who reported pain and mild stiffness at her left hand. The radiological study revealed malorheostosis affecting the lunate, the capitate, the metacarpal bones of the middle and index finger and the proximal and middle finger. The patient was informed about this pathology and proposed operative treatment, but she denied.

Results: The first patient 3 months post operatively showed no improvement in relation to her previous condition. Also, she denied any suggestion of ray amputation of any or both of the affected fingers. The second patient continues her professional as a hair stylist, without the need of any surgical intervention.

Conclusion: Current literature lacks evidence considering effective surgical intervention for the cortical hyperplasia in cases of malorheostosis of the hand. Ray amputation seems as the only alternative in cases of extensive hand dysfunction, only after taking into consideration the special needs of each patient.

P206

DEVELOPMENT OF GENOTYPIC DIAGNOSIS OF DUCHENNE MUSCULAR DYSTROPHY BY MULTIPLEX PCR IN ORAN: A STUDY OF 5 CASES

H. Boulouar¹, F.-Z. Moghtit², S. Mediene Benchechor³

¹Faculté de Médecine «Dr Benzerdjeb Benaouda» Université Aboubekr Belkaid - Tlemcen, Tlemcen, ²Centre Universitaire Belhadj Bouchaib-Ain Témouchent, Ain Temouchent,

³Département de Biotechnologie, Faculté des Sciences de la Nature et de la Vie, Université Oran 1 Ahmed Ben Bella, Oran, Algeria

Objective: Duchenne muscular dystrophy (DMD) is the most common and severe form of muscular dystrophy, reaching one out of every 5000 male births in the world population. It is characterized by progressive muscular degeneration from a young age and leads to serious failures of the body which lead to the death of the patient. The gene responsible for DMD is located on chromosome X. It encodes a membrane cytoskeleton protein the "dystrophin". The alterations affecting this gene are essentially deletions with a proportion of 65%. That is why we have interested to develop in our laboratory a technique that will allow us to detect this type of mutations in 5 sporadic cases with Duchenne myopathy from western Algeria.

Methods: The study consisted in amplifying by PCR multiplex that cover 19 exons of the DMD gene most commonly deleted in 5 Duchenne muscular dystrophy cases recruited at Oran and Tlemcen Hospitals.

Results: This study allowed us to reveal two different deletions, the first involving the promoter of the gene and the second one the exon 43. These first results confirm the data reported in the literature which classify these two regions as deletion hotspots.

Conclusion: The results obtained represent a first in the western Algerian and could lead to the generalization of genotypic diagnosis and genetic counseling with a view to improve the care of patients in Algeria.

P207

BONE MINERAL DENSITOMETRY IN NIGERIAN BLACKS: AN EVIDENCE BASED ANALYSISN. Njeze¹, O. Agwu-Umahi², S. Ezeofor¹, S. Arinze-Onyia³, D. Akpagbula¹¹Foundation for Awareness of Osteoporosis (FAONG), ²University of Nigeria Medical School Nsukka, ³Enugu State University Teaching Hospital, Enugu, Nigeria

Objectives: DXA of bone mineral densitometry is the goal standard for the diagnosis of osteoporosis before fracture occurs. Osteoporosis is an important public health issue that is recognized widely due to its morbidity, mortality and financial involvement when accompanied by complications such as skeletal fractures. There is paucity of data of the use of DXA in our environment hence the study.

Method: This Unigamma machine is in Enugu, southeast Nigeria and has introduced routine BMD screening in this part of the country. Respondents are mostly patients who either came for routine BMD screening or were referred for DXA test on account of need by physicians. They were duly introduced to the topic either at awareness programs and or presented with questionnaires.

Result: This is a prospective study involving 89 subjects. 56 females and 33 males. Age range is from 20-89 y. 60-69 age range was highest frequency. 39 (44.3%) of the participants were obese while 35.2% were overweight. Subjects with normal BMI were 15.9%. 30 out of the 39 obese subjects are osteopenic. The highest frequency of osteopenia was 60-69 age range and were 31 respondents followed by 70-79 age range. Females (47) had more osteopenia than males (27). Osteopenia was demonstrated most in the femur than in the lumbar spine. Osteopenia/ osteoporosis is most demonstrable in the ward triangle followed by greater trochanter then the femoral neck.

Conclusion: Females formed about 2/3 of the total number of study population. Slightly less than half are obese. Most of the respondents have reduced BMD.

P208

CONCENTRATED HYALURONIC ACID INTRAARTICULAR INJECTION IS WELL TOLERATED BY OSTEOARTHRITIC JOINT AND PREVENTS PRO-INFLAMMATORY MECHANISMS IN THE OSTEOARTHRITIC SYNOVIUMR. Largo¹, A. G. Lopez-Reyes², J. P. Medina¹, M. Gimeno³, P. Coronel³, A. Migliore⁴, G. Herrero-Beaumont¹¹IIS-Fundacion Jimenez Diaz UAM. Joint and Bone Research Unit, Madrid, Spain, ²Instituto Nacional de Rehabilitacion, Laboratorio de Liquido Sinovial, Mexico DF, Mexico, ³Tedec-Meiji Farma, Madrid, Spain, ⁴San Pietro Fatebenefratelli Hospital, Unit of Rheumatology, Rome, Italy

Intra-articular (IA) injection of hyaluronic acid (HA), currently administered at 1%, is effective in treating pain and improving function and viscoelasticity in patients with osteoarthritis (OA). The increase in the concentration of this compound could improve its

rheological properties, although its biocompatibility in previously inflamed OA tissues has not been studied. Furthermore, the anti-inflammatory effects of HA in high concentrations on chondrocyte cultures is not well described.

We studied the biocompatibility of 2% HA (Tedec-Meiji Farma S.A.) on the synovial membrane, the cartilage and the subchondral bone in an experimental surgically-induced knee instability model of OA in rabbits that were treated with 3 IA weekly doses of 0.5 ml 2% HA. We also studied the effect of 2%HA in the synthesis of different pro-inflammatory mediators, such as IL-1 β and cyclooxygenase-2, in the synovial membrane, and the presence of metalloproteases in the articular cartilage. We also employ the mice chondrogenic line ATDC5 to determine, by *in vitro* studies, the effect of high concentrations of HA on oxidative stress evoked by H₂O₂ incubation, and in the gene expression of different detoxifying enzymes.

No additional joint damage was observed in rabbits with knee OA treated with 2% HA in comparison to untreated OA ones, neither in swelling nor in post-treatment edema. On the contrary, 2% HA treatment induced a decrease in the protein synthesis of IL-1 β in the synovial membrane of OA rabbits. In turn, the treatment of chondrocytes with high HA concentration partially prevented the deleterious effect of H₂O₂ on the gene expression of superoxide dismutase and hemoxygenase-1, and it has a trend to decrease the gene expression of inducible nitric oxide synthase, as well as catalase. These data suggest that high concentrations of HA decrease oxidative stress in cultured chondrocytes, a process that is partly responsible for the unleashing of the catabolic program in OA cartilage.

2% HA is a biocompatible product for joint tissues that are damaged during OA. It seems that a more concentrated HA may have a specific effect in the control of pro-inflammatory mechanisms in the synovium. The impact of this effect on the progression of OA in patients is not known right now, and should be considered in future studies in human disease.

P209

IS THERE A CONNECTION IN A USE OF THIAZIDE DIURETIC AGENTS AND LOWER INCIDENCE OF HIP FRACTURE?G. Podnar¹, J. Elez², F. Gojkovic², J. Aleksic²¹Railway Healthcare Center, Beograd, ²Railway Healthcare Center, Belgrade, Serbia

Thiazide diuretic agents are known to lower the urinary excretion of calcium and improve calcium balance. Their use has also been associated with increased bone density. However, their role in the prevention of osteoporotic fractures has not been consistently supported by epidemiologic studies.

A prospective study included 476 people 65 or older in our data basis which were people that are ordinary patients in our healthcare center on department of internal medicine. We had opportunity to investigate the relation between the use of thiazide diuretic agents and the risk of hip fracture during four years of follow-up. In this investigation, the differences between thiazide users and

nonusers in BMI, impaired mobility, and several other potential risk factors for hip fracture were taken into consideration. At base line, 24-30% of the subjects were thiazide users. In the subsequent 4 y, 24 subjects had hip fractures. The incidence rates of hip fracture were lower among thiazide users than nonusers. The Mantel-Haenszel relative risk of hip fracture, adjusted for age, was 0.63 (95%CI, 0.46-0.86). The protective effect of the use of thiazides was independent of sex, age, impaired mobility, body-mass index, and current and former smoking status; the multivariate adjusted relative risk of hip fracture was 0.68 (95%CI, 0.49-0.94). Furthermore, the protective effect was specific to thiazide diuretic agents, since there was no association between the use of antihypertensive medications other than thiazides and the risk of hip fracture. These prospective data suggest that in older men and women the use of thiazide diuretic agents is associated with a reduction of approximately one-third in the risk of hip fracture.

P210

LEVEL OF BIOCHEMICAL MARKERS OF BONE METABOLISM IN PATIENTS WITH OSTEOPOROSIS IN THE PRESENCE OF RHEUMATOID ARTHRITIS

Y. Akhverdyan¹, B. Zavodovsky¹, J. Polyakova¹, L. Seewordova¹, E. Papichev¹

¹Federal State Budgetary Institution, Research Institute of Clinical and Experimental Rheumatology named after A. B. Zborovsky, Volgograd, Russia

Objective: To study the biochemical markers of bone metabolism in patients with osteoporosis in the presence of rheumatoid arthritis.

Methods: We observed 70 women with a reliable diagnosis of rheumatoid arthritis (RA) and with osteoporosis (OP). The average disease duration of RA was 6.56±0.88 y. The comparison group included 45 practically healthy women in menopause between the ages of 45-66 y. BMD was studied by the method of DXA using the Lunar DPX Pro apparatus (GE, USA). We studied the biochemical parameters of bone formation (osteocalcin and alkaline phosphatase) and also examined of bone resorption markers (urinary crosslaps in terms of creatinine and tartrate resistant acid phosphatase).

Results: The level of osteocalcin blood (normal 8.8-37.6 ng/ml) in the group of patients with RA against the background of OD was 10.44±2.1 ng/ml, in the group of healthy individuals 12.14±2.2 ng/ml (t=1.38, p>0.05). Crosslaps of urine in terms of creatinine (normal 49-460 µg/ml mol of creatinine) in the group of patients with RA against the background of OP amounted to 542.6±16.4 µg/mmol, in the group of healthy individuals - 92.9±17.6 µg/mmol (t=18.71, p<0.001). The level of acid phosphatase (normal 67-167 nmol/s*l) is 189.6±17.3 nmol/s*l and 113.2±14.6 nmol/s*l, respectively (t=3.35, p<0,001). Thus, markers of bone resorption in patients with OP in the presence of RA complicated by OP were significantly increased.

Conclusions: These data may suggest that osteoclast activity is increased in patients with RA, with normal osteoblast activity. Thus, osteoporosis in RA proceeds mainly with an increase in bone resorption.

P211

ROLE OF BONE TRAP5B AND PINP FOR CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS

N. O. Panko¹, N. S. Shevchenko¹

¹Department of Pediatrics No 2, V.N. Karazin Kharkiv National University, Kharkiv, Ukraine

Objective: Serum band 5 tartrate-resistant acid phosphatase (TRAP5b) reflects the number of osteoclasts and useful as an indicator of bone resorption in adult. Type I collagen with N-terminal propeptides (PINP) is used to investigate bone formation in adult especially due to cancer disorders. But a lack of appropriate reference data has hampered use of PINP and TRAP5b in pediatrics. Our aim was to determine the role of TRAP5b and PINP for patients with juvenile idiopathic arthritis (JIA).

Methods. The study included 10 patients with JIA within 9-18 y; there were 60% of female and 40% of male. Assessment of children was based on physical, laboratory and instrumental tests. ELISA method was used for the measurement of TRAP5b. ECLIA method was used for the measurement of PINP. Stagraphics 3.0 was used for statistic processing of the data.

Results: Patients with JIA were classified as a polyarthritis with negative rheumatoid factor (RF) in 50% of children; 20% of patients had polyarthritis with positive RF; another 20% of kids - oligoarticular form, and 10% - enthesitis-associated arthritis. All patients took NSAID and methotrexate, and 40% of patients were treated with immunobiological preparation. Despite treatment radiological changes III degree by Steinbrocker score in 50% of cases and IV degree in 30% of kids were determined. The levels of TRAP 5b and PINP depend on age and gender. The level of TRAP5b was 7.81±3.79 U/L, PINP 378.78±370.80 ng/ml, serum calcium 2.34±0.07 mmol/L and phosphorus 1.58±0.36 mmol/L, which were within normal range. In patients with JIA bone TRAP5b correlated with patient's age (r=0.68; p=0.03), level of PINP (r=0.76; p=0.01), duration of IBP (r=0.74; p=0.02) and activity of inflammatory process (r=0.55; p=0.01).

Conclusion: Measurement of bone TRAP5b and PINP is not sensitive for determination of osteoporosis in children with JIA. Correlation between level of bone TRAP5b and degree of inflammatory activity and duration of IBP proved importance of this marker as an indicator of osteoclast activation due to autoimmune inflammation.

P212

CORRELATION BETWEEN SAGITTAL ALIGNMENT AND ADJACENT FRACTURE AFTER VERTEBROPLASTY IN OSTEOPOROTIC COMPRESSION FRACTURE

Y. S. Park¹, J. Kim¹, J. S. Park²

¹Department of Orthopaedic Surgery, Hanyang University Guri Hospital, Guri, ²Department of Orthopaedic Surgery, Korea University Ansan Hospital, Ansan, South Korea

Objectives: To investigate the natural history of new fracture following vertebroplasty for osteoporotic vertebral compression fracture (OVCF) and to evaluate the risk factors for adjacent vertebral fracture (AVF) and remote vertebral fracture (RVF) separately.

Methods: 205 consecutive patients who underwent a vertebroplasty for OVCF with a minimum follow-up of 1 y were retrospectively analyzed. A separate survivorship analysis of AVF and RVF was performed using the Cox proportional hazards model.

Results: Of the 47 patients (22.9%) with new vertebral fracture, AVF developed in 21 patients (10.2%) and RVF in 26 patients (12.7%). The median survival time was 4.0 months for AVF and 14.0 months for RVF. Multivariate analyses revealed that sagittal alignment imbalance and initial vertebroplasty at the thoracolumbar junction were independent risk factors for AVF (hazard ratio=9.6 and 4.7, respectively), whereas the significant risk factor for RVF was a sagittal alignment imbalance (hazard ratio=11.5). A low BMD of the spine (T-score \leq -3) was shown to be a risk factor for AVF and RVF on univariate analyses, but not on multivariate analyses.

Conclusions: AVF developed at a median of 4 months and RVF at a median of 14 months. An initial vertebroplasty at the thoracolumbar junction was an independent risk factor for AVF, and patients with sagittal alignment imbalance had a high risk of AVF and RVF after vertebroplasty for OVCF.

P213

ASSOCIATION OF CALCIUM INTAKE WITH OSTEOPOROTIC VERTEBRAL FRACTURES AND QCT BONE MINERAL DENSITY IN A LARGE CHINESE COHORT

L. Wang¹, L. Yin², K. Li¹, X. Cheng¹, W. Tian¹

¹Beijing Jishuitan Hospital, Peking University, ²Fuwai Hospital, Beijing, China

Objective: Calcium is widely recognized as an effective intervention for the prevention of osteoporosis. However, some recent studies and meta-analyses indicate that calcium supplements may be ineffective to prevent fracture. The association of dietary calcium intake with vertebral fracture and spinal volumetric BMD (vBMD) in low calcium intake population is unknown.

Methods: China Action on Spine and Hip Status (CASH) study is a multicenter, community-based cohort study of 3457 participants from 12 centers across China from March 2013 and August 2017.

We documented their baseline dietary calcium intake using validated food frequency questionnaires with a median of 10 y before the spine CT screening of CASH study. Vertebral fracture of CT images was defined as the primary outcome and the main measures included volumetric BMD at participants' median of 10 y visit and dietary calcium intake at baseline. Odds ratio (OR) and 95%CI were obtained for the associations of vertebral fracture with dietary calcium from logistic regression models. Because only 14.5% reached Chinese Dietary Reference Intakes (CDRI) calcium target of \geq 800 mg/d, we selected 500, 600, 700, 800 mg/d of calcium intake from food as cutpoints for modeling, respectively.

Results: Of the 3457 CASH participants, 3273 (94.7%) were used for analysis including 2052 women (mean [SD] age, 52.1 [9.0] y) and 1221 men (53.3 [9.1] y). Total vertebral fracture prevalence was 16.5% (n=551). The mean daily calcium intake from the FFQ was calculated as 517.0 \pm 266.4 mg. 8% reduction of fracture risk was observed per 100 unit increase of calcium intake from food among females (OR, 0.92; 95%CI, 0.87-0.97), but results among males were not significant (OR, 0.98; 95%CI, 0.92-1.04). No interaction was detected between vBMD and calcium intake from food (P>0.05). When high calcium intake groups had enough sample sizes (i.e., calcium \geq 500 or \geq 600 mg/d), negative associations of fracture risk with calcium intake were found among females (\geq 500 vs. <500 mg/d: OR, 0.62; 95%CI, 0.47-0.80; \geq 600 vs. <600 mg/d: OR, 0.59; 95%CI, 0.44-0.79), but this trend as not shown when cutpoints of calcium intake were set as 700 or higher. The same regressions were performed for male participants, but no significance was found. A positive correlation of calcium intake and vBMD was observed for females (P=0.01), but there was a nonsignificant negative trend for males (P=0.16).

Conclusion: Higher dietary calcium intake was associated with lower vertebral fracture among healthy women with low calcium intake. Further, higher calcium intake in women was related to a modestly greater volumetric spine BMD. Among men, more data are required.

P214

TREATMENT OF DYSTROPHIC SKIN CALCIFICATIONS IN PATIENT WITH UNUSUAL COMBINATION OF LIMITED SYSTEMIC SCLEROSIS AND PSORIATIC ARTHRITIS WITH EXTRACORPOREAL SHOCKWAVE LITHOTRIPSY FOLLOWED BY INTRALESION INJECTIONS OF SODIUM THIOSULPHATE: A CASE REPORT

S. Pavlov-Dolijanovic¹, N. Vujasinovic Stupar¹, S. Zeljkovic², R. Milenkovic², M. Perovic², P. Ostojic¹

¹Faculty of Medicine University of Belgrade, Institute of Rheumatology, ²Institute of Rheumatology, Belgrade, Serbia

We report the case of 63-year-old woman, who at the age of 45 had been diagnosed with the limited systemic sclerosis on the basis of Raynaud's phenomenon, sclerodactyly, skin thickening, telangiectasia, anticentromere antibody positivity, and late nailfold videocapillaroscopy pattern. Our patient had been worked for 25 y in the petrochemical industry and where she was exposed to vinyl

chloride monomer. She was treated with vasodilatory therapies. At the age of 53 had been diagnosed with the dystrophic skin calcifications both knees, left elbow and fingertips (right thumb and index and left third finger). On both knees there were fistulas from where the small stones calcification and white, cream-like material spontaneously went out. She was treated with supportive therapies such as pain, treatment of infection, without effective response in regression of lesions. At the age of 61, she had surgical skin incision with drainage on the tip of her right knee, but this treatment is not sufficient. She had slow wound healing, skin infection and decreased range of motion right knee. At the age of 62 had been diagnosed psoriasis and hyperuricemia. She was treated with febusostat 40mg once daily. At the age of 63 had been diagnosed psoriatic arthritis. Rodnan skin score was 7/51. X-ray (knee/elbow/hand) showed diffuse subcutaneous calcification. Laboratory data revealed normal serum phosphorous, calcium and vitamin D level. Rheumatoid factor was negative. DXA scanning showed osteopenia (T-score of total hip was -1.6, and spine -0.2). She had been treated with a methotrexate 15 mg/week, folic acid, calcium channel blocker, febusostat, vitamin D, and pain relief medication. Also, she received 6 extracorporeal shock wave lithotripsy (ESWL) session at week intervals in the both knees. Then she was paused for 6 weeks and again had 6 ESWL sessions. Thereafter, she received intralesional injections of sodium thiosulphate 150 mg/ml every week for 4 weeks. During follow-up calcifications were spontaneously eliminated, with the remnants of crater-shaped defects. Also, we found healing of the ulcers, functional improvement, and partial radiographic regression of calcinosis lesions. In addition, visual analog scale pain scores (range 0-10) decreased from 10 to 2.

P215
RESULTS OF THE TEN-YEAR MONITORING OF OSTEOPENIC DISORDERS IN CHILDREN OF THE EAST REGION OF UKRAINE

T. V. Frolova¹, D. P. McGowan², E. Medvedeva³, I. R. Sinyeva¹, N. F. Stenkova¹, I. I. Tereshenkova¹, E. Atamanova¹, K. A. McGowan⁴, L. L. Lazurenko⁵, K. G. Koleushko¹

¹Kharkiv National Medical University, Kharkiv, Ukraine, ²Spine & Orthopedic Surgery Associates, Kearney, USA, ³National Science Center, Kharkiv Institute of Physics and Technology, Kharkiv, Ukraine, ⁴Carl Vinson Veterans Administration Medical Center, Dublin, USA, ⁵Kharkiv National Medical University, Kharkiv, Ukraine

Objective: Identify factors which determine bone density in the growing child and young adult.

Methods: 10-y prospective cohort study of 2500 eastern Ukrainians aged 9-18. Developmental, medical, family, diet, activity, injury, and social history databases were collected by physician team. The functional state of bone tissue (SFS BT) was measured with Sonos-2000 ultrasound at the heel bone. Laboratory Ca, P, Mg, Se, K, Zn, Cu, I, Zr, and Ni; Toxic Pb, As, Cr, Sr, At, and Al; and ratio isotopes 44Ca/48Ca were all determined. Hair samples

were irradiated by Bremsstrahlung on electron acceleration with E=22 MeV and I=500 uA. Gamma radiation was measured using Ge(Li)-detector.

Results: The prevalence of primary osteopenia (OP) of different degrees of severity was significantly increased from 21.6% to 37.2% from 2007 to present (p<0.005). In 2007, 96.5% primary OP was characterized by impaired calcium metabolism and moderate increase of Pb. Now, 77.8% primary OP is characterized by reduced Ca accumulation and significant increase of Sr in 17%, Al in 74.9%, and Cr in 69.4%. Also, this study documents increasingly significant and prevalent deficiencies of Mg, Zn, and K. The isotope ratio of 44Ca/48Ca in hair without OP is 1.0; with OP, varies from 0.87 to 0.91. Bone mass deficiency of 25% was found in 44.6% of adolescents; 35% deficiency, in 28.2%; and 40% deficiency, in 14.4%. Normal bone density is now found in only 12.8% of young adults aged 17 and 18.

Conclusion: Decreased bone density in growth is related to mineral deficiency and toxic exposure. Decreased bone density is now documented to be increasingly prevalent and severe in Eastern Ukraine. This study indicates a careful history, measurement of SFS BT, and laboratory testing are all indicated in routine pediatric practice to ensure good bone health through adolescence and on reaching maturity as a young adult.

P216
ROLE OF ULTRASOUND IN ASSESSMENT OF JOINT PAIN AMONG HEMODIALYSIS PATIENTS

A. Fahmy¹, A. Alaa Eldin Ahmed Saad², A. Al-Ashkar², M. Sobhy Abdulhameed Abdulkhalik²

¹Al-azhar University in Cairo, Rheumatology Department, ²Al Azhar University in Cairo, Cairo. Egypt

Objective: Few studies including limited number of patients assessed the rheumatologic effects of hemodialysis (HD) on joints using ultrasonography. Joint ultrasound has been emerged as a cheap noninvasive tool for assessment of joint pain among HD patients. This was the aim of our study to make use of such tool in such life quality threatening complaint. Our aim was to determine the role of ultrasound in evaluation of joint pain and its causes among patients on regular HD.

Methods: 104 patients with endstage renal disease (ESRD) who were regular on HD three sessions/week, 4 h/session were subjected to history taking, complete physical examination stressing on musculoskeletal examination and ultrasonography of painful joints by an ultrasonography expert.

Results: Dialysis related arthropathy (DRA) was not the only cause of joint pain among HD patients but there were diverse causes in different joints. As regard affected joints, knee was the most affected one then came wrist, shoulder, ankle and elbow respectively. As regard causes of joint pain, DRA was the commonest one then came osteoarthritis, nonspecific ultrasonographic findings and few cases showed normal ultrasonographic studies.

Conclusion: This study confirmed that joint pain in HD patients has diverse causes not DRA by necessity but other causes must be considered as well as multifactorial etiologies.

P217

RESIDUAL LIFETIME FRACTURE RISKS AND YEARS OF LIFE LOSS DUE TO OSTEOPOROSIS IN THE AUSTRALIAN POPULATION: AN APPLICATION OF AN OSTEOPOROSIS HEALTH ECONOMIC MODEL

L. Si¹, J. A. Eisman², T. Winzenberg³, K. M. Sanders⁴, J. R. Center², T. V. Nguyen², M. Chen⁵, A. J. Palmer³

¹The George Institute for Global Health, Sydney, ²Garvan Institute of Medical Research, Sydney, ³University of Tasmania, Hobart, ⁴The University of Melbourne, Melbourne, Australia, ⁵Nanjing Medical University, Nanjing, China

Objective: To evaluate residual lifetime fracture risks (RLFR) and years of life lost (YLL) due to osteoporosis by sex, BMD level and number of clinical risk factors (CRFs).

Methods: A state-transition microsimulation was developed based on our previously validated osteoporosis model for the Chinese population [1]. Its development followed the recent international guidelines on health economic modelling in osteoporosis [2]. Patients were allowed to have multiple fractures in the simulated lifetime. Tracker variables were used to record patient

characteristics, consequently, transition probabilities were varied in patients with heterogeneity. The FRAX® equations were used to calculate annual fracture risks. First-order Monte-Carlo simulation was conducted with 10,000 hypothetical patients at age 60 y over a lifetime simulation horizon. RLFR of 44% and 25% for Australian women and men aged 60 y were used to determine the reference life expectancies [3]. RLFR and YLL (or years of life gained, YLG) were reported by sex, BMD level (measured by T-score) and number of CRFs.

Results: At age 60 y, RLFR ranged from a low of 8.2% for Australian women with no CRF and a T-score of 0 up to a high of 93.9% for Australian women with 6 CRFs and a T-score of -4.0. Those for Australian men ranged from 4.9% to 88.1%, respectively. There was a clear trend of reduction in YLL with higher T-scores and lower number of CRFs (see Table). The LE gap between those who had T-score of 4.0 and 6 CRFs compared to those who had T-score of 0 and no CRF was 3.9 and 6.1 y for women and men respectively. Of note, reducing CRFs was shown to be as important as improving BMD when impact on LE was considered. For example, for an Australian woman with 5 CRFs and a T-score of -4.0, YLLs could have been 0.34 or 0.32 y less if the CRFs could be reduced to 4 or T-score could be improved to -3.5.

Table. Residual lifetime fracture risk (RLFR) and years of life lost (YLL) due to osteoporosis for Australian women and men aged 60 years

T score	RLFR by number of CRFs, %							YLLs by number of CRFs, years						
	0	1	2	3	4	5	6	0	1	2	3	4	5	6
Women														
-4.0	40.3	53.6	67.1	78.2	86.3	91.3	93.9	-0.11	0.40	0.97	1.54	1.99	2.33	2.60
-3.5	30.9	42.3	55.5	68.4	79.1	86.8	91.2	-0.48	-0.04	0.47	1.00	1.59	2.01	2.33
-3.0	23.9	33.8	45.6	58.4	70.5	80.0	87.2	-0.73	-0.38	0.05	0.59	1.09	1.61	2.03
-2.5	19.4	26.1	36.7	48.8	60.9	72.1	81.6	-0.89	-0.67	-0.29	0.17	0.68	1.16	1.66
-2.0	15.4	21.5	29.4	39.7	52.1	63.7	74.6	-1.03	-0.83	-0.55	-0.19	0.28	0.77	1.28
-1.5	12.4	17.7	24.1	33.5	43.6	56.0	66.9	-1.13	-0.95	-0.74	-0.40	-0.03	0.44	0.90
-1.0	10.7	15.1	20.9	27.7	38.0	48.6	60.1	-1.18	-1.04	-0.85	-0.62	-0.24	0.15	0.61
-0.5	9.5	12.9	17.8	23.9	32.2	42.4	53.2	-1.21	-1.12	-0.94	-0.74	-0.44	-0.06	0.34
0.0	8.2	11.3	15.4	21.0	27.9	36.9	47.6	-1.25	-1.16	-1.01	-0.83	-0.59	-0.26	0.16
Men														
-4.0	27.9	41.0	53.0	64.8	74.8	82.6	88.1	0.26	1.08	1.88	2.75	3.61	4.41	5.00
-3.5	20.4	31.7	43.1	54.2	65.1	74.7	82.9	-0.21	0.46	1.19	1.91	2.74	3.56	4.37
-3.0	16.1	24.3	33.9	45.1	54.9	65.7	76.1	-0.50	-0.03	0.57	1.29	1.93	2.76	3.61
-2.5	12.5	18.9	26.4	36.4	46.5	56.6	68.8	-0.70	-0.37	0.08	0.70	1.35	2.02	2.94
-2.0	9.9	15.1	21.0	29.0	38.7	48.8	60.3	-0.87	-0.58	-0.24	0.25	0.83	1.49	2.27
-1.5	7.9	12.0	17.1	23.8	31.6	40.9	51.7	-0.96	-0.76	-0.48	-0.06	0.39	0.97	1.66
-1.0	6.5	9.9	13.9	19.3	25.8	34.0	44.9	-1.03	-0.89	-0.64	-0.33	0.04	0.53	1.16
-0.5	5.5	8.2	11.6	16.4	21.8	28.9	38.4	-1.07	-0.95	-0.78	-0.51	-0.18	0.22	0.78
0.0	4.9	7.1	10.3	14.3	19.1	25.7	33.4	-1.10	-1.01	-0.86	-0.61	-0.34	0.03	0.45

Note: a negative YLL indicates years of life gained.

Conclusions: We have generated RLFR and YLL due to osteoporosis for Australians with different risk profiles using our osteoporosis health economics model. This modelling suggests that interventions targeted at reducing CRFs could be as important as those improving BMD for reducing life years lost.

References

1. Si et al. 2015 Osteoporos Int.
2. Hilgsmann et al. 2018 Osteoporos Int.
3. Nguyen et al. 2007 J Bone Miner Res.

Acknowledgement: This study is supported by a National Health and Medical Research Council (NHMRC) project grant (APP1127827). LS is a recipient of the NHMRC Early Career Fellowship (GNT1139826).

P218

ASSOCIATIONS OF RANKL AND OPG GENE POLYMORPHISMS IN ARAB WOMEN WITH AND WITHOUT OSTEOPOROSIS

N. Al-Daghri¹, S. Abdi¹, A. Mohammed², M. G. Ansari¹, O. Amer¹, S. D. Hussain¹, N. Aljohani³, D. Al-Disi¹, J.-Y. Reginster⁴

¹King Saud University, Riyadh, Saudi Arabia, ²University of Sharjah, Sharjah, United Arab Emirates, ³King Fahad Medical City, Riyadh, Saudi Arabia, ⁴University of Liege, Liege, Belgium

Objective: RANKL and osteoprotegerin (OPG) genes have been identified as susceptibility loci for postmenopausal osteoporosis in various populations. None of these have been investigated in the Saudi Arabian population. The present study aims to fill this gap.

Methods: A total of 372 postmenopausal Saudi women (osteoporosis group, N=174; without osteoporosis (control group), N=198) were screened for the presence of two single nucleotide polymorphisms (SNPs) in *RANKL* [rs2277438 (290A>G) and rs9533156 (-643C>T)] and two SNPs in *OPG* [rs2073618 (1181G>C) and rs3102735 (163T>C)] using TaqMan genotyping assays. BMD at lumbar spinal (LS) and femoral neck (FN) was measured using DXA. Anthropometrics were measured and fasting blood samples were taken for the assessment of serum 25(OH)D and bone markers.

Results: The distribution of genotype frequencies for *OPG* SNP rs2073618 (1181G>C) varied significantly among the two groups. The heterozygous genotype CG was found to occur less frequently in the osteoporotic group (36.8%) than in the control group (47%) (OR: 0.6, 95%CI: 0.3-0.097; p=0.041). There was no significant difference in the frequency distribution of genotypes or alleles with respect to *OPG* rs3102735 (163T>C), *RANKL* rs2277438 (290A>G), *RANKL* rs9533156 (-643C>T) gene polymorphisms. However, *OPG* rs3102735 (163T>C) genotypes showed significant differences in femoral BMD (p=0.04) among the osteoporosis patients. The *RANKL* rs2277438 (290A>G) heterozygote AG exhibited significantly lower levels of 25(OH)D than other genotypes in the osteoporosis group (p=0.02).

Conclusion: The results require confirmation but suggest a role of *OPG* rs2073618 (1181G>C) in the genetic susceptibility to osteoporosis among postmenopausal Saudi women.

P219

ASSOCIATIONS OF BONE METABOLISM MARKERS WITH NECK CIRCUMFERENCE IN ADULT ARAB WOMEN

S. Sabico¹, R. Bassam¹, A. Alnaami¹, M. Khattak¹, K. Lei², N. Al-Daghri¹, J.-Y. Reginster³, M. Alokail¹

¹King Saud University, Riyadh, Saudi Arabia, ²University of Maryland, Maryland, USA, ³University of Liege, Liege, Belgium

Objective: Body fat distribution is associated with decreased bone resorption and neck circumference (NC), a surrogate measure for upper body fat, has never been tested as a marker that can

reflect bone turnover. This is the first study aimed to analyze the associations between NC and several bone biomarkers among adult Saudi women.

Methods: This cross-sectional study included a total of 265 middle-aged Saudi women [86 nonobese (mean age 52.7±8.1; mean BMI 26.9±2.3) and 179 obese (mean age 50.6±7.5; mean BMI 35.7±4.5)] recruited from primary care centers in Riyadh, Saudi Arabia. Anthropometrics included BMI, NC, waist and hip circumferences, total body fat percentage (%) and blood pressure. Biochemical parameters included glucose and lipid profile which were measured routinely. Serum levels of 25(OH) D, PTH, RANKL, sclerostin, C-terminal telopeptide of collagen I (CTX-I), Dkk1, IL-1β, osteoprotegerin, osteopontin and osteocalcin were measured using commercially available assays.

Results: In all groups, NC was inversely associated with PTH (R=-0.22; p<0.05) and positively associated with osteoprotegerin (R=0.20; p<0.05) even after adjustments for age and BMI. Using all anthropometric indices as independent variables showed that NC was inversely and significantly associated only with CTX-I [β=-0.27 (-0.003-0.001); p=0.049]. In the nonobese, waist-hip ratio (WHR) was significantly associated with sclerostin (R=0.40; p<0.05) and body fat was significantly associated with osteopontin (R=0.42; p<0.05).

Conclusion: NC is modestly but significantly associated with bone biomarkers, particularly the bone resorption markers, among adult Saudi women. The present findings highlight the importance of NC as measure of upper body subcutaneous fat in influencing bone biomarker expression in adult females.

P220

ASSOCIATION OF GENETIC POLYMORPHISMS WITH OSTEOPENIA IN SAUDI POSTMENOPAUSAL WOMEN

S. Abdi¹, A. Mohammed², O. Amer¹, M. G. Ansari¹, N. Aljohani³, M. Alokail¹, J.-Y. Reginster⁴, N. Al-Daghri¹

¹King Saud University, Riyadh, Saudi Arabia, ²University of Sharjah, Sharjah, United Arab Emirates, ³King Fahad Medical City, Riyadh, Saudi Arabia, ⁴University of Liege, Liege, Belgium

Objective: The RANKL/RANK/OPG pathway plays an important role in regulating bone remodeling and bone turnover. However, the association of the gene variants with BMD and osteopenia in Saudi postmenopausal women has not been reported yet. This study aims to investigate the distribution and associations of RANK, RANKL and OPG polymorphisms with osteopenia in Saudi postmenopausal women.

Methods: A total of 437 [223 osteopenia (age in years, 55.8±8.0) and 214 normal (age 53.5±6.0)] adult Saudi women were recruited for genetic analyses. Anthropometrics and fasting blood samples were taken for the assessment of routine glucose and lipids. They were screened for two polymorphisms; RANK (rs1805034 and rs35211496), RANKL (rs2277438 and rs9533156) and OPG (rs2073618 and rs3102735).

Results: No significant differences were found in BMI, WHR and diastolic blood pressure in both normal and osteopenia group. The odds ratio 2.37 (1.00-5.69) of RANK (rs1805034) indicates that patients with the CC genotype are at higher risk of developing osteopenia than the TT genotype. Similarly, RANKL (rs2277438), patients with AG genotype have a significant protective effect 0.36 (0.13-0.96) than the AA genotype. None of the OPG SNPs had a significant association with osteopenia.

Conclusion: The association of RANK polymorphisms with osteopenia shows its clinical importance in the diagnosis and prognosis of bone diseases. Here we suggest that patients with RANK polymorphisms may develop osteoporosis at an earlier age and as such should be considered high risk.

P221

DISCRIMINATION OF HIP FRACTURE TYPE FOR MEN WITH SPATIAL DIFFERENCES IN THE DISTRIBUTION OF BONE

L. Wang¹, R. Zhang², X. Cheng¹, X. Gao²

¹Beijing Jishuitan Hospital, Peking University, Beijing, ²Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China

Objective: Little is known about the spatial distribution differences in volumetric BMD and cortical bone structure at the proximal femur between femoral neck fractures and trochanteric fractures. Fracture types play a distinct role in predictors, but few studies have subdivided fracture into types. Further, DXA-based methods or quantitative computed tomography (QCT) measures or combined assessments have shown limited ability in discrimination of hip fracture types.

Methods: In this case-control study, a total of 67 men with fragility hip fractures, 33 with femoral neck (FN) fractures (mean±SD age: 77.4±9.5 y) and 34 with trochanteric (TR) fractures (76.9±9.5 y), and 115 control subjects (71.0±6.3 y) were included for the comparisons. By using cortical bone mapping based on QCT data, we accurately assess the spatial distribution of cortical and trabecular bone related to hip fracture type. Differences in the spatial distributions of cortical BMD (CBMD), cortical bone thickness (CTh), cortical mass surface density (CM), and endocortical trabecular BMD were investigated using surface-based statistical parametric mapping (SPM). We compared these spatial distributions between controls and both types of fracture, and between the two types of fracture.

Results Using SPM, we showed that all spatial assessments were significantly different in fracture cases vs. cohort in some specific regions, although CBMD, CTh and CM were not different in regions appropriate to fracture type. We also found spatially heterogeneous endocortical trabecular BMD differences between control subjects and subjects with hip fracture that varied by fracture type. SPM results of direct comparisons of two fracture types indicated that there were spatial differences in cortical thickness of specific regions of upper FN between FN and TR cases.

Conclusions Our results suggested that focal cortical bone thinning might be more relevant in FN fractures and endocortical trabecular BMD might play a significant role in hip fracture

P222

OSTEOPOROSIS AND GASTROINTESTINAL DISEASES

N.-E. Loutsidi¹

¹Comenius University in Bratislava, Bratislava. Slovakia

Objectives: Osteoporosis, a condition characterized by decreased bone strength, is prevalent among postmenopausal women but also occurs in men and women with underlying conditions or major risk factors associated with bone demineralization. The aim of this study was first of all to identify the connection between osteoporosis/osteopenia and gastrointestinal diseases.

Methods: Obtaining and processing of patients started on 2013. The study group consisted of 200 patients, 194 female patients and 6 male patients, aged from 35-92 years old. These patients were patients of osteoporotic outpatient department in I. Department of Internal Medicine, in Mickiewiczova. Assessment of BMD (hip and spine) was investigated by the use of wholebody densitometer.

Results: From the 200 patients, 48 had osteoporosis and 152 had osteopenia. Moreover, 69 of them had a positive fracture history and the most common fracture was on upper extremities. In our survey, we found out that out of 200 patients 35% had associated osteoporotic fracture and 65% did not have. In an investigation, which was done in 2000, found that from 337 patients only 28% had associated osteoporotic fracture and 71% did not have any fracture [1]. In a study, which was done in 2002, about gastrointestinal diseases and osteoporosis they found out that the most common related gastrointestinal diseases to osteoporosis are inflammatory bowel disease, celiac disease, post gastrectomy [2]. According to our research, we discovered that out of 200 patients only one had celiac disease and only had post-gastrectomy. In another study was demonstrated that patients who received warfarin or heparin have an increased risk of developing osteoporosis, which complies with the result from our probe [3]. 27 patients received drugs that have an extremely strong connection with high risk of osteoporosis (e.g., levothyroxine sodium, warfarin, etc.).

Conclusion: Osteoporosis is a common disease and has become a major public health problem, especially in the USA and Europe, as the number of elderly people in the population has increased. Despite the profound effect of osteoporosis on the quality of life of millions of people, preventive measures and the various treatment options can be strategically used to minimize both the morbidity of the disease and its burden on society.

References:

- [1] Guo P et al. Shanghai Arch Psychiatry 2012;24:262
- [2] Bernstein CN et al. Gastroenterology 2003;124:795
- [3] Banu L and Russell TM. US Pharm 2011;36:30

P223

BONE EVOLUTION IN PATIENTS TREATED WITH TERIPARATIDE DUE TO OSTEOPOROSIS: NEW RISK OF FRACTUREJ. Pons¹, A. I. Ilundain²¹Hospital Royo Villanova, ²Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain

Objective: Bone fractures, of any type, location or severity, cause resources and worsen the quality of life. They also bring about an increase in morbidity and mortality. Teriparatide is the treatment of choice in case of osteoporosis with fracture, objectifying both in studies and in real life, an optimal bone gain. In this study, the objective is to evaluate whether treatment with teriparatide (for 18-24 months) in patients with osteoporosis and fractures (low impact) decreases the risk of new fractures as a function of bone gain during the treatment period. Bone density with DXA will be assessed at baseline and at the end of treatment. We will include patients with more than six years since they finished treatment with teriparatide.

Methods: Prospective cohort study. Population under study: Patients who have received complete treatment with teriparatide (at least 18 months) for osteoporosis (criteria for BMD) and associated fracture, coming from the rheumatology clinic of the Hospital of Calahorra, with a reference population of 95000 people. The total was 138 patients (126 females and 12 males, all of them over 65 y of age except 4 (females) under the age of 65. Baseline variables: For each patient the following variables: -Clinical variables: Age, sex, time of known evolution of the disease, smoking, weight, height; -Biochemical variables: PTH, vitamin D, calcium, phosphorus, albumin, magnesium, urea, creatinine, TSH, alkaline phosphatase; -Other determinations: radiology of dorsal and lumbar spine and DXA (BMD). Clinical endpoint is the appearance of new bone fracture. Cohort follow-up: all patients are prospectively followed up until the onset of a new fracture, until their death or until the study closes. Follow-up period: start of follow-up in January 2005 and last patient included finished treatment in September 2015. The minimum observation period is 6 y after the end of treatment with teriparatide. All our patients received after this treatment, three doses of intravenous zoledronic acid (once a year during 3 y) except 4 patients who were treated with denosumab instead because of contraindication. Statistical Methods: the quantitative variables are described by their means and standard deviation or by their median and qualitative variables by frequency distribution. The comparison of quantitative variables will be done by student's t-test for independent samples and that of qualitative variables by chi-squared test, with linear trend test where appropriate. As proof of normality we will use the Kolgomorov-Smirnov test.

Results: We have not completed the collection of all the variables because we have many patients that have not completed the minimum followed up of 6 y after treatment yet. However, we notice that the tendency is to reduce the incidence of refracture in those with greater bone mass gain measured through DXA.

Conclusion: In case of reduction of refractures after treatment with teriparatide, cost-efficiency studies should be carried out in order to assess the indication of such treatment in patients at high risk of fracture without a previous low impact fracture.

P224

BONE MINERAL DENSITY EVOLUTION IN PATIENTS AFTER BARIATRIC SURGERY: FIVE YEARS OF FOLLOW-UPA. Ilundain¹¹Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

Objective: Bariatric surgery is an effective treatment for obesity, achieving a significant weight loss and the comorbidities that accompany this disease. Depending on the surgical technique, it is more or less frequent the appearance of nutritional and metabolic deficiencies. These deficits are more frequent when mixed surgical techniques are used, with a restrictive and malabsorptive component, such as gastric bypass or biliopancreatic diversion. Nutritional deficits are due to lower intake and also to malabsorption of fats and fat-soluble vitamins such as vitamins D or A, in addition to other micronutrients such as calcium. As a consequence, alterations in the bone mineral metabolism, the increase of the remodeling and the disorders of the bone mineralization can develop. In this study, the objective is to evaluate the state of BMD of patients after bariatric surgery and the evolution over time. We also want to evaluate the benefit of treatment with calcium, vitamin D and drugs if there is osteoporosis or even as a prevention.

Methods: Prospective cohort study. Population to study: Patients undergoing bariatric surgery in a hospital in Zaragoza. These patients are controlled at the endocrinology clinic specialized in bariatric surgery. Basal Variables: For each patient the following variables: -Clinical variables: age, sex, tall, smoking, weight, physical activity, BMD (by DXA), supplements of calcium and/or vitamin D and treatment for osteoporosis (byphosphonates, denosumab, teriparatide); -Biochemical variables: PTH, calcium, phosphorous, vit D, vit A, urea, creatinine, alkaline phosphatase, albumin, magnesium, urinary calcium and urinary phosphorus. Cohort follow-up: A prospective follow-up of all patients undergoing bariatric surgery is performed. BMD is performed after the intervention and every 2 y to see the evolution. It will be supplemented with calcium and vitamin D, maintaining them at normal serum levels (calcium: 8'4-10'2 mg/dL and vitamin D >40). Follow-up period: start of follow-up in September 2016. Statistical **Methods:** quantitative variables will be described by their means and standard deviation or by their median and the qualitative through frequency distribution. The comparison of quantitative variables will be done by Student t-test for independent samples and that of qualitative variables by chi-square, with linear trend test where appropriate.

Results: In phase of data collection.

Conclusion: Alterations in bone metabolism such as vitamin D deficiency, calcium malabsorption and secondary hyperparathyroidism are frequent after bariatric surgery. In addition, there is a

marked increase in bone remodeling and a loss of bone density following surgery which could be linked proportionally to weight loss. It would be of interest to know and quantify, with objective data, the evolution of the bone density of these patients, as well as the speed of deterioration of the same. Another question to be evaluated would be the cost-efficient benefit of an osteoformer/osteoprotective treatment at initial stages as primary prevention added to the already established supplementation with calcium and vitamin D.

P225

COMPARISON OF PAIN CONTROL AND SHORT AND LONG-TERM EFFECTIVENESS OF INTRAARTICULAR INJECTIONS (CORTICOID VS. HYALURONIC ACID VS. PRP)

I.-A. Badea¹

¹Spitalul Clinic, Dr. Ion Cantacuzino Bucuresti, Sectia Medicina Interna I si Reumatologie, Bucharest, Romania

Objectives: Osteoarthritis (OA) is the most common form of arthritis, affecting millions of patients worldwide. The pathogenesis is not fully understood, inflammatory and degenerative factors concurring towards slowly degradation of the joint cartilage. EULAR recommendations underline the use of non-pharmacological (lifestyle changes, rehabilitation medicine) and pharmacological methods for the management of knee OA. Intraarticular injection of corticoids is recommended especially in acute exacerbations with effusion in the knee, while intraarticular hyaluronic acid does not benefit from too many data in order to formulate a full recommendation. Our aims were:

- to compare effectiveness in short-term and long-term pain management between different modes of intraarticular treatment (corticoid, hyaluronic acid, PRP, combinations) of the knee;
- to compare the cost-efficiency of the methods previously mentioned;
- evaluation of immediate and long-term adverse events.

Methods: 100 patients with knee OA that presented between 1 January 2017 and 15 September 2017 were included in the analysis. 66 patients underwent intraarticular injections with corticoid (46 with betamethasone and 20 with triamcinolone), 26 patients with intraarticular hyaluronic acid (half in combination with corticoid) and 8 with PRP. Pain was evaluated on the patient VAS before and during the procedure, 1 d, 1-3 months and 6 months after the procedure. Range of motion was also evaluated by patient using a scale from 0-10. Ultrasound evaluation was performed in all patients before and after the procedure. Injection was done in the lateral parapatellar recesses of the knee, thickness of fluid accumulation being used as measurement. Statistical analysis was performed using EpiInfo and Jamovi software, applying ANOVA test analysis.

Results: There were reductions VAS of pain in all study groups after the procedure, differences between groups being seen in the persistency of pain control with and without oral NSAIDs, better

early pain control being obtained with corticoids and late control being found in the other therapy groups ($p=0.002$). Improvement in the range of motion was unanimously noticed, being persistent over follow-up period. Ultrasound changes were noticed over the follow-up period, better control in fluid formation being seen in the corticoid and corticoid and hyaluronic acid group compared to the others ($p=0.003$). Other evaluations were made, such as reduction in NSAIDs use (declarative by patients), ability to perform better in household activities and to participate in other activities with family and hobbies.

Conclusions: More data will be needed to fully assess the potential of intraarticular injections and to formulate recommendations (e.g., big randomized cohorts, collaboration between different international centers with different approaches on the subject), especially in patient with acute exacerbation of knee OA. The present analysis does not suggest a superiority of any product, all of them should be used selectively in patients depending on the agreement between the physician and the patient. As a final **Conclusion:** intraarticular injections are an efficient method of pain control, safe if all the precautions are made for good interventions and that improves quality of life in patients with knee OA.

P226

MODULATION OF THE WNT PATHWAY THROUGH INHIBITION OF CLK2 AND DYRK1A BY SM04690: A NOVEL POTENTIAL DISEASE-MODIFYING TREATMENT FOR KNEE OSTEOARTHRITIS

V. Deshmukh¹, A. O'Green¹, C. Bossard¹, M. Ibanez¹, T. Seo¹, L. Lamangan¹, A. Ghias¹, C. Lai¹, S. Anderson¹, R. Harris¹, J. Cahiwat¹, K. Chiu¹, M. Pedraza¹, L. Dellamary¹, S. Kc¹, C. Swearingen¹, P. Marchand¹, C. Barroga¹, J. Tambiah¹, S. Kennedy¹, B. Melchior¹, B. Tam¹, J. Hood¹, Y. Yazici¹

¹Samumed, LLC, San Diego, USA

Objectives: Wnt pathway upregulation contributes to osteoarthritis (OA) through differentiation of stem cells into osteoblasts, increased catabolic enzymes, and inflammation. SM04690, a novel small-molecule Wnt pathway inhibitor, previously demonstrated chondrogenesis and cartilage protection. SM04690 was evaluated in preclinical studies to determine its mechanism of action for Wnt pathway inhibition, chondrogenesis, and anti-inflammatory effects.

Method: Kinase activity was measured using Z-lyte and Lantha assays. Protein phosphorylation in human mesenchymal stem cells (hMSCs), chondrocytes, and synovial fibroblasts was measured by western blot. Expression of Wnt pathway and chondrogenic genes and LPS-induced inflammatory cytokines were measured in siRNA knockdowns in hMSCs and BEAS-2B cells by qPCR. *In vivo*, effects of SM04690 on inflammation, pain, and function were evaluated in rat OA models, followed by single intra-articular (IA) injection of SM04690 or vehicle.

Results: SM04690 primarily inhibited intranuclear kinases cdc-like kinase 2 (CLK2, EC50: 5.8 nM) and dual-specificity tyrosine kinase (DYRK1A, EC50: 26.9 nM). SM04690 inhibited CLK2-me-

diated phosphorylation of alternative splicing regulators, serine/arginine-rich (SR) proteins, and DYRK1-mediated phosphorylation of Sirt1 and FoxO1. siRNA knockdowns identified roles for 1. CLK2 and DYRK1A in Wnt pathway modulation with no effects on β -catenin and 2. CLK2 inhibition in early chondrogenesis with DYRK1A inhibition playing a role in enhancing late chondrocyte function. NF κ B and STAT3 inhibition by SM04690 resulted in reduced inflammatory cytokines compared to controls. DYRK1A knockdown was sufficient, while combined DYRK1A/CLK2 knockdown enhanced DYRK1A knockdown anti-inflammatory effects. *In vivo* models showed SM04690 inhibited inflammatory cytokine production and expression of cartilage degradative enzymes, resulting in increased joint cartilage, decreased pain, and improved function.

Conclusions: Inhibition of CLK2 and DYRK1A by SM04690 demonstrated a novel dual mechanism for inhibiting the Wnt pathway, enhancing chondrogenesis, chondrocyte function, and anti-inflammation in rat models of knee OA. SM04690 shows potential as an agent which may improve structure, symptoms, and function of OA.

P227

EFFECT OF DIGITAL ORTHOPEDIC TECHNOLOGY-ASSISTED MIPPO IN THE TREATMENT OF PROXIMAL TIBIOFIBULAR FRACTURE

L. Meng¹

¹Department of Orthopaedics, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

Objective: To investigate the digital orthopedic technology-assisted MIPPO in the treatment of proximal tibiofibular fracture in patients.

Methods: 32 cases of proximal tibiofibular fractures were randomly divided into two groups: digital orthopedic technology assisted MIPPO group and MIPPO group, sixteen cases in each group. The patients in digital orthopedic technology-assisted MIPPO group use Minmics software to simulate reduction and fixation before operation, and to determine the surgical protocol. The patients in MIPPO group's operation plan was determined according to the imaging data. The incision length, operation time, bleeding volume, fluoroscopy times, hospitalization time, and first healing rate of the wound, functional reduction excellent rate, Johner-Wruhs excellent rate and the healing time of the fracture were compared between two groups.

Results: Between digital orthopedics technology-assisted MIPPO group and MIPPO group, there was no significant difference in aspects of incision length [12 \pm 1.21 cm vs. 13.1 \pm 1.41 cm], wound healing rate (100% vs. 100%), Johner-Wruhs excellent rate (93.8% vs. 87.5%), fracture healing time [3.1 \pm 0.2 m vs. 3.3 \pm 0.7 m]. There were significant differences in aspects of bleeding volume [50.21 \pm 3.1 mL vs. 78.2 \pm 2.7 mL], operation time [46.2 \pm 2.1 min vs. 67.2 \pm 2.1 min], fluoroscopy times (6.2 \pm 3.41 vs. 10.2 \pm 2.1), hospitalization time [8.2 \pm 1.9 d vs. 11.2 \pm 2.1 d], excellent rate of fracture reset function (93.8% vs. 75.0%), $P < 0.05$.

Conclusion: According to patient's condition, digital technology-assisted MIPPO could develop the best surgical plan, shorten operation time, reduce bleeding volume and fluoroscopy times, improve fracture reset function rate, it is worthy of clinical application.

P229

LOW LEVELS OF SEX STEROIDS ARE ASSOCIATED WITH ACCELERATED DETERIORATION OF CORTICAL MICROARCHITECTURE IN OLDER MEN

A. Piot¹, R. Chapurlat¹, B. Claustrat², P. Szulc¹

¹Inserm Umr 1033, Hôpital Edouard Herriot, ²Prosom, Lyon, France

Objective: To study the relationship between baseline sex steroids levels and bone microarchitecture prospectively assessed in older men.

Method: 823 men older than 60 years old were followed during 8 y. At baseline, total estradiol (17 β E2) and total testosterone (tT) were measured and bioavailable estradiol (bio-17 β E2) and apparent free testosterone concentration (AFTC) were calculated. Bone microarchitecture at distal tibia and distal radius was assessed by HR-pQCT at baseline, then after 4 and 8 y.

Results: Men in the lowest quartile of tT (<8.7 nmol/L) had more rapid decrease in cortical area (Ct.Ar), thickness (Ct.Th) and volumetric BMD (Ct.vBMD) at the radius and the tibia ($p < 0.05$ for all) vs. men in the highest quartile. Findings for 17 β E2, AFTC and bio-17 β E2 were similar: at the distal radius, men in the lowest quartile of each of the three above hormones had more rapid decrease in Ct.Ar, Ct.Th and Ct.vBMD vs. the highest respective quartile ($p < 0.05$). At the distal tibia, total vBMD and bone mineral content decreased, whereas trabecular area increased, more rapidly in the lowest bio-17 β E2 quartile vs. the highest one ($p < 0.005$, $p < 0.01$ and $p < 0.005$, respectively). The findings were similar for AFTC. Finally, men having both AFTC (<190 pmol/L) and bio-17 β E2 (<28 pmol/L) in the lowest quartile (high risk group) had faster bone loss compared to men with levels of each hormone in the three upper quartiles jointly "reference group". For instance, Ct.Th decreased more rapidly in the high risk group vs. the reference group at the distal radius (2.61 \pm 0.25 vs. 1.35 \pm 0.44%/y, $p < 0.01$) and at the distal tibia (1.46 \pm 0.20 vs. 0.49 \pm 0.35%/y, $p < 0.005$).

Conclusion: In a cohort of 823 older men followed-up prospectively for 8 y, low levels of AFTC and bio-17 β E2, and less importantly tT and 17 β E2, are associated with accelerated deterioration of cortical bone.

Acknowledgments: This study was supported by grants from the Roche pharmaceutical company, from Agence Nationale de la Recherche, from Abondement ANVAR, and from Hospices Civils de Lyon. The personal research-related expenditures of A. Piot were supported by a research fellowship from the French Society of Rheumatology (2017).

P230

CIRCULATORY PATTERN OF CYTOKINES, ADIPOKINES AND BONE MARKERS IN POSTMENOPAUSAL WOMEN WITH LOW BMD

F. Azizieh¹, D. Shehab², K. Al Jarallah², R. Gupta², R. Raghupathy²

¹Gulf University for Science & Technology, Mubarak Al-Abdullah Area, ²Faculty of Medicine, Kuwait University, Jabriya, Kuwait

Objective: In addition to some well characterized bone turnover markers, cytokines and adipokines have also been suggested to be linked to osteoporosis seen in menopause. However, there is much controversy on the possible association between these markers and BMD. This study was aimed at measuring circulatory levels of selected cytokines and adipokines in postmenopausal women with normal and low BMD.

Methods: The study population included 71 postmenopausal women, 25 of whom 25 had normal BMD, 31 had osteopenia and 13 had osteoporosis. Circulatory levels of selected proresorptive (TNF- α , IL-1b, IL-6, IL-8, IL-12, IL-17), antiresorptive (IFN- γ , IL-4, IL-10, IL-13, TGF- β) and five adipokine markers (adiponectin, adipisin, lipocalin-2/NGAL, PAI-1 and resistin) were measured using the multiplex system and read on the Magpix ELISA platform. Further, two bone turnover markers (PINP, CTX) as well as estradiol levels were assayed from the same samples.

Results: While circulatory levels of cytokines were comparable between groups, women with low BMD had statistically significantly higher median circulatory levels of adipokines as compared to those with normal BMD. Further, while levels of CTX were not different between the two groups; PINP, PINP/CTX ratio and estradiol levels were significantly lower in women with low BMD. Levels of adiponectin, PINP, PINP/CTX ratio and estradiol correlated significantly with BMD of the hip and spine.

Conclusion: While the associations between the studied markers and BMD may be complex and multivariate, our data provide insights into the possible use of circulatory levels of cytokines, adipokines and bone turnover markers on the pathogenesis of postmenopausal osteoporosis.

Acknowledgment: This study is supported by Kuwait Foundation of Advancement of Science (KFAS) projects no. 2013-1302-02 and PR17-18SL-01.

P231

CASE REPORT: APPLICATION OF RADIAL EXTRACORPOREAL SHOCKWAVE THERAPY IN FORMER ATHLETE WITH PLANTAR FASCIITIS

V. Koevska¹, E. Nikolic-Dimitrova², B. Mitrevska², M. Manoleva², C. Gjerakarovska-Savevska², B. Kalcovska-Ivanovska², M. Gocevska², A. Bajalska²

¹Institute of Physical Medicine and Rehabilitation, ²Institute for Physical Medicine and Rehabilitation, Skopje, Macedonia

Objective: Plantar fasciitis (PF) is a problem that is affecting a majority of people who are former athletes. The cause includes inflammation and degeneration of the plantar fascia. These days,

the treatment options available include autologous plasma transfusions, corticosteroid injections, physiotherapy and radial extracorporeal shock wave therapy (RESWT). Our aim was to evaluate the effectiveness of radial shockwave therapy in male patient suffering from PF.

Method: 52 years old sport coach former footballer with diagnosed PF on the right foot. He had foot pain for 3 months. Initially he used nonsteroidal anti-inflammatory drugs for 3 weeks. The pain decreased but was still present and affected daily activities. The treatment included RESWT application and stretch exercise. RESWT with continual frequency was applied once a week, a total of 5 sessions. The pain was determined by a visual analogue scale for pain and functional ability with foot function index (FFI) before therapy and at 6th week after the start of the treatment. At the end of the patient follow-up the score on VAS was decreased and there was significant improvement in the FFI score.

Conclusion: RESWT is safe, alternative treatment for PF. Further studies are needed which includes more patients to show the role of RESWT.

P232

RELATIONSHIP OF THYROID LESIONS AND RHEUMATOID ARTHRITIS

O. V. Paramonova¹, E. G. Korenskaya¹, L. N. Shilova¹

¹Volgograd State Medical University, Volgograd, Russia

Objective: Rheumatoid arthritis (RA) is one of the most urgent problems of modern rheumatology. It affects people of predominantly Mature, most able-bodied age and leads to their early disability. Currently, RA is considered as a systemic disease that leads to damage not only to the joints, but also to the internal organs. Changes in the functional state of the thyroid gland in patients with RA are recognized by many scientists. The range of lesions is 9.8-34% against 0.4-2% in the general population. Some researchers indicate a decrease in the functional activity of the thyroid gland in a significant part of patients with RA, more pronounced in systemic manifestations of the disease. Others determined in these patients increased thyroid function in 9.8-21% of cases, and only 2% hypothyroidism. The aim of our work is to study the data on the functional activity of the thyroid gland in RA, as well as to assess the degree and nature of thyroid lesions in RA in patients undergoing inpatient treatment in the Hospital № 25.

Methods: We examined 43 patients (including 33 women and 10 men) who are on hospital treatment in the rheumatology Department of the Ministry of HEALTH № 25 with a confirmed clinical and laboratory diagnosis of RA. The average age of patients was 54.68 y. The articular form of the disease was noted in 32 patients, articular-visceral in 11 people. The average duration of the disease 10, 5 y. Data patients the study was conducted rheumatoid factor, CEC, antinuclear factor and thyroid function, including determination of the amount of thyroid hormones - TSH, FT4 (ELISA).

Results: Our examination revealed 28 seropositive patients (positive RF) (20 women and 8 men) and 11 patients (10 women and 1 man) had positive ANF. In these patients, thyroid pathology was found in 6.97% at 0.4-2% in the general population. The most common form of thyroid lesions (according to the clinical and

quantitative changes of thyroid hormones – TSH and FT4 – autoimmune thyroiditis, Hashimoto's syndrome hyperthyroidism. An important place among the mechanisms of joint damage in RA is given to the so called "proinflammatory" cytokines: IL-1, TNF, which synthesized in excess by the cells of the synovial membrane have a variety of pathological effects on the components of the joint, thereby causing the degradation of cartilage. These substances can also enhance immune responses, although their direct impact on thyroid cells is not excluded. In turn, thyroid hormones T3 and T4, have a stimulating effect on the functions of the immune system cells. In conditions of deficiency of t-suppressor function of lymphocytes in RA, there are other clones of T-lymphocytes, which promote the synthesis of antibodies to thyroid components, the main of which are IG class G, as well as rheumatoid factor. They interact with the receptors of thyrotropin and stimulate the production of thyroid hormones. Therefore, with an increase in the number of RF, an increase in the number of thyroid hormones - T3 and T4, respectively, should be expected. **Conclusion:** From this it follows that the problem of thyroid pathology in RA remains relevant to this day, since the percentage of its damage may be higher, since the formation of autoantibodies occurs in RA, which can block freely circulating thyroid hormones, thus masking the presence of a pathological process in the thyroid gland.

P233

CLINICAL CHARACTERISTICS OF OSTEONECROSIS OF THE JAW IN OSTEOPOROTIC PATIENTS WITH RHEUMATOID ARTHRITIS

F. Hirano¹, A. Takasoe¹, H. Saito¹, H. Nishimura¹

¹Diabetes and Rheumatic Diseases Center, Department of Medicine, Asahikawa Medical Center, Asahikawa, Japan

Objective: To evaluate clinical characteristics of osteonecrosis of the jaw in osteoporotic patients with rheumatoid arthritis.

Methods: Four female patients (average age 75.2 years old) were referred to the Diabetes and Rheumatic Diseases Center of Asahikawa Medical Center, Japan, for osteonecrosis of the jaw in osteoporotic patients with rheumatoid arthritis. Steinbrocker of stage was II; three, III; one. Steinbrocker of class was 2; two, 3; two. The averages of RA duration, disease activity score 28-ESR, mHAQ in four rheumatoid arthritis patients with osteonecrosis of the jaw were 14.75 y, 3.32 and 0.69, respectively. The mean titers of rheumatoid factor and anticitrullinated protein antibody were 404.7 IU/ml and 195.5 U/ml, respectively.

Results: Four osteoporotic rheumatoid arthritis patients developed typical osteonecrosis of the jaw signs and symptoms, such as bone exposure, and pain and swelling at different sites of the mandible. Only one patient was diagnosed as surgical-triggered osteonecrosis of the jaw as the patient referred tooth extractions. Antiresorptive agents were used in three patients with osteonecrosis of the jaw. The mean duration of anti-resorptive agents was 30 months, one patient; ibandronate and two patients; denosumab. Three patients had received mean 5.5 mg of prednisolone daily. Two patients were provided with treatment of conservative

management with the use of daily hydrogen peroxide mouthwash and antibiotics, the other two patients were needed for surgical management of debridement of necrotic bone.

Conclusions: We have reported four osteonecrosis of the jaw patients with osteoporotic rheumatoid arthritis. Clinical characteristics of osteonecrosis of the jaw in osteoporotic rheumatoid arthritis patients were clinically characterized that the mean treatment duration with anti-resorptive agents was less than that reported for postmenopausal osteoporosis. In collection, rheumatologists and dentists should cooperate possible early to improve dental health in rheumatoid arthritis patients.

P234

NONPHARMACOLOGICAL AND NONSURGICAL INTERVENTIONS TO MANAGE PATIENTS WITH KNEE OSTEOARTHRITIS: WHAT'S NEW?

R. M. Ferreira¹, J. A. Duarte², R. S. Gonçalves³

¹Physical Education and Sports Department, N2i, Institute Polytechnic of Maia, Maia, ²Faculty of Sport, CIAFEL, University of Porto, Porto, ³Coimbra Health School, Physical Therapy Department, Polytechnic Institute of Coimbra, Coimbra, Portugal

Objective: Update the last known umbrella review and summarize the available high quality evidence from systematic reviews on the effectiveness of nonpharmacological and nonsurgical interventions for patients with knee osteoarthritis (OA).

Methods: The systematic reviews were identified through electronic databases, such as MEDLINE, Embase, Physiotherapy Evidence Database (PEDro), The Cochrane Library, SciELO, Science Direct, Google Scholar, Research Gate and B-ON. The studies' selection respected the following terms to guide the search strategy using the P (humans with knee OA) I (nonpharmacological and nonsurgical treatments) C (pharmacological, surgical, placebo, no intervention, or other nonpharmacological/nonsurgical conservative treatments) O (pain, functional status, stiffness, inflammation, quality of life and patient global assessment) model.

Results: Following the PRISMA statement, 41 systematic reviews were found on the electronic databases that could be included in the umbrella review. After methodical analysis (R-AMSTAR), only 35 had sufficient quality to be included. There is good evidence that standard exercise programs can reduce pain and improve physical function in patients with knee OA. Additionally, there is moderate evidence for acupuncture, aquatic exercise, electroacupuncture, interferential current, kinesiotaping, manual therapy, moxibustion, pulsed electromagnetic fields, tai chi, ultrasound, yoga, and wholebody vibration. For other interventions, the quality of evidence is low or did not show sufficient efficacy from the systematic reviews to support their use.

Conclusion: Comparing to the last known umbrella review, similar results were achieved on acupuncture and exercise interventions to improve the patients' pain, stiffness, function and quality of life, but different results were found regarding the utilization of transcutaneous electrical nerve stimulation and low-level laser therapy as they do not improved the patients' pain and physical function.

P235

EFFICACY OF DENOSUMAB IN PATIENTS WITH AROMATASE INHIBITOR INDUCED BONE LOSSM. Tsagareli¹, E. Giorgadze¹, N. Khachidze¹, N. Dolidze¹, T. Sulikashvili¹, N. Jeiranashvili¹¹National Institute of Endocrinology, Tbilisi, Georgia

Objective: Aromatase inhibitors are associated with accelerated bone loss over the 3 y treatment period. The aim of our study was to assess the efficacy of denosumab in estrogen receptor-positive (ER+) breast cancer patients with aromatase inhibitor induced bone loss.

Methods: 42 postmenopausal Caucasian women (48-71 y) with BMD T-score ≤ -2.5 were enrolled in the study. All of them were receiving aromatase inhibitors (AIs): anastrozole or letrozole for 3-5 y. We have measured BMI, calcium ionized (Ca⁺⁺), 25(OH)D values, lumbar spine (LS) and total hip BMD values were obtained using DXA. All patients received 60 mg denosumab injections + elemental calcium 1000 mg/d (calcium carbonate) + Vit D 800-1000 IU/d for 24 months. BMD was measured at the baseline and after 2 y from the initiating treatment.

Results: After 2 y of commencing treatment majority of patients (78%) revealed significant increase of BMD with mean value of 4.3% at LS and 3.6% at PF.

Conclusion: Administration of 60 mg denosumab injections every 6 months effectively increases BMD at LS and PF in patients with ER+ breast cancer patients with aromatase inhibitor induced bone loss.

P236

POTENTIAL EFFECTS OF REACTIVE OXYGEN SPECIESR. Amir¹¹Centre de Santé des Fagnes, Chimay, Belgium

Objective: Reactive oxygen species (ROS) or free radicals are one of the major offenders to provide oxidative damage to biological macromolecules. These unstable ROS are known to cause or aggravate a variety of chronic diseases such as cancer, cardiovascular diseases, arthritis, neurodegenerative diseases as well as aging, diabetes, obesity, and also other less known pathologies.

Methods: ROS correspond to a type of unstable molecules that contains oxygen and that easily reacts with other molecules in a cell. A significant increase of ROS in cells may cause damage to DNA, RNA, and proteins, and may cause cell death. Most ROS are generated as byproducts during mitochondrial electron transport. The sequential reduction of oxygen through the addition of electrons leads to the formation of a number of ROS including superoxide, hydrogen peroxide, hydroxyl radical, hydroxyl ion, and nitric oxide.

Results: Tumor cells of another kind of activated cells can also express increased levels of antioxidant proteins to detoxify from ROS, suggesting that a delicate balance of intracellular ROS level is required for cancer cell function, in this pathological process.

As such a number of defense mechanisms have evolved to meet this need and provide a balance between production and removal of ROS. An imbalance toward the pro-oxidative state is often referred to as oxidative stress. Cells have a variety of defense mechanisms to improve the harmful effects of ROS. Superoxide dismutase (SOD) catalyzes the conversion of two superoxide anions into a molecule of hydrogen peroxide and oxygen. In the peroxisomes of eukaryotic cells, the enzyme catalase converts hydrogen peroxide to water and oxygen, and thus completes the detoxification initiated by SOD. Glutathione peroxidase is a group of enzymes containing selenium, which also catalyse the degradation of hydrogen peroxide, as well as organic peroxides to alcohols.

Conclusion: There are a number of nonenzymatic small molecule antioxidants that play a role in detoxification. Glutathione may be the most important intracellular defense against the deleterious effects of ROS.

P237

FINDINGS OF THE TRABECULAR ANALYSIS BONE SCORE (TBS) OF BONE DENSITOMETRY (DXA) OF WOMEN AFTER 65 YEARS WITHOUT OSTEOPOROSIS DIAGNOSISC. Maksoud¹, Y. M. Leitão¹¹CEPEM Centro de Estudos e Pesquisas da Mulher, Rio de Janeiro, Brazil

Objective: To analyze DXA exams of women aged 65 y and older, without diagnosis of osteoporosis using the categorization of the TBS and the correlation with the femoral neck T-score.

Method: A retrospective cross-sectional study of 139 DXA lumbar spine and proximal femur examinations performed between January and June 2014 of postmenopausal women with a mean age of 69.6 y (65-86 y), without a diagnosis of osteoporosis, using equipment GE Prodigy Primo, enCORE version 13.60 software, and TBS iNspight® software version 2.2.0.0.

Results: Of the 139 women analyzed, 81 had normal TBS ($\geq 1,350$) with 76.6% (n=62) with a diagnosis of low bone mass, 16.2% (n=10) of this group with T-score of colo ≤ -2.0 DP. Among the osteopenic women with a neck T-score > -2.0 DP (n=52) 19.2% presented lumbar spine T-score < -2.0 DP. Of the 52 women in the partially degraded TBS group (1,200 $<$ TBS $<$ 1,350), 76.9% (n=40) had low bone mass and among them 30% (n=12) the T-score of the neck was ≤ -2.0 DP. Out of the 6 women in the degraded TBS group (TBS $\leq 1,200$) only one had T-score < -2.0 DP and 50% (n=3) presented lumbar spine T-score < -2.0 DP.

Conclusion: Additional TBS analysis may help by adding information that reflects bone microarchitecture not accessible to DXA, which may aid in predicting fracture risk and therapeutic decision making. In patients with low bone mass where the lowest T-score is > -2.0 DP, the associated findings of partially degraded or degraded TBS may improve the therapeutic approach and influence monitoring.

P238

OSTEOARTHRITIS AND CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL PATIENTS: THE VICIOUS CYCLE

A. Bajalska¹, B. Mitrevska¹, V. Koevska¹, L. Stojanoska Matjanoska¹, C. Gjerakarovska Saveska¹

¹Institute for Physical Medicine and Rehabilitation, Skopje, Macedonia

Objective: Cardiovascular disease (CVD) and osteoarthritis (OA) are two common diseases in the postmenopausal period and they may be associated in many ways. Both share common risk factors including age, obesity, hypertension, cholesterol, diabetes, exercise, smoking and diets. Studies have shown that the metabolic syndrome (MetS) causes systemic inflammation, increasing the risk of CVD and OA. Drop of oestrogen after menopause causes vessel stiffness, dyslipidemia and change in joint homeostasis. Physical inactivity due to joint pain and muscle weakness and use of NSAIDs for treating pain may increase CVD risk. The objective of this report is to determine the relationship between OA and CVD in our group of patients.

Methods: 142 postmenopausal female patients with OA, aged 50-88 y were recruited. BMI was calculated (25-30 kg/m² for overweight and >30 kg/m² for obesity) and presence of diabetes type 2 (T2D), dyslipidemia, hypertension, myocardial infarction (MI), angina, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), therapy with NSAIDs and smoking status were observed. MetS was defined by the sum of metabolic factors ≥ 3 .

Results: The mean age of OA female patients was 69 y, postmenopausal and with BMI >25 kg/m² (overweight and obese). Hypertension was present in 129 (91%), T2D in 43 (30%), angina in 14 (9.8%), MI in 7 (4.9%), CHF in 17 (12%), dyslipidemia in 71 (50%), MetS in 67 (47%), COPD in 20 (14%), NSAIDs were regularly used in 70 (49%) and 19 (13%) patients were smokers.

Conclusion: Our findings suggest that OA may be positively associated with any heart disease in postmenopausal women. Reducing the common risk factors will be beneficial for both conditions.

P239

METABOLIC SYNDROME IN HAND AND KNEE OSTEOARTHRITIS

A. Bajalska¹, B. Mitrevska¹, V. Koevska¹, L. Stojanoska Matjanoska¹, D. Gecevska¹, C. Gjerakarovska Saveska¹, B. Kalcovska Ivanovska¹

¹Institute for Physical Medicine and Rehabilitation, Skopje, Macedonia

Objective: Osteoarthritis (OA) is a progressive disease, characterized by breakdown, inflammation and loss of cartilage in the joints. Obesity causes cartilage degeneration through mechanical overloading in weight-bearing joints. White adipose tissue has been identified as the source of factors (cytokines, adipokines, etc.) creating a state of chronic low-grade inflammation and having a direct systemic effect on joints. This is especially charac-

teristic for obese, older individuals and postmenopausal women, the populations at high risk for both metabolic syndrome (MetS) and OA. The MetS is a cluster of factors such as: dyslipidemia, type 2 diabetes (T2D), central obesity and hypertension. Growing evidence have been linking hand and knee OA to the MetS. The aim of this report is to show how these facts apply to our group of patients.

Methods: 142 female patients with OA, aged 50-88 y were recruited. Cases of interest were those with hand and knee OA. BMI >30 kg/m², presence of T2D, dyslipidemia and hypertension were observed. MetS was defined by the sum of metabolic factors ≥ 3 .

Results: From the total number of 142 patients, 73 (51.4%) had knee OA, 16 (11.3%) had hand OA and 13 (9.1%) had both forms. In 45 patients (60%) 3 or more risk factors were identified. 25 patients (33%) had T2D, dyslipidemia was found in 36 (47%). Obese patients with knee OA were 57 (78%), and with hand OA, 15 (93.7%). Hypertension was present in 64 (87.7%) or 45% of the total number of OA patients.

Conclusion: Our results suggest that the systemic effect of MetS plays a very important role in the development of hand and knee OA in obese postmenopausal women.

P240

A PROSPECTIVE, RANDOMIZED MULTICENTER STUDY COMPARING RIGID- AND SOFT-BRACE TREATMENT FOR ACUTE OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURE

H. Inose¹, T. Kato¹, A. Okawa¹

¹Department of Orthopedics, Tokyo Medical and Dental University, Tokyo, Japan

Objectives: Bracing is the standard conservative treatment for acute osteoporotic compression fracture; however, the efficacy of different brace treatments has not been extensively studied. We aimed to clarify and compare the preventive effect of the different brace treatments on the deformity of the vertebral body and other clinical results in this patient cohort.

Methods: This multicenter nationwide prospective randomized study included female patients aged 65-85 y with acute one-level osteoporotic compression fractures. We assigned patients within 4 weeks of injury to either a rigid- or soft-brace treatment. Main outcome measure was the anterior vertebral body compression percentage (range 0 [completely collapsed] to 100% [not collapsed]) at 48 weeks. Secondary outcome measures included scores on the European Quality of Life-5 Dimensions (EQ-5D-3L, range -0.111 [worst possible] to 1 [best possible]), visual analog scale for low back pain (range 0 to 100 with higher scores indicating severe pain), and Japanese Orthopaedic Association Back Pain Evaluation Questionnaire at 12-month follow-up duration.

Results: In total, 141 patients were assigned to the rigid-brace and 143 patients were assigned to the soft-brace groups. There were no statistically significant differences in the primary outcome and secondary outcome measures between groups.

Conclusion: Among patients with fresh vertebral compression fractures, the 12-week rigid-brace treatment did not result in statistically greater prevention of spinal deformity, better quality of life, and lesser back pain than the soft-brace treatment. Therefore, the routine use of custom-made rigid-brace for acute vertebral compression fractures is not justified.

P241

BONE COLLAPSE IN OSTEOPOROTIC PATIENTS WITH RADIUS DISTAL FRACTURES

I. Puyuelo Jarne¹, N. Pardina Lanuza¹, E. Gonzalez Buesa¹, A. C. Laga Cuen¹, A. Aguirre Etxebarria¹

¹Hospital San Pedro, Logroño (La Rioja), Spain

Objective: Describe the importance of osteoporosis in radius distal fractures and the posterior collapse. Radius distal fractures are 1/6 of all body's fractures. 90% are Colles' fracture. There are three peaks of age where these fractures occur more frequently, although where more find them are in patients older than 70 years through a mechanism of low energy. They tend to be extraarticular fractures, with dorsal and radial displacement of the distal radius fragment. They require a closed reduction by traction and an immobilization with plaster ferula or plater orthopedic. It is imperative the realization of control x-rays after fracture's reduction for the evaluation of treatment options. If the final treatment is orthopedic, we must follow the patient exhaustively in consultation and we consider that the secondary displacement can appear in this patient.

Methods: We present the case of a radius distal fracture in a female patient aged 75 treated orthopedically. The subsequent follow-up showed the displacement and collapse of the fracture.

Results: We decided to review in the literature and the authors found that the initial dorsal angulation, radial length, and patient age were predictors of malunion and displacement. Authors reported the following as predictors of fracture instability: age (>60 y), dorsal angulation (>20°), dorsal comminution, intra-articular fracture (radiocarpal joint surface), and associated ulnar fracture.

Conclusion: Patient age is predictor of late instability, as there were increased number of patients with late fracture collapse who were over 70 years old. Osteoporosis leading to bone comminution is the main factor of this collapse. With aging, the solid cortical segments of bone become brittle, and the porous trabecular bone takes a significant role in load transmission.

P242

ASSOCIATION OF MUSCLE STRENGTH AND FAT TO MUSCLE RATIO WITH GLUCOSE TOLERANCE TEST DURING SECOND TRIMESTER OF PREGNANCY

J. J. Gardena Garcia¹, M. Martinez Martinez², C. Celestino Zanabria², A. Quiroz Reyes², L. Ruiz Barrera³, M. Camarillo Romero², H. Mendieta Zeron³, E. Camarillo Romero²

¹HGR 251 IMSS, CICMED UAEMex, ²CICMED UAEMex, ³Hospital Perinatal Monica Pretelini, Toluca, Mexico


Objective: To evaluate the association of fat to muscle ratio, and muscle strength with glucose response during a glucose tolerance test in pregnant women participating in a screening program of gestational diabetes.

Methods: It was performed an observational prospective cross sectional study. We evaluate pregnant women between 24-28 weeks of gestation. All patients were evaluated through a physical medical history and physical exam. Corporal composition were measured using (BC-533; Tanita, Tokyo, Japan). Hand grip strength was measured by a dynamometer Takei Scientific Instruments C., Ltd. (Niigata-City, Japan). A 75-g oral glucose tolerance test (OGTT) was performed, plasma glucose were measured before and at 60 and 120 min after the ingestion of 75 g of glucose. The diagnosis of gestational diabetes was made using the criteria outlined by the American Diabetes Association. Statistical tests were performed using SPSS version 14 for Windows, Chicago, IL, USA

Results: A total of 231 patients were included. The mean age was 26.09±6.8 y. The prevalence of gestational diabetes were 12.1%. In the hand grip test patients with gestational diabetes (GD) seems to have more muscle strength compared with normal glucose tolerance test women (NGTTW) (23.14±5.05 vs. 25±4.9) (P<0.010). To evaluate body composition and the impact of muscle mass in oral glucose tolerance test we calculate the fat to muscle ratio (FTMR). Patients with a positive test to GD has a statistical difference FTMR compared with NGTT (0.753±0.16 vs. 0.568±0.168) (p<0.005) When we evaluate the prevalence of a positive test to gestational diabetes in the different tertiles of FTMR we found that prevalence is higher in tertile 3 compared with tertiles 1 and 2. (tertile 1: 2.6%, tertile 2: 9.1%, tertile 3: 24.6%) (p<0.005). When we evaluate the glucose response FTMR tertile 3 patients has lower tolerance to glucose during the OGTT (Figure 1).

Fat to Muscle Ratio tertiles and glucose tolerance test

P<0.005



Conclusion: Fat to muscle ratio is associated with glucose tolerance test response in pregnant women and higher prevalence of gestational diabetes diagnostic

P243

EFFECT OF DENOSUMAB OR TERIPARATIDE ON CIRCULATING NOGGIN LEVELS IN POSTMENOPAUSAL WOMEN WITH LOW BONE MASS

A. Anastasilakis¹, S. Polyzos², M. Yavropoulou³, E. Terpos⁴, G. Hawa⁵, E. Tsourdi⁶, P. Makras⁷

¹424 General Military Hospital, Thessaloniki, Greece, ²First Department of Pharmacology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, ³1st Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁴Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece, ⁵FIANOSTICS GmbH, Vienna, Austria, ⁶Center for Healthy Aging, Technische Universität Dresden Medical Center, Dresden, Germany, ⁷Department of Medical Research and Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital, Athens, Greece

Objective: Noggin inactivates bone morphogenetic proteins (BMPs), possibly exerting negative effects on the skeleton. We aimed to compare the effect of agents with opposite impact on bone turnover (denosumab vs. teriparatide) on noggin circulating levels.

Methods: This was an observational, open label, non-randomized clinical study. Postmenopausal women with low bone mass were treated with either denosumab (n=30) or teriparatide (n=30). Noggin, BMP-2, BMP-4, procollagen type I N-terminal propeptide (PINP) and C-terminal crosslinking telopeptide of type I collagen (CTX) were measured in serum samples obtained at baseline, three and twelve months after treatment initiation. Prevalent fractures were recorded at baseline and lumbar spine BMD (LS BMD) was measured at baseline and twelve months.

Results: Noggin levels remained unchanged after either denosumab or teriparatide treatment. Baseline noggin levels were not different between women with vs. without previous antiosteoporotic treatment, or between those with vs. without vertebral or nonvertebral fractures and were not correlated with age or LS BMD. At 12 months, noggin levels were positively correlated with PINP within the denosumab ($r=0.47$; $p=0.014$), whereas negatively within the teriparatide group ($r=-0.43$; $p=0.019$).

Conclusions: In postmenopausal women with low bone mass noggin levels were not correlated with bone parameters at any time point, except with PINP at 12 months, and remained stable with both denosumab and teriparatide treatment.

P244

MONTHLY IBANDRONATE TREATMENTS RAPIDLY SUPPRESS BONE RESORPTION MARKERS WITHOUT EXCESS

J. Hashimoto¹, H. Hagino², Y. Asao¹, K. Katsumata¹, M. Yamamoto¹, R. Matsumoto³, K. Endo¹

¹Chugai Pharmaceutical Co. Ltd., Tokyo, ²School of Health Science & Rehabilitation Division, Tottori University Faculty of Medicine, Tottori, ³Taisho Pharmaceutical Co. Ltd., Tokyo, Japan

Objective: We previously reported the efficacy of monthly oral ibandronate (IBN) 100 mg in a phase II dose-finding study [1], and the noninferior efficacy of oral IBN 100 mg to monthly intravenous (IV) bolus IBN 1mg in the randomized, double-blind, phase III MOVEST study [2]. However, oversuppression of bone metabolism is a common concern with IV bolus bisphosphonates. Here, we describe the efficacy of the two IBN formulations with respect to the suppression of bone resorption markers.

Methods: Ambulatory Japanese patients aged ≥ 55 y with primary osteoporosis were randomized to receive monthly oral IBN 100 mg plus monthly IV placebo, or monthly IV IBN 1mg plus monthly oral placebo in the MOVEST study. The primary endpoint was noninferiority of oral vs. IV IBN with respect to BMD gains at the lumbar spine after 12 months. Changes in the bone resorption markers urinary CTX (uCTX), serum TRACP-5b, and urinary NTX (uNTX) were examined at baseline, 1, 3, 6, and 12 months. In the dose-finding study, relative changes in uCTX were measured throughout the dosing period.

Results: The mean relative changes from baseline in uCTX, serum TRACP-5b, and uNTX were similar with both IBN formulations. Suppression of uCTX occurred rapidly, with maximum suppression reached within approximately 1 week [1]. Levels of the three bone resorption markers remained above the lower end of the ref-

erence value ranges (defined in healthy Japanese women). In the dose-finding study, uCTX values appeared to return to baseline levels prior to each monthly drug administration. These results suggest that IBN treatment did not result in oversuppression of bone turnover.

Conclusions: Monthly IBN treatments resulted in the suppression of bone resorption markers without excess. These data highlight to clinicians the potential benefits of this agent.

References:

1. J Bone Miner Res 2007;22(Suppl.1):S333
2. Osteoporos Int 2015;26:2685.

P245

SARCOPENIA AND OSTEOPOROSIS IN ECUADORIAN PATIENTS

G. Maldonado¹, C. Rios²

¹Espiritu Santo University, ²Centro de Reumatología y Rehabilitación, Guayaquil, Ecuador

Objective: Sarcopenia is defined as an abnormal loss of muscle mass associated with aging. It has been validated that sarcopenia can predict functional deterioration. The objective of this study is to determine the diagnosis of sarcopenia by conventional methods and gold standard in patients who have undergone a densitometric study.

Methods: Prospective observational study of patients with a densitometric study who visited a rheumatology center, to whom anthropometric and densitometric measurements were taken in order to determine sarcopenia.

Results: 93 patients were studied, of which 78 had a bone densitometry study (BMD). According to the BMD study, 19% were normal, 26% osteopenia and 55% osteoporosis. The mean age was 62.8 ± 7.2 , 88% women and 12% men. 67% presented sarcopenia according to the gold standard. 12% of the normal group, 23% of osteopenia and 65% of osteoporosis. Anthropometric measures were determined, the mean BMI of the normal group, osteopenia and osteoporosis was 26.54 ± 4.69 , 28 ± 4 , 24 ± 5 , respectively. Three tests were performed in addition to the gold standard (Figure 1). The mean of 4m walk test in the normal group, osteopenia and osteoporosis was 0.78 ± 0.22 , 0.74 ± 0.34 , 0.91 ± 1.29 , respectively. 53%, 35% and 42% presented sarcopenia. The mean of the muscle strength test (dynamometer) in the groups was 20.23 ± 7 , 24.23 ± 16.69 , 18 ± 7.16 mmHg, of which 33%, 55% and 70% had sarcopenia. The mean of the SARC-F screening questionnaire in the groups was 3.3 ± 3.2 , 4 ± 2.4 , 2.7 ± 1.8 , respectively, of which 20%, 33% and 16% presented sarcopenia. According to the measurement of muscle mass by DXA (Figure 2), the mean MMAE in the groups was 17.96 ± 3.74 , 16.63 ± 4.15 , 15.28 ± 3.29 kg, respectively. IMMAE 7.31 ± 1.04 , 6.72 ± 1.16 , 6.63 ± 1.13 kg/m³. Total skeletal muscle mass was 23.89 ± 4.98 , 22.12 ± 5.52 , 20.33 ± 4.33 kg. A statistically significant relationship was found between sarcopenia and bone loss [0.004].




Figure 1. Diagnosis of sarcopenia according to the 4m walk test, muscle grip and DXA scan tests.




Figure 2. Diagnosis of sarcopenia according to densitometric scales.

Conclusions: 67% of the studied population presented sarcopenia, it is evident that the prevalence of sarcopenia is higher in patients with greater loss of bone mass. Because they are two prevalent entities in older populations, protocols that include the management of them are required.

P246
EFFICACY OF A PROTOCOL IMPLANTATION FOR THE PREVENTION OF A NEW FRAGILITY FRACTURE: EFFECTS ON VITAMIN D IN HIP FRACTURED PATIENTS

F. J. N. Nistal Rodríguez¹, A. B. D. Bañuelos Díaz¹, J. L. S. López Sánchez¹, I. D. B. De Blas¹, D. F. D. Fernández Díaz¹, R. E. M. Escudero Marcos¹, M. G. A. García Alonso¹

¹Rio Hortega Hospital, Valladolid, Spain

Objectives: To compare the vitamin D levels in patients with fragility hip fracture before and after implantation of the secondary prevention protocol of a new fragility fracture

Methods: A retrospective analysis of patients with hip fragility fractured after the implantation of the new protocol between June 2016 and November 2017 is performed. With the new protocol implantation all fragility fractured patients start treatment with calcium and vitamin D at discharge. Control group were patients treated for consecutive hip fracture in 2012, when the protocol was not been established yet. Inclusion criteria were: age over 65

y and fracture of the hip due to fragility excluding metastatic fractures The following variables were analyzed: age, gender, side, history of previous fragility fractures, previous treatment, new fractures, mortality, vitamin D level at admission and at 3 months.

Results: Results regarding sex side and gender were comparable in both groups. Protocol group included 196 patients, with a mean age of 85.4 y. 30.61% had a previous fracture, 11.22% being hip. 11.74% had previous treatment for osteoporosis. The adherence to treatment was 58.16%. Mean vitamin D level on admission was 14.4 µg/l, only 5,3% of patients showed normal vitamin D level and with 30.61% being severe. Mean vitamin D at three months was 36.48 µg/l. At 3 months in 50% of patients vitamin D levels were normalized. 5.1% of patients suffered a new fragility fracture. Mortality was 18.88%. In the control group, 186 patients were included. Mean age was 85.78 y. Mean vitamin D level on admission was 14.1 µg/l, only 5,1% of patients showed normal vitamin D level and with 32.27% being severe deficit. Mean vitamin D at 3 months was 21.66 µg/l. At three months only 25 patients vitamin D levels were normalized. 29.33% had previous fractures, being 22.66% hip fractures. 2.67% had previous treatment for osteoporosis. 16% suffered new fragility fractures during the follow-up and mortality was 27.34% in the same period of time as the protocol group.

Conclusions: The establishment of a treatment protocol in patients with hip fracture, including vitamin D, could reduce the appearance of new fragility fractures and could have an effect on mortality in the medium term.

P247
MALNUTRITION IN CLUBFOOT PATIENT CAN EFFECT ON PONSSETI TECHNIQUE AND ITS OUTCOME?

M. Muzzammil¹

¹Dr. Ruth K M Pfau Civil Hospital Karachi, Karachi, Pakistan

Objective: Worldwide malnutrition is crucial health problem chiefly in undeveloped and developing countries. The commonest form of congenital orthopedic abnormality is club foot affecting approximately one to two infants per thousand live births. Over the past 20 y, the widely used and acquired method for treatment of clubfoot is Ponseti method. Our aim was to determine the effects of nutritional status of clubfoot patient in outcome of Ponseti technique.

Method: Since Jan 2016 to Dec 2016, 153 clubfoot patients were treated and the WHO classification of weight-for-age index was used to assess the nutritional status of patients.

Results: Out of 153 patients, 112 (79.73) were included in good nutrition group and 42 (20.6%) were malnourished. 15 (36.58%) out of 41 patients with malnutrition had first degree, 14 (34.14%) had second degree and 12 (29.26%) had third degree malnutrition. The average number of casts per patient and 8+ casts given in undernutrition group was higher than the number of 6+ casts given to good nutrition group. The number of Achilles tenotomy performed in undernutrition group was also high.

Conclusion: A significant correlation between patient nutritional status and outcome of Ponseti technique is found, as it influences the number of casts, relapse and possible failure of treatment.

P248

COMPARING PATIENTS COMPLIANCE TO TERIPARATIDE DAILY INJECTION ACCORDING TO THE MODE OF TREATING THE FRAGILITY FRACTURES

A. M. Ali¹, N. Neji¹

¹King Faisal Medical Complex, Taif, Saudi Arabia

Objectives: Comparing the compliance of the patients with fragility fractures to daily teriparatide injection according to the mode of treatment of the fracture; either surgical or nonsurgical treatment.

Methods: A prospective study for 28 months (from June 2016 to October 2018) in King Faisal Medical Complex in Taif which is a referral hospital serving a population of about 2 million citizens. 104 patients included in the study, were suffering from established osteoporosis (BMD <-3.5) and all of them had one or more fragility fracture(s). These patients were stratified into two groups according to the mode of treatment from the orthopedic side; the first group (78 patients) their fragility fractures were treated conservatively (nonsurgically) with splints or supports, while the second group (26 patients) needed surgical intervention for the treatment of their fragility fractures. Teriparatide daily injection with calcium and vitamin D supplements were prescribed for all patients in the study for a period of 24 months. Outpatients visits were scheduled to all patients on regular basis for fracture follow-up and for prescription of the treatment medications. BMD measure was done for all patients yearly.

Results: Patients who continue with the Teriparatide acid injection for more than 12 consecutive months were consider compliant to the treatment. In this series; 85 patients (81.7%) continue to use the teriparatide injection for more than 12 months, 61 of them are from the first group, and 24 patients from the second group (surgical). Hence, compliance in the first group was 78.2%, while in the second group was 92.3%. All patients who were compliant to the treatment showed an increase in BMD after the first year with mean increase in BMD of +1.7.

Conclusion: Surgically treated patients for fragility fractures showed more compliance to the daily injection of teriparatide than those who were treated conservatively. This conclude that hospitalization and undergoing surgery lead to more awareness of the patients to the nature and dangerous of osteoporosis, the importance of anabolic treatment and of the adherence to the treatment regime.

P249

COMBINING FRAILTY AND TRABECULAR BONE SCORE IN PREDICTING RISK OF MAJOR OSTEOPOROTIC FRACTURES

G. Li¹, W. Leslie², J. Zeng¹, A. Papaioannou³, L. Thabane³, M. Levine³, J. D. Adachi³

¹Center for Clinical Epidemiology and Methodology (CEM), Guangdong Second Provincial General Hospital, Guangzhou, China, ²Departments of Medicine and Radiology, University of Manitoba, Winnipeg. Canada, ³McMaster University, Hamilton, Canada

Objective: Findings have shown that 1) trabecular bone score (TBS) as a risk assessment tool is related to osteoporotic fracture risk independently of BMD and age; 2) increased frailty is significantly related to higher risk of fragility fracture; and 3) FRAX (fracture risk assessment tool) in combination with TBS improves predictive accuracy for fracture risk. In this study we aimed to assess the combination of frailty and TBS (with or without adjustment for FRAX) regarding predictive accuracy for risk of major osteoporotic fracture (MOF; i.e., a fracture of upper arm or shoulder, spine, hip, forearm or wrist).

Methods: Data from the Canadian Multicentre Osteoporosis Study (CaMos) were used. TBS values were estimated using lumbar spine (L1 - L4) DXA images. Frailty status was measured by a frailty index (FI) of deficit accumulation; the FI included 30 deficits, ranging from 0 to 1 and with higher scores indicating greater frailty. The outcome was survival time to first incident MOF. Harrell's c-index and AIC were used to assess model performances.

Results: We included 2730 participants (70% women) for analyses (mean follow-up: 7.5 y). Their mean age was 69 (SD: 10) y; the baseline TBS and FI were 1.28 (SD: 0.11) and 0.20 (SD: 0.11), respectively. There were 243 (8.90%) MOFs observed during follow-up. Participants with MOF were significantly older, had higher BMI and FRAX scores, and lower BMD values. Significantly higher FI (0.24 vs. 0.20) and lower TBS (1.23 vs. 1.28) were also found in participants with MOF compared to controls. FI and TBS were significantly related with MOF risk in fully adjusted models: HR=1.24 (95%CI: 1.09 - 1.43) for per-SD increase in FI; HR=1.35 (95%CI: 1.16 - 1.57) for per-SD decrease in TBS. No significant differences in C-indices were found between FI-alone, TBS-alone, and combining FI and TBS models, with C-indices ranging from 0.75 to 0.78. The smallest AIC was found in the model combining FI and TBS, followed by FI-based model and TBS-based models.

Conclusion: Frailty and TBS are significantly related to MOF risk. Minimal improvement of predictive accuracy in MOF risk is found when combining frailty and TBS vs. frailty and TBS alone.

P250

DIABETES MELLITUS ACCELERATES PROGRESSION OF OSTEOARTHRITIS IN STREPTOZOTOCIN-INDUCED DIABETIC MICE BY DETERIORATING BONE MICROARCHITECTURE, BONE MINERAL COMPOSITION AND BONE STRENGTH

X. Zheng¹, H. Wang¹, H. Hou¹, D. Michelle¹, L. Rik¹, Z. Zha¹, C. Zhao²

¹The First Affiliated Hospital of Jinan University, Guangzhou, China, ²Mayo Clinic, Rochester, USA

Objective: Diabetes mellitus (DM) has been demonstrated to be an independent risk factor of osteoarthritis (OA). This new phenotype "diabetic OA" which associates the two most prevalent diseases worldwide will definitely cause significant functional impairment in activities of daily living and in the quality of life of the elderly people. The OA patients with diabetes are more severe in symptoms and structural damage, and also are younger in age for morbidity compared to the OA patients without diabetes. Additionally, diabetes increases the complications and revision rate of arthroplasty procedures. Nevertheless, there are very few studies directly addressing the potential mechanisms and the severity or progression of OA with diabetes. Recent findings have shown subchondral bone (SB) to be crucial for the initiation and progression of osteoarthritis. SB has been shown to be an important shock absorber and providing supportive functions in joints. Moreover, it plays an important role in articular cartilage metabolism. Any histopathology changes in SB will affect the biomechanical properties of the overlying joint cartilage and their intertwined biological relationship, ultimately becoming a crucial contributor to OA pathogenesis. The purpose of this study was three-fold: 1) to develop a DM-OA mice model which would allow for clinically relevant and biological research; 2) to validate that diabetes aggravates OA pathogenesis *in vivo*; and 3) to evaluate the microarchitecture, chemical composition and biomechanical properties of SB as a consequence of the damaged induced by diabetes OA.

Methods: 8 wk old male C57BL/6J mice were randomly divided into three groups: DM-OA group, OA group and Sham group. After acclimatization, the DM-OA group was injected intraperitoneally with 150 mg/kg streptozotocin (STZ) to induce diabetes, while the other two groups were given a PBS vehicle. On the third day after STZ injection, glucose levels were evaluated and mice with a level above 300 mg/dL were considered diabetic. Then, OA was surgically induced in the DM-OA and OA groups by transection of the anterior cruciate ligament (ACL) of the right knee. The sham group was subjected to a similar procedure without the transection of the ACL. Animals were sacrificed at 4, 8, and 12 weeks after the operation. Blood glucose levels, body weight and food intake of all animals were recorded weekly during the entire experimental period. The pancreas was stained with hematoxylin-eosin. The right knee joints from each group at all-time intervals were decalcified and prepared for histological analysis, immunohistochemistry and were scored using a semi-quantitative grading system (OARSI) to grade cartilage and SB degeneration. The undecalcified

joints were used to evaluate the properties of trabecular SB using confocal Raman microspectroscopy to measure the chemical composition (mineral-to-collagen ratio), and microindentation to measure biomechanical properties. Additionally, microCT imaging was performed to evaluate microarchitectural parameters, with subsequent mechanical compression of the SB to investigate fracture properties. ANOVA and the Student Newman Keuls post hoc were used for statistical analyses between the groups.

Results: Glycemic monitoring and pancreas pathological results indicated stable high blood glucose and massive destruction of pancreas and islet cells in the DM-OA group. The OARSI score of the DM-OA group joint was higher than other two groups at 8 and 12 weeks (Figure 1). The number of osteoclasts in the DM-OA group joint was higher than in the other two groups at 8 and 12 weeks. Conversely, the mineral-to-collagen ratio and microindentation elastic modulus and hardness of the DM-OA group joint was lower than other two groups at 8 and 12 weeks. Microarchitectural parameters showed bone volume fraction, trabecular thickness and BMD of the DM-OA group joint to be lower than in other two groups at 12 weeks. On the other hand, trabecular spacing and structural model index was higher compared to the other two groups at 12 weeks (Figure 2). Fracture properties, including stiffness and fracture load, of the DM-OA group were also reduced at 12 weeks.

Figure 1. Histology images of knee joint from DM-OA group (A), OA group (B) and Sham group (C) at each time point of sacrifice.





Figure 2. Tibial subchondral bone from DM-OA group (A), OA group (B) and Sham group (C) were imaged with μ CT at each time point of sacrifice (4, 8 and 12 weeks after operation).



Conclusion: The glycemic and pancreatic pathological results indicated the DM-OA model to be a simple and reliable model induced by STZ and surgery. The pathology results from DM-OA group were worse compared to the other two groups at all-time points, proving diabetes to aggravate OA pathogenesis *in vivo*. Diabetes elevated the number of osteoclasts around trabecular bone and deteriorated the structure of SB. Trabecular biomechanical properties were declined due to a decrease in BMD induced by metabolic derangements in the DM-OA group. All of these histopathology impairments weakened the biomechanical properties of bone and the supportive function of SB, making it more vulnerable to failure. To our knowledge, this work is the first to describe the pathogenesis of diabetic osteoarthritis through diabetes and SB. This work proved that diabetes aggravated OA pathogenesis in a novel DM-OA mice model which could be helpful for clinical and basic science research. More importantly, the results showed the mechanisms in which diabetes accelerates OA by damaging and deteriorating the functions SB including microarchitecture, chemical composition and biomechanical properties.

Reference: [1] King KB, Rosenthal AK. Osteoarthritis Cartilage, 2015;23:841.

Acknowledgement: This study is funded by the grants from China Postdoctoral Science Foundation (2015M582480, 2017T100660), Natural Science Foundation of Guangdong Province (2016A030313100), and National Natural Science Foundation of China (81601219).

P251
ANALYSIS ON CURATIVE EFFECT OF PRONATOR QUADRATES PROTECTING MINIMALLY INVASIVE INTERNAL FIXATION IN TREATING DISTAL RADIUS FRACTURE

H. Xuezhel¹

¹Department of Orthopaedics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

Objective: To investigate the curative effect of pronator quadrates protecting minimally invasive internal fixation in treating distal radius fracture.

Methods: Pronator quadrates protecting minimally invasive internal fixation was applied to treat 43 cases of distal radius fractures, and functions of wrist joints were evaluated by aid of Dienst function evaluation table; functions of wrist joints on the uninjured side and the affected side were compared to analyze the curative effect of minimally invasive internal fixation three months after the surgery.

Results: The results of recovery of wrist joint functions evaluated via the Dienst function evaluation table show that there were excellent 38 cases, 4 good cases, 1 qualified case and 0 poor case, with the rate of excellent and good cases reaching 97%. With respect to comparison in the movement of wrist joints on the uninjured side and the affected side (dorsiflexion $70.2^{\circ} \pm 1.1^{\circ}$ vs. $68.2^{\circ} \pm 2.1^{\circ}$; palmar flexion $72.1^{\circ} \pm 3.6^{\circ}$ vs. $70.2^{\circ} \pm 4.7^{\circ}$; radial deviation $20.5^{\circ} \pm 1.2^{\circ}$ vs. $19.9^{\circ} \pm 3.2^{\circ}$; ulnar deviation $33.6^{\circ} \pm 5.4^{\circ}$ vs. $31.2^{\circ} \pm 2.0^{\circ}$; pronation $79.5^{\circ} \pm 4.6^{\circ}$ vs. $76.2^{\circ} \pm 2.7^{\circ}$; supination $78.2^{\circ} \pm 6.2^{\circ}$ vs. $75.2^{\circ} \pm 2.0^{\circ}$), there was no statistical difference ($P < 0.05$).

Conclusion: Pronator quadrates protecting minimally invasive internal fixation has a positive meaning for the treatment of distal radius fractures. In addition to shortening the operation time and reducing postoperative complications, pronator quadrates protecting minimally invasive internal fixation can also reduce the probability of fracture nonunion, retain the rotation function of patients' forearms to the largest extent, and help patients do functional exercise in the early phase.

P252
A PILOT STUDY ON SEMI-RECUMBENT VIBRATION EXERCISE IN OLDER ADULTS WITH DECREASED PHYSICAL FUNCTION: METHODOLOGY, FEASIBILITY AND SAFETY

B. Buehring¹, M. Taani², E. Siglinsky³, J. Libber³, D. Krueger³, C. Kovach², N. Binkley³

¹Rheumazentrum Ruhrgebiet, Ruhr University Bochum, Herne, Germany, ²University of Wisconsin-Milwaukee, Milwaukee, USA, ³University of Wisconsin-Madison, Madison, USA

Objective: Older adults with decreased physical function are at risk for further decline in part due limited ability to engage in regular exercise. Investigation of effective approaches to exercise in this vulnerable population is needed to improve functional capacity and muscle performance. Our aim was to investigate the feasibility and safety of semi-recumbent vibration exercise in older adults with decreased physical function living in a residential care apartment complex (RCAC).

Methods: Thirty-two RCAC residents, age 70 and older, with short physical performance battery (SBBP) score of ≤ 9 or ≤ 2 in any of the three test components were randomly assigned to a crossover-design study investigating the effectiveness of semi-recumbent vibration exercise on muscle outcomes. The study consisted of two 8-week training periods (vibration and control treatments) with a four-week wash-out period in between. The primary outcome measures were retention and adherence rates and adverse events.

Results: Seven participants dropped out with a retention rate of 78%. Adherence rate was 79.7% during the vibration sessions and 78.6% during the control sessions. Thirty-eight adverse were reported by the participants. Only mild muscle soreness and knee pain were the only adverse events that were deemed to be related to the vibration treatment. Only one participant dropped out due to worsening knee pain. No severe adverse events were related to the study.

Conclusion: Semi-recumbent vibration exercise seems feasible, well tolerated and appeared to be safe in elderly RCAC residents with reduced physical function. Future studies need to examine the effect of this type of exercise on physical/muscle function, mobility, falls and activities of daily living.

P253
EPIGENETIC REGULATION OF OSTEOCLAST DIFFERENTIATION

W. An¹, Y. Shin¹, N. Ghate¹, T. Ulmer¹, V. Punj²

¹University of Southern California, Keck School of Medicine, Department of Biochemistry and Molecular Medicine, ²University of Southern California, Keck School of Medicine, Department of Medicine, Los Angeles, USA

Osteoclasts are multinucleated bone resorbing cells that differentiate from hematopoietic precursor cells. Particular signaling components are expressed during osteoclast differentiation, and their deregulated expression causes various skeletal diseases. Given that all genes encoding osteoclastogenic factors are expressed in the context of chromatin, a fundamental mechanism underlying osteoclast differentiation should involve chromatin-dependent regulatory pathways. Unexpectedly, our recent studies have revealed that matrix metalloproteinase 9 (MMP-9) moves into the nucleus and mediates histone H3 N-terminal tail (NT) proteolysis to activate osteoclastogenic gene expression [1]. Since histone modification and DNA methylation have been implicated in osteoclast gene regulation, we also investigate their possible roles as modulators of MMP-9-dependent H3NT proteolysis and osteoclast differentiation [2, 3, 4]. We show that distinct patterns of epigenetic marks are established by histone methylation (especially H3K4me3, H3K9me3, H3K27me1 and H3K27me3)/histone acetylation (especially H3K9ac, H3K18ac, and H3K27ac)/DNA methylation and profoundly impact MMP-9 activity toward H3NT during osteoclastogenesis. Additionally, our observation that knockdown or inhibition of SET7/G9a/EZH2 histone methyltransferases, p300/CBP histone acetyltransferases and DNMT3 abrogates the observed epigenetic modifications is supportive of the idea that these histone/DNA modifying enzymes are critical for proper regulation of H3NT proteolysis-mediated gene activation during osteoclast differentiation [2, 3, 4]. Consistent with these results, osteoclastogenesis and osteoporosis are significantly affected following the administration of recombinant forms of SET7/G9a/EZH2/p300/CBP into mice. More interestingly, our mechanistic studies indicate that epigenetic signals generated by SET7/G9a/EZH2/p300/CBP play an essential role in regulating the recruitment and activity of MMP-9 and its functional partners at genes encoding factors that are involved in osteoclast differ-

entiation. Taken together, our data establish combinatorial roles for H3NT proteolysis, histone modification and DNA methylation in dictating osteoclast differentiation and bring new possibilities for developing therapeutic strategies to treat osteolytic bone destruction.

References:

1. Kim K et al. Genes Dev 2016;30:208.
2. Kim K et al. Epigenetics Chromatin 2018;11:23.
3. Kim J et al. Oncogene 2018; doi: 10.1038/s41388-018-0356-3.
4. Kim J et al. Cell Rep 2018;24:224.

P254
CADMIUM TOXICITY AS A PROBABLE CAUSE OF SMOKING INDUCED BONE LOSS

A. Elbeialy¹, H. Eldesouky¹, M. Mo'Ezz¹

¹Al-Azhar Faculty of Medicine, Rheumatology Department, Cairo, Egypt

Objective: Cigarette smoking supposed to be a risk factor for osteoporosis. There is an inverse relationship between smoking and both bone mass and fracture risk. Tobacco smoking is the most important single source of cadmium exposure in the general population. The absorption of cadmium from the lungs is much more effective than that from the gut. This study was designed to evaluate the effect of cigarette smoking on BMD, due to cadmium toxicity.

Methods: This study was carried on 100 persons, selected from Al-Azhar university hospital and divided into three groups: group I: included 40 persons with active smokers; group II: included 40 persons with passive smokers and group III included 20 non-smokers. All persons were submitted to full history taking, thorough clinical examination routine lab tests, serum and urinary cadmium and lead, and BMD was measured by DXA.

Results: Serum and urinary cadmium and lead were statistically significantly higher in group I in comparison to groups II or III and in group II in comparison to group III. Also, there was statistically significant decrease of BMD in group I in comparison to either group II or group III and in group II in comparison to group III. There was an inverse statistically significant correlation between serum and urinary cadmium and BMD.

Table (1): Comparison between studied groups as regard serum and urinary cadmium levels

		Mean	S. D	Minimum	Maximum	F	P
Serum cadmium (µg/l)	Group I	0.449	0.287	0.18	1.80	27.92	<0.001(S)
	Group II	0.232#	0.040	0.16	0.32		
	Group III	0.094*	0.047	0.01	0.16		
Urinary cadmium (µg/l)	Group I	0.555	0.304	0.30	2.00	27.16	<0.001(S)
	Group II	0.335#	0.042	0.26	0.42		
	Group III	0.181*	0.052	0.11	0.26		

*= statistically significant decrease in comparison to group I or group II
 #= statistically significant decrease in comparison to group I

Table (2): Comparison between studied groups as regard serum and urinary lead levels

		Mean	S. D	Minimum	Maximum	F	P
Serum lead ($\mu\text{g/l}$)	Group I	22.92	7.98	10.00	50.00	34.86	<0.001(S)
	Group II	17.12 [#]	3.61	12.00	25.00		
	Group III	10.20 [*]	2.14	6.00	14.00		
Urinary lead ($\mu\text{g/l}$)	Group I	33.10	7.85	24.00	60.00	79.10	<0.001(S)
	Group II	27.27 [#]	4.37	20.00	40.00		
	Group III	13.20 [*]	2.19	8.00	16.00		

* = statistically significant decrease in comparison to group I or group II
= statistically significant decrease in comparison to group I

Table (3): Comparison between studied groups as regard bone mineral density (g/cm²)

		Mean	S. D	Minimum	Maximum	F	P
Radial shaft	Group I	0.686 [#]	0.020	0.63	0.73	60.10	<0.001(S)
	Group II	0.712 [*]	0.011	0.69	0.73		
	Group III	0.736	0.017	0.70	0.77		
Femoral neck	Group I	0.811 [#]	0.016	0.77	0.84	116.20	<0.001(S)
	Group II	0.858 [*]	0.023	0.80	0.90		
	Group III	0.908	0.033	0.84	0.97		
Spine (L2-4)	Group I	1.249 [#]	0.022	1.22	1.32	247.85	<0.001(S)
	Group II	1.295 [*]	0.021	1.24	1.36		
	Group III	1.385	0.023	1.32	1.42		

* = statistically significant decrease in comparison to group III
= statistically significant decrease in comparison to group II

Table (4): Correlation between bone mineral density and serum or urinary cadmium and lead in all studied cases

		Radial shaft	Femoral neck	Spine
Serum cadmium	r	-0.583 ^{**}	-0.550 ^{**}	-0.458 ^{**}
	p	<0.001(S)	<0.001(S)	<0.001(S)
Urinary cadmium	r	-0.576 ^{**}	-0.544 ^{**}	-0.451 ^{**}
	p	<0.001(S)	<0.001(S)	<0.001(S)
Serum lead	r	-0.687 ^{**}	-0.488 ^{**}	-0.581 ^{**}
	p	<0.001(S)	<0.001(S)	<0.001(S)
Urinary lead	r	-0.719 ^{**}	-0.593 ^{**}	-0.706 ^{**}
	p	<0.001(S)	<0.001(S)	<0.001(S)

P255 ASSOCIATIONS BETWEEN VITAMIN D SERUM LEVELS AND SELF-REPORTED PHYSICAL ACTIVITY IN ADULTS OVER 20 YEARS

J. Lee¹, Y. Kim¹

¹Catholic University of Korea, Uijeongbu, South Korea

Objective: There is lacking consensus based on self-reported activity levels that physically more active individuals may have higher vitamin D serum levels. The aim of this study was to investigate the association between vitamin D status and self-reported physical activity in adults over 20 y.

Methods: Cross-sectional data from 33,366 individuals (13,119 men and 20,247 women) over 20 y in the Korea National Health and Nutrition Examination Surveys (KNHANES) were analyzed. Self-reported physical activities of participants over 20 y were classified into three physical activity levels (low, moderate and high activity group), using International Physical Activity Questionnaire scoring protocol. The serum 25-hydroxyvitamin D (25(OH)D) level was measured by radioimmunoassay and vitamin D deficiency was defined as 25(OH)D <20 ng/mL. The association of physical activities level and stroke status was analyzed using the general linear models adjusted for anthropometric and clinical confounders.

Results: The adjusted mean 25(OH)D level of participants was significantly different among three activities levels (18.84±0.25 ng/mL in high activity group vs. 17.81±0.24 ng/mL in medium activity group vs. 17.32±0.22 ng/mL in low activity group) and the adjusted mean 25(OH)D level of high activity group was the highest in high activity group, using post hoc analysis (P=0.00). The 25(OH)D level of male (19.12±0.23 ng/mL) was higher than female (16.86±0.23 ng/mL). Nonsmoker, lower educational level, participants without arthritis or cardiovascular diseases had the higher 25(OH)D level (P<0.05), but hypertension and diabetes mellitus did not show significant differences (P > 0.05).

Conclusion: Vitamin D level in low activity level is the lowest among three activities levels, which may indicate that vitamin D level is associated with physical activity levels. The potential confounding factors such sun exposure, important determinant of vitamin D serum levels, need further investigation.

P256 POOR BIOLOGICAL ENVIRONMENT INCREASE THE “CUT OUT” RISK IN HIP FRACTURES

B. Limousin Aranzabal¹, E. Fernandez Tormos¹, O. Marin Peña¹, R. Larrainzar Garijo¹

¹Hospital Universitario Infanta Leonor, Madrid, Spain

Objective: Hip fracture is one of the XXI century epidemics. The most common treatment for pertrochanteric hip fractures is the intramedullary nailing, although other types of devices are used also like the nail-plate. The objectives of this work are: to identify the type indecency of screw “cut-out” in our series; analyze the potential mechanical or biological origin; and study the functional significance in those patients.

Method: We analyzed retrospectively a case series of patients with pertrochanteric hip fracture. In our series are 1349 cases treated between 2009-2017 in our hospital. We selected cases of complications with subsequent reoperation grouped by DRGs. We found 21 cases of “cut out” reoperation. We analyzed demographics data, functional parameters (BARTHEL Index), laboratory parameters (Vit. D), radiological parameters (Tip-Apex Distance (TAD) and Parker Ratio (PR)).

Results: With a comparable groups of cases and controls with respect to demographic data. We found a higher rate of BARTHEL in the series of cases (14%). The analytical parameters indicated a clear hypovitaminosis D in patients with pertrochanteric hip frac-

ture, being more marked in our case series. In our cases the radiological parameters analyzed indicated a TAD > 25 in 64% and 36% TAD < 25. In 100% the screw was in a middle position as PR. The incidence of screw cut-out was 1.55%. We detected a possible mechanical origin in 64% of cases and biological in the remaining 36%. We detected a reduction in the functional parameters of 21.78% in the BARTHEL Index.

Conclusion: Even though we have a low incidence of screw cut-out in our series in comparison to the literature, this has not less importance. This phenomenon has a significant impact on the functional parameters of patients. Two important routes of improvement for reducing the incidence are: improve the surgical technique (TAD < 25 mm and PR > 66%) and improve the biological environment, placing great importance to vitamin D.

P257

BODY COMPOSITION ANALYSIS AND QUANTITATIVE ULTRASOUND DENSITOMETRY IN SCREENING OF BONE STRUCTURAL ABNORMALITIES IN WOMEN

P. Feher¹, D. Annar¹, A. Zsakai¹, E. Bodzsar¹

¹Department of Biological Anthropology, Eotvos Lorand University, Budapest, Hungary

Objective: Numerous studies have confirmed the obvious relationship between BMD and endocrine status. Peak bone mass is reached in the third decade of life and sustained until the fifth decade when the age-related bone loss begins. Beside the age-related bone loss there is an accelerated bone resorption in women within 5-10 y after menopause related to estrogen deficiency. DXA and ultrasound densitometry are widely used to screen osteoporosis and other bone structural diseases. BIA devices can also estimate bone mineral content (BMC) but it has not been recommended for diagnostic purposes. The main aim of the present study was to analyse how estimates of body composition and bone mineral content can predict bone structure in women.

Methods: Healthy premenopausal women (n: 130, 18-45 y) and postmenopausal women (n: 130, 46-75 y) were enrolled to the present analysis. Estrogen level was estimated from saliva samples. Exclusion criteria included history of surgical menopause, hormone replacement therapy, oral contraceptives and chronic metabolic diseases. Menopause was defined as amenorrhea of 12 months duration and was confirmed by measurements of salivary 17-β-estradiol concentrations < 4 pg/ml. BMC (kg) was estimated by InBody 720 analyser. Bone structure was measured by ultrasound osteometer (DTU-One Osteometer). Broadband ultrasound attenuation (BUA, dB/MHz), which estimates the structural characteristics of trabecular bone, e.g., porosity, was used to assess bone structure in the analysis. Body mass components, bone and muscle mass (kg), were estimated by Drinkwater-Ross anthropometric method. Relative body components were expressed in the percentage of stature.

Results: The age changes of 17-β-salivary estradiol concentrations, BMC, relative bone mass, relative muscle mass and bone structural parameters were analysed in premenopausal and post-

menopausal women. BMC (r=0.43, p<0.01), relative muscle mass (r=0.44, p<0.01) and relative bone mass (r=0.38, p<0.01) were strongly correlated (Pearson correlation) with BUA in premenopausal women. In postmenopausal women weaker relationship was identified between BUA and its hypothetical predictive factors.

Conclusion: BMC and the other studied body mass components alone do not provide enough information to identify osteoporosis, but can complete and widen the screening methods for bone structural diseases. The BMD of healthy premenopausal women with low BMC, low bone mass and/or low muscle mass values should be measured. The early monitoring of bone structural ageing and endocrine status in adults is of high importance, especially in premenopausal women.

P258

BODY AND BONE STRUCTURAL EXAMINATIONS OF TURNER SYNDROME PATIENTS

D. Annar¹, P. Feher¹, A. Zsakai¹, A. Muzsnai², E. Bodzsar¹

¹Department of Biological Anthropology, Eotvos Lorand University, ²Department of Paediatric Endocrinology, Saint Janos Hospital and Unified Hospitals of North Buda, Budapest, Hungary

Objective: Turner syndrome is characterized by the absence of the entire or the part of second X sex chromosome. The presence of the X chromosome is necessary for the development of ovaries, which produce estrogen. Estrogen plays an important part in the development of bone mineral content and the formation of peak bone mass. Different treatment schemes are known to mitigate the symptoms and compensate the deficiencies in Turner syndrome. The main aim of the presentation to introduce the results of a body structural study of Turner syndrome patients by highlighting the most important relationships between body structure, karyotype and treatment type in the syndrome.

Methods: 20 girls and women with Turner syndrome, who received or not received hormone replacements, were studied. Bone mass was estimated by the Drinkwater-Ross four component model. Muscle mass, fat mass and visceral fat area were estimated by bioelectrical impedance analysis (InBody 720 device). Bone structure was measured by ultrasound DTU-One osteometer. BMD was measured by XCT 2000 pQCT. The pattern of body and bone structure parameters was analyzed by cluster analysis.

Results: The Turner patients' body structure was very inhomogeneous. Based on the results of the cluster analysis of bone and body structural parameters, we could separate the subgroups of the syndrome, bone density and the relative length of the limb segments were the most important separators. The subgroups were: subgroup A – a group of patients who have 45,X0 karyotypes and received or are receiving hormone replacement; subgroup B: patients with 46,XX/45,X0 mosaic karyotypes; subgroup C – patients with isochromosomes (and subgroup D – patients who could not be classified into the other three groups). The length measures and the bone density of the group with isochromosomes differed significantly from the other groups' values. While

the width, girth, skinfold thickness, body mass components, bone structural parameters of the subgroup with 45,X0/46,XX mosaic karyotype were also different than in the other subgroups.

Conclusion: Regular body and bone structural examinations are of high importance, but the genetic subgroup is also very important in the healthcare of Turner syndrome patients.

P259

CHARACTERIZATION OF SARCOPENIA IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS

A. P. Gonzalez¹, A. M. Medina¹, A. S. Sierra¹, R. W. Rojas¹

¹Fundacion Universitaria Ciencias de la Salud /Hospital San Jose, Bogota, Colombia

Objective: Given the frequency of osteosarcopenia in the postmenopause with increased risk of fracture, it is necessary to know the behavior of this entity in our population to perform diagnostic measures in early intervention. Our aim was to describe the prevalence of sarcopenia in patients diagnosed with primary osteoporosis who attended the endocrinology service between June and October 2018.

Methods: Cross-sectional study. We included patients with postmenopausal osteoporosis between 50-80 y without contraindications to perform diagnostic tests for sarcopenia (upper limbs grip strength, walking speed, muscle mass index). Descriptive statistics was used to analyze the data.

Results: 59 patients were included, 48 met diagnostic criteria (low strength in upper limbs, low muscle mass index, decrease in walking speed). 70.8% presented presarcopenia, 25% sarcopenia and 4.2% severe sarcopenia. 74.1% showed low IMME, 24.1% low grip strength and 12.1% low walking speed. Of the patients with a history of fracture, 44% had presarcopenia, 41.7% sarcopenia and 50% severe sarcopenia. Hypovitaminosis D was found in 32 patients of which 71% had low IMME, 25% decreased grip strength and 18.8% decrease in walking speed.

Conclusions: In patients with osteoporosis, sarcopenia prevalence of 25% was found, therefore it is important to perform an active search in this population. In patients in the presarcopenia group, there was a high frequency of falls, fractures, vitamin D deficiency, which is why early intervention measures must be instituted to reduce complications from this phase. When comparing prevalence according to European consensus 2010-2018 an overdiagnosis was observed in 25% of the population with previous parameters. In the presarcopenia and sarcopenia groups, a high frequency of overweight was observed, 88% and 100% respectively, considering that it is not enough to measure BMI for this entity, with which only 3 and 8% are diagnosed.

P260

EFFECT OF DENOSUMAB ON CHILDREN WITH OSTEOGENESIS IMPERFECTA: A SYSTEMATIC REVIEW

J. Zeng¹, Z. Huang², G. Li¹

¹Center for Clinical Epidemiology and Methodology (CEM), Guangdong Second Provincial General Hospital, ²Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, China

Objectives: Osteogenesis imperfecta (OI) is a rare inherited disorder characterized by increased bone fragility and reduced bone mass and often short stature. Denosumab may be an effective treatment for children with OI. We aimed to perform a systematic review to summarize the evidence from clinical studies assessing effect of denosumab on children with OI.

Methods: We systematically searched the Medline and Embase databases up to August 31, 2017. We included the clinical observational research or intervention studies that provided original data on outcomes of denosumab in children with OI. Primary outcome included BMD and incident fractures. Data were independently extracted by two reviewers.

Results: This review included two pilot prospective trials and one case report, which involving a total of 15 children. One trial including four children who were with type VI OI showed a notable improvement in BMD and bone resorption and formation biomarkers with denosumab. Two of the four children later experienced fractures caused by mild trauma. The other trial focused on 10 children and reported that denosumab significantly improved BMD by week 48. By contrast, the case report including one child who was diagnosed with type VI OI found no clinical improvement in BMD or fractures.

Conclusions: In this review evaluating the treatment effects of denosumab on children with OI, we found the evidence from clinical research was sparse, limited and inconsistent. Limitations existed for the current evidence including limitations of trial designs, uncertain dosages and administration intervals, and small sample sizes. Further large-scale, well designed and long-term studies are needed to clarify the effect of denosumab on pediatric patients with OI.

P261

SERUM TOTAL OSTEOCALCIN LEVEL AND TYPE 2 DIABETES MELLITUS

D. Zaha¹, F. Cioara¹, C. M. Vesa¹, L. G. Daina¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objective: Osteocalcin is a noncollagenous, 49 amino acid glutamate-rich polypeptide bone matrix protein produced by osteoblasts and incorporate it into the bone matrix. Osteocalcin levels are related to increased bone turnover so, it has been used clinically to assess the effectiveness of osteoporosis treatments. It has been discovered that osteocalcin also acts as a hormone to control glucose and energy metabolism on pancreatic β -cells and

adipose and muscle tissues. Studies on the association between serum total osteocalcin level and type 2 diabetes mellitus (T2DM) had reported controversial results. The aim of this study was to assess this association in female patients with T2DM.

Methods: To assess the relationship between serum total osteocalcin and T2DM, we performed a study to determine serum total osteocalcin level on individuals with T2DM. A total of 98 subjects (all women) were selected for this study who voluntarily enrolled for diabetes mellitus checkup including the blood test for serum osteocalcin level and bone density by DXA scan. Multiple regression analysis was used to determine which variables were independently related to osteocalcin levels, osteoporosis and T2DM.

Results: A negative correlation was found between serum osteocalcin levels and BMD grading. Multiple regression analysis adjusted for age, sex, menopausal status, BMI, serum alkaline phosphatase, serum calcium and phosphate showed that osteocalcin negatively correlated with serum glucose ($p=0.04$) and homeostasis model assessment of insulin resistance (HOMA-IR) ($p=0.037$) independently.

Conclusion: Serum osteocalcin level was inversely associated with fasting glucose level and insulin resistance measured by HOMA-IR, suggesting that osteocalcin is important for glucose metabolism.

P262

POTENTIAL HEALTH BENEFITS OF MOLECULAR HYDROGEN (H₂)

R. Amir¹

¹Centre de Santé des Fagnes, Chimay, Belgium

Objective: Clinical and preclinical studies have identified H₂ as being beneficial in the prevention and treatment with a therapeutic effect in a wide range of disease conditions.

Methods: It has been reported that H₂ exerts a therapeutic effect in acute illness such as ischemia – reperfusion injury, shock, and damage healing to chronic illness as metabolic syndrome, rheumatoid arthritis, diabetes, neurodegenerative diseases, asthma, cancer, cardiovascular diseases (congestive heart failure, coronary heart disease, hypertension, stroke and other cerebrovascular disease), and depression. There are many ways to get your body to start benefiting from all that H₂ may offer.

Results: In inflammatory processes, H₂ suppresses the proteins involved in inflammation while also activating the mechanisms that protect against cell death. Several clinical trials studied patients with rheumatoid arthritis after administration of H₂. The preliminary results showed a reduction in DNA damage as well as a reduction in the patient's symptoms, with a great number of patients reaching total remission of their symptoms. Furthermore, it has been demonstrated that taking a hydrogen product may reduce lactic acid accumulation during periods of heavy exercise. H₂ have been leveraged to treat or improve the state of oxidative stress pathologies (OSP) either acute or chronic OSP. One of the first orientation witch result by the synthesis of many different

studies, is that H₂ is an attractive therapy justifying the treatment of many different pathologies, either as an adjunct treatment to the basis treatment or as a therapeutic agent.

Conclusion: Efficacy of H₂ for various diseases has been shown by basic research. When the clinical efficacy or a significant preventive action is confirmed and regulatory approval is obtained, the indications for the use of H₂ will expend over time. However, the clinical efficacy of H₂ needs to be verified scientifically and eventually confirmed. H₂ has various physiological actions such as antioxidant effect, anti-inflammatory effect and a protective effect against cell death, but the molecular mechanisms involved have not yet been clarified.

P263

EFFECTIVE TREATMENT OF A PATIENT WITH PREGNANCY AND LACTATION-ASSOCIATED OSTEOPOROSIS: A CASE REPORT AND A REVIEW OF THE LITERATURE

P. G. Pisano¹

¹G.I.S.T.O., Arezzo, Italy

Objective: Osteoporosis associated with pregnancy and lactation is a syndrome that most often affects the spine, but, albeit to a lesser extent, also at the level of the hip, characterized by atraumatic compression fractures. This case report may highlight on this pathology which can manifest itself in the period between the last 3 months of pregnancy, the delivery and the first months of breastfeeding. It is defined in literature as pregnancy and lactation-associated osteoporosis (PLO or sometimes PAO) and transient osteoporosis of the hip (TOH) and it is still today referred to as a rather rare pathology. But it is dramatically miscalculated. Moreover, there is a significant correlation between the number of fractures at time of diagnosis and subsequent fracture risk. The purpose of this case report is to highlight on this underestimated pathology and discuss on a potential unusual therapy.

Methods: It will be described one of the cases of PLO that I had the opportunity to treat in my private osteoporosis center. A 24-year-old woman who suffered fractures in the vertebral column 1 month after delivery. In this paper the anamnesis, the previous diagnoses, any previous therapies, the tests performed and the proposed therapy are examined. The published literature is also examined and discussed. Combination therapy of menaquinone 7, magnesium, silicon and vitamin D were used for treatment. The follow-up was performed using Brief Pain Inventory, MRI, blood exams and DXA.

Results: After the treatment patient's back pain decreased significantly, the bone metabolic index, BMD improved and she did not experience any recurrence.

Conclusions: Early diagnosis as well as the efficacy of PLO intervention monitoring and evaluation are critical for the success of treatment. A mix of phytochemicals, vitamins and supplements can be considered another option in the therapeutic approach to this rare disease.

P264

HEMATOPOIETIC AUTOPHAGY DETERIORATION LINKS TO OSTEOPOROSIS

Y. Yuan¹, Y. Fang², J. Wang², X. Xu¹

¹Department of Orthopaedics, the Second Affiliated Hospital of Soochow University, ²Hematology Center of Cyrus Tang Medical Institute, Soochow University School of Medicine, Suzhou, China

Objective: Disorders of hematopoiesis affect skeletal system. Osteoporosis is a major risk of complications in hematopoiesis disease such as hematopoietic malignancy, anemia, β -thalassaemia or hematopoietic stem cell transplantation. We examine the correlation between hematopoietic system autophagy and bone homeostasis.

Methods: In clinical research, 4964 samples red blood count (RBC) and BMD were measured for correlation analysis. Femur-derived bone marrow of 30 patients was obtained from young normal BMD (BMD > -1.0, age < 40 y) or aged osteoporosis (BMD < -2.5, age > 60 y) during total hip replacement surgery. Bone marrow monocytes were stained by CD34 and CD45 antibodies. LC3 expression of bone marrow hematopoietic cells was measured by ImageStream. Autophagy related gene expression was measured in patients bone marrow CD34CD45 positive cells.

In animal research, mice were divided into experiment group and control group. In experiment group, Atg7 gene was null in hematopoietic system (Atg7^{fl/fl};Vav-iCre) by using Vav-iCre transgene; the control group was Atg7^{fl/fl} mice. Bone marrow hematopoietic cells LC3-I and LC3-II as well as bone tissue Atg 7 expression were measured to confirm autophagy disordered in hematopoietic cells not in bone tissue. Calcein of 30 mg/kg was injected 7 days and 2 days before harvested. Micro-CT of femur was performed for BMD, cortical thickness and trabecular bone quantification. Femora were tested in three-point bending for bone biomechanical properties. Bone trabecular was observed by electron microscopic images. Bone tissues were sectioned for hematoxylin and eosin (H&E), Masson and Collagen1 staining. Phalloidin, mitochondria, γ -H2AX and DAPI staining were performed on tibia for immunofluorescence. CD31 and EMCN were staining to detect type H vessel. Bone tissue ROS level was detected by flow cytometry. Bone homeostasis related RNAs were measured by RT-PCR. Skeleton samples were stained by Alcian blue and Alizarin red S. Bone tissue was collected for TMT labeled proteome analysis.

Results: In clinical research, RBC count decreased in aged people. RBC count has positive correlation with femur BMD both in male and female. Human hematopoietic stem progenitor cells (CD34+CD45+) LC3 protein was inhibited in aged osteoporosis patients associated with descending autophagy gene expression, with Atg7, Atg5, Atg12, LC3b, Lam2a, P62 involved.

In animal research, bone marrow hematopoietic cells reduced conversion of LC3-I to LC3-II, confirming Atg7 deletion. Deletion of Atg7 in hematopoietic system caused low BMD. MicroCT analysis revealed that trabecular number, bone volume/tissue volume, cortical thickness were decreased. The absence of Atg7 in hematopoietic resulted in weak bone biomechanical strength properties. Scanning electron microscope depicted trabecular microstructure

destruction. There is no size difference in skeleton Alcian blue and Alizarin red S staining. The H&E staining showed Atg7^{fl/fl};Vav-iCre mice trabecular degeneration and more fat tissue. Masson staining showed broken collagenous fiber and elastic fibers. Quantification of calcein labeling showed reduced mineralized surface in Atg7^{fl/fl};Vav-iCre mice, which resulted in a low bone formation rate. Phalloidin staining revealed abnormal osteocyte size and number in Atg7^{fl/fl};Vav-iCre mice. γ -H2AX staining revealed loss of Atg7 in hematopoietic system induced osteocyte DNA damage. Osteocyte ROS level increased in Atg7^{fl/fl};Vav-iCre mice, which was verified by mitochondria staining. Bone homeostasis related gene expression, including SP7, RUNX2, BMP2, BMP6, CTSK, TRAP5, were inhibited in Atg7^{fl/fl};Vav-iCre mice. Integrative proteomics functional enrichment of differentially quantified proteins showed Atg7^{fl/fl};Vav-iCre mice bone tissue skeletal system morphogenesis and development were down-regulated. KEGG analysis revealed collagen1 in ECM(extracellular matrix)-Receptor interaction was down-regulated. The collagen1 staining showed less collagen secretion in Atg7^{fl/fl};Vav-iCre mice. Type H vessels were depressed in Atg7^{fl/fl};Vav-iCre mice.

Conclusions: Deterioration of autophagy in hematopoietic system inhibited osteogenesis in clinical and animal model. This work suggests that hematopoietic autophagy have potential to maintain bone homeostasis, especially collagen1 in extracellular matrix, as well as type H vessels, possibly contributing to osteogenesis.

P265

REHABILITATION PROGRAM IN PATIENTS WITH KNEE OSTEOARTHRITIS AND TYPE II DIABETES

K. C. Kamal¹, M. R. Trăistaru¹, D. Kamal¹, D. O. Alexandru¹, O. C. Rogoveanu¹

¹University of Medicine and Pharmacy of Craiova, Craiova, Romania

Objectives: Knee osteoarthritis (KOA) is a degenerative disease that affects mainly older people who frequently associate comorbidities such as type 2 diabetes. KOA and type 2 diabetes together, have an increased debilitating potential, leading to significant care costs and a significant decrease in quality of life and functionality. Our study objective is to evaluate the role of a complex rehabilitation program in patients diagnosed with KOA and type 2 diabetes.

Methods: Our patients were diagnosed clinically, paraclinical and imagistic with primary KOA and type 2 diabetes. The studied group included 19 patients that received medication and followed a complex rehabilitation program. The control group received only medical treatment and was advised to comply to orthopaedic rules. For the assessment we used 2 parameters: pain by using visual analogue scale (VAS) and functionality with WOMAC. These were measured at the beginning at the study (T1), after the 6 months rehabilitation program (T2), and after 1 y (T3).

Results: We included 37 patients in our observational study, age between 57-71 years old, with a mean age of 67.3 y. 21 of the patients were women and 16 men. In all patients included in the first

group, we found that for VAS scale there were highly significant values just like for the WOMAC index, in T2 evaluation comparing to T1 assessment. After 6 months (T3), improved functional status and pain level were maintained. As for patients in the control group the mean values in T2 comparing to T1 have improved, but they were not statistically significant, but they have not been maintained to T3 evaluation.

Conclusions: An individualised rehabilitation program and drug treatment represents the ideal therapeutic option for patients with knee osteoarthritis and type 2 diabetes for improving pain and functional status.

P266
PREVALENCE OF VERTEBRAL FRACTURES SECONDARY TO CORTICOSTEROIDS IN EGYPTIAN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

H. M. Elhadary¹

¹Kasr Alaini Medical School, Cairo, Egypt

SLE is a chronic autoimmune disease with a complex clinical presentation and course.

Patients with SLE are at risk of generalized osteoporosis. The etiology of bone loss in SLE is supposed to be multifactorial, including traditional osteoporosis risk factors, inflammation, metabolic factors, hormonal factors, serologic factors, and medication induced adverse effects.

Glucocorticosteroids remain the first choice treatment option for SLE. They possess strong anti-inflammatory and immunosuppressive properties, mainly due to their profound effect on the production of pro-inflammatory cytokines. Our goal was to determine the prevalence of vertebral deformities and the frequency of the risk factors associated with symptomatic vertebral fractures in premenopausal SLE patients treated with corticosteroids (Cs).

We conducted the study on 100 adult patients suffering from SLE and 50 healthy age and sex matched individuals as a control group, form the basis of this study. All patients were attending the outpatient clinics of the Rheumatology and Rehabilitation Department, Kasr El-Aini Hospital, Cairo University. The SLE patients

were 94 females and 6 males. Their age ranged between 19-48 y with a mean of 29.26±8.844 y. The total GCs dose was equivalent to prednisone 3.6-64.8 g ±11.6296.

Upper endplate deformity was found in 10 (10%) patients, anterior wedge deformity was found in 12 (12%) patients and compression deformity was found in 2 (2%) patients. Wedge deformity was the most frequently observed type of deformity followed by upper endplate deformity then compression deformity. We did not find any consistent relation between the prevalence of vertebral fractures and cumulative glucocorticosteroid dose, i.e., prevalence of vertebral deformity did not increase with the increase in the cumulative glucocorticosteroids dose.

Our results show that a large proportion of SLE patients get vertebral fractures despite normal BMD. Since some SLE patients are at high risk of thrombosis, impaired microcirculation in bone could damage bone cell viability and subsequently the possibility to repair trabecular damage. Mechanisms leading to impaired bone strength could also be initiated by autoantibodies directed against substances necessary for healthy bone remodeling. Despite the known side effects of glucocorticosteroids we did not find any association between vertebral fracture and corticosteroids in our study.

P267
BISPHOSPHONATE ATYPICAL FEMORAL FRACTURE IN OSTEOGENESIS IMPERFECTA

A. Michael¹, N. Gittoes²

¹Russells Hall Hospital, Dudley, ²Queen Elizabeth Hospital, Birmingham, UK

Case report: A 66-year-old female, while walking heard a crack from her left thigh and fell on her right side. She experienced severe pain, was unable to weight bear and was hospitalised.

Her past medical history included osteogenesis imperfect (OI). She had left wrist fracture when she was 4 years and fractured her left arm when she was 6. At the age of 9 she fractured her left tibia. Between the ages of 9-12 y, she fractured her femur three times and was unable to go to school for 2 y. Her fractures stopped at the age of 12 until she was 59 when she fractured her tibia. She received alendronic acid and her DXA monitoring and drug holiday period are summarised in the Table.

	57 y	59 y	62 y	63/4y	65 y
Mean total hip T	-1.1	-1.8	-1.7		-2.5
Mean total hip Z	-0.3	-0.9	-0.7		-1.3
Bisphosphonates	BPs started	On BPs for 2 y	On BPs for 5 y	BPs holiday 2y	On BPs for 1 y

When admitted she had short stature with some chronic bony deformities. There was no scleral discolouration, dental problems or hearing impairment. X-ray showed left transverse subtrochanteric fracture. There was also alinear transverse fracture across the outer cortex of the right femur. The patient's atraumatic subtrochanteric fractures fulfilled the ASBMR definition of atypical

femoral fractures (AFFs). Left femoral nailing was performed. Prophylactic intramedullary nailing was considered to reduce the risk of fracture of the right femur but bowing of the femur did not allow this.

Discussion: BPs are widely used in children with OI and are also used in older adults with OI. The evidence base for their use in fracture prevention in adults is not well established. The optimum choice of BPs, duration of therapy, longer-term effects and side effects, including the incidence of AFFs, have not been adequately defined in this rare disease. However it is not unexpected that some patients may develop BPs- related fractures. Our patient had BPs for 6 y and she had chronic bone deformities of OI that may have contributed to biomechanical risk factors. Both factors may have contributed to her apparent BPs-related atypical femoral fracture.



P268
VENOUS THROMBOEMBOLISM FOLLOWING DELAYED SURGERY OF A HIP FRACTURE

J. W. Kim¹, J. Y. Yoon¹

¹Asan Medical Center, University of Ulsan, Seoul, South Korea

Objective: Patients with hip fractures are known to be at risk of development of deep vein thrombosis (DVT). Surgical delays may predispose patients to developing venous thromboembolism (VTE). However, surgical delays may often occur due to preoperative medical evaluation and optimization, lack of operation

theaters, and transfer from other hospitals. The goal of this study was to evaluate the incidence of VTE in patients with hip fractures whose surgery was delayed, and the effect of prophylaxis intervention regards to its success in preventing thromboembolic complications.

Methods: This study is a single-center, and retrospective cohort study. The medical records of patients who presented with a fracture from Oct 2016 to Oct 2018 were retrospectively obtained. Inclusion criteria were following; 1) Surgically treated patients with hip fracture, 2) Surgical delay >24 h from injury to surgery, 3) aged 50 years old or older, and 4) low energy injury. Exclusion criteria were 1) pathologic fracture, 2) multiple trauma patient. Delayed surgery was defined as surgery 24 h after injury. All patients had DVT prophylaxis postoperatively.

Our conventional protocol of prophylaxis for VTE was anti-embolism stocking without screening (group 1, n=59). From Sep 2017, our intensive protocol for VTE was performed with indirect DVT computed tomography (CT) and pulmonary embolism (PE) CT (group 2, n=60). When DVT was detected on screening, inferior vena cava (IVC) filter was applied before the operation. Our prophylaxis protocol was consisted of mechanical prophylaxis with intermittent pneumatic compression device immediately after admission and chemical prophylaxis with subcutaneous injection of low-molecular heparin (>) 20 ul/d or fondaparinux 2.5 mg from admission to postoperative 7 d. Overall postoperative symptomatic VTE incidence were evaluated. The relationship were analyzed between VTE and each age, sex, fracture classification, BMI, time from injury to admission, time from admission to surgery, transfer from other hospital, preoperative infection, medical comorbidity using Charlson comorbidity index (CCI), history of DVT or varicose vein, preoperative anticoagulation agent, preoperative ambulation state using Koval score, operation method (osteosynthesis vs. arthroplasty), operation time, ICU stay, and hospital stay. We compared the incidence of postoperative VTE between the two groups.

Results: 111 patients (38 males and 81 females) with a mean age of 78.2 y were enrolled. The percentage of patients transferred from other hospitals was 68.1%. There were 63 cases of femur neck fractures, 49 cases intertrochanteric fractures, and 7 cases of subtrochanteric fractures. The average time from injury to admission was 90.2 h (range, 0.5-2160 h), and the average time from admission to operation was 75.3 h (range, 16-934 h). The average time from injury to operation was 165.5 h (range 25-2250 h). A total 8 patients developed VTE (6.7%), of which 2 had DVT, 3 had PE and 3 patients had both DVT and PE. Four patients (6.7%) were screened on preoperative evaluation in group 2. The other 4 patients developed VTE postoperatively, and they were group 1. In the group 1, postoperative VTE occurred 6.8% (4/59) was higher than that 0% (0/64) in group 2 (p=0.040).

Conclusion: The patients with delayed hip fracture surgery showed a high prevalence of preoperative VTE, but our management protocol showed effective successful prevention of symptomatic VTE including PE.

P269

BONE MINERAL DENSITY LEVEL IN EARLY MENOPAUSE OF OBESE WOMEN IN ZLATIBOR DISTRICT

V. Ristanovic¹, S. Marinkovic²¹Zdravstveni Centar Uzice, Uzice, ²Specijalna Bolnica Za Bolesti Stitastste Zlezde i Bolesti Metabolizma Zlatibor, Zlatibor, Serbia

Objective: To determine a correlation between T-score level of spine and hip, and BMI we measured BMD in women from Zlatibor district experiencing menopause before the age of 40.

Methods: 70 female patients of different age groups were examined in Osteodensitometry Cabinet of Special Hospital for Thyroid Gland and Metabolism Diseases Zlatibor. BMD expressed as a T-score was measured using DXA technology apparatus (Explorer-Hologic). Height, weight, and BMI were subsequently measured.

Results: Average age of patients is 50 ± 4.21 y, average age of female entering menopause is 38 ± 2.78 y. 43 women (63%) comprised an overweight group, while 27 female patients (37%) comprised an obese group. A positive correlation between spine T-score and hip T-score ($r=0.582667$) was identified in a group of patients with BMI<30. A relationship between the T-scores of spine and hip and menopause start year among patients with BMI<30 was found to be immaterial ($r<0.3$), a correlation matrix was obtained (Pearson). A moderate negative correlation was observed between spine T-score and BMI ($r=0.33$) and negligible correlation among other variables was found ($r<0.3$). Further, the correlation between hip T-score and menopause start years was found to be moderate positive ($r=0.424356$) and immaterial correlation among other variables was observed ($r<0.3$). Result obtained $r_{xy}=0.424356$ was tested for 26 patients for which relationship between hip T-score and menopause start year was searched for. Following hypotheses were set in accordance: $H_0: R_{xy}=0$ and $H_a: R_{xy} \neq 0$. With consideration that obtained t value, $t=2.29$, is greater than the limit for 24 degrees of freedom and level of significance equals $p=0.05$, $t(24,0.05)=1.71$ and $p<0.05$, the null hypothesis is rejected and alternative hypothesis is accepted with error $p=95\%$. Having said that we can conclude that there is a high correlation between hip T-score and menopause occurrence onset.

Conclusion: Obese women with BMI>30 kg/m² have a less pronounced BMD decrease on spine and hip. A high correlation between hip T-score and menopause start was proved to exist in the same group of patients.

P270

OSTEOPOROSIS IN THALASSEMIA MAJOR PATIENTS: RESULTS FROM A CROSS-SECTIONAL OBSERVATIONAL STUDY

A. N. Tsartsalis¹, D. Tsartsalis², I. Papassotiriou³, G. Lambrou⁴, E. Vlachou⁵, A. Samartzi⁶, C. Kanaka-Gantenbein⁴, G. Chrousos⁴, A. Kattamis⁴

¹Naval Hospital of Athens, Department of Endocrinology Diabetes and Metabolism, Athens, Greece, ²Department of Clinical Physiology, Linköping University, Linköping, Linköping, Sweden, ³Department of Clinical Biochemistry, "Aghia Sophia" Children's Hospital, Athens, Greece, ⁴First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece, ⁵Department of Nursing, University of West Attica, Athens, Greece, ⁶Graduate of Social Work Department of Athens, Athens, Greece

Objective: Thalassemia major (TM) is a hereditary disease caused by defective globin synthesis. Patients with TM have benefited from a significant increase in life expectancy during the last years. However, they may eventually face many comorbid health conditions, including endocrinopathies and low BMD, usually observed in the aging general population. The aim of the present study was to evaluate biomarkers of bone remodeling in TM patients and to compare them with both osteoporotic and healthy population in order to investigate new therapeutic paths.

Methods: 64 patients with TM (32 men and 32 women) participated in a cross-sectional study design. The patients were recruited from Aghia Sofia Children's Hospital and evaluated using DXA of the lumbar spine and femoral neck and with markers of bone remodeling including RANKL, osteoprotegerin (OPG), C-terminal telopeptide (CTX), and sclerostin. Results were compared with those from a group of 12 postmenopausal women with osteoporosis and a group of 12 postmenopausal women with normal BMD.

Results: The statistical analysis of the biochemical markers of bone metabolism revealed significant differences between the three groups only for RANKL and OPG/RANKL.

Conclusions: Patients with TM do not have a higher probability of suffering from osteoporosis as compared to the general population. However, some markers of osteoclast activity differ between patients with TM and osteoporosis indicating possible differences due to the antiosteoporotic treatment. The lack of significant differences among the three groups regarding the levels of CTX and sclerostin may indicate the potential efficacy of the current osteoporotic treatment for TM patients, as well.

P271

IMPACT OF ARTERIAL STIFFNESS ON PHYSICAL PERFORMANCE IN ELDERLY PATIENTS

S. M. Aurelian¹, A. Zamfirescu¹, R. Mihalache¹, J. Aurelian¹, A. Capisizu¹

¹University of Medicine and Pharmacy Carol Davila, Bucharest, Romania

Objectives: Analyzing physical performance in elderly patients and observing changes in vascular and cognitive parameters according to physical performance.

Method: We noticed 143 elderly patients from the Geriatrics Clinic and we evaluated Short Physical Performance Battery, 4m walking test, cognitive determinations (MMSE and Clock draw test), and PWV (by arteriograph). All determinations are performed according to the protocol and the results are analyzed with SPSS.

Results: Measurement of aortic pulse wave velocity observed a statistically significant difference (Student t-test, p=0.094) in the two groups of analysis: those with low physical activity had a higher average value (10.37±1.89 m/s) vs. those with moderate or good physical activity (9.85±1.73m/s) (Table 1). Mean values of MMSE are significantly lower (21.02±4.68 points) among those with low activity vs. 25.13±4.17 points achieved by those with good physical activity (Student t-test, p<0.001). More than half (51%) of the elderly treated with statins showed good physical activity. Clock draw test 6.63±1.33 points, in the group of those with low physical activity, a statistically significantly lower score than the average score of 7.96±1.72 points among those with a better physical performance (Student t-test, p<0.001).

Table 1 Physical performance and haemodynamic vascular parameters

Characteristics	Low physical activity	Good and very good physical activity	P
PWV ao	10.37 ± 1.89	9.85 ± 1.73	0.094
Aix ao	39.08 ± 10.65	40.36 ± 8.14	0.602
PP	67.06 ± 11.15	60.84 ± 10.77	0.014
SBPa _o	143.95 ± 22.23	142.62 ± 23.95	0.731
HR	69.15 ± 12.14	65.40 ± 10.25	0.047
Systolic blood pressure	145.70 ± 18.77	140.97 ± 20.07	0.149

Conclusion: Arterial stiffness is associated with low physical performance among the elderly. This is in line with the findings of recent interventional studies on young adults on the contribution of physical exercise to arterial stiffness. Physical activity is very important in preventing premature aging, in maintaining functional independence and last but not least, in a healthy mind. The value of the research is the possibility of cardiovascular events prevention through specialized kinethotherapy, even at advanced ages, with monitoring of the vascular profile that causes fragility at this level.

P272

MRI EVALUATION OF AVASCULAR NECROSIS OF THE FEMORAL HEAD IN CHILDREN WITH SICKLE CELL DISEASE ON HYDROXYUREA

R. Gupta¹

¹Faculty Of Medicine / Radiology Department/ Mubarak Hospital/ Kuwait University, Kuwait

Objective: There have been concerns about the safety of hydroxyurea (HU) in sickle cell disease (SCD) patients with the Arab/India haplotype because of the potential risk of avascular necrosis of the femoral head (AVNFB), which is a common complication among patients in Kuwait.

Methods: The present study documents the baseline and follow-up MRI of the hips among Kuwaiti patients with SCD who have been on hydroxyurea for at least one year. The patients were screened for AVNFB by MRI using a 1.5 Tesla GE unit. Spin echo T1- and T2-weighted images and T2 FATSAT sequences in coronal and axial planes in 4mm-thick sections were obtained. The images were examined independently by two radiologists. AVNFB was graded I (mild), II (moderate), or III (severe).

Results: 40 patients, made up of 18 (45%) SS, 19 (47.5%) Sβ0-thal and 3 (7.5%) SD, had pre- and post-HU MRI of the hips for assessment of AVNFB. They were aged 6-20, with a mean of 12.9±4.2 y and had been on HU for 1-15 y. Pre-HU, 29 (72.5%) had normal images while 11 (27.5%) had AVNFB of grade I in 5 and grade II in 3. The mean age of the former was 11.9±4.0 and the latter, 15.3±3.7 y; the difference was statistically significant (p=0.02). Post-HU, of the 29 that were initially normal, 27 (93.1%) remained unchanged, while 2 (6.9%) developed new AVNFB. Of the 11 that had lesions in the initial MRI, 5 (45.5%) remained static while 5 (45.5%) had progressed with more florid lesions and 1 (9%) improved. A previous study from our center showed that, in SCD patients not on HU, AVNFB progressed in 64.7%, while 78% showed new lesions. In the present study, however, of patients on HU, only 6.9% developed new lesions, while 45.5% showed progression.

Conclusions: There is no evidence of enhanced progression of AVNFB lesions in children with SCD treated with HU in Kuwait. The drug may, in fact, prevent new lesions. This may be due to the decreased expression of adhesion molecules that has been reported with the use of HU.

P273

AN INVESTIGATION OF THE RELATIONSHIP BETWEEN TEMPOROMANDIBULAR DISORDER WITH POSTURE AND PEDOBAROGRAPHIC ANALYSIS

G. Ergezen¹, M. Sahin², C. Algun¹

¹Istanbul Medipol University/ School of Health Sciences/ Physical Therapy and Rehabilitation, ²Istanbul Medipol University/ School of Medicine/ Department of Orthopedics and Traumatology, Istanbul, Turkey

Objective: To evaluate the whole body posture and plantar pressure distributions in individuals with temporomandibular disorder (TMD) and also in people with healthy temporomandibular joints.

Methods: A study group aged between 18-35 y, 30 patients, who were diagnosed with Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) who applied us with jaw pain and 30 healthy people at the same age range as a control group were included in the study. Both groups received global postural assessments by using PostureScreen Mobile® (PSM) program which is using four side photographs and the New York Posture Scale (NYPS). Static pedobarographic measurements were taken.

Results: There was no statistically significant difference between groups from anterior and posterior posture assessments in using PSM ($p>0.05$). On the right and left lateral sagittal plane, knee translation and angulation were significantly different ($p<0.05$). There was no statistically significant difference between the groups in terms of body regions in NYPS posterior evaluation ($p>0.05$). On the left side, there was difference between the groups in terms of total scores, neck, chest, lower back and trunk posture ($p<0.05$). Pedobarographic measurements of plantar pressure distributions showed no statistically significant difference between the TMD and the control group ($p>0.05$).

Conclusion: Postural misalignments may result in development of TMD or as a consequence of TMD. Assessment of postural alignment and giving postural alignment exercises will play an active role in preventing or treating TMD.

P274

CASE REPORT: A RARE CAUSE OF PIRIFORMIS SYNDROME, VENOUS VARIX COMPRESSION OF THE SCIATIC NERVE

M. Sahin¹, C. C. Barişik²

¹Istanbul Medipol University/ School of Medicine/ Department of Orthopedics and Traumatology, ²Istanbul Medipol University/ School of Medicine/ Department of Radiology, Istanbul, Turkey

Objectives: Piriformis syndrome is an infrequent cause of entrapment neuropathy of sciatic nerve at the level of the piriformis muscle. Patients usually reporting pain in the gluteal/buttock region radiating down the back of the leg with or without neurologic deficit.

Methods: We introduce a female case with piriformis syndrome caused by venous varix complex. For this case report, we tested X-Ray and MRI of hip and lumbar area and needle EMG.

Results: A 78 years old woman presented with right buttock pain radiating down through the posterior thigh and calf for 2 years of history. Sitting on the affected side provoked pain more than walking or standing. Pain was rapidly relieved by standing and walking. Neurologic examination were normal, there were no motor deficit, diminished reflexes or weakness. The supine straight leg raising test and sitting knee extension test were both negative. Bilateral venous varicosities were noted in the patient's leg. The opposite limb examination was normal. Motor NCSs were normal for the peroneal and tibial nerve with normal F-wave latency and persistence. Sural nerve SNAP decreased bilaterally with a normal NCV. Lumbar nerve root compression was excluded by imaging methods and the clinical history. Coronal and axial MR images demonstrated tubular structure adjacent the sciatic nerve. These were of high signal intensity on T2 fat sat and T2 W

STIR, isointense to muscle on T1 WFES images and identified as a varicosities (Figure 1). Patient's pain relief with surgical decompression and ligation of varix. After 3 months of surgery patient reported no recurrence of her pain.

Conclusions: The common causes of sciatica are lumbar disc pathologies, spinal stenosis and other spinal pathologies. Less common causes include piriformis syndrome and the other nerve compression diseases like tumor or infections. Especially in the elderly patients, varicotic veins are common. While standing and walking these veins collapse, contrary lying down and sitting leads fill up that cause congestion and nerve compression. This mechanism allows clinicians to consider the vascular cause of sciatica. Because of unusual clinical presentation, this condition can be easily misdiagnosed so the clinician should make a request of pelvis MRI.



Figure 1. Coronal T2 W STIR image of varicosities on the right side.

P275

APPLICATION OF CAPSAICIN EXTRACT IN THERAPY OF PAIN SYNDROME IN OSTEOARTHRITIS

R. Yatsyshyn¹, B. Doskaliuk¹

¹SHEI Ivano-Frankivsk National Medical University/ Department of Internal medicine #1, Ivano-Frankivsk, Ukraine

Objectives: Osteoarthritis (OA) is a degenerative disease of the joints, which takes one of the leading positions in rheumatologic pathology among the population. Pain and limitation of movements that accompany this disease significantly reduce the

patients quality of life. The aim was to study the efficacy of phytopharmaceutical standardized capsaicin extract in patients with primary generalized OA.

Methods: The study involved 60 patients aged 52-68, women – 41 (68%), men – 19 (32%). All patients were divided into two groups. The main group of patients received standard therapy, which included nonsteroidal anti-inflammatory drugs (NSAIDs) and physiotherapy procedures. Subgroup of comparison in addition to basic treatment received a standardized capsaicin extract at a dose of 100 mg in the form of a cream for external use. Treatment efficacy was assessed by visual analogue scale (VAS), WOMAC scale, Leken's functional index.

Results: After 14 d of treatment, the following results were obtained: VAS indicators in the main group significantly decreased from 65.71±2.86 mm to 28.13±2.38 mm (p<0.05), and in the subgroup of comparison – from 63.53±2.54 mm (p<0.05) to 21.62±2.12 mm. The decreasing of Leken's functional index in the main group was less (from 8.1±1.2 to 5.5±1.4) (p<0.05) in comparison with group of combined treatment (from 8.2±1.4 to 4.2±1.1) (p<0.05). The improving of indexes of WOMAC subscales in the main group were the following: pain – from 14.6±0.9 to 10.3±1.2; stiffness – from 5.4±0.6 to 4.1±0.5; physical function 51±2.4 to 40±2.7 (p<0.05); in the subgroup of comparison: pain – from 14.3±1.1 to 8.4±0.9; stiffness – from 5.2±0.7 to 3.6±0.4; physical function 53±2.1 to 34±2.3 (p<0.05).

Conclusions: This study proved the efficacy of standardized extract of capsaicin as a treatment for patients with OA. It has also confirmed the possibility to improve treatment results by adding this drug to standard treatment regimen for OA.

P276 EXPEDIENCY OF USING GINGER ROOT EXTRACT IN THE TREATMENT OF PATIENTS WITH OSTEOARTHRITIS

R. Yatsyshyn¹, B. Doskaliuk¹

¹SHEI Ivano-Frankivsk National Medical University/ Department of Internal medicine #1, Ivano-Frankivsk, Ukraine

Objectives: Pain and movement constraints are the leading complaints in patients with osteoarthritis, which have a negative effect on the quality of life in this cohort of people. That is why the reduction of pain syndrome is one of the main tasks in the treatment of this disease. The aim was to investigate efficacy of treatment with herbal drug of standardized extract of ginger root in patients with osteoarthritis; to study impact of this phytopharmaceutical on the dynamics of inflammation process.

Methods: The study involved 45 patients (28 women and 17 men) aged between 54-71 y with primary osteoarthritis. The treatment was provided using phytopharmaceutical standardized extract of ginger root at dose of 300 mg twice daily per os during two weeks. The efficacy of the ginger root extract was evaluated using visual analogue scale (VAS), WOMAC scale, Leken's functional index. To investigate the effect of this herbal drug on inflammation process it was analyzed such parameters as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).

Results: By the end of the study, in 14 d of the treatment, the VAS parameters had significantly decreased from 65.71±2.86 to 37.65±2.86 (p<0.05). The decreasing of Leken's functional index in this patients group was from 8.5±1.32 to 4.4±1.21 (p<0.05). The improving of indexes of WOMAC 3 subscales were following: pain – from 14.6±0.93 to 10.3±1.22; stiffness – from 5.6±0.51 to 3.8±0.62; physical function 54±2.14 to 39±2.42 (p<0.05). CRP by the end of the treatment decreased from 5.78±0.23 to 4.1±0.19 (p<0.05); ESR – from 15.67±1.62 to 10.73±0.51 (p<0.05).

Conclusions: According to the study results it can be concluded that the standardized ginger root extract is effective in the treatment of patients with osteoarthritis. In the course of the treatment, the patients demonstrated reduction in pain intensity by 57%. It was also observed the antiphlogistic effect of ginger root extract exerted by the decreasing of CRP, ESR parameters.

P277 STUDY OF VERTEBRAL FRACTURE PREVALENCE AND SCANOGRAPHIC BONE ATTENUATION COEFFICIENT (SBAC-L1) IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS VS. CONTROLS

M. Fauny¹, E. Albuissou², E. Bauer¹, J. Perrier-Cornet¹, I. Chary-Valckenaere¹, D. Loeuille¹

¹CHRU Nancy, Rheumatology Department, ²CHRU Nancy, Vandoeuvre Les Nancy, France

Objective: To identify the prevalence of vertebral fractures (VFs) and to measure the scanographic bone attenuation coefficient of the first lumbar vertebra (SBAC-L1) based on CT-scan examinations of patients with rheumatoid arthritis (RA), patients with ankylosing spondylitis (AS) and in a control group.

Methods: This monocentric and retrospective study included patients who were evaluated between 2009-2017 with a diagnosis of RA based on the ACR/EULAR criteria, those with a diagnosis of AS based on the New York criteria, and a RA-matched control group. All of the patients received a CT scan. The osteoporosis risk factors, data from DXA and clinical characteristics were collected. VFs were determined via CT scans according to the Genant classification, and the SBAC-L1 was measured in Hounsfield units (HU). SBAC-L1 ≤145 HU (fracture threshold) defined patients at risk of VFs.

Results: A total of 244 patients were included (105 RA, 83 AS, 56 controls). The AS group was younger and primarily consisted of males. Of the 4365 vertebrae studied, 66 osteoporotic VFs were found in 36 patients: 18 (17.1%) patients with RA, 13 (15.7%) patients with AS and 5 (8.9%) controls. The SBAC-L1 was 142.2 (±48.4) HU for the RA group and 142.8 (±48.2) for the AS group, both of which were significantly lower than that of the control group (161.8 (±42.7) HU). Of the 36 patients with VFs and rheumatism, 28% had a T-score ≤ -2.5 SD, and 71.4% had a SBAC-L1 ≤145 HU. A T-score ≤ -2.5 SD and a SBAC-L1 ≤145 HU were associated with the presence of a VF (OR=2.35 [CI95%: 1.12-4.92] and 2.06 [CI95%: 1.04-4.10]), respectively.

Conclusion: The SBAC-L1 was significantly lower in the RA and AS groups than in the control group. Furthermore, SBAC-L1 ≤ 145 HU was associated with a higher risk of VFs, with an odds ratio similar to that of a DXA.

P278

DESCRIPTIVE ANALYSIS OF PATIENTS WITH OSTEOGENESIS IMPERFECTA IN A TERTIARY HOSPITAL IN MADRID

C. Pijoan Moratalla¹, M. A. Teran Tinedo¹, J. R. Quiñones Torres¹, M. Vázquez Díaz¹

¹Hospital Universitario Ramón y Cajal, Madrid, Spain

Objective: Osteogenesis imperfecta (OI) is an inherited connective tissue disorder with an incidence of 1 per 20000 births. It is also called brittle bone disease and is caused by mutations in genes encoding type I collagen. *Clinical* presentation is heterogeneous, varying from only premature osteoporosis to multiple atraumatic fractures. Bisphosphonates are usually used to try to prevent bone fragility, reducing the number of fractures in some patients. Our aim was to analyze both clinical and analytical characteristics of OI patients followed in our hospital and to evaluate the different treatments used in their management.

Methods: A retrospective study was conducted including all patients diagnosed with OI seen in the different departments of our hospital. A database was created and both clinical and epidemiological data were analyzed.

Results: 25 patients with OI followed up in our hospital were included. 72% were female (18) with a mean age at diagnosis of 17 y (range: 1 month to 67 y). All of them had had fractures before the diagnosis. The number of fractures during follow-up varied according to the different types of OI, with an average of 6 fractures (range 3-24) per patient and at least 4.16 orthopedic surgeries. Only 3 patients had family background of OI. Phenotypically, 14/25 (56%) had short stature and 18/25 (72%) had blue sclerae. Only 4 patients suffered from dentinogenesis imperfecta (16%) and 3 suffered from otosclerosis (12%). Regarding analytical parameters, average uric acid in our OI cohort was 5.1 mg/dL ± 1.74 and serum calcium was 9.34 mg/dL ± 0.67 . PTH levels were 44.94 pg/mL ± 13.37 and vitamin D was 23.1 ng/mL ± 11.33 . Urinary calcium excretion rate was 114.41 ± 72.39 . 60% were on current treatment with calcium and 64% (16/25) with vitamin D supplements but only 15/25 received bisphosphonates (4 risedronate, 7 pamidronate, and 4 both zoledronic and pamidronate).

Conclusions: Although a rare disease, OI has an important morbimortality. Severe cases suffer multiple fractures and undergo several orthopedic surgeries during their lives. Treatment for this condition is not standardized and is generally reserved for type III OI patients. Bisphosphonates, calcium and vitamin D are usually used to try to prevent new fragility fractures but fracture rates remain high despite treatment.

P279

FREQUENCY OF SECONDARY HYPERPARATHYROIDISM AMONG PATIENTS WITH OSTEONECROSIS OF THE KNEE

A. Torgashin¹, S. Rodionova¹, A. Torgashina²

¹National Medical Research Center of Traumatology and Orthopedics named after N. N. Priorov, Ministry of Health of the Russian Federation, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia

Objective: Spontaneous osteonecrosis of the knee (femoral condyle and tibial plateau) is more common in women over 60 y of age, occurs spontaneously and has no significant injury to the knee in history. A special role in the development of the disease has recently been given to bone tissue metabolism, the state of the subchondral bone, and the presence of micro-fractures in it. At the same time osteoporosis is considered as an important factor in the development of osteonecrosis. Knowing that in patients with osteoporosis, the frequency of secondary hyperparathyroidism reaches 15-20%, it was interesting to know its occurrence in osteonecrosis. Our aim was to identify the frequency of occurrence of secondary hyperparathyroidism in patients with spontaneous osteonecrosis of the knee.

Methods: 44 patients were examined - 31 women and 23 men diagnosed with spontaneous osteonecrosis of the knee. The average age of the patients was 59.5 y. Before treatment, all patients underwent instrumental (X-ray, MRI, DXA) and laboratory examination.

Results: An analysis of the data revealed that secondary hyperparathyroidism was highly prevalent - 13.6% (3 men and 3 women).

Conclusion: The combination of secondary hyperparathyroidism with spontaneous osteonecrosis of the knee, practically in the same ratio as with osteoporosis, can once again confirm the association of these diseases. In this connection, the use of vitamin D/alfacalcidol and calcium/osteogenon supplementation is necessary for correction of bone metabolism and secondary hyperparathyroidism in spontaneous osteonecrosis of the knee.

P280

MORTALITY FOLLOWING FRAGILITY HIP FRACTURE: DATA FROM A REGIONAL HIP FRACTURE REGISTRY IN SRI LANKA

S. Sabapathipillai¹, S. Lekamwasam², H. B. Lekamwasam³

¹Teaching Hospital, ²Population Health Research Center,

³Polulation Health Research Center, Galle, Sri Lanka

Objective: Fragility hip fracture is a serious health concern in developing countries with resource constrains. We assessed the mortality of hip fracture survivors in southern Sri Lanka.

Methods: All patients with new hip fracture admitted to Teaching Hospital, Karapitiya, Galle in Sri Lanka during June 2014 to Feb 2015 were included in a regional hip fracture registry. Readmissions and old fractures were excluded and patients were followed up for 24 months postfracture.

Results: There were 309 patients (women=211) and mean (SD) age of men and women were 75.1(11.3) and 76.8(8.9) y, respectively. Majority (n=285, 92%) had been physically independent and were able to walk indoors unaided prior to fracture. The crude mortality at 24 months was higher among men (24/98, 24.5%) compared to women (41/211, 19.4%). Most of these deaths (66.6% in men and 73.1% in women) occurred within the first 12 months, postfracture. When compared with age and sex matched national mortality rates, at 24 months, the relative risks of death in men and women were 4.9 and 5.5, respectively.

Conclusions: An increased risk of death following hip fracture was noted among both men and women. The risk was higher in the first 12 months compared to the next 12 months following the fracture. Men had higher crude mortality compared to women.

P281

INFECTIONS AMONG RHEUMATOID ARTHRITIS PATIENTS STARTING OR SWITCHING BIOLOGICAL AGENTS: A SYSTEMATIC LITERATURE REVIEW

M. Novella-Navarro¹, A. Gomez-Gomez², J. L. Cabrera-Alarcon³

¹Rheumatology department, Hospital Universitario Torrejon,
²Rheumatology Department, Hospital Universitario Infanta Sofía,
³Centro Nacional Investigaciones Cardiovasculares (CNIC), Madrid, Spain

Objectives: The increased rate of infections is one of the most relevant issues regarding biological therapies. Hence, we have a large number of studies comparing different biologic agents in order to assess their safety profile. Nevertheless, the main question is whether biologics really increase the risk of infections by themselves. Up to date, different studies tried to clarify the actual role that these drugs have in this potentially serious adverse effect, searching for other predisposing conditions related to patient clinical characteristics such as comorbidities, previous infections, age or RA disease activity. Among this potential risk factors, we must consider that many patients receive different biologic agents during the course of their disease. This may increase the risk of infections, although there is not strong evidence in the literature to support this statement. Our aim was to analyze systematically and critically the available published evidence, comparing risk of infections between patients starting biologic for first time (*naïve*) and patients with an inadequate response to previous biologic (*switchers*).

Methods: A search following Research Unit of the Spanish Society of Rheumatology designed strategy was performed over Pubmed, Embase and Cochrane Library databases (from January 2008 to February 2018). The studies retrieved by search strategies were included according to pre-established criteria fitness: Studies including adult patients (>18 years old) diagnosed with RA treated with biologic agents for the first time (*naïve*) in monotherapy or in association with synthetic DMARDs compared to patients treated with biologic agents who had inadequate response to previous biologic treatment (*switchers*). Regarding designs, meta-analysis, systematic reviews of randomized controlled trials (RCT), RCT, clinical trials or cohort studies were selected. Screening of

studies, data collection and data analysis was performed by 2 reviewers. Methodological quality of included publications was assessed using electronic FLC platform for critical appraisal tools (Osteba), gathering evidence rates in tables, and "SIGN" was considered to classify the scientific evidence of the selected studies.

Results: Eight studies were finally included, with a moderate quality of evidence. Clinical characteristics, regarding to disease activity scores, functional status, age, sex distribution, concomitant antirheumatic therapies, laboratory parameters or comorbidities were quite homogeneous in both groups. Overall infection rate was higher in *switchers* than in *naïve* patients. Looking for potential risk factors related to incidence of overall infections, we found data pointing out mean disease duration, dosage of GC, age, sex, acute phase reactants and severity of comorbidities. The main risk factor identified across all studies was the cumulative dose of GC, which was higher in *switcher* patients; and more specifically, prednisone >10 mg/d was related to more infectious diseases. No significant differences were found among different drugs, so, regarding to this review we are not able to assign an individual risk to specific antirheumatic agents.

Conclusion: Our results show that overall risk of infections is slightly higher in *switchers* patients than in *naïve* patients, specially in those who receive a greater cumulative dose of glucocorticoids. This result may support the fact that biologics and small molecules do not enhance incidence of infections solely. Even in patients who require different therapeutic targets during the course of the disease, were not expected to have more infections attributed to the specific antirheumatic drugs. There are risk factors inherent to the disease and baseline individual patient status that predispose to the development of infections during the course of the disease.

P282

EFFECTS OF TSH AND VITAMIN D ON BONE METABOLISM IN RAT MODEL OF OSTEOPOROSIS

I. Dumić-Čule¹, S. Vukicevic²

¹Department of Diagnostic and Interventional Radiology, Clinical Hospital Dubrava, ²School of Medicine, University of Zagreb, Zagreb, Croatia

Objective: Thyroid-stimulating hormone (TSH) exerts both anti-resorptive and anabolic effects on bone remodeling in aged ovariectomized rats and TSH-/- mice, additionally supported by clinical data reporting association between low level of TSH and increased bone loss (1).

Methods: To further explore the direct effects of TSH on bone metabolism, without interaction with other calciotropic hormones, we introduced a rat model with removed thyroid and parathyroid glands. Surgery resulted in hypocalcemia, low level of parathyroid and thyroid hormone, and decreased concentrations of active form of vitamin D, calcitonin and C-telopeptide.

Results: Intermittent administration of TSH in thyroparathyroidectomized rats resulted in further decrease of serum calcium and C-telopeptide due to the suppression of bone resorption, while osteocalcin was higher indicating an increased bone formation

rate. MicroCT analyses of the distal femur and proximal tibia showed that thyroparathyroidectomized rats treated with vitamin D alone or in combination with TSH had an increased trabecular bone volume, and enhanced trabecular bone quality. Biomechanical indentation test of the trabecular bone showed an increased maximal load for 105% and 235%, respectively, in rats treated with vitamin D alone, or in a combination with TSH. Rats treated with TSH had a significantly decreased number of osteoclasts in comparison to control animals. The decline of the osteoclast number was even greater in rats treated with a combination of TSH and vitamin D, despite the fact that vitamin D alone increased the number of osteoclasts. Addition of TSH to osteoblasts increased the production of the bone specific alkaline phosphatase and had a synergistic effect when combined with vitamin D.

Conclusion: TSH independently of calciotropic hormones suppressed bone resorption and stimulated bone formation, while in combination with vitamin D acted synergistically on bone formation resulting in gain in bone volume.

Reference: (1) Sampath TK et al. J Bone Miner Res 2007;22:849.

P283

STUDY DESIGN OF JAPAN OSTEOPOROSIS LIAISON SERVICE (JOLS) STUDY FOR PREVENTION OF SECONDARY FRACTURE: MULTICENTERED HISTORICAL CONTROL STUDY

M. Ando-Kondo¹, Y. Yoshino¹, T. Katogi², H. Yasuoka³, S. Ikeda⁴, H. Ishibashi⁵, S. Tanaka⁶, H. Hagino⁷, H. Ohta⁸, T. Kurabayashi⁹, T. Sugimoto¹⁰, S. Soen¹¹, A. Suzuki¹

¹Department of Endocrinology and Metabolism, Fujita Health University, Toyoake, ²Department of Rehabilitation, Seirei Sakura Citizen Hospital, Sakura, ³Department of Orthopedic Surgery, Tokorozawa Meisei Hospital, Tokorozawa, ⁴Department of Orthopedic Surgery, Ken-Ai Memorial Hospital, Onga, ⁵Department of Orthopedic Surgery, Ina Hospital, Ina, ⁶Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, ⁷School of Health Science, Faculty of Medicine, Tottori University, Tottori, ⁸Clinical Medical Research Center, Women's Medical Center, Sanno Medical Center, International University of Health and Welfare, Tokyo, ⁹Department of Obstetrics, Niigata City General Hospital, Niigata, ¹⁰Department of Internal Medicine 1, Shimane University Faculty of Medicine, Izumo, ¹¹Department of Orthopedic Surgery and Rheumatology, Kindai University Nara Hospital, Ikoma, Japan

Objectives: Fracture Liaison Service (FLS) is nowadays well accepted as effective coordinator-based system to prevent secondary fracture. Japan Osteoporosis Society offered Osteoporosis Liaison Service including FLS for both primary and secondary prevention of osteoporotic fracture. In this study, we focus on secondary prevention after clinical vertebral fracture and hip fracture to show the efficacy of FLS in super-aging society as in Japan.

Methods: This multicentered historical-control study has been planned to perform in more than 20 hospitals and institutions in Japan. The inclusion criteria are the newly hospitalized patients

with fresh clinical vertebral fracture or hip fracture in postmenopausal women or men equal to or above 50 years old. Multidisciplinary team assesses the risk of osteoporosis, and educates the patients and their family, and registers the patients in database center in Fujita health University during 3 months after the first fracture. On discharge, the pharmacist provides guidance how to use the medicine. After 6, 12, 24 and 36 months, the hospital staff will send letter to each patient to check the adherence.

Results: As for historical control, retrospective surveillance of secondary fracture after clinical vertebral fracture and hip fracture was done in 2744 patients and tentatively got the information in 1371 patients (66.9%). Among these 1371 patients, 298 patients (21.7%) died and 154 patients (11.2%) had new clinical fracture during 12-24 months after first fracture. According to this data, we calculated the number of patients exposed to intervention is about 1300, when we hypothesize the risk reduction rate by FLS is about 30%. This study was approved by IRB at each institution, and has started in June 2018.

Conclusion: This prospective study is expected to provide useful information to improve FLS in super-aging society.

P284

OBESITY AND FLAT VERTEBRA

M. D. P. Ahijado Guzmán¹, R. M. Veiga Cabello², M. Cantalejo Moreira¹, J. Ruiz Ruiz³, A. Zapatero Gaviria⁴

¹Unit Rheumatology/Internal Medicine/ Htal de Fuenlabrada, Fuenlabrada, ²Rheumatology Service/Internal Medicine/ Htal Central de la Defensa Gómez Ulla, Madrid, ³Internal Medicine Service/Htal de Fuenlabrada, Madrid, ⁴Internal Medicine Service/Htal de Fuenlabrada, Fuenlabrada, Spain

Objective: Spine is a mechanical structure, in a young and healthy individual, under a radiological focus, disposes their vertebral bodies in harmony with their stature, and progressively increasing in magnitude from the cervical to the lumbar spine, in a range of vertical growth that it can exceed the horizontal. It is postulated that the important obesity in the early stages of life, could modify the vertebral parameters by skeletal overloads, but the problem is that the current vertebral indexes do not measure a relation of the person height with his vertebra. Thus, to check whether the childhood obesity could modify the vertebral parameters, or it is accepted that it entails a loss of equivalent stature, and in this case would be necessary a study comparative of average height, or whether the harmony of the individual is accepted, it would be necessary to create an index that combine these variables to objectify if its value is a constant, and thus, eliminate the ambiguity of the observer.

Method: We selected a population of obese (BMI \geq 35), both sex, between 20-55 years old, in bariatric surgery protocol, with a significant obesity in their development. Was excluded any cause that could produce vertebral flattening. Figure 1.

Figure 1. Aetiopathogenic classification of the flat vertebra.

1. Defects in development:

- 1.1. Secondary to skeletal stress overloads:
 - 1.1.1. Ehlers-Danlos syndrome.
 - 1.1.2. Kyphosis of Scheuermann.
- 1.2. Bone dysplasias:
 - 1.2.1. Spondylar bony dysplasias: Mutations in the type II collagen gene.
 - 1.2.2. Bone dysplasias associated with bone fragility: Imperfect osteogenesis. Hyperphosphatasia.

2. Non-dysplastic bone fragility:

- 2.1. Metabolic osteopathies with generalized osteoporosis:
 - 2.1.1. States dependent on age: Senile. Postmenopausal
 - 2.1.2. Other: Drugs and alcohol. Endocrinological
- 2.2. Vertebral infiltrative phenomena:
 - 2.2.1. Non-neoplastic conditions: Diseases due to lysosomal storage: Gaucher and Morquio's disease
 - 2.2.2. Neoplastic conditions:
 - Benign nature: Eosinophilic granuloma.
 - Malignant nature: Lymphoma Ewing's sarcoma. Others.

3. Exogenous causes of flat vertebrae:

- 3.1 Post-traumatic
- 3.2 Post radiotherapy.
- 3.3 Infections.

As a control group, was included any patient that went to outpatient visit of rheumatology, and which met the inclusion and exclusion criteria above, except obesity. As variables, sex, age, BMI, and with a chest lateral plate, not rotated, and in the eighth dorsal vertebra, we calculate his length (LVD8) and his height (HVD8), measured in mm. Figure 2.




Figure 2. With a chest lateral plate, not rotated, and in the eighth dorsal vertebra, by proximity to the Scheuermann kyphosis, we calculate his length (LVD8) and his height (HVD8), measured in mm. Thus, from the horizontal one of his pedicle, taken at that height and parallel to the vertebral plate with superior disc contact, LVD8 is 35.50mm. Drawing a line perpendicular to the previous one (90.1°), and measured from the most sclerous area of the vertebral plate with disc contact superior to inferior, passing through the midpoint of its length (17.74mm), we obtain a HVD8 of 20.69mm.

Finally, we applied a comparative study of average of height and vertebral index (VI) Results: $VI=10 \times LVD8 / (HVD8 \times \text{stature})$.

Results: 90 patients were analyzed. 20 patients in the study group (22.2%): 48.1% female, 48.6 years old, 38.2 BMI, and VI 11.6 Meters -1 . And 70 patients in the control group (77.8%): 51.1% females 45.15 years old, 26.2 BMI, and VI 11.2 Meters -1. Figure 3

Control Group				
Sex	Age (Years)	Height (m)	BMI	VI (1/m)
73,3% Male	45,15	1,694	26,9	10,1
76,1% Female	44,8	1,603	25,5	10,2
Obese group				
Sex	Age (Years)	Height (m)	BMI	IV (1/m)
26,7% Male	47,6	1,687	36,6	10.2
23,9% Female	46.9	1,597	40	10.3

Figure 3

Conclusion: It is a small study, and according to height or the created index, it does not seem that obesity in development modifies the overall height or the vertebral parameters. In addition, the index gives a stable value regarding the sex of both populations in the eighth dorsal vertebra.

P285
POSTOPERATIVE DULOXETINE IMPROVES CHRONIC PAIN AFTER UNILATERAL KNEE ARTHROPLASTY

T. Kodama¹

¹Dept of Orthopaedics JCHO Saitama Medical Center, Saitama, Japan

Objective: Chronic pain following operation is defined as a residual pain continuing more than 3 months after the operation. Chronic pain after the operation is not a rare complication, any operation could be a reason for this kind of pain. In our institute 46 patients out of 523 UKAs (Oxford mobile bearings) had chronic pain continuing more than 3 months after the operation. Central sensitization is known as a major cause of chronic pain. Duloxetine which is selective serotonin and norepinephrine reuptake inhibitor is shown to be effective in treating chronic pain.

The objective of this study is to investigate the effect of duloxetine on chronic pain after Oxford UKA.

Methods: I have done 523 Oxford UKA between May 2006 and April 2018. The patients were treated under our multimodal pain management protocol, which include epidural catheter, local infiltration, NSAID, tramadol and acetaminophen. After UKA the patients continued NSAID, tramadol and acetaminophen for at least 1 months. The patients who still had pain beyond 1month continued tramadol and acetaminophen at least 2 more months. 20 patients who attended my clinic between Oct 2016 and April 2018 for chronic pain were included in this study. 20 patients were then switched to duloxetine alone. The dose of duloxetine was gradually increased starting 20 mg/d and kept 60mg/d for at least 24 weeks. Numeric Rating Scale (NRS) was used to determine the levels of pain. The NRS was recorded before and after duloxetine administration periodically. The clinical result was determined by patients themselves, they selected either excellent, good or poor.

Results: The average NRS before switching to duloxetine was 4.4. NRS significantly decreased 2 weeks after starting duloxetine. The average NRS at 6M was 0.7. Clinical result was excellent in 9 patients(45%), good in 7 patients(35%), poor in 1patient(5%). 3 patients(15%) dropped out due to side effect.

Conclusions: Duloxetine significantly reduced chronic pain after Oxford mobile bearing UKA. Central sensitization seemed to be the major cause of chronic pain after Oxford mobile bearing UKA.

P286

THE EFFECTIVENESS OF A COMPLEX REHABILITATION PROGRAM IN FEMALES WITH OSTEOPOROSIS AND HIP OSTEOARTHRITIS

K. C. Kamal¹, M. R. Trăistaru¹, O. C. Rogoveanu¹, D. O. Alexandru¹, D. Kamal¹

¹University of Medicine and Pharmacy of Craiova, Craiova, Romania

Objectives: Osteoporosis and hip osteoarthritis are frequently associated in elderly women. The objective of our study was to assess the role that medication and complex rehabilitation program can have in improving pain perception, functional status and T-score DXA values in female patients diagnosed with both osteoporosis and hip osteoarthritis.

Methods: Group I- 12 patients treated with bisphosphonates and vitamin D for 1 y and other means of conservative treatment - hygiene-dietary measures, lifestyle changes, complex rehabilitation program. Group II 11 patients treated only with medication and advised about hygiene-dietary measures and lifestyle changes. BMD assessment, initially and at the end of the study, was performed using imaging techniques like plain X-rays and DXA. Pain intensity evaluation was performed using the VAS analogue-visual pain scale, and the functionality was evaluated using the Harris hip scale.

Results: 23 females, aged 53-77, with an average age of 65.94 y, were diagnosed with primary hip osteoarthritis and primary osteoporosis. Regarding VAS and Harris hip score values, there was no significant difference between the two groups at the initial evaluation, which allowed us to compare the effect of the two treatments. While both groups showed an improvement in VAS values, the decrease for the first group was greater than the second one, which was also emphasized by the decrease of Student p values when comparing the VAS values at the end of the trial ($p=0.230 > 0.005$ - nonsignificant difference). While both groups showed an improvement in the Harris hip score, the incidence for the first group was greater than the second one ($p=0.0042$ vs. $p=0.037$). When comparing the T DXA score values we concluded that the improvement was greater for the first group, at the final evaluation.

Conclusions: Individualized medical treatment and complex rehabilitation program increases the functionality and reduces pain and also improves the BMD in patients with osteoporosis and hip osteoarthritis.

P287

NEUROPATHIC PAIN COMPONENT IN PATIENTS WITH KNEE OSTEOARTHRITIS

M. Basaric¹, K. Vagic¹, S. Novkovic¹, N. Damjanov¹

¹Institute of Rheumatology, Belgrade, Serbia

Objectives: To determine the frequency of neuropathic pain (NP) in patients (pts) with knee osteoarthritis (OA) and its association with physical function, degree of OA and symptom duration.

Methods: A total 50 pts (15 males, 35 females; mean age 61.8 ± 5.1 y, range 45-75 y) diagnosed with knee OA (according to ACR criteria) were examined. Exclusion criteria: diabetes mellitus, polyneuropathy (sensory-motor, alcoholic, post-herpetic), lumbar radiculopathy, fibromyalgia, cancer, central nervous system diseases. Of these 50 patients, 31 had a diagnosed bilateral and 19 pts with unilateral knee OA. The degree of knee OA and disease activity were determined by symptom duration, movements of the knee, examination ultrasound (synovial hypertrophy, joint effusion), Kellgren-Lawrence grade (KL), visual analogue scales (VAS) and WOMAC. NP was determined using the PainDETECT questionnaire.

Results: Pain from knee OA revealed that 9.8% are likely NP, and 19.2% are possible NP. NP was found more frequently in patients with bilateral knee OA (bilateral OA in 40.2% pts, unilateral in 21.2% pts, $p=0.025$), with a higher radiographic degree ($KL \geq 2$, in 41% pts, $KL \leq 2$, 29.8%, $p=0.046$) and with longer symptom duration (<5 y in 25% pts, >5 y in 45% pts, $p=0.033$). In knee OA patients PainDETECT was in correlation with WOMAC index ($p<0.001$) and VAS ($p<0.001$). Compared with the PainDETECT score, there was positive correlation with the KL grade ($p=0.048$) and symptom duration ($p=0.035$), but there was no correlation between PainDETECT and ultrasound sign ($p=0.587$) and movements of the knee ($p=0.774$).

Conclusions: This study has shown that nearly one-third of our patients with knee OA had likely or possible neuropathic component pain of the knee. Patients with NP had more increased severity of pain, severe form of knee OA and longer duration of symptoms. It is important to be aware of consider the existence of NP in the treatment of knee OA pain.

P288

DENOSUMAB IN PATIENTS WITH CHRONIC KIDNEY DISEASES

S. Monov¹, D. Monova², R. Shumnalieva¹, M. Stambolova²

¹Medical University - Sofia, ²Medical Institute, Medical University-Sofia, Sofia, Bulgaria

Objectives: Due to the rapidly aging population the number of patients with chronic renal failure and osteoporosis has been increasing annually. Many of the therapeutic agents used to treat osteoporosis are known to be affected by the renal function. Denosumab is not excreted by the kidney. The aim of this report is to study the efficacy and tolerability of denosumab in patients with chronic kidney diseases (CKD).

Methods: Patients with CKD who received a single 60 mg subcutaneous dose of denosumab every 6 months for a minimum period of 24 months were included. Data collected included information about the following: CKD stage, fracture history, relevant medications, adverse events, serum creatinine, calcium, phosphorus, magnesium levels and ECG before treatment and every week within the first 8 weeks of treatment and every 3 months after that, vitamin D and PTH levels prior to dosing, BMD before and every year after treatment. Hypocalcaemia or vitamin D de-

ficiency were correct when present. Treatment of hypocalcemia required large doses of oral calcium and calcitriol, and increases in dialysate calcium concentration.

Results: 48 patients (44 female, 4 male; 11 patients with CKD stage 1, 12 patients – CKD-2, 11 patients – CKD- 3, 10 patients – CKD-4, 4 patients – CKD-5) were identified. Mean duration of treatment was 2.8 y, average eGFR - 44 ml/min/1.73 m², mean patient age - 61 y (range 42-86), mean BMI - 26 (range 18-37). The average calcium prior to dosing was 2.41 mmol/l (2.11 to 2.58) falling to 2,01 mmol/l (1.84-2.29) after dosing. Average PTH level prior to dosing was 148 ng/l (38-345) and after was 743 ng/l (154-1642). Hypocalcemia was detected in 18 of the patients studied. 6 patients developed severe hypocalcemia (calcium <194 mmol/l) and 3 of them developed seizure and prolonged QTc.

Conclusions: Denosumab cause a small, but not clinically significant reduction in serum calcium in most patients with CKD. Patients with severe renal dysfunction may have an increased risk of developing hypocalcemia. In patients with preexisting hypocalcemia, serum calcium and vitamin D should be monitored more frequently throughout treatment duration.

P289
CLINICAL CHARACTERISTICS AND PATHOGENIC GENE MUTATIONS IDENTIFICATION OF PAGET'S DISEASE OF BONE IN CHINESE POPULATION

H. Yue¹, Z. L. Zhang¹

¹Metabolic Bone Disease and Genetic Research Unit, Department of Osteoporosis and Bone Diseases, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China

Objective: Paget's disease of bone (PDB) is characterized by highly localized areas of increased bone resorption and disorganized bone remodeling. It is common in western descent. However, it is rare in Chinese. Genetic factors play an important role in the pathogenesis of the disease [1]. The purpose of the study was to characterize the clinical features and identify genetic mutations in Chinese PDB patients.

Methods: 37 clinically diagnosed PDB patients (two were father and son, the rest were sporadic) and 250 healthy donors were recruited. The clinical features were characterized and the whole-exome sequencing (WES) was carried out in patients to detect gene mutation and then confirmed in donors by Sanger sequencing. PolyPhen-2 and CADD analyses were performed to predict the damaging effect of the mutation. Mutant protein structure was constructed as well.

Results: The father and son were early-onset (onset age <30 y). The onset age of sporadic PDB patients (53.2±19.1 y) was younger than that of western patients. One of them was PDB combined with giant cell tumor (GC), had even earlier onset age (23 y) with mild symptoms. The most common lesion sites were the pelvis, femur, and skull. Most patients had high serum alkaline phosphatase (ALP) level and intravenous bisphosphonates was effective to relieve bone pain and reduce ALP level. Vitamin D receptor (VDR) gene mutation was identified in a 25-year-old male, who harbored a heterozygous G-to-A transversion at position 424 in

exon 4 (c.G424A), which resulted in a glutamate-to-lysine (GAG >AAG) substitution at codon 142 (E142K) (Fig. 1). No *SQSTM1* gene mutation was detected in all 37 patients, which was different from the western patients. VDRE142K was predicted to be damaging with PolyPhen-2 score of 1 and CADD score of 37. Meanwhile, the amino acid residues at p.142 is highly conserved across 9 different biological species (Fig. 2). By constructing the mutant protein structure, it was found that the mutation site located in the VDR protein DNA binding region, and which would significantly enhance DNA interaction (Fig. 3).

Conclusion: Vitamin D regulates osteoclast function by binding to VDR [2]. Therefore, VDR dysfunction directly affects the osteoclasts status.




Fig.1 Genetic analysis of the VDR gene mutation




Fig.2 Conservative structures in 9 different species




Fig.3A Protein spatial conformation (normal)




Fig.3B Protein spatial conformation (mutant)

Conclusion: Our study described the clinical features and reported that *VDR* gene mutation contributes to the pathogenesis of PDB in Chinese patients.

References:

1. Albagha OM. Bonekey Rep. 2015; doi: 10.1038/bonekey.2015.125
2. Shibata T et al. J Bone Miner Res 2002;17: 622

P290

PROGRANULIN IS REQUIRED FOR ESTROGEN EFFECT ON POSTMENOPAUSAL OSTEOPOROSIS

G. Li¹, Y. Xu¹, C. Liu²

¹Department of Orthopaedics, The Second Affiliated Hospital of Soochow University, Suzhou, China, ²New York University, New York, USA

Objective: Estrogen is known to prevent bone loss during menopausal transition. We reported previously that progranulin (PGRN) also effectively prevented bone loss in inflammatory arthritis (Tang, et al, Science, 2011). Given that both estrogen and PGRN could inhibit osteoclast formation and bone resorption, this study is to determine whether PGRN plays a role in estrogen's protective influence in postmenopausal osteoporosis.

Methods: Mice experiments are approved by IACUC of New York University. BMMs were isolated from the femurs by flushing the bone. After 24 h, nonadherent cells were collected and treated with M-CSF (30 ng/ml). After 3 d, adherent cells were cultured in α -MEM containing RANKL and M-CSF. Osteoclast formation was measured by TRAP staining. To analyze pit formation, the special Osteo Assay Surface 24-well plates (Corning) were used. Real-time PCR was performed to determine the mRNA gene expression. BMSCs were obtained from mice femurs by flushing, after 24 h, nonadherent cells were removed and adherent cells were cultured in DMEM media which changed every 3 d for 14 d. For osteogenic induction of BMSCs, osteogenic differentiation medium from R&D systems was used. ALP and ARS staining were performed after 2 and 3 weeks of induction, respectively. PGRN levels of cell culture media were measured by ELISA kit. Immunofluorescence was used to localize the PGRN in both BMMs and

RAW 264.7 cells. Genome microarray analysis was performed to identify the difference between bone cells from WT or PGRN-KO mice.

Results: Firstly, in both primary BMMs isolated from WT mice and RAW 264.7 macrophages, we found estrogen significantly upregulated PGRN expression. Secondly, in primary BMMs isolated from WT mice, estrogen markedly inhibited osteoclast formation and bone resorption, as well as levels of osteoclast differentiation gene markers. In contrast, estrogen's inhibitory effect on osteoclastogenesis was totally abrogated in PGRN-KO BMMs. Intriguingly, it is noted that pits of cells from PGRN-KO mice were much bigger than those from WT mice, indicating that loss of endogenous PGRN led to increased bone resorption. Thirdly, in BMSCs derived from both WT and PGRN-KO mice, estrogen slightly increased bone mineralization and osteogenic differentiation markers (no significant difference). In addition, bone mineralization of cells from PGRN-KO mice was markedly reduced compared to those from WT mice. Fourthly, estrogen pellets could not reduce the ovariectomy-induced bone loss in PGRN-knockout mice as that in WT mice. Lastly, by genome microarray analysis, it was revealed that estrogen receptor α (ER α) expression in the bone was significantly reduced when PGRN deficiency.

Conclusions: Above all, this study indicates that PGRN is required for estrogen's effect on postmenopausal osteoporosis, via its interaction with ER α .

Acknowledgement: The work is supported by China Scholarships Council.

P291

LOW TRABECULAR BONE SCORE WITH OR WITHOUT OSTEOPOROSIS IS DIFFERENTIALLY LINKED TO DISTINCT CLINICAL CONDITIONS

V. Rouach¹, I. Yaish¹, M. Arbib¹, N. Stern¹

¹Institute of endocrinology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Objective: Trabecular bone score (TBS) is a bone texture index derived from lumbar spine DXA images. TBS may have a role in the assessment of fracture risk in some causes of secondary osteoporosis. Our aim was to assess which medical conditions are associated with low TBS.

Methods: A cross-sectional study conducted in the bone clinic at the Tel-Aviv-Sourasky medical center. BMD was measured by DXA (Lunar Prodigy Primo) and TBS was measured from DXA L1L4. We collected demographic and clinical data from the medical files. To be included in this analysis, subjects had to present with a L1L4 TBS adjusted T-score (aTBS) <-3.

Results: We identified 110 subjects (F/M=109:1) whose aTBS was <-3, of whom half had osteoporosis by BMD and half were normal/osteopenic. Mean age was 68 \pm 12 and mean BMI 28.3 \pm 5.8 kg/m². The most common conditions reported were obesity (35%), diabetes (27%), cancer (20.6%) and chronic inflammatory diseases (9.3%), nearly 30% were proton pump inhibitors users and 20% used selective serotonin reuptake inhibitors. The group with low aTBS without osteoporosis had significantly higher rates

of obesity (52% vs. 17%, $P < 0.01$) and diabetes (36% vs. 17%, $p = 0.003$). In contrast, the group with low aTBS and osteoporosis included a higher rate of subjects with inflammatory diseases (15.6% vs. 3.6%, $p = 0.035$), chronic steroid treatment (22% vs. 8%, $p < 0.01$) and cancer [papillary thyroid carcinoma (8% vs. 0%, $p = 0.025$); breast cancer cases (16% vs. 12%, NS); overall rate of cancer (29% vs. 14%; $p = 0.075$)].

Conclusion: In our study population, low TBS is significantly linked to distinct medical conditions, in relation to the presence or absence of osteoporosis. Low TBS associated with low BMD segregated with the presence of inflammatory diseases, chronic steroid treatment, and cancer whereas low TBS with normal/osteopenic BMD was associated with obesity and diabetes.

P292
THE PERILS OF PROTON PUMP INHIBITORS

Y. T. Tai¹, C. V. Tong¹

¹Department of Medicine, Hospital Melaka, Melaka, Malaysia

Proton pump inhibitors (PPIs) are the mainstay therapy for all gastric acid related disease and are extremely widely used in current clinical practice. Although widely regarded as safe, PPIs have been associated with a variety of adverse effects, including hypomagnesaemia. The postulated mechanism of PPI-related hypomagnesaemia involves inhibition of intestinal magnesium absorption via transient receptor potential melastin (TRPM) 6 and 7 cation channels. PPI-induced hypomagnesaemia (PPIH) has become a well recognized phenomenon since it first reported in 2006. Clinical concerns arise from growing number of case reports presenting PPIH as a consequence of long-term PPIs use, with more than 30 cases published to date.

In this article, we reported 2 cases of PPIH associated with the use of pantoprazole. Both patients presented with severe hypomagnesaemia and hypocalcaemia. One of them had associated hypokalemia and cardiac arrhythmia. A casual relation with PPIs supported by resolution of electrolytes abnormalities after discontinuation of PPIs.

P293
MIXED OSTEOMALACIA AND LOW BONE DENSITY AS A CAUSE OF STRESS FRACTURES IN A YOUNG MALE MILITARY RECRUIT FROM SINGAPORE

W. J. Loh¹, L. Hughes², D. Chua³, L. Gani¹

¹Department of Endocrinology, Changi General Hospital, Singapore, ²Department of Anatomical Pathology, Concord Hospital, Australia, ³Department of Orthopaedics, Changi General Hospital, Singapore

Background: Despite being a tropical country, vitamin D deficiency is common in Singapore. All young Singaporean males between the age of 18-21 years old have to undergo 2 y of mandatory military service. Stress fractures among recruits have been reported. risk factors include sudden increase in physical activity and vitamin D deficiency. We report the bone histomorphometry findings from a case of bilateral tibial stress fractures in an 18 years old military recruit.

Case presentation: An 18 years old man presented with bilateral leg pain after his first marching session of 200 m. There were no personal or family history of fractures and physical examination was unremarkable except for tenderness on palpation of both proximal tibiae. His BMI was 24.6 kg/m² (weight 73.5 kg, height 1.73m). X-ray of bilateral knees and MRI of both calves confirmed periosteal transverse fractures of the bilateral proximal tibial metaphysis. His BMD revealed a low bone density for his age (Z-score -1.5). Apart from a low vitamin D of 10.7 ug/L, other secondary causes of osteoporosis were negative on investigation. Double tetracycline labelled qualitative bone histomorphometry of the iliac crest suggests a mixed picture of loss of trabeculae connectivity as seen in osteoporosis and delayed mineralization as seen in osteomalacia. His vitamin D was replaced to 41.4 ug/L and his BMD showed a significant improvement of 5.4% in lumbar spine and 3.2% of the hip a year later.

Conclusion: Vitamin D deficiency and osteomalacia in young male recruits may be a cause of low bone density and may predispose them to higher risk of stress fractures. Adequate vitamin D replacement helps to improve their BMD.




Figure 1a: MRI of the calves of the patient showed increased signal at linear T1RM sequence which suggest fluid clefts at both fracture sites

Figure 1b: Bone biopsy showed irregularity, variability and loss of connectivity of bone trabeculae, with some thinning and scattered bone nubbins

P294

THE FIRST RESULTS FROM THE RUSSIAN REGISTRY ON HYPOPARATHYROIDISM AND PSEUDOHYPOPARATHYROIDISM IN ADULTS

S. Gronskaya¹, T. Grebennikova¹, L. Rozhinskaya¹, G. Melnichenko¹, E. Pigarova¹, E. Przhialkovskaya¹, M. L. Brandi², Z. Belaya¹

¹The National Medical Research Centre for Endocrinology, Moscow, Russia, ²Metabolic Bone Diseases Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy

Objective: Hypoparathyroidism and pseudohypoparathyroidism are rare endocrine disorders characterized by low serum calcium due to inappropriate PTH levels or resistance to the action of PTH. This study aimed to estimate the etiological structure, demographic characteristics and hospital management of the hypoparathyroidism among patients, who were referred to the National Medical Research Centre for Endocrinology in Moscow.

Methods: This study adopted the design of the Italian hypoparathyroidism registry database (University of Florence) in order to be able to integrate our data in the future. 132 Russian patients were included (over 1.5 y from 2017-2018) from the National referral endocrine center in Russia. We analyzed the codes corresponding to hypoparathyroidism-related diagnoses: "hypoparathyroidism associated with medical intervention" (E89.2), "hypoparathyroidism" (E20), "idiopathic hypoparathyroidism" (E20.0), "pseudohypoparathyroidism" (E20.1), "other forms of hypoparathyroidism"(E20.8), which included "autoimmune polyglandular syndrome (APS)", "mitochondrial disorders associated with hypoparathyroidism" [including Kearns-Sayre syndrome and mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), "DiGeorge syndrome", "isolated hypoparathyroidism" and "hypoparathyroidism resulting from infiltrative, metastatic, ionizing damage". We have excluded pediatric patients (under 18 years old) and patients with the codes: magnesium metabolism disorders (E83.4), calcium metabolism disorders (E83.5), tetany BDU (R29.0).

Results: Overall, 132 patients with hypoparathyroidism were identified during the entire period. The patients' mean age was 47 (18;79). The mean age of disease onset was 41 (1;72). Most patients were female - 83% (n=110); male- 17% (n=22). The female-to-male ratio was 4.8:1.

The evaluation of the etiology of the disease showed that 82% (n=108) of cases of hypoparathyroidism were associated with a neck surgery procedure. Nonsurgical hypocalcemia was caused by: pseudohypoparathyroidism 3% (n=4), other forms of hypoparathyroidism 3% (n=4): DiGeorge syndrome 1.5%(n=2), autoim-

mune polyglandular syndrome (APS) 0,75%(n=1), mitochondrial disorders associated with hypoparathyroidism (MELAS) 0.75% (n=1). In the reported cohort the majority of patients 92.4% (n=122) had clinical features of hypoparathyroidism (paresthesia, seizures). Only 7.6% (n=10) of patients did not complain about symptoms of hypocalcemia. All patients received treatment: calcium was prescribed in 92% (n=122) of cases, cholecalciferol - 79% (n=105), alfacalcidol - 81% (n=108.0), magnesium preparations 13.6% (n=18), hypothiazide 10% (n=14), calcitriol 6.8% (n=9.0), teriparatide 6% (n=8). Sufficient control of symptoms and calcium levels was achieved in all hospitalized subjects.

Conclusion: The most frequent cause of hypoparathyroidism was neck surgery, which made middle-aged females the most common patients with hypoparathyroidism. Calcium supplement and alfacalcidol were sufficient at maintaining calcium levels in most cases. However the minority of patients needed to receive teriparatide as the only way to maintain calcium levels and to prevent symptoms of hypocalcemia. Consequently the substitution treatment with PTH should be available in certain cases with hypoparathyroidism.

P295

EVALUATION OF INSIGHT VET DXA (DUAL-ENERGY X-RAY ABSORPTIOMETRY) FOR ASSESSING BODY COMPOSITION IN OBESE RATS FED WITH HIGH FAT DIET: A FOLLOW-UP STUDY OF DIET-INDUCED OBESITY MODEL FOR 8 WEEKS

J. Yeu¹, H.-J. Ko², D. Kim¹, Y. Ahn¹, J. Kim¹, W. Lee¹, I. Jung¹, J. Suh², S.-J. Lee²

¹OsteoSys Co., Ltd., Seoul, South Korea, ²WOOJUNGBIO.,Co.Ltd., Suwon, South Korea

Objectives: We examined the precision, accuracy, and capability of detecting changes of DXA for the measurements of total-body weight (TBW), total-body fat weight (TBFW), and total-body lean weight (TBLW) in an 8-week follow-up study of rats.

Methods: 20 male rats (4-week) were divided into 2 diet groups. For 8 weeks, we measured body composition (TBW, TBFW, TBLW) by DXA and TBW by an electronic scale once a week. In week 8, we measured body composition 5 times by DXA and TBFW by dissecting experiment (EXP) of euthanized rats (12-week). Total-body fat ratio (TBFWR) was defined as TBFW/(TBFW+TBLW). The precision of DXA was evaluated by measuring the coefficient of variation (CV) and accuracy was evaluated by comparing DXA-derived data with EXP data. The capability of detecting changes of DXA in follow-up study was verified by analyzing the trend of DXA-derived values over the 8 weeks.

Results: For TBW, TBFW, TBLW of DXA, CVs were 0.02±0.01, 0.10±0.05, 0.03±0.02 and errors were -6.996±3.429(p=0.999), +14.729±3.663(p=0.982), -21.725±4.223(p=0.991). Prediction models were [EXP TBW=-31.767+1.085(DXA TBW), r²=0.998, root mean square error (RMSE)=1.842] and [EXP TBFWR=-0.056+1.177(DXA TBFWR), r²=0.948, RMSE=0.007]. Over 8

weeks, DXA TBW and DXA TBLW steadily increased, DXA TBFW steadily increased followed by saturation or declination, difference of DXA TBFW between 2 diet groups steadily increased.

Conclusions: Our study verified that DXA (iNSIGHT VET DXA, OsteoSys, Korea) is accurate and precise enough to measure body composition of rats. Additionally, we confirmed the possibility that DXA could be used for the long-term follow-up studies.




Figure 1. (a)-(c) Scatter plots of the relationship of the values between DXA and EXP in week 8. (d)-(f) The graphs represent the trend of mean DXA values divided into the high fat diet (HFD) group and the normal diet (ND) group for 8 weeks.

P296
PREDICTIVE VALUE OF ULTRASOUND IN THE DIAGNOSIS OF OSTEOPOROSIS IN PRE- AND POSTMENOPAUSAL WOMEN

C. Prado¹, S. Baselga¹, T. Vaquero¹, M. Diaz-Curiel²
¹University Autonoma of Madrid, ²Fundación Jimenez Díaz, Madrid, Spain

Compare the efficiency for the diagnosis of osteoporosis (OP) by method of ultrasound (US) in relation to the assessment by DXA. Find US osteoporosis diagnostic cut point equivalent to DXA values (T-score).

Cross-sectional study performed in Madrid with 1078 women aged 42 and 80 who attended for a routine control, derived by their family physician, at the Fundación Jimenez-Díaz. Mineral density

was evaluated according two **Methods:** DXA (lumbar spine (CL, L2-L4) and femoral head (CF)) and US (calcaneus). We obtaining in each case the BMD (g/cm²) and the values of T-score. The classification of osteoporosis pathology was made according the WHO reference of (≥ -2.5). ROC curve and Youden index were used to obtain osteoporosis cut points (T-score) by ultrasound technique equivalent to those considered with DXA.

There is an important gap in the classification of the disease using the value of CL DXA and US, nevertheless femoral neck values shows most upcoming and promising results related with US. To optimizes the classification of bone pathology, the value of US T-score estimated by ROC curve and Youden analysis in hip (CF) was (-2.35). In fact, this value get a sample screening very similar (not statistically different) that we obtained by DXA (see table). Only 1.3% of the classification of osteoporosis by densitometry escapes the reclassification by the new value of estimated by US.

Estimated new qualifier US value of T-score, setting resembles results with the obtained by DXA and therefore enables the effective utilization of the US method in population prevention studies.

	DXA CL (WHO)%	DXA CF (WHO)%	US (WHO)%	US estimated for CL (-2.85)%	US estimated for CF (-2.35)%
Not osteoporosis	45.9	<u>74.30</u>	<u>77.3</u>	63.8	<u>73.0</u>
Osteoporosis	50.9	21.8	26.1	36.2	22.0

Bone categories in CL and CF according to DXA T-score and US (who) and the estimated us cutoff point.

P297

CORRELATIONS BETWEEN VITAMIN D AND BONE MINERAL DENSITY IN A RANDOMLY SELECTED, HEALTHY, URBAN MALAYSIAN POPULATION

S. S. Yeap¹, S. C. Thambiah², I. N. Samsudin², S. Y. Zahari-Sham², N. Zainuddin², S. Mohamad-Ismuddin², N. Shahifar², S. Md-Said³, G. Appannah⁴, F. L. Hew¹

¹Department of Medicine, Subang Jaya Medical Centre, Subang Jaya, ²Department of Pathology, Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor, ³Department of Community Health, Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor, ⁴Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor, Malaysia

Objective: Vitamin D plays a key role in bone metabolism. 25(OH)D is the best indicator of vitamin D status. The link between 25(OH)D levels and bone health remains unclear and may be dependent on the population studied. This study aimed to examine the correlations between 25(OH)D and BMD in a healthy Malaysian population.

Methods: A random sample of the population aged between 44-90 y from 2 districts in the state of Selangor, Malaysia, was invited by post to attend for a free bone health checkup. Patients with diseases known to affect bone metabolism or were on treatment for osteoporosis were excluded. All subjects had their BMD measured with DXA. 25(OH)D was measured on the automated ADVIA 1200 Chemistry Analyser (Siemens Healthcare, Germany).

Results: 390 subjects came for assessment. 39% had 25(OH)D levels below 50 nmol/L. Median 25(OH)D levels were significantly lower in females 53 nmol/L compared to males 66 nmol/L (p value?). Chinese subjects had the highest 25(OH)D levels 67 nmol/L, followed by Malays 53 nmol/L and Indians 44 nmol/L. After adjustment for race and gender, 25(OH)D was significantly correlated with femoral neck (FN) (p=0.002) and total hip (TH) (p<0.001) but not lumbar spine (LS) (p=0.386) BMD. Of the 63 patients with osteoporosis, 76.2% were Chinese. In contrast, the majority (48.0%) of 25(OH)D insufficient subjects were of Indian origin. However, both subjects with normal and osteoporotic BMD had 25(OH)D insufficiency in the Indian population (p=0.018) (Table 1), which was not present in the Chinese (p=0.276) or Malays (p=0.850).

Table 1: Proportion of 25(OH)D insufficiency in different BMD categories in the Indian population

	Normal BMD	Osteopenia	Osteoporosis
Sufficient (>50 nmol/L)	17 (26.6%)	21 (51.2%)	1 (14.3%)
Insufficient (<50 nmol/L)	47 (73.4%)	20 (48.8%)	6 (85.7%)

Conclusions: In a healthy Malaysian population, 39% had 25(OH)D levels below 50 nmol/L. Significantly lower levels of 25(OH)D were found in females and Indians. 25(OH)D levels correlated significantly with FN and TH but not LS BMD, after adjusting for race and gender. Thus, 25(OH)D levels need to be interpreted taking into account population characteristics.

Acknowledgement: Project funded by FRGS/1/2015/SKK03/UPM/02/1

P298

RESULTS OF TREATMENT OF EWING SARCOMA/PNET (PRIMARY NEUROECTODERMAL TUMOR)

V. Protsenko¹, O. Burianov²

¹Institute of Traumatology and Orthopedics of NAMS of Ukraine, ²Bogomolets National Medical University, Ministry of Health of Ukraine, Kiev, Ukraine

Objective: Ewing sarcoma/PNET is a bone marrow tumor, of neuroectodermal nature, with high degree of malignancy. The disease proceeds, as a rule, acute with the appearance of pain in the affected part of the bone and an increase in temperature to 38 ° and higher. The feature of the Ewing/PNET tumor is rapid hematogenous metastases in the lungs. The main and relatively effective methods of treatment of this nosology are chemotherapy and radiotherapy.

Methods: Complex treatment was performed for 12 patients with Ewing sarcoma/PNET in accordance with the Scandinavian protocol of treatment, which includes conducting 13 courses of polychemotherapy, as well as radiation therapy up to 40-60 Gray of total grade dosage for the affected segment of the bone, followed by surgical treatment for operable tumors. Six (50%) patients with Ewing's sarcoma/PNET pelvic bones received chemoradiotherapy; in 4 (33.4%) patients after chemoradiotherapy treatment, resection of the articular segment of the bone and joint replacement were performed, in 2 (16.6%) patients completed bone and plastic surgery using autotransplant.

Results: As a result of treatment, relapses of Ewing's sarcoma/PNET were detected in 2 (16.7%) patients. Metastases were observed in 5 (41.7%) patients, of them in 3 (25%) patients in the lungs, 1 (8.3%) in the lung and liver, 1 (8.3%) in the lung and skeletal bones. The 3-y overall survival rate of patients was 52.15±4.5%, and 5-y - 36.7±8.6%.

Conclusions:

1. The prognosis for Ewing's sarcoma/PNET is generally unfavorable, with a standard risk (tumor size <100 cm³, localization in the tubular bones) and a high risk of progression (tumor size >100 cm³, localization in pleural bones, presence of metastases).
2. The use of integrated treatment of Ewing's sarcoma/PNET allowed reducing the number of relapses and tumor metastases.

P299

THE UTILITY OF FRAX SCORES, WITH AND WITHOUT TBS, IN A RANDOMLY SELECTED, HEALTHY, URBAN MALAYSIAN POPULATION

S. S. Yeap¹, S. C. Thambiah², I. N. Samsudin², S. Y. Zahari-Sham², N. Zainuddin², S. Mohamad-Ismuddin², N. Shahifar², S. Md-Said³, G. Appannah⁴, F. L. Hew¹

¹Department of Medicine, Subang Jaya Medical Centre, Subang Jaya, ²Department of Pathology, Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor, ³Department of Community Health, Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor, ⁴Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor, Malaysia

Objective: FRAX combines clinical risk factors with or without BMD to assess future fracture risk. The trabecular bone score (TBS) is an indirect index of trabecular microarchitecture. It has been suggested that TBS could be clinically useful for enhancing fracture prediction from FRAX. This study aimed to look at BMD, FRAX scores and TBS in a healthy Malaysian population.

Methods: A random sample of the population aged between 44-90 years from 2 districts in the state of Selangor, Malaysia, was invited by post to attend for a free bone health checkup. Patients with diseases known to affect bone metabolism or were on treatment for osteoporosis were excluded. As there was no database available for Malaysia, FRAX scores were calculated using the Singapore database.

Results: 390 subjects came for assessment, of which 370 (94.9%) had BMD measured. There were 125 (33.8%) male and 245 (66.2%) female subjects. 155 (41.9%) subjects had normal BMD, 152 (41.1%) had osteopenia (OPe) and 63 (17.0%) had osteoporosis (OP). Median age increased from 57 y in normal BMD, 60 y in OPe and 69 y in OP ($p < 0.001$). There were more females with OPe and OP compared to males ($p < 0.001$). In OPe patients, after application of FRAX, 27/152 (17.8%) had an increased fracture risk that crossed the treatment threshold. After adjustment of FRAX with TBS, a further 8 (5.3%) subjects would be considered for treatment, while 2 (1.3%) subjects dropped below the treatment threshold. TBS was significantly lower in patients with type 2 diabetes mellitus (T2DM) ($p = 0.033$). There was no difference in FRAX major osteoporotic or hip fracture risk, without or with TBS, between those with T2DM and those without ($p > 0.05$).

Conclusions: In this Malaysian population, 17% were found to have OP. In those with OPe, after the application of FRAX, 17.8% were identified as candidates for treatment. However, the additional use of TBS did not add substantially to those requiring treatment. Therefore, we suggest that the use of FRAX with BMD would identify the majority of subjects with OPe requiring treatment in Malaysia.

Acknowledgement: Project funded by FRGS/1/2015/SKK03/UPM/02/1

P300

OBES EOSTEOSARCOPENIA WITH IMPAIRMENT OF MOBILITY AND WEAKNESS IN OUTPATIENT OLDER ADULTS

A. Frisoli¹, J. B. Borges¹, M. C. Cartucci¹, A. Carvalho¹

¹Federal University of Sao Paulo-Cardio Geriatric Section-Cardiology Division, Sao Paulo, Brazil

Objective: In clinical practice, osteosarcopenia has been associated with higher vulnerability to adverse health outcomes, but it is unclear whether the presence of obesity modify the physical capacity of subjects with osteosarcopenia. The goal of this study was to evaluate the mobility and the grip strength of outpatient older adults with osteosarcopenia and obesity.

Methods: Cross-sectional analysis of data from SARCOS, an observational study of the epidemiology of SARcopenia and OSteoroporosis in ambulatory older adults, Sao Paulo, Brazil. SARCOS recruited older adults from 2015-2018. The analytic sample for this study included all older adults who underwent DXA evaluation at baseline, and had available data on muscle and bone mass, as well as, grip strength of dominant hand, mobility tasks by chair stand test (CST) and walking speed ($n = 384$). Osteosarcopenia was diagnosed by the presence of osteoporosis by WHO criteria plus Sarcopenia defined as low skeleton appendicular muscle mass by BMI (FNIH criteria) adjusted for gender. Obesity was considered if the percentage of total body fat $\geq 35\%$. Osteosarcopenia was divided according by the presence of obesity: obese osteosarcopenia (OBOS), and nonobese osteosarcopenia (NOBOS). Loss of mobility was diagnosed if CST (+): Unable to get up and sit in the chair 5 times or low walking speed (LWS) if $v \leq 20\%$ ($v = 0.90\text{m/s women and } v = 1.04\text{m/s men}$), and severe impairment of mobility (SIM): CST (+) plus LWS. Weakness was diagnosed when the grip strength was $\leq 16\text{ kg for women and } \leq 26\text{ kg for men}$.

Results: Osteosarcopenia occurred in 14.9% ($n = 57$), of them 70.37% ($n = 41$) were OBOS, and 29.62% ($n = 16$) were NOBOS. Among OBOS 80.5% were female and among NOBOS 87.5% were male ($p < 0.001$). There is no difference in the mean age between the OBOS and NOBOS (82.2 ± 7.0 vs. 81.3 ± 6.5 yo, respectively). In the adjusted regression analyses, for CST (+) OBOS OR=2.96 (CI:0.34-25.18; $p = 0.320$) vs. NOBOS OR=2.80 (CI:0.30-25.70; $p = 0.361$), for LWS, OBOS OR=3.97 (CI:1.01-15.53; $p = 0.047$) vs. NOBOS OR=1.52 (CI:0.15-15.05; $p = 0.716$); for SIM, OSO OR=15.53 (CI:3.41-70.60; $p < 0.001$) vs. NOBOS OR=8.79 (CI:0.73-106.05; $p = 0.087$) and for weakness, OBOS OR=1.91 (CI:0.93-3.94; $p = 0.078$) vs. NOBOS OR=4.59 (CI:1.37-15.33; $p = 0.013$).

Conclusion: Obese osteosarcopenia and non-obese osteosarcopenia seem to be different syndromes of physical vulnerability. Obese osteosarcopenia is more associated with female gender and impairment of mobility, whereas nonobese osteosarcopenia is associated with male gender and weakness.

P301

TSPAN7 LINKS RANK/ α V β 3 INTEGRIN COMPLEX AND MODULATES INTEGRIN-MEDIATED BONE RESORPTION SIGNALING

P. Doori¹, P. Jin Hee¹, L. Jingjing¹, L. Soo Young¹



¹Department of Life Science and the Research Center for Cellular Homeostasis, Ewha Womans University, Seoul, South Korea

Objective: RANK and α v β 3 integrin are essential factors involved in regulating osteoclast formation and function. RANKL, by mechanisms unknown, directly activates osteoclasts to resorb bone. Here I identify Tspan7, a member of tetraspanin superfamily proteins, is expressed in a specific membrane microdomain, called "TEM", and is crucial for pre-osteoclast fusion and mature osteoclast function. Tspan7 expression can be upregulated by RANKL signaling in the late stage of osteoclastogenesis. Overexpression or knock-down of Tspan7 in BMMs did not affect RANKL-mediated osteoclastogenesis but attenuated mature osteoclast fusion and morphology which suggest a guess in Tspan7 that act as an osteoclast function regulator. The Tspan7-CT is related to pososome belt composed actin ring structure formation. Inhibition of Tspan7 C-terminal by Tspan7-CT peptide inhibitor successfully blocked the c-Src and Syk activation in response to β 3 integrin ligand vitronectin stimuli, and controlled β 3 integrin mediated bone resorption. Furthermore density gradient study clearly established that Tspan7 is localized in TEM in mature osteoclast where Tspan7 can organize RANK and α v β 3 integrin complex. These data suggest that function of Tspan7 and its expression in TEM are crucial for mature osteoclast function. Because α v β 3 integrin and

its associated proteins are therapeutic targets in the context of pathological bone resorption, specific inhibition of Tspan7 could serve as a new therapeutic strategy for treating bone diseases.

Methods: Recombinant TSPAN7-Fc: 293F cells transfected with a gene encoding dimeric form of the large extracellular loop (EC2; aa 113-214) of the TSPAN7 with the Fc region of human IgG1 cloned in pVITRO1-Fc. The secreted purified protein (TSPAN7-Fc) was loaded the protein G sepharose beads column (Thermo Scientific™ Pierce) and eluted with elution buffer (100 mM glycine, PH 2.0, Duchefa Biochemie) contained 1 M Tris-Cl (PH 7.0, Duchefa Biochemie) to immediately neutralize the protein. Collect the tubes containing high concentration of proteins and dialyze over PBS extensively and kept frozen at -80°C. **LPS-induced bone loss in calvarial model:** 5 to 6-week-old C57/BL6 male mice were administered a local calvarial injection of LPS (12.5 mg/kg body weight) two times at intervals of 48 h. After the final LPS injection, TSPAN7-Fc (0.4 mg/kg or 2 mg/kg body weight) or hlgG1 was injected three times over 5 days. On day 6, mice were sacrificed and subjected to histological analysis by hematoxylin and TRAP staining (Sigma). The number of osteoclasts and surface erosion were measured with the OsteoMeasureXP software (OsteoMetrics, Inc.). **Ovariectomy:** Models of osteoporosis induced by ovariectomy (OVX) have been described previously. 8-week-old C57/BL6 female mice were ovariectomized or subjected to sham operation. Four days later, mice were intramuscular injected TSPAN7-Fc (0.4 mg/kg and 2 mg/kg body weight in PBS) or hlgG1 2 times for 4weeks. The experiment was completed at day 31, at which time the histology and μ CT were analysed as described above.

Results:



TSPAN7-Fc suppresses LPS-induced OC formation and bone destruction in calvarial model: Inhibition of LPS-induced (12.5 mg/kg body weight) bone destruction after injection of TSPAN7-Fc (0.4 mg and 2 mg/kg body weight) and hlgG1. (A) TRAP and hematoxylin staining was performed on histological sections of calvaria bone. The scale bar indicates 50 μ m. (B) The number of osteoclasts (left) and eroded surface (right) were analyzed. (C) Increased number of osteoclasts with abnormal morphology on the TSPAN7-Fc treated mice. Scale bar indicates 20 μ m. (D) Representative osteoclasts on the trabecular bone. Data represent the means \pm SD. n=5. *P<0.005, +P<0.0001

Conclusion: The results of this study demonstrated that blocking the TSPAN7 using TSPAN7-fc fusion protein inhibits OC maturation and function *in vitro*. The resultant inhibition of bone resorption occurs through blocking of forming normal morphology of osteoclast *in vivo*. Furthermore, function of Tspan7 and its expression in TEM are crucial for mature osteoclast function. Because avb3 integrin and its associated proteins are therapeutic targets in the context of pathological bone resorption, specific inhibition of Tspan7 could serve as a new therapeutic strategy for treating bone diseases.

P302

HYPERBARIC OXYGEN FOR THE TREATMENT OF BONE MARROW OEDEMA OF THE CARPAL BONES: A RETROSPECTIVE 4-YEAR STUDY

A. Mari¹, K. Raptis¹, C. Koutserimpas¹, D. Antonopoulos¹, S. Tournis¹, V. Kalentzos²

¹Laboratory for the Research of the Musculoskeletal System, University of Athens, KAT Hospital, Athens, ²General Hellenic Navy Hospital - Department of Diving and Hyperbaric Medicine, Athens, Greece

Objective: Very few small case series exist regarding the use of hyperbaric oxygen for the treatment of clinical entities resulting in bone marrow oedema of the carpal bones. Post-traumatic carpal bone marrow oedema, Kienbock and Preiser disease are usually treated in the early stages with cast immobilization and nonsteroid anti-inflammatory drugs. The purpose of this study was to investigate the effectiveness of hyperbaric oxygen in the treatment of such cases.

Methods: From 2013 until 2017 the medical records of all patients treated with post-traumatic carpal bone marrow oedema, Kienbock and Preiser disease were studied. Radiological, as well as clinical findings were evaluated. Complications and total time for clinical improvement were recorded.

Results: A total of 21 patients (15 males- 6 females), with a mean age of 32 y of age were recorded. Nine patients (7 suffering from post-traumatic wrist bone marrow oedema and 2 from Kienbock's disease) received the standard care (group A), including NSAIDs and cast-immobilization, while the remaining 12 (9 suffering from post-traumatic wrist bone marrow oedema, 2 from Kienbock's and 1 from Preiser disease) received additionally 20 sessions of hyperbaric oxygen therapy (group B). In both group of patients time of wrist immobilization was the same (6-8 weeks). Mean

follow-up was 9 months. No complications or recurrence were observed among the study population. Mean time for recovery in group A was 5.8 months, compared to 4.3 months of group B (p-value<0.05).

Conclusion: The present study has shown that patients treated with the addition of hyperbaric oxygen had a statistically significant decrease to the recovery time, when compared to those receiving the standard care. Therefore, it seems that hyperbaric oxygen in such cases may have an important role as part of the treatment.

P303

THE MEASUREMENT OF THE DISTAL FOREARM BONE MINERAL DENSITY PRESENTS GREATER SENSITIVITY FOR THE DIAGNOSIS OF OSTEOPOROSIS IN THE ELDERLY THAN THE LUMBAR SPINE

A. Frisoli¹, J. Borges¹, M. Cartocci¹, A. Carvalho¹

¹Federal University of Sao Paulo-Cardio Geriatric Section-Cardiology Division, Sao Paulo, Brazil

Objective: Osteoporosis in elderly is very frequent and strongly associated with fractures and disability. The aortic calcification and vertebral osteophytes may overestimate the measurement of BMD of the lumbar spine (LS). In these subjects the ISCD recommends to evaluate the distal forearm (DF) BMD. However, it is very difficult in clinical practice, to differentiate all individuals with these changes in the LS, which may lead to underestimation of osteoporosis in the elderly. Our aim was to evaluate the sensibility and specificity of DFBMD or LSBMD, with proximal femur BMD for the diagnosis of osteoporosis in older adults.

Method: Cross-sectional analyses of 401 patients from SARCOS study, an observational study of the epidemiology of sarcopenia and osteoporosis in older outpatients from Cardiology Division of Federal University of Sao Paulo-Brazil. Patients were recruited from outpatient clinic setting. All patients underwent DXA of all bone sites (lumbar spine, femoral neck total femur, and distal forearm-33) and osteoporosis was diagnosed if BMD \leq -2.5SD. Very old was classified individual aged \geq 80 yo. We classified osteoporosis by three criteria: general osteoporosis (GOP), if BMD \leq -2.5SD at any bone site, osteoporosis at lumbar spine and or proximal femur (OPLS) and osteoporosis at distal forearm and or proximal femur (OPDF). Chi-square test and ROC area curve (AC) and sensitivity/ specificity.

Results: The mean age 78.22 (7.16) yo, and 56.2% were women. GOP occurred in 45.6% (183), OPDF 40.1% (161) and OPLS 33.9% (136). OPLS criterion identified 74.3% (p<0.001) of the all individuals with GOP while OPDF identified 88% (p<0.001) of them. In ROC analyses with GOP, OPLS AC=0.872 (0.83-0.91) sensitivity 0.743 and OPDF AC=0.940 (0.91-0.96), sensitivity 0.882. Among very old, OPDF presented AC=0.971 (0.94-0.99), sensitivity of 0.942, and OPLS AC=0.86(0.80-0.91) and sensitivity 0.721.

Conclusion: Osteoporosis diagnosed with DF BMD presents greater sensitivity for the general osteoporosis than LS BMD, in older adults, especially in very old people.

P304

THE IMPORTANCE OF DETERMINING TRABECULAR BONE SCORE IN POSTMENOPAUSAL WOMEN

J. Aleksic¹, F. Gojkovic¹, J. Zvekcic Svorcan², J. Elez³

¹Railway Healthcare Center, Department of Physical Medicine and Rehabilitation, Belgrade, ²University of Novi Sad, Faculty of Medicine, Special Hospital for Rheumatic Diseases, Novi Sad, ³Railway Healthcare Center, Department of Internal Medicine, Belgrade, Serbia

Objective: Osteoporosis is a disease characterized by low BMD and impaired microarchitecture of bone tissue, leading to increased bone fragility and a consequent increase in fracture risk. Conceptual description of the disease puts into focus two important characteristics of bone: BMD and quality, especially bone microarchitecture. Our aim was to investigate the trabecular bone score (TBS) values in relation to fractures.

Methods: Cross-sectional study was conducted in Railway Healthcare Center, Belgrade, in period Jan 1 - April 31, 2018. 275 postmenopausal women, aged 45-83 y, were included. Study included only those who were first time on BMD testing and never had treatment therapy for osteoporosis before. BMD was measured on Hologic Discovery C device, on lumbar spine and hip region. The vertebral fracture assessment was performed, and Th4-L4 region was analysed in aim to detect vertebral fractures on the same device. The lumbar spine scans were reanalysed in TBS iNsite® software (V1.9.2, Med-Imaps, France) and TBS was calculated. All the participants were previously tested using an epidemiological questionnaire.

Results: In relation to the existence of a small trauma fracture, the subjects are divided into two groups: with no previous fracture-134 (48.7%) and group with fracture-141 (51.3%). Postmenopausal women with fractures have a higher percentage of osteoporosis measured on the lumbar spine (48.4% vs. 33.8%; $\chi^2=4.894$, $df=2$, $p=0.08$) according to DXA findings. There is a difference in TBS values between women with and without fractures (TBS<1.200: 86,8% vs. 47.2%; 1.200<TBS>1.250: 10.5% vs. 42.8%; TBS>1.350: 2.7% vs. 10%; $\chi^2=43.10$, $df=2$, $p=0.000$). According to tercile approach, totally degraded microarchitecture is present in 78,8% of women with one fracture, in 90.3% with two fractures and in 92% in those with three or more fractures ($\chi^2=43,67$, $df=6$, $p=0.000$). 78,5% of women with nonvertebral fractures, 94.5% with vertebral, and 91.3% with both localisation of fractures have lowest TBS values ($\chi^2=49,51$, $df=6$, $p=0.000$).

Conclusion: TBS is a useful tool in the evaluation of fracture risk. Combining the normal and osteopenic BMD values with the lowest range of TBS can help in defining a significant subset of non-osteoporotic women at higher risk of fracture which is useful in clinical practice and patient management.

P305

EPIDEMIOLOGY OF HIP FRACTURE IN KAZAKHSTAN ACCORDING TO THE POPULATION-BASED LONGITUDINAL STUDY IN A LARGE INDUSTRIAL CITY

S. Issayeva¹, O. Lesnyak², B. Issayeva¹, A. Zakroyeva³, D. Dilmanova¹

¹Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan, ²Mechnikov North West State Medical University, St. Petersburg, Russia, ³Ural State Medical University, Yekaterinburg, Russia

Objective: Osteoporosis (OP) and its consequence of low trauma fracture are a significant cause of morbidity and mortality, which represent a major health burden in aging population. The number of hip fractures (HF) worldwide will nearly triple by 2050. The aim of this study was to assess the incidence and trends of osteoporotic hip fracture in women and men aged 50 y and over in Kazakh population based on population-based data.

Methods: The investigation was the part of the international multicenter "Epidemiology of osteoporotic fractures in Eurasian counties" study (EVA). Its methodology provides precise definition of all major non-vertebral osteoporotic fractures quantity. The epidemiologic survey was carried out in Taldykorgan city that representative to all Republic ethnically, by gender and age characteristics. In the first, retrospective phase of the investigation (January 1, 2015 to December 31, 2016) we evaluated the fracture rate based only on official hospital records and data of traumatologic centers; beside this we assess the all potential sources of missed information on OP fracture patients. Then we organized a prospective survey (March 1, 2017 to February 28, 2018) that suggested an active search of fragile fractures patients with ICD-10 codes S72,0, S72,1 and S72,2 (femoral neck, intertrochanteric, subtrochanteric, inter- and subtrochanteric fracture) not only from hospital records, but also from outpatient registers and primary care (PC) sources with a mandatory subsequent clinical verification.

Results: In 3 y we revealed 320 low energetic HF in patients older than 50 y, 241 (75%) of these patients were hospitalized, and 181 patients underwent a surgical intervention. According to retrospective survey data, in 2016 the hip fracture incidence was 270 and 231 per 100,000 for women and men acc. In 2017, when we took into account the data from PC sources its incidence increased to 338 and 255 per 100,000 for women and men acc. The HF incidence in men under 70 y was slightly higher than in women, but among the most elderly residents of Taldykorgan, the incidence increased exponentially in both sexes and became 2 times higher among women than among men. Assuming that the fracture rates in Taldykorgan were representative for the whole country, we estimated that the annual number of hip fractures in population of 50 y and older in Kazakhstan in 2018 were 12,256 and it is predicted to increase to 27,595 in 2050.

Conclusion: These epidemiological data allows attributing Kazakhstan to high rank countries of osteoporotic hip fractures rate for men and women and to predict the 2 times increasing

of hip fractures quantity in 2050 that requires the wide national programs aimed the osteoporosis prevention, early detection and treatment.

P306 OSTEOSARCOPENIA PHENOTYPE AND FRAILTY STATUS BY CHS AND SOF CRITERIA

A. Frisoli¹, P. Chaves², J. Borges¹, A. Carvalho¹

¹Federal University of Sao Paulo-Cardio Geriatric Section-Cardiology Division, Sao Paulo, Brazil, ²Florida International University, Florida, USA

Objective: There is a robust physiological interaction between muscle and bone. Sarcopenia and osteoporosis are risk factors for fracture and frailty. Different concepts of frailty have substantial heterogeneity in the physical phenotype. We hypothesized that osteosarcopenia is musculoskeletal manifestations of frailty. To test our hypothesis we evaluate the association among osteosarcopenia (OSP), osteoporosis only (OPON) and sarcopenia only (SARCON) with frailty by Fried criteria and SOF criteria.

Method: Cross-sectional analyses of 386 patients from SARCOS study, an observational study of the epidemiology of sarcopenia and osteoporosis in older outpatients from Federal University of Sao Paulo-Brazil. All patients underwent DXA of total body and bone sites. Frailty was defined by the SOF criterion (2-3 frailty, 1 pre frailty and 0 robust): weight loss, chair stand test; low energy; and by CHS criterion (≥ 3 frailty, 1-2 prefrailty and 0 robust): weight loss, low walking speed, weakness, low energy (adapted), exhaustion. Osteoporosis was diagnosed if BMD ≤ -2.5 SD at any bone site. Sarcopenia was diagnosed only by low muscle mass according to FNIH criterion (appendicular muscle mass/BMI < 0.567 women; < 0.723 men). OSP was diagnosed if osteoporosis and sarcopenia were present.

Results: The mean age was 78.22 (7.16) yo, and 56.2% were women. OSP occurred in 14.8%, SARCON in 39.8% and OPON in 19.2% ($p < 0.001$). Frailty was diagnosed in 17.8% by CHS, and 20.2% by SOF. OSP occurred in 25.8%, SARCON in 41.9%, and OPON in 22.6% of frailty subjects classified by CHS criterion ($p = 0.005$). In the SOF Frailty phenotype, OSP occurred in 16.7%, SARCON in 38.5% and OPON in 21.8% ($p = 0.937$). In the regression analysis for frailty by CHS, OSP presented OR: 19.01 (CI:3.84-93.95; $p < 0.001$), SARCON OR: 4.78 (CI:1.25-18.20; $p = 0.022$), and OPON OR: 3.35 (CI:0.79-14.21; $p = 0.101$). For frailty by SOF criterion, OSP OR: 1.22 (CI:0.54-2.79; $p = 0.624$), SARCON OR: 1.19 (CI:0.61-2.30; $p = 0.597$) and OPON: 1.25 (CI:0.59-2.67, $p = 0.552$).


Conclusion: There are significant differences in the musculoskeletal manifestations of fragility phenotypes, according to the chosen criterion. OSP and sarcopenia are associated only with the frailty by CHS, however, Osteosarcopenia seems to be more specific of the frailty status than other musculoskeletal phenotypes.

P307 ATYPICAL FEMORAL FRACTURE (AFF) IN A PATIENT RECEIVING SEQUENTIAL ANTIRESORPTIVE TREATMENTS IN THE FORM OF HIGH-DOSE DENOSUMAB FOLLOWING PREVIOUS BISPHOSPHONATES

A. Michael¹, A. J. Whallett¹, M. Sinha¹

¹Russells Hall Hospital, Dudley, UK

Case report: An 84-year-old female developed right thigh pain which started following a stumble going up stairs. Three weeks later the pain became so severe that she fell while shopping and had to be admitted to hospital. Her medical history included carcinoma of the breast diagnosed six years earlier and treated with mastectomy and 6 of adjuvant aromatase inhibitors. She commenced on alendronic acid when the breast cancer was diagnosed and continued this for 5 y. 18 months ago, a solitary bone metastasis in the right ilium was diagnosed and she received single fraction palliative radiotherapy and she was switched to subcutaneous denosumab 120 mg monthly and was compliant for the 18 months till her admission. Pelvis x-ray showed a transverse fracture of the proximal shaft of the right femur (Figure). The criteria of the fracture strongly suggested an antiresorptive-related AFF. The patient underwent right locked intramedullary nailing with gradual uneventful recovery. No neoplasia was demonstrated in bone histology from the fracture site.



The patient had AFF after 18 doses of denosumab 120 mg monthly. The direct cause/effect relationship between her denosumab treatment and AFF is difficult to confirm. However Denosumab contribution to the AFF cannot be ignored especially with the high dose (12 times that used in the treatment of osteoporosis). Sequential use of antiresorptives – including alendronic acid for 5 y previously confounds the picture. In a literature review in 2018 of AFF in denosumab treated patients, 9 case reports were identified; in 8 of which the patient had received bisphosphonates before denosumab treatment. Results from the 7 y open-label extension of the denosumab FREEDOM trial showed that for the

2626 patients who completed the trial there were two AFFs. The incidence of AFFs in patients on either bisphosphonates or denosumab therapy is about 1/10000 to 1/1000 patients (BNF). Long duration of therapy, higher dose and multiple antiresorptive medications are risk factors to develop AFF. The etiology is likely to be prolonged suppression of bone turnover in genetically susceptible patients. Hip and lower limb geometry may be a contributing factor. Patients who develop thigh pain while on antiresorptive treatment should have XR of both femurs. Patients who sustain AFF should not receive further antiresorptive medication.

P308

RAPAMYCIN AFFECTS PALMITATE-INDUCED LIPOTOXICITY IN OSTEOBLASTS BY MODULATING APOPTOSIS AND AUTOPHAGY

A. A. Al Saedi¹, C. G. Goodman¹, D. M. Myers², G. D. Duque²

¹Department of Medicine-Western Health, Melbourne Medical School, The University of Melbourne, St. Albans, ²Australian Institute for Musculoskeletal Science (AIMSS), The University of Melbourne and Western Health, St. Albans, Australia

Bone marrow fat infiltration is one of the hallmarks of aging and osteoporotic bones. Marrow adipocytes produce substantial amounts of fatty acids; particularly excessive palmitic acid (PA). PA is toxic to bone-forming osteoblasts in vitro, impacting their differentiation, function, and survival. The mammalian target of rapamycin complex 1 (mTORC1) signaling plays a role in the pathogenesis of osteoporosis via inhibition of autophagy. Since rapamycin (RAP)-induced inhibition of mTORC1 activates autophagy and prevents apoptosis, we therefore hypothesized that RAP may preserve osteoblast viability and reduce PA-induced lipotoxicity. Normal human osteoblasts (NHO) were incubated with RAP in the presence of a lipotoxic dose of PA or vehicle for 24 and 48 hrs. Expression of LC3 protein levels and the phosphorylation of the direct mTORC1 target were quantified by Western blot. Lysosomes and autophagosomes were studied using confocal fluorescence imaging, lysotracker and live-cell imaging. RAP reduced PA-induced apoptosis. In addition, PA-induced autophagosome formation increased substantially over the time-course in the study, an effect that was significantly regulated by the presence of RAP in the media. In summary, this study highlights the role of the RAP-sensitive mTORC1 pathway in NHO under lipotoxic conditions. RAP-associated therapies could, potentially, be targeted for specific roles in osteoporosis and aging bone.

P309

FRAGILITY FRACTURES IN PATIENTS ADMITTED TO ASSAF HAROFEH MEDICAL CENTER: CLINICAL CHARACTERISTICS AND PREFRACTURE RISK ASSESSMENT

D. C. Cantrell¹, K. Or², E. K. Kumar³, S. K. Koren³, Y. Mirovsky⁴

¹Internal Medicine "C", Assaf Harofeh Medical Center, Zerifin, and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Yavne, ²Endocrine Institute. Assaf Harofeh Medical Center, Zerifin, Be'er Ya'akov, ³Endocrine Institute. Assaf Harofeh Medical Center, Zerifin, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Rishon Le'zion, ⁴Orthopedics Department, Assaf Harofeh Medical Center, Zerifin, and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Rishon Le'zion, Israel

Objectives: To investigate the characteristics of patients with fragility fractures and the fracture risk assessed by non-BMD FRAX as a tool to improve primary and secondary osteoporosis (OP) prevention.

Methods: Retrospective and prospective analysis of patients with new fragility fracture admitted to the orthopedic ward at Assaf Harofeh Medical Center from March 2016 to November 2018.

Results: 423 patients were registered, 326 (77.1%) female, mean age 78, DMII 33.8%, steroids use 5.2%, smoking 11%, intact cognition 86%, and 8.7% fully disabled. Cohort previous fracture rates 42% (female rate 48.1%, Male 22.7%). Fracture site: hip 79.4% (F=72.5%, M=83.3%), spine 11.1%, humerus 4%, and tibia + radius 3.3% each. Surgery was performed in 86%, followed by rehabilitation in 77.6%, for average 36 days. Previous BMD was done for 52.1% (F=60.3%, M=25%), previous OP diagnosis 40% (F=46.1%, M=18.8%) and previous and current OP treatment 15.3% and 16.3% respectively. The most common drug for past or current treatment was oral bisphosphonates. Excluding patients on treatment at admission (n=69), the preadmission fracture-risk hip was $\geq 3\%$ in 80% (F/M, no diff) and MOF $\geq 20\%$ for 39%, (F=54%, M=3.5%). Compared to 251 naïve patients, the 166 OP-known group had fewer hip fractures, less surgery, and fewer males. There were 26 (6.4%) new fractures and 72 deaths (F=14.7%, M=24.7%), with a median time to death of 140 d.

Conclusions: As part of an institutional program to improve OP treatment our study suggests wider use of FRAX risk assessment independently of BMD data as a screening tool for primary prevention. Male population and past fracture history were often ignored as future fracture risk. DMII was common in our study and stress the need for better fracture risk assessment among those patients. The impact of fracturing is reflected with high surgery and rehabilitation rates along with meaningful death rates. The use of the non-BMD FRAX score can be easily implemented, along with weight, height, BMI, HR and BP in subjects over 50 y of age.

P310

ELDERLY PATIENT SATISFACTION TOWARD SERVICES OF COUNTY EMERGENCY CLINICAL HOSPITAL

C. D. N. Ilea¹, M. Janto¹, C. M. Vesa¹, C. M. Daina¹, F. Cioara¹, D. Zaha¹, L. G. Daina¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objective: At the Oradea County Emergency Clinical Hospital a patient satisfaction questionnaire is implemented, which contains thirty-two questions. Grouping of questions can be done in five main categories. The aim of this study was to see if satisfaction with hospital conditions in elderly patients differs from that of patients under sixty years of age.

Methods: In 2018, 2279 questionnaires were collected. For this analysis, 50 questionnaires were randomly selected from each quarter. A total of 200 satisfaction questionnaires were analyzed, 99 of patients under 60 y of age (group A) and 101 of patients aged 60 and over (group B). Patient satisfaction with hospital conditions (one of the five main categories) is analyzed in seven questions. These questions are: number 24: hospital food?; number 25: food amount?; number 26: compliance of food delivery schedule?; number 27: how many times/d the salon is cleaned?; number 28: cleanliness in the salon? number 29: the quality of bed linen?; number 30: accommodation conditions? Question No. 27 has four variants of answer and the rest of the questions have three possible answers. Significance was assessed with chi-square and Fisher's Exact test with the help of the R program.

Results: The mean age of the two patients groups was 46.35 y and 67.66 y, respectively. They were 54 women and 45 men in group A and 57 women and 44 men in group B. Regarding hospital food (question No. 24) in group A 52.57% said it was good, 36.08% said it was very good and 11.34% said it was not good. In group B the responses were 62%, 33% and respectively 5%. There is no statistically significant difference ($p=0.18$, $\beta=0.094$). To question No. 25, 5.26% said it was too much, 92.63% said it was enough and 2.1% too little in group A and 6.06%, 91.91% and respectively 2.02% in group B. Group A said it received food in time (question No. 26) 94.89% and group B in 92.85% ($p=0.62$). To question No. 27 the answers were: 2.04% once a day, 27.55% twice a day, 26.53% three times a day and 43.87% several times a day in group A and 5%, 28%, 18% and respectively 49% in group B ($p=0.39$). Group A appreciates the level of cleanliness (question No. 28) in the salon as good in 42.85% and very good in 57.15% and group B in 50.49% and respectively 48.51% ($p=0.31$, $\beta=0.38$). The quality of bed linen was appreciated as good in 50.51% and very good in 46.39% by group A and 64.35% and respectively 31.68% by group B. The χ^2 square test gives us a $p=0.05133$ and

$\beta=0.02$. Group A rated the accommodation as very good in 37.5%, as satisfactory in 59.37%, as bad in 3.12% and group B 26.26%, 72.72%, respectively 1.01%. There was no statistically significant difference ($p=0.1$, $\beta=0.025$). In terms of distribution by sex of patient responses over sixty years there was no statistically significant difference to any of the analyzed questions.

Conclusion: This analysis shows that there is no difference in satisfaction with Oradea County Emergency Clinical Hospital in terms of the conditions offered to elderly patients compared to patients under sixty years of age. However, some more specific questions would be needed. Questions like: Did you need an attendant?; Did you need help for your usual activities?; If so, who helped you?, could have significantly different answers for the elderly.

P311

ELDERLY DONORS AND ORGAN DONATION PATTERNS

P. Cotrau¹, V. Hodosan¹, A. Vladu¹, C. Pantis¹, F. Cioara¹, L. G. Daina¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objective: Organ transplantation has become the best treatment for patients with end of stage organ failure. With continued progress in organ transplantation, the demand for organ transplants has increased markedly and led to progressive increases of waiting lists. Current shortage of organs for transplantation has caused changes in patterns of organ donation. The gap between the demand and the supply of human organs for transplantation is on the rise all over the world, as a result there has been a major increase in the number of patients on transplant waiting lists, also in the number of patients dying while on the waiting list. There are several procedures and pathways which can provide practical and effective solutions to this crisis, such as increasingly accepted as organ donors of elderly individuals. Special attention is paid to the retrieval of multiple organs from individual donors and to the acceptance of organs from donors who would previously have been considered too old. The acceptance of organs from elderly donors is clearly attributable to the shortage of donor organs and gradually donor acceptance criteria changed.

Methods: Univariate statistical analysis was performed on data provided by Oradea Organ Procurement Center over the 5 y, between 2013-2017.

Results: From 2013-2017 the total number of patients included in the national transplant program was 301 patients, from which the number of patients 60 years and older was 155 (51.49%). From 301 patients with brain death diagnosis, 89 became real organ donors (29.56%) and of those, over 60 years old, were 28 patients (31.46%). Elderly donors (60 y and older) represented the majority age group of potential donors 127 (59.90% from total of 212 potential donors).

Conclusion: In light of the continuing organ shortage, it is time to re-examine our strategies to encourage organ donation even among the elderly population. Due to risk and complications in donors 60 y and older, kidneys, liver and cornea were suitable for organ donation.

P312

ANTIBIOTIC CONSUMPTION IN THE INTENSIVE CARE UNIT AMONG ELDERLY PATIENTS

V. Hodosan¹, P. Cotrau¹, A. M. Capus¹, C. M. Daina¹, C. Pantis¹, F. Cioara¹, D. Zaha¹, L. G. Daina¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objective: Intensive care units are generally hospitals departments where the consumption of antibiotics is significantly higher compared to medical or surgical wards. The increased use of broad spectrum antibiotics or reserve antibiotics has led to selection of multidrug resistant pathogens. Elderly patients because of the increased number of comorbidities are more susceptible to nosocomial infections.

Methods: The study is a retrospective, observational study conducted in the Clinical County Emergency Hospital of Oradea. The purpose of the study was to analyze the antibiotic consumption in the Intensive Care Unit of the hospital in 2016 and 2017 in patients over 60 y of age. Data was collected using the IT system of the hospital.

Results: In both years, 2016 and 2017, elderly patients (>60 years old) represented the majority of the total number of patients treated in the Intensive Care Unit of the Clinical County Emergency Hospital of Oradea. They represented 67.56% (1493 patients) of the total number of patients treated in 2016 (2210 patients) and 69.36% (1449) of the total number of patients treated in 2017 (2089 patients). Average hospitalization time was 4.05 d in 2016 and 4.37 d in 2017. The costs related to antibiotics consumption for the healthcare of elderly in the Intensive Care Unit increased from 2016, 501.495 RON, to 2017, 660.963 RON. While the number of treated patients decreased from 2016 to 2017 by 2.95% the antibiotic consumption increased with 31.80%, the average antibiotic prescription cost/patient was 333RON in 2016 and 456 RON in 2017. Concerning the antibiotic classes, the following modifications occurred from 2016 to 2017. Tetracycline's consumption increased 6.8 times, from 3.32% in 2016 of the total antibiotic prescription to 25.98% of the total antibiotic prescription in 2017. Second-generation cephalosporin's consumption increased with 51.93%, third-generation cephalosporin's consumption increased with 34.70% while carbapenems were prescribed 21.72% more frequently in 2017 than in 2016. A significant increase was registered among aminoglycosides, 20.20%, and quinolones, 32.76%. In contrary there were classes of antibiotics that were prescribed less frequently in 2017 than in 2016 among elderly patients, macrolides and lincosamides antibiotics, with a frequency reduced by 34.25% and other antibiotics, 18.27% less frequently prescribed in 2017.

Conclusion: Elderly patients represent the majority of patients treated in the Intensive Care Unit. Antibiotic consumption in this category increased significantly from 2016 to 2017. The antibiotic classes responsible for the increase were in the following order according to the magnitude of increase in consumption: tetracyclines, second generation and third generation cephalosporins, quinolones, carbapenemes and aminoglycosides. Given the

substantial increase of 31.80% in antibiotics consumption in the Intensive Care Unit during a very short interval, 1 y, we believe that are necessary immediate measures to optimize rational antibiotic use in this hospital department.

P313

PREVALENCE OF OSTEOPOROSIS IN PATIENTS WITH ARTHROPLASTIES THROUGH THE NATIONAL ENDOPROTHESIS PROGRAM

E. D. Popovici Mut¹, A. M. Popovici Mut¹, K. Bancsik¹, C. M. Vesa¹, F. Cioara¹, L. G. Daina¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objective: The National Orthopaedic Program in Romania is responsible for ensuring specific sanitary materials for the treatment through endoprostheses of patients with articular afflictions, including primary and revision prostheses. In order to be admitted to the program, patients need to be of elderly age and suffer from either degenerative joint diseases or femoral neck, humeral or elbow fractures. A diagnostic study of patients with prostheses was undertaken in order to evaluate the number of people that presented with osteoporosis as a secondary diagnosis.

Method: The study has as a base the patients which went through arthroplasties within the Orthopaedics Ward (63 beds) of the Clinical Emergency County Hospital in Oradea, Bihor, Romania. The analysis was undertaken between the years 2013-2017, utilizing the statistical database of the hospital, specifically the following indicators: total number of treated patients, total number of patients that have endoprostheses, patients with hip arthroplasties, total number of patients with osteoporosis as a secondary diagnosis, median cost per patient treated through endoprosthesis. This study includes all patients who went through the prosthesis procedure aged between 40-80.

Results: In the analysed period a number of 13.955 patients were treated in total, 12.14% (1731 patients) of which underwent an endoprosthetic procedure. Of these patients, more than 70% (1225 patients) suffered hip arthroplasty and over 95% of them (1173 patients) have osteoporosis as a secondary diagnosis, in various stages and of various types. In a time-based evolution, the number of patients with prostheses grew from 245 in 2013 to 506 in 2017. Also, the number of patients with hip arthroplasty grew from 164 patients in 2013 to 371 patients in 2017. This increase is mainly due to the increase in financing of this program, but today there is still a considerable waiting list because of an even higher number of eligible patients. The number of reported patients with a secondary diagnosis of osteoporosis decreased in the analysed period from 399 patients in 2013 to 126 patients in 2017. The median cost per patient treated through this procedure varied between 831 EUR in 2017 and 1185 EUR in 2015 (an average of 1011 EUR).

Conclusions: From the analysis presented above we can conclude that out of the 1731 patient that underwent endoprosthesis procedures more than 70% underwent hip arthroplasty and over

95% presented with osteoporosis as a secondary diagnosis, in various stages and of different types. The number of patients with a secondary diagnosis of osteoporosis decreased in the analysed period. Because of the advanced age of patients that underwent the procedures and the decrease in time in the number of patients with osteoporosis, in order to have a correct evaluation, there is a need for much more precise diagnostic methods.

P314

SEVERE OSTEOPOROSIS IN A FEMALE WITH TYPE 1 DIABETES MELLITUS AND CELIAC DISEASE: CASE REPORT

C. M. Vesa¹, C. D. N. Ilea¹, P. Cotrau¹, D. Zaha¹, F. Cioara¹, A. R. Popa¹, L. G. Daina¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

The prevalence and severity of osteoporosis in type 1 diabetes patients is increased compared to nondiabetic patients mainly because of the insulin deficiency characteristic for these patients, being known that insulin stimulates osteoblasts proliferation and increases collagen formation. Epidemiological data demonstrated that type 1 diabetes mellitus patients have a 6.5-fold increase in risk of hip fractures compared with healthy controls. The association of type 1 diabetes with celiac disease is not rare, celiac disease being also an autoimmune disorder characterised by gluten intolerance, chronic diarrhoea and malabsorption.

We report the case of a 43 years old female of Caucasian origin suffering from type 1 diabetes mellitus for 30 y. She presented in the Internal Medicine-Diabetes Clinic of Emergency Hospital from Oradea for frequent episodes of hypoglycaemia, generalized fatigue, weight loss, abdominal discomfort in the epigastric region, diarrhoea. The gastric symptoms were present for 6 months in the moment of admission. The patient was underweight, BMI was 17.8 kg/m². Upper gastrointestinal tract endoscopy was performed in order to explore the weight loss. The investigation did not reveal any macroscopic modification; fortunately biopsies were taken from the stomach and duodenum. Microscopic examination of biopsies prelevated from the duodenum revealed modifications of the duodenal mucosa: atrophy of the mucosa villi, crypt hyperplasia and increased intraepithelial lymphocytes. Based on the clinical aspect and the endoscopy a diagnosis of celiac disease was established, stage B1, and the patient was given adequate recommendations about a gluten-free diet that she will have to respect. We sent the patient to DXA examination in order to assess the bone fragility of the patient because we suspected an abnormality given the fact that she was underweight and had a chronic malabsorption disease. The investigation revealed low bone mass and severe osteoporosis. T-score was -4.1 in the region of the right femur, -3.9 in the region of the left femur and -4.5 in the lumbar spine. Laboratory exam revealed mild anaemia (Hb=9.8g/dL) and hypocalcaemia, low total calcium (Ca²⁺=7.6 mg/dL) most probable in the context of malabsorption. The patient was referred to an endocrinologist for osteoporosis treatment.

In the presented case we believe that both diseases contributed to the severity of osteoporosis in a relatively young patient. Type 1 diabetes mellitus had a long history and celiac disease was advanced considering the microscopic aspect of the duodenum. The presence of celiac disease should be investigated in type 1 diabetes patients and if the two diseases coexist bone density should be assessed for an early diagnosis of osteoporosis.

P315

ANALYSIS OF OPERATING SUITE ACTIVITY IN A COUNTY EMERGENCY HOSPITAL

A. Vladu¹, K. Bancsik¹, C. D. N. Ilea¹, C. M. Daina¹, F. Cioara¹, L. G. Daina¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objective: The implementation of a continuing development strategy for the quality of health services is an important component of the health system improvement processes. In 2014, the hospital operating suite was renovated and re-equipped within the Romania-Hungary Crossborder Cooperation Program. Providing advanced medical equipment to the operating suite was made in order to improve the quality of medical services. Through the study, we analyzed the medical activity carried out in the operating suite serving the surgical departments of a county emergency hospital.

Methods: A retrospective study was carried out, analyzing the statistical database of the County Clinical Emergency Hospital Oradea in the period 2014-2017. The number of surgical interventions was analyzed in the 11 operating theaters of the operating suite (general surgery - 2 operating rooms, orthopedics and traumatology - 2 operating rooms, thoracic surgery, vascular surgery, neurosurgery, ophthalmology, otorhinolaryngology, buccomaxillo-facial surgery, plastic surgery).

Results: During the analyzed period, the number of beds in the hospital decreased from 917 beds in 2014 to 885 beds in 2017. Also, the number of cases contracted with the National Health Insurance House decreased during the analyzed period. In this context, the number of cases discharged from the hospital slightly decreased from 42,646 cases in 2014 to 41,581 cases in 2017. The number of patients admitted to surgical departments did not change significantly from one year to another (average 14,443 patients/y). The average length of hospitalization on surgical departments decreased from 5.22 d to 3.17 d in 2014-2017. The number of surgical interventions has increased from 9524 patients operated in 2014 to 9875 patients operated in 2017, with the operability index rising from 65% in 2014 to 68% in 2017. The share of surgical interventions in the operating suite related to specialties is in line with the number of beds, so most interventions were performed by general surgery (42.5%), orthopedics and traumatology (22%) and plastic surgery (14%). Surgical interventions done in 1 day of hospitalization was relatively constant (average of 625 cases/y). Mortality per year was relatively constant at 2.3% and deaths within 48 h from surgery decreased from 2.7% to 1.4% in the 2014-2017 period.

Conclusion: The surgical activity in the operating suite after acquiring new equipment and renovation, shows continuous improvement, pointed by the number of patients and the quality indicators. The average length of stay of the patients undergoing surgery and the deaths recorded within 48 h after surgery were reduced. The refurbishment of the operating suite has increased the degree of operability, performing safe surgical interventions. It required a continuous monitoring of the activity within the operating suite, overseeing the functional circuits and a correct sterilization of the surgical instruments.

P316

SURVEY ON OSTEOPOROSIS IN THE ORTHOPEDICS AND TRAUMATOLOGY DEPARTMENTS OF A COUNTY EMERGENCY HOSPITAL

K. Bancsik¹, A. Vladu¹, E. D. Popovici Mut¹, C. Hozan¹, C. M. Daina¹, F. Cioara¹, L. G. Daina¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objective: Osteoporosis is one of the most common diseases in elderly people, with increased costs for the health system and possible development of disability in case of bone fracture. Through the study we analyzed the frequency of osteoporosis in patients admitted to the Orthopedics and Traumatology departments of an emergency county hospital. It is important to raise awareness among medical professionals about the importance of diagnosing this condition associated with bone fracture at admission.

Methods: A retrospective study was carried out, analyzing the statistical data on the number of patients hospitalized in the Orthopedic and Traumatology Departments of the County Clinical Emergency Hospital Oradea during 2013-2017. Patients over 60 y of age who were diagnosed with osteoporosis at the time of admission were included in the study.

Results: In the study period 13836 patients were admitted, 5.69% (788 patients) were diagnosed with Osteoporosis when they were hospitalized. Patients over 60 y diagnosed with osteoporosis reported the total number of patients diagnosed with osteoporosis was 89.59% (706 patients), 82.36% were women and 67.28% had admission fractures. Hip fractures scored the highest incidence (47.89%), and vertebral compressions were present in 14.73% of the cases. The total number of hospitalized cases with hip fracture diagnosis in the reported period without secondary diagnosis of osteoporosis was 2319 vs. 218 cases with secondary diagnosis of osteoporosis. The highest number of cases of osteoporosis in admitted patients was in the age group 70-80 y (42%), patients presenting comorbidities such as hypertension, ischemic cardiopathy, cerebral atrophy or senile dementia, which resulted in decreased compliance to the treatment of osteoporosis.

Conclusion: About 6% of patients hospitalized in the traumatology orthopedic emergency departments had a diagnosis of osteoporosis. This condition is prevalent in women, and in the 70-80 age group. 67% of patients hospitalized with osteoporosis had fractures at admission. Only 9.5% patients had secondary diag-

nosis of osteoporosis. Considering the increased frequency of hip fractures in the number of cases of osteoporosis, there is a subdiagnosis of osteoporosis as pathology. Thus, for a correct diagnosis, it is necessary to develop a guideline for a proper diagnosis and appropriate therapeutic conduct for the elderly patients with fractures at admission.

P317

DENTAL HEALTH OF THE ELDERLY PATIENT WITH OSTEOPOROSIS

M. Janto¹, A. M. Capus¹, C. M. Daina¹, F. Cioara¹, L. G. Daina¹, V. Hodosan¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objective: Ageing determines at the level of the components of the masticatory apparatus, structural and functional modifications that follow the same trait as in the other tissues and organs; their variety is influenced by individual genetics, rhythm of ageing and lifestyle. Osteoporosis can have a direct connection with dental diseases. It can manifest directly at the dental and oral level by affecting the maxilla and the mandible and indirectly by reducing the sustaining of dentition. We effectuated an epidemiologic study regarding the dental health of the elderly patients with osteoporosis that benefits by dental healthcare services.

Method: An epidemiological study was realized in 12 clinics of dental medicine from urban and rural environment (Oradea City – 6 clinics and Oradea Metropolitan Area – 6 clinics), between October-December 2018. In the study were included 134 patients aged 65 or older, that had the diagnosis of osteoporosis specified in their medical records. During the medical examination were analysed the risk factors for dental pathology, the dental pathology and comorbidities.

Results: From the 134 included patients, 74% (99 patients) were women and 55% came from urban environment. The most frequent dental diseases were: tooth loss (90%), tooth decay (85%), dental sensibility (84%), dry mouth sensation (72%), periodontal disease (53%) and gingivitis (52%). The comorbidities were: heart failure (53%), arterial hypertension (42%), osteoporosis (44%), senile insomnia (39%), eye disease (90%), cancer with different locations (27%), other diseases under 20% (genital-urinary diseases, chronic bronchitis, depression, deafness, hematologic diseases, Parkinson disease). The identified risk factors were psychological stress (61%), alcohol consumption (39%), sedentary lifestyle (31%), and smoking (27%).

Conclusion: A great proportion of elderly patients present at least to dental diseases, the most frequent being tooth loss and tooth decay, but also periodontal disease and gingivitis that are present in more than half of the patients. Analysis of the health of the elderly patients reveals an increased morbidity of the examined patients. There were identified multiple risk factors, psychological stress had the greatest proportion. During their lifetime the patients did not address to dental health services for preventive dental check-ups.

P318

EVALUATION OF ANTIBIOTIC PRESCRIPTION PATTERNS IN ROMANIAN DENTISTRY

A. M. Capus¹, E. D. Popovici Mut¹, M. Janto¹, M. F. Popescu¹, A. M. Popovici Mut¹, C. M. Daina¹, F. Cioara¹, L. G. Daina¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objective: Given the alarming increase of multidrug resistant microorganisms incidence, antibiotic overuse must be suppressed or at least limited in all medical fields, including dentistry. The objective of the current research was to evaluate the patterns of antibiotic prescription among dentists in Romania in order to identify possible antibiotic abuse and develop optimal fighting solutions.

Methods: A questionnaire consisting of 11 items was administered to 183 dentists working in private practices in Romania, both in urban and rural environments between September-November 2018.

Results: Regarding first choice of treatment, 72.1% of dentists used amoxicillin (either associated with clavulanate - 51.9%, or without - 20.2%), 12% ampicillin, 8.7% cephalosporines, 4.3% clindamycin and 2.7% doxycycline. The main reason for prescribing antibiotics was postextractionally (53%), followed by periapical conditions (35.5%) and periodontal disease (11.4%). 81.4% of responders recognised patient's age as a criterion influencing their decision to prescribe antibiotics (main threshold reported at 60 years old by 73.7%), whereas 59% of dentists do not adjust the antibiotic posology in relation to the patient's comorbidities (24% will always adjust, 16.9% will occasionally adjust). As far as the treatment duration is concerned, 56.2% of responders claimed a 7 d median period, 37.1% - 5 d, 3.8% - 10 d and 2.7% - 3 d. Although 55.7% of the interviewed dentists admit the existence of antibiotic overuse in their private practices (the main reasons being the faulty recall/adhesion of the elderly patients secondary to the difficult access to dentistry services, followed by the necessity of continuing a self-initiated antibiotic course), only 42.6% of the respondents regard these clinical situations as decisive contributors to the development of multidrug resistant microorganisms.

Conclusions: The variability of the data from this investigation and its irregular distribution advocate for editing and implementing a national antibiotherapy guide in dentistry adjusted to the medical and socioeconomic aspects of the population. Also, a similar research done on a greater scale is needed in order to get a more accurate picture of antibiotic abuse in Romanian dentistry.

P319

IMPACT OF POPULATION-BASED OR TARGETED INTERVENTIONS ON FRACTURE INCIDENCE

N. C. Harvey¹, J. A. Kanis², E. Liu³, M. Lorentzon⁴, E. V. McCloskey⁵, H. Johansson⁵

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK, ²Centre of Metabolic Bone Diseases, University of Sheffield, Sheffield, UK, ³Mary McKillip Health Institute, Australian Catholic University, Melbourne, Australia, ⁴Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ⁵Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK

Objective: To investigate the impact of population level or targeted alterations to BMD on the incidence of fractures.

Methods: We used a simulated cohort of 50,633 women with UK age and BMI distribution, and prevalence of other clinical risk factors based on FRAX cohorts. We used FRAX probability of major osteoporotic fracture (MOF: hip, clinical vertebral, wrist, proximal humerus) and hip fracture, (with femoral neck BMD) to calculate the expected number of fractures per 1000 person-years (py), stratified by 10 year age band from 50 y. We then investigated the effect of i: bringing all individuals with T-score below -2.5 to be exactly -2.5 (targeted intervention); ii: increasing the entire BMD distribution by 0.5SD (population intervention).

Results: In the base model, the number of expected MOF ranged from 6.9 to 24.6, and hip fracture from 1.1 to 13.6, per 1000py from the lowest (50-59 y) to highest (90-99 y) age band. The targeted intervention led to between a 4.2 and 15.4% relative reduction in the number of MOF and between a 21.3 and 24.5% relative reduction in the number of hip fractures. Percent change for MOF, but less so hip fracture, rose with age. Increasing the population BMD distribution by 0.5SD led to an 13-16% relative reduction in the number of MOF from 50-89 y (10.6% reduction 90-99 y), and a 45.2% relative reduction in hip fracture at 50-59 y, reducing with age to a 14.6% relative reduction in the oldest age band. Accounting for the cohort age structure, the total MOF (hip fracture) saved were 625 (506) with -2.5 as minimum T-score, and 1010 (667) when increasing population BMD by 0.5 SD.

Conclusions: Both population-based and targeted strategies reduced the numbers of expected incident fractures, with contrasting relative impacts by age. These findings support the investigation of both population level interventions and those targeted at high fracture risk groups, for the prevention of osteoporosis-related fractures.

Acknowledgement: HJ and EM are joint senior author

P320

APPENDICULAR LEAN MASS DOES NOT PREDICT INCIDENT FRACTURES INDEPENDENTLY OF BMD: RESULTS FROM THE WOMEN'S HEALTH INITIATIVE (WHI) COHORT

N. C. Harvey¹, J. A. Kanis², E. Liu³, C. Cooper¹, M. Lorentzon⁴, C. Crandall⁵, H. Johansson⁶, E. V. McCloskey⁶

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK, ²Centre of Metabolic Bone Diseases, University of Sheffield, Sheffield, UK, ³Mary McKillop Health Institute, Australian Catholic University, Melbourne, Australia, ⁴Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ⁵School of Medicine, University of California, Los Angeles, USA, ⁶Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK

Objective: To investigate the predictive value of appendicular lean mass (ALM) for fracture outcomes amongst older postmenopausal women in the Women's Health Initiative (WHI), independent of BMD, prior falls and FRAX probability.

Methods: The WHI is a long-term US national health study focused on strategies for preventing heart disease, breast and colorectal cancer, and osteoporotic fractures in postmenopausal women. We used an extension of Poisson regression to investigate the relationship between baseline ALM (measured using DXA and corrected for height) and incident major osteoporotic fracture [MOF (hip, clinical vertebral, wrist or proximal humerus)], and hip fracture. All associations were adjusted for age, time since baseline and randomization group, or additionally for femoral neck BMD T-score, prior falls or FRAX probability (MOF without BMD) and are reported as hazard ratio (HR) for first incident fracture per SD increment in ALM/height².

Results: Complete data were available for 11,187 women (mean(SD) age: 63.3(7.4) years. Mean(SD) ALM was 37.8(5.4) kg. In the base models (adjusted for age and follow-up time), greater ALM/height² was associated with lower risk of incident MOF (HR/SD:0.87; 95%CI:0.82,0.93) and hip fracture (HR/SD:0.81; 95%CI:0.72,0.92). The associations appeared independent of prior falls and marginally attenuated by FRAX probability [MOF (HR/SD:0.94; 95%CI:0.88,1.01); hip (HR/SD:0.87; 95%CI:0.77,0.99)], but were attenuated to null after adjustment for femoral neck T-score: MOF (HR/SD:0.96; 95%CI:0.90,1.03); hip (HR/SD:0.91; 95%CI:0.80,1.03).

Conclusion: In the WHI, and consistent with our findings in older men (MrOS cohorts), DXA-ALM was not predictive of future fracture after adjustment for femoral neck T-score. Other measures of lean mass, such as creatine dilution and pQCT, may offer greater utility than DXA-derived indices in the assessment of sarcopenia.

Acknowledgement: HJ and EM are joint senior author. The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201600018C,

HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. WHI project:3572.

P321

CORRELATION OF DXA WITH DISEASE DURATION, CHANGES IN SACROILIAC JOINTS ON MAGNETIC RESONANCE IMAGING, DISEASE ACTIVITY AND SERUM LEVELS OF SCLEROSTIN AND DICKKOPF-1 IN PATIENTS WITH SPONDYLOARTHRITIS

O. Iaremenko¹, I. Shynkaruk¹, D. Fedkov¹, K. Mazanko¹

¹Bogomolets National Medical University, Kyiv, Ukraine

Objectives: To reveal the presence of osteopenia/osteoporosis in patients (pts) with spondyloarthritis (SpA) and to determine its correlation with disease duration, disease activity, active changes in sacroiliac joints (SIJ) on MRI, serum level of bone turnover markers - sclerostin (Scl) and dickkopf-1 (Dkk-1).

Methods: DXA was performed for 30 pts with SpA (mean age 39.57±10.67, mean disease duration – 8.24±7.71 y). Active inflammatory lesions in SIJ were evaluated with Spondyloarthritis Research Consortium of Canada (SPARCC) MRI SIJ score (0-72). Disease activity was measured by Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI, mm), C-reactive protein (CRP, mg/l) and erythrocyte sedimentation rate (ESR, mm/h). Scl and Dkk-1 serum levels (pmol/l) were conducted by ELISA.

Results: Mean value of DXA parameters were BMD – 0.76±0.09, T-score – -0.09±0.90, Z-score – 0.28±0.89 (forearm); BMD – 0.94±0.15, T-score – -1.28±1.28, Z-score – -1.03±1.27 (spine); BMD – 0.84±0.16, T-score – -0.92±0.94, Z-score – -0.65±1.07 (hip). Mean value of biomarkers were: Scl – 33.0±14.8, Dkk-1 – 96.2±27.2. Osteoporosis was present in 4 (13.3%), osteopenia - in 20 (66.7%) SpA pts. Scl showed significantly correlation with Z-score (r=0.624, p=0.013) and T-score for spine (r=0.557, p=0.031). Dkk-1 correlated with BASDAI (r=0.725, p=0.002), ASDAS-CRP (r=0.636, p=0.011), ASDAS-ESR (r=0.745, p=0.001) and SPARCC score (r=0.552, p=0.033). Disease duration negatively correlated with total T-score (r=-0.411, p=0.024). BMD at hip showed negative correlation with CRP (r=-0.365, p=0.048). There were no other correlations.

Conclusion: Bone density in pts with SpA shows negative correlation with disease duration and CRP, and positive correlation with Scl. Dkk-1 significantly positively correlated with disease activity scores and SPARCC SIJ.

P322

EFFECTS OF TESTOSTERONE THERAPY ON BONE MINERAL DENSITY AND BONE TURNOVER MARKERS IN OBESE DIABETIC HYPOGONADAL MALES: RESULTS OF TWO-YEAR CLINICAL TRIAL

K. Groti Antonic¹, B. Antonic², A. Sabati Rajic¹

¹University Medical Center Ljubljana, ²Blaz Antonic s.p., Ljubljana, Slovenia

Objective: Both hypogonadism and type 2 diabetes mellitus negatively affect BMD. We evaluated changes in bone remodeling parameters due to testosterone replacement therapy (TRT).

Methods: 55 obese diabetic hypogonadal males participated in a 2-y, double-blind, placebo-controlled study. Bone turnover markers (BTM) C-telopeptide of type I collagen (CTX) and procollagen I N-terminal propeptide (PINP), estradiol, 25-hydroxyvitamin D, total, calculated free and calculated bioavailable testosterone levels were assessed at baseline, 12 and 24 months. BMD changes were evaluated after 24 months using DXA. T-test and Wilcoxon's signed rank were used to detect changes from baseline. Normality of distribution of data was assessed with Shapiro-Wilk test.

Results: Participants were randomized into two groups. Group T (n=28) received 1000 mg testosterone undecanoate (TU) both years of the study while group P (n=27) received placebo first year and TU second year. Results show decrease in median CTX from baseline of 1055 (676 to 1344) pmol/l to 911 (556 to 1152) pmol/l after one year of placebo (p=0.012), then to 453 (365 to 665) pmol/l after one year of TRT (p<0.001) in group P and from 887 (648 to 1496) pmol/l to 504 (262 to 804) pmol/l after first year of TRT (p<0.001), then to 372 (165 to 599) after second year of TRT (p<0.001) in group T. Median PINP did not change from 31.4 (27.1 to 40.3) µg/l baseline at statistically significant level after one year of placebo (p=0.469) in group P but decreased to 28.0 (23.6 to 32.0) µg/l after one year of TRT (p=0.009); in group T a decrease from 30.9 (21.9 to 35.3) µg/l to 26.2 (18.6 to 32.1) µg/l was observed after first year of TRT (p=0.005), then to 20.1 (17.8 to 26.5) µg/l after second year of TRT (p<0.001). There were no changes in levels of estradiol. DXA showed no changes in femoral neck BMD in 32 patients from both groups P (n=16) or T (n=16) while a statistically significant increase in lumbar spine BMD by 0.075±.114 g/cm² (95%CI: 0.014 to 0.136; p=0.019) has been observed in group T following two years of TRT with no change observed in group P. TRT normalized testosterone levels in both groups within 12 months.

Conclusions: BTM decreased significantly after TRT and improvement of lumbar spine BMD was observed after 2 y of TRT.

P323

COMMERCIAL LABORATORY REPRODUCIBILITY OF SERUM CTX IN CLINICAL PRACTICE


S. Hindi¹, E. Vittinghof², A. Schafer¹, S. Stuart Silverman³, D. Bauer⁴

¹Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California, San Francisco, ²Department of Epidemiology & Biostatistics, University of California, San Francisco, ³Cedars Sinai Medical Center, UCLA School of Medicine, Los Angeles, ⁴Departments of Medicine and Epidemiology & Biostatistics, University of California, San Francisco, USA

Objective: The use of bone turnover markers (BTM) in clinical practice has been limited by several factors, including assay heterogeneity. In 2011, the IOF/IFCC selected serum collagen type I crosslinked C-peptide (s-CTX) as the reference standard for bone resorption. This study aims to determine the within- and between-laboratory reproducibility for s-CTX assays performed under routine clinical conditions.

Methods: To create standardized pools, serum was collected from ten premenopausal women and ten postmenopausal women. Premenopausal sera were pooled to approximate a population with low bone-turnover; postmenopausal sera were pooled to approximate a population with high bone-turnover; and a third pool was created by evenly mixing sera from pre- and postmenopausal women. Multiple identical aliquots from each pool were created and frozen; all were labeled as routine clinical specimens with factitious patient identifiers. To evaluate longitudinal reproducibility, an aliquot from each of the 3 pools was sent to 4 US commercial laboratories on 5 dates over a 6-month period. To evaluate within-run reproducibility, on the 5th date, each lab received 5 aliquots from each pool. Three labs (Mayo, ARUP, and Quest) used the Roche Diagnostics Elecsys assay, and one (Esoterix/LabCorp) used the IDS-iSYS assay. Reproducibility was assessed using the coefficient of variation (CV) with 95%CI. Labs were unaware of the investigation.

Results: Across labs, mean s-CTX values were 423, 533, and 480 for the premenopausal, postmenopausal, and mixed pools, respectively. The premenopausal pool longitudinal CVs ranged from 5.0% to 18.8%; postmenopausal pool CVs ranged from 3.4% to 19.3%; and mixed-pool CVs ranged from 3.3% to 16.0%. Between-lab patterns were similar for each pool, so results from all 3 pools are combined for this analysis. The longitudinal reproducibility for Esoterix/LabCorp (IDS assay) was higher (CV=18.0%, CI: 13.0-28.9) than for the other labs (Roche assay) (Figure). Within-run reproducibility was also highest for Esoterix/LabCorp (CV=16.3%, CI: 11.9-26.2) compared to the other labs (CVs 9.2-12.3%).



Conclusion: Longitudinal and within-run reproducibility of s-CTX varies across US commercial labs. Reproducibility was poorer for Esoterix/LabCorp, which uses the IDS assay, compared to the other 3 labs, which use the Roche assay. Our results indicate that better commercial lab s-CTX assay calibration is needed.

P324 NICOTINE TREATMENT INDUCES PROLIFERATION VIA β -CATENIN-MEDIATED BCL-XL EXPRESSION IN OSTEOCLAST PRECURSOR CELLS

T. W. Tai¹, Y. L. Chan², C. Y. Chen¹, C. F. Lin³

¹Department of Orthopaedics, National Cheng Kung University Hospital, Tainan, ²Department of Life Science, Chinese Culture University, Taipei, ³Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

Osteoporosis results in a great deal of disability and increases the risk of death especially when hip fracture occurs. Smoking is one of the risk factors related to osteoporosis. Although smoking has been proved to directly lower the BMD which may cause osteoporosis and fracture, the underlying mechanism has not been well investigated. Little has been reported that nicotine has indirect effect in regulating osteoclast growth and altering RANK-RANKL-OPG system. In our study, we found that nicotine induced cell proliferation via ILK/Akt regulated ERK activation, followed by β -catenin-mediated Bcl-xL expression. Pharmacological inhibition of ERK and its upstream molecule results in inhibition of Bcl-xL expression. This results provides a new evidence of how cigarette smoking causes osteoporosis and a possible target in treating osteoclast associated bone disorder.

P325 KUWAIT OSTEOPOROSIS GUIDELINES FOR MANAGEMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS IN ADULT WOMEN AND MEN

T. Alessa¹, N. Al-Ali¹, F. Al-Jarki¹, F. Abutiban¹, S. Al-Kandari¹, S. Al-Enezi¹, A. Al-Obaid¹

¹Kuwait Osteoporosis Society, Safat, Kuwait

Objective: Identifying and treating women and men at age ≥ 18 with high risk for glucocorticoid induced osteoporotic fractures.

Methods: Duration of systemic glucocorticoid therapy of ≥ 3 months selected as an indication to screen for increased risk for osteoporotic fractures. FRAX-based intervention threshold (IT) models used in the UK, USA, Canada and Lebanon were evaluated. A proportion of subjects considered for therapy were based on IT that was set at a 10-y probability of a major osteoporotic fracture (MOF) equivalent to a woman with a prior fragility fracture and a BMI equal to 30.0 kg/m² without BMD or other clinical risk factors. The lower assessment threshold (LAT) was set at a 10-y probability of a MOF in women with BMI equal to 30.0 kg/m², no previous fracture and no clinical risk factors. The upper assessment threshold (UAT) was set at 1.2 times the IT. Other populations consideration for therapy was based on Z-scores (age <40) and on history of a fragility fracture.

Results: Presence of fragility fracture, regardless of glucocorticoid duration, age and BMD, is an indication for osteoporosis therapy. Subjects age <40 with Z-score <-3 at hip or spine, >10%/y BMD loss at hip or spine, or on very high glucocorticoid dose (prednisone >30 mg/d and a cumulative dose of >5 g in the past year) are recommended to receive osteoporosis therapy. In subjects age ≥ 40 , the risk for MOF has to be higher than the age-specific IT which varied from 2.3 to 23% at the age of 40 and 90 y, respectively (Figure). Patients also require therapy if MOF risk is higher than the UAT when BMD is unknown.

10-year probability (%)




Figure: Intervention thresholds for Kuwait as set by FRAX-based 10-year probabilities (%) of a major osteoporotic fracture¹

Conclusion: FRAX-based IT based on fracture probabilities in subjects age ≥ 40 and Z-score intervention threshold in subjects age < 40 , offers a practical method for the detection of subjects at high fracture risk. Subjects with history of fragility fractures should be treated regardless of BMD measurements.

Reference: 1. Johansson H et al. Osteoporos Int 2017;28:3099.

Disclosures: consultant/speaker's bureau/advisory activities

P326

VITAMIN D STATUS IN SLE PATIENTS AND ITS ASSOCIATION WITH CLINICAL AND LABORATORY PARAMETERS

A. Elashmawey¹

¹Rheumatology Department, Cairo, Egypt

Objective: The relationship between vitamin D and systemic lupus erythematosus (SLE) is controversial. We, therefore, planned this study to comparatively determine vitamin D level in SLE patients and control subjects.

Methods: This study was carried out at Al-Hussein University Hospital during the period from January 2013 to March 2014. This study was carried out on 60 persons that age from 25 y to 50 y and divided in to two groups: **Group A:** 30 patients with SLE fulfilling at least 4 of the American College of Rheumatology of SLE taken from outpatient clinic of Physical Medicine and Rheumatology Department. There were 27 female and 3 male. **Group B:** 30 healthy volunteers who participated in the study as a control group. **Patients were subjected to the following procedures:**

- **Clinical:** Careful history and general clinical examination as well as musculoskeletal examination.
- **Laboratory investigations:** Serum concentrations of 25(OH) Vit D, CBC, ESR, liver function tests (ALT, AST and bilirubin), kidney function tests (urea and creatinine), random blood glucose, serum calcium (Ca), & PTH.
- **Statistical analysis.**

Results:

- In our study, patients with SLE had significantly lower serum 25(OH) Vit D level than controls.
- We found that 90% of patients had low vitamin D, (26.7%) of the patients had deficient of vitamin D and (63.3%) of the patients had insufficient of vitamin D.
- We found that 25(OH) Vit D level had a statistically significant inverse correlation with arthritis, photosensitivity and proteinuria.
- We found that 25(OH) vit D level had a statistically significant inverse correlation with the level of anti-dsDNA titer.
- In our study, we did not find any statistical association between vitamin D insufficiency or deficiency with disease duration.
- In our study, we found that no significant correlation was observed between vitamin D levels and SLEDAI scores.

P327

EVALUATION OF IRON ACCUMULATION IN POSTMENOPAUSAL WOMEN AND THEIR AGE-RELATED CORRELATION TO BONE MINERAL DENSITY: A CROSS-SECTIONAL STUDY

Y. Gao¹, Y. J. Xu¹

¹The Second Affiliated Hospital of Soochow University, Suzhou, China

Objectives: To establish normal reference values for serum ferritin and evaluate iron accumulation in healthy Chinese subjects and investigate age-related relationships between body iron stores and BMD.

Methods: This cross-sectional study included 11,037 healthy Chinese subjects aged 20-90 y. Serum ferritin concentrations were measured by electrochemiluminescence immunoassay, and the reference values were calculated with respect to sex and age. BMDs of the lumbar spines and femur necks of 4979 subjects were measured by DXA. The patterns of age-related BMD changes were visualized and correlations between serum ferritin levels and BMD were statistically analyzed in different age-stratified groups.

Results: The concentrations of serum ferritin remained relatively stable in men and premenopausal women, while a dramatic change occurred in postmenopausal women. Based on the age-related trend of changes in serum ferritin concentrations in women, we categorized the subjects into three groups, namely ≤ 50 y, 51-75 y, and ≥ 76 y, for each sex and then analyzed the correlation between ferritin concentrations and BMD. Serum ferritin level was negatively correlated with BMD of the lumbar spines and femoral neck only in women in aged 51-75 y ($r = -0.276$ and -0.227 , respectively; $P < 0.001$). Furthermore, when we divided serum ferritin into quartiles, the odds for prevalent osteopenia and osteoporosis were 2.35-fold (95% CI=1.44-3.84) and 3.16-fold (95% CI=1.34-7.49) higher in women in the highest quartile, respectively, compared with those in the lowest quartile.

Conclusions: This study has identified the association between iron accumulation and bone weakening. Therefore, our findings bring up a clinical awareness that it is important to measure serum ferritin in postmenopausal women aged 51-75 y, and interrupt the process of iron accumulation in body may considered as a noticeably efficient intervention for iron overload-associated bone disease.

Acknowledgement: ClinicalTrials.gov Identifier: NCT03512743, Registered May 1, 2018- Retrospectively registered, <https://clinicaltrials.gov/ct2/show/NCT03512743>

P328

INFLUENCING FACTORS ASSOCIATED WITH LUMBAR SPINE AND FEMORAL NECK BONE MINERAL DENSITY IN POPULATION AGED 50 YEARS AND OLDER IN SUZHOUY. Gao¹, Y. J. Xu¹¹The Second Affiliated Hospital of Soochow University, Suzhou, China

Objective: To investigate the correlations between the gender- and body-site-specific factors and BMD at the lumbar spine and femoral neck in population aged ≥ 50 y and older in Suzhou.

Methods: A total of 2602 subjects who had undergone comprehensive routine health examinations in our hospital from January 2015 to December 2017 were enrolled in this study. The data of age, height, weight, waist circumference and blood pressure were collected, the BMD of lumbar spine and femoral neck was measured, and other biochemical markers and serum tumor markers were assayed.

Results: Multiple linear regression analysis showed that age, waist circumference and ALP were the risk factors for the decline of bone mass in lumbar spine or femoral neck, while height, BMI and systolic blood pressure were protective factors. In addition, serum ferritin is an important risk factor for the decline of BMD in women over 50 y of age. Further logistics regression analysis showed that older age, low height, low BMI and high ALP level may increase the risk of osteopenia or osteoporosis in both men and women. Among women, high serum ferritin level was another important factor for osteoporosis.

Conclusion: This study revealed the relationship between gender- and body-site-specific factors and BMD in people over 50 years old. The older age and high ALP are the risk factors of bone loss in both two genders, while height and BMI have certain protective effect on bone mass. At the same time, iron accumulation in post-menopausal women will further increase the risk of osteoporosis.

Table 1 Baseline characteristics of the study population

	Men(n=1587)	Women(n=1015)
Anthropometric indicators		
age (year)	59.6 ± 8.4	59.2 ± 7.4
height (cm)	169.8 ± 6.0	158.1 ± 5.5
weight (kg)	72.4 ± 9.6	60.4 ± 8.4
BMI (kg/m ²)	25.1 ± 2.9	24.2 ± 3.1
waist circumference (cm)	85.7 ± 7.9	79.4 ± 8.1
systolic blood pressure (mmHg)	131.5 ± 17.2	131.4 ± 18.8
diastolic blood pressure (mmHg)	82.9 ± 11.1	77.7 ± 11.3
BMD		
lumbar spine BMD (g/cm ²)	1.103 ± 0.159	1.023 ± 0.169
femoral neck BMD (g/cm ²)	0.941 ± 0.128	0.884 ± 0.133
normal (n/%)	1116(70.3%)	507(50.0%)
osteopenia (n/%)	442(27.9%)	384(37.8%)
osteoporosis (n/%)	29(1.8%)	124(12.2%)
Serum biochemical markers		
TBIL (µmol/L)	13.3 ± 5.0	11.5 ± 4.3
TP (g/L)	73.0 ± 4.1	74.1 ± 4.3
AG	1.6 ± 0.3	1.5 ± 0.2
ALT (U/L)	22.0 (16.0- 31.0)	17.0 (13.0- 23.0)
AST (U/L)	22.0 (18.0- 26.0)	20.0 (17.0- 24.0)
ALP (U/L)	73.0 (62.0- 86.0)	77.0 (64.0- 92.0)
γGGT (U/L)	30.0 (20.0- 48.0)	18.0 (14.0- 27.0)
LDH (U/L)	164.1 ± 32.6	171.5 ± 32.7
TC (mmol/L)	5.10 ± 0.90	5.42 ± 0.96
TG (mmol/L)	1.5 (1.0- 2.3)	1.4 (1.0- 2.0)
HDL (mmol/L)	1.20 ± 0.29	1.39 ± 0.33
LDL (mmol/L)	3.08 ± 0.763	3.24 ± 0.82
UREA (mmol/L)	5.32 ± 1.28	4.96 ± 1.209
CREA (µmol/L)	73.9 ± 11.6	53.8 ± 9.2
URCA (µmol/L)	352.0 (305.0-403.0)	268.0 (227.0-310.0)
GLU (mmol/L)	5.4 ± 1.4	5.2 ± 1.2
HbA1c (%)	5.9 ± 0.9	5.8 ± 0.8
Serum tumor markers		
CA19-9 (kU/L)	6.570 (4.620- 10.030)	6.910 (4.855- 10.320)
NSE (ng/ml)	2.040 (1.700- 2.560)	2.000 (1.652- 2.490)
CEA (ng/ml)	1.340 (0.890- 2.020)	0.985 (0.690- 1.508)
CA242 (IU/ml)	2.530 (1.840- 3.850)	2.610 (1.950- 4.130)
SF (µg/L)	110.1 (70.1-174.2)	57.8 (28.1-103.6)
β-HCG (mIU/ml)	0.200 (0.130- 0.300)	0.180 (0.110- 0.270)
AFP (µg/L)	1.090 (0.760- 1.640)	1.000 (0.670- 1.600)
CA125 (ng/ml)	7.670 (5.590- 10.438)	6.580 (4.840- 9.450)
CA153 (ng/ml)	4.370 (2.875- 7.605)	4.160 (2.780- 7.188)
HGH (ng/ml)	0.140 (0.070- 0.330)	0.130 (0.060- 0.310)
fPSA (ng/ml)	0.200 (0.120- 0.350)	0.030 (0.020- 0.040)

Table 2 Correlation analysis of BMD and body composition influencing factors

Variables	Men				Women			
	lumbar spine BMD		femoral neck BMD		lumbar spine BMD		femoral neck BMD	
	r	p	r	p	r	p	r	p
Anthropometric indicators								
age	0.018	0.482	-0.144**	0.000	-0.560**	0.000	-0.474**	0.000
height	0.180**	0.000	0.210**	0.000	0.295**	0.000	0.299**	0.000
weight	0.232**	0.000	0.334**	0.000	0.278**	0.000	0.406**	0.000
BMI	0.167**	0.000	0.265**	0.000	0.128**	0.000	0.265**	0.000
waist circumference	0.132**	0.000	0.241**	0.000	0.041	0.201	0.153**	0.000
systolic blood pressure	0.089**	0.000	0.025	0.321	-0.081*	0.011	-0.06	0.058
diastolic blood pressure	0.058*	0.022	0.068**	0.008	0.046	0.149	0.066*	0.039
Serum biochemical markers								
TBIL	-0.004	0.863	0.018	0.484	-0.057	0.067	-0.013	0.671
TP	-0.013	0.603	0.031	0.215	-0.040	0.206	0.001	0.981
AG	-0.016	0.520	0.047	0.060	-0.014	0.646	0.007	0.812
ALT	0.031	0.221	0.082**	0.001	0.020	0.530	0.049	0.117
AST	-0.018	0.466	-0.015	0.538	-0.051	0.106	-0.044	0.163
ALP	-0.159**	0.000	-0.186**	0.000	-0.360**	0.000	-0.235**	0.000
γGGT	0.027	0.284	0.078**	0.002	-0.003	0.913	0.064*	0.043
LDH	0.025	0.315	-0.005	0.842	-0.156**	0.000	-0.130**	0.000
TC	-0.005	0.850	0.020	0.438	-0.095**	0.002	-0.095**	0.002
TG	0.046	0.066	0.154**	0.000	-0.003	0.924	0.012	0.707
HDL	-0.034	0.190	-0.091**	0.000	-0.027	0.407	-0.056	0.082
LDL	-0.011	0.660	-0.008	0.756	-0.088**	0.006	-0.095**	0.003
UREA	0.013	0.595	-0.007	0.781	-0.091**	0.004	-0.073*	0.020
CREA	0.074**	0.003	0.002	0.943	0.012	0.706	-0.029	0.352
URCA	0.077**	0.002	0.118**	0.000	0.038	0.230	0.046	0.145
GLU	0.077**	0.002	0.091**	0.000	-0.086**	0.006	-0.030	0.342
HbA1c	0.093**	0.001	0.064*	0.016	-0.067*	0.041	-0.046	0.166
Serum tumor markers								
CA19-9	0.074**	0.004	0.010	0.684	-0.050	0.114	-0.055	0.087
NSE	0.028	0.260	0.042	0.095	-0.026	0.410	-0.017	0.598
CEA	-0.029	0.250	-0.047	0.063	-0.107**	0.001	-0.113**	0.000
CA242	0.020	0.435	0.023	0.378	0.011	0.732	-0.011	0.735
SF	0.022	0.386	0.050*	0.048	-0.286**	0.000	-0.241**	0.000
β-HCG	0.029	0.263	0.038	0.142	-0.082*	0.011	-0.106**	0.001
AFP	-0.017	0.501	-0.034	0.194	0.002	0.940	0.008	0.813
CA125	-0.005	0.834	0.029	0.255	0.051	0.103	0.013	0.684
CA153	0.026	0.304	0.024	0.331	-0.032	0.313	-0.033	0.297
HGH	-0.022	0.448	-0.049	0.089	0.000	0.997	0.041	0.280
fPSA	0.028	0.283	-0.074**	0.004	-0.072	0.107	-0.067	0.129

R is the correlation coefficient,*P < 0.05, **P < 0.001.

Table 3 Multiple regression analysis to identify significant determinants of BMD in men

Variables	lumbar spine BMD			femoral neck BMD		
	β	SE	p	β	SE	p
age				-0.001	0.000	0.012
height	0.006	0.001	0.000	0.005	0.001	0.000
BMI	0.018	0.003	0.000	0.016	0.002	0.000
waist circumference	-0.005	0.001	0.000	-0.003	0.001	0.004
systolic blood pressure	0.001	0.000	0.002			
ALP	-0.001	0.000	0.000	-0.001	0.000	0.000
HbA1c	0.022	0.008	0.007			

Table 4 Multiple regression analysis to identify significant determinants of BMD in women

Variables	lumbar spine BMD			femoral neck BMD		
	β	SE	p	β	SE	p
age	-0.010	0.001	0.000	-0.007	0.001	0.000
height	0.006	0.001	0.000	0.005	0.001	0.000
BMI	0.010	0.002	0.000	0.018	0.002	0.000
waist circumference				-0.002	0.001	0.009
systolic blood pressure	0.001	0.000	0.017			
ALP	-0.002	0.000	0.000	-0.001	0.000	0.000
SF	-0.000220	0.000	0.004	-0.000162	0.000	0.005




Fig. 1 The risk of osteopenia or osteoporosis in men with different risk factors




Fig. 2 The risk of osteopenia or osteoporosis in women with different risk factors

P329

DRUGS THAT MAY HARM BONE: ASSUAGE THE RISK

S. J. B. Bajuifer¹, A. H. A. Elsalmawy¹, F. A. A. Alhijili¹

¹Alnoor Specialist Hospital KSA, Makkah, Saudi Arabia

Objective: Glucocorticoid, proton pump inhibitors, selective serotonin reuptake inhibitors (SSRIs), certain antiepileptic drugs, and aromatase inhibitors have significant adverse effects on bone. Healthcare providers should monitor the bone health of patients on these agents, supplement their intake of calcium and vitamin D, encourage weight bearing exercise, and initiate osteoporosis-prevention treatment as indicated.

Methods: We updated our statistics among osteoporosis therapies users that reported fracture and BMD among oral GC users. We restricted the analysis to GC initiators (≤6 months) and chronic GC users (>6 months). We estimated the annual probability of vertebral fracture (primary), nonvertebral fracture and percentage change in lumbar spine and femoral neck BMD.

Baseline bone mineral testing was obtained when starting treatment with any of those drugs inducing osteoporosis. We started therapy if the patient's T-score is <-2.0 or if she has any of at

least two of the following fracture risk factors score, <-1.5, age over 65, family history of hip fracture, personal history of fragility fracture after age 50, low BMI (<20 kg/m²), Current or prior history of tobacco use, oral glucocorticoid use for longer than 6 months. Patients with a T-score ≥-2.0 and no risk factors should have BMD reassessed after 1-2 y. Antiresorptive therapy with denosumab 60 mg and evaluation for other secondary causes of bone loss was initiated.

Results: The annual incidence of vertebral and nonvertebral fracture was 4% (93% CrI = 2.8-8.2) and 2.6% (95% CrI = 1.2-4.2) among GC initiators, and 3.2% (95% CrI = 1.8-5.0) and 3.0% (95% CrI = 0.8-5.9) among chronic GC users. There was a nonsignificant effect of group-level variables (mean age, mean BMD, mean GC daily dose, patients with previous vertebral fractures, proportion of women and adjuvant used) on vertebral fracture rate.

Conclusion: Vertebral fracture incidence among GC initiators at Alnoor Specialist hospital is high. Our findings suggest that fracture incidence among oral GC users may be more common than previously estimated. Optimizing GC-induced osteoporosis management during early exposure to GC is essential to prevent fractures.

P330

RELATIONSHIP BETWEEN VITAMIN D SERUM STATUS AND INSULIN RESISTANCE, CARDIOVASCULAR RISK FACTORS AND HYPERTRIGLYCERIDEMIC WAIST PHENOTYPE

M. S. Rashidbeygi¹, D. R. Mirzaei¹

¹Department of Community Nutrition, School of Nutrition and Food Science, Tehran University of Medical Sciences (TUMS), Tehran, Iran

Objective: Recent studies have shown that Vitamin D deficiency is very common in around the world especially in Iranian. Vitamin D deficiency are associated with lipid metabolism. Relationship between vitamin D levels and waist circumference (WC) has been found. Purpose of this study is detecting relationship between vitamin D status and cardiovascular risk factors and hypertriglyceridemic waist phenotype (HTGWP).

Methods: This cross-sectional study was conducted on 265 Tehrani healthy adults. HTGWP was described as serum triacylglycerol concentrations 150 mg/dL and concurrent WC 88 cm (women) and 102 cm (men). Serum glucose, lipids profile, liver enzymes, hs-Crp and body composition were measured in a fasting state.

Results: The mean age (\pm SD) of the participants was 35 \pm 8.78, and the mean BMI was 25.93 \pm 4.8. Vitamin D mean was 22.9 \pm 20.8 and waist mean was 88.8 \pm 12.5. the association of vitamin D status and cholesterol and LDL was significant ($p=0.03$) and ($p=0.018$). considering the association between vitamin D status and phenotype in adjusted model was significant for phenotype 3 (TG >150 and WC<102 in men and WC<88 in women), OR(95%CI) was 20.53(1.34-313.21) and phenotype4 (TG <150 and WC<102 in men and WC<88 in women) OR(95%CI) was 9.21(1.60-52.98), p for trend ($p=0.006$) and ($p=0.04$). We saw the significance of vitamin D in regression models among phenotypes 3 and 4.

Conclusions: We founded significant association between vitamin D status and phenotypes of hypertriglyceridemic waste. Also, there was a relationship between vitamin D and lipid profiles. There is a direct correlation between TG and waist circumference in insulin resistance, in Tehrani healthy adults. Our suggestion for further studies is to do more sampling or to do either RCT or experimental studies, check the status of vitamin D.

P331

VASCULAR RISK AND SERUM TNF A LEVELS IN PATIENTS WITH ACUTE CORONARY SYNDROME AND RHEUMATOID ARTHRITIS

V. Popova¹, A. Batalov¹, Z. Vazhev², M. Geneva- Popova³, S. T. Popova¹, K. Kraev¹, A. Ivanov⁴

¹Medical University Plovdiv. Medical Faculty, Department of Rheumatology, UMHAT "Kaspela", ²Medical University Plovdiv. Medical Faculty, Department of Cardiosurgery, UMHAT "Sv, Georgi", ³Medical University Plovdiv. Medical Faculty, Department of Rheumatology, UMHAT "Sv. Georgi", ⁴Medical University Plovdiv. Medical Faculty, Department of Cardiosurgery, UMHAT "Sv, Georgi", Plovdiv, Bulgaria

Objective: Systemic inflammation and cytokine synthesis from activated proinflammatory cells leads to higher vascular risk in patients with seropositive RA. Local and systemic mechanisms of TNF α synthesis have been identified, which is related to early and more severe manifestations of ACS.

Methods: 46 patients with seropositive RA were studied, 23 of whom had ACS and 23 were non-ACS. The serum level was taken at 24 and 48 h. TNF α ELISA Kit (TNF) Detection Kit AA 77-233 Kit No. ABIN625441, by RayBiotech, hs CRP-kit of AMP Diagnostics BR-5420-S. The cardiovascular risk of new ACS incidents is assessed through GRACE Scale.

Results: In the RA and ACS group, there was a significantly higher serum level of TNF α at both 24 h (9.77 ng/ml $p<0.001$) and 48 h (9.98 ng/ml $p<0.001$) vs. group without ACS (5.07 ng/ml/24h and 5.24 ng/ml/48h, $p 0.001$) hour, higher levels of hs CRP (28.82 g/ml vs. 23.67g/ml $p<0.001$) and the GRACE score (140.45 vs. 125.5 $p<0.001$).

Conclusion: Patients with ACS and RA have significantly higher levels of TNF α associated with a higher level of proinflammatory response and a higher risk of subsequent ACS

P332

PERNICIOUS ANEMIA PRESENTING WITH SYMPTOMATIC VERTEBRAL COMPRESSION FRACTURES

M. Lovy¹, J. Hattenbach², N. Ben-Shlomo³

¹Desert Oasis Healthcare, Palm Springs, USA, ²College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, USA, ³Ben-Gurion Medical School, Beer Sheva, Israel

Objective: Pernicious anemia (PA) has been associated with both low spine BMD and increased fracture risk in retrospective cohort studies. The cause of these observations is obscure. The purpose of this study is to describe and compare the clinical details of a cohort of PA patients who presented with subacute vertebral compression fractures (SVCF) to one without PA.

Methods: A retrospective cohort study was conducted from a population of 159 patients presenting with SVCF to an outpatient fracture clinic. 24 patients with PA diagnosed at the time of presentation, based on low vitamin B12 levels and the presence of

either intrinsic factor (IF) or anti parietal cell antibodies (APCA), were compared to the remaining 135 patients without PA. A complete history and physical exam including review of past medical records, and current and past radiographs was performed. CBC, sedimentation rate, chemistry profile, TSH, urinalysis, vitamin B12, PTH, 25-OH vitamin D, and serum protein electrophoresis was done in all patients.

Results: There were 17 female and 7 male PA patients, ranging in age from 67-92 (mean 79.0 y) and with a BMI of 15-35 (mean 25.2). 13 patients were taking thyroid hormone and 7 were on protein pump inhibitors (PPI). 12 patients had previous fractures. Fractures occurred after falling in 17, lifting in 2, and were spontaneous in 5. The location of the fracture was between T-11 and L-2 in 65% of the cases and 8 patients had multiple fractures. 20 out of the 24 patients with PA had evidence of peripheral neuropathy. IF was present in 14 patients, APCA in 5, and 5 had both. Vitamin D was <20 ng/mL in 7 patients, and serum PTH was >65 pg/mL in 2. There was an increased incidence of peripheral neuropathy (p=0.0007), vitamin D <20 ng/dL (p=0.002), use of PPI (p=0.026), and thyroid disease (p=0.009) in the PA cohort. Age, gender, diabetes, previous fracture, BMI, fracture location, occurrence of multiple fractures, fractures occurring with falling, spontaneous fractures, and the presence of MGUS did not differ between the two cohorts.

Conclusions: This cohort of SVCF patients with PA had a higher incidence of peripheral neuropathy, vitamin D deficiency, PPI use and thyroid disease than SVCF patients without PA. These observations may explain in part the higher incidence of fractures and low BMD found in previous studies of PA patients.

P333
PNEUMOTHORAX SECONDARY TO PROLONG PNEUMONIA AFTER DENOSUMAB INJECTION IN GRAFT VS. HOST DISEASE PATIENT

P. C. Lim¹, S. Velaiutham¹

¹Hospital Pulau Pinang, Penang, Malaysia

Objective: Prolong use of bisphosphonates may increase the risk of adverse events that results in discontinuation of therapy. Sequential therapy with nonbisphosphonate agents such as denosumab may be the choice for high risk osteoporosis patient. However, limited report on the adverse effect of denosumab use in patient with graft vs. host disease. We aimed to report serious pneumothorax secondary to prolong pneumonia after denosumab injections.

Method: This was a case report. The record of the patient was retrieved and reviewed retrospectively.

Results: LEH, 54 years old male, had allogenic stem cell transplant in 2004 and complicated by severe chronic graft vs. host disease. Thus, he was on long term prednisolone and had glucocorticoid induced osteoporosis. He was given alendronate 70 mg weekly for 6 y and was stopped due to teeth falling out spontaneously. Denosumab 60 mg was given in February 2016 and August 2016. Patient developed pneumonia after a week of therapy and depending on oxygen concentrator. He had multiple occasions of

pneumonia and was treated as outpatient. Subsequently he was diagnosed with bronchiolitis obliterans in October 2016. In February 2017, patient was admitted in hospital for pneumonia for 3 d. After a week of discharge, he had readmission for right pneumothorax for 30 d and then 9 d and 11 d in February 2017, April 2017 and May 2017, respectively. Patient stopped depending on oxygen since October 2017.

Conclusion: This case report may exemplify a potential risk of pneumonia and pneumothorax in the use of denosumab in a transplant patient complicated by graft vs. host disease.

P334
THE EFFECTIVENESS OF DIFFERENT HARDNESS CUSTOM INSOLES ON PLANTAR PRESSURE REDISTRIBUTION

R. Gao¹, Y. Meng¹, S. D. Li¹, Y. D. Gu¹

¹Ningbo University, Ningbo, China

Objective: The objective of this study was to investigate the effectiveness of different custom hardness insoles on plantar pressure redistribution during walking and running.

Methods: Six males participated in the walking and running test (age: 24±1.6 y, weight: 67.9±3.6 kg, height: 175.5±4.7 cm). All subjects were instructed to walk and run along a 10m pathway wearing two different hardness insoles (i.e., hard custom insoles (CHI) and soft custom insole (CSI)) and control insole (CI) at their preferred speed. Peak pressure, mean pressure, maximum force, pressure-time integral were collected to analyze using SPSS.

Results: The maximum force, peak pressure, mean pressure and pressure-time integral of midfoot and heel were significantly increased by both kinds of custom insoles. While the CHI significantly increased mean pressure, peak pressure of the medial forefoot, central forefoot compared with the CSI and CI.

Conclusion: The custom insoles showed significantly higher plantar pressure on medial midfoot and lateral midfoot. But CSI was better than CHI because of redistributing the plantar pressure by increasing the plantar pressure of all forefoot. The CHI causes significant high pressure at medial forefoot, which may raise the risk of forefoot pain.



Figure Experimental insoles.

P335

FEAR AVOIDANCE IN PATIENTS WITH LOW BACK PAIN AND SCIATICAA. Knezevic¹, D. Hlapovic¹, S. Tomasevic-Todorovic¹, J. Ivacic², K. Boskovic¹, S. Kevic³, M. Jeremic-Knezevic¹¹Faculty of Medicine, University of Novi Sad, Novi Sad, ²General Hospital Senta, Senta, ³Medical Rehabilitation Clinic, Clinical Centre of Vojvodina, Novi Sad, Serbia**Objective:** To examine differences in severity of fear avoidance behavior between patients with localized chronic low back pain and those with sciatica.**Methods:** The study was designed as a cross-sectional study and included 113 subjects, average age 53.24±15.25 y, who were divided into two groups. The first group comprised patients with low back pain and sciatica, and the second patients with localized low back pain. Data about pain duration (in months) were collected. Subjects filled out questionnaire The Fear-avoidance Components Scale (FACS) (1, 2). Also, subjects graded current pain intensity (at the moment of testing) and average pain intensity (in last 4 weeks) using Numerical Rating Scale (NRS).**Results:** The majority of subjects had low back pain with sciatica - 90 subjects (79.6%), while 23 of them (20.4%) had localized lower back pain. Average pain intensity in last 4 weeks was significantly higher in the sciatica group (6.55±2.13 vs. 5.21±1.91, t=2.748, p=0.007). Similar results were found in current pain intensities (5.87±2.48 vs. 4.22±2.39, t=2.864, p=0.005). Interestingly, there was no significant difference in pain duration between groups (69.39±102.48 vs. 80.27±115.50, t=-0.434, p=0.665). The FACS score was significantly higher in sciatica group (62.12±19.15 vs. 46.83±21.75, t=3.324, p=0.001).**Conclusion:** Although there were no differences in pain duration, the FACS scores in patients with low back pain and sciatica were significantly higher, indicating more pronounced fear avoidance behavior in this group.**References:**

1. Neblett R et al. Pain Pract 2016;16:435.
2. Knezevic A et al. PloS one 2018;13:e0204311.

P336

REDUCING HEALING TIME IN SURGICAL TREATMENT OF COMPLETE FEMORAL FRACTURES ASSOCIATED WITH LONG-TERM BIPHOSPHONATE THERAPYS. M. Kim¹, S. J. Lim²¹Department of Orthopedic Surgery, Korea University College of Medicine, Guro Hospital, ²Department of Orthopedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea**Objectives:** To analyze factors that affect healing time in the operative treatment of complete femoral fractures associated with long-term use of bisphosphonates (BPs). In particular, we sought to determine operatively controllable factors related to fracture healing time.**Methods:** 99 consecutive patients (109 fractures) who had been operatively treated for a complete atypical femoral fracture were recruited. All patients had a documented history of BP therapy at the time of presentation with an average length of 7.4±3.5 y (range, 3-20 y). Baseline demographic data, characteristics of fracture and surgery, and radiographic findings including femoral neck-shaft angle, coronal and sagittal bowing of the femur, and the thickness of femoral cortex were examined. Univariate and multivariate logistic regression analyses were performed to identify predictable factors associated with delayed union or non-union.**Results:** Of 109 fractures, 76 (69.7%) fractures showed bony union within 6 months after the index surgery and were assigned to the successful healing group. The remaining 33 (30.3%) fractures which showed delayed union or nonunion were assigned to the problematic healing group. There were differences in BMI, BP medication period and the incidence of prodromal symptoms between the two groups. Supra-isthmal fracture height, femoral bowing ≥10° in the coronal plane, and mediolateral cortical thickness ratio ≥0.4 were predictable, but uncontrollable factors of the problematic healing. Iatrogenic cortical breakage around the fracture site, and the ratio of the remaining gap to cortical thickness ≥0.2 on the anterior and lateral sides of the fracture site were controllable predictive factors associated with the problematic healing.**Conclusions:** Higher BMI, longer BP duration and the presence of prodromal symptoms yielded adverse effects on fracture healing. Intramedullary nailing without cortical breakage around the fracture site and decreasing the anterior and lateral fracture gaps as much as possible are recommended to reduce healing time in complete femoral fractures associated with long-term use of BPs.

P337

COMPARISON ON ATYPICAL COMPLETE FEMORAL FRACTURES ASSOCIATED WITH BIPHOSPHONATE USE AND NOT ASSOCIATED WITH BIPHOSPHONATE USE

S. M. Kim¹, S. J. Lim²

¹Department of Orthopedic Surgery, Korea University College of Medicine, Guro Hospital, ²Department of Orthopedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Objectives: The purpose of this study is to compare clinical characteristics and surgical outcome of atypical complete femoral fractures associated with bisphosphonates (BPs) use and those of fractures not associated with BPs use.

Methods: 76 consecutive patients (81 fractures) who had been operatively treated for a complete atypical femoral fracture were recruited. Of the 81 fractures, 73 occurred after BPs medication of at least 3 years (BP group) while 8 occurred without a history of BP medication (Non-BP group).

Results: There were no differences in demographic data and fracture- and surgery-associated factors between the two groups. Of 76 patients (81 fractures), 54 (66.7%) fractures showed bony union within 6 months after the index surgery and 23 (28.4%) showed delayed union at a mean of 11.2 months (range, 8-18 months). The remaining 4 fractures were on to nonunion, even 18 months after the index surgery. There was no difference in healing rate between the BP group and the Non-BP group. There were strong correlations between the fracture height and the degree of bowing regardless of BPs medication. All fractures except 1 occurred at the diaphyseal region of the femur when not associated with BP medication.

Conclusions: There were strong correlations between the fracture height and the degree of bowing both in the BP group and in the Non-BP group, although no difference was found in healing rate between the BP group and the Non-BP group.

P338

THE ASSOCIATION BETWEEN RESTING METABOLIC RATE AND SARCOPENIC OBESITY IN OVERWEIGHT AND OBESE ADULT WOMEN

K. Mirzaei¹, N. Rasaei¹, S. F. Sajjadi¹, S. A. Keshavarz²

¹Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), ²Department of clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran

Objective: So far, no study has examined the contribution of resting metabolic rate (RMR) to sarcopenic obesity (SO) in obese and overweight people based on quintile of skeletal muscle mass (SMM) and fat mass (FM). This study was conducted to examine the association between RMR and SO.

Method: This cross-sectional study was conducted on 301 overweight and obese women aged 18-48 (BMI >25 kg/m²). Anthropometric measurements were assessed in all participants. Body composition was measured using body composition analyzer. Resting metabolic rate was measured by means of indirect calorimetry. The usual intake of food was evaluated over the past year by the use of questionnaire a valid and reliable semiquantitative food frequency containing 147 items.

Result: The prevalence of sarcopenia (who had two lower quintiles of SMM) and obesity (who had two highest quintiles of FM) was 19.6%, 20.4% respectively. The rate of SO among participants was 9.9%. Between SO and non-SO individuals there was statistically significant difference in height, BMI, Resting metabolic rate/kg, body fat%, SMM, FM, waist circumference, fat mass index, FBS and T-score (P<0.05). Binary logistic analysis showed that participants with lower RMR/kg had higher odds of SO (OR=0.87, 95%CI=0.78 to 0.98, P=0.03) and the risk of sarcopenia increased by 13%. After adjustment for weight, physical activity and total energy intake, the relationship between the RMR/kg and SO, was still significantly negative (OR=0.87, 95%CI=0.77 to 0.99, P=0.04) and participants with lower RMR/kg had higher odds of SO and the risk of sarcopenia reduced by 13% too.

Conclusion: The findings of this study suggest that there is a negative relationship between SO and RMR/kg, and increasing of RMR/kg, has a significant effect on reducing of incidence risk of SO.

P339

RESTITUTION OF NONUNION OF ATYPICAL SUBTROCHANTERIC FEMORAL FRACTURES USING EXTRAMEDULLARY FIXED ANGLED PLATES

S. M. Kim¹, S. J. Lim²

¹Department of Orthopedic Surgery, Korea University College of Medicine, Guro Hospital, ²Department of Orthopedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

Objectives: This study was conducted to evaluate the outcomes of salvage operation using a 95° angled blade plate for failed osteosynthesis of subtrochanteric femoral fractures associated with long-term bisphosphonates (BPs) use.

Methods: From October 2008 to July 2016, 14 patients with failed osteosynthesis of an atypical subtrochanteric femoral fracture were treated with the angled blade plate. Their mean age was 67.8 y (range, 60-74 y), all of which were female. Outcome variables included the time of union, postoperative complications, Harris hip score, and functional rating scale of Sanders.

Results: Bony union was achieved in 12 (85.7%) of 14 patients at an average of 8.4 months (range, 4 to 12 months). One patient experienced plate breakage and restabilization with the longer plate and strut-allograft. The other patient with plate pullout and varus angulation of the fracture site, refused to undergo further surgery. The mean Harris hip score was 83.1 points at the time of final follow-up. Functional rating scale of Sanders was good or excellent in 78.6% of the patients.

Conclusion: The 95° angled blade plate was shown to be an effective fixation modality for nonunion of atypical subtrochanteric fractures with a high rate of fracture union and functional improvement.

P340

ASSOCIATION OF SERUM BONE AND MUSCLE RELATED BIOMARKERS WITH BODY COMPOSITION AND PHYSICAL FUNCTION IN COMMUNITY-DWELLING MIDDLE-AGED AND ELDERLY ADULTS

K. Moriwaki¹, H. Hagino¹

¹Tottori University, Yonago, Japan

Objective: Muscles interact with bone mechanically and functionally in skeletal tissues. Endocrine factors, as well as mechanical factors, may affect both muscle and bone metabolism. The aims of this study were to evaluate the association of serum bone and muscle related biomarkers with age, gender, body composition, and physical function in community-dwelling middle-aged and elderly adults.

Methods: Serum sclerostin, osteocalcin (OC), IGF-1, myostatin and speed of sound (SOS) through the calcaneus, skeletal muscle mass index, grip strength, gait speed, and tartrate-resistant acid phosphatase-5b (TRACP-5b) were measured at the annual town-sponsored medical checkup in the town of Hino in Tottori Prefecture, Japan. The associations between all criteria were analyzed and independent markers for serum sclerostin, OC, and IGF-1 were analyzed by a multiple regression analysis.

Results: Participants included 97 men and 157 women who lived in a community with a mean age of 74.1±8.4 y (range, 43-99 y). Their mean BMI was 22.4±2.9 kg/m². Sclerostin was positively correlated with age, BMI, SOS, SMI, and grip strength, and negatively correlated with TRACP-5b. OC was negatively correlated with SOS, SMI, and grip strength, and positively correlated with TRACP-5b. IGF-1 was positively correlated with BMI, SOS, SMI, grip strength, and gait speed, and negatively correlated with age and TRACP-5b. Myostatin was not correlated with any of the variables assessed. Multiple regression analysis showed that significant independent predictors for sclerostin were gender, age, SOS, and TRACP-5b, those for OC were gender, SOS, and TRACP-5b, and those for IGF-1 were age, SOS, and BMI.

Conclusions: It was suggested that IGF-1 has a significant relationship with not only muscle mass and function but also with bone, although there was no discernable relationship between serum sclerostin and physical function.

P341

VITAMIN D AND THE RISK OF VFX IN POSTMENOPAUSAL WOMEN WITH PRIMARY HYPERPARATHYROIDISM

E. V. Brutskaya-Stempkovskaya¹, A. P. Shepelkevich², N. A. Vasilieva³, Y. V. Dydyshka²

¹Belarusian State Medical University, Minsk City Polyclinic N31, ²Belarusian State Medical University, ³Republic Medical Rehabilitation and Balneotreatment Center, Minsk, Belarus

Objective: To study vitamin D status and the prevalence of VFX in postmenopausal women with primary hyperparathyroidism (PHPT).

Methods: We studied 43 postmenopausal women with PHPT, average age 62.5±6.12. The control group were 31 postmenopausal women without PHPT, mean age 59.7±6.28 in physiological menopause. Examination: total calcium, phosphorus, albumin, creatinine, PTG, OPG, 25(OH)D, BMD measurements by DXA, LVA.

Results: There were no differences in the age, height, weight, BMI, age of menopause starting, duration of menopause in both groups. The level of vitamin D in postmenopausal women with PHPT was 17.1 (10.0-20.7) ng/mol, in the control group - 21.0 (17.1-27.4) ng/mol (U=389.0, p=0.004). In postmenopausal women with PHPT and with VFX (n=14) severe vitamin D deficiency (<10 nmol/l) was founded in 50.0% (n=7). In postmenopausal women with PHPT and without VFX (n=29) severe vitamin D deficiency (<10 nmol/l) was founded in 17.2% (n=5), $\chi^2=5.04$, p=0.02, OR: 4.8 (1.9-12.5), p<0.05. Significant differences were detected in vitamin D status in postmenopausal women with PHPT compared postmenopausal women without PHPT. The risk of VFX in patients with severe vitamin D deficiency (<10 nmol/l) is 4.8 times higher than in patients without severe vitamin D deficiency.

Conclusion: The results of the study detected the high risk of VFX in postmenopausal women with PHPT and with severe vitamin D deficiency. The data may indicate the potential effect of vitamin D deficiency on the formation of VFX in postmenopausal women with PHPT.

P342

EFFECTS OF ESSENTIAL AMINO ACIDS SUPPLEMENTATION AND REHABILITATION ON FUNCTIONING IN HIP FRACTURE PATIENTS: A PILOT RANDOMIZED CONTROLLED TRIAL

A. De Sire¹, C. Cisari¹, F. D'Andrea², D. Carrera², F. Renò³, S. Migliaccio⁴, G. Iolascon⁵, M. Invernizzi¹

¹Physical and Rehabilitative Medicine, Department of Health Sciences, University of Eastern Piedmont, Novara, ²Clinical Nutrition Unit, University Hospital Maggiore della Carità, Novara, ³Innovative Research Laboratory for Wound Healing, Department of Health Sciences, University of Eastern Piedmont, Novara, ⁴Department of Movement, Human and Health Sciences, Section of Health Sciences, University Foro Italico, Rome, ⁵Department of Medical and Surgical Specialties and Dentistry, University of Campania Luigi Vanvitelli, Naples, Italy

Objective: The high prevalence of sarcopenia in hip fracture patients is a well known issue with a negative impact on disability and functional recovery [1]. In this pilot randomized controlled trial we aimed to evaluate the impact of a 2-month rehabilitative protocol combined with dietetic counseling, with or without essential amino acids supplementation, on functioning in hip fracture patients.

Methods: We recruited patients aged more than 65 y, at 3 months after hip fracture, and randomly assigned them into two groups (A and B). Both groups performed a physical exercise rehabilitative program (5 sessions of 40 min/week for 2 weeks, followed by a home-based exercise protocol) and received a dietetic counselling; only group A was supplemented with 2 sachets of 4 g/d of essential amino acids. We evaluated at baseline and after 2 months of intervention (T1): hand grip strength, timed up and go, and lowa Level of Assistance scale (ILOA). Moreover, patients in both groups were divided in sarcopenic and nonsarcopenic patients, according to Janssen criteria [2], reported by the European Working Group on Sarcopenia in Older People [3].

Results: Of the 32 hip fracture patients assessed (mean age 79.03±7.80 y), 16 (mean age 80.33±6.72 y) were allocated in group A and 16 (mean age 77.65±8.40 y) in group B. The prevalence of sarcopenic patients was 68.8% in group A and 75.0% in group B and the whole prevalence was 71.9%. There were no differences between groups at the baseline. All the participants showed significant differences in all outcomes at T1 ($p < 0.017$). Sarcopenic patients in group A ($n=10$) showed statistically significant differences in all the primary outcomes at T1 ($p < 0.017$), whereas sarcopenic patients in group B ($n=13$) showed a significant reduction of ILOA only. In nonsarcopenic patients we found no differences at T1 in all outcome measures.

Conclusion: Hip fractures are a complex multifactorial condition of the elderly, that determine devastating effects on functioning and independence. In particular, essential amino acid supplementation induced significant improvements in the sarcopenic subpopulation of the study, suggesting a greater efficacy of this intervention in these patients.

P343

HIPOPARA-RED, REAL LIFE EXPERIENCE IN 322 PATIENTS WITH HYPOPARATHYROIDISM IN ARGENTINA

M. B. Zanchetta¹, D. Robbiani¹, B. Oliveri², E. Giacoia³, A. Frigeri⁴, S. Kallsbrum⁵, H. Salerni⁶, B. Perez⁷, S. Lucas⁸, A. Diaz⁸, M. Grandjean⁹, S. Tormo³, A. Kitaigrodsky¹⁰, A. Galich¹⁰

¹IDIM.Universidad del Salvador, ²Mautalen, Salud e Investigación, ³Servicio de Endocrinología y Metabolismo Hospital Posadas, ⁴Unidad de Endocrinología Hospital Dr. T. Alvarez, ⁵Hospital Durand, ⁶Servicio de Endocrinología Hospital Carlos G Durand, ⁷Servicio de Endocrinología Hospital Carlos G Durand, ⁸Sección Osteopatías Médicas, División Endocrinología Hospital de Clínicas JSM-UBA, ⁹Unidad de Endocrinología del Hospital Dr. T. Alvarez, ¹⁰Hospital Italiano, Buenos Aires, Argentina

Objective: Hypoparathyroidism (HPT) is a rare disorder characterized by hypocalcemia and absent or deficient PTH. It is associated with an increased risk of various complications, but only a few data are available on the natural history and correct management of this disease. Our aim was to describe clinical characteristics, treatment, and complications in a group of patients with HPT from 6 referral centers for endocrinological diseases, with expertise in HPT, in Argentina. Secondary, describe how many patients reached guidelines recommendations for rhPTH(1-84) treatment (Brandi ML. JCEM. 2016).

Methods: In this retrospective study patients with a diagnosis of HPT of ≥ 6 months were eligible for inclusion. Patients with pseudoHPT were excluded. Demographics, etiology, management, hospitalizations, clinical manifestations (fracture history, seizures, kidney stones, basal ganglia calcification, between others), and biochemical and DXA values were collected.

Results: 322 HPT patients were included; mean age was 55.2±16.8 y, 85.7% were women. Mean age at diagnosis was 43.8±16.8 y and mean follow-up time was 4.9±5.1 y. Regarding etiology 90% were postsurgical (50.3% for thyroid cancer, 41% for multinodular goiter, 2.7% primary hyperparathyroidism; 3.4% secondary hyperparathyroidism and 2.3% cervical cancer). Nonsurgical etiology included: 5 DiGeorge Syndrome, 9 autoimmune and 16 idiopathic. Nonsurgical patients were significantly younger (45±19.5 vs. 56.3±16.1 y; $p < 0.01$) and were younger at diagnosis (45.1±15.9 vs. 31.4±20.5 y; $p < 0.01$). Treatment regimens were determined by the patients' physician, per usual clinical practice, and most patients were receiving calcium supplementation (mean daily dose: 2019±1426 mg), vitamin D (mean weekly dose 34.368±55.278 UI) and calcitriol (mean daily dose: 0.498±0.279 µg). 13 patients were receiving teriparatide (1-34 human PTH). 25.7% had a history of hypocalcemia requiring hospitalization, 4.6% had fragility fracture history (wrist, hip, humerus, vertebra or tibia) and 4.3% has a history of seizures. Only 41.9% had a renal ultrasound done and 15.5% had positive findings (kidney stones and nephrocalcinosis). 54% had 24-h urine calcium excretion measured and almost half of them had hypercalciuria confirmed (56.3%). Only 18,3% patients had central nervous system imaging performed,

and 38.9% had basal ganglia calcification. Biochemical and DXA values, while on treatment, are shown in Table 1. Finally, 38.8%

met criteria to rhPTH(1-84) treatment according to the guideline; most of them because their daily oral calcium requirements exceeded 2.5 g of calcium.

Table1: Biochemical and DXA values

	All (n=322)	Surgical (n=292)	Non surgical (n=30)	P
Calcium (mg/dl)	8.4 ± 0.8	8.5 ± 0.8	8.3 ± 0.9	0.47
Ionic calcium	4.2 ± 0.5	4.2 ± 0.5	4.1 ± 0.6	0.14
Albumina	4.1 ± 0.4	4.1 ± 0.4	4.3 ± 0.4	0.16
Phosphorus	4.7 ± 0.9	4.7 ± 0.9	4.9 ± 1	0.20
PTH (pg/ml)	13 ± 10.8	13 ± 10.9	11 ± 9.4	0.29
25 OH VitD (ng/ml)	34.8 ± 13.4	34 ± 13.2	41 ± 14.8	0.08
Magnesium	1.89 ± 0.22	1.89 ± 0.23	1.86 ± 0.19	0.54
Urine calcium (mg/24hs)	201.6 ± 130	199.1 ± 133	225.0 ± 103	0.34
C- telopeptides	383 ± 710	357.2 ± 679	757.0 ± 1088	0.22
Bone Phosphatase	12 ± 7.3	11.9 ± 7.5	12.6 ± 5.8	0.83
DXA				
Ts L1-L4	-0.3 ± 1.9	-0.3 ± 2	0.4 ± 1.5	0.38
Zs L1-L4	0.7 ± 2	0.7 ± 2	1.3 ± 1.2	0.53
Ts FN	-0.3 ± 1.5	-0.3 ± 1.5	-0.2 ± 0.8	0.72
Zs FN	0.7 ± 1.3	0.7 ± 1.4	0.9 ± 0.4	0.59

Conclusion: Although these patients were followed by experienced physicians, clinical management and monitoring was heterogeneous and probably insufficient to assess all the potential complications of this chronic disease. rhPTH is not yet available in Argentina, but 38.8% of this group of patients met the criteria for this new treatment. Being aware of this situation is the first step to improve our medical management of HPT in the future.

P344

EFFECT OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND SEROTONIN NOREPINEPHRINE REUPTAKE INHIBITORS ON TRABECULAR BONE SCORE AND BONE MINERAL DENSITY IN PRIMARY FIBROMYALGIA

H. Hamoud¹, Y. Gazar¹, M. Ghit¹, M. Harb¹

¹Rheumatology Department, Faculty of Medicine, Al-Azhar university, Cairo, Egypt

Objective: Fibromyalgia is characterized by chronic widespread pain classified as primary and concomitant. This work aimed to determine the correlation between selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) usage and BMD and trabecular bone score (TBS) changes in primary fibromyalgia patients.

Methods: The present study was conducted on study on 100 Egyptian patients diagnosed as primary fibromyalgia categorized according to drug medication into 2 groups, 50 patients on SSRIs

and 50 patients on SNRIs, recruited from Rheumatology, Physical Medicine and Rehabilitation Departments at Al-Hussein and Sayed Galal, Al-Azhar University Hospitals. In addition to another 50 age matched the control group subdivided into 25 primary fibromyalgia patients not on those drugs and 25 healthy individuals selected by nurses and medical staff, after an informed consent from all subjects from June 2018 to December 2018.

Results: DXA and TBS revealed that usage of SSRIs and SNRI was significantly associated with low BMD (Osteopenia and osteoporosis) specially spine BMD reduction with low TBS (partially degraded and degraded) particularly for old people.

Conclusion: The present study provided evidence that usage of SSRIs or SNRI was significantly associated with low BMD (osteopenia and osteoporosis) specially spine BMD reduction with low TBS (partially degraded and degraded) particularly for old people and despite low BMD was found in the SRI users; it also found in primary fibromyalgia not on SRIs so primary fibromyalgia should also be considered as a contributing factor for low BMD.

P345

ASSOCIATIONS BETWEEN THE MORPHOLOGICAL PARAMETERS OF PROXIMAL TIBIOFIBULAR JOINT AND CHANGES IN TIBIOFEMORAL JOINT STRUCTURES IN PATIENTS WITH KNEE OSTEOARTHRITIS

Z. Zhu¹, J. Chang², W. Han², Y. Zhao², K. Kwoh³, D. Hunter⁴, C. Ding⁵

¹Clinical Research Center, Zhujiang Hospital of Southern Medical University, Guangzhou, China, ²Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³University of Arizona Arthritis Center & Division of Rheumatology, University of Arizona College of Medicine, Tucson, USA, ⁴Department of Rheumatology, Royal North Shore Hospital and Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁵Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China

Objectives: Little attention has been paid to proximal tibiofibular joint (PTFJ) and its contribution to knee osteoarthritis (OA). The longitudinal associations between morphological parameters of PTFJ and joint structural abnormalities have not been investigated. Therefore, the aim of this study was to describe the longitudinal associations between the morphological parameters of the PTFJ and joint structural changes in tibiofemoral compartments in patients with knee OA.

Methods: A total of 408 participants with knee OA were selected from the Vitamin D Effects on Osteoarthritis (VIDEO) study, which was a multicenter, randomized and double-blind clinical trial. PTFJ morphological parameters were measured on coronal and sagittal MRI. The contacting area of PTFJ (S), its projection areas onto the horizontal (load-bearing area, $S\tau$), sagittal (lateral stress-bolstering area, $S\phi$) and coronal plane (posterior stress-bolstering area, Su) were assessed, respectively. MRI knee structural abnormalities including cartilage defects, bone marrow lesions (BMLs) and cartilage volume were evaluated at baseline and 2 y later. Log binominal regression models and linear regression models were used.

Results: In longitudinal analyses, S (RR, 1.45) and $S\tau$ (RR, 1.55) of PTFJ were significantly and positively associated with an increase in medial tibial cartilage defects over 2 y, after adjustment for age, sex, height, weight, ROA, tibial plateau bone area and intervention. $S\tau$ (β , -0.07), Su (β , -0.07) and S (β , -0.06) of PTFJ were significantly and negatively associated with change in medial tibial cartilage volume, after adjusted for covariates. $S\tau$ (RR, 1.55) of PTFJ was positively associated with an increase in medial tibial BML, and $S\phi$ (RR, 0.35) was negatively associated with an increase in medial femoral BMLs. No significant associations were found between PTFJ morphological parameters and osteoarthritic changes at lateral compartment.

Conclusions: The longitudinal study suggests that higher load-bearing area of PTFJ is a risk factor for structural changes in the medial tibiofemoral compartment in knee OA patients. This could provide a theoretical support for proximal fibular osteotomy in the treatment of knee OA in medial tibiofemoral compartment.




Figure 1. Measures of proximal tibiofibular joint morphological parameters




Figure 2. Associations between the areas of PTFJ and change in tibial cartilage volume per annum

P346

VISCERAL OBESITY AND SARCOPENIA AS DETERMINING FACTORS FOR INCREASED RISK OF OSTEOPOROTIC FRACTURES AND OSTEODEFICIENCY IN PATIENTS WITH TYPE 2 DIABETES

A. B. Andruska¹, O. N. Kovalyova¹, L. M. Pasiyeshvili¹

¹Kharkiv National Medical University, Kharkiv, Ukraine

Objective: To assess the incidence of osteodeficiency and osteoporotic fractures risk in patients with type 2 diabetes in the presence of visceral obesity and sarcopenia.

Methods: 49 patients (mean age 61 ± 7.1 y) with type 2 diabetes mellitus (DM) were examined. The estimation of the 10-y probability of the main osteoporotic fracture (OF) was made using the FRAX and QFracture models specific to the respective ethnic group. All patients were exposed DXA, which determined BMD and the content of visceral fat in the body. Diagnosis of sarcopenia was based on the assessment of the content of muscle mass (bioimpedance method) and the determination of the index of muscle strength. The statistical significance of differences in the studied parameters was evaluated by the nonparametric method (by χ^2 criterion).

Results: All examined patients were divided into subgroups depending on the absence/presence of visceral obesity and sarcopenia. In the presence of visceral obesity, the risk of OF is significantly lower ($\chi^2=8.947$, $df=1$, $p=0.003$) than with the normal content of visceral fat in the body, but osteodeficiency (osteopenia and osteoporosis) is more common ($\chi^2=7.139$, $df=1$, $p=0.007$). In patients with type 2 DM and sarcopenia, BMD is significantly lower ($\chi^2=4.864$, $df=1$, $p=0.027$) and the probability of major OF is significantly higher when evaluated with the QFracture calculator ($\chi^2=9.01$, $df=1$, $p=0.003$).

Conclusions: The presence of visceral obesity and sarcopenia in patients with type 2 DM can be considered as potential factors contributing to the development of osteodeficiency and as prognostic indices that increase the probability of osteoporotic fractures. In patients with visceral obesity, there is a discrepancy between the lowered risk of OF and low BMD indices, thus in this category of patients, an additional determination of BMD is recommended. A more sensitive tool for assessing OF probabilities at DM and sarcopenia is the QFracture calculator.

P347

PRESENTATION OF A CLINICAL CASE OF COMBINED TREATMENT DENOSUMAB/ SUPPLEMENTS IN SUBJECTS WITH SUPPRESSION OF TSH: MOC DXA1 REVALUATION AT A REDUCED INTERVAL OF 10 MONTHS

P. G. Pisano¹

¹G.I.S.T.O., Arezzo, Italy

Objective: The interval between two MOC DXA1 assessments is indicated in 18 months. This is due in part to the intrinsic imprecision of the test (perhaps now surpassed by the availability of new equipment) and in part to the more usual therapy represented by antiresorptive drugs, which involves long times to influence the mineralization. These limits could be reevaluated. In consideration of the economic burden of fragility fractures treatment, it is important to identify complementary therapies, to be combined with pharmacological therapies.

Methods: The S.MG patient shows up, at the first medical examination, for having suffered 2 vertebral fractures due to bone fragility and in the presence of TSH suppression (<0.03).

After checkup by MOC DXA¹, BSI (bone structure index, Bestest, new methodology of bone quality survey), blood CTX and evaluation of analysis results, the patient underwent therapy with deno-

sumab (every 6 months) and, daily, with menaquinone 7 (200 μ g), silicon (900 mg), organic lycopene, (10 mg, cis form), collagen (10 g), vitamin D (5000 IU), magnesium bisglycinate (600 mg). Calcium intake was carried out exclusively through the diet, with water high in this mineral. Levothyroxine therapy was corrected.

Results: After 10 months of the therapy, a reevaluation of the tests was performed. The results of analysis showed an increase in lumbar BMD (total) T-score from -4.8 to -3.9, with a improvement of 18.8%. The BSI gained correspondently. CTX was not repeated due to suppressive therapy by denosumab. The densitometric and bestest tests were performed in the same structure, with the same devices and by the same operator to minimize the stochastic probabilities.

Conclusion: The combination of an antiresorptive therapy with supplements, at the pharmacological dosage, can lead to an important increase in bone mass. Furthermore, if required, the suppression of TSH is to be combined with the prevention of side effects on the bone.

A literature review has been done for both, supplements and devices of follow-up used.

(1) BMD scan performed by MOC DXA (Mineralometria Ossea Computerizzata, DXA).

P348

GLUTAMINE USE IN PELVIC SARCOPENIA: A PROSPECTIVE, RANDOMIZED, PLACEBO CONTROLLED STUDY

G. Bahat¹, B. Ilhan², N. Capan³, C. Kilic⁴, C. Yasa⁵, F. Gungor⁵, O. Persil Ozkan⁶, A. Karan³, M. A. Karan¹

¹Istanbul University, Istanbul Medical School, Department of Internal Medicine, Division of Geriatrics, Istanbul, Turkey, Istanbul, ²Dr. Ersin Arslan Research and Training Hospital, Department of Geriatrics, Gaziantep, ³Istanbul University, Istanbul Medical School, Department of Physical Medicine and Rehabilitation, Istanbul, ⁴Istanbul University, Istanbul Medical School, Department of Internal Medicine, Division of Geriatrics, Istanbul, ⁵Istanbul University, Istanbul Medical School, Department of Urogynecology, Istanbul, ⁶Istanbul Arel University, Nutrition and Dietetics, Istanbul, Turkey

Objective: To determine the effect of additional oral glutamine supplementation to Kegel exercise on pelvic floor strength and clinical parameters of urinary incontinence in females.

Methods: It is a randomized, double-blind study. Females with urinary incontinence were included. Digital test and a vaginal manometer were used for measuring the strength of the pelvic floor muscles. 24 h pad weight test was examined. Participants were randomized into 2 groups as oral glutamine 30 g/d and placebo. It was asked to use the supplementation and Kegel exercises to all participants for 3 months. Basic and 3rd month measurements were compared by paired sample T-test and Wilcoxon tests in each group. The progression between measurements at basic and 3rd months was compared between the groups by using Mann-Whitney U test. (Clinical Trials protocol ID: 2014/1203)

Results: There were 11 patients in the glutamine arm and 18 patients in the placebo arm. Mean age was 58.2±6.6 y. Mean BMI was 32.9±4.8 kg/m². There was no age difference between the groups [glutamine 59±3.8, placebo 57.8±7.9 y, p>0.05]. In glutamine arm, vaginal muscle strength assessed by digital test was higher at the end of 3 months [2.9±0.7 vs. 4±0.9; 0-3 months respectively, p=0.014]; perineometer measurements were not statistically different [27.4±8.3 vs. 31.2±8.9; 0-3 months respectively, p>0.05]; 24 h pad weight was not different [p>0.05]. In placebo arm, there was statistically significant progress in vaginal muscle strength assessed by both digital test and perineometer, and 24 h pad weight (p values: 0.005, 0.011, 0.002, respectively). When we compare the progression scores between the groups; there was no statistically significant difference [p>0.05].

Conclusion: Our study suggests that glutamine supplementation does not provide additional benefit in the treatment of pelvic muscle sarcopenia in patients without protein-energy malnutrition.

Acknowledgement: This study is supported by Nestle Health Science.

P349

TEMPORAL TRENDS IN FRACTURE LIAISON SERVICES IN NORTHERN IRELAND

J. R. Lindsay¹, S. English¹, T. R. O. Beringer¹

¹Musgrave Park Hospital, Belfast, UK

Objectives: Fracture Liaison Services (FLS) are clinically and cost effective for fracture prevention. We examined clinical activity and temporal trends in the Belfast FLS over a 12-month period.

Methods: In 2003 the Belfast FLS was rolled out to those aged >50-75 y with fragility fracture for clinical assessment and bone densitometry (DXA). Risk factors, demographics, fracture type, DXA results and outcomes over a 12-month period were analysed. We extracted data from the Glasgow Integrated System for Management of Osteoporosis database.

Results: 16259 individuals were assessed by 2018. Annual fragility fracture cases increased from 302 in 2003, to 1488 in 2018. In 2017 the proportion of low trauma fractures were: wrist 26%, ankle 12%, humerus 11%, hand/foot 11%, hip 9%, tibia/fibula 5%, elbow 5%, vertebral 6%, clavicle 2%, rib 2%, patella 2%, pelvic 1%, other 8%. We observed higher rates of smoking in the current series; lower rates of prior fragility fracture, glucocorticoid use, premature menopause and reported height loss were evident. DXA scanning showed osteopenia (44%), osteoporosis (29%), and normal BMD (35%). FLS interventions included NICE TA161 (97%), calcium/vitamin D (80%) or bisphosphonates (32%). A smaller proportion did not require treatment (17.1%) or were advised to stop bisphosphonate treatment (3%). 266 patients, over the age of 75 y, received an empirical treatment recommendation for primary care led bone protection treatment. 16% were referred to osteoporosis specialist clinics; 31% required follow-up DXA; the remainder (53%) did not require routine follow-up.

Conclusion: We observed increasing service demands over 15 y with high recruitment rates of individuals at risk of fragility fracture. We identified increased proportions of non-hip fractures and

a lower proportion with osteoporosis compared to 2003. We propose a higher age related cutoff for FLS clinic recruitment and to prioritise hip and major fractures to optimise intervention outcomes.

Acknowledgement: Sr. Colette McNally for dedicated service to the Belfast FLS

P350

THE ASSOCIATION BETWEEN DASH (DIETARY APPROACHES TO STOP HYPERTENSION) DIET AND SARCOPENIC OBESITY IN OVERWEIGHT AND OBESE ADULT WOMEN

N. Rasaei¹, K. Mirzaei¹

¹Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran

Objective: This study was conducted to examine the association between DASH dietary pattern and sarcopenic obesity (SO) in obese and overweight people based on quintile of skeletal muscle mass (SMM) and fat mass (FM).

Methods: This cross-sectional study was conducted on 301 overweight and obese women aged 18-48. Body composition was measured using body composition analyzer. Resting metabolic rate (RMR) was measured by means of indirect calorimetry. The usual intake of food was evaluated over the past year by the use of a valid and reliable semiquantitative food frequency containing 147 items. Major dietary patterns were determined by the use of factor analysis of 21 foods groups. Serum HDL_c, LDL_c, TG, fasting blood sugar (FBS), total cholesterol (T_{chol}) and hs_{CRP} were quantified by ELISA.

Results: The prevalence of sarcopenia (who had two lower quintiles of SMM) and obesity (who had two highest quintiles of FM) was 19.6%, 20.4% respectively. The rate of SO was 9.9%. Between SO and non-SO individuals there was significant difference in height, BMI, RMR/kg, body fat%, SMM, FM, waist circumference, fat mass index, FBS and T_{chol} (P<0.05). By the use of factor analysis, 3 major dietary patterns were extracted: DASH dietary pattern (DDP), western dietary pattern (WDP) and unhealthy dietary pattern (UNHDP), and% of variance of each dietary pattern was 11.97%, 9.63%, and 9.02% respectively, that they covering 30.63% of total dietary pattern of our population. Binary logistic analysis showed that participants in the in the upper category of DDP had lower odds of SO (OR=0.27, 95%CI=0.08 to 0.96, P=0.04) and the risk of sarcopenia reduced by 73%. After adjustment for age, physical activity, and energy intake, the relationship between the DDP and SO, was still significantly negative and participants in the in the upper category of DDP had lower odds of SO (OR=0.20, 95%CI=0.05 to 0.77, P=0.01) and the risk of sarcopenia reduced by 80%.

Conclusion: There is a negative relationship between SO and DDP, and adherence to the DDP, has a significant effect on reducing of incidence risk of SO.

P351

DOES VIRTUAL REALITY SIMULATOR USE INFLUENCE MEDICAL STUDENTS' ATTITUDES TO A CAREER IN ORTHOPEDIC SURGERY?

J. Bartlett¹, K. To¹¹University of Cambridge, Cambridge, UK

Objective: With declining interest in orthopedic surgery, there was been increasing investigation into novel means of stimulating interest in this specialty. With the potential advent of virtual reality (VR) based surgical skills acquisition, it is unclear how exposure to these training methods will impact students' attitudes towards orthopedics. We therefore sought to answer the following: does VR arthroscopic simulator use influence medical students' attitudes towards a career in orthopedic surgery?

Methods: 25 medical students completed seven unsupervised sessions on a VR hip-arthroscopic simulator. All participants completed a pre- and post-simulator pseudo-anonymized questionnaire consisting of 10 questions - six 10-point Likert scale questions addressing their interest in orthopedics, surgery and arthroscopy; and four 5-point Likert scale questions addressing their attitudes towards simulation. Pre- and post-paired datasets were analyzed using Wilcoxon signed rank test.

Results: Interest in both orthopedics and surgery was found to increase after simulator use (Orthopedics - 6.3 to 8.6 $P<0.01$; Surgery - 6.9 to 9.0, $P<0.01$). It was also found that simulator use increased participants' interest in arthroscopy (5.4 to 8.3, $P<0.01$) and hip-arthroscopy (4.8 to 7.8, $P<0.01$). Participants reported they were more likely to attend endoscopic and arthroscopic surgical lists after simulator use (7.1 to 8.7, $P<0.01$; and 6.1 to 8.6, $P<0.01$). After using the simulator, participants felt more strongly that VR simulation is a valuable training modality ($P<0.01$), that simulation should be a mandatory part of orthopedics and surgical training ($P<0.01$ and $P<0.01$), and that access to VR simulators improves the quality of surgical training ($P<0.01$).

Conclusions: These results demonstrate that exposure to VR arthroscopic simulation increased medical students' interest in orthopedics, surgery and arthroscopy, without the need for direct supervision. Following VR simulator use, students were more likely to engage with training opportunities, including arthroscopic and endoscopic surgery. The results of this study demonstrate a novel means of stimulating interest in orthopedics and suggest that there would be good engagement of future trainees with VR simulation training modalities.

P352

EFFECT OF TNF INHIBITORS ON BONE MINERAL DENSITY IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING BISPHOSPHONATE

J. S. Lee¹, D. H. Lim², S. Hong¹, C. K. Lee¹¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, ²Division of Rheumatology, Department of Internal Medicine, Ulsan University Hospital, Ulsan, South Korea

Objective: To investigate whether tumor necrosis factor inhibitors (TNFi) have beneficial effects on BMD in rheumatoid arthritis (RA) patients with osteoporosis receiving bisphosphonate.

Methods: A total of 239 RA patients, who were diagnosed with osteoporosis and treated with bisphosphonate between January 2005 and March 2017, were reviewed. The BMD (g/cm²) of the lumbar spine, femur neck, and total hip were measured by DXA. Changes in the BMD percentage were compared between patients treated with and without TNFi. Multivariate analysis was performed to identify the factors associated with BMD improvement.

Results: Among patients receiving bisphosphonate, 35 patients were exposed to TNFi, and 204 patients were not exposed. The last BMD follow-up was obtained at a median of 2.23 (IQR, 1.13–4.25) years after the initial acquisition of BMD. An improvement of BMD in the lumbar spine was observed for patients treated with bisphosphonate; however, there was no significant difference in BMD between patients treated with and without TNFi (4.92% (IQR, -1.6–9.42) vs. 4.99% (IQR, 0.68–10.09), $P=0.437$). In addition, BMD changes in the femur neck, trochanter, and total hip were not significantly different between the two groups. Furthermore, TNFi use was not associated with BMD improvement in any sites. On the other hand, cumulative steroid dose was significantly associated with a lower improvement in BMD.

Conclusions: In RA patients with osteoporosis receiving bisphosphonate, TNFi did not influence BMD improvement, suggesting that TNFi cannot be considered as a preferred therapeutic option in terms of BMD.

P353

A COMPARATIVE STUDY OF THE POLYPHENOLIC COMPONENTS CONTENT AND ANTIOXIDANT CAPACITY OF URTICAE HERBA AND URTICAE FOLIUM

A. Pallag¹, N. R. Suci¹, T. Jurca¹, C. Jurca¹, F. Marc¹, F. Cioara¹¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objective: Flavonoids and polyphenols constitute one of the most numerous, natural substances. There are secondary metabolites in plants that have received more attention since being reported to have a positive influence on human health due to their multiple activities that were associated with a decrease in the incidence of various diseases. Osteoporosis is a public health problem. Phytotherapy in osteoporosis focuses on the use of herbal reme-

dies to help provide more calcium to the bones or help the body to produce the principles that help calcium absorption. It was demonstrated that antioxidant content increases the anti-osteoporotic activity of the medicinal plants. *Urtica dioica* L., stinging nettle, Urticaceae family is widely used species by traditional societies in temperate and tropical Asia, Europe, northern America and northern Africa. For medicinal purposes it uses *Urticae radix* (roots) and *Urticae herba* (aerial parts). The aerial parts of this medicinal plant help to restore bone, which it remineralizes due to its rich content of calcium, magnesium, potassium and iron.

Methods: The purpose of the present study was to investigate the comparative content of phenolic components of *Urticae herba* (aerial parts) and *Urticae folium* (only the leaves) as well as their antioxidant capacity using different alcoholic extracts which were evaluated by Folin Ciocalteu method for determining the total polyphenol content and the total flavonoids. Using the reducing-Cuprac assay and FRAP (ferric reducing antioxidant power) method was determined the antioxidant activity of alcoholic extracts.

Results: Our results show that the studied medicinal plant possesses high levels of antioxidant substances and high antioxidant power. The amounts of total polyphenols is 63.95 mgGAE/100DW in case of *Urticae herba* (aerial parts) and 78.61 mgGAE/100DW in case of *Urticae folium* (only the leaves). The amounts of total flavonoids is 55.24 mgQE/100DW in case *Urticae herba* (aerial parts) 65.43 mgQE/100DW in case in case of *Urticae folium* (only the leaves). Considering our extracts antioxidant capacity, the FRAP method shown 62.55 μ mol Trolox equivalent/gDW (TE) in case of *Urticae herba* and 81.31 μ mol Trolox equivalent/gDW (TE) in case of *Urticae folium*.

Conclusions: The results showed that the alcoholic extracts of *Urtica dioica* (stinging nettle) are rich sources of phenolic compounds, flavonoids and phenolic acids, with antioxidant capacity and reducing power, which can contribute to improve the anti-osteoporotic effect of this herbal remedies. The highest amount of polyphenols, polyphenols and antioxidant capacity was found in *Urticae folium*.

P354

NEW POSSIBILITIES IN OA THERAPY WITH COMBINED MODIFIED HYALURONATES

V. V. Badokin¹, M. A. Strakhov², I. F. Akhtyamov³, K. V. Raymuyev⁴, S. N. Ivanov⁵, M. A. Pogodina⁶

¹Russian Medical Academy of Continuing Professional Education, Moscow, ²Center for Sports Medicine of FMBA of Russia, Moscow, ³Kazan State Medical University, Kazan, ⁴I.I. Mechnikov North-Western State Medical University, St. Petersburg, ⁵The L.G. Sokolov Memorial Hospital №122, St. Petersburg, ⁶Scientific and methodical Center Martinex, Moscow, Russia

Objective: 1. Prove the efficacy of the new generation chondroprotective preparations for intra-articular (IA) injections based on modified hyaluronic acid salts with combined composition (CM HA) with reparative and anti-inflammatory (AI) action. 2. Confirm

the clinical significance of the previously obtained pathogenetic rationale for the differentiated use of 3 different courses, depending on the clinical form of OA.

Methods: In 2015-2018 an open multicenter clinical trial was conducted to assess the efficacy and safety of IA use of 3 courses of CM HA with ascorbyl phosphate and amino acids. 147 patients with OA of the knee or hip joint were observed (from the total amount: 10.2% with coxarthrosis, 31.9% with post-traumatic OA, 32.7% with synovitis). Inclusion: OA with radiological verification without synovitis at the baseline. Patients with synovitis received AI treatment before inclusion. Exclusion: IA HA injections or arthroscopy <6 months prior baseline; post-injection synovitis. Three courses consisted of a combination of two CM HA formulas (F): F-02 with proteinogenic amino acids with reparative action; F-10 with antioxidant complex with AI action. The patients were divided into 3 groups after randomization according to the type of course and received three 2.0 ml IA injections each 14 days. Courses differed from each other in a combination of formulas: reparative (F-02 3 injections), analgesic (F-10 1 injection, F-02 2 injections), cytoprotective (F-10 3 injections). Evaluation of the efficacy was performed at 4 visits using a point scale. Physician assessment: pain during physical examination by VAS 0-10; course tolerability, safety, algo-functional efficacy at the end of the course by scale of 1-5 points (when 5 is excellent). Patient's assessment: pain during walking by VAS 0-10, Lequesne questionnaire.

Results: Pain on joint palpation and during movements decreased 3-5 times after the course. Reparative course reduced the total Lequesne Index by 7.5-7.6, analgesic – by 8.0-8.4, and cytoprotective – by 9.2-9.5 points. Cytoprotective course has been proven to reduce the higher Lequesne Index with the most pronounced initial inflammatory manifestations. Over 90% of physicians rated all courses on tolerability, safety, and algo-functional efficacy at 5 and 4 points. Post-injection synovitis was observed in 1 patient (0.68%), pain and swelling after administration in 2.72%.

Conclusions: CM HA has good tolerability and high safety. Formulas affect reparative potential and reduce oxidative inflammation activity. The differentiated administration of 3 courses was proved depending on the pain or synovitis intensity in patients with synovial joints OA.

P355

IMPACT OF MEDICATION USE PATTERN ON 2-YEAR OUTCOMES OF FRACTURE LIAISON SERVICE PATIENTS

R.-S. Yang¹, T.-H. Yang², W.-J. Huang³, D.-C. Chan⁴

¹Department of Orthopedics, National Taiwan University Hospital, Taipei, ²Department of Orthopedics, National Taiwan University Hospital Hsinchu Branch, Hsinchu County, ³Department of Geriatrics and Gerontology, National Taiwan University Hospital, Taipei, ⁴Superintendent Office, National Taiwan University Hospital Chu-Tung Branch, Hsinchu County, Taiwan

Objectives: Previous studies showed that fracture liaison service (FLS) improved patient outcomes. However, medication use patterns vary among FLS patients. We aim to determine whether medication use patterns would have impacts on subsequent fracture, incident fall, and mortality among participants within a FLS at 2years.

Methods: We prospectively enrolled 600 patients with hip or vertebral fractures from different 2 institutes into a FLS program. Participants were re-grouped to no use (NO, n=60), no change (NC, n=423), late initiation (LI n=28), medication change (MC, n=52), and early termination (ET, n=37). According to baseline medication use pattern, multivariate logistic regressions were performed to identify baseline correlates on two-year mortality, incident fracture, and fall.

Results: Among 600 fracture patients, mortality was significantly higher for NO vs. NC (31.7% vs. 13.2%, $P=0.01$), NO vs. MC (31.7% vs. 5.7%, $P=0.01$), and NO vs. ET (31.7% vs. 5.4%, $P=0.03$). MC group had highest rate for incident fracture over 2-year of follow-up. Multivariate logistic regression analyses showed that medication group, lower BMI, and lower albumin increased mortality risk in 2 y risk factors. The medication group was only risk factor for incident fracture. Older age and higher BMI increased the risk of fall.

Conclusion: FLS patients had different medication use patterns. Patients with fractures but not on osteoporosis medications had the highest mortality rate while patients changed medication had highest incident fractures. For fragility fracture patients, osteoporosis medications should be prescribed and maintained to improve outcomes.

P356

FRAX® TOOL WEBSITE USAGE IN THAILAND

P. Chotiyarnwong¹, E. V. McCloskey¹¹University of Sheffield, Sheffield, UK

Objective: To document usage of the web-based FRAX tool and specifically its usage in Thailand throughout the period from 2010.

Methods: A descriptive retrospective study using data from Google Analytics that provides numerical and geographical information on internet access to the FRAX tool website worldwide.

Results: The USA is the country with the most frequent access to the FRAX tool. There were weak but significant correlations between the absolute number of FRAX sessions and population size ($r=0.165$, $p=0.011$) and country size ($r=0.375$, $p<0.001$). When adjusted for population size, Slovenia is currently ranked highest for access to FRAX. In Thailand, Bangkok is the highest ranked site for FRAX access with more than 20,000 usage sessions since 2010 (3.6 usage session per 1000 population) follow by Khon Kaen and Chiang Mai. It has been accessed from within 76 out of 77 provinces (98.7%). There was a steady increase in access to FRAX from within Thailand of approximately 1000 usage sessions per year between 2010-2016. After the FRAX fracture risk calculation was included in the national guideline for osteoporosis management published in late 2016, the rate of increase in access was 4-fold higher compared to the previous period.

Conclusion: Access to the FRAX tool website is increasing in Thailand. The incorporation of FRAX into national guidelines, in parallel to the adoption of osteoporosis fracture prevention into national policy, has had a rapid and significant impact on its use.

P357

EXAMINATION OF BONE MINERAL CONTENT IN TYPE 2 DIABETES MELLITUS PATIENTS

L. Labashova¹, A. Shepelkevich², Y. Dydyshka²¹Republic Centre of Medical Rehabilitation and Balneotherapy,²Belarusian State Medical University, Minsk, Belarus

Objective: The evidence exists that the level of glycemic control is associated to bone health. Hyperglycemia impairs osteoblast function and antidiabetic medications can contribute to changes in bone tissue. However, patients with type 2 diabetes mellitus (T2DM) do not fit into the classic osteoporosis pathophysiology. With regards to the association between BMC and T2DM, some conflicting results have been reported. The aim of the study was the examination of bone mineral content in T2DM patients comparing with control.

Methods: We measured bone mineral content using DXA in 82 patients with T2DM, the control group consisted of 39 health age- and BMI-matched persons. The statistical differences confirmed by glucose level: 8.14 (5.56-9.9) mmol/l in T2DM and 5.48 (4.91-5.78) mmol/l in control group, $p=0.001$ and by the level of Hb A1c: 7.24 (5.89-8.3)% in T2DM vs. 5.76 (5.52-5.98)% in healthy controls, $p=0.001$.

Results: It has been established that the BMC total in T2DM was lower 2505 (2206-2764) g than BMC total of the control group 2845 (2498-3293) g, $p=0.001$. No differences were found in BMC (arms+legs) between T2DM patients 1310 (1126-1403) g vs. comparison 1416 (1211-1685) g, $p=0.03$; while BMC of Trunk in patients with T2DM was lower 776 (642-876) g than BMC of trunk of controls 948 (778-1166) g; $p=0.0002$.

Conclusions: These findings suggest the hypothesis that patients with T2DM are at higher risk of bone loss and OP risk. The absence of target glycemia level of glycated hemoglobin could be one of the reason of bone content lose in patients with diabetes.

Because of clinical implications of osteoporosis in well being, it is important to identify and refer for osteoporosis evaluation patients with T2DM.

P358
MORBIDITY AND CLINICAL LABORATORY FINDINGS IN ADULTS WITH X-LINKED HYPOPHOSPHATEMIA (XLH)

J. J. Broseta¹, L. C. López², E. Guillén¹, A. Gómez-Bori², S. Mendizábal³, J. Hernández-Jaras²

¹Division of Dialysis/Department of Nephrology and Kidney Transplantation/Hospital Clínic, Barcelona, ²Department of Nephrology/Clinical Area of Kidney and Urinary Tract/Hospital Universitari i Politècnic La Fe, Valencia, ³Division of Pediatric Nephrology/Department of Pediatrics/Hospital Universitari i Politècnic La Fe, Valencia, Spain

Objective: XLH is a rare inherited disease caused by alteration of the PHEX gene that results in an increase in serum levels of fibroblast growth factor 23 (FGF-23) and with it, renal phosphate

wasting, reduced 1,25-dihydroxyvitamin D and, thus, hypophosphatemia which result in defects in bone mineralization. In adults, this defects cause significant morbidity, presenting short stature, bowed or bent legs, osteomalacia, bone and joint pain, fractures, hearing impairment, extraosseous calcifications, tooth abscess, among others. Despite conventional therapy (oral phosphorus supplementation and calcitriol), a significant percentage of patients develop deformities that impact their functionality and quality of life. Our aim was to deepen the understanding of the clinical course and the impact on morbidity and serum and urine laboratory findings in adult patients affected by XLH.

Methods: Longitudinal study with retrospective data collection of a series of 24 no family-related patients affected by XLH who were followed-up in the Outpatient Services of the Department of Nephrology of the Hospital Universitari i Politècnic La Fe. Demographic, clinical and diagnostic variables were collected from the initial diagnosis in childhood until January 2018.


Results:

Age at diagnosis (years)	3,75 ± 3,12		
Sex	Male 35,7%, Female 64,3%		
Follow-up time (years)	17,92 ± 12,09		
	At diagnosis	At the end of follow-up	P
Phosphorus (mg/dL)	2,34 ± 0,62	2,73 ± 0,74	0,1
Calcium (mg/dL)	9,73 ± 0,48	9,4 ± 0,51	0,129
Tubular phosphate reabsorption (%)	76 ± 14	74 ± 16,7	0,531
Calciuria (mg/24h)	95,2 ± 119	128,55 ± 147,87	0,037
PTH (pg/mL)	58,62 ± 35,61	88,89 ± 81,82	0,267
1,25-dihydroxycalciferol (ng/mL)	20,18 ± 5,78	24,85 ± 11,49	0,328
Alkaline phosphatase (UI/L)	361,16 ± 207,27	203,08 ± 153,33	0,02
Creatinine (mg/dL)	0,47 ± 0,25	0,58 ± 0,2	0,07
UACR (mg/g)	5,03 ± 4,43	7,46 ± 10,54	0,521
Proteinuria (g/24h)	0,15 ± 0,07	0,19 ± 0,17	0,369

Values are shown as mean ± standard deviation.

Conclusions: Most adults affected by XLH present short stature and lower limb deformity despite the classical substitution treatment taken since the childhood. Although we found a significant reduction of the levels of alkaline phosphatase, the mean of them did not reach the normality. This can be related to poor compliance because of the bad gastrointestinal tolerance of the treatment. In addition, we encountered relevant treatment adverse events, like secondary hyperparathyroidism and nephrocalcinosis in an unacceptable percentage of patients. It is necessary to advance in better treatments that block the mechanism of the disease to allow a normal childhood growth to these patients, avoiding the consequences of XLH in adulthood, since the current treatment is insufficient and leads to undesirable consequences.

Disclosures: J.J. Broseta and J. Hernández-Jaras have received remuneration for participating in some lectures by Kyowa Kirin.



P359
BILATERAL OVARIO-HYSTERECTOMY INDUCED OSTEOPOROTIC RABBIT MODEL

E. S. Jin¹, J. Y. Kim², J. M. Min², S. R. Jeon³, K. H. Choi⁴, J. H. Jeong⁵

¹Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, South Korea, ²Laboratory of Stem Cell Therapy, College of Medicine, Asan Medical Center, University of Ulsan, Seoul, South Korea, ³Department of Neurological surgery, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, South Korea, ⁴Department of Rehabilitation Medicine, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, South Korea, ⁵Department of Neurosurgery, Soonchunhyang University Bucheon Hospital, Seoul, South Korea

Rabbit models have been proposed for the study of postmenopausal osteoporosis by bilateral ovariectomy with reduced dietary calcium intake or glucocorticoid administration. However, re-

stricting dietary calcium intake or administering a glucocorticoid can cause secondary osteoporosis and is not representative of a pure postmenopausal osteoporosis model. The aim of this study was to establish an experimental rabbit model of osteoporosis induced by ovario-hysterectomy alone. Fourteen female New Zealand rabbits were separated into two groups of a sham (control) and the ovario-hysterectomy-induced osteoporosis group. Tibiae were extracted 24 weeks after ovario-hysterectomy and were scanned by micro-computed tomography. The evaluation parameters were bone mineral density (BMD), trabecular bone volume (BV/TV), trabecular number (Tb.N), trabecular thickness, and trabecular separation (Tb.Sp). The tibial samples were evaluated after hematoxylin and eosin and Masson's trichrome staining. The sham group had significantly higher BMD, BV/TV, and Tb.N values and the lowest Tb.Sp value compared to the ovario-hysterectomy group. The histological analyses revealed a loss of the bony trabeculae and an increase osteoporotic changes in the bone of the ovario-hysterectomy-induced osteoporosis group compared to the control group. Our results indicate that an ovario-hysterectomy-induced rabbit model would be one of the safe, reproducible model for postmenopausal osteoporosis.

P360

THE REGULATORY ROLE OF TYPE 3 INTERFERON CYTOKINE BETWEEN OSTEOBLASTS AND OSTEOCLASTS

Y.-H. Hsu¹, F.-H. Chen¹

¹Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Objective: The dynamic balance between osteoblastogenesis and osteoclastogenesis maintains bone remodeling and homeostasis. An imbalance between bone resorption and formation can result in bone diseases including osteoporosis. IL-29, a member of type 3 interferon family, signals through the IL-28R1 and IL-10R2 heterodimer receptor complex. Previous studies indicated that IL-29 modulates inflammatory response in rheumatoid arthritis and osteoarthritis. However, its biological role in bone homeostasis remains unclear. Our aims were to explore the effects of IL-29 in the bone homeostasis through regulating osteoblast and osteoclasts.

Methods: For osteoblastic experiments, human fetal osteoblast cell line (hFOB1.19) was used in our study. The gene expression of proinflammatory cytokines in IL-29-treated hFOB1.19 cells was analyzed using real-time PCR with specific primers. MTT and BrdU assays were performed to clarify the effect of IL-29 in osteoblast proliferation. To analyze the effect of IL-29 in osteoblastic differentiation, we analyzed the osteoblast-related transcription factor, Runx2, Osterix, and RANKL, using real-time PCR and measured alkaline phosphatase activity. For osteoclastic experiments, we used CD14⁺ monocyte isolated from human peripheral blood mononuclear cells to perform *in vitro* osteoclast differentiation assay, and used TRAP staining to analyze the effect of IL-29 in osteoclastic differentiation.

Results: IL-29 targeted on osteoblast progenitor hFOB1.19 cells to stimulate pro-inflammatory cytokine expression. For the osteoblastogenesis, IL-29 promoted osteoblast proliferation and early differentiation through upregulating osteoblastic gene Runx2 and Osterix. For osteoclastogenesis, we performed *in vitro* osteoclast differentiation system in both human and mouse, and found that IL-29 acted as a negative regulator in osteoclasts differentiation. IL-29 decreased the numbers of osteoclasts, and reduced the TRAP and cathepsin K mRNA expression.

Conclusion: IL-29 expressed in human osteoblasts and promoted osteoblast proliferation. IL-29 significantly inhibited osteoclast differentiation. These findings and further elucidation of the pathways might provide more information to the development of novel agents for treating osteoporosis.

P361

ELDECALCITOL IS MORE EFFECTIVE THAN ALFACALCIDOL IN INCREASING BMD OF CHINESE OSTEOPOROTIC PATIENTS WITHOUT VITAMIN D OR CALCIUM SUPPLEMENTATION

Y. Jiang¹, H. Tang², X. Ma³, Q. Cheng⁴, H. Lin⁵, X. Jin⁶, Z. Zhang⁷, W. Yu¹, S. He¹, T. Kobayashi⁸, S. Uehara⁸, T. Matsumoto⁹, W. Xia¹

¹Peking Union Medical College Hospital, Beijing, China, ²Beijing Friendship Hospital, Beijing, China, ³Tianjin Hospital, Tianjin, China, ⁴Huadong Hospital affiliated to Fudan University, Shanghai, China, ⁵Nanjing Drum tower Hospital affiliated of Nanjing University Medical School, Nanjing, China, ⁶Chengdu Military Central Hospital, Sichuan, China, ⁷Shanghai Sixth People Hospital, Shanghai, China, ⁸Chugai Pharmaceutical Co., Ltd, Tokyo, Japan, ⁹Fujii Memorial Institute of Medical Sciences, Tokushima University, Tokushima-ken, Japan

Objectives: Previous studies have shown that eldecalcitol, a new analog of the active vitamin D, could prevent vertebral fractures and increase BMD under vitamin D sufficiency state. The current study aimed to investigate the effect of eldecalcitol on BMD compared with alfacalcidol in Chinese osteoporotic patients without vitamin D or calcium supplementation.

Methods: In this randomized, active comparator, double-blind multicenter study, 265 Chinese osteoporotic patients were randomized to receive alfacalcidol 1.0 µg/d or eldecalcitol 0.75 µg/d for 12 months without vitamin D or calcium supplementation. The main endpoints were changes from baseline BMD in the lumbar spine, total hip and femoral neck at month 12. Changes in bone turnover markers, incidence of new fracture and safety were also assessed.

Results: Lumbar BMD increased by 2.51% with eldecalcitol treatment for 12 months, while the increase was 0.46% in the alfacalcidol group (LS mean difference, 2.05%; 95%CI, 0.96-3.15; *p*<0.001). Total hip and femoral neck BMD also increased with eldecalcitol, by 1.50% and 1.95% respectively, but were not increased with alfacalcidol. Baseline serum 25(OH)D levels and calcium intakes in both groups were below 20 ng/mL and <550 mg/d, respectively and were almost constant throughout the study. Fur-

ther subgroup analysis was stratified by baseline serum 25(OH) D and calcium intake in the eldecalcitol group and revealed that effect of eldecalcitol on lumbar spine BMD was not affected by serum 25(OH)D or calcium intake. There was no difference in the incidence of any adverse events between the two groups. Serum calcium exceeded 10.4 mg/dL in 5.9% of patients treated with eldecalcitol and 8.7% of patients treated with alfacalcidol. Urinary Ca/creatinine ratio exceeded 0.4 in 5 patients (3.7%) treated with eldecalcitol and 3 (2.4%) treated with alfacalcidol.

Conclusions: These results demonstrate that eldecalcitol increases both lumbar and hip BMD in Chinese osteoporotic patients more than alfacalcidol without sustained hypercalcemia or hypercalciuria, and that eldecalcitol increases BMD in osteoporotic patients regardless of serum 25(OH)D level or calcium intake.

Disclosure: W.B. Xia serves as a consultant for Chugai Pharmaceutical Co., Ltd. The study was sponsored by Chugai Pharmaceutical Co., Ltd.

P362

RADIOLOGICAL INDEX IN THE FLAT VERTEBRA

R. M. Veiga Cabello¹, M. D. P. Ahijado Guzmán²

¹Rheumatology Service/Internal Medicine/Htal Central de la Defensa Gómez Ulla, Madrid, ²Unit Rheumatology/Internal Medicine/Htal de Fuenlabrada, Fuenlabrada, Spain

Objective: Spine is a mechanical structure, which disposes their vertebral bodies in harmony with their stature, and progressively increasing in magnitude from the cervical to the lumbar spine. Defects in type II collagen gene are described, and in these cases, flat vertebra can be found, defined with flattening of the vertebral body, with irregular surface or with nodules of Schmorl, in isolation or in a maximum of two vertebral bodies, to distinguish it from Scheuermann's disease. Current vertebral indexes do not measure a relation between a person height and his vertebra, and if the harmony of the individual is accepted, an index that combines these variables must be created in order to guaranteeing the objectivity of the resultant value.

Methods: Patients attending physician since 1994, both sexes, 20-55 years old, in whom Type II collagen disease or vertebral dysplasia was suspected, were selected for the study. A control group was created from patients that didn't fulfill the last inclusion criteria. Their medical histories were taken. Eighth dorsal flat vertebra in a lateral chest radiograph were assessed by triple observer (two rheumatologists and one radiologist) according to the defined criteria. In all selected patients, a DXA osteoporosis screening was performed, being chest trauma exclusion criteria. Finally, a descriptive study was carried out and a comparative study of average of vertebral index of the eight dorsal vertebra (VIDV8) results was applied: $VIDV8 = 10 \times LVD8 / (HVD8 \times stature)$.




Figure 1. With a chest lateral plate, not rotated, and in the eighth dorsal vertebra (VD8), by proximity to the Scheuermann kyphosis, we calculate his length (LVD8) and his height (HVD8), measured in mm. Thus, from the horizontal one of his pedicle, taken at that height and parallel to the vertebral plate with superior disc contact, LVD8 is 35.50mm. Drawing a line perpendicular to the previous one (90.1°), and measured from the most sclerous area of the vertebral plate with disc contact superior to inferior, passing through the midpoint of its length (17.74mm), we obtain a HVD8 of 20.69mm.

Results: 174 subjects were analyzed, 84 in the study group and 90 in the control one, both homogeneous and without statistically significant differences in sex, age and height, with an average value in the study group of 47.15 years old, 48.8% women, 80.5 kg and 1.64 m. In control group: 44.5 years old, 52.2% women, 78.5 kg and 1.65 m. The VIDV8 value, did not show any significant difference compared to the previous variables, except for patient cohort, with an average value of 10.1 Meters-1 in control group, and 12.5 Meters-1 in pathological one (p<0.001). To a value of 11,108 Meters-1 the sensitivity is 90.5% and specificity 92.2%.

Conclusion: The VIDV8 is stable for the variables sex, age, height, and weight. To an outcome of 11,108 Meters-1, it discriminates both groups with sensitivity of 90.5% and specificity of 92.2%, in order to avoid the ambiguity of the explorer.

P363

FRAILITY IN OLDER COMMUNITY DWELLING ADULTS: A COMPARATIVE STUDY OF THE UK AND JAPAN

E. M. Dennison¹, K. Jameson¹, S. Tanaka², T. Iidaka³, C. Cooper¹, N. Yoshimura³

¹MRC Lifecourse Epidemiology Unit, Southampton, UK, ²Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, ³Department of Preventive Medicine for Locomotive Organ Disorders, 22nd Century Medical and Research Center, The University of Tokyo, Tokyo, Japan

Objectives: Frailty in later life is a major public health problem and associated with adverse health outcomes. It is often viewed as the sequel to sarcopenia development. Several studies have considered the prevalence of the condition in older, institutionalised adults but far fewer data are available in free living older adults. In this unique study we consider the prevalence of the condition in two community based cohorts in Japan and the UK, and relate it to the frequency of osteoporosis, another musculoskeletal condition common in later life.

Methods: Hertfordshire Cohort Study participants were born in Hertfordshire between 1931-1939 and live in the community in Hertfordshire, UK. Data available include lifestyle questionnaires,

and physical performance tests. The ROAD study is a population based prospective study of Japanese adults based in several communities. Lifestyle questionnaire data are also available, and physical performance testing was undertaken. Frailty was defined in both cohorts as the clinical syndrome in which three or more of the following criteria were present: unintentional weight loss (10 lbs in the last year), self-reported exhaustion, weakness (grip strength), slow walking speed, and low physical activity. Osteoporosis was diagnosed in the UK and Japan as a T-score of -2.5 or below at either hip or lumbar spine, as measured by DXA.

Results: The prevalence of frailty in the two countries is shown below:

	UK		Japan	
	M	F	M	F
Age				
65-69	3.2%	8.6%	0%	0%
70-74	8.6%	10.6%	1.2%	4.1%

Osteoporosis at either lumbar spine or femoral neck was present in 5.1% UK and 7% Japanese men respectively; in women the corresponding figures were 11.7% and 34% respectively. Of the study population, 0.7% and 2.9% had coexisting osteoporosis and frailty in UK and Japan respectively.

Conclusions: Frailty becomes more prevalent with increasing age, even in community dwelling older adults, with higher rates in women than men. UK rates in this study were higher than in Japan, possibly reflecting both differences in lifestyle in the two populations and genetic factors. Despite the lower prevalence of frailty in Japanese subjects, this more commonly coexisted with osteoporosis than in the UK.

Acknowledgments: *The Great Britain Sasakawa Foundation funded this study.*

P364 TREATING FIBROMYALGIA PATIENTS WITH OSTEOPENIA WITH TERIPARATIDE DAILY INJECTION

N. Neji¹, A. M. Ali¹

¹King Faisal Medial Complex, Taif, Saudi Arabia

Objectives: This study is showing the clinical results of adding teriparatide injection to the treatment of patients with fibromyalgia who developed osteopenia with teriparatide daily injection along with calcium and vitamin D supplement.

Methods: A prospective study for 35 months (from October 2015 to September 2018) in King Faisal Medical Complex in Taif which is a referral hospital serving a population of about 2 million citizens. Screening of patients diagnosed as fibromyalgia for osteopenia and osteoporosis using BMD was done. 27 patients with osteopenia (BMD between -1.0 & -2.5) were included in our study. In attempt to control fibromyalgia symptoms; teriparatide daily injections were given to those patients for initially 6 months, then, in case there is improvement in the symptoms, the treatment is extended to another 6 months. Written consents were taken from all patients before the start of anabolic bone treatment. All pa-

tients received daily calcium and vitamin D supplements. Patients who were not compliant to the treatment for any reason were removed from the study. BMD was measured at the beginning of the treatment and after one year.

Results: 18 patients (66.67%) reported improvement in the symptoms of fibromyalgia after 3 months of treatment. Improvement was maintained for the whole period of treatment. While 6 more patients (22.22%) reported improvement after 6 months of treatment. Hence, 24 patients (88.89%) in total report improvement and were candidate to extend the treatment for another 6 months. Three patients (11.11%) showed no improvement after 3 and 6 months of treatment and hence the teriparatide injection was stopped after 6 months.

Conclusion: Teriparatide daily injection showed a significant improve in the symptoms of fibromyalgia patients with osteopenia. Improvement is significant after 3 months of starting of the treatment and this improvement continue to the whole period of treatment. The conclusion of this series calls for more research in the field of anabolic bone treatment for fibromyalgia patients with osteopenia.

P365 CLINICAL RISK FACTORS (CRFS) FOR OSTEOPOROTIC FRACTURES (OFS) ARE FUNCTION OF THE FRACTURE SITE: DATA FROM THE FRISBEE STUDY

I. Iconaru¹, M. Moreau², K. Kinnard³, B. Baleanu¹, P. Paesmans⁴, K. Karmali¹, B. Bergmann⁵, B. Body¹

¹Department of Endocrinology, CHU Brugmann, Université Libre de Bruxelles, ²Data Centre, Inst. J. Bordet, Université Libre de Bruxelles, Brussels, ³Department of Internal Medicine, CHU Brugmann, Université Libre de Bruxelles, ⁴Data Centre, Inst. J. Bordet, Université Libre de Bruxelles, ⁵Department of Nuclear Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium

Objective: Several CRFs predicting OFs have been described but their association with a particular site of fracture has not been extensively studied. We evaluated if some CRFs are specific for sites of OFs in the FRISBEE cohort (Fracture Risk Brussels Epidemiological Enquiry).

Methods: We analysed the association between CRFs included in the FRAX model or additional CRFs (falls, early untreated menopause, sedentary lifestyle and diabetes) and the first incident validated MOF (vertebral, hip, shoulder and wrist) or other major fracture (ankle, pelvis/sacrum, elbow, knee, long bones).

Results: 3560 postmenopausal women, aged 60-85 y (median 70), were recruited from 2007-2013, with a median follow-up of 6.2 y. The first incident validated fractures (n=436) were hip (52), vertebra (120), wrist (122), shoulder (68) or other major (74). For MOFs considered together, the risk of fracture was highly associated in uni- and multivariate analyses (P<0.01) with BMD, osteoporosis (DXA), age, prior fracture and fall history (HR=1.38, 2.34, 1.85, 1.97 and 1.28, respectively). For each site analysed separately, in multivariate analyses, total hip BMD, osteoporosis,

age, prior OF and smoking remained independent predictors for hip fractures (HR=1.92, 3.98, 6.40, 2.70 and 3.20, respectively); spine BMD, osteoporosis, age, prior OF and glucocorticoids for vertebral fractures (HR=1.45, 2.08, 2.16, 1.94 and 1.72, respectively); femoral neck BMD, osteoporosis and prior OF (HR=1.56, 1.81 and 1.67, respectively) for wrist fractures; spine BMD, osteoporosis and prior OF (HR=1.31, 2.48 and 1.75, respectively) for shoulder fractures; prior OF and diabetes (HR=2.62 and 2.03) for other major fractures.

Conclusions: Our study confirms a strong association between the risk of fractures and BMD, osteoporosis, prior fragility fracture and age. Smoking for hip fracture, glucocorticoids for vertebral fracture, falls for MOFs and diabetes for other major fractures were also significant predictors. Our study indicates that the relative importance of CRFs is dependent on the fracture site.

P366

LIFE THREATENING SYMPTOMATIC HYPOCALCAEMIA TRIGGERED WITH DENOSUMAB IN PATIENT TREATED WITH CHRONIC ANTIEPILEPTIC THERAPY

A. Zavratnik¹, M. Čokolič¹, U. Kšela¹

¹University Medical Centre Maribor, Maribor, Slovenia

Objective: A strong suppression of osteoclasts with denosumab or bisphosphonates can cause hypocalcaemia. The incidence of it in primary osteoporosis is rare, and is usually asymptomatic. In postmarketing settings rare cases of severe symptomatic hypocalcaemia have been reported in the situations of vitamin D deficiency, malabsorption syndrome, chronic kidney disease and other medical conditions that can cause hypocalcaemia.

Methods: 82 years old woman was urgently hospitalised due to generalized seizures. Since 2001 on antiepileptic treatment for focal motor seizures related to benign tumor at left frontotemporal lobe. Lastly, she received dual antiepileptic therapy (carbamazepine since 2008, and levetiracetam since 2012). Due to high fracture risk 1st denosumab inj. was delivered by general practitioner (April 29, 2015). At the inj. day she experienced pain at jaw, tooth, palm, joints, tingling in limbs. In the following days frequent cramps at limbs occurred. At the admission day (May 9, 2015) generalized seizures developed.

Results: Initial laboratory **Results:** s-Ca 1.32 mmol/L, s-ionised Ca 0.73 mmol/L, s-phosphate 0.55 mmol/L, s-AP 1.85 Ukat/L, s-albumin 39 g/L, GFR >90 ml/min/1,73m², i-PTH 592.2 pg/mL, 25-OH vitamin D <7.5 nmol/L, celiac disease markers negative. Patient was immediately treated with i.v. Ca-gluconate, and long term with vitamin D and oral calcium. She has been followed in outpatients' endocrinology department. The report of denosumab SAE was sent to Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP).

Last laboratory **Results:** s-Ca 2.38 mmol/L, s-P 1.04 mmol/L, s-AP 1.08 ukat/L s-ionised Ca 1.24 mmol/L, 25-OH vitamin D 95.1 nmol/L, i-PTH 85.6 pg/ml. Proposed pathophysiology: Increased metabolism of vitamin D with long term antiepileptic therapy, and limited sun exposure resulted in severe vitamin D deficiency with

subsequent significant secondary hyperparathyroidism. Strong osteoclast suppression with denosumab resulted in life threatening hypocalcaemia.

Conclusion: Acute hypocalcaemia can be life threatening, and immediate correction with i.v. calcium is mandatory. Secondary causes i.e. vitamin D deficiency have to be corrected before starting antiosteoporotic drug. SAEs have to be reported to the appropriate agencies.

P367

INTIMA-MEDIA THICKNESS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH INFlixIMAB AND NON BIOLOGICAL THERAPY

F. Aramburu¹, J. Lopez-Longo², C.-M. Gonzalez-Fernandez², J.-C. Nieto², C. Marin-Huertas¹, E. Becerra-Fernandez²

¹Hospital Universitario HM Sanchinarro, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain

Objective: To evaluate the differences in intima-media thickness (IMT) in patients diagnosed of ASpa with the ASAS criteria treated with infliximab (IFX) or with nonsteroidal antiinflammatory drugs (NSAIDs).

Methods: A cross-sectional study was designed. It included 119 patients. The principal variable was the GIM measured in µm of distal Wall of common right and left carotid 1 cm proximal to carotid bulb. It was measured twice and the mean IMT in right and left sides was made separately. The IMT comparative with general population was made adjusted by sex and gender with **References** founded in the literature. Statistic analysis: The relationship between IMT with different therapies was made with the U Mann Whitney test.

Results: The mean age was 49.3±12.8 y. 83 patients was treated with IFX and 36 with NSAIDs. The distribution of cardiovascular risk factors, BASFI, BASDAI and CRP and SR was homogeneous between the two groups. Atheroma plaques were more frequent in IFX group. The right mean IMT in male <45 y was 520.8 with IFX and 530.8 without IFX (P:0.69). In 45-64.9 years was 570 with IFX and 542.9 without IFX (P:0.56). In ≥65 y was 645.3 with IFX and 618 without IFX (P: 0.55). The left mean IMT in males <45 y was 564 SD 112.9 (287-895) with IFX and 537.8 without IFX (P:0.69), 45-64.9 y was 640.6 with IFX and 489.6 without IFX (P:0.23), ≥65 y was 798 with IFX and 698 without IFX (P: 0.43). The right mean IMT in females was <45 y 473 with IFX and 519 without IFX (P:0.60); 45-64.9 y was 548 with IFX and 581 without IFX (P:0.47); ≥65 years was 644 with IFX and 721 without IFX (P: 0.12). The left mean IMT in females was <45 y 435 with IFX and 503 without IFX (P:0.43); 45-64.9 y was 631 with IFX and 667 without IFX (P:0.49); ≥65 there were no patients with IFX and 577 without IFX.

Conclusions: This study did not find differences in mean left and right IMT of common carotid of patients with ASpa treated with IFX or NSAIDs. Previous studies with smaller sample size show similar results. IMT growth rate may be influenced by the control of the disease in ASpa instead of the type of treatment.

P368

DOES ADIPOSE STEM CELL LOCALLY INJECTION HEAL BONE NONUNION? EXPERIMENTAL RAT MODEL STUDY

H. A. Olçar¹, M. Halıcı², H. I. Kafadar², E. A. Özbek¹, T. Kuru³

¹Yozgat City Hospital, Yozgat, ²Erciyes University School of Medicine Orthopaedic Surgery Department, Kayseri, Turkey, ³Canakkale Onsekiz Mart Medical Faculty, Orthopaedic and Traumatology Department, Kepez, Turkey

Objective: Experimental studies, which are observed the effect of adipose stem cell within bone union pathways, are increasing in literature. The aim of this study was to assess the effects of locally applied adipose stem cell for rats' femur nonunion. We hypothesized that even locally used adipose stem cell for rats' femur nonunion could be supported the bone union by RANK, RANKL and osteoprotegerin (OPG) gene expression.

Methods: 48 female Wistar albino rats were included in this study. Rats were randomly divided into six equal groups. Two groups were made diabetic with streptozocin (Group-A4-B2). Left femurs of five groups were osteotomized after anaesthesia was applied (Group-A2-A3-A4-B1-B2). Osteotomized femurs of rats were fixed by K-wire without gap (Group-A2). Osteotomized femurs were fixed by K-wires and U staple after 1.8 mm gap was performed between bone fragments (Group-A3-A4-B1-B2). Tenth week, bone

union was detected in group-A2 on the other hand femur nonunion was diagnosed in group-A3-A4-B1-B2 with X-Ray. 2 ml 0.9% NaCl serum was locally injected to the osteotomized area of control groups (A2-A3-A4) and 2x10⁶ adipose stem cells were locally injected to the non-union area of study groups (B1-B2) with fluoroscopy. Eighth week after injection; intracardiac blood samples were taken for biochemical analysis, and femur X-Ray were taken after that rats were sacrificed. After the sacrifice, left femurs of rats were taken for histopathological and gene expression evaluation.

Results: There were significant differences between the control(A3-A4) and study(B1-B2) groups' bone healing according to radiological and histopathological evaluation (p<0.05). Although locally injected adipose stem cells' effect to bone healing process was shown, there was no statically significant effect to bone specific RANK, RANKL and OPG gene expression levels (p>0.05).

Conclusion: Our study results were promoted our hypothesis for radiologically and histopathological bone healing. Although the effects of adipose stem cell to gene expression level was not detected, we think stem cells could be affected other genes expression levels to bone healing. Also this new hypothesis could be the aim of further studies in the future.

Figure 1: Femur nonunion is seen after ten week femur osteotomy was applied AP and lateral views of X-Ray (A, B). Femur fully bone union is seen after eight week locally injected adipose stem cell to nonunion area in AP and lateral X-Ray views (C, D).



P369

TRANSIENT MIGRATORY OSTEOPOROSIS: A VERY RARE CASE OF ALL 4 MAJOR LOWER LIMB JOINTS SEQUENTIALLY AFFECTED

A. Karamitros¹, K. Raptis¹, O. Paxinos¹, P. Makras²

¹1st Dept of Orthopaedics, 251 Hellenic Air Force General Hospital, ²Dept of Endocrinology, 251 Hellenic Air Force General Hospital, Athens, Greece

Objective: Transient migratory osteoporosis (TMO) is a rare, self-limiting condition of unknown aetiology. It is characterised by joint pain, usually of acute onset, most prevalent with weight-bearing, and/or limited range of motion. Hip is the joint most typically affected. Involvement of other lower limb joints (knee, ankle) has been described. Radiographs are typically normal, while MR find-

ings are consistent with bone marrow oedema of characteristic distribution. Our aim was too present a very rare case of TMO affecting sequentially all 4 major lower limb joints

Methods: We present a very rare case of a 43 years old male, with TMO affecting both hips and knees sequentially (with each lesion presenting after the previous had resolved) within a period of 24 months. History, clinical presentation and findings as well as diagnostic process and treatment (oral bisphosphonates along with Ca and Vit D supplementation in the first 3 episodes and iv bisphosphonates along with Ca and Vit D supplementation in the latest) are described.

Results: Two years after the latest episode and treatment with iv pamidronate, patient remains free of symptoms and imaging findings on MRI have completely resolved.

Conclusions: Diagnosis of TMO may be difficult as symptoms and findings may overlap with those of early osteonecrosis, bone marrow oedema syndrome and algodystrophy. Identifying presenting features and accurate interpretation of imaging findings enhance diagnosis and allow for prompt management.

P370

CAN WEB INFORMATION AND COMMUNICATION TECHNOLOGIES HELP IN THE MANAGEMENT OF OSTEOPOROSIS?

H. Shukla¹, A. Gupta¹, R. Shukla¹

¹Glangwili Hospital, Carmarthen, UK

Objective: The internet provides a lot of information regarding risk factors, prevention and treatment of osteoporosis. It remains a considerable challenge for healthcare systems to support individuals with chronic diseases and encourage them to assiduously follow their treatment.

Methods: Setting- patients with osteoporosis attending secondary hospital specialist clinic.

A bisphosphonate or denosumab leaflet guide, UK National Osteoporosis Society prepaid card, calcium rich food leaflet and an osteoporosis information guide were given to all patients. The active training group additionally received telephone calls after few months to remind them to read the booklets and see osteoporosis website. All patients were followed in clinic at 18 months.

Results: Out of 92 participants, 80 patients completed the study at 18 months. Age range 50-85 y. 75% were females. At the end of 18 months of therapy, only 50% of patients continued to take their medication in control group and 75% in intervention group. The intervention group significantly increased general osteoporosis and calcium awareness and knowledge, improved their calcium intake as compared with the control group. Nevertheless, participants from the intervention group were not significantly more likely to meet recommendations for behaviour lifestyle and activity changes. Participants wanted more detailed information about weight-bearing activity, exercises, about long term side effects. Some reported that they would be motivated by group education classes, some wanted interactive website discussions.

Conclusions: Well informed patient is more likely to participate in healthy behaviours and to better manage their conditions. Tailored strategies are needed to improve participation and compliance in osteoporosis. Use of interactive web based internet creates new opportunities for individuals to participate actively in monitoring and improving their health themselves with reduced reliance on healthcare providers.

P371

PARAMETERS OF MINERAL-BONE METABOLISM AND FETUIN-A LEVEL IN PATIENTS WITH RHEUMATOID ARTHRITIS

E. V. Papichev¹, B. V. Zavodovsky¹, L. E. Sivordova¹, Y. R. Akhverdyan¹, J. V. Polyakova¹

¹Federal State Budgetary Institution "Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovskiy", Volgograd, Russia

Objective: Fetuin-A (FA) is a multifunctional glycoprotein which plays an important role in systemic inflammation. Recently it was shown, that FA may restrict the inflammation in patients with rheumatoid arthritis (1). More than that, FA is an essential protein for mineral-bone metabolism (2). The aim of this study was to investigate the relationship between FA, parameters of mineral-bone metabolism and BMD in patients with RA.

Methods: We measured FA (BioVendor human fetuin-A ELISA, CZE), 25-hydroxycholecalciferol (25-(OH)D) (IDS, ELA, UK), N-terminal propeptide of type I procollagen (PINP) (Cloud-Clone Corp., ELISA, USA), C-terminal telopeptides of type I collagen (CTX-1) (IDS, ELISA, UK), serum calcium and BMD (Lunar DPX-NT GE) in 110 patients with RA and 30 healthy controls.

Results: The reference values for FA determined from healthy controls were 653.55-972.19 µg/ml (M±2σ). All patients were divided in two groups. Group 1 included 23 patients with low FA levels (≤653.55 µg/ml). Group 2 included 87 patients with normal level of FA (>653.55 µg/ml). 1st group patients had higher rate of osteoporosis (86.9% vs. 36.7%; p<0.001) and osteoporotic fractures (52.1% vs. 13.7%; p<0.001), lower BMD in lumbar spine (L1-L4) (0.905±0.025 vs. 1.064±0.017 g/cm²; p<0.001), femur neck (0.732±0.022 vs. 0.89±0.014 g/cm²; p<0.001) and femur total (0.756±0.027 vs. 0.915±0.015 g/cm²; p<0.001), lower levels of 25-(OH)D (40.43±3.68 vs. 51.48±1.75 nmol/l; p=0.005) and higher levels of CTX-1 (0.9±0.106 vs. 0.678±0.037 ng/ml; p=0.016). PINP and serum calcium concentration were not significantly different in examined groups (62.35±4.1 vs. 58.64±5.05 pg/ml; p=0.713 and 2.364±0.029 vs. 2.388±0.017 mmol/l; p=0.515 respectively).

Conclusion: Low levels of FA associate with lower BMD, higher rates of osteoporosis and osteoporotic fractures, lower levels of 25-(OH)D and higher levels of β-CrossLaps in patients with RA. This data suggests that FA may play a protective role in bone metabolism.

References:

- (1) Papichev EV et al. Klinicheskaya Laboratornaya Diagnostika (Russian Clinical Laboratory Diagnostics) 2018;63:756 (In Russ.).
- (2) Price PA et al. J Biol Chem 2009;284:17092.

P372

RESULTS OF COMPLEX TREATMENT PATIENTS WITH OSTEOGENESIS IMPERFECTA USING DRUGS OF PAMIDRONIC ACID AND SURGICAL CORRECTION WITH TELESCOPIC RODS

I. Guk¹, A. Zyma¹, O. Gayko¹, T. Kinchaya-Polishchuk¹, D. Stewart¹, A. Cheverda¹, Y. Demyan¹, O. Skuratov¹

¹SI "The Institute of Traumatology and Orthopedics" by NAMS of Ukraine, Kyiv, Ukraine

Objective: The disordered structural and functional state of bone in osteogenesis imperfecta complicates surgical interventions. We studied the impact of preoperative pamidronate on surgical outcomes in patients with osteogenesis imperfecta.

Methods: Retrospective analysis of 12 patients with osteogenesis imperfecta (Sillence type I in 5 patients, type III in 7 patients) We assessed structural and functional state of bone by biochemical study of bony metabolism and DXA of lumbar spine with subsequent preoperative treatment of metabolic alterations that included administration of calcium supplements (500-800 mg/d), active forms of vitamin D (0.25-1 µg/d) and pamidronate (0.5-1.0 mg/kg/d provided that serum Ca was above 2.4 mmol/L). Pharmacological preparation included 3 cycles separated by three month intervals. The number of infusions was determined by the level of disturbance of bone density and metabolism. Therapeutic efficacy was assessed by the decrease of β-CTx and increase of Z-factor. Subsequently the patients underwent surgical interventions for correction of long bone axial deformities with intramedullary telescopic rods.

Results: Average age on treatment was 8.5 y (range 3-15 y), with 2-y postoperative follow-up. To evaluate the osseous tissue's condition preoperatively we checked level of serum osteocalcin (118.14±63.61 ng/ml), total PINP (342.07±293.14 ng/ml), β-CTx (1.24±0.68 pg/ml), and DXA Z-score (-4.64±1.14). Analysis of the data received shows that after pamidronate treatment, the rate of bony resorption diminished on average by 25% (β-CTx – 0.93±0.388 pg/ml, p=0.026); Z-score increased by 12% (-3.9±1.4; p=0.04). We noted that the lowering of serum Ca by 0.2-0.3 mmol/l during administration of pamidronate comparing to the baseline parameters was eliminated with calcium supplementation and vitamin D. Visually during the operative intervention we noted the thickening of cortical layer and increase of bony strength. All operative patients experienced timely union of osteotomies. One patient developed fracture of femoral bone on rod after the onset of independent ambulation that was effectively corrected by plaster bandage. 8 patients became community ambulators without support, whereas the remaining 4 patients are at the last stage of surgical intervention.

Conclusion: Preoperative treatment with pamidronate and calcium in patients with osteogenesis imperfecta improves bone quality and does not inhibit bony union after osteotomy.

P373

COMPARISON OF LARGE-SCALE GENE EXPRESSION MICROARRAY STUDIES IN DIFFERENT JOINT TISSUES IN OSTEOARTHRITIS

D. Stathi¹, P. Makras², N. Symeonidis², A. Tsezou³

¹University of Athens / 251 General Air Force Hospital, Athens, ²251 General Air Force Hospital, Athens, ³University of Thessaly, Faculty of Medicine, Larissa, Greece

Objective: Osteoarthritis (OA) affects not only the articular cartilage, but also the subchondral bone and the synovium. The aim of our review is the comparison of large-scale gene expression studies, performed in different joint tissues among patients with OA and healthy subjects as well as animal models using the technology of microarrays.

Methods: The results of 18 published gene expression array studies were compared. Genes that displayed altered regulation in more than one tissue were noted and analyzed for their key functions.

Results: 66 genes had altered regulation in at least two tissues: 11 genes displayed altered expression in all three tissues, 35 genes in both cartilage and subchondral bone, 13 genes in synovium and cartilage and 7 genes in subchondral bone and synovium. Differentially expressed genes in all three joint tissues were involved in collagen synthesis (*COL1A2*, *COL3A1*), extracellular matrix (ECM) (*FN1*, *HAPLN1*), WNT signaling pathway (*WNT5B*), inflammation (*S100A9*, *PTGES*), osteoblast function (*MMP3*), bone development (*BMP6*) and cartilage synthesis (*CILP*). Common genes in synovium and subchondral bone were related to angiogenesis (*STC1*), immune response (*MIF*), osteoclast activation and differentiation (*RANKL*), collagen synthesis (*COL16A1*) and TGF-β/BMP or WNT signaling pathway (*WNT5A*, *RUNX2*). Genes with altered regulation in both cartilage and synovium were predominantly involved in inflammation (*IL6*, *CXCL2*, *S100A8*). Cartilage and subchondral bone shared the majority of differentially expressed genes implicated in collagen synthesis (*COL1A1*, *COL5A1*), ECM breakdown (*MMP13*, *MMP2*), osteoclast differentiation (*ADAM8*, *OPG*), osteoblast differentiation (*IGFBP3*), tissue development and regeneration (*POSTN*), bone remodeling (*ADAMTS5*, *WISP1*), WNT or TGF-β signaling pathway (*FRZB*, *CD14*, *TGFβ2*), inflammation (*CXCL1*, *CTSG*), cartilage and/or bone development (*HOXA11*, *MATN3*) and adipogenesis (*LIPE*).

Conclusion: It is well established that OA is a multitissue disease, rather than a cartilage lesion. On molecular level, several genes related to crucial pathways have altered regulation in more than one tissue, indicating that interplaying mechanisms and pathological processes might be involved in all three of the joint tissues. Further studies are needed.

P374

SUBSCAPULAR SPARING DELTOPECTORAL APPROACH FOR REVERSE TOTAL SHOULDER ARTHROPLASTY IN OSTEOPOROTIC PATIENTS

K. Y. An Ki Yong¹, Y. W. Chung¹, J. W. Seo¹¹Gwangju Veterans Hospital, Gwangju, South Korea

In reverse ball shoulder replacement, surgery is usually performed using a deltopectoral approach or an anterosuperior transdeltoid approach. The deltopectoral approach is to incise the pectoralis major to 1/3 to 1/2, and the scapula should be removed at the lesser tuberosity of the humerus. This approach has the problem of breaking the shoulder deltoid instead of incising the rotator cuff. Therefore, we report a detailed procedure reverse ball shoulder replacement in osteoporotic patients using approach without incision of the pectoralis major muscle and subscapularis muscle.

P375

HYPOCALCEMIA NOT JUST RELATED TO EGFR AND CAN OCCUR UP TO SIX MONTHS POST DENOSUMAB INJECTION

S. Graham¹, S. Naraen¹¹Aintree University Hospital, Liverpool, UK

Objective: Denosumab is recommended as a treatment option for the primary and secondary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures who are unable to comply with the special instructions for administering alendronate and either risedronate or etidronate, or have an intolerance of, or a contraindication to, those treatments. It is also used for male osteoporosis where bisphosphonate are either not tolerated or contraindicated. It has strong antiresorptive function and there is incidence of hypocalcemia in 2-20%. It is most likely to occur in 1-2 weeks post injection in the patients who have EGFR <30. Our aim is an audit to investigate the incidence of hypocalcaemia amongst patients taking Denosumab in our department and to evaluate our level of compliance with national guidance when monitoring hypocalcaemia. Firstly to see whether the patient was on denosumab for the correct indication and on right dose. Secondly whether patients were taking calcium and vitamin D supplement at right dose. Thirdly whether patients at high risk of hypocalcaemia, i.e., EGFR <30 had their calcium checked between 1-2 weeks after the first denosumab dose.

Method: A retrospective study of the patients between 3 January and 3 July 2018. Inclusion criteria: all patients attending the osteoporosis treatment clinic for denosumab over a 6-month period. Exclusion criteria: any patients on 120 mg of denosumab.

Result: 214 patients were identified 1 was excluded. Indication for denosumab were treatment failure in 29.5% (63 patients), poor renal function in 33.8% (72 patients), side effects on bisphosphonate 15% (32 patients), deteriorated on DXA 4.69% (10 patients), other 35/231.

100% of the patients had correct dose of denosumab, baseline renal function were checked in 96% of patients, baseline calcium were checked in 99% and 82% had baseline vitamin D checked. Only 2.5 (5 patients) EGFR was <30. Hypocalcemia was found in 14% at level <2.17 and 2% <2. Of those who developed hypocalcaemia 77% had a calcium profile checked before their last denosumab was administered and all but 3 had Ad Ca >2.25. Only 7% had hypocalcemia within 2 weeks, 27% had within one month, further 20% in 2 months and 27% in 3 months, 3% in 4 months, 10% in 5 months and 13% in 6 months, respectively.

Conclusion: There was no incidence of hypocalcemia found in patients with EGFR <30.

Hypocalcaemia does occur up to 6 months post denosumab. It is not just related to EGFR. Only 7% occurs in first two week. Only 27% patients have hypocalcemia in first month. Maximum number of patients have hypocalcemia at 3 months post denosumab.

P376

GEOGRAPHICAL VARIATION IN OUTCOMES OF PRIMARY HIP REPLACEMENT: STUDY FROM "THE NATIONAL JOINT REGISTRY OF ENGLAND AND WALES"

C. Garriga¹, J. Leal², A. Price¹, G. M. Peat³, D. Prieto-Alhambra¹, A. Carr¹, K. Barker⁴, R. Fitzpatrick², A. Rangan¹, C. Cooper⁵, N. K. Arden¹, A. Judge⁶

¹University of Oxford/Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Oxford, ²University of Oxford/Nuffield Department of Population Health, Oxford, ³Keele University/Research Institute for Primary Care & Health Sciences, Newcastle-under-Lyme, ⁴Nuffield Orthopaedic Centre/Physiotherapy Research Unit, Oxford, ⁵University of Southampton/MRC Lifecourse Epidemiology Unit, Southampton, ⁶University of Bristol/Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, Bristol, UK

Objective: To explore variation in patients' outcomes for primary hip replacement surgery across Clinical Commissioning Groups (CCGs), and to identify whether patient, surgical and hospital factors can explain why such variation exists.


Methods: The National Joint Registry was used, which incorporates data on hip replacement surgeries. Primary operations were linked with Hospital Episode Statistics data which contains records of all inpatient episodes undertaken in NHS hospitals, and Patient Reported Outcome Measures (PROMs). Primary hip replacement in people aged 18 years or over between 2014-2016 were identified. Multilevel regression models were generated for the following outcomes: length of stay (LOS), bed costs, change in Oxford hip score (OHS) 6months after surgery, and complication by 6 months. Models included a wide range of patient, surgical and hospital organisation factors. Geographical Information Systems are used to display maps describing adjusted estimates of variation in outcomes across NHS CCG areas.

Results: 173,107 primary hip replacements were identified within 207 CCG areas. 60% of patients were women, with an average age 69.3 y (SD±10.7 y). Whilst we identified a number of factors

that predicted outcomes of surgery (e.g., age, gender, comorbidity, deprivation, baseline function, surgical volume, numbers of orthopaedic surgeons, beds, operating theatres), these factors did not explain the observed geographical variations in outcomes of

surgery across CCGs. The predicted mean length of stay at hospital oscillated from 2.7 to 6.1 d, bed-day cost £4727 to £8800, absolute predicted change in OHS 18.8 to 24.6, predicted 6-month complication rate from 3.0% to 5.4% (Figure).

Variation in outcome of primary hip replacement across Clinical Commissioning Groups (2014-2016)



Conclusions: We have identified potentially unwarranted variations in patient outcomes of hip replacement surgery. This variation cannot be explained by differences in patients case mix, surgical factors, or hospital organisational factors. This information is informative to patients in making a decision in where they have their surgery, and to commissioners in monitoring variations in outcomes of surgery.

Acknowledgments: We would like to thank the patients and staff of all the hospitals in England and Wales who have contributed data to the National Joint Registry (NJR). The authors thank Ed Burn for his advice using R.

Disclosures: AJ has received consultancy fees from Freshfields Bruckhaus Deringer, and has held advisory board positions (which involved receipt of fees) from Anthera Pharmaceuticals, INC. AP reports personal fees from Zimmer Biomet, outside the submitted work. AR reports grants from DePuy Ltd outside the submitted work. CC received personal fees from: Alliance for Better Bone Health; Amgen; Eli Lilly; GSK; Medtronic; Merck; Novartis; Pfizer; Roche; Servier; Takeda; UCB, outside the submitted work. NKA received grants and personal fees outside the submitted work from: Bioberica; Merck; Flexion; Regeneron; Freshfields Bruckhaus Deringer. DPA received grants from: Amgen; UCB Biopharma; Servier; Astellas; Novartis, outside the submitted work.

P377

PATIENT USE OF INTERNET FOR INFORMATION ABOUT OSTEOPOROSIS

H. Shukla¹, A. Gupta¹, R. Shukla¹

¹Glangwili Hospital, Carmarthen, UK

Objective: To determine patient use of Internet for health information to describe the types of information sought, to evaluate patients' perceptions of the quality of this information, and to determine if patients who use the Internet for health information discuss this with their doctors.

Method: Design: questionnaire study. Setting: specialist osteoporosis hospital clinic. Participants: randomly selected patients with confirmed osteoporosis who completed a structured questionnaire.

Results: 112 patients were included. 75% females. Age range 50-95 y. 95% had internet connection at home. 46% of the patients included in the study had a personal computer. 75% stated that they used the Internet for medical information. Those using the Internet for medical information were more educated ($P < 0.001$) and younger below 65 y ($P < 0.001$). 90% felt osteoporosis information websites were very useful. 20% reported that some websites gave conflicting information. Amongst those using internet 92% felt they had improved their calcium intake and lifestyle habits including overall activity and gained better knowledge about disease and drugs. 35% were seriously concerned about side effects

of drugs especially on teeth, amongst these 90% did discuss their concerns with their dentist. 5% mentioned bisphosphonate drugs caused more fractures. 10% were seriously concerned about cardiovascular side effects of calcium tablets.

Conclusion: Healthcare providers should recognise that patients are using the worldwide web as a source of medical and health information and should be prepared to offer suggestions for appropriate web-based health resources. The use of these new information and communication technologies by patients could be useful as a resource promoting their independence, compliance and empowerment. Internet for healthcare can empower and facilitate patients to become safe and active participants in their own healthcare. Quality of information available on websites needs further research as patient's concerns could affect compliance with prolonged treatments especially for silent disease such as osteoporosis.

P378

OSTEOPOROTIC VERTEBRAL FRACTURES IN IRELAND AND NORTHERN IRELAND: A SYSTEMATIC REVIEW

E. Mc Cabe¹

¹National University of Ireland, Galway and Dept. of Rheumatology, University Hospital Galway, Galway, Ireland

Objective: Vertebral fractures (VF) are the most common subtype of osteoporotic fractures accounting for 15-64% of all fractures in published studies. They are associated with significant morbidity, mortality and are an important predictor of future fracture risk. A 2017 IOF report noted Ireland has the 6th highest incidence of hip fracture worldwide. The epidemiology of VF in Ireland is limited. Published data suggest they represent only 5% of fractures requiring hospitalisation. Empirical evidence at our institution shows that many are under-reported, not coded as a diagnosis, and follow-up is sporadic. Thus, a greater understanding is needed of the scale and impact of VF in Ireland. Our aim was to conduct a systematic literature review of osteoporotic VF in Ireland.

Methods: Searches using PubMed, Medline, Embase, Scopus, Cochrane electronic databases to identify publications from the island of Ireland addressing osteoporotic VF that were eligible for inclusion.

Results: The search produced 1558 citations, 21 of whom met our inclusion criteria, all published since 2000. VF were defined morphometrically in 9 studies, clinically in 11 studies and one study included both definitions. Data was obtained on 191,920 patients with fractures. 10 studies included more than 100 subjects, and 4 >1000. 66.9% were female and 33.1% male with a mean age of 63.8 y (34-94). There was significant heterogeneity in terms of study design and outcome measures. Studies varied from review of administrative claims data on hospitalisations in public hospitals, surgical interventions, medical management, the impact of a fracture liaison service, use of lateral vertebral assessment (LVA) and the economic impact on the burden of osteoporosis and VF. Only 2 studies systematically reviewed spinal imaging on a co-

hort of patients using blinded assessors and validated diagnostic criteria to assess the prevalence of fractures. We found a prevalence ranging from 0.86% to 87% in published studies.

Conclusions: Few publications address osteoporotic VF in Ireland. A large gap exists in our country addressing the epidemiology and importance of VF in Ireland. Detailed studies are urgently needed.

P379

FACTORS INFLUENCING THE ADDRESSABILITY OF PATIENTS SUFFERING OF OSTEOPOROSIS AND THE BENEFITS OF GEOTHERMAL WATER BASED HYDRO-PROCEDURES USED BY A PUBLIC HOSPITAL'S AMBULATORY

A. Bradács¹, C. Iuhas-Ienciu², C. Cladovan², F. Cioara¹, L. G. Daina¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, ²Municipal Hospital of Marghita, Marghita, Romania

Objectives: Osteoporosis usually influences people above the age of 50s. The hydrotherapy used by physiotherapy and medical recovery can improve the symptoms of osteoporosis in its incipient and medium phase. The hydrotherapy using geothermal water from the source 1705 of Marghita city (panonic acvifer) is used by our public hospital's ambulatory for the treatment of rheumatism and post-trauma treatments well as for osteoporosis therapy in its incipient and medium phase. This research is looking for the external factors which might influence the addressability of the patients suffering of osteoporosis and the benefits of geothermal water used during the hydrotherapy at the "Dr. Pop Mircea" Hospital, between 2013-2017.

Methods: statistical indicators of the physiotherapy ambulatory between 2013-2017.

Results: Almost 90% of the patients treated in the ambulatory system of the hospital's physiotherapy have been cured using physiotherapy procedures, the others being treated with drugs. The lowest interest for such treatments was in 2016, followed by 2014. The reasons are related to serious changes in physiotherapy treatments in the last decades. Initially all kind of procedures used by the physiotherapy have been supported and paid by the National Health Insurance. As soon as the National Health Insurance House (NHIS) has been founded, a paid rate has been established for each of the treatments. The amount paid by NHIS is different: sometimes even decreasing. But in the same time the rate paid for each procedure is increasing. For this reason, the number of the procedures supported by thy NHIS is decreasing. Medical recommendations using electrotherapy procedure are the most frequent ones, followed by therapeutic massage and hydrotherapy – sometimes this kind of treatment being not recommended. More than 57% of the patients are older than 50 y; 71% of them suffering from osteopenia and osteoporosis evidenced by DXA or X-ray. It has been evidenced that hydrotherapy for 83% of them has been beneficial.

Conclusions: There is an evidence of negative influence regarding the financing system of the physiotherapy. The hydrotherapy is successfully used for the treatment of patients suffering from osteoporosis, but due to the maladies' pathology the addressability is lower than for treatments using electrotherapy and massage.

P380

OPERATIVE TREATMENT OF THE TIBIA FRACTURE NONUNION USING NONE OF THE ADVANTAGES OF THE NEW CUTTING EDGE BIOMATERIALS

A. Bitzidis¹, D. Zagoudinos¹, D. Konstantinidis¹, N. Samaras¹, A. Kontoudis¹

¹Orthopaedic Department, Mpodosakeio Hospital of Ptolemaida, Ptolemaida, Greece

Objective: The operative treatment of tibial fracture nonunion represents a great challenge. In the last years several treatment options have been described, all using new cutting edge biomaterials analyzing their various advantages. The reported high rate of postoperative complications of nonunited tibial fractures after an open reduction and internal fixation require several revisions and sometimes with a worse outcome. [1] The current trend though for the treatment of tibial fracture non-unions does not promote a single method without the use of any metal work. We would like to present our results regarding the operative treatment of tibial fracture nonunions with the so now considered outdated Phemister technique which was initially described in 1947. According to this we only applied at the nonunion site autologous cortico-cancellous bone graft without any stabilizing factor of a hardware.

Methods: After obtaining approval from our hospital's ethics committee, we reviewed the case notes and x-rays of all patients with a tibial fracture nonunion treated operatively from 1994 until today using the Phemister technique. The year 1994 was chosen as from then we have found available patient data in the Orthopaedic Department. The inclusion criteria were based on the patient reported data, the clinical findings and the images on x-rays. All patients included in the study were complaining of tibial pain on weight bearing 6 months since the fracture with local bone movements and instability on palpation and no radiographic evidence of callus formation bridging the fracture bone ends. The Phemister technique was applied with the patient in supine position in order to harvest the bone-graft of 20-30 g from the anterior iliac crest. The fracture site was approached anterolaterally and a debridement was performed at the nonunion site followed by the positioning of the autologous bone graft. The patient had a log leg cast nonweight-bearing for 3 months.

Results: All 16 patients treated with the Phemister technique achieved radiographic union at a mean of 26 months. No postoperative infection was reported and there was no donor site complication. 11 patients developed a decreased range of ankle joint movement and 6 patients had a leg length discrepancy with a mean of 3.7 cm.

Conclusion: According to our data the Phemister technique although does not follow the current trend by using any of the advantages of the new cutting edge biomaterials, has good results in the operative management of the tibial fracture nonunions.

Reference: 1. Bose D et al. Bone Joint J 2015;97-B:814.

P381

PRIMARY HYPERPARATHYROIDISM WITH BROWN TUMORS AND CALCIFIC PANCREATITIS: A CASE REPORT

A. T. Andreeva¹, L. V. Belousova¹, D. V. Ryzhkova¹, T. L. Karonova²

¹V.A.Almazov National Medical Research Centre, ²V.A.Almazov National Medical Research Centre, I.P. Pavlov First State Medical University, St. Petersburg, Russia

Objective: We describe PHPT case in white young female with brown tumors and calcific pancreatitis.

Methods: Female (F) 30 y.o. with two preterm births (32/33 wks) in anamnesis, seizures in children at the first days of life, lumbar pain during the 2nd pregnancy with inability to walk. MRI performed at wks 26/27 showed pathological heterogeneous masses up to 28*51*41 mm in the right ilium and lateral sacrum., Postpartum PET-CT confirmed multiple metabolic active formations in bones and revealed a pathologic lesion near left thyroid gland lobe. Biopsy of sacroiliac area showed osteoblastoclastoma and F was referred to an oncologist. Detailed biochemical examination was performed only postpartum. Serum iCa level was 1.5 mmol/l (1.16-1.32), total calcium 2.77 mmol/l (< 2.5), PTH 1275 pg/ml (15.0-65.0). PHPT was diagnosed and left parathyroidectomy was performed in Aug 2017. In post-op, serum iCa level and PTH level normalized (1.15 mmol/l and 39.44 pg/ml accordingly), lumbar pain disappeared.

Results: After 6 months, F was hospitalized with hyperglycemia (glucose level up to 48.0 mmol/l, HbA1c 16.9%). DM was diagnosed and basis-bolus insulin therapy initiated. Retrospectively F had gestational diabetes during both pregnancies and was treated by diet only. Negative GAD Ab (0.28 U/ml) and low C-peptide level 0.80 ng/ml (1.10-4.40) confirmed absolute insulin deficiency non-autoimmune etiology. PET-CT data reassessment showed multiple calcinosis of pancreas as sign of PHPT hence DM was associated with PHPT. Genetic analysis did not reveal CaSR mutation, though we found SDHB mutation that is nonspecific for PHPT, but could be associated with MEN syndrome. PET-CT was repeated in Dec 2018 and showed signs of fibrocystic osteodystrophy, brown tumors and absence of hyperfixation in comparison with pre-op PET-CT data.

Conclusion: This case demonstrated unrecognized PHPT with brown tumors and calcific pancreatitis in white young female with the first clinical manifestations in pregnancy.

P382

COMPUTERIZED OSTEOPOROSIS DECISION SUPPORT TOOLS FOR PRIMARY CARE PHYSICIANSI. Goldshtein¹, V. Rouach², V. Shalev³, M. Guindy², A. Grosman¹, D. Levy¹, S. Shmilovitz¹, U. Lerner¹, O. Shamai-Lubovitz¹¹Maccabi Healthcare Services, ²Assuta Medical Centers, ³Tel Aviv University, Tel Aviv, Israel

Objectives: Osteoporosis is a silent yet common disease, managed mainly in the primary care setting; however, recent surveys depict substantial knowledge deficits among family physicians. We aimed to develop and monitor the efficacy of automated personalized alerts to assist clinical decision making in Osteoporosis.

Methods: We utilized the computerized Osteoporosis registry of Maccabi healthcare services (a large payer provider in Israel), including daily data from all bone density tests performed by Maccabi members in Assuta medical centers, as well as fractures events and therapy. To avoid overloading the physicians we focused on naïve patients with either a T-score ≤ -2.5 or vertebral or hip fracture (in accordance with the USA national guidelines). As long as the patient remained naïve, on each visit his/her assigned family physician received a pop-up recommendation to consider treatment. A follow-up screen was designed to conveniently gather links to useful, relevant actions: issue prescriptions (supplements and first line medication), print an information page for the patient, refer to a nutritionist and/or refer to laboratory tests.

Results: On October 2017 the population identified for intervention included 12,000 patients, on average 10 cases per physician, 53% being longstanding cases: untreated for over 1 y since the event (bone density test/fracture). Overtime this population grew according to incident fractures and new bone tests. Within 1 y from activation over 16,000 cases were repeatedly alerted (n=275,820 times), 29% initiated therapy (21% purchased, 8% prescribed), and additional 6% were referred to consult with an endocrinologist, which may start therapy in the near future. Treatment initiation rate was lower for secondary prevention patients (12%/8% for hip/vertebral fractures respectively vs. 25% for those with T-score ≤ -2.5), for men as compared with women, and patients older than 80 years old.

Conclusions: Our targeted alert was efficient in raising attention to missed cases at risk of fracture, although awareness to secondary prevention was still suboptimal. We continue to design further tools to support osteoporosis management in the community, including alerts for potential treatment failure (fractures or bone loss under adherent therapy) and visualization of long-term persistence.

P383

TRADITIONAL CHINESE MEDICINE SUBSIDES KNEE ARTHRITIS WITH EFFUSIONP.-C. Wu¹¹Department of Chinese medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan

Objective: The case to be reported here involved a 82-year-old female patient who visited our traditional Chinese medicine clinic on December 15, 2018, has no hypertension, no diabetes, no cardiovascular disease, and no major immune system disease. She presented to the clinic complaining of right knee pain with swelling, VAS=8-9. She regularly (every 60 d) did sonoguided aspiration about 50-60 cc yellowish serous fluid from the right suprapatellar recess, for about 6 months and take Arcoxia QD for 6 months.

Methods: Initially, the patient complained of severe right knee pain with swelling, VAS=8-9. The sonogram showed much hypo-echoic fluid accumulation at the right suprapatellar recess. She took arcoxia every day and regularly (every 60 d) did sonoguided aspiration about 50-60 cc yellowish serous fluid from the right suprapatellar recess, for about 6 months. The concept of traditional Chinese medicine of the patient's symptom is "Dampness-heat Impeding" and this treatment is adjusting the meridian system through "Clear Heat, Drain Dampness" formula by "Dang Gui Nian Tong Tang".

Results: After one month of receiving traditional Chinese medication (the formula of "Dang Gui Nian Tong Tang" treatment) since December 15, 2018, the follow-up result of the Patient revealed that the VAS=3 and she DC Arcoxia. On 2018/1/16, sonoguided aspiration about 20-30 cc yellowish clear fluid from the right suprapatellar recess. Besides, no obvious side effect was found after these treatment.

Conclusion: The knee arthritis with effusion may cause severe pain in elderly. Thus, some medical therapies for treating these pain were proposed, such as COX-2. Through the positive report in this case, we suggest traditional Chinese medicine may be a safer, simpler, cheaper and more effective treatment for knee arthritis with effusion and severe pain.

P384

TISSUE CYTOKINES AND THEIR ROLE IN THE PATHOGENESIS OF RHEUMATIC DISEASESY. Polyakova¹, E. Papichev¹, T. Kvlivdze², L. Sivordova¹, Y. Akhverdyan¹, B. Zavodovsky³, I. Zborovskaya³¹Federal State Budgetary Institution "Research Institute of Clinical and Experimental Rheumatology named after A. B. Zborovsky", ²Volgograd State Medical University, ³Federal State Budgetary Institution "Research Institute of Clinical and Experimental Rheumatology named after A. B. Zborovsky", Volgograd State Medical University, Volgograd, Russia

Objectives: The scientific interest in adipokines (adiponectin and visfatin) [1,2], hepatokin - fetuin-A [3] and neurohormones nesfatin-1 [4] is associated with their effect on inflammation and clinical

cal manifestations of RA. Our aim was to clarify the pathogenesis of RA by determining the level of adiponectin, fetuin-A, visfatin, nesfatin-1 in the serum of patients with RA.

Methods: 60 patients with RA and 30 healthy individuals were studied. The level of adipokines was determined indirectly by ELISA using commercial test systems.

Results: Adiponectin levels (<0.8 µg/ml) were detected in 25% of patients, fetuin (<653.55 µg/ml), in 27%, high visfatin levels (39 ng/ml) in 91%, nesfatin (37.95 ng/ml) at 60%. The level of tissue cytokines is associated with RA and high activity on DAS 28, positivity for ACCP, and foliar manifestations of RA. The level of fetuin and nesfatin also correlates with marked radiographic changes.

Conclusion: A low level of adiponectin and fetuin-a, a high level of visfatin and nesfatin-1, is characteristic of RA with high activity. The level of fetuin and nesfatin is related to the degree of bone damage. It is interesting to study their relationship with BMD and markers of bone metabolism. Further study of these cytokines may be useful for understanding the pathogenesis of RA and, possibly, other rheumatic diseases.

References:

1. Seewordova L. Ann Rheum Dis 2016;75(Suppl 2):970.
2. Polyakova J. Ann Rheum Dis 2014;73:C886.
3. Papichev E. Ann Rheum Dis 2018;77;1228.
4. Kvlividze T. Ann Rheum Dis 2018;77:A1762.

P385

INCIDENCE OF ASYMPTOMATIC VERTEBRAL FRACTURES IN PATIENTS WITH CHRONIC BACK PAIN

M. D. M. Muñoz Gomez¹, A. Meléndez Laborda², M. Novella Navarro³

¹Rheumatology Department, Hospital Universitario La Inmaculada, Almería, ²Physical Medicine and Rehabilitation Department, Fundación Hospital Calahorra, La Rioja, ³Rheumatology Department, Hospital Universitario de Torrejón, Madrid, Spain

Objective: Vertebral fractures are underdiagnosed, mostly due to the high prevalence of back pain, especially in people older than 65 y diagnosed with degenerative osteoarthritis. Studies show different prevalence of asymptomatic vertebral fractures, varying from 14% to 37%, since they can be unheeded because of chronic back pain. The aim of this study was to analyze the presence of nondiagnosed vertebral fractures in those patients presenting back pain, and to review data available about risk factors of osteoporosis, retrospectively.

Methods: A Cross-Sectional study was carried out. We included patients who presented *de novo* vertebral fracture in spine radiography, attended in Rheumatology and Rehabilitation due to chronic back pain. from 1st July 2018 to 31st December 2018 (6 months). Clinical records of patients with radiological findings of vertebral fracture were recruited: age, sex, BMI, smoking, alcohol consumption, comorbidities, previous study of osteoporosis, clin-

ical history of fractures (patients and family), physical exercise, secondary osteoporosis, osteoporosis treatment, bone densitometry, and FRAX score. Statistical analysis: descriptive statistical analysis: mean and standard deviation for quantitative variables and frequencies for qualitative variables. FRAX score was established as: low risk <10%, moderate risk 10-20% and high >20%.

Results: 270 patients were attended among the study period due to back pain. 42 of them (15.5%) were diagnosed with vertebral fracture in spine radiography. The mean age was 75.17 y ±10.3, and 83% of patients were female. Clinical characteristics related to risk of fractures are shown in *Table 1*.

Table 1

	YES n (%)	NO n(%)
Personal history of fracture	9 (21.42)	33 (78.57)
Family history of fracture	5 (11.9)	37 (88.09)
Alcohol consumption	5 (11.9)	34 (80.95)
Smoking	9 (21.42)	33 (78.57)
Previous Bone Densitometry	22 (52.38)	20 (47.61)
Previous osteoporosis treatment	8 (19.04)	34 (80.95)
Physical exercise	5 (11.9)	37 (88.09)

22 patients were classified in high risk of vertebral fracture according to FRAX >20%, 11 patients with moderate risk (FRAX 10-20%) and 9 patients with low risk. That means, 78,5% of patients had a moderate-high risk of fracture and only 9 patients were previously diagnosed with osteoporosis and risk factors were identified.

Conclusion: In this study, we observed a similar prevalence of asymptomatic vertebral fractures than in other studies. Data draw attention to importance of correct and comprehensive anamnesis about osteoporosis and risk factors of fracture. In order to establish an accurate treatment to prevent new fractures.

P386

DIAGNOSTIC APPROACH OF PARATHYROID CANCER IN THE ELDERLY PATIENT: CASE REPORT AND REVIEW OF THE LITERATURE

J. A. Huertas¹, M. C. Romero¹, J. A. Trejos², L. M. Maldonado¹

¹Endocrine Unit - Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia - Hospital Universitario Nacional, ²Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia - Hospital Universitario Nacional, Bogotá, Colombia

Objective: Parathyroid carcinoma is a rare entity and even more so in geriatric patients. It affects bone metabolism and masks itself with more common pathologies that cause fractures, such as postmenopausal osteoporosis. Our aim was to illustrate the diagnostic approach of atypical fractures and describe clinical-pathological forms of parathyroid cancer, to favor early diagnosis and minimize the impact on morbidity and mortality.

Case presentation: A 71-year-old woman with osteoporosis spontaneously presents an atypical femur fracture. During the diagnostic process constitutional symptoms, anemia, generalized osteolytic lesions, nephrolithiasis and hypercalcemia are documented. Frequent gynecological neoplasms and plasma cell tumors are ruled out. The presence of bone metastatic disease vs. brown tumors is considered. Tc-99m MIBI-negative primary hyperparathyroidism is diagnosed, tomographic studies show pulmonary nodule and 4 cm thyroid nodule. Fine needle aspiration reports oncocyctic follicular adenoma. Patient underwent exploratory surgery after receiving zoledronate and left thyroidectomy with its parathyroids in bloc and right upper parathyroidectomy. Pathology and immunohistochemistry of neck mass are compatible with parathyroid carcinoma, remaining parathyroid glands are unaltered. Postsurgical follow-up shows higher PTH elevation and hypercalcemia, follow-up tomography shows multiple pleural nodules suggestive of metastasis.

Results: Postmenopausal osteoporotic fractures are frequent, but in the presence of atypical fractures or Z-score ≤ -2 , in addition to the tumoral and infectious causes, the early evaluation of phosphocalcium metabolism must be considered to identify primary hyperparathyroidism. Parathyroid carcinoma is more frequent around the 5th decade of life, however, it can occur at any age. In the elderly, it shares clinical characteristics with more prevalent etiologies such as nephrolithiasis, thyroid nodule, anemia and cervical mass.

Conclusion: Parathyroid cancer has a broad clinical spectrum and should be a diagnostic alternative in atypical fractures and hyperparathyroidism, even in the absence of an imaging parathyroid lesion, or in the presence of thyroid disease.

P387

ENTHESEAL AND PERIPHERAL JOINT INVOLVEMENT IN REACTIVE ARTHRITIS: AN ULTRASOUND STUDY

A. Florescu¹, A. M. Bumbea¹, O. C. Rogoveanu¹, P. L. Ciurea¹, L. M. Florescu¹, A. E. Musetescu¹

¹University of Medicine and Pharmacy Craiova, Craiova, Romania

Objectives: Reactive arthritis is an entity of spondyloarthritis characterized by asymmetric mono or oligoarthritis and extra-articular manifestations such as enthesitis which develops after an enteral, genitourinary or poststreptococcal infection [1, 2, 3]. The purpose of this study is to determine the role of ultrasonography in monitoring joint and enthesal involvement in reactive arthritis.

Methods: The study included 12 patients (7 males, 5 females) diagnosed with reactive arthritis following enteral (25%), genitourinary (58.33%) and poststreptococcal (16.67%) infections. Other inflammatory joint diseases were excluded. We performed laboratory tests which included inflammatory markers (erythrocyte sedimentation rate and C reactive protein), rheumatoid factor and human leukocyte antigen (HLA)-B27 determination. Musculoskeletal ultrasound (MUS) of the knees, ankles and Achilles tendons

and other joints with significant arthritis upon clinical examination was performed using a MyLab25Gold machine with a multi-frequency array probe.

Results: Erythrocyte sedimentation rate levels were higher than 10 mm/h in 75% of cases, while C reactive protein was above normal limit in 66.7% of cases. HLA-B27 was positive in 3 patients. Involvement of the large joints was predominant (75%) with ankle and knee arthritis revealed by MUS in 58.33% and 50% of cases, respectively. The presence of tenosynovitis, mainly of the posterior tibialis tendons and peroneus tendons was found in 41.66% of patients. Achilles tendon enthesitis was demonstrated in 8 cases (66.67%), with the presence of enthesophytes in 7 cases (58.33%), increased thickness and hypoechogenicity in 8 cases (66.67%), power Doppler signal in 6 cases (50%) and erosions in 4 cases (33.33%).

Conclusion: MUS is a helpful examination in order to assess disease severity, joint and enthesal involvement in reactive arthritis.

References

1. Musetescu AE et al. Rom J Morphol Embryol 2017;58:801.
2. Musetescu AE et al. Rev Chim (Bucharest) 2018;69:971.
3. Mohammadi A et al. Skeletal Radiol 2013;42:219.

P388

QUALLEFO-41 GREEK VERSION OSTEOPOROSIS QUALITY OF LIFE QUESTIONNAIRE: CLOSING THE VALIDATION'S LOOP

A. Bitzidis¹, S. Spanou², C. Bitzidou³

¹Orthopaedic Department, Mpodosakeio General Hospital of Ptolemaida, Ptolemaida, ²Paediatric Department, Mpodosakeio General Hospital of Ptolemaida, Ptolemaida, ³Faculty of Physical Education and Sports Science, Democritus University of Thrace, Komotini, Greece

Objective: 4 y after the Quallefo-41 (Q-41) Greek version validation and the initial publication of data, we wanted to close the loop of the study and reassess the same group of osteoporotic patients' quality of life (QoL) comparing the results. [1]

Methods: After obtaining the approval of the Western Macedonian Greek Medical Association Ethics Committee, we redistributed the Q-41 to the same cohort of 54 Caucasian patients.

The inclusion criteria were patients diagnosed with osteoporosis according to the WHO standards with at least one low velocity vertebral fracture who were included in the initial study in 2015 and returned the questionnaires. All the participating patients resigned the consent form and completed the Q-41 instrument of osteoporosis QoL measurement voluntarily and anonymously. The Q-41 total and domain scores were adapted so 100 represented the best quality of life value. For the statistical analysis the Stata software (Version 10.1 M.P., Stata Corporation, College Station, T.X. USA) was used and the statistical importance was set at $p < 0.05$.

Results: 47 patients finally participated in the new study as 3 patients could not be reached and 4 did not returned the questionnaires. The Q-41 average total score was 68 and the average domain scores were between 45 and 74 compared to the previous data of 64, 44 and 78 respectively. P values ranged between 0.01-0.37 compared to previous 0.01-0.46. All new values were very close to the data obtained during the first study.

Conclusion: After closing the validation's loop and completing the research methodology by repeating the study based on the same scientific principles, the similar obtained data prove the validity, consistency and reliability of the Q-41 Greek version.

References: 1. <https://www.iofbonehealth.org/quality-life-questionnaires-qualleffo-41>

P389

INCIDENCE OF OSTEOPOROSIS IN PSORIATIC ARTHRITIS: A STUDY GROUP

A. Florescu¹, A. M. Bumbea¹, P. L. Ciurea¹, O. C. Rogoveanu¹, L. M. Florescu¹, A. E. Musetescu¹

¹University of Medicine and Pharmacy Craiova, Craiova, Romania

Objectives: Psoriatic arthritis (PsA) is an inflammatory disease characterized by symmetric joint arthritis, axial and enthesal involvement, associated with cutaneous psoriasis. PsA belongs to the spondyloarthritis group along with ankylosing spondylitis and reactive arthritis [1, 2]. The aim of our study is to investigate the BMD in patients with PsA.

Methods: We included in our study 28 patients with nonaxial PsA (20 females, 8 males) with mean age of 54.25 (± 5.45) y, mean disease duration of 7.45 (± 2.35) y and 28 age and sex matched controls. Neither of the patients or controls had received treatment with corticosteroids. We evaluated the patients through clinical examination and laboratory tests including biological inflammatory syndrome (erythrocyte sedimentation rate and C reactive protein) and measured BMD of the lumbar spine and hip using DXA scanner.

Results: The study group included polyarticular disease (67.85%), oligoarticular disease (25%) and arthritis mutilans (7.15%). Erythrocyte sedimentation rate and C reactive protein levels were above normal limit in 57.14% and 53.57% of patients, respectively. The BMD of the lumbar spine, quantified by the T-score, measured in PsA patients was lower, with a mean value of -1.42 SD (± 0.28) than in the control group with a mean value of -1.23 SD (± 0.16). The measurement of the BMD of the hip proved similar results with the lumbar spine scan, with a mean value of -1.14 SD (± 0.23) in the PsA group and -0.98 SD (± 0.25) in the control group.

Conclusions: Although the existence of systemic osteoporosis in PsA patients has not been extensively studied, our evaluation showed that BMD is lower in patients with arthritis than in the healthy control group.

References:

1. Musetescu AE et al. Rom J Morphol Embryol 2017;58:801.
2. Bumbea AM et al. Farmacia 2017;65:917.

P390

VITAMIN D DEFICIENCY: ASSOCIATED OR NOT WITH DISEASE ACTIVITY IN SPONDYLOARTHRITIS?

A. Florescu¹, O. C. Rogoveanu¹, P. L. Ciurea¹, C. Criveanu¹, A. E. Musetescu¹

¹University of Medicine and Pharmacy Craiova, Craiova, Romania

Objectives: The term spondyloarthritis comprises a group of inflammatory diseases characterized by axial and peripheral joint involvement, such as ankylosing spondylitis, psoriatic arthritis or reactive arthritis [1,2]. The aim of this study is to determine the association between vitamin D deficiency and disease activity in axial spondyloarthritis (axSpA).

Methods: The study included 30 patients (23 males, 7 females) diagnosed with axSpA according to the modified New York criteria with average age of 54.3 years and disease activity ranging from 2-15 y. Patients were undergoing treatment with nonsteroidal anti-inflammatory drugs (56.7%), biological therapy (43.3%) and were not receiving vitamin D supplementation. We determined 25-hydroxyvitamin D3 levels with values <30 nmol/L considered deficient and <20 nmol/L considered insufficient, C reactive protein (CRP), erythrocyte sedimentation rate (ESR), HLA-B27 and calculated the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).

Results: ESR levels were higher than 10 mm/h in 10 patients (33.33%), CRP levels were above 5 mg/dL in 9 patients (30%) and vitamin D levels were deficient in 9 cases (30%). HLA-B27 was positive in 24 cases (80%). Median BASDAI value was 6.1. Patients with biological inflammatory syndrome presented deficient values of 25-hydroxyvitamin D3, emphasizing the fact that active disease has negative effects on serum vitamin D levels. Furthermore, patients with higher BASDAI also had the lowest vitamin D serum values, consistent with our previous findings.

Conclusions: Disease activity indexes and marked biological inflammatory syndrome are linked to vitamin D levels in patients with axSpA. However, the study does not prove whether vitamin D deficiency occurred after the increase in disease activity or before. Further studies have to be conducted in order to prove the immunomodulatory role of 25hydroxyvitamin D3 in spondyloarthritis.

References:

1. Musetescu AE et al. Rom J Morphol Embryol 2017;58:801.
2. Bumbea AM et al. Farmacia 2017;65:917.

P391

FRACTURE RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS: A STUDY GROUP

A. E. Musetescu¹, A. M. Bumbea¹, C. Criveanu¹, P. L. Ciurea¹, O. C. Rogoveanu¹, A. Florescu¹

¹University of Medicine and Pharmacy Craiova, Craiova, Romania

Objectives: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by symmetric, destructive arthritis of the joints and extra-articular manifestations. A variety of treatment

options can be used in RA such as corticosteroids, conventional disease modifying drugs and also biological therapy [1, 2]. Osteoporosis is considered a complication of RA with high risk of fractures. The aim of our study is to determine the correlation between the 10-y risk of fractures using FRAX without BMD assessment and disease activity in RA.

Methods: The study included 35 patients (27 females, 8 males) diagnosed with RA according to the ACR/EULAR 2010 criteria with mean age of 44.92 y (± 4.27) and mean disease duration of 6.37 y (± 1.02). Laboratory tests included erythrocyte sedimentation rate (ESR), C reactive protein (CRP), rheumatoid factor (RF), anti-citrullinated protein antibody (ACPA). Disease activity was calculated using disease activity score (DAS) 28. The 10-y fracture risk was evaluated using FRAX.

Results: ESR and CRP levels were above normal limit in 60% and 54.28% of cases, respectively. RF was positive in 32 patients (91.42%), while ACPA was positive in 25 cases (71.42%). 17.14% patients had low disease activity, moderate and high disease activity were revealed in 54.28% and 28.57% of cases, respectively. Estimated mean risk for hip fracture was of 6.35%, while the mean risk for a major osteoporotic fracture was of 13.75%. Both hip fracture and MOF risk correlated with DAS 28 ($p < 0.005$).

Conclusion: FRAX score is increased in patients with active RA, even in the absence of BMD determination. Disease duration, high biological inflammatory syndrome and disease activity may be possible risk factors for osteoporotic fractures in RA.

References:

1. Bumbea AM et al. *Farmacia* 2017;65:917.
2. Ferro F et al. *Clin Exp Rheumatol* 2017;35:721.

P392

MUSCULOSKELETAL ULTRASOUND RELIABILITY IN EVALUATING EARLY RHEUMATOID ARTHRITIS

A. E. Musetescu¹, O. C. Rogoveanu¹, C. Criveanu¹, A. Florescu¹, P. L. Ciurea¹, A. M. Bumbea¹

¹University of Medicine and Pharmacy Craiova, Craiova, Romania

Objectives: Musculoskeletal ultrasound (MUS) is an important tool in assessing the presence of synovitis, tenosynovitis and erosions in inflammatory diseases such as rheumatoid arthritis (RA) [1]. The detection of early RA is important in order to start treatment and limit disease activity, since the treatment of RA has improved considerably with the introduction of biological agents [2, 3]. The aim of our study is to determine the value of MUS in detecting early RA.

Methods: The study included 34 patients with mean age of 47.4 y and a female to male ratio of 27:7. The mandatory criteria for inclusion in the study were the presence of inflammatory joint pain in at least 5 joints of the hands, lasting for more than 6 weeks. The patients underwent clinical evaluation, laboratory tests, MUS examinations and plain radiographs of the hands. MUS scans of the metacarpophalangeal, proximal interphalangeal joints and wrists were performed using a MyLab25Gold machine with a multifrequency array probe.

Results: Rheumatoid factor was positive in 76.47% of cases. Erythrocyte sedimentation rate and C reactive protein were above normal limits in 47.05% and 52.94% of cases, respectively. Clinical examination of the joints detected tenderness at palpation or swollen joints in 44.11% of patients, while MUS revealed ultrasonographic changes such as synovitis in 82.35%, tenosynovitis in 70.58% and erosions in 44.11% of cases. MUS detected the presence of synovitis in 26.47 of patients who had no swollen joints upon clinical examination and erosions in 11.76% of cases who had no erosions on plain radiographs of the hand. The most affected joints were the second and third MCP and radiocarpal joints.

Conclusions: MUS has proven more useful in detecting subclinical synovitis and erosions than clinical examination and plain radiographs which emphasizes on its important role in diagnosing early RA.

References:

1. Musetescu AE et al. *Rom J Morphol Embryol* 2017;58:801.
2. Bumbea AM et al. *Farmacia* 2017;65:917.
3. Abbasi M et al. *J Cell Physiol* 2018; doi: 10.1002/jcp.27860.

P393

TENOSYNOVITIS IN RHEUMATOID ARTHRITIS: A MARKER OF DISEASE ACTIVITY?

A. E. Musetescu¹, C. Criveanu¹, P. L. Ciurea¹, A. Florescu¹

¹University of Medicine and Pharmacy Craiova, Craiova, Romania

Objectives: Rheumatoid arthritis (RA) is an autoimmune disorder characterized by peripheral symmetric arthritis, mainly involving the small joints of the hand and feet, but also extra-articular manifestations in multiple sites such as the heart or lungs [1,2]. The purpose of this study is to evaluate the presence and clinical significance of tenosynovitis in patients with RA.

Methods: The study included 28 patients (21 females, 7 males) with mean age of 53.75 y (± 12.35) diagnosed with RA according to ACR/EULAR 2010 criteria, naive to biological treatment. Clinical, biological and musculoskeletal ultrasound (MUS) examinations were performed. Mandatory laboratory tests included erythrocyte sedimentation rate (ESR), C reactive protein (CRP), liver enzymes, creatinine, rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA). Disease activity was assessed using the disease activity score (DAS) 28. MUS evaluated the presence of joint effusion, synovial proliferation, erosions and power Doppler signal at the metacarpophalangeal and radiocarpal joints. The presence of tenosynovitis was assessed at the following sites: the extensor compartment of the wrist and the flexors of the fingers.

Results: Seropositivity for RF and ACPA was encountered in 20 patients (71.42%) and 18 patients (64.28%), respectively. ESR was higher than the normal limit (10 mm/h) in 85.71% of cases, with CRP values above normal range (5 mg/L) in 78.57% of patients. DAS 28 calculated with CRP showed low disease activity in 10.71% of patients, moderate disease activity in 35.71% of cases and high disease activity in 53.58% of cases. Tenosynovitis was observed in 17 patients (60.71%) at evaluated sites, synovi-

al proliferation and erosions being present in 26 cases (92.85%). Tenosynovitis was present 10 patients with high disease activity, 5 patients with moderate disease activity and 2 patients with low disease activity, the most frequently involved tendons being the extensor carpi ulnaris, I, II and III flexor digitorum.

Conclusion: Tenosynovitis is an important manifestation in patients with RA, being associated with high disease activity. However, more extensive studies have to be conducted for further assessment of our findings.

References:

1. Bumbea AM et al. *Farmacia* 2017;65:917.
2. Musetescu AE et al. *Rom J Morphol Embryol* 2017;58:801.

P394

DICLOFENAC USE IN ACUTE AND CHRONIC PAIN: WHAT ARE THE SOURCES OF CONFLICTUAL POSITIONS OF REGULATORY BODIES, PRESCRIBERS AND PATIENTS?

F. Berghea¹, D. Belinski Opris¹, M. Bojinca¹, C. Codreanu¹, C. Paulina², D. Gheonea², M. Parvu³, R. Ionescu¹

¹Carol Davila University of Medicine and Pharmacy, Bucharest,

²University of Medicine and Pharmacy, Craiova, ³Colentina Clinical Hospital, Bucharest, Romania

Objectives: Nonsteroidal anti-inflammatory drugs (NSAIDs) are largely used in rheumatic diseases being the core of drug therapy. They are used both for their structural and for their symptomatic role. The class has some important advantages (low prices, wide availability, a long history and various OTC formulations) that made it highly appreciated by physicians. Various regulatory bodies imposed restrictions in usage of NSAIDs due cardiac and digestive adverse reactions are in place. Despite all warnings, the patients continue to prefer them, and family practitioners tend to follow their patient's request. We intended to identify possible sources of this conflictual positions between regulatory bodies vs. prescribers and patients.

Methods: Several scientific experts in internal medicine, rheumatology and gastroenterology fields that cover a jurisdiction of about 20 million European Union inhabitants, debated the present place of diclofenac between the stiffness of international guidelines and the perceptions and behavior of prescribing physicians and the end-user: the patients. The exercise was based on published studies that triggered the debate; however, the clinical experience of attending experts was also discussed.

Results: The expert group agreed that diclofenac remains a major NSAID in every rheumatologist's portfolio. On the positive side the group noted a relatively long history of use (longer than for any specific COX2 molecule), a robust prescribing expertise (especially in mature rheumatologists that have used diclofenac in a time when not so many NSAIDs were available). On the negative side the group noted conflictual reports regarding cardiovascular safety, the EMA position statement and the lack of interest from major pharmaceutical sponsors to support safety studies developed under current guidelines. As a result, diclofenac is perceived

as a mature molecule that for the time being suffers a certain degree of "public image" deterioration. The expert group agreed that regulatory bodies (like EMA or FDA) played a positive major role in increasing the general awareness about NSAIDs safety and their messages have been properly disseminated. However, the June 2013 EMA statement regarding diclofenac probably induced a negative impact on the level of trust the physicians have in this molecule. However, diclofenac efficacy is considered a major asset that has a superior value in the patient's eye compared with safety issues.

Conclusions: The expert group agreed that diclofenac should be actively assessed for safety (systemic and topical formulations) and efficacy (topical formulations) following the major therapeutic guidelines and these studies should have rather a local population cover than an interntional dimesnion. The expert group feels that it is necessary to increase the knowledge and improve a subsequent dissemination of trustful data regarding cardiovascular safety of NSAIDs in general and diclofenac in particular. However the information campaign should be based on local values. The experts considered the importance of a proper understanding of the amplitude of gastrointestinal vs. cardiovascular risks

P395

ASSOCIATION OF SERUM CADMIUM ON BONE MINERAL DENSITY IN POSTMENOPAUSAL SAUDI WOMEN WITH AND WITHOUT OSTEOPOROSIS

E. Alharbi¹, S. Abdi¹, N. Aldaghri², A. Al-Amro¹, S. Yakout²

¹Biochemistry Department, College of Science, King Saud University, ²Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia

Objective: Osteoporosis is a chronic disease including genetic, endocrine, exercise and diet-related factors. It is reported to be common among middle-aged Saudi women. Serum trace elements such as cadmium may be associated with BMD. However, their exact involvement in osteoporosis has not yet been fully clarified. Our aim was to investigate the associations of serum cadmium with BMD and other bone and inflammatory markers in postmenopausal Saudi women with and without osteoporosis.

Methods: A total of 206 postmenopausal Saudi women ≥ 50 years old, 109 with osteoporosis and 97 without osteoporosis were recruited from King Salman Hospital and King Fahd Medical City, Riyadh, Saudi Arabia. BMD (g/cm²) of lumbar vertebrae (L2-L4) were measured using DXA (Hologic QDR 2000 Inc., Waltham, MA). Serum 25(OH)D and osteocalcin were determined using electrochemiluminescence (COBAS e411). Serum calcium, albumin, glucose, lipid profile, and inorganic phosphate were measured by a chemical analyzer (Konelab 20). Serum TNF α , IL-6, IGF-1 and IGF-2 were determined using Luminex xMAP technology. Serum cadmium was determined using inductively coupled plasma mass spectrometry. The correlation between various measured parameters was performed using Pearson's test.

Results: BMD values were significantly lower in patients with osteoporosis than those without at all measured sites ($p < 0.01$). In the osteoporosis group, cadmium was significantly and inversely correlated with T-score of spine ($r = -0.218$, $p = 0.05$) while it was positively associated with total cholesterol ($r = 0.25$, $p = 0.01$). Osteocalcin was also significantly associated with cadmium in all subjects ($r = 0.23$, $p = 0.01$) as well as with TNF α and IGF-1 in the osteoporosis group ($r = 0.5$, $p < 0.01$ and $r = 0.28$, $p < 0.05$ respectively).

Conclusion: Our findings demonstrate the negative associations of cadmium on bone metabolism in postmenopausal Saudi women with osteoporosis.

P396

UNITY IS STRENGTH: DRUGS AND PHYSIOTHERAPY IN THE TREATMENT OF OSTEOPOROSIS

G. Deinite¹, O. L. F. Ragusa²

¹Centre de Soins de Suite et de Réadaptation Orcet Mangini France, Hauteville-Lompnes, France, ²S.C. Medicina Fisica e Riabilitazione ASL TO 3, Venaria Reale, Italy

Objective: Approximately many people (75%) have a condition of skeletal fragility; about 42% of women (between the ages of 70-80) suffers from osteoporosis. It is therefore necessary to implement a series of measures to prevent the evolution of the disease, precisely in relation to the important economic and social consequences that it determines. The physiological evolution of osteoporosis is represented by the fracture, more frequently the vertebral, often unknown, more rarely but disabling the femoral. However, the evolution of the disease always leads to a change in the patient's quality of life, also in relation to pain and physical limitations. Starting from these premises we tried to identify a therapeutic protocol that is not based exclusively on pharmacological treatment to try to reduce the problems related to osteoporosis, also in relation to the obvious side effects that often therapies for the most classic osteoporosis.

Methods: Between June 2014 and January 2017, 213 patients were identified with a diagnosis of primary osteoporosis, of whom 120 were recruited for the study. The average age of the sample was 71.8 aa. (min 64 - max 82). All the selected patients did not show up at the time of recruitment under treatment specific for osteoporosis on average over 2 y and did not present any cognitive disturbances of any kind. About 45% made occasional use of calcium with or without vitamin D3 combination. All patients at the time of recruitment (T0) were subjected to densitometry using the DXA method of the lumbar and femoral spine. The patients were then subjected to a psychiatric and geriatric evaluation, VAS scale, ADL and IADL and QoL. The mean values of VAS were 3.7 of average, while the values of IADL and ADL reflect a certain autonomy in the management of the daily living. The T-score valued at the DXA was on average 2.3. The presence of amplitude reduction of vertebral bodies was not considered relevant. The patients were subdivided into three homogeneous groups by age, clinical characteristics, densitometry and averages of rating scales. One group was treated with alendronate in mono weekly administration (Group A), the second group with denosumab in 6-monthly administration (Group B) and the third group was treat-

ed with denosumab in combination with physical therapy (Group C). Treatment with physical therapy involved 60 min of total body magnetotherapy alternating between 80-100-80 Gauss, TECAR antalgic electrotherapy in the neck and in the loin sacral region, 20 min of gentle gymnastics. The pharmacological treatment was continued uninterruptedly for 12 months, while the physiotherapy treatment involved 10 consecutive sessions to be repeated at 3 months of distance for a total of four cycles. At 12 months, all patients repeated the T0 evaluation. Every 3 months the patients were called by telephone on the general conditions of health.

Results: It was observed a greater improvement in patients performing combined denosumab and physiotherapy treatment, but also between patients who make alendronate and denosumab there are some differences. First, we analyzed the pain: in patients who perform combined treatment (Group C), the mean value of VAS has increased to about 1.8 with a reduction of about 50% compared to the starting value. Patients treated with denosumab alone (Group B) show a reduction of about 24%, while patients with alendronate (Group A) are around 13%. Moreover they reduced the use of drugs in patients in group C significantly compared to six months before the start of treatment in progress; also those in group B indicated a reduction of NSAIDs use, while patients in group A did not report substantial changes. Daily activities and quality of life: both parameters improved in patients undergoing treatment. The group that showed the greatest improvement is group C, with a statistically more significant result compared to patients in group A and with significantly percentages than group B, located in an intermediate position between the two groups.

Conclusion: Therefore, the rehabilitative treatment is useful for patients suffering from osteoporosis and is able to enhance the action of antiosteoporosis drugs. Not all drugs, however, have the same effect. Likely the indirect action of denosumab on osteoblasts, miming a physiological action is able to modulate the process of bone remodeling. This mechanism could be the basis of pain reduction in patients who use it. If it is supposed that the pain is linked to the microfractures to which the bone trabeculae are subjected to microtrauma, which we could define as parapsychological, but not supported by the fragile osteoporotic trabecula, the presence of a drug able to facilitate the reconstruction of the trabeculation, without altering the mechanisms of mineralization, it would ultimately facilitate the reconstruction of the bone itself, obviously in nonadvanced stages of pathology. The action of physical therapy, with the double biostimulating effect of magnetotherapy and mobilization, enhanced in this case by the direct antalgic effect of electrotherapy. We certainly cannot draw firm conclusions from this study. The results achieved can however help us to promote a new way of acting towards a patient with osteoporosis, considering that the quality of the bone is also the quality of life.

P397

EFFECTS OF TWO YEARS OF TERIPARATIDE TREATMENT FOLLOWED BY TWO YEARS OF BISPHOSPHONATES IN REDUCTION IN FRACTURE RATE AND BACK PAIN AT PATIENTS WITH MULTIPLE PRE-EXISTING VERTEBRAL FRACTURES

C. Galesanu¹, I. Pascariu², N. Lisnic², M. R. Galesanu³

¹Endocrinology, University of Medicine and Pharmacy 'Grigore T. Popa', ²Emergency Clinical Hospital "Sfantul Spiridon", ³Romanian Academy of Medical Sciences, Iasi, Romania

Objective: Teriparatide (TPTD) is a therapeutic agent that increases the formation of new bone tissue and provide some remediation of the architectural defects in the osteoporotic skeleton. It is unclear which treatment should be given after stopping teriparatide therapy for severe osteoporosis. Bisphosphonate therapy can maintain BMD gains after medication cessation. Our aim was to evaluate the effect of prior teriparatide exposure and after that the bisphosphonate response and to compare BMD effects of follow-up treatments.

Methods: Ten osteoporotic naïve-patients (7 postmenopausal women and 3 men) are treated with TPTD 20 µg/d for 24 months, followed by risedronate 75 mg/mo for other 24 months. All patients received calcium and vitamin D supplementation. Changes in BMD from baseline to 24 mo, 48 mo were analyzed. Fasting serum was collected for baseline PTH, 25 hydroxyvitamin D, and baseline and treatment 24, 48 mo, PINP, CTX, bone ALP, osteocalcin, serum calcium.

Results: Daily teriparatide treatment for 2 y significantly increased spine BMD by 16.6%, total hip and femoral neck, 7.5% and 11,9% respectively. Under the risedronate the year 2 have had an increase of BMD at the lumbar by 6.7%. and 4.0% at the total hip and -1.6% at femoral neck. Markers of bone formation (PINP, bone ALP, osteocalcin) increased early during TPTD therapy. Under the risedronate markers in bone resorption (CTX) decreased.

Conclusions: BMD increases progressively over 2 y of TPTD therapy in patients with severe osteoporosis. After discontinuation of teriparatide, risedronate 75 mg increases spine and total hip BMD. This confirms the need an antiresorptive treatment to prevent bone loss after TPTD.

P398

USING TERIPARATIDE IN PROMOTING POSTOPERATIVE HEALING OF COMMUNATED FEMORAL SHAFT FRACTURES

T. Elkabalawy¹, A. M. Ali¹

¹King Faisal Medical Complex, Taif, Saudi Arabia

Objectives: To study the effect of using teriparatide injection for 3 months after surgical fixation of comminuted femoral shaft fractures in trauma, healthy, nonosteoporotic adult patients.

Methods: King Faisal Medical Complex in Taif is a referral central hospital accepting road traffic accidents occurring in Taif city and 8 other rural communities around. During the period of 45 months

(from September 2014 to June 2018), we conducted a case series study for selected RTAs victims admitted in our hospital. We included young nonosteoporotic adult patients with comminuted femoral shaft fractures. We excluded patients with associated head injuries and patients with previously hormonal disturbances. All patients underwent surgery with either bridging plate or interlocking intramedullary nail with or without bone substitute. As a result of the comminuted nature of the fractures; none of these fixations were compressing the fracture edges. This situation calls for the use of Teriparatide injection in the first 3 months of the healing period, to catalyze the healing process. Patients were consented about using Teriparatide. Calcium and vitamin D supplements were given. Monthly follow-up with check x-rays were done to all our patients till complete healing.

Results: 37 patients were included in our study; all patients completed the 3 months period of teriparatide injection. 23 patients (62.16%) reached complete healing by the end of the first 3 months, 9 patients (24.32%) reached complete healing in the second 3 months, while 5 patients (13.51%) experienced nonunion which needed revision surgery after 6-12 months of the primary surgery.

Conclusion: In our series it was evident, clinically and radiologically, that teriparatide promotes callus formation and callus volume, thus promoting fracture healing. We are convinced through our experience that teriparatide should be indicated for promoting fracture healing especially for comminuted fractures regardless the presence of osteoporosis. Many case-series studies in the literature agree with our findings. However, more studies are needed to gain required evidence level to consider teriparatide injection in treating comminuted fractures in nonosteoporotic adults.

P399

EVALUATION OF SEASONAL VARIATION EFFECT ON HIGH SCHOOL STUDENTS' PHYSICAL ACTIVITY AND ENERGY EXPENDITURE

C. Bitzidou¹, A. Bitzidis², S. Spanou³

¹Faculty of Physical Education and Sports Science, Democritus University of Thrace, Komotini, ²Orthopaedic Department, Mpodosakeio General Hospital of Ptolemaida, Ptolemaida, ³Paediatric Department, Mpodosakeio General Hospital of Ptolemaida, Ptolemaida, Greece

Objective: We wanted to evaluate the season's variation effect on physical activity and energy expenditure in high school students.

Method: A total of 300 female and male students from 2 different general high schools in a rural area in northern Greece participated in the study. Consent was obtained from a student's guardian. According to the study's design, the International Physical Activity questionnaire (IPAQ) was administered once in the winter time (December) and once in spring (April) to every participant who filled it voluntarily and anonymously. The IPAQ is a self-administered instrument of daily physical activity measurement for a total period of 7 d. The daily physical activity includes all household work, walking, sitting, traveling, activity in school and sports and

it is distinguished in 3 different levels: high, moderate and low. [1, 2] A total score of physical activity is calculated which also represents the weekly energy expenditure in metabolic equivalents (METs). One MET is defined as the amount of oxygen consumed while sitting at rest and is equal to 3.5 ml O₂ per kg body weight x min. [3] For the statistical analysis of the obtained data we used the IBM SPSS software and the Bonferroni and Sidak multiple comparisons tests and the statistical importance was set at p<0.05. [4,5]

Results: 206 students (125 females) completed the IPAQ twice while 75 students (32 males) completed it only once in December. 19 students did not complete it at all. The mean age of the participants (n=206) was 16.74±0.8 y. In Table 1 below are the results regarding the level of the physical activity in the winter and spring with p<0.037.

Table 1.

Level of physical activity	Cohort (n=206)		Female students (n=125)		Male students (n=81)	
	Winter	Spring	Winter	Spring	Winter	Spring
High	143 (69%)	159 (77%)	81 (65%)	90 (72%)	62 (77%)	69 (85%)
Moderate	36 (18%)	31 (15%)	23 (18%)	21 (17%)	13 (16%)	10 (12%)
Low	27 (13%)	16 (8%)	21 (17%)	14 (11%)	6 (7%)	2 (3%)

In Table 2 are the results regarding the seasonal variation effect on energy expenditure expressed in METs of the 3 high school grades with p<0.0267.

Table 2.

Seasonal variation	Female students' METs total score in min/7 days	Male students' METs total score	1 st grade students' METs total score	2 nd grade students' METs total score	3 rd grade students' METs total score
Winter	5346	7437	7726	6241	4343
Spring	5941	7450	6822	6314	6740

Conclusions: According to our data, the seasonal variation does not have an effect on physical activity and energy expenditure in high school students. The students' physical activity and energy expenditure were influenced though by the grade they were at as the first one scored the highest values.

Reference

- Gunn SM et al. Med Sci Sports Exerc 2002; 34:895.
- <http://www.teiath.gr/userfiles/mstamou/IPAQ.pdf>
- Jetté M et al. Clin Cardiol 1990;13:555.
- <https://it.auth.gr/el/software/SPSS>
- The Bonferonni and Šidák Corrections for Multiple Comparisons. H Abdi. In N.J. Salkind Ed.), 2007, Encyclopedia of Measurement and Statistics. Thousand Oaks (CA): Sage. pp. 103-107.

P400
EFFECT OF 3D PRINTING-ASSISTED MIPPO IN THE TREATMENT OF CLAVICLE FRACTURE

B. Weiguo¹

¹Department of Orthopaedics, The First Affiliated Hospital of Xi'an Jiaotong University, Xian, China

Objective: To investigate the effect of 3D printing-assisted minimally invasive percutaneous plate osteosynthesis (MIPPO) in the treatment of clavicular fracture.

Methods: 28 cases of clavicular fractures were randomly divided into two groups: 3D printing-assisted MIPPO group and MIPPO group, fourteen cases in each group. In the 3D printing-assisted MIPPO group, CT scan the healthy clavicle side before the operation to provide inverted image in the software in order to build the 3D printed physical model which is helpful in selecting the steel plate of appropriate length, whose local angle can also be adjusted and preset, whereas the MIPPO group only made a surgical plan based on imaging data. The incision length, bone frac-

ture healing time, operation time, bleeding volume, fluoroscopy times, incidence of complications, Constant score, DASH score and Neer score were compared between two groups.

Results: Between 3D printing-assisted MIPPO group and MIPPO group, there was no significant difference in aspects of incision length [(7.71±1.32) cm VS. (8.04±1.41) cm], bone healing time [(2.9±0.2) months VS. (3.0±0.3) months], Constant scores (97.21±1.26) vs. (94.35±2.31), DASH scores (2.71±0.16) vs. (2.93±0.32) and Neer scores (93.5±3.1) vs. (91.2±2.7). There were significant differences in aspects of bleeding volume [(45.3±4.2) mL vs. (72.4±1.9) mL], operation time [(40.2±6.3) min vs. (53.2±4.1) min], fluoroscopy times (3.4±1.2) vs. (6.2±1.9), rate of superficial infection around the incision (0% vs. 7.146%) and incidence of internal implants protrusion (7.14% VS. 28.6%), $P < 0.05$.

Conclusion: 3D printing-assisted MIPPO has great significance in the treatment of clavicular fracture. It is helpful the doctor to select the appropriate length of anatomic plate before operation and to pre-bend and adjust it. It is also helpful the surgeon to clearly know the expected operation reduction and understand the expected effect. So as to shorten the operation time, reduce the amount of bleeding and reduce the number of fluoroscopy. It is worthy of clinical application.

P401

AN ERR α MODULATOR DERIVED FROM AN HERBAL MEDICINE INHIBITS OSTEOCLAST DIFFERENTIATION

T. Huang¹, M. Yang², M. Guan¹

¹Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences,

²Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of, Shenzhen, China

Objective: To determine andrographolide, a diterpene lactone extracted from *Acanthaceae paniculata* herb, inhibits osteoclast differentiation as an inverse agonist of estrogen-related receptor α (ERR α).

Methods: Autodock Vina was employed to study the possible binding mode of andrographolide to ERR α . Co-immunoprecipitations of ERR α and PGC-1 β was performed from cells extracts to study how andrographolide modulate such interaction. Luciferase reporter assay, real-time PCR and Western blot were used to analyze how andrographolide affect the expression levels of ERR α target genes. Bone marrow monocytes from male mice were isolated and then infected with ERR α -expressing lentivirus and treated by different doses of andrographolide to assess osteoclast differentiation *ex vivo*.

Results: Andrographolide dose dependently suppressed the activity of a reporter luciferase that reflects the extent of interaction between co-activator PGC-1 β and the ligand binding domain of ERR α . Additionally, andrographolide disrupts the interaction between PGC-1 β and ERR α by a co-immunoprecipitation assay. ERR α coordinated with PGC-1 β to facilitate osteoclast differen-

tiation which was enhanced by lentivirus-mediated ERR α overexpression and repressed by andrographolide treatment in a dose dependent manner.

Conclusion: Acting as an ERR α inverse agonist, andrographolide can effectively reduce osteoclast differentiation through disrupting the interaction between ERR α and coactivator PGC-1 β ; thereby, modulating the transcriptional regulation of ERR α in osteoclast.

P402

PRIMARY HYPERPARATHYROIDISM IN IRAQI PATIENTS WITH DISTAL FOREARM FRACTURES

Z. A. Mahmood¹, N. A. Jassim², A. Abdulbari³, M. K. Ahmed⁴

¹College of Medicine, University of Basra, Basra, ²College of Medicine, University of Baghdad, Baghdad, ³Ibn Sina Training Hospital, Baghdad, ⁴Al Karkh General Hospital, Baghdad, Iraq

Objective: Primary hyperparathyroidism is a generalized disorder of calcium, phosphate, and bone metabolism due to an increased secretion of PTH. The elevation of circulating hormone usually leads to hypercalcemia and hypophosphatemia. Since PTH removes calcium from bones, all patients with a parathyroid problem will eventually develop thin bones. Bones with osteoporosis due to parathyroid problems can ache and hurt because the PTH is actively destroying the bone. We showed few cases of undiagnosed hyperparathyroidism in patients who presented with a distal forearm fracture. This study aims to discover the undiagnosed primary hyperparathyroidism in patients with distal forearm fracture and assessment of the prevalence of radiological changes associated with it. Also, it aims to assess serum calcium (Ca), phosphate (Po₄), vitamin D and BMD in those patients with a distal forearm fracture.

Methods: This is a prospective cross-sectional study conducted in Orthopedic Outpatient Unit in Al Fayhaa General Hospital, Basra, Iraq, and Al-Bari Medical center, Baghdad, from April 2017 till July 2018. Participants consent was taken for inclusion in the study. 40 patients were involved in this study. Those patients were men >55 y and women >50 y of age who presented with a distal forearm fracture. The fracture was diagnosed by using plain x-ray which was analyzed by an orthopedic surgeon. Blood samples were collected for measurement of serum level of PTH, total calcium, phosphate, vitamin D, and alkaline phosphatase (ALP). BMD was measured by lumbar DXA scan using Stratos densitometry and analyzed according to Turkish ethnicity.

Results: Most of the patients included in the current study were women (82.5%). The mean age for all patients was 56.98±9.5 y. All patients had normal hands X-ray except one who had a subperiosteal reaction in the phalangeal bones. This patient also had high PTH (≥ 3 -fold), and high ALP (≥ 2 -fold) but normal S.Ca and S.Po₄. There was no significant association between the level of PTH and history of previous fractures, vitamin D level, S. Po₄, and bone status. Most of our patients were had normal S.Ca and ALP even in presence of very high PTH (≥ 3 -fold) (p value=0.037, 0.00 respectively). That means there is subclinical hyperparathyroidism. **Conclusions:** There are few undiagnosed cases of prima-

ry hyperparathyroidism (PHPT) which can be presented as distal forearm fracture. There was no significant association between the level of PTH and history of previous fractures, vitamin D level, S. Po4, and bone status. The biochemical changes are not common to occur in patients with PHPT.

P403

CHANGES IN THE PERIPHERAL BLOOD GENE EXPRESSION ASSOCIATED WITH GLUCOSE METABOLISM AND JOINT DESTRUCTION DURING TYPE II DIABETES DEVELOPMENT IN OSTEOARTHRITIC PATIENTS

E. Tchetina¹, E. Sharapova¹, N. Kashevarova¹, E. Taskina¹, L. Alekseeva¹, A. Lila¹

¹Nasonova Research Institute of Rheumatology, Moscow, Russia

Objective: Osteoarthritis (OA) involves degenerative changes in articular cartilage, remodeling of the subchondral bone and limited synovial inflammation. OA shares similarities with type 2 diabetes (T2D) including chronicity, high prevalence to end-organ failure, and strong association with age and obesity. Moreover, an adverse effect of T2D on OA development, severity, and therapeutic outcomes was observed. However, the molecular mechanisms of T2D and OA association are not completely clear. Here we hypothesized that T2D development in OA patients might involve changes in gene expression related to glucose metabolism and energy generation. Our aim was to investigate the peripheral blood gene expression associated with T2D development in OA patients during longitudinal follow-up.

Methods: Peripheral blood of 5 OA women was obtained annually in the course of 4-6-y follow-up, which included the year of T2D onset. Annual clinical testing comprised physical examination, radiographic and WOMAC scoring, and ultrasonography. Peripheral blood of 27 healthy volunteers was used as a control. Protein levels were quantified by ELISA. Expression of the genes related to glucose metabolism, extracellular matrix destruction, and general metabolic regulation was performed with quantitative real-time RT-PCR.

Results: Gene expression analyses in five examined OA patients revealed similar changes during T2D development. Specifically, the onset of T2D and further progression of the comorbidity was associated with upregulation of genes related to ATP generation in glycolysis and tricarboxylic acid cycle as well as increased expression of the genes encoding pentose phosphate cycle enzymes (G6PD and TKT) and matrix metalloproteinases (MMP-9 and MMP-8). Augmented expression of AMPK α and mTOR was also noted. In contrast, expression of HIF1 α and hexosamine pathway related genes (GFAT and OGT) decreased at T2D onset.

Conclusions: T2D onset in OA patients might be associated with augmented ATP requirements, increased redirection of glucose into pentose phosphate cycle, and greater extracellular matrix degradation. This might be caused by disturbances in protein glycosylation due to hexosamine pathway attenuation.

P404

COMBINED ALFACALCIDOL AND ALENDRONATE THERAPY IS SUPERIOR TO THE RESPECTIVE MONOTHERAPIES IN ESTABLISHED POSTMENOPAUSAL OR MALE OSTEOPOROSIS

J. D. Ringe¹, P. Farahmand¹

¹Medical Clinic 4, WOZ, Leverkusen, Germany

Objective: To compare the efficacy and safety of a treatment with alfacalcidol and alendronate combined to the treatment with either alfacalcidol or alendronate alone in patients with established postmenopausal or male osteoporosis.

Methods: 90 patients were included as matched pairs to receive randomly either 1 μ g alfacalcidol + 500 mg calcium daily (group A, n=30) or 70 mg Alendronate weekly + 1000 mg calcium + 1000 IU vitamin D daily (group B, n=30) or 1 μ g alfacalcidol daily + 70 mg alendronate weekly + 500 mg calcium daily (group C n=30). The three groups were well matched in terms of sex, mean age, height, weight, baseline mean BMD at lumbar spine and femoral neck, the prevalence rates of falls, vertebral and nonvertebral fractures. BMD was measured at the lumbar spine and at the femoral neck with DXA (Lunar) at the beginning and after 12 and 24 months.

Results: During the 2-y study we observed significant increases of BMD at the lumbar spine of 3.0% in group A compared to baseline, of 5.4% in group B and of 9.6% in group C respectively. The differences between the combination therapy and alfacalcidol (6.6%) and alendronate (4.2%) were highly significant with $P < 0.001$. We also observed significant increases of the BMD at the femoral neck of 1.5% in group A, of 2.4% in group B and of 3.8% in group C respectively. The differences between the combination therapy and alfacalcidol (2.3%) and alendronate (1.4%) were again significant. The 2-y number of patients with vertebral fractures were 5 in group A, 4 in group B and 1 in group C. The 2-y incidences of non-vertebral fractures were 4 in group A, 6 in group B and 1 in group C, i.e., the fracture data support the view of a relevant superiority of alfacalcidol and alendronate combined vs. either alfacalcidol or alendronate alone.

At month 24 (80%) of the patients in the combination therapy group were free from back pain, compared to 43.3% in the alfacalcidol group and 30.0% in the alendronate group.

Conclusion: The combination therapy of alfacalcidol and alendronate exhibited superiority over either alfacalcidol or alendronate alone. In addition the overall safety profiles of the three treatment regimens were found to be similar in this study.

P405

PRIMARY HYPERPARATHYROIDISM SURGERY: OUR EXPERIENCE

B. Varas de Dios¹, M. Martín Fuentes¹, R. Sánchez Almaraz¹, J. L. Porrero Carro

¹Santa Cristina Hospital, Madrid, Spain

Objective: We analyzed the surgical experience of the primary hyperparathyroidism (PHPT) in a University Hospital of Madrid. Extended results.

Methods: A retrospective study was conducted on 60 patients operated of PHPT from January 2005 to January 2017. We collected epidemiological and clinical data, biochemical parameters, the surgical characteristics included the measurement of intraoperative PTH (ioPTH) and osteoporosis data (fracture risk factors, densitometric data and drugs).

Results: 60 operated patients aged 55.5±15.3 y (85% female) were studied. The main surgical criterium was the hypercalcemia, but 15% of the patients had normocalcemic hyperparathyroidism. Patients who achieved healing after surgery were significantly younger. Patients with normocalcemic hyperparathyroidism had lower PTH in all measurements, higher levels of vitamin D and creatinine. We compared the clinical characteristics in patients with osteoporosis with respect to those who did not have it. Patients with OP received significantly more vitamin D supplements. They had more peripheral fractures (no significant results for vertebral and hip fractures). In addition, we found significant results in terms of the age of the patients. It was higher in those with osteoporosis (63±11.6 y vs. 49±15.6; p<0.000). The preoperative calciuria was lower in patients with OP (220.4 mg/24h±107.6 vs. 446.7±214.7; p<0.000) and ioPTH at 15 min was significantly higher in patients with smaller bone masses (82.9 pg/mL±58.0 vs. 45.3±39.0 p<0.013). Patients with PTH had a worse densitometric value in the lumbar spine before surgery (BMD in femoral neck preoperative -1.7±0, 9 vs. BMD in lumbar spine -2.5±1.1). There was improvement in both the femoral neck (BMD -2. 1±1.1) and the lumbar spine (-2.1±1.1) after surgery although it was not significant.

Conclusions: PHPT occurs in clinical practice with an increasingly broad spectrum. As it is demonstrated in the literature, the densitometric results after the PHPT surgery of our series, improve and especially at lumbar spine. The measurement of ioPTH is a useful tool in the surgical treatment and it provides a prognostic value in the follow-up of these patients.

P406

THE EFFECT OF A HOLISTIC THERAPEUTIC EXERCISE PROGRAM IN PATIENTS WITH SYMPTOMATIC HIP DYSPLASIA

V. Angelopoulos¹, P. Gkrilias¹, P. Megas², E. Tsepis¹, C. Matzaroglou¹

¹Technological University of Western Greece, Human Assessment and Rehabilitation Lab, ²University Hospital of Patras, University of Patras, Aigio, Greece

Objectives: To investigate the effect of a holistic therapeutic exercise program in different parameters (e.g., strength, balance, flexibility and functionality) in a patient with symptomatic hip dysplasia. In our knowledge, this study constitutes the first quantitative examination of the above-mentioned parameters on a patient with hip dysplasia at preoperative stage.

Methods: Five patients (females, mean age 62.8 years old) who performed 8 weeks (24 sessions) of a holistic therapeutic exercise program. Knee flexion and extension peak torque of the pathological limb was assessed by isokinetic dynamometry in two angular velocities (60o/s and 120o/s). Balance was evaluated in single leg stance with open and closed eyes (pathological limb). Flexibility was measured by sit and reach test. Furthermore, functionality was examined with the usage of three functional tests (6-min walk test, 30-s chair-test, time up and go). The functional tests were carried out in three subsequent examinations: initial, intermediate (end of program) and final examination (8 weeks after the end of program) to detect the adjustments over time.

Results: The evaluated parameters showed improvement in all patients, during the intermediate and final assessment in addition to initial assessment.

Isokinetic Dynamometry						
Angular Velocity	Knee Extension (Peak Torque)			Knee Flexion (Peak Torque)		
	Initial (N.m)	Final (N.m)	Variation (%)	Initial (N.m)	Final (N.m)	Variation (%)
60°/s	63.4	86.9	37	32.4	42.8	32
120°/s	50.9	66.1	29.8	28.7	27.6	-3.8

Balance		
Single Leg Stance	Initial	Final
Open eyes	5 s	56 s
Closed eyes	2 s	8 s

Flexibility and Functional Tests			
Test	Initial	Intermediate	Final
Sit and Reach	16 cm	19 cm	19 cm
30-s Chair test	8 reps	17 reps	17 reps
Time up and Go	6.6 s	5 s	5.3 s
6-min Walk test	378 m	444 m	435 m

Conclusion: The holistic program that was designed and implemented was effective in all patients with hip dysplasia, in improving all the “functional” parameters as indicated by the results of this study.

P407
ABSOLUTE RISK OF OSTEOPOROTIC FRACTURES (FRAX®) AND WELFARE INDICATORS IN URBAN POPULATION OF THE RUSSIAN FEDERATION

M. Miagkova¹, I. Skripnikova¹, S. Shalnova¹, A. Deev¹
¹Federal State Institution “National Medical Research Center for Preventive Medicine” of the Ministry of Healthcare of the Russian Federation, Moscow, Russia

Objective: To estimate associations of absolute risk (AR) of major osteoporotic fractures (MF) and hip fractures (HF) with certain basic economic features of cities and parameters of healthcare availability to the citizens.

Methods: A representative sample was formed from the population of 8 Russian cities: Vologda, Ivanovo, Volgograd, Tyumen, Kemerovo, Krasnoyarsk, Vladivostok, Vladikavkaz. In total 9143 Russian residents aged 40-69 y participated in the study (6324 women, 2819 men). AR of fractures was calculated on the basis of the Russian model FRAX without BMD using the batch data processing. The associations between the AR of fractures and the following indicators: total regional product (TRP) per capita, mean individual income (MII) and mandatory state health insurance (MHI) were studied. The official data of the Russian state statistical agency Rosstat and the regional funding of MHI programs for 2013 were used.

Results: Mean AR of MF and HF in the sample were 7.8% and 0.7% respectively. The highest AR of MF and HF was observed in Vologda and Vladivostok, and the lowest rates were noted in Tyumen and Krasnoyarsk. The significant difference in AR of MF was detected between these cities, however no clear north-to-south gradient was observed. According to the official data of Rosstat, Tyumen and Krasnoyarsk had more favorable economic conditions. The correlation coefficients between welfare indicators and mean AR of fractures in each city were quite high, but cannot be deemed statistically significant due to the insufficient number of cities included in the study: for MF with TRP $r=-0.48$ ($p=0.19$) and MII $r=-0.49$ ($p=0.18$); for HF with TRP $r=-0.44$ ($p=0.24$) and MII $r=-0.46$ ($p=0.21$). However, the low negative correlation coefficients

between the economic parameters of the cities, including MHI, the individual AR of MF ($p=0.0001$) and the individual AR of HF ($p=0.0001$) were determined to be statistically significant.

Conclusion: The AR of fractures negatively correlated with the economic parameters of the healthcare availability and the population’s welfare. Consequently, this might be indicative of the fact that the economic conditions of each particular region, along with climate and geography, might play a significant role in the risk of fractures.

P408
POLYPHARMACY AND OTHER GERIATRIC SYNDROMES

D. Erbas Sacar¹, G. Bahat Ozturk¹, P. Kucukdagli¹, M. A. Karan¹

¹Istanbul University, Istanbul, Turkey

Objective: Polypharmacy is also defined as the use of multiple medications and generally ranges from 5-10 medications. When older people compared with younger individuals, they tend to have more chronic diseases and more prescriptions for these conditions. We aimed to assess the relationship between polypharmacy and frailty, malnutrition, functionality, urinary incontinence and falls.

Methods: 1107 individuals ≥ 60 y of age admitted to Istanbul Medical School Geriatrics outpatient clinic for the first time the period between 2013-2016 were enrolled to study. We used The International Association of Nutrition and Aging’s FRAIL scale. Polypharmacy was defined as the use of five and more medications. Patients were asked about their falls, urinary incontinence, activities of daily living (ADL), instrumental activities of daily living (IADL), and assessed about their nutritional status by Mini Nutritional Assessment (MNA).

Results: 1107 patients were analyzed with a comprehensive geriatric assessment. The sample was composed of women (66.8%) and men (33.2%) with mean age of 78.5 ± 5.7 y. Prevalance of polypharmacy was 16% ($n=179$). Univariate and multivariate regression analysis were performed to investigate the association between polypharmacy and other factors. In multivariate analysis polypharmacy was found independently associated with urinary incontinence ($p=0.022$) and malnutrition ($p=0.028$).

Conclusions: Polypharmacy is a common problem among older adults; which is an independent risk factor for inappropriate medication use and adverse events. In our study malnutrition and

urinary incontinence were found independently associated with polypharmacy. Clinicians should be aware of polypharmacy and prevent patients from poor outcomes associated with this condition.

P409

SUBGROUP ANALYSIS OF THE EFFECT OF DENOSUMAB (DMAB) COMPARED WITH RISEDRONATE (RIS) ON PERCENTAGE CHANGE IN LUMBAR SPINE BONE MINERAL DENSITY AT 24 MONTHS IN GLUCOCORTICOID-TREATED INDIVIDUALS

K. Saag¹, N. Pannacciulli², P. Geusens³, J. D. Adachi⁴, E. Lespessailles⁵, J. Malouf-Serra⁶, B. Langdahl⁷, P. W. Butler², X. Yin², W. Lems⁸

¹University of Alabama, Birmingham, USA, ²Amgen Inc., Thousand Oaks, USA, ³Maastricht University, Maastricht, The Netherlands, ⁴McMaster University, Ontario, Canada, ⁵University Hospital, Orleans, Orleans, France, ⁶Hospital San Pablo, Barcelona, Spain, ⁷Aarhus University Hospital, Aarhus, Denmark, ⁸VU University Medical Center, Amsterdam, The Netherlands

Objectives: Analyse the effects of DMAB and RIS on lumbar spine (LS) BMD in subgroups of glucocorticoid (GC)-treated individuals at 24 months (mos).

Methods: This phase 3, randomized, double-blind, double-dummy study enrolled patients age ≥18 y receiving ≥7.5 mg prednisone or equivalent daily for <3 mos (GC-initiating [GC-I]) or ≥3 mos (GC-continuing [GCC]) before screening (Saag *ACR* 2016; Saag *ECTS* 2018). Subjects were randomized 1:1 to DMAB 60 mg SC every 6 mos or RIS 5 mg PO daily for 24 mos. All subjects were to receive daily calcium (≥1000 mg) and vitamin D (≥800 IU). The treatment difference (DMAB – RIS) for percentage change from baseline LS BMD at 24 mos was estimated in the GC-I and GC-C subpopulations, overall and in 7 prespecified subgroups.

Results: The study enrolled 795 subjects (290 GC-I, 505 GC-C; baseline characteristics balanced between treatment groups within each subpopulation). DMAB was superior to RIS for gains in LS BMD at 24 mos in both the GC-I and GC-C subpopulations. Within each subgroup (Table), DMAB was consistently associated with greater gains in LS BMD at 24 mos vs. RIS. Significant quantitative interactions were observed only in the sex and race subgroups in the GC-I subpopulation; qualitative tests indicated the direction of the DMAB effect did not differ significantly by sex or race in this subpopulation.

Table. Treatment Difference (DMAB – RIS) in Lumbar Spine BMD Percentage Change From Baseline at Month 24

	Glucocorticoid-initiating Subpopulation (N = 133 RIS / 128 DMAB)				Glucocorticoid-continuing Subpopulation (N = 230 RIS / 228 DMAB)			
			Least Square Mean Estimate of Difference (95% CI)	Interaction P value			Least Square Mean Estimate of Difference (95% CI)	Interaction P value
	DMAB (n)	RIS (n)			DMAB (n)	RIS (n)		
Overall subpopulation	107	113	4.5 (3.2, 5.8)*	–	183	174	3.2 (2.0, 4.3)*	–
Sex								
Female	69	72	5.7 (4.0, 7.5)*	0.013	141	131	3.7 (2.4, 5.0)*	0.13
Male	38	41	2.1 (0.1, 4.1)*	(0.50*)	42	43	1.4 (-1.1, 4.0)	
Race								
Caucasian	92	97	3.9 (2.4, 5.3)*	0.024	166	158	3.3 (2.1, 4.5)*	0.63
Not Caucasian	15	16	7.6 (3.8, 11.4)*	(0.50*)	17	16	1.9 (-1.6, 5.4)	
Age								
< 60 years	28	41	2.9 (0.1, 5.8)*	0.089	79	86	2.9 (1.2, 4.6)*	0.72
≥ 60 years	79	72	5.1 (3.6, 6.6)*		104	88	3.4 (1.9, 5.0)*	
Baseline LS T-score								
≤ -2.5	17	21	4.6 (1.0, 8.1)*	0.066	66	68	3.4 (1.1, 5.6)*	0.44
> -2.5	90	92	3.9 (2.5, 5.2)*		117	106	2.9 (1.6, 4.2)*	
Baseline LS T-score								
≤ -1.0	55	60	5.4 (3.6, 7.3)*	0.13	142	141	3.2 (1.8, 4.5)*	0.89
> -1.0	52	53	2.8 (1.0, 4.6)*		41	33	2.9 (1.0, 4.8)*	
Geographic region								
Europe	65	73	4.0 (2.4, 5.6)*	0.24	135	122	3.2 (1.8, 4.6)*	0.90
Non-Europe	42	40	5.3 (2.9, 7.8)*		48	52	2.6 (0.8, 4.5)*	
Menopausal status								
Premenopausal	9	3	11.4 (1.2, 21.7)*	0.77	20	20	3.9 (0.2, 7.6)*	0.98
Postmenopausal	59	67	5.7 (3.9, 7.6)*		119	109	3.7 (2.3, 5.1)*	
Baseline GC dose[†]								
≥ 7.5 to < 10 mg	20	28	6.3 (2.8, 9.7)*	0.57	61	67	3.4 (1.6, 5.2)*	0.88
≥ 10 mg	85	85	4.3 (2.8, 5.8)*		121	107	3.2 (1.7, 4.7)*	

CI = confidence interval; N = Number of randomized subjects with a baseline measurement and ≥ 1 postbaseline measurement for the lumbar spine BMD; n=number of subjects with observed value. *p<0.001, DMAB vs RIS. †p<0.05, DMAB vs RIS. *Qualitative p-values >0.05 support consistent directionality of treatment effect within the subgroups. †In prednisone equivalents.

Conclusion: DMAB consistently increased LS BMD more than RIS at 24 mo in GC-I and GC-C patients, with no evidence of directional heterogeneity in treatment effect across 7 prespecified subgroups of GC-treated individuals. DMAB may be a useful addition to the osteoporosis armamentarium in the common clinical setting of GC use.

Disclosures: Amgen Inc. sponsored this study and provided medical writing assistance for this abstract. K Saag: Consultant for Amgen and Merck. P Geusens: Grants/research support from MSD, P&G, W&C, Amgen, Servier, Schering Plough, Abbott, Novartis, Will-Pharma, Eli Lilly, Aventis, Nycomed, Pfizer, J&J, Roche, GE, Hologic, and UCB; consultant for Amgen. J D Adachi: Grants/research support from Amgen and Eli Lilly; consultant for Amgen and Eli Lilly; speakers' bureau for Amgen. E Lespessailles: Grants/research support from Amgen, Eli Lilly, MSD, and UCB; consultant for Amgen, Expanscience, Eli Lilly, MSD, and UCB. J Malouf-Sierra: Speaking fees from Eli Lilly, Amgen, and Grunenthal. B Langdahl: Grants/research support from Amgen, Novo Nordisk; consultant for Amgen, UCB, Merck, Eli Lilly; speakers' bureau for Amgen, Eli Lilly, Teva. N Pannacciulli, P Butler, X Yin: Employee of and stock/stock options from Amgen Inc. WF Lems: Speakers' bureau for Amgen, Merck, Novartis, Eli Lilly, and Pfizer.

P410

FRACTURE RISK ASSESSMENT (FRAX) IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THERAPY WITH ANTI-TNF α

D. Anghel¹, L. Otlocan², M. M. Negru², E. Busuioc¹, R. Bursuc¹, V. Smedescu¹, A. Manolache¹, C. Jurcut¹

¹"Carol Davila" Central Military Hospital, ²"Sfanta Maria" Clinical Hospital, Bucharest, Romania

Objective: Osteoporosis is an extraarticular complication of rheumatoid arthritis (RA) associated with increased risk of fractures, morbidity, mortality, and healthcare costs. FRAX is online tool for assessing risk of osteoporotic fracture. We verified the fracture risk assessment tool (FRAX) and we compared the probability of osteoporotic fracture in 2 groups of patients with rheumatoid arthritis (RA). One group with anti-TNF therapy and another with DMARDs therapy (leflunomide, methotrexate).

Methods: 83 RA patients were enrolled from our rheumatology clinic and predicted 10-y risk of hip fracture and major osteoporotic fracture (MOF) calculated online by FRAX. 52 patients were treated with anti-TNF therapy, and 31 patients with DMARDs therapy. We assessed 10-y fracture risk using country specific FRAX and its relationship with disease activity score, disease duration in RA, age, current smoking and glucocorticoids therapy. Clinical information was obtained from a questionnaire of their case history and medical records. Their lumbar spine and femoral BMD were determined by DXA. The gender, age, disease duration, menopause status, BMI and accumulative dose of glucocorticoid were obtained in retrospect.

Results: We studied the correlation between the BMD and clinical information. Compared with the patients with normal BMD, the subjects with low BMD had significantly older age, longer period for corticoids usage, higher day dose and accumulated dose of corticoids.

Corticotherapy at the dose above 10 mg/d correlated positively with increased risk of fracture in DMARDs therapy group more than in anti-TNF therapy patients who have lower doses of corticosteroids below 10 mg/d ($p=0.01$). FRAX estimated significantly enhanced fracture risk in active RA ($DAS28>2.6$), MOF and hip fracture risk correlated with $DAS28$ and disease duration. Patients with anti-TNF treatment have lower disease activity and, implicitly, lower risk of fracture ($p=0.001$). The group of patients between 40-50 y had a significantly lower risk of fracture than patients over 50 y ($p=0.001$). Also smoking as a risk factor has been correlated with increased risk of fracture in both groups.

Conclusions: Patients with active rheumatoid arthritis have an increased FRAX score indicating an enhanced 10-y probability of MOF and hip fracture. Long disease duration, high disease activity are potential disease specific risk factors for osteoporotic fractures in rheumatoid arthritis. The risk of fracture was higher across patients with rheumatoid arthritis in treatment with DMARDs than anti-TNF group patients. It is necessary to eliminate all risk factors for the prevention of MOF.

P411

BONE MINERAL DENSITY IS MAINTAINED OR INCREASED UPON TRANSITION FROM DENOSUMAB TO ALENDRONATE: EVIDENCE FROM THE DENOSUMAB ADHERENCE PREFERENCE SATISFACTION (DAPS) STUDY

D. Kendler¹, A. Chines², P. Clark³, P. R. Ebeling⁴, M. McClung⁵, Y. Rhee⁶, S. Huang², D. B. Crittenden², N. Freemantle⁷

¹University of British Columbia, Vancouver, Canada, ²Amgen Inc., Thousand Oaks, USA, ³Hospital Infantil de Mexico Federico Gómez and National University of Mexico, Mexico City, Mexico, ⁴Monash University, Melbourne, Australia, ⁵Oregon Osteoporosis Center, Portland, USA, ⁶Yonsei University College of Medicine, Seoul, South Korea, ⁷University College London, London, UK

Objective: Limited data are available on patients transitioning from denosumab (DMAb), a reversible antiresorptive agent, to bisphosphonates, which are more gradually reversible. The Denosumab Adherence Preference Satisfaction (DAPS) study (NCT00518531), which reported that subjects were more adherent, persistent, and compliant with subcutaneous DMAb injection compared with oral alendronate (ALN) (Freemantle *Osteoporos Int* 2012), assessed changes in BMD. Here, we further characterize the BMD response in patients during 1 y of DMAb treatment followed by 1 year of ALN.

Methods: DAPS was a 24-month, open-label, randomized, crossover study designed to compare adherence to 12 months of DMAb treatment (60 mg Q6M SC) with ALN (70 mg QW PO) in postmenopausal women with a T-score ≤ -2.0 to ≥ -4.0 at the lumbar spine (LS), total hip (TH), or femoral neck (FN). BMD was measured by DXA at the LS, TH, and FN at baseline and months 12 and 24. Patients from the DMAb to ALN sequence arm were evaluated. BMD values were summarized using descriptive statistics, and a 3% BMD threshold was selected to represent subjects who lost, maintained, or gained BMD (change $\leq -3\%$, $> -3\%$ and $< 3\%$, or $\geq 3\%$, respectively).

Results: A total of 126 subjects were randomized to the DMAb/ALN sequence, and 115 subjects (91%) transitioned to ALN at month 12. At study baseline, subjects had a mean age of 65 y and mean BMD T-scores for the LS, TH, and FN of -2.0, -1.6, and -2.0, respectively. BMD increased after 1 y of DMAb and was maintained after switching to ALN (Table). From baseline to month 12 of DMAb treatment, BMD increased by 5.6%, 3.2% and 3.1% at the LS, TH and FN, respectively. From month 12 to 24 of ALN treatment, 63% (52/82), 82% (75/92), and 61% (56/92) of subjects maintained the BMD gains initially achieved with DMAb at the LS, TH, and FN, respectively, and 21% (17/82), 11% (10/92), and 17% (16/92) showed gains in BMD. A small number of subjects lost BMD [13/82 (16%) at LS, 7/92 (8%) at TH, and 20/92 (22%) at FN]. Treatment with DMAb was well tolerated, and adverse event profiles were similar between groups.

Table. Changes in bone mineral density during 1 year of denosumab (M0 - 12) followed by 1 year of alendronate (M12 - 24).

	Lumbar Spine	Total Hip	Femoral Neck
	N = 93	N = 109	N = 109
Change in BMD (%) from M0 to M12, % (SD)	5.6 (3.8)	3.2 (3.2)	3.1 (4.1)
	N = 82	N = 92	N = 92
Change in BMD (%) from M12 to M24, % (SD)	0.6 (3.4)	0.4 (2.4)	-0.1 (3.8)
Subjects stratified by BMD change from M12 to M24, n (%) ^a	N = 82	N = 92	N = 92
Lost	13 (15.9)	7 (7.6)	20 (21.7)
Maintained	52 (63.4)	75 (81.5)	56 (60.9)
Gained	17 (20.7)	10 (10.9)	16 (17.4)

M = month

BMD = bone mineral density

SD = standard deviation

^a Based on a 3% BMD threshold. A BMD change ≤-3% indicated that subjects lost BMD; >-3% and <3% indicated maintained BMD; and ≥3% indicated a gain in BMD.

N = Number of subjects with measurements at baseline (M0 or M12) and timepoints of interest

Conclusions: Transitioning to ALN is effective at preserving the bone mass gained after 1 y of DAb. Additional studies are needed to determine the BMD effect of longer-term DAb exposure on the transition to other antiresorptive treatments.

Disclosures: This study was sponsored by Amgen Inc. D Kendler has grant/research support from Amgen, AstraZeneca, and Eli Lilly and consultant/speaker's bureau/advisory activities with Amgen, Pfizer, and Eli Lilly; P Clark has grant/research support from CONACyT (Mexico) Fondos Federales (Mexico); consultant/speaker's bureau/advisory activities with Amgen, Eli Lilly, and Pfizer; board membership with IOF and National University of Mexico UNAM; and patent licensing for 613227; PR Ebeling has grant/research support from Amgen and Eli Lilly and consultant/speaker's bureau/advisory activities with Amgen, Alexion, and Eli Lilly; M McClung has grant/research support from Amgen and consultant/speaker's bureau/advisory activities with Amgen and Radius Health. Y Rhee has grant/research support from the Korean Ministry of Health and Welfare, Korean Ministry of Science and ICT and consultant/speaker's bureau/advisory activities with Amgen; S Huang is a company employee of Amgen; A Chines and DB Crittenden are company employees and have stock ownership or royalties with Amgen; and N Freemantle has grant/research support from Ipsen, Takeda, PTC, and Allergan and consultant/speaker's bureau/advisory activities with Sanofi Aventis, Ipsen, Novo Nordisk, Biogen, and AstraZeneca.

P412

STIMULATION OF OSTEOGENESIS IN SURGICALLY TREATED PERTROCHANTERIC FRACTURES

B. Mitrevska¹, E. Nikolik- Dimitrova², V. Koevska³, C. Gerakaroska-Savevska⁴, M. Gocevska⁴, B. Kalcovska-Ivanovska¹, M. Manoleva¹, E. Grkova-Miskovska⁵

¹Institute for Physical Medicine and Rehabilitation, ²Institution of Physical Medicine and Rehabilitation, ³Institution of Physical Medicine and Rehabilitation, ⁴Institute of Physical Medicine and Rehabilitation, ⁵City Hospital 8th of September, Skopje, Macedonia

Objective: The fractures of the proximal part of the femur are more common with an increase in the average length of life. Non-surgical treatment methods do not offer satisfactory anatomical and functional results. Surgical treatment, dynamic implants is the method of choice in pertrochanteric fixation of fractures. Our aim was to compare the effects of two physical modalities, magnetic therapy vs. treatment with interferential currents in the physical treatment and rehabilitation of patients with surgically determined pertrochanteric femoral fracture with DHS and indicate the reasons for any differences .

Methods: The study represents a prospective randomized clinical trial implemented at the Institute for Physical Medicine and Rehabilitation - Skopje. Include two groups with 90 participants with surgical pertrochanteric femoral fracture, Kyle types I, II with dynamic fixation implant-DHS (dynamic hip screw). Respondents are divided into two groups: Examined group - 45 patients is treated with kinesitherapy and Magnetic therapy and control group - which has 45 patients treated with kinesitherapy and interferential currents. Respondents were followed for one year, during which were performed three examinations, the first control on the

day of discharge, 6 and 12 months, from the first review which is input for selected patients who meet the criteria for inclusion in research.

Results: Tested difference between the two groups in terms of sex and age, for $p > 0.05$, indicated no statistically significant difference. After the analysis, patients in the experimental group have 4,125 times more likely, after 12 months have shaped callus compared to control group. Upon physical examination after discharge, 6 and 12 months.

Conclusions: In the postoperative rehabilitation of pertrochanteric femoral fractures, Kyle type I, II with fixation dynamic implant-DHS, therapy of choice is magnetic therapy and kinesitherapy, from which improvement in functional status as well as in the stimulation of osteogenesis and quality of life in elderly patients.

P413

PHOSPHATURIC MESENCHYMAL TUMOR: A RARE TUMOR LOCALIZATION IN AN ELDERLY PATIENT – A CASE REPORT AND REVIEW

A. Zaina¹, D. Nikomarov², M. Weiler-Sagie³, N. Roguin Maor⁴, E. Baron¹

¹Endocrinology and Metabolism Department, Zvulon Medical Center, Clalit Medical Healthcare Services, Kiryat Bialik,

²Orthopedic Surgery Department, Rambam Healthcare Campus, Haifa, ³Nuclear Medicine Department, Rambam Healthcare Campus, Haifa, ⁴Clalit Medical Healthcare and the Clinical Research Unit, Haifa, Israel

Objective: Phosphaturic mesenchymal tumor (PMT) represents a rare cause of osteomalacia. The clinical signs and symptoms are vague and the diagnosis is commonly delayed for years. In the presence of hypophosphatemia and relatively high urine phosphate excretion this entity should be taken into account in the deferential diagnosis of osteomalacia.

Methods: We describe a case of a 81 years old man presented to our clinic for evaluation due to osteopenia. Laboratory tests disclosed hypophosphatemia, relatively increased urine phosphate excretion and increased level of FGF-23. A 68-Gallium DOTANOC PET/CT revealed pathological uptake in the upper aspect of the left shoulder adjacent to the coracoid process.

Results: For suspected PMT a wide resection of the tumor was performed and pathological findings were consistent for PMT. Laboratory tests were normalized postoperatively. Reviewing the literature, we had identified 33 reported cases of PMTs among elderly patients age ≥ 70 . Unlike previously reported data, where tumors predominantly localized in the lower extremities and pelvis, our search disclosed high rate of tumor localization (10 cases, 33.3%) in the head with equal number of tumors (14 cases, 42.4%) localized in the head and upper extremity as well as in pelvis and lower extremity.

Conclusions: The present case describes an elderly patient with unique phosphaturic mesenchymal tumor localization. Unlike previously reported data, our review disclosed a high rate of tumor localization in the head among elderly patients.

P414

ROLE OF GENDER IN THE CLINICAL PRESENTATION OF PRIMARY HYPERPARATHYROIDISM; IMPACT OF MENOPAUSE

E. Kardalas¹, I. Fistonic²

¹Evangelismos Hospital, Athens, Greece, ²Obstetrics, Gynecology & Menopause Health Center and Institute for Women's Health, Zagreb, Croatia

Objective: Primary hyperparathyroidism (PHPT) is a common endocrinological problem. It is predominant among women with a female to male ratio 3:1. Few studies have focused on the clinical presentation of this common endocrinological entity in regard with the gender of the patients and the effect of menopausal status.

Methods: A retrospective study evaluating differences regarding gender, biochemical values and clinical presentation in 164 enrolled patients with PHPT: 36 male (55.7 \pm 16.5 y) and 128 female (61.3 \pm 13.3 y), of whom 22 were premenopausal (F-pre) and 106 postmenopausal (F-post).

Results: Male patients were significantly younger ($p=0.0049$) and more frequently symptomatic than women (63.8% vs. 46.87%, $p=0.044$). No gender difference was found in serum PTH, corrected calcium for serum albumin, creatinine and urinary calcium levels whereas serum phosphate was higher in women. 25OHD levels were significantly higher among male patients. Nephrolithiasis (detected by imaging or positive medical history) was more frequent in men (44.4% vs. 21.29% in women, $p=0.021$) and osteoporosis (T-score < -2.5 at any site) in women (54.68% vs. 47.22% in men, $p=0.003$). Symptomatic PHPT was reported in 49.5%, 34.78% and 63.8% of F-post, F-pre and men, respectively, with highest prevalence among male patients. Osteoporosis was more frequent, and nephrolithiasis was less frequent in F-post than in F-pre (62.2% vs. 8.8% and 19.8% vs. 34.78%, respectively). Osteitis fibrosa cystica was more often reported among male patients in comparison with female of any age. After combining symptomatic and asymptomatic patients, no gender difference was observed in the proportion of patients referred for surgery (86% male vs. 82,8% female).

Conclusion: Gender does not seem to affect the biochemical activity of PHPT, but clinical presentation of this common endocrinological entity is substantially different among male and female patients, mostly due to menopausal status. On the other hand, both male and female patients met the established surgical criteria for surgical treatment on equal levels.

P415

GREATER INCREASES OF CORTICAL AND TRABECULAR VBMD BY 3D MODELING OF HIP DXA IN PATIENTS TREATED WITH DENOSUMAB VS. BIPHOSPHONATES

M. Almohaya¹, N. Sami², R. Winzenrieth³, D. Kendler⁴

¹King Fahad Medical City, Riyadh, Saudi Arabia, ²Prohealth Clinical Research Center, Vancouver, Canada, ³Galgo Medical, Barcelona, Spain, ⁴University of British Columbia, Vancouver, Canada

Patients taking denosumab have greater increases in DXA aBMD at hip than patients on bisphosphonate¹. This may reflect denosumab's greater access to the cortical bone compartment with reduction in cortical porosity. 3D-SHAPER software, provides a 3D model of femoral compartments from hip DXA scans, allowing the evaluation of volumetric cortical and trabecular bone².

We retrospectively reviewed 239 consecutive patients at an osteoporosis referral center, either treatment-naïve started on denosumab (tnDmab, n=89), bisphosphonate (tnBP, n=44) or switched from bisphosphonates to denosumab (Switch, n=106). Hip aBMD by DXA and hip cortical and trabecular vBMD by 3D-SHAPER (v2.7.3, Galgo Medical SL, Spain) was performed at baseline, 1, 2, 3 and 4 y of therapy.

Patients (218 females, 21 males) had mean age 71.8±10 y; groups had similar baseline hip aBMD (0.677 g/cm²±0.109). tnDmab and Switch hip aBMD increased significantly at one-year (2.64% and 1.64% respectively) with progressive increases to the 4th year (8.79% and 5.96% respectively). tnBP aBMD remained stable at one and two years, with increases of 0.48% in the third year. Trabecular vBMD improved significantly across all groups; there were greater increases in tnDmab (20.4%) and Switch (18.9%) compared with tnBP (9.9%) at the third year (p<0.001 for all). The greatest increases in cortical vBMD were observed in tnDmab (2.25% at 1 year, 5.18% at 4 years). In Switch, cortical vBMD increased 2.85% at 2 years, then remained stable to the 4th year. Cortical vBMD increased more at 1 y in tnDmab vs. tnBP (2.25% v. 0.12%, p=0.01). In all patients, DXA aBMD correlated more with cortical vBMD (r=0.85; p<0.001), than trabecular vBMD (r=0.79; p<0.001).

3D-SHAPER determination of changes in cortical and trabecular bone compartments may be helpful to differentiate the longer-term efficacy of denosumab vs. bisphosphonate. Denosumab's greater access to cortical bone may account for its greater hip vBMD efficacy compared to bisphosphonate. This may contribute to the progressive decline in nonvertebral fractures in patients treated long-term with denosumab.

References:

1. Seeman E. et al. J Bone Miner Res 2010;25:1886.
2. Humbert et al., IEEE Trans Med Imaging 2017;36:27.

P416

SARC-F SCORE IS NEGATIVELY ASSOCIATED WITH FUNCTIONAL INDEPENDENCE IN GENERAL REHABILITATION PATIENTS

I. Churilov¹, L. Churilov², K. Brock¹, D. Murphy¹, R. J. Macisaac¹, E. I. Ekinci³

¹St Vincent's Hospital Melbourne, Fitzroy, ²The University of Melbourne, Parkville, ³Austin Health, Heidelberg. Australia

Objectives: SARC-F is a screening tool for sarcopenia, with the score of above 3 predictive of sarcopenia. Functional independence measure (FIM) is a measure of patients' independence, commonly used in rehabilitation. Association of SARC-F with FIM and quality of life in general rehabilitation patients is currently unknown. We hypothesized that patients with higher SARC-F scores would exhibit higher functional dependence and poorer quality of life on admission to rehabilitation.

Methods: A cross-sectional study was conducted in a general rehabilitation unit in a tertiary referral metropolitan hospital, Melbourne, Australia, enrolling cognitively intact patients. The association between admission SARC-F and FIM (adjusted for age and Charlson comorbidity index (CCI)), and SARC-F and quality of life (as measured by EQ visual analogue scale (EQ VAS), adjusted for age, CCI and gender) was investigated using quantile regression with bootstrapped standard error estimation.

Results: 208 patients were recruited: median age 64.5 (IQR 54.5-73), 110 (53%) male, median CCI 2 (IQR 0-3). Diagnostic streams: 34 (16%) amputee, 67 (32%) musculoskeletal, 39 (19%) neurological, 47 (23%) deconditioning/other, 21 (10%) spinal. SARC-F median was 7 (IQR 5-8). FIM score median was 87 (IQR 75.5-99). Adjusted for age and Charlson score, 1 extra point on SARC-F was associated with a lower FIM score: 3.7 (95%CI 2.19-5.2) for the median patient, 3.7 (95%CI 1.48-5.86) for the 25th percentile, and 3.13 (95%CI 1.72-4.54) for the 75th percentile (all p<0.001). Adjusted for age, Charlson score and gender, 1 extra point on SARC-F score was associated with a lower EQ VAS: 0.37 (95%CI 0.14-0.59, p=0.002) for the median patient, 0.35 (95%CI 0.16-0.53, p<0.0001) for the 25th percentile, and 0.24 (95%CI 0-0.48, p=0.05) for the 75th percentile.

Conclusions: Higher SARC-F scores on admission to rehabilitation were associated with higher functional dependence and lower quality of life.

P417

EVALUATION OF THE CAUSAL ASSOCIATION BETWEEN BLOOD METABOLITES AND RHEUMATOID ARTHRITIS: A MENDELIAN RANDOMIZATION STUDY

S. Yao¹, K. Zhang¹, J. C. Feng¹, J. M. Ding¹, H. Wu¹, S. S. Dong¹, Y. Guo¹, T. L. Yang¹

¹Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China

Objective: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by uncontrolled joint inflammation and destruction of bone and cartilage. Metabolomics is a nontargeted analysis of global changes of the complete set of metabolites in organisms, and many metabolites have been reported to be associated with RA using this method. The aim of this study is to explore the causal associations between blood metabolites and RA.

Methods: We used available summary-level genome-wide association studies (GWAS) data for blood metabolites from large samples (sample sizes of up to 24,925) which including amino acids, lipids, carbohydrates, et al. And then selected near-independent GWAS SNPs for each blood metabolites at a suggestive threshold ($P < 1 \times 10^{-5}$) using the clumping algorithm in PLINK (r^2 threshold=0.05 and window size=1 Mb) with the 1000G-imputed ARIC data as the reference for linkage disequilibrium estimation. Only the metabolites with more than 10 independent SNPs were used in this study to ensure the strong power. The summary-level GWAS data for RA was computed from meta-analysis in a total of 103,638 subjects. We then performed a multi-SNP Mendelian randomization analysis using summary-level data from GWAS to test the causal associations of blood metabolites with RA via GSMR.

Results: We analyzed a total of 989 blood metabolites and 913 of them had more than 10 independent SNPs after clumping. We identified 50 blood metabolites had risk effects on RA and 36 blood metabolites had protective effects on RA with a suggestive P value ($P < 0.05$). After multiple testing corrections, two glycerophospholipids still showed risk effects on RA, lysophosphatidylcholine acyl C20:4 (odds ratio, OR=1.33, $P=1.74 \times 10^{-5}$), phosphatidylcholine diacyl C38:4 (OR=1.38, $P=1.99 \times 10^{-5}$), and one kind of amino acid still showed protective effect on RA, glycine (OR=0.67, $P=2.37 \times 10^{-5}$).

Conclusions: We investigated the causal effect of global blood metabolites on RA using summary data-based Mendelian randomization analyses. Our results suggest the risk/protective effects of three candidate blood metabolites for association with RA.

Acknowledgement: The study was supported by grant from National Science Foundation of China (81573241).

P418

EVALUATION OF THE CAUSAL ASSOCIATION BETWEEN BLOOD METABOLITES AND MULTIPLE OSTEOPOROSIS ASSOCIATED PHENOTYPES: A MENDELIAN RANDOMIZATION STUDY

S. Yao¹, K. Zhang¹, J. M. Ding¹, J. C. Feng¹, Y. J. Zhang¹, S. S. Dong¹, Y. Guo¹, T. L. Yang¹

¹Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China

Objective: Osteoporosis is a common metabolic bone disease characterized by decreased bone mass and increased tendency of fragility fractures. In this study, we explored the causal associations between blood metabolites and all the osteoporosis associated phenotypes via Mendelian randomization (MR).

Methods: Four available summary-level genome-wide association studies (GWAS) data for blood metabolites with near 1000 blood metabolites were used as exposures. Risk factors including amino acids, lipids, carbohydrates, nucleotides, peptides, et al. We then applied the clumping algorithm in PLINK to select near-independent GWAS SNPs for each blood metabolites (r^2 threshold=0.05, window size=1 Mb and $P=5 \times 10^{-8}$). Eight osteoporosis associated phenotypes are femoral neck BMD (FNBMD), lumbar spine BMD (LSBMD), forearm BMD (FABMD), and osteoporosis with large samples. We then applied the GSMR method to test for causal associations between blood metabolites and four osteoporosis associated phenotypes.

Results: We analyzed 989 blood metabolites. And identified a total of 63 blood metabolites had increasing effects on more than one osteoporosis associated phenotypes and 114 blood metabolites had decreasing effects on osteoporosis associated phenotypes with a suggestive P value ($P < 0.05$). However, there are no significant casual association between blood metabolites and osteoporosis associated phenotypes after multiple testing corrections ($P < 6.32 \times 10^{-6}$). The most significant increasing effect is androsterone sulfate on FNBMD (beta=0.109, se=0.027, $P=5.92 \times 10^{-5}$) and the most decreasing effect is the ratio of bis-Lallylic bonds to double bonds in lipids on FABMD (beta=-0.089, se=0.021, $P=3.31 \times 10^{-5}$).

Conclusions: We investigated the causal effect of global blood metabolites on available osteoporosis associated phenotypes using summary data-based Mendelian randomization analyses. Our results suggest the modest increasing/ decreasing effects of blood metabolites for association with osteoporosis associated phenotypes.

Acknowledgements: The study was supported by grant from National Science Foundation of China (81573241).

P419

SECONDARY BONE SIZE DEFICIT IN PATIENTS WITH EHLERS-DANLOS SYNDROME

T. Banica¹, C. Verroken¹, P. Calders², I. De Wandele², F. Malfait³, H. G. Zmierczak¹, S. Goemaere¹, M. Coussens², L. Rombaut², B. Lapauw¹

¹Unit for Osteoporosis and Metabolic Bone Diseases, Department of Endocrinology, Ghent University Hospital,

²Department of Rehabilitation Sciences and Physiotherapy, Ghent University, ³Centre for Medical Genetics, Ghent University Hospital, Ghent, Belgium

Objective: Ehlers-Danlos Syndrome (EDS) is a group of connective tissue disorders caused by defects in the biosynthesis or secretion of fibrillar collagens, which might impair bone strength in EDS patients. We compared volumetric BMD (vBMD), areal BMD (aBMD), bone geometry, muscle size and body composition between patients with EDS hypermobility Type (EDS-HT) and controls.

Methods: Cross-sectional data comprised 43 EDS-HT females (age 41.0±10.8 y) and 43 age-matched females, 8 y later 30 EDS-HT and 17 control subjects were re-evaluated. Tibial vBMD, bone geometry and lower leg muscle cross-sectional area (CSA) were measured using pQCT. DXA determined body composition and aBMD.

Results: Although EDS-HT patients did not differ from controls regarding vBMD, periosteal- and endosteal circumference, muscle density and bone/muscle area ratio (BMR), they had significant smaller trabecular bone area and content, cortical bone area, cortical thickness, aBMD and muscle CSA (all p<0.05). Longitudinal data showed similar decreases in lumbar and subtotal aBMD and muscle CSA in both groups, EDS-HT patients showed a significant decrease in muscle density (all p<0.05).

Conclusion: EDS-HT patients have a trabecular and cortical bone size deficit compared to controls, possibly contributing to their increased fracture risk. Decreased muscle CSA and normal BMR suggest that this bone size deficit is secondary to decreased mechanical loading. Further, there were no arguments for accelerated bone loss in EDS-HT subjects. Decreases in muscle CSA were comparable between both groups although only EDS-HT subjects showed a decline in muscle density.

P420

MORTALITY AFTER OSTEOPOROTIC HIP FRACTURE: OUR SURVEILLANCE

S. Tomkova¹, T. Sevcik², Z. Lorinczova¹

¹Faculty of Medicine Pavol Jozef Safarik University in Kosice, Department of Internal Medicine Hospital Kosice-Saca, ²Faculty of Medicine Pavol Jozef Safarik University in Kosice, Department of Musculoskeletal and Sport Medicine, Hospital Kosice-Saca, Kosice, Slovakia

Objective: To evaluate the mortality rate of osteoporotic hip fracture patients in four periods of time. We compare mortality in two files, from years 2003-2010 and 1995-2002.

Methods: We retrospectively reviewed the medical records patients who were treated for osteoporotic hip fractures. Data was obtained from hospital information system ORDINIS and database E-health. Patients up to 50 years old and with pathological fracture were excluded. There were evaluated 4 interval of mortality rate: 10-d mortality rate, 10-90-d mortality rate, 90-365-d mortality rate and cumulative 1-y mortality rate. The purpose of this study was to compare the 1-y mortality after osteoporotic hip fracture with two periods of time: 2003-2010 to 1995-2002.

Results: There were reviewed 240 patients in 1995-2002 (79 men, 161 women) and 314 in 2003-2010 (99 men, 215 women). 10-d mortality rate in our group (2003-2010) was 9.09% in men and 4.18 in women. 10-90-d mortality rate was 12.12% in men and 13.95% in women. Mortality rate 90-365-d was 13.13% in men and 13.48% in women. Cumulative one-year mortality was 34.34% in men and 31.62% in women. Cumulative one-year mortality in 1995-2002 was 25.83% and in 2003-2010 was 30.3%. Statistically significant difference of cumulative 1-y mortality was not found between these two periods of time (p=0.238). Statistically significant difference of 10-d mortality rate is between men and women (p=0.084) in group 2003-2010.

Conclusion: Despite our ambition to decrease one-year mortality rate of osteoporotic hip fracture, there persist about 30% death to one year from injury. In group 2003-2010 is higher 10-d mortality rate in men according to available studies.

P421

ORGANIZATION OF INTERACTION BETWEEN DOCTORS OF DIFFERENT SPECIALTIES IN THE FIGHT AGAINST OSTEOPOROSIS IN THE FRAMEWORK OF ST. PETERSBURG OSTEOCLUB

S. N. Ivanov¹, A. U. Kochish²

¹The L.G. Sokolov Memorial Hospital №122, ²Russian Scientific Research Institute of Traumatology and Orthopedics named after R.R. Vreden, St. Petersburg, Russia

Objective: According to the standards of medical care in the Russian Federation doctors of different specialties deal with the problem of osteoporosis. Treatment approaches among these doctors vary for such patients despite that there are osteoporosis treatment guidelines issued by the National Antiosteoporotic Association. The problem is particularly actual for patients with osteoporotic bone fractures. Traumatologists usually treat these patients and traditionally pay insufficient attention to osteoporosis treatment. Our aim was to show the benefits of work coordination for osteoporosis treatment made by doctors from different medical establishments and specialties in the modern megapolis by means of interaction in the framework of voluntary public organization – the Osteoclub.

Methods: The Osteoclub was established in March 2015 in St. Petersburg on the initiative of the management of the National Antiosteoporotic Association. The Osteoclub unites about 30 city opinion leaders, practicing doctors of different specialties and scientific researchers who study various aspects of osteoporosis problem. During 2018 14 meetings were held and 48 reports

were made and discussed by doctors of different specialties from: trauma, therapy, rheumatology, endocrinology, gerontology, obstetrics and gynecology, pediatrics, radiology and laboratory diagnostics. Representatives from patients' organizations took part in the Osteoclub meetings as well.

Results: Work coordination of doctors of different specialties in the framework of the Osteoclub has allowed to solve the following tasks: 1. To inform doctors systematically about the latest scientific achievements and developments according to reports from appropriate international and Russian scientific congresses. 2. To organize the information spread for doctors about the National Antiosteoporotic Association resolutions. 3. To conduct discussions about interesting clinical cases regularly. 4. To solve questions about treatment optimization for patients in St. Petersburg. 5. To distribute and popularize advanced practice in the fight against osteoporosis. 6. To solve current organization questions, e.g. establishing prophylaxis service for repetitive fragility fractures. 7. To plan to hold specific public events, e.g. the International day of osteoporosis in St. Petersburg. 8. To schedule and coordinate collective scientific studies and preparation of scientific reports about osteoporosis made by doctors of different specialties. 9. To discuss projects of the clinical guidelines dedicated to various aspects of osteoporosis problem. 10. To perform functions of the regional department of the National Antiosteoporotic Association.

Conclusion: Four years' experience of the Osteoclub service has confirmed its establishing experience and revealed practical usage of its functions in the framework of this voluntary organization making for doctors of different specialties the opportunity to coordinate osteoporosis treatment in St. Petersburg.

P422

X-LINKED HYPOPHOSPHATAEMIA: PREVALENCE AND MORTALITY RATE WITHIN THE UK CLINICAL PRACTICE RESEARCH DATALINK

S. Hawley¹, N. J. Shaw², A. Delmestri¹, D. Prieto-Alhambra¹, C. Cooper³, R. Pinedo-Villanueva¹, M. K. Javaid¹


¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, ²Birmingham Children's Hospital NHS Foundation Trust, Birmingham, ³University of Southampton, Southampton, UK

Objectives: To determine the prevalence of X-linked hypophosphataemia (XLH) in children and adults in the UK and compare mortality rates between XLH cases and matched controls.

Methods: The Clinical Practice Research Datalink (CPRD) GOLD was used to identify XLH cases (1995-2016) in primary care using Read codes identifying rickets, hypophosphataemia and osteomalacia. Two clinicians with experience in paediatric (NS) and adult XLH (MKJ) independently reviewed potential cases using Read codes, laboratory values including serum phosphate, alkaline phosphatase, timing and duration of prescriptions, and features inconsistent with a diagnosis of XLH. Cases were graded as highly likely, likely, possible or unlikely. Four non-XLH patients

of same age, gender and GP practice were matched to each case. Temporal trends in XLH prevalence were estimated using CPRD annual denominator data. Mortality incidence rates were calculated for cases and controls and compared using extended Cox regression. Main analyses included all possible cases, with sensitivity analyses focusing only on highly likely and likely cases.

Results: Weighted kappa between assessors was 0.88. From 522 potential cases, 122 were scored as at least possible XLH (least conservative) while 62 were defined as likely or very likely (most conservative). In main analyses, prevalence [95%CI] increased from 3.0 [1.2-7.2] per million in 1995/6 to 15.6 [12.0-20.4] per million in 2015/6. Corresponding estimates using the most conservative definition were 3.0 [1.2-7.2] to 8.4 [5.9-12.1] (Figure). Nine (7.4%) cases died during follow-up (at median age 64 y) at a rate of 12.1/1,000 person-years. Fourteen (2.9%) controls died (at median age 72.5 y) at a rate of 4.8/1,000 person-years. This yielded a hazard ratio of 2.93 [1.24 - 6.91]; p=0.014. Under the most conservative analysis, the hazard ratio was 6.65 [1.44 - 30.72]; p=0.015.



Conclusions: XLH prevalence estimates have increased in the UK, most likely due to improved coding practice. Adults with XLH appear to have shortened survival. This has implications for how adults are managed by clinicians, including potential use of novel therapies.

Disclosures: Kyowa Kirin Hakin International providing funding for this project to the University of Oxford. The funder was provided reports at the end of each stage of work but had no other influence on the development, conduct and reporting of the project.

P423

FRAGILITY FRACTURE SERVICE IN HONG KONG: FROM THEORY TO PRACTICE

K. L. Tiu¹, P. C. Cheung¹, K. B. Lee¹, W. Y. Li¹

¹Department of Orthopaedic & Traumatology, Queen Elizabeth Hospital, Hong Kong, China

Objective: Hip fractures are common among frail elderly populations and often have serious consequences on function, mobility and mortality. International studies have shown that

interdisciplinary, multidirectional and systemic assessment for fragility fracture in elderly is beneficial to patients. However, in Hong Kong previously, there was no systemic management of fragility fractures until the setup of Key Performance Index for hip fractures in elderly in Hospital Authority. A working group on Fragility Fracture has been set up in 2013, followed by a formal Fragility Fracture Registry subcommittee. The aim is to promote integrated clinical care in terms of holistic management journey from admission, operation to rehabilitation, until the patients return to community. Prevention of secondary fracture is important. Leung et al 2017 conducted a pilot study in 6 major public hospitals to capture the essential data (acute management, rehabili-

tation and 1 y follow-up) for managing fragility fracture patients. Data in 2012 of these 6 hospitals were collected and analyzed. Overall 91% of patients received orthopaedic care within 4 h of admission. 60.5% received surgery within 48 h. 3.5% of patients received preoperative Orthogeriatric service. Only 22.9% patients were discharged with bone health protection medication. 16.2% of patients required institution stay on discharge. Only 35.1% of patients attended outpatient clinic follow-up 1 y after fracture, and morbidity had deteriorated to 69.9% compared with that of the premorbid state. Death occurred in 17.3% of patients within 1 y postsurgery, compared with 1.6% mortality rate in age-matched Hong Kong general population.

Comparison of six standards for hip fracture care between Hong Kong (HK) and the National Hip Fracture Database of the United Kingdom (UK NHFD)³ in 2012

Standard	HK (%)	UK NHFD (%)
1. Admission to orthopaedic ward within 4 hours	91.0	52
2. Surgery within 48 hours and during working hours	60.5 (exactly 48 hours)	83
3. Patients developing pressure ulcers	5.3	3.7
4. Preoperative assessment by an ortho-geriatrician	3.5	43
5. Discharged with bone protection medication	22.9	69
6. Received a falls assessment prior to discharge	98	92

The efficiency and quality of acute care for fragility hip fracture patients was documented. The next step is to promote the standard setting for the management of the fragility hip fracture in Hong Kong. A unified multidisciplinary Fragility Hip Fracture Pathway (FHFP) from admission to rehabilitation and back to community was established in 2015. The acute phase of the pathway was put into pilot in Queen Elizabeth hospital.

Method: A retrospective review of two-year outcome after the implement of the fragility hip fracture pathway. Patients admitted to Queen Elizabeth hospital from 1/1/2016 to 31/12/2017 with a hip fracture resulting from fall on standing height were included. Major outcome parameters were studied.

Results: There were total 1572 patients included, age from 65-102 (average 83.72), male to female ratio is 2:5. Overall 1317 hip operations performed (832 fixations, 478 hemiarthroplasties and 7 excisional arthroplasties) including 3 patients presented and operated for bilateral hip fractures in single admission. 88.58% of patients received orthopaedic care within 4 h of admission. 58.7% received surgery within 48 hours. 67.7% of patients had acute length of stay within 10 days. 41.4% patients were discharged with bone health protection medication in 2016 and increase to 94.4% in 2017. Only 5.69% received antiosteoporotic agents in 2017. One year secondary fracture incidence is 4.67%. Operative complications in one year is 4.44% on fixations and 3.69% on arthroplasties. One year mortality is 13.44% and 14.17% in 2016 and 2017 respectively. Only 20.5% had DXA study performed. 79.8% in range of osteoporosis (T-score < -2.5), 17.7% in osteopenia and 2.4% had normal T-scores.

Conclusions: Two year outcome evaluation has been done and the result is very convincing. The FHFP has been shown to have better functional outcome, and shorter length of stay. Further integration such as orthogeriatric collaboration, 7-d rehabilitation, fracture liaison service, community programme, bone health and sarcopenia management are all crucial to optimize the FHF care in the near future. With the increasing awareness of the society, and more collaboration, we hope the policy makers will be convinced and recognize the important of setting a standardized territory-wide policy in managing the fragility fracture in Hong Kong in future. Finally, we strongly believe that the quality of life of the elderly will improve then.

Reference: Leung KS et al. Hong Kong Med J 2017;23:264.

Acknowledgement: Thanks to the dedication, passion and trust to all members of the QEH PTF team.

P424

ADIPONECTIN AS NEW DIAGNOSTIC BIOMARKER OF BONE TISSUE METABOLISM DISORDERS IN RHEUMATOID ARTHRITIS

L. Sivordova¹, J. Polyakova¹, Y. Akhverdyan¹, E. Papichev¹, B. Zavodovsky²

¹Treatment and Prevention of Joint Disease Laboratory / Federal State Budgetary Institution Zborovsky Research Institute of Clinical and Experimental Rheumatology, ²Treatment and Prevention of Joint Disease Laboratory / Federal State Budgetary Institution, Zborovsky Research Institute of Clinical and Experimental Rheumatology, Volgograd State Medical University, Volgograd, Russia

Objective: BMD and proteins/peptides determination in blood and urine as markers of bone resorption and formation are currently used to diagnose osteoporosis (OP) and metabolic bone diseases. Recent evidence suggests that in RA changes in the secretion of hormones of white adipose tissue can be revealed [1,2,3,4,5]. One of them is Adiponectin possessing anti-inflammatory, antidiabetic and anti-atherogenic properties. Changes in adiponectin levels may reflect influence of immune inflammation on bone turnover. Our aim was to study the clinical and diagnostic value of serum Adiponectin determination in RA patients complicated by OP.

Methods: We examined 88 women with documented diagnosis of RA and mean disease duration of 6.56±0.88 y and control group of 45 healthy females were included in the study. We measured serum adiponectin levels (µg/ml) using human adiponectin ELISA commercial test systems (BioVendor, Czech Republic, cat № RD195023100). We diagnosed OP using DXA with Lunar DPX Pro (GE, USA).

Results: Serum adiponectin levels in the control group were 12.5±0.9 µg/ml (M±m). Adiponectin levels in healthy subjects measured as M±2d, ranged between 0.44-24.56 µg/ml. Patients with OP and RA had significantly higher levels of serum adiponectin (p<0.001). Mean serum adiponectin levels in RA patients who had normal bone density and had no OP were 35.21±0.6 µg/ml. Mean serum adiponectin levels in RA/OP patients with low BMD were 52.42±0.69 µg/ml. Adiponectin levels of 44 µg/ml and higher were associated with osteoporosis. Adiponectin levels of 43.9 µg/ml and lower were associated with normal bone density.

Conclusion: Adiponectin levels depend on osteoporosis presence in RA patients. We suppose that adiponectin determination may be useful laboratory marker for OP diagnosis. The test may be used to reduce the risk of low-energy fractures and to improve the quality of life in RA.

References:

1. Akhverdyan Y et al. Ann Rheum Dis 2017;76(suppl.2):1149.
2. Aleksandrov AV et al. Ann Rheum Dis 2016;75:1054.
3. Kvlividze Z et al. Ann Rheum Dis 2018;77:A1762.
4. Papichev E et al. Ann Rheum Dis 2018;77:A1228.
5. Polyakova J et al. Ann Rheum Dis 2014;73 (Suppl.2).

P425

HIGH LEVEL OF ADIPOKINES AND OVERWEIGHT AS FACTORS CONTRIBUTING TO OSTEOARTHRITIS PROGRESSION

V. Kravtsov¹, L. Sivordova², L. Aref'Eva³, G. Kravtsov³, V. Polyakov³, T. Rogatkina³

¹Treatment and Prevention of Joint Disease Laboratory / Federal State Budgetary Institution, Zborovsky Research Institute of Clinical and Experimental Rheumatology, Volgograd State Medical University, ²Treatment and Prevention of Joint Disease Laboratory / Federal State Budgetary Institution, Zborovsky Research Institute of Clinical and Experimental Rheumatology ³Volgograd State Medical University, Volgograd, Russia

Objective: Obesity is a condition that prolongs chronic inflammation and promotes synthesis and secretion of pro-inflammatory factors by adipose tissue, such as classical cytokines, TNF-α, adipokines (leptin, adiponectin, resistin, nicotinamide phosphoribosyl transferase (visfatin, Nampt)) and other newly identified proinflammatory factors (hemerin, lipokain, serum amyloid protein 3) [1,2,3,4,5,6]. We investigated the relationship the effect of weight loss over 5 kg on the clinical manifestations of OA and Nampt serum levels in patients with OA.

Methods: We observed 160 patients with different forms of OA and the control group (60 healthy individuals). Nampt level in serum was determined by ELISA using a commercial test systems.

Results: We observed significant decrease in the severity of the clinical manifestations of OA (decrease the level of pain on the VAS scale at rest and during walking, total score on the WOMAC), visfatin level, CRP, and glucose levels and lipid profile in the group of patients who were able to reduce body weight by 5 kg and more (36 pers.).

Conclusion: As a result of our study patients with OA with weight loss of more than 5 kg had more obvious pain relief, a significant improvement in carbohydrate and lipid metabolism, a decrease in the activity of the inflammatory process and level of visfatin.

References:

1. Akhverdyan Y et al. Ann Rheum Dis 2013;72(Suppl 3):702.
2. Cherkashina IV et al. Voprosy kurortologii, fizioterapii, i lech-ebno fizicheskoy kultury 2016;93:13.
3. Duan Y et al. Rheumatol Int 2012;32:985.
4. Zavodovsky BV et al. Ter Arkh 2016;88:78.
5. Papichev EV et al. Osteoporos Int 2018;29:S239.
6. Polyakova J et al. Ann Rheum Dis 2015;74:372.

P426

EXERCISE AS A TREATMENT TO ATTENUATE BONE LOSS IN WOMEN AFTER ROUX-EN-Y GASTRIC BYPASS: A RANDOMIZED CONTROLLED TRIAL

I. H. Murai¹, H. Roschel¹, W. S. Dantas¹, S. Gil¹, C. A. Merege-Filho¹, V. Caparbo¹, L. Takayama¹, A. L. Sá-Pinto¹, R. Cleva¹, M. A. Santo¹, J. Kirwan², R. M. Pereira¹, B. Gualano¹

¹University of Sao Paulo, Sao Paulo, Brazil, ²Pennington Biomedical Research Center, Baton Rouge, USA

Objectives: To investigate the role of an exercise training program in mitigating bone loss in morbidly obese women after Roux-en-y gastric bypass.

Methods: 70 women were randomly allocated into one of two groups: bariatric surgery (RYGB, BMI=48.5±8.1 kg/m²) and bariatric surgery plus exercise training (RYGB+ET, BMI=49.8±7.0 kg/m²). Subjects were evaluated at baseline (PRE), three (POST3), and nine months (POST9) after surgery. Exercise training started after the POST3 assessments. Serum bone turnover markers (CTX, PINP) were assessed by electrochemiluminescence. DKK-1, sclerostin, osteocalcin and osteopontin were quantified using the Luminex® xMAP® technology. Lumbar spine, femoral neck, total hip, distal radius and whole-body aBMD, as well as body composition were evaluated by DXA. HR-pQCT at the radius was used to evaluate volumetric density (vBMD) and structural parameters. aBMD data were converted into percent changes (POST9 to PRE), and thereafter analyzed by a mixed-model assuming group as a fixed factor. The remaining dependent variables were analyzed by a mixed-model for repeated measures assuming group and time as fixed factor and single-degree-of-freedom contrasts to determine whether the means significantly differed between groups. Significance level was set at $P < 0.05$.

Results: CTX, PINP and sclerostin increased in both groups at POST3 ($P < 0.001$ for all markers) and POST9 ($P < 0.001$ for all markers) compared to PRE. Interestingly, CTX ($P = 0.002$), PINP ($P = 0.024$) and sclerostin ($P = 0.046$) were significantly greater in RYGB compared to RYGB+ET at POST9. DKK-1, osteocalcin and osteopontin did not significantly differ between groups. Both groups demonstrated a significant sustained reduction in all aBMD sites along the time ($P < 0.05$). Importantly, aBMD percent changes were attenuated in RYGB+ET compared to RYGB for femoral neck ($P = 0.007$), total hip ($P = 0.009$) and distal radius ($P = 0.038$), but no differences were observed for lumbar spine and wholebody aBMD. No significant changes between groups were found for radius vBMD and structural parameters.

Conclusions: Our findings indicate that a supervised exercise training program effectively attenuated bariatric surgery-induced bone loss by modulating bone turnover markers and aBMD reduction, suggesting that exercise should be incorporated into the routine of postbariatric patients in order to alleviate the adverse effects of surgery on bone.

P427

EFFECTS OF CALCIUM SUPPLEMENTATION ON BONE MINERAL DENSITY IN LACTATING WOMEN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS

G. Cai¹, J. Tian¹, T. Winzenberg¹, F. Wu¹

¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia

Objective: To evaluate the effect of calcium supplementation on BMD in lactating women.

Methods: Design: systematic review and meta-analysis. Data sources: electronic search of Embase, Medline, Web of Science, Cochrane Central Register of Controlled Trials and clinical trial registries to October 2018. Eligibility criteria for selecting studies: randomised controlled trials (RCTs) of calcium supplementation (including from food, with or without co-intervention of vitamin D) for at least 3 months in lactating women with BMD of the total body, total hip, femoral neck, lumbar spine or forearm, or total body bone mineral content or fracture as an outcome. Data extraction: two authors screened studies, extracted data and assessed the risk of bias and quality of evidence of eligible studies. The percentage of change in BMD at each site for each study group, where possible, was pooled using the random-effects model, in which BMD measures at baseline and the longest time point were used. Pooled results were reported as weighted mean differences (WMD) with 95% CIs.

Results: Five RCTs totaling 567 lactating women were included. All included trials had a low certainty of evidence with serious risk of bias. Compared to placebo or blank control, calcium supplementation showed no effect on BMD of either the lumbar spine (WMD 0.7%, 95%CI -0.1% to 1.6%) or forearm (0.5%, -0.4% to 1.4%). BMD at other sites was assessed by only one of the included trials; calcium supplementation had a small to moderate effect on total hip BMD (3.3%, 1.5% to 5.1%) but no effect on the total body or femoral neck.

Conclusions: Calcium supplementation in lactating women may have no or small effect on BMD, which is unlikely to translate into an improvement in the prevention of fractures in later life. This suggests that the current recommended calcium intake in lactating women may be appropriate. However, high quality RCTs are needed to confirm these findings.

Acknowledgement: PROSPERO registration number CRD42015022092.

P428

BUROSUMAB RESULTED IN GREATER IMPROVEMENT IN PHOSPHATE METABOLISM, RICKETS, GROWTH, AND MOBILITY THAN CONTINUATION WITH CONVENTIONAL THERAPY IN CHILDREN WITH X-LINKED HYPOPHOSPHATEMIA (XLH)

W. Högl¹, A. Imel², P. Whyte³, C. Munns⁴, P. Anthony⁵, L. Ward⁶, H. Simmons⁷, R. Padidela⁸, N. Namba⁹, H. Cheong¹⁰, O. Nilsson¹¹, M. Mao¹², A. Skrinar¹², C.-Y. Chen¹², J. San Martin¹², F. Glorieux¹³

¹Dept of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria, ²Indiana University School of Medicine, Indianapolis, USA, ³Shriners Hospitals for Children, St. Louis, USA, ⁴The Children's Hospital at Westmead, Sydney, Australia, ⁵University of California, San Francisco, San Francisco, USA, ⁶University of Ottawa, Ontario, Canada, ⁷Vanderbilt University School of Medicine, Nashville, USA, ⁸Royal Manchester Children's Hospital, Manchester, UK, ⁹Osaka Hospital, Japan Community Healthcare Organization and Osaka University Graduate School of Medicine, Osaka, Japan, ¹⁰Seoul National University Children's Hospital, Seoul, South Korea, ¹¹Karolinska Institutet and Örebro University, Stockholm, Sweden, ¹²Ultragenyx Pharmaceutical Inc., Novato, USA, ¹³Shriners Hospital for Children-Canada, McGill University, Montreal, Canada

Objective: Compare the efficacy and safety of burosumab, a fully human monoclonal antibody to FGF23, to conventional therapy, multiple daily doses of oral phosphate and active vitamin D (Pi/D), in children with XLH.

Methods: In this Phase 3 trial (UX023-CL301, NCT02915705), 61 children with XLH (1-12 years old) were randomized 1:1 after a 7-day Pi/D washout to receive burosumab starting at 0.8 mg/kg SC Q2W or reinitiate Pi/D titrated by investigators for 64 weeks. Eligibility criteria included a total Rickets Severity Score (RSS) ≥2.0 despite prior Pi/D treatment. Healing of rickets was assessed by radiologists blinded to treatment using the Radiographic Global Impression of Change (RGI-C).

Results: Compliance in both arms was high (>95% based on dosing days). Compared with Pi/D, burosumab demonstrated greater improvement in serum phosphorus, serum 1,25(OH)2D, alkaline phosphatase, global RGI-C (primary endpoint), and lower limb deformity (**Table**). Using the generalized estimating equation model, burosumab showed significantly greater increases in recumbent length/standing height Z-score, growth velocity Z-score, and percent predicted distance walked in the 6-minute walk test. The baseline nephrocalcinosis scores in the Pi/D group were 0 for 23 (72%) subjects, 1 for three (9%) subjects, 2 for three (9%) subjects, and 3 for three (9%) subjects. Baseline scores in the burosumab group were 0 in 24 (83%) subjects, 1 in two (7%) subjects, 2 in two (7%) subjects, and 3 in one (3%) subject. At Week 64, nephrocalcinosis score remained the same in 25 (78%) conventional therapy and 26 (90%) burosumab subjects; decreased 1 in five (6%) and two (7%) subjects, respectively; and decreased 2 and 3 in one (3%) subject each with conventional therapy. Adverse

events (AEs) of interest were more frequent with burosumab, including hypersensitivity (38% vs. 19% of subjects) and injection site reactions (52% vs. N/A), and were mild to moderate in severity overall. Three serious AEs occurred per group, all unrelated to treatment and resolved. No subject discontinued study drug.

Endpoint	Week	Change from Baseline		p value
		Pi/D (N=32)	Burosumab (N=29)	
Serum Phosphorus, mmol/L LS mean (SE) change from Baseline	40	+0.06 (0.02)	+0.29 (0.03)	< 0.0001
	64	+0.07 (0.02)	+0.29 (0.03)	< 0.0001
Serum 1,25(OH)2D, pmol/L LS mean (SE) change from Baseline	40	+44.19 (8.62)	+71.07 (8.93)	0.0318
	64	+2.85 (6.68)	+23.76 (5.36)	0.0144
RGI-C Global Score (primary endpoint at Week 40) LS mean (SE) (positive values indicate improvement)	40	0.77 (0.107)	1.92 (0.110)	< 0.0001
	64	1.03 (0.136)	2.06 (0.072)	< 0.0001
Lower Limb Deformity Score by RGI-C (primary analysis Week 64) LS mean (SE) (positive values indicate improvement)	40	+0.21 (0.119)	+0.62 (0.123)	0.0204
	64	+0.29 (0.119)	+1.25 (0.170)	< 0.0001
Serum Alkaline Phosphatase, U/L % mean change from Baseline (decreases indicate improvement)	40	-7%	-24%	< 0.0001
	64	-5%	-33%	< 0.0001
Standing Height/Recumbent Length Z Score (primary analysis Week 64) LS mean (SE) change from Baseline	40	+0.03 (0.031)	+0.16 (0.052)	0.0408
	64	+0.02 (0.035)	+0.17 (0.066)	0.0490
Growth Velocity Z Score (primary analysis Week 64) LS mean (SE) change from Baseline	40	+0.73 (0.339)	+1.76 (0.337)	0.0386
	64	+0.41 (0.265)	+1.53 (0.264)	0.0047
6-Minute Walk Test (6MWT), % Predicted Distance LS mean (SE) change from Baseline	40	-1.1 (2.2)	+5.6 (2.6)	0.0633
	64	+1.9 (2.8)	+9.2 (2.1)	0.0496

Conclusions: Burosumab resulted in significantly greater improvements in phosphate metabolism, rickets, leg bowing, growth, and mobility than continued treatment with Pi/D in 1-12 years old children with XLH.

P429

ASSOCIATION OF BODY COMPOSITION, PHYSICAL ACTIVITY AND PHYSICAL PERFORMANCE WITH KNEE CARTILAGE THICKNESS AND SUBCHONDRAL BONE AREA IN YOUNG ADULTS

T. Meng¹, B. Antony¹, A. Venn¹, F. Eckstein², F. Cicuttini³, L. March⁴, M. Cross⁴, T. Dwyer⁵, G. Jones¹, L. Laslett¹, C. Ding⁶

¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Institute of Anatomy, Paracelsus Medical University, Salzburg, Austria, ³Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia, ⁴Institute of Bone and Joint Research, University of Sydney, Sydney, Australia, ⁵The George Institute for Global Health, Nuffield Department of Obstetrics & Gynaecology, University of Oxford, Oxford, UK, ⁶Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China

Objective: To describe associations of body composition, physical activity and physical performance with knee cartilage thickness and subchondral bone area in young adults.

Material and Methods: Body composition, physical activity and physical performance were measured 4-5 y prior to knee MRI. Cartilage thickness and bone area were measured quantitatively from MRI. Associations were assessed using linear regressions. Age, gender, height (if fat mass or lean mass was predictor) and BMI (if physical activity or physical performance was predictor) were examined as confounders and included in the regressions. Mediator was identified using mediation analysis (Stata's Medeff command).

Results: Participants were aged 31-40 y, 48% were female (n=186). Greater lean mass, but not fat mass, was positively associated with total knee cartilage thickness ($\beta=6.50 \mu\text{m}/\text{kg}$,

95%CI: 0.86 to 12.13) and bone area ($\beta=13.66 \text{ mm}^2/\text{kg}$, 95%CI: 5.73 to 21.59). Physical performance measures were positively associated with total knee cartilage thickness (long jump: $\beta=2.36 \mu\text{m}/\text{cm}$, 95%CI 0.68 to 4.04; hand grip strength: $7.65 \mu\text{m}/\text{kg}$, 1.53 to 13.77; physical work capacity: $1.04 \mu\text{m}/\text{watt}$, 0.27 to 1.81) and bone area (long jump: $\beta=4.25 \text{ mm}^2/\text{cm}$, 95%CI 1.01 to 7.50; hand grip strength: $19.89 \text{ mm}^2/\text{kg}$, 8.23 to 31.55; leg strength: $3.32 \text{ mm}^2/\text{kg}$, 1.25 to 5.40; physical work capacity: $3.00 \text{ mm}^2/\text{watt}$, 1.54 to 4.45). Mediation analysis suggested these associations were mediated by lean mass (effect mediated: 29-95%). Physical activity measures (including walking, moderate activity, vigorous activity and total activity) were not associated with total knee cartilage thickness or bone area.




Figure. Scatter plots and linear regression lines for associations between lean mass and knee cartilage thickness (A: MFTC; B: LFTC; C: Patella).

R and P values are from models adjusted for age, gender and height.

MFTC, medial femorotibial compartment; LFTC, lateral femorotibial compartment.

Conclusion: Greater lean mass and better physical performance measures were associated with greater knee cartilage thickness and subchondral bone area in young adults, and the associations of physical performance were largely mediated by lean mass. These findings suggest lean mass may play an important role in maintaining knee joint health in young adults.

P430

ASSOCIATION OF GLUCOSE HOMEOSTASIS MEASURES AND METABOLIC SYNDROME WITH KNEE CARTILAGE DEFECTS AND CARTILAGE VOLUME IN YOUNG ADULTS

T. Meng¹, A. Venn¹, F. Cicuttini², L. March³, M. Cross³, T. Dwyer⁴, G. Jones¹, L. Laslett¹, B. Antony¹, C. Ding⁵

¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia, ³Institute of Bone and Joint Research, University of Sydney, Sydney, Australia, ⁴The George Institute for Global Health, Nuffield Department of Obstetrics & Gynaecology, University of Oxford, Oxford, UK, ⁵Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China

Objective: To describe the associations of glucose homeostasis measures and metabolic syndrome (MetS) measures with knee cartilage defects and cartilage volume in young adults.

Methods: Australian young adults from the Childhood Determinants of Adult Health Study were selected to undergo knee MRI scans during 2008-2010 (aged 31-41 y). Fasting blood sample, waist circumference and blood pressure measures were collected during 2004-2006 (aged 26-36 y). Glucose, insulin, triglyceride and high-density lipoprotein cholesterol (HDL-C) were measured using serum samples. Homeostatic model assessment 2-insulin resistance (HOMA2-IR), HOMA2-beta cell function (HOMA2-β), HOMA2-insulin sensitivity (HOMA-S) and MetS were calculated or defined. Cartilage defects and cartilage volume were measured from MRI scans. Data were analysed using log binomial or linear regressions and were adjusted for age, gender, BMI and physical activity.

Results: Among 328 participants (47.3% were females), 40 (12.7%) had hyperglycaemia and 21 (6.7%) had MetS. Glucose homeostasis measures (except fasting glucose) were associated with tibiofemoral cartilage defects (fasting insulin: relative risk (RR) 1.05/mU/L, 95%CI 1.01 to 1.08; HOMA2-IR: 1.44, 1.08 to 1.92; HOMA2-β: 2.59, 1.33 to 5.07; HOMA2-S: 0.36, 0.18 to 0.72), but not patellar cartilage defects. There were no associations between glucose homeostasis measures and knee cartilage volume. MetS measures were not associated with either cartilage defects or cartilage volume, except the associations between high waist circumference and tibiofemoral cartilage defects (RR 2.32, 95%CI 1.18 to 4.54) and between low HDL-C and tibiofemoral cartilage defects (RR 1.99, 95%CI 1.08 to 3.69).

Conclusion: Insulin resistance was associated with higher risk of tibiofemoral cartilage defects amongst young adults. MetS was not associated with neither cartilage defects nor cartilage volume. These suggest that glucose homeostasis, but not MetS, may play a role in cartilage damage in young adults and may lead to knee osteoarthritis in later life.

P431

COMPARISON OF TWO DIFFERENT MOBILIZATION TECHNIQUES IN SUBACROMIAL IMPINGEMENT SYNDROME

B. Ozkaraoglu¹, D. Karagozoglu Coskunsu¹, D. Ozkaraoglu²

¹Bahcesehir University, ²Istanbul Medipol University, Istanbul, Turkey

Objective: To investigate the efficacy of two different manual therapy methods that cervical mobilization and shoulder mobilization in subacromial impingement syndrome (SIS).

Methods: A total of 40 patients (18-60 years old, 28 female and 12 male) were included in the study. The patients were randomized into two groups. The effectiveness of the treatments applied in both groups were assessed before and after treatment with Numerical Pain Rating Scale (NPRS), Shoulder Range of Motion (ROM), Disabilities of The Arm Shoulder and Hand (Quick-DASH), Rotator Cuff Quality of Life (RC-QOL). Both groups received physiotherapy program comprised of 15 therapy sessions (5 d/week). Conservative treatment included ultrasound, transcutaneous electrical nerve stimulation, cold pack and therapeutic exercises for SIS. In addition to conservative treatment, Group I received shoulder mobilization techniques, while Group II received cervical mobilization techniques.

Results: Regarding comparisons within the groups, both groups showed statistically significant improvement as determined by NPRS, Quick-DASH, ROM and RC-QOL scores ($p < 0.05$), whereas in comparisons between the groups, Group I showed significantly greater improvement compared to Group II for all parameters except resting NPRS and shoulder abduction measurement ($p < 0.05$).

Conclusion: It can be said that utilization of either of the mobilization techniques in the conservative treatment method will be beneficial. Nonetheless, mobilization techniques that involve shoulder complex are found to be more effective than cervical mobilization techniques in SIS for most of the assessment parameters in terms of reducing patients pain and enhancing functionality, ROM and life quality.

P432

CLINICAL, BIOCHEMICAL AND RADIOLOGICAL PROFILE OF NORMOCALCAEMIC HYPERPARATHYROIDISM: A MULTICENTRIC CROSS-SECTIONAL EVALUATION

A. M. Naciu¹, G. Tabacco¹, S. Falcone², A. Santonati³, D. Maggi¹, L. D'Onofrio⁴, S. I. Briganti¹, D. Castellitto⁵, A. Casini⁵, C. Pedone⁶, A. Fabbri², N. Napoli¹, P. Pozzilli¹, S. Manfrini¹, R. Cesareo⁵, A. Palermo¹

¹Unit of Endocrinology, University Campus Bio-Medico, Rome,

²Unit of Endocrinology and Metabolic Diseases, CTO A.

Alesini Hospital, University Tor Vergata, Rome, ³Department

of Endocrinology, San Giovanni Addolorata Hospital,

Rome, ⁴Department of Experimental Medicine, Sapienza

University of Rome, Rome, ⁵Thyroid and Metabolic Bone

Diseases Center, Santa Maria Goretti Hospital, Latina, ⁶Unit of

Geriatric, University Campus Bio-Medico, Rome, Italy

Objective: Normocalcaemic hyperparathyroidism (NHPT) has been defined as a condition with persistently normal total and ionized calcium levels in the presence of high levels of PTH. The clinical aspects of NHPT have been evaluated in different cohorts but the interpretation of these findings is confounded by differing methods used to rule out secondary hyperparathyroidism and by the small number of NHPT subjects enrolled. Our aim was to assess the clinical, biochemical and radiological profile of NHPT in comparison with primary hyperparathyroidism (PHPT) and control subjects.

Methods: We enrolled in a multicentric cross-sectional study patients with NHPT and PHPT diagnosed according to criteria of the "Fourth International Workshop of Asymptomatic Hyperparathyroidism". BMI and age matched control subjects were consecutively recruited. All patients underwent a biochemical examination including calcium-phosphorus metabolism and bone turnover markers. We assess the lumbar spine (L1-L4), total hip, femoral neck, and nondominant forearm BMD and the trabecular bone score. Morphometric vertebral fracture (VF) were assessed by DXA scan.

Results: From December 2016 to July 2018, we identified 47 patients with NHPT, 41 with PHPT and 39 control subjects. All study groups had no significant differences in terms of age, BMI and kidney function. NHPT and PHPT patients had significantly higher PTH and 25(OH)vitamin D levels ($p < 0.001$) and lower Ca*P ($p < 0.001$) than controls. NHPT has lower CTX levels confronted with PHPT ($p = 0.039$). NHPT ($p = 0.035$) and PHPT ($p = 0.003$) group have lower total hip BMD than controls; NHPT showed higher nondominant forearm BMD than PHPT subjects ($p = 0.017$), while compared to controls presented similar values. No significant differences in TBS between the three groups have been founded. After adjustment for confounding factors, only PHPT group had an increased risk of VF compared to controls (OR:5.10, 95%CI:1.34 to 21.58). 31% of NHPT and 12% of PHPT patients fulfilled the criteria for asymptomatic hyperparathyroidism.

Conclusion: Up to now, our study described the biochemical and radiological profile of the largest cohort of NHPT subjects. Our findings suggest that the profile of NHPT subjects is closer to control one.

P433

INFANT FEEDING AND BONE HEALTH IN LATER LIFE: EVIDENCE FROM THE HERTFORDSHIRE COHORT STUDY

S. Carter¹, C. Parsons¹, S. Robinson¹, E. M. Dennison¹, C. Cooper¹

¹University of Southampton, MRC Lifecourse Epidemiology Unit, Southampton, UK

Objectives: Research into the relationship between infant feeding and infant growth has determined that different patterns of milk feeding are linked with differences in growth in infancy and adult leg length. As both weight gain in infancy and adult leg length have been associated with higher BMD and BMC in older age, this study aims to examine the associations between type of infant feeding and bone health in later life by comparing spinal and femoral BMD and BMC in 996 older adults, aged 59-73 y, who were breastfed or bottle fed in infancy.

Methods: Using data from the Hertfordshire Cohort Study (HCS), this analysis utilized linear regression to examine the relationship between type of infant feeding, and spinal and femoral BMD and BMC. Information on how HCS participants were fed as infants (breastfed, breast and bottle fed, or bottle fed), in addition to their birth weights (kg) and weights at 1 (kg), was collected by health visitors between 1931-1939 in Hertfordshire. In addition to these early life variables, models adjusted for age, smoking behaviour, alcohol consumption, diet, and adult leg length.

Results: While type of infant feeding had no significant association with bone health for women in this sample, it was a significant predictor of bone health in later life for men: type of infant feeding was associated with spinal BMD ($b = -.035$, 95%CI $-.064$, $-.007$, p -value: 0.014) and spinal BMC ($b = -2.932$, 95%CI -5.641 , $-.223$, p -value: 0.034), with men who were breastfed in infancy being more likely to have higher spinal BMD and BMC measurements. These associations between infant feeding and markers of bone health in men remained significant in fully adjusted models.

Conclusion: The observed associations between infant feeding and spinal and femoral BMD and BMC in men indicate that exclusive breastfeeding may be protective for the bone health of male babies as they age. The evidence presented here underscores the potential lifelong benefits of breastfeeding and highlights differences between osteoporotic risk factors for men and women.

P434

MOBILE TECHNOLOGIES FOR NUTRITIONAL SUPPORT AND EXERCISE FOR IMPROVING LIFE OF PATIENT WITH HIV: CASE REPORT

V. Krylov¹

¹Sechenov University, Moscow, Russia

Objective: There are a lot of conditions associated with HIV such as lipodystrophy, fat atrophy, insulin resistance, low levels of high-density lipoprotein cholesterol, and hypertriglyceridemia. A diet program combined with exercises can help to treat patients with HIV.

Methods: We used an online system for patient education based on video lessons, full of humor, pictures, and cartoons to convey the necessary information on good nutrition and exercises.

Results: A 42-year-old white man received the diagnosis of HIV infection in 2014 and was treated with a combination of stavudine, lamivudine, and nevirapine beginning in 2017. In January 2014, his blood HIV RNA level was 2583 copies/mL and subsequently, from January 2014 through the most recent test on June 2018, was <400 copies/mL; The CD4 count was 434 cells/mm³ in January 2014, and 560 cells/mm³ in June 2018. From January 2014 through September 2016, he gained 12 kg and was diagnosed with lipodystrophy. Watching the short movies, the patients formed the habits of good nutrition during the first month already, which includes a moderate-fat, low-glycemic-index, high-fiber diet with an exercise program for home and fitness center and push-notifications through the special online system. At 6 months he decreases his body weight by 6.5 kg. His maximal dynamic strength increased by 58%. His dietary intake of protein increased from 12% to 21% of total calories, and his intake of saturated fat decreased from 20% to 10% of total calories. His intake of dietary fiber more than doubled.

Conclusion: So online systems could improve the quality and duration of life of our patients to make motivation and remind about treatment, diet, and exercises. So, we need to improve the quality of information material, including using online technologies to improve the quality and duration of life of our patients.

P435

ECTOPIC ADRENOCORTICOTROPIC HORMONE (ACTH-ECTOPIC) SYNDROME AND OSTEOPOROSIS. RARE CASES AND DIFFICULT TREATMENT

V. Krylov¹, E. Dobрева², S. Kharnas¹, N. Kuznetsov²

¹Sechenov University, ²Endocrine Research Centre, Moscow, Russia

Objective: ACTH-ectopic syndrome (EAS) is a rare cause of ACTH-dependent endogenous hypercortisolism. The objective of this study was to analyze the clinical, biochemical, and radiological features, management, and treatment outcome of patients with EAS.

Methods: It was a retrospective case-record study of 47 patients with EAS. Clinical, biochemical, and radiological features and response to therapy and survival rate were measured.

Results: The median follow-up was 7 y (range, 1-13 y). None of the dynamic tests achieved 100% accuracy. Imaging correctly identified the lesion at first investigation in 80.9% of cases. Bronchial carcinoid tumors were the most common cause of EAS (n=27; 57.5%), followed by other neuroendocrine tumors (n=11, 23.4%). In 19.1% (9) of patients, the source of EAS was never found. Tumor histology and the presence of distant metastases were the main predictors of overall survival (P<0.05). It is interesting that 40 patients (85.1%) have steroid osteoporosis. 10 patients were treated with calcium and vitamin D, 35 patients by bisphosphonates, 2 patients by denosumab and 3 by teriparatide.

Conclusions: ACTH-ectopic syndrome is a very rare condition with severe complications. There is no significant data and guidelines for osteoporosis treatment in such disease. So we need to improve our to improve the quality of life of such difficult patients.

P436

VITAMIN D DEFICIENCY AND POST-STROKE DEPRESSION IN PATIENTS WITH LOW BONE MINERAL DENSITY

S. Tomasevic-Todorovic¹, K. Boskovic¹, S. Pantelinac¹, A. Knezevic¹, S. Kevic¹, L. J. Milasinovic-Stanojevic², F. Hanna³

¹Faculty of Medicine, University of Novi Sad, Medical Rehabilitation Clinic, Clinical Center Of Vojvodina, Novi Sad, ²Latrija, Novi Sad, Serbia, ³Public Health Program, Department of Health Sciences, Torrens University Australia., Melbourne, Australia

Objective: Post-stroke depression is common and has high clinical relevance as it may hinder a full and optimal recovery. Low serum levels of 1,25-dihydroxyvitamin D has been reported in patients with post-stroke depression (PSD). Our aim was to evaluate the frequency of depression and serum vitamin D levels in stroke patients

Methods: Our cross-sectional study included 60 (50 women, 10 men) stroke patients (35 with osteoporosis, 25 with osteopenia) of average age of 69.52±9.46 y, who received treatment at the Clinic for Medical Rehabilitation, Clinical Center of Vojvodina in Novi Sad. The inclusion criteria were patients after a first stroke (≤1.5 y from a stroke). Lunar Prodigy Primo densitometer was used to determine the BMD in all participants. DXA measurement was performed at the lumbar spine L2-L4 segment in anteroposterior (AP) position. Serum levels of 25-hydroxyvitamin D [25(OH)D] were measured by competitive protein-binding assay (reference values: >30 ng/dl). Depression severity was quantified using the Hamilton Depression Rating Scale (HDRS), and functional status using Barthel Index (BI).

Results: Minor depression (HDRS score 8-15) was found in 25 (41.67%) patients while major depression (HDRS score ≥16) was found in 1(1.67%) patient after stroke. The study also showed low levels of serum 25(OH)vitamin D [<30 ng/dl (p<0.001)] in 8 (23.53%) patients without depression and 20 patients with depression. The mean BI scores were significantly higher in patients without PSD than in those with PSD (<0.001).

Conclusion: Low BMD and low levels of serum 25(OH)vitamin D are associated with PSD in stroke patients. Longitudinal studies are required to confirm the causation between risk factors and outcome. Additional research on vitamin D supplementation is also warranted to improve the outcome of patients with PSD.

P437

A NOVEL FIVE "I" MODEL OF FRACTURE LIAISON SERVICE: SUCCESSFUL EXPERIENCE IN TAIWAN

W.-C. Hung¹, C.-H. Yang², W.-L. Chin³, C.-H. Wu⁴

¹E-Da hospital/I-Shou University, Kaohsiung, ²I-Shou University, Kaohsiung, ³E-Da Hospital, Kaohsiung, ⁴National Cheng Kung University Hospital, Tainan, Taiwan

Objectives: Fracture liaison services (FLSs) using three "I" model (identification, investigation, and initiation), are effective modules for fragility fracture prevention. Although FLSs are cost-effective, the poor medical adherence, high manpower demands and implementation costs are the caveats of FLS implementation.

Methods: The E-Da hospital serving approximately 1,000,000 (outpatients)/40,000 (inpatients) person-times/year is a tertiary referral hospital in southern Taiwan. Its FLS program was successfully implemented using the five "I" model based on three "I" model to improve FLS caveats, especially the low adherence in 2016. The fourth "I" focusing on long-term treatment adherence implies adherence improvement. In the era of artificial intelligence (AI), FLS models established by smart healthcare systems can assist clinicians and case managers to identify, investigate, and initiate treatments and improve adherence efficiently. The role of AI will become increasingly important and comprise a fifth "I" (intelligence).

Results: The smart healthcare case management system in this hospital completely satisfies the five "I" model. On an average, the AI system has automatically analyzed 20,480 and 479 reports of X-ray and DXA examinations, respectively, and has identified 967, 803, 87, and 206 patients with hip fractures, vertebral compression fractures, osteoporosis, and low bone mass, respectively, each month at the E-Da hospital. Moreover, the system's data analysis not only save manpower and reduce the rate of omitted patients, but also reach a 93.6% rate of 1-year medication adherence. The FLS of E-Da Hospital was accredited as a 100% golden program by the IOF in 2017.

Conclusions: The smart healthcare case management system demonstrates that the novel five "I" model based on the original three "I" model but with the two "I," i.e., "Improvement of adherence" and "Intelligence," can be a novel module to achieve better outcomes in the fragility fracture prevention program of FLSs, especially in a sizable hospital.

Acknowledgements: This study is supported by research project of E-Da hospital, Taiwan (grant number: EDAHP106002).

P438

ARE THE OTTAWA RULES HELPFUL TO PREDICT ANKLE AND FOOT FRACTURES IN SPORTS ACTIVITIES ?

C. Matzaroglou¹, V. Angelopoulos¹, P. Gkrialias¹, P. Megas², C. Menos Aikateriniadis³, J. Gliatis², M. Tyllianakis²

¹Technological University of Western Greece, Human Assessment and Rehabilitation Lab, Aigio, ²University Hospital of Patras, University of Patras, Patras, Greece, ³KTH Royal Institute of Technology, Stockholm, Sweden, Stockholm, Sweden

Objective: This instrument (Ottawa rules out) consists of a questionnaire for assessment of the ankle and foot and need for radiography after trauma. Our purpose was to validate the Ottawa ankle rules to predict ankle and foot fractures in sports activities as clinical setting, when they are used in emergency department.

Methods: We used a prospective patient survey by emergency physicians in Orthopaedic emergency department of a university hospital. The study group consisted of 356 consecutive patients aged 18 years and older who presented with acute ankle or mid-foot injuries during a 8-month period. Radiography was performed in each patient after clinical evaluation findings were recorded.

Results: 29 ankle and 12 midfoot fractures were diagnosed. The decision rules had a sensitivity of 0.89, a specificity of 0.34, and a negative predictive value of 0.89 in detecting ankle fractures, a sensitivity of 0.85, a specificity of 0.29, and a negative predictive value of 0.9 in detecting midfoot fractures. The rules failed to predict 4 avulsion fractures in the ankle group. Application of these rules by emergency physicians would have reduced ankle or midfoot radiography requests by 22%.

Conclusion: Use of the Ottawa ankle rules by emergency physicians resulted in 85% sensitivity and had a potential of reducing radiography requests by 23%. Since the Ottawa ankle rules is an instrument that is calibrated towards high sensitivity of 100%, in our patients were less sensitive than clinical suspicion alone. In our opinion low sensitivity for all fractures (ankle and midfoot) would not allow physicians to safely reduce the number of radiographs with Ottawa rules.

P439

IMPACT OF COMORBIDITIES ON PHYSICAL PERFORMANCE IN LATER LIFE

G. Bevilacqua¹, M. A. Clynes¹, K. A. Jameson¹, C. Cooper¹, E. M. Dennison¹

¹MRC LEU, University of Southampton, Southampton, UK

Objectives: An increase in life expectancy has led to a higher prevalence of chronic, noncommunicable diseases. Physical performance (PP) test score has been linked with nursing home and hospital admissions, and may predict falls and therefore fracture risk. Here we examine the impact of different comorbidities (CM) on PP.

Methods: Data were available for 222 men and 221 women who participated in the UK component of the European Project on Osteoarthritis (EPOSA). Participants completed a questionnaire

detailing CMs. PP was determined from assessments of walking speed, chair stands and balance to create a composite score (0-12); low PP was defined as ≤ 9 . All findings were adjusted for age, BMI, smoker status, alcohol consumption, social class, and physical activity. Results are reported as regression coefficients, with 95%CI.

Results: The mean (SD) ages were 75.5 (2.5) and 75.8 (2.6) years for men and women respectively. The proportion of individuals with a low PP score was high in both women and men (71.2% and 56.9% respectively). Rheumatoid arthritis was associated with weaker grip strength [-4.36 (-8.23, -0.49) kg, $p < 0.03$]; and lower PP score in women [-0.73 (-1.42, -0.04) z-score, $p < 0.05$], but otherwise stronger relationships were generally seen in men. Hence, osteoarthritis was associated with weaker grip strength [-3.69 (-5.72, -1.66) kg, $p < 0.001$] and lower PP score in men [-0.39 (-0.71, -0.08) z-score, $p < 0.03$], and with weaker grip strength in women [-2.61 (-4.22, -0.99) kg, $p < 0.01$]; diabetes was associated with weaker grip strength in men [-2.77 (-5.50, -0.03) kg, $p < 0.05$] but not in women; stroke was associated with lower PP score in men [-0.67 (-1.31, -0.03) z-score, $p < 0.05$], but not in women. Heart disease was associated with a higher risk of a low PP score in men only [OR 2.73 (1.14, 6.58), $p < 0.05$]. No association was found between low PP and hypertension, lung or thyroid disease in either gender. An increasing number of CMs was associated with a higher risk of a low PP score in both men and women [OR 1.40 (1.02, 1.91), $p < 0.05$ and OR 1.35 (1.00, 1.82), $p < 0.05$ respectively].

Conclusion: The impact of CMs on PP varied according to gender, and the comorbid disease being reported. Specifically, osteoarthritis, stroke, diabetes and heart disease were more strongly associated with functional impairment in men.

P440

BONE INVOLVEMENT IN SYSTEMIC MASTOCYTOSIS: CASE SERIES FROM A SINGLE CENTER

O. Ibarquengoitia¹, J. M. Blanco¹, I. Calvo¹, D. Montero¹, L. Vega¹, E. Galindez¹, M. L. García¹, M. E. Ruiz¹, A. R. Inchaurre¹, I. Torre¹, E. Cuende¹, O. Fernandez¹, C. E. Pérez¹

¹Basurto University Hospital, Bilbao, Spain

Objective: Systemic mastocytosis is a clonal disease of mast cell progenitors in bone marrow that causes abnormal growth and accumulation of mast cells in different organs. Bone involvement is rare as a form of disease presentation although it occurs in 70% of cases. Our aim was to describe the main demographic and clinical features of patients with systemic mastocytosis, especially focusing on bone involvement.

Methods: Review of systemic mastocytosis patients diagnosed in our hospital (by Rheumatology, Allergy and Hematology departments) and description of the main epidemiological and clinical characteristics.

Results: 7 cases of systemic mastocytosis diagnosed in a 25-y period in our hospital were registered. The study includes 4 women and 3 men and ages ranged from 27-70 y. Every patient had a bone marrow biopsy compatible with systemic mastocytosis. The disease was presented with respiratory involvement in 2 cases, digestive in 1 case, skin in 1 case and with bone involvement in 3 patients. 4 patients had allergic reactions in some stage of evolution, 3 skin symptoms and 3 patients had hypotension, dizziness, palpitations and syncope. The delay of diagnosis from the onset of symptoms varies between 3-13 y. Regarding the musculoskeletal system 6 patients had bone involvement: 1 patient was previously diagnosed with chronic osteomyelitis and 5 patients with osteoporosis and multiple vertebral fractures. One patient also had multiple rib fractures. Tryptase levels were elevated in 5 patients, whereas urine histamine levels were elevated in all 6 patients. All patients were treated with bisphosphonates and none of them had new bone collapses while in treatment.

Conclusions: Systemic mastocytosis is a rare cause of secondary osteoporosis. Although bone involvement can occur, osteoporosis is uncommon as first manifestation of the disease. In our review, 4 of the cases had been admitted to our department for vertebral fractures and we made the diagnosis in 3 of them. Tryptase and histamine levels should be included in the laboratory examinations in patients with osteoporosis and fractures after excluding common causes because up to 9% of "idiopathic" male osteoporosis may be caused by mastocytosis

P441

FACTORS THAT PREDICT ONE-YEAR INCIDENT HIP AND NON-HIP FRACTURES FOR LONG-STAY HOME CARE RECIPIENTS IN ONTARIO, CANADA

C. McArthur¹, G. Ioannidis¹, M. Jantzi², J. D. Adachi³, L. Giangregorio⁴, J. Hirdes², L. Hillier⁵, A. Papaioannou¹

¹GERAS Centre for Aging Research, McMaster University, Hamilton, ²University of Waterloo, Waterloo, ³McMaster University, Hamilton, ⁴University of Waterloo, Schlegel-UW Research Institute on Aging, Waterloo, ⁵Ontario Osteoporosis Strategy for Long-term Care, London, Canada

Objectives: To determine the factors that predict one-year incident hip and non-hip (spine, pelvis, humerus, distal radius) fractures for home care (HC) recipients in Ontario, Canada.

Methods: This is a retrospective cohort study of linked population data for people receiving HC services for more than 60 d. We excluded those with multiple admissions, endstage disease, no one-year reassessment, or receiving hospice care. Potential predictors (e.g., age, sex, cognition) were obtained through the interRAI Resident Assessment Instrument-HC, and one-year incident hip and non-hip fractures in the Discharge Abstract Database and National Ambulatory Care Reporting System. Factors associated with one-year incident hip and non-hip fractures were determined through multivariate logistic regressions. Odds ratios (OR) and 95%CI were calculated.

Results: Of the 112,649 HC recipients included, 2743 (2.5%) and 3541 (3.1%) experienced hip and non-hip fractures within one year, respectively. Factors independently predicting hip fracture were (OR, 95%CI): age (1.04, 1.04-1.05), female sex (1.46, 1.34-1.58), moderate cognitive impairment (1.80, 1.39-2.34), fracture in the past year (1.32, 1.19-1.46), fall in the past 180 d (1.20, 1.15-1.26), wandering behaviour (1.64, 1.40-1.92), current smoking (1.64, 1.42-1.90), unexpected weight loss of 5-10% (1.26, 1.12-1.41), morbid obesity (0.44, 0.31-0.62), and Parkinson's Disease (1.31, 1.11-1.54). Factors independently predicting non-hip fracture were: age (1.02, 1.01-1.02), female sex (1.78, 1.64-1.92), mild cognitive impairment (1.20, 1.01-1.43), fracture in the past year (1.71, 1.58-1.86), fall in the past 180 d (1.17, 1.12-1.22), current smoking (1.35, 1.19-1.52), morbid obesity (0.79, 0.65-0.97), and taking a psychotropic medication (1.16, 1.09-1.25).

Conclusions: The HC population has unique fracture risk factors, including wandering, unexpected weight loss, Parkinson's Disease, and taking psychotropic medication. The fracture prevalence and risk factors of HC recipients is more similar to those of frail, older adults residing in long-term care than to community-dwelling older adults.

Acknowledgements: This work was supported by a Fellowship from the Canadian Institutes of Health Research.

P442 EFFECT OF BUROSUMAB (KRN23), A FULLY HUMAN ANTI-FGF23 MONOCLONAL ANTIBODY, ON OSTEOMALACIA IN ADULTS WITH X-LINKED HYPOPHOSPHATEMIA (XLH)

P. Kamenický¹, K. Insogna², N. Ito³, T. Kubota⁴, A. Nakamura⁵, M. Mealiffe⁶, J. San Martin⁶, A. Portale⁷

¹Université Paris-Sud, Le Kremlin Bicêtre, France, ²Yale School of Medicine, New Haven, USA, ³University of Tokyo Hospital, Tokyo, Japan, ⁴Osaka University Hospital, Osaka, Japan, ⁵Hokkaido University Hospital, Hokkaido, Japan, ⁶Ultragenyx Pharmaceutical Inc., Novato, USA, ⁷University of California, San Francisco, San Francisco, USA

Objective: We evaluated the efficacy of burosumab, a fully human monoclonal antibody against FGF23, on improving osteomalacia in adults with XLH.

Methods: In the open-label, phase 3 study, UX023-CL304 (NCT02537431), 14 adults with XLH who had not received oral phosphate and vitamin D therapy within 2 y of enrollment were administered subcutaneous burosumab, 1.0 mg/kg every 4 weeks for 48 weeks. The primary endpoint was improvement in osteoid volume/bone volume assessed by transiliac bone biopsies obtained at Baseline and week 48.

Results: Fourteen subjects enrolled (mean age 40 y, 57% female), 13 completed 48 weeks, and 11 completed paired biopsies. At Baseline, all subjects demonstrated severe osteomalacia. At Week 48, all osteomalacia-related histomorphometric measures improved significantly (Table). We observed increases in mean cancellous bone volume/tissue volume (mean [SD]: Baseline 31.12 [7.43]%; Week 48 38.55 [12.77]%), cortical width (Baseline

1056.90 [293.83] µm; Week 48 1150.00 [457.47] µm), eroded surface/bone surface (Baseline 3.36 [2.25]%; Week 48 6.73 [2.72]%), single label surface/bone surface (Baseline 5.64 [4.60]%; Week 48 12.05 [7.84]%), and trabecular thickness (Baseline 150.70 [52.93] µm; Week 48 165.64 [58.86] µm). Mean serum phosphorus concentration also increased. Markers of bone formation and resorption increased at Week 48 (LS mean increase: PINP +77%, CTx +36%; both p<0.0001). Of the 4 pseudofractures detected at Baseline, 3 were healed and 1 was not assessed at Week 48. Scores for Worst Pain in the Brief Pain Inventory (LS mean change -1.86 p=0.0054) and Global Fatigue in the Brief Fatigue Inventory (-1.20 p=0.0359) decreased significantly. All subjects had ≥1 adverse event (AE). Two subjects experienced serious AEs (migraine; paresthesia) that were unrelated to treatment and resolved. Most AEs were mild to moderate in severity. Eleven subjects reported biopsy-related AEs: pain (14 AEs), itch (2), headache (1), and bandage irritation (1). There were no deaths or incidents of hyperphosphatemia; 1 subject withdrew consent at Week 44.

Table 1. Efficacy Assessments in UX023-CL304

Assessment	All Subjects (n = 11) ^a Mean (SD)
Osteoid Volume/Bone Volume, %	
Baseline	26.1 (12.4)
Week 48	11.9 (6.6)
P value based on percentage change from Baseline	<0.0001
Osteoid Thickness, µm	
Baseline	17.2 (4.1)
Week 48	11.6 (3.1)
P value based on percentage change from Baseline	<0.0001
Osteoid Surface/ Bone Surface, %	
Baseline	91.7 (3.4)
Week 48	67.8 (13.7)
P value based on percentage change from Baseline	<0.001
Mineralization Lag Time, days^b	
Baseline	1539.8 (1587.1)
Week 48	195.5 (77.7)
P value based on percentage change from Baseline	<0.05
Serum Phosphorus, mg/dL	
Baseline	2.24 (0.396)
Midpoint of the dose interval between Baseline & Week 24 (ie Weeks 2, 6, 14, and 22)	3.31 (0.380)

^aBaseline Osteoid Volume/Bone Volume and Week 48 Mineralization Lag Time n = 10; Serum phosphorus N = 14. ^bUsing imputed results.

Conclusion: By normalizing phosphate homeostasis, burosumab significantly reduces osteomalacia in adults with XLH, which may explain observed improvements in skeletal complications of this disease.

P443 CHANGING FACE OF SILVER TRAUMA WITH GERIATRIC INPUT

M. Qaffaf¹, H. Lorimer¹, S. Montandon¹, P. Davie¹, C. Pollard¹, T. Humphries¹, C. Walsh¹, S. Burton¹, S. Naraen¹

¹Aintree University Hospital, Liverpool, UK

Objective: Major trauma is changing from being young and male to being older with a lower degree of male predominance. A fall of <2 m is now the most common mechanism of injury causing major trauma. On arrival to hospital elderly are more likely to be treat-

ed by more junior staff and a low proportion of these patients are assessed in resuscitation. A small but clinically significant group, (3.2% of major trauma patients) either admitted directly to medical ward or sustained injury while inpatient. High quality care for older people with hip fracture has led to sustained improvement in care process and outcome. However, this approach needs to extend beyond patients with fractures of the proximal femur to all types of major trauma. Our aim was to find out the mechanism of major trauma impact on older people with multiple co morbidity and whether regular geriatric input has any role in their outcome.

Method: A pilot project was under taken for small sample of 120 patients. a retrospective study of all the notes were done.

Result: The patient reviewed by geriatrician were 50% (60/120 patients). There were 53% (32/60 patients) female and 47% (28/60 patients) male. Maximum number of patients age between 70-90 36.6% (22/60 patients) had major trauma from falling height of <2 m and out of which 21.6%(13 patients) were above 86. There were 82% (49 patients) referred from other hospitals and only 18% (11/60 patients) had direct admission. Most of the patients 91.6% (55/60 patients) were admitted from their own homes. 93% of patients (56/60 patients) had <5 comorbidity and only 7% (4/60 patients) >5 comorbidity. The patients reviewed once were 55% (33/60 patients) and only one patients was seen 9 times. Majority of the patients 22% (13 patients) had only one investigation requested by geriatrician. Most of the patients 63% (38/60 patients) had Falls assessment done. 63.3% (38/60) of patients were found to have developed one or more complications and out of which respiratory complication was more common. 48% (29/60 patients) had good recovery and only 13% (8/60) patients died mostly due to head injury.

Conclusion: Older people living at their own home with relatively less comorbidity suffer a variety of trauma, mainly with low energy mechanism; i.e., fall of standing height in their own home. With geriatric input maximum has good recovery even though maximum patients had developed medical complications. there were fewer investigation requested, and very little referral to other specialties. Most of the mortalities were due trauma. Most of the patients are referred from different hospitals in the region.

P444

QUALITY OF LIFE: SYSTEMIC LUPUS ERYTHEMATOSUS AND AEROBIC TRAINING

B. G. Bogdanovic¹, **S. N. Stanisavljevic**¹, **S. L. J. Stojanovic**¹

¹CHC Bezanijska Kosa, Beograd, Serbia

Objective: Quality of life (QOL) measures have become a vital and often required part of health outcome appraisal. Because lupus causes joint pain and inflammation, muscle pain, and fatigue, the very thought of exercising can be a challenge for patients. Our aim was to determine if supervised aerobic training improves quality of life in patients with SLE.

Methods: 30 women with SLE (ages 39.74±10.58), remain of illness 6.8±2.9 y, in steady state (measured by SLEDAI score) comparing to 30 healthy women, were evaluated using Short

Form 36 (**SF36**). Both groups of women had aerobic training on bicycle ergometer for 15 min, 3 times a week for 6 weeks. SF36 were analyzed at baseline and after 6 weeks.

Results: Statistical analysis values of SF36 before supervised aerobic training shows significantly worse quality of life in woman with SLE in all parameters of SF36: physical functioning 36.96±7.01 vs. 57.144.64±2.12, physical health 34.12±5.74 vs. 56.2±8.74, pain 38.52±5.57 vs. 62.8±6.53, general health 35.21±6.97 vs. 41.19±3.62, vitality 44.64±2.12 vs. 68.54±5.12, social functioning 33.61±5.57 vs. 67.32±6.97, emotional health 29.69±7.17 vs. 64.52±7.95, mental health 31.08±6.07 vs. 63.6±5.52 in 2 general parameters physical health 36.96±7.01 vs. 60.0±7.05 mental health 33.65±3.93 vs. 64.6±5.32. After aerobic training there is no statistical difference between group of women with SLE and control group except with parameter and general health 41.19±3.62 vs. 68.20±7.64 (p<0.005). Exercise did not exacerbate disease measured by SLEDAI score.

Conclusion: This study showed significant improvement in QOL after a supervised aerobic training on bicycle ergometer in patients with SLE.

P445

PRIMARY KNEE OSTEOARTHRITIS: COMPLEX ASSESSMENT AND COMPLETE MANAGEMENT

R. Traistaru¹, **D. Kamal**², **C. Kamal**¹, **O. Rogoveanu**¹

¹University of Medicine and Pharmacy, ²Elga Clinic, Craiova, Romania

Objective: Knee osteoarthritis (KOA) - a progressive, incurable joint disease resulting in the breakdown of cartilage and bone - is an important cause of chronic pain and physical disability (1). Synovitis and joint effusion are secondary phenomena in OA as a consequence of chondrolysis. Goals of complete rehabilitation program in KOA include controlling pain, maintaining and improving the range of movement and stability of affected joints, and limiting functional impairment, for an optimal quality of life (2). Biochemical markers of cartilage and bone degradation are becoming increasingly important in the evaluation of KOA. In our prospective study, we assessed the efficacy of rehabilitation program (TENS, ultrasound and exercise program) over the presence of synovitis or joint effusion in patients with painful primary KOA. We evaluated the correlation between these sonographic aspects, serum C-terminal crosslinking telopeptide of collagen type II (CTX-II) and functional parameters.

Methods: We studied 46 patients (29 women, 17 men), aged between 71-82 y. All patients were clinical, functional (VAS scale, Lequesne index and WOMAC scale) and imagistic (X-rays and sonography) evaluated. The complex rehabilitation program (educational, dietetic, pharmacological, physical - kinetic) was performed 5 d/week, 2 weeks. All subjects were evaluated at baseline (T1) and at 2 (T2) and 12 (T3) weeks.

Results: The studied parameters had improved, especially in T2 moment (p<0.05). The mean value of serum CTX-II was correlated with imagistic aspects. Multivariate analysis showed that sonographic aspects correlated statistically with VAS score, Lequesne

index and WOMAC score. The pain improvement is correlated with sonographic aspects. After 12 weeks, improved functional status was maintained.

Conclusion: Our results reflected two aspects: the first - the favorable complex effect (clinical, functional and sonographic) of rehabilitation performed in patients with painful KOA; the second - serum CTX-II is a useful biochemical marker for quantify the rehabilitation and patient self-management programs in KOA.

References:

1. Traistaru R et al. Rev Chim 2018;69:3205
2. Traistaru R et al, Farmacia 2018;66:507

P446

LOW BACK PAIN IN FEMALES WITH SEVERE OSTEOPOROSIS: ASSESSMENT AND REHABILITATION

R. Traistaru¹, O. Rogoveanu¹, D. Kamal², C. Kamal¹, A. M. Bumbea¹

¹University of Medicine and Pharmacy, ²Elga Clinic, Craiova, Romania

Objectives: Chronic low back pain (LBP) is one of the most common symptoms in osteoporosis females, leading to complex disability and reduces quality of life significantly (1). The prevalence of vertebral fractures increase the risk of a subsequent vertebral fractures and the recovery of quality of life after a new vertebral fracture is less than after the previous. Various rehabilitation programs have been proposed for chronic low back pain in females with severe osteoporosis. We assessed the effects of a 6 week complex rehabilitation program (pharmacotherapy, educational sessions, multi-modal exercise training and Hessing orthotic device) on quality of life and self-control of the complex disorders, in females with severe osteoporosis and low back pain.

Methods: 56 females (63.5 y mean age) with severe osteoporosis (mean disease duration 3.5 y), were randomly assigned to a rehabilitation group – RG (n=29) and a pharmacotherapy (bisphosphonates) group – PG (n=27). Clinical evaluation, lab tests, exercise tolerance tests (6-min walking distance - 6MWD), visual analogue scale (VAS) for pain, and Osteoporosis Quality of Life Questionnaire (OQOLQ). BMD was measured by DXA in lumbar spine. Statistical analysis and correlation between data were done with the ANOVA and chi-square tests.

Results: All studied females had a value for BMD >2.5 SD and one or more vertebral fragility fractures. We found a significant correlation between the mean of T-score and pain. The RG females were more satisfied with the overall outcome compared with PG subjects, also both groups had an improvement of mean values of studied parameters (6 MWD, VAS and OQOLQ).

Conclusions: Severe osteoporosis females with chronic low back pain benefit from strategies to improve their quality of life. Multi-modal exercise (based on the coordination aerobic exercise and strengthening lower limb exercises) and Hessing orthotic device represent the adequate mode of recovery and is more effective

in improving psychological status. Type and duration of physical training must be individualized to each patient, in accordance with low back pain status.

References: 1. Pavel OR et al. Rom J Morphol Embryol 2016;57:121

P447

CORRELATION BETWEEN LEVELS OF VITAMIN D AND FALLS IN PATIENTS TREATED IN A PHYSICAL MEDICINE AND REHABILITATION CLINIC

M. Saridogan¹, O. Besli¹, U. Akarirmak¹

¹Istanbul University Cerrahpasa, Cerrahpasa Medical Faculty, Physical Medicine and Rehabilitation Department, Istanbul, Turkey

Objective: Vitamin D insufficiency appears as an endemic problem throughout the world, especially in the elderly population and is effective on balance, muscle strength, physical performance, sarcopenia, falls and fragility fractures. The objective of this study was to assess correlation between vitamin D levels and risk of falling in inpatients.

Methods: In this clinical study performed in 2017, a total of 395 patients treated in a Physical Medicine and Rehabilitation Clinic, were assessed for the correlation between fall risk ratios and vitamin D levels. According to the fall risk classification patients were divided into three groups; first group with no risk, second with low risk and third with high risk for falling. Also they received a falls risk point according to age and demographic features.

Results: Vitamin D level ≥ 30 ng/ml was detected in 101 patients in high risk group(94.39%), two patients in low risk group (1.87%) and four patients in no risk group (3.74%). Fall risk points were mean 9.07 ± 3.69 ; median 8.00 respectively. Vitamin D levels 20-29 ng/ml was detected in 84 patients in high risk group (86.60%), one patients in low risk group (1.03%) and 12 patients in no risk group (12.37%). Fall risk points were mean 9.39 ± 5.10 , median 9.00. Vitamin D levels 10-19 ng/ml was detected in 107 patients in high risk group(87.70%), seven patients in low risk group(5.74%) and eight patients in no risk group(6.56%). Fall risk points were mean 8.44 ± 4.36 , median 7.50. Vitamin D level <10 ng/ml was detected in 46 patients in high risk group (88.46%), six patients in no risk group (11.54%). Fall risk points in this group were mean 8.46 ± 4.90 , median 7.00 respectively.

Conclusion: The high number of patients with normal vitamin D level and the the reason for vitamin D insufficiency having apparently no effect on falls needed explanation. Inpatients before internalizing procedure received standard vitamin D replacement treatment in the outpatient clinic. The time period following vitamin D replacement treatment although being successful in increasing serum vitamin D level was still not sufficient to show it is efficiency on muscle performance.

P448

THE PREVALENCE OF RISK FACTORS FOR OSTEOPOROSIS TO FEMALE PATIENTS WITH TYPE 2 DIABETES

S. Patru¹, I. R. Marcu¹, D. Matei¹, A. C. Bighea¹¹University of Medicine and Pharmacy of Craiova, Craiova, Romania

Objective: Many clinical studies showed that patients with diabetes mellitus (DM) had an increased fracture risk, probably due to long-term complications and the association of osteoporosis and type 2 diabetes is common among elderly population. We tried to assess the prevalence of risk factors for osteoporosis to female patients with type 2 diabetes from Rehabilitation Department of Clinical Emergency Hospital Craiova, Romania.

Method: We included from 1 January to 1 December 2018 a total of 300 females with type 2 diabetes and we collect demographic data, patients medical history, medication intake, BMI, BMD, smoking, early menopause.

Results: Age was a risk factor for a decreased BMD (mean age 51.6 vs. 62.2 y for women without osteoporosis than patients with osteoporosis, $P=0.005$). 89 women had osteoporosis and 135 female patients had osteopenia. BMD was found to decrease with reduction in BMI. Use of oral hypoglycemic agents increased the risk of decreased BMD in cases with osteoporosis, $p=0.013$.

Conclusions: Age, BMI and oral hypoglycemic agents were significant difference in the distribution of cases with osteoporosis, while other co morbidities, medication, smoking or early menopause were no significantly different in osteoporosis group compared to normal group.

P449

EFFICACY OF TECAR THERAPY TO PATIENTS WITH CHRONIC CERVICAL PAIN SYNDROMES

S. Patru¹, D. Matei¹, I. R. Marcu¹, A. C. Bighea¹¹University of Medicine and Pharmacy of Craiova, Craiova, Romania

Objective: This randomized controlled study was aimed to evaluate the efficacy of the Tecar therapy, a capacitive and/or resistive energy transfer system that operates within the long wave radio frequency range for treating chronic cervical pain syndromes compared to conventional physiotherapy.

Method: Were randomized a total of 30 subjects (15 patients/group) from the outpatients Rehabilitation Department of Emergency Clinical Hospital of Craiova. The patients assigned to treatment group T received an application of the capacitive electrode for 5 min followed by the application of the resistive electrode for 5 min during the patient has to make active movements, ended with a 5-min treatment capacitive, one session a day for 6 consecutive days. The patients from group C received conventional modalities for six consecutive days. Patients were evaluated baseline and at the end of the study using a visual analogue scale from 0 to 10 cm, where 0 means no pain and 10 means very severe pain and neck pain questionnaire (NPQ).

Results: The average decrease of the pain perception in the Tecar group was 65% and 49% in the Conventional modalities group. There was a significant decrease in NPQ score from 33.67% to 15.36% at the end of treatment for group T.

Conclusions: Tecar therapy was more effective solution in treatment of chronic cervical pain syndromes painful conditions compared to the conventional physical therapy methods.

P450

RELATIONSHIP BETWEEN PHYSICAL PERFORMANCE VARIABLES AND FRACTURE RISK INDEX IN A GROUP OF ELDERLY SARCOPENIC SUBJECTS

A. Antoun¹, E. Watelain², J. Grillasca², R. El Hage¹¹University of Balamand, Faculty of Arts and Sciences, Kelhat, El-Koura, Lebanon, ²Université de Toulon, Laboratoire IAPS, Toulon, France

Objectives: The purpose of this study was to explore the relationships between physical performance variables and fracture risk in a group of elderly sarcopenic subjects.

Methods: This cross-sectional study included 136 women and 64 men whose ages range between 65-85. Body composition and bone mineral content (BMC) of the whole body (WB) were evaluated by bioelectrical impedance analysis and the skeletal muscle mass index (SMI) was calculated. The fracture risk assessment tool (FRAX) was used. A composite physical performance evaluation tool was also used (short physical performance battery, SPPB). Hand grip strength was measured by an electronic dynamometer. Sarcopenia was defined according to the criteria of the European group based on the values of the hand grip strength.

Results: In men, hand grip strength was correlated with the 10-y probability of hip fracture and major osteoporotic fracture. Lean mass was significantly correlated with the 10-y probability of hip fracture and major osteoporotic fracture in both sexes. SMI was positively correlated with WB BMC and negatively correlated with the 10-y probability of hip fracture and major osteoporotic fracture in both sexes. The SPPB score was negatively correlated with the 10-y probability of hip fracture and major osteoporotic fracture in both sexes. The SPPB score was a predictor of sarcopenia in both sexes. Based on the results of the logistic regressions, it appears that for every 1 SD increase in SPPB, the risk of sarcopenia decreases by 41.1% in women and 53.5% in men. The presence of correlations between SPPB and bone health parameters suggests a relationship between these parameters. 57% of women and 40% of men had sarcopenia. SPPB scores, the 10-y probability of hip fracture and major osteoporotic fracture, and WB BMC values were significantly different between the two groups (sarcopenic and nonsarcopenic). In sarcopenic women, SPPB score was positively correlated with WB BMC and negatively correlated with the 10-y probability of hip fracture. In sarcopenic men, SPPB score was negatively correlated with 10-y probability of major osteoporotic fracture.

Conclusion: This study conducted on a group of elderly sarcopenic subjects reinforces the idea of increasing lean body mass, muscle strength and physical performance to prevent the occurrence of osteoporotic fractures.

P451

RISK FACTORS ASSOCIATED WITH FALLS IN INPATIENTS OF A PHYSICAL MEDICINE AND REHABILITATION CLINIC

U. Akarimak¹, O. Besli¹, M. Saridogan¹

¹Istanbul University Cerrahpasa, Cerrahpasa Medical Faculty, Physical Medicine and Rehabilitation Department, Istanbul, Turkey

Objective: Falls are an important public health problem resulting in fragility fractures especially in the elderly population. It is well known that fractures are a cause of mortality, morbidity and disability in the long course. Falls are also encountered during inpatient follow-up in rehabilitation clinics. In the last years it is recommended to assess osteosarcopenia in patients and aim at protective strategies. Therefore our objective was to evaluate risk factors for falls in inpatients of the University Hospital.

Methods: A total of 395 inpatients between the dates 1 January to 31 December 2017 were assessed. With regard to age groups, patients <65 comprised 56.7% of the patients (n=224), 65-79 y comprised 32.66% (n=129), patients >80 y comprised 10.63% (n=42). Mean age was 61.85±14.25 y. Classification of fall risk according to risk factors divided patients into three groups: high risk, low risk and no risk. A standard fall risk assessment was performed by an officially advised scale of the Ministry of Health.

Results: 273 (69,11%) patients were female, 122 (30.89) were male. Mean BMI was 28.92±6.01. With regard to clinical diagnosis, degenerative peripheral and spinal joint diseases took the first place in 45.82% (n=181) patients. Neurologic disorders, especially stroke rehabilitation were the second frequent group with 18.22% (n=72). In most of the remaining patients there were multiple diagnosis. Risk factors detected in the patients with highest risk for falls were; fall history in the last month (100%, n=29), history of chronic disease (97.88%, n=277), need for physical assistance during standing or walking (99.15%, n=117), like walker, walking stick, assistance of another person etc., urinary/fecal disorders (98.28%, n=57), poor eye sight (95.24%, n=20), multipharmacy of more than four drugs (100%, n=211) and orthostatic hypotension in the first rank.

Conclusion: The high risk for falls in inpatient of PMR clinics makes it recommendable to assess patients carefully according to these risk factors and take effective preventive measures as well as to aim at a careful follow-up of these conditions.

P452

IMPACT OF OSTEOARTHRITIS ON ACTIVITIES OF DAILY LIVING: DOES JOINT SITE MATTER?

M. A. Clynes¹, K. A. Jameson¹, M. H. Edwards¹, C. Cooper², E. M. Dennison¹

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK, ²MRC Lifecourse Epidemiology Unit, University of Southampton and NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Southampton and Oxford, UK

Objectives: Osteoarthritis (OA) is the most common joint disorder affecting older people, but the impact of the condition has been little studied in individuals not awaiting joint replacement surgery. Here we consider the relationships between a clinical and radiological diagnosis of knee or hip OA and activities of daily living (ADL) in older men and women.

Methods: Data were available for 222 men and 221 women who participated in the UK component of the European Project on Osteoarthritis. Participants reported if they had difficulties with mobility, self-care, usual activities and movement around their house. Hip and knee radiographs were taken and graded for overall Kellgren-Lawrence score, with a positive definition defined as a 2 or above. Clinical OA was defined using American College of Rheumatology criteria.

Results: The mean (SD) age of study participants was 75.5 (2.5) and 75.8 (2.6) years in men and women respectively. 3.2% of men and 6.0% of women had a clinical hip OA. Radiographic hip OA was more common affecting 46.3% of men and 40.6% of women. Knee OA was overall more common than hip OA in both sexes with the radiographic diagnosis again being more prevalent (50.2% of men and 58.7% of women) compared with the clinical diagnosis (12% of men and 19% of women). In men, a clinical diagnosis of hip or of knee OA were both associated with difficulties in mobility, ability to self-care and perform usual activities (hip OA: OR 17.6, 95%CI 2.07, 149 p=0.009; OR 12.5, 95%CI 2.51, 62.3 p=0.002; OR 4.92, 95%CI 1.06, 22.8 p=0.042 respectively. Knee OA: OR 8.18, 95%CI 3.32, 20.2 p<0.001; OR 4.29, 95%CI 1.34, 13.7 p=0.014; OR 5.32, 95%CI 2.26, 12.5 p<0.001 respectively). Very similar relationships were seen in women, where in addition a radiological diagnosis of knee OA was associated with similar, though less marked, reported difficulties (OR for difficulties performing ADL 3.25, 95%CI 1.61, 6.54 p=0.001). In general, men reported stronger associations between moving around the house, specifically around the kitchen (clinical hip OA: OR 13.7, 95%CI 2.20, 85.6 p=0.005; clinical knee OA OR 8.45, 95%CI 1.97, 36.2 p=0.004) than women with OA.

Conclusions: Clinical OA is strongly related to ability to undertake ADL in older adults, particularly men. It is important to consider this in clinic consultations when seeing patients with OA.

P453

BONE MASS IMPROVEMENT AFTER GLUCOCORTICOID WITHDRAWAL AND DISEASE CONTROL IN CROHN'S DISEASE

I. S. Soare¹, A. E. Sirbu², B. R. Mateescu³, S. Fica²

¹University of Medicine and Pharmacy Carol Davila Bucharest, ²University of Medicine and Pharmacy Carol Davila Bucharest-Elias Hospital, Department of Endocrinology, ³University of Medicine and Pharmacy-Colentina Hospital, Department of Gastroenterology, Bucharest, Romania

Patients with inflammatory bowel disease (IBD) are at increased risk for osteopenia or osteoporosis and fractures. Glucocorticoid excess, endocrinological disturbances, vitamin D deficit and chronic inflammation are well known risk factors. Disease control and withdrawal of glucocorticoid have important impact on increase of BMD.

Case report: We report the case of a 22-year-old, male, non-smoker, diagnosed with Crohn's disease in 2012. In 2017, he performed a DXA scan who revealed BMD L1-L4 spine=0.932 g/cm², T-score=-2.4 DS, Z-score=-1.8 DS and left hip BMD=0.906 g/cm², T-score=-0.8 DS, Z-score=-0.5 DS. At the moment, his Crohn disease activity index CDAI=250, he was on methyl prednisolone high dose (2015-2017, 32 mg/d), and since therapy with anti-TNF- α was not efficient in his case, he started etrolizumab (anti-b7 integrins). He was lost for follow-up and further endocrinological checkup was not done at that moment. In November 2018, as he was admitted in our department for evaluation, DXA revealed BMD spine 1.046 g/cm², T-score=-1.2 DS, Z-score=-1.5 DS and left hip BMD 1.068 g/cm², T-score=-0.2 DS, Z-score=0.1 DS. His blood evaluation showed 25 hydroxyvitamin D=19.8 ng/ml, normal count blood cells, normal inflammation markers, normal gonadal and thyroid function. His current CDAI index activity was 0, receiving at the moment etrolizumab (anti-b7 integrins) since the last examination and ASA. He was initiated vitamin D 4000 UI/d for 6 weeks and then repeat 25 hydroxyvitamin D.

Conclusion: Bone mass improvement is associated with glucocorticoid withdrawal and control of disease in IBD. Recent studies show that anti-TNF α can have a beneficial role on bone, but for newer drugs for Crohn's disease there are no data. Further follow-up is needed.

P454

EFFICACY OF COMBINED TREATMENT WITH CINACALCET AND LOW DOSE OF ALFACALCIDOL IN PREVENTION OF FRACTURES AND BONE LOSS IN CHRONIC KIDNEY DISEASE PATIENTS ON HEMODIALYSIS

L. P. Martynyuk¹, S. M. Butvyn¹

¹Ternopil State Medical University, Ternopil, Ukraine

Objective: To study the safety and efficacy of a combined cinacalcet and low-dose alfacalcidol therapy in the prevention of bone loss and fractures in chronic kidney disease (CKD) patients on hemodialysis with secondary hyperparathyroidism (SPTH).

Methods: We analyzed data on 97 adults (48 men and 49 women) CKD 5 stage on hemodialysis and SPTH, mean age 48.2 \pm 14.5 y from a single dialysis center. The laboratory investigations included evaluation of PTH, serum total and ionized calcium, serum phosphate, serum level of alkaline phosphatase concentrations. PTH level in serum was evaluated by solid phase chemiluminescent immunoassay. BMD was measured at 2 sites: lumbar spine (L1-L4) and femoral neck using DXA. Laboratory examination and BMD evaluation were performed at baseline and after 12 months of treatment. Patients were randomized into two groups: in first group 47 patients were prescribed low phosphate diet and sevelamer as phosphate binder in individual doses to control hyperphosphatemia. All patients in this group received fixed dose of cinacalcet 30 mg daily orally and alfacalcidol 0.25 μ g once daily. In second group (50 patients) a low phosphate diet and sevelamer were prescribed.

Results: In cinacalcet and alfacalcidol group the mean iPTH level declined significantly and achieved target levels according KDIGO recommendations 85.1% CKD patients (587.67 \pm 67.33 vs. 1876.89 \pm 94.62, p<0.01), both the phosphorus level and alkaline phosphatase activity declined significantly after 12 months of treatment. In the control group the levels of iPTH and alkaline phosphatase activity increased significantly. In cinacalcet and alfacalcidol group BMD at lumbar spine increased in 4.12 \pm 0.68% from baseline. In the control group the mean BMD at lumbar spine decreased in -5.57 \pm 0.56% from at baseline (p<0.01). No patients in combined treatment group had new low energy fractures compared to control group were 4 (8%) patients were diagnosed new (1 hip and 3 forearm) fractures. No patients had side effects of the therapy.

Conclusion: Combined treatment with Cinacalcet and low-dose of alfacalcidol shows benefits in prevention bone loss and fractures in CKD patients on hemodialysis with SPTH and reduced BMD.

P455

VITAMIN D-RELATED GENETIC VARIANTS PREDICT CIRCULATING VITAMIN D LEVELS BUT NOT BONE DENSITY IN THE HERTFORDSHIRE COHORT STUDY

M. A. Clynes¹, E. M. Curtis¹, K. A. Jameson¹, C. Cooper², E. M. Dennison¹

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, ²MRC Lifecourse Epidemiology Unit, University of Southampton and NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Southampton and Oxford, UK

Objectives: Studies have shown that vitamin D deficiency is associated with increased fracture risk. While single-nucleotide polymorphisms (SNPs) in genes related to vitamin D metabolism have been shown to be associated with serum 25-hydroxyvitamin D (25(OH)D) concentration, no previous studies have related these SNPs to bone density. In the current study we consider relationships between previously identified SNPs and (i) circulating vitamin D levels and (ii) bone density in late adulthood, using participants from the Hertfordshire Cohort Study (HCS).

Methods: Fasting blood samples were taken and 25(OH)D levels were measured using a DiaSorin Liason automated chemiluminescent assay. Bone mineral content (BMC), bone area and BMD were measured by DXA at the lumbar spine and proximal femur using a Hologic QDR 4500 instrument. SNPs at rs12785878 (DHCR7), rs10741657 (CYP2R1), rs6013897 (CYP24A1), and rs4588 (GC) were genotyped by LGC Genomics (Hoddeston, UK) using KASP competitive allele-specific polymerase chain reaction. Associations between 25(OH)D and the SNPs were assessed by linear regression using an additive model (β represents the change in 25(OH)D per additional common allele (nmol/l)). The results presented are adjusted for confounders (season of blood collection, age, BMI, social class, smoking, alcohol, activity, calcium and vitamin D intake).

Results: Data were available for 495 men and 488 women. The mean age (SD) was 64.3 (2.5) years for men and 65.6 (2.5) for women. DHCR7 was associated with 25(OH)D levels in men ($\beta=0.16$; 95%CI, 0.02 to 0.31; $p=0.027$) and women ($\beta=0.16$; 95%CI, 0.02 to 0.30; $p=0.030$), whereas GC was associated with 25(OH)D levels in men only ($\beta=0.16$; 95%CI, 0.02 to 0.29; $p=0.025$). No significant associations were observed between any of the SNPs and BMC, bone area or BMD.

Conclusions: Genetic variation in DHCR7, which encodes 7-dehydrocholesterol reductase in the epidermal vitamin D biosynthesis pathway and GC, which may affect vitamin D binding protein synthesis or metabolite affinity, appears to modify 25(OH)D levels in a cohort of older adults. This increase in circulating 25(OH)D levels was not, however, associated with improved bone density.

P456

EVALUATION OF BALANCE FUNCTION IN PATIENTS WITH OSTEOPOROTIC VERTEBRAL FRACTURES

L. Marchenkova¹, E. Makarova¹, L. Shakurova¹, M. Eryomushkin¹

¹National Medical Research Center of Rehabilitation and Balneology, Rehabilitation department for somatic patients, Moscow, Russia

Objective: To estimate the change in static and dynamic balance function in osteoporotic patient with vertebral fractures (VF).

Methods: 90 patients aged 43-80 with primary osteoporosis were enrolled. Study group comprised of 56 women and 4 men (age 65.4±7.1 y) with at least 1 VF confirmed by X-rays. Control group included 28 women and 2 men (age 62.0±5.2 y) with the same BMI, BMD and without any osteoporotic fracture. Stabilometry, Fukuda-Unterberger test and one-leg-standing test were performed.

Results: Study group was characterized by change vs. control group of balance coefficient (BC) (77.2±7.6 vs. 85.7±9.4% with opened eyes, $p=0.002$, 67.1±9.8 vs. 73.4±9.9% with closed eyes, $p=0.03$), pressure center of media-lateral (PCML) deviation in sagittal plane (1.2 [-1.1;1.5] vs. -1.2 [-1.5;1.2] mm, $p=0.025$) and PCML displacement in sagittal plane (6.8 [3.1;37.7] vs. to 4.8 [1.8;10.7] mm, $p=0.01$). BC correlated with age ($r=0.41$ with

opened eyes, $r=0.40$ with closed eyes, $p=0<0.01$) and BMI ($r=0.16$ with opened eyes, $p=0<0.05$). PCML deviation in sagittal plane correlated with age ($r=-0.42$, $p=0<0.01$), number of VFs ($r=0.40$, $p=0<0.001$) and femoral neck BMD ($r=-0.43$, $p=0<0.05$), and in frontal plane only with age ($r=-0.27$, $p=0<0.05$). PCML displacement in sagittal plane correlated with age ($r=-0.29$, $p=0<0.01$), number of VFs ($r=0.22$, $p=0<0.01$) and femoral neck BMD ($r=-0.38$, $p=0<0.05$) and in frontal plane only with BMI ($r=-0.15$, $p=0<0.05$). Fukuda-Unterberger test results showed greater side dislocation in patients with VF vs. controls (40° [25.0;45.0] vs. 30° [10.0;45.0], $p=0.02$). Side dislocation correlated with number of VFs ($r=-0.30$, $p<0.05$). Patients with VF lose their balance measured with One-leg-standing test faster vs. controls with open eyes (5.0 [1.0;10.0] vs. 7.5 [5.0;10.5] sec, $p<0.05$) and with closed eyes (2.0 [0;3.0] vs. 3.5 [3.0;5.0] sec, $p<0.05$). One-leg-standing test results correlated only with age ($r=-0.35$, $p<0.001$ with open eyes, $r=-0.42$, $p<0.01$ with closed eyes).

Conclusions: VFs negatively effect on static and dynamic balance function. Age, high BMI, low BMD and number of VFs are the main factors of balance dysfunction in patients with osteoporosis.

P457

ANTI-OSTEOARTHRITIS AND ANTI-DIABETIC PROPERTIES OF CITRUS LEAF EXTRACT IN STREPTOZOTOCIN-INDUCED RATS

S. Solehah¹, L. Fong², S. Mohamed¹

¹Institute of Bioscience, University Putra Malaysia, Malaysia,

²Faculty of Veterinary Medicine, University Putra Malaysia, Malaysia

Objective: Diabetes accelerates osteoarthritis development due to enhanced oxidative stress and inflammation. Citrus leaf is an important south Asian culinary ingredient with anti-oxidant, anti-inflammation, and cardioprotective properties. This study investigated the effects of citrus leaf extract on diabetic osteoarthritis development.

Methods: Streptozotocin (~70 mg/kg) induced diabetic rats were treated with 150 and 300 mg/kg citrus leaf extract (CLE) or metformin 250 mg/kg for 8 weeks and compared nontreated diabetic control and normal healthy rats (n=6). Fasting blood glucose, body weight, walking function test, serum oxidative stress, and inflammation biomarkers levels and osteoarthritis development were monitored.

Results: The CLE reduced the average osteoarthritis scores and walking function tests compared to the nontreated control diabetic group and Metformin group. The CLE significantly lowered the fasting blood glucose level, oxidative stress and inflammation biomarkers levels that were elevated in the diabetic rats. There was no significant difference in rats' body weight increase between groups throughout the study suggesting no toxic effects. The 150 mg CLE /kg body weight dose was apparently better than the 300 mg/kg dose.

P458

MEDICAL MANAGEMENT OF ATYPICAL FEMUR FRACTURES: A SYSTEMATIC LITERATURE REVIEW

D. M. van de Laarschot¹, M. J. McKenna², M. C. Zillikens¹

¹Erasmus University Medical Centre, Rotterdam, The Netherlands, ²St. Vincent’s University Hospital, Dublin, Ireland

Atypical femur fractures (AFFs) are considered serious side effects of bisphosphonates and often show delayed or non-healing. After an AFF, bisphosphonates are usually discontinued. It is unclear if certain osteoporosis drugs can promote healing and how patients at high risk of fragility fractures should be treated after AFF. We performed a systematic literature review to evaluate the effect of teriparatide, raloxifene and denosumab both on healing and occurrence of AFF in order to advise on medical treatment after AFF. We retrieved 910 References and reviewed 66 papers, including 31 case reports, eight retrospective cohort studies and three prospective studies that reported the effect of teriparatide, but no randomized controlled trials. We pooled data on reported fracture union from these articles and found that radiological healing occurred within six months of teriparatide use in 13 of 29 conservatively treated incomplete AFFs (45%), nine of 10 incomplete AFFs with surgical intervention (90%) and 41 of 55 complete AFFs (75%). In nine of 29 incomplete AFFs on conservative treatment (31%) no union was achieved after 12 months of teriparatide and progression to complete fractures occurred in 4 patients. New AFFs occurred in six patients during or after teriparatide, but always after prior use of antiresorptives. AFF on denosumab was reported in 21 patients, including 11 patients treated for metastatic bone disease and seven without prior bisphosphonate exposure. Continuation or initiation of denosumab after AFF was associated with recurrent incomplete AFFs in one patient and two cases of contralateral complete AFF. Eight patients had used raloxifene prior to AFF, including one patient without prior bisphosphonate use. We conclude that teriparatide may lead to faster healing of surgically treated AFFs, but not of conservatively managed incomplete AFFs and we present options for treatment of osteoporosis after AFF in different scenarios.

P459

IS THE “PEDIATRIC” ORIGIN OF IDIOPATHIC OSTEOPOROSIS POSSIBLE IN MEN?

S. S. Rodionova¹, U. R. Khakimov¹, M. S. Krivorotko¹

¹National Medical Research Center of Traumatology and Orthopedics named after N.N. Priorov, Ministry of Health of the Russian Federation, Moscow, Russia

Objective: There is a point of view that idiopathic osteoporosis begins at the age of formation of peak bone mass, but is clinically (fractured) manifested at an older age. It was clarified the contribution of age in the formation of BMD deficiency in the primary osteoporosis in men.

Methods: The study included 231 patients with primary osteoporosis. The reason for the diagnosis of idiopathic osteoporosis in men was the presence of low-energy fractures of the vertebral bodies or peripheral skeletal bones or loss of BMD correspond-

ing to <-2.5 SD by the T-criterion for people over 50 or <-2.0 SD by the Z-criterion for individuals younger than 50 y. The inclusion in the analysis of patients aged 17-19 y was based on the data that in the population of healthy Russian men the formation of peak bone mass in the lumbar spine and neck of the femur is completed by 15 y. Patients with hypogonadism, osteomalacia, hypophosphatemia, and pathology that could affect bone tissue metabolism were excluded from the study. IPC in g/cm² was estimated at L1-L4 and Neck (Lunar Prodigy, NHANES database used). **Statistics:** contingency tables were used for the analysis of interval variables. The presence of a relationship between the studied parameters was assessed using Fisher’s exact test.

Results: The values of BMD in g/cm² are presented in Tables 1 and 2.

Table 1. BMD in L1-L4 of various age groups.

Age groups	Number of patients	BMD L1-L4 (g/cm ²)
17-20 years	26	0.87±0.09
21-50 years old	103	0.93±0.16
51 and older	102	0.95±0.18

Kruskal-Wallis test p=0.066

Table 2. The magnitude of the BMD in the neck of the femur of different age groups.

Age groups	Number of patients	BMD neck (g/cm ²)
17-20 years	26	0.87±0.09
21-50 years old	103	0.93±0.16
51 and older	102	0.95±0.18

Kruskal-Wallis test p=0.032

It was revealed that differences in BMD deficiency in the lumbar spine (in absolute values in g/cm²) in the selected age groups are only close to reliable (p=0.032). In the femoral neck, differences were significant (p=0.032), but only between the age group of 21-50 years old and the group over 51 years old, while there were no differences between the groups of 17-20 years old and the group over 51 years old.

Conclusion: The lack of a clear relation between BMD deficiency and age of patients calls into question the postulate that the number of patients with osteoporosis increases with increasing age. It gives us a reason to consider the primary forms of osteoporosis in some men over 50 years old, as a result of the juvenile osteoporosis that was not diagnosed in a timely manner (impaired peak bone mass formation).

P460

FORTIFICATION OF DIET WITH VITAMIN D AS A POTENTIAL FOR REACHING PHYSIOLOGICAL VALUES IN THE REGION OF EASTERN MORAVIA, THE CZECH REPUBLIC

P. N. Novosad¹, V. R. Vrána¹, H. P. Hrdý¹, M. Z. Málek², Z. M. Zemánek³

¹Osteology Academy Zlín, ²Thyrea, ³Imalab Ltd. Zlín, Zlín, Czech Republic

Objectives: Epidemiological data of vitamin D in the region of eastern Moravia with approx. 1.5 mil inhabitants and a terrain of 200-1300 m above the sea level with regular winter seasons of 4 to 5 months. Values of vitamin D from the years 2016 and 2017 were used. Evaluation of the sunshine intensity: fluctuating decrease of the sunshine in winter months is from 70 to 80% and index of UV on the cloudless days of the winter season is degree of 2.

Methods: Cohorts of patients: Group 1: patients from osteological clinics (n=25742, average age 68) 1.25(OH)2D3 (n=3073, average age 67.2); Group 2: patients from other clinics (n=1042, average age 66) as a control group. PTH polymorphisms of vitamin VDR (FokI, Apal, BsmI, TagI), D-binding protein and its variants DBP rs7041 and DBP rs4855.

Laboratory Methods: determination of 25-OH for vitamin D and determination of 1.25-(OH)2 for vitamin D. These examinations are carried out on Liaison XL analyser. PTH is measured with analysis (ECLIA) using Cobas e 411 equipment. Vitamin D binding protein was determined with help of Immundiagnostic AG method ELISA. Detection of all the polymorphisms was carried out with real-time PCR device LC 480 II.

Results:

25(OH)D3 Group 1: total value 68.9 nmol/l, 1Q (January to March) 61.9 nmol/l 3Q (July-September) 69.68. Difference between 1Q-3Q $p < 0.005$. Group 2: total 57.43 nmol/l, 1Q -48.6 nmol/l, 3Q -56.11 nmol/l. Difference between 1Q and 3Q $p < 0.001$.

1.25(OH)2D3 Group 1: total value 119.60 pmol/l, 1Q -121.46 pmol/l, 3Q -118.57 pmol/l - statistically irrelevant. Group 2: total 108.21 pmol/l, 1Q -101.16 pmol/l 3Q -109.2 pmol/l - statistically irrelevant. PTH in total - 53.56 pg/ml, 1Q - 48.50 pg/ml, 3Q -49.49 pg/ml - statistically irrelevant.

In Group 1 the frequency of polymorphism VDR was given in % (only Mut) FokI - 30.8% Apal - - 21.3% TagI - Mut-13.5% BsmI - Mut - 45.1

D-binding protein average value 343.3 mg/l. Variants of DPB in % - rs 4588-CC-38.4%, AC-49.6%, AA-12.0%, rs 7041 -CC-38.4% AC 54.0% AA-21.6%

Conclusion: For both cohort groups there is a statistically relevant difference between the 1st and 3rd quarter for values of 25(OH) D. When detailed stratification of values for vitamin 25(OH)D in both groups, shows values between 10-20 nmol/l. The values of 1.25 (OH)2D and PTH do not show these changes. One possible

option how to approach desired physiological values is an implementation of food fortification, specifically in milk, margarine, and baked goods.

P461

ASSOCIATIONS OF PREFRACTURE PSYCHOLOGICAL RESILIENCE AND PREFRACTURE GENERAL MENTAL HEALTH WITH PHYSICAL FUNCTION AFTER HIP FRACTURE SURGERY

K. K. Lim¹, D. B. Matchar¹, C. S. Tan², W. Yeo³, T. Østbye¹, T. S. Howe⁴, J. S. B. Koh⁴

¹Programme in Health Services & Systems Research, Duke-NUS Medical School, ²Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, ³Orthopaedics Diagnostic Centre, Department of Orthopaedics Surgery, Singapore General Hospital, ⁴Department of Orthopaedic Surgery, Singapore General Hospital, Singapore

Objective: To examine the associations of prefracture psychological resilience and prefracture general mental health with physical function among older adults with hip fracture surgery.

Methods: Using data from Singapore General Hospital Hip Fracture Registry, we performed multiple linear regressions with generalized estimating equations to examine the associations of psychological resilience (10-item Connor-Davidson Resilience Scale) and general mental health (Short-Form 36 mental health subscale) with physical function (Short-Form 36 physical functioning subscale) measured at four time points - prefracture (based on recall), 1.5-, 3- and 6-month after surgery. Our analyses adjusted for age, gender, ethnicity, chronic disease counts, type of fracture, type of surgery and past fall. We performed sensitivity analyses by applying the final regression model on patients with complete and incomplete physical function data at follow-up, separately.

Results: Of 152 patients, majority were females (72.4%), of Chinese ethnicity (91.4%), experienced neck of femur fracture (66.4%), treated with internal fixation (50.7%) and had no falls in the past 1 year (73.7%). The average age of the patients was 75.5±8.8 years old; the average prefracture psychological resilience score was 28.1±6.7; the average prefracture general mental health scores 87.2±15.1. Follow-ups were 90.8%, 82.9% and 76.3% at 1.5-, 3- and 6-month respectively. Prefracture psychological resilience had an association with physical function; one unit increase in prefracture psychological resilience score was associated with 1.15 units (95%CI 0.71,1.59) higher physical function score across four time points. In contrast, the association between prefracture general mental health and physical function varied over time; one unit increase in prefracture general mental health score was associated with 0.42 units (95%CI 0.18,0.66) higher physical function score at prefracture, 0.02 unit (95%CI -0.22, 0.18) lower at 1.5-month, 0.23 unit (95%CI -0.03,0.49) higher at 3-month and 0.39 unit (95%CI 0.09,0.68) higher at 6-month after surgery. Sensitivity analyses yielded estimates with similar direction and strength.

Conclusion: Prefracture psychological resilience is associated with physical function among older adults with hip fracture surgery, independent from prefracture general mental health. The magnitude of this association suggests the potential for interventions aimed at strengthening psychological resilience to improve physical function among those undergoing hip fracture surgery. Our findings also call for more studies on psychological factors affecting physical function recovery after hip fracture surgery.

P462

BONE MINERAL DENSITY AND ITS RELATIONSHIP WITH MINERAL BONE METABOLISM PARAMETERS IN CHRONIC KIDNEY DISEASE

F. J. Toro Prieto¹, C. Grande Cabrerizo¹, I. Dominguez Pascual², M. A. Guerrero Riscos¹

¹Nefrología. Hospital Virgen del Rocío, ²Análisis Clínicos, Hospital Virgen del Rocío, Seville, Spain

Objective: The determination of BMD reliably determines the presence of bone fragility and predicts the risk of fracture in most clinical scenarios. The identification of modifiable factors that contribute to an accelerated loss of bone mass and risk of fracture could suggest new therapeutic strategies that would reduce fracture rates in this high-risk population. Our aim was to determine the relationship of BMD with bone mineral metabolism (BMM) parameters in patients with advanced chronic kidney disease (ACKD).

Methods: Prospective descriptive study of a cohort of patients with CKD from 2015-2017. Demographic data, smoking, history of fractures, diabetes mellitus (DM), renal disease etiology, BMI were collected. Analytical data such as calcium, phosphorus, magnesium, sodium bicarbonate (HCO₃), eGFR measured by MDRD-4 IDMS, PTH, 25(OH)vitamin D₃, 1,25(OH)vitamin D₃, FGF-23 (Liaison XL chemiluminescence Diasorin) and in urine proteinuria, phosphaturia and calciuria, albumin creatinine ratio (CAC). Measurement of BMD was performed by DXA (QDR 4500A, Hologic). Treatments with nutritional and active VitD, binders (calcium/noncalcium). Statistical analysis using SSPS 22.0.

Results: We analyzed data from 183 patients with a median age of 64 (21) years. 53.5% males. Etiology more frequent with 23.1% diabetic nephropathy. DM 35.9%. Arterial Hypertension 90.4%. 42.1% smokers. 9.7% history of fractures. Use of phosphorus binders 25.5%, nutritional VitD 27.1%, VitD active 35.2%. eGFR 21.5 (7.9) ml/min. IMC 28.5 (8). ICharlson without age: 3 (3). Analytical data: Calcium 9.5 (0.6) mg/dl. Phosphorus 3.9 (1.3) mg/dl. Magnesium 2.1 (0.4) mg/dl. CAC 496 (1587). PTH 139 (82) pg / ml. Vit D_{25OH} 22.4 (15.32) ng/ml. Vit D 1.25OH 52 (46) pmol/L. FGF-23: 213. Hb 11.5 (1.5) g/dl. HCO₃ 23. Phosphaturia 529 (320), calciuria 39.1 (47.9). Data BMD: BMD column 0.955 (0.228). BMD femoral neck 0.720 (0.217). T-score column -1.1. T-score femoral neck -1.3. Z-score column -0.3. T-score femoral neck -0.3. Osteoporosis column 19.9%. Femoral neck osteoporosis 24.2%.

Between 60-80% of our patients have a decrease in BMD. The BMD correlates with sex and age, if we eliminate these variables, in hip it does so in a positive and significant way with BMI and negative with PTH and eGFR. PTH correlates negatively and significantly with eGFR and 25 (OH)vitD, and there is a significant correlation between BMD and vitD deficit. PTH increases with the decrease in BMD, although it is only significant in femoral neck osteoporosis. Patients with greater proteinuria have more osteopenia. We found association with renal function in a significant way only in Z-score femoral neck although not with the rest of the BMD parameters.

Conclusions: In our study, the use of BMD is of limited utility in relation to other BMM parameters in patients with CKD, probably due to the influence of hyperparathyroidism in this patient profile. However, vitamin D deficiency continues to be a factor that negatively influences BMD. Advanced stages of CKD have a negative influence on BMD, especially in the hip, although more studies are needed to establish this relationship.

P463

BONE DENSITOMETRY: IS IT USEFUL IN THE MANAGEMENT OF MOM IN PATIENTS WITH ADVANCED CKD?

F. J. Toro Prieto¹, C. Grande Cabrerizo¹, B. Villacorta Linaza¹, I. Dominguez Pascual², M. A. Guerrero Riscos¹

¹Nefrología. Hospital Virgen del Rocío, ²Análisis Clínicos. Hospital Virgen del Rocío, Seville, Spain

Objective: The presence of bone fragility and the prediction of fracture risk is reliably established by the measurement of BMD. On the other hand, in advanced chronic kidney disease (ACKD), the excess of FGF23, phosphaturia and calcitriol deficiency cause significant bone loss and fractures such as clinical presentation. The relationship between alterations in bone mineral metabolism (MOM) in CKD and the risk of fracture is not clear. Our aim was to evaluate the situation with respect to BMD in patients with CKD incidents, determining their relationship with parameters of bone mineral metabolism (BMM).

Methods: Prospective descriptive study of a cohort of patients with ACKD from May 2015 to January 2018. We analyzed demographic data, smoking, history of fractures, diabetes mellitus (DM), etiology kidney disease, BMI, eGFR measured by MDRD-4 IDMS, calcium, phosphorus, magnesium, phosphaturia and calciuria in urine 24 h, PTH, 25(OH)vitamin D₃, 1,25(OH)vitamin D₃, FGF-23, (chemiluminescence Liaison XL by Diasorin), BMD (DXA) (QDR 4500A; Hologic). Nutritional and active VitD use, phosphorus binders. Statistical analysis using SSPS 22.0.

Results: We analyzed 191 incident patients with ACKD from May 2015 to January 2018. 54.4% were males. Age: 63 y. The most frequent etiology of CKD was that associated with diabetes (23.3%). 9.1% had a history of fractures and 43% were smokers. BMD: BMD lumbar spine 0.929 g/cm². BMD femoral neck 0.671 g/cm². T-score lumbar spine -1.3. T-score femoral neck -1.8. Z-score lumbar spine -0.3. T-score femoral neck -0.6. 35.3% had osteoporosis either in the spine (18.7%) or the femoral neck (22.3%), being more frequent in women (p<0.027) and in the hip and in

those with a deficit of 25(OH)vitD ($p < 0.034$). 78% of patients have osteopenia, increasing with age ($p < 0.007$). Only 16.1% had normal levels of 25(OH)vitD. PTH was correlated with 25OHvitD, 24-h phosphaturia, FGF-23 and Z-score lumbar spine. They were not found correlations between parameters of BMD and FGF-23, although there is a nonsignificant positive association between high levels of FGF-23 and BMD (Z-score). In those with no history of fractures, the T-score of the lumbar spine correlates with the highest quartile of FGF-23 ($p = 0.023$).

Conclusions: In our study, the use of BMD is of limited utility in its relationship with other BMM parameters in patients with CKD, probably due to the influence of secondary hyperparathyroidism in this patient profile, finding no relationship between FGF 23 levels and risk of fracture, although increased values of FGF-23 could indicate early onset of BMD loss. Vitamin D deficit continues to be one of the factors that negatively influence BMD and its correction becomes a priority in patients with ACKD.

P464

43 PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) PRESENTING WITH SYMPTOMATIC VERTEBRAL COMPRESSION FRACTURES (SVCF)

M. Lovy¹, J. Hodgkins¹, N. Ben-Shlomo², B. Hodgkins¹

¹Desert Oasis Healthcare, Palm Springs, USA, ²Ben-Gurion Medical School, Beer Sheva, Israel

Objective: The presence of MGUS has been associated with vertebral fracture, is more prevalent among patients with SVCF, and is associated with an increased risk of fracture. A clinical description of patients with MGUS and SVCF is lacking. The objective of this study is to describe and compare the clinical details and circumstances of fracture in a cohort of patients with MGUS who presented with SVCF to a cohort with SVCF and no MGUS.

Methods: The clinical details of 43 patients with SVCF found to have MGUS was compared to those of 143 SVCF patients without MGUS. All patients were seen in a community based outpatient fracture clinic. All patients had a complete history and physical, review of past medical records and radiographs, CBC, sedimentation rate, chemistry profile, TSH, urinalysis, vitamin B12, PTH, 25-OH vitamin D, serum protein electrophoresis (SPE) and immunofixation.

Results: Among the patients with MGUS there were 23 females and 20 males ranging in age from 66-96 (mean 80.8 y), with a BMI of 19-36 (mean 26.0) and an average of 1.45 comorbid conditions. 18 patients had previous fractures. 2 patients were on steroids. 24 fractures occurred after falling, 14 spontaneously, 7 while lifting, and 1 with bending. 4 patients with pernicious anemia and one each with primary biliary cirrhosis, Kaposi sarcoma, CAPS, Schnitzler's and hepatitis C were diagnosed at the time of presentation. 14 patients had peripheral neuropathy. There were 53 fractures including 11 patients with 2 fractures. 66% of fractures were distributed from T-11 to L-2. M-spike ranged from 0.1-2.0% composed of IgG -25, IgM -7, IgA-5, with lambda light chains

in 21 and kappa in 18. SPE failed to detect a paraprotein found on immunofixation in 6 patients as well as in 5 with lambda light chain MGUS.

There were more men ($p = 0.029$) among the MGUS patients but all other clinical, laboratory, and fracture comparisons to non MGUS SVCF patients did not reach statistical significance.

Conclusions: Other than a higher percentage of males, MGUS patients presenting with SCVF did not differ from those without MGUS. Immunofixation is a better screening test for MGUS than SPE in patients with SCVF. Even with the understanding of the deleterious effect of MGUS on bone, the fact that MGUS is asymptomatic makes preemptive therapeutic intervention a challenge.

P465

EFFECT OF ULTRASOUND-GUIDED POPLITEAL NERVE BLOCK COMBINED WITH COCKTAIL THERAPY ON POSTOPERATIVE PAIN OF ANKLE FRACTURE

W. Jiang¹

¹Department of Ultrasound Diagnosis, Fourth Hospital of Xi'an, Xi'an, China

Objective: To explore the effect of ultrasound-guided popliteal nerve block combined with cocktail therapy on postoperative pain of ankle fracture.

Methods: 30 patients with ankle fracture were divided into experimental group (ultrasound-guided popliteal nerve block +cocktail therapy group) and control group, according to the order of admission, 15 cases in each group. Ankle fractures were perfected by routine surgical approach. Ultrasound-guided popliteal nerve block was used before operation and cocktails were injected around the wound after operation. VAS scores (rest and activity), incidence of adverse reactions, patients' functional compliance, time to start functional exercise and ankle passive mobility were compared between the two groups at each time point after operation.

Results: Compared with the control group, the VAS score and the incidence of adverse reactions in the experimental group were significantly lower at each time point after operation, the patients' functional compliance was increased, the time of starting functional exercise was shortened, and the range of motion of ankle joint was increased.

P466
USING ARTIFICIAL INTELLIGENCE TECHNOLOGY TO IMPROVE CASE FINDING FOR VERTEBRAL FRACTURES IN THE FRACTURE LIAISON SERVICE (FLS) SETTING


S. Connacher¹, R. Eckert¹, R. Mansour², M. K. Javaid³
¹Oxfordshire Fracture Prevention Service, Oxford University Hospitals NHS Foundation Trust, ²Radiology Department, Oxford University Hospitals NHS Foundation Trust, ³NDORMS, University of Oxford, Oxford, UK

Objective: To evaluate the impact of semi-automatic artificial intelligence technology for identification of vertebral fractures in the FLS setting.

Method: We tested the implementation of a novel artificial intelligence technology embedded in tertiary hospital radiology system. All CT scans including thoracic or lumbar spine were automatically analysed by the Zebra platform to identify those with a potential vertebral fracture. The results are outputted in a spreadsheet with a visualisation of the sagittal reconstruction to permit rapid verification by the FLS nurses (RE/SC), who have attended national and local training. Patients were classified as having definite vertebral fractures, nonfracture deformities or where the visualisation was not clear enough to decide. Patients with definite fractures were assessed for antiosteoporosis therapy. A consecutive series of 55 negative scans were checked for vertebral fractures.

Results: In 4 weeks, 4623 scans were sent to Zebra. Of these, 3318 (72%) were classified as negative. Of the 1305 positive scans, 633 (49%) required more detailed analysis using the PACS system, leaving 683 scans of which 279 (41%) were identified by the FLS nurses as definite fractures and 393 (58%) as negative. None of the Zebra negative scans sampled were found to have a vertebral fracture; if true for all negative scans, this gives an expected sensitivity of 100% and specificity of 89% excluding sub-optimal scans. By age, 50% of screen positive scans were confirmed as definite vertebral fractures in those aged of 75 years and older vs. 32% in those aged 50-74 y (p<0.01).

Figure: Clinical outcomes for 50 patients who completed FLS assessment following identification by the Zebra AI technology



Conclusion: Using the Zebra AI system, 73% of eligible CT scans did not require further clinical review, a significant saving in terms of FLS time. The positive predictive value of screen positive scans was higher in those aged over 75 y vs. those aged 50-75 y, despite concerns that older patients would have more degen-

erative changes. Work is ongoing to improve the visualisation of the sagittal reconstruction and assess the impact of the pathway on anti-osteoporosis treatment recommendations and healthcare savings.

P467
CLINICAL OBSERVATIONAL STUDY OF OSTEOPOROSIS RISK FACTOR ASSOCIATION IN TYPE I DIABETIC PATIENTS AND MANAGEMENT

R. Shukla¹, A. Gupta¹, H. Shukla²

¹West Wales General Hospital, Carmarthen, ²UHW Hospital, Cardiff, UK

Objective: Type 1 diabetes has detrimental effect on bone quality and has an association with increased fracture risk. We studied the association of risk factors for osteoporosis and management of bone health.

Methods: Design- Prospective observational cohort study. Setting- patients attending a large teaching hospital in UK. Subjects - randomly selected patients. Inclusion criteria-age >18 y, type 1 diabetes >5 y duration. Data was collected on structured proforma from patient questionnaire and medical records.

Results: 100 Patients included in the study. 55% were females. Age range 18-85 y, median age 40 y. Risk factors noted were family history of osteoporosis (30%), smoking (20%), excess alcohol (35%), steroids (12%), low BMI (22%), high BMI (35%), previous fragility fracture (15%), poor glycemic control (75%), nephropathy (18%), neuropathy (35%), falls history (5%), hypoglycemic episodes (65%), vitamin D deficiency (45%). Management- DXA scan done in 15% eligible patients out of which showed osteopenia (25%), osteoporosis (35%). Prescription for eligible patients- vitamin D (5%), calcium (5%), antiresorptive treatment (7%).

Conclusions: Our clinical real world observational data shows that risk factors for fractures and falls are widely prevalent in diabetics. Bone health management is not being adequately recognised and addressed by professionals. Appropriate measures aimed at risk factor control and fracture prevention needs to be considered by general practitioners and specialists as part of a routine care for diabetic patients. Further large studies are needed to allow risk stratification and targeting treatments for especially high risk patients which can reduce the economic burden associated with diabetes and its complications.

P468

ASSOCIATION OF CLINICAL RISK FACTORS FOR OSTEOPOROSIS AMONGST TYPE 2 DIABETIC PATIENTS AND MANAGEMENT: AN OBSERVATIONAL STUDY

R. Shukla¹, A. Gupta¹, H. Shukla²

¹West Wales General Hospital, Carmarthen, ²UHW Hospital, Cardiff, UK

Objective: Type 2 diabetes has detrimental effect on bone quality and has an association with increased fracture risk. We studied the association of clinical risk factors for osteoporosis in diabetic patients and current practice of management of bone health.

Methods: Design- Prospective observational cohort study. Setting- patients attending a large teaching hospital in UK. Subjects - randomly selected patients. Inclusion criteria- type 2 diabetes >10 y duration. Data was collected on structured proforma from patient questionnaire and medical records.

Results: 120 Patients included in the study. 75% were females. Age range 50-90 y, median age 72 y. Risk factors noted were family history of osteoporosis(20%), smoking (20%), excess alcohol (15%), steroids (12%), low BMI (22%), high BMI (35%), previous fragility fracture (25%), poor glycemic control (65%), nephropathy (18%), neuropathy(45%), falls history (45%), hypoglycemic episodes (45%), vitamin D deficiency (65%) poor mobility (65%). Management- DXA scan done in 25% patients out of which showed osteopenia (45%), osteoporosis(68%). Antidiabetic drugs used metformin (75%), thiazolidinediones (0%), sulfonylurea (45%), SGLT2 and DPP4 inhibitors (25%), insulin (25%). Prescription for eligible patients- vitamin D (20%), calcium (55%), antiresorptive treatment (27%).

Conclusions: Our clinical real world observational data shows that risk factors for fractures and falls are widely prevalent in diabetics. Bone health management is not being adequately recognised and addressed by professionals. Appropriate measures aimed at risk factor control and fracture prevention needs to be considered by general practitioners and specialists as part of a routine care for diabetic patients. Further large studies are needed to allow risk stratification and targeting treatments for especially high risk patients which can reduce the economic burden associated with diabetes and its complications.

P469

VALIDATION OF THE 10-YEAR RISK OF OSTEOPOROTIC FRACTURES SCORE (FRAX) FOR THE CAUCASIAN POPULATION OF SIBERIA

E. Mazurenko^{1,2}, O. Rymar¹, S. Mustafina¹, M. Bobak³, S. Malyutina¹

¹Research Institute of Internal and Preventive Medicine – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk, ²Novosibirsk Research Institute of Traumatology and Orthopaedics n.a. Ya. L. Tsvivan, Novosibirsk, Russia, ³University College, London, UK

Objective: To validate the FRAX scale of the 10-y risk of osteoporotic fractures in Siberian population.

Method: The study was based on a population cohort (the HAPIEE Project, Novosibirsk) examined at baseline in 2003-2005, n=9360 men and women aged 45-69 y. In 2017-2018 during the repeated examination (n=828), we collected retrospectively the incident cases of osteoporotic fractures over the 10-y follow-up and calculated the 10-y risk of fractures by the FRAX scale. Totally, 574 subjects who were 50-69 years old at baseline survey (2003-2005) and only postmenopausal women were included for analysis. FRAX scale validation was carried out using ROC-analysis.

Results: Among studied 574 subjects (mean age 59.0±5.2) there were 234 men and 340 women. During the 10-y follow-up, osteoporotic fractures occurred in 9.6% subjects, women had fractures 4.5 times more often than men (13.2% and 4.3%, respectively, $p=0.001$). In studied sample the mean value of the risk of major osteoporotic fractures on the FRAX scale was 7.3±3.6% and in women it was significantly higher than in men, $p=0.001$. Observed FRAX values were higher than so called 'intervention point' (according to Russian FRAX version) in 3.5% individuals (3.2% - women, 0.4% - men). When validating the FRAX scale, the sensitivity (Se) was calculated as the proportion of those who had an incident fracture and a risk above the Russian intervention point by FRAX among total group with a fracture; Se comprised 9.1%. Specificity (Sp) was determined as the proportion of those with a risk of fracture below the intervention point among total group without fracture over the 10-y period; Sp comprised 97.1%. When using the ROC model for osteoporotic fractures, the area under the AUC curve was 0.65, which corresponds to the average quality of the model. In the range of risk distribution according to FRAX (from 2.2% to 26.0%), the cutoff point is defined by maximal Se and Sp and was of 7.65% (Se=61.8%, Sp=66.3%). The cutoff values for FRAX in the age subgroups (50-54, 55-59, 60-64, 65-69 y) were 6.15-7.65-7.65-7.85% respectively.

Conclusions: In studied Siberian population sample we observed a rather low sensitivity and high specificity of the Russian version of FRAX model in defining the risk of fracture. The cutoff point identified in the study has a good diagnostic potential for identifying subjects with a high risk of fractures.

Acknowledgement: The study was supported by RSF grant No. 14-045-0030-П

P470

ENERGY EXPENDITURE OF NURSING HOME RESIDENTS AND PARTICIPATION IN EXERCISE CLASSES: AN ANALYSIS OF THE SENIOR COHORT

A. Charles¹, F. Buckinx¹, A. Mouton², J.-Y. Reginster^{1,3}, B. Gruslin¹, O. Bruyère^{1,2}

¹WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Ageing, Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ²Department of Sport and Rehabilitation Sciences, University of Liège, Liège, Belgium, ³Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia

Objective: Despite the positive effects of regular physical activity on health, the majority of nursing home residents spend most of their time inactive. However, data are lacking as to whether physical activity programs, organized in nursing homes in the form of exercise classes, increase weekly energy expenditure (WEE) of residents. This study aims at comparing, in Belgian nursing homes, the WEE generated by leisure physical activity of residents involved in group exercise classes to the WEE of residents who do not take part in such exercise classes.

Methods: We conducted a cross-sectional analysis of the baseline data collected from the SENIOR (Sample of Elderly Nursing home Individuals: An Observational Research) cohort. Self-reported energy expenditure over the last 7 days was assessed through the Minnesota Leisure Time Physical Activity (MLTPA) questionnaire. Residents were considered having participated in the exercise classes if they attended all exercise classes organized by the nursing home in the last two weeks prior to the evaluation.

Results: Among the 649 subjects (aged 83.2±9 y, 72.7% of women) with complete data, 25.3% (n=164) took part in all exercise classes. Taking into account the WEE related to such leisure physical activity (i.e., walking, climbing stairs and exercise classes), residents who participated in the exercise classes spent more energy per week compared to nonparticipants (respectively, 1230.92±811.37 vs. 740.67±734.83 kcal/week, p<0.001). After adjusting for potential confounding variables (i.e., age, sex and frailty status), the difference between the two groups remained statistically significant (p<0.001). Moreover, when we compared the WEE without the energy spent in exercise classes, there was no significant difference between the 2 groups (P=0.12).

Conclusion: Residents who participate in regular exercise classes generally spend more energy related to leisure physical activity during the week than those who do not participate. This means that residents who participate do not tend to be less active than the nonparticipating residents outside exercise classes. However, the self-reported nature of the MLTPA questionnaire justifies some cautions in the interpretation of the results.

P471

JUMPING JOINTS: THE COMPLEX RELATIONSHIP BETWEEN OSTEOARTHRITIS AND A JUMPING MECHANOGRAPHY

N. R. Fuggle¹, C. Shere¹, K. A. Jameson¹, C. Cooper¹, E. M. Dennison¹, K. A. Ward¹

¹MRC Lifecourse Epidemiology Unit, Southampton, UK

Objectives: Jumping mechanography is a novel technique which has been validated for lower limb muscle assessment. We investigated the relationship between lower limb osteoarthritis (OA) and jumping mechanography outcomes in the Hertfordshire Cohort Study, comprised of UK community dwelling older adults.

Methods: We recruited 249 older adults (144 males and 105 females). OA was assessed clinically by a qualified healthcare professional according to ACR criteria and radiographically via X-ray. Two-footed jumping tests were performed using a Leonardo Mechanography Ground Reaction Force Platform (Leonardo software version 4.2; Novotec Medical GmbH) to assess maximum muscle force, power and Esslinger Fitness Index. Linear regression was used to assess the relationship between OA and jumping outcomes in models adjusted for anthropometric, dietary and social factors, grip strength (in all participants), pain (when examining associations with radiographic OA), years since menopause and hormone replacement therapy use (in females).

Results: The mean age of participants was 75.2 y (SD 2.6). There were no significant sex differences in the prevalence of clinical or radiographic OA at the knee or hip (p>0.1). In terms of jumping mechanography, males had a significantly higher maximum total power during lift off (mean 25.7 W/kg vs. 19.9 W/kg, p<0.001) and maximum total force during lift off 21 N/kg vs. 19.9 N/kg, p<0.001) than females. We found significant associations between maximum total power and clinical knee OA in males (-1.32 (-1.90, -0.73) z-score p<0.001) and clinical hip OA in females (-1.07 (-1.96, -0.18) z-score p<0.02). Esslinger fitness index was significantly associated with clinical knee OA in males (-1.31 (-1.89, -0.73) z-score p<0.001) and clinical hip OA in females (-1.09 (-1.98, -0.20) z-score p<0.02). No significant associations were observed for maximum total force.

Conclusions: We observed significant negative associations between maximum total power and Esslinger Fitness Index and clinical OA in both sexes. The absence of associations with force concurs with findings from leg dynamometry. Our findings provide an insight into the complex relationship between a novel measure of muscle function and OA in older adults.

P472

CROSS-CULTURAL ADAPTATION AND VALIDATION OF THE ARABIC VERSION OF THE INTERMITTENT AND CONSTANT OSTEOARTHRITIS PAIN QUESTIONNAIRE

S. I. Nasef¹, T. M. El-Shafei², A. E. Fahim³, M. S. Ghaly¹

¹Rheumatology and Rehabilitation Department, Faculty of Medicine, Suez Canal University, ²Rheumatology and Rehabilitation Department, Ismailia General Hospital, ³Occupational Medicine Department, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Objective: To translate and evaluate the validity and reliability of the Arabic version of the intermittent and constant osteoarthritis pain questionnaire (ICOAP-AR) in Egyptian knee osteoarthritis (OA) patients.

Methods: The study included 210 patients who fulfilled the ACR criteria for knee OA. History taking, clinical examination and plain x-ray on both knees were done for diagnosis and grading of knee OA according to Kellgren-Lawrence scale. Questionnaire translation was conducted in 2 stages; forward translation from the original English version into Arabic, backward translation into English, face validation, and validation of the consolidated version. All the patients answered the questionnaire twice with an interval of 2-3 d. For test-retest reliability, intraclass correlation (ICC) was used and ICC of ≥ 0.70 was considered acceptable. Internal consistency was assessed by Cronbach's alpha coefficient and a Cronbach's alpha of ≥ 0.70 was considered satisfactory. Criterion validity was tested against the Arabic version of Knee Injury and Osteoarthritis Outcome Score (KOOS) and the severity of relevant clinical symptoms measured by 10-cm visual analog scales (VAS). Construct validity was analyzed using Spearman's rank correlation.

Results: The study included 75 males (35.7%) and 135 females (64.2%). The mean age was 54.2 ± 10 y. According to Kellgren-Lawrence grading scale, 81 patients (38.5%) were grade 3, 66 patients (31.4%) were grade 2, and 60 patients (28.6%) were grade 4. The ICOAP-AR was well accepted in the face validity phase and satisfactorily understandable by the patients. Test-retest reliability yielded strong ICC of (0.99) for the total score, (0.992) for constant pain, and (0.995) for intermittent pain. Internal consistency using Cronbach's alpha was (0.904 for total score), (0.986 for constant pain), and (0.980 for intermittent pain). The validity of ICOAP-AR was confirmed by negative correlations that existed between total score of ICOAP-AR and total KOOS ($r = -0.682$) ($p = 0.0001$), KOOS Symptoms ($r = -0.658$) ($p = 0.001$), and KOOS Pain ($r = -0.650$) ($p = 0.001$). There was a significant weak positive correlation between the total score of ICOAP-AR and VAS ($r = 0.339$) ($p = 0.004$).

Conclusion: The ICOAP-AR is a reliable and valid instrument to be used with Egyptian patients with knee OA.

P473

ANTIRESORPTIVE PATIENTS IN RHUMATOLOGY: INTEREST OF PREVENTION IN ORAL MEDICINE: ABOUT TWO CASES

S. Benamara¹, L. Harfouche¹, R. Lattafi¹

¹CHU Beni messous Alger, Alger, Algeria

Antiresorptive and Antiangiogenic agents have clearly been shown to be effective anti-osteoporotic drugs with a specifically bone mechanism of action, nevertheless they have a major side effect which is osteonecrosis of the maxillae, which despite its rarity in osteoporotic patients compared to those treated for malignant diseases must be taken into consideration, particularly by multidisciplinary support between rheumatologist and stomatologist by applying a prevention strategy for patients in pre-treatment or after finishing the treatment.

We illustrate two clinical cases; the first represents the restoration of the oral cavity before the initiation of bisphosphonate therapy through intravenous in SAPHO syndrome, the second case, an osteoporotic patient on oral bisphosphonate therapy who benefited from dental extraction without precautions.

P474

ASSOCIATED ALCOHOLISM EATING DISORDERS: AN INCREASED RISK FOR OSTEOPOROSIS DISEASE

A. Medioli¹, L. Scaglia

¹Alcohol Rehabilitation Department/Palazzolo S/O/Fondazione Richiedi, Palazzolo S/O (BS), Italy

Objective: The present study aims to confirm how alcoholism and eating disorders are often associated and how this gives a greater chance of manifesting osteoporosis.

Methods: We analyzed meta-analysis studies from the search engine PubMed concerning eating disorders associated with alcohol use disorders. Only studies of the last 3 y have been analyzed. Subsequently, the data relating to the patients admitted for an alcoholic rehabilitation cycle have been analyzed.

Results: Food and alcohol disturbance, colloquially coined "drunkorexia," is a set of behaviors that encompasses restriction of calories, and other compensatory behaviors before, during, or after alcohol use to offset caloric intake or maximize intoxication. Many studies conclude that BMD in patients with alcohol dependence was significantly lower than that in healthy controls, and the rates of osteopenia and osteoporosis are higher. Importantly, abstinence from alcohol increases bone density. Alcoholic patients therefore have an increased risk of developing osteoporosis compared to the general population. The association between eating behavior disorders and osteoporosis is equally well known. 1145 patients admitted for an alcoholic rehabilitation cycle were considered: they were for 71% males and for 28.2% females. Of these 1145.36 (3.14%) presented eating disorders declared; they were all females, they had an average age of 42.35. The association of these risk factors amplifies the possibility of developing osteoporosis.

Conclusions: Our data show how alcoholism and eating behavior disorders can often be associated. Scientific studies show that this can lead to an increased risk of developing osteoporosis.

P475

APPLICATION OF QUANTITATIVE BONE SCAN USING KBONE VALUES FOR THE ASSESSMENT OF REGIONAL BONE METABOLISM IN POSTMENOPAUSAL OSTEOPOROTIC WOMEN TREATED EITHER WITH ALENDRONATE OR TERIPARATIDE

V. Dixit¹, G. Parida², S. Sen¹, H. Sati², R. Kumar², R. Malhotra¹, B. Garg¹

¹All Indian Institute of Medical Sciences, ²All India Institute of Medical Sciences, New Delhi, India

Objectives: To compare and analyze the visual changes in the whole body ^{99m}Tc-MDP bone scan images in patients receiving either alendronate (AL) or teriparatide (TP) with bone scans at baseline, 3rd, 12th and 18th months of treatment and also to analyze these bone scan changes with bone turnover markers level in serum as well.

Methods: A total of 36 postmenopausal women with osteoporosis were included followed by written consent. Diagnosis of osteoporosis was made by DXA scan (T-score <-2.5 or below). Patients were categorized in two treatment groups (group 1 & 2) by random allocation methods. Group 1 and 2 were designated as AL arm and TP arm respectively. The changes recorded in patients were observed at baseline, 3rd, 12th and 18th months of therapy either with AL or TP. Patients were injected with 600 MBq ^{99m}Tc-MDP and diagnostic bone scan images were assessed at 3.5 h. Additionally, whole-body scans at (10 min, 1, 2, 3 and 4 h), further analyzed for ^{99m}Tc-MDP skeletal plasma clearance (Kbone). Regional Kbone differences were obtained for the whole skeleton and following six regions (calvarium (CL), spine (S), pelvis (P), lower extremities (LE), upper extremities (UE) and whole skeleton (WS) sites. Bone turnover markers such as urine NTx, BCTx BSAP and PINP were also measured with standard methods and were further correlation with bone scan values. Two-sample Wilcoxon rank-sum (Mann-Whitney) test was used. Data were represented in median (min-max) values and p value was considered significant as <0.001.

Results: The mean age, height and weight of patients were 59.68±8.01 y, 149.17±6.00 cm, and 54.88±9.40 kg respectively. The BMD, PTH, vitamin D, calcium, ALP and phosphorous were -3.9±0.8 g/cm³, 49.23±17.30 pg/ml, 48.40±34.33 ng/ml, 9.17±0.54 mg/dl, 194.62±73.38 Ka/IU and 4.05±0.98 mg/dl respectively. Upon comparison at different regional bone changes in two groups, values were analyzed within and between groups at scheduled follow-ups. The between group p values of two bone resorption and formation markers were not statistically significant. Upon comparison the values of bone scan at different skeletal sites such as calvarium, spine, pelvis and upper extremity

were not statistically significant. However, at lower extremity and whole skeleton sites the values were p .080 and p. 022 respectively and were found statistically significant.

Conclusion: By enlarge, TP & AL provides a comparable results for the treatment of osteoporosis but TP therapy appears moderately better than AL for the improvement at specific bone regions . However, it would be too early to frame a conclusion due to small sample size studied and thus a further large sample size based non-inferior trial is needed. Meanwhile, oral bisphosphonate (AL) being effective and affordable may remain a first line of therapy for the treatment of osteoporosis.

P476

CUTOFF OF LOW BONE MINERAL DENSITY IN β-THALASSEMIA MAJOR PATIENTS

Z. Hamidi¹, M. R. Mohajeri-Tehrani¹, F. Arab¹, S. Salemkar¹, N. Darvishian¹, F. Mohseni¹, H. Gerami¹, B. Larijani¹

¹Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Objective: As different cutoff point for low BMD in thalassemia patients reported and low BMD is more treatable in early periods, it is very desirable if we find cutoff age for its incidence and help patients before that it is too late. In this study we tried to find such cutoff point via statistical analysis.

Method: Data from 741 major β-thalassemia patients, extracted from questionnaires of a BMD department. Questionnaires filled during a face to face interview by BMD operator. All of BMD measurements did only by one device Mean age of patients was 19.7±7 y/o and female to male ratio: 384/357. Children (<20 y/o) formed 49% of participants.

Results: Medical records of 741 patients used in this study. Prevalence of low BMD of neck and spine was 27% and 31% respectively. Negative significant correlations found between age, sex, diabetes, levothyroxine and Z-score BMD of femur (P values, <0.001, 0.003, <0.001 and 0.027, respectively). This significant correlation found also with Z-score BMD of spine (P values, <0.001, <0.001, <0.001 and 0.032, respectively). Male sex was a risk factor for low BMD in both regions (P values, <0.039 and 0.001, respectively). Being 17 and older increased the risk femur low BMD more than other ages and 40 times compared to younger patients (P values <0.001). Being 17 and older increased the risk spine low BMD more than other ages and 52 times compared to younger patients (P values <0.001). Being 17 and older also increased the risk femur and spine low BMD significantly and more than other ages, even when men and women analyzed separately.

Conclusion: On the basis of our results, we suggest that awareness about Low BMD and monitoring for it in thalassemics, should be done in their late childhood, for example in patients as young as 11 y/o.

P477

PREVALENCE OF VERTEBRAL FRACTURES IN POST LIVER TRANSPLANT PATIENTSS. Shah¹, B. Bansal¹, A. Mithal¹, A. S. Soin², J. P. Sharma³

¹Division of Endocrinology and Diabetes, Medanta The Medicity Hospital, Gurugram 122001, Haryana, India ²Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity Hospital, Gurugram 122001, Haryana, ³India Radiology and Imaging, Medanta The Medicity Hospital, Gurugram 122001, Haryana, India

Objective: To determine the prevalence of radiological vertebral fractures in post liver transplant patients.

Methods: We performed a prospective study of 84 consecutive patients aged >18 y who had undergone liver transplant from 2010-2017. Vertebral fractures were assessed semiquantitatively from lateral spine X-rays using Genant scoring.

Results: The prevalence of vertebral fractures was 46.4% patients. Thoracic fracture was seen in 26.2% patients (Grade 1- 18.3%, Grade 2- 8.3%, Grade 3- 3.6%) and lumbar fractures in 28.6% patients (Grade 1- 22.6%, Grade 2- 4.8%, Grade 3- 1.2%). There was no significant difference in the prevalence of fracture in patients with history of diabetes, smoking, alcohol, previous history of vertebral or upper limb fractures and receiving calcium and vitamin D supplementation however fractures were more common with increasing age. There was no significant differences in blood parameters like S.calcium, S.phosphorus, S.PTH, Vit D levels between patients with and without vertebral fractures. Vertebral fractures were also more prevalent in patients who had undergone transplant in the previous 1 year.

Conclusions: Bone status of the patients should be evaluated before and within 1 year after liver transplantation. Hence prevention of pre- and post-transplant fractures should focus on optimizing bone mass prior to transplant and prevention of further bone loss in the early post-transplant period.

P478

RELATIONSHIP BETWEEN OSTEOCALCIN, OSTEOPOROSIS AND ABDOMINAL AORTIC CALCIFICATION IN CHRONIC KIDNEY DISEASE PATIENTSP. J. Chi^{1,5}, J. P. Tsai^{2,6}, S. Y. Hung¹, H. H. Liou^{1,3}, B. G. Hsu^{4,5}

¹Division of Nephrology, E-DA Hospital, E-DA Cancer Hospital, I-Shou University, Kaohsiung city, Kaohsiung, Taiwan, ²Division of Nephrology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan, ³Division of Nephrology, Department of Medicine, Hsin-Jen Hospital, New Taipei city, Taiwan ⁴Division of Nephrology, Department of Medicine, Buddhist Tzu Chi General Hospital, Hualien, Taiwan ⁵Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan ⁶School of Medicine, Tzu Chi University, Hualien, Taiwan

Objective: Osteocalcin, a bone formation marker, is associated with arteriosclerosis and osteoporosis. We aimed to investigate the relationships among osteocalcin, abdominal aortic calcification (AAC), and BMD in chronic kidney disease (CKD) patients.

Methods: A total of 95 CKD patients, stage 2 to 5, were enrolled in our study. Serum osteocalcin was tested by electrochemiluminescence immunoassay. BMD was measured by DXA and AAC by lateral lumbar radiographs findings.

Results: 23 (24.2%) of CKD patients were found with osteoporosis and 43 (45.2%) with osteopenia. Compared with normal subjects (N=29) or osteopenia patients, osteoporosis group had older age (p=.001), more female (p<.0001), lower hemoglobin (p=.003), higher urine protein creatinine ratio (UPCR) (p=.001), higher osteocalcin (p<.0001), higher intact PTH (iPTH) (p=.0001), higher AAC score (p=.0002). and higher phosphorus (p=.032). Multivariate logistic regression showed age (b=1.156, p=.012), osteocalcin (b=1.11, p=.012) and female gender (b=12.05, p=.032) are independent risk factors for osteoporosis in CKD patients. Osteocalcin was positively correlated with Na (r=.23, p=.028), phosphorus (r=.263, p=.013), HbA1c (r=.259, p=.021), UPCR (r=.214, p=.038), AAC score (r=.225, p=.029), iPTH (r=.402, p<.0001), calcium channel blocker (CCB) use (r=.273, p=.007), Erythropoietin (EPO) use (r=.24, p=.019), while negative correlated with pulse rate (r=-.26, p=.011), eGFR (r=-.334, p=.001), hemoglobin (r=-.298, p=.005), BMD (r=-0.462, p<.0001), female gender (r=-.328, p=.001). After stepwise multivariate regression analysis, lower BMD (b=-4.684, p=.001), higher iPTH (b=.114, p=.014), EPO use (b=19.499, p=.022) were independently correlated with osteocalcin level.

Conclusions: We observed higher serum osteocalcin level is an independent risk factor for osteoporosis in CKD patients. Hyperparathyroidism, EPO use were positively correlated with serum osteocalcin level in CKD patients.

P479

XANTHINE OXIDASE AND XANTHINE DEHYDROGENASE ACTIVITIES IN RHEUMATOID ARTHRITIS AFTER GLUCOCORTICOID TREATMENT

E. E. Mozgovaya¹, S. A. Bedina¹, A. S. Trofimenko¹, S. S. Spitsina¹, E. A. Tikhomirova¹, M. A. Mamus¹

¹Federal State Budgetary Institution "Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky", Volgograd, Russia

Objective: to assess the changes of xanthine oxidase and xanthine dehydrogenase activities in plasma and lysed lymphocytes of rheumatoid arthritis (RA) patients when average therapeutic doses of methylprednisolone and betamethasone were administered.

Methods: 47 RA patients (verified with ACR/EULAR criteria (2010)) with moderate disease activity in accordance with DAS28 were included in the study. The control group consisted of 30 healthy individuals. RA patients were divided into 2 groups comparable by sex, age and clinical manifestations. Patients of the first group were treated with methylprednisolone (metipred, Orion Corporation (30 mg)). Patients of the second group were treated with betamethasone (diprosan, Schering-Plough Labo N.V. (7 mg)). Glucocorticoids were administered intramuscularly in both groups. The changes of xanthine oxidase (XO, EC 1.2.3.2) and xanthine dehydrogenase (XDG, EC 1.2.1.37) activities were studied in plasma and lysed lymphocytes in RA patients when average therapeutic doses of methylprednisolone and betamethasone were administered as previously described [1].

Results: Mean age of patients (\pm SD) was 41.8 ± 1.05 y, mean RA duration (\pm SD) was 7.9 ± 0.21 years. Decreased XO activity and increased XDG activity were observed in plasma of RA patients just after the injection of the average therapeutic doses of glucocorticoids, as well as in lysed lymphocytes just after the injection of metipred. While enzymatic patterns did not reach the level of healthy controls. The switchover of the final stage of purine metabolism along the way of utilization of hypoxanthine and xanthine under the catalysis of XDG leads to decrease in the production of active forms of oxygen (AOS). It can be considered that a decrease in the production of AOS along with the characteristic ability of glucocorticoids to stabilize lysosomal and cell membranes also helps to reduce the formation of neutrophil extracellular traps.

Conclusion: The increase of XDG activity and the decrease of XO activity were observed in plasma and in lysed lymphocytes of RA patients after methylprednisolone (metipred) treatment. The increase of XDG activity and the decrease of XO activity were observed in plasma of RA patients after betamethasone (diprosan) treatment. XO-mediated AOS production during glucocorticoid treatment is decreased, and this effect can exert beneficial influence on autoimmune inflammation in RA.

Reference: 1. Zborovsky AB et al. *Terapevticheskiy Arkhiv* 2010;82:48

P480

OSTEOID OSTEOMA: IMAGING DIAGNOSIS

A. Venter¹, L. G. Daina¹, C. M. Daina¹, I. Oswald¹, C. Buhas¹, I. Moga¹, F. Cioara¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objective: Osteoid osteoma represents 10 to 12% of all benign bone tumors. Jaffe described in 1935 by first, usually presenting a typical clinical and radiological picture. It arise in children, adolescents, and adults up to the age of 35 y, consulting with a history of pain occurring mostly at night and which is relieved by salicylates. The diagnosis of osteoid osteoma hinges upon detection of the nidus, a focus of bone tissue showing variable mineralization, embedded in a highly vascular connective tissue stroma. The nidus represents the tumor with the zone of sclerosis representing the host bone's response to the presence of the lesion. Our aim was illustrating the imaging aspects of osteoid osteoma.

Method: the study included 6 patients who performed radiography, CT and RM in the Oradea County Hospital with histopathological confirmation.

Results: Our series comprise six patients with osteoid osteoma (4 M/2 W). The nidus was seen in all six cases: a radiolucent focus known as the nidus surrounded by reactive sclerosis; an area of low attenuated with a central high attenuation component; a ring-like or rounded area of intermediate SI on T1 and of relatively high SI on T2. Central calcification of the nidus present in two cases, and peripheral hyperostosis in all cases were seen as areas generating no signal on both SE-sequences on MR. Surrounding medullary involvement had an intermediate SI on T1 and a relatively high SI on T2 and was seen in three cases. Synovial thickening or fluid at the adjacent joints was seen only once.

Conclusions: The radiologist's duty is to recognize the imaging features, exclude mimics. CT is the most useful imaging modality to confirm a suspected osteoid osteoma.

P481

CT ASPECTS IN TRAUMATIC CONDITIONS OF THE COXO-FEMORAL JOINT IN PATIENTS WITH OSTEOPOROSIS

O. C. Rogoveanu¹, L. M. Florescu¹, L. M. Sas¹, A. Florescu¹, T. N. Sas¹

¹UMF Craiova, Craiova, Romania

Objectives: Osteoporosis is a metabolic bone disorder characterized by a reduction of the BMD below the normal limit, resulting in an increased bone fragility that is associated with an increased risk of bone fracture caused by microtraumatism or moderate intensity trauma [1]. The aim of our paper was to correlate computed tomography (CT) data from patients with traumatic lesions of the femoral head or congenital disorders of the femur (femoral head avascular necrosis, malformations etc.), with the patient's medical history and data obtained from DXA performed after the initial examination [2].

Methods: The clinical study was performed on a group of 183 patients (114 women, 69 men), aged between 47-82 y, who presented to the Emergency Department of the County Clinical Emergency Hospital of Craiova during 2017-2018. The CT examinations were performed on a 16-slice Toshiba Astelion machine.

Results: Out of 183 patients included in the study group, 76 had a displaced fracture of the femoral neck and associated an ascension of the distal fragment. Also, structural bone changes like demineralisation of the bone tissue in the proximal part of the femur as well as thinning of the cortical bone were reported. Subsequent evaluation of patients with fractures included in the study during hospitalization through DXA test revealed incipient osteoporosis in 24 patients and advanced osteoporosis in 52 patients. In 8 patients, the DXA test did not reveal osteoporotic changes but other bone pathologies were described (femoral head avascular necrosis – 2 cases and genu varum/genu valgum type malformations – 6 cases).

Conclusion: The subsequent evolution and medical recovery of these 8 patients required hospitalization for a longer duration and complex medical procedures compared to the group of patients with fractures caused by osteoporosis.

References:

1. Link TM. Radiology 2012;263:3.
2. Trăistaru MR et al. Rom J Morphol Embryol 2015;56:1447.

P482

THE ROLE OF MAGNETIC RESONANCE IMAGING IN ASSESSING VERTEBRAL BONE PATHOLOGY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOPOROSIS UNDERGOING CORTICOTHERAPY TREATMENT

O. C. Rogoveanu¹, L. M. Florescu¹, L. M. Sas¹, A. Florescu¹, T. N. Sas¹

¹UMF Craiova, Craiova, Romania

Objectives: Osteoporosis in patients with rheumatoid arthritis can often be asymptomatic and patients are most frequently diagnosed based on the associated risk factors or fractures caused by an increased bone fragility [1]. MRI can be used to evaluate the trabecular structure of the bones thus offering additional information regarding the structure of the bone marrow. Some of the structural bone changes that affect the spine in patients with osteoporosis include: intravertebral disc herniations (Schmorl nodes), bone edema associated with asymptomatic microfractures and, in some cases, vertebral body collapse and fractures [2].

Methods: The study included 50 female patients diagnosed with rheumatoid arthritis and undergoing corticotherapy, aged between 59-76 y, who underwent musculoskeletal MRI examinations on a Philips Ingenia 3 Tesla device in the Medical Imaging Department of the University of Medicine and Pharmacy of Craiova.

Results: Out of 50 patients included in the study group, 20 had intravertebral disc herniations, 12 had bone edema affecting the vertebral plates adjacent to one or more intervertebral discs, 3

had vertebral body compression fractures and only one patient presented noninfectious spondylodiscitis caused by osteoporosis.

Conclusion: The technological progress allowed MRI bone examinations to establish an accurate and early diagnosis of axial lesions caused by osteoporosis.

References:

1. Ene CG et al. Rev Chim (Bucharest) 2018;69:1851.
2. Link TM. Radiology 2012;263:3.

P483

INCIDENCE OF HEPATIC OSTEOPATHY IN PATIENTS WITH LIVER CIRRHOSIS

O. C. Rogoveanu¹, R. Traistaru¹, F. Gherghina¹, A. E. Musetescu¹, I. Rogoveanu¹

¹UMF Craiova, Craiova, Romania

Objective: Hepatic osteopathy refers to the changes that occur in the bone structure in patients with liver cirrhosis and mainly includes osteopenia, osteoporosis and osteomalacia.

Methods: The study included 150 patients diagnosed with liver cirrhosis caused by various etiological factors. We evaluated the bone structural changes through DXA and determined the bone density through computed tomography (CT) and correlated this data with parameters of the bone metabolism (serum levels of vitamin D, calcium, calcitonin, PTH) and biochemical parameters that reflect the liver function. The study also included a control group (150 patients without any liver pathology) in which we evaluated the exact same parameters.

Results: The results of the study highlighted a decrease of the bone density affecting the spine in 20 patients (13.3%) and the peripheral regions in 38 patients (25.3%), compared to the control group where osteoporosis recorded an incidence of 5% and 7%, respectively. Osteopenia was described in 60 patients (40%). Regarding the etiology of liver cirrhosis, osteoporotic changes were more frequently encountered in alcoholic patients, rather than in patients with hepatitis B or C viral infections. This was caused mainly because of the reduced enteral absorption of calcium due to the prolonged cholestasis. The changes affecting the bone structures remain asymptomatic for a long period of time; however, in time, they can generate fractures that affect the vertebral bodies or the femoral neck.

Conclusion: Hepatic osteopathy occurs relatively frequently in alcoholic liver cirrhosis and is correlated with the severity of the liver disease. Clinical manifestations are caused by an alteration of the phosphocalcic metabolism generated by the malabsorption process and are associated with an increased risk of developing bone deformities and bone fractures in these patients.

P484

ROLE OF BONE MARKERS IN EVALUATING THERAPEUTIC RESPONSE IN PATIENTS WITH OSTEOPOROSIS

O. C. Rogoveanu¹, A. Balseanu¹, F. Burada¹, A. O. Docea¹, D. Calina¹

¹UMF Craiova, Craiova, Romania

Objective: Osteodensitometry is the most commonly used method for diagnosing osteoporosis. However, regardless of the treatment, measuring BMD for assessing treatment efficiency is only suitable after one year of proper treatment. Therefore, bone markers are considerably more useful in monitoring treatment efficiency and in estimating the risk of osteoporotic fractures.

Methods: We studied a group of 50 female patients diagnosed with postmenopausal osteoporosis. We evaluated the initial grade of osteoporosis using DXA and serum levels of β -Cross-Laps (β -CTx) and osteocalcin. One year after following osteoporosis specific treatment, the patients included in the study group were re-evaluated using the same protocol as before treatment.

Results: After one year of proper treatment with bisphosphonates and bone matrix fixators, the DXA test performed in all 50 patients included in the study revealed an improvement of the T-score in 42 patients (84%), while the serum levels of the bone markers were elevated in 44 patients (88%). This aspect suggested an increased efficiency of the treatment and was associated with an increased bone formation rate.

Conclusion: The sensitivity of serum bone markers is superior to osteodensitometry in assessing the effectiveness of the osteoporosis treatment after one year.

P485

EFFECT OF BIOLOGICAL THERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH SPONDYLOARTRITIS

S. Novkovic¹, M. Basaric¹, K. Vagic¹

¹Institute of rheumatology, Belgrade, Serbia

Objective: To investigate the effect of biological DMARD (disease modifying antirheumatic drugs) therapy to BMD in patients with spondyloarthritis.

Methods: The research included 96 male patients with ankylosing spondylitis and psoriatic spondyloarthritis. The respondents were divided into two groups: group A (64 patients) received treatment with biological medicines (etanercept-50 mg/week; adalimumab-40 mg/2 weeks and infliximab 5mg/kg/8 weeks) and the group B control group (32 patients) was not given the biological therapy. In both groups there were little patients who were treated with nonbiological DMARD therapy and none of them received systemic glucocorticoids in the last year. For measuring of BMD we used DXA method with Hologic. Measuring was performed on hip at the beginning of the research and repeated after 24 months. Responders did not receive therapy for osteoporosis, except supplements. Appropriate statistical methods were applied using SPSS.

Results: The groups were comparable by age (group A: 38.2±11.4 y, group B: 40.2±10.6 y), duration of illness (group A: 7.3±6.4, group B: 8.5±6.7 y) and number of patients who received non biological DMARD therapy (group A: 29.5%, group B: 24.4%). The average value BMD (g/cm²) was not significantly different between groups at the beginning of the research (group A: 0.972 g/cm², group B: 0.957 g/cm², p=0.424). After 24 months, we recorded significant increase of BMD in the group A (1.015 g/cm², p<0.05) and significant decrease in the group B (0.897 g/cm², p<0.05). At the end of this research we detected statistically significant increase in the group treated by biological DMARD drugs in comparison to the control group (p<0.05). Five osteoporotic fractures in group A and 11 osteoporotic fractures in group B were recorded, which was a statistically significant difference (p<0.05).

Conclusion: 24 months long treatment with biological DMARD therapy at our patients with spondyloarthritis caused significant improvement of BMD and reduction in frequency of osteoporotic fractures.

P486

FRACTURE RISK ASSESSMENT (FRAX) IN WOMEN THROUGH RADIOFREQUENCY ECHOGRAPHIC MULTISPECTROMETRY

N. Kirilov¹, E. Kirilova²

¹Medical University of Sofia, Stara Zagora, Bulgaria, ²Trakia University, Stara Zagora, Bulgaria

Objective: Due to the global burden of the osteoporotic fractures, FRAX model was released in 2008 by the WHO Collaborating Centre at Sheffield to compute 10-y probabilities of major osteoporotic and hip fractures. Country specific FRAX models have been developed based on both incidence of fractures and mortality. The aim of this study was to assess the fracture risk in women through radiofrequency echographic multispectrometry (REMS).

Methods: FRAX tool of the University of Sheffield was used to assess the 10-y probability of major osteoporotic fracture (clinical spine, forearm, hip or shoulder fracture) and hip fracture. Following risk factors were investigated: previous fractures, parent fractured hip, current smoking, rheumatoid arthritis, glucocorticoids, secondary osteoporosis, alcohol three or more units/d and BMD. Patients between 40-90 y were included in the study. Due to the lack of country specific FRAX model for Bulgaria, FRAX model of Romania was used. BMD values of lumbar spine and femoral neck were measured through REMS technology.

Results: 97 women with mean age 62.9±11.1 y (range 40-84) were included in the study. According to the BMD assessment of the lumbar spine, the mean 10-y absolute fracture risk for major fractures was 15.4±11.3%, and for hip fractures 4.6±6.1%. According to the BMD assessment of the femoral neck, the mean 10-y absolute fracture risk for major fractures was 17.7±13.5%, and for hip fractures 5.9±8.4%. The prevalence of some major risk factors for osteoporosis was as follows: previous fractures – 39.2% of all women, parent fractured hip – 2.1%, smoking – 21.6%, rheumatoid arthritis – 30.9%, glucocorticoids – 18.6%, secondary osteoporosis – 0% and alcohol three or more units/d –

6.2%. The factors associated with significantly increased fracture risk were previous fractures ($p=0.000$) and use of glucocorticoids ($p=0.008$).

Conclusion: This is the first study which reported 10-y absolute fracture risk for major fractures and hip fractures through REMS technology. In this study, we could identify that previous fractures and use of glucocorticoids were significantly associated with increased fracture risk.

P487

COMPARISON OF THE IMPROVEMENT OF T-SCORE IN SENILE PATIENTS WITH OSTEOPOROSIS BETWEEN THE GROUPS WITH DENOSUMAB/NANDROLONE DECANOATE AND IBANDRONIC ACID/NANDROLONE DECANOATE

N. Kirilov¹, E. Kirilova²

¹Medical University of Sofia, Stara Zagora, Bulgaria, ²Trakia University, Stara Zagora, Bulgaria

Objective: In some patients with severe osteoporosis, a lack of change in T-score measured with DXA method after one year could be observed, despite the administration and good tolerance of the main medications. After assessing the risk factors and clinical evaluation in these cases, nandrolone decanoate could be included in the main therapy. Anabolic steroids are an effective remedy for the treatment of postmenopausal and senile osteoporosis in the absence of contraindications. They increase both bone and muscle strength and muscle volume.

Methods: A total of 51 senile patients with osteoporosis were included in the study. Inclusion criteria was previous therapy either with denosumab or with ibandronic acid in patients with osteoporosis without any improvement of the T-score within the first year of the main treatment. 47% (24/51) of the patients were treated with combination of denosumab and nandrolone decanoate and 53% of the patients (27/51) were treated with combination of ibandronic acid and nandrolone decanoate. Baseline T-score values of lumbar spine and T-score values of lumbar spine after one year were measured using DXA method.

Results: The mean age of the patients treated with denosumab/nandrolone decanoate was 72 ± 6.6 y and 69 ± 2.2 y of those treated with ibandronic acid/nandrolone decanoate. The mean baseline T-score value of the patients treated with combined therapy of denosumab and nandrolone decanoate was -3.02 ± 0.42 SD and the mean T-score value after one year was -2.71 ± 0.36 SD. The mean baseline T-score value of the patients treated with combined therapy of ibandronic acid and nandrolone decanoate was -2.92 ± 0.25 SD and the mean T-score value after one year was -2.76 ± 0.60 SD. Improvement of the T-score with 0.31 SD after one year has been achieved with denosumab/nandrolone decanoate and with 0.16 SD with ibandronic acid/nandrolone decanoate.

Conclusion: Combined therapy with denosumab and nandrolone decanoate in senile patients showed better improvement of the T-score value after one year compared to those treated with ibandronic acid and nandrolone decanoate.

P488

MINODRONATE IS MORE EFFECTIVE THAN RALOXIFENE IN PREVENTING FRACTURES IN POSTMENOPAUSAL OSTEOPOROTIC WOMEN WITH MODERATELY DECREASED BMD: SUBGROUP ANALYSIS OF JAPANESE OSTEOPOROSIS INTERVENTION TRIAL (JOINT-04)

T. Sone¹, Y. Uemura², H. Hagino³, S. Mori⁴, T. Nakamura⁵, M. Shiraki⁶, H. Ohta⁷, S. Soen⁸, H. Orimo⁹

¹Kawasaki Medical School, Kurashiki, ²Tokyo University Hospital, Tokyo, ³Tottori University Faculty of Medicine, Tottori, ⁴Seirei Hamamatsu General Hospital, Hamamatsu, ⁵Touto Sangenjaya Rehabilitation Hospital, Tokyo, ⁶Research Institute and Practice for Involutional Diseases, Nagano, ⁷International University of Health and Welfare, Tokyo, ⁸Kindai University Nara Hospital, Nara, ⁹Japan Osteoporosis Foundation, Tokyo, Japan

Objective: To clarify clinical factors affecting the therapeutic effectiveness of the antifracture agents, minodronate (MIN) and raloxifene (RLX), against osteoporosis in a subgroup analysis of JOINT-04.

Methods: JOINT-04 is a multicenter, openlabel randomized controlled, headtohead comparison of MIN and RLX in Japan. The participants comprised postmenopausal women aged >60 y with at least one risk factor for fractures (age >70 y, at least one previous vertebral fracture, low BMD and T-score <-3.0). The incidence of clinical vertebral and major osteoporotic femur, radius and humerus fractures was assessed during a period of 2 y. Both MIN and RLX were essentially equally effective in preventing overall fractures (presented at IOF Regional Sydney 2018). Therefore, we compared the antifracture effects of both agents among subgroups of participants based on fracture risk at baseline.

Results: Osteoporotic fractures occurred in 211 of 1623 and in 226 of 1624 participants in the MIN and RLX groups, respectively, during the observation period. These values did not significantly differ. In contrast, among participants with vertebral fractures stratified according to age, number of previous vertebral fractures and baseline BMD, risk was significantly reduced in those with BMD T-scores ≥ -3.0 (IRR 0.47; 95%CI 0.30-0.75; $p=0.0012$), but not in those with BMD T-scores <-3.0 within the MIN group. A significant effect modification was not found in interaction tests. The incidence of vertebral fractures did not differ between MIN and RLX subgroups stratified by age or number of previous vertebral fractures. The results were similar for major osteoporotic fractures.

Conclusion: The incidence of osteoporotic fractures was lower in MIN, than in RLX subgroups with BMD T-scores of ≥ -3.0 . Therefore, MIN might prevent fractures more effectively than RLX in postmenopausal women with moderately, but not extremely decreased BMD.

P489

VITAMIN D DEFICIENCY AMONG PATIENTS WITH METFORMIN INDUCED B12 DEFICIENCYM. Alvarez¹, O. Rincon²¹Universidad Militar Nueva Granada. Hospital Militar Central,²Hospital Militar Central, Bogota, Colombia

Objective: Metformin produce low vitamin B12 levels by mechanisms related to alterations in gut absorption 1-10. The objective of this study is to evaluate if patients with metformin induced vitamin B12 deficiency have higher prevalence of vitamin D deficiency.

Methods: Cross sectional study. 156 patients were included. Patients were classified in three groups according to B12 levels, low, <200 pg/ml and borderline, 201-300 pg/ml or normal, >300 pg/ml. Vitamin D status was obtained from the records of the patients and was classified as deficiency, <20 ng/mL, insufficiency, 20-30ng/mL, or normal, >30 ng/mL. The prevalence of vitamin D insufficiency and deficiency was evaluated in the three groups.

Results: 156 patients were collected. Low level of vitamin D was found in 27% (CI95%:21-35%) and deficient level of vitamin D in 16% of the total population (CI 95%: 11 – 22%). In patients with low levels of B12, 42% (CI95% 21-67%) had low levels of vitamin D, in patients with borderline B12 levels, 27% (CI 95% 15-44%) had low levels of vitamin D and patients with normal B12, 25% (CI 95% 18-34%) had low levels of vitamin D. There was a positive correlation between B12 levels and Vitamin D levels.

Conclusion: Low level of vitamin D is frequent among metformin treated patients in the studied population. Patients with low and borderline levels of vitamin B12 have a higher prevalence of low levels of vitamin D. There were a positive correlation between B12 levels and vitamin D levels. More studies are needed to confirm if there is any association between metformin use and vitamin D deficiency.

References:

1. Kos E et al. Endocr Pract 2012;18:179.
2. Out M et al. Diabetes Obes Metab 2018;20:1951
3. Forouhi NG et al. Diabetes Obes Metab 2016;18:392
4. Wilson LR et al. Proc Nutr Soc 2017;76:392
5. Berchtold P et al. Diabetologia 1969;5:405
6. Aroda VR et al. J Clin Endocrinol Metab 2016;101:1754
7. Reinstatler L et al. Diabetes Care 2012;35:327
8. Ko SH et al. J Korean Med Sci 2014;29:965
9. de Jager J et al. BMJ 2010;340:c2181
10. Rodriguez R et al. Am J Med Sci 2017;354:165

P490

CORRELATION OF SARCOPIENIA WITH EARLY FUNCTIONAL OUTCOME AND 1-YEAR MORTALITY IN HONG KONG CHINESE GERIATRIC PATIENTS WITH HIP FRACTUREI. L. Y. Au¹, A. C. M. Chan¹, W. L. D. Chan¹, K. B. Lee², K. L. Tiu², J. C. K. Lau²¹Physiotherapy Department, Queen Elizabeth Hospital,²Department of Orthopaedics and Traumatology, Queen Elizabeth Hospital, Hong Kong, China

Objective: Hip fracture is common in elderly after fall, causing disability, lower quality of life, mortality and increase in health-care burden. Annually, over 8000 patients were admitted to Hospital Authority due to traumatic hip fracture while Queen Elizabeth Hospital (QEH) accounted for 13.7%. Hip fracture is mostly treated operatively, followed by rehabilitation. Rehabilitation plan and prognosis can be determined by early functional outcome. Meanwhile, 1-y mortality of hip fracture patients is high, approximately 18% in Hong Kong. Numerous factors are shown to be significant prognostic predictors; however, limited studies have investigated the contribution from Sarcopenia on functional outcome and 1-y mortality. Our aim was to investigate the correlation among sarcopenia, early functional outcome and 1-y mortality in geriatric ambulatory patients with hip fracture.

Methods: A retrospective study was conducted. Patients aged 65 years old or above and admitted to QEH due to acute hip fracture after fall with DXA received within 1 month from April 2016 to March 2017 were reviewed. Outcome measures on 1) relative appendicular skeletal muscle mass index (RASM) measured by DXA, 2) handgrip strength (HGS), 3) elderly mobility scale (EMS) at first ambulation (EMS-1), 4) EMS at discharge from QEH (EMS-DC) and 5) 1-y mortality were retrieved for analysis. Definition of sarcopenia developed by the Asian Working Group for Sarcopenia, analyzing RASM and HGS, was adopted. Correlation between sarcopenia and EMS was evaluated by rank-biserial correlation analysis. Correlation between sarcopenia and 1-y mortality was evaluated by Pearson's chi-square test. Prediction model of 1-y mortality was evaluated using logistic regression analysis.

Results: 219 patients (mean age=83.0±7.2 y) (82 males, 137 females) were reviewed. Prevalence of sarcopenia was 51.6%. 1-y mortality rate was 12.8%. There were significant correlations between sarcopenia and EMS-1 ($r_{rb}=-0.160$, $p=0.023$), and between sarcopenia and EMS-DC ($r_{rb}=-0.269$, $p<0.001$). Sarcopenia was associated with 1-y mortality ($\chi^2=5.290$, $p=0.021$). 1-y mortality rate of patients with sarcopenia and without sarcopenia was 18.0% and 7.5% respectively. Patients with sarcopenia were more likely to face mortality within 1 y ($R^2=0.046$, $OR=2.692$, $p=0.025$).

Conclusion: Early detection of sarcopenia is crucial for early implementation of appropriate rehabilitation and treatment in Hong Kong Chinese geriatric ambulatory patients with hip fracture.

P491

IMPACT OF ORAL VITAMIN D SUPPLEMENTATION ON SERUM CARBOXYPEPTIDASE N AND NITRIC OXIDE LEVELS IN SAUDI ADULTS

A. Alaskar¹, S. Abdi¹, N. Al-Daghri², S. Yakout²

¹Biochemistry Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia ²Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh 11451, Saudi Arabia

Objective: Vitamin D deficiency is highly prevalent in Saudi Arabia. It is therefore important to recognize which biochemical markers are modulated by vitamin D status in response to vitamin D supplementation in such a population. The study aimed to determine the associations of carboxypeptidase N (CPN) and nitric oxide (NOx) levels with serum 25(OH) D in response to vitamin D supplementation in a Saudi population.

Methods: A total of 111 vitamin D deficient (25OHD <50nmol/l) adult Saudis aged 18-50 years old (57 females & 54 males) were enrolled in this 6-month interventional study and were given 50000 IU cholecalciferol given weekly for first 2 months, then twice a month for next 2 months, followed by daily 1000 IU for the last 2 months. Serum NOx concentration was measured, using the Griess method, concentration of carboxypeptidase N was measured using ELISA according to the standard protocols and manufactures guidelines. 25(OH)vitamin D was analyzed using COBAS e-411 automated analyzer (Roche Diagnostics, Indianapolis, USA). All parameters were measured at baseline and after intervention.

Results: Postsupplementation median 25(OH) D was significantly higher ($p < 0.001$) in all females [58.3 (50.6-71.2)] and males [57.8 (51.0-71.8)]. HDL-cholesterol significantly increased ($p = 0.05$) while NOx significantly decreased ($p = 0.02$) in males postsupplementation. The postsupplementation serum levels of CPN2 did not differ significantly among male subjects. CPN2 was significantly inversely correlated with NOx ($r = -0.218$, $p = 0.05$) among the male subjects postsupplementation.

Conclusion: Vitamin D supplementation reduces NOx, particularly in males. Inhibition of NOx synthesis may be one mechanism responsible for the anti-inflammatory effects of vitamin D supplementation.

P492

EROSIONS AND SYNOVITIS: ASSOCIATED OR NOT WITH LOW BONE MINERAL DENSITY IN PATIENTS WITH RHEUMATOID ARTHRITIS?

A. Florescu¹, P. L. Ciurea¹, A. E. Musetescu¹, C. Gofita¹, R. Traistaru¹, O. C. Rogoveanu¹

¹University of Medicine and Pharmacy Craiova, Craiova, Romania

Objectives: To assess the correlation between BMD of the wrist and the presence of wrist erosions and synovitis determined by ultrasound in a group of patients with rheumatoid arthritis (RA).

Methods: The study included 40 females diagnosed with RA according to ACR/EULAR 2010 criteria with mean age of 52.4 (± 11.2) y and average disease duration of 3 y (1-14). The BMD was measured using DXA of the nondominant forearm and lumbar spine. Erosions and synovitis were assessed through musculoskeletal ultrasound (MUS) of the wrist with both longitudinal and transverse scans. Mandatory laboratory tests consisted of C reactive protein (CRP) and erythrocyte sedimentation rate (ESR) [1, 2].

Results: Rheumatoid factor (RF) was positive in 77.5% of cases, while anticitrullinated protein antibodies (ACPA) were positive in 70% of patients. Disease activity determined by disease activity score (DAS) 28 with CRP was low in 17.5%, moderate in 40% and high in 42.5% of cases, respectively. 45% of patients had osteoporosis, while osteopenia was encountered in 47.5% of cases assessed by both wrist and lumbar spine DXA. The percentages of erosions (72.22% vs. 63.15%) and synovitis (61.11% vs. 52.56%) in the osteoporosis group were higher than in the osteopenia group. Positive RF and ACPA rates were also higher in osteoporosis group. DAS 28 proved a strong correlation with wrist BMD ($p < 0.05$).

Conclusions: Disease activity has an important impact on the development of wrist osteoporosis in RA patients. Also, the presence of RF and ACPA predict the risk of low BMD. Erosions and synovitis determined by MUS are more frequent findings in patients with wrist osteoporosis.

References:

1. Traistaru MR et al. Rom J Morphol Embryol 2016;57:215.
2. Ene CG et al. Rev Chim (Bucharest) 2018;69:1851.

P493

RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO COMPARE THE EFFICACY OF COMBINATION OF LIDOCAINE WITH KETOROLAC OR TRIAMCINOLONE VS. LIDOCAINE ALONE FOR SOFT TISSUE INJURIES

D. R. Sindhupakorn¹, M. S. Jomkoh², M. R. Namkuntee²

¹Orthopedics, Nakornratchasema, Thailand, ²Medicine, Nakornratchasema, Thailand

Objectives: Corticosteroids injections and local anesthetics are commonly used in sports medicine. It showed superior short-term pain relief (6 weeks) but potentially serious complications such as skin discoloration, chronic tendinopathy, infections and tendon rupture. Ketorolac tromethamine (ketorolac) is a short-term pain-reducing nonsteroidal anti-inflammatory drug (NSAIDs). Different injection techniques have previously been tested but no studies have yet compared the efficacy of the ketorolac and steroid injection. Our primary objective is to evaluate the pain intensity scores among lidocaine, ketorolac 30, mg 60 mg, and triamcinolone 10 mg, 20 mg, 40 mg. We tested the hypothesis that ketorolac should reduce the pain as same as steroids.

Methods: 144 patients were recruited. A randomized, double-blind, parallel-group, placebo-controlled 6 arms study, we divided in 1:1:1:1:1:1 ratio to receive either one of lidocaine(control), ketorolac 30 mg, 60 mg, and triamcinolone 10mg, 20 mg, 40 mg (experimental). 18 subjects were excluded due to decline to participate. We randomized 126 subjects in 6 group. In each 5 experimental group we had 1 loss follow-up. Discontinued 1 subject in control group. 20 subjects in each group were accessed. The primary endpoint evaluated by the pain intensity scores (scale from 0-100 mm). The time intervals were accessed at 10 min, 30 min, 1 h, 2 h, 6 h, 1 d, and 7 d. Secondary endpoints were the ability to return to normal activity within 30 min, time to have the first pain medication, assessment of patient satisfaction levels on pain control at 2 h and at 24 h after intervention and adverse event effect.

Results: For the primary objective, in 1 h the pain significantly decreased in ketorolac 30 mg (p=.022), 60 mg (p=.017) as the same as triamcinolone 10 mg (p=.003) and 40 mg (p=0.008). For secondary objective, the ability to return to normal activity within 30 min was the highest in ketorolac 60 mg, ketorolac 30 mg, and triamcinolone 20 mg, respectively. Average time to normal activity was the lowest in triamcinolone 20 mg (12.35 min) and the highest in triamcinolone 40 mg (20.65 min). Time of having first pain medication was the lowest in ketorolac 30 mg for 9 h. The highest satisfaction average score at 2 h and 24 h were ketolac 30 mg and ketorolac 60 mg. 1 adverse event in control group. Subject had more pain intensity.

Conclusions: It is well established that ketorolac had a short-term benefit. It confirms that ketorolac had the same efficacy as triamcinolone. But less complication and safer than triamcinolone. Findings in this study may help the practitioners who want to avoid the side effect of steroids. However, the larger study focus on the role of ketorolac in local soft tissue injection may need to proof the concept of this study.

P494

KNEE OSTEOARTHRITIS IN PATENTS WITH HYPOTHYROIDISM: AN ULTRASOUND STUDY

A. E. Musetescu¹, P. L. Ciurea¹, A. Florescu¹, D. Calina¹, C. Gofita¹, O. C. Rogoveanu¹

¹University of Medicine and Pharmacy Craiova, Craiova, Romania

Objectives: To evaluate the musculoskeletal ultrasound (MUS) findings in knee osteoarthritis (OA) in patients with hypothyroidism.

Methods: Our study group included 26 females with mean age of 57.4 (±9.54), diagnosed with hypothyroidism, undergoing hormonal substitutive treatment. All patients had history of mechanic knee joint pain with morning stiffness lasting up to 30 min. Clinical assessment of both knees and MUS using a linear multi-frequency array probe were considered mandatory tests for inclusion in the study.

Results: Clinical examination of the knee joint showed crepitations during flexion and extension of the knee in 61.53% of patients, tenderness at palpation in 50% of cases and bulge sign

in 11.53% of patients. Uni and bilateral knee pain was present in 20.77% and 69.23% of cases, respectively. Ultrasound evaluation of both knees assessed irregularities of the margins of the articular cartilage in 69.23% of cases, with the loss of hyperechogenicity in the same percentage. "Step-up" bone cortical irregularities with femoral and tibial osteophyte aspect were described in 46.15% of patients, predominantly in the medial compartment. Protrusion of the medial meniscus with the elongation of the medial collateral ligament was discovered in 38.46% of cases. Joint effusion and Baker cysts were assessed in 26.92% and 19.23% of patients, respectively.

Conclusions: Hypothyroidism is associated with the risk of osteoarthritis and more ultrasound changes upon examination due to the fact that thyroid hormones have known effects at the cellular level on proliferation and differentiation of bone and cartilage.

P495

THE ENIGMA OF FRAGILITY FRACTURE WITH NORMAL BONE MASS: EXPERIENCE OF A LIAISON SERVICE FRACTURE UNIT

A. Naranjo¹, S. Ojeda¹, A. Saavedra¹, C. Sepulveda¹, F. Rubiño¹, A. Molina¹, T. Marrero¹, M. P. Afonso¹, N. Martin¹, A. Olivares¹, C. Rodriguez-Lozano¹

¹Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas, Spain

Objectives: Fragility fracture with normal bone densitometry (DXA) is controversial. The hypothesis varies between the fragility and a lower quality of bone. Our aim was to describe the characteristics of patients with fragility fracture and normal DXA treated in an FLS unit.

Methods: Prospective 6-y observational study of a FLS fracture unit. Demographic variables, FRAX items, DXA and TBS were collected. The characteristics of patients with normal and abnormal DXA are described. The statistical analysis was performed by means of a descriptive, comparing the normal DXA / osteopenia / osteoporosis groups by means of contingency tables, Fisher's exact test, Student's t-test or ANOVA, as appropriate, as well as regression analysis.

Results: 1631 patients were included, 205 with normal DXA (12.5%), 747 with osteopenia (45.8%) and 680 with osteoporosis (41.6%). Patients with normal DXA were characterized by a higher percentage of males, a younger age and a higher BMI. Hip fracture was less frequent in patients with normal DXA, while the frequency of other fractures was higher. The frequency of previous fracture, history of hip fracture of the parents and secondary osteoporosis was lower in patients with normal DXA. The TBS and FRAX values were higher in the cases of normal DXA compared to osteopenia and osteoporosis. In the multiple regression analysis, excluding TBS, remained significant associated with abnormal DXA age (OR 1.04; 1.03-1.06), sex (OR 2.48; 1.71-3.58), BMI (OR 0.91; 0.89-0.94) and parent hip fracture (OR 1.99; 1.11-3.58). Including TBS <1,230 as a dichotomous variable (N=451 cases) remained significant age (OR 1.03; 1.00-1.06), sex (OR 3.58; 1.81-7.10) and TBS (OR 5.23; 1.55-17.68).

Table.

	Bone densitometry		
	Normal	Osteopenia	Osteoporosis
N	205	747	680
Sex (male), N (%)**	54 (26)	140 (19)	84 (12)
Age in years, mean (DE)**	68,8 (10)	71,3 (9)	74,2 (10)
BMI, mean (DE)**	31,4 (10)	29,4 (5)	27,1 (7)
Type of fracture, N (%)			
Forearm**	75 (36)	284 (38)	206 (30)
Hip**	21 (10)	188 (25)	148 (22)
Humerus**	44 (21)	111 (15)	168 (25)
Spine*	14 (7)	61 (8)	79 (11)
Others**	51 (25)	102 (13)	76 (11)
FRAX items, N (%)			
Previous fracture**	18 (8)	111 (14)	145 (21)
Parent's hip fracture**	14 (7)	73 (10)	98 (14)
Smoking	23 (11)	92 (12)	80 (13)
Corticoids	14 (7)	51 (7)	42 (6)
Rheumatoid arthritis	3 (1)	16 (2)	16 (2)
Secondary osteoporosis**	24 (12)	117 (15)	150 (22)
Alcohol	10 (5)	40 (5)	28 (4)
>1 fall in the last year, N (%)§	65 (43)	211 (40)	200 (41)
TBS, mean (DE) **	1,220 (469)	1,166 (426)	1,115 (435)
Degraded TBS, N (%)**&	3 (5)	38 (18)	47 (25)
FRAX, mean (DE)			
Major fracture**	5 (3)	9 (5)	18 (10)
Hip fracture**	1 (1)	3 (3)	9 (8)

*P<0,05; **P<0,01; § analyzed in 1.161 patients; & analyzed in 451 patients

Conclusions: Patients with fragility fracture and normal DXA are younger, with more frequent males and with BMI and higher TBS values.

P496

CHEILECTOMY AND MOBERG-AKIN OSTEOTOMY OF THE PROXIMAL PHALANX AS TREATMENT FOR MILD AND ADVANCED OSTEOARTHRITIS OF THE FIRST METATARSOPHALANGEAL JOINT OFFERS A BENEFICIAL CLINICAL AND RADIOLOGICAL EFFECT AFTER 6 AND 12 MONTHS: A PROSPECTIVE STUDY

D. Maes¹, J. De Vil¹, A. Kalmar¹, T. Lootens¹

¹Maria Middelaes Hospital, Gent, Belgium

Objective: This study assessed the clinical and radiological outcome after cheilectomy and proximal phalangeal biplanar osteotomy in a large cohort of patients with mild and advanced stages of hallux rigidus.

Methods: A total of 105 feet (Coughlin and Shurnas grade 0 to 4) were prospectively included in this study and were treated with cheilectomy and a Moberg-Akin osteotomy of the proximal phalanx. All patients were clinically assessed preoperatively and followed up for 12 months by range of motion, VAS pain score, American Orthopaedic Foot and Ankle Society (AOFAS) score, Short Form 36 (SF-36) score, and weight-bearing radiographs. All parameters were analysed at different points in time and results for low-grade (grade <3) and high-grade (grade ≥3) hallux rigidus were compared.


Results: We observed a statistically significant (P<0.001) improvement of mobility, pain, function and quality of life for all patients and both subgroups. No significant differences in VAS scores, AOFAS scores and SF-36 scores were observed between subgroups at 12 months.

Table 1: SF-36 score, VAS pain score, AOFAS score and ROM for hallux rigidus grade < 3 and grade ≥ 3 at different points in time. Results of the overall scores are presented as mean values and standard deviations.

	n	Preoperative	5 weeks	6 months	12 months
SF-36 grade < 3	63	73.12 ± 15.78	64.93 ± 15.04 *	81.52 ± 12.64 *	84.03 ± 10.79 *
SF-36 grade ≥ 3	38	70.11 ± 15.77	64.41 ± 14.98 *	75.27 ± 18.81	79.48 ± 12.85 *
VAS grade < 3	63	5.14 ± 2.13	2.71 ± 2.23 *	2.71 ± 2.21 *	1.64 ± 1.44 *
VAS grade ≥ 3	38	6.18 ± 1.76	3.13 ± 2.17 *	2.55 ± 2.15 *	1.89 ± 2.02 *
AOFAS grade < 3	63	59.62 ± 9.74	73.51 ± 8.70 *	78.98 ± 12.71 *	84.07 ± 10.94 *
AOFAS grade ≥ 3	38	55.24 ± 10.36	72.26 ± 10.18 *	78.71 ± 10.85 *	80.38 ± 15.05 *
Active ROM gr < 3	63	44.90 ± 13.69	42.25 ± 12.98	56.14 ± 13.79 *	62.34 ± 18.68 *
Active ROM gr ≥ 3	38	36.41 ± 14.42	35.61 ± 10.71	47.50 ± 11.09 *	51.35 ± 12.98 *
Passive ROM gr < 3	63	55.29 ± 14.13	52.41 ± 13.19	65.32 ± 14.03 *	71.32 ± 17.59 *
Passive ROM gr ≥ 3	38	45.03 ± 14.56	44.82 ± 14.36	57.32 ± 14.15 *	61.57 ± 13.34 *
Passive dorsiflexion gr < 3	63	21.54 ± 9.66	24.63 ± 10.41 *	33.41 ± 13.94 *	36.59 ± 16.27 *
Passive dorsiflexion gr ≥ 3	38	13.08 ± 7.92	18.76 ± 6.67 *	27.26 ± 11.80 *	30.76 ± 12.69 *

*Significant difference compared to preoperative situation (P < 0.05).

Evolution of SF-36, AOFAS and VAS scores for low- and high grade hallux rigidus



Conclusion: Cheilectomy and biplanar osteotomy of the proximal phalanx is a safe and effective procedure with a positive effect on clinical and radiological outcome after 6 and 12 months and offers an attractive alternative for arthrodesis, even in advanced stage hallux rigidus.

P497

INTRA-ARTICULAR PTH(1-34) IMPROVED KNEE FUNCTION IN A PRECLINICAL AGING-RELATED OSTEOARTHRITIS MODEL WITHOUT AFFECTING SUBCHONDRAL BONE

C.-H. Chen¹, L.-H. Chang², S.-Y. Lin³, Y.-S. Lin³, J.-K. Chang³, M.-L. Ho²

¹Kaohsiung Municipal Ta-Tung Hospital, ²Kaohsiung Medical University, ³Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Osteoarthritis (OA) is prevalent in geriatrics and incurable. Intra-articular PTH(1-34) improved OA in papain-induced OA model. Subcutaneous PTH(1-34) is a potent agent for osteoporosis treatment and high dose of subcutaneous PTH(1-34) can alleviate OA progression. Thus, we examined the roles of PTH treatment on aging-related OA. The purposes of this study were to study whether PTH can alleviate OA progression in an aging-related knee OA in Dunkin Hartley (DH) strain guinea pigs. Specifically we set out to determine (1) whether PTH improves knee function; (2) PTH can alleviate OA progression in histological study; and (3) the effects of PTH is related to subchondral bone change or not. Fifteen 6-month-old male guinea pigs were divided into the 9M group (n=7) and the 9M+PTH group (n=8) and twelve 7-month-old male guinea pigs were divided into the 11M group (n=6) and the 11M+PTH group (n=6). The treatment right knees were intra-articular injected with 40 µl of 10nM PTH (1-34) or vehicle once weekly for 3 months until 9 month-old at both 9M and the 9M+PTH groups and till 10 month-old at both 11M and the 11M+PTH groups. Another eight 6-month-old guinea pigs and 7-month-old guinea pigs were served as young control groups, 6M and 7M respectively. The time of the guinea pigs can withstand in the treadmill were evaluated before sacrifice. The bone mass of tibia plateaus were analysis by µCT and histological study. PTH(1-34) increased the endurance in the treadmill test and GAG stain. In addition, PTH(1-34) decreased OARSI score and chondrocyte apoptosis rate. In

µCT, there was no difference in subchondral plate bone density and trabecular bone volume at metaphysis between control and treatment group both at 9 and 11 months. In this study, we further found PTH(1-34) could improve aging-related OA in guinea pig in histology by increasing GAG and decreasing OARSI score and knee function by increasing the endurance in the treadmill test. Subchondral bone plays a crucial role in the initiation and progression of OA. Previous study showed subcutaneous PTH(1-34) improved knee OA via improving subchondral and metaphyseal bone mass. In this study, we demonstrated low dose intra-articular injection PTH(1-34) improved spontaneous OA via direct cartilage effect rather than subchondral and metaphyseal bone effect.

P498

INFLUENCE OF FEMORAL NECK BONE MINERAL DENSITY ON FRACTURE RISK ASSESSMENT USING THE COUNTRY-SPECIFIC FRAX TOOL IN REPUBLIC OF MOLDOVA

V. Cazac¹, L. Groppa¹, E. Russu¹, L. Chislari¹, L. Rotaru¹

¹State University of Medicine and Pharmacy "Nicolae Testemitanu", Chisinau, Moldova

Objective: To compare 10-y major and hip fracture risk, using the local country-specific FRAX assessment tool, with and without femoral neck BMD in Republic of Moldova.

Methods: A total of 162 women and 75 men were included in the study. A careful medical history was taken, followed by physical examination, in order to assess 10-y fracture risk using the country-specific FRAX assessment tool for Republic of Moldova. Bilateral hip DXA scan was performed, followed by repeated fracture risk assessment, with added femoral neck T-score to the FRAX tool. Mean fracture risk comparison was performed, both between study groups, as well as between assessments before DXA and after DXA scan, with subsequent femoral neck T-score input.

Results: 10-y probability risk was higher in women than men. For major fractures this was true before DXA evaluation (10.9% vs. 5.4%, p<0.05), as well as after DXA evaluation (8.0% vs. 6.5%, p<0.05). A similar situation was found for hip fractures before DXA (3.9% vs. 1.2%, p<0.05), as well as after DXA (2.4% vs. 1.9%, p<0.05). When comparing mean fracture risk in women, a higher probability of fracture was determined before input of femoral neck T-score (10.9% vs. 8.0% for major fracture and 3.9% vs. 2.4% for hip fracture, p<0.05). In men, an opposite result was found, with higher fracture risk after input of femoral neck T-score (5.4% vs. 6.5% for major fracture and 1.2% vs. 1.9% for hip fracture, p<0.05).

Conclusion: Preliminary studies show that the use of the country-specific FRAX tool for Republic of Moldova, without input of femoral neck T-score values, tends to yield a slightly higher, but significant, fracture risk in women, and a slightly lower fracture risk in men, compared to the fracture risk assessment using the femoral neck T-score.

P499

ASPECTS OF RECOVERY OF LOW BACK PAIN IN THE ELDERLY PATIENTL. Vicas¹, C. D. Nistor-Cseppento¹, L. Lazar¹, F. Cioara¹¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objective: Low lumbar pain caused by muscololigamental imbalance produces static and kinetic behavior inadequate to daily demands. In a person over 60, persistence of pain can be a risk factor for his ability to cope with self-care needs. There is a correlation between age, pain, fragility, comorbidity, and later disabilities. Physical therapy is an important therapeutic tool in the prophylaxis, therapy and recovery of these painful syndromes. Most of the studies conducted and published reveal the benefits of acquiring and systematically practicing a physical exercise program and joint hygiene corresponding to the etiology, diagnosis and stage of the lumbar pain syndromes. This study aimed to measure the therapeutic effects on the quality of life and lower lumbar pain in patients over 60 years of age, with or without the genetic predisposition of fragility syndrome.

Methods: We tracked two groups of patients relatively homogeneous from the point of view of the demographic and clinical characteristics but between them in the presence of the genetic predisposition of the elderly fragility syndrome between November 2017 and November 2018. At the introduction of the study, the patients had algomatic and functional symptoms in the lumbosacral column with at least one year of age. Both groups have performed balneotherapy-based spa programs in Felix Resort, thermotherapy, masotherapy, electrotherapy and last but not least kinesitherapy and occupational therapy, applied over three decades over a 1-y period. Physical therapy was continued at home at a rate of three sessions per week. We evaluated pain, static and dynamic rash syndrome, root, dural and myofascial, global physical performance, inventory of Beck anxiety and quality of life. Data was processed statistically.

Results: The results evaluated before and at the end of the monitoring showed improvement in the statistical significance ($p \leq 0.05$) in physical performance scales, in patients with "active and healthy aging" in those with equilibrium disorders of easily controllable causes (high blood pressure, alcohol consumption, sedatives) and who have had an increased complement to the program. Patients with a poor initial physical condition with the genetic predisposition to fragility syndrome and who had anxiety with worrying potential had temporary improvements.

Conclusions: The persistence of pain in an elderly person may become a future deficit in the picture of fragility syndrome. Identifying genetic predisposition and changing lifestyle leads to improved physical condition and prevents the early appearance of fragility syndrome. Medical recovery (e.g., early mobilization, avoidance of prolonged bed rest), physical exercise and occupational therapy maintain functional and cognitive status. Completion of treatment depends on prophylaxis and professional therapy with a full team engagement

P500

LOW ONE- AND TWO-YEAR MORTALITY RATE IN ELDER HIP FRACTURE BY FRACTURE LIAISON SERVICE PROGRAMC.-H. Chen¹, S.-Y. Lin², H. Hsu³, R.-S. Yang⁴, Y.-T. Chen¹, T.-J. Fang², Y.-M. Lu²¹Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, ²Kaohsiung Medical University Hospital, Kaohsiung, ³Shu Zen College of Medicine and Management, Kaohsiung, ⁴National Taiwan University Hospital, Taipei, Taiwan

Objectives: Hip fractures cause acute pain and loss of function, and often lead to hospitalization. After acute hip surgery, in-hospital mortality may be as high as 9.5% and 1-y mortality as high as 14-36%. Therefore, care to reduce mortality after hip fracture is an important task for orthopedic surgeons. Orthogeriatric management in patients with hip fracture can reduce mortality rates as well as institutional costs through reduced length of inpatient stay. Fracture liaison services (FLS) are coordinator-based, secondary fracture prevention services implemented by healthcare systems for the treatment of osteoporotic patients. The FLS is designed to close the care gap for fracture patients and enhance communication between healthcare providers by providing a care pathway for the treatment of fragility fracture patients. This study reported one year medical effectiveness of a care model of hip fracture patients cared by orthopaedic surgeon and some complicated patients cared by with orthogeriatricians with subsequent FLS program.

Methods: This prospective cohort study was conducted at a tertiary referral hospital and a secondary referral hospital approved by the institutional review board of the hospital. All patients with fragile hip fracture who were aged ≥ 60 y and who underwent surgery between Jan 2014 to May 2016 were included in this study. When the patients had complicated medical conditions unsuitable for surgery or unstable condition after surgery, orthogeriatricians were consulted for co-care in the Orthopedic ward or they will take over the patients for further care in Geriatric ward if the patients were highly complicated for care in the Orthopedic ward. FLS was conducted after patients signed inform consent following the 13 'Capture the Fracture Best Practice Standards'. Core strategies include BMD, FRAX estimation, lifestyle consultations, screening for secondary osteoporosis, medications, and fall assessments (high risk only) provided mainly by coordinators. The FLS system is set up to remind patients to take their medications at home or to return to clinic for regular injections of medications. Major outcomes included the completion rates of BMD, vertebral fracture examination, secondary causes of osteoporosis, treatment initiation rate, and medication review. Each patient would be assessed at baseline, and every 3 months for the first year.

Results: We screened 224 patients to enroll 207 of them. Mean age was 75.12 ± 10.11 y, 73.7% were women. BMD < -2.5 were found in 184 patients. 137 (66.2%) had previous vertebral fracture. 37 patients were co-cared by orthogeriatricians with mean Charlson comorbidity index (CCI) of 3.7. Ten of them were transferred to geriatric ward for further care. We had 100% completion

rate for fall prevention services, lifestyle assessments and medication review. 191 of the 207 patients had anti-resorptive pharmacological treatment, 8 with anabolic agent and 8 with calcium and vitamin D supplement only. Among the antiresorptive medication, denosumab was used in 134 patients due to its convenience. There was no in-hospital mortality in patients participating in FLS. After during the first year, 6 patients withdrew from the study due to leaving from the care hospital or inconvenience to come back for follow-up. At the end of study, 201 patients finished the study with 196 patients survived. One-year mortality rate was 2.49% (5/201). Two-year mortality rate was 3.98% (8/201).

Conclusion: High incidence of previous vertebral fractures (66.2%) before hip fracture occurred. The results indicated treatment of vertebral fractures with antiresorptive medication such as alendronate, zoledronate or denosumab may decrease the subsequent hip fractures. The previous data of one year mortality after hip fracture was 18% in male and 11.2 in female on 2009 in Taiwan which was lower than many previous reports. Orthogeriatric management in patients with hip fracture can reduce mortality rates; however, the care capacity by orthogeriatricians was limited due to few orthogeriatricians available. Therefore careful selection of patients for orthogeriatricians co-care or transfer to Geriatric ward for further care is important. In our care model, most of the patients co-cared by orthogeriatricians had multiple comorbidities. Previous studies have demonstrated that CCI higher than 3 leads to 2.4 times higher mortality rate.

When the patients were more complicated and required frequent visits by doctors and nurses, transferring the patients to Geriatric ward were suggested. Not only doctors but also nurses in Geriatric ward are more capable of caring patients having multiple medical underlying diseases than doctor and nurse in Orthopedic ward. Experienced nurses in Geriatric ward are alert and able to find the medical situation changes of patients than nurses in Orthopedic ward. With the co-care of patients with multiple comorbidities by with orthogeriatricians with subsequent FLS program, the one year mortality rate decrease to 2.49% (5/201) and two year mortality rate was 3.98% (8/201). FLS was able to increase the rates of assessment of BMD for bone health and the rates of osteoporosis treatments in elderly with high fracture risks. This co-care model with orthogeriatricians in high risk patients who usually had multiple comorbidities with subsequent FLS program increased the treatment rate of underlying disease and therefore reducing mortality after hip fracture. Co-care care with orthogeriatricians program also can enhance the ability of orthopedic surgeons for the management of medical condition of patients. With meticulous reviews of medical underlying disease, the patients were advised to receive follow-up at geriatric or medical clinic after discharge. Keeping treatment of comorbidities after discharge may be the important factor to reduce mortality. FLS program can efficiently follow not only the treatment of osteoporotic fractures, but also encourage patients to keep treatment of their comorbidities at geriatric or medical clinic.

P501

LOW BONE QUALITY IN POSTMENOPAUSAL WOMEN WITH TYPE 2 DIABETES WITH OR WITHOUT ANTIRESORPTIVE THERAPY

D. J. Chung¹, J. O. Chung¹, D. H. Cho¹

¹Chonnam National University Hospital, Department of Internal Medicine, Gwangju, South Korea

Objective: Type 2 diabetes is a risk factor for osteoporotic fracture. In addition to increased falling risk due to various diabetic complications, decreased bone quality such as bone microstructure is thought to be an important contributing factor. Trabecular bone score (TBS) is a novel texture index that evaluates the pixel gray-level variations in lumbar spine DXA images and is related to bone microarchitecture independent of BMD.

Methods: We investigated lumbar spine TBS as an indicator for skeletal microarchitectural deterioration in type 2 diabetes. We included 86 type 2 diabetic and 212 nondiabetic Korean postmenopausal women older than 50 y with or without antiresorptive medications who visited the Chonnam National University Hospital. Medical records were reviewed retrospectively. Serum 25OHD, CTX, osteocalcin and other laboratory data were acquired after overnight fasting. BMD was measured at the lumbar spine using DXA (Hologic Discovery-Wi). All TBS measurements were performed retrospectively using the TBS iNsight Software, ver. 3.0.2.0 (Med-Imaps) using spine DXA files from the database.

Results: The number of patients with antiresorptive drugs and duration of medication use were not significantly different between diabetic and nondiabetic women. Lumbar spine BMD was higher in type 2 diabetic women (0.828 ± 0.170 vs. 0.750 ± 0.107 g/cm², $P < 0.01$) than in nondiabetic women, whereas lumbar spine TBS was not significantly different between two groups (1.329 ± 0.077 vs. 1.328 ± 0.071). Both serum osteocalcin (14.40 ± 7.11 vs. 17.11 ± 8.30 ng/ml, $p < 0.01$) and CTX (0.250 ± 0.135 vs. 0.300 ± 0.186 ng/ml, $p < 0.05$) levels were significantly lower in diabetic women than in non-diabetic women. Serum 25OHD level was similar between two groups (22.5 ± 11.2 vs. 24.7 ± 10.2 ng/ml).

Conclusion: Although lumbar spine BMD was higher in diabetic women, lumbar spine TBS was not different between diabetic and nondiabetic women with or without antiresorptive medications. It suggests deterioration of bone microarchitecture in diabetic women when considering the higher BMD status.

P502

CORRELATION OF VITAMIN D STATUS AND NEWLY DEVELOPED OSTEOPOROTIC FRACTURES IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS DURING A YEAR OF BISPHOSPHONATE THERAPY

L. Aleksic¹, S. Stojanovic¹, B. Stamenkovic¹

¹Institute for Treatment and Rehabilitation "Niska Banja", Nis, Serbia

Objectives: Vitamin D, its active metabolites and analogues represent the group of compounds with numerous functions within the organism. The primary role of vitamin D is in the metabolism

of phosphorus and calcium. It is also known that vitamin D helps with bone formation. Osteoporosis is a generalized bone disease characterized by disordered bone stiffness increases causing a predisposition to fractures. Vitamin D status within the organism is determined by measuring the level of 25(OH)D in the serum. The purpose of this research was to determine the status of vitamin D in women with newly diagnosed postmenopausal osteoporosis and to determine the correlation of vitamin D status and newly developed osteoporotic fractures after 12 months of bisphosphonate therapy.

Methods: The research included 104 women with newly diagnosed postmenopausal osteoporosis and who haven't taken vitamin D as prevention of osteoporosis. The examinees were prospectively followed for 12 months, during which they were at the following therapies: bisphosphonate (alendronate 70 mg weekly or ibandronate 150 mg monthly), vitamin D 800 IU daily. All the examinees were determined with the level of 25(OH)D by ELISA method. All of the examinees were defined with their BMD on the lumbar spine and hip, measured with DXA on the Hologic Discovery machine. New fractures were confirmed by a radiographic image.

Results: The examined group consisted of 104 women with newly diagnosed postmenopausal osteoporosis and with insufficiency, deficiency and normal status of vitamin D. Average age of the examinees was 63.56 ± 7.35 , average duration of menopause was 13.74 ± 8.35 y and average value of 25(OH)D was 47.46 ± 10.52 nmol/L. With all examinees the level of Ca, P and ALP in serum and level of Ca and P in 24-h old urine were in reference limits. A normal vitamin D status was found in 12 examinees (11.54%), deficiency of vitamin D in 81 (77.89%) and insufficiency of vitamin D in 11 (10.57%). In the group of 11 examinees with vitamin D insufficiency, 4 of them (36.36%) had fractures, before the start of therapy; in the group of 81 women with vitamin D deficiency 18 of them (22.22%) had fractures; in the group of 12 women with normal vitamin D status fractures had 2 of them (16.67%). The difference between compared groups was statistically significant ($p < 0.01$). After 12 months of bisphosphonate therapy, in the group of examinees with vitamin D insufficiency, 2 of them (18.18%) received new osteoporotic fractures (in total 54.54%); in the group with vitamin D deficiency, new osteoporotic fractures received 2 of them (2.47%) (in total 24.69%); in the group with normal vitamin D status, not even one examinee did not receive a new osteoporotic fractures. The difference between compared groups was statistically significant ($p < 0.01$). Univariate and multivariate logistic regression analysis showed that the initial level of 25 (OH) D as an important predictor of the presence of new fractures occurred during the 12 months of bisphosphonate therapy and that any initial increase in 25 (OH) D for 1 nmol/l was associated with a reduction in the risk of new fractures by 1.6%.

Conclusion: Our results show that the insufficiency and deficiency of vitamin D in women with postmenopausal osteoporosis represent a significant risk factor for osteoporotic fractures.

The initial vitamin D status was significantly associated with the newly developed osteoporotic fractures after 12 months of bisphosphonate therapy.

P503

COMPARISON OF OSTEOPOROSIS IN SAUDI FEMALE PATIENTS WITH BRONCHIAL ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

M. Z. Zaghoul¹, E. B. Barakat¹, S. A. Abdulatif¹, G. E. Elfayoumi²

¹Saudi German Hospital, ²King Fahd Hospital Jeddah, Jeddah, Saudi Arabia

Objectives: Comparison of osteoporosis in Saudi female patients with bronchial asthma and chronic obstructive pulmonary disease. To compare the degree of osteoporosis in Saudi females with bronchial asthma (BA) and those with chronic obstructive pulmonary disease (COPD) who had never received systemic corticosteroids.

Methods: A total of 176 Saudi female patients with bronchial asthma (n=96) and COPD (n=80) or who had not received systemic corticosteroids were enrolled in the study with (mean age, 54.6 ± 4.2 y). All patients received chest physiotherapy, at Saudi German Hospitals, Jeddah. Medina, Riyadh, KSA. Total body and lumbar BMD were measured by DXA, and the data were compared between the two groups. Serum levels of osteocalcin and total urinary deoxyypyridinoline were measured in urine samples. Blood calcium, phosphate, total protein, albumin, BUN, creatinine, alkaline phosphatase, and urinary concentration of calcium, phosphate and creatinine were measured. BMI was calculated in all patients. In addition, the association between bone mass and clinical variables was determined.

Results: When lumbar BMD was expressed as a Z-score, the Z-scores of patients with COPD were significantly lower than those of patients with BA ($p < 0.01$). The T-scores of patients with chronic obstructive pulmonary diseases (-2.54 ± 0.32) were significantly lower than those of patients with bronchial asthma (-1.01 ± 0.35) ($p < 0.01$). The prevalence of osteoporosis was also significantly higher in patients with COPD ($p < 0.05$). In patients with COPD, BMI was positively correlated with BMD in the lumbar spine ($p = 0.02$) and total body ($p < 0.03$).

P504

BCOR SARCOMA: BREAKING THE NEW GROUND

A. Nuño Alves¹, J. Martínez Trufero¹, M. E. Ortega Izquierdo¹, A. Urgel Granados², A. Antón Torres¹

¹University Hospital Miguel Servet, Zaragoza, ²University Hospital Obispo Polanco, Teruel, Spain

Objective: To review BCOR sarcomas and the main clinical, histological, prognostic and treatment options.

Methods: We present a review of a clinical case of a 19-year-old male diagnosed of BCOR-CCNB3 Ewing-like sarcoma, who was treated with immunotherapy. This led to a review of this emerging entity.

Results: A 19-year-old male who underwent an infracondylar amputation for an undifferentiated fusiform and round cell sarcoma, pT1apNXpMX. He was treated with adjuvant chemotherapy and he

was followed up. Five months later a CT revealed 4 lung nodules, the FDG - PET CT was positive for metastatic disease; therefore he underwent thoracic surgery. A year later the CT demonstrated a mass in the superior left lung, a paratracheal implant and another subcarinal mass. He was enrolled in the phase I-II trial (GEIS 52) with the combination of sunitinib plus nivolumab. In the clinical trial, there was a histologic review with NGS (next generation sequencing) and a genetic fusion BCOR-CCNB3 was identified. After 8 months of treatment, during which imaging changes were acknowledged, CT revealed progression disease. He was started on chemotherapy. Actually, the patient has responded to chemotherapy and presents partial response.



The sarcoma classification is very complex. The discovery of genomic alterations has added an important biologic perspective and has expanded the spectrum of some diagnostic subgroups.

Ewing sarcoma represents the prototypical round cell sarcoma. Approximately 90% of Ewing sarcomas harbor t(11;22) (q24;q12) leading to EWSR1-FLI1 fusion. BCOR is associated with the BCL6 oncoprotein and with a variety of histone modifying enzymes, suggesting that it acts as a gene expression suppressor, through epigenetic mechanisms. BCOR rearranged sarcomas arise most frequently in bone and soft tissue of children with a mean age of 13-15 y and are more common in male patients. BCOR-rearranged sarcomas are usually treated following Ewing sarcoma therapeutic

guidelines. The prognosis has been difficult to determine. In some series the survival of BCOR-CCNB3 sarcoma is 75% at 5 years.

Conclusions: BCOR sarcomas are an infrequent pathology from which little is known. Is immunotherapy an effective treatment? Are they more sensitive to chemotherapy retreatment?

P505

OVERWEIGHT/OBESITY IN CHILDHOOD AND ADOLESCENCE DOES NOT NEGATIVELY AFFECT BONE MASS ACCRUAL IN ADOLESCENCE. THE TROMSØ STUDY: FIT FUTURES – A NORWEGIAN LONGITUDINAL COHORT STUDY

E. Evensen¹, A. Winther¹, N. Emaus²

¹University Hospital of North Norway, ²UiT The Arctic University of Norway, Tromsø, Norway

Objective: The implication of increasing prevalence of overweight and obesity among children is still a concern regarding future bone health. The objective was therefore to study the relationship between childhood and adolescent BMI and bone accrual in adolescence, in absolute terms.

Methods: This longitudinal study included 633 adolescents (48% girls) from The Tromsø Study - Fit Futures, a population-based cohort study conducted in 2010-2011 and 2012-2013 in Norway. From childhood health records, we retrospectively collected height and weight at two ages. BMI were calculated and categorized according to International Obesity Task Force cutoff values for children. Bone mineral content (BMC, g) and areal BMD (aBMD, g/cm²), was measured at total hip (TH) by DXA At mean age 16.5 and 18.5 y. By fitting linear mixed models, we evaluated associations between BMI categories: underweight, normal weight and overweight/obesity and repeated measurements of BMC and aBMD as continuous outcomes. All sex stratified analyses were adjusted for height and bone area, additionally at 16.5 y, for pubertal maturation and physical activity.

Results: The prevalence of overweight/obesity combined was 11.4%, 17.6% and 22.2% in girls, 8.0%, 10.4% and 22.0% in boys at 2.5, 6.0 and 16.5 years of age, respectively.

Compared to normal weight, overweight/obesity at 6.0 and 16.5 y of age were associated with higher TH BMC and aBMD at 16–18 years of age. Girls: TH BMC (95%CI): 1.87 (0.76, 2.98), 2.99 (1.97, 4.01), aBMD (95%CI): 0.06 (0.02, 0.09), 0.09 (0.06, 0.13) at 6.0 and 16.5 y of age, respectively. Boys: TH BMC (95%CI): 0.87 (-0.99, 2.73), 3.11 (1.88, 4.34), aBMD (95%CI): 0.02 (-0.03, 0.07), 0.08 (0.05, 0.12). We found no significant association between BMI category at 2.5 y of age and BMC and aBMD in adolescence.

Conclusion: Overweight/obesity at 6.0 and 16.5 y of age were positively associated with higher BMC and aBMD in adolescence. No negative effect of overweight/obesity was observed on TH bone mass accrual in adolescence.

Acknowledgment: This work was supported by a grant from the Northern Norway Regional Health Authority (grant number SFP1226-15).

P506

EFFECTS OF EXERCISE ON QUALITY OF LIFE AND MOOD IN ELDERLY WITH SARCOPENIA: A RANDOMIZED CONTROLLED TRIAL

M. Tsekoura¹, E. Billis¹, E. Tsepis¹, C. Matzaroglou¹, Z. Dimitriadis², M. Tyllianakis³, E. Panagiotopoulos³, J. Gliatis³

¹Technological Educational Institute of Western Greece, Physiotherapy Department, Aigio, ²Hospital Attikon, Physiotherapy Department, Athens, ³University Hospital of Patras, Department of Orthopaedics Surgery, Rio, Greece

Objective: To investigate the effects of a 12 week group-based vs. home-based exercise programme on quality of life (QoL) and mood (anxiety and depression) among Greek sarcopenic individuals 60 years old and over.

Methods: 54 elderly (47 women, 7 men; aged 72.87±7 y) were randomly assigned to one of three interventions: supervised group exercise (n=18), individualized home-based exercise (n=18) and control group (n=18). Participants were diagnosed sarcopenic based on the algorithm developed by the European Working Group on Sarcopenia in Older People. Body composition was determined using bioelectrical impedance analysis, Handgrip strength (HGS) was measured using a standard hydraulic hand dynamometer and gait speed with the 4m test. QoL was assessed with Greek Sarcopenia Quality of Life (SarQoL_GR) questionnaire while mood via Hospital and Anxiety and Depression scale (HADS). All participants were assessed at baseline, immediately post-intervention (week 12), and at 3 months post-intervention (week 24). Ethical approval was given by the Ethics Committee of the School of Health and Welfare of the Technological Educational Institute (TEI) of Western Greece. The study has been registered at www.isrctn.com following identification number: ISRCTN92538100.

Results: Comparison between pre- and post- intervention changes in QoL and mood (at 12 and 24 weeks) showed significant group x time interactions (p<0.001). Participants on the group-based programme improved in QoL by 12.77% while participants in the home-based programme improved by 6.05%. Participants in the group programme improved in domains: 'Physical and Mental Health' (p≤0.05), 'Locomotion' (p≤0.05), 'Functionality' (p≤0.05), 'Fears' (p≤0.05) and 'Activities of Daily Living' (p≤0.001). Additionally in the questionnaire's domains, group-based exercise programme was superior to home-based exercise only in the 'Activities of Daily Living' domain. In terms of depressive and anxiety symptoms (HADS questionnaire), greater improvements in mean scores favored the group-based program compared to the home-based program (at 12 and 24 weeks).

Conclusions: Results suggest that exercise is beneficial for sarcopenic elderly. Supervised group-based exercise seems to be superior to home-based exercise therapy for QoL and anxiety and depression.

P507

MUSCLE STRENGTH AND BODY COMPOSITION IN OSTEOPOROTIC PATIENTS WITH VERTEBRAL FRACTURES

E. V. Makarova¹, L. A. Marchenkova¹, L. R. Shakurova¹, M. A. Eryomushkin¹, E. I. Chesnikova¹, D. V. Razvalayeva¹, E. M. Styazhkina¹

¹National Medical Research Center of Rehabilitation and Balneology, Moscow, Russia

Objective: To evaluate the degree of muscle dysfunction and relationship of trunk muscle strength and body composition in patients with osteoporotic vertebral fractures (VFs).

Methods: Study comprised 90 men and woman 40-80 years old with primary osteoporosis. Study group (n=60) included patients with at least 1 VF (confirmed by X-rays), control group (n=30) consisted of osteoporotic patients of the same age, BMI and BMD without any fracture. Trunk muscles strength was measured with tensodynamometry at Back-Check Dr. Wolff diagnostic unit. Body composition was evaluated by DXA Total Body. Muscle function was evaluated with up-and-go test, 10m walk test, testa for static and dynamic of back and abdomen muscles.

Results: Patients with VFs had a significant muscle strength deficiency in trunk flexors (TF) -40.9% and extensors (TE) -18.1% with an adequate function of the left (LLF) and right lateral flexors (RLF). Patients in study group had lower muscle strength vs. controls in TF (15.6±9.8 vs. 27.7±9.9 kg, p<0.001), TE (14.6±8.9 vs. 21.3±8.4 kg, p<0.001), LLF (13.1±7.2 vs. 24.1±8.9 kg, p<0.001) and RLF (13.4±7.4 vs. 24.3±7.7 kg, p<0.0001). No significant difference in functional tests results were registered (p>0.05). Body composition analyses showed differences between study and control groups in relative skeletal muscle index (RSMI, 6.5±1.2 vs. 7.5±2.1 kg/m², p=0.02) and fat mass (29717±8367.4 vs. 35464±9127.4 g, p=0.01). There was no significant difference in soft tissue mass and lean (muscle) mass between groups. Strength of all studied trunk muscles strongly negatively correlated with the number of VFs (p<0.001) and positively correlated with femoral neck BMD (g/m²), fat mass, soft tissue mass and lean mass (p<0.001), but not with age and RSMI (p>0.05).

Conclusions: Patients with VFs have a decrease in trunk muscles strength and lower RSMI, mass and% of body fat in compared with patients without fractures. Number of VFs, low BMD, fat mass, soft tissue mass and lean mass are the main factors of trunk muscle dysfunction in osteoporotic patients. Functional tests showed less specificity for estimation of muscle function than tensodynamometry.

P508

MULTIPLE BONE INFARCTS WITHIN THE PPP SYNDROME CONTEXT: A HARDLY KNOWN BONE AFFECTATION – A CASE REPORT

I. Calvo¹, O. Ibarquengoitia¹, D. Montero¹, L. Vega¹, M. L. García¹, E. Galindez¹, O. Fernandez¹, E. Ruiz¹, C. Perez¹, I. Torre¹, A. R. Intxaurbe¹, E. Cuende¹, J. M. Blanco¹

¹Rheumatology, Basurto University Hospital, Bilbao, Spain

Objectives: The triad formed by polyarthritis, panniculitis and pancreatitis is known as PPP syndrome. The typical patient is a middle-aged man who starts with low limbs polyarthritis and has previous history of alcohol abuse and pancreatitis. Laboratory findings include elevation of acute phase reactants (APR) and pancreatic enzymes. MRI typically shows intraosseous fat necrosis and lytic lesions are usual in plain radiography in late stages. Our aim was to review and describe 2 PPP syndrome cases and their main epidemiological and clinical characteristics diagnosed in our hospital.

Results: First patient was a 65 years old man with history of heavy alcohol abuse, chronic pancreatitis and panniculitis. He developed acute ankle arthritis. He denied fever, trauma or skin involvement. Laboratory examination showed elevated erythrocyte sedimentation rate, C-reactive protein and lipase. Amylase and white blood cells rates were normal. In plain radiography multiple osteolytic lesions in tibia, peroneal malleolus and calcaneus could be seen. MRI showed multiple foci of serpiginous peripheral low signal due to granulation tissue within the marrow of the affected bones compatible with multiple bone infarcts. Gammagraphy revealed an increased uptake at periphery of calcaneus, ankles and distal left femur with granular pattern. Given the previous pancreatitis and panniculitis diagnosis and current diagnosis of arthritis due to bone infarct he was diagnosed with PPP syndrome. Treatment with steroids and NSAIDs was started with complete resolution. Second patient was a 60 years old woman. She had alcohol abuse history, chronic pancreatitis and panniculitis. The patient developed acute swelling of the left knee. MRI showed multiple bone infarcts in distal femur, tibia and patella. Amylase, lipase and APR were elevated.

Conclusions: PPP syndrome is a rare cause of multiple bone infarcts and arthritis. Differential diagnosis includes other infarcts causes as corticoids, post-radiation, sickle cell disease, Caisson disease, etc. Most patients have none abdominal symptoms, leading to a delay in diagnosis. An early treatment of pancreatitis is necessary to prevent the release of enzymes to the systemic circulation and avoid bone involvement. Despite being an infrequent syndrome, physicians should consider it.

P509

EFFECTS OF WEIGHT LOSS ON FUNCTIONAL TESTS IN PATIENTS WITH OBESITY

V. Vasileva¹, L. Marchenkova¹, M. Eryomushkin¹, E. Makarova¹, L. Shakurova¹

¹FSBI National Medical Research Center for Rehabilitation and Balneology of the Ministry of Health of Russia, Moscow, Russia

Objective: To estimate the changes in functional tests in patients with obesity after the weight loss.

Methods: 80 patients aged 21-69 (52.4±11) y, with obesity (BMI>30 kg/m²) were enrolled in the study. The average weight was 111.3±24.5 kg, BMI was 40.3±8.1kg/m², waist girth (WM) was 113.4±16 cm, hip girth (HG) was 124.2±16 cm. All patients undergo height and weight measurements, BMI calculation, WG and HG measurements; walking speed (WS) was estimation by 10m walk test; lower extremities strength was estimated by up-and-go test; tests for back and abdomen static and dynamic muscle endurance were performed. Measurements and tests were performed at baseline and past 21 d, after the rehabilitation program. The rehabilitation program included 4 Methods: 1) interactive sensomotor trainings on COBS platform (Physiomed, Germany), daily, 15 min, #10; 2) kinesiolydrotherapy in a pool, daily, 30 min, #10; 3) complex of physical exercises in a gym, daily, 30 min, #10; 4) Ergocycle trainings, daily, 20 min, #10.

Results: In comparison with baseline data, after the rehabilitation program there was significant reduction in body weight (111.32±24.48 kg vs. 107.96±23.13 kg, p=0.000), reduction of BMI score (40.3±8.13 kg/m² vs. 39.14±7.7 kg/m², p=0.000), thinning of WG (113.42±15.97 cm vs. 109.29±15.14 cm, p=0.000) and HG (124.17±15.55 cm vs. 119.75±14.17 cm, p=0.000). There was great improvement in WS (0.84±0.15 m/s vs. 0.88±0.17 m/s, p=0.000) according to 10m walk test; increase in lower extremities muscle strength (8.43±2.18s vs. 7.9±2.1s, p=0.000) according to up-and-go test. Higher static endurance of abdomen muscles (13.09±9.71 s vs. 16.49±12.8 s, p=0.000) and back muscles (14.84±11.93 s vs. 18.67±14.9 s, p=0.000) were stated. Higher dynamic endurance of abdomen muscles (29.92±11.24 times vs. 34.84±11.93 times, p=0.000) and back muscles (9.07±7.42 times vs. 12.18±9.23 times, p=0.000) were stated.

Conclusions: Body weight loss in patients with obesity is associated with improvement in walking speed, static and dynamic muscle endurance, increase in lower extremities strength. Those changes improve balance function and decreases risk of falling.

P510

OSTEOPOROSIS AND RISK OF LOW BONE MINERAL DENSITY IN UNTREATED FEMALE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

S. T. J. Tofiloska Josifoska¹, T. B. P. Bajraktarova Prosheva², S. J. Jordanova¹

¹Clinical Hospital Internal, Shtip, ²Clinical Hospital Endocrinology, Skopje, Macedonia

Objective: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by chronic inflammation and multisystem damage. Studies in various parts of the world have shown osteoporosis and low BMD in patients with SLE, especially in female patients. In several incisions, osteopenia is found in 7% to 62% of patients with SLE and osteoporosis in 3% to 28% of patients with SLE. BMD reduction was observed in patients with SLE. **Purpose** of this study was to investigate the incidence of osteoporosis and osteopenia in untreated female patients with SLE using DXA and to identify the possible risk factors associated with low BMD in patients with SLE.

Methods: 11 untrained patients with SLE for 2 y. In this follow-up, osteoporosis was defined as the T-score or Z-score ≤ -2.5 in the lumbar spine or total hip and osteopenia as a T-score or Z-score < -1 , but > -2.5 .

Results: Osteopenia was present in 6 patients with osteoporosis in 3 patients with SLE untreated. 2-y follow-up of patients confirmed that the incidence of nonvertebral and vertebral fracture in patients SLE was 1.26 and 0.94. The prevalence of spinal fracture in SLE ranged between 10% and 20%. These fractures can cause disability and contribute to a significant reduction in quality of life.

Conclusion: Patients with SLE are at increased risk of bone loss and fractures for many reasons. Old age, postmenopausal status and low BMI have been found to be possible risk factors for osteoporosis in SLE. Furthermore, chronic inflammation, immobility, and vitamin D deficiency due to a lack of sun exposure and glucocorticoid treatment may be frequent factors that significantly increase the risk of osteoporosis in these patients being either treated or untreated.

P511

HIP FRACTURES AND MEDIATORS OF LOW BONE MINERAL DENSITY IN MULTI-ETHNIC SINGAPORE WOMEN

E. Yong¹

¹National University of Singapore/Obstetrics & Gynecology, Singapore

Objective: Hip fractures result in increased morbidity, disability and mortality risks amongst elderly women. Menopausal osteoporosis as identified by BMD measurement correlates closely with risk of hip fractures. Studying hip fracture trends amongst Singapore's multi-ethnic population of Chinese, Malays and Indians enable a comparison of hip fracture incidence and BMD across three major ethnic groups of rapidly ageing Asian women.

The aim of this study was to identify those at highest risk of hip fractures in Singapore using nationwide inpatient databases, and determine mediators for antecedent low BMD in Chinese, Malay and Indian women.

Methods: Hip fractures in Singapore from 2000-2017 were examined using national medical insurance claims among female residents aged ≥ 50 y. Mediators for low BMD were studied in a prospective cohort (n=1201) of midlife Singaporean women (45-69 y) where information on variables affecting bone health were collected using standardized questionnaires, physical measurements and validated performance tests (Thu, 2018). BMD of the hip was measured using DXA.

Results: During the years 2000-2017, 24,902 first hip fractures in women were recorded in Singapore. Chinese women had 1.4- and 1.9-fold higher age-adjusted rates than Malay and Indian women: 264 (95%CI; 260, 267) vs. 185 (95%CI; 176, 193) and 141 (95%CI; 132, 150) fractures/100,000/year, respectively. Despite their higher fracture rates, Chinese women were the only ethnic group exhibiting a decline in age-adjusted fracture rate of -5.3 (95%CI; -6.0, -4.5) fractures/100,000/year. In contrast, no significant changes in hip fracture rates were observed in Malay or Indian women over the same period. In a prospective cohort of midlife women, Chinese had significantly lower femoral neck BMD than Malay and Indian subjects. Of the more than 20 variables examined, age, BMI, and height accounted for almost all the observed ethnic differences in femoral neck BMD between Chinese and Malays.

Conclusions: Although the absolute number of fractures increased, steep drops in elderly Chinese, but not Malay or Indian, women drove a reduction in overall age-adjusted hip fracture rates. BMD in middle-aged Asian women differ by ethnicity. Particular attention should be paid to underweight women of Chinese ethnic origin, who are at highest risk of osteoporosis at the femoral neck and hence hip fractures. Increases in the older population will lead to a rise in total number of hip fractures, requiring budgetary planning and new preventive strategies.

Reference: Thu WPP et al. Int J Epidemiol 2018;47:389

P512

PROSPECTIVE, MONOCENTRIC, POST-CE MARK STUDY TO ASSESS EFFICACY AND SAFETY OF HYMOVIS® ONE (32MG/4 ML) INTRA-ARTICULAR INJECTION IN ACTIVE PATIENTS AFFECTED BY KNEE OVERUSE SYNDROME

A. Bernetti¹, V. Santilli¹

¹Sapienza University Rome, Rome, Italy

Objective: Knee chondropathy is often a pathological manifestation of a joint overload in people who play sports involving strong mechanical stress to the lower limbs. In this context, the management of osteoarthritis (OA) is crucial, especially considering the impact of this disease in terms of functional limitation and disability. Nowadays, the intra-articular (i.a.) injections of chemical modified hyaluronic acid (HA) (Hymovis) is increasingly widespread. This innovative MO.RE. (mobile reticulum) technology acts both from a biological and i.a. physical level. Hymovis

(24mg/3ml) given as 2 weekly i.a. injections has been shown to be efficacious and well tolerated for the treatment of pain associated with knee OA1. However, sport players require a quick return to play and are rarely compliant in long term treatments and in long time of rest. On this view, a single injection is justified to improve patient compliance and convenience and to increase the safety. Up to date, no available studies analysed the changes in knee pain correlating this parameter with knee function and biomechanics, in regular casual sport players affected by knee overuse syndrome that underwent a single i.a.-HA injection. The aim of this study is to evaluate the efficacy and safety of Hymovis ONE (32 mg/4 ml) single i.a. injection, in the management of pain caused by knee osteochondral lesions.

Methods: 31 patients (23 male, 8 female), were enrolled and treated at the Physical Medicine and Rehabilitation Outpatient Clinic of our Department. All patients enrolled performed a clinical (VAS, WOMAC, KOOS) and biomechanical (Gait Analysis) evaluation at the baseline. At this stage all the patients underwent a single i.a. injection of Hymovis ONE (32 mg/4 ml). The same evaluations were repeated through 4 follow-up visits (1, 3, 6 and 12 months after injection). Primary outcome was to demonstrate that a single i.a. injection of Hymovis ONE (32 mg/4 ml) decrease the difficulties in sport and recreational activity. The outcome measure is represented by the fourth item (SP1-SP5) of the KOOS questionnaire 90 days after injection. An objective secondary outcome was used to assess biomechanical parameters through gait analysis system.

Results: 23 patients completed the 12 months follow-up. However, after 1 month each patient resumed the sport activity practiced according to (SP1-SP5) KOOS item ($p<0.001$), from this point of view the primary outcome of the study was completely achieved. Furthermore, after 1 month follow-up there was a statistical improvement of VAS ($p<0.001$), WOMAC A ($p<0.001$) and C ($p<0.001$) subscales values. These results have been maintained also at the final follow-up visit after 12 months ($p<0.001$). Biomechanical results show a statistically significant improvement of spatial-temporal parameters (step and stride length, walking velocity, cadence). No patients reported adverse events.

Conclusions: Results suggest the efficacy and safety of Hymovis ONE (32 mg/4 ml) single i.a. injection, in the management of knee pain caused by osteochondral lesions in young active patients, representing a valid therapeutic strategy in the treatment of this kind of patients.

Reference: 1 Benazzo F et al. Eur Rev Med Pharmacol Sci 2016;20:959

P513

EPIDEMIOLOGY OF OSTEOPOROTIC NONVERTEBRAL FRACTURES IN MOLDOVA. POPULATION-BASED LONGITUDINAL STUDY

A. G. Zakroyeva¹, O. M. Lesnyak², V. Cazac³, L. Groppa³, E. Russu³, L. Rotaru³, L. Chislari³, H. Johansson⁴, N. C. Harvey⁵, E. V. McCloskey⁶, J. A. Kanis⁶

¹Ural State medical university, Ekaterinburg. Russia, ²Mechnikov North West State Medical University, St. Petersburg. Russia, ³State University of Medicine and Pharmacy "Nicolae Testemitanu", Kishinev. Moldova, ⁴Institute for Health and Ageing, Catholic University of Australia, Melbourne, Australia, ⁵MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton. UK, ⁶Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK

Objective: The osteoporosis (OP) and the colossal medical and economic consequences of fragile fractures is a challenge to modern healthcare systems due to the people aging and the growth of social and health problems associated with it. The purpose of the study was to investigate the incidence of major nonvertebral fragile fractures (hip, distal forearm) in Republic of Moldova and to compare it with the OP fracture rate in neighbor's country Romania as well as with some other Eastern European and Central Asian Russian-speaking countries where the epidemiologic data are robust and the osteoporotic fractures has been studied well.

Methods: The investigation was the part of the Multicenter Multi-national Study in Eurasia Countries (EVA study). Its methodology provides precise definition of all major nonvertebral osteoporotic fractures quantity for further FRAX model creation for each country. The Republic of Moldova since 2010 has significantly facilitated the development of injury data surveillance systems It allowed us to carried out the retrospective population-based study covered 24-month period (from 1 January 2011 to 31 December 2012). In both settings, the medical records of all fractures in men and women aged 40 years or older were provided from the central city hospital registers, the outpatient trauma unit data, and emergency service data according to ICD-10 codes. The data on the following low energy fractures were collected: hip (ICD-10 codes S72.0, S72.1, S72.2), distal forearm (S52.5, S52.6) and humerus (S 42.2) fracture Cases of high energy fractures were excluded from the analysis.

Results: In 2011-2012 among people older than 40 y we identified a total of 1515 fractures of which 340 were hip, 197 – humerus, 494 – distal forearm and 484 – ankle fracture. The forearm fractures were the most frequent, their incidence reached 367.3 (515.0 and 171.1 per 100,000 for women and men respectively) that was 1.4 times higher than the hip fracture and 2.4 times higher than the humerus fracture rates. The peculiarity of the forearm fractures epidemiology was the peak character of their age distribution with maximal rate in 60-year-old women and men and its subsequent gradual diminishing. The ratios in age-standardized incidences of forearm/hip fractures in Moldova in were 1.4 times higher and in women 1.8 times higher than would be predicted

from the incidences of hip fracture using “Malmo ratio” indexes. In comparison with the Russian-speaking countries of EVA project the indexes “Distal forearm/Hip ratio” and “Humerus/Hip ratio in Moldova were 1.5-2 times higher than in Armenia for both sexes, but 1.5-2 times lower than in Russia. At all the annual incidence of hip fractures in individuals older than 50 y was 293.9 and 239.0 for women and men per 100,000 respectively that was 1.7 and 1.8 times higher than in neighbor country Romania. The main epidemiologic features of the hip fracture age and sex distribution were the similar to countries of the EVA project: Russia, Armenia, Belarus. The annual estimated number of OP hip fracture in Moldova in 2015 was 3749 and it is predicted to increase to 6327 in 2050. The nonstandardized incidence of low energy humeral fractures was 204.2 and 92.4 for women and men per 100,000 acc.; it was the rarest type of fragility fractures we recorded in Moldova.

Conclusion: Epidemiologic characteristic of OP fractures in Moldova significantly distinguishes from the neighbor Romania by a higher incidence of all type fragile fractures. Among EVA-project Eurasia countries with the valid epidemiological data the Republic of Moldova has the highest incidence of hip fracture (293.9 and 239.0 for women and men per 100,000). It allows Moldova to be classified as a country with the high level of OP fracture rate. The other characteristic of Moldavian epidemiology is the predominance of forearm fractures in the structure of low energy fractures. It is much closer to Russian population-based epidemiologic trends, than to the parameters of geographically similar rural country of Armenia and West European region and requires future exploration

P514

BOOTS STUD SHAPE ON FOOT LOADING USING BIOMECHANICAL ANALYSIS

Z. Y. Li¹, S. R. Shao¹

¹Ningbo University, Ningbo, China

Objective: Several studies had revealed the effects of different soccer stud configurations on biomechanical characteristics. Therefore, the purpose of this study was to investigate the effect of different stud shaped football shoes on lower limb kinetics during straight-ahead running and 45° left sidestep cutting movements.

Methods: 12 male football players were recruited from university football teams. They were asked to perform six trials under a straight-ahead running and a 45° left sidestep cutting conditions while wearing football shoes with knife studs (KS), triangle studs (TS) and round studs (RS) with firm ground design (FG) on artificial turf.

Results: TS showed significant larger peak vertical ground reaction force compared with KS ($p=0.002<0.01$) and RS ($p=0.005<0.01$) in the straight-ahead running. Moreover, KS ($p<0.001$) and TS ($p=0.003<0.01$) showed a larger peak vertical ground reaction force than RS in 45° cutting. Peak pressure (PP) and force time integral (FTI) were collected at different anatomical regions for

the analysis of impact on different stud shapes. As showed in figure 5, KS had a larger PP and FTI in the big toe area than the other two groups but had a smaller pressure in the other toe area.

Conclusions: The different stud shapes of FG soccer shoes have little effect on the traction. The knife stud has a stronger ability to provide a stable support but it also could potentially be deemed relatively more harmful due to the larger pressure under the lateral forefoot, predisposing the foot to injuries. The triangle stud showed good explosive force and had good ability on direction changing. It was also more friendly to the medial metatarsal than round stud design. Round stud generally has the minimum peak vertical ground reaction force and good capability of changing directions among the three shoes.

P515

THE FRENCH PATIENT'S ASSOCIATION AFLAR HAS GENERATED THE FRENCH NATIONAL ALLIANCE AGAINST OSTEOPOROSIS AND THE FIRST GENERAL CONVENTION FOR OSTEOPOROSIS, THAT IS A CAMPAIGN TO CREATE A NATIONAL PROMOTING TOOL TO IMPROVE THE MANAGEMENT OF OSTEOPOROSIS

L. Grange¹, B. Cortet², T. Thomas³, P. Guggenbuhl⁴, C. Roux⁵, F. Tremollières⁶, G. Chalès⁷, F. Alliot-Launois⁸, F. Srour⁹, C. Roques¹⁰, J. M. Féron¹¹, C. Cochet¹², D. Buchon¹³, P. Monod¹⁴, C. Bonnet¹⁵, H. Blain¹⁶, E. Senbel¹⁷, G. Thibaud¹⁸, C. Rolland¹⁹, D. R. Bertholon²⁰, J. Giraud²⁰, D. Lafarge²¹, C. Chau¹

¹AFLAR, Paris, ²Rheumatology, University Hospital Center Lille, Lille, ³Rheumatology department, University Hospital Center Hôpital Nord Saint-Etienne, Saint Etienne, ⁴Rheumatology Department, University Hospital Center Hôpital Sud, Rennes, ⁵Rheumatology Department, University Hospital Center Cochin, Paris, ⁶Menopause Unit and Metabolic Bone Diseases, Paule de Viguier Hospital, Toulouse, ⁷AFLAR, Paris, ⁸pro rhumato, Paris, ⁹National Adviser, College of Masseur-Physiotherapists, Paris, ¹⁰AFRETH, Paris, ¹¹Orthopaedic Surgery and Traumatology Department. HUEP – Saint-Antoine, Paris, ¹²College of Chiropodists, Paris, ¹³General Medicine, University Limoges, Limoges, ¹⁴CFMR, Castelnau, ¹⁵Rheumatology Department, University Hospital Center Limoges, Limoges, ¹⁶Prevention and Treatment Center for Diseases of Ageing Antonin Balmes, Regional University Hospital Center Montpellier, Montpellier, ¹⁷SNMR, Marseille, ¹⁸ANDAR, Montpellier, ¹⁹Asthma & Allergies Association, Paris, ²⁰EMPATIENT, Paris, ²¹AFS, Tulle, France

Objective: Osteoporosis is a major public health issue with 5 million of French affected. Overall, she seriously underestimated, and costs are barely covered in France. Considering this situation, AFLAR were urged to create the so called National Osteoporosis Alliance made up of 15 various stakeholders and patients.

Methods: National consultations on osteoporosis rely methodologically on 2 pillars. First the bottom-up reporting on patient needs and expectations. Second the conduct of coordination meetings with various osteoporosis key stakeholders and pa-

tients as part of regional panel discussions. The aim is to provide an overview of real obstacles contributing to the lack of government subsidies for osteoporosis and write consensual proposals compiled into a white paper.

Results: An online survey along with a citizen's panel were key to provide feedbacks on difficulties, knowledges and beliefs but also patient needs. From November 2016 to June 2017, 10 days of dialogue and debate covering 5 various topics were convened in 10 different cities: Consultation and consolidation work regard-

ing proposals made during various panel-discussions allowed synthesis around one call: the creation of a real public health plan against osteoporosis-related fractures relying on 7 key axis.

Conclusions: The human and medico-economic rational considering dramatic fallouts caused by osteoporosis has been illustrated many times over. The policy makers mobilization made by stakeholders through white paper release, a real manifesto for public health plan against osteoporosis-related fracture, remain a significant challenge to face.

THE FIRST GENERAL CONVENTION FOR OSTEOPOROSIS IN FRANCE	
1	Transmitting real messages regarding osteoporosis through information campaigns dedicated to the public and concerned/relevant health professionals training.
2	Elaborating an osteoporosis prevention strategy at an early-age for relevant persons
3	Generalizing real care pathways soon after the first osteoporosis-related fracture.
4	Involving General Practitioners in osteoporosis care.
5	Promoting and sustaining medico-economic research plan considering cost challenges caused by multiplying fractures.
6	Facilitating empowerment and acting efficiently against risks of falling among people suffering from osteoporosis.
7	Creating a national register of osteoporosis-related fractures.

P516
RENOPROTECTIVE EFFECT OF URATE LOWERING THERAPY IN GOUTY PATIENTS WITH STAGE 3 CHRONIC KIDNEY DISEASE

E. Calvo¹, M. Novella-Navarro², F. Aramburu³, I. Janta⁴, J. L. Cabrera-Alarcon⁵, L. Sala², A. Prada²

¹Rheumatology Department, Hospital Universitario Infanta Leonor, ²Rheumatology department, Hospital Universitario Torreon, ³Rheumatology Department, Hospital Universitario HM Sanchinarro, ⁴Rheumatology Department, Hospital Universitario Gregorio Marañon, ⁵Centro Nacional Investigaciones Cardiovasculares (CNIC), Madrid, Spain

Objective: Approximately 25% of gouty patients suffer from chronic kidney disease (CKD). High serum uric acid (sUA) levels have been related to estimated glomerular filtration-rate (eGFR) imbalance. Beneficial effect of treatment with xanthine oxidase inhibitors (XOI), mostly allopurinol, has already been proved in patients with CKD and asymptomatic hyperuricemia. Although several studies have described the efficacy and renal safety of treatment with XOI in gout, few authors have analyzed its effect on GFR in gouty patients with moderate CKD. Our aim was to assess the effect of XOI therapy in gouty patients with moderate CKD, in terms of eGFR changes.

Methods: In this multicenter, retrospective study, we included patients from 4 centers diagnosed with gout (EULAR/ACR criteria) and stage-3 CKD according to Cockcroft-Gault formula (eGFR 30-59 ml/min/m²) who received XOI (febuxostat and allopurinol) with a follow-up for 6 and 12 months. We used clinical records to collect patient features (age, sex, BMI, sUA, hypertension (HTA),

diabetes mellitus (DM), dyslipidemia (DL), cardiovascular events), treatments (lipid-lowering drugs, antihypertensives, antidiabetics, antiplatelet therapy, NSAIDs, urate lowering treatments and colchicine) and gout history (duration of disease, tophi presence, clinical and ultrasonographic (US) pattern (monoarticular, oligoarticular, polyarticular). Statistical analysis: descriptive analysis of variables. Mixed effects model lineal regression Differences were considered significant p<0.05.

Results: 52 patients with gout and stage-3 CKD were identified. We obtained complete 6 and 12-months follow-up from 37 patients (33 males and 4 females). Mean age was 74.11±6.96 y, 32.4% DM, 83.78% HTA, 56% DL, 40% tophaceous gout, Clinical and US pattern (37.8% polyarticular, 37.8 oligoarticular and 24.3% monoarticular). Febuxostat 19 patients, Allopurinol 18. Mean baseline sUA was 8.63±1.33 mg/dl, and baseline eGFR was 47.77±8.45 ml/min/m². To assess the effects of considered variables over eGFR a linear mixed model was adjusted using *nlme R-package*. Within the adjusted model we obtained significant differences in eGFR between baseline and 6 months (p=0.0081), and between baseline and 12-months (p=0.0028). sUA decreased significantly between baseline and 6 (p=0.0181) and 12 months (p=0.0188).

Conclusions: Reduction of sUA levels in gouty patients with XOI entitles an improvement of eGFR in stage-3 CKD. These findings suggest that the response to urate lowering therapy take place in the first 6 months, leading to an improvement in eGFR in this period. From 6 months to 1 year, sUA levels are stabilized and so is eGFR.

P517

EFFECT OF ORAL CHONDROITIN SULFATE ON FUNCTIONAL STATUS IN PATIENTS WITH KNEE OSTEOARTHRITIS: OUTCOMES OF A COMPREHENSIVE META-ANALYSIS EXPLORING INCONSISTENCIES IN RANDOMISED, PLACEBO-CONTROLLED TRIALS

G. Honvo¹, O. Bruyère¹, A. Geerinck¹, N. Veronese², J.-Y. Reginster³

¹Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium; WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liège, Belgium, ²National Research Council, Neuroscience Institute, Aging Branch, Padova, Italy, ³WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liège, Belgium; Chair for Biomarkers of Chronic Diseases, Department of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia

Objective: To determine whether chondroitin sulfate (CS) is effective at improving functional status in patients with knee osteoarthritis (OA) and to assess whether brand of CS, risk of bias, dose of CS and duration of study explain inconsistencies in trials using CS for the symptomatic management of OA.

Methods: A systematic review of randomised, placebo-controlled trials was conducted, searching the Medline, CENTRAL and Scopus databases. Random-effects meta-analysis was performed, using Tau² and I² statistics to assess heterogeneity. The Lequesne index (LI), a composite index measuring pain and function, score was expressed as standardised mean difference (SMD), with 95%CI. Heterogeneity was explored by stratifying the analysis, according to pre-specified study-level characteristics, and assessing the sources of funnel plot asymmetry.

Results: The inclusion criteria yielded 18 trials. Compared to placebo, CS significantly but inconsistently improved function (SMD: -0.82; 95%CI: -1.31, -0.33; I²=95%, p<0.05). When limiting the analysis to studies with a low risk of bias, the pharmaceutical-grade CS of IBSA origin showed a greater and consistent effect on function (SMD: -0.33; 95%CI: -0.47, -0.20; I²=53%, p=0.07), compared to the other preparations (SMD: -0.18; 95%CI: -0.36, +0.01; I²=0%). Assessing funnel plots asymmetry in the studies with a low risk of bias, we found a strong correlation between the CS effect on the LI and study size (rS=0.86; p<0.05). Finally, there was no residual heterogeneity in the CS effect when the smallest studies were removed from the analyses.

Conclusion: This new meta-analysis suggests that CS provides a high effect on function in knee OA, however, with large heterogeneity. Our analyses showed that the risk of bias, brand and study size were the factors explaining inconsistency among the clinical trials results. The pharmaceutical-grade CS preparation of IBSA origin generated greater benefit on functional status than the other CS in the studies with a low risk of bias.

Acknowledgement: This study was funded by an Unrestricted Educational Grant from the IBSA (Institut Biochimique SA). However, preparation of the study protocol, data analysis, and writing and submission of this abstract were under the sole responsibility of the authors.

P518

TOTAL HIP BMD COMBINED WITH AGE AND FRACTURE HISTORY ARE HIGHLY PREDICTIVE OF HIP FRACTURE RISK IN ACTUAL PRACTICE SETTINGS: A REAL WORLD COHORT INCLUDING 21,278 POSTMENOPAUSAL WOMEN FROM CATALONIA

C. Tebe¹, N. Pallares¹, A. Diez-Perez², X. Nogues-Solan², D. Martinez-Laguna³, D. Prieto-Alhambra⁴

¹Biostatistics Unit, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Spain, ²Hospital del Mar de Investigació Mèdica/CIBERFES, Barcelona, Spain, ³GREMPAL Research Group, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain, ⁴CSM, NDORMS, University of Oxford, Oxford, UK

Objectives: We used a large population-based healthcare database to examine the performance of total hip BMD (thBMD) combined with age and fracture history to predict hip fracture risk amongst postmenopausal women.


Methods: A retrospective cohort including all women age 50 to 94 with 1+ thBMD measures recorded in electronic medical records from Catalonia (www.sidiap.org). Participants were followed-up from first DXA until a hip fracture occurred or 5 years follow-up. We used a Cox regression model to test the discrimination and calibration of a model combining thBMD, age, and fracture history to predict 5-year hip fracture risk.

Results: A total of 21,278 women with mean age 65.9 years (SD 9.2) were included; 3,022 had a previous fracture (20%). Median (interquartile range) thBMD T-score was -1.60 (-2.30 to -0.90). 231 (1.09%) sustained a new hip fracture during a median 3.13 (2.06 to 4.25) years of follow-up. Incidence rate was 3.18/1,000 person-years, 95%CI (2.78, 3.62). As expected, thBMD had an inverse and linear association with hip fracture risk (adjusted HR 0.68 [95%CI 0.59-0.77]). The derived equation had AUC 0.82 [95%CI 0.80-0.85], and excellent calibration (Figure 1).

Conclusions: A simple tool combining thBMD, age, and fracture history, is highly predictive of 5-year fracture risk in primary care actual practice settings. More data are needed on the performance of a similar tool for men.

Disclosures: ADP reports grants from Amgen, personal fees from UCB, Mereo, Sandoz, Gilead, and other from Active Life Sci, outside the submitted work. DPA reports unrestricted research funding from UCB, Amgen, and Servier Laboratoires outside of the submitted work; DPA's department has received fees for speaker services from Amgen outside of the submitted work. DML reports personal fees from Amgen, Lilly, Novartis, Ferrer And Rubió outside the submitted work. CT, NP and XNS have nothing to disclose.

Figure 1. AUC ROC and calibration (observed vs. predicted) plots.



P519
CORRELATION BETWEEN DURATION OF MENOPAUSE AND REDUCED BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN AND VITAMIN D AS A RISK FACTORS FOR BONE LOSS

B. Erdeljan¹, M. Maksimovic-Simovic¹, T. Jankovic¹, S. Subin-Teodosijevic²

¹Special Hospital for Rheumatic Diseases Novi Sad, Novi Sad, ²General Hospital "Dr Djordje Joanovic", Zrenjanin, Serbia

Objective: To show the correlation between duration of menopause and reduced BMD in postmenopausal women with risk factors for osteoporosis.

Methods: The prospective analysis is performed from October to December 2018 at the Special Hospital for Rheumatic Diseases in Novi Sad, Serbia. The study involved 85 postmenopausal women who had risk factors for reduced BMD. In the first visit to the rheumatologist all respondents were examined, BMD was measured by DXA and serum vitamin D tests were performed. The central tendency measures and Pearson correlation test were used for statistical analysis.

Results: The average age of participants was 63.29±9.33 y. Duration of menopause was 13.2±10.1 y. All women had vitamin D deficiency with average vitamin D level 53.55±24.3 nmol/l. Average T-score of the femur neck was -1.70±1.78, average hip T-score was -1,60±0.82, average vertebral T-score was -2.0±2.84, average BMD of the femur neck was 0.79±0.2, BMD of the hip 0.80±0.22, vertebral BMD was 0.94±0.32. We found statistically significant negative correlation between duration of menopause and reduced BMD (BMD of the femur neck R=-0.27, p<0.012; hip BMD R=-0.314,

p<0.003; vertebral BMD R=-0.211, p<0.05). There was also statistically significant negative correlation between duration of menopause and average T-score of the hip (R=-0.32, p<0.02), femur neck(R=-0.29, p<0.06) and vertebral T-score (R=-0.23, p<0.030).

Conclusion: Postmenopause is a period of a decrease in BMD. Many factors have impact on this process. Vitamin D deficiency is one of them, which points out that adequate supplementation with vitamin D in population of postmenopausal women can slow down this process.

P520
HIGH-RISK PATIENT CAPABILITY FOR OSTEOPOROTIC FRACTURES / FUSEX * PROPOSAL FOR THE INCLUSION OF PATIENTS IN A NATIONAL DATABASE. (RELEVANCE OF FLS - FRACTURE LIAISON SERVICES)

P. C. Portinho¹

¹Hospital Militar de Área de Brasília, Brasília, Brazil

Objectives: We are currently experiencing a pandemic of osteoporotic fractures. The prevalence is over 200 million people in the world with osteoporosis. The incidence of hip fractures will increase substantially in the year 2050: 240% in women, 320% in men. The hip fracture will increase from 1.7 million in 1990 to 6.3 million in 2050 (IOF, 2015). In this way, we can extract our users according to the parameters listed above and perform osteoporosis fracture prevention. We should avoid the first fracture, if it is not possible, to make the first fracture the last. In the military sphere, the movements of the military and their families to the various workplaces distributed throughout the national territory may compromise the patient's follow-up and treatment and, conse-

quently, facilitate the occurrence of complications (new fractures requiring new surgical treatment) burdening the user and FUSEX. The uptake of these patients is fundamental for the elaboration of a database and follow-up of the treatment instituted. The database together with a protocol of diagnosis and treatment favor the patient in the extraterritorial and direction of the appropriate treatment with subsequent follow-up. These measures reduce the risk of prescribing high-cost medications, favor secondary prevention of refractures, disabling the patient and FUSEX.

Methods: In the Military Hospital of Brasília Area (HMAB), we have been doing this process for 6 y in the orthopedic outpatient clinic. We have the possibility to perform a multidisciplinary treatment (related specialties) and medication (severe osteoporosis) benefiting the user of the FUSEX. The most important is to achieve the patient's adherence to the treatment instituted and the follow-up of the resolution of the clinical picture of the patient. Certainly, the uptake of high-risk patients plays an important role in the efficiency of FLS. By including these patients in a national database we can track them during their movement around the country and monitor their clinical evolution, even at a distance. The Army's telemedicine service can access remote areas and guide professionals who are in contact with at-risk patients. Telemedicine also serves to publicize educational guidelines on osteoporosis for the population and health professionals.

We implemented several opportunities for capturing patients served by FUSEX:

- Regular educational campaigns in media: Radio interviews, printed media distributed in institutions that use FUSEX, FLS disclosure in the hospital and army e-mail address. We have a telemedicine service that we use to guide our professional colleagues in remote regions, avoiding the need for patient displacement. This channel is for professional improvement events integrating several FUSEX health units.
- Prevention campaigns through regular events such as HMAB Osteoporosis Prevention Week, when we carry out screening tests. We use forearm ultrasound, calcaneal ultrasound, and forearm densitometry. At this time, basic laboratory tests are requested to evaluate untreated patients. This measure brought us an average of 90 new patients / year to FLS. The event takes place in October and serves to spread our FLS to the medical class in the region.
- Outpatient clinics of the related specialties (orthopedics, rheumatology, geriatrics, nutrition, endocrinology and gynecology) integrated through a specific protocol for diagnosis and drug treatment. Multidisciplinary control of adherence to treatment and notification of complications (atypical fractures, mandible osteonecrosis, therapeutic failure). With several professionals involved in the treatment of the patient, there is a decrease in GAP between the diagnosis and adherence of the treatment by the patient.
- Compulsory notification of fragility hip fractures arriving at the orthopedic emergency room, as well as subclinical fractures of the spine without the diagnosis of osteoporosis.
- Patients treated at health institutions accredited to FUSEX and requiring surgical treatment (total hip prosthesis, osteosynthesis, spine surgeries) are referred to the refractive prevention clinic. All fractured patients who require surgical treatment, women above 49 years and men over 69 years, are evaluated for fragility fractures.
- Patients referred from outpatient clinics of other specialties for evaluation of bone health that presented altered bone density tests (bone densitometry, Rx, tomography). We evaluated the densitometry of diabetic patients with TBS (trabecular bone score) to capture patients with osteopenia who are at high risk for fractures (Leslie WD et al, JCEM 2013;98:602).

Conclusions: These measures have made it possible to increase the dissemination of our FLS to users and also to increase the uptake of high-risk patients. When we entered patients into our database, we were able to decrease GAP between diagnosis and the start of osteoporosis treatment. Today we have 539 patients monitored by our FLS / FUSEX database, obtained during the 6 years of implementation of the service of prevention of refractories / HMAB (*Data obtained in the OPME / FUSEX / HMAB sector, in Brasília / DF*). As FUSEX operates throughout the national territory, the proposal of an integrated diagnosis and treatment protocol with an effective collection of high-risk patients seems to us a reasonable measure to maintain the control of the treatment of our patients. Such measures are reasonable due to the low cost of its implantation, easy reproducibility to the health professionals and viable administrative structure in all the health institutions of the Brazilian Army.

P521

TRABECULAR AND CORTICAL BONE HEALTH IN POSTMENOPAUSAL WOMEN RECEIVING AROMATASE INHIBITORS FOR EARLY BREAST CANCER TREATMENT: THE B-ABLE PROSPECTIVE COHORT STUDY

X. Nogue Solan¹, R. Rodriguez², M. Rodríguez-Sanz³, R. Winzenrieth², L. Humbert², M. Pineda-Moncusí³, S. Servitja⁴, N. Garcia-Giralt⁵, T. Martos⁴, I. Tusquets⁴, M. Martínez-García⁴, R. Rodríguez Morera⁶, A. Dies Perez¹, J. Albanell⁴

¹IMIM (Hospital del Mar Research Institute), Red Temática de Investigación Cooperativa en Envejecimiento y Fragilidad (RETICEF), Barcelona, Spain; Internal Medicine Department, Hospital del Mar, Universitat Autònoma de Barcelona, ²Galgo Medical SL, ³MIM (Hospital del Mar Research Institute), Red Temática de Investigación Cooperativa en Envejecimiento y Fragilidad (RETICEF), ⁴Cancer Research Program, IMIM (Hospital del Mar Research Institute), Medical Oncology Department, Hospital del Mar, Universitat Autònoma de Barcelona, ⁵IMIM (Hospital del Mar Research Institute), Red Temática de Investigación Cooperativa en Envejecimiento y Fragilidad (RETICEF), ⁶Internal Medicine Department, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain

Objectives: Aromatase inhibitor (AI) therapy is critical for breast cancer (BC) management. However, it induces muscle weakness, joint pain and a marked bone impairment. The aim of this study was to evaluate the effects of AI, after 24 months of treatment, on bone health in a prospective cohort (B-ABLE) composed of women suffering from early BC (EBC).

Methods: Details on the B-ABLE study design have been published previously (Servitja et al., The Breast, 2011). From January 2006 to November 2017, 837 consecutive women with EBC, about to start adjuvant AI therapy with and without bisphosphonates (BP and BP- respectively) protective treatment have been recruited. All participants had a DXA exploration (QDR4500, Hologic, USA) at spine and non-dominant femur before AI initiation and after 12 and 24 months of AI therapy. A software algorithm (3D-SHAPER® v2.8, Galgo Medical, Spain) was used to derive QCT-like subject-specific 3D models from the hip DXA scans of the participants and compute the trabecular volumetric BMD (trabecular vBMD) and the cortical surface BMD (cortical sBMD). The follow-up changes from baseline were normalized at 12 and 24 months and evaluated in terms of percentage. Paired tests were used to compare parameters at 12 and 24 months follow-up and at baseline.

Results: Ultimately, 464 postmenopausal women were deemed eligible for the study. Among them, 21% received BP protective treatment. After 24 months of AI, BP- subjects exhibited significant decrease at both spine (-2.4%) and at total femur (-1.3%) considering areal BMD (aBMD) parameter but more marked at spine (Figure 1a&b) while BP subjects exhibited an increase (+3 and +2.6% respectively, Figure 1c&d). 3D measurements showed similar bone impairment at both cortical and trabecular compart-

ments in BP- (-1.7 and -2.1% for cortical sBMD and trabecular vBMD respectively, Figure 2a&b) with a more marked decreasing rate on the trabecular bone after 12 months (3 times more). In BP group, both cortical sBMD and trabecular vBMD increased (+4.5% and +3.7% respectively, Figure 2c&d) at 24 months. Furthermore, in the same group, trabecular vBMD increase reached a plateau at 12 months while Cortical sBMD continued to increase.




Figure 1 : Cumulative changes in % after 12 and 24 months of follow-up in subjects treated with AI with and without BP protective treatment.




Figure 2 : Top, 3D distribution of the differences (in %) observed in Cortical sBMD after 24 months of AI. Increases are presented in blue-green colour while decreases are presented in yellow-red colours. Bottom, distribution of the average changes in vBMD observed after 24 months of AI in both trabecular and cortical bone in the mid coronal between controls and GCs subjects.

Conclusion: As expected, AI impaired both trabecular and cortical compartments in BP- group while BP protective treatment compensated the negative AI effects. Consistently with aBMD at spine, BP- had a more marked decrease of the trabecular compartment at femur. Interestingly, 3D analysis showed that BP protective treatment stops to overcome the negative effect of AI on trabecular bone after 12 months, suggesting a possible decrease of the trabecular bone after 24 months of AI.

P522

MULTIPLE OSTEOPOROTIC FRACTURES IN PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS: CASE REPORTS. Subin-Teodosijević¹, B. Erdeljan², J. Zvekić-Svorcan², T. Janković²¹General Hospital "Dr Djordje Joanovic", Zrenjanin, ²Special Hospital for Rheumatic Diseases, Novi Sad, Serbia

Objectives: We summarized the diagnosis, clinical picture, disease course and management of osteoporotic complications in patient with systemic lupus erythematosus focusing on secondary osteoporosis and fracture risk.

Methods: Female patient. 60 years old diagnosed with SLE with pulmonary involvement 10 y ago, treated with corticosteroids (mean dose 7.5 mg prednisolone per day), concomitantly with different immunosuppressants - initially cyclophosphamide, then azathioprine and finally mycophenolate mofetil. In order to prevent bone loss she was also treated with vitamin D and calcium, and was regularly referred to DXA examinations. Her initial BMD was in range of osteopenia. Besides corticoid therapy she had early menopause as factor risk for osteoporosis, due to hysterectomy and adnexectomy when she was 40 year old (cervical carcinoma, without any additional treatment).

Results: Five years from diagnosis SLE she accidentally fell in her home. RTG was performed and fracture of left tibia was diagnosed. DXA results at that time was - vL1-4 T-score -2.1 BMD 0.875 g/cm². total hip T-score -2.5 BMD 0.812 g/cm². Bisphosphonate therapy was initiated (alendronate 70 mg once weekly). Alfacalcidol and calcium supplements. After 6 months she fell again - fracture of wrist was diagnosed, and soon after that fracture, she came in our clinic because of back pain with sudden onset, multiple vertebral fractures v Th 12, v L1,2,3 / wedge type/ was diagnosed on plain radiography. Bone turnover markers were increased, 25OHD was sufficient, so we decided to change bisphosphonate, and treat her with parenteral zoledronic acid 5 mg once a year, because teriparatide was contraindicated. In spite of that treatment she got one more fracture next year (humerus) and she was operated. Other reasons included spreading malignant disease were previously eliminated.

Conclusions: We wanted to highlight increased bone fragility in patients with diagnosis of SLE due to longstanding use of corticosteroids, inactivity, due to joint pains, premature menopause due to hormonal changes or other diseases, like our patient had, and insufficient awareness of sufficient prevention bone complications which decreased quality of life, in spite of good control of lupus activity.

P523

MEDITERRANEAN DIET AND KNEE OSTEOARTHRITIS OUTCOMES: A LONGITUDINAL COHORT STUDYN. Veronese¹, C. Cooper², G. Guglielmi³, R. Rizzoli⁴, L. Punzi⁵, N. Al-Daghri⁶, L. Smith⁷, J.-Y. Reginster⁸, S. Maggi¹

¹Consiglio Nazionale delle Ricerche, Padova, Italy, ²Oxford NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford, Oxford, UK, ³University of Foggia, Foggia, Italy, ⁴University of Geneva, Geneva, Switzerland, ⁵University of Padova, Padova, Italy, ⁶Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College of Science, King Saud University, Ryhad, Saudi Arabia, ⁷The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK, ⁸Department of Public Health, Epidemiology and Health Economics, University of Liege, CHU Sart Tilman B23, Liege, Belgium

Objectives: Mediterranean diet has several beneficial effects on health, but data regarding the association between Mediterranean diet and knee osteoarthritis (OA) are limited mainly to cross-sectional studies. We investigated whether higher Mediterranean diet adherence is prospectively associated with lower risk of radiographic OA (ROA), radiographic symptomatic knee OA (SxOA) and pain worsening in North American people at high risk or having knee OA.

Methods: Adherence to the Mediterranean diet was evaluated using a validated Mediterranean diet score (aMED), categorized in five categories. Knee OA outcomes included incident (1) ROA, (2) SxOA, as the new onset of a combination of a painful knee and ROA, (3) knee pain worsening, i.e. a Western Ontario and McMaster Universities Osteoarthritis Index difference between baseline and each annual exam of $\geq 14\%$.

Results: 4330 subjects (mean age: 61.1 y; 58.0% females) were included. Based on a multivariable Poisson regression analysis, during a mean follow-up period of 4 y, participants who were more highly adherent to a Mediterranean diet (Q5) reported lower risk of pain worsening (relative risk, RR=0.96; 95%CI: 0.91-0.999) compared to those in Q1. In 2994 people free from SxOA at baseline, higher adherence to a Mediterranean diet was associated with a lower risk for SxOA during follow-up by 9% (Q5 vs. Q1; RR=0.91; 95%CI: 0.82-0.998). No significant associations emerged between aMED and incident ROA.

Conclusion: Higher adherence to Mediterranean diet is associated with a lower risk of pain worsening and symptomatic forms of knee OA.

P524

ASSOCIATION BETWEEN DIETARY MAGNESIUM INTAKE AND MAGNETIC RESONANCE PARAMETERS FOR KNEE OSTEOARTHRITIS

N. Veronese¹, S. Maggi¹, L. La Tegola², G. Guglielmi²¹Consiglio Nazionale delle Ricerche, Padova, ²University of Foggia, Foggia, Italy

Objectives: To evaluate the relationship between dietary magnesium (Mg) intake and prevalence of osteoarthritis (OA) of the knee in a large cohort from North America.

Methods: 783 participants in the Osteoarthritis Initiative (59.8% females; mean age: 62.3 y) in possession of a MRI assessment (a coronal 3D FLASH with Water Excitation MR sequence of the right knee) were enrolled in our cross-sectional study. Adherence to the Mediterranean diet was evaluated using a validated Mediterranean diet score (aMED). The strength of the association between aMED and knee MRI parameters was gauged using an adjusted linear regression analysis, expressed as standardized betas with 95% CIs.

Results: Using an adjusted linear regression analysis, each increase of one standard deviation (SD) in the aMED corresponded to a significant increase in the central medial femoral cartilage volume ($\beta=0.12$; 95%CI: 0.09 to 0.15), in the mean central medial femoral cartilage thickness ($\beta=0.13$; 95%CI: 0.01 to 0.17), in the cartilage thickness of the mean central medial tibiofemoral compartment ($\beta=0.12$; 95%CI: 0.09 to 0.15), and in the cartilage volume of the medial tibiofemoral compartment ($\beta=0.09$; 95%CI: 0.06 to 0.12).

Conclusions: Higher Mg dietary intake is associated with lower prevalence of knee OA, also when adjusting for potential confounders.

P525

EFFECT OF NUTRITIONAL SUPPLEMENTATIONS ON PHYSICAL PERFORMANCE AND MUSCLE STRENGTH PARAMETERS IN OLDER PEOPLE: A SYSTEMATIC REVIEW AND META-ANALYSIS

N. Veronese¹, P. Soysal², S. Maggi¹¹Consiglio Nazionale delle Ricerche, Padova, Italy, ²Department of Geriatric Medicine, Bezmialem Vakif University, Faculty of Medicine, Istanbul, Turkey

Objective: Malnutrition plays a role in the development of poor physical performance, frailty and sarcopenia. The use of nutritional supplementations for improving physical performance and muscle strength parameters in older people is still debated. We therefore aimed to summarize the effect of nutritional supplementations compared to placebo on physical performance and muscle strength outcomes in older people in randomized controlled trials (RCTs).

Methods: A literature search in major databases was undertaken until 1 September 2018. Eligible studies were RCTs investigating the effect of nutritional supplementations vs. placebo in older

people (people having an age >60 y). Standardized mean differences (SMD) and 95% CIs were used through a random effect model.

Results: Over 4007 potentially eligible articles, 32 RCTs for a total of 4137 older participants (2097 treated and 2040 placebo) (mean age: 76.3 y; 65% females) were included. Compared to placebo, multinutrient supplementations significantly improved chair rise time (n=3; SMD=-0.90; 95%CI: -1.46 to -0.33; I²=87%). Multinutrients significantly improved handgrip strength when compared to placebo (n=6; 780 participants; SMD=0.41; 95%CI: 0.06 to 0.76; I²=79%), similarly to nutritional supplementations including proteins (n=7; 535 participants; SMD=0.24; 95%CI: 0.07 to 0.41; I²=16%). Nutritional supplementations also led to a significant improvement in chair rise time and in handgrip strength in participants affected by frailty/sarcopenia and in those affected by medical conditions.

Conclusion: Nutritional supplementation can improve a small number of physical performance outcomes in older people, particularly when they are multinutrients and in people already affected by specific medical conditions, or by frailty/sarcopenia.

P526

STUDY OF CORTICAL AND TRABECULAR COMPARTMENTS THROUGH 3D-SHAPER IN LUNG TRANSPLANTED PATIENTS

M. Barceló-Bru¹, A. Erra¹, C. Espinet²¹Rheumatology. Hospital Universitari Vall d'Hebron, ²Nuclear Medicine. Hospital Universitari Vall d'Hebron, Barcelona, Spain

Objectives: Osteoporosis in lung transplant (LT) patients is a frequent complication. Glucocorticoid treatment (GC) is a prominent risk factor (RF) that alters both bone mass and architecture. Studying the volumetric BMD using 3D-SHAPER software would help the study of architecture. Our aim was to study the change in cortical surface density, volumetric trabecular density and integral volumetric density measured by 3D-SHAPER before and after LT as well as changes in BMD measured by DXA.

Methods: LT patients assessed in Rheumatology are included. The demographic characteristics, diagnosis of lung disease and RF of low bone mass prior to LT are collected. Patients were grouped into 3 groups according to the type of disease, these being: chronic obstructive pulmonary disease (COPD), interstitial lung diseases (ILD) and other pathologies. Bone mass was evaluated by DXA (GE-Lunar) before and 6 months after LT and 3D-SHAPER software (v2.7, Galgo Medical) was applied in all DXAs.

Results: 49 LT patients were included (46.9% women), with an average age of 56.9±8.7 y. In the ILD group, a higher proportion of patients with a low calcium intake (p=0.027) and with high doses of GC (p=0.001) was observed. COPD group presented the highest proportion of smokers (p=0.027). Prevalence of osteoporosis prior to LT was 24.5%, higher in COPD (p=0.007). Values of BMD and 3D-SHAPER as well as the percentage of post-transplant variation are shown in Table 1. Of the 47 patients, 19 (38.8%) started osteoactive treatment before LT, with a higher percentage of patients treated in the COPD group (p=0.007). Of 42 patients, we

have DXA at 6 months post-transplant, with a prevalence of os-

teoporosis of 23.8%. 27/42 patients underwent post-transplant osteoactive treatment, with an average treatment time until DXA was 19.2±26.1 months, with no differences between groups.

PRE-TRASPLANT	TOTAL (n=47)	COPD (n=11)	ILD (n=30)	OTHERS (n=8)
BMD pre-trasplant (mean)	g/cm² (T-score)	g/cm² (T-score)	g/cm² (T-score)	g/cm² (T-score)
. Lumbar Spine	1.074 (-1,02)	0.927 ^{**} (-2,18 ^{**})	1.131(-0,55)	1.051(-1,18)
. Femoral Neck	0.868 (-1,28)	0.798 (-1,89 [†])	0.899(-1,04)	0.846(-1,35)
. Total Hip	0.907 (-1,15)	0.812 [†] (-2,07 ^{**})	0.950(-0,79)	0.878(-1,27)
3D-SHAPER (mean)				
. BMDs Cortical; g/cm ² (T-score [#])	155,6 (-1,19)	143,9 (-1,90 [†])	163,3 (-0,97)	142,7 (-1,26)
. BMDv Trabecular; g/cm ² (T-score [#])	146,1 (-1,69)	115,4 ^{**} (-2,65)	155,3 (-1,64)	153,6 [†] (-1,06 [†])
. BMDv Integral; g/cm ³	296,0	258,4 [*]	309,4	297,5
6 m POST-TRASPLANT	TOTAL (n=42)	COPD (n=10)	ILD (n=25)	OTHERS (n=7)
% change BMD (mean±DE)				
. Lumbar Spine	- 1,26 ± 10,3	9,38 ± 11,6 ^{**}	- 3,92 ± 7,3	- 7,03 ± 7,7 [†]
. Femoral Neck	- 4,34 ± 7,3 [†]	- 0,74 ± 6,5	- 5,43 ± 6,9	- 5,57 ± 9,3
. Total Hip	- 3,22 ± 6,0 ^{**}	1,18 ± 3,5 [*]	- 4,07 ± 6,2	- 6,58 ± 5,6 ^{††}
% change 3D-SHAPER (mean±DE)				
. BMDs Cortical	- 1,59 ± 5,9	0,14 ± 4,9	- 2,53 ± 6,5	- 0,59 ± 4,9
. BMDv Trabecular	- 4,42 ± 11,6 ^{**}	8,63 ± 8,6 ^{**}	- 8,12 ± 9,5	- 11,66 ± 5,1 ^{††}
. BMDv Integral	- 3,11 ± 6,3 ^{**}	1,87 ± 4,3 [*]	- 4,67 ± 6,5	- 5,20 ± 3,9 [†]

[^]p<0.05, ^{^^}p<0.01 respect previous, ^{*}p<0.05, ^{**}p<0.01 COPD vs. ILS; [†]p<0.05, ^{††}p<0.01 COPD vs. Others; # only in women

Conclusions: • Prevalence of low bone mass is high both before and after the transplant. • Prevalence of some osteoporosis RFs was different between the lung disease groups. • COPD group presented a worse bone mass before LT. Subsequently, they experienced a significant improvement in BMD and volumetric measurements with respect to the other two groups, which showed losses of these parameters. COPD was the group most treated for osteoporosis and with a lower proportion of patients with GC at high doses. • Trabecular BMD was the most altered measure of 3D-SHAPER, with greater decrease in patients with GC at high doses and lower in those with osteoactive treatment.

P527

BONE HEALTH TELE-ECHO: A GLOBAL STRATEGY TO REDUCE THE OSTEOPOROSIS TREATMENT GAP

E. Lewiecki¹, M. Bouchonville li¹, R. Rochelle¹, E. Brodie¹

¹University of New Mexico Health Sciences Center, Albuquerque, USA

Objective: Bone Health TeleECHO (Extension for Community Healthcare Outcomes) uses videoconferencing for ongoing interactive case-based learning to improve the level of knowledge of healthcare professionals for the care of patients with skeletal diseases. Participants can be located anywhere there is an electronic connection. The ECHO model of learning recapitulates familiar learning methods of postgraduate medical training programs. Bone Health TeleECHO aims to reduce professional isolation of clinicians worldwide and offer more patients with skeletal diseases better care, closer to home, at lower cost than referral

a specialty center. We aimed to report 39-month progress of the proof-of-concept Bone Health TeleECHO program and global development of the ECHO model of learning for skeletal diseases.

Methods: Bone Health TeleECHO participants register online with the Osteoporosis Foundation of New Mexico (www.ofnm.org). Demographic information and attendance for weekly teleECHO sessions are collected and processed by Project ECHO at University of New Mexico Health Sciences Center (<https://echo.unm.edu>). Other Bone Health TeleECHO programs collect data independently through a variety of methods. ECHO experiences are shared on the ECHO website, personal communications, quarterly collaborative videoconferences, and periodic live ECHO congresses.

Results: The prototype Bone Health TeleECHO program was launched on October 5, 2015. Since then, weekly (excluding holidays) sessions have been held. Over 39 months, 437 individuals from the USA and 25 from other countries have registered to participate. Average attendance each week has grown from 13 in 2015 to 42 in 2018. Regular participation has improved self-confidence in 20 different domains of osteoporosis care (previously reported). Other Bone Health TeleECHO programs have been established in Grand Blanc, Michigan; Washington, DC; Galway, Ireland; and Moscow, Russia. At least 3 additional programs are expected to be launched in 2019. Challenges for global development of Bone Health TeleECHO include funding, staffing, recruitment of participants, and bureaucratic barriers.

Conclusions: Bone Health TeleECHO offers educational opportunities with minimal disruption of office routines. It provides relief of professional isolation that occurs in many practice settings. Bone Health TeleECHO offers opportunities to leverage scarce healthcare resources and expand capacity to deliver best practice skeletal care for patients with osteoporosis and rare bone diseases, as well as enhance effectiveness of fracture liaison services.

P528

PSEUDOHYPOPARATHYROIDISM: A TALE OF HYPOCALCEMIA AND HYPERCALCEMIA WITH A GENETIC SOLUTION

R. C. Rosenblum¹, Y. Einbinder², O. Twito¹, G. Mantovani³, F. M. Elli³, P. Rotman Pikielny¹

¹Endocrine Institute, Meir Medical Center, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Kfar Saba, Israel, ²Nephrology Institute, Meir Medical Center, affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Kfar Saba, Israel, ³Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy

Objective: Pseudohypoparathyroidism (PHP) is a rare, genetic disease characterized by renal resistance to PTH, presenting with hypocalcemia, hyperphosphatemia and elevated PTH. We describe a PHP patient who presented with significant hypercalcemia.

Case description: A 46-year-old woman with history of hypocalcemia presented to the emergency department with new-onset hypercalcemia, renal failure and anemia. She had hypocalcemic episodes throughout life with elevated PTH and hypocalciuria,

suggestive of PHP. Medications included calcium 1800mg/d, alfacalcidol (1 α -OHD3) 3 μ g/d and cholecalciferol (25-OHD3) intermittently. Lab tests revealed hypercalcemia at 13.9mg/dL (nl 8.5-10.5), albumin 3.8 g/dL (nl 3.5-5.5 g/dL), phosphate 4.3 mg/dL (nl 2.5-5.0 mg/dL), creatinine 4.7 mg/dL (nl 0.5-1.2 mg/dL), and hemoglobin 9.8 g/dL (nl 12-16 g/dL). Urinary calcium excretion was high, 485 mg/24h (nl 0-250 mg/24h). PTH levels were <5.5 pg/mL (nl 6.7-38.8); thus, defining the hypercalcemia as PTH-independent. Lab tests 4 months earlier were normal. Calcium and vitamin D supplements were immediately stopped with rapid normalization of calcium levels.

A previous PTH infusion test supported the diagnosis of PHP. There were no Albright Hereditary Osteodystrophy features, resistance to other hormones or family history of calcium homeostasis dysregulation. Due to these factors, PHP type 1B seemed most likely. Genetic analysis revealed broad methylation defects in the *GNAS* (Guanine Nucleotide Binding Protein, Alpha Stimulating) locus, diagnostic for sporadic PHP1B. Vitamin D intoxication was suspected as the cause of hypercalcemia; yet, low 25-OHD3 and 1,25-OHD3 levels excluded this. The patient then became hypocalcemic and lower dose supplements resumed. She remains normocalcemic.

Conclusion: PHP is characterized by hypocalcemia in the face of elevated PTH. Treatment includes calcium and hydroxylated vitamin D supplements to maintain normocalcemia and lower PTH levels as much as possible. Hypercalcemia is rarely reported in PHP, but frequently in hypoparathyroidism due to vitamin D intoxication. We speculate that our patient's hypercalcemia was caused by calcium overdose, although she did not report a change in the regular dose. Close surveillance is essential in PHP to prevent potentially life-threatening electrolyte disturbances.

P529

IN-HOSPITAL MORTALITY RATE AFTER OSTEOPOROTIC HIP FRACTURE IN A SPECIALIZED CENTER IN BUCHAREST

R. Dobre¹, D. Niculescu², C. Poiana²

¹National Institute of endocrinology C.I. Parhon, ²National Institute of endocrinology C. I. Parhon, Bucharest, Romania

Objective: Hip fracture remains the most important clinical manifestation of osteoporosis, with a high and relatively unchanged in the last decades mortality rate. We aimed to evaluate the in-hospital mortality rate after osteoporotic hip fracture in patients treated surgically or functionally in a specialized center in Bucharest.

Methods: We calculated the in-hospital mortality in 589 patients (women 430 [73%], men 159 [27%], with a mean age of 79.42 \pm 11 y), operated or functionally treated for fragility hip fracture in a 12-month period.

Results: In-hospital mortality rate was 5.77% (n=34, women 64.7%). The male sex is a risk factor with a mortality rate of 7.54% (n=12), compared to 5.11% in women. Average BMI was 23.6 kg/m², with 9%, 54.5%, 27.2% and 9% for under, normal, overweight and obese. Average length of hospitalization was 20.34 d, with a total of 691 d. Out of the 29 patients, 44.8% had a femoral neck

fracture, 3.44% an intracapsular one, 38% intertrochanteric and 13.8% atypical fracture in absence of bisphosphonates. 11.74% had previous fragility fractures, with none being diagnosed with osteoporosis. 85.3% of the patients had a history of one or more cardiac pathology (41.17% with atrial fibrillation), 26.4% with strokes, 1/3 of them with hemiparesis, 32.35% with one form of dementia, 20.58% with anemia, 17.64% with chronic kidney disease stages III-IV, 10.25% with diabetes and 8.82% with chronic pulmonary disease. Regarding the treatment, 58.82% sustained surgical interventions (n=20) with average day of intervention of 8.37 after admission. None of the patients had osteoporosis treatment before the event, 1 had a history of glucocorticoids and in average 4.1 medications with increased risk of falling and fracture. Only 2.94% and 5.88% were consumers of tobacco and alcohol.

Conclusion: In-hospital mortality rate is very high, in concordance or even higher compared to other studies, probably this being related to the age of the patients and high comorbidity associated. Male sex is a risk factor.

P530

COMPARISON OF THE EFFECT OF TRANSITIONING FROM TERIPARATIDE TO DENOSUMAB OR BISPHOSPHONATES ON BONE MINERAL DENSITY OF LUMBAR SPINE AND FEMORAL NECK IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS

E. Mole¹, I. Mole², S. Theodorakopoulos¹, D. Moschou¹, K. Zoupidou¹, S. Gazi¹

¹Department of Rheumatology, "KAT" General Hospital of Attica,

²Gynecologist and Obstetrician, Private Practice, Chalkida, Greece

Objectives: To clarify the effect of transition from teriparatide to denosumab (DNS) or per os bisphosphonates (BIS), in terms of BMD of lumbar spine (LS) and femoral neck (FN), in postmenopausal women with osteoporosis.

Methods: Retrospective study of 36 postmenopausal women who previously received 24 months of teriparatide (20 µg/d), followed by 36 months of DNS 60 mg/6mo (group A, n: 22) or 36 months of per os BIS (group B, n: 14). Bone densitometry of LS and FN was performed at 0, 1, 2 and 3 y.

Results: The mean age (70.18±11.07 vs. 71±11.43 y, p: 0.8318) and the postmenopausal years (23.9±15.6 vs. 26.29±14.34, p: 0.6470) were comparable between two groups. Baseline BMD at both measured skeletal sites was also comparable between groups (LS: 0.775±0.06 vs. 0.809±0.19, p: 0.4376, FN: 0.666±0.09 vs. 0.692±0.08, p: 0.3973). Patients in group A had significant greater increases in BMD of all measured skeletal sites at the end of the third year (LS: 0.775±0.06 to 0.815±0.02, p: 0.005, FN: 0.666±0.09 to 0.786±0.09, p: 0.001). At the end of third year BMD of LS in group B significantly decreased (0.809±0.19 to 0.700±0.05, p: 0.047), whereas a nonsignificant improvement in BMD of FN was observed (0.692±0.08 to 0.715±0.06, p: 0.3973).

Switching from teriparatide to DNS resulted higher increase from baseline compared to BIS (group A vs. B LS: +7.36% vs. -15.57%, p: 0.0019, group A vs. B FN: +15.27% vs. +3.22%, p: 0.0137).

Conclusion: Transitioning from teriparatide to DNS results in improvements in BMD of both measured skeletal sites, whereas switching to BIS results in progressive bone loss in LS and insignificant gain in FN.

P531

PREDICTORS OF REDUCED BONE MINERAL DENSITY IN CHILDREN AND ADOLESCENTS WITH CEREBRAL PALSY

A. Delalić¹, M. Zonić-Imamović¹, A. Bijedić¹, A. Čičkušić¹

¹Department of Physical Medicine and Rehabilitation, University Clinic Center Tuzla, Tuzla, Bosnia-Herzegovina

Objective: Determine the predictors of reduced BMD in children and adolescents with cerebral palsy (CP) compared to the tested parameters.

Methods: The study included 82 children and adolescents with CP, average age 10.8±3.6 y (range 5-19.4 y), with different degrees of functional disability estimated on the basis of Gross Motor Function Classification System (GMFCS). The BMD was measured in the lumbar spine region with DXA and results are determined as Z-score. BMD is estimated in relation to age, sex, clinical form, mobility, nutrition status, daily physical activity and the use of antiepileptic therapy. Relation between variables has been used by Pearson correlation, with statistical significance p<0,05.

Results: Lower bone density, defined as BMD Z≤-2, was present in 37 or 45.2% of subjects with statistically significant differences in particular clinical forms (p<0.001), among which the highest representation was recorded in quadriplegic (86%) and dyskinetic form (60%). All tested parameters, except age and sex, had a statistically significant effect on bone density reduction. The highest incidence of reduced bone density (p<0.001) was found in undernourished (94%) and immobile patients (80%). The average value of BMD Z-score in the mentioned groups were around -2.6, unlike the average of subjects with less severe functional disability and better nutritional status in which the BMD Z-score was >-2 (p<0.001).

Conclusion: Reduced bone density is significantly present in children and adolescents with CP. The best predictors of decreased bone density are nutritional status and degree of functional disability.

P532

INFORMING A PATIENT ABOUT THE ONSET OF CHRONIC RHEUMATIC DISEASE (CRD) RHEUMATOLOGIST'S (RH) EXPERIENCE: PATIENT'S (PA) FEELING

P. Lemesle¹, X. Grapton¹, N. Bouhedja¹¹Private Practice, Bois Colombes, France

Objective: Informing a patient about the diagnosis of CRD can cause an emotional shock. As a result, the relationship between the Rh and the Pa can be at stake. Our aim was to compare the point of views of Rh/Pa for items related to the information. Bring a better approach by the Rh.

Methods: 39 Rh/222 Pa. CDR including 56% rheumatoid arthritis (Ra), 27% spondyloarthritis (SPA), 17% others. Only Ra and SPA are included. Female 78% Ra/52% SPA, average age/average duration of disease: Ra 58/8 y, SPA 42/13 y.

Results: The Rh's approach for informing a patient differs with the type of CDR 59%, of its form 29%, of the patient's profile 82%. The consultation takes longer 62% Rh/57% Pa. Empathy is noted for 98% Rh/82% of Pa. Frankness 72% Rh/82% Pa. Time is given to digest the information 93% Rh/73% Pa, to exchange 90% Rh/73% Pa. All explanations are provided (sometimes rephrased 32%) but not sufficiently according to 24% of patients. An anxious, depressed or patient in denial is seen a second time in 29%. He is listened to and the rheumatologist adjusts accordingly. The Rh is empathic/recomforting 98% Rh/64% Pa. He is supportive and tends to be optimistic. Confidence comes for 87% Pa with him being available, listening and explaining. The Rh brings up the quality of life 51%/63% Pa, the evolution 92%/72% Pa. He encourages the patients to be involved in the management of the disease and insists on treatment compliance.

Conclusion: The findings show there is no substantial difference between the judgment of the Rh and the perception of the Pa for the items evaluating the first information about the diagnosis of CDR, even though the items are less noted by the Pa. The Rh uses tact and reassurance, he takes time but not enough according to Pa. He brings up the quality of life and remains available, which is appreciated by the Pa. For the 31 items, SPA patients are less optimistic than the Ra patients.

P533

THE EFFECT OF SOCIODEMOGRAPHIC CHARACTERISTICS ON THE QUALITY OF LIFE IN POSTMENOPAUSAL WOMEN WITH REDUCED BONE MINERAL DENSITY

J. Zvekic-Svorcan¹, Z. Vucic², K. Filipovic³, T. Jankovic¹, J. Aleksic⁴, S. Subin-Teodosijevic⁵

¹University of Novi Sad, Faculty of Medicine Novi Sad, Special Hospital for Rheumatic Diseases, Novi Sad, ²University of Novi Sad, Faculty of Medicine, Novi Sad, ³Artfizio, Specialistic Office for Physical Medicine and Rehabilitation., Novi Sad, ⁴Railway Healthcare Center, Belgrade, ⁵General Hospital "Djordje Joanovic", Zrenjanin, Serbia

Aim: To establish if postmenopausal women with reduced BMD that differ in sociodemographic characteristics report statistically significantly different quality of life across various dimensions.

Methods: The retrospective study included 112 postmenopausal women aged 60-70 y with reduced BMD, who were referred for osteodensitometry (DXA) scan at the Special Hospital for Rheumatic Diseases in Novi Sad, Serbia, from February 2017 to January 2018. BMD in hip and spine (L1-L4) was measured in all patients, and the values were expressed as T-scores. All participants completed the QUALEFFO-41 Serbian Version questionnaire for quality of life assessment, and the demographic characteristics were obtained from medical records. Statistical analyses were conducted using SPSS ver. 24 to ascertain if scores on quality of life (QoL) dimensions are affected by differences in demographic characteristics.

Results: The pain score was statistically significantly the lowest for those with primary education only (59.55±22.69). Participants that engage in physical labor also report lower QoL (58.33±22.99 vs. 41.3±21.65). Everyday activity score was the lowest in patients with primary education only (28.6±17.54). Ability to perform everyday activities was compromised in those that had experienced fracture (26.08±16.62 vs. 19.18±15.47). Household chores are more challenging for unemployed (27.73±19.38). Better quality of leisure time is reported by participants from rural areas (62.58±23.19). Leisure time quality is the lowest for those with primary education only (68.64±18.31), but is also reduced in women that walk and perform physical activities at work (74.69±14.84). Patients with post-secondary education report the lowest quality of mental functioning (64.14±7.27). Overall quality of functioning is lower in those that have primary-level education only (49.05±11.94) relative to other educational levels, as well as among employed (55.92±13.88) relative to unemployed women (43.02±11.27).

Conclusion: When analyzing quality of life in individuals with reduced BMD, it is essential to consider their demographic characteristics.

P534

EFFECT OF CLINICAL CARE PATHWAYS ON HEALTH-RELATED QUALITY OF LIFE AND PHYSICAL FUNCTION FOLLOWING FRAGILITY FRACTURE: A SYSTEMATIC REVIEW AND META-ANALYSIS

J. Talevski¹, K. Sanders², C. Connaughton³, G. Duque², A. Beauchamp², D. Green², L. Millar², S. L. Brennan-Olsen¹

¹University of Melbourne, ²University of Melbourne, ³Australian Catholic University, Melbourne, Australia

Objectives: This meta-analysis aimed to evaluate the effect of clinical care pathways (CCPs) on health-related quality of life (HRQoL) and physical function following fragility fracture of the most common sites – hip, wrist, vertebrae and humerus.

Methods: We searched 4 online databases for all published studies that involved participants aged >50 years who sustained a fragility fracture; evaluated the effects of a CCP compared to usual post-fracture care; and reported outcomes of HRQoL or physical function.

Results: 22 studies (17 randomized controlled trials, 5 nonrandomized studies) were included comprising 5842 participants. 21 studies included hip fracture patients, and one included wrist fracture patients. 82% of studies were assessed as high quality. Meta-analyses showed moderate improvements in the CCP group for HRQoL [standardized mean difference (SMD)=0.24; 95%CI, 0.12-0.35; n=10 studies] and physical function (SMD=0.21; 95%CI, 0.10-0.33; n=15 studies) compared with usual care. Sensitivity analyses by study design showed no difference in effects. CCPs with >5 components showed greater improvements in HRQoL (SMD=0.32; 95%CI, 0.22-0.43; n=5 studies) and physical function (SMD=0.21; 95%CI, 0.06-0.36; n=10 studies) compared to CCPs with <5 components. Larger improvements in HRQoL and physical function were found for CCPs that included a care coordinator; geriatric assessment; rehabilitation; nutritional advice; discharge planning; or home modifications.

Conclusions: Meta-analysis by fracture type was not possible due to lack of non-hip fracture studies. Treatment with CCPs following hip fracture showed improvements in HRQoL and physical function compared with usual care. Further research is warranted to assess the combination of CCP components that provide the most beneficial results; evaluate the effect of CCPs in patients with non-hip fractures; and determine which patient groups are more likely to benefit from CCPs.

Acknowledgments: JT is supported by an Australian National Health and Medical Research Council (NHMRC) Postgraduate Scholarship (1151089) and SLB-O is supported by a NHMRC Career Development Fellowship (1107510).

P535

OBESITY ASSOCIATED WITH LOW LEAN MASS AND/OR LOW BONE DENSITY FURTHER WORSEN CARDIORESPIRATORY FITNESS IN MIDDLE AGED AND OLDER ADULTS

N. De França¹, S. Gil², A. L. Pinto³, B. Gualano², L. Martini¹

¹Department of Nutrition, School of Public Health, University of São Paulo, ²Applied Physiology & Nutrition Research Group, Rheumatology Division, School of Medicine, University of São Paulo, ³Rheumatology Division, School of Medicine, University of São Paulo, Sao Paulo, Brazil

Objective: Cardiorespiratory fitness (CRF), expressed by maximal oxygen uptake (VO₂peak), is a strong predictor of mortality. Aging is associated with changes in body composition that could compromise the VO₂peak. We aimed to investigate the impact of disturbances in body composition on the CRF in middle aged and older persons.

Methods: This is a small-scale, hypothesis-driven, cross-sectional study with 43 individuals (55% male; aged 57-85 y) recruited from the Health Survey-Sao Paulo 2015. Appendicular lean mass (ALM), fat mass and BMD were measured by DXA. Obesity was defined as fat mass (kg) divided by height squared >9 kg/m² and >13 kg/m² for men and women, respectively. Low lean mass was set as ALM divided by BMI <0.789 for men and <0.512 for women. Osteopenia was defined as T-scores at lumbar spine and femoral neck <-1.0. Subjects were then clustered into groups according to the presence or not of body composition disturbances. VO₂peak, ventilatory anaerobic threshold (VAT) and respiratory compensation point (RCP) were assessed by incremental exercise test on a treadmill. Serum vitamin D, leisure physical activity and grip strength were assessed as potential confounders.

Results: The groups were as follows: 8 (50% male) individuals "without disturbances", 16 (56% male) with "osteopenia and/or low lean mass", 9 (44% male) with "obesity alone", and 10 (70% male) with "obesity plus osteopenia and/or low lean mass". The group with "obesity plus osteopenia and/or low ALM" showed lower VO₂ at the RCP than the groups "without disturbances" (-5.1 ml/kg/min, p=0.008) and "osteopenia and/or low lean mass" (-5.2 ml/kg/min, p=0.008). The group with "obesity plus osteopenia and/or low lean mass" also showed lower VO₂peak than the group with "osteopenia and/or low ALM" (-4.5 ml/kg/min, p=0.026). Serum vitamin D, leisure physical activity and grip strength did not change the results.

Conclusion: In this sample of middle aged and older adults, obesity combined with low lean mass and/or osteopenia resulted in poorer aerobic conditioning, which suggests that showing a cluster of body composition disturbances may predispose to higher morbimortality risks.

Acknowledgments: São Paulo Research Foundation (FAPESP) [2014/26787-0].

P536

LIPOPOLYSACCHARIDES AND LIPOTEICHOIC ACID SHOW THE OPPOSITE EFFECT ON BONE FORMATION THROUGH THE REGULATION OF OSTEOCLAST ACTIVATION

M.-F. Chen¹, C.-H. Chang², H.-N. Shih³, S. W. N. Ueng³, Y. Chang³

¹Bone and Joint Research Center, Chang Gung Memorial Hospital, ²Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, ³Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Objective: Osteoblasts and osteoclasts play crucial roles in bone formation processes. Osteogenesis and osteoblast differentiation produce new bone cells. Osteoclast activation can be metabolized to aging bone cells and is important for bone remodeling. Appropriate balance between the activities of these two cell types is essential for maintaining bone function and prevent osteoporosis. Additionally, after treating bone infection with antibiotics, dead bacteria tend to remain as cell wall components, which stimulate the activity of osteoblasts and osteoclasts. However, the mechanisms of lipopolysaccharides (LPS) and lipoteichoic acid (LTA) on the activity of osteoblasts and osteoclasts remains unclear.

Methods: In this study, we conducted animal experiments to confirm the opposite effects of LPS and LTA on osteogenesis in mice. We also conducted cell culture experiments to investigate the effects of LPS and LTA on the osteogenic differentiation and osteoclastogenesis in osteoblasts and osteoclasts.

Results: First, we found that LPS or LTA injection into the femur bone marrow cavity in a mouse model confirmed that LPS can cause bone loss, whereas LTA does not alter microCT-related parameters. By contrast, LTA appears to increase the number of trabecular bones. Staining of the femoral bone slices with H&E and Masson's trichrome stains revealed that the bone image in the LPS group showed tissue necrosis and enhances cathepsin K expression in osteoclasts. By contrast, LTA does not appear to cause bone tissue necrosis, and the LTA-treated group appears to reduce the cathepsin K expression in osteoclasts. Second, we established a mouse femur bone implant surgery and induced a bone defect of size 1 mm. LTA promotes bone healing, whereas LPS worsens bone healing. LPS treatment also causes fractures in mice. LTA not only enhances callus formation but also promotes the hardening of the callus bones into dense bones. H&E and Masson's trichrome stains were used to stain the femoral bone slices, and the results showed that LTA can promote new bone formation. Third, we found that the effects of LPS and LTA on osteoblast differentiation are activation in vitro. The osteoblastic cell line (MC3T3-E1) was treated with osteogenic factor in the presence or absence of LPS or LTA. The results demonstrated that LPS inhibited osteoblast differentiation, but LTA slightly promoted osteoblast differentiation.

Conclusions: Our research findings revealed the effects of LPS and LTA on osteoblasts and osteoclasts are reversed in vivo and in vitro. We believe that it can help in the development of a novel strategy for the treatment of bone infection and contribute to the field of bone physiology.

P537

ASSOCIATION BETWEEN BONE MINERAL DENSITY AND TUMOR MARKERS IN HEALTHY WOMEN

H. A. Seo¹, K. H. Bae¹, E. H. Kim¹

¹Departments of Internal Medicine, Daegu Fatima Hospital, Daegu, South Korea

Objective: We investigated the relationship between BMD and tumor markers.

Methods: A total of 314 female, who had undergone comprehensive routine health examinations at the Daegu Fatima Hospital, were included in this study. The BMD of lumbar spines (L1 to L4) was measured by DXA. Serum α -fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 125 and carbohydrate antigen (CA) 19-9 levels were checked. Patients with malignancy were excluded.

Results: The mean age of total patients was 48.58 ± 12.65 . In univariate analysis, the BMD of lumbar spines (L1 to L4) was associated with CEA, CA 125 and CA 19-9. AFP was not related with BMD of lumbar spines. After adjusted for age and BMI, AFP and CA 19-9 were associated with the BMD of lumbar spines, but CEA and CA 125 were not related with BMD of lumbar spines. The regression coefficients between AFP and BMD of lumbar spines were 0.137 for L1, 0.104 for L2, 0.129 for L3 and 0.117 for L4, whereas those between CA 19-9 and BMD of lumbar spines were -0.082 for L1, -0.097 for L2, -0.119 for L3 and -0.134 for L4.

Conclusion: In the present study, we found that the level of AFP and CA 19-9 is significantly associated with BMD in women. Further studies are needed to provide a definite relationship and elucidate the mechanism.

P538

ONE YEAR TREATMENT OF ANTI-TNF THERAPY AFFECTED SYSTEMIC BONE LOSS IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) DIFFERENTLY ACCORDING TO THE DISEASE DURATION

M. J. Lim¹, W. Park¹, S. R. Kwon¹, K. H. Jung¹, S. Y. Lee¹

¹Inha University Hospital, Incheon, South Korea

Objective: In this study, we tried to find out how disease duration affects systemic bone metabolism in patients with RA after one year anti-TNF treatment. The disease duration of rheumatoid arthritis is classified as recent onset RA (≤ 3 y) and established RA (> 3 y).

Methods: 32 seropositive RA patients were enrolled. They had been refractory to antirheumatic drugs and anti-TNF therapies including etanercept, adalimumab and infliximab were administered for 1 y. Etanercept, adalimumab and infliximab at approved dose were given to 11, 13 and 8 patients, respectively. BMDs were

measured at baseline and one year after treatment. Blood sampling was done at baseline, 6 months and 1 y after the treatment. Peripheral blood mononuclear cells were cultured and number of osteoclasts was counted. Bone turnover markers including c-terminal telopeptide (CTX), bone specific alkaline phosphatase (BSALP) were measured using ELISA. In addition, RA disease activity including DAS28 was assessed.

Results: BMD at femur and total hip decreased after 1 y in recent onset RA although BMD did not differ in established RA. In recent onset RA, bone resorption pit by cultured osteoclasts as well as calcified nodule produced by cultured osteoblasts did not change in 6 months of anti-TNF treatment. In contrast, bone resorption pit decreased and calcified nodule by osteoblasts increased in 6 months in established RA patients. The number of osteoclasts decreased in 1 y in both groups. BSALP increased in recent RA and CTX increased in established RA but both markers seemed not to reflect systemic bone metabolism. DAS28 in both groups responded well to anti-TNF treatment.

Conclusion: Recent onset RA showed significant systemic bone loss although BMD in established RA stayed still after one year of anti-TNF treatment. Decreased activity of osteoclasts and improved activity of osteoblasts at 6 months seemed to prevent bone loss in established RA. It is suggested that RA patients with anti-TNF therapy may benefit from earlier bone protective treatment to prevent systemic bone loss.

P539

PELVIS FRACTURES IN OLDER PEOPLE POSE A HIGH RISK OF INSTITUTIONALIZATION

P. Benzinger¹, J. Bauer², C. Becker³, G. Büchele⁴, K. Rapp³

¹Geriatrisches Zentrum der Universität Heidelberg, Heidelberg, ²Geriatrisches Zentrum der Universität Heidelberg, Heidelberg, ³Department of Clinical Gerontology, Robert Bosch Hospital, Stuttgart, ⁴Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany

Objective: Fall-related fractures are a serious threat to the health and wellbeing of older persons. Long-term consequences of hip fractures such as institutionalization and mortality are well known. The impact of pelvis fractures is less well understood. The aim of this study was to estimate risks of institutionalization and death following pelvis fracture and compare them with the corresponding risks after hip fracture.

Methods: Data was retrieved from a German health insurance company. Crude and age-standardized 6 months incidence rates for institutionalization and death were calculated. To compare the risks of institutionalization or mortality multivariate regression models were applied.

Results: Between 2005-2008 19,670 people suffering an incident hip fracture were identified with 2776 being newly institutionalized and 3199 deceased during the following six months. During the same period 4574 people suffered an incident pelvis fracture with 590 being institutionalized and 499 deceased. Crude and age-adjusted rates of institutionalization and mortality were higher in patients with hip fracture compared to pelvis fracture. How-

ever, after adjustment for age, prefracture functional status and comorbidity, relative risks of institutionalization after pelvis fracture in women (0.94; 95%CI 0.86;1.02) and in men (0.89; 95%CI 0.70;1.12) were not statistically different compared to hip fractures while relative risks of death after pelvis fracture were still lower than after hip fracture in women (0.71; 95%CI 0.64;0.78) and in men (0.75; 95%CI 0.63;0.88) .

Conclusions: Both fracture sites are presumably associated with a significant decline in physical function. People suffering from fractures of hip and pelvis experience immediate loss of mobility. Hence, the link between hip and pelvis fractures and subsequent institutionalization may be the result of mobility limitations. While rehabilitative programs are standard of care after hip fracture comparable programs for people recovering from pelvis fracture have to be developed first.

P540

IMPACT OF REHABILITATION THERAPY FOCUSED ON THE MUSCULOSKELETAL CAPACITY IN OSTEOPOROTIC-DIABETIC PATIENTS

M. D. Clantau¹, B. I. Mitoiu¹, G. Gheorghievici¹, R. Nartea¹, G. Mologhianu¹, S. A. Nica¹

¹UMF "Carol Davila", Bucharest, Romania

Objective: Comorbidities such as diabetes and osteoporosis affect the quality of life in elder patients, outlining negative aspects of daily life, including the risk of falls. Bone tissue microarchitecture determines the bone quality and is associated with high risk of bone fragility, especially in elder patients. Proper management of these patients includes rehabilitation therapies that increase musculoskeletal strength.

Methods: We present a group of 5 in patients with diabetes, osteoporosis and musculoskeletal pathology that followed a rehabilitation program including physical therapy, antalgic electrotherapy and manual therapy in INRMFB 3rd Clinic. Management started after a detailed clinical assessment including cardiologic, diabetologic, neurological and functional evaluation.

Results: Among our group of patients 80% of them accused intense musculoskeletal pain (VAS=8/10) and 60% had lower functional level in admission. After 2 weeks of medical treatment and physical therapy the level of pain was reduced to 20% and the intensity of pain was mild (VAS=3/10). The functional level was increased due to improving the strength in muscles. The main key is of treatment is the long time association with medication that can improve the bone microarchitecture and mineralization.

Conclusions: Understanding the pathophysiology of the illness provides the key to establish the proper therapeutic management and can provide the quality of life for these patients. Multidisciplinary approach is required for an optimal result. We intend to realize a prospective study with a larger group of individuals in order to analyze the long term benefits of associating rehabilitation therapy to patients with comorbidities.

P541

EFFECTS OF ARONIA MELANOCARPA FRUIT JUICE ON METABOLIC INDICES IN A RAT OVARECTOMY-INDUCED MODEL OF BONE LOSS

S. Valcheva-Kuzmanova¹, V. Kuzmanova², A. Kuzmanov², M. Eftimov¹, M. Todorova¹, A. Georgieva¹, K. Kuzmanov³, S. Marchev², M. Vlaskovska⁴

¹Department of Pharmacology and Clinical Pharmacology and Therapeutics, Medical University Prof. Dr. Paraskev Stoyanov, Varna, ²Medical University Prof. Dr. Paraskev Stoyanov, Varna, ³Vivarium, Medical University Prof. Dr. Paraskev Stoyanov, Varna, ⁴Department of Pharmacology and Toxicology, Medical University, Sofia, Bulgaria

Objective: Polyphenols are intensively studied because of their beneficial effects on human health. The aim of the study was to investigate the effects of polyphenol-rich *Aronia melanocarpa* fruit juice (AMFJ) on metabolic indices in a rat ovariectomy-induced model of bone loss.

Methods: Female Wistar rats were divided into 4 groups, each of 14 animals: SO (sham-operated), OV (ovariectomized), OV+AMFJ5 and OV+AMFJ10. Beginning 2 weeks after the operation, in the course of 10 weeks, the animals were treated daily orally. SO and OV groups received distilled water. OV+AMFJ5 and OV+AMFJ10 groups were respectively treated with AMFJ at doses of 5 and 10 ml/kg. Weight was measured throughout the experiment and weight gain was calculated. At the end of the experiment, femur BMD was evaluated by DXA, fat deposits (total, retroperitoneal and mesenteric) and blood lipids were measured.

Results: AMFJ dose-dependently antagonized OV-induced BMD reduction. Thus, in OV+AMFJ10 group the BMD was significantly higher ($p < 0.05$) than that of OV group. OV rats had a significantly higher ($p < 0.05$) weight gain than SO rats. The total and retroperitoneal fat deposits of OV group were significantly higher ($p < 0.01$) than those of SO group and the mesenteric fat was insignificantly increased. This accounted for significantly higher ratios of total fat/body weight ($p < 0.05$) and retroperitoneal fat/body weight ($p < 0.01$) of OV rats compared to SO rats. Blood cholesterol level of OV group was significantly higher ($p < 0.05$) than that of SO group. AMFJ in the two doses could not counteract these effects of ovariectomy on metabolism. Thus, the weight gain, total fat, retroperitoneal fat and the calculated ratios of total fat/body weight and retroperitoneal fat/body weight, as well as the blood cholesterol of OV+AMFJ5 and OV+AMFJ10 groups were significantly higher than those of SO group and were not significantly different from those of OV rats.

Conclusion: In a rat ovariectomy-induced model of bone loss, *Aronia melanocarpa* fruit juice antagonized the reduction of BMD but could not antagonize the effects of ovariectomy on lipid metabolism.

Acknowledgements: This research was funded by project 14016 of Science Fund of Medical University, Varna, Bulgaria.

P542

DEVELOPMENT OF A FRAILTY SPECIFIC PATIENT REPORTED OUTCOME (PRO): THE FRAILQOL

F. Buckinx¹, C. Beaudart¹, J. Y. Reginster¹, Y. Rolland², M. Cesari³, R. Rizzoli⁴, J. Petermans⁵, O. Bruyère¹

¹1. Department of Public Health, Epidemiology and Health Economics, University of Liège, Belgium. WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Ageing, Liège, Belgium, ²2. Gérontopôle, University Hospital of Toulouse III, Toulouse, France, University of Toulouse III, France, Toulouse, France, ³3. Geriatric Unit, Fondazione Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy, Milano, Italy, ⁴4. Service of Bone Diseases, Department of Internal Medicine Specialties, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland, Geneva, Switzerland, ⁵5. Department of Geriatrics, CHU-Liège, Liège, Belgium, Liège, Belgium

Objective: In recent years, there has been an increased focus on placing patients at the center of healthcare research. Currently, the impact of frailty on quality of life of the older is assessed by generic tools only. However, these tools may not detect subtle effects of this geriatric condition on quality of life. Therefore, the aim of this study was to develop a frailty specific Patient Reported Outcome (PRO).

Methods: A two-stage process was followed: (I) Item generation based on a literature review, a Delphi survey conducted among professionals in the field of frailty (i.e., members of the working groups on frailty from the EUGMS or ESCEO), and two focus groups (i.e., one in frail community-dwelling older subjects and one in frail nursing home residents). (II) PRO generation reviewed by 2 linguists.

Results: The first version of the questionnaire consists of 40 items translated into 17 questions rated on a 4-point Likert scale. These items are organised into 6 domains, based on the concept of intrinsic capacity proposed by the WHO: locomotion, sensory, vitality, psychosocial, cognition and others.

Conclusion: The first version of the FRAILQOL, a frailty specific PRO, has been developed. Investigations are now required to test the psychometric properties (internal consistency, test-retest reliability, divergent and convergent validity, discriminant validity, floor and ceiling effects) of this PRO. The number of items will probably be reduced during the validation analyses to lead to a final version.

P543

LONG-TERM TREATMENT WITH TNF α INHIBITORS IMPROVES BONE MINERAL DENSITY BUT NOT VERTEBRAL FRACTURE PROGRESSION IN ANKYLOSING SPONDYLITIS

K. J. Beek¹, T. Rusman¹, M. A. C. Weijden², W. F. Lems¹, J. C. Denderen³, M. Konsta⁴, I. Visman³, M. T. Nurmohamed¹, I. E. Horst-Bruinsma¹

¹Amsterdam Rheumatology and immunology Centre/VUmc and Reade, Amsterdam, The Netherlands, ²Dept Rheumatology, Groene Hart Ziekenhuis, Gouda, The Netherlands, ³Amsterdam Rheumatology and Immunology Centre/Reade, Amsterdam, The Netherlands, ⁴Department of Rheumatology, Veterans Administration Hospital (NIMTS), Athens, Greece

Objectives: To evaluate the long term effects of TNF inhibitors (TNFi) on BMD and the incidence of vertebral fractures (VFX) in patients with ankylosing spondylitis (AS).

Method: Consecutive patients with active AS with a TNFi treatment duration up to 4 y, with available DXA scans and spine X-rays, were included. BMD (classified according to the WHO criteria for osteoporosis) of hip and lumbar spine, the VFX (classified as a Genant score >1 / >20% height loss) and radiological progression (modified stoke ankylosing spondylitis spinal score; mSASSS) scores were performed at baseline and 4 y of TNFi treatment.

Results: Overall, 135 AS patients were included. At baseline, 40.1% of the patients had a low BMD of the hip and 40.2% of the lumbar spine. This decreased respectively to 38.1% (p=0.03) with a low hip BMD and 25.3% (p<0.001) for the lumbar spine after 4 y of TNFi treatment. VFX were present at baseline in 11.1% of the 131 patients, which increased to 19.6% after 4 y of TNFi treatment. A Genant score \geq 2, was found at baseline in, 3 out of 14 VFX (21.4%) which increased to 7 out of 27 VFX (25.9%) after 4 y. All disease activity parameters, The Ankylosing Spondylitis Disease Activity Scale (ASDAS, both CRP and ESR), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), C-reactive protein and erythrocyte sedimentation rate decreased all significantly (p<0.001). The mean radiological progression (n=80) increased significantly from a median mSASSS-score of 4.0 (1.5-16.0) at baseline to 6.5 (2.1-22.9) after 4 y of TNFi treatment (p<0.001).

Conclusion: Despite the improvement of BMD and well-known decrease in disease activity, we still found new VFX, increase in severity in the number and grade of VFX and radiographic progression during 4 years of treatment with TNFi in AS patients with a long disease duration.

Table 1: BMD measurement in spine and hip of 107 AS patients treated with TNFi.

	Baseline*	After 4 y of TNFi**	p-value
Osteopenia LS	34 (31.8)	25 (23.4)	
Osteoporosis LS	9 (8.4)	2 (1.9)	
Low BMD LS	43 (40.2)	27 (25.3)	<0.001
Osteopenia total hip	39 (36.4)	31 (29.0)	
Osteoporosis total hip	4 (3.7)	3(2.8)	
Low BMD total hip	43 (40.1)	34 (31.8)	0.03
Patients with VFX	13 (12.1)	21 (19.6)	0.004
Total number of VFX	14	26	

*1 patient with spondylodesis; 4 patients with a total hip replacement

** 2 patients with spondylodesis; 5 patients with a total hip replacement

LS: lumbar spine, Abnormal BMD= osteopenia and/or osteoporosis according to WHO guideline

Vertebral fractures (VFX) are presented in number of patients with a VFX and the actual prevalence of VFX. Outcomes are presented in n (%)

P544

CLINICAL AND RADIOLOGICAL EFFICACY OF COMBINATION THERAPY OF RHEUMATOID ARTHRITIS WITH SYSTEMIC MANIFESTATIONS

S. Spitsina¹, A. Trofimenko¹, L. Shilova¹, S. Bedina², E. Tikhomirova², M. Mamus²

¹FSBI "Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky", FSBEI HE "Volgograd State Medical University" MOH Russia, ²FSBI "Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky", Volgograd, Russia

Objective: To evaluate clinical and radiological efficacy of infliximab (IF) in combination with methotrexate for treatment of rheumatoid arthritis (RA) with systemic manifestations.

Methods: RA patients with any systemic involvement were intended to include in the study. All the patients were initially treated with methotrexate 12.5-20 mg/week during at least 6 months in combination with different NSAIDS. Intravenous IF 3 mg/kg was then added using the common protocol. We assessed RA activity before initiation of IF therapy (week 0) and after its completion (week 54) using DAS28-CRP(4) score. The number of tender and swollen joints, the VAS data according to patient's assessment, and changes in X-ray manifestations of hands and feet were evaluated both at week 0 and week 54. Results were presented as mean \pm SD, differences were considered significant when p<0.05.

Results: 12 patients with RA and systemic manifestations (only with mild anemia) were included in study. The average age of these patients was 46 \pm 8.4 y. 10 (83.3%) of them were positive for rheumatoid factor, 100% - for anticitrulline antibodies. Radiographic stages III and IV of RA were detected in 8 (66.7%) cases.

All the patients had high disease activity with DAS28-CRP (4) >5.2. Positive effects of infliximab was observed in terms of intensity of articular inflammation including time of the morning stiffness and number of painful and swollen joints. By the end of 54th week DAS28-CRP(4) was 2.77 ± 0.9 , and this decrease was significant ($p < 0.05$). The mean VAS score was also lower at 54th week comparing to week 0: 65.0 ± 12.9 mm and 16.5 ± 10.07 mm, respectively; $p < 0.05$. On hand and feet radiographs at 54th week, there was no increase in cyst-like bright colored structures and erosions. **Conclusion:** Combination therapy with infliximab and methotrexate leads to increase of the efficacy of RA treatment with anemia in terms of clinical activity and radiological progression.

P545

MICRORNA-125B EMBEDDED IN BONE MATRIX EXERTS PROTECTIVE EFFECTS ON OVARECTOMY- AND NEURECTOMY-INDUCED BONE LOSS BY SUPPRESSING OSTEOCLAST FORMATION

T. Minamizaki¹, F. Faisal¹, N. Nushrat¹, S. Ito¹, K. Tanimoto¹, Y. Yoshiko¹

¹Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan

Objective: Growing evidence indicates the roles of microRNAs (miRNAs) in bone. We found that miR-125b expressed in osteoblasts accumulates in bone matrix as a "cargo" of matrix vesicles, key players in the initiation of bone mineralization. During bone resorption, miR-125b is released from bone matrix and acts on osteoclast precursors, resulting in impaired osteoclast formation by downregulating the transcription repressor PRDM1 and subsequent increase in negative regulators of osteoclastogenesis, such as IRF8 and MAFB. Transgenic (Tg) mice overexpressing miR-125b under the control of the human osteocalcin promoter displayed increased bone volume with decreased number of osteoclasts and without affecting bone formation. We therefore aimed to determine whether MV-based transfer of miR-125b to bone matrix represents a potential therapeutic target for bone loss using mouse models.

Methods: 8-week-old female and 10-week-old male wildtype (WT) and Tg mice were ovariectomized (OVX) and sciatic-neurectomized (NX), respectively. Four weeks postoperation, bone parameters in tibiae/femurs were analyzed by microCT and histology and compared with those of sham-operated control mice. To determine the direct effect of miR-125b on bone, LPS was injected subcutaneously into newborn WT mice over the calvaria with transfection of miR-125b mimic or control microRNA. LPS-induced osteolysis was measured by TRAP staining.

Results: OVX increased body weight gain with hypoplastic uterus in both phenotypes. OVX-induced trabecular bone loss, as declines in BMD, bone volume, trabecular thickness and so on, was much lower in Tg compared to WT mice. An increase in the number of osteoclasts per bone perimeter was obvious in OVX-WT but not OVX-Tg mice. Similarly, trabecular bone loss was significantly blunted in Tg mice compared to WT mice subjected to

NX. LPS-induced osteolysis visualized by tartrate-resistant acid phosphatase staining was significantly attenuated, when miR-125b mimic was transfected.

Conclusion: Our findings reveal that osteoblast-derived miR-125b which accumulates in bone matrix can protect bone from OVX- and NX-induced bone loss. These data may provide a novel therapeutic target for bone diseases.

P546

PLACENTAL VOLUME IN EARLY PREGNANCY IS ASSOCIATED WITH OFFSPRING BONE AND LEAN MASS: FINDINGS FROM THE SOUTHAMPTON WOMEN'S SURVEY

S. D'Angelo¹, E. M. Curtis¹, P. A. Mahon¹, S. R. Crozier¹, Z. A. Cole¹, E. M. Dennison¹, K. M. Godfrey¹, H. M. Inskip¹, C. Cooper¹, N. C. Harvey¹

¹MRC Lifecourse Epidemiology Unit, Southampton, UK

Objectives: Growth in utero is associated with later musculoskeletal health. We therefore investigated associations between placental volume measured in early pregnancy (EP: 11 weeks' gestation), and bone and lean mass at birth and at age 6 years.

Methods: The Southampton Women's Survey is a longitudinal study of women (recruited preconception) and their children. To assess placental volume, 3D ultrasound scanning in early pregnancy was performed in a subset (n=242) using a Kretz Voluson 730 scanner with a 3D curvilinear multi-frequency transducer (Zipf, Austria). Maternal height was measured and information on smoking in early pregnancy and parity was collected via questionnaire. DXA was performed on the neonates within the first 2 weeks of life and again at 6 years. Linear regression was used to assess associations between placental volume, bone mass and body composition.

Results: We observed positive relationships between placental volume at 11 weeks and neonatal bone area ($\beta = 0.385$ (95%CI 0.063 to 0.707) cm^2/cm^3 , n=83), bone mineral content (BMC) ($\beta = 0.24$ (95%CI 0.044 to 0.44) g/cm^3 , n=83), and lean mass ($\beta = 4.47$ (95%CI 0.39 to 8.55) g/cm^3 , n=83) after adjustment for gestational age at ultrasound, child's sex, gestation duration at birth, age at DXA, maternal height, smoking in early pregnancy and parity. Significant positive associations were also found at 6 years with bone area ($\beta = 1.057$ (95%CI 0.101 to 2.012) cm^2/cm^3 , n=103), BMC ($\beta = 1.80$ (95%CI 0.47 to 3.13) g/cm^3 , n=103) and BMD ($\beta = 0.001$ (95%CI 0.0002 to 0.002) $\text{g}/\text{cm}^2/\text{cm}^3$, n=103) adjusted for the same maternal and childhood factors. At 6 y lean mass was of borderline significance after adjustment ($p = 0.07$).

Conclusions: We found that placental volume in early pregnancy was positively associated with childhood bone area, BMC and BMD at age 6 y, independent of maternal factors known to be associated with childhood bone mass. Our findings emphasise the importance of maternal placental development in early pregnancy in determining a child's future musculoskeletal health.

P547

COST EFFECTIVENESS OF AN FLS IN A BRAZILIAN HEALTHCARE PROVIDERB. Stolnicki¹¹Prevrefrat - Programa de Prevenção a Refraturas, Rio de Janeiro, Brazil

Objective: Fiosaúde is a healthcare provider that has approximately 15.000 beneficiaries. 27% of them are over 60 years of age. In January of 2015 we started an FLS in the Fiosaúde Clinic. Men and women over 50 years of age with a history of fragility fractures were referred. From 2016, patients with a high risk of fractures (BMD <2.5 SD in the lumbar spine or neck of the femur or total femur) were referred without previous fractures. The objective of this presentation is to demonstrate the cost effectiveness of FLS in this environment and the avoided cost in fractures.

Methods: From January 2015 to December 2018, 144 patients (127 women and 17 men) were assigned to receive targeted intervention to reduce fracture or refracture rates. The patients data related to fractures and incidence of new fractures are reported.

Results: 108 had previous fractures and 36 had no fractures. 47 patients had 1 previous fracture, 38 had 2 fractures and 23 had 3 or more previous fractures. 67 patients were assigned to receive yearly zoledronic acid 5 mg infusion. 65 patients were assigned to receive twice daily subcutaneous injection of denosumab 60 mg. 12 patients were assigned to receive monthly ibandronate 150 mg. 4 new fractures occurred (2 transtrochanteric and 2 pelvis). In this environment the cost of a fragility fracture is U\$10,500. The annual cost of a patient in the FLS is \$786, including medical fees, medication and laboratory and imaging tests. There was no additional investment by the health infrastructure operator in the implementation of FLS. It is estimated that 66 fragility fractures were avoided. Calculating the annual cost of patients in the FLS, the cost of the 4 fractures occurred and the avoided cost of the fractures, the balance is positive at U\$546,133.33.

Conclusion: The FLS in the healthcare provider environment is high cost effective.

Reference: 1. King AB et al. Osteoporos Int 2005;16:1545.

P548

FRAILITY INTERVENTIONS TO IMPROVE PHYSICAL PERFORMANCE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALSA. Negm¹, C. Courtney², I. Cameron³, L. Thabane⁴, A. Veroniki⁵, J. D. Adachi⁶, J. Richardson¹, M. Petropoulou⁵, J. Alzahrani⁷, A. Papaioannou²

¹McMaster University, School of Rehabilitation Science, Hamilton, Ontario, Canada, ²Hamilton Health Sciences, Geriatric Education and Research for the Aging Sciences, Hamilton, Ontario, Canada, ³University of Sydney, John Walsh Centre for Rehabilitation Research, Sydney, Australia, ⁴McMaster University, Department of Health Research Methods, Evidence, and Impact, Hamilton, Ontario, Canada, ⁵University of Ioannina, Department of Primary Education, Ioannina, Greece, ⁶McMaster University, Department of Medicine, Hamilton, Ontario, Canada, ⁷Prince Sattam Bin Abdulaziz University, College of Medicine, Alkharj, Saudi Arabia

Objectives: Frailty, falls and age-related declines in physical performance are reversible. To guide clinical management, a systematic review and network meta-analysis (NMA) were performed. The latter methodology enables the simultaneous assessment of the effects of multiple interventions for the same condition. Our objective is to determine the comparative effectiveness of frailty interventions on physical performance measured by short physical performance battery (SPPB). Secondary outcomes included knee strength, balance, walking speed, grip strength, and adverse events.

Methods: Randomized controlled trials (RCTs) were identified by systematic search of several databases (MEDLINE, EMBASE, CINAHL, AMED). Duplicate title/abstract and full-text screening, data extraction and risk of bias assessment were performed. Inclusion criteria were singular or multifaceted interventions targeting frailty and/or improvement in physical performance. Comparators were standard care, placebo or another intervention. We performed both standard pairwise meta-analysis and Bayesian NMA under a random-effects model. Pooled estimates of treatment effects were odds ratios for dichotomous outcomes and standardized mean difference (SMD) for continuous outcomes. Interventions of each outcome were ranked using the surface under the cumulative ranking curve (SUCRA) and presented in a rank-heat plot. The GRADE approach specific to NMA was used to assess the quality of the evidence.

Results: A total of 180 RCTs were included after screening of 7090 citations and 749 full-text articles. The mean age of included studies ranged between 75 and 85 years, BMI between 25 and 30; 62.5% of participants were female. Of the included RCTs, 77.7% had overall high risk of bias. The NMA for SPPB (including 36 RCTs, n=4568, 9 interventions) suggested that medication management intervention, when compared to placebo/standard care, were associated with the greatest improvement in SPPB score (SMD, 3.94 (95%CI, 0.93 to 6.98) followed by physical activity with nutritional supplementation (SMD, 2.41 (95%CI, 1.21 to

3.63). According to SUCRA, medication management intervention and physical activity plus nutritional supplementation were the most effective interventions (100% and 88% likelihood, respectively).

Conclusion: Medication management and physical activity with nutritional supplementation were most effective in improving physical performance of older adults. Given the low quality of evidence available, more intervention studies that rigorously examine treatments to improve physical performance are required.

P549

ESTIMATION OF CALCIUM, VITAMIN D, AND ALKALINE PHOSPHATASE IN POSTMENOPAUSAL WOMEN

M. Vuković¹, S. Nejkov¹, V. Bokan Mirković¹, Z. Škarić Karanikić¹

¹Center for Physical and Rehabilitation Medicine, Clinical Center of Montenegro, Podgorica, Montenegro

Objective: To evaluate the correlation between serum calcium (Ca), alkaline phosphatase (ALP), vitamin D and BMI in group of postmenopausal women.

Methods: 20 women with low BMD participated in the study. Reference values for Ca level in serum are 2.15-2.55 mmol/l, and for ALP <104 IU/L. The level of vitamin D <30 nmol/l is defined as a deficiency, 30-50 nmol/l is insufficient, and the level higher than 50 nmol/l as sufficient.

Results: 10 patients had BMD at osteoporosis level (G1 group) and 10 at osteopenia (G2 group) level. The groups were homogeneous in ages (G1- mean ages 62.3±5.31, G2- mean ages-62.2±8.65, t=-0.031, p=0.975). Median values of Ca in G1(2.41; 2.13-2.56) and in G2 (2.39; 2.30-2.74) and the difference is not statistically significant (Mann-Whitney test W=50.5, p=1). There is no statistically significant difference in median ALP values in G1 and G2; G1 med (50.5; 21-220), G2 med (66; 42-85) (Mann-Whitney test W=61.5, p=0.405). Mean value of vitamin D G1 72.11±29.42, G2 mean 69.83±24.67, t=-0.188, p=0.853. Mean value of BMI in G1 23.49±3.51, in G2 28.01±4.07, there is a statistically significant difference in BMI between G1 and G2 (t=2.655, p=0.016). There is no statistically significant correlation in Ca and ALP levels in G1 (Spearman's rank correlation coefficient 0.235 p=0.514), while in G2 there is a positive moderate correlation (Spearman's rank correlation coefficient 0.683, p=0.03, S=52.317). There is no statistically significant correlation between the levels of vitamin D and ALP in both groups (G1 Spearman's rank correlation coefficient -0.237 p=0.51, S=204.12; G2 Spearman's rank correlation coefficient 0.584 p=0.076, S=68.708).

Conclusion: There was no statistically significant difference in Ca, vitamin D and ALP levels between these two groups, while BMI values were statistically significantly higher in the osteopenia group. In osteopenia group there is a positive moderate correlation between the level of Ca and ALP.

P550

A BIOMECHANICAL ANALYSIS ABOUT FIXING THE LOCKING COMPRESSION PLATE OF DISTAL FEMUR FRACTURES

I. Park¹, C. Oh¹, J. Lee¹


¹Kyungpook National University Hospital, Daegu, South Korea

Objective: A locking compression plate with the technique of minimal invasive plate osteosynthesis has been the most commonly used procedure in distal femur fractures. However, when the patient is old and the bone is osteoporotic, it is difficult to fix a sufficient number of screws at the distal part of the plate. From this viewpoint, this study aimed to identify how biomechanical stability varies according to the numbers of distal part screws of the LCP - DF, which is a standard implant for the distal femur fractures.

Methods: Biomechanical stability was compared between three LCP-DF fixation groups (3-screw group, 4-screw group, and 6-screw group). For each group, 6 synthetic adult-sized femur models (Model 3403, Pacific Research Laboratories) were used for the biomechanical research. The composite replicate femurs was used to simulate the distal femur fracture with comminution. After fixing the LCP-DF, the bone of 6 cm and 8.5 cm above the distal edge of knee part, was removed with a gap of 2.5 cm. For the biomechanical analysis, the servohydraulic testing machine (MTS 810 Material Test System, MTS Systems, Eden Prairie, MN) was used. For the cyclic loading, an axial loading of 100-1000 N, 3 Hz, and 100,000 cycle was given, after a 100 N preload was given. For the failure test, an axial load at a velocity of 10 mm/min was given so that the load to failure, mode of failure and displacement at load to failure were all recorded and analyzed.

Results: During the cyclic loading test, there was no failure in all of the 3-screw, 4-screw and 6-screw groups. In load-to-failure test, average load to failure was 4214.8N (ranging from 4138-4390 N) for the 3-screw group, 4273.2 N (from 4143-4329 N) for 4-screw group, and 4713.3 N (from 4587-4955 N) for the 6-screw group (p=0.007). Every sample taken from the three groups showed cracks. The average displacement in the failure showed an average of 10.3 mm (ranging from 9.6-11.8 mm) for the 3-screw group, 9.1 mm (ranges from 6.5-11.7 mm) for the 4-screw group and an average of 8.8 mm (ranges from 6.4-10.4 mm) for the 6-screw group. As expected, 6 screws group was the strongest biomechanical construct of LCP-DF in the fixation of extra-articular distal femur fractures.

Conclusion: However, when there is no osteoporosis in fractures with the difficulty to fix 6 screws at the distal fracture segment, the fixation of 3-4 screws were also achieved an acceptable stability, biomechanically. However, the further study is needed in the model of the elderly people or osteoporotic fractures.



ysis of the cortical and trabecular bone could potentially provide insightful information to monitor patients undergoing bariatric surgery.




Figure 1: Anatomical distribution of mean changes in cortical sBMD after bariatric surgery

P551

CHANGES IN FEMORAL CORTICAL AND TRABECULAR BONE AFTER BARIATRIC SURGERY

L. Humbert¹, R. Winzenrieth¹, C. Gomez-Vaquero², N. Vilarrasa³, C. Xammar², F. Guerrero³, A. Casajoana⁴

¹Galgo Medical, ²Rheumatology Department, Hospital Universitari de Bellvitge, ³Endocrinology and Nutrition Department, Hospital Universitari de Bellvitge, ⁴Bariatric Surgery Unit, Hospital Universitari de Bellvitge, Barcelona, Spain

Objective: To evaluate changes in femoral cortical and trabecular bone after bariatric surgery.

Methods: Male and Female adults who underwent bariatric surgery were included in this study. Hip DXA scans were performed before the surgery, and between 6-18 months after the surgery. Scans were acquired at the Hospital Universitari de Bellvitge (Barcelona, Spain) using a Hologic QDR 4500 scanner. Areal BMD (aBMD) was calculated at total femur. 3D analysis of the cortical and trabecular bone was performed from the hip DXA scans using the 3D-SHAPER software (v2.9, Galgo Medical, Barcelona, Spain). Trabecular volumetric BMD (vBMD) and cortical surface BMD (sBMD) were calculated at total femur. Changes in DXA-derived aBMD and 3D measurements between baseline and follow-up visit were expressed as a percentage and compared using paired Student's t-test.

Results: 13 subjects (9 female and 4 male) were included in this study. Mean (SD) age at baseline (i.e., before surgery) was 53.4 (6.6) y. Follow-up scans were performed on average at 13.4 (3.6) months from baseline. Mean weight was 89 (16) kg at baseline and 73 (12) kg after surgery ($p < 0.001$). An 8.3% decrease in total hip aBMD was observed after surgery ($p = 0.001$). Decrease was 12.8% ($p = 0.001$) in trabecular vBMD and 6.0% ($p = 0.005$) in cortical sBMD. Figure 1 shows that the mean changes in cortical sBMD were more pronounced at the lateral aspect of the greater trochanter (magenta area). Although decreased, bone density measurements after surgery were normal for their age with Z-scores of 0.5 for total hip aBMD, 0.8 for cortical sBMD and 1.3 for trabecular vBMD.

Conclusion: Patients who underwent bariatric surgery, although suffering from marked decrease in trabecular and cortical density, showed normal bone density for their age. DXA-based 3D anal-

P552

PREDICTORS OF BONE MINERAL DENSITY AND BONE MINERAL CONTENT IN TYPE DIABETES MELLITUS

B. Karnwal¹

¹Gajra Raja Medical College, Gwalior, India

Objective: Obesity and hyperinsulinemia can lead to lower bone turnover in type 2 diabetes mellitus (T2DM) patients. Studies assessing BMD in T2DM have given mixed results with few suggesting normal to increased BMD whereas others documenting decreased BMD. Factors modulating BMD in T2DM have not been well determined. This study analysed the effect of body fat distribution on BMD and bone mineral content (BMC) in patients of T2DM. We compared BMD and BMC in normal (BMI < 25 kg/m²) and obese (BMI > 25 kg/m²) T2DM patients with age and BMI matched controls, and evaluated the impact of lean mass and body fat distribution on them.

Method: Anthropometric assessment and blood sampling was done in 70 T2DM patients and 70 normal controls. BMD, BMC, lean mass and body fat distribution were measured by DXA.

Results: Obese individuals had significantly higher BMD, BMC, fat mass and significantly lower 25(OH)vitamin D levels. Lean mass showed strong positive correlation with BMC and BMD as compared with fat mass. Percent body fat showed negative correlation with BMC and BMD. BMI and android/ gynoid (A/G) ratio showed positive correlation with BMD and BMC. T2DM patients had higher central obesity (A/G ratio) and waist circumference was best predictor of A/G ratio. Regression analysis revealed lean as the strongest predictor of BMC after adjusting for age, sex, BMI and 25(OH)vitamin D, both in normal individuals and in patients with T2DM. Fat mass and percent body fat were significantly higher in females whereas BMD, BMC, lean mass and A/G ratio were significantly higher in males.

Conclusion: T2DM and obese individuals have increased BMD and BMC with lean mass being the strongest predictor of BMC in normal individuals and T2DM.

P553

VITAMIN D IMPROVES GLYCEMIC OUTCOMES IN PREDIABETES THROUGH REDUCED FETUIN-A AND SYSTEMIC INFLAMMATION

M. Kumar¹, D. Dutta², S. Mukhopadhyay³, S. Mondal³

¹CEDAR (Center for Endocrinology Diabetes and Research), Chandigarh, ²Venketeshwar Hospital, Delhi, ³IPGME&R, Kolkata, India

Objective: To evaluate the impact of VitD supplementation on FetA and systemic inflammation [IL6, IL1 β , TNF α , soluble TNF receptor (sTNFR)1, sTNFR2] in IPD, and their relationship with long-term glycemic outcomes.

Methods: From an initially screened 2245 individuals, 207 IPD with persistent IFG and/or IGT over 2 successive OGTTs with vitD <30 ng/ml were randomized into intervention group (Group-I) (cholecalciferol 60,000 U once weekly for 8 weeks and then monthly with 1250 mg of calcium carbonate/d for study duration), and control groups [Group-C1 (calcium control group: 1250 mg of calcium carbonate/d); and Group-C2 (placebo control group: placebo tablet similar to calcium tablet)]. All received therapeutic lifestyle modification. Glucose tolerance, insulin, 25OHD, lipids, IL6, TNF α and hsCRP were done baseline and annually. Data from IPD with at least 1-y follow-up were analyzed.

Results: Data from 192 IPD (males: females=122:70) with at least 1-y follow-up were analyzed (mean follow-up: 27.68 \pm 9.72 months). At end of study, IPD in intervention group had greatest reduction in FBG, 2hPGBG, HbA1c, fetuin-A, total cholesterol, IL6, sTNFR1, sTNFR2, which was statistically significant. Group-I IPD also had greatest increase in 25OHD (Δ 25OHD: 22.96 [11.54 – 40.30] ng/ml; P<0.001). Quantum of decrease in serum triglycerides, LDL-C and HDL-C was greatest in Group-I. Placebo control group (Group-C2) had greatest increase in hip circumference and IL1 β . Analysis based on glycemic outcomes revealed IPD who reverted to normoglycemia had highest baseline 25OHD, sTNFR2, along with greatest reduction (Δ change) in FetA, sTNFR1 and sTNFR2. 42.7% (41/96) IPD in intervention group reversed back to normoglycemia, in contrast to 22.92% (22/96) in control groups (P=0.003). With regards to progression to T2DM, it was 10.41% (10/96) in intervention group and 17.70% (17/96) in control groups (P=0.144). Cox regression revealed that FBG, 25OHD, fetuin-A, HOMA-IR, sTNFR1 and Group-I independently predicted prediabetes reversal to normoglycemia. Only FetA was an independent predictor of prediabetes progression to T2DM. Every 1 mg/dl increase in blood glucose was associated with 3.7% decreased reversal to normoglycemia. Every 1ng/ml increase in serum 25OHD was associated with 3% increased reversal to normoglycemia. Every 1 μ g/ml increase in FetA was associated with 0.4% decreased reversal to normoglycemia and 0.6% increased progression to T2DM. Kaplan Meier analysis also showed significantly higher rates of prediabetes reversal to normoglycemia in intervention group (P=0.033; log rank test [Mantel-Cox]). 42.7% IPD in intervention group reversed back to normoglycemia in contrast to 22.92% in the control groups. This evaluation achieved power of 83.7%, keeping a (type I error) at 0.05.

Conclusion: VitD supplementation in prediabetes was associated with improved glycemic outcomes, significant reduction in serum FetA, decreased IR and systemic inflammation.

P554

WILL THERE BE A FRACTURE IN THEIR FUTURE? BONE MINERAL DENSITY FINDINGS IN YOUNG SOUTHEAST ASIAN WOMEN WITH ANOREXIA NERVOSA

M. Chandran¹, Y. Hao²

¹Osteoporosis and Bone Metabolism Unit, Singapore General Hospital, ²Health Services Research Unit, Singapore General Hospital, Singapore

Objective: Anorexia nervosa carries with it an increased risk of bone loss and fractures. No prior study has explored the bone density findings of Southeast Asian women with this condition and therefore that was the aim of our study.

Method: Case notes of 100 young women aged 20-30 with a history of anorexia nervosa and who were seen in the Endocrinology clinic of a large public hospital for evaluation of their bone health were retrospectively reviewed. 75 of them had DXA scans performed at the time of initial diagnosis and these scans were examined and these patients were analysed further.

Results: 49 (65%) had a diagnosis of restrictive type anorexia nervosa. The remaining carried a diagnosis of binge purge type. 97% of the women were Chinese, the remaining were Malay or Indian. The mean (SD) age and BMI at presentation was 18.5 (5.7) and 14.2 (2.0) respectively. The mean (SD) duration of amenorrhea in months at the time that the DXA scans were done was 16.5 (14). 19 of the 85 women had a Z-score \leq -2 at the LS or neck of femur. Age at presentation (17.1 (5.3) vs. 22.1 (5.9); p=0.005), duration of untreated illness in years (1.51 (1.45) vs. 3.9 (3.1); p=0.001 and duration of amenorrhea in months (12.48(12.6) vs. 31.2 (30.9) were significantly associated with Z-score of \leq -2 at either lumbar spine or neck of femur. None of the women had been started on any potential bone metabolism modifying agents including oral contraceptives at the time the DXA scans were done.

Conclusion: Early identification and treatment that will help to shorten the duration of illness and amenorrhea may help to ameliorate bone density losses in anorexia nervosa. This may potentially prevent complications such as fragility fractures in later life.

P555

RELATIONSHIP AMONG SPINAL ALIGNMENT, BONE MINERAL DENSITY, AND MUSCLE MASS IN ELDERLY OSTEOPOROSIS PATIENTS

K. Ayumu¹, M. Masayuki¹, F. Hisako¹, I. Gen¹, N. Toshiyuki¹, I. Takayuki¹, S. Wataru¹, U. Kentaro¹, S. Eiki¹, O. Seiji², I. Kazuhide², T. Masashi¹

¹Department of Orthopedic Surgery, Kitasato University, School of Medicine, Sagamihara,

²Department of Orthopedic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan

Objective: Elderly patients with osteoporosis often complain of back pain associated with pathological vertebral fractures which cause abnormal spinal alignment. Recently, the relationship between abnormal spinal alignment and low back pain has become increasingly more apparent, and corrective surgery for such conditions is being performed. There were few reports to evaluate the relationships among muscle mass, BMD, spinal sagittal alignment and low back pain. We hypothesized that decreasing muscle mass in elderly patients with osteoporosis could also cause abnormalities in spinal alignment. This study evaluated the relationship among spinal alignment, BMD, and muscle mass in elderly patients with osteoporosis.

Methods: A total of 50 patients aged over 75 y with severe osteoporosis and pathological vertebral fractures were included in this study. We evaluated the sagittal vertical axis (SVA), pelvic tilt (PT), pelvic incidence minus lumbar lordosis (PI-LL), bone density by DXA analysis, and trunk and limb muscle mass by bioelectrical impedance analysis. Low back pain was evaluated by the Oswestry disability index (ODI). Corrected trunk muscle mass and corrected limb muscle mass (skeletal mass index: SMI) were also measured.

Results: The mean age of patients was 80.3 y and the average number of vertebral bodies fractured was 3.4. There was significant low positive correlations between TMI and SVA or PI-LL ($r=0.31$, and $r=0.30$, respectively). Further, there were significant low positive correlations between SMI and SVA ($r=0.30$, respectively). When we compared between normal group and imbalance group, regarding the PI-LL, TMI, SMI, ODI score in imbalance group were significantly higher than those in normal group ($p<0.05$). Further, here were more vertebral fractures in imbalance group compared with the normal group ($p<0.05$).

Conclusion: Elderly osteoporosis patients with spinal sagittal imbalance had more vertebral fractures and a higher risk of low back pain as we expected. Interestingly, patients with spinal sagittal imbalance tended to have a higher muscle contrary to hypothesis. However, since muscle mass is not necessarily proportional to muscle strength, a concurrent evaluation of muscle strength is necessary in the future.

P556

MUSCULOSKELETAL DISORDERS AMONG GREEK COMPETITIVE WATER POLO ATHLETES

P. Gkrilias¹, C. Matzaroglou¹, A. Kaloudis¹, I. Andriopoulos¹

¹Technological Educational Institute (TEI) of Western Greece, School of Health and Welfare, Department of Physical Therapy, Aigio Achaïas, Greece

Objectives: The highly repetitive nature of competitive water polo associated with injuries^{1,2}. The purpose of this study was to record the musculoskeletal symptoms per anatomical body region in adult Greek competitive water polo players.

Methods: The Greek version of Nordic Musculoskeletal Questionnaire (NMQ)³, was given to adult participants during the 2017 water polo season. Participants in NMQ were asked whether they had pain /discomfort in 9 different anatomical regions (neck, shoulders, elbow, wrists/hands, upper back, lower back, hips/thighs, knees and ankles/feet) during the preceding 12 months and if those symptoms prevented their normal activity during the last year as well as the 7 previous days. Analysis consisted of descriptive statistics.

Results: 75 (23 in A1-first category, 52 in B-third category) water polo players (age: 23.5 ± 6.4 y, height: 1.84 ± 0.06 m, weight: 85.1 ± 12.0 kg, BMI: 25.2 ± 2.8 kg/m², training age: 11.7 ± 5.5 y, training h/week: 10.7 ± 5.6 h) completed the NMQ. The 12-month prevalence rate of pain/discomfort was 58,7% in shoulders, followed by the neck (34.7%), lower back (24%), elbows-knees-wrists/hands (20%), hips/thighs (10.7%), upper back (8%) and ankles/feet (5.3%). Those symptoms prevented athlete's normal activity (functionally) during the last 12 months with different prevalence rate per anatomical body region (shoulders: 30.7%, neck: 16%, wrists/hands: 10.7%, elbows and lower back: 8%, knees and upper back: 5.3%, hips/thighs: 4% and ankles/feet: 2.7%).

Conclusion: The high prevalence of musculoskeletal pain/discomfort in adult water polo players, highlights the need for specific injury prevention programs.

References:

1. Wolf BR et al. Am J Sports Med 2009;37:2037.
2. Mountjoy M et al. Br J Sports Med 2010;44:522.
3. Antonopoulou M et al. Eur J Gen Practice 2004;10:35.

P557

ATYPICAL FEMORAL FRACTURE INCIDENCE IN AN ORTHOPAEDIC SETTING

J. C. Fernandes¹, J. Delisle¹, B. Benoit¹, G. Y. Laflamme¹, S. Leduc¹, M. Malo¹, H. Nguyen¹, P. Ranger¹, S. Morin²

¹CIUSSS NIDM- Hopital Jean Talon, ²McGill University Health Center, Montreal, Canada

Objective: Atypical femoral fractures (AFFs) are mostly associated with patients taking antiresorptive osteoporosis therapy. The reported absolute risk of AFFs in this population ranges from 3.2 to 50 cases out of 100,000 people/year and with long term exposure to antiresorptive osteoporosis therapy, it may increase up to

100 out of 100,000 people/year. Also, two-thirds of the AFF are bilateral. The goal of the study was to determine the incidence of AFF in all femoral and subtrochanteric fragility fractures seen our orthopaedic surgery department.

Method: 576 femoral fragility fractures were admitted between October 2011 and August 2015 in our institution. All X-rays were reviewed to identify AFFs. Descriptive statistics (mean, standard deviation, proportions) were used to present patients characteristics. Men & women were compared using student t-test and Pearsons X2/Fisher's exact test. Antiresorptive osteoporosis therapy status was compared using Fisher's exact test. All analysis were done with SPSS v 25.0 (IBM corp. 2017, Armonk, NY), $p < 0.05$ was considered statistically significant.

Results: Mean age of the cohort of patients ($n=576$) was 82.9 ± 10.2 and 76.5% were women. We identified 11 AFFs (2% overall incidence) and all were sustained by women. All were treated by long intramedullary locking nailing. At the time of the fracture, eight out of 135 patients taking anti-resorptive osteoporosis therapy (5.9%) and three out of 441 patients that were not (0.7%) sustained an AFF. Patients under anti-resorptive osteoporosis therapy had a significantly higher incidence of AFF compared to patients that were not ($p < 0.001$). Only three out of 11 (27%) were initially identified as AFF by the treating orthopaedic surgeon. Two out of 11 underwent contralateral investigations, and one of them presented with a bilateral AFF.

Conclusion: The overall incidence of AFF in all femoral and subtrochanteric fragility fractures seen in our orthopaedic surgery department is 2%. They were all sustained by women. Not recognizing an AFF may lead to delay in healing and to miss contralateral AFF identification and prophylactic nailing. It may also result in a failure to adjust antiresorptive osteoporosis therapy accordingly.

P558

EFFECTS OF 12 MONTHS OF RESISTANCE TRAINING VS. ENDURANCE TRAINING ON BONE MINERAL DENSITY, HIP GEOMETRY INDICES AND TRABECULAR BONE SCORE IN A GROUP OF YOUNG OVERWEIGHT WOMEN

A.-J. Berro¹, S. Kazwini¹, S. Ahmaid², R. El Hage¹

¹University of Balamand, Faculty of Arts and Sciences, Kelhat, El-Koura, Lebanon, ²EA-3300, APERE, Sport Sciences Department, University of Picardie Jules Verne, Amiens, France

Objective: To analyze the effects of two different training protocols on body composition, bone mineral content (BMC), BMD, geometric indices of hip bone strength, composite indices of femoral neck strength and trabecular bone score (TBS) in a group of young overweight women.

Methods: 43 young overweight women (BMI > 25 kg/m²) whose ages range from 18-35 y were randomly assigned to a resistance training group (RTG, $n=15$), an endurance training group (ETG, $n=14$), or a control group (CG, $n=14$). The experimental groups performed incremental training of 3 sessions per week for the period of 12 months. Weight, height, body composition, BMC, BMD, TBS, geometric indices of hip bone strength (cross-sectional area

(CSA), cross-sectional moment of inertia (CSMI) and strength index (SI)), maximal half-squat strength and maximal aerobic velocity were measured before and after the training period. Composite indices of femoral neck (FN) strength (Compression strength index (CSI), bending strength index (BSI) and impact strength index (ISI)) were calculated before and after the training period as previously described [1].

Results: Both experimental groups (RTG and ETG) showed significant decreases in weight, BMI, fat mass, fat mass percentage, hip and waist circumferences. Both experimental groups (RTG and ETG) showed significant increases in lumbar spine BMD and WB BMC values. RTG showed significant improvements in lean mass, maximal strength, maximal aerobic velocity, TBS, SI, CSI, BSI and ISI. ETG showed significant increases in maximal aerobic velocity and maximal strength but a significant decrease in trunk fat mass percentage. In the CG, weight, BMI and hip circumference were increased but CSI, BSI and ISI were significantly decreased. In the RTG, The variation of TBS was positively correlated with the variation of vertical jump and that of maximal half-squat strength. RTG showed the highest improvements in maximal strength and ETG showed the highest improvement in maximal aerobic velocity.

Conclusion: The present study shows that resistance training is an effective method to decrease fat mass and to increase lean mass, BMD, trabecular bone score and composite indices of femoral neck strength in young overweight women.

References: 1. Karlamangla AS et al. Osteoporos Int 2004;15:62.

P559

RAINE SYNDROME AS A RARE CAUSE OF HYPOPHOSPHATEMIA AND OSTEOSCLEROSIS IN AN ADULT PATIENT

D. Davtyan¹, E. Mamedova¹, E. Przhialkovskaya¹, E. Vasilyev¹, A. Tiulpakov¹, Z. Belaya¹

¹The National Medical Research Centre for Endocrinology, Moscow, Russia

Raine syndrome is an extremely rare hereditary disease, of which one of the clinical presentations may be hypophosphatemia, caused by increased loss of phosphate in the urine due to increased levels of fibroblast growth factor 23 (FGF23). It has been found that a mutation in the gene FAM20C is the cause of the Raine Syndrome phenotype. With accordance to previously described cases of Raine syndrome, it is considered to be a fatal disease leading to death within few hours of birth or in a childhood.

A 38 year old female patient (height – 166 cm; weight – 58 kg) was referred to our clinic due to pain in long bones and joints of her extremities, exacerbated by physical activity. These symptoms have gradually progressed over the last seven years. The patient also reported dental prosthesis due to amelogenesis imperfecta since childhood. On examination, signs of dysmorphism were noted such as nose hypoplasia, low-set ears, exophthalmos. On X-Ray, CT and DXA scans we found craniosynostosis, osteosclerosis, cerebral calcification; +2.25 Z-score DXA lumbar Spine, but -1.5 Z-score at the femoral neck. Low phosphate levels were

registered in all presented laboratory tests varying from 0.51-0.6 mmol/l (reference range 0.74-1.52 mmol/l); tubular phosphate reabsorption – 47%. In addition to this she had vitamin D deficiency – 10 ng/ml; which was associated with secondary hyperparathyroidism PTH- 76.9 pg/ml (15-65 pg/ml); calcium – 2.28 mmol/l (2.1-2.55 mmol/l); calcium ionized – 1.14 mmol/l (1.03-1.29 mmol/l), alkaline phosphatase, creatinine and bone remodeling markers were within the reference ranges. Interestingly, the patient had increased calcitonin – 30.2 pg/ml (reference range <8.8 pg/mL), without any signs of thyroid gland abnormality. A whole exome sequencing revealed compound heterozygous mutations in the gene *FAM20C*: c.1107_1108insTACTG (p.Y369fs) and c.1375C>G (p.R459G), which has not been reported before.

In summary, this is one of the few adult clinical cases of osteosclerosis and low phosphate levels caused by Raine syndrome which was confirmed by the exome sequencing. The type of mutation probably explains the mild phenotype of this patient.

P560

MUSCULOSKELETAL DISORDERS AMONG GREEK COMPETITIVE TABLE TENNIS ATHLETES

P. Gkriilas¹, I. Aivaliotis¹, C. Matzaroglou¹, K. Fousekis¹, E. Tsepis¹

¹Technological Educational Institute (TEI) of Western Greece, School of Health and Welfare, Department of Physical Therapy, Human Assessment & Rehabilitation Lab TEI of Western Greece, Aigio Achaïas, Greece

Objectives: To record the musculoskeletal symptoms in each anatomical body region in Greek competitive table tennis athletes.

Methods: The Greek version of the Standardized Nordic Questionnaire¹ (SNQ) was administered to participants during the scheduled table tennis games of the 2017-2018 season. Participants in SNQ were asked whether they had pain/discomfort in 9 different anatomical regions (neck, shoulders, elbows, wrists/hands, upper back, lower back, hips/thighs, knees and ankles/feet) during the preceding 12 months and if those symptoms impeded their normal activity during the last year as well as the 7 previous days. Analysis consists of descriptive statistics.

Results: 31 (22 male & 9 female) table tennis athletes (age: 21.0±6.0 y, height: 1.76±0.05 m, weight: 70.5±13.3 kg, BMI: 22.6±2.9 kg/m², training age: 10.4±4.9 y, training h/week: 13.1±6.2 h) competing in 3 different categories (A1, A2 and B division) completed the SNQ. The 12-month prevalence rate of pain/discomfort was 61.3% in shoulders followed by the knees (29.0%), wrists/hands (25.8%), neck (22.6%), ankles/feet (12.9%), lower back (12.9%), elbows (9.7%), hips/thighs (6.5%) and upper back (6.5%). Those symptoms impeded athletes' normal activity (functionality) during the last 12 months with different prevalence rate per anatomical body region (shoulders: 45.2%, knees: 22.6%, neck: 19.4%, wrists/hands: 9.7%, lower back: 6.5%, ankles/feet: 6.5%, hips/thighs: 3.2%, upper back: 3.2% and elbows: 3.2%).

Conclusions: The high prevalence of region-specific musculoskeletal pain/discomfort in competitive table tennis athletes, highlights the need for specific injury prevention programs.

References:

1. Antonopoulou M et al. Eur J Gen Practice 2004;10:35.

P561

BIOMARKERS OF SARCOPENIA IN VERY OLD PATIENTS WITH HIP FRACTURE

C. Sánchez-Castellano¹, S. Martín-Aragón², P. Bermejo-Bescós², A. Merello-Miguel¹, M. N. Vaquero-Pinto¹, A. J. Cruz-Jentoft¹

¹Hospital Universitario Ramón y Cajal, IRYCIS, ²Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain

Objectives: Hip fracture is both a cause and a consequence of sarcopenia. Older persons with sarcopenia have an increased risk of falling, and the prevalence of sarcopenia may be increased in those who suffer a hip fracture. The aim of this study was to explore potential biomarkers (neuromuscular and peripheral pro-inflammatory and oxidative stress markers) that may be associated with sarcopenia in very old persons with hip fracture.

Methods: We recruited 150 consecutive patients ≥80 years old admitted to an orthogeriatric unit for a traumatic hip fracture. Muscle mass was assessed preoperatively using bioimpedance analysis; Janssen's (J) and Masanés (M) reference cutoff-points were used to define low muscle mass. Muscle strength was assessed with handgrip strength (Jamar's dynamometer). Sarcopenia was defined by having both low muscle mass and strength. Peripheral markers of pro-inflammatory and oxidative stress parameters were determined either in the plasma or in the erythrocyte fraction obtained from peripheral whole blood of every patient preoperatively.

Results: Mean age was 87.6±4.9 y, 79% were women. The prevalence of sarcopenia was 11.5% with Janssen's and 34.9% with Masanés cutoffs. Among the four pro-inflammatory cytokines tested in plasma, only TNFα was different (lower) in sarcopenic than nonsarcopenic participants using both cutoffs (J 7.9±6.2 vs. 8.3±5.8, M 6.8±4.7 vs. 9.1±6.2). Erythrocyte glutathione system showed a non-significant tendency to lower GSH levels and GSH/GSSG ratios in sarcopenic participants compared to nonsarcopenic subjects. Catalase (CAT) activity was also lower in sarcopenic participants (J 2904±1429 vs. 3329±1483, M 3037±1430 vs. 3431±1498). No significant differences were found between groups in chymotrypsin-like activity of the 20S proteasome, SOD, GPx and BuChE activity, CAF, IFNγ or IL-1β.

Conclusion: The prevalence of sarcopenia in patients with hip fracture varies according to the muscle mass reference cutoff points used, being higher with national References. We did not find differences in most neuromuscular, pro-inflammatory or oxidative stress markers, except for lower peripheral TNFα levels and catalase activity in sarcopenic participants, which may be markers of an early inflammatory reaction that is hampered in sarcopenic patients.

P562

EFFECT OF GLUCOCORTICOSTEROID THERAPY ON THE BODY'S METABOLIC PROCESSESE. G. Korenskaya¹, O. V. Paramonova¹, L. N. Shilova¹¹Volgograd State Medical University, Volgograd, Russia

Objective: Traditional therapy for rheumatic diseases (RD) includes the appointment of nonsteroidal anti-inflammatory drugs (NSAIDs), basic drugs and glucocorticosteroids (GCS). Studies show that GCS in combination with NSAIDs provide an earlier regression of the manifestations of articular syndrome, as well as indicators of the inflammatory process. It is known that small doses of GCS with their long-term administration can slow down the destruction of articular cartilage and bone in patients with RH due to the inhibitory effect on T-lymphocytes, and thus on the systemic autoimmune process as a whole. In addition, GCS is prescribed for other autoimmune diseases, in particular, the thyroid gland. Currently, the relationship of RD, (systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)), and pathology of thyroid gland is not in doubt. All of them are associated with HLA-DR3 and HLA-DR4, and dysfunction of T-lymphocytes. Our aim was to assess the effect of GCS on the structure of the two main components of these diseases - BMD and the thyroid function.

Methods: The study included 96 patients with a reliable diagnosis of SLE, of whom there were 7 men (7.29%) and 89 women (92.71%) aged 20-76 y and 30 patients with RA (the average age of patients was 42.2±13.4 y, the average duration of the disease - 9.47±8.83 y), along with basic therapy, receive systemic GCS at a dose of 15-40 mg/d. The diagnosis of SLE and RA was made in accordance with international criteria. The study of the function of the thyroid gland and the evaluation of BMD were performed on inpatient patients in the department of rheumatology of hospital No. 25 of Volgograd. All 96 (100%) patients with SLE received GCS therapy, and 12 (12.5%) of them underwent pulse therapy according to standard regimens. GCS therapy in the group of RA patients was administered to 15 (50%) patients.

Results: According to the ELISA data, patients taking GCS showed a marked decrease in the level of all thyroid hormones: the level of FT4 before the start of therapy, GCS was 18.1±1.1 pmol/ml, after 1 month of treatment - 14.0±0.9 pmol/ml ($p=0.02$); level of FT3 - 3.88±1.8 pmol/ml and 3.26±0.33 pmol/ml ($p=0.0099$). As a result of our examination, 51.04% of patients with SLE and RA were diagnosed with osteoporosis (OP) of varying severity. Of these, 11.46% of patients had OP, and 39.58% had osteopenia. The dependence of the decrease in BMD and the increase in the cumulative dose of GCS ($p<0.05$) was also revealed. The obtained dependence of the state of the bone tissue on GCS therapy may be related to the fact that in the physiological state glucocorticoids play an important role in the regulation of bone remodeling.

GCS, both endogenous and exogenous, are inhibitors of TSH secretion and suppress T4 - T3 deiodination. In addition, the corticosteroids cause a decrease in the level of T3 and T4 due to a violation of intrasubstance delivery to the periphery and a decrease in the concentration of thyroxin-binding globulin, which is

the main blood protein that binds to 85% of T3 and T4 and limits the fraction of free hormones by adjusting the speed of their delivery to free blood flow.

Conclusions: Thus, when used in the complex treatment of patients with GCS, an increased destruction of bone tissue and a decrease in the level of thyroid hormones are observed, which limits their use in thyroid pathology and OP manifestations. GCS assignment to patients with RB should be carried out after the diagnostic examination of thyroid status, in order to exclude the appearance or enhancement of the possible negative effect of GCS on the auto thyroid function. As well as with long-term treatment of GCS, a study of BMD should be conducted for all patients.

P563

RELATIONSHIP BETWEEN PHYSICAL PERFORMANCE VARIABLES AND DXA PARAMETERS IN A GROUP OF MIDDLE-AGED MENB. Finianos¹, G. Zunquin², H. Devanne², R. El Hage¹¹University of Balamand, Kalhat, Al-Kurah, Lebanon, ²Université du Littoral Côte d'Opale, Dunkerque, France

Objective: The purpose of this study was to explore the relationships between many physical performance variables and DXA parameters in a group of middle-aged men.

Methods: 24 middle-aged men whose ages range from 48-55 y participated in this study. Body composition (bone mineral content, fat mass and lean mass), BMD and geometric indices of hip femoral neck (FN) strength (cross-sectional area (CSA), cross-sectional moment of inertia (CSMI), section modulus (Z), buckling ratio (BR) and strength index (SI)) were evaluated by DXA. BMD was evaluated at the whole body (WB), total radius (TR), lumbar spine (L1-L4), total hip (TH) and femoral neck (FN). Handgrip, vertical jump, maximum power of the lower limbs (watts), maximal half-squat strength, maximal bench-press strength, sprint performance (10 m) and maximum oxygen consumption (VO2 max, L/min) were evaluated by validated tests.

Results: Handgrip, maximum power of the lower limbs, lean mass and VO2 max (L/min) were positively correlated to WB BMC, WB BMD, FN BMD, CSA, CSMI, and Z. Lean mass was a strongest determinant of WB BMC and CSA than handgrip. VO2 max (L/min) was a strongest determinant of WB BMD, TH BMD, and FN BMD than lean mass.

Conclusion: The current study suggests that VO2 max (L/min), lean mass and handgrip are the strongest determinants of bone variables in middle-aged men.

P564

PREVALENCE OF SEVERE HYPOVITAMINOSIS D IN YOUNG FEMALE PATIENTS AND RISK FACTORS PRESENTED WITH PERSISTENT AND NONSPECIFIC BACKACHE AND KNEE PAIN IN TWO TERTIARY CARE HOSPITAL KARACHI PAKISTAN

M. Muzzammil¹¹Dr. Ruth K M Pfau Civil Hospital Karachi, Karachi, Pakistan

Objective: To assess the prevalence of hypovitaminosis D in young female patient in outpatients department of two tertiary care hospital of Karachi, Pakistan with persistent, nonspecific backache and knee pain syndromes refractory to initial medical management.

Methods: This cross-sectional study includes 200 young female patient age range between 14-35 y presented consecutively between June 2018 and Dec 2018 with persistent, nonspecific backache and knee pain to the OPD of two tertiary care hospital of Karachi, Pakistan. A questionnaire was designed and filled after taking consent includes details regarding age, gender, occupation, area of skin and sun exposure duration, dietary habits, type of clothing and residence used. Patient BMI and plain x-ray lumbosacral spine and knee were taken to exclude other pathologies. Serum vitamin D3 levels were determined and compared with serum calcium levels, serum phosphorus and alkaline phosphatase levels. Serum vitamin D level <20 µg/ml defined as deficiency.

Results: Among 200 patients, 100 from each hospital ranging from 13-35 y, mean 24±7.21 SD. Patients were predominantly married 136 (68%). Exposure of face and hands while outdoor by most of them was 96 (48%). Sun exposure duration in majority of participant was 1-2 h/d 116 (58%). Mostly are resident of apartments 152 (76%). Variable coloured clothes used by majority participant 128 (64%) and variable fabric 164 (82%). 178 (89%) patients had deficiency of vitamin D and correlated with duration of sunlight exposure significantly, also with exposure of large skin area, dietary consumption of vitamin D rich food and worn variable clothing colours. Serum phosphorus level and serum alkaline phosphatase level were negatively correlated with vitamin D significantly whereas positively correlated with serum calcium.

Conclusion: All patients with persistent, nonspecific backache and knee pain are at high risk for the consequences of unrecognized and untreated severe hypovitaminosis D. female of child-bearing age with such pain appear to be at greatest risk for misdiagnosis or delayed diagnosis. Because osteomalacia is a known cause of persistent, nonspecific musculoskeletal pain, screening all outpatients with such pain for hypovitaminosis D should be standard practice in clinical care.

P565

EVALUATION AND CLASSIFICATION OF FOOT MEDIAL LONGITUDINAL ARCH HEIGHT IN ADULTS

G. Ergezen¹, M. Sahin²

¹Istanbul Medipol University/ School of Health Sciences/ Physical Therapy and Rehabilitation, ²Istanbul Medipol University/ School of Medicine/ Department of Orthopedics and Traumatology, Istanbul, Turkey

Objective: Foot as a complex system which provides interaction between ground and lower extremity during locomotion are comprised of bones, muscles and ligaments. Medial longitudinal arch is one of the arches that supports the foot and absorb the weight pressure priorly and its shape depends on genetic factors or age.

Methods: Aged between 18-40 y, 344 (184F, 160M; age 24.38±6.10; BMI 23.61±11.90) adult volunteers were included in the study. Medial Longitudinal Arch (MLA) analysis was carried out Navicular Drop (ND), Feiss Line (FL) and Longitudinal Arch Angle (LAA) measured by a ruler while foot loaded and unloaded. Foot length and foot width has been measured and calculated mean values.

Results: MLA normal values for ND was between 3.08-4.82 cm, FL was between -1.52 to -0.42 and for LAA was between 145.16-158.72. According to prediction limits, lower number of normal limits present low arch, higher numbers present high arch. Many variables show statistically differences between male and female and duration of standing time in a day.

Conclusion: These cutoff values may be used by clinicians to classify MLA on patients.

P566

RELATIONSHIP OF NESFATIN-1 LEVEL WITH BONE MINERAL DENSITY, TOTAL BODY COMPOSITION, BONE FORMATION AND RESORPTION MARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS

T. Z. Kvlividze¹, B. V. Zavodovsky², Y. R. Akhverdyan², J. V. Polyakova², L. E. Sivordova², A. T. Yakovlev¹¹Volgograd State Medical University, Volgograd, Russia,

²Treatment and Prevention of Joint Disease Laboratory, Federal State Budgetary Institution "Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky", Volgograd, Russia

Nesfatin-1 is a molecule associated with the melanocortin signaling system. The effect of nesfatin in the regulation of appetite, glucose metabolism, lipids, thermogenesis, anxiety, depression, cardiovascular and reproductive system functioning has been studied [1]. There is evidence of the pro-inflammatory activity of nesfatin-1 [2]. Among the pleiotropic effects of nesfatin, its osteogenic activity deserves attention. In an experiment on ovariectomized rats (OVX) with intravenous administration of nesfatin for 2 months, an increase in BMD in vertebrae and femoral bones was proved. Treatment of mouse preosteoblast cells MC3T3-E1 with nesfatin led to an increase in their differentiation and mineralization. Revealed some inhibition of osteoclastogenesis in mice [3]. The degree of activity of bioactive molecules depends on the

expression of target cells, their functions may differ in normal and pathology. Our aim was to study the correlation of nesfatin-1 level with BMD, total body composition, markers of bone formation and resorption in patients with rheumatoid arthritis (RA).

Methods: We studied 110 patients with RA (mean age 54.07±11.32; M±SD). The diagnosis of RA is made according to the ACR/EULAR criteria for RA (2010). All patients with RA were examined using a Lunar DPX-Pro densitometer and underwent clinical and laboratory examination. Serum nesfatin-1 levels were measured using a commercial test system (RaiBiotech, cat. EIA-NESF) according to the instructions attached to the kit.

Results: The average level of nesfatin-1 in patients with RA was 50.49±34.05 ng/ml. Patients with RA were divided into group 1 (n=44) with normal serum nesfatin-1 concentration (<37.95 ng/ml) and 2nd (n=66) with elevated nesfatin-1 level (>37.95 ng/ml). Differences in the serum C-terminal telopeptide type I collagen in the 1st and 2nd groups were not detected. A statistically significant correlation was found between nesfatin-1 and the N-terminal telopeptide of type I procollagen (PINP) (r=0.218, p=0.022). There was no significant relationship between serum nesfatin-1 and BMD with muscle or fat mass.

Conclusions: We did not identify the relationship between elevated serum nesfatin-1 (BMD) and total body composition in patients with RA. We noted the relationship between nesfatin-1 and PINP, which confirms the effect of nesfatin-1 on differentiation and osteoblast function.

References:

1. Schalla MA and Stengel A. J Endocr Soc 2018;2:1188.
2. Kvlivdize TZ et al. Osteoporos Int 2018;29(S1):C469 .
3. Li R et al. PLoS One 2013;4:e61619.

P567

NUTRITIONAL STRATEGIES FOR MAINTAINING MUSCLE MASS AND STRENGTH FROM MIDDLE AGE TO LATER LIFE: A NARRATIVE REVIEW

A. J. Cruz-Jentoft¹, B. Dawson-Hughes², D. Scott³, K. Sanders⁴, R. Rizzoli⁵

¹Servicio de Geriatria, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain, ²Bone Metabolism Laboratory at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, USA, ³School of Clinical Sciences at Monash Health, Monash University, Victoria, Australia, ⁴The University of Melbourne, Sunshine Hospital, Victoria, Australia, ⁵University Hospital of Geneva, Geneva, Switzerland

Objective: To determine evidence on the role of dietary intake and nutritional supplementation in maintaining muscle mass and strength from midlife through old age.

Methods: PubMed and Cochrane databases were searched to identify original research including observational studies of dietary intake and nutritional interventions for sustaining muscle mass and strength.

Results: Progressive age-related reductions in muscle mass/strength (i.e., sarcopenia) can cause substantial morbidity. The benefits of exercise, particularly progressive resistance training, to muscle mass and strength with/without dietary interventions are well documented. Protein and amino acid (particularly leucine) intake should be considered, and supplementation may be warranted for those not meeting recommended intakes. Other nutrients may contribute to sustaining/improving muscle mass and strength. Vitamin D receptors are expressed in muscle tissue; meta-analyses have shown that vitamin D benefits muscle strength. Data suggest that milk and other dairy products containing different bioactive compounds (i.e., protein, leucine) can enhance muscle protein synthesis, particularly combined with resistance exercise. Omega-3s can improve muscle mass and strength by mediating cell signaling and inflammation-related oxidative damage, but no studies were specifically conducted in sarcopenia. Low-dose antioxidants (e.g., vitamins C and E) can protect muscle tissue from oxidative damage, but relevant studies are limited. Magnesium is involved with muscle contraction processes and data have shown benefits to muscle strength. Acidogenic diets (e.g., limited fruits/vegetables) increase muscle protein breakdown, which is exacerbated by aging. Supplementation with alkalizing compounds (e.g., bicarbonates) can promote muscle strength. Small studies of probiotics and plant extracts have generated interest, but few large studies have been conducted.

Conclusions: Based on available data, dietary and supplemental interventions may add to benefits of exercise on muscle mass and strength; effects independent of exercise have not been consistently shown.

Disclosures: This review was sponsored by Pfizer Consumer Healthcare. Medical writing support was provided by Dennis Stancavish of Peloton Advantage, LLC, and was funded by Pfizer. RR has received consultation fees from Danone, EffRx, Nestlé, ObsEva, Pfizer, Radius Health, Sandoz, and TEVA/Theramex. AC-J has received speaker fees from Abbott Nutrition, Fresenius, Nestlé, Nutricia, Sanofi-Aventis; consulting fees from Abbott Nutrition, Boehringer Ingelheim Pharma, Nestlé, Pfizer, and Regeneron; and has worked on research projects with Novartis, Nutricia, and Regeneron. BDH has received consulting fees from Intrinsic Therapeutics and TTY Biopharma Co, Ltd, and investigator-initiated research funding from Pfizer and DSM. DS has received speaker fees/honoraria from Amgen Australia, and consulting fees from Pfizer, Inc. USA. KMS has received speaker fees from Sanofi-Aventis and Amgen Australia.

P568

THE PREDICTORS OF SARCOPENIA IN COPD PATIENTS

A. Suleymanova¹, I. Baranova¹¹Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia

Objectives: COPD often coexist with other disease (comorbidities) that may have a significant impact on prognosis. Sarcopenia is one of the frequent important comorbidities in the COPD patients, is often under-diagnosed. The aim of the study was to analyze predictors of sarcopenia in COPD patients.

Patients and Methods: The cross-sectional study included 86 patients with stable COPD (68 males/18 females, mean age 66,6 ± 8,7 years). Patients were assessed according to GOLD consensus report. The following data were obtained and analyzed: clinical parameters (including the COPD symptoms assessment, exacerbation history), pulmonary function test data, serum 25OHD level. Sarcopenia was diagnosed according to EWGSOP2 criteria. The Appendicular Skeletal Muscle Mass was estimated using DXA.

Results: According to the EWGSOP2 algorithm, sarcopenia was diagnosed in 44.1% of patients. It was registered at any severity of COPD, but the following predictors were identified. In patients with predominantly emphysematous phenotype of COPD, the risk of sarcopenia was higher than in patients with predominantly bronchitic phenotype (OR 2.8 (95% CI 1.1; 6.8), p<0.03). Sarcopenia was more common in patients with severe symptoms: "more breathless" persons (mMRC ≥2 grades) had sarcopenia more often than "less breathless" persons (OR 4.6 (95% CI 1.8; 11.6), p=0.001). Patients with severe and very severe airflow limitation (FEV1<50%) have significantly higher rate of sarcopenia than patients with FEV1≥50% (OR = 4.4 (95% CI 1.7-11.4, p=0.001). Strangely, we didn't reveal correlation between sarcopenia and exacerbation rate (including hospitalization). Most of the COPD patients were vitamin D deficient or insufficient (94,1%).

Conclusion: Although sarcopenia was seen in all groups of COPD patients, this comorbidity was observed more often in patients with more severe symptoms, with emphysematous phenotype and with severe and very severe airflow limitation.

P569

ULTRASOUND CHARACTERISTICS OF GOUTY DACTYLITIS: ICONOGRAPHIC STUDY

A. Guillen-Astete¹, M. Luque-Alarcon²¹Ramon y Cajal University Hospital, ²San Carlos University Hospital, Madrid, Spain

Objective: Dactylitis is a well known hallmark of spondyloarthritis but also can be found in other autoimmune or infectious diseases. Also, dactylitis is a manifestation of gout that can occur on debut or throughout the disease. From the clinical perspective, dactylitis is defined as the swollen of a finger with or without associated pain but with a corresponding limitation on its arc of movement. Although it is usually considered a sign of chronicity or a hallmark of long-term disease, gouty dactylitis can be as-

sessed as part of the physical examination of patients with their first flare. Classically, the synovitis or tenosynovitis mediated by the deposit of microcrystals and the presence of tophi has been interpreted as the cause of gouty dactylitis. There are, however, no etiological study based on imaging studies. The present study aims to determine the prevalence of different ultrasonographic features of dactylitis of the hands in patients with gout.

Method: A cross-sectional study was conducted based on a registry of ultrasound images of patients with gout and clinical dactylitis either in debut or throughout evolution. Source of registries: In 2013 we started a rheumatology clinic dedicated to assessing patients on self-demand into the urgency and emergency department of our hospital. Our clinic protocolized the use of ultrasonography in almost all patients assessed. Every image was recorded into a database related to the corresponding clinical case using an identification code. To gather registries for the purposes of the present study, we accessed that database and the corresponding demographic, epidemiologic and clinical information from the electronic registries. The selection of patients followed strictly clinical criteria based on the corresponding medical reports. All images were obtained in a medium-high gamma GE equipment and were obtained by the same operator over three years. Given that no comparisons were planned, no masking of the clinical situation of the patients was made in the eyes of the interpreter. The interpretation of findings was dichotomous in the determination of synovitis, tenosynovitis, and enthesopathy according to EULAR definition criteria. The identification of tophi was made according to the definition of Avila Fernandes et al. (doi: 10.1007 / s00256-010-1008-z) The overlapping of findings was counted independently at the moment of establishing the prevalence.

Results: We included images of 66 patients diagnosed with gout and with dactylitis of at least one finger at the time of the ultrasound evaluation. The mean age of the patients was 59.2 SD 4.3 years. 62 patients were male. Of the total number of patients, 60 had tenosynovitis of the flexor tendinous apparatus (90.9%). Four of these patients also presented tenosynovitis of the tendinous extensor apparatus. No patient presented only extensor tenosynovitis. Enthesopathy was identified in 6 patients (9.1%), in no case did enthesopathy occur with power Doppler signal. Synovitis was identified in 43 patients (65.1%). Of these, in 13 patients a grade I was registered and in 26 a power Doppler signal was demonstrated. Tophi were identified in 16 patients (242%).

Conclusions: This is, as far as we know, the first iconographic study of gouty dactylitis based on ultrasound. According to our results, tenosynovitis of the flexors is the most frequent finding in gouty dactylitis while enthesopathy is rather rare. The presence of significant synovitis is the second most frequent finding while tophi as conditioning agents of synovitis were the least frequent finding. We understand that the knowledge of the echographic characteristics of gouty dactylitis can serve as a clinical guide when making therapeutic decisions in cases where this clinical sign lasts despite the control of other manifestations.

P570

DOES HISTORY OF OSTEOPOROTIC FRACTURES AFFECT QUALITY OF MENTAL FUNCTIONING?

K. Filipovic¹, Z. Vucic², J. Zvekcic-Svorcan³

¹Artfizio, Specialistic Office for Physical Medicine and Rehabilitation., ²University of Novi Sad, Faculty of Medicine, ³University of Novi Sad, Faculty of Medicine Novi Sad, Special Hospital for Rheumatic Diseases, Novi Sad, Serbia

Objective: To establish the effect of prior osteoporotic fractures on the quality of mental functioning in postmenopausal women.

Methods: The retrospective study included 112 postmenopausal women aged 60-70 y with reduced BMD, who were referred for osteodensitometry (DXA) scan at the Special Hospital for Rheumatic Diseases in Novi Sad, Serbia, in the period from February 2017 to January 2018. BMD in hip and spine (L1-L4) was measured in all participants, and the values were expressed as T-scores. All participating women completed the QUALEFFO-41 Serbian Version questionnaire for quality of life assessment, and the information pertaining to osteoporotic fractures was obtained from medical records, along with patients' demographic and clinical characteristics. Questionnaire reliability was determined via Cronbach's Alpha coefficient, calculated at 0.899 and 0.911 for the full scale and the mental functioning subscale, respectively, indicating high instrument reliability. Analyses included effects of the number of prior vertebral and non-vertebral osteoporotic fractures on mental functioning in postmenopausal women. Data was statistically analyzed using SPSS ver. 24.

Results: Average participant age was 65.98±3.27 y, while the average age of menopause onset was 48.07±4.86 y. Average T-score for all three regions of interest was at the level of osteopenia, 1.74±0.78 SD, -1.48±0.83 SD, and 1.93±1.15 SD for femur, hip and lumbar spine (L1-L4), respectively. History of minor fractures was noted in 43 participants, whereby 0.9% of the sample suffered hip fracture, 8% had vertebral fractures (7.1% had one, while 0.9% respondents had two), while 33.9% of the women suffered non-vertebral fracture (31.2% had one, while 2.7% had two). Quality of mental functioning was statistically significantly lower in women that had one (61.46±7.03; p = 0.043) and two (70.37±8.49; p = 0.018) non-vertebral fractures.

Conclusion: Postmenopausal women with reduced BMD that have experienced at least one nonvertebral fracture report lower quality of mental functioning.

P571

INCIDENCE OF SARCOPENIA IN STABLE COPD PATIENTS: COMPARISON OF EWGSOP AND EWGSOP2 DIAGNOSTIC ALGORITHMS

A. Suleymanova¹, I. Baranova¹

¹Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia

Objectives: Sarcopenia is one of the frequent comorbidities in the COPD patients. In 2018, the European Working Group on Sarcopenia in Older People (EWGSOP) published the updated consensus

paper (EWGSOP2). The new diagnostic algorithm differs significantly from the previous one (EWGSOP, 2010). The aim of the study was to compare the incidence of the sarcopenia and the severe sarcopenia on the same sample of COPD patients using the old (EWGSOP) and the new (EWGSOP2) algorithms.

Methods: EWGSOP and EWGSOP2 criteria were applied to 86 patients (68 males/18 females, mean age 66.6±8.7 y) with stable COPD. The clinical evaluation included: anthropometry, handheld dynamometry, the different tests (the 4m gait speed, the chair stand test, the timed-up and go test, the SPPB tests). The appendicular skeletal muscle mass (ASM) was estimated using DXA, ASM index was calculated (ASM/height²).

Results: According to the EWGSOP algorithm, the gate speed was measured in all patients, then the grip strength was defined in 25 patients with the gate speed >0.8 m/s. To confirm the sarcopenia, the muscle mass was measured by DXA in 62 persons (72% of the total patients number, here and below). Sarcopenia was diagnosed in 38 (44.1%) patients, 20 patients had severe sarcopenia (23.3%). EWGSOP2 recommends use of the SARC-F questionnaire on the first step. After that only 64 persons were needed in measuring of the muscle strength. DXA was indicated in 51 patients (59.3%) with probable sarcopenia. The diagnosis of sarcopenia and severe sarcopenia were confirmed in 38 (44.1%) and 34 (39.5%) patients, respectively.

Conclusion: By using EWGSOP and EWGSOP2 algorithms in the same COPD patients group, the incidence of the confirmed sarcopenia did not differ (44.1%). But EWGSOP2 diagnostic criteria allowed to reduce the number of examinations, including expensive ones, and to identify a greater number of COPD patients suffering from severe sarcopenia.

P572

ALENDRONATE ATTENUATES THE GENE EXPRESSION OF PROINFLAMMATORY CYTOKINES AND MMP-8 IN APICAL PERIODONTITIS OF OSTEOPOROTIC RATS

P. C. Romualdo¹, M. P. Lucisano¹, F. W. G. Paula-Silva¹, R. A. B. Silva¹, L. A. B. Silva¹, P. Nelson-Filho¹

¹School of Dentistry of Ribeirão Preto, University of São Paulo, Department of Pediatric Dentistry, Ribeirão Preto, Brazil

Objective: To evaluate the gene expression of proinflammatory cytokines and matrix metalloproteinases in apical periodontitis (AP) of osteoporotic rats treated or not with Alendronate (ALD).

Methods: 25 12-week-old female Wistar rats were submitted to ovariectomy (OVX) or sham surgery and followed by 9 weeks. Then, the dental pulp of upper first molars was exposed to the oral environment for induction of AP. The groups were as follows: sham-AP, OVX-AP and OVX-AP-ALD. After 21 days of AP induction, the animals were euthanized and the blocks containing teeth and bone were collected to be analyzed by RT-PCR for quantification of proinflammatory cytokines and matrix metalloproteinases genes (*Il1b*, *Tnfa*, *Il6*, *Mmp8* and *Mmp13*).

Results: AP in OVX rats showed increased expression of *Il1b*, *Il6* and *Mmp8* compared with AP in sham rats ($p < 0.05$). Alendronate treatment reduced *IL-6* and *MMP-8* expression to the same level as the AP in sham group ($p < 0.05$).

Conclusion: AP in OVX rats have increased expression of proinflammatory cytokines (*Il1b* and *Il6*) and matrix metalloproteinase (*Mmp8*) genes and ALD treatment reduced *Il6* and *Mmp-8* to the same level as the AP in sham group. So, we speculate that the osteoporotic condition aggravates inflammation and degradation of extracellular matrix components and ALD treatment attenuates this condition.

Acknowledgments: This work was supported by the São Paulo Research Foundation (FAPESP) grant 2013/18231-9 and 2014/13238-8.

P573

ORTHOPEDIC SURGEON: SHOULD AND SHOULDN'T FOR THE MANAGEMENT OF PATIENTS WITH FRAGILITY FRACTURES – A SINGLE CENTER RETROSPECTIVE OBSERVATIONAL STUDY

C. Coppola¹, D. Agnusdei², R. Boyd³, F. Lepore⁴

¹St Maria Loreto Nuovo General Hospital - Dept of Orthopedics & Traumatology, ASL Napoli 1 Centro, Naples (Italy), Napoli, Italy, ²Independent Scientific Consultant, Siena, Italy, ³Consultant Orthopedics and Traumatology, Buenos Aires, Argentina, ⁴Orthopedics Department at the University of Naples "Luigi Vanvitelli", Naples (Italy), Naples, Italy

Objectives: The implementation of the fracture liaison service (FLS) has provided an important improvement in the definition of orthopedic surgeons (OS) role for care in patients with fragility fractures (FFx). Here we present a 3-y experience with a FLS at the Orthopedic Department of St Maria Loreto Nuovo General Hospital in Naples (Italy). The main aim is to show how an immediate and appropriate identification of the fragile patient, a quick surgery, a correct underlying osteoporosis therapy and a multidisciplinary approach for the follow-up may improve adherence and reduce the refracture index.

Methods: At the admission, a dedicated "Proforma" was developed to record the mortality rate of lateral vs. medial proximal femur fractures, the osteoporosis therapy history and to enroll the patient in the FLS care. A similar questionnaire was administered at discharge. Between January 2013-December 2015, 1100 consecutive patients, women and men, were enrolled in this retrospective study; 750 patients survived for the 3 year follow-up. The mean age was 77.5 ($\pm 12/20$). All the patients presented with a proximal femur fracture (482 lateral, 268 medial). Adherence to OP therapies with teriparatide (TPTD), denosumab (DNB) and bisphosphonates (BPs) was evaluated every 6 months and throughout the study period by clinical examination and/or phone interview.

Results: In the entire study population (n=750), lateral femoral fractures were more frequent (64%, from which type AO A2.2 n=293 were 60%). Thirty-three percent of patients referred a previous FFx and only 17.5% received an osteoporosis therapy for a

maximum of 12 months. During the 3-y study, the FLS care was able to improve the identification of osteoporotic patients from 13% (standard care) up to 83% (FLS). In this population the adherence to osteoporosis therapy was higher in the TPTD & DNB groups (98%), than in the BP group (53%); 47% abandoned the BP therapy and in 32% of them a new fracture was reported, while in patients treated with TPTD and DNB no fracture or side effects were recorded.

Conclusions: The results of this study show that OS play a key role; before surgery, they *should* identify patients with fragility fractures and perform a proper diagnosis; after surgery, discharge them with an appropriate osteoporosis therapy to slow down the fracture cascade, and through the FLS perform an adequate follow-up. What OS *should not do* is to leave these patients without any follow-up, thus speeding up the fracture cascade.

P574

COMPLEX EVALUATION OF CLINICAL RESULTS OF THE EFFECTIVENESS OF LOCAL THERAPY OF PLATELET RICH AUTOLOGOUS PLASMA AND CONDITION OF ARTICULAR CARTILAGE, USING TECHNIQUES T2 MAPPING AMONG PATIENTS WITH OSTEOARTHRITIS OF THE KNEE

M. N. Lobanov¹, D. I. Kazantsev¹, A. V. Popovtseva², V. A. Peleganchuk¹

¹Federal State Budgetary Institution, Federal Center of Traumatology, Orthopedics and Endoprosthesis Replacement of the Ministry of Health of the Russian Federation, Barnaul, ²Helix Laboratories, St. Petersburg, Russia

Objective: The use of autologous platelet-rich plasma (PRP) has recently become widely used in the treatment of osteoarthritis of the knee (OA), not only to reduce the severity of pain, but also as a factor of influence on reparative processes of articular cartilage (AC). Our aim was to evaluate complex clinical results of the effectiveness of local therapy of PRP and condition of AC, using T2 mapping in patients with OA.

Methods: In the study, results were obtained in 12 patients with OA stage II-III according to Kellgren-Lawrence grading scale, aged 44-72 y (mean age 56.4 \pm 9.2 y), stage II is exhibited in 6 persons, stage III - in 6. The effectiveness of the therapy was assessed by the dynamics of pain intensity and functional activity of the joints on the third, sixth, ninth and twelfth months after the treatment according to the visual analogue pain intensity scale - VAS (score), the functional index WOMAC (%) and the total Leken index (score). To obtain PRP, the technology of a "double syringe" was used. PRP was administered intra-articularly to 5.0 ml 3 times at intervals of 2 weeks. All patients underwent MRI of knee joints on a scanner with induction of a magnetic field of 1.5T before and 3 months after therapy. To assess the degree of hydration of the AC, T2 mapping was used to obtain T2 values (typical T2 values for healthy cartilage range from 35-65 ms) with the construction of color maps of the central sections of the condyles of the femur.

Results: The poll showed a positive dynamic according VAS after 6 months in patients with OA stage II from 4.4 ± 1.51 to 1.40 ± 0.89 scores ($p=0.005$), after 9 months to 1.6 ± 0.54 scores ($p=0.005$) and after 12 months to 2.0 ± 1.22 ($p=0.02$), in patients with OA stage III after 3 months from 7.3 ± 1.36 to 2.6 ± 2.65 scores ($p=0.003$), after 6 months to 3.1 ± 2.04 ($p=0.002$), after 9 months to 3.5 ± 2.07 ($p=0.004$) and after 12 months to 3.0 ± 1.58 ($p<0.001$). After 3 months, there was a significant improvement in the Leken index in patients with OA III stage from 13.8 ± 3.18 to 7.8 ± 5.26 scores ($p=0.003$). Also, the significant dynamics of the WOMAC index was noted. Significant differences were obtained in patients with OA stage III from $55.6 \pm 18.47\%$ to $20.16 \pm 14.55\%$ ($p=0.004$) after 3 months, unlike to patients with OA stage II from 3 to 12 months. Evaluation of AC in patients with OA stage II, T2 values initially got for the medial condyle were 59.1 ± 6.93 ms and in patients with OA stage III - 66.9 ± 10.15 ms, in the lateral condyle in patients with OA II stage were 53.3 ± 5.38 ms and in patients with OA stage III - 55.2 ± 7.74 ms. Reliable differences in T2 values were obtained after 6 months for the medial condyle of the femur in patients with OA stage III stage ($p=0.003$). There were no significant differences anymore in the T2 values for the medial and lateral condyles in patients with OA stage II and stage III.

Conclusions: The conducted study showed significant therapeutic efficacy of PRP in patients with OA stage II and III, which is confirmed by a significant decrease in pain syndrome, an increase in the functional activity of the knee joint. T2 mapping techniques revealed more pronounced structural changes in the AC of the medial condyle of the femur only after 6 months of PRP therapy in OA stage III. Thus, T2 mapping of articular cartilage does not provide convincing correlations with clinical and functional data and requires further study.

P575

SERUM PERIOSTIN LEVELS ARE ALTERED IN 131 PERSONS WITH SPINAL CORD INJURY

P. Garnero¹, L. Maïmoun², F. Ben Bouallègue², A. Gelis³, S. Aouinti⁴, T. Mura⁵, P. Philibert⁶, M. Piketty⁷, D. Mariano-Goulart², C. Fattal⁸

¹INSERM Research Unit 1033, Lyon, ²Département de Médecine Nucléaire, Hôpital Lapeyronie, Montpellier, ³Centre Mutualiste PROPARA, Montpellier, ⁴Unité de Recherche Clinique et Epidémiologie, Hôpital La Colombière, Montpellier, ⁵Departement de Biochimie et d'Hormonologie, Hôpital Lapeyronie, Montpellier, ⁶Departement de Biochimie et d'Hormonologie, Hôpital Lapeyronie, Montpellier, ⁷Laboratoire des Explorations Fonctionnelles, Hôpital Necker, Paris, ⁸Centre de Rééducation et Réadaptation Fonctionnelle La Châtaigneraie, Menucourt, France

Objective: Spinal cord injury (SCI) induces an acute alteration in bone metabolism that is characterised by increased bone resorption and bone loss under the neurological lesion. Although the aetiology of the bone disturbances is not precisely known, immobilisation reduces mechanical loading and the differentiation of osteocytes, which are considered as the primary mechanosensors. Our aim was to determine for the first time in subjects with SCI, the effects of lesion levels (tetraplegia vs. paraplegia) and

time since surgery on the osteocytes synthesized molecules periostin and sclerostin and their relationship with bone turnover and BMD.

Methods: 131 persons with SCI (96 males and 35 females; aged 42.8 ± 13.7 y) with a mean duration of SCI of 14.2 ± 12.1 y were prospectively evaluated and compared to 64 able bodied controls. The serum levels of total periostin (Biomedica), sclerostin (Biomedica) and bone turnover markers (S-CTX, PINP; Roche Diagnostics) and areal BMD (aBMD) at the femoral neck, total hip, radius and lumbar spine were measured in all SCI subjects and controls.

Results: Compared to controls, persons with SCI presented reduced aBMD at the femoral neck (-32% $p<0.001$) and total hip (-31% , $p<0.001$) and these differences were accentuated in acute patients (time since injury <2 y) and more marked in persons with tetraplegia ($n=34$) than in persons with paraplegia ($n=97$). Serum periostin (854.7 ± 253.8 vs. 734.6 ± 164.9 pmol/l, $p=0.002$) was increased and serum sclerostin (53.7 ± 38.2 vs. 63.4 ± 30.4 pmol/l, $p=0.002$) was decreased in all subjects with SCI compared to controls whereas no difference was observed for bone turnover markers. For all the biological parameters, but sclerostin, values were higher in acute patients ($p<0.001$) while the lesion levels have little influence.

Conclusion: This large study confirmed that SCI induces a dramatic loss of BMD in the lower limbs associated with intense bone remodeling during the acute phase. These bone alterations might be linked to a transient increase in periostin levels, suggesting that this factor is involved in the regulation or protection of bone in patients with SCI.

P576

CHILDREN IN RISK OF LOW BONE MASS HAVE MORE THAN 2 RISK FACTORS

B. Magallares¹, D. Cerdà², J. Betancourt³, G. Fraga⁴, E. Quesada-Masachs⁵, M. López-Corbeto⁶, N. Pardo⁷, M. Torrent⁷, A. M. Marín⁸, S. Herrera⁸, J. Casademont⁹, H. Corominas¹⁰, J. Malouf⁸

¹Rheumatology / Santa Creu i Sant Pau Hospital, ²Rheumatology / Moises Brogi Hospital, ³Pediatrics / Santa Creu i Sant Pau Hospital, ⁴Pediatrics / Santa Creu i Sant Pau Hospital, ⁵Pediatric Rheumatology, Vall d'Hebrón Hospital, ⁶Pediatric Rheumatology / Vall d'Hebrón Hospital, ⁷Pediatrics / Santa Creu i Sant Pau Hospital, ⁸Bone Metabolism Unit, Internal Medicine. Santa Creu i Sant Pau Hospital, ⁹Internal Medicine, Santa Creu i Sant Pau Hospital, ¹⁰Rheumatology, Santa Creu i Sant Pau Hospital, Barcelona, Spain

Objective: Low bone mass (LBM)/infantile osteoporosis (IOP) require an active evaluation for its diagnosis and prevention. Therefore, its incidence is unknown and could be undertreated. The systematic collection of risk factors associated with LBM/IOP could help identify the population at risk of presenting it. Our aim was to assess the prevalence and number of risk factors (RF) in the pediatric population at risk of developing LBM/IOP. Assess its influence on BMD.

Methods: Demographic and clinical data were prospectively collected from patients from 2-20 years of age, who had at least one risk factor for LBM/IOP, among them: chronic diseases, treatment with immunosuppressants and/or corticosteroids and insufficient calcium intake. Calcemia, calciuria, and vitamin D were determined in blood samples, and whole body and lumbar DXA were performed. The calcium intake, the number of previous fractures and other RF were collected

Results: Data were collected from 103 patients, with an average age of 9.8 y, 52.4% women, and 80% Caucasians. Of these, 9 were preschoolers (2-3 years old), 33 schoolchildren (4-9 y), 55 teenagers (10-17th) and 6 young people (18-20th). The most frequent diagnoses were malabsorption/food allergies: 46.6%, JIA: 17.5%, nephropathies: 17.8%, hematological diseases: 6.8%, and vasculitis and connective tissue diseases: 3.9% each.

Table 1. The frequency of RFs

	%
Insufficient calcium intake in the diet	84.5
Association of a second chronic diagnosis	4.9
Hypovitaminosis D in blood (<30 nmol/L)	8.1
Sedentary lifestyle (PAQ test <2)	13.6
History of long bone or vertebral fractures	12.6
24-h urine hypercalciuria	3.1
Proteinuria ≥0.20 g/L in 24-h urine	17
Drugs with osteopening potential (noncorticosteroid immunosuppressants)	31.1
Corticosteroids at the time of inclusion	19.4
Corticosteroids prior to inclusion in the study	18.4

The average dose of current corticoids was 0.21 mg/kg/d of prednisone with a total cumulative average dose of 7 g, with an exposure of 1 to 144 months.

4.3% of the sample had an isolated RF, 38% had 2 RF, 31% 3, 15% 4, and 12% 5 or more. 8.7% of the sample presented a LBM and 4.8% met criteria for Opi for vertebral fractures, 3 of them asymptomatic and discovered by morphometry. In the multiple linear regression analysis: age, Latin ethnicity, gender, and hypovitaminosis D were the main RFs related to lumbar BMD. Likewise, age, Latin ethnicity and sedentary lifestyle were the RF related to the BMD of the whole body without head (BMDwbwh). In lumbar BMD, these 4 FR explained up to 85% of the BMD variation, where the age adds 0.032 per year gained, the male sex subtracts 0.061, the hypovitaminosis D sum 0.077 and the Latin ethnicity subtracts 0.070. Up to a 90.8% variation of BMDwbwh is explained by these 3 RF: age adds 0.036 per year gained, sedentary life subtracts 0.084 and Latin ethnicity subtracts 0.055.

Conclusion: The child population at risk of LBM/IOP associates 2 or more risk factors. 8.7% of children with risk factors have LBM and 4.8% IOP. The RFs related to changes in BMD are age, sex, sedentary lifestyle and ethnicity. Hypovitaminosis D correlated positively with lumbar BMD.

P577

SEVERE HYPOVITAMINOSIS D AT DELIVERY IN JAPANESE WOMEN: DISCREPANCY WITH QUANTITATIVE ULTRASONOMETRY (QUS)

M. Shibata¹, Y. Nakura², Y. Asada³, E. Tomatsu³, M. Kondo-Ando³, Y. Yoshino¹, T. Takayanagi¹, T. Sekiya², T. Fujii², A. Suzuki¹

¹Department of Endocrinology and Metabolism, Fujita Health University, ²Department of Obstetrics and Gynecology, Fujita Health University, ³Department of Endocrinology and Metabolism, Fujita Health University, Toyoake, Japan

Objective: Serum 25-hydroxyvitamin D (25-OHD) concentrations is thought to reflect vitamin D stores, and vitamin D deficiency can cause secondary hyperparathyroidism, osteomalacia, bone loss and increased risk of fracture. In addition, recent studies suggest that maternal hypovitaminosis D could increase the risk of preeclampsia, cesarean section, and craniootabes. We have previously reported high prevalence of hypovitaminosis D in Japanese pregnant women with threatened premature delivery (Shibata M et al 2011). However, the relationship between mothers' bone metabolism and vitamin D has not yet been fully elucidated. This study is aimed to assess the bone microarchitecture by calcaneal QUS and its relationship with vitamin D levels.

Methods: Japanese women just after their delivery in Fujita Health University Hospital were recruited from February to December in 2018 (n=119, cesarean/vaginal delivery=60/59. age 33.5±5.1 years old). On the third day after their delivery, calcaneal QUS was estimated by ALOKA AOS-100 (n=80) and AOS-100SA(n=31). At the same time, blood sampling was performed to assess their bone metabolism.

Result: Mean osteosonindex (OSI) was 2.58±0.33 (Z-score: -0.45±1.23), and speed of sound (SOS) was 1557.6 m/s (Z-score: -0.31±1.49). Mean serum 25OHD level was 9.0±3.6 ng/mL. Therefore, we found that mean serum 25OHD level was very low, but mean OSI and SOS were within normal range. Their intact PTH, BAP, and TRACP-5b levels were 28.2±10.4 pg/mL, 8.4±4.0 µg/L, 262.9±104.9 mU/dL, respectively. Adjusted Ca level and creatinine levels were 9.5±0.4 mg/dL and 0.5±0.1 mg/dL. Serum 25-OHD was significantly associated with creatinine concentration (r=0.254, n=119, p=0.005), while not related to OSI nor SOS. Other laboratory test data were not associated with 25OHD.

Conclusion: Japanese women at delivery showed very low vitamin D levels, while QUS indices were normal.

P578

BEHAVIORAL EFFECTS OF ARONIA MELANOCARPA FRUIT JUICE IN RATS WITH OVARIECTOMY-INDUCED REDUCTION OF BONE MINERAL DENSITY

S. Valcheva-Kuzmanova¹, M. Todorova¹, A. Georgieva¹, M. Eftimov¹, V. Kuzmanova², A. Kuzmanov², K. Kuzmanov³, M. Vlaskovska⁴

¹Department of Pharmacology and Clinical Pharmacology and Therapeutics, Medical University Prof. Dr. Paraskev Stoyanov, Varna, ²Medical University Prof. Dr. Paraskev Stoyanov, Varna, ³Vivarium, Medical University Prof. Dr. Paraskev Stoyanov, Varna, ⁴Department of Pharmacology and Toxicology, Medical University, Sofia, Bulgaria

Objective: Aronia melanocarpa fruit juice (AMFJ), rich in polyphenols, possesses pronounced effects on central nervous system functions. This study aimed to investigate AMFJ effects on locomotor activity, anxiety and depressive behavior in rats with ovariectomy-induced reduction of BMD.

Methods: Female Wistar rats were divided into 4 groups: SO (sham-operated), OV (ovariectomized), OV+AMFJ5 and OV+AMFJ10. Beginning 2 weeks after the operation, rats were treated daily orally with distilled water (SO and OV groups) or with AMFJ at doses of 5 and 10 ml/kg (OV+AMFJ5 and OV+AMFJ10 groups, respectively). After 10 weeks, femur BMD was measured and animal behaviors were recorded in the open field test (OFT), social interaction (SI) test and forced swim test (FST).

Results: AMFJ dose-dependently antagonized OV-induced BMD reduction. In the OFT, ovariectomy caused a slight reduction in locomotor activity. The horizontal movements of OV+AMFJ5 and OV+AMFJ10 groups were significantly lower ($p < 0.01$) than those of SO and OV rats and the vertical movements of OV+AMFJ10 group were significantly lower ($p < 0.05$) than those of SO group. This AMFJ-induced dose-dependent decrease in locomotion was probably due to a sedative effect. The SI time of OV rats was significantly decreased ($p < 0.01$ vs. SO group) showing the development of an anxiety state. The SI time of OV+AMFJ5 group was not significantly different from that of SO rats demonstrating an anti-anxiety effect of that AMFJ dose. The SI time of OV+AMFJ10 group was similar to that of OV group, probably affected by the higher reduction of locomotion by 10 ml/kg AMFJ. In the FST, the immobility time (IT) of OV group was significantly increased ($p < 0.01$ vs. SO group) indicating the development of depression. The IT of OV+AMFJ5 group did not differ significantly from that of OV group. For OV+AMFJ10 group, the IT was significantly lower ($p < 0.05$) than that of OV group, not significantly different from that of SO group, indicating an anti-depressive effect of that AMFJ dose.

Conclusion: AMFJ reduced the locomotor activity probably due to sedation, antagonized ovariectomy-induced anxiety and depressive behavior in rats.

Acknowledgements: This research was funded by Science Fund of Medical University, Varna, Bulgaria.

P579

UPPER GASTROINTESTINAL SAFETY WITH THE BUFFERED SOLUTION OF ALENDRONATE 70 MG: 6 YEARS OF POST-MARKETING EXPERIENCE

P. Fardellone¹, B. Böezenec², B. Cortet³

¹Service de Rhumatologie Hôpital Nord, Amiens, ²Laboratoires Expanscience, Paris La Défense, ³Service de Rhumatologie, Hôpital Roger Salengro, Lille, France

Objective: Alendronate (ALN) and other bisphosphonates have been the mainstay in osteoporosis management and fracture prevention for over 20 y. While ALN reduces risk of vertebral, non-vertebral and hip fractures by 48%, 27% and 53% respectively in osteoporotic patients with T-score < -2.5 1, adherence to treatment is problematic and $>50\%$ discontinue within 12 months². Upper gastrointestinal (GI) side effects are one of the most common reasons for treatment discontinuation³. ALN 70 mg effervescent (ALN EX) was developed to improve the GI tolerability; ingested as a buffered solution of fully dissolved ALN to increase pH in the stomach and to eliminate contact of solid ALN with oesophageal mucosa⁴. Our aim was to assess the impact of ALN EX on occurrence of upper GI adverse reactions (AR).

Methods: The post-marketing experience with ALN EX, launched in 2012, comprises approximately 4,394,833 prescriptions, which translate into 366,236 patient years and 17,579,332 ingestions. Number of upper GI AR, descriptive of GI tolerability and associated with use of ALN EX were extracted from the pharmacovigilance database.

Results: 5 serious GI AR: erosive esophagitis: 1; abdominal pain upper: 3; rectal bleeding: 1 and 123 non serious GI AR were reported. Among the nonserious AR were abdominal pain: 30; dyspepsia: 25; dysphagia: 4; nausea: 31; gastritis: 5; GI pain: 1; vomiting: 5 and GI disorders: 22.

Conclusion: The reported frequency of esophagitis with ALN Tablets is 0.1-1%⁵. Assuming the same frequency for ALN EX in the 366,236 patient years, at least 366 cases of esophagitis would be expected. Even considering that only 6-10% of all ARs are reported⁶ post-marketing, the number of ALN EX cases is appreciably below the level expected for ALN Tablets.

The available safety data suggest that ALN EX is associated with a lower frequency of upper GI AR than reported for ALN Tablets and that it is a well-tolerated oral bisphosphonate for the management of osteoporosis.

References:

1. Black D. J Clin Endocrinol Metab 2000;85:4118.
2. Briesacher B. Pharmacotherapy 2008;28:437.
3. Invernizzi M. Aging Clin Exp Res 2015;27:107.
4. Hodges L. Int J Pharm 2012;432:57.
5. Fosavance SPC. www.ema.europa.eu; accessed 12. Jan 2017
6. Mazzitello C. J Pharmacol Pharmacother 2013;4:S20.

P580

DXA-BASED DIAGNOSIS OF SARCOPENIA IS NOT CORRELATED WITH MUSCULAR FAT INFILTRATION AND RISK OF FALL IN OSTEOPOROTIC ELDERLY WOMEN

L. Sconfienza¹, E. Fascio¹, J. Vitale¹, F. Galbusera¹, S. Corbetta¹, G. Lombardi², G. Banfi¹, C. Messina¹

¹IRCCS Istituto Ortopedico Galeazzi, ²IRCCS Istituto Ortopedico Galeazzi - Gdańsk University of Physical Education & Sport, Milano, Italy

Objective: Sarcopenia is a progressive degenerative condition characterized by loss of muscle mass, strength or function and, additionally, muscular fat infiltration. Declined muscle quality and performance may increase the risk of fall in sarcopenic people. 1,2 To date DXA is the preferred method for diagnosis of sarcopenia. The aim of the study is to assess the correlations between skeletal muscle mass index (SMI) from DXA-scan and muscular fat infiltration and risk of fall in osteoporotic, post menopause, women aged over 60 y.

Methods: 21 subjects were recruited (age: 60–85 y; median femoral T-score: -2.8). Patients with recent fractures, treated with anti-osteoporotic drugs and glucocorticoids, affected with diabetes, neoplasia, kidney or liver failure, were excluded. All participants underwent a wholebody DXA-scan, a MRI-scan using Dixon sequence automated water-fat segmentation method and were assessed for the risk of fall using a stabilometric computerized platform (OAK, Khymeia Group), whose scores are based on Brief-Balance Evaluation System Test3. These assessments respectively lead to the evaluation of the SMI, the muscular fat infiltration and the risk of fall.

Results: Pearson correlation coefficients between SMI and muscular fat infiltration and risk of fall were respectively $\rho=0.169$ ($p=0.517$) and $\rho=-0.091$ ($p=0.704$).

Conclusion: Collected data failed to detect any significant correlation between the investigated parameters suggesting that DXA derived SMI does not reflect a clinical outcome like risk of fall neither muscular fat infiltration distinctive for sarcopenic condition. The lack of associations between SMI definition of Sarcopenia and clinical outcomes appears to be a critical issue of this assessment technique.

References:

1. Cruz-Jentoft AJ et al. Age Ageing 2010
2. Scott D et al. Curr Osteoporos Rep 2015
3. Padgett PK et al. Phys Ther 2012

P581

FACTORS AFFECTING THE TENDENCY TO FALL IN PATIENTS WITH LOW-ENERGY PROXIMAL FEMUR FRACTURES IN BELARUS

E. Rudenka¹, H. Ramanau², N. Predko³

¹Belarusian State Medical University, Minsk, ²Gomel State Medical University, Gomel, ³Minsk Clinical Consulting and Diagnostic Centre, Minsk, Belarus

Objective: To evaluate the factors affecting the increased likelihood of falls in patients with proximal femur (PF) fracture over the age of 50.

Methods: A special questionnaire was developed for patients who have had a PF fracture after 50. The questionnaire included family history information, question about where the fracture occurred (at home or outdoor), about visual impairment, the presence of osteoarthritis (degree more than 2 stage), history of smoking, the low-energy previous fractures and fractures among first-line relatives. Frequent fall was considered to fall at least once a month and often. We have analyzed data of self patient records, which visit to "Minsk Clinical Consulting and Diagnostic Centre" and "Minsk City Clinical Hospital No. 1".

Results: A total of 300 questionnaires were issued to fill out 150 in each of the medical institutions. 218 questionnaires were returned, of which 200 questionnaires were accepted as completed correctly and included in the further analysis. The study involved 166 women and 34 men aged from 51-98 y. All respondents were divided into 2 groups: group of patients #1 with frequent falls ($n=39$) and group of patients #2 with rare falls ($n=161$). Statistical frequency analysis was carried out as a result of which it was found that patients from group #1 were more likely to live alone than patients from group #2 (34.4% vs. 16.8%; $\chi^2=4.9$; $p=0.027$), have poor vision and constantly use glasses (34.4% vs. 11.5%; $\chi^2=10.1$; $p=0.002$), have a history of osteoarthritis of the lower limb joints (53.1% vs. 19.1%; $\chi^2=15.6$; $p<0.001$), smoke at present (18.8% vs. 4.6%; $\chi^2=7.6$; $p=0.006$). When analyzing other questions of the questionnaire, it was found that, regardless of the tendency to fall, a PF fracture in patients of both groups occurred equally often indoors (34.4% vs. 33.6%; $\chi^2=0.2$; $p=0.656$), have previous low-energy fractures (59.4% vs. 63.4%; $\chi^2=0.2$; $p=0.676$) and low-energy fractures in first-line relatives (18.8% vs. 11.4%; $\chi^2=1.2$; $p=0.269$).

Conclusion: Patients with a PF fracture who have a tendency to fall, more often live alone, have poor eyesight, smoke and suffer from osteoarthritis.

P582

RISK ASSESSMENT OF OSTEOPOROTIC FRACTURES: BMD vs. FRAX® (10-YEAR PROSPECTIVE COHORT STUDY)

O. Nikitinskaya¹, N. Toroptsova¹, N. Demin¹¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia

Objective: Evaluate the performance of DXA and FRAX, with and without BMD measurement, in predicting the occurrence of fragility fractures over 10 y.

Methods: 256 postmenopausal women aged 50-81 years with a complete set of data on FRAX clinical risk factors and DXA scans of lumbar spine and proximal femur of the nondominant side at baseline were observed during ten years. The 10-y fracture risk probability for major osteoporotic fractures (MOF) (with and without the femoral neck BMD value) for each individual case was calculated using the Russian version of the FRAX tool at the time of inclusion in the study and assessed by comparison with fractures during follow-up prospective observation. Receiver operating characteristic (ROC) area under the curve (AUC) analyses was conducted to explore the fracture risk stratification using FRAX with/without neck BMD and the prediction of BMD alone.

Results: Within 10 y, 120 participants suffered fractures, among them 44 women had more than one fracture and six people - hip fracture. The predictive performance of FRAX for MOF was slightly better to that of BMD alone. AUC of hip BMD was 0.64 (95%CI 0.57 to 0.72) and AUC of lumbar spine BMD - 0.62 (95%CI 0.54 to 0.68). AUC for FRAX without BMD was 0.67 (95%CI 0.60 to 0.74). We did not find any significant improvement in predicting of MOF when neck BMD was added to FRAX clinical risk factors (AUC=0.69 (95%CI 0.62 to 0.76, p<0.05). The Russian age-dependent threshold of therapeutic intervention demonstrated 42% sensitivity and 78% specificity of FRAX without the femoral neck BMD, 39% sensitivity and 81% specificity of FRAX with BMD.

Conclusion: The using of FRAX tool identifies individuals at high fracture risk more effectively than the use of BMD data only. Russian version of the FRAX tool provided sufficiently fracture prediction and can be used in routine clinical practice.

P583

ASSESSMENT OF THE KNEE'S FUNCTIONAL STATUS IN RELATION TO THERAPY

S. Kevic¹, S. Tomasevic-Todorovic², K. Boskovic², A. Knezevic²¹Medical Rehabilitation Clinic, Clinical Centre of Vojvodina,²Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia

Objective: Arthrosis of the knee is a chronic degenerative disease accompanied by chronic pain, a feeling of stiffness of the joints, limited mobility of joints, disturbed gait and difficulty in performing daily activities. It most often occurs after the age of 40 and more often in women. Our aim was to determine the efficiency of the applied therapy and the functional status of the patients depending on the applied therapy.

Methods: The study included 60 patients with osteoarthritis of the knee, treated at Clinic for Medical Rehabilitation CCV during 2018. The diagnosis was achieved according to the ACR criteria. The patients were divided into two groups: Group A (30) patients were treated with outpatient physical therapy. The treatment was conducted over a period of 8 weeks. Group B (30) patients received three applications of 1% hyaluronate ia for 7 d and then had physical procedures. This treatment also lasted 8 weeks. All patients were processed according to a unique questionnaire and clinically appraised by orthopedists and rheumatologists. The average age was 68.4. The representation of women was 80%. Radiological changes were assessed according to the Kellgren-Lawrence classification, 70% had stage III and 30% stage II. The assessment of the functional status, before and after treatment, was made according to the Oxford Knee Score. The assessment of the degree of pain with VAS, before and after treatment. The assessment of the activities of daily life was estimated with the WOMAC Index before and after treatment.

Results: In patient group A, before treatment, the average degree of pain according to VAS was 8, after treatment it was 6. The average value of the functional score was 22 before treatment and 31 after treatment (p<0.005). The average value of WOMAC Index was 44.7 before treatment and 62.5 after treatment. In patient group B, before treatment, the average degree of pain according to VAS was 9 and after treatment 4, the average score of the functional status was 22 and 38 after treatment (p<0.005). The average WOMAC Index was 50 before treatment and 69.7 after treatment.

Conclusion: The patients who received ia 1% hyaluronate and then had physical therapy had a more significant reduction of pain after treatment, as well as a more improved functional status compared to patients who only had combined physical therapy conducted on them.

P584

FACTORS ASSOCIATED WITH LOW BACK PAIN IN OSTEOPOROSIS

M. Miyagi¹, K. Murata¹, T. Koyama¹, A. Kawakubo¹, H. Fujimaki¹, K. Uchida¹, G. Inoue¹, M. Takaso¹¹Department of Orthopaedic Surgery, Kitasato University, School of Medicine, Sagamihara, Japan

Objectives: Patients with osteoporosis often experience low back pain (LBP) despite no evidence of new compression fractures. We performed multivariate analyses to identify factors that may affect LBP.

Methods: Retrospective data from 262 osteoporosis patients (48 men, 214 women, mean age: 71.3 y) were analyzed for age, gender, BMI, lumbar spine BMD, TRACP5b, trunk muscle mass, sagittal vertical axis (SVA: spinal sagittal balance), existing vertebral fractures, secondary osteoporosis, Charlson comorbidity index (CCI), CONUT score (nutritional status) and Japanese Orthopaedic Association back pain evaluation questionnaire (JOABPEQ; included five domains: pain-related disorders, lumbar spine dys-

function, gait disturbance, social life dysfunction, and psychological disorders as LBP score). Multivariate analyses ($p < 0.05$) were reviewed for associations to low back pain.

Results: Pain-related disorders was associated with primary osteoporosis, low trunk muscle mass, and high SVA, while high CONUT score, high BMI, low trunk muscle mass, and frequent vertebral fractures were associated with lumbar spine dysfunction. Aging, high TRACP5b, high BMI, low trunk muscle mass, and high SVA were associated with gait disturbance. High CCI, TRACP5b, high SVA, and frequent vertebral fractures were associated with social life dysfunction. High TRACP5b and high SVA affected psychological disorders.

Conclusions: Results suggest aging, obesity, high bone turnover, spinal sagittal imbalance, existing vertebral fractures, low trunk muscle mass, poor systemic condition, and poor nutritional status adversely affect low back pain scores. Especially, LBP-related disorders, lumbar dysfunction, and gait disturbance were associated with spinal sagittal imbalance and low trunk muscle mass. However, spinal BMD was unrelated to low back pain scores. Other than pharmacotherapy to increase BMD, exercise therapy to treat low muscle mass and obesity, and nutritional counseling may prove effective in improving ADL due to low back pain in osteoporosis.

P585

A SYNTHETIC PEPTIDE DERIVED FROM THE SIBLING PROTEIN MEPE INHIBITS ECTOPIC MINERALIZATION BUT NOT BONE FORMATION

T. Minamizaki¹, M. Toshishige¹, H. Yoshioka², F. Ahmed¹, Y. Mine¹, Y. Yoshiko¹

¹Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, ²International University of Health and Welfare, Chiba, Japan

Objective: A peptide fragment of the acidic serine- and aspartate motif (ASARM) derived from the family of noncollagenous proteins in bone matrix, known as SIBLING (small integrin binding ligand N-glycosylated) proteins, may act as an endogenous anti-mineralization factor. We have focused on ASARM in matrix extracellular phosphoglycoprotein (MEPE), a member of the SIBLING proteins, and tested the potential use of its synthetic peptides for the management of ectopic mineralization disorders.

Methods: The designed peptide fragments with or without phosphorylated serine residues were synthesized based on human MEPE-ASARM. Rat/mouse osteogenic cell cultures and mouse aorta organ cultures were used to determine mineralized matrix formation in vitro. Normal mice were subjected to analyze bone morphometric parameters and biochemical tests. Warfarin-treated rats were used as vascular mineralization models. Mice transplanted intramuscularly with atelocollagen sponges including bone morphogenetic protein (BMP)2 were developed. Synthetic peptides were given every second or third day in vitro and intravenously using osmotic pumps in vivo.

Results: None of peptides synthesized altered the proliferation and differentiation of osteogenic cells, while ASARM including phosphorylated serine residues (pASARM, 2 μ M or less) inhibited matrix mineralization. pASARM suppressed phosphate-induced mineralization in mouse aorta organ cultures, which was characterized by differential gene expression profiles. Of the amino acid sequence of pASARM, not only two phosphorylated serine residues, but also cleavage sites by the phosphate regulating neutral peptidase PHEX were necessary for its anti-mineralization effect. Vascular calcification in warfarin-treated rats and BMP2-induced bone-like nodules in muscle pouches were abolished by treatment with pASARM (0.5 mg/mice/d or less). However, injections of pASARM (3 mg/mice/d) for a week did not affect bone parameters and biochemical tests.

Conclusion: pASARM has a potential to inhibit ectopic mineralization in a wide range of diseases without affecting bone formation.

Acknowledgement: A part of this study was supported by AMED (DNW-14017).

P586

IMMINENT FRACTURE RISK AMONGST NEW USERS OF ORAL BISPHOSPHONATES IN ACTUAL PRACTICE SETTINGS: A MULTINATIONAL EUROPEAN COHORT STUDY FROM DENMARK, SPAIN, AND THE UK

S. Khalid¹, M. Thomsen Ernst², M. A. Javaid¹, C. Libanati³, C. Cooper¹, A. Delmestri¹, D. Martinez-Laguna⁴, E. Toth, B. Abrahamsen², D. Prieto-Alhambra¹

¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, ²Odense Patient Data Explorative Network OPEN, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark, ³UCB Biopharma Sprl, Brussels, Belgium, ⁴GREMPAL Research Group, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain

Objective: Nonvertebral fracture efficacy for bisphosphonates is not rapidly accomplished. Patients who fracture despite treatment face a high risk for refracture. We calculated imminent (1- and 2-year) fracture risk (IFR) amongst incident users of oral bisphosphonates from three European countries; and after a fracture while on treatment.

Methods: Patients aged 50+ starting oral bisphosphonates (12-month wash-out) were identified from Danish, Spanish and UK electronic medical records. Participants were followed from therapy initiation to the earlier of a fracture, death, migration, or end of study. A cohort of patients who fractured while on treatment were identified and analysed separately from then onwards. Incidence rates (per 1000 person-years) and 95% confidence intervals of fracture in the 1 and 2 years following index were calculated after stratification by fracture history.

Results: A total of 209,670 patients who started bisphosphonates and 32,235 who fractured while on treatment were included from Denmark, compared to 53,549 and 1,880 from Spain, and 148,507 and 28,930 from the UK. Average age at treatment ini-

tiation ranged from 68.9 (ES) to 74.2 (UK), and previous fracture prevalence from 12.0% (ES) to 33.3% (DK). IFR is high (2.5% to 5.6%) in the first year amongst treatment initiators, and higher in patients with a previous fracture history (4.0% to 8.7%). Risk is even higher (5% to 9.2%) in those followed from a fracture while on treatment [Table 1]. Rates in the second year were similar but slightly reduced.

Conclusion: IFR risk is high in the first 2 years of bisphosphonate therapy, particularly for those on secondary fracture prevention. Fracture while on treatment is a marker of subsequent higher short-term re-fracture risk.

Disclosures: DPA's institution has received research grants, speaker, and advisory board fees from AMGEN, research grants from Servier Laboratoires and UCB Pharma, and consultancy fees from UCB; CC reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB; MKJ reports personal fees from Amgen outside the submitted work; DML reports personal fees from Amgen, Lilly, Novartis, Ferrer and Rubió outside the submitted work; BA reports research support from Novartis and UCB and advisory board and consulting fees from UCB; CL and ET are employees and own stock of UCB.

Table. One-year IFR in the first year of bisphosphonate therapy, and in the year after a fracture while on treatment with oral bisphosphonates.

	1-y IFR following bisphosphonate initiation						1-y IFR following fracture while on treatment		
	With prior Fx			Without prior Fx			IR (/1000 py)	95CI	
DENMARK	IR (/1000 py)	95CI		IR (/1000 py)	95CI			IR (/1000 py)	95CI
Hip	28.172	27.115	29.230	12.605	11.901	13.308	34.06		31.93
Clinical spine	6.988	6.464	7.512	4.689	4.261	5.118	7.21	6.23	8.18
Non-hip non-spine	46.037	44.679	47.394	27.529	26.485	28.573	69.12	66.05	72.19
Hip/shoulder/wrist	52.689	51.234	54.145	28.066	27.012	29.120	39.95	37.64	42.26
SPAIN	IR (/1000 py)	95CI		IR (/1000 py)	95CI		IR (/1000 py)	95CI	
Hip	7.289	5.951	8.628	3.890	3.257	4.524		7.61	4.56
Clinical spine	5.364	4.217	6.511	3.676	3.061	4.292	12.01	6.99	17.03
Non-hip non-spine	28.818	26.140	31.495	18.795	17.397	20.194	77.31	64.27	90.35
Hip/shoulder/wrist	22.327	19.975	24.680	13.989	12.784	15.193	28.66	20.87	36.44
UK	IR (/1000 py)	95CI		IR (/1000 py)	95CI		IR (/1000 py)	95CI	
Hip	27.514	25.664	29.363	13.263	12.582	13.945		28.88	26.78
Clinical spine	6.436	5.547	7.326	3.750	3.388	4.112	8.01	6.92	9.11
Non-hip non-spine	59.485	56.740	62.231	26.556	25.588	27.524	55.30	52.37	58.22
Hip/shoulder/wrist	45.826	43.427	48.226	21.790	20.914	22.665	43.89	41.29	46.49

P587

DETECTING BONE MARROW LESIONS ON PLAIN RADIOGRAPHS USING ARTIFICIAL INTELLIGENCE (AI): DATA FROM THE OSTEOARTHRITIS INITIATIVE (OAI) STUDY

H. P. Dimai¹, T. Paixao², Z. Bertalan², R. Ljuhar², C. Goetz², D. Ljuhar³, S. Nehrer⁴, A. Fahrleitner-Pammer¹, A. Kurth⁵

¹Division of Endocrinology and Diabetology, Dept. of Internal Medicine, Medical University of Graz, Graz, Austria, ²Image Biopsy Lab, Vienna, Austria, ³Braincon Technologies, Vienna, Austria, ⁴Danube University, Krems, Austria, ⁵Gemeinschaftsklinikum Mittelrhein, Kemperhof, Koblenz, Germany

Objectives: Bone marrow lesions (BMLs) are a MRI finding associated with various pathologies such as osteoarthritis of the knee. They have been linked to reduced BMD, raising the hypothesis that these alterations might also be detectable on plain ra-

diographs (1). The aim of the study presented here was to test whether utilization of a convolutional neural network (CNN) is able to detect BMLs from plain radiographs of the knee.

Methods: We used radiographic and MRI images from the Osteoarthritis Initiative (OAI) study, a large longitudinal study focusing on knee osteoarthritis (<https://data-archive.nimh.nih.gov/oai/>). MRI readings according to the MRI Osteoarthritis Knee Scoring method (MOAKS) were provided. We matched radiographic images to BML readings (MOAKS BML subscore) from MRI, resulting in a dataset of 5214 radiographic images of single knees, labeled with respect to the presence, number, and location of BMLs in the corresponding MRI. We split this dataset into train (2085), validation (1564), and testing (1565) subdatasets which were used to train, and independently cross-validated an 8 layer CNN to detect BMLs from plain radiographs. Class imbalance was dealt with by oversampling the minority class.

Results: We found that our CNN achieves an average weighted class accuracy >70% in the test dataset, with a sensitivity of 0.72 and a specificity of 0.69, when classifying presence/absence of BML from plain radiographs. Furthermore, saliency analysis indicates that the CNN is able to discriminate the joint compartments in which BMLs are located.

Conclusions: Our results show that BMLs can be detected on plain radiographs by using AI-based software. Given that - due to the very limited access to MRI and its high cost - the number of BML cases in a given population is likely to be greatly underestimated, diagnosis of BML by using conventional radiographs could potentially improve healthcare quality even in countries with lower healthcare expenditure per capita.

Reference:

1. Berman N et al. Bone Rep 2016;5:308

P588

ASSOCIATION BETWEEN SUN EXPOSURE AND LIFESTYLE VARIABLES IN PORTUGUESE CHILDREN

E. Alexandre dos Santos¹, L. Araújo Martini¹, A. Gama², A. Machado-Rodrigues², V. Rosado-Marques², H. Nogueira², M.-R. Silva², C. Padez²

¹Nutrition Department. School of Public Health. University of São Paulo, São Paulo, Brazil, ²Research Centre for Anthropology and Health, Department of Life Sciences, University of Coimbra., Coimbra, Portugal

Objective: To investigate whether sun exposure is related to lifestyle variables, nutritional and socioeconomic status.

Methods: This is a cross-sectional study carried out with children of both sexes participating in the Study of Social Inequalities in the Health of Portuguese Children: The Impact of the Economic Crisis on Childhood Obesity. Information about lifestyle habits and socioeconomic status were obtained through standardized questionnaires. Sun exposure questionnaire was adapted from Hanwell et al, 2010. Trained professionals performed weight and height measurements, children's BMI was categorized in normal weight and overweight/obese according to IOTF cutoff points. Chi-square Fisher test were used to assess the presence of associations between sun exposure and body surface sun exposed with socioeconomic status, BMI and with following lifestyle variables: active play (hours a day), sporting activity besides school, sporting activities (times a week), TV viewing (in hours a day), use of vitamin D supplements and time in summer outdoor activity. Significance was considered when $p < 0.05$.

Results: The total sample was 4849 children with a median age of 7.10 y (2.91 - 11.81) being 49.6% male (n=2406). The highest time of sun exposure (up to or equal to 2 h/d) was associated with higher socioeconomic status ($p=0.000$), greater active play ($p=0.000$), sporting activity besides school practice ($p=0.000$), higher times a week in sporting activities ($p=0.003$) and higher time spent in sports ($p=0.019$). There was no association between sun exposure with nutritional status ($p=0.115$) and TV viewing

($p=0.433$). Higher socioeconomic status was associated with use of vitamin D supplements and greater time in summer outdoor activity.

Conclusion: The present study demonstrated that sun exposure was related to a better lifestyle habits, mainly in physical activities.

P589

ANALYSIS OF BMD DEVELOPMENT IN ORGAN TRANSPLANT RECIPIENTS ORIGINALLY TREATED WITH DENOSUMAB

J. Brunova¹, S. Kratochvilova¹

¹Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Objective: The recommended treatment of osteoporosis in solid organ transplant recipients includes vitamin D, calcium supplementation and bisphosphonates. Denosumab inj. is the possible therapeutic option for patients with impaired renal function.

Methods: We already published our positive experience with osteoporosis therapy with Denosumab in 63 patients after solid organ transplantation (Tx) and moderate renal function impairment (liver 14, kidney 34, kidney and pancreas in 15 patients) between years 2012-2017.

Results: 52/63 patients is still followed (9 patients died and 2 patients moved away). Denosumab therapy was continued in 29/52 Tx recipients and not continued in 23 patients in 2018. The reason for the therapy discontinuation was mainly BMD improvement (14 patients), re-introduction of dialysis (5), patients' renal function allowed bisphosphonates administration (3), major surgery (1). The denosumab therapy improved L spine T-score from -2.6 ± 1.1 to -2.0 ± 1.0 ($p < 0.01$) and proximal femur T-score increased from -2.5 ± 0.8 to -2.1 ± 0.9 in the whole group. BMD of L spine increased by $13.3 \pm 8.3\%$ and proximal femur by $10.4 \pm 13.7\%$ in patients continuing Denosumab therapy without any interruption (21/29 persons). The mean duration of treatment was 2.83 y (1-5 y). 8/29 patients currently on denosumab had their therapy interrupted for 1-4 y (mean 2.1 y) and then again restarted. Their total mean duration of treatment was 2.75 y (2-3 y) and BMD increase in L spine was $7.2 \pm 7.1\%$ and $4.9 \pm 6.0\%$ in proximal femur. Last 20 patients originally treated with Denosumab had their therapy completely terminated after 1-2 y (mean 1.7 y) and after BMD increase by $11.4 \pm 7.5\%$ in L spine and $6.0 \pm 5.6\%$ in proximal femur. The discontinuation of Denosumab resulted in BMD decrease by $4.7 \pm 7.7\%$ in L spine BMD and by $4.6 \pm 5.6\%$ in proximal femur site over 1-5 y (mean 2.7 y). BMD of L spine further increased or remained stable in 6/20 patients after the Denosumab termination and in 5/20 for hips.

Conclusion: Denosumab therapy is associated with the BMD improvement in organ transplant recipients. The cessation of therapy resulted in BMD decrease in most patients but relatively small one, probably due to effect of successful transplantation.

Acknowledgement: Supported by the Ministry of Health of the Czech Republic (MZO 00023001)

P590

TEN-YEAR FRACTURE PROBABILITY IN SYRIA USING A SURROGATE MODEL

H. Johansson¹, G. Adib², E. V. McCloskey³, N. C. Harvey⁴, M. Lorentzon⁵, E. Liu¹, J. A. Kanis¹

¹McKillop Health Institute, Australian Catholic University, Melbourne, Australia, Melbourne, Australia, ²Osteoporosis Center, Italian Hospital, Damascus-Syria, Damascus, Syria, ³Center for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK, ⁵Geriatric Medicine, Sahlgrenska University Hospital, Mölndal, Sweden

Objective: To estimate the 10-y probability of major osteoporotic fracture (MOF) in Syria according to age and BMD T-score at the femoral neck, based on the FRAX® methodology, but using a surrogate country model.

Methods: Hip fracture data from Syria were not available for construction of a country-specific FRAX model. A surrogate model was developed according to International Society for Clinical Densitometry and International Osteoporosis Foundation recommendations, using data on fracture risk from Lebanon from 2007 and death rates for Syrian Arab Republic from UN for year of 2009. Fracture probability from the new model for Syria was studied and compared to fracture probability from Lebanon.

Results: In this study, the 10-y probability of major osteoporotic fracture in Syria increased markedly with increasing age and decreasing femoral neck BMD T-scores in both women and men. For a woman without clinical risk factors and a BMI of 25 kg/m², the 10-y probability of a major osteoporotic fracture (MOF) was 1.0% at the age of 50 years and 25% at the age of 90 years. When comparing the 10-y probability for men and women using Syrian FRAX model it was very similar to the probability observed using Lebanon FRAX model. For men the probability was at most 0.1% higher for Lebanon for ages below 85 y. At the age of 85 y the 10-y probability of MOF was 9.1% for both Syria and Lebanon, for a man without clinical risk factors and a BMI of 25 kg/m². The same was true for women where the biggest difference was 0.2% at the age of 75 y (9.8% in Syria and 10% in Lebanon) for the same scenario.

Conclusions: The Syrian FRAX model for 10-y probability using hip fracture incidence from Lebanon was similar to the FRAX model for Lebanon. The surrogate model for Syria can be recommended for use, with appropriate updates when fracture data become available from within Syria.

P591

TEN-YEAR FRACTURE PROBABILITY IN SERBIA ACCORDING TO AGE AND OTHER FRAX MODELS IN THE REGION

H. Johansson¹, R. Matijevic², V. Harhaji², E. V. McCloskey³, N. C. Harvey⁴, M. Lorentzon⁵, E. Liu¹, J. A. Kanis¹

¹McKillop Health Institute, Australian Catholic University, Melbourne, Australia, Melbourne, Australia, ²University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia, ³Center for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK, ⁵Geriatric Medicine, Sahlgrenska University Hospital, Mölndal, Sweden

Objective: To estimate the 10-y probability of major osteoporotic fracture (MOF) in Serbia according to age and BMD T-score at the femoral neck using the FRAX® risk assessment tool calibrated to the epidemiology of Serbia.

Methods: Hip fracture data were obtained from hospitalization data in Vojvodina for 2016. The catchment population data (size by age) were obtained from Institute of Public Health of Vojvodina and death rates came from the UN data from 2015. Since there were no country specific data regarding spine, forearm or humeral fractures, the incidences of fracture at these three sites were imputed from the hip fracture incidence from Serbia, using the relationship between hip fracture incidence and other sites in Sweden (Malmö). Fracture probability from the new model for Serbia was studied and compared to comparable fracture probabilities elsewhere in the region (Italy, Hungary, Croatia, and Romania).

Results: 10-y probability of MOF in Serbia increased markedly with increasing age and decreasing femoral neck BMD T-scores in both women and men. For a 75-year-old man without clinical risk factors and BMI of 25 kg/m², the 10-y probability of a major osteoporotic fracture (MOF) was 3.8%, which was higher than for an equivalent man in Romania (3.3%) and lower than in Croatia, Hungary and Italy (4.4%, 4.8% and 6.0% respectively). The situation was similar for a woman in the same scenario from Serbia when comparing to other countries in the region. Her Serbian 10-y probability of MOF was 8.2%, which was higher than a woman from Romania (7.1%) and lower than in Croatia, Hungary and Italy (9.7%, 12% and 12% respectively).

Conclusions: The 10-y probability calculated using hip fracture incidence from Serbia was similar to the established FRAX model from Romania. We then recommend the application of the Serbian risk profile to calculate the absolute fracture risk for Serbian subjects.

P592

FRactal Dimension Can Describe Changes in Vessel Structure of Bone TissueP. Troshin¹, O. Sachenkov¹, Y. U. Agachev¹, D. Lisenkov¹, E. Semenova¹, T. Baltina¹, N. Kharin¹¹Kazan Federal University, Kazan, Russia

Objective: Studies performed in conditions of a microgravity models the hypothesis that influence of gravitational load on a various parts of the musculoskeletal system can be a consequence of evolution of biomechanical structures. It was shown previously that in the conditions of a microgravity anisotropic properties of the bone tissue changes (1). To understand the mechanism the origin of the structure changes vessels were studied.

Method: The femoral bones and shoulder bones were dissected from all tested rats with following weight measurement, and measurement of geometrical parameters. Bones was scanned on μ CT in diaphysis regions. After scanning the threshold was calculated. Then vessel network was determined. To solve this problems the special software was created. The samples were analyzed by multifractal analysis. This method allows to obtain additional quantitative information about vessel structure. For this purpose, the box-counting method was applied to 3D and 2D scans. It turned out that the $f(\alpha)$ spectrum is essentially different in each sample.

Results: Average dimensions for vessel networks were: 0.51 ± 0.05 for control group, 2.14 ± 0.32 for microgravity group (21 d), 1.12 ± 0.13 for microgravity group (38 days) and 0.81 ± 0.13 for microgravity group (60 d). The behavior of changes of dimensions values correlates with fractional anisotropy of bone tissue (2).

Conclusion: Fractal dimension can describe changes of vessel network and correlates with anisotropy properties of bone tissue. Understanding the biomechanical mechanism of vessel network growing can help to understand the processes which appear in bone structure during microgravity. And multifractal characteristics can be used to distinguish between samples, and to understand the distribution of scales inside the structure.

References:

1. Baltina T et al. BioNanoScience 2018;8:864
2. Gerasimov OV et al. Osteoporos Int 2018;29:S271

Acknowledgement: The research was funded by the subsidy allocated to Kazan Federal University for the state assignment in the sphere of scientific activities, project № 1.12878.2018/12.1.

P593

Secular Changes in Hip Fracture Incidence in Ecuador and Implications for FRAXH. Johansson¹, E. Lopez Gavilanez², M. Navarro Grijalva², E. V. McCloskey³, N. C. Harvey⁴, M. Lorentzon⁵, E. Liu¹, J. A. Kanis¹

¹McKillop Health Institute, Australian Catholic University, Melbourne, Australia, Melbourne, Australia, ²AECE research group from Association of Clinical Endocrinologists of Ecuador, Guayaquil, Ecuador, ³Center for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK, ⁵Geriatric Medicine, Sahlgrenska University Hospital, Mölndal, Sweden

Objectives: The construct for FRAX model outputs depends on country specific fracture incidence and mortality. The current FRAX model for Ecuador is based on hip fracture data from 2008. A recent publication showed a higher hip fracture incidence in the Ecuadorian population for 2016. The aim of the present study was to examine the impact of these more recent data on the FRAX probability outputs for Ecuador.

Methods: Hip fracture incidences for Ecuador from 2016 and mortality data from the UN for Ecuador in 2015 were used to build a new FRAX model for Ecuador. The new FRAX model for Ecuador was compared to the old model which was derived using hip fracture data from 2008 combined with UN mortality data from 2009. For both the old and new models, a ratio from Malmö was used to calculate the incidence of clinical spine, forearm, humerus fractures. The 10-y probability of major osteoporotic fracture (MOF) was used when comparing old and new FRAX model. An example is given for a woman with no clinical risk factors and BMI 25 kg/m², where the BMD was not known.

Results: For younger women the difference between the old and new FRAX model was minor up to the age of 60 y (Figure). From the age of 65 the difference between the old and new model was greater, with the new model having higher probabilities. The largest difference between old and new model was seen for ages 80 and 85 where the difference was 1.6% points (5.7% vs. 4.1% for the age of 80 y and 7.6% vs. 6.0% for the age of 85). For the age of 90 y the new 10-y probability was lower than the old model.

Conclusion: Use of the more recent hip fracture incidence data impacts on the outputs from FRAX, leading to higher probabilities than the old model for ages between 60-87 y. These findings support the need for an updated FRAX model for calculating fracture probabilities in Ecuador.




Figure. The 10-y probability of a major osteoporotic fracture (%) for a woman with no clinical risk factors, BMI 25 kg/m² where the BMD was not known.

P594

PROTON PUMP INHIBITORS USE IN HEMODIALYSIS PATIENTS AND INCREASED RISK OF FRACTURES: RESULTS FROM THE DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (DOPPS)

M. Fusaro¹, M. Gallieni², G. D'Arrigo³, A. Pitino¹, G. Iervasi¹, F. Tentori⁴, B. Robinson⁵, A. Aghi⁶, B. Bieber⁵, K. McCullogh⁵, F. Fabris⁶, M. Plebani⁷, S. Giannini⁶, F. Locatelli⁸, M. L. Brandi⁹, G. Tripepi³

¹National Research Council (CNR) – Institute of Clinical Physiology (IFC), Pisa, Italy, ²Nephrology and Dialysis Unit, ASST Fatebenefratelli Sacco, Department of Clinical and Biomedical Sciences 'Luigi Sacco', University of Milan, Milano, Italy, ³Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, CNR, Institute of Clinical Physiology, Reggio Calabria, Italy, ⁴DaVita Clinical Research, Minneapolis, USA, ⁵Arbor Research Collaborative for Health, Ann Arbor, MI, USA, ⁶Department of Medicine, Clinica Medica 1, University of Padova, Padova, Italy, ⁷Laboratory Medicine Unit, Department of Medicine, University of Padova, Padova, Italy, ⁸Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy, ⁹Department of Surgery and Translational Medicine, University of Florence, Bone Metabolic Diseases Unit, University Hospital of Florence, Florence, Italy

Objective: Proton pump inhibitors (PPIs) are extensively used for the chronic treatment of common gastrointestinal disorders dialysis patients. PPIs interfere with the active transport of magnesium causing hypomagnesemia. Magnesium is deposited in large quantities in bone, is essential for bone health and severe osteoporosis has been reported in patients on chronic PPI treatment. This study aims to assess the relationship of PPIs use with bone and hip fractures in 27097 hemodialysis patients enrolled in the observational Dialysis Outcomes and Practice Patterns Study (DOPPS).

Methods: Observational prospective cohort of 27097 hemodialysis patients from the DOPPS study. After data collection, the hypothesis of a relationship between PPI treatment and the incidence rate of bone and hip fractures was tested by the Fine

and Gray method, considering the competitive risk of mortality, as well as by a cause-specific hazards Cox model dealing death as a censoring event. In Cox models fitted according to the Fine and Gray method, data were expressed as sub-distribution hazard ratios (SHR), 95%CI and P values. In cause-specific hazards Cox models, data were expressed as hazard ratio (HR), 95%CI and P values.

Results: Out of 27,097 hemodialysis patients, 13,283 patients (49%) were on PPI treatment. The prevalence of PPI treated patients ranged from 28.6% in Japan to 73.5% in Spain. Across the follow-up period (median 19 months), 3.8 bone fractures x 100 person-years and 1.2 hip fractures x 100 person-years were observed. In multiple Cox models, taking into account the competitive risk of mortality, the incidence rate of bone (SHR: 1.22, 95%CI: 1.10-1.36, P<0.001) and hip fractures (SHR: 1.35, 95%CI: 1.13-1.62, P=0.001) was significantly higher in PPI treated than in PPI untreated patients and these relationships held true also in multiple, cause-specific, hazards Cox models matching patients according to the prescription time (bone fractures, HR: 1.47, 95%CI: 1.23-1.76, P<0.001, hip fractures (HR: 1.85, 95%CI: 1.37-2.50, P<0.001).

Conclusion: The use of PPIs requires caution in hemodialysis patients.

P595

FAT DISTRIBUTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS MEASURED USING DXA

L. Labashova¹, A. Shepelkevich²

¹Republic Centre of Medical Rehabilitation and Balneotherapy, ²Belarusian State Medical University, Minsk, Belarus

Objective: Many health problems such as diabetes mellitus, metabolic syndrome, dyslipidemia, atherosclerosis are closely connected with wrong diet and obesity. Studies have shown that the consequences of the obesity-associated diseases do not correlate with body fat accumulation but closely related to fat distribution. The separation of android and gynoid localization of adipose tissue is caused not only by the regional location, but first of all by the different functional activity of adipocytes in these areas. Measurement of fat distribution is important for understanding mechanisms involved in metabolic regulation.

Methods: A sample of 83 patients with type 2 diabetes mellitus and 39 healthy participants were recruited to participate in the clinical research. The mean age of the participants was 46.5±5.2 y, BMI ranged from 18.4-42.1 kg/m². Total body fat, fat trunk, android and gynoid fat were measured using DXA.

Results: We revealed the higher absolute amount of total body fat in patients with type 2 diabetes mellitus vs. controls: 37513 (31154-42697) vs. 33119 (25285-48222)g, p<0.05 and higher absolute amount of fat trunk: 21647 (17877-25363) vs. 18146 (13914-22575)g (p<0.05), but percentage amount of total body fat and fat trunk did not reveal statistically relevant differences (p>0.05). At the same time fat android was remarkable higher in participants with type 2 diabetes mellitus than in healthy con-

trols calculated in grams 4009 (3096-5056) vs. 3115 (2196-3984) g, $p < 0.05$ and in percent 49.2 (46.1-53.5) vs. 44.9 (39.8-52.7)%, $p < 0.05$.

Conclusion: Visceral fat accumulation but not total body fat and fat trunk was positively associated with type 2 diabetes mellitus in our research.

P596

THE EFFECT OF MARITAL STATUS ON THE RISK OF HIP FRACTURE IN SWEDEN

D. Mellström¹, C. Lewerin², P. Johansson², H. Johansson³

¹Geriatric Medicine, Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden, ²Section of Hematology and Coagulation, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³McKillop Health Institute, Australian Catholic University, Melbourne, Australia, Melbourne, Australia

Objective: We have previously shown an increased risk of hip fracture among spouses in the Swedish population. The aim of this study was to investigate the effect of marital status as a risk factor for hip fracture in the Swedish population.

Methods: We addressed this hypothesis by examining the incidence of hip fracture in men and women aged 50 y and more from Sweden between 1995-2016. In order to reduce double counting, only one hip fracture per period of 5 months was counted per individual. Men contributed with 105,205 hip fractures in 34,423,992 person years and women 247,898 hip fractures in 38,582,172 person years. The effect of marital status was examined by an extension of the Poisson regression model for men and women and was adjusted for age, calendar year, season, latitude and population density.

Results: As expected, hip fractures rates were higher in women than in men and the risk of hip fracture increased with age, latitude and population density for both men and women. The risk of hip fracture declined with calendar year for women with 1-2%/y. For men the same was true for 2009-2016 but for 1995-2009 the risk was stable. Both men and women who were unmarried, widowed or divorced had a higher risk of hip fracture compared to a married individual, HR 1.59 (95%CI: 1.57-1.61) for men and HR 1.28 (95%CI: 1.26-1.29) for woman. There was a significant interaction between age and marital status for both men and women ($p < 0.001$). For men the HR at age of 60 y was 3.11 (95%CI: 3.02, 3.19) and at the age of 80 y the HR was 1.55 (95%CI: 1.53, 1.57). The corresponding HR for women was 1.97 (95%CI: 1.92, 2.01) and 1.21 (95%CI: 1.20, 1.23). There was no significant interaction between marital status and calendar year ($p > 0.30$ for both men and women).

Conclusions: Marital status is important for the risk of hip fracture in Sweden adjusted for age, calendar year, season, latitude and population density. The effect is larger at lower ages.

P597

ASSOCIATION BETWEEN INSULIN RESISTANCE (HOMA), TRABECULAR BONE SCORE (TBS) AND DXA-DERIVED 3D MEASUREMENTS OF THE CORTICAL AND TRABECULAR BONE IN NONDIABETIC POSTMENOPAUSAL WOMEN

R. Usategui¹, J. Gil², A. Ruiz de Temiño³, F. Campillo⁴, L. Humbert⁵, J. L. Pérez-Castrillón³

¹IOBA.University of Valladolid, Valladolid, ²Servicio Medicina Interna, Hospital Nuestra Señora de Sonsoles, Avila, ³Servicio de Medicina Interna, University Hospital Río Hortega, Valladolid, ⁴Servicio de Ginecología, Hospital Clínico Universitario, Valladolid, ⁵Galgo Medical SL, Barcelona, Spain

Objective: Study the association between insulin resistance measured by HOMA and bone quality and quantity as measured by TBS and DXA-derived 3D measurements of the cortical and trabecular bone.

Methods: A cohort of postmenopausal, nondiabetic women with possible osteoporosis was analysed. Basal glucose, insulin and HOMA (insulin resistance) were measured. The bone densitometry study was performed using a GE-Lunar iDXA scanner. TBS was calculated using the software TBS Nsight v2.1 (Med-Imaps, Pessec, France) from the lumbar DXA scans (L1-L4). The trabecular volumetric BMD (trabecular vBMD) cortical surface BMD (cortical sBMD) were analysed from the hip DXA images using the 3D-SHAPER software v2.7 (Galgo Medical, Barcelona, Spain). The subjects included in this study were stratified by quartiles of HOMA and differences between groups were analysed using anova test. The statistical analysis was performed with SPSS v22 software. The study was approved by the Clinical Research Ethics Committee of the University Hospital Río Hortega.

Results: 381 postmenopausal women with an age of 62±9 years old were included in this study. The analytical values were 90±24 mg/dl of glucose, 13±14 IU/l of insulin and HOMA of 3.3±4.6. No statistical relationship was found between HOMA, TBS and densitometry parameters. However, when stratifying by quartiles of HOMA, our results showed that women with higher HOMA had higher levels of cortical sBMD and trabecular vBMD. compared to women with low HOMA ($p < 0.05$). Similar data was observed with total hip BMD

Conclusion: In nondiabetic postmenopausal women, the insulin resistance (measured by HOMA) was associated with higher values of cortical sBMD and trabecular vBMD, showing a potential association between insulin resistance and bone quality.

P598

DENOSUMAB TREATMENT EFFICACY EVALUATED BY THE INDEX OF THE OSTEOPOROTIC RISKS. Shubeska Stratrova¹, S. Markovich¹, S. Mishevka Jovanovska¹¹Clinic of Endocrinology, Diabetes and Metabolic Disorders, Medical Faculty, Skopje, Macedonia

Objective: The relationship of N-MID osteocalcin (O) and β -Cross-Laps (CTX) determined as an index of the osteoporotic risk (IOR) showed predomination of bone resorption compared to bone formation in postmenopausal osteoporotic women. The aim of this study was to discover the change of O and CTX relation, IOR inversion during Denosumab treatment (DT).

Methods: Bone turnover markers N-MID osteocalcin and β -Cross-Laps were determined, as well as their ratio $IOR=O/CTX$, and their post-treatment values. O and CTX levels were expressed in ng/ml. The mean percentage (%) of O and CTX reduction and IOR increase from the basal levels were also determined during DT.

Results: Pretreatment mean O levels were 21 ± 3.28 ng/ml, and lowered to 13.9 ± 3.99 ng/ml ($p<0.007$) and 11.98 ± 3.4 ng/ml ($p<0.0001$), after 3 and 6 months of DT as well as the correspondent CTX levels 0.39 ± 0.059 ng/ml, lowered to 0.1 ± 0.05 ng/ml and 0.04 ± 0.029 ng/ml ($p<0.0001$). Pretreatment IOR mean levels were 64.35 ± 18.89 and increased to 159.4 ± 75.33 and 238.3 ± 83.6 ($p<0.0001$) after 3 and 6 months of DT. The mean% of CTX reduction for the first 3 months was $73\pm 11\%$, and for 6 months $87.96\pm 2.66\%$. The mean% of O reduction for the first 3 months was $28.98\pm 34.83\%$ and for 6 months $36.37\pm 15.77\%$. The mean% of IOR increase for the first 3 months was 153 ± 122 , and for 6 months 328 ± 240 .

Conclusion: DT enabled significant O decrease, highly more significant CTX and CTX% decrease, IOR significant increase, which confirmed bone formation predomination compared to bone resorption and decreased bone turnover. This indicated lower bone loss and reduced osteoporotic risk in postmenopausal women on DT. Determination of the relation of the two processes, bone resorption and bone formation through IOR will greatly assist in the conduction and evaluation of clinical trials, and follow-up of the level of the osteoporotic risk and the efficacy of the treatment. IOR confirmed very high efficacy of DT in postmenopausal osteoporosis.

P599

WORK RELATED MUSCULOSKELETAL DISORDERS AND WORK ANXIETY PROFILE AMONG GREEK PHYSIOTHERAPISTSD. Chrysanthakopoulou¹, P. Gkrilias¹, L. Mata², C. Matzaroglou¹, E. Papadopoulou³¹Technological Educational Institute (TEI) of Western Greece, School of Health and Welfare, Department of Physical Therapy, Aigio Achaïas, Patras, ²Technological Educational Institute (TEI) of Western Greece, School of Health and Welfare, Department of Physical Therapy, Aigio Achaïas, Athens, ³Hellenic Center for Mental Health and Research, Patra Achaïas, Patras, Greece

Objective: It is known that physiotherapists are often affected by musculoskeletal injuries¹. The purpose of this study was to record the musculoskeletal symptoms in each anatomical body region in Greek physiotherapist. Also, to investigate if these symptoms can be associated with anxiety profile.

Methods: The Greek version of the Nordic questionnaire for the musculoskeletal symptoms (NMQ)² and the State Trait Anxiety Inventory (STAI-X)³ were given to professional Greek physiotherapists in 2017. Participants in NMQ were asked whether they had pain/discomfort in 9 different anatomical regions (neck, shoulder, elbow, wrists/hands, upper back, lower back, hips/thighs, knees, ankles/feet) during the preceding 12 months and if those symptoms prevented their normal activity during the last year as well as the 7 previous days. In STAI physiotherapists were asked to fill in an inventory of 40 questions which measures two types of anxiety: a) State-anxiety and b) Trait-anxiety.

Results: 65 (36 male, 29 female) Greek physiotherapists (age: 41.9 ± 10.9 y, BMI: 25.5 ± 3.8 k/m², working years: 16.6 ± 10 y, working h/week: 42.1 ± 9.4 h) completed the NMQ. The 12-month prevalence rate of pain/discomfort was 67.7% in lower back, followed by the neck (63.1%), shoulders (53.8%), upper back (47.7%), wrists/hands (43.1%), knees (32.2%), elbows (21.5%), hips/thighs (15.4%) and ankles/feet (15.4%). The same group completed the STAI-X, scoring 48 ± 5.8 in State-anxiety and 43.1 ± 6.7 in Trait-anxiety. Trait-anxiety associated with musculoskeletal symptoms in the area of the wrists/hands in the last 12 months ($r=0.264/p=0.033$) and in the area of upper back pain/discomfort in the last 7 days ($r=0.259/p=0.037$).

Conclusion: Physiotherapists own a high place in the appearance of musculoskeletal symptoms. Correlation of trait anxiety with musculoskeletal injuries was found.

References:

1. Milhem M et al. *Int J Occup Med Environ Health* 2016;29:735.
2. Antonopoulou M et al. *Eur J Gen Practice* 2004;10:35.
3. Spielberger CD et al. *Manual for the state-trait anxiety inventory*. Consulting Psychologists Press, Inc., Mountain View, 1983.

P600

OSTEOPOROSIS AND DENTISTRY CORRELATIONS

S. Adarnli¹¹Al Kindi Clinics Center, Doha, Qatar

Osteoporosis and its treatments has some negative effects on periodontal tissues of the patients and also on some treatments including oral surgery, dental implants insertion, and alveolar bone augmentation.

Bisphosphonates related osteonecrosis of the jaws is a potential complication that may happen after any oral surgery, and also osteoporotic patients has lower success rates for bone augmentation and dental implantation.

This lecture proposes area of cooperation between physicians and dentists in these fields:

- Oral features of osteoporosis and how can dentist predict osteoporosis
- Antiresorptive agent-related osteonecrosis of jaws (ARONJ)
- Dental treatments for patients who receive antiresorptive therapy
- Dental implants placement with/without bone augmentation for osteoporotic patients

This cooperation aims to ensure the optimum control of oral health status and beneficial dental treatments for osteoporotic patients.

P601

THE BENEFITS OF REGULAR WEIGHT BEARING ACTIVITY THROUGHOUT THE LIFE-COURSE: DO MEN AND WOMEN REAP THE SAME REWARDS?

J. Zhang¹, M. Clynes¹, K. Jameson¹, C. Cooper¹, E. M. Dennison¹¹MRC, Lifecourse Epidemiology Unit, Southampton, Southampton, UK

Objective: Higher levels of physical activity (PA) are thought to be beneficial for musculoskeletal health but few studies have considered relationships between reported PA levels at different stages of life, and musculoskeletal outcomes in late adulthood, particularly in men. We considered this in the Hertfordshire Cohort Study, a cohort of free living men and women born 1931-9.

Methods: The study population comprised 128 men and 130 women from the Hertfordshire Cohort Study. Participants completed a questionnaire that asked about participation in sports/leisure time exercise involving weight bearing activity up to age 18 y; aged 18-29 y; aged 30-49 y and since age 50 y. Responses were coded as none/ once a month/ once a week/ more than once a week. Current lifestyle and PA levels were recorded in the same questionnaire. Grip strength was assessed using a Jamar dynamometer. Bone densitometry was performed at the total femur (Hologic QDR 4500).

Results: The mean age of participants was 75.4 (SD 2.5) years in men and 75.7 (SD 2.6) years in women. Women were currently more physically active than men, recording a median activity time/d of 206 (IQR 146-277) min daily, vs. 194 (IQR 110-298) min daily in males. However, men tended to report higher levels of past PA through the life-course, with significant differences in weight bearing activity up to the age of 18 y ($p=0.006$) and also 18-29 y ($p<0.001$), when only 15.6% of women reported PA more than once a week, compared to 41.6% of men. In women, we observed greater BMD at the total hip in women who reported regular weight bearing PA at ages 18-29 y (β weekly exercise 0.72, $p=0.02$; β more than once a week exercise 0.83, $p=0.01$), and 30-49 y (β weekly exercise 0.52, $p=0.04$; β more than once a week exercise 0.78, $p=0.02$). compared with those who reported no weight bearing PA, even after adjustment for age, BMI, social class, smoker status, alcohol consumption, current physical activity and dietary calcium intake. No such relationships were apparent in men, before or after adjustment. No relationships were observed between past PA and grip strength in this sample.

Conclusions: Regular weight bearing activity around the time of peak bone mass acquisition was less common in women than men in this historical cohort. However, we observe higher hip BMD in those women participating in regular PA throughout the life-course, highlighting the need to promote exercise among young women.

P602

EFFECTS OF PHYSIOTHERAPY IN PATIENTS WITH KNEE OSTEOARTHRITIS

S. Nejkov¹, M. Vukovic¹, V. Bokan-Mirkovic¹, Z. Skaric-Karanikic¹, T. Matejevic²¹Clinical Center of Montenegro, Podgorica, Montenegro, ²Special Hospital for Rehabilitation Ribarska Banja, Ribarska Banja, Serbia

Objective: The aim of the study was to evaluate effects of physiotherapy (electro and kinesitherapy) in patients with knee osteoarthritis(KOA).

Methods: The study included 16 patients (15 women and 1 man), with diagnosis KOA based on the ACR criteria. All patients were submitted to electrotherapy and kinesitherapy (combination of elements strength training and active range of motion exercise) for a period of 15 d. We measured the range of motion (ROM), with goniometer and strength of quadriceps femoris muscle (QFM) based on manual muscle testing (MMT) in diseased knee, before/after therapy. All patients completed the short form McGill Pain Questionnaire (SF-MPQ) before/after therapy, which consisting of 15 descriptors (descriptors 1-11 represent the sensory dimension of pain experience and 12-15 represent the effective dimension), which are rated on an intensity scale as 0=none, 1=mild, 2=moderate or 3=severe.

Results: Mean value of baseline characteristics of subjects in the sample were: age 62.31±6.97 y, body weight 76.81±7.96 kg, height 167.81±5.94 cm, BMI 27.4±3.34. There were more patients with right KOA 68.75% than left 31.25%. There is statistically significant difference (Single sample t-test $t=39.92$, $df=15$, $p\text{-value} <$

2.2e-16) in mean value flexion of the knee before $109.87 \pm 20.43^\circ$ and after the therapy $122.18 \pm 12.24^\circ$. There is a statistically significant difference in mean value of MMT QFM before 2.81 ± 0.54 and after the therapy 3.25 ± 0.45 (single sample t-test $t=29.069$, $df=15$, $p\text{-value}=1.324e-14$). A statistically significant difference was found between all descriptor pain experience, rated on an intensity scale, before/after therapy, the most expressive in mild level (single sample t-test $t=4.1414$, $df=15$, $p\text{-value}=0.0008701$). A statistically significant correlation between all descriptors SF-MPQ and ROM after therapy was not found (using Pearson's correlation).

Conclusion: Physiotherapy in patients with KOA, influenced the improvement flexion of the diseased knee, MMT QFM, as well as mild level pain experience.

P603

DETERMINING THE EFFICACY OF PLATELET RICH PLASMA ON PATIENTS DIAGNOSED WITH LATERAL EPICONDYLITIS

A. Bitzidis¹, S. Spanou², N. Samaras³

¹Orthopaedic Department, Mpodosakeio General Hospital of Ptolemaida, ²Paediatric Department, Mpodosakeio General Hospital of Ptolemaida, ³Orthopaedic Department, Mpodosakeio General Hospital of Ptolemaida, Ptolemaida, Greece

Objective: We wanted to evaluate the Platelet Rich Plasma (PRP) efficacy on patients diagnosed with lateral epicondylitis based on patient related outcomes (PROs).

Method: After obtaining the approval of our Hospital Ethics Committee, we recruited 16 patients who were primarily diagnosed with lateral epicondylitis from January to December 2018 and had no other treatment before the application of a PRP preparation. All the participants have given written consent and answered voluntarily and anonymously the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire before and 2 months after the application of 2 ml of PRP on their lateral epicondyle. None of the participants had physiotherapy or any other additional treatment until the second assessment. The DASH questionnaire is a self-administered specific measurement tool which has been previously validated for the Greek population. It uses 30 items to measure physical function and symptoms in persons with musculoskeletal disorders of the upper extremity for the previous seven days. The scoring system is on a 0-100 scale and higher values mean greater disability. [1]

Results: From the initial group of participants, 2 patients did not attend their follow-up assessment and were not included in the final data analysis. In our cohort ($n=14$) there were 12 males and 4 patients (2 females) who have been diagnosed with lateral epicondylitis of their nondominant hand. The average DASH score was 69 before the PRP application and 31 at the 2 month assessment.

Conclusion: According to our data based on PROs, the application of PRP on patients diagnosed with lateral epicondylitis has a favorable effect on their symptoms and disability.

Reference: 1. http://www.dash.iwh.on.ca/sites/dash/files/downloads/quickdash_info_2010.pdf

P604

FOOT PRONATION INCREASED MEDIAL KNEE LOADING AFTER LONG DISTANCE RUNNING

Q. Mei¹, L. Xiang², Y. Gu², J. Fernandez¹

¹Auckland Bioengineering Institute, University of Auckland, Auckland, New Zealand, ²Faculty of Sports Science, Ningbo University, Ningbo, China

Objective: This study aimed to investigate the changes of foot postures, joint kinematics, moments and contact forces to the lower extremity after a 5k treadmill run, and analyse correlation of foot posture index with knee and ankle loading.

Methods: Twenty recreational male heel strike runners participated in this study. All had history of running and free from lower extremity injuries or foot deformities. Foot posture, three-dimensional markers trajectories, ground reaction force and surface electromyography (EMG) were recorded pre and post 5k treadmill running with standard running shoes. Customized knee joint was adapted for modelling the medial and lateral compartment loadings in this study, and musculoskeletal modelling techniques from OpenSim were employed to calculate the joint kinematics, moments and contact forces. Simulated EMG activations were compared against experimental EMG signals to validate the model. One-dimensional statistical parametric mapping (SPM1d) package was used for statistical analysis.

Results: Hip moments and contact forces to joint increased significantly and temporally during initial contact and mid stance post 5k. Knee abduction moment and medial contact force increased but extension moment decreased significantly and temporally. The significantly increased ankle plantarflexion moment and contact forces were observed temporally during stance. Foot posture index showed increased correlations with peak knee moment and medial contact force.

Conclusion: Recreational male runners presented pronated foot postures after 5k treadmill running with neutral shoes. Changes of lower extremity angles, moments and contact forces during stance could integrate into etiological framework of loads magnitude and distribution to investigate the causation of running-related injuries.

P605

LIVER CANCER DERIVED EXOSOMES PROMOTE OSTEOCLAST DIFFERENTIATION THROUGH TRANSFER OF TUMOR NECROSIS FACTOR

C.-H. Li¹, K.-T. Sun², C.-Y. Li¹

¹Graduate Institute of Biomedical Sciences, China Medical University, ²Department of Pediatric Dentistry, China Medical University Hospital, Taichung, Taiwan

Objective: Bone is the common extrahepatic site for cancer metastasis. Hepatic cancer is associated with higher incidence of pathological fracture, however this important regulatory mech-

anisms remains unexplored. Thus, exosome mediated cell-cell communication between tumor and bone might be key to osteolytic bone destruction.

Methods: RAW264.7 cells were stimulated with RANKL and M-CSF for osteoclast differentiation in the presence/absence of exosomes. Exosome uptake was determined using fluorescent labelling of exosomes. The osteoclasts formation was visualized using TRAP staining. Exosomal marker expressions, TNF α , TNFR1, NF- κ B, CTSK, TRAP expressions were determined by western blot.

Results: We found that exosomes released by liver cancer cells (Huh-7) promoted osteoclast differentiation. Exosomes showed exosome marker expressions such as CD63, TSG101 and Alix. RAW 264.7 cells readily uptakes huh-7 exosomes as evidenced by cellular uptake of PKH labelled exosomes by fluorescent staining. TRAP staining showed that, exosomes significantly increased the number of osteoclasts formation in the presence of minimal RANKL/M-CSF levels. In specific, these exosomes were predominantly enriched with tumor necrosis factor- α . Importantly, exosomes induced TNFR1 activation in the RAW 264.7 cells and promoted osteoclast differentiation through NF- κ B/CTSK/TRAP pathway. Thus, studies from neutralizing exosomal TNF α and knockdown TNFR1 expressions in RAW 264.7 cells showed that TNF α -TNFR1 signaling is key to liver cancer induced osteoclast differentiation.

Conclusion: Collectively, our findings show cellular communication of liver cancer derived exosomal TNF α regulates osteoclast differentiation through TNFR1/NF- κ B/CTSK/TRAP signaling. Thus, exosomal TNF- α might act as important therapeutic target to prevent pathological bone disease during cancer metastasis.

P606

EXOSOMAL MIRNAS FROM LIVER CANCER CELLS PROMOTE OSTEOCLAST DIFFERENTIATION THROUGH CHIP /TRAF6 REGULATION

C.-H. Li¹, K.-T. Sun², C.-Y. Li¹

¹Graduate Institute of Biomedical Sciences, China Medical University, ²Department of Pediatric Dentistry, China Medical University Hospital, Taichung, Taiwan

Objective: Exosomes orchestrate multiple systemic pathophysiological processes through cellular communication. Exosomes are 40-100 nm nanosized vesicles released into the extracellular space and act as messenger cargo to modulate recipient cell function. Exosomal miRNA are small, noncoding RNAs that are involved in various biological processes, including cancer metastasis and cellular differentiation.

Methods: RAW264.7 cells were stimulated with RANKL and M-CSF for osteoclast differentiation in the presence/absence of exosomes. Exosome uptake was determined using fluorescent labelling of exosomes. The osteoclasts formation was visualized using TRAP staining. Exosomal miRNA expressions were determined using miRNA RT-qPCR analysis. CHIP expression and osteoclast markers such as TRAF6, NFATc1, TRAP, CTSK were determined by western blot.

Results: We identified novel findings that, liver cancer regulates bone remodeling through exosome mediated cell-cell communication. Released exosomes from the liver cancer cells (Huh-7) promoted osteoclast differentiation under stimulation of RANKL/M-CSF at low levels. The isolated exosomes showed exosome specific marker expressions such as CD63, TSG101 and Alix. Fluorescence staining showed that liver cancer exosomes was taken up by RAW cells and further promoted osteoclasts formation as observed by TRAP staining. Exosomes regulated CHIP degradation and thereby upregulated TRAF6 expressions during osteoclast differentiation. Expressions of miRNA targeting CHIP protein expression such as miR-30a-5p, miR-26b-5p, miR-21-5p, miR-1178-3P, miR-764-5p were determined in the huh-7 exosomes. We found that, exosomes promoted osteoclast formation through TRAF6/NFATc1/TRAP signaling.

Conclusion: Altogether, exosome mediated CHIP degradation and subsequent regulation of TRAF6/NFATc1 axis is important for liver cancer mediated osteoclast differentiation. Thus, liver cancer exosomal miRNA might serve as biomarker and therapeutic targeting of miRNA might suppress cancer mediated osteolytic bone disease.

P607

EVALUATION OF THE CAUSAL ASSOCIATION BETWEEN BLOOD METABOLITES AND OSTEOARTHRITIS: A MENDELIAN RANDOMIZATION STUDY

K. Zhang¹, S. Yao¹, J. C. Feng¹, J. M. Ding¹, S. S. Dong¹, Y. Guo¹, T. L. Yang¹

¹Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, China

Objective: Osteoarthritis (OA) is a prevalent chronic joint disease which the incidence is rising because of the ageing population and the epidemic of obesity. Metabolism is important for cartilage and synovial joint function and drastically altered in OA. In this study, we explored the causal associations between blood metabolites and OA using Mendelian randomization (MR).

Methods: We used four summary-level genome-wide association studies (GWAS) data for blood metabolites involving 963 metabolites as exposures. And then selected near-independent GWAS SNPs for each blood metabolites using the clumping algorithm in PLINK at a suggestive threshold ($P < 1 \times 10^{-5}$, r^2 threshold = 0.05 and window size = 1 Mb). To ensure a strong power, we selected the metabolites with more than 10 independent SNPs for later study. The summary-level GWAS data for OA was from UK Biobank in a total of 108,039 subjects. We then performed the GSMR method to test the causal associations between blood metabolites and OA.

Results: We analyzed a total of 905 blood metabolites which had more than 10 independent SNPs after clumping. We identified 13 blood metabolites had risk effects on OA and 27 blood metabolites had protective effects on OA with a suggestive P value ($P < 0.05$). However, there are no significant causal association be-

tween blood metabolites and OA after multiple testing corrections ($P < 5.52 \times 10^{-5}$). It indicated that glycine ($\beta = 0.48$, $P = 7.64 \times 10^{-4}$) had the most risk effect on OA and choline ($\beta = 1.60$, $P = 8.3 \times 10^{-4}$) had the most protective effect on OA.

Conclusions: We investigated the causal effect of global blood metabolites on OA using summary data-based Mendelian randomization analyses. Our results suggest the modest risk/protective effects of blood metabolites for association with RA.

Acknowledgements: The study was supported by grant from National Science Foundation of China (81573241).

P608

OSTEOPOROSIS RISK ASSESSMENT TOOLS TO SCREEN POSTMENOPAUSAL WOMEN IN SRI LANKA

H. Subasinghe¹, S. Lekamwasam², P. Ball³, H. Morrissey³, E. I. Waidyaratne²

¹Faculty of Allied Health Sciences, University of Ruhuna, Galle, Sri Lanka, ²Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka, ³School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK

Objective: This study aimed to develop and validate Osteoporosis risk assessment tool for Sri Lankan postmenopausal women (PMW) to be used either with or without quantitative ultrasound data.

Methods: Community-dwelling PMW were enrolled to development ($n=602$) and validation ($n=339$) samples. Clinical risk factors of osteoporosis were assessed. BMDs (by DXA) in the total hip and lumbar spine were assessed. Radial ultrasound (US) bone scan was done. Linear regression models were used with regional BMDs as the dependent and clinical risk factors as independent variables to develop formulae. WHO criteria based on BMD were used to diagnose osteoporosis. Sensitivity (sn), specificity (sp), positive and negative predictive values (PPV and NPV) were assessed to validate the new tools.

Results: Mean (SD) age of the development and validation samples were 67.3 (8.3) years and 63.8 (9.3) years respectively. Age, body weight (BW) and US T-scores showed positive correlations with BMDs of all three sites. Osteoporosis risk assessment tool 1 (OPRAT-1) was built with age, body weight and US T-score. Osteoporosis risk assessment tool 2 (OPRAT-2) was built with age and BW. OPRAT-1 included following formulae.

- T.Hip.E1 = $-1.635 + (-0.029 \times \text{age}) + (0.044 \times \text{BW}) + (0.18 \times \text{T_US})$
 - T.FN.E1 = $-1.889 + (-0.028 \times \text{age}) + (0.045 \times \text{BW}) + (0.171 \times \text{T_US})$
 - T.Spine.E1 = $-6.203 + (0.019 \times \text{age}) + (0.052 \times \text{BW}) + (0.287 \times \text{T_US})$
- OPRAT-2 included following formulae.
- T.Hip.E2 = $-1.696 + (-0.038 \times \text{age}) + (0.049 \times \text{BW})$
 - T.FN.E2 = $-1.984 + (-0.036 \times \text{age}) + (0.050 \times \text{BW})$
 - T.Spine.E2 = $-5.239 + (-0.01 \times \text{age}) + (0.058 \times \text{BW})$

Prevalence of osteoporosis, in the validation sample was 74.3%. It was 75.4% and 75.5% according to OPRAT-1 and OPRAT-2, respectively. Sn were high (OPRAT-1 and OPRAT-2; 83.2% and 82.5%) while Sp were moderate (44.8% for both). PPV of OPRAT-1 and OPRAT-2 were 79.5% and 81.2%. Both tools showed moderate NPV (OPRAT-1 and OPRAT-2: 51% and 47%).

Conclusion: Both OPRAT-1 and OPRAT-2 have high performance in screening postmenopausal women in Sri Lanka for high risk of osteoporosis. OPRAT-2 is more convenient and can be used in any healthcare setting with limited resources to identify women who will be benefitted by DXA. OPRAT-1 can be used if the radial US facility is available.

Acknowledgement: Funded by the University of Wolverhampton.

P609

BIOLOGICAL FEEDBACK THERAPY IN THE COMPREHENSIVE TREATMENT OF RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS

E. A. Bondarenko¹, A. S. Trofimenko², E. G. Korenskaya¹, L. N. Shilova¹

¹Volgograd State Medical University, ²Research Institute for Clinical and Experimental Rheumatology, Volgograd, Russia

Objective: Psychological rehabilitation is a seminal adjunct to the common therapeutic approaches in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) that influence treatment outcomes. One of upcoming methods of psychological rehabilitation is biological feedback therapy (BFBT) technique. This study was a comparative estimation of BFBT efficiency in RA and AS against the background of its common treatment strategies.

Methods: 47 patients with verified AS and 68 patients with verified RA were included in the study. Each of these groups was randomized into BFBT subgroup or placebo control (PC) subgroup. Both BFBT subgroups were treated with Reacor rehabilitation equipment (Medicom MTD, Russia) in combination with the standard pharmacological therapy, PC was performed by BFBT simulation. Complete course consisted of 10 BFBT sessions. Disease activities were assessed using either BASDAI or DAS28 scores, pain severity was estimated by VAS. State anxiety and depression levels were tested according to Khanin modification of the STAI and the BDI, respectively.

Results: All 4 subgroups were comparable in basic demographic features, RA and AS paired subgroups were also well matched in terms of initial disease activity, psychological pattern, and basic treatment. We revealed significant decrease of pain intensity, anxiety, and depression levels in RA-BFBT subgroup ($n=41$) as compared to RA-PC subgroup ($n=27$). DAS28 response to basic immunosuppressive therapy was also slightly higher in RA-BFBT subgroup, while being below the significant level. There was consistent and significant decrease in pain intensity, anxiety, and depression after BFBT therapy of AS ($n=27$) comparing to placebo ($n=420$); BASDAI score was also lower after BFBT. Differences between BFBT and PC subgroups in anxiety, depression, and VAS scores after treatment were significantly higher in AS than in RA.

Conclusions: BFBT is therefore a useful and safe tool that enables to improve outcomes of standard RA and AS treatment.

P610 TRACKING OF MUSCLE STRENGTH AND MASS FROM ADOLESCENCE TO EARLY ADULTHOOD AND FACTORS ASSOCIATED WITH DEVIATION FROM TRACKING

Y. Yang¹, F. T. Wu¹, T. Winzenberg¹, G. Jones¹

¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia

Objectives: Analogous to peak bone mass, optimising muscle strength and mass in young adulthood is also important to the prevention of falls and fractures in later life, but factors affecting the development of muscle strength and mass from childhood to adulthood are poorly studied. This study aimed to assess whether muscle strength and mass track from adolescence to adulthood and identify factors associated with deviation from tracking.

Methods: Participants (N=201) were followed from 16-25 years old. Outcomes were handgrip and leg strength measured by dynamometer, and total body lean mass by DXA at ages 16 and 25. Other factors measured were physical activity (strenuous, light activities), time spent in watching TV (or videos) / play computer games and competitive sports participation by questionnaires, anthropometrics, serum 25-hydroxyvitamin D, fitness (by physical work capacity (PWC170)) at ages 16 and 25.

Results: From age 16-25, muscle strength increased by 18% in males and 10% in females and lean mass by 12% in males and 7% in females. There was a moderate to strong tracking of muscle strength (correlation coefficients: males, 0.41-0.59; females, 0.54-0.64) and stronger tracking of lean mass (males, 0.74; females, 0.75) from age 16 to 25. Overall, 47-58% of participants kept their muscle strength and 63-69% kept their lean mass tertile positions over 9 years follow-up. For males, strenuous activity, PWC170 at age 16, change of PWC170 were associated with a positive deviation of tracking in muscle strength and mass. In females, light physical activity was associated with a positive deviation of tracking in lean mass; no other associations were found.

Conclusions: Muscle strength and mass track from adolescence to early adulthood in both males and females. Improving fitness and strenuous activity in males and light activity in females during adolescence might be effective strategies to improve muscle strength and mass in early adulthood. These findings highlight the importance of preserving high muscle strength and mass in early life to reduce fracture risk in later life.

P611

A REAL-WORLD PILOT STUDY ON ZOLEDRONATE-BASED TREATMENT OF OSTEOPOROSIS IN JAPANESE WOMEN AGED OVER 65 YEARS INCLUDING VERY ADVANCED AGE: CASE REPORT

K. Hiraku¹, S. Wataru², M. Sei³, N. Jin³, O. Narihiro⁴, K. Masato⁵

¹Sakaisakibana Hospital Japan, Sakai, ²Department of Orthopaedic Surgery, Sakaisakibana Hospital Japan, Sakai, ³Department of Orthopaedic Surgery, Sakaisakibana Hospital Japan, Sakai, ⁴Department of Orthopaedic Surgery, Sumoto-itsuki Hospital Japan, Sumoto, ⁵Department of Orthopaedic Surgery, Nara Hospital Kindai University Japan, Ikoma, Japan

Objective: One of the results demonstrated that the increase in hip BMD was negatively correlated with age.

Methods: The age of the study patients ranged from 65-95 y (mean, 79.1±8.6 y), and BMI ranged from 14.6-29.0 kg/m² (mean, 20.6±2.8 kg/m²). We introduced two cases for typical gain and loss after zoledronate (Zol, Asahi Kasei Medical Co., Ltd.) treatment.

Results: Two typical cases

Case 1. A 65-year-old woman with postmenopausal osteoporosis with a BMI of 18.2 kg/m². She could perform independent gait and did not have complications or a history of surgery. Following treatment with VD (Edirol) and BP (risedronate), her hip BMD decreased from 67% to 62%. Because a painless vertebral compression fracture occurred, treatment was switched to VD + Zol infusion. After the administration of two courses, her hip BMD increased from 62% to 79%, and the bone resorption marker (cross-linked N-terminal telopeptides [NTX]) level decreased from 18.0 to 13.4. During the study period, we did not observe low-trauma fractures or adverse reactions. The case patient was a relatively young, lean woman without complications or a history of surgery.

Case 2. A 92-year-old woman with osteoporosis with a BMI of 16.3 kg/m². This patient was kyphotic and had undergone a surgery for a bilateral proximal femoral fracture. She was also hypertensive and had chronic gastritis and dementia. She used complete dentures and was chair- and/or bed-bound. Because she had been treated with VD alone, Zol infusion was initiated. Although two courses were administered, her hip BMD decreased from 52% to 44%, and her NTX level increased from 10.1 to 21.6. This was a case of an extremely advanced age patient with a low BMI, complications, a history of surgery, and high need of care.

Conclusion: When the analysis was limited to seven women aged 90 years and older, Hip-BMD increased by a mean of 1.4% (range, -8% to 9%) after treatment. Because Japan now has reached an era when people commonly live up to 100 y, various drugs for very advanced age citizens need to be assessed in future studies. Zol is an effective drug for elderly and lean Japanese women.

P612

A REAL-WORLD PILOT STUDY ON ZOLEDRONATE-BASED TREATMENT OF OSTEOPOROSIS IN JAPANESE WOMEN AGED OVER 65 YEARS INCLUDING VERY ADVANCED AGE

O. Narihiro¹, K. Hiraku², S. Wataru³, M. Sei⁴, N. Jin⁴, K. Masato⁵

¹Department of Orthopaedic Surgery, Sumoto-itsuki Hospital Japan, Sumoto,²Sakaisakibana Hospital Japan, Sakai, ³Department of Orthopaedic Surgery, Sakaisakibana Hospital Japan, Sakai, ⁴Department of Orthopaedic Surgery, Sakaisakibana Hospital Japan, Sakai, ⁵Department of Orthopaedic Surgery, Nara Hospital Kindai University Japan, Ikoma, Japan

Objective: This study included 50 elderly Japanese women aged 65 years and older with osteoporosis treated with zoledronate (Zol, Asahi Kasei Medical Co., Ltd.) infusion who were followed up for 1 year or longer across three participating institutions.

Methods: The age of the study patients ranged from 65-95 y (mean, 79.1±8.6 y), and BMI ranged from 14.6-29.0 kg/m² (mean, 20.6±2.8 kg/m²). There were 23 women who had received one course of infusion and 27 who had received two courses or more. Surgery for bone fractures were performed prior to infusion in 20 women, and 30 women had no history of surgery. Observed complications included periodontitis, kyphosis, osteoarthritis/spondylosis, hypertension, diabetes mellitus, and dementia. Various pretreatment procedures were used that ranged from vitamin D monotherapy to PTH replacement.

Results: There was no significant correlation between age and BMI ($r=0.07$). The increase in H-BMD was negatively correlated with age ($r=-0.50$), but it tended to show a positive correlation with BMI ($r=0.31$). The increase in H-BMD was 1.45±3.93 in the surgery group and 3.32±5.32 in the non-surgery group, indicating a larger increase in the latter. The proportion of patients showing an increase of 3% or more between before and after infusion was 7/20 (35%) in the surgery group and 16/30 (53%) in the nonsurgery group. Moreover, the increase in H-BMD was 2.35±5.29 in the one-course group and 2.81±5.45 in the two-course group with no significant differences.

Conclusions: During the study period, Zol infusion was not discontinued in any patients and the incidence of low-trauma fractures was only 6%. This was deemed to be an effective treatment procedure that can be administered even for lean, very advanced age patients. Zol infusion can be reliably administered rapidly over 15 min once a year, and is an effective drug for elderly and lean Japanese women as long as CKD is considered.

P613

ASSOCIATION BETWEEN BONE TURNOVER MARKERS AND BMD AND TBS IN THE LUMBAR AREA IN ELDERLY WOMEN: BUSHEHR ELDERLY HEALTH (BEH) PROGRAM

N. Panahi¹, N. Fahimfar¹, S. Gharibzadeh², P. Khashayar³, G. Shafiee⁴, R. Heshmat⁴, F. Razi⁵, I. Nabipour⁶, A. Soltani⁷, B. Larijani⁸, A. Ostovar¹

¹Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ²Department of Epidemiology and Biostatistics, Pasteur Institute of Iran, Tehran, Iran, ³Center for Microsystem Technology, Imec and Gent University, Zwijnaarde, Gent, Belgium, ⁴Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ⁵Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ⁶The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran, ⁷Evidence Based Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ⁸Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Introduction: Increased bone turnover markers (BTMs) can suggest bone microarchitecture deterioration and may predict the risk of osteoporotic fractures in addition to low BMD in elderly population. The aim of this study was to assess the relationship between BTMs including osteocalcin (OC), bone specific alkaline phosphatase (BAP), C-terminal telopeptide of type 1 collagen (CTX), and Tartrate-resistant acid phosphatase (TRAP), and bone status determined with lumbar spine BMD and trabecular bone score (TBS).

Methods: This study was conducted on a subsample of 214 elderly women, with the mean age of 69.5 (±6.6) y, who were randomly selected from 2426 participants of Bushehr Elderly Health Program. The levels of BTMs were measured using electrochemiluminescence (for OC and CTX) and ELISA (for BAP and TRAP). Association of BTMs with lumbar spine BMD and TBS were assessed using univariable and multivariable linear regression analysis by adjustment for age, BMI, years since menopause, delivery times, smoking, physical activity, and vitamin D levels.

Results: All BTMs showed significant negative correlation with BMD (OC: $\beta=-0.0017$, $P<0.001$; CTX: $\beta=-0.1565$, $P<0.001$; BAP: $\beta=-0.0032$, $P=0.008$; TRAP ($\beta=-0.0245$, $P=0.004$) in univariable analysis. OC, CTX, and BAP were negatively correlated with TBS ($\beta=-0.0006$, $P=0.031$; $\beta=-0.0601$, $P=0.006$; $\beta=-0.0018$, $P=0.019$, respectively); however, no significant association was detected for TRAP. In multivariable analysis, after adjustment for possible confounders, only CTX and BAP showed significant association with BMD ($\beta=-0.0943$, $P=0.005$; $\beta=-0.0032$, $P=0.049$); none of the markers were significantly associated with TBS after adjustment.

Conclusions: CTX and BAP were negatively associated with lumbar BMD in women, adjusted for conventional risk factors. However, bone turnover markers were not associated with TBS in elderly women.

P614

KLOTHO, A CALCIUM AND PHOSPHATE REGULATOR, NOT ONLY MODERATE CALCIUM ABSORPTION BUT ALSO MALE REPRODUCTION

L. Ying-Hung¹

¹Graduate Institute of Biomedical and Pharmaceutical Science, Fu Jen Catholic University, New Taipei City, Taiwan

The *KLOTHO* gene encodes the α -KLOTHO, β -KLOTHO protein, and Klotho-related protein through alternative splicing. They are involved in regulating the absorption of calcium, phosphate, and vitamin D, as a hormone. In mouse model, an insertion mutation in the 5' region of *Klotho* reveals the premature aging phenotypes, including soft tissue calcification, hyper-phosphatemia, osteoporosis, hypoglycemia, arteriosclerosis, skin atrophy, gonadal dysplasia, and infertility. However, whether mutation of *KLOTHO* in clinical also affect male reproduction is still unknown. In this study, we screen the genetic variants from 12 cases with teratozoospermia through next generation sequencing. We found two genetic variants in *KLOTHO* gene. One is within α -KLOTHO (c.911A>G; p.Asn304Ser; 1/12); the other is localized at β -KLOTHO (c.1825A>G; p.Thr609Ala; 1/12). And, this two variants localized within its function domains. This is first time to link *KLOTHO* functions with male reproduction in clinical cases. We suggest that KLOTHO may also be involved in mammalian spermatogenesis through regulating the absorption of calcium, phosphate, and/or vitamin D.

P615

TRAJECTORY ANALYSIS COMBINING PAIN AND PHYSICAL FUNCTION IN PATIENTS WITH KNEE AND HIP OSTEOARTHRITIS: RESULTS FROM THE FRENCH KHOALA COHORT

M. Wiecek¹, C. Rotonda¹, J. Coste², J. Pouchot³, A. Saraux⁴, F. Guillemin¹, A.-C. Rat¹

¹Université de Lorraine, EA 4360, Vandoeuvre-lès-Nancy,


²Biostatistics and Epidemiology Unit, Hôtel Dieu, AP-HP, Paris,

³Service de Médecine Interne, Hôpital Européen Georges Pompidou, Assistance Publiques - Hôpitaux de Paris, Université Paris Descartes, Sorbonne Paris Cité, Paris, ⁴Rheumatology Department, CHU Brest, Brest, France

Objectives: Self-perceived severity of pain and functional limitations levels may not be always matched. Thus, combining pain and physical function outcomes in trajectories may better reflect the patients' experience over the course of the disease. The aims of this study were 1) to identify homogeneous subgroups of knee and/or hip osteoarthritis (OA) patients with distinct trajectories of the combination of pain and physical function over time and 2) to determine the baseline predictive factors associated with these trajectories.

Methods: The KHOALA cohort is a French population-based multicenter cohort of 878 patients with symptomatic knee and/or hip OA (ACR criteria), aged between 40-75 years old. Pain and physical function were measured annually with the SF-36 questionnaire over 5 years, with lower scores indicating greater pain and functional limitations. They were fit into a multitrajectory model using SAS Proc Traj. The choice of models was based on maximizing the Bayesian information criterion, the proportion of patients in each group (>5% of the total sample) and the statistical significance of the modelled equation. Multinomial logistic regressions were performed to determine the predictive baseline characteristics associated with each group and were adjusted for sociodemographic and clinical factors.

Results: Comparison of separate trajectories of pain and physical function showed that 41% of patients included in the trajectory of severe functional limitations did not belong to the more severe pain trajectory. Multitrajectory modeling revealed 4 distinct trajectories of pain and physical function (see Figure). In multivariate analyses, female sex (odds ratio [OR]=5.38, 95%CI=2.46-11.76), an older age (OR=1.10, 1.06-1.15), a high BMI (OR=1.17, 1.10-1.24), a high number of comorbidities (OR=1.46, 1.16-1.84), a low vitality score (reflecting a low vitality)(OR=0.88, 0.86-0.90) and a high Kellgren grade (OR=7.66, 3.18-18.43) were associated with the more severe symptoms trajectory membership.



Conclusion: Over 5 years, we identified four distinct trajectories combining pain and physical function. The management of comorbidities, weight and fatigue seems important to maintain function and limit pain in patients with lower-limb OA.

P616
EVALUATION OF LIPID METABOLISM, INFLAMMATION AND BONE TURNOVER IN A RAT MODEL OF OVARIECTOMY-INDUCED BONE LOSS

S. Valcheva-Kuzmanova¹, A. Kuzmanov², V. Kuzmanova², M. Eftimov¹, A. Georgieva¹, M. Todorova¹, K. Kuzmanov³, S. Marchev², M. Vlaskovska⁴

¹Department of Pharmacology and Clinical Pharmacology and Therapeutics, Medical University Prof. Dr. Paraskev Stoyanov, Varna, ²Medical University Prof. Dr. Paraskev Stoyanov, Varna, ³Vivarium, Medical University Prof. Dr. Paraskev Stoyanov, Varna, ⁴Department of Pharmacology and Toxicology, Medical University, Sofia, Bulgaria

Objective: Ovariectomized (OVX) rat is an animal model which simulates the clinical findings in postmenopausal conditions. The aim of the present study was to make a complex evaluation of lipid metabolism, inflammation and bone turnover in an ovariectomized (OVX) rat model of postmenopausal bone loss using anthropometric and biochemical indices.

Methods: Female Wistar rats were divided into 2 groups, each of 14 animals: SO (sham operated) and OVX. Three months after the operation, femur BMD was measured by DXA using a computer program for small subjects. Weight was measured throughout the experiment and weight gain was calculated. At termination of the experiment, fat deposits (total, retroperitoneal and mesenteric)

and blood lipids were measured. Inflammation was evaluated by serum concentrations of TNF α . Serum alkaline phosphatase (ALP) was determined as a marker of bone turnover.

Results: Three months after ovariectomy, the femur BMD of OVX rats was reduced but not significantly. OVX rats had a significantly higher ($p < 0.05$) weight gain (12.4%) than SO rats (3.9%). The total and retroperitoneal fat deposits of OVX group were significantly higher ($p < 0.01$) than those of SO group while the mesenteric fat was also increased but not significantly. This accounted for significantly higher ratios of total fat/animal weight ($p < 0.05$) and retroperitoneal fat/animal weight ($p < 0.01$) of OVX rats compared to SO rats. Blood cholesterol level of OVX group was significantly higher ($p < 0.05$) than that of SO group. The ALP concentration was significantly elevated ($p < 0.05$) in OVX group showing an increased bone turnover. TNF α was significantly higher ($p < 0.05$ vs. SO) in the OVX group indicating the development of inflammation.

Conclusion: At the stage when the reduction in BMD was not significant, estrogen deficiency in OVX rats caused a state of obesity, dyslipidemia and inflammation.

Acknowledgements: This research was funded by project 14016 of Science Fund of Medical University Prof. Dr. Paraskev Stoyanov, Varna, Bulgaria.

P617

XANTHINOXIDASE AND XANTHINE DEHYDROGENASE ACTIVITIES IN RHEUMATOID ARTHRITIS: ENZYMATIC PROFILING OF BLOOD PLASMA

S. A. Bedina¹, E. E. Mozgovaya¹, A. S. Trofimenko², S. S. Spitsina², M. A. Mamus¹, E. A. Tikhomirova¹, I. A. Zborovskaya²

¹Federal State Budgetary Institution 'Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovskiy', ²Federal State Budgetary Institution 'Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovskiy', Volgograd State Medical University, Volgograd, Russia

Objective: Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease. Recent evidences suggest that aberrant formation of neutrophil extracellular traps (NETs) could play important roles in the pathogenesis of RA. However, the participation of prooxidant enzyme systems in the mechanisms of NETosis are still poorly understood. This study aimed to disclose enzymatic patterns of xanthinoxidase (XO) and xanthine dehydrogenase (XDG) in blood plasma in patients with RF-negative and RF-positive RA.

Methods: 75 adult RA patients and 35 healthy controls were included in the study. Diagnosis of RA had been established using ACR/EULAR 2010 criteria. RF-positive RA was observed in 49 (65.3%) patients. Enzymatic activity in plasma was determined by spectrophotometric method (1). Statistical comparison tests are selected in line with common guidelines, differences were considered significant when $p < 0.05$.

Results: Reference intervals ($M \pm 2\sigma$) for XO activity was 2.60–3.96 nmol/min/ml and the XDG activity was 4.49–5.93 nmol/min/ml. Enzymatic profile in plasma of RA patients are characterized by increased XO activity ($p < 0.001$). XO activity is increased ($p < 0.001$), CDG activity is decreased ($p < 0.001$) in patients with RF-negative RA. XO activity ($p < 0.001$) and CDG activity ($p < 0.05$) is increased in patients with RF-positive RA. Plasma XO and XDG activities is also higher in patients with RF-positive RA than in patients with RF-negative RA ($p < 0.001$).

Conclusion: The results demonstrate that activation of the xanthine oxidase/xanthine dehydrogenase enzyme complex to play an important role in induction and maintenance of the autoimmune rheumatoid process.

References: Martemyanov VF et al. Int J Applied Fundamental Res 2015;12:1048.

P618

THE RATE OF MODIC II FINDINGS ON MRI IN POSTMENOPAUSAL WOMEN AND BONE MINERAL DENSITY

K. Sirakova¹, N. Temelkova², A. Gerganova², P. Popivanov²

¹Department of Imaging Diagnostics, Medical Faculty, Medical University, ²Department of Clinical Densitometry, University Hospital "Alexandrovska", Sofia, Bulgaria

Objective: Modic II pathological MR finding represents the replacement of bone marrow by fat. Some studies suggest that vertebral marrow fat increase with age and decreasing of BMD. Our aim was to observe the rate of Modic II in postmenopausal women and to investigate the correlation between age and vertebral marrow fat, as well as vertebral marrow fat and BMD.

Methods: In this pilot study we observed 100 patients (50-65 y of age) with lumbar (L1-L4) MRI scans, which were performed on GE Signa HDxt 1,5 T or 3T Siemens Verio. Some of them were additionally referred for a DXA scan. The measurements of BMD at the lumbar spine (L1-L4) were performed on a DXA machine Hologic Discovery A.

Results: In 70% of the cohort was observed Modic II in L1-L4. In 62%, 2 or more lumbar vertebrae have any Modic II. In 32.8% of the patients, the size of Modic II zones was < 10 mm, and in 67.2% - it was above 10 mm. In 40,8% of the examined vertebrae was found any Modic II pathological finding. No association between the presence of Modic II and age was confirmed ($p = 0.15$). We noted a slight correlation between age and the number of vertebrae with Modic II ($r = 0.28$; $p = 0.005$) and the number of Modic II zones in the region of interest - L1-L4, ($r = 0.31$; $p = 0.001$). In patients who both have undergone MRI and DXA scan we observed that the greater the Modic II zone, the greater the decrease in BMD of the respective vertebra. However, their number is pretty insufficient and the results did not achieve statistical significance.

Conclusion: In our study no association was confirmed between age and Modic II, but it was found that there is a discrete correlation between age and number of Modic II zones, as well as age and number of vertebrae engaged with it. Limitations of the study: 1. Small number of patients in the cohort. 2. Limited number of patients, who have undergone both MRI and DXA scan.

P619

THE RATE OF LUMBAR VERTEBRAL HAEMANGIOMAS IN POSTMENOPAUSAL WOMEN AND BONE MINERAL DENSITY

K. Sirakova¹, N. Temelkova², A. Gerganova², P. Popivanov²

¹Department of Imaging Diagnostics, Medical Faculty, Medical University, ²Department of Clinical Densitometry, University Hospital "Alexandrovska", Sofia, Bulgaria

Objective: Vertebral haemangiomas (VHs) are the most common type of noncongenital benign spine neoplasms. Some studies report that they are age- and sex-dependent and have proved that there is a relationship between vertebral haemangiomas and os-

teopenia/osteoporosis. Our aim was to observe the rate of lumbar vertebral hemangiomas in postmenopausal women and to investigate their correlation with age and with BMD.

Methods: In this pilot study 100 patients (50-65 y of age) were examined with lumbar (L1-L4) MRI scans, which were performed on GE Signa HDxt 1,5 T or 3T Siemens Verio. Some were additionally referred for a DXA Hologic Discovery A scan.

Results: In 36% of the patients one or more hemangiomas have been found in L1-L4 as an incidental finding. 74% of them have 2 or more hemangiomas. 14,3% of the vertebrae are engaged with any hemangiomas. In 88% of the patients, the size of the hemangiomas was <10 mm, and in 22% - it was above 10 mm. No association between the presence of a hemangioma and age was confirmed. We were not able to find an association neither between the size of the hemangioma, nor with the number of the vertebra with hemangiomas. In patients who both have undergone MRI and DXA scan, we observed that the greater the size of the hemangioma, the greater the decrease in BMD of the respective vertebra. However, their number is pretty insufficient and the results do not achieve statistical significance.

Conclusion: In the target population we were able to establish that the frequency of the hemangiomas is 36%! No association has been proven neither between age and the presence of hemangiomas, nor between age and the number of the engaged vertebra. Correlation was not confirmed also between age and the size of the hemangiomas. Limitations of the study: 1. Small number of patients in the cohort. 2. Limited number of patients, who have undergone both MRI and DXA scan.

P620

QUALITY OF LIFE FOR ASSESSMENT OF TREATMENT EFFICIENCY IN OSTEOARTHRITIS PATIENTS

A. Grekhoff¹, B. Ramkhelawon²

¹Zborovsky Research Institute for clinical and experimental rheumatology, Volgograd, ²Euromedical Family Clinic, Victoria, Seyshelles, Russia

Objectives: To study the quality of life (QoL) of patients suffering from osteoarthritis (OA), and its changes depending on the clinical features of the disease and the psychological characteristics of the patients.

Methods: We examined 50 OA patients before and after treatment. The control group comprised of 30 healthy residents of the same age and gender who did not suffer from serious somatic diseases. We used the SF-36 questionnaire (Ware JE, 1993) for QoL investigation.

Results: The QoL scores on all SF-36 scales were significantly lower in patients with OA than in the control group ($p<0.05$). This showed the lowest scores in QoL of OA patients ever had before treatment. The physical activity in OA patients was considerably affected due to the physical ($p<0.001$) and role functioning (RF, RP) ($p<0.001$), as well as indicators of somatic pain (BP) ($p<0.01$). Factors that significantly impaired the physical component of QoL in OA patients were age of patients, stage of disease, the severity of joint pain on a visual analogue scale (VAS), and presence of

clinically manifested anxiety ($p<0.05$). Factors that significantly impaired social and psychological component of QoL in OA patients were stage and duration of the disease and increased functional insufficiency of the joints ($p<0.05$). Therapeutic measures significantly had a positive impact on the basic parameters of QoL in patients with OA by improving of physical components of health (physical and role functioning, somatic pain) and psychological components (role emotional functioning, mental health) ($p<0.05$). Role physical (RP) and role emotional (RE) functioning significantly changed by more than 42% ($p<0.001$). The regularities were significantly associated with decreasing functional failure of the joints, decrease in the intensity of joint pain in VAS and decrease in ESR ($p<0.05$).

Conclusions: Thus, OA patients had a significant improvement in physical health, noted by pain reduction and physical limitations, and, as a consequence, improved performance after the treatment. The effectiveness of therapy in a hospital environment contributed in the formation of a positive subjective assessment of the health status in patients with OA.

P621

PRO-OXIDANT ACTIVITY OF LYMPHOCYTES IN RHEUMATOID ARTHRITIS

I. A. Zborovskaya¹, S. A. Bedina², E. E. Mozgovaya², A. S. Trofimenko¹, S. S. Spitsina¹, E. A. Tikhomirova², M. A. Mamus²

¹Federal State Budgetary Institution 'Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky', Volgograd State Medical University, ²Federal State Budgetary Institution 'Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky', Volgograd, Russia

Objective: Increased levels of neutrophil extracellular traps (NETs) in rheumatoid arthritis (RA) patients have been found in previous studies. ROS are essential for formation of NETs. In this connection, the study of the pro-oxidant activity of the enzymes is an issue of considerable interest. Our aim was to disclose enzymatic patterns of xanthinoxidase (XO) and xanthine dehydrogenase (XDG) in lymphocytes in patients with RF-negative and RF-positive RA.

Methods: 75 adult RA patients and 35 healthy controls were included in the study.

Diagnosis of RA had been established using ACR/EULAR 2010 criteria. RF-positive RA was observed in 65.3% patients. Enzyme activity in lymphocytes was measured spectrophotometrically and expressed as nmol/min/ml (1). Enzyme activities were normalized to 1×10^7 cells/ml. Statistical tests are selected in line with common guidelines, differences were considered significant when $p<0.05$.

Results: Reference range ($M \pm 2\sigma$) for XO activity was 14.2-27.8 nmol/min/ml and the XDG activity was 22.5-40.7 nmol/min/ml. Enzymatic profile in lymphocytes of RA patients are characterized by decreased XO and CDG activities. XO activity and CDG activity is decreased ($p<0.001$) in patients with RF-negative RA

and RF-positive RA. Lymphocyte XO and XDG activities is lower in patients with RF-positive RA than in patients with RF-negative RA ($p < 0.001$).

Conclusion: Lymphocyte *pro-oxidant enzyme activities* in patients with *rheumatoid arthritis* depends on the presence rheumatoid factor. We consider these enzymes to play a role in development and progression of RA.

References: Martemyanov VF et al. Int J Applied Fundamental Res 2015;12:1048.

P622

COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT WITH ABALOPARATIDE FOLLOWED BY ALENDRONATE VS. ALENDRONATE MONOTHERAPY FOR USA WOMEN AT INCREASED RISK OF FRACTURE

M. Hilgsmann¹, S. A. Williams², L. A. Fitzpatrick², S. Silverman³, R. Weiss², J.-Y. Reginster⁴

¹Maastricht University, Maastricht, The Netherlands, ²Radius Health, Inc., Waltham, MA, USA, ³Cedar-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, USA, ⁴University of Liège, Liège, Belgium

Objective: Emerging evidence supports sequential therapy with osteoanabolic followed by antiresorptive in patients at high-risk of fragility fractures. Further cost-effectiveness evaluation of sequential abaloparatide (ABL) followed by alendronate (ALN) vs. ALN monotherapy is needed to inform prescribers about the economic value of anabolic first for those at high risk of fracture. This study aims to assess the cost-effectiveness of sequential ABL followed by ALN (ABL/ALN) vs. ALN monotherapy for postmenopausal osteoporosis, from the US payer perspective.

Methods: A Markov microsimulation model was developed to estimate the cost-effectiveness of sequential ABL/ALN vs. ALN with a lifetime horizon from the US payer perspective. Patients were assumed to receive 18 months ABL followed by 5 years ALN. The effects of ABL on fracture risk were derived from the ACTIVEExtend trial and were assumed to be maintained during subsequent ALN treatment, consistent with ACTIVEExtend. Evaluation was completed for high-risk patients 50-80 years old with a BMD T-score ≤ -3.5 or BMD T-score between -2.5 and -3.5 and a history of ≥ 1 osteoporotic fracture.

Results: In simulated populations, sequential ABL/ALN was cost-effective (threshold of \$150,000/QALYs) vs. generic ALN monotherapy, in women ≥ 60 years with a BMD T-score ≤ -3.5 without a history of prior fracture and in women with BMD T-score between -2.5 and -3.5 and history of osteoporotic fracture. In patients aged 70 years with BMD T-score ≤ -3.5 , sequential ABL/ALN reduced the expected number of fractures per patient by 0.340 and increased lifetime QALY gained by 0.163 over a patient's lifetime.

Conclusion: Sequential ABL/ALN therapy is cost-effective vs. ALN monotherapy for US postmenopausal women at increased risk of fractures.

Acknowledgment: Funded by Radius Health, Inc., Waltham MA

P623

DYSLIPIDEMIA AND ATHEROSCLEROSIS WITHIN THE FRAMEWORK OF RHEUMATIC AUTOIMMUNITY: ADVANCES AND CURRENT TRENDS

A. S. Trofimenko¹, A. S. Kuchina², M. D. Maklakova², A. A. Dudkina²

¹Research Institute for Clinical and Experimental Rheumatology, ²Volgograd State Medical University, Volgograd, Russia

Cardiovascular risk is significantly increased in rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, and other autoimmune rheumatic diseases (ARD), being a prominent factor of elevated mortality. The risk is strongly related to the traditional factors; it however remains elevated even among rheumatic patients without the relevant history. So called "lipid paradox" exists even when respective patients with increased cardiovascular risk tend to have lower total cholesterol and LDL levels than non-rheumatic adults. Particular features of lipoprotein structure in these individuals lead to misjudgments when ubiquitous lipoprotein markers are involved, as opposed to apoA1, apoB, and other particle concentration markers. Systemic inflammation itself is suggested to underlie this phenomenon and contribute significantly to atherosclerosis, endothelial dysfunction, as well as triggering of plaque vulnerability and atherothrombotic events. Active systemic inflammation can also substantially alter HDL function. Other disease specific factors are antiphospholipid antibodies, glucocorticoid treatment, and possibly cyclosporin A. The metabolic syndrome is also associated with ARD and cardiovascular events. The management of dyslipidemia and atherosclerosis in ARD remains suboptimal. Increasing evidences indicate that prolonged control of disease activity with disease-modifying agents can lead to substantial reduction of cardiovascular risk. Several antirheumatic drugs, including anticytokine agents, methotrexate, hydroxychloroquine, can markedly reduce CV risk, as opposed to glucocorticoids and NSAIDs. In view of demand for more aggressive primary and secondary cardiovascular prevention statins are now a common tool to decrease atherosclerotic lesions in ARD. The wide variety of their pleiotropic effects on vascular and immune systems additionally contribute to the beneficial action. Emerging lipid-lowering and modulating agents are also extensively discussed with regard to their possible implementation in clinical practice.

P624

EFFECT OF BISPHOSPHONATE ON URINARY ALBUMIN EXCRETION IN TYPE 2 DIABETES PATIENTS

T. Takayanagi¹, T. Kawakami¹, Y. Asada¹, E. Tomatsu¹, Y. Yoshino¹, M. Kondo-Ando¹, S. Sekiguchi-Ueda¹, Y. Seino¹, A. Kakita¹, M. Shibata¹, M. Makino¹, A. Suzuki¹

¹Department of Endocrinology and Metabolism, Fujita Health University, Toyoake, Aichi, Japan

Objective: Diabetes mellitus is often complicated by osteoporosis. However, there is few information about the effect of anti-osteoporotic drugs on diabetic complications. In the present study, we aimed to evaluate the effect of bisphosphonates (BPs) on urinary albumin excretion, which is a surrogate marker for early diabetic nephropathy in diabetes patients.

Methods: A total of 40 medical records of diabetes patients including 10 males and 30 females (67.1±13.9 years old), treated with BPs between April 2013 and March 2018, were retrospectively reviewed. Estimated glomerular filtration rate (eGFR) of the investigated subjects was above 30 ml/min/1.73m². Urinary albumin/creatinine ratio (UACR, mg albumin/gram creatinine) was examined before and after BP treatment. The breakdown of BPs was 17 alendronate, 11 risedronate, 11 minodronic acid and 1 ibandronate. The increment of UACR/duration of treatment (days) was defined as delta-UACR. Statistical analyses were performed by multiple regression analysis or single regression analysis as appropriate.

Results: Median UACR of before and after BP treatment was 19.6 (9.23-76.7, 25 th-75th) and 24.2 (9.03-52.0, 25th-75th), respectively. Median duration of BP treatment was 151 days (91-330, 25th-75th) . In univariate analysis, UACR before BP administration correlated negatively to delta-UACR. There was no statistically significant correlation between delta-UACR and duration of BP treatment. In multivariate analysis, regression coefficient of UACR before BP administration was statistically significant and there was a causal relationship between decrease in UACR and UACR before BP administration adjusted by duration of BP treatment. **Conclusion:** Our results suggest that BPs does not affect the progress of diabetic nephropathy in type 2 diabetes patients.

P625

INDIVIDUAL AND SOCIAL FACTOR CAN INFLUENCE THE QUALITY OF LIFE OF KNEE OA PATIENTS: A SYSTEMATIC REVIEW

J. Verges¹, M. Vitaloni¹, M. Bibas¹, R. M. Sciortino², M. Quintero², J. Monfort³, F. De Abajo⁴, E. Oswald¹, M. Matucci⁵, P. Du Souich⁶, I. Möller⁷, G. Eakin⁸, A. Botto-Van Bemden⁸

¹Osteoarthritis International Foundation, Barcelona, Spain, ²De Los Andes University, Merida, Venezuela, ³Del Mar Hospital, Barcelona, Spain, ⁴Alcalá University, Madrid, Spain, ⁵Florence University, Florence, Italy, ⁶University of Montreal, Montreal, Canada, ⁷Poal Institute, Barcelona, Spain, ⁸Arthritis Foundation, Atlanta, USA

Objective: Knee OA (KOA) associates with remarkable functional restrictions due to the pain that seriously affects social and emotional well-being, reducing the quality of life (QoL). The identification of therapies and factors that influence QoL in KOA patients may mitigate the clinical, economic, and social burden of this disease. Thus, the assessment of QoL in KOA, and individual factors associated, has a great interest in research and clinical practice. Still, a general recompilation of these data is missing. Our aim was to recapitulate the existing information on QoL in KOA patients as an international tool to raise awareness on their condition and guide future actions for patient's management.

Methods: A systematic review of QoL in KOA patients (up to 2017). We identify articles in scientific databases using relevant keywords as KOA, QoL, and well-being. Articles were reviewed by 3 independent reviewers. Original articles were included when containing information on QoL of KOA patients. Inclusion criteria were QoL compared to one or more demographic, lifestyle or comorbidity factors, or a control group. A quality appraisal was performed.

Results: We retrieved 610 articles, 62 fulfilled inclusion criteria. The instrument used to assess QoL were SF-36 and EQ-5D. The participants' mean in the studies was 561, the majority were female, the mean age was 63 years. KOA patients report a worse QoL compared to a control group, having women worst QoL than men. Obesity, little physical activity, and higher energy expenditure correlate with worse QoL. Higher educational level and mindfulness can improve QoL while poverty, physiological distress, depression and having dysfunctional families can reduce it. The delivery of a knee self-management program by health professionals can improve QoL. Surgical interventions result in good outcomes but the results were influenced by individual factors.

Conclusion: This is the first review pertaining to QoL in KOA patients. KOA has a strong impact on QoL. Individual factors (sex, weight, exercise, mental health, education) can influence QoL. These factors affect treatment outcomes and should be considered for a better patient's management. These data are a valuable tool for health professionals, to better understand the disease and to implement a more adequate standard of care.

P626

CORRELATION OF BONE TURNOVER MARKERS, VITAMIN D LEVELS AND STEROIDAL HORMONES WITH BONE DENSITY IN HEALTHY MALE POPULATION

P. Kokkoris¹, E. Chatzellis¹, N. Marmara¹, A. Panagiotopoulou¹, A. Papatheodorou¹, G. Toloumis¹

¹Hellenic Air Force General Hospital, Athens, Greece

Objective: To find any possible factors which may influence bone density in otherwise healthy male population. More specific to examine if there is any correlation between bone turnover markers, vitamin D levels and steroidal hormones with BMD measured by DXA scan.

Methods: 300 men of relatively young age participated in the study. They all had a DXA scan in both the lumbar spine and the femoral neck. Additionally we measured the following: bone turnover markers: (osteocalcin, alkaline phosphatase and PINP for bone formation, and CTX for bone resorption), 25(OH)vitamin D levels, steroidal hormones (testosterone and estradiol), and calcium and phosphorus levels. Finally using the SPSS statistical program we examined if there is any correlation between all the above measurements with the bone density.

Results: The mean age of the population of the study was 33.9±7.7 years, mean weight 84.1±10.8 kg, and mean BMI 26.1±4.2 kg/m². The mean BMD was 1.26±0.15 g/cm² for the lumbar spine and 1.08±0.14 g/cm² for the femoral neck. The mean values for the markers that were described above were as following: Osteocalcin 18.3±7 ng/ml, alkaline phosphatase 63±17.2 IU/l, PINP 51.7±25 ng/ml, CTX 0.36±0.18 ng/ml, 25(OH)vitamin D 21.7±9.2 ng/ml, testosterone 5.5±2.3 ng/ml, estradiol 43.6±17.3 pg/ml, calcium 9.5±0.6 mg/dl and phosphorus 3.2±0.5 mg/dl. As for the correlations we found the following: Positive correlation between BMD and osteocalcin, PINP and CTX respectively (p<0.05), negative correlation between BMD and alkaline phosphatase (p<0.05). We did not find any correlation either positive or negative between BMD and 25(OH)vitamin D, testosterone, estradiol, calcium and phosphorus. Additionally we found positive correlation between BMI and BMD (p<0.05), and negative correlation between BMI and 25(OH)vitamin D and testosterone, while we found no correlation between BMI and estradiol.

Conclusion: Our study showed that in relatively young healthy male population, bone turnover markers (apart from the alkaline phosphatase) are positively correlated with BMD, while in that age steroidal hormones, vitamin D, calcium and phosphorus are not correlated with BMD. Additionally, body weight is positively correlated with BMD and negatively correlated with vitamin D and testosterone.

Table 1:

P627

INFLUENCE OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS ON INFLAMMATORY SONOGRAPHIC FEATURES IN EROSIIVE HAND OSTEOARTHRITIS

X. Xi Xia¹, R. Wittoek²

¹Ghent University, ²Dept. of Rheumatology, Ghent University Hospital, Ghent University, Gent, Belgium

Objectives: Erosive hand osteoarthritis (HOA) is a subtype of hand osteoarthritis affecting the interphalangeal (IP) finger joints, characterized by a more inflammatory burden. Hitherto, pharmacologic treatment options are restricted to symptomatic. NSAIDs may affect the presence of inflammatory features on ultrasound (US). The aim of this study was to examine whether inflammatory US features (i.e. synovial proliferation (SP), effusion (EFF) and Power Doppler (PD) signal) in erosive HOA patients change when discontinuing NSAIDs intake for two weeks before US.

Methods: 99 patients with erosive HOA were enrolled. The patients were allocated to the NSAIDs or control group according to their intake at baseline (no NSAIDs use=control group; intake of NSAIDs on a regular base=NSAIDs group). US was performed at baseline (T0) and 2 weeks after discontinuation of all NSAIDs (T1). The inflammatory features were scored using a semi-quantitative scale ranging from 0-3 (1). Binomial mixed models with logit function were fitted for ultrasound scores SP (score>2), EFF (score>2), and PD (score>1) with a random intercept for patient and with age, sex, duration of illness, joint, side, anatomical phase group, NSAID group, time, and a two-way interaction between NSAIDs group * time as fixed factors. The Odds ratios (OR) of having an ultrasound score of at least '2' vs. at most '1' for SP and EFF, and '0' vs. '≥1' for PD are shown.

Results: 47 patients were included in the NSAIDs group and 52 in the control group. Both groups were comparable at baseline for VAS pain, disease duration, number of radiographic affected joints and BMI, but not for age (p=0.005). The US baseline data were comparable between both groups (all p>0.05). At T1, in the NSAIDs withdrawal group, more SP and PD was seen compared to baseline (p=0.018 and 0.031, respectively). However, the interaction term time*NSAIDs was not found significant for any variable (Table 1).

Conclusion: No significant changes in inflammatory US features were seen in erosive HOA patients after withdrawal of NSAIDs for two weeks. This study suggests that an NSAIDs free period is not necessary before assessing inflammatory disease activity in erosive HOA patients.

References: (1) Mathiesen A et al. Arthr Rheumat [Abstract] 2017;69(S10).

Variable	Group	OR*	95%CI	P-value
Synovial proliferation	No Nsaids	1.304	0.958 - 1.775	0.091
	Nsaids withdrawal	1.552	1.079 - 2.232	0.018
	Interaction term time*Nsaids	-	-	0.470
Effusion	No Nsaids	1.027	0.761 - 1.387	0.860
	Nsaids withdrawal	1.164	0.872 - 1.554	0.303
	Interaction term time*Nsaids	-	-	0.560
PD	No Nsaids	1.016	0.715 - 1.444	0.929
	Nsaids withdrawal	1.480	1.036 - 2.116	0.031
	Interaction term time*Nsaids	-	-	0.140

P628

ASSOCIATION OF 25-HYDROXY VITAMIN D WITH BONE TURNOVER MARKERS AND BONE MINERAL DENSITY IN AN IRANIAN ELDERLY POPULATION: BUSHEHR ELDERLY HEALTH (BEH) PROGRAM

S. Gharibzadeh¹, N. Fahimfar², G. Shafiee³, R. Heshmat³, N. Mehrdad⁴, F. Razi⁵, P. Khashayar⁶, A. Raiesi⁷, I. Nabipour⁸, B. Larijani⁹, A. Ostovar²

¹Department of Epidemiology and Biostatistics, Pasteur Institute of Iran, Tehran, Iran, ²Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ³Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ⁴Elderly Health Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ⁵Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ⁶Center for Microsystems Technology, Imec and Ghent University, Ghent, Belgium, ⁷The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran, ⁸The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran, ⁹Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Objective: To investigate the associations between serum 25-hydroxyvitamin D (25-OH D), bone turnover markers, and BMD in an elderly population.

Methods: The present study was conducted within the framework of the Bushehr Elderly Health (BEH) programme, a population-based prospective cohort study being conducted in Bushehr, a southern province of Iran. In brief, 400 persons (186 men and 214 women) from participants of the second stage were selected; serum bone turnover markers (bone-specific alkaline phosphatase (bALP), amino-terminal procollagen propeptide of type I collagen (PINP), osteocalcin (OC), tartrate-resistant acid phosphatase

isoenzyme 5b (TRAP)) and vitamin D were measured. Vitamin D deficiency and insufficiency were defined as serum 25-OHD below 50 ng/mL and between 50-75 ng/mL, respectively. Nonparametric Spearman's rho was used to assess the correlation between different measurements.

Results: Vitamin D deficiency and insufficiency were detected in 253(63.25%) and 71(17.75%) of participants, respectively. Vitamin D status was significantly different in men and women (chi-square=15.55, p=0.001). We found a significant inverse association between vitamin D levels and bALP in the total population (rho=-0.20, p<0.001). In vitamin D deficiency group, there were inverse correlations between vitamin D levels and both OC, and CTX (p<0.001) and direct correlation with BMD of all sites (p<0.001). We also found a significant reverse correlation between bALP and vitamin D levels among women (rho=-0.27, p<0.001)

Conclusions: Our findings suggest that in elderly participants with vitamin D deficiency, 25(OH) D levels were significantly and negatively related with serum CTX and serum OC and negatively associated with L1L4, femoral neck, and total hip BMD.

P629

ASSOCIATION OF OPIUM USE AND OSTEOPOROSIS IN OLD MEN: BUSHEHR ELDERLY HEALTH (BEH) PROGRAM

N. Fahimfar¹, B. Larijani², S. Gharibzadeh³, G. Shafiee⁴, R. Heshmat⁴, A. Raiesi⁵, K. Vahdat⁶, I. Nabipour⁷, A. Ostovar¹

¹Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, ²Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, ³Department of Epidemiology and Biostatistics, Pasteur Institute of Iran, Tehran, ⁴Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, ⁵School of Medicine, Shiraz University of Medical Sciences, Tehran, ⁶The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, ⁷The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran

Objective: Over 200 million people worldwide suffer from osteoporosis and 15-30% of elderly men will experience ≥ 1 fragility fractures in their lifetime. Worldwide, nearly 27 million people are estimated to suffer from drug abuse disorders or drug dependence. The knowledge behind the association of illicit drug use and bone health is scarce. This study aimed to investigate this possible association among elderly men of Bushehr, Iran.

Methods: Retrospectively, the data of Bushehr Elderly Health program was used. Drug use referred to current consumption of illicit drugs, regularly or occasionally. Femoral and spinal osteoporosis were defined as a T-score ≥ 2.5 standard deviations (SD) below the mean of a young healthy reference population in the femoral or lumbar spine site, respectively. Total osteoporosis was noted to have osteoporosis at either mentioned site. Using multivariable logistic regression models, the association of drug use and osteoporosis was assessed adjusting for age, education, smoking, BMI and physical activity.

Results: In all, 1075 men aged ≥ 60 y were included in this study. Drug use was detected in 9.71% and 3.22% of nonosteoporotic populations (p -value <0.001). Among drug users, opium was the most prevalent consuming drug (82.6%). Total osteoporosis was detected in 37.0% (23.9%-52.2%) of drug users, while the values in nonusers was 15.3% (13.2%-17.6%). Figure 1 compares the prevalence of osteoporosis in different age groups, by drug use situation. Adjusting for the conventional risk factors, drug use was associated with total, femoral and spinal osteoporosis. The odds of total osteoporosis in drug users is almost 2.75 (1.39-5.40) folds higher than those who never consumed illicit drugs. Opium use increased the chance of total osteoporosis by 2.95 (1.43-6.11).

Conclusion: The study result indicates that the opium consumption has positive association with osteoporosis, independent of other conventional risk factors. Since drug use may also increase

the fracture risk through cognitive effects, osteoporosis among opium users should be considered carefully, especially in countries where drug use is prevalent.




Figure 1: The prevalence of total osteoporosis in different age groups, by drug use situation (0: nondrug users 1: drug users)

P630

DICHOTOMIZED MUSCLE MASS CAN ACTUALLY DISCRIMINATE WEAKNESS, BUT A NEW CUTOFF POINT IS NEEDED IN WOMEN WITH HIP FRACTURE: A CROSS-SECTIONAL STUDY

M. Di Monaco¹, C. Castiglioni², F. Bardesono³, E. Milano¹, G. Massazza³

¹Osteoporosis Research Center, Division of Physical Medicine and Rehabilitation, Fondazione Opera San Camillo, ²Osteoporosis Research Center, Division of Physical Medicine and Rehabilitation, Fondazione Opera San Camillo, ³Division of Physical and Rehabilitation Medicine, Department of Surgical Sciences, University, Torino, Italy

Objective: To investigate the relationship between measures of muscle mass and grip strength in women with subacute hip fracture. Firstly, we aimed to assess the capability of the current thresholds for appendicular lean mass (aLM), aLM-to-BMI ratio and aLM/height² to separate weak and nonweak women. Secondly, we aimed to explore alternative thresholds for the 3 measures of muscle mass to discriminate weakness.

Methods: We performed a cross-sectional study of 160 women with hip fracture admitted consecutively to a rehabilitation hospital. We assessed aLM by DXA and grip strength by a Jamar hand dynamometer. Weakness was defined as grip strength < 16 kg according to the definition released from the Foundation for the National Institutes of Health.

Results: We found a significant positive correlation between aLM and grip strength ($p=0.227$; $p=0.004$). 134 of the 160 women (i.e., 84%; 95%CI 78%-90%) had aLM < 15.02 kg whereas 81 women (i.e., 51%, 95%CI 43%-58%) had handgrip strength < 16 kg. No significant association was found between aLM < 15.02

kg and grip strength <16 kg: χ^2 (1, n=160)=0.86 (p=0.476). ROC curve analysis showed that aLM significantly discriminated the patients with grip strength either ≥ 16 kg or <16 kg (area under the curve=0.62; 95%CI 0.53-0.71, p=0.01). By using the optimal threshold (aLM=11.87 kg), low aLM and low grip strength were significantly associated: χ^2 (1, n=160)=10.77 (p=0.001). We correctly classified 42 of the 81 women with low grip strength and 59 of the 79 women with non-low grip strength (sensitivity=52%, specificity=75%, positive predictive value=68%, negative predictive value=60%). The association between aLM <11.87 kg and grip strength <16kg persisted after adjustment for age and BMI (odds ratio=2.50; 95%CI 1.17 - 5.34; p=0.018). 71 of the 160 women (i.e., 44%; 95%CI 37%-52%) had aLM/BMI < 0.512, whereas 129 women (i.e., 81%; 95%CI 74%-87%) had aLM/height² < 5.67 kg/m². Grip strength was significantly correlated neither with aLM/BMI ($\rho=0.009$; p=0.905), nor with aLM/height² ($\rho=0.09$; p=0.235). ROC curve analyses showed that neither aLM/height² nor aLM/BMI were able to discriminate the women with grip strength either <16 kg or ≥ 16 kg: the areas under the curve were 0.56 (95%CI 0.47-0.65, p=0.158) and 0.504 (95%CI 0.41-0.59, p=0.939), respectively.

Conclusions: Data show that the current thresholds for measures of muscle mass do not discriminate weakness in women with subacute hip fracture. For aLM an alternative cutoff point actually separated weak and nonweak women.

P631

CULPRIT HIDDEN IN PLAIN SIGHT (INTRATHYROIDAL PARATHYROID CYST)

A. Archana¹, M. Kumar²

¹Alchemist Hospital, Panchkula, ²CEDAR (Center for Endocrinology Diabetes and Research), Chandigarh, India

Parathyroid cysts are uncommon 0.8 -3.4% of all parathyroid lesions and usually arise secondary to cystic degeneration of parathyroid adenoma. Intrathyroidal parathyroid cysts are extremely rare. We present a 32 years old female with clinical and biochemical features of primary hyperparathyroidism (PHPT) but no obvious lesion found for years.

Case report: Patient presented with features of diffuse bone pains and proximal weakness for 2 years and osmotic symptoms for 4 months. She had biochemical evidence of hypercalcemia, hypophosphatemia, elevated intact PTH (iPTH) and skeletal imaging suggestive of PHPT. She had severe proximal muscle weakness in both lower limbs. No culprit lesion was revealed in Tc99m sestamibi scan. Neck ultrasonography(USG) revealed 24 X 20 mm cystic lesion in lower pole of left lobe of thyroid suggestive of simple thyroid cyst. Patient was managed conservatively for last 3 years and presented to us with same biochemical features of PHPT and gradually increasing calcium levels (calcium 13.2 at presentation). Patients calcium levels were stabilised and re-evaluation did not show any tracer uptake on sestamibi scan. USG guided fine needle aspiration (FNA) was done of thyroid cyst followed by iPTH measurement from the needle washing (FNA-iPTH). 2 ml of serous fluid was aspirated, iPTH measurement of which revealed a level of 2450 pg/ml. Patient underwent left

hemithyroidectomy. She had a fall of >90% in preoperative and 20 min postoperative iPTH (880 pg/ml to 20.5 pg/ml), indicating surgical cure of PHPT. Postoperative period was uneventful. Histopathology of surgical specimen revealed a cystic lesion lined by chief cell variant parathyroid cells without any nuclear atypia, capsular or vascular invasion, surrounded by normal thyroid follicular cells, suggestive of intrathyroidal cystic parathyroid adenoma. Patient is asymptomatic postsurgery (during follow-up at 6 months).

Conclusion: Sometimes culprit lesion is hidden in plain sight and needle tip iPTH can help in differentiation of thyroid cyst from parathyroid cyst when in doubt.

P632

SECONDARY PREVENTION OF OSTEOPOROTIC FRACTURES: EVALUATION OF THE LILLE UNIVERSITY HOSPITAL'S FRACTURE LIAISON SERVICE BETWEEN JANUARY 2016 AND JANUARY 2018

A. Pfiimlin¹, A. Gournay¹, I. Delabrière², C. Chantelot³, F. Puisieux², B. Cortet¹, J. Paccou¹

¹Service de Rhumatologie, CHU, ²Service de Gériatrie, CHU,

³Service de Traumatologie, CHU, Lille, France

Objective: A fracture liaison service (FLS) was implemented at Lille University Hospital in 2016. The main purpose of this study was to assess the performance of the FLS using criteria proposed by the International Osteoporosis Foundation.

Methods: The criteria used were patient identification, patient evaluation, postfracture assessment timing, vertebral-fracture identification, blood and BMD testing, falls prevention, multifaceted health and lifestyle risk factor assessment, and medication initiation and review.

Results: Between January 2016 and January 2018, 736 patients (≥ 50 years old) with a recent history of fragility fracture (≤ 12 months) were identified. The identification rate for hip fractures was 74.2%. However, patient evaluation was quite low (30.3%) since many patients failed to attend the FLS unit. The reasons for nonattendance were refusal, agreed but subsequently failed to attend, and still waiting to be seen. In all, 256 patients (76.6% female, mean (SD) age 74.3 (11.0) y) were seen at the FLS. Mean (SD) postfracture assessment timing was 13.3 (9.3) weeks. Of the 139 patients seen for a nonvertebral fracture, 103 were assessed for vertebral fractures, and at least one new vertebral fracture was found in 45 of them (43.7%). Osteoporosis medication was prescribed for 243 (94.9%) patients. The main osteoporosis drug prescribed was zoledronic acid (60.2%).

Conclusion: Secondary prevention of osteoporotic fractures has improved since the implementation of the FLS. However, patient identification, patient evaluation, and postfracture assessment timing still need to be improved.

P633

EFFECT OF DENOSUMAB ON LOW BONE MINERAL DENSITY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND POSTMENOPAUSAL WOMEN (2-YEAR RESULTS)

O. Dobrovolskaya¹, P. Kovalenko¹, N. Toroptsova¹, I. Dydykina¹, O. Nikitinskaya¹, E. Nasonov¹

¹Nasonova Research Institute of Rheumatology, Moscow, Russia

Objectives: To compare the effect of denosumab treatment on BMD in female osteoporosis (OP) patients with rheumatoid arthritis (RA) and postmenopausal women.

Methods: 79 women enrolled in the study: 27 patients with RA (mean age 60±7 y) and 52 women with postmenopausal OP (mean age 62±11 y). All patients were prescribed denosumab 60 mg every 6 months for 2 y. All patients additionally take 500-1000 mg of calcium and 800-1000 IU of vitamin D per day. BMD was measured in the lumbar spine (LS), total hip (TH) and one-third radius (R1/3) by DXA (Hologic 4500A) at baseline and annually. Reports of adverse events including information about new clinical fractures were collected at each visit. Serum chemistries measurements were performed also at each visit.

Results: Denosumab significantly increased LS, TH and R1/3 BMD by 6.0%, 2.8%, and 2.2%, respectively, in patients with RA and by 7.6%, 3.6% and 1.6%, respectively, in postmenopausal women without any difference between two groups. The effect of denosumab did not depend on the initial level of immunological markers of inflammation and the use of glucocorticoids in patients with RA. Long-term therapy with denosumab did not have effect on the activity of RA. Adverse event rates were 3.8%, but they did not lead to denosumab withdrawal. There were no cases of hypocalcemia; the average level of serum calcium did not significantly change in the both groups. Creatinine values for the entire observation period did not significantly change. There were no clinical fractures and infection events during the study. Adherence to denosumab treatment was 85% after 2 years.

Conclusion: Denosumab significantly increased BMD in the LS, TH and R1/3 in female patients with RA and in postmenopausal women for 24 months of treatment. Denosumab is effective for OP treatment in RA patients with and without glucocorticoids use. Adherence to denosumab treatment was 85%.

P634

THE DAILY MONITORING OF ARTERIAL STIFFNESS PARAMETERS IN WOMEN WITH OSTEOPOROSIS

S. Tsarenok¹, V. Gorbunov¹, S. Verkhoturova², T. Aksenova

¹Chita State Medical Academy, ²Railway Hospital in Chita, Chita, Russia

Objective: To estimate arterial stiffness parameters in women with osteoporosis.

Methods: 79 postmenopausal women were examined. All patients were divided into groups. The first group included 36 women with osteoporosis, mean age was 69.4±9.1; the second group included 43 women without osteoporosis, mean age was 66.7±9.5. An anamnesis of fractures, an assessment of other risk factors for osteoporosis, a calculation of the FRAX and X-ray densitometry were conducted. Daily monitoring of aortic pressure and parameters of arterial stiffness was performed in all patients. Both group were similar in age, level of arterial pressure and BMI. For statistical analysis we used Statistica 10.0. We used Wald Wolfowitz criterion, Spirman correlation and γ -correlation.

Results: In women with osteoporosis average daily parameters of systolic aortic pressure (SPao), diastolic aortic pressure (DPao) and mean aortic pressure were higher on 4.52% ($p=0.014$), 8.3% ($p=0.0008$) and 5.24% ($p=0.03$) respectively, than in the control group. Some parameters of arterial stiffness differed between groups. Mean pulse wave velocity (PWV) was higher on 2% ($p=0.01$) in patients with osteoporosis. Also in this group the index of arterial stiffness, ambulatory rigidity index and augmentation index were higher on 1.6% ($p=0.0002$), 25.9% ($p=0.0004$) ($p=0.0004$) respectively, then in the control group (Table 1).

Table 1. The parameters of central aortic pressure and arterial with daily monitoring in women with osteoporosis.

Parameter	Women with osteoporosis, n=36	Control group, n=43	P
Systolic Pressure ao, mmHg	123.23±11.45	117.66±10.05	0,014
Diastolic Pressure ao, mmHg	77.17±9.19	70.73±9.98	0,0008
Mean pressure ao, mmHg	99.47±10.41	94.26±9.47	0,32
Pulse pressure ao	46.05±8.31	46.04±9.43	0,03
Alxao,%	31.75±10.43	34.9±13.28	0,001
PPA, mmHg	118.7±4.41	110.73±22.57	0,09
PWV, m/s	8.4±1.62	8.24±0.9	0,01
ASI, mmHg	164.64±32.79	162.06±32.53	0,0002
Alxao cp.,%	1.64±18.06	5.12±18.03	0,000078
Alxao mean PR,%	-6.11±25.20	-13.13±27.73	0,0004
Pulse pressure, mean	52.87±10.05	52.16±10.67	0,00000
AASI	0.54±0.23	0.40±0.22	0,0004

To clarify the relationship between the parameters of rigidity and osteoporosis, we conducted a correlation analysis between the parameters of arterial rigidity and aortic pressure and the history of fractures, as well as their number and indicators of the 10-y risk of osteoporotic fractures. It was established a direct correlation between the levels of SPao, DPao, augmentation index, ambulatory index of rigidity and the presence of osteoporotic fractures in history. A positive relationship was found between the number

of osteoporotic fractures, the index of the absolute ten-year risk of fractures and the levels of SPao, DPao, mean arterial pressure in the aorta, augmentation index, and ambulatory rigidity index (Table 2).

Table 2. The correlation relationships between central pressure, arterial stiffness and a history of osteoporotic fractures, their number, the risk of FRAX fractures.

Parameter	Systolic pressure ao	Diastolic pressure ao	Mean pressure ao	Alxao mean with PR	ASI	AASI	Mean pulse pressure
History of fractures	$\gamma=0.45$ $p=0.00075$	$\gamma=0.43$ $p=0.0024$	$\gamma=0.46$ $p=0.0002$	$\gamma=0.37$ $p=0.0021$	-	$\gamma=0,37,$ $p=0,0021$	-
Number of fractures	$r=0.33$ $p=0.0016$	$r=0.34$ $p=0.002$	$r=0.33$ $p=0.0018$	$r=0.33$ $p=0.0016$	-	$r=0,36$ $p=0,0012$	-
MO	$r=0.33$ $p=0.004$	$r=0.27$ $p=0.018$	$r=0.35$ $p=0.003$	$r=0.29$ $p=0.0012$	-	$r=0,27$ $p=0,018$	-
HF	$r=0.25$ $p=0.02$	-	$r=0.3$ $p=0.0042$	$r=0.38$ $p=0.0002$	$r=0.28$ $p=0,016$	$r=0,25$ $p=0,02$	$r=0,27$ $p=0,018$

Conclusion: In women with osteoporosis, an increase in average daily indices of SPao, DPao and mean aortic pressure were revealed. Parameters of arterial stiffness in the group of women with osteoporosis were increased compared with the control group. Correlations between the pressure levels in the aorta, the stiffness parameters and the history of osteoporotic fractures, their number and the 10-y risk of fractures according to FRAX have been established.

P635

THE EVOLUTION OF PAIN AND RECOVERY IN POSTTRAUMATIC SHOULDER PATIENTS QUANTIFIED WITH DASH (DISABILITIES OF THE ARM, SHOULDER AND HAND)

C. D. Nistor Cseppento¹, D. M. Tit², C. Iovan³, C. Sava⁴, L. Lazar¹, A. M. Sabau⁵, S. Bungau², F. Cioara¹, L. Vicas¹, C. Judea⁶, C. Bochis⁷

¹Department of Psycho Neuroscience and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, Oradea,

²Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, ³Department of Preclinical

Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, ⁴Department of Medical Disciplines, Faculty

of Medicine and Pharmacy, University of Oradea, Oradea,

⁵Department of Physical Education, Faculty of Geography, Tourism and Sport, University of Oradea, Oradea, ⁶Faculty of Medicine and Pharmacy Department: Morphological Disciplines, Oradea, ⁷Maxillofacial surgery clinic of Timisoara, Timisoara, Romania

Objective: From the point of view of the post-traumatic pathology of the shoulder, it can be seen: contusions, dislocations, fractures, wounds, burns. The shoulder, along with the entire scapular belt, arm, forearm and hand, provides the mobility required to complete ADLs, mobility that is affected by trauma at any level of the upper limb. The objectives of recovery are to combat pain and local inflammation, increase mobility and joint stability, and to restrict kinetic and open chain mobility with gesture recovery. The purpose of the study was to follow the evolution of the functional deficit caused by the shoulder trauma through the DASH score that quantifies disability in the upper limb.

Method: 43 patients with shoulder trauma (who addressed the specialty ambulatory of Clinical Hospital "Avram Iancu" from Oradea, Romania) were included in the study, in the period 5 January 2018 - 4 January 2019. All patients met the established inclusion criteria and were included in a complex recovery program: antiallergic electrotherapy, articular massage, passive mobilizations, active, neuroproprioceptive facilitating techniques. For evaluation, the DASH Questionnaire (which included 30 pain and ADL scores, ranging from 0-100, the maximum values representing the functional deficit) were applied.

Results: The age of patients benefiting from the recovery program was between 34-82 y, the mean age being 57.4. Depending on trauma, patients were divided into 3 categories: 73% with contusions, 21% with fractures, and 6% with dislocations. Of the 9 cases with shoulder fractures, 5 cases were osteoporotic fractures, so about 55% of the cases included in the study. The mean DASH score at baseline was 83.37, representing a significant functional shortage, and at the end of the treatment an average of 28.41 was obtained. The best results were achieved in patients with fractures (89% improvement in DASH score), followed by patients with contusions (78% improvement). On the last place there were the cases with dislocations, with improvement of just 65%.

Conclusion: It is important to mention the increased incidence of osteoporotic fractures in the study group, known as the risk of an osteoporotic fracture in women worldwide, is 40%. Improving allegiance and joint mobility has been achieved with the best results for fractures due to the orthopaedic conduction that enabled active mobilization with early articular deco exercises as well as due to the lack of damage to the rotator coil. In the case of contusions, MRI images demonstrated the presence of subacromy-lodeltoid bursitis, "a minima" rupture of the supra-spinal muscle tendon, with significant joint damage to the shoulder. Also, in the case of dislocations, the results were modest, on the one hand, due to the rotator coat damage, on the other hand their relapse, encountered in 2 of the cases included in the study.

P636

SARCOPENIA AND OSTEOPOROSIS ARE INDEPENDENTLY ASSOCIATED WITH PREVALENT VERTEBRAL FRACTURES: A CROSS-SECTIONAL STUDY OF 350 WOMEN WITH SUBACUTE HIP FRACTURE

M. Di Monaco¹, C. Castiglioni², F. Bardesono³, E. Milano¹, G. Massazza³

¹Osteoporosis Research Center, Division of Physical Medicine and Rehabilitation, Fondazione Opera San Camillo,

²Osteoporosis Research Center, Division of Physical Medicine and Rehabilitation, Fondazione Opera San Camillo, ³Division of Physical and Rehabilitation Medicine, Department of Surgical Sciences, University, Torino, Italy

Objective: To evaluate the association between the burden (number and severity) of vertebral fractures and sarcopenia, osteoporosis, or the concurrent presence of both the conditions (osteosarcopenia) in women with hip fracture.

Methods: We investigated 350 women with hip fracture. Lateral radiographs of the spine were taken 18.2±4.5 d after fracture occurrence. For each vertebra the extent of fracture deformation was graded by Genant's method. To obtain a summary measure of the vertebral fracture status of the spine, we calculated the spinal deformity index (SDI) by summing the fracture grades of all vertebrae (T4 to L4). Body composition was assessed by DXA. Low muscle mass was identified with appendicular lean mass < 15.02 kg. Low BMD was diagnosed with a T-score <-2.5 at the unfractured femur.

Results: Osteoporosis was diagnosed in 256 of the 350 women. These women with osteoporosis had an SDI score (median 2, IQR 0-4) higher than the one found in the 94 women without osteoporosis (median 1, IQR 0-3): U=9388, z=-3.23, p=0.001. Sarcopenia was diagnosed in 299 of the 350 women. These women with sarcopenia and an SDI score (median 2, IQR 0-4) higher than the one found in the 51 women without sarcopenia (median 1, IQR 0-2): U=5862, z=-2.70, P=0.007. A linear multiple regression showed that the SDI scores were significantly associated with the presence of both sarcopenia (P=0.033) and osteoporosis (P=0.032) independently of each other and independently of age, percentage of body fat and type of hip fracture.

The 350 women were categorized into 3 groups according to the absence of both osteoporosis and sarcopenia (N=25), presence of either osteoporosis or sarcopenia (N=95) or presence of both osteoporosis and sarcopenia (N=230). We found a significant difference in SDI scores across the 3 groups: χ^2 (2, N=350)=15.29; $p < 0.001$. By comparing pairs of groups, we found that SDI scores were significantly lower in the 25 women who had neither osteoporosis nor sarcopenia (median 0; IQR 0-2) than in the 95 women with either osteoporosis or sarcopenia (median 1; IQR 0-3): $U=848$; $z=-2.29$; $P=0.022$. These 95 women had in turn lower SDI scores than the 230 with both osteoporosis and sarcopenia (median 2; IQR 0-4): $U=9260$; $z=-2.21$; $P=0.027$. A linear multiple regression showed that the SDI scores were significantly associated with the categorization of the 350 women into the 3 groups ($P=0.001$) independently of age, percentage of body fat and type of hip fracture.

Conclusions: Data show that both osteoporosis and sarcopenia are independently associated with the burden of prevalent vertebral fractures in women with hip fracture. The concurrent presence of sarcopenia and osteoporosis is associated with a higher SDI score than the presence of only one of the two conditions. Despite caution due to the cross-sectional design of our study, we support a role for sarcopenia independent of osteoporosis in the genesis of bone fragility.

P637

KNOCKOUT DISCOIDIN DOMAIN RECEPTOR 1 SUPPRESSES TERMINAL DIFFERENTIATION AND APOPTOSIS OF CHONDROCYTES IN AMELIORATING OSTEOARTHRITIS

C.-H. Chen¹, Y. Chou², Y.-H. Lin³, L.-Y. Chou², S.-S. Li², Y.-S. Lin³, S.-Y. Lin³, C.-Z. Wang²

¹Kaohsiung Municipal Ta-Tung Hospital, ²Kaohsiung Medical University, ³Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Objective: Discoidin domain receptor 1 (DDR1) plays a major role in skeletal development, but undefined role in osteoarthritis (OA) progression. Because there is no drug specifically for OA treatment, it can only relieve pain. Herein, we hypothesized that DDR1 regulates chondrocyte function and terminal differentiation during OA progression.

Method: The roles of DDR1 in OA progression were evaluated in an anterior cruciate ligament transection (ACLT)-induced OA model for knee-functional evaluation (weight-bearing distribution), histological OA Research Society International (OARSI) scoring and immunohistochemical analysis.

Results: We first demonstrated that DDR1 was overexpressed in ACLT-induced OA in rats and mice articular cartilage. Chondrocyte-specific *Ddr1* knockout mice with ACLT (CKO Δ *Ddr1*-ACLT) exhibited amelioration of weight-bearing performance than those without *Ddr1* KO, accompanied with OA features improvement presenting in Hematoxylin and eosin (H&E), Safranin-O/Fast-Green stains and OARSI scoring of articular cartilage in CKO Δ *Ddr1*-ACLT mice. Terminal differentiation markers ColX, Ihh and MMP-13,

and apoptotic marker caspase-3 were down-regulated in CKO Δ *Ddr1*-ACLT mice compared with *Ddr1**f/f*-ACLT mice. Moreover, enhanced autophagy with down-regulating mTOR and elevating LC3 contributed to the chondroprotection of CKO Δ *Ddr1* mice during OA progression. Furthermore, DDR1-absence induced reduction of HtrA1 may also involve in this chondroprotective effect.

Conclusions: Our findings suggest that DDR1 plays a novel OA-related marker in promoting OA progression by regulating chondrocytes terminal differentiation, autophagy, and apoptosis. The results revealed the great potential of DDR1-silencing in providing chondroprotection to articular cartilage and ameliorating OA progression.

P638

BILATERAL ASEPTIC NECROSIS OF A FEMORAL HEAD IN A PREGNANT WOMAN AFTER AN IN VITRO FERTILIZATION PROCEDURE

M. D. Borovskikh¹, O. V. Teplyakova¹

¹Federal State Budgetary Institution of Higher Professional Education "Urals State Medical University" of the Ministry of Healthcare of the Russian Federation, Ekaterinburg, Russia

The pathogenesis of femoral head aseptic necrosis development during pregnancy has not been studied. The literature describes 40 cases only.

Case presentation: A 45-year-old woman came to a rheumatologist with complaints of ankle and left knee joint pain of a mechanical nature, a change of gait to a waddling type. It was the second pregnancy at the age of 44 - IVF with her own oocytes. Considers herself sick from the 24th week of pregnancy, when the above symptoms appeared and gradually progressed. She did not apply for specialized help. In the postpartum period, meloxicam was prescribed. (During laboratory examination of signs, laboratory activity was not detected, RF, antibodies to DNA were negative.) 1.5 months after delivery, the patient noted a decrease in pain. During this period, she had the primary consultation of a rheumatologist. Comorbidities: hypothyroidism, taking levothyroxine sodium 50 mg/d. The knee, ankle and hip joints have no visual changes. During palpation no pathology was revealed. The abduction in the left hip was 50, the flexion was 110°, the extension was 180°. Movement in other joints - in full range. Pain by VAS - 48 mm. The level of vitamin D was 10.20 ng/ml (the standard is over 30), the level of calcium and phosphorus was at the normal range. There were no data of antiphospholipid syndrome detected. CT of the hip: symmetric areas of bone loss were 15x8 mm on the left and 10x6 mm on the right, with smoothness of the bone spongy substance pattern and eggshell type solution of continuity of the cortical plate. CT of the ankle joints: regional osteoporosis, Looser zones were not identified. Diagnosis: III A bilateral aseptic necrosis of the femoral heads by Steinberg. Vitamin deficiency. Due to the small size of the damage zone, a decision was made on conservative treatment: relief of joints, meloxicam 15 mg/d on demand and cholecalciferol 50,000 IU/week for 2 months.

After 2 months - the absence of complaints of pain, the full range of movements in the hip joints, the normalization of vitamin D level.

Conclusion: A feature of the presented case is the development of aseptic necrosis after the IVF procedure. It is not excluded that stimulation of the ovaries, as well as additional support with progesterone, could be a risk factor for the disease.

P639

DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS IS A NEW RISK FACTOR FOR VERTEBRAL FRACTURE IN OLDER MEN: THE PROSPECTIVE MINOS STUDY

P. Szulc¹, A. Guiot¹, R. Chapurlat¹

¹INSERM UMR 1033, University of Lyon, Hôpital Edouard Herriot, Lyon, France

Objective: Diffuse idiopathic skeletal hyperostosis (DISH) is associated with high prevalence of vertebral fractures. We studied the association of DISH with bone status in 782 men aged 51-85 y followed up prospectively for 8 y.

Methods: DISH was diagnosed on the antero-posterior radiography of the spine using Resnick's criteria. BMD was measured by DXA at the lumbar spine, hip, whole body, and distal forearm. Incident vertebral fracture was diagnosed as a 20% decrease in any vertebral body height vs. baseline.

Results: In 170 men with DISH, BMD did not differ from the controls. After adjustment for age, BMI, BMD, prior vertebral fractures, endplate irregularities and disc space narrowing (DSN)^{1,2}, DISH was associated with higher vertebral fracture risk (OR=2.89, 95%CI: 1.15–7.28, p<0.05). Low spine BMD and DISH contributed to the vertebral fracture risk (OR=11.91 vs. men who without these two characteristics, 95%CI: 2.99–47.39, p<0.05). Men who had multilevel DSN and DISH, had higher vertebral fracture risk vs. men who did not (OR=11.60, 3.25–41.46, p<0.001). DISH was associated with higher vertebral fracture risk in men free of other risk factors for this fracture, e.g., endplate irregularities (OR=6.60, 95%CI: 1.66–26.33, p<0.05) or prior vertebral fracture (OR=3.98, 95%CI: 1.52–10.44, p<0.05). Men who had at least one degenerative spine disorder (multilevel DSN, endplate irregularity, DISH) had higher vertebral fracture risk vs. men who were free of these diseases (OR=4.05, 95%CI: 1.47–11.11, p<0.01). The risk increased with the number of these disorders (p for trend <0.001). DISH was not associated with nonvertebral fractures.

Conclusion: In older men DISH is associated with higher risk of vertebral fracture. Along with our prior studies^{1,2}, these data show that in older men, degenerative spine disorders increase the risk of vertebral fracture.

References: 1) Estublier C Rheumatology 2017;56:37. 2) Gaudé M Bone 2018;117:116.

P640

CHEMICAL AND MECHANICAL STIMULATION OF THE SUBCHONDRAL BONE INDUCES MICROCOMPUTED TOMOGRAPHY AND HISTOLOGICAL CHANGES OF BONE AND CARTILAGE IN AN OVINE MODEL

E. Hontoir¹, V. Simon¹, P. Clegg², R. van't Hof², N. Kirschvink¹, J.-M. Vandeweerdt¹

¹University of Namur - NaRILiS (Namur Research Institute for Life Sciences) -IVRU (Integrated Veterinary Research Unit), Namur, Belgium, ²University of Liverpool - Institute of Ageing and Chronic Disease, Liverpool, UK

Objectives: Subchondral bone (SB) alteration has been suggested to be responsible for osteoarthritis initiation. Our aim was to assess early changes of bone and cartilage associated with SB mechanical and chemical stimulation.

Methods: 18 ewes were anaesthetized. Stimulation of the medial femoral condyle SB was achieved either by ethanol injection or by force impact, via extra-articular access. Sheep were euthanized at 2, 4, 6 and 8 weeks after stimulation (N=4x4) or the day of the stimulation (N=2). Microcomputed tomography (μCT) and histology were performed on osteochondral plugs.

Results: Apparent bone density showed a significant increase at 4 weeks poststimulation in both models. This was associated with an increase in trabecular thickness (259.00 μm±12.00), a decrease of trabecular separation (338.00 μm±24.00), and a slight decrease in trabecular number (2.18±0.12) for the ethanol-stimulated limbs; while it was associated to a slight increase in trabecular number for the impact-stimulated limbs. Histology revealed a slight degradation of cartilage overtime in the ethanol-stimulated limbs; and a slight improvement in the impact-stimulated limbs. A high number of osteoblasts around the trabeculae of the SB of the condyle were observed in 4 of 9 ethanol-stimulated limbs and in 5 of 9 impact-stimulated limbs. Impact-stimulated limbs showed TUNEL stain in 5 of 9 limbs for SB. The drill hole was filled with fibrous tissue and multinucleated giant cells (osteoclasts).

Conclusions: These results indicate that the SB stimulation induces a transitory increase in bone volume rather due to increase of trabecular thickness than to change in organization of the bone itself. These changes have been proven to occur in SB in the course of osteoarthritis in man. Moreover, it seems that the mechanical stimulation was mimicking changes associated to micropicking, a procedure where microfracture of the SB is induced to stimulate cartilage repair.

P641

DIFFERENT EFFECTS OF ETHANOL ON BONE MICROSTRUCTURE OF MICE AFTER SUBACUTE AND SUBCHRONIC ADMINISTRATION

M. Martiniakova¹, A. Sarocka¹, R. Babosova¹, E. Kapusta², Z. Goc², A. Gren², G. Formicki², R. Omelka¹

¹Constantine the Philosopher University in Nitra, Nitra, Slovakia,

²Pedagogical University of Cracow, Cracow, Poland

Objective: Alcohol is considered a leading risk factor for osteopenia. Our study aimed to compare in detail bone microstructure of mice after subacute and subchronic administration to ethanol.

Methods: 15 clinically healthy 12-week-old Swiss mice (males) were randomly divided into three groups: E1 group - mice drank a solution of 15% ethanol and water (1.7 g 100% ethanol kg⁻¹ b.w. per day) during 2 weeks; E2 group - males received equal solution of ethanol for 8 weeks; and a control (C) group. Modern 2D and 3D imaging methods were used to determine bone microstructure. The study was approved by the First Local Ethic Committee on Experiments on Animals in Cracow (No. 175/2012).

Results: Alcohol consumption negatively affected compact bone microstructure in both E1 and E2 groups. Increased cortical porosity (four times more resorption lacunae in E1 group, five times more of these structures in E2 group), decreased relative bone volume and BMD (P<0.05) were detected in ethanol-fed mice. These results were also supported by consistent findings of reduced serum alkaline phosphatase and glutathione (P<0.05) in E1, E2 groups. No changes in trabecular bone morphometry were observed in E1 group. On the contrary, relative bone volume, trabecular number, trabecular thickness, bone surface were significantly decreased (P<0.05) in E2 group. Serum calcium, phosphate were significantly lower (P<0.05) in mice after subacute exposure to ethanol. However, they remain unchanged after subchronic administration.

Conclusion: Our results suggest different effects of ethanol on bone microstructure after subacute and subchronic consumption. They also support recent findings that compact and trabecular bones should be considered two separate entities because of their dissimilar bone remodeling levels.

Acknowledgements: The study was supported by projects VEGA 1/0653/16 and VEGA 1/0505/18.

P642

BENEFITS OF THE COMPLEX RECOVERY TREATMENT ON CEREBELLAR ATAXIA SYNDROME

C. D. Nistor Cseppento¹, S. Bungau², D. M. Tit², L. Lazar¹, A. M. Sabau³, D. C. Iovanovici⁴, F. Cioara¹, C. Bochis⁵, C. Judea⁶, A. Damner⁷, R. N. Suciu¹, L. Vicas¹

¹Department of Psycho Neuroscience and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, Oradea,

²Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, ³Department of Physical Education, Faculty of Geography, Tourism and Sport, University of Oradea, Oradea, ⁴University of Medicine Timisoara, Timisoara, ⁵Maxillofacial surgery clinic of Timisoara, Timisoara, ⁶Faculty of Medicine and Pharmacy Department: Morphological Disciplines, Oradea, ⁷Clinical Rehabilitation Hospital Baile Felix, Oradea, Romania

Objective: The posture characteristic of the human species is the vertical one; this is done by maintaining balance, a function that allows awareness of the body's position. Affecting balance leads to disruption of body stability in sitting, orthostates, walking. Ataxia is loss of stability, impairment of initiation and movement support. It can be hereditary, idiopathic or acquired. The acquired ataxia has the following causes: craniocerebral traumas, vascular accidents, multiple sclerosis, compressive tumors, intoxications, inflammatory lesions, cerebellar atrophy, etc.

The purpose of the paper. Trace the benefits of complex recovery treatment to cerebellar ataxia syndrome.

Method: The study group consisted of 15 patients with cerebellar ataxia syndrome diagnosed in the Rehabilitation Clinical Hospital, Baile Felix, Romania. Patients followed a complex recovery program; the means used were kineto-therapy for increasing static, dynamic and coordination equilibrium, occupational therapy, hydro-kineto-therapy, electrotherapy and virtual reality. Improving gait and balance play an essential role in preventing deconditioning syndrome, resulting in loss of muscle and bone mass, increased risk of falls and the incidence of osteoporotic fractures, female sex being the most exposed. Over time, a number of scales have been used to evaluate the ataxia. For the patients' evaluation we used the Hauser Ambulation Index and the SARA scale. Studies show that the latter is one of the most reliable methods of evaluating ataxia. Patient evaluation is performed in sitting, orthostatic and on the go, on the day of admission and after 10 d of treatment.

Results: The age of patients was between 27-65 y, with an average of 46.13. The gender distribution shows that 80% of the patients are males, the urban environment being the urban one. The SARA scale demonstrates significant improvement in all patients in terms of sitting equilibrium. Twelve patients made significant progress in orthostates and walking during the 10 d of treatment, by increasing the duration of their orthostates, walking distance and walking speed. Using the Hauser Ambulation Index to measure mobility, monitoring the time and the degree of assistance, we obtained the following **Results:** 25% of the patients were in the 4th stage, went with unilateral support; 55% are in stage 3,

requiring supervision; 20% were in stage 5 with bilateral support. At the end of the 10 d of treatment, the following distribution was obtained: 60% in stage 3 with stage assistance, 21% in stage 4, and 19% in stage 5.

Conclusion: The intensive recovery program should be initiated immediately after the onset of equilibrium disturbances, with significant results in equilibrium in sitting, orthostates or walking. It should also be sustained throughout life, the results being influenced by the time of initiation and the age of the patients, as shown by the specialty studies.

P643

LEVEL OF OSTEOPOROSIS AWARENESS AND ITS RELATED FACTORS IN LOW DENSITY DISTAL RADIUS FRACTURES PATIENTS AGED 50 YEARS AND OLDER IN ASIAN COUNTRY

M. Muzzammil¹

¹Dr. Ruth K M Pfau Civil Hospital Karachi, Karachi, Pakistan

Objective: Osteoporosis is an important health problem with regard to morbidity, mortality, and negative effects on quality of life as well as health-related costs. With rapid ageing of the Asian population, osteoporosis has become one of the most prevalent and costly health problems. Distal radius fracture is one of the most frequent fractures and it has been shown to be associated with an increased risk of further fractures. Not much is known about the level of awareness of the condition among these patients of distal radius fracture in Asian country. Awareness and treatment of osteoporosis is important to prevent further fractures in patients with osteoporosis. The aim of this study was to evaluate the awareness of osteoporosis and related factors in distal radius fracture patients.

Method: Cross-sectional study conducted on low energy distal radius fracture patients aged 50 y and over came in Emergency Department of tertiary care hospital Karachi, Pakistan from Jan 2016 to Dec 2016. A questionnaire was designed had three sections: demographic information, knowledge about osteoporosis and risk factors for osteoporosis, applied in all patients after they gave their consent. Data was analyzed on SPSS 21 for statistical significance.

Results: Total number of patient with distal radius fracture were 480, 352(73.33%) female and 128(26.66%) male. only 98(20.41%) had awareness about osteoporosis, and 382(79.58%) did not. About the educational levels 210(43.75%) of patients were not able to read and write or goes primary school, 52.5%, 158(32.91%) did not get primary education and 112(23.33%) were secondary or high school graduates. Awareness of osteoporosis was positively correlated with education. With regard to sources of information, 312(65%) of patients reported physicians/doctors as the main source of information, followed by TV, newspaper. Other sources of information included: books (%), family members (%), friends (%), radio (%), pharmacists (%) and internet (%). 382(79.58%) indicated they did not know anything about osteoporosis and could not answer the remainder of the questionnaire. The average age was 72.5 y, with a minimum of 50 and a maximum of 95 (standard

deviation=31.81 years). Lifestyle practices varied considerably. While nearly 15% reported smoking or having smoked mostly in male patients, 20% indicated they exercised at least 30 minutes daily, and 1% reported drinking alcoholic beverages occasionally. Only small number of patients indicated that they take calcium and vitamin D supplements on regular basis (25% and 15%, respectively). 382(79.58%) patients did not know what factors contribute to the development of osteoporosis. More than three quarters of patients could not identify risk factors such as vitamin D deficiency, family history of osteoporosis, poor eating habits, smoking, alcohol consumption, increasing age, some medications and menopause. There appeared to be a relationship between education and awareness of risk factors. When compared to respondents with a lower educational level (high school or less), a greater proportion of respondents with higher educational level (college or postgraduate education) were able to identify risk factors such as lack of exercise (32% vs. 11%), vitamin D deficiency (22% vs. 8%), family history (18% vs. 8%), smoking (12% vs. 6%), alcohol consumption (6% vs. 2%), and certain medicines (5% vs. 1.5%).

Conclusion: We demonstrated that the level of awareness of osteoporosis is associated with educational level in distal radius fracture patients. Awareness of osteoporosis and thus to begin treatment earlier is important to prevent further fractures in distal radius fracture patients especially in Asian population. Public education campaigns must address risk factors and the strategies to overcome those that are modifiable in order to prevent the development of osteoporosis and its complications.

P644

HYPOPHOSPHATEMIA AND MULTIPLE BONE FRACTURES AFTER DENOSUMAB DISCONTINUATION IN HEMODIALYSIS PATIENT WITH TYPE 1 DIABETES MELLITUS

S. O. Mazurenko¹, A. A. Enkin², O. G. Mazurenko³, L. G. Ermolaeva¹

¹Saint Petersburg State University, ²Leningrad Regional Hospital, ³Saint Petersburg Hospital named after L.G. Sokolov, Saint Petersburg, Russia

Denosumab is widely used for therapy of postmenopausal osteoporosis. It is not absolutely contraindicated for patients with chronic kidney disease, however it cannot be widely used for patients receiving hemodialysis therapy due to risk of hypocalcemia and rebound bone loss after denosumab therapy discontinuation.

We report a 44-year old woman with diabetes mellitus type 1, receiving hemodialysis therapy for 6 y. She was directed to the center for osteoporosis due to multiple fractures. 4 y ago low BMD was revealed. The patient consulted with endocrinologist and therapy with denosumab 60 mg given subcutaneously every 6 months was started. Two years of therapy (four injections of denosumab) was quite successful. She also received alfacalcidol and supplements of calcium carbonate. BMD increased after first year of treatment, and did not change significantly after the second year. Four injections of denosumab were performed, the last one in December 2016. Then the patient stopped the thera-

py with denosumab. Eight months had passed since the last injection, and in August 2017 she suffered bilateral femoral neck fracture after falling down from dialysis chair. Bilateral endoprosthetic total hip replacement was performed. In 6 months after hip replacement the patient was examined for bone pain and chest deformity. Multiple rib and scapular fractures were revealed. Laboratory analysis showed low level of phosphates (0.42 mmol/l), 25(OH) Vit D (22 ng/ml), high level of alkaline phosphatase and bone metabolites (β -isomers of CTX - 1.620 ng/ml; PINP - 1425 ng/ml. Intact PTH was 12.1 pmol/l (lab reference ranges: 0.7-5.6 pmol/l). This condition was diagnosed as hypophosphatemic osteomalacia complicated by multiple bone fractures. High doses of alfacalcidol and phosphate-rich diet were prescribed. Seven months later plasma phosphates level raised to 0.79 mmol/l, intact PTH lowered to 5.2 pmol/l, level of calcium raised slightly, but alkaline phosphatase did not change significantly.

Conclusion: Denosumab should not be used in hemodialysis patients without serious reasons. However, if one starts therapy with denosumab, one must envisage what to do after its discontinuation.

P645

EFFECTS OF ANNUAL APPLICATION OF BIOLOGICAL THERAPY ON MINERAL BONE DENSITY IN PATIENTS WITH RHEUMATOID ARTHRITIS

T. Jankovic¹, J. Zvekic Svorcan¹, S. Teodosijevic Subin²

¹Faculty of Medicine, University of Novi Sad Special Hospital for Rheumatic Diseases, Rheumatology, Novi Sad, ²General Hospital "Dr Djordje Joanović", Rheumatology, Zrenjanin, Serbia

Objective: Rheumatoid arthritis (RA) is a disease that is triggered and maintained by proinflammatory cytokines. They cause joint destruction and the occurrence of systemic manifestations - osteoporosis. The biological agents used in the treatment of RA are targeted against several proinflammatory cytokines. Our aim was to test the impact of biological drugs on the change in BMD and their mutual difference after 1-y administration in patients with RA.

Methods: The study includes 60 patients with rheumatoid arthritis which does not last longer than 10 y and are experiencing menopause for no longer than 5 y. All patients are taking a stable dose of methotrexate of 10 mg per week, without Glucocorticoid therapy and receive some of the biological drugs. Patients are divided into three groups of 20 patients who are on the anti-TNF inhibitors treatment, tocilizumab or on rituximab. At the beginning of the application of the biological drug and after 1 y, BMD T-score on a Lunar-type device were measured on lumbar spine and hip in all patients. Risk factors for osteoporosis and fractures were identified in all patients. Statistical analysis was done in the computer program SPSS ver. 24 (Statistical Package for the Social Sciences).

Results: The measured T-score values in a group of patients at the beginning of treatment with anti-TNF inhibitors were such that 47% of patients had a normal finding, 33% osteopenia and 20% os-

teoporosis. After a year of administration of these drugs, 50% had a normal finding, 37% osteopenia, while 13% had osteoporosis. In patients on Tocilizumab therapy, the measured T-score at the start of the treatment: 43% had a normal finding, 31% osteopenia and 26% osteoporosis. After one year 48% had a normal finding, 40% osteopenia, and 12% osteoporosis. Patients who had been on therapy with rituximab, at the beginning of therapy 39% had a normal finding of T-score, 42% osteopenia and 20% osteoporosis. After a year 39% had a normal finding, 42% had osteopenia and 19% had osteoporosis. There were 4.4% of patients without risk factors, 37.8% had one risk factor, two 31.1%, and three or more risk factors had 26.7% of subjects. 9% of patients had fractures. 6% had 1 fracture, 2% two fractures and 1% of patients had more than 3 fractures.

Conclusion: The application of all tested biological drugs has led to an improvement in BMD. The greatest improvement was observed in the group of patients treated with tocilizumab.

P646

CLINICAL UTILITY OF FOCAL BONE MINERAL DENSITOMETRY IN PATIENTS WITH COMPLEX REGIONAL PAIN SYNDROME

S. Di Gregorio¹, M. L. Brance², M. Minoves¹, A. Ponce¹, L. Del Río Barquero¹

¹Cetir/Ascires, Barcelona, Spain, ²Reumatología y Enfermedades Óseas. Rosario, Rosario, Argentina

Objective: Evaluate the clinical utility of bone mineral densitometry and bone mineral content (BMC) in patients with complex regional pain syndrome (CRPS).

Methods: 37 patients with CRPS were included. All the patients underwent whole body bone mineral densitometry by DXA. The affected region was compared with its respective contralateral with specific ROI. Also nearest articulation and homolateral limb were compared to contralateral. In addition, bone scintigraphy, clinical features, time of evolution, lumbar spine, femoral neck and total hip BMD were evaluated. BMC $\geq 3\%$ for lower limbs and $\geq 10\%$ for superior limbs as pathological asymmetry were considered. Changes in BMC between 5-10% were considered as probable.

Results: Females (n=27) and male (n=10) were included. The most frequent affected sites were wrists (57.9%), ankles (7.9%), feet (7.9%) and others (26.3%). The mean time between the bone event and scan BMD was 4 months in patients without changes in focal BMD (35%) and 6.5 months in patients with significant changes in focal BMD (65%) compared to its contralateral limb. The BMC was -17.6% and the BMD -11.8% in the affected region while BMC was -11.5% and the BMD were -8.3% in the whole homolateral limb. In 35.1% the whole homolateral limb was also affected. In the specific ROI analysis, 15/37 patients has BMC criteria for pathological asymmetry and 3/37 patients has probable asymmetry. All the patients had bone scintigraphy which was negative for diagnosis in 2/37. Only one patient bone scintigraphy was not concordant with BMD. The BMC measured by DXA has sensitivity: 60% and specificity: 83% (Fisher's exact test; p=0.01)

Conclusion: Our study confirms focal DXA is useful for the assessment of unilateral bone loss caused by limb RSDS. In other wise its useful is important because can estimate BMC and it allows the bone evolution with a quantified parameter.

P647

EVALUATION OF ASYMMETRIES IN BONE MINERAL DENSITY, BONE MINERAL CONTENT AND LEAN MASS BECAUSE DOMINANCE OF PHYSIOLOGICAL LATERALITY

S. Di Gregorio¹, M. L. Brance², L. Del Río Barquero¹

¹Cetir/Ascires, Barcelona, Spain, ²Reumatología y Enfermedades Óseas, Rosario, Argentina

Objective: Evaluation of asymmetries in BMD, bone mineral content (BMC) and lean mass between both right and left superior and lower limbs.

Methods: A retrospective analysis of 857 whole body densitometry by DXA were done. Healthy subjects ≥ 20 years old were included. Bone, muscle and neurological diseases were excluded. The following variables were analyzed in both right and left arm and leg: BMD (g/cm²), BMC (g) and lean mass (g). The results were stratified by sex, superior and lower limbs, BMD, BMC, lean mass, and decades (20, 30, 40, 50, 60, 70-80), nondominant (ND) and dominant (D). The results are expressed as % of the mean difference between left and right mean (% MD), and % that represent the lower 95%CI (% L95%CI). Differences between groups were analyzed using Student t-test and $p < 0.05$ were considered significant.

Results: Only statistically significant differences are shown. In women in superior limbs Δ BMD was 3.72% (ND BMD: 0.621 vs. D: 0.645, $p < 0.0001$); Δ BMC: 5.33 (ND 128 vs. D: 135, $p < 0.0001$). In lower limbs Δ BMD: 0.47, (ND BMD: 1.051 vs. D: 1.056, $p < 0.0001$); Δ BMC: 0.77 (ND: 363 vs. D: 366, $p < 0.0001$). In men in superior limbs Δ BMD was 3.52% (ND: 0.777 vs. D: 0.806, $p < 0.0001$); Δ BMC: 4.65%, ND 204 vs. D: 215, $p < 0.0001$); In lower limbs Δ BMD was 0.22% (ND BMD: 1.302 vs. D: 1.305, p : ns); Δ BMC: 0.45 (ND BMD: 548 vs. D: 549, p : ns). We found differences between both arms in all decades and both sex in BMD and BMC. The maximum difference for BMD and BMC in both sex was found at 20's decade in arms: women BMD (%MD: 4.3%; L95%-CI: 5.3%), men BMD (%MD: 4.1%; L95%-CI: 5%), women BMC: (%MD: 5.1%; L95%-CI: 8.0%). The highest difference in lean mass was found at since 60's decade.

Conclusion: The asymmetry because of physiological the dominance by laterally is observed in upper limbs. The knowledge of physiological values of asymmetry would allow us to evaluate pathologies with focal demineralization and its follow-up control.

P648

ANALYSIS OF BONE STRUCTURAL PARAMETERS BY DXA-3D IN CERVICAL AND TROCHANTERIC HIP FRACTURES

S. Di Gregorio¹, M. L. Brance², S. Martinez³, P. Sánchez Ortuño⁴, L. Del Río Barquero¹

¹Cetir/Ascires, Barcelona, Spain, ²Reumatología y Enfermedades Óseas, Rosario, Argentina, ³Servicio de Reumatología, Hospital Mutua de Terrassa., Barcelona, Spain, ⁴Densitometría. Hospital Mutua Terrassa., Barcelona, Spain

Objective: Analyze bone structural parameters by DXA-3D and by type of hip fracture (cervical (CHF) or trochanteric (THF) of elderly patients.

Method: A case-control study with patients (225) with hip fracture and a control group (305) matched by age, sex, BMI and WHO BMD classification was carried out. The interval between fracture and DXA scan was < 15 days. BMD (g/cm²) was determined by DXA (Prodigy). 3D analysis of the femur was performed with 3D-SHAPER software (Galgo Medical). The results are expressed as mean \pm SD. t-test were used to compared groups and lineal regression for correlations.

Results: 530 patients (75.9% postmenopausal women, 24.1% men) were included (57.7% controls (CG), 42.3% with hip fractures (HF), trochanteric (n=119) and cervical (n=106). According WHO classification we found in the CG 18.8% normal BMD, 43.4% low BMD and 37.8% osteoporosis. We found 10.1% and 3.8% normal BMD, 38.7% and 50% low BM and 51.3% and 46.2% osteoporosis in THF and CHF respectively. There were no significant differences between THP and CHP in normal BMD patients. In low BMD patients we found in THF significantly lower trabecular trochanter vBMD (mg/cm³, CHF: 104.97 \pm 25.56; THF 94.83 \pm 16.56). In addition, cortical.Th lateral and medium FN (mm) were significantly lower in CHF. In patients with osteoporosis we found in THF significantly lower cortical trochanter BMC (g, CHF: 2.430 \pm 0.073; THP: 2.150 \pm 0.068), intertrochanteric cortical.Th (mm, CHF: 1.65 \pm 0.14; THF: 1.59 \pm 0.14), lateral intertrochanteric cortical.Th (mm, CHF: 1.16 \pm 0.19; THF: 1.09 \pm 0.15). In patients with THF the cortical trochanter BMC has correlation with leg lean mass in nonfracture leg (r: 0.573). In patients with cervical hip fractures the cortical femoral neck BMC has correlation with the lean mass (r: 0.619).

Conclusions: DXA-3D would be useful for the differentiation among the different bone structural parameters according cervical or trabecular hip fractures.

P649

AN OVERVIEW OF THE ETIOLOGY, CLINICAL MANIFESTATIONS, MANAGEMENT STRATEGIES AND COMPLICATIONS OF HYPOPARATHYROIDISM FROM THE CANADIAN NATIONAL HYPOPARATHYROIDISM REGISTRY

Y. A. Alalawi¹, Y. H. Hakami¹, R. El-Werfalli², M. Braga³, A. Millar³, Z. Punthakee³, K. Vassallo³, A. Zahid³, N. Siraj³, H. Zariffah³, T. Khan³, A. Waldbillig³, J. Young⁴, A. Khan

¹McMaster University, Hamilton, ²The Bone Research and Education Centre, Oakville, ³Bone Research and Education Centre, Oakville, ⁴University of Toronto, Toronto, Canada

Objectives:

- identify the etiology and presenting symptoms of patients with hypoPTH.
- evaluate current treatment practice in Canada.
- assess differences in presentation based on etiology of the disease.
- compare parameters of calcium homeostasis amongst those developing complications of nephrolithiasis or nephrocalcinosis vs. those without complications.
- assess fracture risk and microstructure in Canadian patients with hypoPTH.

Methods:

- Prospective observational registry of 116 patients >18 y of age.
- The inclusion criteria:
 1. Chronic hypoPTH (low PTH in the presence of low serum calcium [total or ionized] for at least 6 months prior to enrolment)
 2. HypoPTH (including postsurgery) requiring calcium/calcitriol replacement to maintain normal calcium (total or ionized) level for at least 6 months prior to enrolment
 3. Pseudohypoparathyroidism with elevated PTH and low serum calcium (total or ionized), normal vitamin D and hyperphosphatemia
- Exclusion criteria: Transient hypoPTH which resolved within <6 months of treatment.
- We reviewed etiology, initial clinical presentation, laboratory investigations, management strategies, markers of skeletal health including fractures, BMD, and complications including nephrolithiasis/nephrocalcinosis, and basal ganglia calcification. Fracture risk was determined using the Canadian Association of Radiologists and Osteoporosis Canada (CAROC) tool

Results: Most patients (84/116) had postsurgical hypoparathyroidism, followed by idiopathic/autoimmune disease (29/116) and pseudohypoparathyroidism (3/116). The mean age of onset was 41.6 y. All patients were receiving calcium supplements (100%) with calcitriol being used by 82.8% and 4 patients received PTH. Nephrolithiasis or nephrocalcinosis were present in 25.4%

of treated patients despite a mean calcium phosphate product <4.4 mmol²/L². Basal Ganglia calcification was present in 7 of the 30 patients reviewed. A substantial number of patients (31.0%) required hospitalization at initial presentation. Patients with idiopathic/autoimmune disease were twice as likely to be hospitalized compared to those with postsurgical disease.

Conclusions:

1. HypoPTH is associated with a significant disease burden and leads to hospitalization in a large number of patients.
2. Renal complications of nephrocalcinosis and nephrolithiasis were present in 25.4% of treated patients despite maintenance of a calcium phosphate product in the desired range (<4.4 mmol²/L²). The ideal calcium phosphate product needs to be reconsidered.
3. Fracture risk was low in the absence of traditional osteoporosis risk factors.

P650

TOTAL ANTIOXIDANT CAPACITY AND FRAILITY IN OLDER MEN

M. C. Tembo¹, K. L. Holloway-Kew¹, C. C. Bortolasci¹, S. X. Sui¹, S. L. Brennan-Olsen², L. J. Williams¹, M. A. Kotowicz¹, J. A. Pasco¹

¹Deakin University, Geelong, ²Department of Medicine-Western Health, The University of Melbourne, Melbourne, Australia

Objective: There is some evidence that frailty, a clinical syndrome characterised by multisystem dysregulation, is associated with elevated oxidative stress. We investigated the association between serum total antioxidant capacity (TAC) and frailty in older men.

Methods: This cross-sectional study included men (age 60-90 y) from the Geelong Osteoporosis Study. Frailty referred to ≥ 3 of the following: unintentional weight loss, exhaustion, low physical activity, slowness and weakness. TAC was measured by quantitative colorimetric determination, using Cell Biolabs' OxiSelect™ Total Antioxidant Capacity (TAC) Assay Kit, with results expressed as uric acid equivalents. TAC values were expressed as standard deviation units in Pearson's correlation tests and multivariable logistic regression models for determining their relationship with frailty. Adjustments for potential confounders and effect modifiers were made. A sensitivity analysis excluded participants in the upper quartile of TAC, who were likely to have hyperuricemia.

Results: Among 581 men, 50 (8.6%) were frail. TAC was weakly correlated with age ($r=0.07$, $p=0.1$) and BMI ($r=0.1$, $p=0.01$). Higher TAC was associated with increased likelihood of frailty (OR 1.34, 95%CI 0.99-1.80), with borderline significance. Adjustment for age and BMI attenuated the association (OR 1.26, 95%CI 0.93-1.71). No effect modifiers or other confounders were identified. Sensitivity analysis revealed a positive association between TAC and frailty, which was significant before (OR 1.79, 95%CI 1.02-3.13), and after adjustment (OR 1.79, 95%CI 1.01-3.17).

Conclusion: These results suggest a positive association between TAC levels and frailty, supporting the notion that this biomarker could be useful in identifying individuals at risk of frailty.

We speculate that a milieu of heightened oxidative stress in frailty may elevate the oxidative stress regulatory set-point, raising anti-oxidant activity. This warrants further investigation.

P651

PROSPECTIVE COMPARISON OF INTRA-ARTICULAR SHAM VS. PLACEBO INJECTIONS: DATA FROM A RANDOMIZED, CONTROLLED PHASE 2B TRIAL OF SM04690, A WNT PATHWAY INHIBITOR FOR KNEE OSTEOARTHRITIS

Y. Yazici¹, J. Tambiah¹, C. Swearingen¹, S. Kennedy¹, V. Strand², B. Cole³, M. Hochberg⁴, R. Bannuru⁵, T. McAlindon⁵

¹Samumed, LLC, San Diego, ²Stanford University of Medicine, Palo Alto, ³Midwest Orthopedics at Rush University, Chicago, ⁴University of Maryland School of Medicine, Baltimore, ⁵Tufts Medical Center, Boston, USA

Objectives: Intra-articular (IA) placebo (PBO) comparators in knee osteoarthritis (OA) trials demonstrate consistent and durable symptom improvements over baseline. There is controversy concerning whether responses to IA saline represent a true PBO effect vs. actual physiologic benefit.¹ To test if the effects are due to intrinsic saline properties, one arm of a 24-week phase 2b study of SM04690 (IA Wnt pathway inhibitor in development as a potential disease-modifying knee OA drug) compared effects of IA vehicle PBO to sham. Primary study results are presented separately.

Methods: Subjects with knee OA, Kellgren-Lawrence grade 2 or 3, and Pain Numeric Rating Scale (NRS) scores ≥ 4 and ≤ 8 in the target knee and < 4 in the contralateral knee were randomized to receive a blinded single IA 2 mL injection of vehicle (PBO, 0.5% carboxymethylcellulose sodium and 0.05% polysorbate 80 in pH 7.4 saline), sham (dry needle), or SM04690 at baseline. Patient reported outcomes (PROs) included change from baseline in weekly average of daily target knee pain by NRS, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain, WOMAC Physical Function, and Patient Global Assessment. Baseline-adjusted analysis of covariance was used to estimate change over time differences in outcomes between sham and PBO.

Results: 207 out of 233 PBO and sham subjects completed the 24-week study. Both PBO and sham subjects showed clinically relevant improvement ($>10\%$) from baseline at first post-baseline measurement that persisted through Week 24.2 However, no clinically meaningful or statistically significant differences were evident between the two groups at any timepoints (Figure).

Conclusion: Subjects with knee OA receiving a single IA injection of PBO reported no differences in changes from baseline in knee OA PROs compared to subjects who received sham injections. These data suggest that the observed effects were "contextual," meaning that they resulted from the injection procedure, rather than from direct therapeutic effects of PBO or saline in the joint.


References:

1. Altman, Roy D, et al. *Sem Arthr Rheum*
2. Devji, Tahira, et al. *BMJ open*5 (2017): e015587.

Disclosures: All authors are employees or consultants of Samumed, LLC

Figure: Observations over time depicting mean improvements of PBO and sham injection

A. Pain NRS, B. WOMAC Pain, C. WOMAC Function, and D. Patient Global Assessment; in all subjects



P652
COGNITION, BODY COMPOSITION AND MUSCLE FUNCTION IN OLDER MEN: GEELONG OSTEOPOROSIS STUDY

S. X. Sui¹, N. K. Hyde¹, M. C. Tembo¹, P. G. Rufus-Membere¹, K. L. Holloway-Kew¹, L. J. Williams¹, S. Cowdery¹, M. A. Sajjad¹, S. Leach², J. A. Pasco¹

¹Deakin University, ²GMHBA, Geelong, Australia

Objective: We have reported links between physical and mental health decline, but not with cognition. This study examined body composition (fat and lean mass), muscle strength and muscle quality (MQ) in relation to cognitive function in older men.

Methods: For 176 men (ages 60-92 y) in the Geelong Osteoporosis Study, we measured total fat mass (FM, kg), total lean mass (LM, kg), appendicular lean mass (ALM, kg) and arm lean mass (kg) by DXA (Lunar). FM, LM and ALM were also indexed to height (m²). Maximum handgrip strength (HGS, kg) was measured by dynamometer (Vernier, LoggerPro3) and MQ calculated as HGS/arm lean mass. Cognitive function was assessed in four domains: psychomotor function, visual identification/attention, visual learning and working memory/attention (CogState-Brief-Battery) and a composite score calculated, for overall cognitive function (OCF). Higher scores represent better performance. Associations

between fat/muscle parameters and OCF were tested using Pearson correlation, and multivariable regression analyses after accounting for age and height.

Results: LM, HGS and MQ declined with age ($r=-0.19, -0.40, -0.28$, respectively, all $p<0.012$). OCF also declined with age ($r=-0.35$, $p<0.001$) and was positively associated with ALM, HGS and MQ ($r=0.19, 0.28, 0.23$, all $p<0.01$); weak associations were apparent with LM and ALM/height² (both $r=0.15$, $p<0.056$) and none with FM ($r=0.11$, $p=0.145$) or FM/height² ($r=0.08$, $p=0.288$). After age adjustment, positive associations persisted between OCF and ALM ($\beta=0.018$, $p=0.044$), HGS ($\beta=0.018$, $p=0.030$) and MQ ($\beta=0.117$, $p=0.046$); height did not contribute to models.

Conclusion: ALM, HGS and MQ were positively associated with cognitive function, independent of age; however, there was little evidence of an association between FM and cognition. Cognitive decline in tandem with loss of muscle mass, strength and quality could place the ageing individual at increased risk for personal injury, poor mobility and loss of independence.

P653

PRIOR FRACTURE AND PARENTAL HIP FRACTURE ARE ASSOCIATED WITH LOWER BONE MATERIAL STRENGTH INDEX IN MEN

P. Rufus-Membere¹, K. Holloway-Kew¹, A. Diez-Perez², M. Kotowicz¹, J. Pasco¹

¹Deakin University, Geelong, Australia, ²Hospital del Mar-IMIM, Autonomous University of Barcelona, Barcelona, Spain

Objectives: Impact microindentation (IMI) is an emerging technique for measuring bone material strength index (BMSi) in vivo. However, it is unclear how well BMSi discriminates fracture risk. We aimed to investigate if BMSi was associated with prior fracture and parental hip fracture, which are recognised risk factors for fracture.

Methods: For 357 men (ages 33-96 y) from the Geelong Osteoporosis Study, BMSi was measured on the tibial plateau using the OsteoProbe according to international guidelines¹. Prior fracture was any low trauma adult fracture (excluding toe, skull, finger, face) and was self-reported and confirmed radiologically where possible. Parental hip fracture was self-reported. Associations between BMSi and fracture risk factors were identified using Pearson's correlation and 2-sample t-tests. Multiple regression models were used to determine whether differences in BMSi were independent of age and anthropometry.

Results: There were 38 (11.9%) men with prior fracture and 34 (9.5%) with parental hip fracture. Mean (\pm SD) for BMSi, age and BMI were 82.6 \pm 6.9, 63.3 \pm 13.8 y and 26.8 \pm 3.2 kg/m² respectively. Inverse associations were observed between BMSi and age ($r=-0.131$, $p=0.014$), weight ($r=-0.109$, $p=0.040$) and BMI ($r=-0.083$, $p=0.001$), no correlations were detected between BMSi and height ($r=0.087$, $p=0.10$). Mean BMSi for men with and without prior fracture were (80.2 \pm 6.9 vs. 82.8 \pm 6.1, $p=0.024$) and parental hip fracture (80.1 \pm 6.1 vs. 82.8 \pm 6.9, $p=0.029$). Best model for BMSi in association with prior fracture included age, and for parental fracture, age and BMI. Adjusted mean(\pm se) BMSi \pm prior fracture (80.5 \pm 1.1 vs. 82.8 \pm 0.4, $p=0.044$) and for parental fracture, (79.9 \pm 1.2 vs. 82.9 \pm 0.4, $p=0.015$).

Conclusions: Prior fracture and parental hip fracture were both associated with lower mean BMSi in men from the general population. These data suggest that IMI may be useful for differentiating fracture risk.

Reference: 1Diez-Perez A et al. Bone Rep 2016;5:181

P654

INTRODUCING A FRACTURE LIAISON SERVICE: ESTABLISHING BASELINE ABSOLUTE RISK OF SUBSEQUENT FRACTURE

S. Frost¹, A. Kelly², J. Gaudin², C. White³, J. Center⁴, J. Eisman⁴, T. Nguyen⁴, G. Hassett²

¹South Western Sydney Centre for Applied Nursing Research, Western Sydney University, Liverpool, ²Department of Rheumatology, Liverpool Hospital, Liverpool, ³Department of Endocrinology Prince of Wales hospital, Randwick, ⁴Garvan Institute of Medical Research, Sydney, Australia

Introduction: One in three women and one in five men are expected to experience a minimal trauma fracture after the age of 50 y, which increases the risk of subsequent fracture. Importantly, timely diagnosis and optimal treatment in the form of a fracture liaison service (FLS), has been shown to reduce this risk of another fracture. However, the baseline risk of subsequent fracture among this group of FLS patients has not been well described. Therefore, this study aims to estimate the absolute risk of subsequent fracture among women and men aged 50 y or more, presenting to a hospital with a minimal trauma fracture.

Methods: Women and men aged 50 y or more with a minimal trauma fracture, presenting to hospitals across the South Western Sydney Local Health District (SWSLHD), Australia, between January 2003 and December 2017 were followed to identify representation to a hospital with a subsequent fracture. The absolute risk of refracture was estimated by taking into account the competing risk of death.

Results: Between January 2003 and December 2017 - 15,089 patients presented to the emergency departments of the five hospitals in the SWSLHD (11,150, women [74%]), with minimal trauma fractures. Subsequent fractures identified during the follow-up period (median=4.5 years [IQR, 1.6-8.2 y]), occurred in 2,023 (13.4%) patients. Death during the initial hospital stay, or during a subsequent hospital visit was recorded among 1645 patients (10.9%). Women were observed to have 7.1% risk of subsequent fracture after 1 y, following an initial fracture; and, the risk of subsequent fracture after 1 y was 6.2% for men. After 5 y the rate among women was 13.7%, and 11.3% for men, respectively. Cumulative risk of subsequent fracture when the initial fracture is classified a proximal or distal are also presented.

Conclusion: In the context of implementing a fracture liaison service, this study has estimated the baseline risk of subsequent fracture among the women and men presenting to hospital with minimal trauma fractures. Importantly, this information can be used to communicate risk to patients deciding to participate in osteoporosis refracture prevention programs, and highlight the need for screening, and initial of treatment when indicated, once a minimal trauma fracture has occurred to prevent a subsequent fracture.

P655

SARCOPENIC OBESITY AND INCREASED LIKELIHOOD OF ANXIETY SYMPTOMSJ. A. Pasco¹, M. C. Tembo¹, S. X. Sui¹, K. L. Holloway-Kew¹, N. K. Hyde¹, A. L. Stuart¹, L. J. Williams¹¹Deakin University, Geelong, Australia

Objective: Skeletal muscle activity and adipocytes modulate immune function and redox status that impact neurological pathways. We aimed to determine associations between the components of sarcopenic obesity with anxiety symptomatology.

Methods: This cross-sectional study involved 313 postmenopausal women aged >60 y, participating in the Geelong Osteoporosis Study; median age 70.6 y (IQR 65.0-75.8), mean weight 73.6 kg (\pm SD 15.1). Sarcopenia was identified as low DXA-derived appendicular lean mass expressed relative to height (rALM <6.0 kg/m², Lunar) in combination with low handgrip strength (maximum HGS <16 kg, Jamar) according to EWGSOP2 criteria. Obesity was identified as high DXA-derived body fat mass, expressed as the fat mass index (FMI; FMI >11.8 kg/m²). Anxiety symptomatology was documented via the Hospital Anxiety and Depression Scale (HADS-Anxiety score >8). Multivariable logistic regression was used to determine the likelihood of anxiety in association with sarcopenic obesity. Potential confounders included age, physical inactivity, smoking, alcohol consumption and energy intake.

Results: Among 75 women with anxiety, compared to 238 without, 25 (33.3%) vs. 55 (23.1%) ($p=0.08$) had low-rALM, 13 (17.3%) vs. 32 (13.5%) ($p=0.4$) had low-HGS, 9 (12.0%) vs. 11 (4.6%) ($p=0.03$) had sarcopenia, 45 (60.0%) vs. 125 (52.5%) ($p=0.3$) were obese, 3 (4.0%) vs. 1 (0.4%) ($p=0.04$) had sarcopenic obesity. There was evidence to suggest that sarcopenia and obesity were independently associated with anxiety: sarcopenia OR 3.35 (95%CI 1.29-8.72) and obesity OR 1.56 (0.90-2.71). There was no sarcopenia*obesity interaction and no confounders identified.

Conclusion: These findings warrant further research to consider the extent of muscle deficit, obesity severity and anxiety subtypes. However, our data suggest that sarcopenia, particularly the low lean mass component, in conjunction with obesity tended to be associated with anxiety symptomatology, and that their effects are additive rather than multiplicative.

P656

STRUCTURAL CHANGES OF MYOCARDIUM IN WOMEN WITH OSTEOPOROSIS IN COMBINATION WITH ISCHEMIC HEART DISEASES. Tsarenok¹, V. Gorbunov¹, T. Aksenova, O. Makkaveeva², S. Verkhoturova²¹Chita State Medical Academy, ²Railway Hospital in Chita, Chita, Russia

Objective: To determine the characteristics of structural changes of myocardium and aorta by echocardiography in women with ischemic heart disease (IHD) cause-specific from the presence of osteoporosis.

Methods: we examined 170 postmenopausal women aged from 57-78. Inclusion criteria: female, age over 50 y, the presence of menopause, the presence of IHD. Exclusion criteria: endocrine system disease, severe heart failure, respiratory insufficiency, secondary osteoporosis. All women were divided into 2 groups: group 1 – 72 women with proven diagnosis of osteoporosis and IHD, group 2 – 98 patients with isolated IHD (comparison group). IHD was represented by 2 forms: angina pectoralis and post infarction cardiosclerosis. The frequency of post infarction cardiosclerosis was not statistically different between groups. Also the group were comparable in age, bodyweight index, levels of peripheral (office) blood pressure.

Results: In women with osteoporosis and IHD we revealed higher value of interventricular septum thickness ($p=0.034$), left ventricle posterior wall ($p=0.004$), and the relative thickness of left ventricular posterior wall ($p=0.00038$) Table 1.

Table 1. Echocardiography characteristics in women with ischemic heart disease with and without osteoporosis

Parameters	1 st group, n=72	2 nd group, n=98	p
Right ventricle end-diastolic dimensions, mm	27.54±2.77	27.26±2.24	0.65
Left ventricle end-diastolic dimensions, mm	44.18±5.55	43.73±5.64	0.88
Interventricular septum thickness, mm	12.71±3.44	11.79±1.57	0.034
Left ventricular posterior wall thickness, mm	11.92±2.9	11.39±1.55	0.004
Left ventricular relative wall thickness, mm	0.56±1.14	0.53±0.55	0.0038
Left ventricular mass, g	197.68±52.35	178.44±55.26	0.19
Left ventricular mass index, g/m ²	109.05±24.93	107.33±34.14	0.17
Ejection fraction,%	70.33±11.43	69.78±8.55	0.17
Postsystolic shortening,%	40,72±9,33	36,86±13,2	0,65
Systolic volume, ml	62.41±19.47	55.72±15.69	0.12
Cardiac output, ml	4.14±0.84	3.83±1.77	0.042
Peak velocities of early and late filling ratio (E/A), a.u.	1.13±0.58	1.08±0.35	0.47
E-wave deceleration time (DTe), ms	215.0±40.52	203.16±42.16	0.0024
Length of the isovolumetric relaxation (IVRT), ms	113.5±32.27	91.66±12.88	0.0001
Local wall motion abnormalities, n (%)	8(11.1)	8(8.2)	0.51

An increasing rate of left ventricular hypertrophy was observed in patients with combination of osteoporosis and IHD – 51.4% vs. 39.8% in women with IHD without osteoporosis (p=0.002). Osteoporosis was associated with a higher incidence of diastolic left ventricular dysfunction: 90% vs. 70.4%, as well as with pathological types of left ventricular remodeling (p=0.01). Concentric remodeling type dominated among women with combined pathology (p=0.09). A higher incidence of aorta calcification 1.86 times (p=0.00013) and calcified aortic stenosis (13.8% vs. 4.08%, p=0.02) were noted in patients with osteoporosis.

Conclusion: We found that osteoporosis in postmenopausal women was associated with an increasing of heart remodeling parameters, an increasing of diastolic dysfunction frequency and pathological types of left ventricle geometric remodeling with prevalence of concentric type remodeling. Patients with osteoporosis had a higher prevalence of aortic calcification and calcified aortic stenosis.

P657

HIP STRUCTURE IN ATYPICAL FEMUR FRACTURES: A CASE-CONTROL DENSITOMETRIC STUDY

H. Nguyen¹, A. Lakhani¹, C. Shore-Lorenti¹, A. Vincent², F. Milat³, P. R. Ebeling¹

¹Department of Medicine, Monash University, ²Monash Centre for Health Research and Implementation, Monash University, ³Hudson Institute of Medical Research, Clayton, Victoria, Australia

Objectives: Atypical femur fractures (AFFs) are rare complications of antiresorptive drugs (bisphosphonates/denosumab). Biomechanical strain and femoral morphology have been implicated in the development of AFFs¹. We aimed to describe hip geometric parameters in an AFF cohort at a tertiary hospital.

Methods: Cross-sectional case-control study comparing DXA-derived femoral parameters of 18 women with AFF (cases were confirmed using ASBMR Task Force criteria¹) to 18 women who sustained typical osteoporotic femur fractures at Monash Health, Victoria, Australia from 2009-2017. Data extraction from hospital records and GE Lunar Prodigy densitometer [femoral neck (FN) BMD, FN T-score, height, BMI]. Hip structural analysis used Advanced Hip Analysis software. Analysis included Mann Whitney U test and logistic regression.

Results: Median(range) age of AFF cases and control group were 72 (56-81) and 68 (53-81) y, respectively. Antiresorptive therapy use was more common in AFF cases than controls (100% vs. 33%, p<0.001). Median comorbidity severity index² and Asian ethnicity rates were similar between groups. Compared with controls, AFF cases were shorter [151.7 (145.9-159.6) vs. 156 (144.8-168.0) cm, p=0.038] with higher BMI [(27.8 (20.8-36.2) vs. 22.2 (17.4-32.6) kg/m², p=0.003]. After adjustment (age, antiresorptive use, Asian ethnicity, height), AFF cases had higher FN BMD, FN T-score, and lower FN buckling ratio (BR) conferring lower risk of FN fragility fractures than controls (Table). Intertrochanteric (IT) cortical width, IT cortical ratio, and femoral shaft (FS) cortical ratio was higher in AFF cases than controls (Table). FN BR, IT cortical width and IT cortical ratio remained significant after adjustment for BMI.

Femoral parameters	AFF cases N=18	Control group N=18	P
FN BMD	0.793(0.554-0.969)	0.688 (0.354-0.873)	0.032*
FN T-score	-1.6(-3.5 - -0.1)	-2.4 (-5.2 - -0.9)	0.032*
FN BR	2.71(1.67-5.13)	5.17 (2.48 - 7.66)	0.004*#
FN cortical width	5.70(3.44-9.07)	3.63(2.78-7.20)	0.016
FN cortical ratio	19.45(11.36-31.76)	11.44(8.33-22.25)	0.009
IT cortical width	3.79(2.39-4.85)	2.49(2.17-5.00)	0.014*#
IT cortical ratio	7.54(4.49-9.85)	5.00(4.22-8.97)	0.006*#
FS cortical width	4.33(3.30-8.67)	3.90(2.12-5.70)	NS
FS cortical ratio	14.77(10.38-29.50)	12.67(7.76-20.65)	0.047*

Data expressed as median(min-max)

*p<0.05 after separate adjustments for age, antiresorptive use, Asian ethnicity and height

#p<0.05 after adjustment for BMI

Conclusion: AFF cases have favourable FN parameters and higher IT and FS cortical parameters than controls. These findings may provide insight into densitometric risk profile and pathogenesis of AFFs. Future longitudinal studies controlling for antiresorptive use are needed to examine the role of hip geometry as an AFF risk prediction tool.

References:

¹ Shane et al. J Bone Miner Res 2014;29:1

² Silverman et al. Osteoporos Int 2016;27:75

P658

COST-EFFECTIVENESS ANALYSIS OF FRACTURE LIAISON SERVICE (FLS) MODEL OF CARE FOR HIP FRACTURE PATIENTS IN TAIWAN

R.-S. Yang¹, L.-N. Chien², Y.-F. Li³, T.-H. Yang⁴, W.-J. Huang⁵, H.-Y. Tsai⁶, Z. Zhao⁷, D.-C. Chan⁸

¹Department of Orthopedics, National Taiwan University Hospital, Taipei, ²School of Healthcare Administration, College of Management, Taipei Medical University, Taipei, ³Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, ⁴Department of Orthopedics, Hsinchu Branch, National Taiwan University Hospital, Hsinchu County, ⁵Department of Geriatrics and Gerontology, National Taiwan University Hospital, Taipei, ⁶Amgen Taiwan Ltd, Taipei, Taiwan, ⁷Amgen Inc, Thousand Oaks, USA, ⁸Superintendent Office, National Taiwan University Hospital Chu-Tung Branch, Hsinchu County, Taiwan

Objectives: In Taiwan, the cost-effectiveness of a less intensive fracture liaison service (FLS) is unknown. Thus, the objectives of this study was 1) to examine health resource use of hip fracture patients in hospital-based post-fracture FLS program comparing to patients who received usual care; 2) to perform a cost-effectiveness analysis of the FLS program in Taiwan among the patients newly sustained hip fractures.

Methods: This study included patients with newly diagnosed hip fractures who were enrolled in hospital-based FLS program in NTUH from January 2014 to June 2016 with 2 y of follow-up data. Patients who received usual care were selected by propensity score matching using baseline characteristics in claim-based dataset (NHIRD) from January 2012 to December 2013. Each patient was followed up for 2 y. The net monetary benefit (NMB) regression framework was conducted to evaluate cost-effectiveness.

Results: The number of the patients enrolled in FLS program was 179, and 1697 patients identified as receiving usual care. The baseline characteristics between two groups were similar. Overall, patients enrolled in FLS had better overall survival days and refracture survival days. FLS program intervention was cost-effective compared to usual care, regardless of the WTP from 1 time of the GDP per capita (approximately \$65 US) to infinity. Similar results were observed for the hip refracture free survival days and the overall survival days.

Conclusion: This population-based study showed that the FLS program was cost-effective. The government may adopt the program to not only reduce the refracture but also prolong the overall survival among patients who had a history of hip fracture.

Acknowledgment: This study was supported by research funding from Amgen Taiwan Ltd. The funding of Amgen Taiwan Ltd. is for academic research only and not for commercial purposes.

P659

ROMOSUZUMAB OR ALENDRONATE FOR FRACTURE PREVENTION IN EAST ASIAN PATIENTS: A SUBANALYSIS OF THE PHASE III, RANDOMIZED ARCH STUDY

E. M. C. Lau¹, R. Dinavahi², Y. C. Woo³, C.-H. Wu⁴, J. Guan⁵, J. Maddox², C. Tolman⁶, W. Yang², C. S. Shin⁷


¹Hong Kong Orthopaedic and Osteoporosis Center for Treatment and Research, Hong Kong, China, ²Amgen, One Amgen Center Drive, Thousand Oaks, California, USA, ³Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China, ⁴Department of Family Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Chinese Taipei, ⁵UCB Pharma, Brussels, Belgium, ⁶Amgen Asia, Hong Kong, China, ⁷Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea

Objectives: Romosozumab (Romo) is a sclerostin antibody and bone-forming agent that exerts a dual effect on bone, increasing bone formation and decreasing bone resorption. In the global, double-blind, Phase III ARCH (NCT01631214) study, Romo followed by alendronate (ALN) in postmenopausal women with osteoporosis at high fracture risk showed superiority in reducing the risk of new vertebral, clinical and nonvertebral fractures vs. ALN alone.¹ We report the efficacy and safety of Romo vs. ALN in East Asian patients enrolled in ARCH.


Methods: ARCH enrolled 4093 postmenopausal women aged 55-90 y with high fracture risk (BMD T-score \leq -2.5 at total hip [TH] or femoral neck [FN] and either \geq 1 moderate/severe or \geq 2 mild vertebral fractures [VF], or BMD T-score \leq -2.0 at TH or FN and either \geq 2 moderate/severe VF or hip fracture sustained 3-24 months prior). Patients were randomized 1:1 to Romo 210 mg QM or ALN 70 mg QW for 12 months, followed by open-label ALN in both groups. Primary endpoints were cumulative incidence of new VF at 24 months and clinical fracture at primary analysis (clinical fractures in \geq 330 patients and all patients completed month 24 visit).

Results: 275 patients from Hong Kong, Republic of Korea and Taiwan were included in this *post hoc* subgroup analysis. Romo followed by ALN reduced the risk of new VFs at 24 months by 60% and clinical fractures at primary analysis by 44% vs. ALN alone, although differences were not statistically significant as the analysis was not powered to demonstrate differences between subgroups (Figure). Romo followed by ALN significantly increased BMD at 24 months from baseline by 9.0% at the lumbar spine, 3.3% at TH and 3.0% at FN vs. ALN alone. Efficacy outcomes were generally similar between the global and East Asian populations. Adverse event (AE) rates, including those of positively adjudicated serious cardiovascular AEs (1.4% vs. 1.6% at 12 months for ALN vs. Romo), were similar across treatment groups.

(A) Cumulative incidence of new vertebral fractures through 24 months



(B) Cumulative incidence of clinical fracture at time of primary analysis*



*The primary analysis of the ARCH study was performed when clinical fracture events had been confirmed in at least 330 patients and all patients had completed the month 24 visit.

Conclusion: Romo followed by ALN reduced the risk of new vertebral and clinical fractures vs. ALN alone among East Asian patients in ARCH.

Reference:

1. Saag KG et al. N Engl J Med 2017;377:1417

Disclosures: Funded by Amgen Inc, Astellas Pharma, and UCB Pharma. CW has received honoraria from Amgen. RD, JM, CT and WY are employees of Amgen. JG is an employee of UCB Pharma.

P660

RELATIONSHIP BETWEEN INAPPROPRIATE MEDICATION USE AND FALLS

P. Kucukdagli¹, G. Bahat¹, T. Erdogan¹, O. Yilmaz¹, B. Turkmen¹, M. A. Karan¹

¹Istanbul University/Istanbul Faculty of Medicine/Internal Medicine/Division of Geriatrics, İstanbul, Turkey

Objective: Polypharmacy and inappropriate medication use in older adults is a major public health problem associated with morbidity and mortality. Aging is associated with metabolic changes and decreased drug clearance, increased drug-drug interactions, prescribing cascades, and potentially inappropriate medications (PIMs). The purpose of this study was to evaluate the association

between a wide variety of common geriatric syndromes and potentially inappropriate medication use among older adults detected by Beers 2012 criteria.

Methods: Study participants were recruited and randomised among patients admitted to Istanbul Medical School Geriatrics outpatient clinic between June 2000-June 2014 and were evaluated retrospectively by a geriatrician using the patients' records according to Beers 2012 criteria.

Results: Among the 667 enrolled patients, 421 (63.1%) were women and 246 (36.9%) were men. Presence of PIM was not associated with age or sex. Polypharmacy (OR 4.3, 95%CI 2.8-6.4, $p < 0.001$), presence of fall in the previous year (odds ratio (OR) 3.2, 95%CI 2.1-4.7, $p < 0.001$), depression (OR 2.6, 95%CI 1.7-3.9, $p < 0.001$) constipation (OR 2.0, 95%CI 1.2-3.5, $p = 0.008$), malnutrition (OR 1.5, 95%CI 1.1-1.9, $p = 0.006$) were independently associated with the use of PIM.

Conclusion: Identifying the association of inappropriate medication use with common geriatric syndromes in older people can help to prevent, delay, and reduce PIM use and related adverse health outcomes. Especially falls are associated with the risk of osteoporotic fractures in older patients. Falls are a marker of frailty, immobility, and acute and chronic health impairment in older persons. Therefore PIM use should be evaluated in older patients with falls.

P661

RUSSIAN VALIDATION OF THE SARQOL®: A QUALITY OF LIFE QUESTIONNAIRE SPECIFIC TO SARCOPENIA

Y. Safonova¹, O. Lesnyak¹, E. Zotkin², I. Baranova³, A. Suleymanova³

¹Northwestern State Medical University named after I. Mechnikov, St. Petersburg, ²Nasonova Research Institute of Rheumatology, Moscow, ³National Medical Research University named after N.I. Pirogov, Moscow, Russia

Objectives: The aim of this cross-sectional study was to translate and adjust the SarQoL into Russian and to standardize the validity of this method for the assessment of sarcopenic individuals in Russia with regard to psychometric properties. The English version was used for the translation process.

Methods: A total of 100 community-dwelling subjects aged 74.0 ± 6.5 y (70% females) were studied, with 50 participants being diagnosed sarcopenic. Sarcopenia was diagnosed according to the algorithm proposed by the European Working Group on Sarcopenia in Older People (EWGSOP, 2010). The translation and crosscultural adaptation was carried out in five phases according to specific standard guidelines. There were no major linguistic issues in the translation process. To test the psychometric performance, discriminative power, internal consistency, floor and ceiling effects, and construct validity analyses were made. We assessed the correlation between SarQoL and similar/ different domains of other two QoL questionnaires (SF-36 and EQ-5D).

Results: The data confirmed a good discriminant validity, i.e., significantly lower scores for all domains (reduced global QoL in sarcopenic subjects compared to nonsarcopenic ones: 50.65 ± 14.23 vs. 75.10 ± 14.46 , $p < 0.001$), high internal consistency (Cronbach's alpha coefficient was 0.924), as well as good construct validity with 81.4% of hypotheses confirmed. The moderate correlation of the SarQoL scores with those of other questionnaires (SF-36 and EQ-5D) that are supposed to have similar dimensions indicated the consistent construct validity of the SarQoL ($p < 0.0001$). No floor/ceiling effects were found. An excellent agreement was found between the test and the retest (intraclass coefficient correlation = 0.935, 95%CI 0.91-0.96).

Conclusions: The first Russian version of the SarQoL questionnaire is valid and consistent and therefore may be used with reliability for clinical and research purposes regarding QoL assessment of sarcopenic individuals

P662

AMYGDALIN AFFECTS VIABILITY, CELL SIZE, AND GENE EXPRESSION IN CULTIVATED HUMAN OSTEOBLASTS

R. Omelka¹, V. Kovacova¹, M. Adamkovicova¹, V. Mondockova¹, A. Sarocka¹, P. Sranko¹, A. Kolesarova², M. Martiniakova¹

¹Constantine the Philosopher University in Nitra, ²Slovak University of Agriculture in Nitra, Nitra, Slovakia

Objective: Amygdalin (AMG) is often used as an alternative cancer treatment. However, little is known about the impact of AMG on nontumor cells. This study was designed to investigate the effect of AMG on cultivated human osteoblasts.

Methods: Primary human osteoblasts (PromoCell) were incubated without (control group) or with different concentrations of amygdalin (100, 1 000 and 10 000 $\mu\text{g} \cdot \text{ml}^{-1}$) in growth medium for 72 h. Cell viability was analysed by CCK8 assay (Merck), morphometry was determined using light microscopy. An expression of 10 selected genes associated with osteoblast-specific pathways, oxidative stress and apoptosis was assessed by real-time PCR (RT2 Profiler PCR Array, Qiagen).

Results: AMG at the highest concentration decreased osteoblast viability (-27.3%; $P < 0.05$) and reduced their size (-23.2%; $P < 0.05$). The BGLAP, TNFSF11, and WNT5A genes were upregulated by 10 000 $\mu\text{g} \cdot \text{ml}^{-1}$ AMG, counting 1.31, 1.30, and 1.25 in fold change ($P < 0.05$), respectively. In contrast, this concentration of AMG decreased the expression of COL1A1 (-1.21 in fold regulation, 0.82 fold change), and ALPL genes (-2.14 in fold regulation, 0.47-fold change, $P < 0.05$). The COL1A1 gene was downregulated also at 100 $\mu\text{g} \cdot \text{ml}^{-1}$ AMG (-1.12 in fold regulation, 0.89-fold change; $P < 0.01$). No changes in expression were identified for RUNX2, BAX, CASP1, SOD1 and GPX1 genes in all experimental groups. The AMG concentration of 1 000 $\mu\text{g} \cdot \text{ml}^{-1}$ did not affect expression of any analysed gene.

Conclusion: AMG in a high concentration negatively affected size and viability of osteoblasts; however, mechanisms other than BAX and CASP1 pathways were involved. The effect of AMG on

gene expression showed reduced collagen production, bone mineralization and accelerated bone resorption without modulation of oxidative stress.

Acknowledgements: The study was supported by projects VEGA 1/0653/16 and VEGA 1/0505/18.

P663

FALLS AND RELATED FACTORS

P. Kucukdagli¹, G. Bahat¹, T. Erdogan¹, O. Yilmaz¹, B. Turkmen¹, M. A. Karan¹

¹Istanbul University/Istanbul Faculty of Medicine/Internal Medicine/Division of Geriatrics, Istanbul, Turkey

Objective: Falls are an important health problem in terms of medical and economic consequences that are frequently encountered in the elderly population. In addition to high mortality and morbidity, it causes long-term immobilization and associated complications. Falling injuries and osteoporotic fractures as well as the fear of falling in person; it can cause functional impairment, depression and social isolation by adversely affecting ambulation. To identify individuals at risk for falls and to take preventive measures, factors associated with falls should be identified. In this study, we aimed to investigate the factors associated with falls in older patients.

Methods: Study participants were randomized and recruited among patients admitted to Istanbul Medical School Geriatrics outpatient clinic for the first time between June 2000-June 2014. Patients' data about number of chronic diseases and prescribed drugs, falls (in the preceding year), nutritional status, frailty and presence of polypharmacy. SPSS (statistical package for social sciences) version 21 program was used for statistical analysis.

Results: Among the 300 patients, 198 (% 66) were women and 102 (34%) were men. The mean age was 75,6±6.8 years. Prevalence of falls was% 39 (117). Frailty, polypharmacy and malnutrition were associated with the presence of falls. In regression analysis frailty was independently associated with falls (p=0.11).

Conclusion: The results of our study showed that falls are independently associated with frailty. Clinicians should routinely assess the risk of falls, particularly in frail older people, and regulate underlying modifiable risk factors.

P664

COMPARISON BETWEEN 3D-SHAPER® ANALYSIS AND STANDARD 2D DXA SCAN OF THE PROXIMAL FEMUR

A. Gerganova¹, N. Temelkova¹, K. Sirakova², K. Temelkova³, P. Popivanov¹

¹Department of Clinical Densitometry, University Hospital "Alexandrovska", ²Department of Imaging Diagnostics, Medical Faculty, Medical University, ³University Hospital for Children's Diseases "Ivan Mitev", Sofia, Bulgaria

Objective: The fracture resistance is mainly determined by volumetric, rather than areal bone mass, but it only could be evaluated by quantitative computed tomography (QCT). The 3D-SHAP-

ER software provides volumetric models of the proximal femur shape and bone density from anteroposterior DXA scans, which parameters are profoundly correlated with QCT. Our aim was to assess the correlation between volumetric BMD (vBMD) at proximal femur derived from 3D-SHAPER software and respective DXA measurements.

Methods: In this pilot retrospective study were included 119 scans of 40 Caucasian white healthy women, between 40-60 y of age, with BMI between 21-30 kg/m². In the research were not included patients with diseases or on medication that deteriorate bone health. All of them have undergone a DXA scan at proximal femur, performed on a DXA machine Hologic Discovery A, which was subsequently analysed with 3D-SHAPER software (version 2.8.0, Galgo Medical S.L, Barcelona, Spain). It was used to obtain a 3D QCT-like patient-specific model of the proximal femur.

Results: Our data shows powerful correlation between DXA BMD at total hip and trabecular vBMD (mg/cm³) – r=0.86, p=0.000; integral vBMD (mg/cm³) – r=0.868, p=0.000; and with surface density total (sdensTotal, mg/cm²) – r=0.920, p=0.000. Statistically significant association was confirmed also between DXA BMD at neck and trabecular vBMD – r=0.826, p=0.000; integral vBMD – r=0.766, p=0.000, and with sdensTotal – r=0.732, p=0.000.

Conclusion: There is a robust correlation between 3D-SHAPER analysis and standard 2D DXA scan of the proximal femur. Limitations of the study: The design of the study obscured the advantages of the 3D-SHAPER analysis.

Acknowledgements: The research could not have been realized without the provided from Galgo Medical S.L. 3D SHAPER software.

P665

3D-SHAPER® ANALYSIS OF VOLUMETRIC BMD AT PROXIMAL FEMUR DURING MENOPAUSAL TRANSITION

A. Gerganova¹, N. Temelkova¹, K. Sirakova², K. Temelkova³, P. Popivanov¹

¹Department of Clinical Densitometry, University Hospital "Alexandrovska", ²Department of Imaging Diagnostics, Medical Faculty, Medical University, ³University Hospital for Children's Diseases "Ivan Mitev", Sofia, Bulgaria

Objective: The standard reference BMD curves of DXA manufacturers express BMD as a function of calendar age, but in our preceding study a better correlation was observed between BMD at proximal femur and onset of menopause, rather than with calendar age. Our aim was to assess volumetric BMD (vBMD) at proximal femur during menopausal transition and its dependence on calendar age or onset of menopause.

Methods: In this pilot retrospective study was performed a 12-y follow-up of 40 (119 scans) Caucasian white healthy women, between 40-60 y of age, with BMI between 21-30 kg/m². Exclusion criteria are early onset of menopause and risk factors for secondary osteoporosis. All of them have undergone a DXA scan at proximal femur on Hologic Discovery A, at baseline and follow-up during peri- and postmenopausal period (-5/+5 years after the on-

set of menopause). Their scans were subsequently analysed with 3D-SHAPER software (version 2.8.0, Galgo Medical S.L, Barcelona, Spain), which was used to obtain a 3D QCT-like patient-specific model of the proximal femur.

Results: In this pilot study a strong negative correlation was observed between the onset of menopause and trabecular vBMD (g/cm³) $r=-0.860$, $p=0.01$; integral vBMD (g/cm³) $r=-0.831$, $p=0.02$; and total surface density (sdensTotal) $r=-0.799$, $p=0.03$. Nevertheless, no correlation was found between calendar age and trabecular vBMD $r=0.079$, $p=0.789$; integral vBMD $r=0.165$, $p=0.573$; and sdensTotal $r=0.165$, $p=0.573$.

Conclusion: 3D-SHAPER parameters at proximal femur noticeably correlate with the onset of menopause and as expected does not depend on calendar age. Limitations of the study: Relatively small number of the cohort.

Acknowledgements: The research could not have been realized without the provided from Galgo Medical S.L. 3D-SHAPER software.

P666

PHYTOTHERAPY OF POSTMENOPAUSAL OSTEOPOROSIS

N. R. Suciu¹, F. Marc¹, M. Muresan¹, D. Zaha¹, M. Cevei¹, F. Cioara¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objective: Numerous studies indicate that phytotherapy may be a complementary treatment for postmenopausal osteoporosis [1, 2, 3, 4, 5, 7]. Much of the recent research of phytochemical influence on skeletal health has focused on polyphenols, especially the flavonoid subgroup [2, 6, 7]. The effects of these polyphenols are worthy of study considering the need for new therapies to prevent and treat osteoporosis as well as arthritic diseases. Worldwide osteoporosis estimates by WHO are 15% for those 50-59 and 70% for those over 80 [2, 6, 7, 8].

Methods: The purpose of the present study was to continue the analysis on the use and evolution of using the herbal remedies in postmenopausal osteoporosis. In our previous study [1] we examined the use of herbal products along three years, between 2011-2013. Our study showed a continuous increase in the use of herbal products. We continued this study between 2014-2018 with analysed the use and evolution of using the herbal products in postmenopausal osteoporosis in Bihor county, Romania. Medicinal plant species recommends in postmenopausal osteoporosis are: *Urtica dioica*, *Valeriana officinalis*, *Melissa officinalis*, *Equisetum arvense*, *Anethum graveolens*, *Rubus idaeus*, *Rubus fruticosus*, *Rosmarinus officinalis*.

Results: Our previous study showed a continuous increase in the use of herbal products in the studied three years (2011-2013). In that period all of the recommended postmenopausal osteoporosis herbal products consumption increases with 20% [1, 7]. The current study shows a continuous increase in the use of herbal products. All of the studied herbal products consumption increases with 35% compared to 2013 values.

Conclusions: These results are due to a better information of the target population. Patients who used phytotherapeutic remedies along with allopathic treatment observed a better symptom improvement than patients who did not use these remedies.

References:

1. Pallag A et al. *Osteoporos Int* 2014;25:P527
2. Jones DR. *Adv Food Technol Nutr Sci Open J* 2016;SE(2):S27
3. Pallag A et al. *Farmacia* 2016;64:372
4. Mraz C et al. *Farmacia* 2012;60:264
5. Pallag A et al. *Oxidative Med Cell Longevity* 2018; Article ID 306052
6. Pallag A et al. *Chim (Bucharest)* 2018;69:445
7. Țiț DM et al. *Iranian J Public Health* 2017;46:1128
8. WHO: Chronic Rheumatic Conditions (2016) www.who.int/chp/topics/rheumatic/en

P667

INFLUENCE OF DIACEREIN ON THE MECHANOSENSITIVE SIGNAL-TRANSDUCTION AND PIEZO1 IN CHONDROCYTES

L. Weigl¹, B. Lohberger², H. Kaltenecker², C. Kratschmann¹, V. Glanz¹, A. Leithner², W. Kullich³, B. Steinecker-Frohnwieser³

¹Division of Special Anaesthesia and Pain Medicine, Medical University of Vienna, Vienna, ²Department of Orthopaedics and Trauma, Medical University of Graz, Graz, ³Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Saalfelden, Austria

Objectives: For many years, diacerein in its role as a disease modifying osteoarthritis drug (DMOAD) has been used to treat osteoarthritis (OA). Symptom relief by diacerein has been substantiated by several clinical trials (1). Inhibiting the production and activity of IL-1 represents one main mechanism. Former studies revealed diacerein to be involved in influencing histamine induced Ca²⁺ release (2). Via the present study we expanded the spectrum of diacerein's mode of action, concerning delay of OA progression, by exploring the impact of diacerein on the mechanosensitive signal transduction including the integrin-FAK-MAPKs and the mechanosensitive ion channel Piezo1.

Methods: Changes in the expression level were detected by qPCR, the modulation of phosphokinases and transcription factors Stat3 and NFAT was analyzed by western blot. The expression of Piezo1 was additionally visualized by immunofluorescence. Changes in [Ca²⁺]_i were measured by the calcium imaging technique in Fura-2 loaded cells pretreated with diacerein. Yoda, as an activator of Piezo1, was applied in different concentrations to provoke calcium signaling.

Results: We were able to detect the mechanosensitive ion channel Piezo1 by qPCR and immunofluorescence in Tc28/2a cells and in primary OA chondrocytes. The observed concentration dependent increase in intracellular calcium by Yoda (activator of Piezo1) application in both cell types was driven mainly by a

Ca²⁺ influx. However, a Ca²⁺ release cannot be excluded when performing experiments on cells preincubated with cyclopiazonic acid. McHugh et al., 2013, showed that Piezo1 (Fam38A) mediates integrin activation by recruiting the small GTPase Ras to the ER (3). In our study diacerein induced a downregulation of Piezo1 (as well as KCNMA1 and TRPV5) accompanied with a reduction in ITGbeta1 expression. According to the downstream situated pathway a decrease in the activation (phosphorylation) of FAK and Stat3 was observed, while preliminary reporter assay analysis revealed increased Stat3 activity by Yoda over time.

Conclusion: From our results we conclude that diacerein might influence integrin induced mechanosensitive mechanisms by changing the expression of ion channels, and slows down their signal transduction. From the literature it is well known that mechanical stress counts as a major risk factor for OA. A reduction in sensitivity for mechanical stimulation might therefore protect chondrocytes developing an OA phenotype.

References:

- (1) Pavelka et al. Drugs Aging 2016;33:75
- (2) Steinecker et al. Osteoporos Int 2016;27:S450
- (3) McHugh et al. J Cell Sci 2010;123(Pt 1):51

P668

HYALURONIDASE SPAM1 KNOCKOUT PREVENTS SUBCHONDRAL BONE LOSS AND CARTILAGE DEGRADATION IN MICE MODEL OF OSTEOARTHRITIS

S. Lafont¹, M. Cardinal¹, T. Roels¹, C. Behets¹, D. Manicourt¹

¹IREC/MORF/UCLouvain, Bruxelles, Belgium

Objectives: In osteoarthritis (OA), subchondral bone loss and cartilage degradation are triggered by biomechanical stress and inflammatory signaling pathways. Small molecular weight fragments of hyaluronan (HA) have potent pro-inflammatory properties. Their production is due to the acid-active hyaluronidases 1 and 2, and the neutral-active hyaluronidase Spam1. Preliminary studies in mice indicate up-regulation of the expression of Spam1 in both OA chondrocytes and OA osteoblasts. Therefore, we induced knee OA in Spam1^{-/-} mice and assessed the impact of Spam1 deficiency on OA joint lesions.

Methods: We resected the medial meniscus and transected anterior cruciate ligament in the right knee of 10-week-old Spam1^{-/-} and wildtype (WT) mice. Mice were euthanized at day 0, 3, 7, 14, 28, 56 and 70 postsurgery. The right knees were analyzed by pQCT, microCT and histology. The right knee of nonoperated Spam1^{-/-} and WT mice was analyzed as control at the different experimental times and later, until 365 d.

Results: In nonoperated mice, BMD of the tibial subchondral bone was significantly lower in Spam1^{-/-} than WT from age 70-365 days. In the operated mice, microCT and histology revealed that osteophytes were significantly fewer and smaller in Spam1^{-/-} than in WT. Histological OA joint damages were less extensive in operated Spam1^{-/-} than WT mice. At day 3 postsurgery, mi-

croCT based BMD of the tibial subchondral bone was significantly decreased ($p < 0.001$) in WT mice and significantly increased ($p < 0.05$) in Spam1^{-/-} mice. The subchondral bone fraction (BV/TV) showed similar Results: -8% in operated WT mice and +14% in operated Spam1^{-/-} mice. This changes were associated with a reduction of trabecular thickness (-12%) in operated WT mice and an increase (+23%) in operated Spam1^{-/-} mice.

Conclusion: The absence of Spam1 expression contributed to counteract subchondral bone loss in the early stage of OA and to reduce OA severity during all the disease process up to 70 d postsurgery.

P670

COST-EFFECTIVENESS ANALYSES OF INTERVENTIONS TO IMPROVE OSTEOPOROSIS MANAGEMENT

J. Martin¹, M. Viprey¹, B. Castagné¹, M. Barral¹, R. Chapurlat², C. Julien³, H. Serrier³, A.-M. Schott¹

¹University Claude Bernard Lyon 1, Hesper EA7425, ²INSERM Unit 1033, Department of Rheumatology, Hôpital Edouard Herriot,

³Hospices Civils de Lyon, Pôle de Santé Publique, Lyon, France

Objective: Osteoporosis (OP) is a major public health concern leading to a large number of fractures and important economic burden. As OP management is far from meeting guidelines, interventions have been developed since 2003 to improve appropriate BMD and treatment prescriptions. A recent meta-analysis (1) showed that three types of interventions were effective, but in the current context of limited resources, it is of major importance to evaluate their efficiency. Our objective was to perform a cost utility analysis of existing effective intervention designed to improve osteoporosis management.

Methods: The two effectiveness criteria of interventions were BMD and treatment prescription. We developed a model consistent with the management of a 50 years old woman with a first fragility fracture. We adopted the collectivity perspective and chose a 30-y time horizon. Markov models with a 1-y cycle length were applied according to different patient situations: normal T-score, low T-score (<-1) not treated and low T-score treated. Analyses were conducted on 3 intervention types: structural (I), educational by exchanging (II) and educational by sending (III). Types II and III were respectively composed of two and three subtypes according to the involvement of patient and/or healthcare professional (HCP) in the intervention.

Results: Interventions type I and III (all subtypes) are cost-saving strategies. Interventions type II subtype 1 (educational intervention by exchanging, with patient involvement) had an incremental cost effectiveness ratio of €13,684 per quality adjusted life year (with a fixed €50 000 willingness-to-pay).

Conclusion: Our results suggest that structural interventions and interventions consisting in sending educational material to improve OP management are at least cost-effective and cost-saving.

Reference: (1) J Martin et al. Les interventions visant à améliorer la prise en charge de l'ostéoporose: revue de la littérature et méta-analyse. Poster affiché au 31ème congrès français de rhumatologie; 9-11 Dec 2018; Paris.

Disclosure: R. Chapurlat: speaking fees and/or research funding and/or consulting: Amgen, UCB, Lilly, Radius. J.Martin, M. Viprey, B. Castagné, M. Barral, C. Julien, H. Serrier and A.-M. Schott: nothing to declare.

P671

BONE MICROINDENTATION AND TRABECULAR BONE SCORE IDENTIFY PRIOR FRACTURE IN MEN WITH AND WITHOUT CHRONIC KIDNEY DISEASE

K. L. Holloway-Kew¹, P. G. Rufus-Membere¹, K. B. Anderson¹, M. A. Kotowicz¹, A. Diez-Perez², N. K. Hyde¹, J. A. Pasco¹

¹Deakin University, Geelong, Australia, ²Autonomous University of Barcelona, Barcelona, Spain

Objective: Patients with chronic kidney disease (CKD) are at higher risk of fracture. Studies using BMD to predict fractures in CKD patients have shown inconsistent results¹, though measures such as trabecular bone score (TBS)² and impact microindentation (IMI)³ show promise. This study determined whether these methods identify prior fracture in men with and without CKD.

Methods: Men (n=305, age 33-96 y) enrolled in the Geelong Osteoporosis Study were included. Femoral neck BMD was measured using DXA (Lunar Prodigy). TBS was determined from lumbar spine scans using TBS iNsight software (Version 2.2). BMSi was measured according to guidelines⁴. CKD was defined as an eGFR <60 mL/min/1.73m² (n=51). Prior low trauma fractures (n=32) were ascertained from radiological reports. Associations were examined using binary logistic regression, adjusting for other potential confounders (e.g., age, lifestyle factors).

Results: Higher BMSi was associated with a lower likelihood of prior fracture (odds ratio (OR) 0.949; 95%CI 0.901-0.999, p=0.046) and men with CKD were at a higher likelihood of prior fracture (OR 2.463, 1.075-5.641, p=0.041). There was no interaction between BMSi and CKD detected (p=0.773), indicating that BMSi performed similarly in identifying the likelihood of prior fracture, regardless of CKD status. Femoral neck BMD was not associated with prior fracture (p=0.280), however higher TBS was associated with lower likelihood of prior fracture (OR 0.867, 0.774-0.971, p=0.021). There were no interactions with CKD for BMD or TBS (p=0.352 and p=0.410).

Conclusions: Both BMSi and TBS were associated with prior fracture in men with and without CKD. BMD was not associated with prior fracture in this group of men. Men with CKD were at a two-fold higher likelihood of fracture.

References:

1. Torres et al. J Nephrol 2017;30:653
2. Damasiewicz et al. JBMR plus 2018;2:309
3. Perez-Saez et al. Osteoporos Int 2017;28:2723

4. Diez-Perez et al. Bone Rep 2016;5:181

P672

THE RELATIONSHIP BETWEEN SUPPLEMENTATION OF CHOLECALCIFEROL IN VARIOUS DOSES AND PTH LEVELS IN PATIENTS WITH TYPE 2 DIABETES AND DEFICIENCY/INSUFFICIENCY OF VITAMIN D

A. Stepanova¹, T. Karonova², E. Vasileva²

¹First Pavlov State Medical University of St. Petersburg,

²Almazov National Medical Research Center, Saint-Petersburg, Russia

Objective: Common among patients with type 2 diabetes mellitus (TDM2): deficiency/insufficiency of vitamin D (VD) and secondary hyperparathyroidism are modifiable factors. We studied the relationship between the addition of different doses of cholecalciferol in deficiency/insufficiency of VD and levels of 25(OH)D and PTH in patients with TDM2.

Method: A single-center controlled clinical trial involving 62 patients with TDM2. Serum levels of 25(OH)D and PTH were studied before and after 24 weeks of treatment with cholecalciferol in dose of 5000 IU/week (Gr1, n=31, F 16) and 40000 IU/week (Gr2, n=31, F 15). Groups of patients were comparable in age, sex, BMI, duration of diabetes (more than 5 y), the level of HbA1c (up to 9%), the treatment received, which did not change during the study period. Comparisons between groups were made using covariance analysis (ANCOVA).

Results: Initially, deficiency/insufficiency was detected in 78% of the examined (n=48. 25 (OH) D 23.1±12.9 ng/ml), the level of PTH corresponded to 41.1±34.1 pg/ml. There were no differences between the groups in the levels of 25 (OH) D and PTH (p=0.7482 and p=0.6328, respectively). After 24 weeks in Gr1, level 25 (OH) D changed from 22.6±14.6 ng/ml to 28.5±13.2 ng/ml (p=0.0012), and in Gr2 from 23.7±11.1 ng/ml to 77.4±27.2 ng/ml (p=0.0001). PTH level decreased in Gr1 from 37.6±21.1 pg/ml to 30.0±15.3 pg/ml (p=0.0594), and in Gr2 from 41.1±34.1 pg/ml to 32.1±13.0 pg/ml (p=0.0967). A negative correlation was established between the level of VD and PTH (r=-0.150), however, the strength of communication is weak and the dependence of symptoms is not statistically significant (p=0.0972).

Conclusions: For starting therapy of VD deficiency/insufficiency in patients TDM2, it is preferable to use supraphysiological doses of cholecalciferol. With the normalization of VD status, there is a tendency to a decrease in the level of serum PTH.

P673

USING ARTIFICIAL INTELLIGENCE TO PREDICT INCIDENCE OF KNEE OSTEOARTHRITIS: DATA FROM THE OSTEOARTHRITIS INITIATIVE (OAI) AND THE MULTICENTER OSTEOARTHRITIS STUDY (MOST)

Z. Bertalan¹, T. Paixao¹, R. Ljuhar¹, H. P. Dimai²

¹Imagebiopsy Lab, Wien, ²Medizinische Universitat Graz, Graz, Austria

Objective: Osteoarthritis (OA) is the most common joint disorder worldwide. However, predicting its incidence at the individual level has remained a challenge. Here, we aim at a prognosis model that deploys deep learning techniques to leverage the large image datasets in OAI and MOST to predict the incidence of OA based solely on image data.

Methods: We screened conventional posterior-anterior knee radiographs of men and women from the Osteoarthritis Initiatives Study (OAI) and Multicenter Osteoarthritis Study (MOST) database for modality and digitalization artifacts, resulting in a total of 2900 images. These were classified as incident or non-incident over the observation period, based on Kellgren & Lawrence scoring (KL>1). This dataset was split into train- (1885), validation-(508) and test- (507) datasets. Class imbalance between incident/non-incident images was approximately 1:4 and was controlled by oversampling the minority class. We trained a convolutional neural network to predict OA incidence on these images, with or without clinical data (such as JSW and KL score).

Results: We show that the accuracy and sensitivity of the convolutional neural network at predicting the incidence of OA based solely on image-data is significantly above 50%.

Conclusion: This study provides evidence that applying deep convolutional neural networks has the potential to predict incidence knee OA based solely on the information contained in a conventional 2D radiograph before any radiographic signs of the disease. Adding additional clinical data could potentially further increase the prediction of OA.

P674

TRENDS IN HIP FRACTURE INCIDENCE IN WOMEN AND MEN OVER 1980-2015 IN OLMSTED COUNTY, MINNESOTA, USA

D. I. Bekele¹, A. E. Kearns¹, E. J. Atkinson¹, S. Amin¹

¹Mayo Clinic, Rochester, USA

Objective: Hip fracture incidence, which has been generally declining in North America, may have recently plateaued in women (Lewiecki, et al 2018). We examined the trends in hip fracture incidence over 1980-2015, in both women and men, from Olmsted County, Minnesota, USA.

Methods: Using the Rochester Epidemiology Project, a unique medical records linkage system that allows access to all (inpatient and outpatient) community medical records for Olmsted County residents, we identified all incident hip fractures among residents age ≥ 18 y between 1980-2015. Available medical records were reviewed by trained nurse abstractors to validate hip fractures identified and to determine their antecedent cause (pathological process [e.g., malignancy], severe trauma [e.g., motor vehicle accidents] and those due to no more than moderate trauma [by convention, equivalent to a fall from standing height or less]). Overall incidence rates were summarized separately for women and men, as well as by 5 y strata for different age groups (ages 18-39, 40-59, 60-79 and ≥ 80 y). Rates for women and men were each directly age-adjusted to the population distribution of US whites in 2010.

Results: Between 1980-2015, we identified 2488 hip fractures in women (73%, median age 84 y) and 918 hip fractures in men (27%, median age 80 y), 97.4% of which were in whites. The majority of hip fractures were due to no more than moderate trauma (88% in women; 81% in men). The overall age-adjusted annual incidence of first hip fracture over 1980-2015 was 154 per 100,000 person-years (p-y) for women and 98 per 100,000 p-y for men. Hip fracture rates have decreased overall in women since 1980 (Table), however since 2005, there has been a trend for increasing hip fractures among women age 40-59 and since 2010, a possible plateau vs. slight increase in hip fracture rate for women age ≥ 80 y. In men, there has been a general decrease in rates among those age 60-79 and, at least since 2005, in men age ≥ 80 y, but there may be a trend for increasing hip fractures since 2010 in men age 40-59 (Table).

Hip Fracture Incidence per 100,000 p-y by Age Group								
	18-39 y		40-59 y		60-79 y		≥ 80 y	
Years	Women	Men	Women	Men	Women	Men	Women	Men
1980-84	2	4	43	7	345	175	1954	1173
1985-89	4	4	32	11	329	163	1892	1188
1990-94	2	3	26	19	282	122	1914	771
1995-99	4	3	20	17	302	168	2117	1116
2000-04	2	6	10	9	199	132	1788	1300
2005-09	5	4	27	10	203	134	1320	1148
2010-15	4	4	27	29	162	125	1413	811

Conclusion: There appears to be different trends in hip fracture rates for women and men and by age groups. The factors contributing to the observed recent increases in hip fracture rates among women and men ages 40-59 warrant further attention. As suggested by others, there may be a recent plateau vs. slight increase in hip fracture rates in older women, which we noted in women age ≥ 80 y since 2010.

Reference: Lewiecki EM et al. Osteoporos Int 2018;29:717

Acknowledgements: Supported by grants AG04875 and AG034676 from the National Institutes of Health.

P675

24,25(OH)2D AS A MARKER OF VITAMIN D DEFICIENCY IN CHILDREN: A RETROSPECTIVE ANALYSIS ON 1200 CASES

A. Ladang¹, L. Hughebaert, C. Le Goff¹, E. Cavalier¹

¹CHU de Liège, University of Liege, Liège, Belgium

Objective: Vitamin D deficiency definition is a matter of intense debate. CYP24A1, the enzyme responsible for 25(OH)D degradation metabolite of 25(OH)D, has been shown to be induced when 25(OH)D levels started to reach sufficiency levels. In this study, we retrospectively measured 25(OH)D and 24,25(OH)2D, the metabolite of CYP24A1, in a population of 1200 children to evaluate the 25(OH)D threshold above which the enzyme was induced.

Method: Serum samples from 1200 children (from 5 months to 20 years old, mean age: 12±5.5 years old) who underwent a blood sampling for allergy exploration were used to simultaneously quantify 25(OH)D and 24,25(OH)2D with our previously described LCMS/MS method. The limits of quantification of 24,25(OH)2D and 25(OH)D were 0.5 and 2 ng/mL, respectively.

Results: Median levels were 20.6 ng/mL (interquartile range: 14.4; 27.2 ng/mL) for 25(OH)D and 1.40 (IQR: 0.78; 2.20) ng/mL for 24,25(OH)2D. None of the children presented a 25(OH)D/24,25(OH)2D ratio higher than 50, the threshold generally used to detect idiopathic infantile hypercalcemia. The Spearman coefficient of rank correlation between 25(OH)D and 24,25(OH)2D was 0.83 (p<0.001). The relation between 25(OH)D and 24,25(OH)2D

and the Loess representation showed an inflexion point around a 25(OH)D value of 20-25 ng/mL. Above this point, the slope is steeper, showing 2 different kinetics modes for the enzyme.

Conclusion: The relation between 25(OH)D and 24,25(OH)2D in children shows that CYP24A1, the enzyme responsible for 25(OH)D degradation has a bimodal role: below a 25(OH)D value of about 20-25 ng/mL, the slope between moieties shows a smooth increase, whereas this slope becomes steeper above the threshold. Our data confirm that the value defining vitamin D sufficiency should be around 20-25 ng/mL.

P676

NOVEL ELISA ALLOWS ACCURATE QUANTIFICATION OF INTACT FIBROBLAST GROWTH FACTOR 23 (FGF23) IN SERUM AND PLASMA

J. Wallwitz¹, E. Gadermaier¹, G. Berg², G. Himmler¹

¹The Antibody Lab GmbH, ²Biomedica Medizinprodukte GmbH, Vienna, Austria

Objective: FGF23 is a bone-derived hormone, suppressing renal phosphate reabsorption and vitamin D synthesis, and stimulating calcium reabsorption in distal tubules of the kidney. The bioactive intact FGF23 contains 251 amino acids and is glycosylated and phosphorylated. Its activity is mediated by binding to FGFR/Klotho receptor complex at the target cell surface. FGF23 is cleaved between Arg179 and Ser180 to an inactive N- and C-terminal fragment. Increased serum concentrations of intact FGF23 are a hallmark of renal phosphate-wasting diseases such as ADHR, X-linked hypophosphatemia (XLH), tumor-induced osteomalacia, or autosomal recessive hypophosphatemic rickets.

Methods: Here, we show the development, characterization and validation of a new intact FGF23 ELISA. Epitopes of both monoclonal antibodies were analyzed by overlapping linear peptides spotted to a microarray and binding kinetics were determined with biolayer interferometry. The assay was validated according to standard quality guidelines regarding its specificity, precision, robustness, accuracy, and linearity. Assay performance as well as sample measurements of apparently healthy and diseased human subject were compared with other commercially available assays.

Results: The structural epitope of the coating antibody is located in the N-terminal part of FGF23, whereas the horseradish peroxidase labelled detection antibody detects a linear epitope at the C-terminal fragment. Both antibodies bind with high affinity to the intact FGF23 molecule. The sandwich immunoassay generates highly specific signals for human intact FGF23 and does not interfere with FGF3, FGF19 and FGF21. Accuracy, parallelism, as well as intra- and inter-assay precision are within the standard of acceptance according to the international ICH quality guidelines. The intact FGF23 ELISA correlates well with other existing commercial assays ($R_2 > 0.95$) when apparently healthy and diseased samples are compared. The assay shows a broader overall calibration range and samples require a shorter incubation period when compared to other assays.

Conclusion: This well characterized ELISA can be used for the reliable measurement of intact FGF23 in human serum and plasma samples and may support further FGF23 research in the field of bone and mineral diseases.

P677

A MULTICENTER STUDY TO EVALUATE HARMONIZATION OF ASSAYS FOR N-TERMINAL PROPEPTIDE OF TYPE I PROCOLLAGEN (PINP): A REPORT FROM THE IFCC-IOF WORKING GROUP FOR THE STANDARDIZATION OF BONE MARKER ASSAYS

E. Cavalier¹, R. Eastell², N. Jorgensen³, S. Tournis⁴, S. Vasikaran⁵, J. A. Kanis⁶, C. Cooper⁷, H. Pottel⁸, K. Makris⁹, H. Morris¹⁰

¹CHU de Liège, University of Liege, Liège, Belgium, ²Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK, ³Department of Clinical Biochemistry, Rigshospitalet, Glostrup, Denmark, ⁴Laboratory for Research of the Musculoskeletal System "Th. Garofalidis", Medical School, University of Athens, Athens, Greece, ⁵PathWest Laboratory Medicine, Fiona Stanley Hospital, Murdoch, Australia, ⁶Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK, ⁷MRC Epidemiology Resource Centre, Southampton General Hospital, University of Southampton, Southampton, UK, ⁸Department of Public Health and Primary Care, KU Leuven Campus Kulak, Kortrijk, Belgium, ⁹Clinical Biochemistry Department, KAT General Hospital, Athens, Greece, ¹⁰School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia

Objective: Biochemical bone turnover markers (BTM) are useful tools to assess bone remodeling at the cellular level. N-terminal propeptide of type I procollagen (PINP) has been recommended as a reference marker for bone formation in research studies.

Methods: We describe the results of a multicenter study for routine clinical laboratory assays for PINP in serum and plasma. Four centers (Athens GR, Copenhagen DK, Liege BE and Sheffield UK) collected serum and plasma (EDTA) samples from 796 patients presenting to osteoporosis clinics. Specimens were analyzed in duplicate with each of the available routine clinical laboratory

methods according to the manufacturers' instructions. Passing-Bablok regressions, Bland-Altman plots, V-shape evaluation method and Concordance correlation coefficient for PINP values between serum and plasma specimens and between methods were used to determine the agreement between results. A generalized linear model was employed to identify possible variables that affected the relationship between the methods.

Results: We showed that both EDTA plasma and serum were suitable for PINP determination. We observed a significant proportional bias between Orion radioimmunoassay and the automated methods for PINP (Roche Cobas and IDS iSYS), which both gave very similar results. The multivariate model did not improve the excellent correlation that was observed between the methods.

Conclusion: Harmonization of PINP assays is possible by applying a correction factor or correctly assigning the values of the calibrators. This work will benefit from further collaboration between assays manufacturers and clinical laboratory professionals.

P678

THE ROLE OF VITAMIN D IN OSTEOPOROSIS

M. Muftic¹, A. Kovac¹, E. Haskovic¹, D. Avdic², M. Dzibur-Aganovic³, E. Turkic⁴, K. Miladinovic⁵

¹Faculty of Health Science University of Sarajevo, BiH, ²Faculty of Science Department of Biology; BiH, ³General hospital "Prim. dr A. Nakas", ⁴CBR Sarajevo; BiH, ⁵University clinical center; Sarajevo; BiH, Sarajevo, Bosnia-Herzegovina

According to definition of the WHO, osteoporosis is a disease that is characterized by losing mineral bone density and losing bone mass through determined period of time which leads to fractures. Vitamin D is the most important in maintaining human bone health and in specific cases it needs supplementation.

The goal of this essay, besides its educational character, is to show that the lack of vitamin D affects the quality of life of those diseased with osteoporosis, as well as the development of the disease. In accordance with that, the working and null hypothesis are set.

Working hypothesis: Subjects that have DXA diagnosed osteoporosis and that started menopause early have a lower bone mass, lower concentration of vitamin D and worse quality of life compared to the women that entered menopause later.

Null hypothesis: Subjects that have DXA diagnosed osteoporosis and that entered menopause early have the same concentration of vitamin D and the same quality of life compared to the women that entered menopause later.

The research is a comparative, descriptive and prospective study conducted within a group of women aged between 42-60. Results of the research show that subjects that entered menopause earlier have smaller concentration of vitamin D and worse quality of life compared to the subjects who started menopause in the physiologically expected time frame or later and also the statistical data, related to the bone mass, shows significant changes. This research shows that osteoporosis and vitamin D are closely connected.

P679

THE GLOBAL OSTEOARTHRITIS PATIENT PERCEPTION SURVEY (GOAPPS): A PILOT STUDY

A. Botto-Van Bemden¹, G. Eakin¹, R. M. Sciortino², M. Quintero², J. Monfort³, F. De Abajo⁴, M. Matucci⁵, P. Du Souich⁶, I. Moller⁷, D. Scotton¹, M. Bibas⁸, M. Vitaloni⁸, J. Verges⁸

¹Arthritis Foundation, Atlanta, USA, ²De Los Andes University, Merida, Venezuela, ³Del Mar Hospital, Barcelona, Spain, ⁴Alcalá University, Madrid, Spain, ⁵Florence University, Florence, Italy, ⁶University of Montreal, Montreal, Canada, ⁷Poal Institute, Barcelona, Spain, ⁸Osteoarthritis International Foundation, Barcelona, Spain

Objective: Globally, osteoarthritis (OA) is the third condition associated with disability. Science holds the key to finding better treatments and a cure. Still, it is essential to learn what's important to patients from them to implement the most effective global management of OA. We created the Global OA Patient Perception Survey (GOAPPS)-the first global survey to compare the quality of life (QoL) & patient perceptions of care across countries. The goal was to help all OA stakeholders develop a better understanding of patients' perceptions and how they may differ between cultures by collecting data on OA patient perceptions regarding their OA care.

Methods: Observational, cross-sectional study by online survey data collection translated into three languages. We collected data on patient demographics, symptomology, OA impact on daily activity and QoL to investigate the relationship between patient perceptions of their OA care, symptoms and impacts, and QoL. The questionnaire comprised of 4 sections: clinical characteristics, relationship with physicians and treatment, perception of attention, treatment and information received, and auto-evaluation of QoL. Inclusion criteria included resident age 18 or older with an OA.

Results: 1485 surveys were completed from 7 countries (1264 in English, 218 in Spanish, 3 in Italian); data prevented the analysis of cultural differences in this pilot. The majority of the respondents were female (90%), > 55 years (82%). The majority had knee (73%), hand (57%) and spine (54%) OA. Comorbidities included hypertension (50%) and obesity (43%). Patients stated limitations related to physical activities (97%), work activities (49%), social interaction (43%) and sex life (23%). The 37% of patients had emotional or mental health issues. The 58% says the doctor adequately explained the diagnosis, 55% understand the treatment options. The 41% was unsatisfied with the treatment and 79% would like access to no-drug/no-surgical treatments. While 52% of respondents rate their QoL as good, 95% would rate it better if their OA was removed.

Conclusion: The results emphasize the significant impact of OA on patients' daily activities and their desire to play an active role in managing their disease. The majority asks for access to additional options for no-drug/no-surgical treatments proving the need for an OA management improvement.

P680

EVALUATION OF THE STABILITY OF IONIZED MAGNESIUM AND IONIZED CALCIUM ON THE "STAT PROFILE PRIME PLUS ANALYZER" OF NOVA BIOMEDICAL

M. Gilson¹, F. Watar¹, S. Kovacs¹, R. Gadisseur¹, E. Cavalier¹

¹CHU de Liège, University of Liege, Liège, Belgium

Objective: Magnesium (Mg) is an abundant (mostly) intracellular ion in the human body and can be found as free ionized (65-70%), bound (35%) or complexed forms. The bound form is the most frequently measured in routine. Ionized Mg (iMg) is however the active form but is poorly described in the literature, mainly due to a lack of methods allowing its determination. Recently, Nova Biomedical developed concomitant measurement of iMg and iCa on the *Stat Profile PRIME Plus* blood gas analyzer. If it is well known that iCa is not very stable and must be measured rapidly after sampling, nothing is known about iMg stability. In this study, we aimed at evaluating iMg and iCa stability in a population of 10 healthy individuals.

Methods: Ten healthy subjects (6W/4M, mean age 32.6 yo, ranging from 26-60) agreed to participate and gave consent to give each 7 lithium heparin samples. One sample was immediately measured (T0) and the others were kept unprocessed during 1 and 4 h at room temperature (RT) and during 1, 4, 8 and 24 h at +4°C and were measured after homogenization on the Nova Biomedical Stat Profile PRIME Plus Analyzer blood gas analyzer. Evaluation of the stability was achieved with the Wilcoxon test and with the Acceptable Change Limit (ACL) and the Total Change Limit (TCL) concepts, using published results for intra-individual biological variation (CVi).

Results: iMg was shown to be unstable whatever method used for stability evaluation. iCa was shown to be stable 1 h at RT or +4°C according to ACL and TCL concepts, but not with the Wilcoxon test.

Conclusions: Our results show that storage-induced pH decrease leads to iMg and iCa concentrations increase. This increase is already significant after 1 h at RT or +4°C for iMg. Hence, iMg determination must be performed as fast as possible after sampling. We also confirm that iCa must be measured within the hour after sampling. These results are of importance for the further evaluation of clinical role of iMg.

P681

RISK FACTORS FOR OSTEOPOROSIS IN WOMEN WITH RHEUMATOID ARTHRITISA. Rudenka¹, L. Skrynnik², V. Kozlova², E. Rudenka², G. Babak³¹Belarusian Medical Academy of Postgraduate Education,²Belarusian State Medical University, ³Minsk City Clinical Hospital No. 1, Minsk, Belarus**Objective:** To identify the most important risk factors (RF) for OP in women with rheumatoid arthritis (RA); estimate 10-y risk of fractures using FRAX calculator.**Methods:** 50 women (mean age 48.15±10.89 y) with RA were examined. BMD measurement of lumbar spine (LS) and proximal femurs (PF) was performed by DXA (Lunar Prodigy, GE, USA). OP was diagnosed according WHO criteria. RA activity was determined by DAS28. 10-y risk of fracture was calculated with FRAX. Statistical analysis was carried out using the software Statistica 6.0.**Results:** The frequency of OP in the studied sample was 22.2% in LS; 11.1% in FN. 10 women (20%) had preserved menstrual function, 40 women (80%) were menopausal. In postmenopausal women OP was determined in 37.5% of cases (n 15), osteopenia in 55% (n 22), normal BMD in 7.5% (n 3). In patients with preserved menstrual OP was determined in 10% (n 1), osteopenia in 40% (n 4), normal BMD in 50% (n 5). The average age in patients with high and moderate RA activity was 57.3 (±14.3) and 61.5 (±16.02) y, respectively. The average age in patients with low RA activity or remission was 50.6 (±18.14) and 49.95 (±18.01), respectively. The sample was divided into 3 groups: I - patient with OP (n 20, mean age 66.65±13.5), II - osteopenia (n 21, mean age 63.2±12.65), III - normal BMD (n=9, mean age 48.15±10.89). Mean RA duration in group I was 174. II - 169.14. III - 91.1 month. % of patients with high RA activity in group I was 43%, II - 36%, III - 20%. Mean CRP level: I - 19.4 mg/l; II- 32.48 mg/l; III - 16.5 mg/l. Mean period of GC treatment: I - 18 months, II - 31.23; III - 16.8, average daily dose of GC during the year (I- 3 mg/d, II- 3.23 mg/d, III- 3.3 mg/d). OP in GC users was diagnosed in 56%: in LS - 89%, in FN - 11%. 10-y probability of fracture by FRAX was higher with a combination of factors: menopause, GC, family history of OP.**Conclusions:** OP in patients with RA is associated with RF of the disease itself (duration and activity of RA, duration of GC therapy, annual dose of GC), as well as with generally accepted RF OP: menopause, family history of OP. The most significant factors of FRAX questionnaire that increase the 10-y probability fractures in patients with RA are long-term GCS therapy, older age.

P682

CHONDROCYTE SIZE IS A PATHOPHYSIOLOGY MARKER IN OAP. Gratal¹, I. Prieto-Potin¹, A. Mediero¹, A. Villalvilla¹, A. Lamuedra¹, G. Herrero-Beaumont¹, R. Largo¹¹IIS-Fundacion Jimenez Diaz UAM, Joint and Bone Research Unit, Madrid, Spain**Objective:** Terminal differentiating growth plate chondrocytes are mainly characterized by an increase of their cell size and by the expression of hypertrophic markers such as type X collagen. Likely, during osteoarthritis (OA) progression, articular chondrocytes acquire a similar protein profile, and, therefore, they have been commonly described as hypertrophic-like chondrocytes. We aimed to assess whether an increase in chondrocyte size might be a feature of the articular cartilage (AC) hypertrophic-like phenotype both in experimental and in human OA. The anatomical location of these enlarged cells in the cartilage layers was also evaluated.**Methods:** New Zealand female rabbits were randomly assigned to four groups: healthy (n=8), osteoporosis (OP, n=7), OA (n=8) and OA preceded by OP (OPOA, n=8). OP was induced by ovariectomy followed by metilprednisolone administration (1 mg/kg/d) during four weeks. OA was induced by anterior cruciate ligament section and partial medial meniscectomy, lasting over a period of 6 weeks. All animals were euthanized and tibias were collected for histological analysis. Cartilage damage and chondrocyte size were assessed in Safranin-O fast green stained sections. Type X collagen and metalloproteinase-13 presence was analyzed by immunohistochemistry. Nine human samples were obtained during total knee replacement surgery to perform identical histological studies after the informed consent was gained. Both the cell size and the gene expression of type X collagen were further analyzed in primary murine chondrocyte cultures. Statistical comparisons were performed using Kruskal-Wallis and Mann Whitney tests, whereas correlations were done with Spearman test.**Results:** Mankin score showed an increase in cartilage damage in all groups in comparison to healthy rabbits. The most severe cartilage damage was observed in the OPOA group (Healthy: 1.0 (0-1.5), OP: 2.3 (1.5-4.5), OA: 8.0 (7-13), OPOA: 13 (11-16)). Chondrocyte size in OA and OPOA cartilages were greater than that in healthy cartilage, and significantly greater in OPOA vs. OA (Healthy: 133.0 (91.1-158.7), OP: 140.7 (119.7-198.3), OA: 180.9 (120.5-266.4), OPOA: 217.4 (183.6-303.5)). However, no differences in the mean chondrocyte size were found between the deepest and in the most superficial regions of the AC in any of the groups analyzed. Chondrocyte size and cartilage damage were significantly and positively correlated (p<0.001, r=0.718). In addition, chondrocyte size was also associated with immunoreactive type X collagen staining (p<0.05, r=0.444). Regarding human OA cartilage, chondrocyte size also correlated with cartilage damage and with type X collagen presence (p<0.001, r=0.921 and p<0.05, r=0.663 respectively). In cell cultures, accretion of hypertrophic markers and cell enlargement were found to occur synchronized

Conclusions: We observed an enhancement in the mean size of chondrocytes at the OA cartilage, which showed correlation with cartilage damage, both in human and in experimental OA. The enlarged chondrocytes were homogeneously distributed throughout the AC. Our results suggest that chondrocyte size could be a reliable measure of disease progression, of potential use in the histopathological assessment of OA cartilage.

P683

EFFICACY OF HIGH-INTENSITY LASER THERAPY IN THE MANAGEMENT OF LOW BACK PAIN

M. Gocevska¹, E. Nikolikj-Dimitrova¹, M. Manoleva², B. Kalcovska Ivanovska¹, V. Koevska¹, B. Mitrevska¹

¹Institute of Physical Medicine and Rehabilitation, Faculty of Medicine, "Ss Cyril and Methodius" University in Skopje,

²Institute of Physical Medicine and Rehabilitation, Skopje, Macedonia

Objective: Chronic low back pain lasts longer than 12 weeks and is characterized by pain, muscle weakness, reduced functional ability and psychosocial burden. Our aim was to compare the effects of two physical modalities, high-intensity laser against ultrasound therapy in treatment of patients with chronic low back pain.

Method: This was a prospective, monocentric, controlled clinical study comprising a group of 54 patients at the age between 25-65 y. Patients were divided into two groups: examined group of 27 patients (high-intensity laser and exercises) and control group of 27 patients (ultrasound therapy and exercises). The results were evaluated by the Numeric Pain Rating Scale, Oswestry Disability Index and Schober's test. Clinical findings were evaluated at same time points for all patients, prior to treatment, at two weeks and at three months following treatment. Statistical analyses were made in order to compare the differences between the results obtained on admission and on the two consecutive control checkups. Statistical significance was defined as a P value <0.05.

Results: The examined group showed statistically significantly better results than control group after completion the treatment (at two weeks) and at follow-up after three months.

Conclusion: This study has shown that patient with chronic low back pain treated with high-intensity laser has significantly reduced low back pain, reduced disability and improved range of motion. Its positive effect maintained for 3 months. It seems to be an effective, safe and useful physical modality in treatment of patient with chronic low back pain.

P684

AN EXPERT CONSENSUS ON THE APPROPRIATE USE OF ORAL SYSADOAs FOR THE TREATMENT OF THE OSTEOARTHRITIC PATIENT IN PRIMARY HEALTHCARE: A DELPHI STUDY

J. Monfort¹, B. Abarca², X. Carné³, S. Giménez⁴, I. Möller⁵, M. Romera⁶, M. Bibas⁷, M. Vitaloni⁷, J. Verges⁷

¹Del Mar Hospital, Barcelona, ²Sagrado Corazón Health Center, Lugo, ³Clinical Pharmacology, Clinic Hospital, Barcelona, ⁴El Limonar Health Center, Malaga, ⁵Poal Institute, Barcelona, ⁶Bellvitge Hospital, Barcelona, ⁷Osteoarthritis International Foundation, Barcelona, Spain

Objective: Clinical studies have demonstrated that osteoarthritic pain is linked to disability and quality of life (QoL). The therapeutic modalities in the treatment of osteoarthritis (OA) are numerous and despite evidence-based guidelines for OA management, agreement on treatments is lacking. There is disagreement about symptomatic slow-acting drugs (SYSADOA), use in OA clinical practice. Our objective was to prepare a consensus document on the appropriate use of oral SYSADOAs: chondroitin sulfate (CS), glucosamine (G), diacerein (D) and the combination of CS plus G for OA management in primary care (PC).

Methods: A two-round Delphi. The questionnaire validated by the expert committee (3 rheumatologists, 2 PC physicians, 1 clinical pharmacologist) included 24 questions, 206 outcomes. 15 experts constituted the Delphi panel with experience in OA treatment and the use of oral SYSADOAs. Items that reached consensus by at least 80% across both panels were included in the guidelines. The fieldwork of the study lasted 4.5 months. This study was promoted by the International Osteoarthritis Foundation (IOF) with the support of the Spanish Ministry of Health, Social Services and Equality.

Results: Consensus statements emerged: (1) patient phenotypes affects SYSADOAs action; (2) SYSADOAs are effective in primary and secondary OA, in the three first grade of knee OA, hand and hip; no appropriate for erosive hands, shoulder, spine, and ankle OA; (3) CS, G and association can reduce pain, inflammation, improve QoL and functional capacity and have a chondroprotective effect; (4) CS and D can reduce synovial membrane inflammation, all oral SYSADOAs, except D, can decrease cell death and the enzymes responsible for cartilage destruction; (5) The maximum therapeutic efficacy is reached after 3/6 months; (6) SYSADOAs can be prescribed to patients having comorbidities. There is disagreement in the prescription of oral SYSADOA in patients with liver and kidney disease.

Conclusion: This study sheds light on the appropriate use of oral SYSADOAs in PC by providing added value to published evidence. The diffusion of our results among PC practitioners will contribute to improving OA patient management protocols to ensure a personalized treatment to OA patients and to ameliorate their QoL.

P685

USEFULNESS OF TRABECULAR BONE SCORE IN DIALYSIS PATIENTS

O. Malle¹, M. Bergthaler¹, C. Müller¹, P. Krisper¹, H. P. Dimai¹, A. Kirsch¹, A. Rosenkranz¹, T. Pieber¹, B. Obermayer-Pietsch¹, A. Fahrleitner-Pammer¹

¹Medical University of Graz, Graz, Austria

Objective: The number of patients on dialysis is steadily increasing. Associated comorbidities include impaired mineral and bone metabolism leading to a higher fracture possibility, increased morbidity and mortality rate and decreased quality of life. Representing the structural condition of the bone microarchitecture DXA is often used in combination with trabecular bone score (TBS) to assess metabolic bone disorders. The aim of this study was to evaluate the clinical relevance of DXA and TBS with regard to fracture prediction in dialysis patients.

Methods: 82 patients, who underwent dialysis at the university hospital of Graz, were included. All patients were interviewed for prevalent fractures and musculoskeletal pain. Statistical analysis was performed to correlate the results of DXA and TBS with musculoskeletal pain and fracture rate considering the kind and duration of dialysis as well as the number of kidney transplantations.

Results: 36 out of 82 patients (43.9%) patients suffered from musculoskeletal pain and 32 out of 82 patients (39%) had a positive history of fracture. There was a significant linkage between dialysis duration and fracture rate ($p < 0.05$) as well as musculoskeletal pain ($p < 0.01$). No significant correlation between the DXA- and TBS-parameters and musculoskeletal pain could be established. DXA scores did not correlate with fracture history with the exception of DXA radius measurements. However, a high fracture rate in patients on dialysis significantly correlates with a low TBS ($p < 0.001$).

Conclusion: DXA has a limited role in fracture prediction in patients on dialysis. However, the TBS seems to be a better predictor regarding the fracture risk in this patient population.

P686

OMEGA-3 INTAKE IN PRESARCOPENIC AND SARCOPENIC ELDERLY

J. Dupont¹, L. Dedeyne¹, K. Koppo², S. Verschueren³, J. Tournoy¹, E. Gielen¹

¹Gerontology & Geriatrics, Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), KU Leuven, ²Exercise Physiology Research Group, Department of Movement Sciences, KU Leuven, ³Research Group for Musculoskeletal Rehabilitation, Department of Movement Sciences, KU Leuven, Leuven, Belgium

Objectives: Omega-3 polyunsaturated fatty acids (PUFAs) are gaining an important role in sarcopenia research. Higher levels of omega-3 PUFAs intake have been associated with an improvement of sarcopenia defining parameters (muscle strength, mass and quality) and physical performance. Accordingly, omega-3 PUFAs supplements may be a potential therapeutic agent for sarcopenia. However, data about omega-3 PUFA intake in the (pre)

sarcopenic elderly are scarce. The objective of present study is to determine the omega-3 PUFAs intake of participants at baseline without supplementation in the Exercise and Nutrition for Healthy Ageing (ENHANCE) randomized controlled trial (RCT).

Methods: ENHANCE is an ongoing 5-armed RCT (ClinicalTrials.gov: NCT03649698) that examines the effect of an individualized nutritional intervention (protein supplementation and/or omega-3) combined with a physical exercise program in community-dwelling (pre)sarcopenic older persons aged ≥ 65 y. Self-reported dietary intake is estimated through 4 day food diaries and analyzed for total omega-3 PUFAs intake. US Dietary reference daily intake (RDI) is used as cutoff for adequate intake (men: 1.6 g/d and women 1.1 g/d).

Results: As on 23 January 2019, 37 participants completed their baseline food diaries (mean age 74.76 ± 6.4 y, 45% female, hand-grip strength 31.82 ± 10.93 kg, gait speed 1.06 ± 0.25 m/s). The study population consists of 29 presarcopenic and 8 (severe) sarcopenic elderly, defined according to the European Working Group for Sarcopenia in Older Persons consensus (EWGSOP1). The overall mean omega-3 PUFAs intake was 1.65 ± 0.75 g/d. Of the male participants only 50% reached the RDI with a mean of 1.76 ± 0.78 g/d, whereas 71% of female participants reached the RDI with a mean of 1.51 ± 0.70 g/d. When analyzed according to EWGSOP1 classification, 71% of presarcopenic and 63% of sarcopenic elderly reached RDI.

Conclusions: The majority of (pre)sarcopenic elderly in our study reached the RDI for omega-3 PUFAs. This raises the question whether the RDI is also the appropriate intake for maintaining muscle mass and function in an elderly (pre)sarcopenic population. Similar to specific recommendations for protein intake in elderly, a higher intake than RDI might be needed for this purpose.

P687

(PRE)SARCOPENIC OLDER PEOPLE HAVE AN INADEQUATE AND UNEVEN PROTEIN INTAKE, BUT ADEQUATE ENERGY INTAKE

L. Dedeyne¹, J. Dupont¹, J. Tournoy¹, K. Koppo², S. Verschueren³, E. Gielen¹

¹Division of Gerontology & Geriatrics, Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), KU Leuven, ²Exercise Physiology Research Group, Department of Movement Sciences, KU Leuven, ³Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium

Objectives: The protein recommended daily allowance (RDA) for healthy adults is 0.8 g protein/kg bodyweight (BW)/d. Expert groups, such as the PROT-AGE study group, recommend a protein intake and up to 1.5 g protein/kg BW/d, for elderly with acute or chronic diseases, to overcome anabolic resistance and prevent loss of skeletal muscle mass and function with ageing. Additionally adequate energy intake, 29 kcal/kg BW/d or 2232 kcal/d for men and 1870 kcal/d for women aged above 70 y, is recommended. Up to now however, daily protein and energy intake have not been described in a (pre)sarcopenic older population.

Methods: A 4-d estimated dietary record was completed by community-dwelling (pre)sarcopenic individuals (≥ 65 y). (Pre)sarcopenia was diagnosed by the assessment of gait speed, handgrip strength and muscle mass according to the European Working Group on Sarcopenia in Older People (EWGSOP1) criteria.

Results: 37 (pre)sarcopenic community-dwelling adults (45% female, 74.76 ± 6.40 y, 24.35 ± 2.95 kg/m², gait speed 1.06 ± 0.25 m/s, handgrip strength 31.82 ± 10.93 kg) had a higher average protein intake (1.04 ± 0.25 g/kg BW/d, 71.88 ± 17.95 g/d) than the current RDA, but lower than the recommendations of the PROT-AGE study group. The timing of protein intake was unevenly distributed, reaching only at lunch the level for optimal muscle protein synthesis (Figure 1). The average energy intake was only slightly below the recommended intake for men (2039.65 ± 405.42 kcal/d, 26.98 ± 5.31 kcal/kg BW/d) and sufficient (1856.65 ± 366.51 kcal/d, 30.21 ± 5.47 kcal/kg BW/d) for women.




Figure 1. Daily protein intake (g) distributed per meal (mean and SD) in (pre)sarcopenic older individuals, dark grey; men, grey; women, light grey. The horizontal line at 25 g and 30 g represents the amount of protein required per meal to maximally stimulate muscle protein synthesis.

Conclusions: Both the amount and timing of protein intake are suboptimal in community-dwelling (pre)sarcopenic elderly. Since both higher protein intake and an even protein intake distribution are associated with higher muscle mass and function, we must rethink strategies on how to increase for protein intake and distribution in community-dwelling (pre)sarcopenic elderly. A higher protein intake may consequently result in higher energy intake.

P688

AN EXPLORATION OF THE STRUCTURAL VALIDITY OF THE SARCOPENIA QUALITY OF LIFE (SARQOL®) QUESTIONNAIRE WITH EXPLORATORY AND CONFIRMATORY FACTOR ANALYSIS

A. Geerinck¹, C. Beaudart¹, N. Dardenne², J.-Y. Reginster¹, O. Bruyère¹

¹Department of Public Health, Epidemiology and Health Economics, University of Liège, WHO Collaborating Center for Public Health Aspects of Musculoskeletal Health and Ageing, ²Department of Public Health, Biostatistics, University of Liège, Liège, Belgium

Objective: The SarQoL questionnaire is a patient-reported outcome measure specific to sarcopenia. Several of its psychometric properties have previously been examined, but its structural validity has not yet been analyzed. The theoretical factor structure, formulated by a group of experts during the development of the questionnaire, categorizes the items in 7 domains of health-related dysfunction. This study explores the factor structure of the SarQoL questionnaire through a series of exploratory (EFA) and confirmatory factor analyses (CFA), and compares these to the theoretical model.

Methods: A dataset with 2227 sarcopenic and non-sarcopenic subjects from 8 countries (Brazil, Czech Republic, France, Belgium, Poland, Romania, Spain & Switzerland) with complete data for the SarQoL questionnaire was used. The dataset was randomly split into 2 samples, one of which was used for EFA (n=1119, 50.2%), and the other for CFA (n=1108, 49.8%). EFA was carried out with a matrix of polychloric correlations and the Promax rotation. The number of factors to extract was based on the Scree plot, the traditional Kaiser criterion and Velicer's MAP test. CFA was then performed using the weighted least squares mean and variance (WLSMV) adjusted estimator. Fit of the models was evaluated with the comparative fit index (CFI), the Tucker-Lewis index (TLI), the root mean square error of approximation (RMSEA) and the standardized root mean square residual (SRMR).

Results: The ratio of the 1st eigenvalue (27.5) to the 2nd eigenvalue (2.6) indicated the presence of a single factor. The traditional Kaiser criterion indicated 10 factors and Velicer's MAP test indicated 7 factors. The 1-factor model explained 49% of the total variance, the 7-factor model 54% and the 10-factor model 64%. The 1-, 7- and 10-factor models obtained through EFA were tested in CFA. All three models showed adequate fit, as did the theoretical model (CFI between 0.975 and 0.998; TLI between 0.974 and 0.998; RSMEA between 0.019 and 0.062; SRMR between 0.035 and 0.071).

Conclusions: Several models for the factor structure of the SarQoL questionnaire showed acceptable fit. However, an analysis with only sarcopenic subjects would be advisable before drawing conclusions.

Disclosures: CB, OB & J-YR are shareholders of SarQoL sprl.

P689

DETERMINING INDIVIDUAL TRAJECTORIES OF JOINT SPACE LOSS: A BAYESIAN APPROACH FOR ASSESSING OSTEOARTHRITIS PROGRESSION

C. M. Parsons¹, R. Meyer², A. Judge³, O. Bruyere⁴, F. Petit Dop⁵, R. Chapurlat⁶, J.-Y. Reginster⁴, H. Inskip¹, C. Cooper¹

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK, ²University of Auckland, Auckland, New Zealand, ³University of Bristol, Bristol, UK, ⁴University of Liège, Liège, Belgium, ⁵Servier, Suresnes, France, ⁶INSERM, Université de Lyon, Lyon, France

Osteoarthritis-related changes in joint space measurements over time are small and sensitive to measurement error, and there is considerable variation in disease progression between individuals. This study aimed to examine Bayesian modelling as a new approach to estimating individual trajectories of knee osteoarthritis (OA) progression.

Joint space width (JSW) on radiograph were taken from two datasets: the control arm of the Strontium Ranelate Efficacy in Knee Osteoarthritis trial (SEKOIA), a 3-y multicentre, double-blind, placebo-controlled phase 3 trial, and the Osteoarthritis Initiative (OAI), an open-access longitudinal dataset from the USA of America on participants followed over 8 y. Bayesian hierarchical modelling was used to determine annual estimates of JSW for each study participant. Noninformative priors were assigned to all hyperparameters within the model, and both a random intercept and random slopes were used in the model.

Results from the Bayesian modelling indicated, on average, knee joint space width decreased by 0.14mm/y during the SEKOIA study and 0.08 mm/y in the OAI. When considering individual annual change, the posterior estimates from the Bayesian modelling ranged from -0.64 to 0.15 in SEKOIA and -0.60 to 0.37 in the OAI. Thus at one extreme an individual's average JSW reduction was as large as 0.64 mm/y in SEKOIA and 0.60 mm/y in the OAI, while at the other end another individual's average indicated an increase of 0.15 mm/y in SEKOIA and 0.37 mm/y in the OAI.

Bayesian modelling could prove valuable in monitoring of disease progression and in identification of risk factors for the progression of knee OA that have not yet been discovered. Bayesian modelling allows individual estimates of OA progression to be obtained, which can be used in further analysis to investigate phenotypes for disease progression. Furthermore, application of Bayesian methodology in other clinical areas may aid in monitoring of other conditions.

P690

THE EXERCISE AND NUTRITION FOR HEALTHY AGEING (ENHANCE) PROJECT: PROTOCOL OF A TRIPLE BLINDED, RANDOMIZED CONTROLLED TRIAL

L. Dedeyne¹, J. Dupont¹, J. Tournoy¹, K. Koppo², S. Verschuere³, E. Gielen¹

¹Division of Gerontology & Geriatrics, Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), KU Leuven, ²Exercise Physiology Research Group, Department of Movement Sciences, KU Leuven, ³Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium

Objective: The ENHANce project aims to assess the combined effect of exercise and nutritional interventions to overcome anabolic resistance and prevent loss of skeletal muscle mass and function with ageing, and to determine the underlying mechanisms of action.

Methods: 180 community-dwelling (pre)sarcopenic individuals (≥ 65 y) will be randomly allocated into five groups for a 12 week intervention period, followed by a 12-week follow-up period: 1) exercise intervention + protein placebo + omega-3 placebo; 2) protein + omega-3 placebo; 3) exercise intervention + protein + omega-3 placebo; 4) exercise intervention + protein + omega-3 polyunsaturated fatty acids; 5) protein placebo + omega-3 placebo. All interventions are adapted to the physical capabilities and nutritional needs of the participants. (Pre)sarcopenia will be diagnosed by the assessment of gait speed, handgrip strength (dynamometer) and muscle mass (DXA) according European Working Group on Sarcopenia in Older People (EWGSOP1) criteria. Participants and researchers are blinded to omega-3 and protein treatment. Compliance to the exercise, protein and omega-3 interventions will be objectively measured, by respectively monitoring their movement by an activity monitor, determining nitrogen content in urine and analyzing the composition of the red blood cell membrane. The primary outcome is the change in short physical performance battery score. Secondary endpoints will be, among others, changes in muscle mass and strength, objective compliance to interventions, changes in muscle and blood biomarkers related to sarcopenia, cognition, quality of life and falls.

Conclusion: To our knowledge, this is the first RCT in well defined (pre)sarcopenic elderly that investigates the effects of combined and personalized anabolic interventions including omega-3 supplementation, compared to single or placebo interventions. Moreover, innovative technology is used to objectively measure compliance to the interventions. Also metabolic parameters and specific markers in muscle and blood will be examined to help to understand the mechanism of action behind the changes in physical performance. This project will pioneer in research assessing both physiological aspects and mechanistic insights of anabolic interventions, in order to develop more effective interventions for sarcopenia.

P691

POSTMENOPAUSAL WOMEN AT HIGH RISK OF OSTEOPOROSIS CONSUME HIGH AMOUNTS OF FRUITS AND VEGETABLES BUT TOO LITTLE DAIRY PRODUCTS: THE COLAUS/OSTEOLAUS COHORT

A. Lanyan¹, P. Marques-Vidal¹, E. Gonzalez Rodriguez¹, D. Hans¹, O. Lamy¹

¹Lausanne University Hospital/Internal Medicine, Lausanne, Switzerland

Objective: A healthy lifestyle, especially diet, plays a major role in the prevention of chronic diseases like osteoporosis (OP). We aimed to evaluate the link between nutrients, diet patterns or compliance to dietary guidelines and bone health among postmenopausal women. Influence of nutrition on trabecular bone score (TBS) was evaluated for the first time.

Method: we assessed 1475 women 50-80 y from the CoLaus/OsteoLaus cohort. Exclusion criteria were OP treatment and extreme energy intake. BMD, TBS and vertebral fracture were evaluated with DXA, OP risk factors, calcium supplements, and prevalent major OP fractures via questionnaire. Dietary intake was assessed using a validated, self-administered, semiquantitative food frequency questionnaire.

Results: 1057 women (63.9±7.5 y, BMI 25.8±4.4) met the inclusion criteria; 126 had OP on BMD, 67 a low TBS (<1.23) and 110 prevalent OP fractures. In multivariate analysis, women with OP consumed more vegetal proteins (21.9±0.5 vs. 20.2±0.2 g/d, p=0.005), more fibers (18.8±0.6 vs. 17.1±0.2 g/d, p=0.01), less animal proteins (40.1±1.3 vs. 43.9±0.5 g/d, p=0.007), and less calcium (914±36 vs. 1036±13 mg/d, p=0.002). According to dietary guidelines, they had a higher compliance for vegetables: OR (95%CI): 1.88 (1.03-3.43) p=0.041, and a lower compliance for dairy: 0.34 (0.14-0.82) p=0.016. Women taking calcium supplements had a higher compliance to dairy products: 1.72 (1.11-2.66), p=0.015. Dietary pattern "fruits and vegetables" was more prevalent in OP women: 1.77 (1.10-2.84), p=0.019. No association was found between TBS values and nutrients, dietary patterns or compliance to dietary guidelines.

Conclusion: Postmenopausal women with OP consume a high amount of vegetables, a too low amount of dairy products and animal proteins. The negative effect of vegetables on BMD may be due to the lower value of vegetable proteins and decreased calcium absorption due to fibres. TBS does not seem to be influenced by diet.

P692

A PROPOSAL FOR THE ADJUSTMENT OF BONE MINERAL DENSITY FOR BODY DIMENSIONS IN CHILDREN

A. Zsakai¹, D. Annar¹, A. Muzsnai², P. Feher¹, E. Bodzsar¹

¹Eotvos Lorand University, Department of Biological Anthropology, ²Saint Janos Hospital and United Hospitals of North Buda, Paediatric Endocrinology, Budapest, Hungary

Objectives: Describing the biological development of a child is very important in bone structure assessment. The precise age estimation is of high importance in BMD evaluation in children, since the bone structure of a studied child is evaluated by using the age and gender dependent References. In addition, the biological age – the bone age in this case – estimation could help this bone structural evaluation process, since the developmental status of the skeletal system can significantly alter from the theoretical developmental status determined by chronological age in healthy, but early or late maturing children. The aims of the study were (1) to check whether volumetric BMD Z-scores estimated by considering chronological age and biological age differ significantly in children aged between 6-18 y, and (2) in the case of significant inaccuracy of Z-score estimation based on only chronological age to construct new BMD standards adjusted for bone age or body developmental status.

Methods: Body structural and densitometry data of 476 healthy children aged between 7-18 y were used in the analysis. pQCT measurements were performed at the distal radius using Stratec XCT-2000 equipment (Stratec Inc, Germany). The centile curves of BMD parameters were estimated by using lmsChartMaker Pro 2.3 software.

Results: The total and 'cortical + subcortical' BMD changed by age in the studied age interval in both genders. Our results confirmed that when the biological age of a child significantly differs from her/his chronological age, BMD evaluation should be done by considering her/his biological age. If the estimation of any biological age cannot be carried out, BMD References adjusted for height or other body dimensions should be used in the bone health status estimation in children.

Conclusion: Due to the increase in individual variability of rate and timing of pubertal developmental processes, the sensitivity of BMD evaluation by considering body developmental status was the lowest in the age between 12-16 y in the boys and between 10-12 y in the girls. Therefore the suggested BMD adjustments for biological ages are highly recommended to use at least in children with ages outside these age intervals.

P693

SARCOPENIA: PERFORMANCE OF THE SARC-F QUESTIONNAIRE ACCORDING TO THE EUROPEAN CONSENSUS CRITERIA, EWGSOP1 VS. EWGSOP2

M. Hajaoui¹, M. Locquet¹, C. Beaudart¹, J.-Y. Reginster¹, J. Petermans², O. Bruyère¹

¹Department of Public Health, Epidemiology and Health Economics, University of Liège, ²Geriatric Department, CHU of Liège, Liège, Belgium

Objective: To compare the impact of the European Working Group on Sarcopenia in Older People definition published in 2010 (EWGSOP1) and its update in 2018 (EWGSOP2) on performance of a screening tool for sarcopenia, the SARC-F questionnaire.

Methods: Data from the SarcoPhAge (*Sarcopenia and Physical Impairment with advancing Age*) cohort were used. In 2010, sarcopenia is considered to be present when a person has low mus-

cle mass (i.e., appendicular skeletal muscle mass (ASM)/height² ≤5.5 kg/m² for women; ≤7.26 kg/m² for men) in combination with low muscle strength (i.e., handgrip strength <20 kg for women; <30 kg for men) and/or low physical performance (i.e., Short Physical Performance Battery (SPPB) ≤8 points). In 2018, with the revision of the definition, EWGSOP2 characterizes “*sarcopenia confirmed*” as low muscle strength (handgrip strength <16 kg for women; <27 kg for men) along with low muscle mass (ASM/height² <6.0 kg/m² for women, <7.0 kg/m² for men). If a person also presents with low physical performance (SPPB ≤8 points), they are considered to have “*sarcopenia severe*”. The diagnostic accuracy of the SARC-F was judged using sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV) and area under the curve (AUC).

Results: A total of 306 community-dwelling subjects over 65 years old (74.8±5.9 y, 59.5% of women) were included, with 16.7% of subjects diagnosed as sarcopenic when using the EWGSOP1 criteria and 10.5% with the EWGSOP2 criteria. With EWGSOP1 definition, results of SARC-F questionnaire were: Se 36.0%, Sp 87.1%, PPV 35.3%, NPV 87.4% and AUC 0.710 (95%CI: 0.636-0.785). With EWGSOP2 definition, results were: Se 46.9%, Sp 86.5%, PPV 28.9%, NPV 93.3% and AUC 0.774 (0.695-0.852) for *sarcopenia confirmed*; Se 66.7%, Sp 86.1%, PPV 23.1%, NPV 97.6%, AUC 0.872 (0.817-0.926) for *sarcopenia severe*.

Conclusions: From a clinical point of view, the SARC-F questionnaire seems to have a good discriminative power and a good performance in identifying subjects without sarcopenia with a high confidence (i.e., high Sp). The recommendation of EWGSOP2 to use the SARC-F questionnaire as a screening test is well founded.

P694

LEVEL OF DEPRESSION AND GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH KNEE OSTEOARTHRITIS AND WITH TYPE 2 DIABETES MELLITUS THROUGH DIFFERENT THERAPIES

R. Zyngirov¹

¹Moscow city hospital № 71, Moscow, Russia

Objective: Osteoarthritis is the most common joint damage, accompanied by dysfunction. The course of osteoarthritis and concomitant diabetes can lead to depression. The purpose of study are to analyze the correlation of different types of therapy with depression and the level of glycosylated hemoglobin.

Methods: Author conducted research from December 2017 to December 2018. The study included 80 patients with osteoarthritis and with type 2 diabetes mellitus through different therapies. These patients were identified through rheumatology database of hospital. Patients were determined index a disease activity as WOMAC and conducted blood analysis, including monitoring of the level of glycosylated hemoglobin every 2 months. Patients completed 2 questionnaires: SF-36, Beck depression inventory.

Results: The mean age of surveyed patients was 65 y, and 70% were female. The average disease duration was 6 y. All patients had well controlled diabetes mellitus. 3 group patients: 1 group with chondroitin sulfate 1000 mg/d -25 persons, 2 group with

glucosamine hydrochloride 1500 mg/d -25 persons and 3 group patients with combination of 1500 mg of glucosamine hydrochloride with 1200 mg of chondroitin sulfate -30 persons. They received 2 courses of treatment for 3 months and a break in treatment 4 months. In the group of patients with monotherapy glucosamine hydrochloride the level of depression was higher moreover, than patients with another groups (p<0.05). The level of glycosylated hemoglobin by the end of the 2nd course of treatment in the glucosamine hydrochloride group was much higher -7.94% (p<0.05). Quality of life more better in group patients with combination of 1500 mg of glucosamine hydrochloride with 1200 mg of chondroitin sulfate.

Conclusions: The choice of therapy for patients with OA with type 2 diabetes should include medications whose improve the quality of life and do not aggravate glucose metabolism in patients with type 2 diabetes.

P695

MONITORING PROGRAM OF POSTMENOPAUSAL OSTEOPOROSIS LONG-TERM THERAPY

A. S. Trushyna¹, E. V. Rudenka¹, A. M. Evdokimova²

¹Belarusian State Medical University, ²City Center of Osteoporosis, Minsk, Belarus

Objective: To develop a complex monitoring program of postmenopausal osteoporosis (PMO) long-term therapy.

Methods: The monitoring program includes: DXA, SF-36, QUALEFFO-41, triple-component numeric pain rating scale (NPRS), the test for patient compliance evaluation. The viewed group: 71 women with PMO, age 50 and 65; control group: 22 women without osteoporosis, comparable to the viewed group in age, education and occupation. The viewed group regimen: alendronate 70 mg/week taken with calcium 1000 mg/d and vitamin D 800 IU/d. The control group regimen: the same dose of calcium and vitamin D. SF-36, QUALEFFO-41 and NPRS were filled on the 3rd, 6th and 12th months of the first treatment year (P3, P6 and P12 accordingly) and twice a year afterwards. The test for patient compliance evaluation and DXA were filled once a year. The results of the first year of treatment are presented in this abstract.

Results: After 3 months of therapy no significant differences in questionnaires data and rating scale were observed in both study groups (p>0.05). After 6 and 12 months of treatment, the comparison of quality of life indicators of the questionnaires demonstrated the greater sensitivity and specificity of QUALEFFO-41 compared to SF-36 (p<0.01). At P6 and P12, affected by alendronate treatment, a significant vertebral pain level decrease was achieved in all three NPRS components. After a year of alendronate treatment, a significant increase of lumbar spine BMD by +0.047 (+0.025; +0.093) was detected, which represented +5.85 (+3.15;+10.68)% (p<0.01). Increase of femoral neck BMD after 12 months of alendronate treatment is uncertain.

Conclusion: The 12-month alendronate treatment in case of high patient's compliance (MPR>80%) causes a significant increase of lumbar spine BMD. QUALEFFO-41 is recommended to use independently as well as in combination with triple-component NPRS

as criteria for evaluation of clinically significant effect of PMO therapy. Evaluation of therapy is justified after 6 and 12 months of alendronate treatment.

P696

SINGLE INTRA-ARTICULAR PLATELET-RICH PLASMA VS. HOME-BASED THERAPEUTIC EXERCISE PROGRAM IN INDIVIDUALS WITH KNEE OSTEOARTHRITIS IN THE TREATMENT OF KNEE OSTEOARTHRITIS

C. Matzaroglou¹, C. Foe¹, P. Gkrilias¹, I. Gelalis², A. Spyridonidis³, V. Angelopoulos¹, D. Papachristou³

¹Technological University of Western Greece, Human Assessment and Rehabilitation Lab, Aigio, ²University of Ioannina, Department of Orthopaedics, Spinal Surgery and Adult Reconstructive Surgery, Ioannina, ³Department of Medicine, University of Patras, Patras, Greece

Objective: To compare the effects of single intra-articular platelet-rich plasma (PRP) and home-based therapeutic exercise program in individuals with knee osteoarthritis in the treatment of knee osteoarthritis.

Methods: 69 patients aged 63-87 y of either sex (10 m/ 59 f), diagnosed with knee osteoarthritis, with >6 months duration were included. 39 patients received single injection (4 ml) of PRP (PRP Group), and 30 patients received a single home based exercise program (HBEP Group). All patients were prospectively followed for 6 and 52 weeks with WOMAC, KOOS, VAS and HADS tools.

Results: 32 patients in PRP group and 27 patients in HBEP Group finished the entire 52 weeks study period. At 6 weeks, WOMAC, KOOS, VAS and HADS scores, in PRP group were 15% better, compared to HBEP Group. In ROM, PRP group showed significant improvement in passive flexion, compared to HBEP respectively. No major complications were observed in any patients. At 52 week follow-up no statistical differences observed in two groups with WOMAC, KOOS, VAS and HADS tools.

Conclusions: At 6 week follow-up, a single dose of PRP injection was found to be more effective than a home-based therapeutic exercise program in terms of improving pain, disability, ROM in patients. At 52 week follow-up, a single dose of PRP injection was not found to be more effective than a home-based therapeutic exercise program of the knee, in individuals with knee osteoarthritis.

P697

UNDERSTANDING PATIENTS' PREFERENCES FOR OSTEOPOROSIS TREATMENT: THE IMPACT OF PATIENTS' CHARACTERISTICS

D. Cornelissen¹, A. Boonen², S. Bours², S. Evers¹, C. Dirksen³, M. Hiligsmann

¹Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, ²Department of Internal Medicine, Rheumatology, Maastricht University Medical Centre and CAPHRI, Maastricht University, ³Department of Clinical Epidemiology and Medical Technology Assessment, CAPHRI, Maastricht University, Maastricht, The Netherlands

Objectives: This study was designed to identify different profiles of treatment preferences and to investigate how patient characteristics influence patients' preferences for antiosteoporosis medication.

Methods: Data from a discrete-choice experiment among 188 Dutch osteoporotic patients were used. Patients were asked to repetitively choose between two hypothetical treatments (and an opt-out) that differed in four characteristics: treatment efficacy, side effects and mode combined with frequency of administration. First, a mixed logit model was used to measure heterogeneity across the sample. Then latent class modelling (LCM) was applied to identify potential latent classes regarding patient characteristics. Finally, multinomial logistic regression (MLR) and chi2 explored associations between patients' characteristics and the identified latent classes.

Results: All treatment characteristics were important for patients' decision regarding osteoporotic treatment. Significant heterogeneity was observed for most attributes. Three latent classes were identified, in which 6-month subcutaneous injection was preferred in two classes (86%), while oral tablets were preferred in the third class (14%). No statistically significant associations between the latent classes regarding sociodemographic or clinical characteristics (besides BMI) could be found.

Conclusions: This study revealed patterns in patients' preferences for osteoporosis treatment, which cannot be related to specific sociodemographic or clinical characteristics. This implicates underlying reasons for the preferences which were not observed. This implicates the necessity to address patient preferences for each individual patient when discussing starting or switching treatment to ensure that more patients stay adherent to anti-osteoporotic medications.

P698

MAJOR OSTEOPOROTIC FRACTURE RISK FOLLOWING BARIATRIC SURGERY: A SELF-CONTROLLED CASE SERIES INCLUDING 5492 PEOPLE FROM THE UK CPRD AND LINKED HES DATABASES

D. E. Robinson¹, I. Douglas², G. D. Tan³, C. Cooper⁴, A. Delmestri¹, M. K. Javaid⁵, A. Judge⁶, V. Y. Strauss¹, D. Prieto-Alhambra¹

¹CSM, NDORMS, University of Oxford, Oxford, ²Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, ³Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford University Hospitals NHS Foundation Trust, Oxford, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, ⁵NDORMS, University of Oxford, Oxford, ⁶Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

Objective: Bariatric surgery is increasingly common due to the obesity epidemic but there is controversial evidence about the risk of fracture after bariatric surgery potentially due to differences between the patients who receive surgery and those who do not. We aim to investigate the association between bariatric surgery and risk of three fracture locations, using a within person study design comparing a) the 5-y incidence postsurgery to the 5-y presurgery risk and b) splitting the 5-y postsurgery risk into two windows 0-2 and 2.01-5 y.

Methods: A self-controlled case series analysis was conducted. Patients undergoing bariatric surgery and experiencing fracture were identified in the clinical practice research datalink (CPRD) GOLD dataset and linked to hospital episode statistics (HES) data. Primary outcome was any fracture (any skeletal sites except skull and digits). Secondary outcomes were major (hip, vertebrae, forearm and humerus) and peripheral fractures (forearm and lower leg). Poisson models were fit to calculate incidence rate ratios (IRR) for the aforementioned time windows.

Results: Of 5492 patients undergoing bariatric surgery, 252 patients had 272 any fractures, 75 had 80 major osteoporotic fractures and 126 had 135 peripheral fractures. Average BMI was 43.9. Major fracture risk increased nearly 3-fold following surgery: IRR (95%CI) 2.70 (1.31, 5.57). Conversely, the incidence of any and peripheral fractures did not change in the 5 y postsurgery compared to previously: IRRs 1.17 (0.86, 1.60) and 0.92 (0.60, 1.42) respectively. Any and major fracture risk increased further in the 3rd to 5th year post-surgery: IRRs of 1.73 (1.08, 2.77), 4.98 (1.94, 12.78) respectively.

Conclusions: Few patients had fractures after surgery (252/5492). The incidence of major osteoporotic fracture is increased after bariatric surgery by nearly 3-fold; this further increases to 5-fold in the 2.01-5 year window. Further research is needed on post-bariatric surgery care to minimise fracture risk.

Acknowledgements: This project was funded by the NIHR RfPB (project number PB-PG-1215-20017) and supported by the NIHR Oxford BRC. The views expressed are those of the author(s).

Disclosures: CC reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda and UCB. MKJ reports personal fees from Stirling Anglia, Consilient Health and Internis. AJ has received consultancy fees, lecture fees and honoraria from Servier, UK Renal Registry, Oxford Craniofacial Unit, IDIAP Jordi Gol and Freshfields Bruckhaus Deringer, is a member of the Data Safety and Monitoring Board (which involved receipt of fees) from Anthera Pharmaceuticals, Inc., and received consortium research grants from Roche. DPA's institution has received research grants, speaker, and advisory board fees from AMGEN, research grants from Servier Laboratoires and UCB Pharma, and consultancy fees from UCB. All conflicts are outside the submitted work.

P699

IMPACT OF OBESITY ON VITAMIN D STATUS AND MUSCLE MASS IN POSTMENOPAUSAL WOMEN UNDER 65 YEARS OLD FROM BUENOS AIRES

A. G. Díaz¹, V. Lerena¹, F. Jerkovich, E. Genovesi¹, D. Marin Ossa¹, B. Oliveri¹, D. Gonzalez, B. Fabre, K. Danilowicz, S. P. Lucas¹

¹Hospital de Clinicas Universidad de Buenos Aires, Buenos Aires. Argentina,

Objectives: To describe the impact of obesity on serum 25 hydroxyvitamin D status, BMD and sarcopenia in Argentinian ambulatory postmenopausal women between 50-65 y of age.

Methods: A total of 239 women (56.7±0.3 y) attended a community activity to evaluate osteoporotic risk and muscle health. They were asked to answer a questionnaire about history of osteoporotic risk factors, chronic diseases, use of medication, and osteoporotic fractures. The clinical evaluation included BMI, hand-grip strength test (by dynamometry) and short physical performance battery test. Serum 25-hydroxyvitamin D was measured by Advia Centaur. Body composition and BMD in femoral neck (by Lunar) was performed in 121 participants. Women were classified as normal (BMI 18-24.9 kg/m²), overweight (BMI 25-29.9 kg/m²) and obese (BMI ≥30 kg/m² or fat percentage >33%). Sarcopenia was determined according to EWGSOP: ALM/ht² ≤5.67 kg/m² and gait speed: >0.8 m/s or grip strength <20 kg, and the FNIIH criteria: ALMBMI <0.512 and grip strength <16 kg. Statistical analysis by SPSS20.0, significance p<0.05.

Results: According to BMI, 29.1% of participants had normal weight, 35.4% had overweight and 35.3% were obese. In comparison with the nonobese group (n=153), obese women (n=84) showed similar physical performance, no differences were found in gait speed or sit-chair test neither in the hand grip strength test. Obese women presented higher BMD in femoral neck (0.918±0.017 vs. 0.829±0.12 g/cm², p<0.0001, respectively) and higher T-score (-0.51±0.1 vs -1.25±0.1, p<0.001, respectively). However, obese people presented higher total lean (p<0.0001) and fat mass (p<0.0001) and higher ALM/ht² (p<0.0001). But,

when ALM was adjusted to BMI, participants showed a significant lower ALMBMI (0.4585 ± 0.009 vs. 0.5703 ± 0.009 , $p < 0.0001$). However, no differences were found in incidence of falls or osteoporotic fractures. 80% of participants had serum 25-hydroxyvitamin D < 20 ng/mL, no differences were found between nonobese and obese group (14.35 ± 0.55 vs. 13.97 ± 0.94 ng/ml, respectively).

Conclusions: In postmenopausal women under 65 y, obesity did not impact in 25-hydroxyvitamin D deficiency or physical performance. Despite higher BMD in femoral neck and higher ALM/ht2, obese people showed lower muscle mass when evaluated adjusted to BMI, suggesting this way of measuring it.

P700

MOLECULAR CODES IN HIGH-GRADE TYPES OF OSTEOSARCOMA

G. Palmini¹, C. Romagnoli¹, R. Zonefrati¹, G. Galli¹, F. Marini¹, A. Aldinucci², G. Leoncini¹, A. Franchi³, G. Beltrami⁴, D. A. Campanacci⁵, R. Capanna³, M. L. Brandi^{1,6}

¹Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, ²Central Laboratory, Azienda Ospedaliero-Universitaria Careggi, Florence, ³Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, Pisa, ⁴Ortopedia Oncologica Pediatrica, AOU Careggi-AOU Meyer, Florence, ⁵SOD Ortopedia Oncologica e Ricostruttiva, AOU Careggi, Florence, ⁶Fondazione Italiana Ricerca sulle Malattie dell'Osso (FIRMO Onlus), Florence, Italy

Objective: In this study, the existence of CSCs in high grade types of osteosarcoma (OS) (i.e., the telangiectatic osteogenic sarcoma (TOS), the small cell osteosarcoma (SCO) and the conventional osteosarcoma (OSA)), and the presence of a common expression of microRNAs (miRNAs) is showed.

Methods: The human SCO, TOS and OSA samples have been collected at the "Unit Ortopedia Oncologica e Ricostruttiva", AOU Careggi, Florence, with informed consent approved by the local Ethical Committee. First, the primary cancer cell lines of TOS, SCO and OSA have been established. After that, the subpopulation of CSCs has been isolated from all of these cell lines. Consequently, several cellular assays/stainings and molecular analyses have been performed to demonstrate the CSCs phenotype. We have also tested the neoplastic capacity to infiltrate surrounding tissues by the invasion assay. At last, we have analyzed the miRNAs expression in the CSCs lines.

Results: Firstly, we have established a primary cell line of a SCO, a TOS and an osteoblastic OSA, from the samples collected, respectively marked as OSA3, OSA4 and OSA5. Consequently, from these we have isolated CSCs and we have established a SCO-, a TOS- and a OSA-CSCs lines, named as OSA3-, TOS1- and OSA5-CSCs. The stemness of these lines has been confirmed by observing their capacity to differentiate into osteoblasts and into adipocytes, by showing the positive presence of the mesenchymal and embryonic stem cells markers into the lines, and by evaluating

their clonogenic capacity. We have also confirmed the neoplastic capacity of these lines. Finally, we have analysed and preliminary observed a common miRNAs expression code in these CSCs lines.

Conclusions: We have settled three new in vitro models of OS. The preliminary results obtained about the analysis of the miRNAs expression profile in these lines could be important because seems to identify a common "miRNA code" among these types of OS, that could be used to develop new molecular therapies against this aggressive primary bone tumour.

Acknowledgements: Supported by the Istituto Toscano Tumori (ITT) _Regione Toscana Grant Proposal 2010 and by Fondazione Italiana Ricerca sulle Malattie dell'Osso (FIRMO Onlus).

P701

RISK OF HAND OSTEOARTHRITIS IN NEW USERS OF HORMONE REPLACEMENT THERAPY: A NESTED CASE-CONTROL ANALYSIS

T. Burkard¹, M. Rauch¹, J. Spoendlin¹, D. Prieto-Alhambra², S. S. Jick³, C. R. Meier¹

¹University Hospital Basel, Basel, Switzerland, ²University of Oxford, Oxford, UK, ³Boston Collaborative Drug Surveillance Program, Lexington, USA

Objective: To estimate the risk of hand osteoarthritis (OA) in new users of hormone replacement therapy (HRT).

Methods: We conducted a nested case-control study using data from the UKbased Clinical Practice Research Datalink (1998-2017). In an inception cohort of women entering at age 45, we matched patients with hand OA during follow-up (cases) to at the time OA-free controls 1:4 on age and calendar date (index date). We applied multivariable conditional logistic regression to calculate odds ratios (OR) with 95%CI of hand OA in association with new HRT use when compared to non-use and stratified by timing of HRT exposure (current, past). We performed the same analysis in a subgroup of patients with recorded menopause (MP) and within intervals between the first MP record and the index date (≤ 2 y, > 2 y). In the interval of > 2 y after MP, we further assessed the timing of HRT initiation with regards to MP in current HRT users and of HRT cessation before the index date in past HRT users compared to nonusers.

Results: Among 3440 cases and 13,760 controls (mean age 50.9 years), we observed an overall adjusted OR (aOR) of hand OA of 1.32 (95%CI 1.17-1.48) in HRT users compared to nonusers which attenuated to 0.98 (95%CI 0.85-1.14) in patients with recorded MP. Compared with nonusers, the aOR of hand OA in HRT users with a MP record ≤ 2 y before the index date was lower (0.75, 95%CI 0.55-1.03) than that of HRT users with MP recorded > 2 y before the index date (1.07, 95%CI 0.901-1.26). In all analyses, compared to nonusers, current HRT use was associated with lower and past use with higher aORs of hand OA than overall HRT use. In patients with a MP record > 2 y before the index date, we observed a non-significantly decreased aOR of hand OA in current users if HRT was initiated within 90 d before or after recorded MP (0.72, 95%CI 0.491-1.05), aORs increasing with later HRT initiation. Furthermore, among past users, compared to nonusers, the aOR of hand OA

was nonsignificantly increased (1.42, 95%CI 0.922.21) if HRT was stopped ≤ 1 y before the index date and aORs decreased with earlier HRT cessation.

Conclusion: HRT use is associated with a decreased risk of hand OA if initiated around MP and with an increased risk of hand OA shortly after ceasing HRT.

Disclosure: DPA has received research grants, speaker, and advisory board fees from Amgen, research grants from Servier Laboratoires and UCB Pharma, and consultancy fees from UCB.

P702

CORRECTION OF A HYPOVITAMINOSIS D AT CHILDREN WITH A CYSTIC FIBROSIS OF THE CITY OF ST. PETERSBURG

A. A. Pashkevich¹, A. V. Orlov², L. A. Zhelenina¹, M. M. Kostik¹

¹Saint-Petersburg State Pediatric Medical University, ²North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia

Objective(s): To study efficiency and features of correction of a hypovitaminosis of vitamin D.

Material and Methods: Control of observance of the mode of intake of vitamin D within 18 months was established in families of 92 children of patients with a cystic fibrosis. Until inclusion in a research none of them received D3 vitamin drugs on a regular basis in adequate doses according to the existing recommendations. In 18 months at patients serum concentration 25(OH)D was three times measured in blood. After the analysis of the obtained data of a dose of D3 vitamin were adjusted.

Results: As a result of a research it was established that only at 68 (74%, average age of 6 years) from 92 children (average age of 7.7 years) the compliance, administration of drug made more than 80% that indicated adequacy of therapy. 68 patients at primary inspection have level 25(OH)D in blood ≥ 30 ng/ml is noted in 25% of cases (n=17), and level 25(OH)D in the range of 20-30 ng/ml - at 35% (n=24) of children, at 40% of children (n=27) - level 25(OH)D was lower than 20 ng/ml. When determining serum concentration of vitamin D at the end of a research at patients with good commitment to treatment level 25(OH)D in blood serum ≥ 30 ng/ml is revealed more, than at a half of patients - 57% (n=39, average age of 5.8 years), and in the range from 20 ng/ml to 30 37% had level 25(OH)D (n=25, average age of 6.3 years) children. At 6% (n=4, average age of 11 years) of children it was not succeeded to reach, despite regular administration of drug, minimum target (≥ 20 ng/ml) level 25(OH)D in blood serum.

Conclusion(s): Children of preschool age at observance of the mode of dosing reached target level 25(OH) in blood serum when using of the recommended age dosages. Despite a good compliance of patients, at children in a prepubertata (average age of 11 years) it was not succeeded to reach minimum target (≥ 20 ng/ml) level 25(OH)D in blood serum that probably testifies to higher need for D3 vitamin for this age group and demands revision of the recommended drug dose.

Acknowledgments: charitable foundation «Islands».

P703

SECONDARY OSTEOPOROSIS IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM

L. Yanevskaya¹, E. Ivanova², A. Bakhtiyarova², K. Pogosyan¹, A. Andreeva², M. Boriskova¹, U. Farafonova¹, I. Sleptsov³, T. Karonova⁴

¹Pavlov First Saint Petersburg State Medical University, ²Almazov National Medical Research Centre, ³Saint-Petersburg State University Clinic of High Medical Technologies N.I. Pirogov, ⁴Almazov National Medical Research Centre, Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia

Objective: Primary hyperparathyroidism (PHPT) seems to significantly increase the risk of secondary osteoporosis.

Methods: We reviewed the medical records of 449 patients admitted to three Medical Centers (Saint-Petersburg, Russia) between Jan 2011 and May 2018. Anamnesis, anthropometric data, laboratory (PTH, serum total Ca and iCa, phosphorus, 24-h calciuria level, alkaline phosphatase, 25(OH)D) and instrumental (ultrasonography, scintigraphy, CT/MRI scan, DXA) tests were analyzed.

Results: Out of 449 patients, clinical forms of PHPT (osteoporosis, urolithiasis, peptic ulcer, cholelithiasis, acute erosive lesions) were identified in 310 cases. Osteoporosis was detected in 63.5% cases. We found significant difference in age between pts with and those without osteoporosis (62 y (56; 69) & 57 y (49; 64) accordingly, $p < 0.00001$). Patients with symptomatic PHPT were divided into groups: "osteoporosis", "urolithiasis", "osteoporosis+urolithiasis". Patients without these pathologies were included in "other manifestations" group. 98.5% of patients with "osteoporosis" were women compared to "urolithiasis" and "osteoporosis+urolithiasis" groups where 50% were men ($p = 0.006$). Patients with "osteoporosis" or "osteoporosis+urolithiasis" were older than those with normal bone remodeling ($p = 0.0002$). We found that pts with "osteoporosis + urolithiasis" had higher incidence of fragility fractures than "osteoporosis" pts (14 (21.2%) & 11 (8.5%), $p = 0.046$). Correlation analysis revealed the association between PTH and T-score L1-L4 ($r = -0.298$, $p = 0.0024$), Neck ($r = -0.230$, $p = 0.043$) and Radius ($r = -0.478$, $p = 0.006$), as well as between T-score Radius and Ca ($r = -0.510$, $p = 0.0077$). In addition, there was an association between the age and the T-score Radius ($r = -0.437$, $p = 0.02$), as well as between the BMI and the T-score L1-L4 ($r = 0.325$, $p = 0.009$).

Conclusion: Study results showed that PHPT most often manifested itself in the form of impaired bone remodeling. PHPT pts with osteoporosis are older than those having normal bone density. The incidence of fragility fractures is significantly higher when patients had combination of osteoporosis+urolithiasis compared to those with osteoporosis only. Besides correlation analysis showed increased PTH level associated with decreased BMD.

P704

SERUM RESISTIN LEVELS AS PREDICTOR OF LOW BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMENS. Tariq^{1,2}, S. Khaliq³, K. P. Lone⁴

¹University Medical and Dental College, The University of Faisalabad/ Physiology Department, Faisalabad, ²University Medical and Dental College, The University of Faisalabad/ Pharmacology Department, Faisalabad, ³University of Health Sciences, Lahore. Physiology and Cell Biology, Lahore, ⁴Government College University, Lahore, Pakistan

Objective: Resistin is a predictor of BMD in postmenopausal women.

Methods: In this correlational analytical study, postmenopausal women (n=160) between the age of 50-70 y were recruited and divided into two groups. Postmenopausal nonosteoporotic women (n=70) having T-score \geq -1.0 and postmenopausal osteoporotic women (n=90) with T-score \leq -2.5. BMD was evaluated by DXA. Serum resistin levels were assessed by ELISA. Mann-Whitney U test was used for comparisons and stepwise multiple regression analysis was used to predict BMD.

Results: Serum resistin levels ($p < 0.001$), BMD at lumbar spine ($p < 0.001$), right femoral neck ($p < 0.001$), right hip ($p < 0.001$), left femoral neck ($p < 0.001$) and left hip ($p < 0.001$) were significantly different between the two groups. Serum resistin levels, height, weight, BMI, waist circumference, hip circumference, and W/H ratio were used to predict T-scores. At lumbar spine, the independent predictors were body weight (β 0.047, $p < 0.001$) and serum resistin levels (β -0.000075, $p < 0.001$) that uniquely accounted for 16% and 7% of the variance of T-scores. At Right femoral neck, the independent predictors were weight (β 0.034, $p < 0.001$) and serum resistin levels (β -0.000070, $p < 0.001$) that contributed 11% and 8% of the variance of T-scores. At Right hip, the independent predictors were weight (β 0.034, $p < 0.001$) and serum resistin levels (β -0.000054, $p < 0.001$) contributing 13% and 5% of the variance of T-scores. At Left femoral neck, the independent predictors were weight (β 0.036, $p < 0.001$) and serum resistin levels (β -0.000069, $p < 0.001$) contributing 13% and 8% of the variance of T-scores. At left hip, the independent predictors were weight (β 0.035, $p < 0.001$) and serum resistin levels (β -0.000064, $p < 0.001$) contributing 14% and 8% of the variance of T-scores.

Conclusion: High serum resistin levels and low weight are independent contributors to low BMD and can influence BMD at lumbar spine, right femoral neck, right hip, left femoral neck, and left hip in postmenopausal women.

Acknowledgments: The research is funded by a grant from higher education commission, Pakistan.

P705

OSTEOARTHRITIS IN RAT KNEES: INDUCTION BY INTRA-ARTICULAR INJECTION OF SACCHAROMYCES CEREVISIAEG. Poletto¹, M. H. Leonardi¹, V. Caron², F. Tabushi³

¹Faculdade Evangélica Mackenzie, ²Universidade Tuiuti, ³Universidade Federal do Paraná, Curitiba, Brazil

Objective: To evaluate the effectiveness, of *Saccharomyces cerevisiae* in the induction of osteoarthritis in rat knees, by clinical and radiological evidence.

Method: An osteoarthritis induction model was used with *Saccharomyces cerevisiae*. A total of 40 adult male Wistar rats weighing 280-300 g and 90 days old were used. The injection of the arthritis-inducing agent was individually performed under general anesthesia, with isoflurane (2 to 5% in oxygen). On day 0 of the experiment, all animals were anesthetized and an arthrocentesis was performed on the right femoro-tibial-patellar joint of the 40 animals, followed by an intra-articular injection of *Saccharomyces Cerevisiae* dissolved in 10 ml of water in the dose of 50 μ L in a single dose. On day 8, radiographic projections were made for joint evaluation after osteoarthritis induction.

Results: the results showed a reduction in range of motion based on motion-induced nociceptive analysis with 'knee-bend test' behavioral tests, while radiographic analysis showed that 72.5% of the rats presented lesions that confirmed osteoarthritis and 27.5% showed no alterations.

Conclusion: The induction of osteoarthritis with *Saccharomyces cerevisiae* is effective and can be confirmed radiologically. The knee bend test proved to be a subjective method for the evaluation of osteoarthritis.





P706
PREVALENCE OF VITAMIN D DEFICIENCY AND METABOLIC SYNDROME AMONG POSTMENOPAUSAL WOMEN IN CARPATHIAN REGION

I. Pankiv¹

¹Bukovinian State Medical University, Department of Clinical Immunology, Allergology and Endocrinology, Chernivtsi, Ukraine

Objective: No report is available regarding the association of 25-hydroxyvitamin D status and metabolic syndrome (MS) among postmenopausal women in Carpathian region. Aim of the study was to find out the prevalence of 25(OH)D deficiency and MS as well as their association among postmenopausal women in this region.

Methods: This cross-sectional study was conducted among 495 randomly selected postmenopausal women in Carpathian region, Ukraine. Serum 25(OH)D, waist circumference (WC), fasting blood glucose (FBG), triglycerides (TG) and high density lipoprotein cholesterol (HDL-C), blood pressure (BP) were measured using standard procedures. MS was defined as per International Diabetes Federation criteria. Statistical tests were done using SPSS software.

Results: Prevalence of MS was 56.2%. 66.9% and 27.9% postmenopausal women were vitamin D insufficient and deficient, respectively. 28.1% and 69.4% women having MS were vitamin D insufficient and deficient, respectively. Among the postmenopausal women, 20.8% and 46.9% with WC ≥ 80 cm; 17.9% and 61.8% with FBG ≥ 5.8 mmol/l; 28.9% and 56.9% with TG ≥ 1.7 mmol/l; 27.9% and 61.8% with HDL-C < 1.25 mmol/l, 23.8% and 57.8% with BP $\geq 130/85$ mm Hg were vitamin D insufficient and deficient, respectively. Significant statistical association between FBG and 25(OH)D status existed ($p=0.04$). Significant positive correlation between WC and 25(OH)D level ($p=0.001$) and significant negative correlation between FBG and 25(OH)D level observed ($p=0.03$).

Conclusion: High prevalence of vitamin D insufficiency and deficiency as well as MS existed among postmenopausal women in Carpathian region. 25(OH)D had significant inverse and direct relationship with FBG and WC. Low 25(OH)D may be one of the potential risk factors for developing MS in postmenopausal women.

P707
GASTROESOPHAGEAL REFLUX DISEASE IN BISPHOSPHONATE THERAPY IN PATIENTS WITH OSTEOPOROSIS

D. Ruci¹, M. Jordhani¹, A. Zoto¹

¹Rheumatology Department, Tirana, Albania

Objectives: One of the possible side effects of bisphosphonate therapy in patients with osteoporosis is gastroesophageal reflux disease (GERD). Due to patients' noncompliance or other organic gastrointestinal disorders, GERD is one of the most frequent side effects of bisphosphonate therapy. This disease is also one of the most frequent causes of omission of therapy or alternative ways of application (intravenous injection). The aim of this study was to evaluate the frequency of GERD in patients with osteoporosis that are using bisphosphonates and to observe the frequency of inappropriate way of taking bisphosphonates.

Methods: This is an observational study which included 54 female patients treated with alendronate 70 mg/week for more than 6 months. All patients were evaluated for their gastrointestinal status. They were evaluated about the time reflux had begun.

Results: In our study it was observed that 29 patients (53.7%) had somehow gastrointestinal issues after taking the bisphosphonate drug with 12 (41.3%) of them diagnosed with gastroesophageal reflux disease, confirmed by gastrohepatologist consultation. From all evaluated patients, 6 of them (11.1%) had the need to switch to intravenous bisphosphonates due to their aggressive

GERD status. After asking the patients about the way they take the drug, it was found that 34 patients (62.9%) did not take the drug as indicated by their rheumatologist.

Conclusions: From our study it was observed that a significant number of patients with osteoporosis had GERD while on therapy with bisphosphonates. Rheumatologists should be aware of this disorder before prescribing the bisphosphonates orally, and they should warn the patients about the way they should take these drugs, in order to decrease the frequency of this side effect.

P708

LOW DOSE MEDICINE INCREASES BONE MINERAL DENSITY IN WOMEN WITH POSTMENOPAUSAL OSTEOPENIA

R. Nestorova¹, T. Z. Petranova², P. Todorov³

¹Rheumatology Centre "St. Irina", Sofia, ²Clinic of Rheumatology, Medical university, Sofia, ³Clinic of Rheumatology, University Hospital "Caspela", Plovdiv, Bulgaria

Objective: The source of most fractures arises from the larger numbers of women at the more moderate fracture risk caused by osteopenia (T-score between -1 and -2.5 SD).^(1,2) The aim of this study was to evaluate the effectiveness of low dose medicine (LDM)- hormones and essential amino acids (Guna Osteobios) regarding BMD in postmenopausal women with osteopenia.

Methods: We enrolled 14 women in a total course of treatment 52 weeks, following the scheme: 20 drops Guna Osteobios two times daily. BMD was measured in all women before treatment by DXA (femoral neck and total hip) and after treatment on 52 week. DXA was performed in a control group of women with osteopenia without treatment.

Results: BMD and T-score significantly improved on 52 week in a group of LDM, unlike the control group. Mean percentage increase in BMD were as follows: at the femoral neck, 1.52% (n=14; p=0.037) and total hip, 2.14% (n=9; p=0.022). T-score improvement was as follows: at the femoral neck, 0.12 (p=0.014) and total hip, 0.12 (p=0.030).

Conclusions: LDM, presented by Guna Osteobios provides significantly increase of BMD and T-score at the femoral neck and total hip in women with postmenopausal osteopenia. It is an innovative and effective approach in osteoporosis prevention with total absence of side effects.

References:

1. Sanders KM et al. Bone 2006;38:694
2. Seeman E et al. J Bone Miner Res 2008;23:433

P709

PREOPERATIVE FUNCTIONAL STATUS PREDICTS OUTCOMES AFTER PRIMARY TOTAL SHOULDER ARTHROPLASTY

M. J. Best¹, K. T. Aziz¹, R. M. Amin¹, A. Bansal¹, E. Huish¹, U. Srikumaran¹

¹Johns Hopkins Hospital, Department of Orthopaedic Surgery, Baltimore, USA

Objective: To evaluate the effect of dependent functional status on outcomes after primary total shoulder arthroplasty for patients with osteoarthritis of the glenohumeral joint.

Methods: The American College of Surgeons National Surgical Quality Improvement Program was used to identify patients who underwent primary total shoulder arthroplasty (anatomic or reverse) from 2011-2016. Patients whose functional status prior to surgery was dependent were compared with patients who had independent functional status prior to surgery. Demographic data, length of hospital stay, and postoperative complications within 30 d were analyzed. Multivariable logistic regression was used to isolate the effect of functional status on postoperative complications and readmission within 30 d of surgery.

Results: We identified 12,982 patients who underwent primary total shoulder arthroplasty (anatomic or reverse). Patients with dependent functional status comprised 3.2% of the cohort. Dependent patients were older (71.4 y vs. 69.0 y, P<0.001) and were more likely to be female (70.5% vs. 55.6%, P<0.001). Dependent patients had longer hospital stays (3.1 d vs. 1.9 d, P<0.001), higher rate of comorbidities (P<0.001), and higher mean American Society of Anesthesiologists class (P<0.001). Complications including pneumonia (P<0.001), urinary tract infection (P=0.005), cerebrovascular accident (P=0.019), and intraoperative or postoperative blood transfusion (P<0.001) were higher in dependent patients. Logistic regression revealed that dependent functional status was an independent predictor for occurrence of any complication (OR 2.0, P<0.001) and for readmission (OR 2.6, P<0.001).

Conclusions: Patients with dependent functional status prior to undergoing primary total shoulder arthroplasty for osteoarthritis are at increased risk for short-term complications and readmission within 30 d of surgery. Understanding preoperative risk factors for poor outcomes can aid in medical optimization and risk stratification prior to surgery.

P710

SHORT-TERM COMPLICATIONS AND READMISSION FOLLOWING TOTAL SHOULDER ARTHROPLASTY

M. J. Best¹, K. T. Aziz¹, U. Srikumaran¹

¹Johns Hopkins Hospital, Department of Orthopaedic Surgery, Baltimore, USA

Objective: Incidence of total shoulder arthroplasty (anatomic and reverse) is increasing as indications for its use expand. The purpose of this study is to identify predictors of short-term complications and readmission following total shoulder arthroplasty for patients with osteoarthritis of the shoulder.

Methods: The American College of Surgeons National Surgical Quality Improvement Program was used to identify 12,982 patients who underwent total shoulder arthroplasty (anatomic or reverse) from 2011-2016. Demographic data, postoperative complications, and readmission within 30 d were analyzed. Multivariable logistic regression was used to determine independent risk factors for complications and for readmission occurring within 30 d of surgery.

Results: Mean age of the cohort was 69.1 y and 56.1% were female. Postoperative complication rate was 5.6% and readmission rate was 2.8% within 30 d of surgery. Mean American Society of Anesthesiologists (ASA) classification score was 2.6. Independent predictors for any complication included preoperative dependent functional status (OR 1.9, P<0.001), incremental increase in ASA class (OR 1.9, P<0.001 for each increase in class above 1), age >75 y (OR 1.5, P=0.001), and female gender (OR 1.4, P=0.001). Independent predictors for readmission included congestive heart failure (OR 3.3, P=0.002), dependent functional status (OR 2.7, P<0.001) and incremental increase in ASA class (OR 1.6, P<0.001 for each increase above 1).

Conclusions: Short-term complications and readmission following total shoulder arthroplasty are not uncommon. Patients with dependent functional status, age >75 y, congestive heart failure, and incremental increase in ASA classification above 1 are at increased risk for postoperative complications and readmission. Preoperative risk stratification and medical optimization is important in these patients.

P711

IMMOBILIZATION OSTEOPOROSIS AND SARCOPENIA IN PATIENTS WITH VERTEBROMEDULLARY TRAUMA

M. L. Cevei¹, D. Stoicanescu², R. N. Suci¹, F. Cioara¹

¹University of Oradea, Faculty of Medicine and Pharmacie, Oradea, ²University of Medicine and Pharmacie., Victor Babes, Timisoara, Timisoara. Romania

The study was performed on a group of 76 patients hospitalized in Medical Rehabilitation Clinical Hospital Baile Felix, Romania, 84.21% men, diagnosed with vertebromedullary trauma. Their mean age was 36.10 y, ranging from 21-73 y. According to ASIA classification 36.84% had ASIA-A, 31.57% had ASIA-B, 15.78%

ASIA-C and 10.52% had ASIA -D. Osteoporosis was present in 85.71% of cases with ASIA score of A, all patients with B, 33.3% with C and 50% with D. Sarcopenia was present in 42.85% of cases with ASIA score of A, all patients with B, 66.6% cases with C and 50% with ASIA-D. The classification of spasticity using the modified Aschwort scale showed that 57.89% of the cases had spasticity. Out of these 18.18% had modified Aschwort 1, 54.54% had 2, 18.18% had modified Aschwort 3 and 9.09% had 4. The mean duration from the time of the vertebromedullary trauma to the DXA investigation was 38.9 months. 73.68% of these cases had osteoporosis and 63.15% had sarcopenia. Depending on the lesion topography, sarcopenia and osteoporosis were installed in 85.7% patients with cervical vertebromedullary trauma, in 33.3% cases with dorsal vertebromedullary trauma and in 66.6% cases with lumbar trauma. The mean time from the motor deficit onset to sarcopenia detection was 50.5 months in patients with cervical trauma, with variations between 8-104 months; 23.66 months in patients with dorsal trauma, range between 10-50 months; 22.5 months in patients with lumbar trauma, range between 9-36 months.

Conclusions: Osteoporosis and sarcopenia also occur in patients who perform an assisted pathological gait, not only in immobilized cases. Spasticity did not prevent the occurrence of osteoporosis and sarcopenia.

P712

BLOOD TRANSFUSION IN PATIENTS UNDERGOING TOTAL SHOULDER ARTHROPLASTY FOR OSTEOARTHRITIS OF THE GLENOHUMERAL JOINT

M. J. Best¹, K. T. Aziz¹, U. Srikumaran¹

¹Johns Hopkins Hospital, Department of Orthopaedic Surgery, Baltimore, USA

Objective: To identify predictors for blood transfusion in patients undergoing total shoulder arthroplasty for glenohumeral joint osteoarthritis.

Methods: The American College of Surgeons National Surgical Quality Improvement Program was used to identify 12,982 patients who underwent total shoulder arthroplasty (anatomic or reverse) from 2011-2016. Patients who underwent intraoperative and postoperative blood transfusion were identified and compared to those who did not receive a blood transfusion. Multivariable logistic regression was used to determine independent risk factors for blood transfusion.

Results: The rate of intraoperative and postoperative blood transfusion was 3.5% over the study period. Patients who received a blood transfusion were older (73.4 y vs. 68.9 y, P<0.001) had longer operative times (137.8 min vs. 110.71 min, P<0.001), had longer hospital stays (3.9 d vs. 1.9 d, P<0.001) and were more likely to be female (74.2% vs. 55.4%, P<0.001) compared with patients who did not undergo blood transfusion. Patients who received a blood transfusion had higher mean American Society of Anesthesiologists (ASA) classification scores (2.8 vs. 2.5, P<0.001). Logistic regression identified dialysis treatment (OR 3.0, P=0.012), bleeding disorders (OR 2.4, P<0.001), smoking (OR

1.4, $P=0.038$), and female gender (OR 1.8 $P<0.001$) as independent predictors of blood transfusion. Each incremental increase in ASA class was associated with higher odds of blood transfusion (OR 1.9, $P<0.001$). Patients with independent functional status before surgery were least likely to require blood transfusion (OR 0.5, $P<0.001$).

Conclusions: In patients undergoing total shoulder arthroplasty, preoperative factors such as ASA classification, smoking, and functional status can be used to identify patients at increased risk for requiring blood transfusion.

P713

TRABECULAR BONE SCORE IS PREDICTED BY PHALANGEAL QUANTITATIVE ULTRASOUND IN BREAST CANCER POSTMENOPAUSAL WOMEN RECEIVING AROMATASE INHIBITORS

A. Catalano¹, F. Bellone¹, R. M. Agostino², N. Morabito¹, A. Gaudio³, A. Lasco¹

¹University of Messina, Department of Clinical and Experimental Medicine, Messina, ²Medical Oncology Unit, Grand Metropolitan Hospital, Reggio Calabria, ³University of Catania, Department of Clinical and Experimental Medicine, Catania, Italy

Objective: Quantitative ultrasound of bone (QUS) and trabecular bone score (TBS) are recognized tools to explore bone health beyond BMD. The aim of our research was to explore the association of TBS with QUS measurements at phalangeal site in a setting of postmenopausal women taking aromatase inhibitors (AIs).

Methods: BMD at lumbar spine, femoral neck and TBS were evaluated by a DXA densitometer (Hologic Discovery). Amplitude Dependent Speed of Sound (AD-SoS), Bone Transmission Time (BTT) and Ultrasound Bone Profile Index (UBPI) were detected at phalangeal site by Bone Profiler (Igea).

Results: In 102 postmenopausal women (60 AIs treated and 42 controls), at baseline examination, TBS was negatively associated with age ($r=-0.39$, $p<0.001$) and positively related with T-score values at lumbar spine and femoral neck. After 18 months, AD-SoS, UBPI and BTT values were significantly decreased in BC women receiving AIs (-3.7%, -6.45%, -8.5%, respectively, $p<0.001$ for all), but not in controls (-0.7%, -3.53%, -2.97%, respectively). Change of BMD at lumbar spine was significantly different between AIs treated women and controls (-2.94% vs. -0.69%, $p=0.001$) and the same result was observed as for BMD at femoral neck (-2.5% vs. -0.39%, $p=0.01$). Percent change of TBS was significantly greater in AIs treated women in comparison with controls (-2.2% vs. -0.4%, respectively, $p=0.02$). In AIs treated women, but not in controls, CTX levels significantly increased after 18 months [0.47 (0.36 to 0.62) vs. 0.66 (0.43 to 0.77), $p=0.0004$] and the same trend was observed as for BSAP levels [14 (13.01 to 15.57) vs. 15 (13.75 to 16.75), $p=0.003$]. At a multiple regression analysis, change of TBS was independently predicted by change of AD-SoS, after correcting for BMD change at lumbar spine and femoral neck and for modification of CTX and BSAP levels ($\beta=0.37$, $SE=2.44$, $p<0.001$).

Conclusions: TBS modification was independently predicted by phalangeal QUS measurement in AIs treated BC women. Phalangeal QUS may represent an alternative tool to evaluate bone quality also in this setting of patients.

P714

SARCOPENIA IN PATIENTS WITH DEFICITS OF NEUROLOGICAL ETIOLOGY

D. Stoicanescu¹, M. L. Cevei²

¹University of Medicine and Pharmacie, Victor Babes, Timisoara.

²University of Oradea, Faculty of Medicine and Pharmacie, Oradea, Romania

Sarcopenia is a muscle disease characterized by low muscle strength, loss of muscle quantity and quality and low physical performance. Sarcopenia was categorized into primary and secondary. Secondary sarcopenia may occur due to disease-related immobility or disability that leads to physical inactivity. We investigated a group of 78 patients hospitalized in Medical Rehabilitation Clinical Hospital Baile Felix, Romania, 71.8% men. They were diagnosed with vertebromedullary trauma (48.71%), stroke (17.94%) and the remaining cases had other neurological diseases like tumors, meningoencephalitis, multiple sclerosis, congenital arteriovenous malformations, hereditary myopathies, hereditary neuropathies. All patients had motor deficits and have been investigated for the detection of osteoporosis and sarcopenia with DXA. Patients' mean age was 42.2 y, ranging from 21-76 y. 76.92% of the patients had osteoporosis and 48.71% met criteria for diagnosing sarcopenia. In the entire lot, the time from the onset of motor deficit installation to the DXA investigation was on average 40.84 months, range from 6-104 months. In patients with sarcopenia this duration was 38.33 months, range from 6-104 months. Mean muscle mass scaled to height squared in all cases was 0.5527 and in cases with sarcopenia it was 0.4459. Mean number of comorbidities in the study group was 2.79 and in patients with sarcopenia it was 3.

Conclusions: Immobilization or physical inactivity following the installation of motor deficit of various etiologies leads to the early occurrence of sarcopenia. The number of comorbidities did not influence time of onset of sarcopenia.

P715

HANDGRIP STRENGTH TO DISCRIMINATE HIGH FRACTURE RISK IN TYPE 2 DIABETES MELLITUS PATIENTS

F. Bellone¹, N. Morabito¹, C. Scarcella¹, G. Martino¹, A. Sardella¹, G. T. Russo¹, A. Gaudio², A. Lasco¹, A. Catalano¹

¹University of Messina, Department of Clinical and Experimental Medicine, Messina, ²University of Catania, Department of Clinical and Experimental Medicine, Catania, Italy

Objective: To find a useful clinical tool that identifies type 2 diabetes mellitus (T2DM) subjects with poor bone health, finally preventing fragility fractures.

Methods: In a setting of Caucasian subjects with T2DM, anthropometric data and information about metabolic control and diabetic complications were recorded. Handgrip strength by dynamometer, FRAX derived 10-years probability of major osteoporotic fractures and hip fractures were also assessed. Bone evaluation was performed by a DXA densitometer at the lumbar spine (L1-L4) and at the femoral neck; based on specific software, the trabecular bone score (TBS) was calculated. Lateral scan of thoracic and lumbar spine was assessed to investigate morphometric vertebral fractures (Vfx).

Results: 29 patients (female 65%) [median age 67 (60-70)] with T2DM were considered. Morphometric vertebral fractures were detected by DXA in 17% of patients without any gender differences (males vs. females, $p=0.6$). The median ten years probability of fractures was 8.1% and 2.3% as for major osteoporotic or hip fracture respectively. Median femoral neck T-score value [-1.1 SD (-1.8 to -0.5)] was indicative of a slight osteopenia while lumbar spine T-score was even in the normal range [-0.8 SD (-1.5 to -0.1)]. The median TBS value was 1.28 (1.2 to 1.31) and TBS was positively associated with BMD at lumbar spine and femoral neck. Median handgrip strength value was 22.3 kg (18.9 to 31.3). At multiple regression analysis, handgrip strength predicted both lumbar ($\beta=0.009$, SE 0.0034, $p=0.01$) and femoral neck BMD values ($\beta=0.006$, SE 0.002, $p=0.01$). Age ($\beta=-0.008$, SE 0.002, $p=0.007$) and handgrip strength ($\beta=0.01$, SE 0.002, $p=0.0001$) were also independently associated with TBS score, after correcting for mean HbA1c values and time since T2DM diagnosis.

Conclusions: These findings suggest that handgrip strength may be a reliable tool to investigate bone fragility in T2DM.

P716

TRENDS IN INCIDENCE AND IMPROVEMENT IN PERIOPERATIVE MORTALITY FOLLOWING REVISION TOTAL HIP ARTHROPLASTY OVER TWO DECADES: A TESTAMENT TO MULTIDISCIPLINARY PERIOPERATIVE CARE

M. J. Best¹, S. Nguyen², K. T. Aziz¹, R. S. Sterling¹, H. S. Khanuja¹

¹Johns Hopkins Hospital, Department of Orthopaedic Surgery, Baltimore, ²University of California Davis, Department of Urologic Surgery, Sacramento, USA

Objective: To describe the trends in incidence and risk factors for perioperative mortality following revision total hip arthroplasty in the USA.

Methods: The National Hospital Discharge Survey was used to identify all patients who underwent revision total hip arthroplasty from 1990-2010. A cohort of 698,590 patients was identified over the study period. Trends in incidence and mortality over the 20-y period were analyzed and logistic regression was used to isolate independent variables associated with mortality.

Results: Population-adjusted incidence increased from 9.2 per 100,000 in 1990 to 15.3 per 100,000 in 2010 ($P<0.001$). Perioperative mortality was 0.9% over the 20-y period and decreased from 1.5% during the 1990-1999 period to 0.5% in the 2000-2010 period

($P<0.001$). When controlling for confounders, multivariable logistic regression showed that acute myocardial infarction (OR 36.7; 95%CI 33.4 to 40.2, $P<0.001$), pneumonia (OR 16.5; 95%CI 15.0 to 18.1, $P<0.001$) and pulmonary embolism (OR 13.3; 95%CI 11.5 to 15.3, $P<0.001$) were the strongest risk factors for perioperative mortality. When comparing reasons for revision, multivariable regression showed that periprosthetic fracture was associated with the highest odds of mortality ($P<0.001$).

Conclusions: The incidence of revision total hip arthroplasty has increased in the USA while perioperative mortality has decreased over the two decades of the study. Periprosthetic fracture is associated with higher odds of perioperative mortality compared with other reasons for revision. This study highlights the importance of multidisciplinary care, both preoperatively with risk stratification and medical optimization, and postoperatively with improved therapy and pain management protocols for patients undergoing revision hip arthroplasty for osteoarthritis and periprosthetic fractures. A multidisciplinary team approach has contributed to these improved outcomes.

P717

ASSOCIATION BETWEEN COGNITIVE IMPULSIVITY AND BONE MINERAL DENSITY: A CROSS-SECTIONAL STUDY IN POSTMENOPAUSAL WOMEN EVALUATED FOR OSTEOPOROSIS

A. Sardella¹, F. Bellone¹, G. Martino¹, C. Lasco¹, N. Morabito¹, A. Catalano¹

¹University of Messina, Department of Clinical and Experimental Medicine, Messina, Italy

Objectives: The potential involvement of executive functions impairment on BMD is still unclear. The aim of this study was to investigate the correlations between cognitive impulsivity, BMD and fall risk.

Methods: Cognitive impulsivity was measured by Stroop Color and Word Test (SCWT) administration in a setting of 40 consecutively recruited postmenopausal women referring to a outpatients clinic for the evaluation of fracture risk. SCWT is a neuropsychological test able to assess the ability to inhibit cognitive interference: during the administration, women were required to quickly read three different tables of which two represented the "congruous condition" in which participants were invited to read names of colors printed in black ink and name different color patches. In the third table, named "incongruous condition", color-words were printed in inconsistent color ink (e.g. the word "red" is printed in green ink) and participants were required to name the color of the ink instead of reading the word. Women with Mini Mental State Examination (MMSE) score <24 , known neurologic or psychiatric disorders, history of significant hearing or visual impairment, or significant physical disability, history of uncontrolled diabetes and abnormal thyroid function, cancer, heart, respiratory, kidney or liver failure were excluded. BMD was measured at lumbar spine and femoral site by a DXA densitometer (Hologic Discovery). History of falls in the previous 12 months was recorded

Results: Cognitive impulsivity, as highlighted by making errors at the SCWT, was significantly associated with lumbar spine and femoral neck T-score ($r=-0.39$, $p=0.01$ and $r=-0.43$, $p=0.008$; respectively). MMSE score was not associated with T-score values, neither at lumbar spine ($r=0.09$, $p=0.5$) nor at femoral neck ($r=0.2$, $p=0.21$); differently MMSE score was significantly associated both with Stroop test error ($r=-0.34$, $p=0.02$) and time interferences ($r=-0.39$, $p=0.01$). Furthermore, time interference was positively associated with the self-reported history of falls ($r=0.342$; $p=0.031$).

Conclusions: Cognitive impulsivity was significantly associated with BMD values and higher prevalence of falls in postmenopausal women. It could be considered as a possible clinical risk factor for osteoporotic fractures.

P718

QUALITY OF LIFE OF PATIENTS WITH KNEE OSTEOARTHRITIS AFTER REHABILITATION

S. Jandric¹

¹University of Banjaluka, Faculty of Medicine, Department of Physical and Rehabilitation medicine, Banjaluka, Republic of Srpska, Bosnia-Herzegovina

Objectives: Physical therapy and rehabilitation may have a favorable therapeutic effect on the quality of life (QoL) in patients with knee osteoarthritis (OA). The aim of this study was to establish an association between QoL at the end of the rehabilitation with QoL and pain at the beginning of the rehabilitation, duration of rehabilitation and age of the patients with knee OA.

Methods: The study was designed as a retrospective study that included 40 consecutive knee OA patients (30 female and 10 male), average age of 66.7 ± 7.9 y with diagnosis of knee OA according to American College of Rheumatology, that were hospitalized and treated in rehabilitation center. The average duration of the rehabilitation was 18.3 ± 5 d. Program of kinesitherapy, occupational therapy, balneotherapy as well as procedures of the physical therapy were performed in all patients. The instrument used for assessment of the QoL of these patients is a modified version of WOMAC and VAS scale for the pain assessment. All patients completed the questionnaires at the end of rehabilitation. ANOVA test was used to analyze numerical data. WOMAC score at the end of the rehabilitation was dependent variable and predictors were WOMAC score and VAS scale at the beginning of the rehabilitation, duration of rehabilitation and age of the patients.

Results: Average value of the WOMAC score was 24 , 6 ± 11.2 at the beginning and 17.9 ± 9.3 at the end of rehabilitation. WOMAC score of the patients with knee OA at the end of the rehabilitation shows significant association with predictors ($F=22.9$, $p<0.001$). WOMAC score and VAS scale at the beginning of the rehabilitation were significantly associated with WOMAC score at the end of the rehabilitation ($t=4.9$, $p<0.001$, $t=2.5$, $p<0.05$ respectively), but not with duration of rehabilitation and age.

Conclusion: Results of our research show that quality of life at the end of the rehabilitation of the knee OA patients is significantly associated with quality of life and pain at the beginning of the rehabilitation. These findings can be important for planning of early rehabilitation of these patients.

P719

PREVALENCE OF VITAMIN D DEFICIENCY IN RHEUMATIC PATIENTS IN LIMA, PERU

L. F. Vidal Neira¹, R. Morales Olazabal², K. Cueva Tovar², M. Vidal Wilman¹, N. Pasapera Alban², J. Rojas Vilca³

¹Centro de Diagnostico de Osteoporosis y Enfermedades Reumaticas, ²Hospital Maria Auxiliadora, ³Universidad Cayetano Heredia, Lima, Peru

Objective: To assess the status of vitamin D in women ≥ 50 y in three rheumatology outpatient clinics in Lima, Perú.

Methods: 157 patients were evaluated and 25(OH)D, intact PTH, calcium and phosphorus were measured in all the subjects. The mean age was 63.3 ± 8.6 y, most of the patients had a diagnosis of fibromyalgia (50%) and osteoarthritis (30.57%). Women who were taking drugs with potential to alter bone mineral metabolism were excluded as well as those who cannot perform their daily activities.

Results: The average value of 25(OH)D was 18.7 ± 6.7 ng/mL, no difference was found between the subgroups stratified by age (50-60, 61-70 and >70 y) in the values of calcium, phosphorus, 25(OH)D and PTH. No correlation was found between age and 25(OH)D ($r=0.099$, $P=0.212$). We found a weak direct correlation between age and PTH ($r=0.183$, $P<0.05$); and a weak inverse correlation between the values of 25(OH)D and PTH ($r=-0.179$, $P<0.05$). We found values of 25(OH)D <20 , between 20-30 and ≥ 30 ng/mL in 58.6%, 36.9% and 4.5% of patients respectively. The average values of 25(OH)D were lower in the obese patients, compared to the non-obese ones (16.94 vs. 19.42 ng/mL, $P<0.05$). The proportion of subjects with vitamin D deficiency was distributed homogeneously in the different diagnostic categories (fibromyalgia, osteoarthritis, chronic low back pain, others, etc.).

Conclusions: Vitamin D deficiency is highly prevalent in patients with rheumatic conditions; our study found 60% of patients with 25(OH)D ≤ 20 ng/mL that require pharmacologic therapy to correct the deficiency. It is advisable to identify and to correct the deficiency of vitamin D due its impact in different parameters of health.

Disclosures: This study was funded by Laboratorios Perulab, Perú. L. F. Vidal and R. Morales have received research support from Perulab.

P720

TRABECULAR BONE SCORE VALUE IS ASSOCIATED WITH NEW BONE FORMATION INDEPENDENTLY OF FAT METAPLASIA ON SPINAL MRI IN PATIENTS WITH ANKYLOSING SPONDYLITIS

K. Y. Kang¹, J.-Y. Jung¹, S. K. Lee², H. K. Min¹, Y. S. Hong¹, S.-H. Park¹, J. H. Ju¹

¹Catholic University of Korea, Seoul, ²Dongkuk University, Ilsan, South Korea

Objective: To evaluate the association between trabecular bone score (TBS) value and new bone formation in ankylosing spondylitis (AS) patients, and to investigate whether TBS is independently associated with new bone formation.

Methods: 68 patients with AS underwent spinal MRI and DXA of the lumbar spine to measure TBS and BMD at baseline. Lateral radiographs of the cervical and lumbar spine (baseline and 2 years) were assessed for new bone formation (syndesmophyte formation and/or growth combined), and spinal MRIs were assessed for the presence or absence of fat metaplasia (FM) at the 1st–4th lumbar spine segments. The factors associated with new bone formation were analyzed at the patient level and the vertebral level.

Results: New bone formation had developed in 17 (25%) patients at 2-y follow-up. Patients with new bone formation had a higher incidence of FM and lower TBS at baseline than patients without new bone formation ($p=0.013$ and $p=0.041$). At the patient level, baseline syndesmophytes, FM on MRI, and low TBS (<1.23) were significantly associated with new bone formation. At the vertebral level, new bone formation had developed in 25 out of 231 vertebrae (11%) after 2 y. Vertebrae with both FM on MRI and low TBS tended to have more new bone formation ($p<0.001$). Syndesmophytes and low TBS (<1.23) independently increased the risk of new bone formation at the level of individual vertebrae.

Conclusion: At both patient and individual vertebrae levels, low TBS was associated with new bone formation independently of FM on MRI.

P721

INCIDENCE RATES OF FRAGILITY FRACTURES IN A MEXICAN HEALTH SYSTEM

D. Cazares Montiel¹, J. F. Torres Naranjo², A. Fernandez Cortes¹, J. D. D. Meza García¹

¹Hospital de Especialidades ISSSTEP, Puebla, ²Centro de Investigación Ósea CIO, Guadalajara, Mexico

Objective: Fragility fractures are recognized to be a major public health problem in many western nations. Particularly In Latin America is expected that the incidence of fracture increase associated to the demographic changes that will lead to huge increases in the elderly populations of those countries. In the other hand there are effective osteoporosis treatments and best practice frameworks for the prevention of fractures. Health system in Mexico are dealing with the high cost of fractures however the epidemiological trends of fractures have not been studied exten-

sively in our country. Our aim was to evaluate the incidence rates of fragility fractures in middle-aged and elderly men and women in a Mexican health system.

Methods: Individuals over 40 y, who were attended in ISSSTEP (Puebla, Mexico) and sustained a fragility fracture, between 1 January 2005 and 31 December 2018, were included. Medical electronic diagnosis registers were used to identified fracture patients. Age-adjusted and age-specific incidence rates for men, women were calculated.

Results: A total of 1800 hip fractures (713 men, 1087 women, 632 vertebral fractures (157 men, 475 women), and 6197 wrist fractures (1404 men, 4793 women) were identified. The age-adjusted fracture rates per 10,000 were for hip 11 and 7, wrist 48 and 13, and vertebral 5 and 2 for women and men, respectively. Age specific fracture incidence rates were significantly higher in women than in men, and the highest incidence rates for hip fracture (27, 95%CI 22 – 30) were observed in women over 70.

Conclusion: Incidence rates adjusted for age of hip, wrist and vertebral fracture in men and women over 40 are lower than international reports. Future research is guaranteed to explore the causes.

P722

A TOOL TO IDENTIFY POSTMENOPAUSAL WOMEN WITH HIGH FRACTURE RISK IN SRI LANKA

H. Subasinghe¹, S. Lekamwasam², P. Ball³, H. Morrissey³, E. I. Waidyaratne²

¹Faculty of Allied Health Sciences, University of Ruhuna, Galle, Sri Lanka, ²Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka, ³School of Pharmacy, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK

Objective: To develop and validate fracture risk prediction tool for Sri Lankan postmenopausal women (PMW) to be used in areas with no DXA facility.

Methods: Two groups of community-dwelling PMW were enrolled to development (n=602) and validation (n=339) samples. Risk of osteoporotic fracture, both major (MOFR) and hip (HFR) were estimated with Sri Lankan FRAX model. Radial ultrasound (US) bone scan was also done. Linear regression models were used with fracture risks as dependent and clinical risk factors as independent variables to develop formulae. $MOFR \geq 11$ or $HFR \geq 3$ were considered as intervention thresholds¹. Sensitivity (sn), specificity (sp), positive and negative predictive values (PPV and NPV) were assessed to validate the new tools. R², SEE and Bland-Altman plots were used to assess difference of actual and estimated values.

Results: Mean (SD) body weight (BW) of the development and validation samples were 53.8 (10.1) and 51.8 (10.4) kg, respectively. Both samples were within 40-89 y age. Fracture risk assessment tool 1 (FRAT-1) was built with age, body weight and US T-score while, Fracture risk assessment tool 2 (FRAT-2) was built with age and body weight. FRAT-1 included the following formulae.

$$\bullet \text{ MOFR.E1} = -7.984 + (0.264 * \text{age}) + (-0.057 * \text{BW}) + (-0.376 * \text{T_US})$$

- $HFR.E1 = -1.541 + (0.104 * age) + (-0.065 * BW) + (-0.196 * T_US)$
- FRAT-2 included the following formulae.
- $MOFR.E2 = -6.377 + (0.273 * age) + (-0.087 * BW)$
- $HFR.E2 = -1.099 + (0.115 * age) + (-0.08 * BW)$

Prevalence of high fracture risk in the validation sample was 35.3% and it was 33.2% and 30.8% based on FRAT-1 and FRAT-2 estimations. Sensitivity and specificity of FRAT-1 were 59.7% and 81.5%. The corresponding values of FRAT-2 were 59.3% and 84.7%. PPV of FRAT-1 and FRAT-2 were 64.2% and 68% while NPVs were 78.5% and 79.2%. FRAT-2 showed higher R2 and lower SEE than FRAT-1. All Bland-Altman plots showed >94% agreements between estimated and actual MOFR and HFR.

Conclusion: Compared to FRAT1, FRAT-2 has high predictive ability of MOFR and HFR and more convenient to use in settings with limited facility.

Reference: 1. Lekamwasam S. Arch Osteoporos 2013;8:148

Acknowledgement: Funded by the University of Wolverhampton.

P723

EVALUATION OF CALCIUM INTAKE OF CHILDREN IN DIFFERENT AGE GROUPS

K. Belova¹, O. Ershova², A. Marusina², K. Gordzheladze¹

¹Yaroslavl State Medical University, ²Yaroslavl State Medical University, Yaroslavl, Russia

Objective: Adequate calcium intake is an important requirement for bone tissue growth and development in childhood and adolescence. Due to the change of modern dietary stereotypes, many children do not consume enough dairy products. It can lead to a calcium intake shortage and peak bone mass insufficiency.

Methods: We conducted a survey among children who study at 2nd (7-9 y), 6th (11-13 y) and 10th (15-17 y) grades of secondary school (totally 243 kids). It included questions devoted to consumption of dairy products (milk, yogurt, cottage cheese, cheese) with the specification of the portion size and the number of such portions per week. Normal calcium intake according to the Institute of medicine (IOM, USA) guidelines was estimated: 1000 mg/d for 4-8 year-olds, 1300 mg/d for 9-18 year-olds. We used the one factor Fisher ANOVA analysis.

Results: The average calcium intake was 1194 mg/d (for 7-9 year-olds – 1461 mg/d, for 11-13 year-olds – 1119 mg/d, for 15-17 year-olds – 950 mg/d (p1.2<0.05, p2.3=0,05, p1.3<0.001)). 111 (45.68%) children had the normal calcium consumption, 82 (33.74%) consumed 50-99% of the daily norm, 50 (20.58%) children had <50%. In the age groups of 7-9, 11-13 and 15-17 year-olds the normal calcium intake was observed in 49.44%, 51.32%, 35.90% of children, respectively; 50-99% of the daily norm was consumed by 34.83%, 26.32%, 39.74% in these groups, <50% was taken by 15.73%, 22,37% and 24, 36%.

Conclusions: Thus, the lowest calcium intake was consumed by the children aged 15-17. In the age groups of 11-13 and 15-17, there was insufficient average calcium intake. In the age groups of 7-9 and 11-13, a normal amount of calcium was revealed in

about 50% of children, in the group of 15-17 their share reduced to 36%. The limitation of the study may be self-completion of the questionnaire by children, so calcium intake may not be accurately assessed, especially in younger children. Thus, national programs are required to increase calcium intake by children, especially among teenagers.

P724

FRAILTY SYNDROME AND RELATED FACTORS IN A SENIORS' SAMPLE IN IRAN: A CROSS-SECTIONAL ANALYSIS

F. Sharifi¹, Z. Badrkhahan², G. Shafiee³, H. Fakhrzadeh¹, M. Arzaghi¹, R. Heshmat³, N. Mehrdad⁴, A. Ostovar⁵, I. Nabipour⁶, L. Bagher⁴

¹Tehran University of Medical Sciences/ Endocrinology & Metabolism Population Sciences Institute/ Elderly Health Research Center, Tehran, ²Tehran University of Medical Sciences, School of Medicine, Tehran, ³Tehran University of Medical Sciences/ Endocrinology & Metabolism Population Sciences Institute/ Chronic Diseases Research Center, Tehran, ⁴Tehran University of Medical Sciences/ Endocrinology & Metabolism Clinical Sciences Institute/ Endocrinology & Metabolism Research Center, Tehran, ⁵Tehran University of Medical Sciences/ Endocrinology & Metabolism Clinical Sciences Institute/ Osteoporosis Research Center, Tehran, ⁶Bushehr University of Medical Sciences/ The Persian Gulf Biomedical Sciences Research Institute/ The Persian Gulf Marine Biotechnology Research Center, Bushehr, Iran

Objective: Frailty is a condition with a decline in reserve and function that is accompanied by several adverse health outcomes. The distribution of frailty syndrome in older population in the Middle East has not been reported. The aims of this study were an estimation of the prevalence of frailty and associated factors in a community-dwelling elderly population in Iran.

Methods: The sampling was conducted in Bushehr city by a multistage cluster random method in 2016. Demographic, past medical history, and lifestyle data were gathered by interviewing. Anthropometric measures were collected based on a standard guideline. Overnight fasting blood samples were taken and fasting blood sugar (FBS), HbA1C, using automatic standardized devices. diabetes mellitus and hypertension were defined according to standard guidelines. Survey analysis was performed for all analyses. Frailty was defined according to Fried's frailty phenotype. The criteria included self-reported unintentional weight loss ≥10 lbs in the past year, self-reported exhaustion, the slowness that was defined based on sex and height, the weakness that was considered as the lowest quintile of mean hand grip measures, and low physical activity that was defined as the lowest metabolic equivalents (METs) quintile. Prefrailty and frailty phenotypes were defined when existed one or two criteria and three or more criteria, respectively.

Result: Finally, data of 2392 subjects were analyzed. The mean age of them was 69.29(SD=6.34) and 51.6% of them were female. The prevalence of prefrailty and frailty were calculated as 8.06% (7.06% - 9.20%) and 42.89% (40.87% - 44.94%), respectively. Frail-

ty was more common in female than male [9.63 (8.18-11.32) vs. 6.40 (5.11-7.97)]. The prevalence was increased by the aging of the participants (2.53% in 60-64 years group vs. 55.55% in 80+ years one). After adjustment for age, gender, BMI, smoking and alcohol consumption, there was an association between frailty and age (odds ratio=1.17; 1.14-1.20), gender(male/female) (OR=0.46; 0.32-0.65), and BMI (0.93; 0.89-0.97).

Conclusion: It seems that the prevalence of frailty syndrome in a sample of the Iranian population is similar to southern Europe. Moreover, frailty is more frequent in the oldest age, tinny female than other elderly population.

P725

GEOMETRY OF THE PROXIMAL FEMORAL BONE IN TYPE 1 DIABETIC WOMEN

N. Karytska¹, A. Shepelkevich², Y. Dydyska², N. Vasilyeva³, V. Zhukouskaya⁴, V. Vadzianava⁵

¹10th city clinical hospital, Minsk, Belarus, ²Belarusian State Medical University, Minsk, Belarus, ³Republic Center of Endocrinology and Medical Rehabilitation, Minsk, Belarus, ⁴Department of Clinical Medicine and Surgery, Division of Endocrinology, University of Naples Federico II, Naples, Italy, ⁵Belarussian Medical Academy of Postgraduate Education, Minsk, Belarus

Objective: In type 1 diabetic patients there are changes in bone quality and density and increase in the number of traumatic falls, which leads to an elevated risk of fractures. The fractures of the proximal femoral bone are associated with increased mortality, morbidity, disability, sharp decrease in the quality of life and increased healthcare costs. The aim of the study was to compare femoral bone density, structure, and strength assessments obtained from DXA measurements in a group of women with and without type 1 DM.

Methods: The study was performed on 68 women with type 1 diabetes (mean age: 31.5±8.6; duration of DM: 11±7.4 y; age of onset: 17±6.67) and 53 healthy women matched for age, weight, and height. BMD in the femoral neck, hip axis length (HAL), cross-sectional area and moment of inertia (CSMI), compressive strength index (CSI) and impact strength index (ISI), femur strength index (FSI) and glycated hemoglobin (HbA1c) were measured.

Results: Femoral neck BMD and HAL were significantly lower in the fracture group in comparison with control group. Mean CSMI was not significantly different between women with type 1DM and control group. However, there is a tendency of decreased CSMI in the diabetic women. CSI and ISI are significantly lower in fracture group compared with the controls. Differences in FSI did not reach statistical significance. BMD changes and hip strength parameters did not correlate with HbA1c.

Conclusion: We conclude that femoral variables are significant independent predictors of hip fracture.

P726

ASSOCIATION OF SARCOPIENIA AND ITS PARAMETERS WITH METABOLICALLY HEALTHY OBESITY: THE BUSHEHR ELDERLY HEALTH (BEH) PROGRAM

R. Heshmat¹, G. Shafiee¹, A. Ostovar², N. Fahimfar², F. Sharifi³, S. Gharibzadeh², I. Nabipour⁴, A. Raeisi⁵, B. Larijani⁶

¹Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, ²Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, ³Elderly Health Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, ⁴The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, ⁵School of Medicine, Shiraz University of Medical Sciences, Shiraz, ⁶Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Objective: Sarcopenia is a common problem in elderly with the adverse outcomes and characterized by progressive and generalized loss of skeletal muscle mass and muscle function. The aim of this study was to associate the sarcopenia and its parameters with metabolic phenotype in older adults with and without obesity.

Methods: A total of 2426 Iranian adults aged ≥60 y, participating in the stage II of Bushehr Elderly Health (BEH) program, a population-based prospective cohort study; were included.

Skeletal muscle mass index (SMI) <7.0 kg/m² and <5.4 kg/m² were considered as low muscle mass among men and women, respectively low muscle strength was defined as grip strength <26 kg or <18 kg for men and women, respectively, and a usual walking speed ≤0.8 m/s was defined as low physical performance for both genders. Body composition was measured by the DXA method. The metabolically healthy phenotype was defined using the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) criteria. Overweight/obesity was defined as BMI ≥25.0 kg/m². Study participants were categorized into four groups: 1. metabolically healthy nonobese (MHNO) subjects: BMI<25.0 kg/m² and <2 metabolic syndrome traits; 2. MUNO subjects: BMI <25.0 kg/m² and ≥2 metabolic syndrome traits; 3. MHO: BMI ≥25.0 kg/m² and <2 metabolic syndrome traits; or 4. MUO: BMI ≥25.0 kg/m² and ≥2 metabolic syndrome traits. Logistic regression was used to calculate odds ratios and 95% CIs.

Results: Overall, the prevalence of sarcopenia in MUO, MHO, MUNO, and MHNO was 19.6%, 22.4%, 62.5% and 62.2%, respectively (P<0.001). In multivariate logistic regression analyses, regardless of metabolically healthy status, high BMI significantly decreased risk of sarcopenia independent of age, sex, physical activity, smoking and total body fat [OR = 0.11 (0.08-0.15 in MUO, OR = 0.22 (0.14-0.34 in MHO)]. Also, high BMI was shown to be a protective factor for low SMI and low muscle strength regardless

of metabolically healthy status (MHO, MUO). However, there was excess risk in people with MUO for low physical performance (OR: 1.40; CI: 1.02-1.97).

Conclusions: High BMI represents a possible protective factor for sarcopenia, low SMI and low muscle strength regardless of metabolically healthy status among a group of community-dwelling Iranian elderly.

P727

COMPARISONS OF PREVALENCE OF AND RISK FACTORS FOR SARCOPENIA BY EWGSOP1 AND EWGSOP2 DIAGNOSTIC CRITERIA AMONG COMMUNITY DWELLING OLDER PEOPLE OF IRAN: THE BUSHEHR ELDERLY HEALTH (BEH) PROGRAM

G. Shafiee¹, R. Heshmat¹, A. Ostovar², F. Sharifi³, N. Fahimfar², S. Gharibzadeh², I. Nabipour⁴, A. Raeisi⁵, B. Larijani⁶

¹Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, ²Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, ³Elderly Health Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, ⁴The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, ⁵School of Medicine, Shiraz University of medical Sciences, Shiraz, ⁶Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Objective: In early 2018, the European Working Group on Sarcopenia in Older People (EWGSOP2) focused on low muscle strength as a key characteristic of sarcopenia, and provided clear cutoff points for variables identifying sarcopenia. Therefore, due to different criteria i.e. different measures, correction factors and cutoff points, the prevalence rates vary across literature. This study aimed to compare the prevalence and risk factors of sarcopenia in community-dwelling older people by the EWGSOP1 and EWGSOP2 diagnostic criteria in Iran.

Method: A total of 2426 Iranian adults aged ≥ 60 y, participating in the stage II of Bushehr Elderly Health (BEH) program, a population-based prospective cohort study, were recruited.

We compared the prevalence of sarcopenia in our population by 2 diagnostic criteria of EWGSOP. According to EWGSOP1 definition, individuals were considered: presarcopenia (low muscle mass), sarcopenia (low muscle mass with low hand grip strength/low muscle performance) and severe sarcopenia (low muscle mass with low hand grip strength+low muscle performance). Based on EWGSOP2 definition, individuals were considered: probable (low muscle strength), sarcopenia (low hand grip strength with low muscle mass) and severe sarcopenia (The existence of 3 parameters together). Reference data from a normative Iranian population are available for detecting parameters of sarcopenia. Accordingly, the cutoff values for low skeletal muscle mass index

(SMI) were 7.0 kg/m² and 5.4 kg/m² among men and women, respectively. The muscle strength were handgrip strength < 26 kg for men and < 18 kg for women; while the cutoff value for low physical performance was a usual walking speed < 0.8 m/s for both genders. Body composition was measured by DXA.

Results: The prevalence of sarcopenia was 21.8-13.6% in men and 13.0-8.0% in women according to EWGSOP1 and EWGSOP2 criteria. The prevalence of severe sarcopenia was 13.9% in men and 18.5% in women, with both criteria. However, using EWGSOP1 criteria, the prevalence of presarcopenia was higher in men than women (27.3% vs. 5.3%). When it is defined by EWGSOP2 criteria, 37.9% of women have probable sarcopenia. The multiple logistic regression models of the risk factors for sarcopenia reveal that the coefficient of age is > 1 indicating that getting older increases the odds of sarcopenia in both genders, in both sarcopenia definitions. Similarly, high fat mass among men and women seems to have higher odds ratio of sarcopenia in two definitions (OR between 2.18 and 2.57 in men, 2.37 and 5.79 in women).

Conclusions: The prevalence of sarcopenia varied largely using different criteria. If the probable sarcopenia, sarcopenia, and severe sarcopenia are determined in Iranian population based on EWGSOP1 definition and Iranian cutoff, the result will be different from that of with EWGSOP2 definition and Iranian cutoff. Some adverse outcomes should be considered for estimating the risk of sarcopenia among old Iranian to compare the accuracy of EWGSOP1 and EWGSOP2.

P728

CURRENT KNOWLEDGE AND ACCEPTANCE OF SAME STAGE BILATERAL KNEE REPLACEMENT AMONG HONG KONG CHINESE PATIENTS WITH OSTEOARTHRITIS

C. M. L. Lau¹, Y. H. Hung², K. B. Kwok², C. H. J. Fan², K. Y. Chung³, K. W. K. Ho⁴

¹Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, ²Department of Orthopaedics & Traumatology, Alice Ho Miu Ling Nethersole Hospital, ³Department of Orthopaedics & Traumatology, Prince of Wales Hospital, ⁴Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, China

Objective: Prevalence of knee osteoarthritis is increasing globally and same stage bilateral knee replacement (SSBKR), with controversial risks and benefits, is one potential treatment option for well-selected patients. Patient knowledge and acceptance of SSBKR in developed countries has not yet been explored in previous literature. This study aimed to examine the current state of knowledge and attitudes to SSBKR to help inform future patient education.

Methods: This is a cross-sectional survey study. The included subjects are TKR candidates referred to a public sector joint replacement centre from January 2016 to December 2016 and they completed a standardized questionnaire. The Primary outcome was the proportion of patients who were aware of and accepted

SSBKR. Secondary outcomes included factors associated with barriers to accepting SSBKR and their preferred medium of education.

Results: 43.8% of patients were unaware of the option of SSBKR. 57.2% of patients reported that they would opt for SSBKR if they were given the choice. Age and employment status significantly affected choice of operation. Effect of SSBKR on daily activity during recovery period was the main concern for 48.6% of the patients. Nurse clinics, patient sharing groups and educational videos were well-accepted methods for delivering patient education.

Conclusions: Nearly half of the TKR candidates in this study were unaware of the option of SSBKR, which could be a surgical option with good patient selection. Knowledge transfer for SSBKR could be improved through nurse clinics, patient sharing groups and educational videos.

P729

RESPONSE OF PTH IN VITAMIN D DEFICIENCY IN A RANDOMLY SELECTED, HEALTHY, URBAN MULTIETHNIC MALAYSIAN POPULATION

S. C. Thambiah¹, Y. Y. Lai¹, S. S. Yeap², I. N. Samsudin¹, S. Y. Zahari Sham¹, N. Zainuddin¹, N. Shahifar¹, S. Md Said³, G. Appannah⁴, F. L. Hew²

¹Department of Pathology, Faculty of Medicine and Health Sciences, University Putra Malaysia, ²Puchong Specialist Centre, Puchong; Subang Jaya Medical Centre, Subang Jaya, ³Department of Community Health, Faculty of Medicine and Health Sciences, University Putra Malaysia, ⁴Department of Nutrition and Dietetics, Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor, Malaysia

Objective: Not all subjects with vitamin D deficiency (VDD) develop secondary hyperparathyroidism (SHPT). Inappropriately normal PTH levels in VDD is known as 'functional hypoparathyroidism' (FHPT)¹. This study aimed to compare FHPT to SHPT in VDD subjects in a healthy Malaysian population.

Methods: A random sample of the population aged between 44-90 y from 2 districts in the state of Selangor, Malaysia, was invited by post for a free bone health checkup. Patients with diseases known to affect bone metabolism or were on treatment for osteoporosis were excluded. All subjects had their BMD measured with DXA. 25(OH)D, iPTH, calcium, phosphate, magnesium, creatinine and C-terminal telopeptide of type I collagen (CTX), procollagen type I N-terminal propeptide (PINP) were measured on Siemens and Roche analysers, respectively. VDD was defined as 25(OH)D <50 nmol/L. FHPT (≤ 7.63 pmol/L) and SHPT (> 7.63 pmol/L) were defined arbitrarily based on the iPTH level within and above the laboratory reference range, in the presence of VDD.

Results: 401 subjects came for assessment. 155 (39%) had VDD. Median iPTH was significantly higher in VDD group (5.7 pmol/L) compared to non-VDD (4.9 pmol/L). Further analysis was done in VDD only. 77% (119/155) subjects had FHPT. No significant difference was noted between FHPT and SHPT for age, gender and race. However, within female ($p=0.041$) and Chinese ($p=0.045$) subjects, femoral neck (FN) BMD was higher in FHPT compared

to SHPT. Phosphate ($p=0.034$) and iPTH (<0.0001) were higher and lower in FHPT than SHPT, respectively. iPTH was negatively correlated with phosphate ($p<0.0001$) only. After adjustment for phosphate, magnesium, adjusted calcium, creatinine and 25(OH)D, iPTH was positively correlated with CTX ($p=0.004$).

Conclusions: 39% of healthy Malaysians had VDD; 77% had FHPT. In Chinese and females, FHPT was associated with higher FN BMD than SHPT. Magnesium and calcium did not explain the PTH response in VDD. This study identifies a distinct group of subjects with VDD who show FHPT-related bone protection. This may be one of the reasons why 25(OH)D does not always correlate with BMD.

Reference: 1. Sahota O et al. Bone 2004;35:312

Acknowledgement: Project funded by FRGS/1/2015/SKK03/UPM/02/1

P730

MALE OSTEOPOROSIS CAUSES IN A DEVELOPING COUNTRY

R. Clapauch¹, S. Buksman², Y. Schrank³

¹Universidade do Estado do Rio de Janeiro, ²Instituto Nacional de Traumatologia Ortopedia (INTO), ³Diagnósticos da América, Rio de Janeiro, Brazil

Objective: To investigate causes of male osteoporosis in Brazil, a multiracial country with a developing economy, according to WESP World Economic Situation and Prospects 2017 (United Nations).

Methods: Men diagnosed as osteoporotic through a spontaneous demand densitometry campaign were referred to a tertiary center where identification data, medical history and laboratorial exams were collected.

Results: 110 consecutive men were analyzed. Mean age was 68 ± 8 y and mean BMI 24 ± 4 kg/m². Constitutional factors were present in 83% of the osteoporotic patients (more than one can apply): being white (73%), age ≥ 70 y (41%) and familiar history of osteoporosis (22%, among which 14% from their mother). However, only 2 men (1, 8% of the sample) showed only constitutional causes for their osteoporosis. Lifestyle factors were present in 76% of the sample: 67% were longtime smokers, with a mean 750 cigarettes/d/y; 40% reported drinking and 21% assumed more than one dose of alcohol per day, during more than 50 y; 32% of all men were simultaneously smokers and drinkers. Hypogonadism was diagnosed in 28% of the osteoporotic men; prolonged use of corticosteroids in 16%; malabsorption in 10%; rheumatoid arthritis in 7%; primary or secondary hyperparathyroidism in 6%.

Conclusions: The majority of our sample (81, 2%) showed mixed constitutional and acquired (related to lifestyle) causes for osteoporosis. Hypogonadism was prevalent in more than one fourth of these men, but it can also be related to lifestyle habits, such as drinking. Incident medications and diseases were minor osteoporosis causes in our setting. In a multiracial country with a developing economy and upper middle per capita income, constitutional factors still represented an important determinant of fu-

ture osteoporosis. Screening as they age and especially lifestyle preventive measures should be emphasized to white men with a familiar history of osteoporosis in a developing country.

P731

WHAT IS YOUR RISK? PATIENT SELF-PERCEIVED FRACTURE RISK AND ITS COMPARISON TO FRAX ASSESSMENT

L. Tripto-Shkolnik¹, G. Zacay², S. Cohen³, I. Vered¹, A. Tirosh¹

¹Division of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, ²Department of Family Medicine, Meuhedet Health Fund, Kiriati Ono, ³Division of Diagnostic Imaging, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

Objective: Osteoporosis is underdiagnosed and undertreated. Self-perceived estimation of poor outcome by patients influences health-related behavior. BMD measurement is a mainstay of osteoporosis diagnosis, with fracture risk calculation by FRAX assisting in treatment decisions. Data on self-perceived vs. actual fracture risk is scarce. We aimed to compare self-assessed fracture risk and concern in a cohort of individuals undergoing BMD measurement to the FRAX-derived risk.

Methods: DXA examinees were offered a patient reported outcomes (PRO) tool regarding fracture risk, concern of fractures and willingness to receive treatment. Routine pre-test questionnaire provided information on risk factors. BMD and trabecular bone score (TBS) results were recorded. TBS-adjusted FRAX score was calculated using country-specific model.

Results: 69 patients (aged 63.2±11.3, 73% women) completed the PRO tool. Median TBS-adjusted major osteoporotic fracture (MOF) and hip fracture risk were 8.9 (IQR 5.2-14.45) and 1.8 (IQR 0.4-4.3), respectively. In general, a significant correlation existed between FRAX-derived and self-perceived risk for MOF ($R=0.291$, $p<0.05$). Fracture concern similarly correlated with MOF-FRAX score ($R=0.335$, $p<0.05$). Most examinees overestimated their fracture risk ($Z=-3.732$, $p<0.001$). Logistic regression showed that previous fracture or parental hip fracture increased the risk of underestimation by an odds ratio of 5 and 7.3, respectively ($p<0.05$). No correlation was shown between self-perceived risk or concern and willingness to receive treatment.

Conclusions: Surprisingly, while overall people were inclined to overestimate their risk, they tend to ignore well recognized fracture risk factors. Educational efforts must be exerted to bridge the gap between self-perceived and actual fracture risk, mainly in the high-risk group.

P732

USE OF THE METHOD OF PERSONALIZED PHYSIOTHERAPY IN THE REHABILITATION OF WOMEN WITH OSTEOPOROSIS COMBINED WITH RHEUMATOID ARTHRITIS

N. V. Aleksandrova¹, V. A. Aleksandrov², I. V. Cherkashina³, L. N. Shilova², M. V. Nikitin⁴, A. V. Aleksandrov⁵, I. Y. Alekhina⁶, I. A. Zborovskaya¹

¹Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovskiy, Volgograd, ²Volgograd State Medical University, Volgograd, ³S.M. Kirov Military Medical Academy, Saint-Petersburg, ⁴"Sanatorium-resort complex Vulkan" - Branch Federal state budget institution "National Medical Research Center for Rehabilitation and balneology", Gelendjik, ⁵Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovskiy, Volgograd State Medical University, Volgograd, ⁶Stavropol State Medical University, Stavropol, Russia

Objective: Rheumatoid arthritis (RA) occupies a special place among various diseases that may be the cause of secondary osteoporosis (OP). For rational patient care it is proposed to use the method of personalized physiotherapy with a preliminary assessment of the phenotypic parameters that determine the effectiveness of treatment. Our aim was to find the determinants of the effectiveness of personalized physiotherapy during the medical rehabilitation of women with osteoporosis in combination with RA.

Methods: The study included 63 RA female patients with minimal pathological process activity (DAS28 <3,2). The presence of OP was diagnosed on the basis of DXA in the proximal femur and lumbar spine. The patients were divided into two groups: the main (n=45) and control (n=18). The rehabilitation program (the main group) included kinesiotherapy (dosed walking), hydrokinetic therapy and low-frequency magnetotherapy (0.3-100 Hz, up to 5 mT, duration of exposure 30 min, 10 procedures every other day).

Results: The results of the linear correlation analysis made it possible to establish the presence of a reliable correlation of the improvement in the complex clinical indicator DAS28 after the course of rehabilitation with initial values of the pain scores on the VAS scale ($r=0.80$, $p=0.035$), morning stiffness ($r=0.81$; $p=0.041$), level of ESR ($r=0.67$, $p=0.043$), C-reactive protein ($r=0.63$, $p=0.029$), antibodies to xanthine oxidase ($r=0.66$; $p=0.036$) and the BMD of the hip bone according to the T-criteria ($r=0.54$; $p=0.04$). To determine the main groups of indicators characterizing the effect of the rehabilitation program, a canonical correlation analysis was performed. The data obtained were confirmed by the results of factor analysis, which showed that the main factors that significantly affect the dynamics of the DAS28 parameter (73% of the variance of the indicator) are clinical and functional indicators (37%), parameters of inflammatory process activity (23%) and psychophysiological parameters (13%).

Conclusion: Thus, personalized physiotherapy of OP with RA patients represents a new approach to the prescription of physical therapeutic factors (for example, such as low-frequency physiotherapy), which is based on data on the clinical, biochemical and immunological status of patients.

P733

FRACTURE RISK ASSESSMENT IN PATIENTS WITH OSTEOPOROTIC FRACTURES INCLUDED IN SECONDARY FRACTURE PREVENTION PROGRAM

O. Ershova¹, K. Belova¹

¹Yaroslavl State Medical University, Yaroslavl, Russia

Objective: Secondary fracture prevention services are being established in many countries. One of their main objectives is the assessment of the subsequent fractures risk. Our aim was to assess the risk of subsequent fractures in patients with osteoporotic fractures included in secondary fracture prevention program in Emergency Regional hospital n.a. N.V. Soloviev, Yaroslavl, Russian Federation.

Methods: Fracture risk assessment was performed in 582 patients (mean age 72.54±9.86 y). The assessment of the subsequent fractures risk included: analysis of the risk factors; calculation of 10-y probability of fracture (FRAX); DXA (Hologic Explorer, USA, 2006).

Results: Among surveyed patients risk factors of osteoporosis were noted in 526 (90.38%) patients, the majority had several of them (two - 225 (38.66%), three - 85 (14.60%), four or more - 19 (3.26%)). Previous low-energy fractures were found in 261 (44.85%) people, two fractures – in 75 (12.89%), three or more – in 16 (2.75%). The other risk factors were smoking (12.20%), early menopause (22.32% among included women), hip fracture in parents (6.01%). FRAX was calculated in 573 (98.45%) patients. A high risk of fractures was revealed in 116 (20.24%) patients. Assessment of BMD was performed in 292 (50.17%) patients, examination of the rest was not carried out due to the severity of their condition after surgery (more than 90% of them had hip fracture). Osteoporosis by DXA was revealed in 141 (48.29%) persons, osteopenia in 117 (40.07%), normal BMD - in 34 (11.64%).

Conclusion: Thus, fracture risk assessment in patients included in secondary fracture prevention program revealed a high prevalence risk factors of osteoporosis, the most common were previous fragility fractures, early menopause, smoking, hip fracture in parents. High fracture risk by FRAX was diagnosed in 20.24%. Osteoporosis in DXA was found less than in 50% of patients, and more than 10% of fractures occurred in patients with normal BMD.

P734

CHANGES OF ORTHOTROPIC PROPERTIES OF BONE TISSUE DURING UNLOADING HANGING

N. Kharin¹, O. Sachenkov¹, T. Baltina¹, O. Gerasimov¹, M. Baltin¹, A. Fedyanin¹, P. Bol'Shakov¹

¹Kazan Federal University, Kazan, Russia

Objective: Studies performed that anisotropic properties of the bone tissue can be reduced to orthotropic properties. It means that physical activity influence on the musculoskeletal system and it can be a reason of evolution of biomechanical structures. It means that biomechanical structure of bone tissue can be described by 9 numerical parameters and 3 directions instead of 27 numerical parameters. All tests were conducted on nonlinear laboratory rats (180-200 g). As a model of gravitational unloading we used antiortostatic support model (1). All experiments were performed according to bioethical standards and were approved by local ethical committee of the Kazan Federal University. Chloral hydrate was used for anesthesia (5 mg/kg, intraperitoneal, Sigma-Aldrich).

Method: Extracted femoral bones were scanned on μ CT in diaphyseal region. μ CT data was discretized by cubes. For every cube orthotropic properties was calculated. For this purpose numerical mechanical tests were carried out. Statistical analysis was used to understand is orthotropic properties constant or depend on location in space. Different groups were investigated: control and microgravity groups with different time of unloading hanging (7, 14, 21, 30 and 40 d).

Results: The results of orthotropic properties of diaphysis of the bone were as follows. For control group transversal isotropy was detected: the greatest stiffness was directed in longitudinal direction and stiffness is equal in transverse direction. During unloading the stiffness directions starts to rotate. Stiffness in longitudinal direction became not constant (it decreases in distal regions). With increasing unloading time the main stiffness turns in transverse direction.

Conclusion: These results emphasize that the bone orthotropic properties changes during unloading. Bone tissue in unloaded bones adapt to external forces and orthotropic properties of the tissue changes significantly. These results mean that bone tissue can be described by 9 parameters.

Reference: 1. Baltina T et al. BioNanoScience 2018;8:864

Acknowledgement: The work was supported by the Russian Science Foundation within the scientific project No. 18-75-10027.

P735

CORRELATION OF THE IL-6 AND IL-17 VALUE WITH THE BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN WITH CARDIOVASCULAR DISEASES

O. Ershova¹, K. Belova¹, A. Baranov¹, I. Novikova¹, M. Ilyin¹

¹Yaroslavl State Medical University, Yaroslavl, Russia

Objective: The increased production of proinflammatory cytokines (IL-6 and IL-17) leads to an acceleration of bone resorption by the expression of RANKL [1]. Although there are data that IL-17 can have a protective effect on the bone through the suppression of adipogenesis and subsequent expression of leptin [2]. In addition, the level of IL-6 and IL-17 is significantly higher in postmenopausal women with cardiovascular diseases due to the subclinical inflammation in the vascular wall because of atherosclerosis. Our aim was to assess the level of IL-6 and IL-17 in women with cardiovascular diseases in relationship to the BMD.

Methods: The study included 172 postmenopausal women aged 50-80 y (average 62.8±8.9 y): women in main group (n=132) had various cardiovascular diseases (coronary heart disease and/or hypertension without severe heart failure), the control group (n=40) did not have any. BMD assessment was done in spine and femoral neck (Hologic QDR 4500C Elite), serum IL-17 and IL-6 were examined by enzyme immunoassay, Bender MedSystems (Austria). We used the nonparametric Mann-Whitney test.

Results: The concentration of IL-6 and IL-17 in the main study group was 0.57±1.89 pg/ml and 0.36±1.17 pg/ml, respectively, against the values in the control group 0.05±0.14 pg/ml and 0.03±0.09 pg/ml, p<0.001. Depending on the spine BMD value the tendency for inverse relationship with the concentration of IL-6 was revealed (among women with normal BMD it was 0.23±0.52 pg/ml, among the osteopenic 0.35±0.68 pg/ml, among the osteoporotic 1.04±3.19 pg/ml, p>0.05) and the decrease of IL-17 (0.64±1.75 pg/ml; 0.14±0.43 pg/ml and 0.09±0.42 pg/ml, respectively, p>0.05). There were no any correlations between femoral neck BMD and cytokines values.

Conclusion: We revealed the significant increase of IL-6 and IL-17 levels in postmenopausal women with cardiovascular diseases. At the same time, there was only a tendency of IL-6 concentration increase and IL-17 decrease among the women with osteopenia and osteoporosis. The identified patterns require further study.

References:

1. Lencel P and Magne D. *Med Hypoth* 2011;76:317
2. Goswami J et al. *J Immunol* 2009;39:2831

P736

MUSCLE STIMULATION CAN LEAD TO CHANGES IN MECHANICAL PROPERTIES OF BONE TISSUE

T. Baltina¹, O. Gerasimov¹, N. Kharin¹, A. Eremeev¹, M. Baltin¹, A. Fedyanin¹, I. Lavrov², O. Sachenkov³

¹Kazan Federal University, Kazan, Russia, ²Mayo Clinic, Rochester, USA, ³Kazan National Research Technical University, Kazan, Russia

Objective: Physical activity or microgravity condition can make bone tissue worse. It was shown that physical activity influence structure of bone tissue (1, 2) and it leads to changes of strength. The hypothesis that influence of gravitational load on a various parts of the musculoskeletal system can be a consequence of evolution of biomechanical structures and can be restored by applying external loads. For this purpose microgravity models was studied. Additionally microgravity models with putting on animal's feet and spinal cord stimulation were carried.

Method: Nonlinear laboratory rats (180-200 g) were used. Anti-ortostatic support model were used. All experiments were performed according to bioethical standards and were approved by local ethical committee of the Kazan Federal University. Then femoral bones were dissected from all tested rats. Bones was scanned on μ CT in diaphysis, metaphysis and epiphysis regions. Fabric tensor was used for analysis of distribution porosity. Additionally stress tests were performed. It was investigated different groups: control, microgravity models for 7 d of unloading hanging, models 7 d of unloading hanging with putting on animal's feet for 3 h every day and models 7 d of unloading hanging with cord stimulation.

Results: In microgravitational models Jung's module decreased slightly (25%), but limits of tension decreased significantly (60%). In case of putting on animal's feet Jung's module restores its value (deviation about 5%) and limits of tension increases up to 33% (in comparison with "hypogravitational" models). In case of cord stimulation Jung's module restores its value (deviation about 12%) and limits of tension increases up to 31% (in comparison with "hypogravitational" models).

Conclusion: The results emphasize that the bone structure can be decreased by influence of external forces. It mean that rehabilitation strategy should take into account muscle activity, because muscle also helps to support bone structure.

References:

1. Baltina T et al. *BioNanoScience* 2017;7:67
2. Baltina TV et al *Osteoporosis Int* 2018;29:S253

Acknowledgement: This work was funded by the subsidy allocated to Kazan Federal University for the state assignment in the sphere of scientific activities No. 17.9783.2017/8.9

P737

OBESITY ASSOCIATED WITH LOW LEAN MASS AND/OR LOW BONE DENSITY SHOWS HIGHER IMPACT ON GENERAL HEALTH IN MIDDLE AGED AND OLDER ADULTS

N. De França¹, B. Peters¹, M. Lima¹, E. Santos¹, P. Santos¹, L. Martini¹

¹Department of Nutrition, School of Public Health, University of São Paulo, Sao Paulo, Brazil

Objective: Population aging and lifestyle changes are associated with disturbances in body composition that can affect the quality of life. We aimed to investigate the impact of disturbances in body composition on biochemical profile and function in middle aged and older persons.

Methods: This is a cross-sectional study with 218 individuals (48% male; aged 50-94 y) recruited from the Health Survey-Sao Paulo 2015. Appendicular lean mass (ALM), fat mass and BMD were measured by DXA. Obesity was defined as fat mass (kg) divided by height squared >9 kg/m² and >13 kg/m² for men and women, respectively. Low lean mass was set as ALM divided by BMI <0.789 for men and <0.512 for women. Osteopenia was defined as T-scores at lumbar spine and femoral neck <-1.0. Subjects were clustered into groups according to the presence/absence of body composition disturbances. Muscle function was assessed by handgrip strength and gait speed (4 m). Blood samples were collected to evaluate 25(OH)D, lipid and glycaemic profile.

Results: The groups were as follows: 33 (60% male) individuals "without disturbances", 100 (38% male) with "osteopenia and/or low lean mass", 33 (57% male) with "obesity alone", and 52 (51% male) with "obesity plus osteopenia and/or low lean mass". There was no difference in lipid profile among the groups. Those with "obesity alone" and "obesity plus osteopenia and/or low lean mass" showed higher HOMA-IR (+2, p<0.001), with no differences between both. The "osteopenia and/or low lean mass" group was significantly weaker than the group "without disturbances" and those with "obesity alone" (-6 kg, p=0.009). The group with "obesity plus osteopenia and/or low lean mass" showed lower handgrip strength than the group with "obesity alone" (-5.6kg, p=0.009) and a tendency of slower gait speed than those with "osteopenia and/or low lean mass" (-0.08, p=0.033). Results were controlled for age, 25(OH)D, and global physical activity.

Conclusions: Obesity associated with low lean mass and/or osteopenia showed poor general health profile, with an increased insulin resistance and poorer muscle function. The results suggest higher morbimortality risks when a cluster of body composition disturbances is present.

Acknowledgements: São Paulo Research Foundation (FAPESP) [2014/26787-0].

P738

REHABILITATION TECHNOLOGY WITH THE USE OF MAGNETOTHERAPY REDUCE RELAPSE OF INFLAMMATORY PROCESSES IN THE JOINTS

N. V. Aleksandrova¹, A. V. Aleksandrov², M. V. Nikitin³, L. N. Shilova², V. K. Degtiarev³, V. A. Aleksandrov², N. V. Nikitina¹, I. A. Zborovskaya¹

¹Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky, Volgograd, ²Volgograd State Medical University, the Department of Hospital Therapy, Volgograd, ³"Sanatorium-resort complex Vulcan" - Branch Federal state budget institution "National Medical Research Center for Rehabilitation and balneology", Gelendjik, Russia

Objective: Various technologies of nonpharmacological effects have certain effectiveness in the medical rehabilitation of patients with inflammatory joint disease. Our aim was to evaluate the effectiveness of three-component rehabilitation complex in patients with OA and RA in frequency of inflammation relapses in the joints.

Methods: The study included 83 patients with OA and 63 patients with RA with the inflammatory process in the joints (confirmed by clinical, laboratory and ultrasound data). The patients were divided into two groups, comparable by sex, age, duration and activity of disease and background therapy factor: the main group - 50 patients with OA and 45 patients with RA; control group - 33 patients with OA and 18 patients with RA. Patients from the main group were given a three-component rehabilitation program: kinesitherapy (gymnastics, dosed walking), hydrokinesitherapy (therapeutic swimming in a pool with sea water for 20-40 min, at a water temperature of 26°C, course - 18-20 daily procedures), and low-frequency magnetic therapy (from 0.3-100 Hz; up to 5 mTl; 10 manipulations of 30 min). This program was carried out for 3 weeks.

Results: In the first 3 months after the completion of the rehabilitation complex, recurrences of the inflammatory process among patients of the main group were observed in 5 (10%) patients with OA and in 6 (13.3%) patients with RA, and in patients from the control group - in 10 (30.3%) and 11 (61.1%) people, respectively. From 4 to 9 months in patients from the main group relapses were noted in 72% of cases with OA and in 77.8% in RA, in the control group - in 63.6% and 38.9%, respectively. Evaluation of the results obtained in more remote periods allowed us to establish the duration of remission for more than 9 months in 9 (18%) patients with OA and in 4 (8.9%) patients with RA from the main group, whereas in patients from the control group - only in 2 (6.1%) patients with OA. There were significant differences in the recurrence rate in patients with OA of the studied groups in terms of up to 3 months of observation (p=0.042) and in patients of RA in terms of up to 3 months (p=0.025) and 4-9 months of observation (p=0.039). Presumably, the positive effect of magnetic therapy on metabolic processes in cartilage tissue occurs due to the effect on microcirculation in the synovial membrane and periarticular tissues, which are less affected in OA than in RA.

Conclusion: The use of a three-component rehabilitation complex allows to achieve a significant reduction in the inflammatory process in the joints of patients with OA and RA (maintaining a positive effect for at least 3 months), with a longer remission observed in patients with OA.

P739

GREATER COST EFFECTIVENESS WITH ONE STAGE VS. TWO STAGE SEQUENTIAL BILATERAL TOTAL KNEE REPLACEMENT

C. M. L. Lau¹, Y. H. Hung², C. H. J. Fan², K. B. Kwok², C. W. R. Wan², K. Y. Chung³, K. W. K. Ho¹

¹Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, ²Department of Orthopaedics & Traumatology, Alice Ho Miu Ling Nethersole Hospital, ³Department of Orthopaedics & Traumatology, Prince of Wales Hospital, Hong Kong, China

Objective: Knee osteoarthritis (KOA) is a common orthopaedic problem and yet approximately one third of knee replacement patients exhibit KOA bilaterally. Same-stage bilateral knee replacement (in 1 surgery) was shown to be equally safe compared to two stage bilateral knee replacement (in 2 surgery) in selected patients. In this study, we compare cost effectiveness among two stage bilateral primary knee replacement vs. same stage bilateral knee replacement.

Methods: This is a single center retrospective study of all primary unilateral and same stage bilateral knee replacement (including unicompartmental and total knee replacement) performed from January 2016 to December 2017. All procedures were performed by same surgical team with standardised operative protocol, pre- and post-operative rehabilitation program. The number of pre-operative clinic sessions, perioperative rehabilitation session, length of stay, operation theatre (OT) turnover and cost of instrument preparation between unilateral vs. bilateral knee replacement were analysed.

Results: 241 and 230 patients received knee replacement in 2016 and 2017 respectively (41 bilateral and 200 unilateral knee replacement in 2016; 53 bilateral and 177 unilateral knee replacement in 2017). Comparing same stage vs. two stage sequential bilateral knee replacement, if one patient undergo Same-stage bilateral TKR, we can save 3 pre-op clinic session, 8.7 pre-op physiotherapy session, 13 postop physiotherapy session, 4.7 length of stay, 60 min operation theatre preparation time and \$HK2400 for instrument preparation.

Conclusions: Same-stage bilateral knee replacement resulted in significant cost reduction through improvement in clinic session, rehabilitation session, inpatient bed occupancy and Operation theatre efficiency.

P740

CORRELATION OF PAIN AND CHANGES IN THE SYNOVIAL MEMBRANE OF THE KNEE JOINT

N. V. Nikitina¹, N. V. Aleksandrova¹, V. A. Aleksandrov², L. N. Shilova², A. V. Aleksandrov², I. A. Zborovskaya¹

¹Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky, ²Volgograd State Medical University, the Department of Hospital Therapy, Volgograd, Russia

Objective: To investigate the clinical significance of ultrasound criteria of changes in the synovial membrane of the knee joint cavity and its role in the assessment of pain in gonarthrosis.

Methods: 30 people aged 30-50 y with osteoarthritis of the knee joint were under observation; assessment of the severity of pain in the knee when walking was at least 40 mm on a visual analogue scale (VAS). Ultrasound examination of the knee joint was carried out according to standard procedure using a linear sensor with a frequency of 05.12 MHz in an ultrasonic diagnosis system Accu-vix V10 (Samsung Medison, Korea).

Results: The evaluation of ultrasound changes was performed in the upper inversion of the knee joint according to the following criteria: the severity of intraarticular effusion (1), synovial proliferation (2), local vascularization of the synovial membrane by power Doppler (3). All patients were divided into three groups, according to the severity of pain in the knee joint: group I (12 people) - 41–59 mm, group II (10 people) - 60–79 mm, group III (8 people) - 80-100 mm on the VAS scale. By comparing changes in the knee joint by ultrasound data in patients of different groups, the following results were obtained: group I: severity of intraarticular effusion - 10 people (minimal changes in 60%, moderate in 20%, expressed in 20%), synovial proliferation - 4 people (moderate changes in 50%, expressed in 50%), local vascularization of synovium - 6 people (minimal changes in 66.7%, moderate in 16.7%, expressed in 16.6%); Group II: severity of intraarticular effusion - 9 people (55.6%, 22.2% and 22.2%), synovial proliferation - 3 people (0%, 33.3% and 66.7%), local vascularization of the synovial membrane - 4 people (25%, 25% and 50%, respectively); group III: severity of intraarticular effusion - 8 people (62.5%, 12.5% and 25%), synovial proliferation - 5 people (20%, 40% and 40%), local vascularization of the synovial membrane - 3 people (per 33.3%, respectively).

Conclusion: The use of ultrasound in the diagnosis of diseases of the knee joints allows to reliably determine the structural and functional changes in all components of the knee joint. The severity of pain in gonarthrosis is most associated with the presence of synovitis in the joint.

P741

EFFECT OF DIACEREIN ON METABOLIC SYNDROME IN PATIENTS WITH KNEE OSTEOARTHRITIS

E. A. Taskina¹, L. I. Alekseeva¹, N. G. Kashevarova¹, E. P. Sharapova¹, S. G. Anikin¹, E. A. Strebkova¹, T. Raskina², E. V. Zonova³, E. N. Otteva⁴

¹VA Nasonova Research Institute of Rheumatology, Moscow, ²FSBEI HE Kemerovo State Medical University, Kemerovo, ³FSBEI HE Novosibirsk State Medical University, Novosibirsk, ⁴RSBEI SVE "Institute of Advanced Training for HC professional" MOH Khabarovskiy krai, Khabarovsk, Russia

Objective: An open prospective observational study was conducted in the frames of multicenter "Osteoarthritis: evaluation of progression in real clinical practice" program to assess the efficacy and safety of diacerein therapy in pts with knee (KOA) and metabolic syndrome.

Methods: 55 outpatients (50 females and 5 males) from 4 federal RF entities with MS and KOA stages II and III *Kellgren-Lawrence*, pain intensity >40 mm VAS were included in the study. Mean age was 59.7±7.3 y (45-74), mean BMI 33±5.49 kg/m², disease duration – 8 (5-10) y (from 1-30). The duration of the study was 9 mo (6 mo therapy and 3 mo FUP). Diacerein was administered at 50 mg (1 capsule) a day during the first months, and 50 mg x 2 times a day during the following 5 months. Efficacy and safety was assessed based on WOMAC index dynamics, health status by VAS, quality of life by EQ-5D questionnaire, physician's global assessment and patient's self-assessment, and by daily demand in NSAIDs. Anthropometry and lab parameters of protein, carbohydrate and lipid metabolism were assessed at baseline and in the end of the study.

Results: Statistically significant pain mitigation (VAS assessment) while walking was documented in one month after initiation of treatment (56 (50-65) vs. 50 (41-60) mm, $p<0.0001$), with subsequent further improvement during all 6 mo of treatment. There was no aggravation of pain after discontinuation of the drug (during 3 mo FUP), indicating strong aftereffect of diacerein. Similar trends were observed with WOMAC assessments (baseline pain - 245.0±79.8, at the end of treatment - 149.6±73.3 mm; stiffness - 99.4±39.8 vs. 63.4±35.7 mm; FI - 819.1±306.8 vs. 529.2±290.6 mm, respectively, $p<0.0001$). Statistically significant EQ-5D assessed quality of life improvement was observed during the entire FUP - 0.52(0.52-0.59) vs. 0.62 (0.52-0.71), $p<0.0001$. By the end of treatment 92.5% were categorized as responders by OMERACT-OARSI criteria, 64.2% pts did not take any NSAIDs. Diacerein therapy resulted in significant decrease in BMI (35.2±5.3 vs. 34.9±5.2 kg/m², $p=0.005$), LDL (3.3 (3.0-3.9) vs. 3.04 (2.6-3.4) mmol/l, $p<0.001$), TG (1.9 (1.3-2.2) vs. 1.8 (1.1-2.0) mmol/l, $p<0.01$), glucose (5.3 (5.0-6.1) vs. 5.3 (4.7-6.0) mmol/l, $p<0.05$), uric acid (346 (286-390) vs. 312 (280-350) μmol/l, $p<0.05$) (Fig.1-4). Adverse reactions (frequent stools) were documented in 3 pts (5.5%), resulting in discontinuation of treatment and withdrawal from the study.

Conclusion: Obtained results allow to recommend Diacerein as the disease modifying therapy in OA pts with MS. Diacerein therapy reduces pain, stiffness, and use of NSAIDs, improves quality of life and joint function, significantly reduces body weight, improves the lipid profile and parameters of protein and carbohydrates metabolism. The drug demonstrated a favorable safety profile and sustainable aftereffect, lasting for at least 3mo post-treatment.

Figure 1




Figure 2




Figure 3





Figure 4



P742

TREAT-TO-TARGET CONSENSUS MANAGEMENT APPROACH FOR PEDIATRIC OSTEOPOROSIS

Y. El Miedany¹, W. Salah², H. Lofty³, D. Mekawy⁴, N. Elaroussy⁴, M. Hassan⁵, M. Mortada⁶, G. Elderiny⁷, N. Ismail⁸, Y. Farag³, Y. Suliman⁹, M. Eissa¹⁰, M. El Gaafary¹¹

¹King's college, London, UK, ²Rheumatology and Rehabilitation Benha University school of medicine, Benha, ³Pediatrics-Pediatric Rheumatology Cairo University School of Medicine, Cairo, ⁴Rheumatology and Rehabilitation Ain Shams University School of Medicine, Cairo, ⁵Rheumatology and Rehabilitation Tanta University School of Medicine, Tanta, ⁶Rheumatology and Rehabilitation Zagazig University School of Medicine, Zagazig, ⁷Pediatrics Alexandria University School of Medicine, Alexandria, ⁸Rheumatology and Rehabilitation Suez Canal University School of Medicine, Ismailia, ⁹Rheumatology and Rehabilitation Assiut University School of Medicine, Assiut, ¹⁰Rheumatology and Rehabilitation Cairo University School of Medicine, Cairo, ¹¹Community and Public Health Department Ain Shams University School of Medicine, Cairo, Egypt

Objective: Osteoporosis has been increasingly recognised in paediatric practice as a consequence of several factors. Whilst on one hand, the multifactorial underlying pathology add to the complexity of the condition and the possible treatment approach-

es, on the other hand the improved care provided to children with chronic illness has also led to many of them living long enough to develop osteoporosis. Our aim was to develop a target-oriented, steered therapeutic approach for children with osteoporosis with emphasis on the key pediatric-specific biological principles, and incorporating the recent advances in diagnosis, prevention and management of osteoporosis

Methods: Strategies for identifying and evaluating those at high risk; the use of BMD and biochemical markers in diagnosis and assessing response to management; recommendations regarding nutrition and physical activity; as well as the selection of pharmacologic therapy for the prevention and management of osteoporosis in children were reviewed by a steering Committee who formulated a set of recommendations. These were subsequently deliberated and voted on by an international Task Force. Using the nominal group technique and Delphi method, a multidisciplinary, evidence- and consensus-based treatment recommendations for pediatric osteoporosis were developed based on three consensus discussions.

Results: The management approach outline detailed recommendations pertaining to all aspects of osteoporosis as well as strategies for identifying those at increased risk. Ten statements regarding risk factors, diagnosis, scanning, drug therapy (including both stabilization and maintenance phases of management) and fracture prevention were generated. Percentage of positive votes

ranged between 87-100%; whereas mean±SD level of agreement was 9.7±0.5. Meticulous screening and monitoring of children at high fracture risk is mandatory to endorse early diagnosis of osteoporosis. For the children with persistent risk factors and reduced probability of spontaneous recovery, medical treatment with bisphosphonates should be considered. The main treatment outcome, which should be based on a shared decision with parents/patients, was defined as clinical stability, entailing 1. Absence of new vertebral/ nonvertebral fractures in previously normal vertebral bodies and absence of further loss of vertebral height at sites of previous fractures; 2. increases in spine BMD Z-score appropriate for height; and, 3. Improve child mobility. Treatment should be steered to achieve such level of stability. Treatment can be discontinued in patients whose underlying disease or risk factors resolve once they are clinically stable for 6-12 months.

Conclusion: It is important to recognise that a multidisciplinary approach is often required for the case finding, diagnosis and management of children with osteoporosis. Consensus-based, Delphi procedure recommended a steered therapy for treating pediatric osteoporosis to target, being aware that the evidence may not be strong at some points and needs to be expanded by future research. These recommendations can be considered as clinician's guide regarding the strategies to adopt to reach optimal outcomes for pediatric osteoporosis.

Acknowledgement: Collaborative group: K. Khawaja (Al Mafrag Hospital, UAE); R. Dagher (Notre Dam University Hospital, Lebanon); K. Alsaeid (Kuwait University, Kuwait), K. Alsufyani (Mekkah, Saudi Arabia)

P743

A CASE REPORT OF TUMOR-INDUCED OSTEOMALACIA AND DETECTION OF PHOSPHATURIC TUMOR WITH SOMATOSTATIN-RECEPTOR SCINTIGRAPHY

A. Zhukov¹, A. Petrushkina¹, E. Pigarova¹, L. Rozhinskaya¹, K. Slashuk¹, P. Rummyantsev¹, D. Beltsevich¹, G. Melnichenko¹, E. Kogan², Y. Osmanov²

¹Endocrinology Research Centre, ²Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia

Objective: Tumor-induced osteomalacia is a rare paraneoplastic syndrome in which FGF23 hyperproduction by tumor causes renal phosphate wasting, severe hypophosphatemia and osteomalacia. Localization of the tumor can be a major diagnostic challenge.

Methods: We present a clinical case concerning a 62-year-old woman previously diagnosed with hypophosphatemic osteomalacia, with a slight improvement of clinical and laboratory manifestations after initiation of medical treatment.

Results: The patient had 10-y history of pronounced lower back pain, decrease in height by 16 cm during life, multiple atraumatic fractures of the ribs and pelvic bones. 6 years earlier she underwent surgical treatment for the mass lesion of the proximal part of the left femur (histologic examination – osteoma). She

was diagnosed with hypophosphatemic osteomalacia 4 ys earlier and received treatment with alfacalcidol 3 µg/d, cholecalciferol 15 000 IU/week, calcium 1000 mg/d. The examination showed hypophosphatemia 0.6 mmol/l (0.74-1.52), elevated PTH 111 pg/ml (15-65), normal levels of total and albumin-adjusted serum Ca, a slight increase in alkaline phosphatase (ALP) 158 IU/l (50-150) and CTx 0.836 ng/ml (0.01-0.69), 25(OH)D 23.4 ng/ml. Low tubular maximum reabsorption of phosphate corrected for glomerular filtration rate (TmP/GFR) 0.45 indicated loss of phosphate with urine. Considering likely ectopic hyperproduction of FGF23, we performed whole body scintigraphy with somatostatin analogue, which revealed focal intensive radiotracer uptake in left inguinal region. CT scan of the pelvic area excluded the presence of a primary focus in the area of a previously removed osteoma.

After tumor-removal surgery, follow-up blood test on the 3rd day showed normalization of serum P level. Four months after surgical procedure, P level remained within the normal range, TmP/GFR showed no renal phosphate wasting. Ca level also remained within the normal range, while elevation of ALP 209 IU/l (40-150) as well as PTH 99 pg/ml (15-65) was observed, 25(OH)D 20.4 ng/ml. Marked elevation of osteocalcin 153 ng/ml (11-43) and CTx 2.34 ng/ml (0.01-0.69) suggested intense bone remodeling. Therapy with alfacalcidol, cholecalciferol and calcium was continued with increase of calcium dose up to 2000 mg/d.

Conclusion: The diagnosis of tumor-induced osteomalacia is a challenge and is commonly delayed for years. Attention to biochemical values (especially serum P level) and thorough use of imaging techniques are the key steps. Only surgical removal of causative tumor can provide complete cure.

P744

MUSCLE QUALITY DIFFERENCES IN MALE AND FEMALE CROSS-COUNTRY RUNNERS

T. C. Shoepe¹, W. P. McCormack¹, J. W. Labrie¹, H. C. Almstedt¹

¹Loyola Marymount University, Los Angeles, USA

Objective: Handgrip strength (HG) has been demonstrated to predict nutrition status, osteoporosis, hospitalization, disability, and mortality. However, muscle quality (MQ), or the ratio of strength per unit muscle mass, might provide greater insight than strength alone. Following accrual of strength and attainment of peak muscle mass, consistent, age-related declines occur. The purpose of this study was to evaluate MQ among collegiate runners (RUN) and a group of age and height-matched non-athlete controls (CON).

Methods: Data from a larger study that investigated lifestyle and musculoskeletal health among college students were used in the analysis. Participants (female vs. male: age=20.5±1.8 vs. 20.3±0.9 y; height=162.9±6.1 vs. 178±5.6 cm; weight=55.4±5.2 vs. 66.3±4.8 kg; BMI=20.9±1.5 vs. 20.8±1.4 kg/m²) were recruited from the cross-country team and broader student body to produce four groups: male RUN=18 and female RUN=18 and male CON=22 and female CON=24. HG of both limbs was measured by dynamometer and DXA was used to quantify lean mass

of each arm. MQ, a unitless ratio, was calculated by dividing the combined right and left HG by the combined fat-free mass (FFM) of both arms.

Results: Female RUN and CON were significantly lower than male counterparts in HG (RUN=55.7±8.5 vs. 80.2±11.6 kg; CON=59.2±6.9 vs. 86.5±11.3 kg) and FFM (RUN=3.8±0.5 vs. 6.0±0.6 kg; CON=3.7±0.4 vs. 6.1±0.8 kg), but significantly higher in MQ (RUN=15.7±2.1 vs. 14.4±1.5; CON=15.3±2.2 vs. 13.2±1.6). Male RUN were significantly higher than male CON in HG (86.5±11.3 vs. 80.2±11.6 kg) and MQ (14.4±1.5 vs. 13.1±1.6), while female RUN were not different than female CON for HG, FFM, or MQ. Significance was set at $p < 0.05$.

Conclusion: Muscle adaptations to competitive running appear to be sex specific at a critically important stage of musculoskeletal development.

P745

RELATIONSHIP BETWEEN KISSPEPTIN AND NEUROKININ B LEVELS AND MARKERS OF WATER-ELECTROLYTE BALANCE AND CALCIUM-PHOSPHATE METABOLISM IN PATIENTS WITH NEUROENDOCRINE DISORDERS

E. Pigarova¹, S. Vorotnikova¹, A. Petrushkina¹, A. Zhukov¹, L. Nikankina¹, L. Dzeranova¹

¹Endocrinology Research Centre, Moscow, Russia

Objective: To study the effect of neurohormones kisspeptin and neurokinin B on the indices of electrolyte and calcium-phosphate metabolism in patients with neuroendocrine pathology.

Methods: 82 female patients were included in this pilot study divided into 2 groups: "Cushing's disease" group (n=51) and "Acromegaly" group (n=31). Median age was 33 y [27; 38] in "Cushing's disease" group and 39 y [32; 45] in "Acromegaly" group. Kisspeptin levels were measured using an ELISA test-system "Kisspeptin-54 S-1308" (Peninsula Laboratories International, Inc., USA) on a Luminometer Photometer LMA01 (Beckman Coulter, Czech Republic). Extraction of peptide from plasma was performed according to the manufacturer's protocol. Measurement of the level of neurokinin B was carried out by the ELISA method on Cobas 6000 Module e601 analyzer (Roche, Switzerland), set "Neurokinin B S-1271" (Peninsula Laboratories International, Inc., USA).

Results: The median serum levels of kisspeptin in the "Cushing's disease" and "Acromegaly" groups were 10.8 [3.0; 13.5] and 7.9 [0.14; 11.7] ng/ml, neurokinin B – 0.11 [0.08; 0.13] and 0.07 [0.06; 0.1] ng/ml, sodium - 142 [140; 143] and 140 [139; 141] mmol/l, potassium – 4.4 [4.2; 4.8] and 4.6 [4.2; 5.0] mmol/l, chlorides - 106 [105; 108] and 107 [105; 109] mmol/l, total calcium – 2.39 [2.28; 2.46] and 2.38 [2.31; 2.45] mmol/l, phosphate – 1.14 [1.07; 1.26] and 1.34 [1.24; 1.53] mmol/l respectively. We observed statistically significant difference in kisspeptin, sodium and phosphate levels between groups ($p < 0.05$). In the correlation analysis, no significant dependencies were obtained between neuropeptides and sodium, potassium and chloride blood levels. Negative cor-

relation was observed between kisspeptin and neurokinin B in "Cushing's disease" group ($r = -0.55$, $p < 0.05$), between kisspeptin and serum phosphate in "Acromegaly" group ($r = -0.45$, $p < 0.05$).

Conclusion: In a pilot study assessing the impact of new neuroendocrine hormones, there is no correlation between kisspeptin, neurokinin B and sodium, potassium, chloride levels, which negates their significant role in the control of water and electrolyte parameters of blood. Relationship between the studied neuroendocrine hormones and calcium-phosphate metabolism is not clearly understood and may be the subject of further research.

P746

PREGNANCY-RELATED OSTEOPOROSIS AND ITS MANAGEMENT: A SERIES OF CASES

A. Petrushkina¹, E. Pigarova¹, L. Rozhinskaya¹, L. Dzeranova¹, S. Arapova¹, T. Zenkova¹

¹Endocrinology Research Centre, Moscow, Russia

Objective: Pregnancy-related osteoporosis is a rare disorder with severe complications and incompletely understood pathogenesis. There is lack of clinical practice guidelines due to low incidence of this disease and few published cases.

Methods: We present 8 cases of pregnancy-related osteoporosis in women aged between 28-42 y. Six of them were diagnosed between 1 month and 3 y postpartum and 2 were diagnosed in the third trimester of pregnancy. Only one woman had risk factors promoting osteoporosis before pregnancy (heparin treatment).

Results: Blood tests showed high normal serum Ca and P in most patients. All patients except one had PTH level within normal range (one patient had secondary hyperparathyroidism due to vitamin D deficiency). Serum osteocalcin level was available in 4 patients, 3/4 had low levels of osteocalcin. Seven patients had multiple vertebral compression fractures at X-ray with a prominent decrease in BMD (spinal Z-score from -2.2 to -4.4) and one patient suffered bilateral femoral neck fracture. Treatment approaches included therapy with calcium (1000-2000 mg/d) and vitamin D (alfacalcidol 0.5-3 µg/d or cholecalciferol 10000-15000 IU/week) in all patients; 5 patients had received specific treatment for osteoporosis: 2 patients received bisphosphonates, 1 patient received calcitonin spray, 1 patient received denosumab and 1 patient sequentially received strontium ranelate, denosumab and teriparatide. Three women underwent vertebroplasty and one woman had bilateral hip replacement. Follow-up data was available in 6 patients with median 2 y, 5/6 had radiological improvement in lumbar spine.

Conclusion: Described cases confirm the severity of pregnancy-related osteoporosis and its challenging management. Women diagnosed with pregnancy-related osteoporosis should be advised to have appropriate calcium and vitamin D intake and counseled regarding the risk of potential detrimental effects on the bone health during breastfeeding and newborn care. Necessity and regimen of specific treatment are the subject for further research.

P747

A 12-MONTH STUDY OF ORAL CONTRACEPTIVE USE, BONE TURNOVER MARKERS, AND BONE MINERAL DENSITY IN COLLEGE-AGED FEMALESH. C. Almstedt¹, M. M. Cook¹, L. F. Bramble¹, D. V. Dabir¹, J. W. Labrie¹¹Loyola Marymount University, Los Angeles, USA

Objective: In 2015, 600 million women worldwide were using oral contraceptives (OCs), while in the USA, about 56% of females 15-19 years old have ever used OCs. The hormones included in OCs may influence bone metabolism and BMD, especially during young adult years when the skeleton is consolidating. Due to the widespread use of OCs, it is important to investigate potential effects these drugs may have on bone. **Objective:** The purpose of this study was to compare BMD and bone turnover markers between OC and non-OC users over 12 months.

Methods: Data was analyzed from a larger study investigating bone health among university students. Participants (n=62, age=19.2±0.6 years) were labeled as OC users (n=34) and non-OC (n=28) users based on reports of medication use. Using ELISA, serum samples collected at baseline, 6 months, and 12 months were quantified for CTX and PINP, markers of bone resorption and formation. BMD was measured at the three time points with DXA.

Results: OC and non-OC users were similar in age, height, weight, lean mass, physical activity, and calcium intake at baseline. OC users had greater CTX than non-OC users at baseline (18.6±8.2 vs. 13.8±5.3 ng/mL, p<0.05) and 6 months (20.4±10.3 vs. 14.2±8.5 ng/mL, p<0.05). Non-OC users showed higher PINP at baseline (95.7±30.4 vs. 82.3±28.3 ng/mL, p=0.05). While controlling for lean mass, groups did not exhibit different BMD at the hip, spine, or whole body. However, while non-OC users maintained BMD at the spine across 12 months, the OC users had a decline in BMD at the lateral (0.772±0.014 to 0.756±0.014 g/cm², p<0.005) and anterior-posterior spine (1.005±0.015 to 0.998±0.015 g/cm², p<0.05). Both groups exhibited increases in BMD of the whole body over the year.

Conclusion: The young women in this study were increasing BMD of the whole body, however OC users displayed elevated bone turnover, which may explain their decline in bone mass at the spine.

P748

A PATIENT WITH TWO RARE DISEASES – PFEIFER-WEBER-CHRISTIAN DISEASE AND CENTRAL FORM OF MULTIPLE SYMMETRIC LIPOMATOSIS: CASE REPORTS. Pavlov-Dolijanovic¹, T. Milicic², M. Botic³, I. Jeremic⁴, S. Prodanovic¹, R. Milenkovic⁴, N. Vujasinovic Stupar¹

¹Institute of Rheumatology, Faculty of Medicine, University of Belgrade, ²Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, ³Institute of Pathology, Faculty of Medicine, University of Belgrade, ⁴Institute of Rheumatology, Belgrade, Serbia

Pfeifer-Weber-Christian disease (PWCD) is a rare inflammatory disorder of the subcutaneous fatty tissue. The diagnosis and therapy of this rare type of panniculitis is still controversial. Multiple symmetric lipomatosis (MSL) is a rare metabolic condition characterized by multiple symmetric accumulations of nonencapsulated fatty tissues throughout the body.

Case presentation: We report a 46 years old white woman, who presented with tender rounded circumscribed mass in the right masseteric space, with mild erythema in overlying skin, associated with fever, oral aphthous ulcers, arthralgia/arthritis, myalgia, dry eyes and mouth, Raynaud's phenomenon and generalized weakness. A skin biopsy showed focal lobular inflammation of adipose tissue with lymphocytes, fat cell necrosis and lipophagia. All other causes of panniculitis including polyarteritis nodosa, sarcoidosis, systemic lupus erythematosus, vasculitis, thrombophlebitis, alpha 1 antitrypsin deficiency are excluded and diagnosis PWCD was made. Also, patient was presented with dyslipidemia (high levels of cholesterol, LDL-ch, and triglycerides), hypertension, absence of insulin resistance and autonomic neuropathy. Her BMI was 23.3 kg/m². She had multiple, bilateral, symmetric, soft, nonencapsulated lipomatous, subcutaneous masses involving the lower trunk, arms and upper legs. These masses varied in size from 1 cm x 1 cm to 6 cm x 4 cm. In addition, diagnosis of central form MSL was made. Patient treated conservatively (dual lipid-lowering therapy) for MSL because she had no other complaints related to the excess fat tissue. Treatment with oral metilprednisolon (20-30 mg/d) for 6 months for PWCD was not effective. Patient improved following cyclosporine A (5 mg/kg/d) for 6 months with no activity reported and no appearance of any new swelling.

Conclusion: We describe, for the first time, an unusual case with two rare diseases PWCD and MSL. Even though the pathogenesis of PWCD is not finally resolved, the fact the patient responded to cyclosporine A support the hypothesis that PWCD is a T cell mediated autoinflammatory condition.

P749

TOTAL HIP REPLACEMENT IN PATIENTS WITH OSTEOARTHRITIS AND INCREASED BODY MASS INDEX: LONG-TERM RESULTS

S. Lapshina¹, I. Akhtyamov¹, I. Gilmutdinov², S. Ardashev¹, L. Myasoutova¹, E. Sudoruk¹

¹Kazan State Medical University, ²Republic Clinical Hospital, Kazan, Russia

Objective: The urgency of the problem. Patients with osteoarthritis (OA) and obesity are often denied joint replacement of the knee and hip joints, due to excessive body weight. It is believed that in this group of patients there is a pronounced pain syndrome after the operation for a long time, and a sufficient function of the joint is not restored. The aim of the study was to conduct a comparative analysis of clinical and functional disorders in patients with pathology of the hip joint, having an increased BMI in the perioperative period.

Methods: The study included 48 patients (13 men and 35 women) aged 24-78 y (average 58.8) with a reliable diagnosis of OA and increased BMI, with indications for surgery - aseptic necrosis of the femoral head and coxarthrosis 3-4 X-ray stages. The growth of patients was 137-179 cm (average 160.5), body weight 74-128 kg (average 92.3), BMI: 29-50 kg/m² (average 35.8). Alimentary constitutional obesity: I degree in 28 patients, II degree in 10 patients, III degree in 9 patients, IV degree in 2 patients. The survey included detailed localization of the Harris index and VAS pain before and after surgery. Before surgery, the Harris index was 20-70 (average 40.9), VAS: 70-95 mm (average 82.2). Concomitant pathology: hypertension, coronary heart disease, type 2 diabetes. The correlation analysis method was used for statistics.

Results: All patients were classified according to the BMI. A high connection was found between growth, BMI, and the need for total hip replacement. BMI in men was 10% higher than in women. The duration of hip replacement surgery in patients with normal BMI is on average 40 min., in patients with elevated BMI, on average, this time increases by 20%, in men by 40%. Blood loss was measured intraoperatively and along drains throughout the day. It was found that obesity increases the volume of intraoperative blood loss after primary total arthroplasty in women more than in men. This may be due to the fact that in men most of the excess weight is concentrated around the waist, and in women it is around the hips, which makes the operation longer, blood loss during surgery is more than 20 ml. In the early and late postoperative period, patients with obesity did not have any complications. The need for analgesic therapy in duration (+2 d) and dose of NSAIDs (by 30%) was higher in women compared to men. Reduction of pain in VAS 10 days after surgery compared to the original was 56.3%, improvement of joint function on the Harris scale 28.1%. There was a significant (>0.01) decrease in pain intensity in VAS in 3 months after surgery by 56.9%, in 12 months by 96%. The dynamics of joint function on the Harris scale 3 months after surgery in relation to the initial was 28.3%, 1 year 8.5%. At the same time, in patients the first 3 months after surgery there was a tendency to

reduce body weight and the implementation of the rehabilitation program, in the future, the change in body weight of patients was less significant, and the load on the joint increased.

Conclusion: Hip joints replacement is an effective method of improving the functional state, relief of pain and helps to increase the physical activity of patients suffering from excessive body weight.

P750

RISK FACTORS ASSOCIATED WITH FOREARM OSTEOPOROSIS IN FEMALES WITH RHEUMATOID ARTHRITIS

E. A. Taskina¹, L. I. Alekseeva¹, I. S. Dydykina¹, N. V. Dyomin¹, A. V. Smirnov¹

¹VA Nasonova Research Institute of Rheumatology, Moscow, Russia

Objective: Bone loss and osteoporosis are known to develop predominantly in the forearm of RA patients, although risk factors are yet not clearly outlined. Our aim was to identify risk factors (RF), associated with forearm OP development in RA patients.


Methods: 143 female RA patients (ACR criteria) aged 20-75 y (mean age 55.3±10.1 y) were included. The following info was included in each individual pts' files: anthropometric parameters, social and demographic data, case history, clinical examination and lab findings, traditional OP RF, pts' joint status, comorbidities status, pain intensity assessments and VAS evaluation of pts' general health status. Hand and distal feet plain X-rays were taken for each patient. Van der Heijde modified Sharp method was used to score the erosions and joint space narrowing in hands and feet. Based on the forearm OP status all pts were divided into 2 groups: pts with OP-70 (49%), and pts without OP-73 (51%).

Results: OP pts were older as compared to pts without OP (60.5±10 vs. 51.6±10.6 y, p<0.0001), with longer RA duration (14 (8-25) vs. 8 (7-15) y., p=0,004) and more pronounced destructive changes by Sharp score (169 (86-236) vs. 92 (52-128), p<0,0001), including more cases of stage IV (Steinbrocker x-ray classification) rheumatoid arthritis (51.5% vs. 26.8%, relative risk (RR)=1.9; 95%CI 1.23-3.02, p=0.005) (Fig.1). OP pts demonstrated significantly higher incidence of severe functional decline (mean HAQ 1.7±0.8 vs. 1.2±0.8, p=0.003): 38.2% of these patients had HAQ >2 vs. 16.4% among OP-negative (RR=2.33, 95%CI 1.25-4.32, p=0.008). There was no intergroup differences in terms of inflammatory activity and glucocorticoid (GC) dosage or duration of treatment. Analysis of traditional risk factors showed that OP pts had lower body weight (66±12.2 vs. 72.6±14.4 kg, p=0.004), the majority of them were in postmenopause (92.9% vs. 63%, RR=1.47, 95%CI 1.22-1.78, p<0.0001), experienced long immobilization periods (>2 months) earlier (23.2% vs. 9.7%, RR=2.38, 95%CI 1.05-5.44, p=0.04) and fractures (52.9% vs. 27.4%, RR=1.93, 95%CI 1.25-2.98, p=0.003). Comorbid diseases were more common in OP-positive participants (84.3% vs. 57.5%, RR=1.47, 95%CI 1.17-1.83, p=0.0009), among which certain cardiovascular diseases (arterial hypertension (70% vs. 47.9%, RR=1.46, 95%CI 1.1-1.9,

p=0.01), coronary artery disease (40.6% vs. 11%, RR=3.7, 95%CI 1.8-7.6, p=0.0001) and GI tract diseases (49.3% vs. 26.4%, RR=1.87, 95%CI 1.2-2.9, p=0.008) prevailed.

Conclusion: Forearm OP in patients with RA is not only associated with traditional OP risk factors (age, low body weight, long immobilization periods, fractures, comorbidity), but also with certain RA-dependent factors, such as disease duration, x-ray hand and feet lesion stage and severe HAQ functional impairment.

Figure 1.



P751 ONSET OF PERIPHERAL SPONDYLOARTHRITIS AFTER ADMINISTRATION OF IBANDRONATE: CASE REPORT

L. Franekova¹

¹Department of Internal Medicine - Outpatient Department of Rheumatology and Osteology, First Faculty of Medicine, Charles University and Military University Hospital Prague, Prague, Czech Republic

Bisphosphonates are characterised by high affinity to the bone mineral and capability after internalisation to suppress the activity of the osteoclast and induce its apoptosis. The simple bisphosphonates such as etidronate interfere with phosphorylation. The nitrogen-containing bisphosphonates such as ibandronate block farnesyl pyrophosphate synthetase (FPPS) that is part of the mevalonate pathway (synthesis of cholesterol). Inhibition of FPPS leads to cumulation of isopentenyl pyrophosphate (IPP), which after bonding on the receptor of the $\gamma\delta T$ lymphocytes may induce production of the tumor necrosis factor - alpha. The transitory production of pro-inflammatory cytokines is considered as the cause of the reaction in the acute phase after administration of the first infusion of the intravenous form of bisphosphonate. The patients may suffer fever, headache, aching of the joints, muscles and nausea. Rarely, uveitis develops not only after administration of intravenous, but also oral bisphosphonates. The presence of HLA B 27 in such affected patients is unknown. HLA B 27 positive people have a higher risk of uveitis and also inflammatory rheumatic diseases that affect the spine and joints, so-called, spondyloarthritis.

Case: The case of a 63-year-old woman was presented, who has to date been treated for hypertension, dyslipidemia, glaucoma and uveitis of the right eye. From the indication of postmenopausal osteoporosis, ibandronate was administered to her. In the following 3 d after the first tablet, she had influenza-like syndrome. In subsequent days, symptoms developed that indicated enthesitis of the adductors of the thighs in the groins and calf muscles in the poplitea, arthritis of the left shoulder and wrist and increase in C-reactive protein. Rheumatologic examination diagnosed peripheral spondyloarthritis, HLA B 27 positive. Treatment with sulfasalazine induced remission.

Conclusion: This is the first described case of peripheral spondyloarthritis in an HLA B 27 positive female patient in which administration of oral ibandronate was the trigger of the disease. It is possible to assume that apart from genetic disposition (HLA B 27), the etiopathogenesis of the disease could also be characterised by the pro-inflammatory effect of ibandronate, which is known from the in vitro and in vivo studies.

P752 SERUM VITAMIN D LEVEL ASSOCIATED WITH COGNITIVE AND PHYSICAL FUNCTIONING OF POSTMENOPAUSAL WOMEN

A. A. Popov¹, N. V. Izmozherova¹, E. A. Safianik¹, A. A. Vikhareva¹, V. M. Bakhtin¹, M. A. Shambatov¹

¹The Urals State Medical University, Ekaterinburg, Russia

Objective: Vitamin D insufficiency has been reported to be associated with increased risk of falls, low bone mineral mass, bone fractures and low quality of life in older adults [1]. Moreover, lack of vitamin D may be related to additional cardiovascular events, infections, several types of cancers and other causes of multimorbidity and premature death [2]. Our aim was to assess cognitive and physical functioning of postmenopausal women in relation with serum vitamin D level.

Methods: In a prospective cohort nested sample of 80 independently living postmenopausal women aged between 64-69 (median 67) serum 25OH-cholecalciferol level was assessed [1]. Mini Mental State Evaluation (MMSE) tool was used for cognitive impairment screening. Short Physical Performance Battery (SPPB) and grip strength were used to measure physical functioning.

Results: In this sampling menopause occurred at the age of 45-52 (median 50), 32 persons had low traumatic fractures, 9 women had traumatic fractures. Only 21 subjects had normal serum vitamin D level, 26 women had vitamin D insufficiency and 33 participants were vitamin D deficient. Low levels of serum vitamin D were associated with mild cognitive impairment (Spearman R=0.36: P=0.001) and decrease of grip strength (Spearman R= -0.32: P=0.002). Low serum vitamin D group showed significantly higher occurrence of inability to perform SPPB tests ($\chi^2=7.27$; P=0.02).

Conclusion: In a small but homogenous sampling of independently living postmenopausal women low level of serum vitamin D was associated with impairment of both cognitive and physical functioning.

References:

1. Holick M. *Ann Epidemiol* 2009;19:73
2. Dawson-Hughes B et al. *Osteoporos Int* 2010;21:1151
3. Celis-Morales CA et al. *BMJ* 2018;361:k1651

P753

25OH VITAMIN D LEVELS IN REFERENCE HOSPITAL LABORATORIES FROM TURKEY: A MULTICENTER NATIONWIDE STUDY

D. Gogas Yavuz¹, R. Ersoy², H. Bilen³, Z. Canturk⁴, Y. Altuntaş⁵, S. G. Turvida⁶

¹Marmara University School of Medicine, Istanbul, ²Yıldırım Beyazıt University, Ankara, ³Ataturk University, Erzurum, ⁴Kocaeli University, Kocaeli, ⁵Saglik Bilimleri University, Istanbul, ⁶Multipl, Istanbul, Turkey

Objective: Vitamin D deficiency is an epidemic. Diagnosis and treatment of vitamin D deficiency and toxicity depends on laboratory measurements of 25OH vitamin D levels. The aim of this study was to evaluate 25OHD levels which was measured in main clinical hospitals from Turkey in a year. Thus, to determine frequency of deficiency and toxicity of vitamin D in hospital admitted patients.

Method: Available whole results of 25OHvit D measurements for year of 2016, measurement date, gender and age parameters was included in the study from 33 hospital laboratories around Turkey, samples of age over 18 y with no exclusion criteria include in final analysis. All labs were used immunochemiluminescence method for measurement of serum 25OHvitD. Vitamin D deficiency defined as level of serum 25OHD <30 ng/dl and toxicity defined serum level of 25OHD >150 ng/dl.

Results: Totally 774126 serum samples evaluated and mean 25OHvitD level was 21.6±3.4 ng/dl. 78.7% of the samples were reported to be <30 ng/dl, 24.8% was <10 ng/dl that defined severe vitamin D deficiency. 25OH D levels was over 88 ng/dl range in 0.83% (n:7978) of the samples and 0.66% (n:4125) was in toxic range. 25OHvit D levels were similar between women (20.8±2.9 ng/dl) and men (21.08±2.7 ng/dl) (p=0.94) in whole group. Vitamin D levels was higher in September serum samples (24.05±4 ng/dl, n:55947) compared to march serum samples (19.07±3.3 ng/dl, n:76348) (p<0.0001).

Conclusion: Although this retrospective study that was not able to exclude vitamin D related diseases and vitamin D treated patients, we observed vitamin D deficiency and sufficiency most of the measured serum samples in hospital admitted patients that requires vitamin D supplementation. Interestingly toxic levels was consisting nearly 1% of adult patients; that need to pay attention inappropriate use of vitamin D and associated disorders in patients admitted to reference hospitals.

P754

RECOMMENDATIONS FOR THE REPORTING OF HARMS IN MANUSCRIPTS ON STUDIES ASSESSING OSTEOARTHRITIS DRUGS: A CONSENSUS STATEMENT FROM THE EUROPEAN SOCIETY FOR CLINICAL AND ECONOMIC ASPECTS OF OSTEOPOROSIS, OSTEOARTHRITIS AND MUSCULOSKELETAL DISEASES (ESCEO)

G. Honvo¹, R. R. Bannuru², O. Bruyère¹, F. Rannou³, G. Herrero-Beaumont⁴, D. Uebelhart⁵, C. Cooper⁶, N. Arden⁷, P. G. Conaghan⁸, J.-Y. Reginster⁹, T. Thomas¹⁰, T. McAlindon¹¹

¹Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium; WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liège, Belgium, ²Center for Treatment Comparison and Integrative Analysis, Division of Rheumatology, Allergy and Immunology, Tufts Medical Center, Boston, MA, USA, ³Division of Physical Medicine and Rehabilitation, Department of Rheumatology, AP-HP Cochin Hospital, Université Paris Descartes Sorbonne Paris Cité, and INSERM U1124, Paris, France, ⁴Department of Rheumatology, Bone and Joint Research Unit, Fundación Jiménez Díaz, Universidad Autonoma, Madrid, Spain, ⁵Division of Musculoskeletal, Internal Medicine and Oncological Rehabilitation, Department of Orthopaedics and Traumatology, Hôpital du Valais (HVS), Centre Hospitalier du Valais Romand (CHVR), CVP, Crans-Montana, Switzerland, ⁶MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK; National Institute for Health Research (NIHR) Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, ⁷National Institute for Health Research (NIHR) Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK; Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis, University of Oxford, Oxford, UK, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, ⁹WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liège, Belgium; Chair for Biomarkers of Chronic Diseases, Department of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia, ¹⁰Department of Rheumatology, Hôpital Nord, CHU de St-Etienne & INSERM 1059, Université de Lyon, Saint-Etienne, France, ¹¹Division of Rheumatology, Tufts Medical Center, Boston, MA, USA

Objective: There is strong evidence of under-reporting of harms in manuscripts reporting the outcomes of randomized controlled trials (RCTs) compared with the volume of raw data retrieved from these trials. Many guidelines have been developed to tackle this, but they failed to address some important issues that would allow for standardization and transparency. The ESCEO aimed at delivering accurate recommendations for better reporting of harms

in clinical trials manuscripts on anti-osteoarthritis (OA) drugs, which could help better inform clinicians on harms reported from RCTs and further help researchers conducting meta-analyses.

Methods: Using the outcomes of several systematic reviews on the safety of anti-OA drugs, we summarized the ways in which harms have been reported in OA RCT manuscripts up until now. Next, we drafted some recommendations and initiated a modified Delphi process that involved a panel of clinicians and clinical researchers, to build an expert consensus on recommendations from the ESCEO for the reporting of harms in future manuscripts on RCTs assessing anti-OA drugs.

Results: These recommendations emphasize that all treatment-emergent adverse events (AEs) should be taken into account for harms reporting, with no threshold, further describing how specific AEs should be reported and providing a list of the most relevant organ systems to be considered according to each class of drug for reporting of harms within the results section of manuscripts. Irrespective of the drug, the ESCEO recommends that total, severe and serious AEs, and withdrawals due to AEs should always be reported; guidance on the reporting of specific events pertaining to each category is provided. The ESCEO also recommends the reporting of information on drug effect on biological parameters, with specific guidance.

Conclusions: These recommendations may contribute to improving transparency in the field of safety of anti-OA medications. Pharmaceutical companies developing drugs for OA and researchers conducting clinical trials are encouraged to comply with them, when reporting harms-related results in manuscripts. The ESCEO also encourages journals to refer to these recommendations in their Instructions to Authors for publication of manuscripts on trials of anti-OA drugs.

P755

HEALTHY LIFESTYLE FOR THE PREVENTION OF OSTEOPOROSIS

T. Petrusic¹

¹Health Centre, Nis, Serbia

Objective: Osteoporosis is a serious health problem, a disease characterized by high morbidity, mortality and socioeconomic costs. It is a disease characterized by a decrease in bone density. Bones become porous, crutches and, therefore, subject to fractures, which occur spontaneously or with a force less than needed to break the healthy bone. Our aim was to see the frequency of osteoporosis and the possibility of its prevention.

Methods: Data from the medical records and protocols for physical medicine and health of the Health Center Nis have been analyzed after the screening of the examination of patients of both sexes and apparent genus for four weeks (28 d), in October 2018, on the Sonost 3000 densitometer apparatus.

Results: A total of 202 patients were examined, 170 of them (84.15%) of women and 32 (15.84%) of men. The normal finding of T-score 0-1 had 104 (51.48%) patients, of which 45 women and 59 men. Osteopenia and T-score -1-2.5 had a total of 55 (27.23%),

of which 38 women and 17 men. Osteoporosis T-score >-2.5 was diagnosed in 43 (21.29%) individuals and in 31 female populations and 12 male populations.

Conclusion: To prevent the occurrence of osteoporosis and slow down its osteoporosis, proper nutrition is needed, which provides a recommended daily intake of calcium and vitamin D and adequate physical activity according to age and healthcare possibilities of the patients. Certainly, young patients are recommended sports activity, and older elderly. It is necessary to eliminate the harmful habits (consumption of cigarettes and alcohol) and timely measurement of bone density in persons at risk. Ultrasound osteodensitometry is a fast, cost-effective method without radiation. Measurement is performed on the heel bone, and this measurement can be used as a screening method in the prevention of osteoporosis.

P756

IN VIVO ELEMENTAL ANALYSIS OF HUMAN CALCIFIED TISSUE

A. Pejovic-Milic¹, J. Grafe¹

¹Ryerson University, Toronto, Canada

Objectives: Several elements are toxic when present in excessive amounts, and such overexposure typically occurs in an occupational setting (lead), although some environmental exposures (lead and strontium) and medical treatments (strontium, lanthanum and gadolinium) are also of concern. *In vivo* elemental analysis of human calcified tissue is an approach that is not widely available in clinical practices worldwide. This presentation will introduce to the wider medical community a non-conventional, *in vivo*, radiation-based calcified tissue analysis of lead, strontium, lanthanum and gadolinium, based on the *in vivo* X-ray fluorescence (IVXRF) diagnostic tool.

Methods: Instead of collecting a sample, such as a bone biopsy for *in vitro* chemical analysis, the stored quantity of a toxic element is determined *in vivo*. The approach of the *in vivo* elemental analysis is non-invasive; consequently, no sample is taken, and by extension, there is no discomfort to the patient. The relationship between chronic exposure to an element and the health effects of this exposure are best explored by examining the quantity of the element in question that is stored in the body *in vivo*. Depending on the bone site, detection and quantification of these elements can provide information on long-term exposure to an element that is distinct from other, more conventional, methods of exposure assessment. The limiting factor of these approaches, however, is that the radiation dose must be kept as low as reasonably possible, and within the range of other diagnostic procedures to allow for the monitoring of element's accumulation over time.

Results: The IVXRF of bone lead [1], strontium [2], lanthanum [3] and gadolinium [4] are going to be summarized. The method can identify exposure to these elements and detect concentrations at the parts per million level. Lead and strontium can be reliably measured in the controls and non-exposed population as well.

Conclusions: A nonconventional, *in vivo*, radiation-based calcified tissue analysis of lead, strontium, lanthanum and gadolinium, is a useful but underutilized diagnostic tool in clinical practice. Moreover, the IVXRF could be adapted to other elements with a clinical relevance or need, as long as they are accumulated in human calcified tissue.

References:

- [1] McNeill FE et al. *Physiological Measurement* 2017;39:015005.
- [2] Moise H et al. *Bone* 2014;61:48.
- [3] Nguyen J et al. *Physiol Meas* 2017;38:1766.
- [4] Lord ML et al. *Radiology* 2018;287:96.

P757

USEFULNESS OF 3D RECONSTRUCTION IN PLANNING SURGICAL TREATMENT FOR PERIPROSTHETIC PELVIC OSTEOLYSIS: IS IT THE ULTIMATE TOOL?

I. Pérez-Coto¹, M. A. Sandoval-García², S. Roncero-González², A. Sierra-Pereira²

¹Hospital Carmen y Severo Ochoa, Cangas del Narcea, ²Hospital San Agustín, Avilés, Spain

Objectives: To analyze the capacity of 3D reconstruction as a tool for the diagnosis and planning of prosthetic replacement surgery as a treatment for bone destruction secondary to the wear of polyethylene in long-term hip implants.

Method: We used a series of 30 cases of long-standing total hip replacements (THR) with suspicion of periprosthetic bone loss. They were studied with xray, MRI and 3D reconstruction based on computerized tomography (CT). Using this models, the characteristics of the osteolysis were analyzed and revision surgery was planned in the cases that were reoperated. Finally, the information was evaluated and compared, as well as its usefulness preoperative planning, with the rest of the methods.

Results: Of the 30 cases, the 23 that presented osteolysis on MRI (still considered as gold standard), were selected. Using volumetric reconstruction on CT, an average of 2.35 injuries in 2,48 pelvic areas were detected per case (with an average volume of 7.15 cm³ per injury and 12.72 cm³ per case). Considering the utility to determine the geography of the lesions, the study considered the CT as the most valuable (4.13 over 5). For the planning of surgery, the greatest utility was attributed to 3D reconstruction models (4.55). Finally, when comparing to the intraoperative findings, 3D models again obtained the highest score (4.73).

Conclusions: Periprosthetic osteolysis in longstanding THR is considered the problem of the future for these implants. The current technology of 3D reconstruction based on CT are what a greater help suppose for the surgeon at the time of diagnosing and studying this disease, as well as at the time of planning and executing the surgery. This technique, associated with the brand new 3D printing, in which we are now working, are probably the ultimate tool we were searching for.



P758

HOW POSTMENOPAUSAL FEMALE AGE AND BONE MINERAL DENSITY AFFECT JAW BONES

A. Slaidina¹, B. Springe¹, E. Nikitina¹, U. Soboleva¹, A. Lejnieks¹

¹Department of Prosthodontics, Riga Stradins University, Riga, Latvia

Objective: To detect impact of age and general BMD on density and quantity of the edentulous jaw bones of postmenopausal females.

Methods: In the present study were included 91 postmenopausal edentulous females aged 55-91 y (average age 69.7±9 y), attending for dental implant treatment. BMD measurements of lumbar spine and both hips by DXA (*Lunar DXA DPX-NT, GE Medical Systems*) were made. The worst T-score reading from both were taken into account. To analyse jaw bones cone beam computer tomography (CBCT) (*Next generation i-CAT, Kavo eXam vision*) examinations were performed. CBCT images were analysed with *Dolphin Imaging* software. Volumes and average Hounsfield units (HU) of the maxilla and mandible were calculated. *Pearson* correlation was used to determine correlation between different variables.

Results: There was significant positive correlation between general BMD and bone density (HU) of maxilla ($r=0.36$; $p=0.001$) and volume of mandible ($r=0.41$; $p=0.0001$) and maxilla ($r=0.21$; $p=0.04$). There was no correlation between general BMD and bone density of mandible. We found significant negative correlation between age and bone density of mandible ($r=-0.33$, $p=0.002$) and maxilla ($r=-0.34$, $p=0.01$), but we did not find correlation between age and volume of maxilla and mandible.

Conclusions: Postmenopausal female with reduced general BMD had reduced amount of edentulous mandible and amount and density of edentulous maxilla. Postmenopausal female age have effect on density of edentulous jaw bones.

Acknowledgments: This project was supported by "Postdoctoral Research Aid" 1.1.1.2/VIAA/1/16/139.

P759

THE IMPACT OF DIABETES MELLITUS ON SURVIVAL AFTER HIP FRACTURE: A SINGLE CENTER EXPERIENCE

V. Medvedovsky¹, R. Gat², U. Yoel¹, L. Baraf¹, D. Dayana¹, T. Tamar¹, V. Novack³, E. Siris⁴, M. Fraenkel⁵

¹Endocrinology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel, ²Clinical Research Center, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel, ³Clinical Research Center, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁴Division of Endocrinology, Columbia University Medical Center, New-York, USA, ⁵Endocrinology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel

Objective: Diabetes mellitus (DM) is a risk factor for osteoporotic fractures, possibly associated with increased mortality rate following fracture. We aim to assess the association between DM status and all-cause mortality risk following hip fractures (HF).

Methods: Patients insured by Clalit Health Service over age 50 admitted to Soroka University Medical Center with HF (ICD-9 820) between January 2012 to November 2018 were included. DM was diagnosed according to one of the following: HbA1C >6.5%, ICD-9 code 250, purchase of 2 or more antidiabetic drugs or random glucose level >200 mg/dl prior to HF. Demographic data, comorbidity, drug purchase and laboratory data were retrieved from the electronic medical records.

Results: 2840 HF patients were included; 40% were diagnosed with DM prior to HF. Mean age and female sex were similar in both groups (78.6 y and 66.4% respectively). Medical treatment for osteoporosis following HF did not differ by diabetes status. Follow-up was 855 [305-1468] days in patients without DM and 622 d in those with DM [182-1249] (median, IQR) $p < 0.001$. At last follow-up, death occurred in 45.1% of patients with DM and in 37.7% without DM ($p < 0.009$). Cox regression adjusted for age, sex and comorbidities (malignancies, lung diseases, congestive heart failure, chronic kidney disease, dementia, peripheral vascular disease, cardiovascular disease and liver disease) showed a 26% increase in the risk of death after HF in patients with DM compared with nondiabetic patients (HR 1.26, CI 1.114-1.419; $p < 0.001$). Cox regression in a sub analysis according to sex, showed that the effect of diabetes on mortality was significant only in females (HR 1.334, CI 1.143-1.556). Assessment of survival according to

bands of mean hemoglobin A1C in the 2 years before HF showed a trend for worse outcome with higher A1C that did not reach statistical significance.

Conclusions: DM patients have a 26% increased post hip fracture mortality compared to nondiabetics. The increased risk was higher in females and nonsignificant in males.

P760

SURGICAL VS. CONSERVATIVE TREATMENT FOR VERTEBRAL COMPRESSION FRACTURES: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

M. Azharuddin¹, M. Adil², M. Sharma², P. Ghosh³

¹Department of Pharmaceutical Medicine, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, ²Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, ³Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth, Pune, India

Objective: Surgical and conservative interventions are the main treatment strategy of vertebral compression fractures (VCFs). However, there is clinical uncertainty over adequate management. Therefore, the objective of this study to compare the outcomes of surgical and conservative interventions for the treatment of VCFs.

Methods: Medline and Cochrane Central Register of Controlled Trials, were systematically searched, pairing relevant keywords to identify English language articles for last 5 years. The eligible randomized controlled trials (RCTs) evaluating the surgical vs. conservative treatment for patients with VCFs. The outcome measures were the pain, quality of life and incidence of new fractures event. A random-effects model was used to calculate the pooled mean difference (MD) or risk ratios (RR) with 95%CI.

Results: Four RCTs met the inclusion criteria, with a total of 504 participants. The mean age of patients was ranged with 70-78 y, and the majority was female. Compared with conservative treatment, surgical treatment significantly showed greater pain relief at follow-up; 6 months (MD -1.19, 95%CI (-1.80, -0.58, $p = 0.001$)), 12 months (MD -0.82, 95%CI (-1.41, -0.22, $p = 0.007$)) and disability on the Roland-Morris Disability Questionnaire (RMDQ) at 6 months (MD -1.64, 95%CI (-2.38, -0.91)), 12 months (MD -1.29, 95%CI (-3.26, -0.69)). Surgical treatment showed no significant improvement in quality of life on the QUALEFFO at follow-up; 6 months (MD 0.65, 95%CI (-4.57, 5.87, $p = 0.81$)), 12 months (MD -1.97, 95%CI (-7.78, 3.85, $p = 0.51$)), when compared with the conservative treatment. No significant difference was reported in the pooled results for the incidence of new fracture event (RR 0.82, 95%CI (0.59, 1.13, $p = 0.22$)), compared to conservative treatment.

Conclusion: This study suggests that surgical treatment was more effective in reducing pain in the short term and long terms follow-up period. However, no significant difference was found in the quality of life. Furthermore, evidence from well-controlled RCTs and real-world studies with long term follow-up required to make this result robust

P761

HIGH FREQUENCY OF OSTEOARTHRITIS IN MEXICAN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND ITS CONSEQUENCES ON EXERCISE PERFORMANCE

S.-I. Macías-Hernández¹, T. I. Nava-Bringas¹, E. Cruz-Medina¹, R. Zepeda-Mora¹

¹Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Orthopedic Rehabilitation Division. Osteoporosis Clinic, Mexico City, Mexico

Objectives: To describe the frequency of osteoarthritis (OA) in postmenopausal women diagnosed with osteoporosis (OP), and the impact in exercise performance.

Methods: A cross-sectional study was performed. We included women older than 60 y, who fulfilled the classification criteria for OP according to the WHO, we excluded women with hysterectomy, and those with previous fractures. Patient records were reviewed, and patients meeting OA clinical criteria were located to perform X-ray to corroborate the presence of OA. The positive case were those who accomplished both criteria. Other data collected were age, BMI, BMD, treatment, location of osteoporosis, and exercise performance.

Results: We included 256 women diagnosed with OP, the mean age was 70.53±9.85 y, a range of 60-92 y, and the mean BMI was 27.46±5.18; the mean of the spine T-score was -3.23±0.74, femoral neck -2.72±0.54. 166 (65%) presented pain in at least one joint on the majority of days of the last month, of which 146 (57%) presented positive radiological findings for OA at the site of pain. The frequency by site was: hip 33 (12.9%); knee 81 (31.6%), hands 30 (11.7%), spine 87(34%), other 47(18.3). The mean of days doing exercise per week in patients with OA was 1.89±1.95. and 2.90±2.00 in those without OA (p<0.001). No association was found between OA and T-score values.

Conclusions: The overall prevalence of OA was 57%, greater than reported in the general Mexican population. Previously reported relationship between OP and OA was not corroborated in this study. The mean number of days of exercise was significantly minor in those with OA, witch suggest that OA interferes in physical performance, so is necessary to take it into account for the exercise prescription in OP.

P762

IMPACT OF TYPE 2 DIABETES ON TBS EVALUATED BONE QUALITY IN OBESE WOMEN

A. Sirbu¹, M. Buturoiu¹, M. Popa², I. Soare¹, S. Martin¹, C. Barbu¹, S. Fica¹

¹Carol Davila University of Medicine and Pharmacy, Endocrinology Department, ²Elias University Hospital, Bucharest, Romania

Objective: Altered bone quality due to the metabolic changes of type 2 diabetes (DM) has been shown to have an important impact on bone strength in these patients. The objective of our study was to evaluate the impact of DM on trabecular bone score (TBS), an indirect measure of lumbar bone architecture.

Methods: We evaluated 277 obese postmenopausal women (mean age 63.47±8.96 y, mean BMI 35.16±4.41 kg/m²) consecutively referred for DXA evaluation in a tertiary endocrinology center. Lumbar BMD was measured using GE Lunar DXA equipment and TBS was evaluated with TBS iNsight software.

Results: 94 patients (34%) had type 2 DM. Compared with obese nondiabetic patients, those with type 2 DM had slightly higher BMI (36.06±5.25 vs. 34.4±3.72, p<0.01) and also higher L1-L4 BMD T-score (-1.29±0.94 vs. -1,60±1.03 SD, p<0.01); however, the difference in BMD lost its significance after controlling for BMI and age. Osteoporosis was present in 14.45% of patients, with a higher prevalence in non-DM obese (18.2% vs.7.4%, p<0.05) but, despite this difference, fracture prevalence was similar (19.1% in non-DM, 19.8% in DM). TBS positively correlated with BMI (r=0.303, p<0.001) and L1-L4 BMD T-score (r=0.569, p<0.001). After controlling for BMI and BMD T-score, TBS was significantly lower in obese DM patients (estimated marginal mean for obese DM patients: 1.32 [1,30 – 1,33], for obese non-DM patients 1.35 [1.33 – 1.36], p=0.03)

Conclusion: Obese patients with DM have lower TBS values compared with nondiabetic obese and this might impact the risk of subsequent fracture.

P763

PREDICTORS OF DEPRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS

J. Jovanovic¹, V. Jovanovic², M. Karadzic¹, S. Bozilov¹

¹Institute for Treatment and Rehabilitation "Niska Banja", Niska Banja, ²Clinic for Orthopedics, Clinical Centre, Nis, Serbia

Objective: Depression is the most common and most significant psychological variable in patients with RA. The aim of this study was to examine the association of demographic parameters, functional class and disease activity with depression in patients with RA.

Methods: The study included 121 patients with RA. The degree of depression was measured by BDI (Beck Depression Inventory). Functional disability was presented HAQ questionnaire. The index of disease activity was measured by the DAS 28 SE index.

Results: Our results showed an association between high disease activity, functional disability and disease duration with depression in patients with RA. The high activity of disease (DAS28 SE >5.1) $p < 0.001$. severity of the HAQ functional disability (HAQ >1.000) $p < 0.001$ and the duration of the disease more than 10 years, $p < 0.05$ are associated with a greater degree of depression. Gender and age were not associated with significant depression in patients with RA in our research.

Conclusion: Depression is present in a significant percentage of patients with RA, and therefore early detection and treatment is very important. The high activity of the disease, the severity of the HAQ functional disability, and the longer duration of the disease are associated with a higher degree of depression, while the age and gender did not affect depression significantly in patients with RA in our research.

P764

INVESTIGATING VITAMIN D STATUS OF WOMEN IN ARMENIA

V. Babalyan¹, N. Hutchings², O. Lesnyak³, S. Baghdasaryan¹, M. Qefoyan⁴, P. Bilezikian⁵

¹Osteoporosis Center of Armenia, Yerevan, Armenia, ²University of California, Irvine - School of Medicine, Orange, USA, ³North-Western State Medical University, St Petersburg, Russia, ⁴Yerevan State Medical University, Yerevan, Armenia, ⁵Columbia University - College of Physicians & Surgeons, New York, USA

Objectives: Great strides have been made in recent years in Armenia towards improving the capability to diagnose and treat osteoporosis, but any effort to treat the disease begins with prevention, and adequate vitamin D nutrition is a key preventive measure. Preliminary research has shown that regardless of age, sex and season, vitamin D levels of residents of Armenia are low, despite plentiful sunny days. The objectives of our proposed study are to characterize the level of vitamin D nutrition in women in Armenia, to investigate the prevalence of osteoporosis among postmenopausal women in the country, and to assess popular knowledge and attitudes towards osteoporosis.

Methods: We propose a nationwide modified cluster model cross-sectional age- and geographically-representative study. Using the well-developed healthcare infrastructure, we will randomly select 40 public community clinics, from which we will randomly select 35 registered women for a total of approximately 1400 participants. From each participant, we will obtain dried blood spot sample which will be sent to the collaborating laboratory for analysis of vitamin D. We will also obtain height, weight, grip strength, and haemoglobin measurements for each participant. All participants will complete a questionnaire about lifestyle and dietary habits. Those participants who are post-menopausal will complete an additional questionnaire about knowledge and attitudes towards osteoporosis, and then will be invited to undergo bone densitometry scan at a collaborating centre.

Results: This study will provide reliable and accurate countrywide measures of vitamin D nutrition in the population, and allow for stratification based on age, geography, and multiple demographic

and lifestyle criteria. It will also provide a measurement of the prevalence of osteoporosis as determined by DXA among postmenopausal women in Armenia. Lastly, it will provide valuable insight into the popular knowledge and opinions among postmenopausal women towards osteoporosis.

Conclusion: The findings of this study will help characterize the risk and the burden of osteoporosis among women in Armenia, and will inform policies and interventions to effectively address the needs of the community and target the populations most at risk. This study will be conducted in 2019.

P765

IMPAIRMENT OF MUSCLE AND BONE MASS IN IMMOBILIZED PATIENTS WITH STROKE

D. Stoicanescu¹, M. L. Cevei², I. Gasparik³

¹University of Medicine and Pharmacie, Victor Babes, Timisoara,

²University of Oradea, Faculty of Medicine and Pharmacie,

Oradea, ³University of Medicine si Pharmacie Tg- Mures, Targu-Mures, Romania

Post-stroke muscular dysfunction and bone mass removal are considered to be multifactorial phenomena. After stroke individuals lose muscle mass in both paretic and nonparetic limbs. The concept of stroke-related sarcopenia is relatively new. We report 42 cases diagnosed with stroke admitted to the Rehabilitation Clinical Hospital Baile Felix, Romania. Besides clinical examination all cases performed DXA. Patients' mean age was 55.85 y, range from 32-73 y. The mean duration from the onset of stroke to the DXA investigation was 13 months, range from 6-35 months. 85.71% of these patients had osteoporosis, their mean age was 53.16 y and mean duration to the DXA investigation was 14 months. 42.85% of the cases met all diagnostic criteria for sarcopenia, their mean age was 60.66 y and mean duration to the DXA investigation was 6.66 months. Mean muscle mass scaled to height squared in all investigated cases was 0.5799, but in patients with sarcopenia it was 0.4886. 57.14% of the cases had left side paralysis and the rest right side paralysis. 71.42% of the patients had muscular hypotonia on the affected side. 42.85% of the patients were immobilized and the others could walk with assistive devices.

Conclusions: Patients diagnosed with sarcopenia had a higher mean age and the DXA investigation was performed between 6 and 10 months after stroke. It is therefore possible that sarcopenia may have already been installed, motor deficit being an additive factor for the loss of muscle and bone mass. The localization of the motor deficit on the left or right side was not relevant for the occurrence of sarcopenia. A key point in managing these cases would be an early diagnosis in the first year from the event that causes immobilisation, year in which bone loss is increased but early therapy has very good results.

P766

ACHILLES TENDON RUPTURE ASSOCIATED WITH THE USE OF FLUOROQUINOLONES IN PATIENTS OLDER THAN 60 YEARS

A. Briones-Figueroa¹, W. A. Sifuentes-Giraldo¹, J. L. Morell-Hita¹, M. Vázquez Díaz¹

¹Department of Rheumatology, Ramón y Cajal Hospital, Madrid, Spain

Objective: To describe the epidemiological and clinical features of patients diagnosed with fluoroquinolones (FQ)-associated Achilles tendon rupture (ATR) in a Spanish tertiary hospital.

Methods: A retrospective observational study was performed, which included patients aged >60 y diagnosed of ATR in our center between 2000-2017, identifying patients previously treated with FQ. The demographic, clinical and outcome data were obtained from medical records.

Results: 44 patients with ATR were identified, 8 (14.6%) of them previously treated with FQ. In this group, the mean age at diagnosis of ATR was 77.37±9.54 y, being male 6 (75%). 50% received concomitant treatment with corticosteroids (CS) and one patient underwent kidney transplantation due to nephroangiosclerosis.

Seven patients (87.5%) received cefvofloxacin and one case ciprofloxacin, all of them orally. The indication for FQ treatment in 50% was acute bronchitis and in the other half exacerbations of respiratory pathology (chronic obstructive pulmonary disease/diffuse interstitial lung disease). The mean duration of FQ treatment was 6.16±2.4 d, while the mean time from the start of treatment to the diagnosis of ATR was 19.25±14.83 d. Seven patients (87.5%) had spontaneous rupture. 87.5% were total ruptures and all cases required surgical treatment, without recurrence reported. The comparison of the characteristics of patients with ATR who had or not received FQ is shown in the Table, identifying significant differences in favor of a higher percentage of patients who were smokers, received CS and had spontaneous rupture in the group treated with FQ.

Conclusions: The Achilles tendon is the most frequent location of tendinopathy associated with FQ. Factors associated to an increased risk of FQ-induced ATR includes age >60 y, male gender, chronic treatment with CS and organ transplantation, all these being present in our cases. Despite being a relatively frequent adverse event, it is underdiagnosed and the risk of ATR is not usually assessed when indicating FQ treatment. It is important to perform a risk/benefit assessment, specially in patients with risk factors, because ATR may be a potential cause of disability.

	Fluoroquinolones	Non-fluoroquinolones	p-value
Age (y)	77.37±9.54	70.13±8.3	0.48
Sex (male)	6 (75%)	25 (69.4%)	0.75
Smoking	5 (62.5%)	1 (2.8%)	0.00
Treatment with CS	4 (50%)	2 (5.6%)	0.01
Type of rupture			
Spontaneous	7 (87.5%)	8 (25.8%)	0.01
Traumatic	1 (12,5%)	23 (74.2%)	

P767

BODY COMPOSITION DIFFERENCES IN OBESE CHILDREN/ADOLESCENTS WITH AND WITHOUT METABOLIC SYNDROME

D. Lopez-Gonzalez¹, L. Diaz-Escobar², P. Reyes-Delpech², N. Garibay-Nieto³, P. Clark²

¹Hospital Infantil de Mexico/Clinical Epidemiology Research Unit, Ciudad De Mexico, ²Hospital Infantil de Mexico Federico Gomez/Clinical Epidemiology Research Unit, Ciudad De Mexico, ³Hospital General de Mexico/Childhood Obesity Clinic, Mexico City, Mexico

Objective: Around 13% of obese children without cardiometabolic disturbances, continue to grow into adulthood as obese and maintaining a healthy cardiometabolic profile. This condition is known as “metabolically healthy obesity” (MHO). BMI correlates well with increased adiposity, and current clinical classification of obesity relies on specific cutoff values. Nevertheless, it does not

inform regarding the distribution of such mass within the different body compartments. Our objective was to compare the body composition (BC) of obese children and adolescents with metabolic syndrome MS against those with MHO.

Methods: This was a cross-sectional study of children and adolescents aged 5-17.9 y recruited at their first visit to any of two participating Childhood Obesity Clinics in Mexico City. We carried a medical and nutritional evaluation, anthropometry, biochemistry analysis (fasting glucose, lipid profile, and insulin) and BC assessment by DXA. We divided our sample into eight groups: children-adolescents divided by sex and with MS according to IOF criteria, and children- adolescents with MHO defined as those with BMI >p85th for age-sex and having none criteria for MS. Statistical analysis: We did conventional descriptive statistics. Then we looked for differences between groups by student T-test adjusted for multiple comparisons. We also explored indexes to better adjust for relevant variables.

Results: We studied 248 obese subjects. We observed a MS frequency of 115(46%). The BC data is shown in Table 1. Obese children with MS had significantly more fat than their peers with MHO. Such differences were not significant in adolescents.

Table 1. Mean differences in body composition by age group and sex according MHO vs. MS.

Body Composition	Children				Adolescents			
	Male		Female		Male		Female	
	MHO	MS	MHO	MS	MHO	MS	MHO	MS
Fat mass kg	16.39	21.78*	16.89	22*	31.32	31.67	31.61	33.59
Truncal fat (g)	7,796	1,1131*	8,320	11,697*	17,083	17,284	16,139	17,660
Android fat (g)	1,264	1,864*	1,339	1,925*	2,966	3,004	2,728	3,003
Gynoid fat (g)	2,500	3,115*	2,619	3,325*	5,032	4,860	5,510	5,606
Fat mass index (kg/m ²)	9.16	10.78*	9.66	11.23*	11.11	11.47	12.71	13.67
Fat percentage (%)	39.44	42.82*	42.03	44.36*	37.68	38.49	43.46	44.83
Lean mass kg	22.8	27.34*	21.06	25.74*	48.39	47.95	38.22	38.93
Lean fat height index	0.85*	0.65	0.88*	0.65	0.6	0.57	0.51	0.48
Bone mineral content (g)	1,196	1,396*	1,128	1,331*	2,641	2,459	2,280	2,143

*Differences that reached statistical significance (P<0.05).

Conclusion: In Mexican children with obesity, we found significant differences in body composition between subjects with MS and those with MHO. Such differences were not evident in obese adolescents with MS and MHO.

P768
COMPARISON BETWEEN A HOLISTIC PROGRAM AND AN EDUCATIONAL PROGRAM IN OA TREATMENT

G. P. Ocampos¹, M. U. De Rezende¹, N. L. R. Brito¹, O. P. De Camargo¹

¹Institute of Orthopedics and Traumatology/Osteometabolic group/Hospital das Clinicas/Faculty of Medicine/University of São Paulo, Sao Paulo, Brazil

Objective: Osteoarthritis (OA) is the leading skeletal cause of years lived in disability. Education, diet overweight and exercise are considered core treatment. The aim of this study was to compare the results of a two-day educational program with 2-day educational program with a multiprofessional care for 6 months, and secondly to evaluate midterm results at 12 months.

Methods: Prospective randomized clinical trial with 120 patients with grades II and III K&L knee OA (KOA) were randomized in two groups: control (usual care and 2 days of lectures, 2 months apart, about OA with a multiprofessional group) and intervention (same program of control group plus 7 sessions of collective physical therapy, 7 sessions of physical fitness, 2 group sessions of discussion about diet with the nutritionist and 2 about engaging the program with the psychotherapist) along the first 6 months of the program. VAS, WOMAC, Lequesne, and measures such as

BMI and adherence to physical activity were taken at baseline, 6 and 12 months. After 6 months, patients of the intervention group were oriented, as the control group was oriented in classes, to continue diet and exercises at local gyms or at home. Patients were re-evaluated at 12 months.

Results: Groups were similar at baseline (p>0.05) except for WOMAC stiffness, function and total. Control group had a higher number of dropouts at one year (15 in total, 13 in the first 6 months), whereas 7 abandoned the intervention group (6 in the first 6 months). At 6 months evaluation, all parameters were better in the intervention group (p<0.05). WOMAC improved in average 15 points in the intervention group and 9.5 in the control group. WOMAC function (at six months) was better in the intervention group than in the control group (p=0.032). In the first 6 months of the program, the control group increased BMI and then reduced statistically from 6 months to 12 months (p=0.035), but at no time of evaluation was there a significant mean difference between the groups (p> 0.05) in respect to BMI. WOMAC pain, stiffness, function and total and Lequesne improved from baseline values to 6 and 12 months (p<0.05) in both groups. The stiffness domain and the total WOMAC were higher in the control group than in the intervention group in all the moments (p=0.003 and p=0.022, respectively). Adherence to physical activity increased progressively from baseline in each follow-up irrespective of the group (p<0.001) but mostly in the intervention group with 91.8% adherence at one year.

Conclusions: The holistic program improves adherence (to the program and physical activity) and function when compared to a educational program. Although there was no difference in BMI between groups only the intervention group has shown a decrease in BMI in all the moments.

P769

EPIDEMIOLOGICAL PROFILE OF PATIENTS WITH OSTEOPOROTIC FRACTURES COMPARED TO OA PATIENTS AND FACTORS THAT DECREASE SECONDARY PREVENTION OF OSTEOPOROTIC FRACTURES

G. P. Ocampos¹, M. U. De Rezende¹, R. M. Xavier¹, I. C. Giarola¹, P. G. Plapler¹, O. P. De Camargo¹

¹Institute of Orthopedics and Traumatology/Osteometabolic group/Hospital das Clinicas/Faculty of Medicine/University of São Paulo, Sao Paulo, Brazil

Objectives: To compare the epidemiological profile of patients with osteoporotic fractures and patients with osteoarthritis; Identify factors that diminish adherence to secondary prevention of osteoporotic fractures.

Methods: 108 patients with OF were compared to 86 patients with OA; Patients who did not follow the secondary prevention protocol were compared with those adhering to the program.

Results: Group OF was older ($p < 0.001$), with lower BMI ($p < 0.001$), less literate ($p = 0.012$), more frequently whites ($p = 0.003$), less frequently married ($p < 0.001$), presented more falls, cognitive deficiency, previous fractures, old fracture, fall in the last year. Thw OF Group also need more help and take more medicine for osteoporosis ($p < 0.05$), showed less pathology in the feet, muscle weakness, less vitamin D intake and lower Katz & Lawton ($p < 0.001$). Increases chance of non-adhesion: older age ($P = 0.020$), falls ($p = 0.035$), cognitive deficiency ($p = 0.044$) and presence of depression/apathy/confusion ($p < 0.001$).

Conclusion: Patient age, ethnicity, marital status, previous falls, foot pathologies, muscle weakness, previous fractures, use of vitamin D, use of osteoporosis drugs and the Katz & Lawton scale define the OF group. Increases the chance of nonadherence: older age, sedatives, cognitive disorders and symptoms of depression / apathy / confusion.

P770

COMPARISON OF TWO ORTHOSES IN THE TREATMENT OF FEMORO-PATELLAR OSTEOARTHRITIS

G. P. Ocampos¹, M. U. De Rezende¹, G. J. Yamamoto¹, M. C. M. Luzo¹, C. A. C. Da Silva¹, F. E. S. De Farias¹, O. P. De Camargo¹

¹Institute of Orthopedics and Traumatology/Osteometabolic Group/Hospital das Clinicas/Faculty of Medicine/University of São Paulo, Sao Paulo, Brazil

Objective: To compare the result of an orthosis designed to stabilize the patellofemoral joint compared to a patellar-shaped neoprene orthosis in patients with femoro-patellar osteoarthritis.

Methods: 57 patients with femoro-patellar osteoarthritis were allocated in two groups that received: femoro-patellar functional orthosis or a neoprene orthosis with a patellar orifice. Both groups were instructed on the clinical treatment of osteoarthritis and completed the daily consumption of medications one month before orthosis and up to three months after the placement of the orthosis. They were evaluated with the WOMAC and Lequesne questionnaire and performed five times sit-to-stand test, timed-up-and-go test and the 6-min walk test, immediately before the orthosis was placed and after one and three months.

Results: Both groups improved pain, stiffness and function with no difference between groups. Drug consumption declined in both groups in the first month, increasing in the third month. The consumption of naproxen was progressively higher in the control group.

Conclusion: Both knee orthoses improved pain, function, and altered drug use only in the first month. The functional knee orthosis provided analgesia without increased consumption of naproxen.

P771

THE ROLE OF POLYMORPHIC VARIANTS OF CANDIDATES OF BONE TISSUE METABOLISM (VDR BSM1 C.IVS7G> A, LCT 13910 T> C, COL1A 12046 G-> T) IN THE DEVELOPMENT OF OSTEOPOROSIS IN WOMEN OF RUSSIAN AND BURYAT NATIONALITIES

S. Verkhoturova¹, S. Tsarenok¹, T. Aksenova¹, V. Gorbunov¹, T. Gorbunova¹, N. Iljamakova²

¹Chita State Medical Academy, ²Russia Railway Clinical Hospital, Chita, Russia

Objective: To study the frequency of alleles and genotypes of polymorphisms of the vitamin D receptor gene Bsm1 c.IVS7G> A, lactase gene LCT 13910 T> C and collagen gene COL1A1 2046 G-> T in patients with osteoporosis (OP) and healthy women of Russian and Buryat nationalities.

Methods: 86 women with OP (48 Russian and 49 Buryat nationalities aged from 50-80 y) and 97 healthy women of the same age were examined. The material for the molecular genetic analysis of the DNA samples was extracted from peripheral venous blood.

The online calculator was used for data processing (http://genexp.ru/calculator_or.php). The χ^2 test was used to compare allele frequencies between analysed groups. The differences were considered significant at $P < 0.05$. The degree of risk of events was calculated by the method of assessing chances with a 95%CI.

Results: The comparative analysis of the frequencies of alleles and genotypes for LCT 13910 T> C, COL1A 12046 G-> T between the clinical and control groups did not reveal any significant differences. The analysis of the polymorphism of the vitamin D receptor gene VDR Bsm1 c.IVS7 G>A revealed that patients with OP had prevailing polymorphic recessive allele A ($p = 0.0001$; OR = 2.33 (1.5-3.62)). White healthy women most commonly had dominant allele G ($p < 0.05$). The polymorphism study of the VDR gene - Bsm1 c.IVS7G> A, taking into account national peculiarities, showed that the dominant allele G was significantly more common presents among healthy women of Buryat nationality ($p < 0.05$; OR=0.51; CI (0.26; 0.99)). The relative risk calculation revealed a positive association of the A/A genotype of the VDR gene of the Bsm1 c.IVS7G> A polymorphism with the development of osteoporosis among the Buryat nationalities (RR=1.7; CI (1.1 - 2.8)), compared to Russian women. Relative probability of detecting lactase C/C and C/T genotypes with women having OP has increased by 1.5 times in comparison with healthy women ($p < 0.05$). This pattern was typical for women of both nationalities (RR=1.5; CI (0.8 - 2.5)). The G/T and T/T genotypes of the COL1A1 2046 G>T polymorphism are associated with the development of OP in Buryat postmenopausal women (OR=1.7; CI (1.04 - 2.7)).

Conclusion: The gene allele A of the VDR Bsm1 c.IVS7G> A, genotypes G/G and G/T of the COL1A1 2046 G> T were associated with a higher risk of OP in women of Buryat nationality. The genotypes of lactase gene LCT 13910 T> C were associated with the development of OP in people of both nationalities.

P772

HOSPITAL MORTALITY AFTER HIP FRACTURE SURGERY IN RELATION TO TYPE OF SURGERY AND LENGTH OF HOSPITAL STAY: A 8-YEAR COHORT STUDY IN BRAZIL

V. C. U. Peterle¹, P. E. Bezerra Junior², J. C. Geber Junior³, R. C. Portela², J. B. Silva Junior², R. T. Magalhães², A. V. Lima⁴, M. R. C. Garbi Novaes⁵

¹University of Brasília / Faculty of Health Sciences / Postgraduation in Health Sciences, ²Department of Health of the Federal District / School of Health Sciences / Medical Residency, ³Department of Health of the Federal District / School of Health Sciences, ⁴Instituto Brasileiro de Segurança no Trânsito (IST), ⁵Department of Health of the Federal District / School of Health Sciences / Postgraduation and Extension, Brasília. Brazil

Objective: To identify the factors associated with in-hospital mortality in elderly with fragility hip fracture.

Methods: A cohort of 407 patients over 60 y, hip fracture by minimal trauma, admitted for 8 y (Jan 2010-18) at the Orthopedic Public Health Service at Brasília, D.C. Association the variables with the outcome (mortality) and comparison between groups

(death vs. survival), through the chi-squared test and Mann-Whitney. The odds ratio of the selected variables on mortality, through the logistic regression (Stepwise method). The Nagelkerke's R2 model=0.80 adjusted for age and gender [95%CI $p > 0.005$]. Survival through logistic regression of COX and Kaplan-Meier curves. And ROC graphs which the cutoff points defined by the highest concomitant sensitivity and specificity.

Results: Mean of 79 y (± 9.4), predominance of women ($n = 265$), arterial hypertension (58.7%) and moderate/high surgical risk (Detsky,1997) (78.1%). The anatomical classification in transtrochanteric: 157(38.6%), neck: 145(35.6%) and subtrochanteric: 12(2.9%) were in agreement with the profile of the surgical interventions ($n = 314$): osteosynthesis: 170(41.7%), followed by arthroplasty in 144(35.4%). The mean to perform the surgery was 20.4 d, with the mean total length of hospital stay 26.6 d (± 22.2). Overall, the prevalence of mortality during observation was 19.9% ($n = 81$). The patients who underwent surgery, there were 44 (14.0%) deaths, being osteosynthesis [HR=1.56 95%CI:1.22-1.98], infection ($n = 35$) [OR=4,08], ICU length of stay (43.5% - mean/d: 6.57) [OR=1.10] and postoperative time with cutoff point defined at 6.5 d (S/E>0.70), were included in the risk model ($p < 0.005$).

Conclusion: Patients older and more comorbid, such as low BMD in women, agree with the mechanisms of fall and type of intervention. In turn, factors related to greater hospitalization after surgery also increase the risk for mortality.

P773

ASYMPTOMATIC ULTRASONOGRAPHIC CHANGES IN ANTERIOR CHEST WALL JOINTS AND THEIR RELATION TO THE CHEST EXPANSION IN RHEUMATOID ARTHRITIS PATIENTS

F. Abdelrahman¹, M. Mortada¹, A. Abdulsattar¹

¹Rheumatology Department, Zagazig University, Zagazig, Egypt

Objective: Anterior chest wall (ACW) joints can be involved during the course of rheumatoid arthritis (RA), however its clinical implications appear to be underestimated by the rheumatology community. Our aim was to detect the ultrasonographic changes of asymptomatic ACW joints in RA patients and their relation to the chest expansion and disease activity.

Methods: The study included 88 sternoclavicular joints (SCJ) and 44 manibrusternal joints (MSJ) in 44 subjects (22 RA and 22 control). Ultrasound (US) assessments were performed to detect synovitis, erosions, ankylosis, osteophytes, or Power Doppler (PD) signals. Chest expansion was measured. In RA group, Disease Activity Score (DAS28) and Health Assessment Questionnaire Disability Index (HAQDI) were recorded.

Results: US detected subclinical changes of ACW joints in (74.2%) in RA patients, and (21.2%) in control subjects. There was a highly significant difference between total US changes in RA (74.2%) and control (21.2%) ($p < 0.001$). SCJ synovitis (77.3%) and erosions (72.3%) were the most frequent changes in RA patients. None of our control subjects had erosions, PD activity or ankylosing in MSJ. MSJ ankylosing was highly associated with limited chest expansion in RA group ($P < 0.001$). All RA patients

(100%) with ankylosed MSJ by US had limited chest expansion. Ultrasonographic changes in RA patients were found to be higher with smoking, longer disease duration and high DAS28.

Conclusions: Our study demonstrated high frequency of subclinical ultrasonographic changes in ACW joints in RA patients. Ankylosing of the MSJ is highly associated with limited chest expansion in RA patients. Our data suggest that US is a highly valuable and accessible tool for detecting early changes in ACW joints in RA even before being clinically manifested.

P774

USE OF PAIN MEDICATION AMONG PERSONS WITH OSTEOARTHRITIS IN CANADA

J. A. Kopec¹, E. C. Sayre², J. Cibere¹, L. C. Li¹, N. Bansback¹, H. Wong¹, J. M. Esdaile¹

¹University of British Columbia, Vancouver, ²Arthritis Research Canada, Richmond, Canada

Objectives: Analgesics are the most important medication type in osteoarthritis (OA) but population data on their use are limited. The aim of the study was to estimate the frequency of treatment with four classes of analgesics in Canada according to demographic characteristics, OA stage, and pain level.

Methods: We analyzed Canadian data from the National Population Health Survey, Canadian Community Health Survey, and administrative data (including all prescriptions) in the province of British Columbia. We estimated the use of conventional non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen (paracetamol), COX-2 inhibitors (coxibs), and opioids according to age, sex, OA stage (diagnosis of OA <5 y, OA ≥5 y, joint replacement (JR) <5 y and JR ≥5 y), and level of pain as measured by the Health Utilities Index.

Results: In 2012, NSAIDs were taken (in the last 2 days) by 17% of all persons 12 y of age or older in Canada, acetaminophen by 8%, opioids by 2%, and coxibs by 1%. Between 1994-2012, self-reported use of NSAIDs increased substantially, opioids increased slightly, whereas coxibs and acetaminophen declined. Among those with OA, the proportions taking each type of medication were, depending on OA stage, 38-43% for NSAIDs, 19-28% for acetaminophen, 4-7% for coxibs and 6-7% for opioids. Probability of taking opioids adjusted for age, sex and OA increased rapidly with pain, whereas other analgesics plateaued at moderate pain.

Conclusion: NSAIDs are by far the most common type of medication used by persons with OA, followed by acetaminophen. Opioids are used mostly for severe pain and their use has increased slightly over time.

Acknowledgement: The study was funded by the Canadian Institutes of Health Research.

P775

USE OF TRABECULAR BONE SCORE (TBS) AS A COMPLEMENTARY APPROACH TO BONE MINERAL DENSITY IN GAUCHER DISEASE PEDIATRIC PATIENTS

M. Larroude¹, G. Aguilar², I. Rossi², L. Brun³, G. Drelichman⁴, D. Hans⁵

¹CD Rossi, Buenos Aires, Argentina, ²CD Rossi, Buenos Aires, Argentina, ³Laboratorio de Biología Osea Universidad Nacional De Rosario, Rosario, Argentina, ⁴Hospital Ricardo Gutierrez, Buenos Aires, Argentina, ⁵Center Of Bone Diseases, Bone and Joint Department Lausanne University Hospital, Lausanne, Switzerland

Objective: Trabecular bone score (TBS), an index of lumbar spine trabecular texture, has not been explored fully in pediatric patients. Our aim was to evaluate the TBS in pediatric patients with Gaucher disease (GD).

Methods: We conducted an observational and descriptive study in 64 GD pediatric patients under enzyme replacement therapy (imiglucerase, mean dose 60.5±17.2 U/kg [range: 39-120]) with a follow-up of 3 y. The lumbar spine BMD was measured by DXA (Lunar Prodigy). The TBS was performed by TBS iNsite (Medimaps) and "rawTBS" were adjusted for soft tissue thickness "corrTBS" according to pediatric subjects. Data are expressed as mean±SD and differences were considered significant if p<0.05.

Results: 39 female (60.96%) and 25 male (39.1%) were included, mean age 12.6±3.8 y [range: 3.8-19.8] (85% had splenomegaly and 66.1% hepatomegaly). According to BMB, 30.8% of the patients showed bone marrow infiltration. The age at diagnosis was 59.9±43.2 months (range 4-196) and the mean values of quinosidase was 383±465 (range 0-1500). BMD was normal in 88% and 12% showed OP. A significant increase in the lumbar spine BMD was found throughout the 3 years follow-up (percentage of change: +9.5%, +13.8% and 18.0% vs. basal, respectively; Wilcoxon signed rank test p<0.05). No correlation was found between TBS and rowTBS but a positive correlation was found between BMD and corrTBS (r=0.68, p<0.0001). Therefore, a significant increase in the corrTBS was found throughout the 3 years follow-up (percentage of change: +3.4%, +4.1% and 7.3% vs. basal, respectively; Wilcoxon signed rank test p<0.05). No differences in corrTBS according to BMB score was observed. No differences in corrTBS between normal or osteoporosis BMD was found. However, 66.7% of patients with normal BMD and 83.3% of those with OP showed altered bone quality assessed by corrTBS.

Conclusions: The densitometry allowed us to evaluate the gain in the bone mass in pediatric GD patients under imiglucerase treatment and the corrTBS could detect patients with alteration of the bone quality.

P776

LOW BONE DENSITY FREQUENCY IN YOUNG EXTENSIVE BURNED PATIENTS: A CROSS-SECTIONAL STUDY

S.-I. Macías-Hernández¹, G. M. Martínez-Morales¹, M. Morales-García², K. Tolentino-Bazan², T. I. Nava-Bringas¹, R. Zepeda-Mora¹, J. D. Morones-Alba¹

¹Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Orthopedic Rehabilitation Division, Osteoporosis Clinic, ²Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra. Burned Unit, Mexico City, Mexico

Objective: To describe the frequency of low bone density (LBD) in young extensive burned subjects.

Methods: An observational, cross-sectional and descriptive study was performed. We included pre-menopausal women older than 19 y, and men aged between 19-50 y; with any type of burn that compromise more than 30% of the body surface area burned or an electric burn; with a spine and hip DXA; more than 6 months of evolution, with scarred lesions and without previous known diseases affecting bone mass. LBD was diagnosed with a Z-score <-2.0 in total lumbar spine and/or total femur or neck.

Results: A total of 42 patients fulfilled criteria, the average age was 32.83±9.53 y; 32 (76.2%) men; 23 (28.5%) with an electric burn; the mean evolution time was 7.7±1.4 months. 8 (19.04%) had LBD. None presented fragility fractures. Only the electric burn type was significantly associated with LBD (p=0.05).

Conclusion: The frequency of LBD was 19.04%, similar to that reported in other diseases well known causing bone loss. Electric burns seem to be more associated to the development of LBD. Other factors such as age, BMI, depth of burn, time of hospitalization, treatment, walking or amputations did not influence the presence of LBD. It is necessary to perform longitudinal studies and with larger sample size to assess the long-term changes and corroborate the association of the burn as a mayor risk factor developing LBD.

P777

ASSOCIATIONS BETWEEN PHYSICAL ACTIVITY (PA) AND CAM AND PINCER MORPHOLOGY

H. Ahedi¹, T. Winzenberg², S. Bierma-Zeinstra³, L. Blizzard¹, M. van Middelkoop⁴, R. Agricola⁵, J. H. Waarsing⁴, F. Cicuttini⁶, G. Jones¹

¹University of Tasmania, Hobart, Australia, ²University of Tasmania, Hobart, Australia, ³Department of General Practice, ERASMUS MC, Department of Orthopaedics, Erasmus MC, Rotterdam. The Netherlands, ⁴Department of General Practice, Erasmus MC, Rotterdam. The Netherlands, ⁵Department of Orthopaedics, Erasmus MC, Rotterdam, The Netherlands, ⁶DEPM, Monash University, Melbourne, Australia

Objective: To describe the cross-sectional and longitudinal associations between cam and pincer morphology and physical activity (PA) in a large community-based sample.

Methods: At baseline, cam (abnormal shape of the femoral head) and pincer (excessive coverage of the acetabulum) was assessed by anteroposterior hip radiographs of 914 subjects from the Tasmanian Older Adult Cohort (TASOAC). We assessed cam and pincer measuring α angle (cutoff point 60°) and Wiberg's angle (cut off point 40°) in both hips using statistical shape modelling (SSM). α angle was measurable in 914 participants and Wiberg's angle in 890 participants. Cam morphology was categorised into hip sides (unilateral and bilateral) and intensity (moderate cam: α angle > 60° & < 83° and severe cam α angle > 83°). At baseline PA was measured by pedometers only while at follow-up (2.5 and 5 y later) it was assessed by using both pedometer and accelerometer. Accelerometer determined PA was assessed by absolute time spent engaged in sedentary (< 1.5 Metabolic equivalents (METs)), light (1.5–2.9 METs), moderate (3–5.9 METs), and vigorous (≥ 6 METs) intensity activity.

Results: Of 914 participants, 67% had no cam morphology, 23% had unilateral, and 10% had bilateral cam morphology. Of 890 participants, 94% had no pincer and 6% had pincer morphology. At baseline, PA measured by pedometer (per 1000 steps) was associated with pincer [Prevalence Ratio (PR): 0.99, 0.99-0.99], unilateral cam morphology (PR: 0.96 95%CI:0.92-0.99) and severe cam morphology (PR:0.94 95%CI:0.90-0.99) but these associations were lost after adjustment for other demographic factors. Over the period of five years, amount of steps per day was associated with all categories of cam (PR ranging from 0.96-0.99) and pincer (PR: 0.99 95%CI:0.99-0.99). Furthermore, participants who were active and took more than 10,000+ steps were less likely to have cam morphology [Unilateral (PR: 0.75, 95%CI:0.70-0.84), bilateral (PR: 0.76 95%CI:0.63-0.91), moderate (PR:0.72 95%CI:0.61-0.84) and severe (PR:0.85 95%CI:0.76-0.93)]. Higher steps/d were also associated with pincer (PR: 0.82 95%CI:0.70, 0.97). Sedentary minutes were associated with a higher risk of having a moderate cam (on average per 100 minutes: PR:1.01 95%CI:1.00-1.02) and light, moderate and vigorous activity lowered the risk of having moderate cam by 2%, 3% and 36% METs respectively. Similarly, participants who were involved in light or vigorous activity lowered their risk of having pincer by 1% and 8% respectively.

Conclusions: Presence of hip shape variations, especially cam morphology, are one of the strongest predictors of hip osteoarthritis (OA). This community-based study suggests that amount and intensity of PA is associated with lower risk of cam and pincer while sedentary time is adversely associated. Overall, the risk of cam and pincer was greater in substantially lower physical activity.

P778

EFFECT OF HORMONE TREATMENT ON BONE HEALTH IN TRANSGENDER FEMALES: A SYSTEMATIC REVIEW

M. Bourque¹, A. Varghese², P. Corcoran³, N. Nigil Haroon²

¹UCC, CORK, Ireland, ²NOSM, SUDBURY, Canada, ³UCC, DUBLIN, Ireland

Background: Not much data exists on the effect of transgender hormone treatment on bone health.

Objective: We conducted a systematic review of studies to examine the effect of hormone treatment on BMD in transgender females.

Methods: Two authors independently searched Embase and Medline for studies.

Results: Nineteen studies (ten cohort and nine cross sectional, N=931 subjects, age range 21-41) were eligible. Duration of hormone treatment ranged from 3 months to 15 years. Among the cross sectional studies, three studies reported lower BMD at the lumbar spine and hip at baseline compared to controls. Out of the

ten studies analyzing BMD in a longitudinal fashion, three reported significant increase in lumbar spine and others documented maintenance of BMD at spine and hip (Table 1). Among the five studies analyzing BMD at 24 months, significant increase was noted by three studies at the lumbar spine and at the femoral neck by one study. Stable trends were noted by two studies at both hip and spine.

Conclusion: Hormone treatment in transgender females either increases or maintains BMD. Significant heterogeneity was noted in the methodology, sample size, duration of hormone treatment and BMD follow-up across studies.

Table 1. Change in BMD at 12 and 24 months in transgender women undergoing hormone treatment

Author	Site	Baseline			12 months			24 months			
		Mean g/cm ² (SD)	ρ	Z-score	Mean g/cm ² (SD)	ρ	Z-score	Mean g/cm ² (SD)	ρ	Z-score	ρ**
Dittrich et al.	FN	1.072 (0.131)			1.091 (0.125)	0.42		1.097 (0.111)	0.09		
	LS	1.201 (0.146)			1.257 (0.126)	0.07		1.263 (0.150)	<0.05*		
Wiepjes et al.	FN	0.799 (0.128)	0.960		0.813 (0.130)	0.834					
	LS	0.972 (0.140)	0.362		1.007 (0.139)	0.470					
	TH	0.938 (0.134)	0.942		0.947 (0.135)	0.905					
Figuera et al.	FN	1.010 (0.170)		-0.2 (1.3)							
	LS	1.150 (0.160)		-0.3 (1.3)							
	TF	1.010 (0.150)		-0.4 (1.0)							
Gava et al.	LS-1	1.1 (0.2)			1.1 (0.2)						
	LS-2	1.0 (0.2)			1.0 (0.1)						
	WB-1	1.1 (0.1)			1.2 (0.1)						
	WB-2	1.2 (0.1)			1.2 (0.1)						
Van Caenegem et al.	FN	0.795 (0.119)	<0.001*		0.807 (0.129)			0.807 (0.123)			
	LS	0.952 (0.150)	<0.001*		0.983 (0.156)			0.982 (0.136)			
	HIP	0.947 (0.134)	<0.001*		0.952 (0.141)			0.955 (0.145)			
	WB	1.088 (0.086)	<0.01*		1.090 (0.090)			1.100 (0.090)			
	R	0.614 (0.058)	<0.01*		0.621 (0.057)			0.622 (0.062)			
Haraldsen et al.	FN	1.04 (0.17)	0.18								
	LS	1.13 (0.16)	0.01*								
	WB	1.18 (0.12)	0.03*								
Mueller et al., 2005	FN	1.068 (0.142)		0.15 (1.02)	1.08 (0.138)	0.23	0.20 (1.05)	1.109 (0.116)	0.010*	0.45 (0.92)	
	LS	1.200 (0.125)		0.20 (1.32)	1.234 (0.140)	0.034	0.25 (1.03)	1.274 (0.112)	0.0001*	0.42 (0.97)	0.0003*
Mueller et al., 2011	FN	1.09 (1.03-1.17)			1.12 (1.04-1.17)	0.08		1.09 (1.04-1.17)	0.081		0.81
	LS	1.20 (1.13-1.27)			1.25 (1.15-1.29)	0.002*		1.30 (1.16-1.29)	0.006*		0.06
Van Kesteren et al., 1998	LS	1.04 (0.12)			1.08 (0.13)			1.04 (0.14)			0.002*
Van Kesteren et al., 1996	LS	1.05 (0.16)			1.09 (0.16)	<0.01*					

Data is expressed as mean±SD or as median (IQR)

*Statistically significant (<0.05) **Comparison between 12 and 24 months of hormone therapy, 1-GnRHα + CHT, 2-AA + CHT

P779 DOES BIPHOSPHONATE DELAYS BONE HEALING AFTER PROXIMAL FEMORAL NAIL ANTI-ROTATION FIXATION FOR INTERTROCHANTERIC FRACTURE IN ELDERLY PATIENT

D. R. Phruetthiphat¹, P. Songpatanasilp¹

¹Royal Thai Army Hospital, Bangkok, Thailand

Objective: Hip fracture has been recognized as the most serious complication of osteoporosis because of its consequence including disability, poor quality of life, increased risk of mortality, and healthcare costs [1-4]. Therefore, bisphosphonates are widely used for osteoporotic patients and their efficacy are reduction of the risk of fragility fracture in clinical trial (8-10). Previous animal

studies demonstrated that delayed a single dose of zoledronic acid (1 or 2 weeks after fracture) displayed significantly increasing bone strength and fracture repair (5) while a yearly intravenous zoledronic acid in clinical study (The HORIZON-RFT) significantly reduced any new clinical fracture for a secondary prevention of hip fracture (6). However, current studies lack data demonstrating whether bisphosphonate delays bone healing after hip fracture repair in clinical practice. Therefore, the purpose of our study is to define whether BPs after proximal femoral nail anti-rotation fixation for elderly intertrochanteric fracture interrupts the fracture repair.

Method: After Institutional Research Board Approval, 174 elderly patients with intertrochanteric fractures from low energy trauma underwent PFNA fixation. Demographic data, comorbidity, time to union, functional outcome and complications were collected. Patients were classified into 2 groups: patients taking bisphos-

phonate after fracture repair and those who did not receive bisphosphonate. All patients received supplemental vitamin D and calcium. The primary outcome was measured by time to clinical union and radiographic union (weeks) between groups. The secondary outcome measured the functional outcome (Harris Hip Score) and complications including mortality rate between groups.

Results: There was comparable functional class and comorbidities between those with bisphosphonate and those without bisphosphonate intake. The former group had significantly lower mortality rate than the latter group (6.7% vs. 23.5%, $p=0.004$) while there was no difference in time to clinical union (6.9 weeks vs. 6.7 weeks, $p=0.505$), radiographic union (12.4 weeks vs. 12.1 weeks, $p=0.223$), and functional outcome (HHS) ($p=0.410$) between both groups.

Conclusion: Bisphosphonate is useful for osteoporotic hip fracture including significantly decreased mortality rate without inhibit bone healing after fracture fixation in clinical practice.

Reference:

1. Weiss NS et al. *J Chronic Dis* 1983;36:879.
2. Cumming SR et al. *Epidemiol Rev* 1985;7:178.
3. Sexson SB and Lehner JT. *J Orthop Trauma* 1987;1:298.
4. Bonar SK et al. *J Am Geriatr Soc* 1990;38:1139.
5. Amanat N et al. *J Bone Miner Res* 2007;22:867.
6. Black DM et al. *N Engl J Med* 2007;356:1809.
7. Hollick RJ and Reid DM. *Menopause Int* 2011;17:66.
8. Das De S et al. *J Bone Joint Surg Br* 2010;92:679.
9. Girgis CM and Seibel MJ. *Bone* 2011;48:963.
10. Somford MP et al. *J Bone Miner Res* 2009;24:1736.
11. Cheung RK et al. *Hong Kong Med J* 2007;13:485.
12. Lenart BA et al. *Osteoporos Int* 2009;20:1353.
13. Neviasser AS et al. *J Orthop Trauma* 2008;22:346.

P780

ASSOCIATIONS BETWEEN CAM MORPHOLOGY AND HIP OSTEOARTHRITIS IN A COMMUNITY-BASED SAMPLE OF OLDER ADULTS

H. Ahedi¹, T. Winzenberg², S. Bierma-Zeinstra³, L. Blizzard¹, M. van Middelkoop⁴, R. Agricola⁵, J. H. Waarsing⁴, F. Cicuttini⁶, G. Jones¹

¹University of Tasmania, Hobart, Australia, ²University of Tasmania, Hobart, Australia, ³Department of General Practice, Erasmus MC, Department of Orthopaedics, Erasmus MC, Rotterdam. The Netherlands, ⁴Department of General Practice, Erasmus MC, Rotterdam. The Netherlands, ⁵Department of Orthopaedics, Erasmus MC, Rotterdam, The Netherlands, ⁶DEPM, Monash University, Melbourne, Australia

Objective: Cam-morphology plays a significant role in hip OA (osteoarthritis) but less studied in older adults. This study aimed to describe the associations of cam morphology with demographic, clinical and MRI features of OA.

Methods: Anteroposterior hip radiographs of 914 participants from the prospective Tasmanian Older Adult Cohort (TASOAC) were scored at baseline for α angle (cam morphology) in either one or both hips. Radiographic hip OA was assessed at baseline. Hip pain and hip structural changes were assessed by MRI at five years and total hip replacement (THR) data was acquired 14 years from baseline.

Results: Of 914 participants, 67% had no cam-morphology, 23% had unilateral, and 10% had bilateral cam-morphology. At baseline, participants with either unilateral or bilateral cam-morphology were older, more likely to be males and had higher BMI in comparison to those without cam-morphology. Bilateral cam-morphology was associated with higher prevalence of radiographic hip OA. At follow-up, bilateral cam-morphology predicted higher hip pain and threefold risk of THR. Hip effusion-synovitis at multiple sites and hip cartilage defects were more common in those with cam-morphology. High cartilage signal and hip bone marrow lesions were not associated with cam-morphology.

Conclusion: In this large prospective study cam-morphology was associated with increasing age, BMI and male sex. Bilateral cam-morphology was associated with hip ROA and predicted hip pain, hip effusion-synovitis, cartilage damage and THR. These findings suggest that cam-morphology plays a significant role in development of OA and can be a precursor or contribute to hip OA in later life.

P781

SCREENING OF FRACTURE RISK AND OSTEOPOROSIS AMONG THE ELDERLY IN THE LONG-TERM AND DAY-CARE INSTITUTIONS: A PROSPECTIVE COHORT STUDY IN TAIWAN

S.-H. Fu¹, C.-Y. Wang², C.-C. Huang¹, C.-C. Hung¹, R.-S. Yang³, F.-Y. Hsiao⁴, C.-Y. Li⁵

¹Department of Orthopedics, National Taiwan University Hospital Yun-Lin Branch, Yunlin, ²School of Pharmacy, College of Medicine, National Taiwan University, Taipei, ³Department of Orthopedics, National Taiwan University Hospital Yun-Lin Branch, Taipei, ⁴Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, ⁵Department of Public Health, National Cheng Kung University, Tainan, Taiwan

Objectives: Screening of fracture risk and osteoporosis treatment of the elderly in long-term and day-care institutions.


Methods: The elderly in long-term and day-care institutions are featured with multicomorbidities and expected to be most susceptible to osteoporotic fracture. Because of limited literature about this population, especially in Asia, we conduct a prospective longitudinal follow-up pragmatic cohort study. Patients older than 50 y old and living in long-term and day-care institutions

were included as our study population. By using the fracture risk assessment tool (FRAX) and face to face questionnaire process, we assess the 10-y fracture risk of major osteoporotic and hip fracture (FRAX-history) of those elderly. In addition, those identified as moderate or high risk are recommended for further fracture risk assessment by DXA. Detail study design was represented in Figure 1.

Results: In 2018, there are 41 long-term care institutions and 17 day-care institutions in Yunlin County, Taiwan. Among them, 17 (41.5%) long-term care institutions and 11 day-care institutions (64.7%) were enrolled in this project. There are 600 residents underwent FRAX-history evaluation and face to face questionnaire, and only 25 patients (4.2%) have antiosteoporosis medication (AOM) treatment currently. Among these residents, 166 (27.7%) and 382 (63.7%) were identified as moderate and high risk, respectively. Among patients with FRAX-history moderate or high risk, 109 (19.9%) patients went to hospital for further fracture risk evaluation by DXA and assessed for AOMs therapy.

Conclusions: Approximate 90% elderly in the long-term or day-care institutions were identified as moderate or high fracture risk by FRAX. But only few residents (4.2%) already had AOM treatment. More effort is warranted to fulfill the unmet treatment gap.

Acknowledgments: Syun-Ping, Fu, Wen-Yan Hsu



P782

VITAMIN D INSUFFICIENCY: A RISK FACTOR FOR VERTEBRAL FRAGILITY FRACTURES IN BOTH MEN AND WOMENM. -H. Hsieh¹, J.-T. Chien², H.-R. Chang³

¹Fracture Liaison Service, Department of Orthopedics, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Institute of Medicine, Chung Shan Medical University, Chia-Yi, ²Department of Orthopedics, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, ³Institute of Medicine, Ching Shang Medical University, Taichung, Taiwan

Objectives: Vitamin D insufficiency is defined as a risk factor for osteoporotic fractures but the association between vertebral fragility fractures and vitamin D, especially in males, remains unclear. The aim of this study was to evaluate serum levels of 25-hydroxyvitamin D (25OHD) in high fracture risk patients with or without fragility fractures and to clarify the relationship whether patients with a vertebral fracture were at greater risk of vitamin insufficiency.

Methods: From 2016-2018 we measured the serum 25OHD levels of 92 patients admitted with vertebral fractures, 69 patients with hip fractures, and 33 patients without fractures who recruited from fracture liaison service to evaluate the prevalence of vitamin D insufficiency. Those who received antiosteoporosis therapy within 2 y and who were related with glucocorticoid induced osteoporosis were excluded. Totally 174 patients (38 males and 136 females) were recruited in this study.

Results: The average ten year probability of fracture (%) of major osteoporotic and hip fracture were 21.2% and 10.3% separately. Vitamin D insufficiency was prevalent in high fracture risk patients (61%) and equally distributed between male and female patients. Univariate logistic regression analysis showed age, gender, bone mass index (BMI), femoral neck BMD, calcium, and vitamin D levels were significantly different between patients with fragility fractures and the control group. After stepwise multivariate logistic correlation analysis adjusted by age, gender and BMI, lower 25OHD level is significantly associated with vertebral fragility fractures (odds ratio, 2.86, 95%CI, 2.72-3.02, p=0.036). 25OHD levels was not significantly associated with their underlying diseases, such as diabetes mellites, hypertension or stage of chronic kidney disease. The other markers, albumin, alkaline phosphatase, PTH, or osteocalcin were not significantly associated with 25OHD levels either.

Conclusion: Vitamin D insufficiency was shown to be a risk factor for vertebral fragility fractures in both men and women.

P783

MAJOR OSTEOPOROTIC FRACTURE TO HIP FRACTURE RATIOS: A SYSTEMATIC REVIEW OF OBSERVATIONAL STUDIESM. Chakhtoura¹, H. Dagher¹, S. Sharara¹, N. Chamoun¹, J. Cauley², Z. Mahfoud³, G. El Hajj Fuleihan¹

¹American University of Beirut - Medical Center - Lebanon, Hamra, Lebanon, ²University of Pittsburgh, Pittsburgh, PA, USA., Pittsburgh, USA, ³Weill Cornell Medical College, Al Rayyan. Qatar

Objectives: The risk of osteoporotic fracture at the lumbar spine, hip, and other sites varies by geographic location, ethnicity, socio-economic status and year [1, 2, 3, 4]. This review evaluates incidence rate ratios of major osteoporotic fracture (MOF: hip, lumbar spine, humerus, or forearm) to hip fracture, by age and gender, across countries.

Methods: We conducted a systematic search in Medline, PubMed, and Embase until May 2018, with no time or language restriction. We used MeSh terms and keywords relevant to osteoporosis, epidemiology, hip and MOF. We selected studies ≥ 1 y. After title, abstract and full text screening, we extracted data in duplicate. We derived incidence rate ratios of MOF/hip fractures and assessed the quality of studies using a modified quality score [5, 6]. Statistical analyses evaluating the difference in rate ratios between countries are in progress.

Results: We screened 321 full articles and included 25 studies: 3 from Asia, 13 from Europe, 7 from USA and Canada, and 2 from Oceania. The MOF/hip fracture incidence rate ratios are higher in women, and as expected, decrease with age across countries. The discrepancy is largest at younger ages. For ages 50-54, it ranges between 6 (Switzerland) and 54 (South Korea) in women, and between 3.7 (Australia) and 16 (Iceland) in men. At 85+ years, rate ratios vary from 1.4 to 4 in women, and 1.3 to 3.6 in men, in Switzerland and Korea, respectively.

The quality assessment revealed low scores in some studies, related to lack of definition of osteoporotic fractures (n=20 studies), ICD code fracture identification (n=15 studies), ethnicity (n=23 studies), or sample size (n=14 studies). The majority of the studies (64%) were retrospective.

Conclusion: The MOF/Hip fracture incidence rate ratios vary widely across countries. The FRAX tool resulted in a major shift in the approach to patients with osteoporosis [7]. FRAX assumes for most countries models that the age and gender adjusted MOF/hip ratio is the same as in Malmo, Sweden. Further research is needed to elucidate the effect of the variability in MOF/hip incidence ratios on the ultimately FRAX derived risk estimates.

References

1. Cauley Nat Rev Endocrinol 2014
2. Kanis Osteoporos Int 2012
3. Sibai Osteoporos Int 2011
4. Ballane Osteoporos Int 2017
5. Cauley J Clin Densitom 2011

6. El Hajj Fuleihan J Clin Densitom 2017

7. Leslie Osteoporos Int 2019

P784

HISTOMORPHOMETRY OF BONE TISSUE IN OSTEOSYNTHESIS OF FEMORAL DIAPHYSIS FRACTURE IN RATS WITH OSTEOPOROSIS MODEL WITH MAGNESIUM IMPLANTS WITH DIFFERENT TYPES OF COATINGS

I. Maistrovskaia¹

¹Pacific State Medical University, Vladivostok, Russia

Objective: To assess the state of bone tissue during osteosynthesis of femur fracture in rats with experimental osteoporosis using magnesium implants with calcium-phosphate coating and calcium-phosphate coating with polytetrafluoroethylene.

Methods: 24 rats of Wistar males, divided into four groups, glucocorticoid-induced osteoporosis was reproduced, followed by modeling of the closed fracture of femur. In two groups of animals, fixation of fragments was performed by method of closed intramedullary retrograde osteosynthesis using magnesium implants coated with hydroxyapatite and hydroxyapatite with polytetrafluoroethylene. Comparison groups were formed by animals, the healing of fractures without use of implants, and animals with osteoporosis without fracture. On 14th, 30th and 60th day of experiment, a histological and morphometric assessment of bone tissue condition was performed.

Results: The use of implants coated hydroxyapatite and polytetrafluoroethylene in osteosynthesis in condition of osteoporosis led to earlier regeneration of bone tissue. The thickness of cortical bone and thickness of trabeculae were significantly higher in rats with coated hydroxyapatite and polytetrafluoroethylene magnesium implants comparing magnesium implants coated hydroxyapatite (152.5±4.9 mcm and 136.6±4.5 136.6±4.5 mcm on 14th day; 135.9±2.0 mcm and 138.3±2.9 mcm on 30th; 150.3±2.6 mcm and 146.8±1.9 mcm, p<0.01). On 14th day in group of animals, with use of magnesium implants coated with hydroxyapatite and polytetrafluoroethylene in projection of callus, equal ratio of fibroreticular tissue and osteoid was observed. On 30th day in animals of this group there was a significant increase in the density of the cancellous bone. Osteoid decreased in size and almost completely disappeared in areas far from the fracture, coarse-fibrous bone tissue began to transform into a lamellar bone. On 60th day in bone tissue of animals in groups with different types of implants, morphological picture was not significantly different.

Conclusions: The dynamics of bone tissue condition in fractures in rats with model of osteoporosis show to acceleration of regeneration process due to use of magnesium implants coated hydroxyapatite with polytetrafluoroethylene. The use of such devices could be as a promising way to improve results of fracture treatment in conditions of systemic osteoporosis.

Acknowledgement: This research was supported by Russian Science Foundation (project No. 14-33-00009).

P785

COMPARATIVE COMORBIDITIES, FUNCTIONAL OUTCOME, AND COMPLICATIONS OF TKR BETWEEN POSTTRAUMATIC AND PRIMARY OSTEOARTHRITIS OF THE KNEE

D. R. Phruetthiphat¹, Y. Gao², P. Callaghan²

¹Royal Thai Army Hospital, Bangkok, Thailand, ²University of Iowa Hospital and Clinics, Iowa City, USA

Objective: Fracture around the knee (distal femoral fracture, tibial plateau fracture) can lead to posttraumatic osteoarthritis (PTOA) of the knee. 1-4 Malunion, malalignment, intra-articular osseous defects, retained internal fixation devices, and compromised soft tissues may affect the outcome of total knee replacement (TKR). 1 On average, the posttraumatic OA patients were approximately 10 y younger than those for primary OA knee. 5-6 Additionally, tibial plateau fracture fixation in older patients and those with more severe fractures are more likely to need TKR. 7 Only a few literatures have defined surgical challenges and outcomes of total knee replacement in PTOA that was lower functional outcome than those TKR in primary OA. 8-12 However, not much data demonstrating the patient's comorbidities, functional outcome, and complication between PTOA (fracture around the knee and ligamentous injury of the knee) and primary OA of the knee. The purpose of this study was to compare comorbidity, functional outcome, and complication of TKR among posttraumatic OA caused by fracture, posttraumatic OA after knee ligamentous injury, and primary OA knee.

Method: After the Institutional Review Board Approval, patient's medical records were reviewed. Between January 2008 and December 2013, a total of 1225 patients underwent TKRs at our arthroplasty center. Finally, 852 patients undergoing TKRs were recruited in this study. Patients were divided into 3 categories: 716 patients with primary OA knee, 32 patients with PTOA (fracture around the knee subgroup), and 104 PTOA (knee ligamentous injury subgroup).

Primary OA knee was defined as osteoarthritis of the knee which has no specific cause while PTOA knee was defined as osteoarthritis of the knee caused by previous traumatic event. The PTOA group was further categorized into 2 subgroups; fracture PTOA subgroup and ligamentous injury PTOA subgroup. Patients were reviewed demographic data, comorbidity including ASA classification and Charlson comorbidity index (CCI), preoperative alignment, preoperative visual analogue scale (VAS), preoperative WOMAC score. Functional outcomes were assessed with the WOMAC¹³⁻¹⁴ at 2-year follow-up.

Results: There were significantly different in age, gender, and obese between posttraumatic OA knee (PTOA) and primary OA knee (POA). PTOA patients were significantly younger (56.5 vs. 63.8 years; P<0.0001) at time of surgery, with a higher proportion of men (51.5% vs. 36.9%; P=0.001) compared with the primary osteoarthritis group. On the contrary, POA group undergoing TKR predominantly in female, with a significantly higher obesity rate than PTOA group. However, smoking and alcoholic drinking had no significant difference in both groups (Table 1). The

POA group had higher comorbidities than PTOA group including anticoagulant usage (51% vs. 30.9%, p=0.0002), ASA class ≥ 3 (38.8% vs. 21.6%, p<0.0001), number of disease ≥ 4 (69.6% vs. 45.3%, p<0.0001), and Charlson Comorbidity Index (3.6 vs. 2.8, p<0.0001) (Table2). According to radiographic alignment preoperatively, there was significantly different of anatomical axis between groups: PTOA group was valgus alignment (-1.6 \pm 9.8) while POA group was varus alignment (2.2 \pm 8.9) (p<0.0001). However, there was comparable mechanical axis preoperatively between groups. In addition, posterior slope was almost significant between groups (8.1 vs. 7.2, p=0.052) (Table 3). Postoperatively radiographic assessment defined that there was no significantly different of anatomical (-4.3 vs. -4.3, p=0.867) and mechanical axis (0.4 vs. 0.9, p=0.263) between groups, except PTOA group had more posterior slope than POA group (2.9 vs. 2.1, p=0.018) (Table 3). Preoperative visual analogue scale (VAS) was comparable among three groups. On the contrary, postoperative VAS in Fracture PTOA subgroup was significantly higher than primary OA

group while there was no significant difference in pain score between ligamentous PTOA subgroup and primary OA group (Table 4). There were no differences in all three components of preoperative WOMAC score among subgroups of posttraumatic OA Knee (Fracture PTOA and Ligamentous PTOA) and primary OA knee (POA) (Table 5). PTOA subgroup had significantly lower pain component and stiffness component than primary OA group. However, there were no differences in all components of WOMAC score between ligamentous PTOA subgroup and primary OA group (Table 6). There was no difference in postoperative complications (surgical site infection, urinary tract infection, venous thrombotic event) including readmission within 90 days (Table 7).

Conclusion: The outcome following TKR in Fracture PTOA subgroup was poorer than the outcome with primary osteoarthritis of the knee in midterm follow-up. However, the outcome undergoing TKR was comparable between ligamentous PTOA subgroup and primary OA knee.

Table 1 Patient’s demographic data between posttraumatic osteoarthritis of the knee (PTOA) and primary osteoarthritis of the knee (POA)

Demographic data	PTOA	POA	p-value
Age* (y)	56.5 (31.0-82.0)	63.8 (30.0-95.0)	<0.0001
Gender** -Male	70 (51.5%)	264 (36.9%)	0.001
-Female	66 (48.5%)	452 (63.1%)	
BMI [‡] -Normal (18 to <25 kg/m ²)	14 (10.4%)	42 (5.9%)	0.025
-Overweight (25 to <30 kg/m ²)	37 (27.4%)	128 (17.9%)	
-Obesity (>30 kg/m ²)	84 (62.7%)	544 (76.0%)	
Smoking**	8 (5.9%)	35 (4.9%)	0.627
Alcohol drinking**	59 (43.4%)	255 (35.6%)	0.085
* =mean, range; ** =n, percentage; [‡] The values are given as the number of patients, with the percentage in parentheses; Statistic significance at p<0.05			

Table 2 Patient’s comorbidities between posttraumatic osteoarthritis of the knee (PTOA) and primary osteoarthritis of the knee (POA)

Patient’s comorbidities	PTOA	POA	p-value
Anticoagulant** Yes	42 (30.9%)	365 (51.0%)	0.0002
No	94 (69.1%)	351 (49.0%)	
ASA classification[‡] 1	7 (5.2%)	11 (1.6%)	<0.0001
2	98 (73.1%)	424 (59.6%)	
≥ 3	29 (21.6%)	276 (38.8%)	
Number of disease** 1-3	70 (54.7%)	214 (30.4%)	<0.0001
≥ 4	58 (45.3%)	488 (69.6%)	
Charlson Comorbidity Index*	2.8 \pm 1.4 (0.0 -7.0)	3.6\pm1.5 (0.0 -10.0)	<0.0001
* =mean, range; ** =n, percentage; [‡] The values are given as the number of patients, with the percentage in parentheses; Statistic significance at p<0.05			

Table3: Radiographic findings between posttraumatic osteoarthritis of the knee (PTOA) and primary osteoarthritis of the knee (POA)

Radiographic alignment	PTOA	POA	p-value
Anatomical axis*			
Preoperative	-1.6±9.8 (-31.0 to 26.0)	2.2±8.9 (-30.0 to 30.0)	<0.0001
Postoperative	-4.3±3.0 (-10.0 to 7.0)	-4.3±2.4 (-11.0 to 7.0)	0.867
Mechanical axis*			
Preoperative	3.2±10.4 (-28.0 to 34.0)	4.0±9.4 (-27.0 to 34.0)	0.570
Postoperative	0.4±3.7 (-8.0 to 10.0)	0.9±3.6 (-12.0 to 18.0)	0.263
Posterior slope*			
Preoperative	8.1±3.5 (0.0 to 19.0)	7.2±4.1 (-3.0 to 23.0)	0.052
Postoperative	2.9±3.2 (-6.0 to 11.0)	2.1±2.2 (-2.0 to 12.0)	0.018
* =mean, range; In AP x-ray (+=varus knee, -=valgus knee); In lateral x-ray (+=posterior slope, -=anterior slope)			

Table 4 Visual analogue scale (VAS) among subgroups of posttraumatic OA knee (fracture PTOA and ligamentous PTOA) and primary OA knee (POA)

Pain score	Mean±SD	Range	p-value
Preoperative VAS -Fracture PTOA	8.3±1.4	6.0-10.0	0.64
-Ligamentous PTOA	8.0±1.3	4.0-10.0	0.99
-POA*	8.0±1.3	3.0-10.0	
Postoperative VAS -Fracture PTOA	2.1±1.8	0.0-6.0	0.019
-Ligamentous PTOA	1.7±1.8	0.0-8.0	0.063
-POA*	1.3±1.7	0.0-10.0	
* =Reference; significant at p<0.05			

Table 5: Preoperative WOMAC among subgroups of posttraumatic OA knee (fracture PTOA and ligamentous PTOA) and primary OA knee (POA)

Preoperative WOMAC	Mean±SD	Range	P-value
Pain Component -Fracture PTOA	40.5±30.6	0.0-100.0	0.20
-Ligamentous PTOA	43.6±19.7	0.0-100.0	0.11
-POA*	48.7±21.9	0.0-100.0	
Stiffness Component -Fracture PTOA	36.4±30.6	0.0-100.0	0.70
-Ligamentous PTOA	39.4±21.3	0.0-87.5	0.95
-POA*	40.2±21.6	0.0-100.0	
Functional Component -Fracture PTOA	41.2±24.2	5.7-87.5	0.39
-Ligamentous PTOA	45.3±21.4	0.0-95.5	0.80
-POA*	46.7±19.0	0.0-97.7	

Table 6: Postoperative WOMAC among subgroups of posttraumatic OA knee (fracture PTOA and ligamentous PTOA) and primary OA knee (POA)

Postoperative WOMAC	Mean±SD	Range	P-value
Pain Component -Fracture PTOA	70.0±25.0	25.0-100.0	0.007
-Ligamentous PTOA	80.2±23.8	0.0-100.0	0.16
-POA*	85.7±19.6	10.0-100.0	
Stiffness Component -Fracture PTOA	50.0±25.0	0.0-100.0	0.013
-Ligamentous PTOA	63.2±22.8	0.0-100.0	0.98
-POA*	63.8±18.3	0.0-100.0	
Functional Component -Fracture PTOA	60.9±21.0	22.7-89.8	0.08
-Ligamentous PTOA	73.6±20.6	18.2-97.7	0.83

Table 7: Complications including Readmission between Posttraumatic (PTOA) and Primary OA knee (POA)

Parameters	PTOA (n=136)	POA (n=716)	P-value
Complications¥			0.262
Surgical site infection**	2 (1.5%)	2 (0.3%)	
Urinary tract infection**	0 (0%)	1 (0.1%)	
VTE event	1 (0.7%)	1 (0.1%)	
No complication**	133 (97.8%)	712 (99.5%)	
Readmissions**			
Within 30 days	2 (1.5%)	21 (2.9%)	0.561
Between 30-90 days	2 (1.5%)	15 (2.1%)	1.000
**=n, percentage; ¥ The values are given as the number of patients, with the percentage in parentheses; Statistic significance at p<0.05			

P786

STANDARDIZED CEMENT AUGMENTATION IN EXTRACAPSULAR HIP FRACTURES: IS A SAFE AND REPRODUCIBLE TECHNIQUE TO INCREASE ANCHORAGE IN OSTEOPOROTIC BONE?

F. J. N. Nistal Rodríguez¹, R. E. M. Escudero Marcos¹, A. S. Sanz¹, S. C. N. Campesino Nieto¹, A. Q. Quintanilla¹, M. G. A. García Alonso¹, J. L. S. Javier¹

¹Rio Hortega Hospital, Valladolid, Spain

Objectives: Evaluate safety, complications and functional result of extracapsular hip osteoporotic fractures treated with standardized cement augmentation with the PFNA-Augmentation© nail.

Methods: A retrospective analysis of 81 consecutive patients with extracapsular osteoporotic fracture of the proximal femur treated with PFNA-Augmentation nail was performed between 2010-2017. Demographic data, AO classification, quantity and distribution of cement, complications associated with its use (necrosis, leak to the joint, cartilage damage). radiological assessment such as fracture reduction, blade position, mechanical complications and functionality were collected.

Results: 81 patients (65 women and 16 men) with a mean age of 85.88 y [54-101, SD-7.71]. were reviewed. Most frequent fracture types were unstable: type 31A2.3 (30), 31A3.3 (17) and 31A2.2

(22). Mean amount of cement was 3.5 ml [3-5, SD-0.54]. No definite pattern of distribution was observed. Up to 10 different surgeons performed 3 or more interventions. There was an intraoperative complication, without clinical consequences for the patient, in which the cement migrated to the joint. Fracture reduction was good in 55 patients, acceptable in 19 cases and poor in 7 cases. Mean follow-up was 14.5 months (12-24 months). 15 patients died during the follow-up for reasons unrelated to the surgical technique. Mechanical complications were observed in 4 cases (1 peri-implant fracture that needed surgical revision, and 3 "back-out"), but none associated with cement augmentation. Of the 81 patients, 71 walked previously (19 without help, 19 with simple help and 33 with walker). 57.5% of patients achieved their prefracture functional status. 17 patients could not walk again

Conclusion: Osteosynthesis with standardized cement augmentation technique in extracapsular osteoporotic hip fractures is a reliable, safe and reproducible technique that could reduce number of mechanical complications and improve functional results by increasing the anchorage of the implant to the frail bone.

P787

LACK OF CONVINCING KNOWLEDGE ABOUT OSTEOPOROSIS AMONGST TOP CLINICIANS OF MULTIPLE SPECIALTIES IS A MAJOR RISK FACTOR FOR FRAGILITY FRACTURES IN INDIA

D. R. Bajaj¹

¹Falls Institute of India [FII], Unit of Laxmidevi Bajaj Geriatric & Preventive Research Centre Pvt. Ltd., Nagpur, India

Objective: To prove that lack of convincing knowledge about Osteoporosis amongst top clinicians of multiple specialties is a major risk factor for fragility fractures in India.

Methods: The data is collected from the research facility where around 5000 patients were screened between 2012-2019 in the monthly camps of BMD, ECG, RBG & BP. The prescriptions from other specialists of about 500 patients having Osteoporosis diagnosis by T-score of -2.5 or even lower in these camps, were studied by the principal investigator (PI). The specialists were gynaecologists, diabetologists, orthopaedic surgeons, endocrinologists, nephrologists, physicians, etc., and AAYUSH specialists.

Results:

1. Very few had advised DXA Scan. Though the peripheral densitometry BMD Camps are common. But even after knowing the adverse value of T-score, only calcium and vit D were prescribed. Doctors took adverse results of ECG, random blood sugar and hypertension very seriously as against adverse T-score. Very few gave the prescription containing AOM.
2. There was minimal or no referral from specialists to physiotherapist, occupational therapist or podiatrist as a preventive strategy. All **References** were postoperative, to save surgical failures.
3. Very few specialists were aware of FRAX and no one is actually using it.
4. Regular Calcium consumption was significantly low for the fear of getting kidney stone or lack of evidence based encouragement & knowledge.
5. Most of the prescriptions were full of pain killers (NSAID), steroidal preparations, antirheumatic, antiarthritic drugs but rarely a prescription of AOM was seen.
6. Not a single blood work report of any of the bone marker (like s-PINP /s-CTX) was seen before initiation or for monitoring any oral or parenteral AOM.

Conclusions:

1. The Indian super specialists are convincingly not aware about the risk of fragility fractures in their postmenopausal patients (as they don't suggest any precautions, intervention, investigations or treatments) due to lack of their knowledge leading to fragility fractures in their postmenopausal patients coming to their hospitals with any complaints regarding their health.
2. They don't suggest DXA Scan for knowing the status of major joints prone for fracture due to fall or frailty.

3. They don't write any antiosteoporosis medication (AOM). It is not a part of their routine prescription. They are also convincingly unaware that AOM are to be written for lifetime like medications for other lifestyles diseases HTN, HD, DM, etc.
4. They contribute indirectly in spreading, adding negativity regarding the side effects of AOM disproportionately. At least they can oppose the rumours by educating their patients.
5. The reality can be judged by the fact that Indian Menopause Society has been ceased to exist as a CNS member society of IOF since last many years.
6. There is no entity or no listing in the specialists' categories claiming to treat osteoporosis called as osteoporocians like orthopaedicians, physicians, dieticians, etc.
7. Pharma are doing great job for promotion of PMO - calcium, vit D, etc.
8. No Indian national medical organisations are doing promotional works for PMO.
9. Indian females don't do exercises, failure of doing it reflects the worst tally of medals In Olympics.
10. Many specialists take lead from front in discouraging patients or their relatives either in 'not permitting' to start the AOM or to stop the ongoing t/t.
11. The concept of FLS is as good as unknown and nonexistent.

P788

AREA OF ANTERIOR SKIN NUMBNESS AFTER TOTAL KNEE ARTHROPLASTY: A PROSPECTIVE COMPARISON STUDY BETWEEN DIABETIC AND NONDIABETIC PATIENTS

D. R. Phruetthiphat¹, M. Chanpoo¹, S. Taosuwan¹, P. Callaghan²

¹Royal Thai Army Hospital, Bangkok, Thailand, ²University of Iowa Hospital and clinics, Iowa city, USA

Objective: Total knee arthroplasty (TKA) is one of the most successful procedures for patients with painful knee osteoarthritis. However, anterior skin numbness from injury of the infrapatellar branch of saphenous nerve (IPBSN) and/or the inferior branch of the femoral cutaneous nerve (IBFC) have been reported as a common complication after TKA, which may affect the patients' outcome (1-5). Recently, Tanavalee et al. demonstrated that there was no difference of skin numbness between minimally invasive and standard approach for TKA (6). To our knowledge, no study has compared the skin numbness including warmness between diabetic patients and non-diabetic patients undergoing TKA. Moreover, no literature can explain why some patients have large skin numbness including the upper-lateral area adjacent to the patella.

Methods: Phase I study: Initially, we evaluated 120 patients undergoing TKA. Five diabetic patients with skin numbness around the knee before TKA were excluded. 41 type II diabetic and 74 nondiabetic patients underwent TKA. Area of anterior skin numbness (cm²) was periodically evaluated and were compared out

to minimum 2-year follow-up (FU). Phase II study: 30 normal cadaveric knees were dissected. The course and distribution of the IPBSN and the IBFC were specifically identified.

Results: In the clinical study, there was no difference in prevalence of skin numbness (73.2% vs. 68.9%, $p=0.36$) and warmth (97.6% vs. 97.3%, $p=1.00$) between diabetic and nondiabetic patients. The average numbness (cm²) was comparable between groups at 2 weeks and 1 year. However, duration of numbness recovery after TKA in diabetic patients was significantly longer than the non-diabetic group (8.6 months vs. 5.3 months, $p=0.001$). Moreover, the characteristic of skin numbness was significantly different between groups. The former group had a higher rate of global anterior numbness compared to the latter group (48.3% vs. 22.9%, $p=0.045$).

The clinical study demonstrated a prevalence of the superior-lateral skin numbness of 1.7%, presumed to be injury to the anterior-inferior branch of the femoral nerve. This correlated with the cadaveric study where 10% of the nerves crossed the midline incision.

Conclusion: The duration of numbness recovery was significantly longer in diabetic patients. This information is useful for counseling patients undergoing TKA. Additionally, a longer skin incision proximally (i.e., more than 2 cm above the proximal pole of the patella) should be avoided to minimize superior-lateral skin numbness.

Reference:

1. Borley NR et al. J Arthroplasty 1995;10:13.
2. Johnson DF et al. Am J Orthop 2000;29:863.
3. Hopton BP et al. Knee 2004;11:289.
4. Sundaram RO et al. Knee 2007;14:375.
5. Subramanian S et al. Acta Orthop Belg 2009;75:649.
6. Tanavalee A et al. J Arthroplasty 2016;31:2499.

P789

BODY COMPOSITION, LEVEL OF PHYSICAL ACTIVITY AND COGNITIVE DYSFUNCTION IN PATIENTS WITH NEW LOW-ENERGY FRACTURES

D. Krutko¹, D. Isaenkova¹, R. Baskakova¹, S. Mazurenko¹

¹Saint Petersburg State University, Medical Faculty, Department of Introductory Course of Internal Diseases, Saint Petersburg, Russia

Objectives: We assessed body composition, level of physical activity and cognitive dysfunction in patients with new low-energy fractures.

Methods: The study group included 33 patients (28 women) with new low-energy fracture. The average age was 75.7 ± 12.6 y. We assessed the level of physical activity, and MMSE (Mini-Mental State Examination) score. We performed bioelectrical impedance analysis to assess body composition.

Results: The mean MMSE score was 20.8 ± 8.4 . 17 patients (52%) had MMSE score more or equal 24 (no dementia), 6 patients (18%) demonstrated mild dementia, 6 patients (18%) demonstrated moderate dementia, and 4 patients (12%) showed severe cognitive impairment. We assessed patients' physical activity with the original questionnaire, where 0 means bed-ridden level of physical activity (2 patients, 6%), 1 means ambulatory within own apartment/house (11 patients, 33%), 2 means ambulatory to and from a shop/workplace (13 patients, 39%), 3 means daily walking no <2 hours (4 patients, 12%), 4 means moderate physical activity daily (1 patient, 3%), 5 means vigorous physical activity most days of the week (1 patient, 3%). We asked about the number of spontaneous falls during the last year. The mean number was 2.1 ± 2.8 (quartile 1 to quartile 3, 0.0-4.0). The weight mean was 80.3 ± 5.5 kg in men and 68.2 ± 13.9 kg in women. The mean fat mass value was 20.5 ± 9.7 kg. Fat free mass mean value was 54.7 ± 9.1 kg in men and 48.5 ± 9.1 kg. Mean skeletal muscle mass in men was 31.0 ± 5.2 kg, mean skeletal muscle mass in women was 27.5 ± 3.4 kg. There was no correlation between number of falls for the last year and level of physical activity of MMSE score. We found a negative correlation between the level of physical activity and number of falls for the last year ($R_s = -0.69$; $p < 0.05$). We couldn't find any correlation between weight of different body compartments and the MMSE level, level of physical activity, and number of falls.

Conclusion: Patients with new low-energy fractures demonstrated high prevalence of cognitive impairment and low level of physical activity. There was a significant correlation between the level of physical activity and number of spontaneous falls.

P790

PREVALENCE OF SARCOPENIA IN ELDERLY PATIENTS WITH OR WITHOUT LOW-ENERGY FRACTURES SUFFERING FROM NEW STROKE OR TRANSITORY ISCHEMIC ATTACK

D. Krutko¹, A. Gruzmanov¹, I. Nurullaev¹, S. Mazurenko¹

¹Saint Petersburg State University, Medical Faculty, Department of Introductory Course of Internal Diseases, Saint Petersburg, Russia

Objective: To assess body composition, muscle strength, and prevalence of sarcopenia in patients with or without low-energy fractures in the past admitted to the hospital with new stroke or transitory ischemic attack (TIA).

Methods: We included in the study 60 patients with new stroke or TIA (15% of all cases), which were divided into two groups. First group with low-energy fractures in the past consisted of 26 patients (53.8% females). There were 34 patients (61.7% females) in the second group without low-energy fractures in the past. We performed bioelectrical impedance analysis. Skeletal muscle mass (SMM) was calculated by the following equation: $SMM (kg) = 0.566 \cdot FFM$ (fat free mass). Skeletal muscle mass index (SMMI) was calculated as $SMM (kg) / \text{height} (m)^2$. Muscle strength was measured using a Jamar hand dynamometer.

Results: According to the European Working Group on Sarcopenia in Older People consensus 11 patients (7 females) from the first group and 17 patients (13 females) from the second group demonstrated low handgrip strength ($p>0.05$). 4 men from the first group and 2 men from the second had SMMI lower than the

cutoff values ($p>0.05$). In our study two men met EWGSOP criteria for sarcopenia diagnosis, both were from the first group. Four men from the first group and two men from the second group were diagnosed with presarcopenia ($p>0.05$).

	First group		Second group		
	Men	Women	Men	Women	
Age, years	67.9±11.8	74.7±13.5	69.2±12.1	76.9±8.6	$p>0.05$
Weight, kg	81.1±15.0	69.2±19.4	83.7±16.9	69.7±9.7	$p>0.05$
BMI	27.3±5.2	25.7±6.4	27.1±4.3	27.9±4.5	$p>0.05$
Handgrip strength, kg	34.8±9.1	17.8±6.7	38.7±11.1	16.3±5.5	$p>0.05$
Fat body mass, kg	21.4±10.7	21.0±10.4	20.4±11.8	22.4±6.5	$p>0.05$
SMM, kg	34.5±5.1	27.6±5.6	36.2±4.5	26.8±2.6	$p>0.05$
SMMI	11,6±1.5	10,3±1.8	11,7±0.9	10,6±1.0	$p>0.05$

Conclusion: Elderly patients with new stroke or TIA did not demonstrate high prevalence of sarcopenia or presarcopenia in our study. There was no statistical difference in the prevalence of low handgrip strength between two groups. Although there were two patients against zero with sarcopenia in the group of patients with low-energy fractures in the past, this difference did not achieve statistical significance.

P791

THE COMPONENTS OF ICF CLASSIFICATION IN EVALUATION OF REHABILITATION RESULTS IN PATIENTS WITH LUMBAR PAIN SYNDROME

A. Kadić¹, N. Vavra- Hadžiahmetović¹, K. Miladinović¹

¹Clinic for Physical Medicine and Rehabilitation, Clinical Centre University of Sarajevo, Sarajevo, Bosnia-Herzegovina

Objective: The International Classification of Functioning, Disability and Health (ICF) contains important factors for the program of rehabilitation and evaluation of the outcome of rehabilitation. The aim of this study is to compare the components of ICF Classification ("Body functions", "Body structures" and "Activities and Participation") with areas of assessment and specific elements that appear in the standardized assessments in the rehabilitation of the patients with Lumbar Pain Syndrome (Barthel index, Visual analogue scale, Oswestry Low Back Disability Questionnaire, Back Depression Inventory).

Methods: This research is a clinical retrospective study. The research pattern is formed by 60 patients, selected randomly, all of them hospitalised at the Clinic for Physical Medicine and Rehabilitation at the Clinical Centre University of Sarajevo in the period from 01.01.2018. until 01.12.2018. years.

Results: The average age was 48.91±10.98 y (28-70). Using the Paired t-test, a significant difference in values of Barthel index was established. The average value of Oswestry Questionnaire at reception was 29.16±11, while the average value at release was

statistically significantly smaller 14.20±8.72 ($t=17.424$; $p=0.001$). Although there is statistical significance in average value of Back Depression Inventory at reception and release ($t=5.085$; $p=0.001$), patients were in the group of mild mood disorders. At reception, the average value of the Visual analogue scale was 6.96±1.74, while at release, the average value was significantly lower (3.10±1.80). By using the analytical function all patients had weakness of muscle strength, and when it came to energy levels, all were 100% motivated. The analysis of changes related to anatomical spinal column structure was found that 45% have changes related to the spinal cord, all patients have changes in the disk structure, while additional musculoskeletal changes related to the movement has 16.7%. Descriptive statistical analysis of "Activity and participation" found that walking for no more than 10 minutes had 68.3%, and the ability of business had 60% of patients. Of the total number of patients, 58.3% were dressed independently while 90% could go to the toilet alone.

Conclusion: The components of ICF Classification implicitly support the program of evaluation and treatment outcomes in rehabilitation.

P792

PLATELET RICH PLASMA IN THE TREATMENT OF TENDINOPATHY IN SPONDYLOARTHRITIS

S. Parisi¹, M. C. Ditto¹, M. Priora¹, S. D'Antico², C. L. Peroni¹, A. Laganà¹, E. Fusaro¹

¹Rheumatology Unit Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, ²Banca Del Sangue Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy

Objective: The traditional approach to the treatment of chronic tendinopathy is the local infiltration of a glucocorticoids (GC), however this method has a high recurrence rate after 6 weeks. The infiltration of growth factors in the form of platelet rich plasma (PRP) or autologous platelet concentrate is an alternative

treatment of recent statement. The rationale of the treatment with the PRP is based of Factors that counteract the pro-inflammatory immune response and of that that stimulate the cells pertaining to the musculoskeletal system. Spondyloarthritis (SpA) are a group of diseases that share clinical and genetic features, including inflammation with predilection for the axial skeleton (spine and sacroiliac joints), asymmetrical arthritis, enthesitis, uveitis, psoriasis and inflammatory bowel manifestations. The musculoskeletal manifestations of SpA are the result of inflammation, which mainly occurs at the level of the enthesis, i.e., the insertion sites of tendons, ligaments. The enthesitis occurs more frequently at sites that bear a greater mechanical stress, such as at the Achilles tendon or the insertion of the patellar tendon. The pathogenesis involves cells and mediators of the immune system, in particular helper T cells, as demonstrated by genetic and immunological studies.

Methods: We have recruited 20 patients with spondyloarthritis with enthesitis already locally treated with GC therapy (at least 2 infiltration of triamcinolone acetonide 40 mg). 10 patients were

suffering from tendinitis of the Achille's tendon, 6 from epicondylitis and 4 from enthesitis of the patellar ligament. All patients were given two PRP infiltrations (at baseline and after two weeks). An ultrasound check Power Doppler (PWD) has been performed in all patients (in according to Omeract criteria for PWD), before starting the infiltrative cycle, after 2 weeks and after 3 months of follow-up.

Results: Our data, showed a good efficacy of the PRP in the treatment of tendinopathy, evaluated both clinically and with ultrasound, in patients with SpA (Δ tot VAS PAIN -7.2 and Δ PWD tot 2.1 $p < 0.05$ – Table 1). The active components of the PRP are the TGF- β and growth factors such as IGF, PDGF, etc.; it is known that TGF- β at appropriate concentrations inhibits the immune response mediated by Th17 cells, countering the priming and converting the T cell naive in TReg suppressors. The TGF- β also has the ability to inhibit other inflammatory cells, such as macrophages and other lymphocyte phenotypes, while the platelet growth factors, on the other hand, stimulate the tenocytes to produce collagen that repairs tendon lesions.

Table 1. Mean changes from the baseline values

Site of Enthesitis	Baseline VAS Pain (0-10)	Baseline PWD (0-3)	2 week VAS Pain (0-10)	2 week PWD (0-3)	3 month VAS Pain (0-10)	3 month PWD (0-3)	Δ VAS Pain (0-10)	Δ PWD (0-3)
Achille's tendon	7,9 SD±0,7	2,6 SD±0,5	3,6 SD±0,9	1,6 SD±0,5	1,0 SD±1,0	0,4 SD±0,5	-6,9	-2,2
Epicondyle	8,3 SD±0,6	2,3 SD±0,6	4,5 SD±0,5	1,0 SD±0,0	0,8±0,8	0,3 SD±0,6	-7,5	-2,0
Patellar Ligament	7,7 SD±0,3	2,0 SD±0,0	3,5 SD±0,7	0,5 SD±0,7	0,5 SD±0,7	0,0 SD±0,0	-7,2	-2,0
Total	8,0 SD±0,6	2,4 SD±0,5	3,9 SD±0,8	1,2 SD±0,6	0,8 SD±0,8	0,3 SD±0,5	-7,2	-2,1

p-value <0,05

Conclusion: PRP could be a viable alternative to the GC local treatment of these pathologies, but further studies are needed for comparison with a larger sample of patients.

P793
PREDICTORS OF RADIOGRAPHIC PROGRESSION IN HAND OSTEOARTHRITIS: A TEN-YEAR PROSPECTIVE COHORT STUDY

L. Pardaens¹, T. Vanhaverbeke¹, R. Wittoek²

¹Ghent University, ²Dept. of Rheumatology, Ghent University Hospital, Ghent University, Gent, Belgium

Objective: To identify new prognostic factors and to confirm existing evidence on already identified prognostic factors for radiographic progression in HOA after follow-up of 10 y.

Methods: A total of 106 patients from 270 from the original Ghent HOA cohort consented for a 10 years-follow-up visit. Presence of tender and swollen joints was assessed. Grip strength was measured. Questionnaire for functional impairment as FIHOA and AUSCAN were completed. Pain was scored on a visual analogue scale from 0-100 mm (VAS pain). X-rays of hands were taken and scored using the anatomical phase scoring system¹. Patients were defined as radiographic progressor when two or more joints

progressed to another phase within the scoring system, except for N-phase to S-phase. Logistic regression was performed on the clinical data and outcomes as presence of tenderness (yes or no), soft tissue swelling (yes or no), VAS pain (≤ 33 mm vs. > 33 mm), disease duration (≤ 5 vs. > 5 y), FIHOA and AUSCAN. Odds ratios (OR) with 95% CIs were calculated.

Results: After a mean follow-up of 9.7 y, 73.3% of the patients showed radiographic progression. The following clinical factors were associated with radiographic progression on patient level (OR [95%CI]): presence of tenderness (4.19 [1.52-11.61]), soft tissue swelling (2.73 [1.08-6.92]) and disease duration > 5 years (4.00 [1.50-10.66]). Other variables were: VAS pain (1.02 [1.00-1.04]), total FIHOA (1.12 [1.03-1.23]), total AUSCAN (1.02 [1.01-1.04]), AUSCAN pain (1.07 [1.02-1.12]), AUSCAN function (1.03 [1.01-1.06]) and VAS pain > 33 mm (2.87 [1.14-7.24]). The mean number of E and R joints was 1.2 and 1.4 at baseline, and 0.2 and 5.2 after 10 y ($p < 0.001$). The total number of joints that progressed to the E-phase and R-phase over a period of ten years was respectively 20 (1.05%) and 399 (21%).

Conclusion: Clinical presence of pain and soft tissue swelling at baseline remain strong predictors of radiographic progression in HOA after ten years. Tenderness upon pressure, moderate VAS

pain and moderate impaired function at baseline are identified as new predictors. After 10 y, more remodeling and less erosive joints are seen.

References: 1. Verbruggen G and Veys EM. *Arthritis Rheum* 1996;39:308.

P794

CLINICAL AND LABORATORY PREDICTION OF EFFICACY OF COMBINED TREATMENT IN RHEUMATOID ARTHRITIS

S. Spitsina¹, L. Shilova², A. Trofimenko¹, S. Bedina³, E. Tikhomirova³, M. Mamus³

¹FSBI "Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky", FSBEI HE "Volgograd State Medical University" MOH Russia, ²FSBEI HE "Volgograd State Medical University" MOH Russia, ³FSBI "Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky", Volgograd, Russia

Objective: Identification of the relationship between the level of TNF α and clinical manifestations with the effect of treatment in patients with rheumatoid arthritis (RA) receiving methotrexate (MT) with infliximab (IF).

Methods: 18 patients with RA were included in study. Mean disease duration was 13.2 \pm 5.3 y. RF positive RA was detected in 83.3% of patients, ACCP-positive – in 66.8%. RA radiographic stages III and IV were detected in 66.8%. All patients were treated with MT 12.5–20 mg per week during at least 3.6 years in combination with various NSAIDs. 50% of the patients took methylprednisolone 8 mg per day. IF was prescribed at the rate of 3 mg/kg. ESR, CRP, concentration of TNF α were determined in serum before (week 0) and after IF therapy (week 30). Disease activity and therapeutic effect were assessed using DAS28-CRP(4). Results. All RA patients had initial DAS28-CRP(4) > 5.6. In 55.5% of patients BMI was normal, and 44.5% of them were pre-obese. Mean ESR became decreased at 30th week (from 26.8 to 12.2 mm/h) as well as CRP (from 25.4 to 4.8 mg/l). Elevated TNF levels were revealed in 11.1% of RA sera at week 0, with mean concentration 6.96 pg/ml. All these patients were included in the group with good effect of therapy. The average value of VAS score on week 0 was 68.3 mm, after 30 weeks - 26.0 mm. The response to the therapy was evaluated: on the 30th week the group with good effect was 33.3%, with satisfactory - 50%, without effect - 16.7%. The groups with good and satisfactory response were patients with a CRP level exceeding the upper limit of the norm by more than 3 times, normal BMI (19.6-23.3 kg/m²), initially more high rates of DAS28-CRP (4) and higher concentrations of TNF α , which decreased during treatment.

Conclusion: Groups with a good and satisfactory response to week 30 of treatment with MT and IF included patients with normal body mass, high activity of disease, high concentrations of CRP and TNF.

P795

THE NONIONIZING RADIOFREQUENCY ECHOGRAPHIC MULTISPECTROMETRY (REMS) APPLIED ON A SPANISH COHORT FOR THE OSTEOPOROSIS DIAGNOSIS ON LUMBAR SPINE AND FEMORAL NECK

D. Ovejero Crespo¹, X. Nogues¹, A. Diez-Perez¹

¹Department of Internal Medicine, Hospital del Mar, Barcelona, Barcelona, Spain

Objective: To evaluate REMS [1] accuracy for the diagnosis of osteoporosis compared with the rd DXA in European women.

Methods: Within a European multicenter clinical trial, 595 subjects (aged 51-70 y) enrolled at the Department of Internal Medicine of the Hospital del Mar (Barcelona, Spain) underwent spinal and femoral examinations by both DXA and REMS technology. REMS is based on a highly selective automatic identification of target bones and regions of interest (ROIs), combined with advanced differential measurements between frequency spectra of RF signals backscattered from patient bones and reference spectral models, which had been previously derived from osteoporotic and healthy patients. All DXA acquisitions were double-checked by two different experienced operators in order to avoid possible inaccuracies [2]. At the same time, a quality control on all REMS data allowed to verify the correct transducer depth and focus selection. To evaluate REMS accuracy, its capability to discriminate osteoporotic patients from healthy individuals was assessed with Cohen Kappa and SEE (standard error of the estimate) estimation.

Results: We observed an high REMS sensitivity of 92.7% and 93.0% and specificity of 93.5% and 95.0% for spinal and femoral site, respectively, for the discrimination between individuals with and without osteoporosis. The diagnostic accuracy of the REMS technique was also confirmed by the SEE value equal to 0.040 and 0.039 g/cm² and the Cohen Kappa in the range 0.77-0.76 for spine and femur.

Conclusions: In a Spanish population REMS has been shown to be an accurate nonionizing approach for the diagnosis of osteoporosis in lumbar spine and femoral neck. The clinical use of this precise and automatic technology will also open new perspectives for early osteoporosis diagnosis and fracture risk estimation in children and in adult patients.

References:

- [1] Di Paola et al. *Osteoporos Int*, 2018
- [2] Messina et al. *Eur Rad*, 2015

P796

TREATMENT OF SEVERE OSTEOPOROSIS IN RUSSIA

O. M. Lesnyak¹, E. N. Gladkova², N. O. Aleksandrov³, N. V. Bezludnaya⁴, Z. E. Belaya⁵, T. A. Grebennikova⁵, A. V. Dreval⁶, O. B. Ershova⁷, K. Y. Belova⁸, S. O. Mazurenko⁹, I. V. Kryukova⁶, O. V. Dobrovolskaya¹⁰, D. V. Priymak³, L. Y. Rozhinskaya⁵, R. R. Samigullina², N. V. Toroptsova¹⁰

¹Mechnikov North-Western State Medical University, St. Petersburg, ²Mechnikov North-Western State Medical University, St. Petersburg, ³Lilly Pharma LLC, Moscow, ⁴Federal State Budgetary Institution Federal Center of Traumatology, Orthopedics and endoprosthesis replacement of Ministry of Health of the Russian Federation, Cheboksary, ⁵Endocrinology Research Centre, Moscow, ⁶Moscow Regional Research and Clinical Institute named M.F. Vladimirskiy, Moscow, ⁷Federal State Budgetary Educational Institution of Higher Education "Yaroslavl State Medical University", Yaroslavl, ⁸Federal State Budgetary Educational Institution of Higher Education "Yaroslavl State Medical University", Yaroslavl, ⁹Federal State Budgetary Educational Institution of Higher Education "Saint-Petersburg State University", St. Petersburg, ¹⁰Nasonova Research Institute of Rheumatology, Moscow, Russia

Objective: To review and analyze peculiarity of medical therapy and treatment results in patients with severe osteoporosis in selected clinics in Russia.

Methods: Within the study source, data analysis was performed for the patients who were observed for at least 1 y. Total number of patients included in analysis was 1000: 955 women and 45 men aged from 35-95 y. Observation period was 2864.5 person-years.

Results: At the time of diagnosis of osteoporosis, more than 90% of the patients had at least one fracture in their history, and 70% of the patients had multiple vertebral fractures. During the observation period, new fractures occurred in 23.9% of patients, frequency of hip fractures was 28.8%, vertebral fractures - 24.8%. There was registered high level used of oral and parenteral bisphosphonates at baseline (55% and 30.2%, respectively). Antiosteoporosis treatment was changed or canceled in 48.3% patients with severe osteoporosis. The most often reasons were low efficacy, adverse events and the patient's inability to pay for treatment. Oral bisphosphonates were the most frequently canceled medications (71.3%). Parenteral bisphosphonates and denosumab were more frequently used at the time of last observation (42.8% and 36.6%, respectively). Over 5% of patients with severe osteoporosis received anabolic therapy (teriparatide). The best results of treatment were observed in patients who was initially prescribed intensive therapy (parenteral bisphosphonates at least 3 y, denosumab or teriparatide at least 1 y). In this group, new fractures occurred with a lower frequency than in other patients (22.1% and 29.6% for all fractures, 9.9% and 17.1% for vertebral fractures, and 0.6% and 3.5% for hip fractures, respectively).

Conclusion: Treatment of patients with severe osteoporosis should be started with intensive therapy (parenteral bisphosphonates, denosumab, teriparatide) in order to reduce the risk of fractures.

P797

PRE-ANALYTICAL VARIABILITY OF BONE TURNOVER MARKERS IN AND ELDERLY POPULATION IN IRAN: BUSHEHR ELDERLY HEALTH (BEH) PROGRAM

S. Gharibzadeh¹, N. Fahimfar², G. Shafiee³, R. Heshmat³, N. Mehrdad⁴, F. Razi⁵, P. Khashayar⁶, A. Raiesi⁷, I. Nabipour⁸, B. Larijani⁹, A. Ostovar²

¹Department of Epidemiology and Biostatistics, Pasteur Institute of Iran, Tehran, ²Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, ³Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, ⁴Elderly Health Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, ⁵Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, ⁶Center for Microsystems Technology, Imec and Ghent University, Ghent, Belgium, ⁷School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran, ⁸The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran, ⁹Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Objective: To evaluate the pre-analytical variability of four BTMs, osteocalcin (OC), C-terminal telopeptide of type I collagen (CTX), bone specific alkaline phosphatase (bALP), and tartrate-resistant acid phosphatase (TRAP) in an elderly population.

Methods: A random subsample of 400 individuals (186 men and 214 women) from the baseline survey of the Bushehr Elderly Health (BEH) programme, a population-based prospective cohort study being conducted in Bushehr, a southern province of Iran, was selected for this study. OC and CTX were measured using electrochemiluminescence method (Roche Diagnostics, cobas e 411) and bALP and TRAP were measured using ELISA method (immunodiagnostic systems). Robust multiple linear regression models (Hampel's M-estimator) were used adjusted for age, sex, smoking, alcohol, history fractures, drugs, bed/rest immobility, circadian, physical activity, taking corticosteroids more than three months, renal disease, liver disease, type 2 diabetes mellitus (T2DM), thyroid disorder, menopausal status, delivery, and years after menopause (<10 y as early post menopause vs. >10 y as late post menopause). To avoid sparsity, low-frequency variables were omitted from the analysis.

Results: The coefficients of multiple determination of the models for men and women, respectively, were as follows: OC [R²=0.09 (P=0.01), R²=0.21 (P<0.01)], CTX [R²=0.14 (P<0.01), R²=0.12 (P<0.01)], bALP [R²=0.03 (P=0.64), R²=0.03 (P<0.19)], and TRAP [R²=0.06 (P=0.03), R²=0.07 (P<0.05)]. Age had significant effect on the OC and CTX in both genders and on TRAP in men, the most important determinant of OC and CTX in both genders was T2DM

that causes severe decrease in BTM levels. Late postmenopause women experienced significant decrease on their TRAP levels vs. early postmenopause women (this variable explained 56% of variability that accounted for by the model). Physical activity changed the CTX levels in men and women in opposite directions.

Conclusion: Pre-analytical sources of variability should be taken into account when interpreting BTMs in clinical practice. This may be very important in elderly, in whom several coexisting factors may influence the level of BTMs.

P798

BONE MINERAL DENSITY CHANGES IN PATIENTS RECEIVING LIVER TRANSPLANTATION AND INFLUENCE OF TREATMENTS TARGETING BONE REMODELING

A. Grandjean¹, S. Dharancy², P. Mathurin, B. Cortet¹, I. Legroux-Gérot¹

¹Department of Rheumatology, Lille University Hospital,

²Department of Hepatogastroenterology, Lille University Hospital, Lille, France

Objectives: Chronic hepatic diseases and liver transplantation can be responsible for bone fragility with an increase morbidity and mortality. The objectives of this study were to determine the prevalence of osteoporosis before transplantation, its evolution along the follow-up and the influence of treatments targeting bone remodeling and BMD.

Methods: This prospective, monocentric cohort study included liver transplant patients between 2006-2015. Patients were assessed with a systematic rheumatologic evaluation before their transplantation (V0) including clinical and biological evaluations, radiographs of the thoracolumbar spine and bone densitometry by DXA. They were then followed in outpatient visits of rheumatology 6 months (V1) and 3 y (V2) after the transplant.

Results: 251 patients were included at V0, 202 attended V1 and 112 V2. Our patients were 75.3% of men, mean age 54.9±8.8 y. Prevalence of osteoporosis before transplantation at least at one site according to the results of DXA was 26%. An antiosteoporotic treatment was introduced at V0 for 34.3% of the patients, 40.6% at V1 and 43.7% at V2. Alendronate was mainly prescribed (in 55 cases or 64%). In the whole of the transplanted population, BMD lowered significantly between V0 and V1 at the femoral neck (-4.82%, p<0.0001) and at the total hip (-3.63%, p<0.0001). Between V1 and V2, it increased significantly at the total hip (+4.88%, p<0.0001), at the femoral neck (+2.14%, p=0.0224) and at the spine (+6.83%, p<0.0001). Bisphosphonates (BP) allowed a significant increase at the spine between V0 and V1 (2.11%, p=0.043) and between V1 to V2 (3.1%, p=0.05) and at the femoral neck between V1 and V2 (0.5%, p<0.0001) in comparison with untreated patients. Zoledronic acid (n=18, 22%) allowed a higher gain than the oral BP between V0 and V1 at the spine.

Conclusion: The liver transplanted patients presented with a greater bone fragility before and after the transplant. A significant improvement was found with BP treatment, particularly with zoledronic acid.

P799

OSSEOTIDE, SYNTHETIC SELECTIVE OSTEOGENIC PEPTIDE FOR THE TREATMENT OF OSTEOPOROSIS: FROM DISCOVERY OF AND EFFICACY EVALUATION

J. Y. Lee¹, D. W. Lee¹, B. S. Jo¹, K. S. Park², Y. S. Park³, C. P. Chung¹, Y. J. Park²

¹Nano Intelligent Biomedical Engineering Corporation (NIBEC), Seoul, ²Seoul National University, Seoul, South Korea, ³Chungbuk National University, Cheongju, South Korea

Objective: Osseotide, a new synthetic peptide has been identified from the protein-protein interaction between collagen and osteopontin during bone tissue biomineralization procedure. Osseotide has been developed to selectively target and distribute to skeletal tissue thereby enhancing osteogenesis. The objective of the study is to demonstrate the selective bone formation by the peptide Osseotide is through the stimulation of osteoblast differentiation, which is clear contrast to current therapy targeting osteoclast.

Methods: The osteogenic differentiation activity and cell signal pathway by Osseotide peptide were examined through stem cell culture to delineate the mode of action. In vivo tissue distribution of Osseotide was measured by imaging of the animal after IV and SC injection. Therapeutic effect of Osseotide was examined using osteoporosis mice models. Further GLP based safety evaluation was conducted for phase I clinical study.

Results: Osseotide increased osteogenic differentiation as reflected by the upregulation of osteogenic markers including RUNX2. In contrast, PPAR γ level, which is the marker of adipogenesis was decreased by Osseotide, indicating the peptide has selective target differentiation primarily to bone formation. The selective bone targeting by Osseotide has been further evidenced by the skeletal-selective distribution after IV and SC injection. The selective bone distribution of Osseotide is anticipated to prevent side effects by nonspecific tissue distribution. In an osteoporosis animal model, Osseotide restored bone mass with significant bone formation, which is even better than the other marketed medication, PTH. In addition, significant decrease in total fat and subcutaneous fat was observed in Osseotide treated group, which is additional advantage of this peptide over the other medication. From the GLP toxicity study result demonstrated that there has been no specific toxicity related to Osseotide even at high dose.

Conclusion: These results suggest that Osseotide could be an effective therapeutic agent for osteoporosis and other skeletal bone regenerative practice due to its new mode of action such as selective targeting osteogenic differentiation.

Acknowledgments: This study was supported by the Bio and Medical Technology Development Program of the National Research Foundation funded by the Ministry of Science and ICT (NRF 2017M3A9B3063635).

P800

EFFECTS OF PHYSICAL THERAPY ON PAIN AND FUNCTIONALITY OF PATIENTS WITH ANKYLOSING SPONDYLITISA. Jurisic Skevin¹, V. Grbovic¹, J. Milosevic¹, D. Pavlovic², M. Veselinovic¹¹Faculty of Medical Sciences University of Kragujevac, Kragujevac, ²Specialized Rehabilitation Hospital "Bukovicka Banja" Arandjelovac, Arandjelovac, Serbia**Objective:** Ankylosing spondylitis (AS) is a form of arthritis that primarily involves the spinal column. It causes inflammation of the spinal joints (vertebrae) that could lead to severe, chronic pain and reduced functionality of the diseased. Our aim was to examine the effects of physical therapy on the pain and functionality of patients with diagnosed ankylosing spondylitis.**Methods:** Prospective study includes 64 patients. Patients were at least 18 years old and had a diagnosis of AS according to the modified New York criteria. For functional evaluation the **Bath Ankylosing Spondylitis Functional Index (BASFI)**, The Bath as Metrology Index (BASMI), Otto test and Shober were tested. Pain was performed using VAS scales. All patients were treated with a combined physical procedure lasting 20 therapeutic days. Control functional evaluation was performed 10 d after completed physical treatment.**Results:** A total of 64 AS patients participated in the study, including 94% men, 48±11 years old with disease duration 15.9±8.52 y. Involvement of the axial skeleton was observed at 100% patients, uveitis at 28.12% patients and peripheral arthritis at 34.37% patients. The percentage of HLA-B27 + was 90.63. Before the use of physical therapy, total score of BASMI was 5.60±1.90. Total score of BASFI was 6.40±1.40 indicating a moderate functional impairment. The Otto test (cm) was 1.95±0.60, the Shober test (cm) was 2.20±0.80. The total score of VAS was 6.8±1.70. After practicing physical therapy total score of BASMI was 4.40±1.70. Total score of BASFI was 4.80±1.90. The Otto test was 2.35±0.50. The Shober test was 3.40±0.60. The total score of VAS was 3.6±2.40.**Conclusion:** The application of physical therapy has led to statistically significant reduction in pain and improvement in the functional status of patients.

P801

CHILDHOOD PQCT DERIVED BONE SIZE IS RELATED TO MATERNAL, BUT NOT PATERNAL, BONE SIZE: RESULTS FROM THE SOUTHAMPTON WOMEN'S SURVEYC. R. Holroyd¹, S. R. Crozier¹, H. M. Inskip¹, K. Godfrey¹, C. Cooper¹, N. C. Harvey¹¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK**Objectives:** We have previously described greater magnitude associations between mother-child than father-child DXA bone size within the Southampton Women's Survey (SWS) cohort. This study aimed to investigate further parent-child bone relationships using pQCT within the same cohort.**Methods:** The SWS is a cohort of 12,583 initially non-pregnant women aged 20-34 y, from which 3158 live births were followed. In a subset of participants, pQCT assessment of tibial bone mass, including total cross-sectional area (CSA) was obtained in the child (age 6-7 y) and both parents, at 4% (metaphyseal) and 38% (mid-tibial) sites. Linear regression methods were used to assess relationships. β coefficients represent the SD change in child bone outcome per 1 SD change in parental predictor. Differences between β coefficients were tested to establish whether there were significant differences between parental effects.**Results:** Data were available for 104 parent-offspring trios. At the 4% site, a strong positive association was observed between mother-child total CSA (β (95%CI)=0.41 (0.12-0.61), $p<0.0001$); this remained robust to adjustment for paternal total CSA (β (95%CI)=0.42 (0.13-0.62), $p<0.0001$). In contrast, no relationship was observed between father-child 4% total CSA (β (95%CI)=0.01 (-0.10-0.12), $p=0.80$), and adjustment for maternal total CSA hardly altered this (β (95%CI)=0.02 (-0.13-0.08), $p=0.69$). Mother-child associations were generally much weaker at the 38% compared with 4% site.**Conclusions:** Mother-child bone size associations at 4% tibial (metaphyseal) site were of greater magnitude than those for father and child. These findings support an intrapartum mechanism linking maternal to offspring skeletal size.

P802

THE STRUCTURAL CHANGES OF BONE TISSUE IN WOMEN WITH TYPE 1 DIABETES MELLITUSV. V. Vadzianava¹, A. P. Shepelkevich², N. S. Karytska³, N. A. Vasilyeva⁴¹Belarusian Medical Academy of Postgraduate Education, ²Belarusian State Medical University, ³10th City Clinical Hospital, ⁴Republican Medical Rehabilitation and Balneotherapy Centre, Minsk, Belarus**Objective:** To assess, whether hip geometric parameters are inter-related with vertebral fractures (VFX) in type 1 diabetes mellitus (T1D) females.

Methods: We examined 73 type 1 diabetic females, age: 32 (25-38) y, duration of DM: 11(7-20) y, HbA1c: 8.6 (7.1-9.8)%, BMI: 23.1 (21.9-25.7) kg/m². The control group consisted of 58 health age- and BMI-matched females. BMD was measured with DXA, geometric parameters were determined using Advanced Hip Analysis program. VFx were analyzed with DXA.

Results: T1D females had lower BMD at femoral neck (T1D: Z-score -0.6((-1.1)-0.2) vs. controls: Z-score 0.1 ((-0.6)-0.8), $p=0.007$, respectively), higher frequency of fragility Fx (T1D: $n=10$ vs. controls: $n=2$, $p=0.042$, respectively), VFx (T1D: $n=12$ vs. controls: $n=1$, $p<0.01$, respectively) compared with controls. T1D females had shorter hip axis length (HAL) than in control group (T1D: 105(100-110) vs. controls: 107(103-110) mm, $p=0.035$, respectively). T1D females with VFx had lower CSMI (cross-sectional moment of inertia) (T1D with VFx: 7836 (6533-10377) vs. T1D without VFx 10140(8770-12522) mm⁴, $p=0.035$, respectively) and CSA (cross-sectional area) (T1D with VFx: 122(104-137) vs. T1D without VFx 144(129-165) mm², $p=0.006$, respectively) compared with T1D females without VFx. The threshold value of CSA was determined to be 132 mm², (AUC=0.754±0.093, $p=0.022$; Se 75%, Sp 69%). Using the threshold value with CSA ≤132 mm² it is possible to identify individuals with a high probability of VFx (OR=2,9 95%CI 1,3-6,4). In the logit regression analysis VFx were associated with BMD spine, CSA and daily insulin dose ($\chi^2=42,55$, $df=3$, $p<0,001$). The presence of VFx, shorter HAL, lower CSMI and CSA may indicate a decreased bone quality indirectly characterizing the qualitative parameters of the bone.

Conclusions: Structural changes of bone tissue might potentially predispose to higher fracture risk in T1D females.

P803

MICROELEMENTAL COMPOSITION OF HUMERUS IN RATS AFTER IMPLANTATION OF BIOGENIC HYDROXYAPATITE INTO TIBIA AND PER OS APPLICATION OF CALCIUM DRUGS

A. Koch'Jan¹, V. Luzin², D. Astrakhantsev², N. Mosyagina²
¹SBHI 'Staritskaya CDH', Staritsa, Russia, ²SE 'St. Luke Lugansk State Medical University', Lugansk, Ukraine

Objectives: To analyze microelemental composition of humerus in rats after implantation of biogenic hydroxyapatite in tibia and per os application of calcium drug "Biomim MK" in dosage of 90 mg per kg of body weight.

Methods: The study involved 210 male rats with initial body weight of 135-145 g. The 1st group comprised intact animals, the 2nd group comprised animals with 2.2 mm defect in the tibia between proximal metaphysis and diaphysis, and the 3rd group comprised the animals with the same 2.2 mm defects filled with biogenic hydroxyapatite implants OK-015. In the 4th group, the animals with empty defects received second generation calcium drug "Biomim MK" in dosage of 90 mg per kg of body weight, and in the 5th group, the animals with OK-015 fillings received "Biomim MK" in the same dosage. The animals were withdrawn from the

experiment by the 7th, the 15th, the 30th, the 60th, the 90th, and the 180th days. Upon expiration of observation terms right humeri were prepared for chemical analysis.

Results: A plain defect in tibia resulted in destabilization of the microelemental composition of humerus; the alterations started manifesting from the 7st day of observation and persisted throughout the whole experiment. In the 3rd group, alterations in comparison with the 2nd group recovered faster from the 60th day. Application of calcium drug "Biomim MK" to the animals with both empty and OK-filled defects substantially reduces fracture effects on microelemental composition of humerus. In the 4th group copper share increased as compared to the 3rd group values from the 30th to the 180th days by 4.64%, 9.21%, 7.74% and 5.25% respectively and manganese share by the 30th to the 90th days – by 8.78%, 5.57% and 7.05% ($p<0.05$ in all cases). In the 5th group, manganese share increased as compared to the 3rd group values from the 15th to 30th days by 8.55% and 6.45%.

Conclusions: Administration of calcium drug "Biomim MK" under conditions of tibia fracture significantly reduces adverse fracture effects on microelemental composition of humerus.

P804

PREVALENCE OF VERTEBRAL FRACTURES USING THE WHOLE SPINE X-RAY PHOTOGRAPHS: THE THIRD SURVEY OF THE ROAD STUDY

N. Yoshimura¹, C. Horii², T. Iidaka¹, S. Tanaka²

¹Department of Preventive Medicine for Locomotive Organ Disorders, 22nd Century Medical & Research Center, University of Tokyo, ²Department of Orthopaedic Surgery, University of Tokyo, Tokyo, Japan

Objective: This study aimed to determine the prevalence and site of morphometric VF classified by sex and age in Japan, using whole spine X-ray photographs, and to analyze associated factors of the presence of VF.

Method: Using the whole spine X-ray photographs in the population-based cohort study, entitled the Research on Osteoarthritis/Osteoporosis Against Disability (ROAD) study 3rd survey performed in 2012-2013, we estimated sex- and age- specific prevalence of VF in Japanese people. Genant's semiquantitative method (SQ) was used to define VF; SQ ≥1 as VF, SQ=1 as mild VF, SQ ≥2 as severe VF.

Results: Participants were consisted of 506 men (mean age 66.3 years old, standard deviation (SD):13.0) and 1,038 women (mean age 65.3 years old, SD:12.6). The prevalence of VF at age under 40, 40s, 50s, 60s, 70s, and 80 years or older were 17.4%, 7.9%, 18.5%, 25.6%, 26.3%, and 41.5%, respectively, in men, and 2.9%, 2.4%, 7.3%, 10.3%, 27.1%, and 53.0%, respectively, in women. Low back pain and decreased walking ability were independently associated with severe VF. Decreased walking ability was associated with multiple VFs in women.

Conclusion: The characteristics of mild and severe VF were different, such as mild VF had male dominance, whereas severe VF had female dominance; not mild VF but severe VF was significant-

ly associated with low back pain and decreased walking ability. Further, we revealed that multiple VFs were associated with decreased walking ability in women.

P805

A CASE REPORT OF A PATIENT WITH SEVERE MUSCULOSKELETAL MANIFESTATIONS OF FAMILIAL AMYLOID POLYNEUROPATHY AND OSTEOARTHRITIS

V. Boyadzhieva¹, N. Stoilov¹, E. Krasimirova-Kurteva²

¹University Hospital "Sv. Iv. Rilski" Clinic of Rheumatology,

²University Hospital "Sv. Iv. Rilski" Laboratory of Clinical Immunology, Sofia, Bulgaria

Objective: Familial amyloid polyneuropathy (FAP) is a rare disease, inherited in an autosomal dominant pattern, caused by abnormal deposits of amyloids around peripheral nerves and other tissues. Osteoarthritis (OA) is the most common chronic joint condition which cause musculoskeletal symptoms. We report a case of a patient experiencing persistent severe musculoskeletal manifestations due to FAP in combination with OA.

Methods: The clinical case of a patient with osteoarthritis, diagnosed with FAP demonstrates the management of difficult to diagnose diseases due to common symptoms and the results from the on time treatment.

Results: A case report of a 55-year-old patient who has been followed for 3 y after diagnosed with OA of small joints of the hands, hips, knees, cervical and lumbar section of the spine due to complaints of arthralgia, myalgia and tingling of upper and lower limbs. Routine blood test (in reference range), anti-CCP (negative), RF (negative), X-rays of the affected joints and electromyography (EMG) were performed. The diagnose carpal tunnel syndrome of both hands, was accepted due to EMG changes of the median nerve. After consultation with orthopedist, the patient was operated and nerve decompression was performed bilaterally. For a short period of time the patient has small relieve of the musculoskeletal pain and the tingling of the hands. The patient had a 1-year treatment with various NSAIDS and vitamins B6, B12, with insufficient effect and worsening of the symptoms: severe pain in the joints and numbness of the upper and lower limbs, slipping off different objects from the hands, forcing the patient to leave her current job. In addition, episodes of diarrhea, shortness of breath, caught without expectoration, tachycardia appeared every other day. After a consultation with a cardiologist and neurologist she was diagnosed with cardiomyopathy and polyneuropathy. Due to the family history of a mother with similar complaints, the patient was sent for genetic test for FAB. Mutation in exon 3 of TTR gene – c.325G>C; p.Glu89Gln (p.Glu109GIN) was proven and therapy with Tafamidis has been initiated.

Conclusions: Successful treatment of the rare disease improves the quality of life of the patient and allows to avoid unnecessary treatments and manipulations.

P806

ASSOCIATION OF GENE VARIANTS OF MEVALONATE AND WNT PATHWAYS WITH RESPONSE TO BISPHOSPHONATE TREATMENT IN POSTMENOPAUSAL OSTEOPOROTIC WOMEN

P. Marozik¹, V. Alekna², E. Rudenko³, M. Tamulaitiene², A. Rudenka⁴, A. Mastaviciute², V. Samokhovec⁴, A. Cernovas², K. Kobets¹

¹Institute of Genetics and Cytology of the National Academy of Sciences of Belarus, Minsk, Belarus, ²Vilnius University, Vilnius, Lithuania, ³Belarusian State Medical University, Minsk, Belarus, ⁴Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus

Objective: Bisphosphonates (BPs) are still the most commonly prescribed medications in patients with postmenopausal osteoporosis (PMO). However, in some patients this therapy is not effective due to individual resistance, cause different side effects and complications. The evaluation of a poor BMD response to BPs treatment takes at least one year. The identification of genetic factors, responsible for resistance to BPs therapy, may enable drug therapy optimization and more effective treatment. The aim of this study was to analyze the influence of bone and drug metabolism gene polymorphisms on the response to BPs treatment of PMO.

Methods: A total of 208 postmenopausal women with BPs therapy, of them 119 responders (with an increase of BMD after treatment) and 89 nonresponders (decrease in BMD that exceeded the LSC) were recruited to the retrospective cohort study. BMD was measured by DXA (Prodigy, GE Lunar, USA). *SOST* (sclerostin, rs1234612), *PTH* (rs7125774), *FGF2* (fibroblast growth factor 2, rs6854081), *FDPS* (farnesyl diphosphate synthase, rs2297480), *GGPS1* (geranylgeranyl diphosphate synthase, rs10925503), and *LRP5* (low density lipoprotein receptor-related protein 5, rs3736228) markers were determined using the quantitative PCR.

Results: We found that *SOST* T/T, *PTH* T/T, *FDPS* G/G, *GGPS1* T/T genotypes were significantly over-represented in nonresponders (P<0.05). Further multiple analysis of their association with response to BPs therapy revealed allelic combination of increased (T-T-G-C) and decreased (C-C-T-C) risk of BPs resistance (Fig. 1). None significant association was revealed for *FGF2* and *LRP5* genes.




Fig 1. The frequencies distribution of estimated SOST, PTH, FDPS, and GGPS1 allelic combinations

Conclusion: Our findings highlight the importance of identified single gene variants and their allelic combinations for pharmacogenetics of BPs therapy of osteoporosis, complex screening of these genetic markers can be used as a new strategy for personalized antiresorptive therapy.

Acknowledgement: This work was funded by a grant from the Research Council of Lithuania (No. S-LB-17-3), and from the Belarusian Republican Foundation for Fundamental Research (project B17LITG-008).

P807

USE OF COMPOSITE INDICES OF FEMORAL NECK STRENGTH IN ORDER TO PREDICT LOW ENERGY FRACTURES IN WOMEN WITH TYPE 2 DIABETES MELLITUS

V. V. Vadzianava¹, A. N. Mikhailov¹, E. E. Malevich¹, A. P. Shepelkevich², N. S. Karytska³, N. A. Vasilyeva⁴

¹Belarusian Medical Academy of Postgraduate Education,

²Belarusian State Medical University, ³10th City Clinical Hospital,

⁴Republican Medical Rehabilitation and Balneotherapy Centre, Minsk, Belarus

Objective: Bone fragility depends on its mineral density (BMD), material composition and structural design. The aim of this study was to compare composite indices of femoral neck strength in a group in women with type 2 diabetes mellitus (T2D) with and without low energy fractures (Fx).

Methods: We examined 94 type 2 diabetic females, age: 57.5(53.8-60.9) y, duration of DM: 56.2(51.4-59.2) y, duration of menopause 7(3-11) y, HbA1c: 8.6(6.8-10.4)%, BMI: 32.8(28.4-36) kg/m². BMD at femoral neck (FN) and at lumbar spine (LS) was measured with DXA. Vfx were analyzed with DXA. Geometric parameters were determined using Advanced Hip Analysis program. CSI- compression strength index, ISI-impact strength index were calculated using the formula of Karlamangla.

Results: To assess the relationship between the presence of Fx (including vertebral fractures) and structural changes in the geometric parameters of the hip, the examined patients with type 2 diabetes were divided into 2 subgroups: patients with Fx (n=23) and without Fx (n=71). Both analyzed subgroups were comparable in age (60 (55-66) vs. 60 (55-63) y; p=0.460), duration of menopause (9 (4-17) vs. 8 (4-12) y; p=0.418), height (159 (153-166) vs. 160 (154-163) cm; p=0.715) and weight (90 (69-95) vs.

81 (71- 93) kg; p=0.602). BMD (T-score) at LS (-1.3 (-2.8-0.1) vs. 0.8 (-1.7-0.2); p=0.105) and at FN (-1.1 (-1.8- -0.1) vs. -0.4 (-1.2-0.4); p=0.047) were comparable in both subgroups. The FN diameter (35 (33-36) vs. 33 (32-35) mm, p=0.040) was significantly higher, and the CSI (3.5 (3.1-4.1) vs. 3.9 (3.4-4.4) g/kg*m, p=0.043) and ISI (0.22 (0.2-0.27) vs. 0.26 (0.24-0.29) g/kg*m, p=0.020) were lower in women with T2D with Fx compared with the subgroup without Fx.

Conclusions: Composite indices of FN strength can be used in order to predict the probability of low energy fractures in T2D women.

P808

INFLUENCE OF CORTICOSTEROID THERAPY ON BONE METABOLISM AND MINERALIZATION IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE

M. Kostik¹, T. Gabruskaya¹

¹Saint-Petersburg Pediatric Medical University, Saint-Petersburg, Russia

Objectives: Disturbances of bone metabolism in inflammatory bowel disease (IBD) can include osteoporosis, increased risk of low-energy fractures and linear growth failure and have multifactorial nature: systemic inflammation, malabsorption, vitamin D deficiency, corticosteroid (CS) therapy. CS is a first line treatment for severe and moderate IBD, but it can deteriorate bone mineralization and metabolism. The aim of our study was to evaluate influence of CS therapy on bone metabolism and BMD.

Methods: 113 children with IBD (64M and 49F) aged 2-17 y (median age 14.0) were included in the resent study. Lumbar spine BMD (DXA), serum osteocalcin (OC), C-terminal telopeptides (CTT), 25-OHD3 and cumulative corticosteroid dosage were measured. We used Mann-Whitney U test, Wilcoxon test, chi-square test, ROC-analysis.

Results: The median cumulative dose of CS in our study was 48.8 mg/kg. The dose of CS associated with increased risk of low BMD was 100 mg/kg (OR: 2.3-20.4, p=0.0003).

Main characteristics of bone metabolism in children who received dose of CS <100 mg/kg did not differ from bone metabolism parameters of children with no use of CS. Data about bone metabolism are in the Table 1.

Conclusions: According to our data cumulative dose of CS <100 mg/kg seems to be safe for bone health in children.

Table 1. Influence of CS dose on bone metabolism and bone density in children with IBD

Parameter	CS<100mg/kg, (n=73)	CS>100mg/kg, (n=26)	No use of CS, (n=29)	Control group, (n=40)	P ₀	P ₁	P ₂
BMD, Z-score, SD	-1.1 (-1.9; -0.4)	-2.2 (-3.1; -1.4)	-1.1 (-1.8; -0.4)	0.3 (-0.0; 1.5)	0.00001	0.003	0.0007
25(OH)D3,ng/мл	17.7 (14.0; 24.0)	14.3 (10.0; 17.6)	19.0 (14.8; 23.7)	-	-	0.14	0.06
CTT, upper normal level	1.0 (0.7; 1.3)	0.7 (0.6; 1.1)	1.0 (0.9; 1.6)	0.6 (0.5; 0.9)	0.0001	0.06	0.003
Ca ²⁺ , mmol/l	1.12 (1.05; 1.2)	1.09 (1.06; 1.15)	1.21 (1.2; 1.34)	1.06 (1.0; 1.1)	0.01	0.11	0.66

p₀-all 4 groups, p₁-3 groups, p₂- CS<100mg/kg vs. CS>100mg/kg

P809
EFFECTS OF THERMOTHERAPY TREATMENT ON PATIENTS WITH HAND OSTEOARTHRITIS: A RANDOMIZED CLINICAL TRIAL

I. R. Marcu¹, S. Patru¹, D. Matei¹, A. C. Bighea¹

¹University of Medicine and Pharmacy, Craiova, Romania

Objective: Osteoarthritis of the hand (OA) is a common condition that affects hand strength and function and causes disability in activities of daily living. Applying heat is known to be a good therapeutic choice for many chronic conditions and local heat applications can be used safely in hand OA. The aim of this study was to evaluate both the short-term and the long-term effectiveness of thermotherapy in patients with primary hand osteoarthritis.

Methods: We conducted a prospective randomized, single blind controlled trial. 61 outpatients with primary bilateral hand OA (12 males), aged 57.47±1.23, were included in the study and randomized to one of two groups. One group (n = 31) was treated with 12 daily local paraffin packs (50oC, 20 min) and galvanic thermal baths (37oC, 30 min) added to usual treatment. The control group (n = 30) continued regular outpatient care routine (exercise, NSAIDs and/or analgesics). Each patient was examined at baseline, after 12 d, and after 3, 6 and 12 months. Primary outcome measures were global spontaneous hand pain on a visual analogue scale and the functional index for hand osteoarthritis (FIHOA) score; secondary outcomes were health assessment questionnaire (HAQ), duration of morning stiffness and medical outcomes study 36-item short form (SF-36).

Results: The results of the study demonstrated that the efficacy of thermotherapy was significant in all the assessed parameters, both at the end of therapy and after 3 months; the values of FIHOA and HAQ continued to be significantly better after 6 months in comparison with baseline. There were no significant modifications of the parameters throughout the follow-up in the control group. Differences between the two groups were significant for all parameters at the 12th day and at 3 months follow-up; regarding FIHOA and HAQ, the difference between the two groups persisted and was significant at 6month follow-up. Tolerability of thermotherapy proved to be very good.

Conclusion: Our results confirm that the beneficial effects of thermotherapy in patients with hand OA last over time.

P810
POSTPARTUM OSTEOPOROSIS ASSOCIATED WITH VERTEBRAL FRACTURES

N. Temelkova¹, A. Gerganova¹, K. Temelkova², K. Sirakova³, P. Popivanov¹

¹Department of Clinical Densitometry, University Hospital "Alexandrovska", ²University Hospital for Children's Diseases "Ivan Mitev", ³Department of Imaging Diagnostics, Medical Faculty, Medical University, Sofia, Bulgaria

Osteoporosis in postpartum period is a very rare, but severe condition. Its etiology and pathogenesis are not well studied, but it is assumed that it could be due to genetic, hormonal or associated with calcium-phosphorus metabolism disorders.

Case report: We present a case of postpartum osteoporosis associated with multiple vertebral fractures. Two months after the delivery of twins a 35-year-old primipara patient experienced severe low back pain following minor physical activity. The subsequently performed MRI scan showed L1 compression fracture and multiple fractures on the upper vertebral end plates from Th8 to L5. The patient has undergone a couple of stimulations for in-vitro fertilization and during the last year she took intermittently 4 mg methylprednisolone for approximately 4 months. A DXA scan was performed on GE Lunar DPX, which revealed Z-score of - 4.2, height of 159 cm, and weight- 45 kg. The patient does not have family history of osteoporosis or any diseases that alter BMD. No pathological finding was observed from the lab results - 25(OH) vitamin D - 33 ng/ml, low rate of calciuria. The initialised treatment was calcium carbonate 600 mg, cholecalciferol 1500 IU and teriparatide 20 µg subcutaneous injection daily. Afterwards, L1 vertebroplasty was done. The ongoing therapy resulted in very good clinical outcome. 6 months after the beginning of the treatment patient's Z-score was - 2.4. The patient reported that she felt her spine more stable. Current lab results in reference range.

Conclusion: Postpartum osteoporosis is a rare condition, that has substantial health consequences. Currently no guideline regarding the treatment is established. At this juncture the therapy includes calcium and vitamin D supplementation and attempts

with variable bisphosphonates regimens. Besides our data, many case reports in the literature support the concept of teriparatide-induced stimulation of trabecular bone growth as a promising opportunity to favourably influence this kind of patients.

P811

GENETIC POLYMORPHISM OF RANK/RANKL/OPG MAY AFFECT INDIVIDUAL RESPONSE TO DENOSUMAB TREATMENT IN POSTMENOPAUSAL OSTEOPOROSIS

E. Rudenko¹, V. Alekna², M. Tamulaitiene², A. Rudenka³, V. Samokhovec³, K. Kobets⁴, P. Marozik⁴

¹Belarusian State Medical University, Minsk, Belarus, ²Vilnius University, Vilnius, Lithuania, ³Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus, ⁴Institute of Genetics and Cytology of the National Academy of Sciences of Belarus, Minsk, Belarus

Objective: Denosumab is a human recombinant monoclonal antibody to RANKL for osteoporosis treatment. RANKL is the main protein of bone resorption, which binds to RANK on osteoclasts, activating their differentiation. The RANKL mechanism is largely regulated by genetic factors, and the polymorphism of genes, involved in this pathway, may substantially influence individual resistance to denosumab. The aim of this study was to analyze the influence of *RANK/RANKL/OPG* pathway gene polymorphisms on the response to denosumab treatment of postmenopausal osteoporosis.

Methods: A total of 83 postmenopausal women (age median 66.0 y) with at least 12 months of denosumab therapy, of them 67 responders (with an increase of BMD after treatment) and 16 nonresponders (decrease in BMD that exceeded the LSC) were recruited to the study. BMD was measured by DXA (Prodigy, GE Lunar, USA). The *OPG* (osteoprotegerin, rs3134069, rs3102734), *RANKL* (rs9594738, rs9594759) and *WNT4* (rs7521902) markers were determined using the PCR analysis.

Results: We revealed that *OPG* rs3134069 and rs3102734, *RANKL* rs9594738 are statistically significantly associated with the resistance to denosumab treatment (OR=4.6, 95%CI 1.2-16.9 and OR=12.3, 95%CI 1.3-111.9, respectively, $P < 0.02$). We also revealed a strong direct linkage disequilibrium ($P < 2.0 \times 10^{-16}$), suggesting that risk alleles of *OPG* and *RANKL* markers are preferably inherited jointly. The multiple analysis of haplotypes distribution frequencies, constructed from *OPG* rs3134069, rs3102734, *RANKL* rs9594738, rs9594759, *WNT4* rs7521902 markers, revealed a haplotype C-A-T-T-C, constructed from unfavorable alleles, which dramatically increases in patients the risk of resistance to denosumab treatment (OR=16.6, 95%CI 1.4-185.9, $P = 0.029$).

Conclusion: Our finding revealed four informative genetic markers of resistance to denosumab therapy and suggest their implementation as a strategy for personalized antiresorptive therapy of bone metabolism disorders. We suggest repetition of this work in other studies.

This work was funded by a grant from the Research Council of Lithuania and from the Belarusian Republican Foundation for Fundamental Research.

P812

A MULTICENTER CLINICAL TRIAL TO EVALUATE THE PERFORMANCE OF THE RADIOFREQUENCY ECHOGRAPHIC MULTISPECTROMETRY (REMS) FOR THE NONIONIZING DIAGNOSIS OF OSTEOPOROSIS AT FEMORAL NECK AND LUMBAR VERTEBRAE

S. Gonnelli¹, G. Arioli ^{*2}, G. Bianchi ^{*3}, C. Caffarelli ^{*1}, L. Cavalli ^{*4}, M. M. Cerinic ^{*5}, L. Cianferotti ^{*4}, F. Conversano ^{*6}, M. Di Paola ^{*6}, D. Gatti ^{*7}, G. Girasole ^{*3}, A. Giusti ^{*3}, M. Manfredini ^{*2}, M. Muratore ^{*8}, R. Nuti ^{*1}, P. Pisani ^{*6}, E. Quarta ^{*8}, M. Rossini ^{*7}, O. Viapiana ^{*7}, M. L. Brandi⁴

¹Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, ²Department of Neurosciences and Rehabilitation, "Carlo Poma" Hospital, ASST-Mantova, Mantova, ³SC Rheumatology, ASL 3 Genovese, Genoa, ⁴Department of Surgery and Translational Medicine, University of Florence, Metabolic Bone Diseases Unit, University Hospital of Florence, Florence, ⁵Department of Experimental and Clinical Medicine, University of Florence & SOD Rheumatology AOUC, Florence, ⁶National Research Council, Institute of Clinical Physiology, Lecce, ⁷Rheumatology Unit, Department of Medicine, University of Verona, Verona, ⁸O.U. of Rheumatology, "Galateo" Hospital, San Cesario di Lecce, ASL-LE, Lecce, Italy

*Equal contributors listed in alphabetical order

Objective: To evaluate the accuracy of REMS [1] in the diagnosis of osteoporosis with respect to DXA on spine and femur in 7 different clinical contexts.

Methods: Within an observational multicenter study, both REMS scans and DXA examinations were performed on 1672 subjects (aged 50-75 y) on lumbar vertebrae and 1759 (of the same age) on proximal femur, according to their medical prescription. An accurate quality control on all the DXA and REMS measurements was performed by two independent experienced operators in order to verify their compliance with the corresponding guidelines and recommendations. All the inaccurate cases were excluded or reanalyzed where possible. Then, DXA outcome was assumed as the ground truth to assess REMS accuracy considering the following parameters: the capability to discriminate osteoporotic from nonosteoporotic subjects together with the estimation of Cohen's kappa (k), the mean BMD difference and the SEE (standard error of the estimate) parameter.

Results: REMS showed both sensitivity (92.7% and 92.1%) and specificity (93.4% and 92.4%) above 90% for spinal and femoral site, respectively. The high REMS diagnostic accuracy was also confirmed by the SEE value equal to 5.2% for spine and to 5.8% for femur and by the very low average difference (bias \pm 2 SD) between BMD measured by the two techniques (-0.004 \pm 0.087 g/cm² for spine and -0.006 \pm 0.075 g/cm² for femur). The strong diagnostic

concordance between REMS and DXA was confirmed by Cohen's Kappa value (k =equal to 0.841 for spine and k =0.807 for femur; p <0.001 for both).

Conclusions: The outcome of this multicenter clinical trial confirmed that REMS is an accurate nonionizing approach to detect osteoporosis disease in lumbar spine and femoral neck and could be apply for bone fracture prevention.

Reference:

[1] Di Paola et al, Osteoporos Int, 2018

P813

ASSESSMENT OF BONE MINERAL DENSITY IN PATIENTS WITH ALKAPTONURIA ON X-RAY DENSITOMETRY (DXA)

A. V. Kuzin^{1,2}, A. V. Smirnov², E. M. Zaytseva¹, D. M. Kudinskiy², L. M. Blank², V. Y. Murylev^{3,7}, A. E. Dimitreva¹, E. A. Dolzhenkova⁴, H. G. Ismailov⁵, A. S. Krylov⁶, A. B. Bludov⁶, A. D. Ryzhkov⁶

¹Russian Medical Academy of Continuous Professional Education, Moscow, Russia ²Research Institute of Rheumatology named after V. A. Nasonova, Moscow, Russia ³Moscow Botkin City Clinical Hospital, Moscow, Russia ⁴Ryazan Regional Clinical Hospital, Ryazan, Russia ⁵Central Military Clinical Hospital named after A.A. Vishnevsky, Moscow, Russia ⁶National Medical Research Center of Oncology named after N.N. Blokhina, Moscow, Russia ⁷First Moscow State Medical University named after I.M. Sechenov (Sechenov University), Russia

Objective: To assess the BMD of the skeleton using the Hologic Discovery A DXA among adult patients with alkaptonuria (A).

Methods: A - a rare autosomal recessive disease (1 case per 250,000), in which severe damage of the spine/large joints and significant decrease in BMD occurs. Given the single publications on this topic, this study was conducted. We included 25 adult patients - 14 men (M) and 11 woman (W) with a reliable diagnosis of A, aged 33-76 y (61.04±8.9).

Results: The BMD of the proximal femur was evaluated in 18 patients (in 7 cases assessment was not possible due to the bilateral total hip arthroplasty). Normal BMD values (N) were detected in 2 patients (2 W) - 11.1%, osteopenia (Op) in 9 (6 M, 3 W) - 50% and osteoporosis (OP) in 7 (4 M, 3 W) - 38.9%. BMD of the forearm (Total program, n=21): N were detected in 1 patient (1 W) - 4.8%, Op in 5 (3 M, 2 W) - 23.8%, OP in 15 (9 M, 6 W) - 71.4% BMD of the forearm (Program 1/3, n=21): 1 patient showed N (1 W) - 4.8%, 11 Op (7 M, 4 W) - 52.4%, and 9 OP (5 M, 4 W) - 42.9%. In the lumbar spine (n=25) N were established in 17 patients (12 M, 5 W) - 68%, Op in 6 (2 M, 4 W) - 24%, OP in 2 (2 W) - 8%. BMD was also evaluated separately for M and W. In M, all indicators of BMD (except for the femur) were statistically significantly higher than in W - p <0.05 (Table):

	Spine (g/cm ²)	Neck (g/cm ²)	Dist. For. (g /cm ²)	Forearm (g / cm2)
Men	1.166 [1.053; 1.287] N=14	0.665 [0.526; 0.713] N=10	0.696 [0.640; 0.717] N=12	0,524 [0,472; 0,550] N=12
Women	0.878 [0.810; 1.024] N=11	0.646 [0.574; 0.793] N=8	0.549 [0.435; 0.584] N=9	0,418 [0,368; 0,459] N=9

Conclusion: In adults with A, reduces the mineral bone density with the development of osteopenia and osteoporosis equally in women and men, which often requires antiosteoporotic therapy. In the lumbar spine, these changes due to the development of calcification of intervertebral discs and ligamentous apparatus are rarely detected, in contrast to the proximal femur and forearm.

P814

OSTEOPOROSIS AMONG PATIENTS WITH SPINAL CORD INJURY

K. Miladinovic¹

¹Clinical Center University of Sarajevo/Department for Physical Medicine and Rehabilitation, Sarajevo, Bosnia-Herzegovina

Objective: There is still not enough awareness among clinicians of the existence of osteoporosis in patients with spinal cord injury (SCI). This secondary osteoporosis is induced by the spinal lesion itself. Our aim was to establish the existence of consequent osteoporosis among patients with SCI.

Methods: This observational study included 73 patients with SCI, treated as in or outpatients, at the Clinic for physical medicine and rehabilitation of Clinical Centre University of Sarajevo. Used diagnostic tool for osteoporosis was finding of DXA densitometry of proximal femur, performed on Hologic QDR 4000. Statistical processing was done according to SPSS 16.0 program.

Results: The studied group was made up of 75% male and of 25% female patients. The average age was 42.7 y, and average period from the onset of SCI was 13 y. Injury at cervical level had 9.6% of patients, at the thoracic level 65.8% and at the lumbar 24.6% of patients. According to T-score, in 80% of patients osteoporosis was found, and according to Z-score in 73% of patients. The average value of T-score was -3.3. SD, and of Z-score - 2.9 SD.

Conclusion: This study found high prevalence of osteoporosis among patients with SCI (80%). Clinicians should start with therapy for osteoporosis in early phase of SCI, in order to prevent its development as well as development of complications connected to disturbed bone metabolism. Any further complication will worsen already compromised quality of life in this group of patients.

P815

DO BODY MASS INDEX AND KNEE OSTEOARTHRITIS STATUS AFFECT MENISCAL EXTRUSION AND SIZE?

I. P. Munugoda¹, D. A. Aitken¹, W. W. Wirth², F. Eckstein²

¹Menzies institute for Medical Research, University of Tasmania, Hobart, Australia, ²Institute of Anatomy, Paracelsus Medical University Salzburg & Nuremberg, Salzburg, Austria

Objective: To test the hypotheses that in women, BMI is significantly associated with meniscus extrusion (and size) in knees with osteoarthritis (OA) while BMI is not significantly associated with meniscus extrusion and size in knees without OA.

Methods: Of 4796 participants from Osteoarthritis Initiative (OAI), 38 normal and 38 strongly obese (BMI: 35-40 kg/m²) women were selected. Each group consisted of 19 women with (frequent pain and radiographic OA (KLG₂)) and 19 women without OA. Between the normal and obese groups, participants were matched 1:1 by age, sex and height. Medial and lateral menisci were manually segmented on MRIs with blinding to BMI and OA status. Quantitative measures of meniscus position and size were calculated using custom software, which included 1) maximum extrusion distance, 2) area of the meniscus not covering (i.e. extruding) the tibial plateau, 3) tibial coverage (by the meniscus) (position), 4) width and 5) height (size). Statistical analysis was done using T-tests for pairwise comparisons between BMI and OA groups.

Results: In women with OA, obese participants had a significantly lower tibial plateau coverage (normal, mean (SD): 33 (11) mm²; obese: 21 (13) mm², p<0.01) and smaller width (normal: 6.8 (1.3) mm; obese: 5.6 (1.6) mm, p<0.01) and height (normal: 2.1 (0.2) mm; obese: 2.0 (0.3) mm, p<0.05) of medial meniscus (MM) compared to normal participants, while other position measures were not significantly different. In women without OA, MM position and size did not differ significantly between the normal and obese

groups. None of the lateral meniscus parameters differed significantly between the BMI groups, neither in those with, nor in those without knee OA.

Conclusions: This confirms the hypotheses that BMI is significantly related to MM position and size in OA knees, but not in non-OA knees. Therefore, we speculate that in a healthy joint, there is sufficient "structural and functional reserve of the meniscus" to compensate greater loading by the greater BMI, without the meniscus decompensating mechanically and structurally. However, once the joint is affected by OA, this reserve is also affected, and the higher load would contribute to a negative impact on meniscus health and function.

P816

FRACTURE RISK ASSESSMENT TOOL (FRAX) VALIDATION AMONG THE ELDERLY IN LONG-TERM AND DAY-CARE INSTITUTIONS

C.-Y. Wang¹, S.-H. Fu², C.-C. Huang², C.-C. Hung², C.-Y. Li³, R.-S. Yang⁴, F.-Y. Hsiao⁵

¹School of Pharmacy, College of Medicine, National Taiwan University, Taipei, ²Department of Orthopedics, National Taiwan University Hospital Yun-Lin Branch, Yunlin, ³Department of Public Health, National Cheng Kung University, Tainan, ⁴Department of Orthopedics, National Taiwan University Hospital, Taipei, ⁵Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan

Objectives: To assess the validity of the FRAX score at institutions (without BMD) in the prediction of the FRAX with BMD, diagnosis of established (severe) osteoporosis, and the fulfillment of guideline-recommended AOMs therapy among the elderly in long-term and day-care institutions.

Methods: Among the cohort study of Yunlin Long-term Care FRAX project. Residents identified as FRAX (without-BMD) moderate or high risk in the institutions were recommended to receive DXA test and X-ray to ascertain the fracture risk and evaluate the needs for antiosteoporosis medication (AOMs) therapy. Patients with concomitant BMD_z≤-2.5SD and hip/vertebral fracture were defined as "established (severe) osteoporosis". Patients with BMD_z≤-2.5 SD or hip/vertebral fracture are indicated for guideline-recommended AOMs therapy. Finally, patients with established (severe) osteoporosis or osteopenia with more than 2 osteoporotic fractures were qualified to initiate AOMs under National Health Insurance (NHI) in Taiwan.

Results: Among 548 residents defined as moderate or high FRAX risk by using FRAX (without BMD) score, 109 (19.9%) residents accepted further fracture risk evaluation. Among them, 94 (87.2%) patients were diagnosed as osteoporosis, and 55 (50%) patients actually had established (severe) osteoporosis. Eventually, 76 (69.7%) patients fulfilled the reimbursement criteria of NHI in Taiwan for AOMs therapy. Detail information was provided in Table 1.

Conclusions: Among residents in the long-term and day-care institutions with moderate or high FRAX, approximately 90% of patients were ascertained osteoporosis and 70% of patients could

receive AOMs therapy under the NHI system. The FRAX (without BMD) score was a valid predictor for the assessment of osteoporosis diagnosis and treatment in these population in Taiwan.

Acknowledgments: Syun-Ping, Fu, Wen-Yan Hsu

Table 1. Results of the elderly with FRAX-history score and return for further assessment for osteoporosis therapy

	Overall	Long-term care institution				Day Care Facility			
		Female		Male		Female		Male	
FRAX-history	-	High	Moderate	High	Moderate	High	Moderate	High	Moderate
Case number	109	31	4	18	4	17	9	10	16
FRAX-BMD-High	101	30	4	14	7	17	7	8	14
BMD T-score≤-2.5	108	26	1	8	1	9	3	3	2
Osteoporotic fracture	93	31	3	17	4	15	6	6	11
Osteopenia	10	0	1	1	0	1	2	1	3
Osteoporosis	95	31	3	17	4	15	7	7	11
Established (severe) Osteoporosis	55	28	1	9	1	10	2	2	2
Osteoporosis & severe osteoporosis	95	31	3	17	4	15	7	8	10
Treatment recommended	94	31 (100%)	3 (75%)	17 (94%)	4 (100%)	15 (88%)	7 (78%)	8 (80%)	10 (63%)
NHIRD+	76	29 (94%)	3 (75%)	13 (72%)	3 (75%)	14 (82%)	5 (56%)	6 (60%)	3 (19%)

Osteoporosis : Either hip or spine BMD T-score ≤ -2.5 or osteoporotic fracture (Hip, vertebral, proximal humeral , and distal radius)
 Established (Severe) osteoporosis: BMD T-score ≤ -2.5 concomitant with osteoporotic fracture (hip or spine)
 Treatment recommended: Patients with : BMD T-score ≤ -2.5 or osteoporotic fracture. (hip or spine)
 NHIRD+: Patients with BMD T-score ≤ -2.5 + one hip or vertebral fracture or -2.5<BMD T-score ≤-1 + two hip or vertebral fracture

P817
OSTEOARTHRITIS IN YOUNG PEOPLE BY USING ULTRASOUND

P. Onita¹, O.-E. Branea, M. Costin, M. Copotoiu

¹Emergency Clinical County Hospital of Targu Mures, Targu Mures, Romania

Objective: Osteoarthritis is the most common musculoskeletal affection characterized initially by pain and then followed by impairment. Osteoarthritis was considered to be an elderly disease, but new mechanism of action has been discovered and new cases of osteoarthritis affecting young people were described. The study planned to outline a pattern of early osteoarthritis in young people and such to start a preemptive rehabilitation program.

Method: This is a prospective, noninterventional and transversal study. For 6 months, 97 subjects were enrolled in the study and they were scanned by ultrasound at the level of the knee and ankle joint. The following lesions were scan: "step-up" lesions, "step-down" lesions, bursitis, the alteration of echogenity of hyaline cartilage, the width of hyaline cartilage and Baker's Cyst. A linear transducer with frequency between 10-15 MHz was used to see the modifications in two sections: transversal and longitudinal. The data were analyzed using ReCal1.0 and GraphPadPrism7.0.

Results: The mean age of the patients included in the study was 55.24±67.1 years old with a average time of clinical symptoms of 24.18±2.03 y. "Step-up" lesions (osteophytes) of the ankle were associated with similar lesions at the level of the knee (same

limb) and early modification of echogenity of the tibial hyaline cartilage (p: 0.010, p: 0.033). Medial compartment degenerative changes were correlated with contralateral knee involvement (p:0.001). Suprapatellar bursitis was associated with lateral compartment presence of step-up lesions (p: 0.026). "Step-up" knee lesions were correlated with early changes of hyaline cartilage of the tibio-talar joint. The presence of Baker's cyst in one published study was linked to a worse outcome of OA. Thankfully we did not find a correlation with other OA changes in our study (p>0.05).
Conclusions: Osteoarthritis can affect young people. It is advisable to monitor by ultrasound the knee and the ankle if one of those are presenting echography alteration. The physical rehabilitation program should focus on both joints.

P818

CHANGE OF NATIONAL HEALTH INSURANCE REIMBURSEMENT CRITERIA AND SUBSEQUENT OSTEOPOROTIC FRACTURE OF PATIENTS WITH VERTEBRAL FRACTURE

C.-Y. Wang¹, S.-H. Fu², C.-C. Hung², C.-C. Huang², C.-Y. Li³, R.-S. Yang⁴, F.-Y. Hsiao⁵

¹School of Pharmacy, College of Medicine, National Taiwan University, Taipei, ²Department of Orthopedics, National Taiwan University Hospital Yun-Lin Branch, Yunlin, ³Department of Public Health, National Cheng Kung University, Tainan, ⁴Department of Orthopedics, National Taiwan University Hospital, Taipei, ⁵Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan

Objectives: To evaluate the impact of the reimbursement contraction of antiosteoporosis medications (AOMs) use since 2011 on the clinical outcome among patients encountered vertebral fracture.

Methods: By using the National Health Insurance Research Database, patient with outpatient visit or hospitalization for vertebral fractures from 2009-2011 were defined as our study population. Patients younger than 50 years old, with any diagnosis associated with any fracture or prescribed with AOMs within one year prior to cohort entry date were excluded. The proportion of patients receiving AOMs within 1 y post index fracture was evaluated. The incidence of subsequent osteoporotic fracture related visits within 2 y post index fracture was estimated. Subsequent osteoporotic fractures included any visit with any diagnosis for hip, humeral, and wrist fracture; in addition, hospitalization with a primary diagnosis code for spine fracture concomitant with spine imaging examinations, and occur more than 8 weeks post the index spine fracture. We adopt the interrupted time series study design to explore the association. The evaluation interval was defined in a monthly manner from 2009 to 2011. The segmented regression model was used to evaluate the impacts of the intervention on the prescription rate of AOMs and incidence of subsequent osteoporotic fracture.

Results: The AOMs prescription rate was 34.5% for patients encounter spine fracture on January 2009. After the introduction of the reimbursement change, the prescription rate drop to 25.4% on 2011 (Level change: -4.98%, 95%CI-7.16 - -2.79, p=0.0001). While the contraction policy of AOMs use was not associated with an increase of the incident of encountering subsequent fracture (Level change: 1.16%, 95%CI-0.14-2.46, p=0.07).

Conclusions: Under the nationwide reimbursement system, the changes of policy significantly influence the prescription pattern of AOMs. While some buffer system may compensate for the impact on clinical outcomes.

P819

FREQUENCY AND CLINICAL CHARACTERISTICS OF OSTEOSARCOPENIA IN PATIENTS WITH ISCHEMIC HEART DISEASE

T. Raskina¹, I. Grigoreva¹, O. Barbarash², A. Kokov², V. Masenko²

¹Federal State Educational Institution of Higher Education "Kemerovo State Medical University", Kemerovo, ²Federal State Budgetary Scientific Institution "Scientific-Research Institute of Complex Issues of Cardiovascular Disease", Kemerovo, Russia

Objective: Osteosarcopenia (OSP) is a newly defined condition that consists of both sarcopenia and osteoporosis (OP). However, the studies investigating the patients with OSP are limited. The aim of this study is to find out the frequency and clinical characteristics of OSP in patients with ischemic heart disease.

Methods: 45 patients were included in the study (36 males/9 females, mean age 63.16±6.71 y). According to European Working Group on Sarcopenia in Older People (EWGSOP2) definition, a person who had low muscle mass and low muscle strength as well as low physical performance was identified as having sarcopenia. Muscle mass was assessed using computed tomography of psoas area (cm²) and calculating L3 muscle index (LMI) (<52.4 cm²/m² in men; <38.5 cm²/m² in women). Low muscle strength was defined as grip strength <27 kg and <16 kg for men and woman, respectively. Muscle functioning was estimated on the basis of with SPPB test (gait speed, chair-stand time and standing balance). Low physical performance was defined as <8 SPPB total score for both gender. BMD was measured by DXA in the lumbar spine and hip.

Results: The frequency of the sarcopenia and OSP was 28.8% (13/45) and 15.5% (7/45), respectively. Sarcopenia was more common in patients with low BMD than patients with normal BMD (23.5% vs. 50%, respectively, p=0.009). The patients with OSP had worse results of grip strength, SPPB total score, including gait speed test and chair-stand test, higher total cholesterol, lower left ventricular ejection fraction compared to nonsarcopenic patients and patients who had one OP or sarcopenia (all parameters had p<0.05). LMI correlated with L1-L4 BMD (r=0.373, p<0.05), handgrip strength (r=0.785, p=0), left ventricular ejection fraction (r=0.522, p=0.002).

Conclusion: This study has shown that nearly a half of the patients with sarcopenia may also have OSP (7/13). Moreover, every second patient with osteoporosis/osteopenia may be sarcopenic.

P820

MAGNETIC RESONANCE IMAGING MARKERS IMPROVE THE PREDICTION MODEL FOR TOTAL KNEE REPLACEMENT OVER 13 YEARS IN OLDER ADULTS

B. E. Antony¹, I. P. Munugoda¹, D. Aitken¹, P. Otahal¹, M. Lorimer², S. E. Graves³, J.-P. Pelletier⁴, J. Martel-Pelletier⁴, G. Jones¹

¹University of Tasmania, Hobart, Australia, ²Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), Adelaide, Australia, ³South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, ⁴Osteoarthritis Research Unit, University of Montreal Hospital Research Centre, Montreal, Canada

Objectives: To describe whether knee MRI abnormalities are associated with total knee replacement (TKR) over 13 y and to estimate the additive effect of MRI measures for risk prediction of TKR.


Methods: 1082 participants (62.8 y, 50% female) were randomly recruited from Tasmania and followed over 13.3 y. A 1.5T MRI scan of the right knee was acquired at baseline (n=930). Cartilage defects (grade 0-4), BMLs (grade 0-3), effusion-synovitis (grade 0-3), meniscal tears (grade 0-3) and meniscal extrusion (grade 0-2) were scored at baseline using T1-weighted and T2-weighted MRI. The incidence of primary TKR was determined by data linkage to the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR).

Results: After adjustment for age, sex, BMI, and radiographic OA, baseline cartilage defects (grade 2, RR=6.71; grade 3, RR=11.17; grade 4, RR=13.2; p<0.01) were significantly associated with TKR over 13 years independent of other MRI pathologies. BMLs (grade 1, RR=2.74; grade 2, RR=2.64; grade 3, RR=4.01, p<0.05 except grade 2), grade 3 effusion-synovitis (RR=2.74, p<0.05) and suprapatellar effusion-synovitis area were associated with TKR. Those who had TKR all had a meniscal tear at baseline, with 96% of them having a grade 3 tear.

Compared to the baseline model with age, sex and BMI (area under the ROC curve [AUC=0.62]), Model 1 with the addition of ROA and WOMAC pain performed better (AUC=0.77). Addition of cartilage defects to Model 1 resulted in a significant increase of AUC to 0.84. The combination of all MRI pathologies to Model 1 resulted in a significant increase in AUC to 0.82.

- Base model – Age, sex, BMI
- Model 1 – Base model + WOMAC + knee ROA
- Model 2 – Model 1 + Cartilage defects
- Model 3 – Model 1 + BMLs
- Model 4 – Model 1 + Effusion Synovitis
- Model 5 – Model 1 + Cartilage defects + BMLs + Effusion Synovitis

Combined model for comparison.



Conclusion: Baseline knee MRI structural pathology markers can predict TKR over the long-term in the general population. Cartilage defects significantly improve the model performance for prediction of TKR over 13 y, and hence could be utilized in prediction/decision making of TKR.

P821

A CASE REPORT OF A PATIENT WITH SIX VERTEBRAL FRACTURES AFTER 5 YEARS TREATMENT WITH DENOSUMAB

N. Stoilov¹, V. Boyadzhieva¹

¹University Hospital "Sv. Iv. Rilski" Clinic of Rheumatology, Sofia, Bulgaria

Objective: Many therapeutic options for osteoporosis have appeared in the last 10 y, but still none of them is able to restore BMD and architecture in most patients with advanced disease. We present a case of a patient who has been treated for osteoporosis with denosumab for 5 y and two months after the last injection, got 6 vertebral fractures.

Methods: The clinical case presents the management of osteoporosis in a patient who has been followed up for 5 y, without additional risk factors. Although, supplementation with vitamin D and her DXA T-score on spine and femur, TBS demonstrates improvement of BMD, the patient experienced multiple vertebral fractures.

Results: A 50-year-old female patient, non-smoker with BMI 23.4 and menopause since the last 5 y, was diagnosed with osteoporosis. In routine DXA T-score on spine was -5.3, femur -3.4. Lab tests confirm: P, Ca, β-CrossLaps in serum – within reference range; PTH: 45 pg/mL (11 - 67); 25-OH vit. D3/2: 30 ng/ml (<12 - deficiency); alkaline phosphatase: 67 U/L (<120 U/L); TSH: 1.13 mIU/l (0.3 - 4.2). The patient was treated 4 y with denosumab with good result – increase in BMD (DXA spine – 3.4; femur – 3.0)

and vitamin D levels in serum (42 ng/ml). Concomitant diseases: hypothyroidism after treatment with radioactive iodine due to hyperthyroidism. Two months after the 10th s.c application of denosumab 60 mg the patient experience light trauma and severe musculoskeletal pain in thoracic vertebrae. X-ray and MRI revealed fractures on Th8, Th9, Th10, Th11. Vertebroplasty was performed at levels Th9 and Th10 with good therapeutic effect for a month. Due to increasing pain new X-ray and MRI was performed which registered fractures on Th6, Th7. Vertebroplasty at levels Th6 and Th8 was performed. At the present moment no deviation of PTH, Ca, P, β -CrossLaps, TSH are found in the serum. The supplementation with vit. D continues and treatment with teriparatide was initiated.

Conclusions: Treatment with denosumab during the first 4 y of therapy resulted in increased BMD and improvement in clinical complaints, but with longer use and severe cases of osteoporosis showed insufficient effect on the prevention of vertebral fractures, which confirms new literature data.

P822

HISTOLOGICAL STRUCTURE OF THE PROXIMAL EPIPHYSEAL CARTILAGE OF THE TIBIA AFTER IMPLANTATION OF SELENIUM ENHANCED HYDROXYAPATITE INTO IT

O. Meriuts¹, V. Luzin¹, I. Prikhodchenko¹, Y. U. Venidiktova¹
¹SE 'St. Luke Lugansk State Medical University', Lugansk, Ukraine

Objectives: The study is aimed at investigation of structure of the proximal epiphyseal cartilage (EC) of the tibia after implantation of selenium enhanced hydroxyapatite into it.

Methods: The study involved 252 rats with body weight of 135-145 g. The 1st group comprised intact animals, the 2nd group comprised animals with 2.2 mm defect in the tibia, and the groups 3 through 6 comprised the animals with the same 2.2 mm defects filled with pure hydroxyapatite implants and hydroxyapatite implants enhanced with 0.15%, 0.3%, and 0.5% share of selenium. Upon expiration of observation terms (the 7th, the 15th, the 30th, the 60th, the 90th, and the 180th day), HE stained frontal sections of proximal epiphyses were put to morphometry of EC zones.

Results: A plain defect in the bone is manifested with narrowing of EC and widening of osteogenic zone in the period from the 7th to 90th day of observation. Implantation of pure hydroxyapatite resulted in widening of both EC and osteogenic zone as compared to the 2nd group in the period from the 7th up to the 90th day. Width of the osteogenic zone in the bones filled with 0.15% Se implants grew as compared to the 3rd group by 5.51% by the 60th day. With selenium concentration increase up to 0.3% changes in EC turned into two-phase process: by the 7th and the 15th days of observation EC was narrower than that of group 3 by 2.69% and 2.98% respectively and in the period from the 60th to the 180th day EC narrowed by 4.48%, 4.89%, and 3.90%. In the group 6 above-mentioned changes constituted 3.99% and 3.97%, and 5.76%, 5.41%, and 6.90%. In the group 5, by the 30th day, osteo-

genesis zone width and osteoblasts quantity values were higher than those of the group 3 by 5.08% and 5.01% and in the group 6 – by 5.25% and 3.62%.

Conclusions: Implantation of selenium enhanced hydroxyapatite restores structure of the proximal epiphyseal cartilage of the tibia related to formation of bone cuff around fracture point. The highest efficacy is yielded from the implants with 0.5% share of selenium.

P823

LOCALISED PAIN SEVERITY AND GENERALISED PAIN ARE ASSOCIATED WITH PREVALENT AND INCIDENT FRACTURES IN OLDER ADULTS: A 10.7-YEAR COHORT STUDY

E. Pan¹, J. Tian¹, D. Aikten¹, F. Cicuttini², G. Jones¹

¹University of Tasmania, Menzies Institute for Medical Research, Hobart, ²Monash University Medical School, Department of Epidemiology and Preventive Medicine, Melbourne, Australia

Objectives: To describe the associations of localised pain severity and generalised pain with incident fractures, and to explore whether their associations are independent of falls risk, BMD and potential confounders.

Methods: Data from a longitudinal population-based study of older adults (mean age 63 y, 51% female) were utilised. Follow-up was performed at 2.6, 5.1 and 10.7 y later, respectively. Pain severity in the knee was measured by the WOMAC pain questionnaire. Presence/absence of pain at the neck, back, hands, shoulders, hips, knees and feet was assessed by questionnaire at baseline. Fractures were self-reported at each time point. BMD was measured by DXA. Falls risk was calculated based on the short form Physiological Profile Assessment.

Results: A total of 455 fractures at baseline and 154 new fractures were reported during follow-up. In multivariable analyses, both pain severity and number of painful sites were associated with prevalent fractures at any site. Pain severity was associated prevalent vertebral fractures, while number of painful sites was associated with prevalent fractures at nonvertebral and hip. Furthermore, pain severity was associated with increased risk of incident fractures at any site [relative risk (RR) 1.04, 95%CI 1.02-1.06], major (including the femur, radius, ulnar, vertebral, rib and humerus) (RR 1.10, 95%CI 1.05-1.15) and vertebral (RR 1.04, 95%CI 1.01-1.08). Similarly, number of painful sites was also associated with increased risk of incident fractures at any site [RR 1.69, 95%CI 1.13-2.53], major (RR 2.17, 95%CI 1.12-4.22) and vertebral (RR 6.44, 95%CI 1.64-25.33). There was a dose-response relationship between number of painful sites and risk of incident fractures. These associations remained significant after further adjustment for falls risk and BMD.

Conclusions: Both pain severity and generalised pain are associated with increased risk of prevalent and incident fractures, which is independent of falls risk, BMD and potential confounders, suggesting that pain may be an independent marker of fracture risk. Pain management may have potential to prevent fractures in older adults.

P824

SARCOPENIA IN PATIENTS WITH ISCHEMIC HEART DISEASE: THE FIRST RESULTS OF THE STUDYT. Raskina¹, I. Grigoreva¹, O. Barbarash², A. Kokov², V. Masenko²¹Federal State Educational Institution of Higher Education "Kemerovo State Medical University", ²Federal State Budgetary Scientific Institution "Scientific-Research Institute of Complex Issues of Cardiovascular Disease", Kemerovo, Russia**Objective:** Low muscle mass is one of the most frequent conditions in patients with ischemic heart disease (IHD) and depends on many factors such as age, reduced physical activity etc. Osteoporosis was evaluated in most of IHD studies, but studies examining sarcopenia are limited. The aim of this study is to investigate the relationship between sarcopenia and clinical parameters in patients with IHD.**Methods:** The study included 45 patients with IHD (36 males/9 females, mean age 63.16±6.71 years) verified by coronary angiography. The following data were obtained and analyzed: sociodemographic data, clinical parameters (SPPB tests, handgrip strength, BMD of the lumbar spine, total hip and femoral neck, muscle mass was assessed using computed tomography of psoas area (cm²), L3 muscle index (LMI) (cm²/m²)). A diagnosis of sarcopenia has been made according to European Working Group on Sarcopenia in Older People (EWGSOP2) definition.**Results:** 13 (28.8%) patients had sarcopenia. Sarcopenia was more common in patients with low BMD compared to patients with normal BMD (23.5 vs. 50%, respectively, p=0.009). The following significant association were revealed. Total psoas area (TPA) (cm²) has positive correlation with BMD in all localizations (r=0.480, p=0.006 for L1-L4; r=0.547, p=0.001 for femur; r=0.597, p<0.001 for neck of the femur), handgrip strength (r=0.715, p=0 for right hand; r=0.868, p=0 for left hand) and weight (r=0.597, p<0.001). There was negative correlation between TPA and IHD duration (r=-0.417, p=0.002), age (r=-0.536, p=0.001). LMI (cm²/m²) positively correlated with L1-L4 BMD (r=0.373, p<0.05), left ventricular ejection fraction (r=0.522, p=0.002). There was no association between TPA/LMI and laboratory tests (total cholesterol and lipids fractions, glucose).**Conclusion:** In this study sarcopenia was a frequent condition among patients with IHD. It was associated with IHD duration, low BMD, old age, heart function. Further studies are needed to clear the main risk factors for sarcopenia in IHD patients to evaluate the prognosis for this group of patients.

P825

DIRECT ORAL ANTICOAGULANTS DECREASE BONE FORMATION IN MC3T3-E1 CELLSS. Hochberg-Klein¹, I. Gurt², E. Rosen³, R. Dresner-Pollak²¹The Department of Internal Medicine, Mount Scopus and the Coagulation Unit, Hadassah-Hebrew University Medical Center, ²The Department of Endocrinology and Metabolism, Division of Medicine, Hadassah-Hebrew University Medical Center, ³Hebrew University-Hadassah Medical School, Jerusalem, Israel**Objective:** The use of anticoagulation is common in many medical conditions, at times for a relatively short period and at times for an extended period in cases of venous thromboembolism (VTE), atrial fibrillation and mechanical heart valves. Treatment with heparin derivatives and vitamin K antagonists is rapidly being replaced with direct oral anticoagulants (DOACs), which have gained popularity due to their safety profile and easier surveillance. Therefore, an increasing number of young patients are and will be treated in the future with these medications for the long term. Long-term heparin treatment is a known risk factor for the development of osteoporosis. The effect of DOACs on bone health has yet to be established. Herein we address this paucity of information via *in vitro* studies examining the effect of DOACs on osteoblast proliferation, differentiation and function in an osteoblastic cell line model.**Methods:** MC3T3-E1 cells were maintained in DMEM/10%FB-C/1%Pensterp/1%L-Glut/ 0.5%HEPES. The cells were induced to osteogenesis with 10mM βGP/50μl/ml ascorbic acid. The effect of DOACs (apixaban, rivaroxaban and dabigatran at final concentrations of 0.013 μg/ml) on cell survival was determined by XTT assay (cat. 20-300-1000, BI) 7 d post treatment initiation. Differentiation was determined by alkaline phosphatase activity assay (AB83369, Abcam) 14 d post treatment initiation and osteoblast function was determined by mineralized nodule formation with alizarin red staining (cat. A5533, Sigma-Aldrich) at 21 d of treatment. Heparin (0.2 U/ml) was used as a positive control.**Results:** No difference in cell survival between DOACs- and vehicle-treated cells was found. Treatment with all DOACs significantly decreased (2-fold) alkaline phosphatase activity compared to vehicle-treated cells. Impaired mineralized nodule formation was observed in DOACs-treated cells with a 3-fold decrease in mineralization in DOACs-treated cells and was not significantly different from heparin-treated cells.**Conclusion:** Apixaban, rivaroxaban and dabigatran adversely affect osteoblast differentiation and function in MC3T3-E1 cells. Future *in vivo* animal and human studies are warranted.

P826

METABOLIC SYNDROME AND MRI-DETECTED KNEE STRUCTURAL CHANGEF. Pan¹, J. Tian¹, S. Maisarahmattap¹, F. Cicuttini², G. Jones¹¹University of Tasmania, Menzies Institute for Medical Research, Hobart, ²Monash University Medical School, Department of Epidemiology and Preventive Medicine, Melbourne, Australia

Objectives: Metabolic syndrome (MetS) has been suggested a crucial role in the pathophysiology of osteoarthritis (OA); however, currently none of studies have examined the associations between MetS and structural changes on MRI. This study aimed to describe the associations between MetS and its components and structural changes on MRI including knee cartilage volume (CV) loss and bone marrow lesion (BML) change over 10.7 y.

Methods: Longitudinal data on 435 participants (mean age 61 y, 50% of females) from a population-based cohort study were analysed. Blood pressure, glucose, triglycerides, and high-density lipoprotein (HDL) were collected. MetS was defined based on the National Cholesterol Education Program-Adult Treatment Panel III criteria. MRI of the right knee was performed to measure CV and BML. Radiographic knee osteoarthritis (ROA) was assessed by X-ray.

Results: 32% of participants had MetS and 60% had ROA. In multivariable analysis, the following were independently associated with medial tibial CV loss [MetS: $\beta=-0.30\%$; central obesity: $\beta=-0.26\%$; low HDL: $\beta=-0.26\%$ per annum]. MetS, hypertriglyceridemia and low HDL were also associated with higher risk of BML size increase in the medial compartment [MetS: relative risk (RR) 1.72, 95%CI 1.22-2.43; hypertriglyceridemia: RR 1.43, 95%CI 1.01-2.02; low HDL: RR 1.67, 95%CI 1.18-2.36]. After further adjustment for central obesity, MetS and low HDL remained significant with both medial tibial CV loss and BML size increase. The number of components of MetS correlated with greater CV loss and BML size increase (both P for trend <0.05). There were no statistically significant associations in the lateral compartment.

Conclusions: MetS and low HDL are associated with medial compartment CV loss and BML worsening, suggesting that targeting MetS has the potential to prevent or slow structural change in knee osteoarthritis.

P827

ASSESSMENT OF BONE QUALITY AND QUANTITY IN THE LUMBAR SPINE IN TYPE 1 DIABETES PATIENTSY. Dydyska¹, N. Karytska², A. Shepelkevich¹, N. Vasilieva³, V. Zhukouskaya⁴¹Belarusian State Medical University, Department of Endocrinology, Minsk, Belarus, ²10th city clinical hospital, Minsk, Belarus, ³Republic Center of Endocrinology and Medical Rehabilitation, Minsk, Belarus, ⁴Department of Clinical Medicine and Surgery, Division of Endocrinology, University of Naples Federico II, Naples, Italy

Objective: According to modern data, the presence of diabetic osteopathy in patients with type 1 diabetes (T1DM) is beyond doubt. However, to understand the mechanisms of its development, it is not enough just to quantify the bone component. Thus, the aim of the study was to study of the quantitative and qualitative characteristics of the lumbar spine in T1DM patients.

Methods: 158 patients with T1DM (105 women, 53 males) (mean age: 33.6 (27.9–37.5) y, duration of DM: 13 (7–20) y, age of manifestation: 19 (14–23) y, BMI: 23.58 (22.06–25.76) kg/m²; HbA1c: 8.2 (7.6–8.9)%) and 100 (68 women, 32 men) controls, comparable in sex, age and anthropometric data. The research involved general clinic examination, DXA. BMD was taken as a quantitative assessment and trabecular bone score (TBS) was used as qualitatively parameter.

Results: There were no significant differences in L1-L4 BMD and TBS in women compared with men: 1.16 (1.08 – 1.16) vs. 1.15 (1.08 – 1.27) g/cm²; (U=5597; p=0.727) and 1.40 (1.35 – 1.46) vs. 1.44 (1.37 – 1.49) (U=3230; p=0.097). Similar results were obtained in subgroups of T1DM patients and controls. There was a definite significant correlation between BMD (L1-L4) and TBS (L1-L4) – r²=0.33, p<0.001. Lower L1-L4 BMD and TBS were significantly found in patients with diabetes compared to controls: BMD 1.14 (1.04 – 1.22) vs. 1.23 (1.13 – 1.33) g/cm²; U=3685; p<0.001; and TBS 1.39 (1.33 – 1.46) vs. 1.45 (1.39 – 1.48); U=2775; p<0.001. Detailed assessment in lumbar spine showed the largest decline in the first lumbar vertebra as T1DM patients as a control group, but more pronounced reduction was proved in T1DM patients – BMD L1 1.02 (0.94–1.13) vs. 1.12 (1.03–1.24) g/cm²; U=3439; p<0.001; and TBS L1 1.29 (1.22 – 1.39) vs. 1.34 (1.29 – 1.42); U=2898; p=0.002).

Conclusions: There were no differences BMD and trabecular bone index by gender. T1DM patients have BMD and TBS decreased in the lumbar spine with a predominance this trend in the first vertebra.

P828

POSTTRAUMATIC MORTALITY IN PATIENTS WITH OSTEOPOROTIC HIP FRACTURES

T. Raskina¹, J. Averkieva¹, O. Malyshenko¹, I. Grigoreva¹¹Federal State Educational Institution of Higher Education "Kemerovo State Medical University", Kemerovo, Russia

Objective: To assess posttraumatic mortality in older age patients with osteoporotic hip fractures within 12 months after the fracture.

Methods: 432 patients with osteoporotic hip fractures were included (328 women and 104 men, mean age was 75.4±9.27 y and 71.5±10.39 y, respectively). Mortality rates were evaluated both in hospital and during 12 months after the fracture.

Results: It was found that in the first 12 months after injury 137 out of 432 patients under observation died: in women - 104 (24.1%) cases, in men - 33 (7.7%) ($\chi^2=9.22$; $p<0.0001$). Overall mortality was 31.8%. In the structure of mortality by gender, no statistically significant differences were found: 104 out of 328 women died (31.78%), out of 104 men - 33 (31.73%) ($\chi^2=0.01$; $p=1.0$). When assessing the causes of mortality after a fracture, the majority of deaths in both men and women were attributable to cardiovascular system diseases. The total number of fatal cases was 93 (67.8%): for men - 22 (66.0%) cases, for women - 71 (68.3%) ($p=0.65$). Diseases of the respiratory system caused death in 23 (16.8%) patients: in men - 5 (15.1%) cases and in women - 18 (17.3%) ($p=0.31$). The causes of death from oncological diseases accounted for 15 (10.9%) cases without statistically significant differences by gender: for men - 3 (9.09%) cases and for women - 12 (11.5%) ($p=0.45$). Diseases of the digestive system, as the cause of death, were detected in 5 (3.6%) men and women (2 (6.06%) and 3 (2.9%) cases, respectively ($p=0.1$)).

Conclusion: During all periods of observation, most of the deceased men and women had cardiovascular and respiratory diseases.

P829

THERAPEUTIC MANAGEMENT IN OSTEOPOROSIS IN TURNER SYNDROME

S.- A. Preda¹, M. Popescu², S. Comisel³, A. Predescu⁴, A. Covei⁵, D. M. Albuiescu⁶, I. A. Moraru⁷, M. Cojocar⁷, M. J. Tuculina⁷¹University of Medicine and Pharmacy, Faculty of Dentistry,²University of Medicine and Pharmacy, Department of Endocrinology, ³Emergency County Hospital, Department of Endocrinology, ⁴University of Medicine and Pharmacy of Craiova, Research Center for Microscopic Morphology and Immunology, ⁵Philanthropy Hospital, Endocrinology Department, ⁶University of Medicine and Pharmacy, Department of Radiology, ⁷University of Medicine and Pharmacy, Department of Odontology, Faculty of Dentistry, Craiova, Romania

Objectives: Turner syndrome is a multiple malfunctions syndrome defined by four elements: disharmonic hypotrophy stature, severe somatic malformations, modified karyotype-specific as

frequency 45, XO, and severe ovarian failure through anovarium. Perturbation of the hormonal biosynthesis process by altering the sexualisation process and the exclusion of the sex hormones and thyroids from the body's economy influences the bone structure representing the main cause of osteoporosis^{1,2,3}.

Methods: The study was performed on 12 cases with female phenotype syndrome with age between 12-30 years old. The biochemical markers of bone turnover (serum osteocalcin and CrossLaps) were evaluated, BMD was assessed by absorption of DXA patients received pharmacological therapy - in the past - growth hormone, estrogen therapy and thyroid hormone substitution and currently are associated with 150 mg ibandronic acid 30 d4 .

Results: Osteoporosis was confirmed on 7 cases and in 5 cases the T-score was suggestive for osteopenia. The efficiency of ibandronic acid treatment after 12 months of administration was noted in 82% of cases with osteoporosis on both the lumbar spine and the femoral neck. BMD is also increased in the lumbar spine 4.1% and in the femoral neck 2.2% .

Conclusions: The study of BMD and biochemical markers of bone turnover is binding in all cases with Turner syndrome. At patients with osteopenia, the major objective is the prophylaxis of hypogonadal osteoporosis with the aim of increasing bone mass and reducing the incidence of fragility fractures^{5,6} .

References:

1. Popescu M et al. Rev Chim 2018;8:2089
2. Albuiescu DM et al. Rev Chim 2018;9:2438
3. Radu L et al. Rev Chim 2018;10:2754
4. Albuiescu DM et al. Rev Chim 2018;7:1692
5. Albuiescu DM et al. Rev Chim 2018;12:3683
6. Radu L et al. Rev Chim 2018;12:3483

P830

PRESENTATION OF FINDINGS FOR BONE DENSITOMETRY, FRACTURES AND MOST COMMON RISK FACTORS FOR OSTEOPOROSIS IN PATIENTS EXAMINED IN BANJA KOVILJACA AT ANNUAL LEVEL

Z. Grujic¹, T. Tomic¹, A. Jovanovic¹¹Specialized Rehabilitation Hospital Banja Koviljaca, Banja Koviljaca, Serbia

Objective: Analysis of all parameters from bone densitometry finding of the low back and hip, most common risk factors and both previous and new fractures.

Methods: The study was conducted in Specialized Rehabilitation Hospital in Banja Koviljaca, in a period between January and December 2018. BMD was measured in low back vertebrae bodies (L1L4) and femoral neck with Lunar DPX Prodigy device as per the standard procedure prescribed for central DXA. Findings of bone densitometry and data from questionnaire for 395 patients, both men and women, were processed. BMD and T-score values ob-

tained in hip and low back, number and location of previous and new fractures, age of subjects and most common osteoporosis risks were all observed.

Results: The average age of patients was 66.48 y, while the mean BMD value in the hip was 3.52 g/cm² and 0.84 g/cm² in the low back. At the latest examination, most common T-score values in the hip were at osteoporosis level (48% of respondents), and in the low back spine these were at the level of severe osteoporosis (80% of respondents). At the initial examination, 39 vertebral and 63 nonvertebral fractures were recorded, while at the latest examination 9 vertebral and 5 nonvertebral new fractures were recorded. Most common were hip fractures (31) and forearm fractures (19) in the age of 71- 80 (28 respondents). The most significant risk factor for osteoporosis was previous fractures, and the most frequent occurrence of fractures was recorded in this group, in 79 respondents. Within a group of rheumatic patients, the lowest values of bone density in spine and hip were in respondents with systemic sclerosis (hip BMD 0.659 g/cm², spine BMD 0.772 g/cm²).

Conclusion: On average, BMD values and T-score values were lower in the low back spine than in the hip. Higher age and previous fractures are significant risk factors for osteoporosis and new fractures, but a number of new fractures is considerably less in patients who have passed diagnostics and been treated.

P831

BONE MANIFESTATIONS IN THE THYROID HORMONE DEFICIT

S.- A. Preda¹, M. Popescu², S. Comisel³, A. Predescu⁴, A. Covei⁵, M. J. Tuculina⁶, I. A. Moraru⁶, D. M. Albuлесcu⁷

¹University of Medicine and Pharmacy, Faculty of Dentistry, ²University of Medicine and Pharmacy, Department of Endocrinology, ³Emergency County Hospital, Department of Endocrinology, ⁴University of Medicine and Pharmacy of Craiova, Research Center for Microscopic Morphology and Immunology, ⁵Philanthropy Hospital, Endocrinology Department, ⁶University of Medicine and Pharmacy, Department of Odontology, Faculty of Dentistry, ⁷University of Medicine and Pharmacy, Department of Radiology, Craiova, Romania

Objectives: Hypothyroidism is the clinical expression of thyroid hormone biosynthesis deficiency as well as its transport and/or receptiveness. Hypothyroidism may be primary, secondary, or tertiary depending on the center of the disorder: the thyroid itself, the pituitary or the hypothalamus. The consequence of hypothyroidism on the osteoarticular system is represented by the increase in BMD. At women with menopause, the management of osteoporosis associates active forms of 25-OHD to prevent vitamin D intoxication by excessive accumulation 1,2,3. There are researches that demonstrates that autoimmune thyroiditis may interfere as a confounding factor in the 25-OHD interpretation in relation with thyroid characteristics. Identification of cases with thyroid deficiency, clinical and paraclinical objectification of hypothyroidism etiology, BMD measurement by DXA 4,5 .

Methods: The study includes 24 cases (5 males and 19 females) with age between 27-46, from which 8 developed post-surgical thyroidectomy hypothyroidism and 16 have occurred through autoimmune mechanism. The following investigations were performed: T4 dosing, TSH, ATPO titer, thyroid echography, and indirect thyroid function was evidenced by changes in lipid metabolism, glucose, enzyme, osteodensitometry was assessed in all cases.

Results: In all cases investigated with DXA, T-scores were between - 2.8 DS and - 3.9 DS. All cases showed high TSH values and the ATPO titre was increased at cases with autoimmune hypothyroidism.

Conclusions: Osteoarticular disorders are particularly common in cases of severe hypothyroidism (mixedem) . The therapeutic attitude is differentiated in relation to the evolutionary stage, visceral complications and osteo-articular complications.

References:

1. Popescu M et al. Rev Chim 2018;8:2089
2. Albuлесcu DM et al. Rev Chim 2018;9:2438
3. Radu L et al. Rev Chim 2018;10:2754
4. Albuлесcu DM et al. Rev Chim 2018; 12:3683
5. Radu L et al. Rev Chim 2018; 12:3483

P832

RISK ASSESSMENT OF OSTEOPOROTIC FRACTURES IN THE FRAX SCALE IN MEN WITH CORONARY HEART DISEASE DEPENDING ON THE INDICATORS OF LIPID

T. Raskina¹, A. Voronkina², M. Letaeva¹, O. Barbarash³, V. Fanaskov⁴

¹Federal State Educational Institution of Higher Education "Kemerovo State Medical University", ²State Autonomous Healthcare Institution of the Kemerovo region "Regional Clinical Hospital of Emergency Medical Care named M. Podgorbunsky", ³Federal State Budgetary Scientific Institution "Scientific-Research Institute of Complex Issues of Cardiovascular Disease", ⁴State Autonomous Healthcare Institution of the Kemerovo Region "Regional Clinical Hospital for War Veterans", Kemerovo, Russia

Objective: To assess the risk of osteoporotic fractures on the FRAX depending on the parameters of the blood lipid spectrum in men with coronary artery disease.

Methods: 93 men over 50 y (mean age – 60.8±6.9 y) with coronary artery disease verified by coronary angiography were examined. Based on the information on the presence of clinical risk factors for osteoporotic fractures and densitometry data (Excel XR-46, Norland, USA) in all patients included in the study, the FRAX calculator was used to quantify the probability of major osteoporotic fractures and proximal femur fractures in the next 10 y. The concentration of total cholesterol (OHS), triglycerides (TG), high and low density lipoprotein cholesterol (HDL and LDL cholesterol) in serum was determined by spectrophotometric method.

Results: The 10-y absolute risk of major osteoporotic fractures by FRAX was 9.88 ± 7.22 , the risk of proximal femoral fracture was 3.97 ± 6.27 in all patients included in the study. Dyslipidemia was found in most men with coronary artery disease (95.7% of patients): hypercholesterolemia – 76.3%, elevated LDL – 81.7% of patients, hypertriglyceridemia – 49.5% of cases, decrease in HDL – 44.1%. The results of the correlation analysis revealed a significant direct correlation between the level of OHS and the risk of hip fractures by FRAX ($r=0.21$; $p=0.050$). For other lipidogram parameters, there was no correlation with osteoporotic fractures.

Conclusion: Hypercholesterolemia is associated with an increased risk of osteoporotic fractures on the FRAX scale in men with coronary heart disease.

P833

BONE TURNOVER MARKERS IN A COHORT OF COMBINED ASYMPTOMATIC AND SYMPTOMATIC ROMANIAN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM

A. M. Sirbu¹, D. Vidican¹, A. Socaliuc¹, D. Grigorie¹

¹National Institute of Endocrinology CI Parhon, Bucharest, Romania

Objective: Primary hyperparathyroidism (PHPT) has appeared to change in its clinical presentation, being mostly asymptomatic in western countries; in Romania is still common to see various clinical presentations. A regular feature that has not changed is evidence for increased bone turnover. Our aim was to evaluate bone turnover markers (BTM) in a wide variety of presentation forms, from asymptomatic to osteitis fibrosa cystica.

Methods: Our retrospective study included 236 patients with PHPT: 88.6% women, mean age at diagnosis 60.25 ± 11.42 y, mean PTH= 253.9 ± 348.1 pg/ml, mean sCa= 11.4 ± 1.2 mg/dl, symptomatic hypercalcemia in 15.4%, osteitis fibrosa cystica in 3%, fractures in 25%, spine osteoporosis in 50%, hip osteoporosis in a quarter, 42% with kidney stones/nephrocalcinosis. 63% underwent surgery and 40.6% were treated with bisphosphonates. Serum intact PTH, C-telopeptide (CTX) and osteocalcin (OC) were measured using the chemiluminescence immunoassay. BMD was measured by DXA at the femoral neck and lumbar spine.

Results: Mean BTM levels were: CTX 1.22 ± 1.68 ng/ml, OC 66.2 ± 24.7 ng/ml, ALP 140 ± 80 U/l in the whole group of untreated patients and CTX 0.64 ± 0.45 ng/ml, OC 34.79 ± 20.56 ng/ml, ALP 92.22 ± 34.52 U/l in asymptomatic PHPT. There was an inverse correlation between the age at diagnosis and BTM: CTX ($r=-0.148$, $p=0.023$), OC ($r=-0.240$, $p<0.001$) and ALP ($r=-0.308$, $p<0.001$). BMI also inversely correlated with CTX ($r=-0.178$, $p=0.006$) and OC ($r=-0.127$, $p=0.05$), but not with ALP. Patients with symptoms of hypercalcemia had higher levels of BTM ($p<0.001$ for CTX and OC and $p=0.002$ for ALP). We found an inverse correlation between BMD and BTM, with higher correlation indices between LS and FN Z-scores and bone formation markers. Patients with fractures were older and had higher levels of OC; patients with kidney stones were younger and also had higher levels of OC ($p<0.001$). sCa correlated with PTH, CTX, OC and ALP ($p<0.05$ for all) in a uni-

variate analysis, but only the correlations with PTH ($p<0.001$) and CTX ($p=0.003$) remained statistically significant in a multivariate regression analysis.

Conclusion: Symptomatic patients have higher levels of BTM than asymptomatic ones. Patients with younger age at onset, low BMI and symptoms of hypercalcemia are likely to have more active bone disease.

P834

OSTEOPOROSIS IN ENDOCRINE DISEASES

S.- A. Preda¹, S. Comisel², A. Predescu³, A. Covei⁴, D. M. Albulescu⁵, M. J. Tuculina⁶, M. Popescu⁷

¹University of Medicine and Pharmacy, Faculty of Dentistry,

²Emergency County Hospital, Department of Endocrinology,

³University of Medicine and Pharmacy of Craiova, Research Center for Microscopic Morphology and Immunology,

⁴Philanthropy Hospital, Endocrinology Department, ⁵University of

Medicine and Pharmacy, Department of Radiology, ⁶University of

Medicine and Pharmacy, Department of Odontology, Faculty of

Dentistry, ⁷University of Medicine and Pharmacy, Department of

Endocrinology, Craiova, Romania

Objectives: The study focused on the identification and follow-up, during the study (2014-2016), of osteoporosis secondary evolution from endocrine disease before and after specific treatment^{1,2}. There are studies demonstrating the influence of endocrine diseases on osteoporosis³. Our aim were to evaluate the starting moment of secondary osteoporosis at patients included in the study, to monitor the progression of osteoporosis in relation to the staging of endocrine diseases, to evaluate the curative and symptomatic differentiated therapeutic algorithm as well as to evaluate the way in which the evolution of endocrine and osteoporosis was influenced⁴.

Methods: 52 patients were randomly assigned to the study: 15 patients with hyperthyroidism, 27 patients with hypothyroidism, 6 patients with acromegaly, 1 with pheochromocytoma, 3 patients with hypercortisolism. All patients are aged between 31-53 y, and BMD was determined by DXA over 3-month period.

Results: Osteodensitometry revealed the presence of osteoporosis in 87% of all cases included in the study, and the rest of the patients - 13% - the T-score was suggestive of osteopenia (-1.80 to -2.30 DS)

Conclusions: The BMD study should be performed periodically to identify patients who are rapidly losing bone mass and have highly risk of osteoporosis. The therapeutic approach is different in relation with evolutionary stage, visceral complications and osteo-articular complications⁵.

References:

1. Popescu M et al. Rev Chim 2018;8:2089
2. Radu L et al. Rev Chim 2018;10:2754
3. Albulescu DM et al. Rev Chim 2018;9:2438
4. Albulescu DM et al. Rev Chim 2018; 12:3683
5. Radu L et al. Rev Chim 2018; 12:3483

P835

CONSIDERATIONS REGARDING SECONDARY CAUSES OF POSTMENOPAUSAL OSTEOPOROSIS

S.- A. Preda¹, M. Popescu², S. Comisel³, A. Predescu⁴, A. Covei⁵, D. M. Albulescu⁶, I. T. Dascalu⁷, M. J. Tuculina⁸

¹University of Medicine and Pharmacy, Faculty of Dentistry, ²University of Medicine and Pharmacy, Department of Endocrinology, ³Emergency County Hospital, Department of Endocrinology, ⁴University of Medicine and Pharmacy of Craiova, Research Center for Microscopic Morphology and Immunology, ⁵Philanthropy Hospital, Endocrinology Department, ⁶University of Medicine and Pharmacy, Department of Radiology, ⁷University of Medicine and Pharmacy Craiova, Faculty of Dentistry, Department of Orthodontics, ⁸University of Medicine and Pharmacy, Department of Odontology, Faculty of Dentistry, Craiova, Romania

Objectives: Postmenopausal osteoporosis is the most common form of bone lysis of endocrine etiology, induced by drastic estrogen deficiency in menopause, but there are other secondary causes of osteoporosis in postmenopausal women. Bone mass loss in postmenopausal is caused by trabecular bone but also cortical. Numerous hormones, growth factors, cytokines with implications in the immune system have important effects on the bone 1,2,3. The purpose of this study was to analyze the prevalence of diseases that contribute to postmenopausal bone loss and to assess the impact of these disorders and its severity.

Methods: The study was performed on 48 postmenopausal women with age between 45-79 y who were diagnosed with osteoporosis by DXA. For all patients under study were evaluated the serum PTH, vitamin D, thyroid hormones, cortisol and calcium 4,5.

Results: 37 patients (77.08%) had low levels of 25-OHD (<30 ng/ml), 11 women (22.92%) had elevated levels of PTH (>65 pg/ml). PTH levels were age-related and were higher at women with femoral Z-score-2.0 (P=0.03). Women with low vitamin D had low BMD and T-score in the lower femoral neck. In addition, patients with vertebral fractures had a higher prevalence of vitamin D levels <20 ng/ml (P<0.05). 10 women (20.83%) had elevated serum thyroid hormone levels.

Conclusions: There are secondary causes of postmenopausal bone loss represented by vitamin D deficiency, PTH disorder and thyroid hormone.

References:

1. Radu L et al. Rev Chim 2018;10:2754
2. Popescu M et al. Rev Chim 2018;8:2089
3. Albulescu DM et al. Rev Chim 2018;9:2438
4. Albulescu DM et al. Rev Chim 2018;12:3683
5. Radu L et al. Rev Chim 2018;12:3483

P836

PREDICTIVE VALUE OF BIOCHEMICAL MARKERS OF BONE TURNOVER IN OSTEOPOROSIS

S.- A. Preda¹, M. Popescu², S. Comisel³, A. Predescu⁴, A. Covei⁵, D. M. Albulescu⁶, M. J. Tuculina⁷

¹University of Medicine and Pharmacy, Faculty of Dentistry, ²University of Medicine and Pharmacy, Department of Endocrinology, ³Emergency County Hospital, Department of Endocrinology, ⁴University of Medicine and Pharmacy of Craiova, Research Center for Microscopic Morphology and Immunology, ⁵Philanthropy Hospital, Endocrinology Department, ⁶University of Medicine and Pharmacy, Department of Radiology, ⁷University of Medicine and Pharmacy, Department of Odontology, Faculty of Dentistry, Craiova, Romania

Objectives: The progression of osteoporosis is asymptomatic until the occurrence of a fracture, the circumstance in which the primary diagnosis is made before clinical presentation of osteoporosis. Affects both sexes. Estrogen deficiency affects the rate of bone turnover that condition the age of bone tissue and its various physical and chemical properties 2,3,4,5.

Methods: A total of 82 patients with osteoporosis with age between 35-75 y were randomly assigned after menopause installation criteria - 47 patients with osteoporosis and physiological menopause 10 patients with premature ovarian failure (35-40 y) 37 patients with physiological menopause (47-75 y) and 25 patients with surgical menopause (44-75 y) The biochemical markers of bone turnover were evaluated (bone-specific alkaline markers phosphatase, serum propeptide of type I procollagen) and (serum cross-linked N-telopeptide, serum crosslinked C-telopeptide). At all patients BMD was evaluated by DXA. The FRAX algorithm has identified the risk of fragility, vertebral or nonvertebral fracture.

Results: At all cases investigated by DXA, the value of T-score were between - 2.8 DS and - 3.9 DS. In cases with premature ovarian failure - 5 cases serum osteocalcin 22.9 ng/ml and 115 ng/ml (comparable to those of postmenopausal women) - 3 cases 5 serum osteocalcin 18.7 ng/ml \pm 7.2 ng/ml (comparable to premenopausal women) - 2 cases normal. Bone resorption - values between 0.197-1.768 ng/ml comparable to pre- and postmenopausal.

Conclusion: Early menopausal patients correlate the mean markers of bone turnover with the risk of major fracture vertebral or nonvertebral. The age of menopause installation correlates directly with the risk of fracture

References:

1. Popescu M et al. Rev Chim 2018;8:2089
2. Albulescu DM et al. Rev Chim 2018; 9:2438
3. Radu L et al. Rev Chim 2018;10:2754
4. Albulescu DM et al. Rev Chim 2018;12:3683
5. Radu L et al. Rev Chim 2018;12:3483

P837

FOR ALL PRACTITIONERS AND RESEARCHERS TO ASSESS HAND DYSFUNCTION IN HAND OSTEOARTHRITIS (OA): THE QUICK, FRIENDLY AND AVAILABLE FOR FREE FUNCTIONAL INDEX FOR HAND OA WEBSITE FIHOA.NET

E. Maheu¹, R.-L. Dreiser²

¹Rheumatology Saint Antoine Hospital, ²Rheumatology Bichat Hospital, Paris, France

Objective: Hand osteoarthritis (HOA) is a frequent polyarticular disease, which may lead to considerable pain and physical limitations. Applied to the almost 500 million inhabitants of the European Union, HOA might represent 150 million radiographic hand OA affected individuals of which 30 million will suffer from hand pain, stiffness, deformities and impaired function.

The functional Index for hand OsteoArthritis (FIHOA) has been validated to assess HOA's functional impairment in 10 questions, both in daily clinical practice and in studies or clinical trials and is currently a recommended tool to be used for clinical studies/therapeutic trials by international recommendations for the conduct of trials in HOA (1,2). We aimed at providing to all practitioners and the rheumatologic/orthopedic research community a free-of-charge, free-of-copyright and rapidly accessible numeric format, a free FIHOA website under the responsibility of the instrument's coauthors.

Results: FIHOA website provides the FIHOA scoring for daily clinical practice use, allows for a rapid assessment of the functional impairment of symptomatic hand OA, facilitates the assessment of treatments efficacy in clinical practice. or in therapeutic trials or hand dysfunction in a survey/cohort of HOA patients. It contains the 10 FIHOA's assessing questions in 21 different linguistic versions (new available validated linguistic versions: Persian, Korean, Japanese, Arab). Other linguistic versions are currently under validation (Portuguese, Brazilian, Turkish, Danish). It results in a direct calculation of the score, available for the patient's file either in a numeric or paper format. The website also provides users with a short history of the instrument and all **References** available in the international literature. Last, it allows for contacting directly the authors by email.

Conclusion: We assume that the FIHOA.net website should be helpful to practitioners for hand OA patients management in ambulatory practice, and will also help the entire scientific community involved in the field of researches in hand OA, and teams conducting therapeutic trials.

References:

- (1) Kloppenburg M et al. Osteoarthr Carti 2015;23:772
- (2) Reginster JY et al. Semin Arthritis Rheum 2018;48:1

P838

STUDY OF INCIPIENT CARIES EVOLUTION AT PATIENTS WITH OSTEOPOROSIS

S.-A. Preda¹, I. A. Moraru², C. Petcu³, M. Bataiosu⁴, I. T. Dascalu⁵, D. M. Albulescu⁶, M. J. Tuculina²

¹University of Medicine and Pharmacy, Faculty of Dentistry, ²University of Medicine and Pharmacy, Department of Odontology, Faculty of Dentistry, ³University of Medicine and Pharmacy Craiova, Faculty of Dentistry, Department of Odontology, ⁴University of Medicine and Pharmacy Craiova, Faculty of Dentistry. Department of Pedodontics, ⁵University of Medicine and Pharmacy Craiova, Faculty of Dentistry, Department of Orthodontics, ⁶University of Medicine and Pharmacy, Department of Radiology, Craiova, Romania

Objectives: The study was performed on a group of 24 patients with osteoporosis who had explosive caries and hypomineralization. An analysis of the particularities of the caries evolution and of the evidence of the precarious hypomineralization state was made at patients with osteoporosis. The purpose of this study was to draw dentists attention about the early detection of hypomineralization and incipient caries in all day examinations.

Methods: In the study had participated 24 patients (34-55 y); 20 women - 4 men. Most patients were amateurs of sweets, acidified beverages, they do not prefer dairy products. 16 patients showed signs of gastritis and 2 chronic bronchitis. At 18 of the patients examined, oral hygiene was faulty. All patients were adequately treated for osteoporosis. Patient diet was not consistent with the regimen at most patients, glucose and acidified beverages was predominant.

Results: At all patients examined the diagnostic was certainly explosive caries. To all patients were given a complex local and general treatment. Beside local remineralizing treatment, patients had a general remineralization treatment. After 1-2 months of treatment, at the majority of patients, macular caries areas and hypomineralization are starting to remineralize becoming hard and glossier.

Conclusions: The causes of these severe manifestations can be: hormonal changes^{1,2,3,4,5}; the association of gastrointestinal, renal ^{6,7} or respiratory diseases. Early detection of dental demineralization and hypomineralization, and also administering curative and preventive measures can reduce the speed of the evolution and ultimately the early loss of teeth.

References:

- 1. Albulescu DM et al. Rev Chim 2018;9:2438
- 2. Popescu M et al. Rev Chim 2018;8:2089
- 3. Radu L et al. Rev Chim 2018;10:2754
- 4. Albulescu DM et al. Rev Chim 2018;12:3683
- 5. Radu L et al. Rev Chim 2018;12:3483
- 6. Zaharie M et al. Rev Chim 2018;6:1435
- 7. Răescu M et al. Environm Engineering Manag J 2010;9:1521

P839

METABOLIC SYNDROME IS ASSOCIATED WITH PAIN SEVERITY AND MULTISITE PAIN TRAJECTORIES

F. Pan¹, J. Tian¹, F. Cicuttini², G. Jones¹

¹University of Tasmania, Menzies Institute for Medical Research, Hobart, ²Monash University Medical School, Department of Epidemiology and Preventive Medicine, Melbourne, Australia

Objectives: To describe the associations of metabolic syndrome (MetS) and its components with trajectories of localised knee pain (pain severity) and generalised pain (number of painful sites (NPS)) in a general older population.

Methods: 1099 participants from a population-based older adult cohort study were recruited at baseline. 875, 768 and 563 participants attended years 2.6, 5.1 and 10.7 follow-up, respectively. Data were collected on demographic, psychological, lifestyle and comorbidities, blood pressure, glucose, triglycerides, and high-density lipoprotein (HDL) cholesterol. MetS was defined based on the National Cholesterol Education Program-Adult Treatment Panel III criteria. Radiographic knee osteoarthritis (ROA) was assessed by X-ray. Knee pain was measured by Western Ontario and McMaster Universities Osteoarthritis Index pain questionnaire at each time-point. Presence/absence of pain at the neck, back, hands, shoulders, hips, knees and feet was collected by questionnaire at each time-point. Group-based trajectory modelling was applied to identify pain trajectories. Multi-nominal logistic regression was used for the analyses.

Results: Of 985 participants included in this study, 32% of participants had MetS and 60% had ROA at baseline. Three localised knee pain severity trajectories were identified: 'Minimal pain' (52%), 'Mild pain' (33%) and 'Moderate pain' (15%). Three NPS trajectories were identified: 'Low NPS' (12%), 'Medium NPS' (38%), and 'High NPS' (49%). In multivariable analysis without adjusting for central obesity, central obesity increased risk of belonging to both 'Mild pain' and 'Moderate pain' trajectories as compared to the 'Minimal pain' trajectory group, but MetS, hypertriglyceridemia and low HDL were only associated with 'Moderate pain' trajectory [relative risk (RR): 1.67-2.26, all P<0.05]. Similarly, central obesity was also associated with both 'Medium NPS' (RR 2.35, 95%CI 1.40-3.92) and 'High NPS' trajectories (RR 3.07, 95%CI 1.85-5.08) compared to 'Low NPS' trajectory group, whereas MetS was only associated with 'High NPS' trajectory (RR 2.60, 95%CI 1.54-4.41). These associations became weak and non-significant after further adjustment for central obesity or BMI.

Conclusions: MetS is predominantly associated with trajectories of localised and generalised pain through central obesity, suggesting that weight management may be the foundation of treatment for pain.

P840

A STUDY ON CLINICAL EVOLUTION OF CERVICAL DENTAL EROSION LESIONS AT PATIENTS WITH OSTEOPOROSIS

S.- A. Preda¹, I. A. Moraru², C. Petcu³, M. Bataiosu⁴, I. T. Dascalu⁵, D. M. Albulescu⁶, M. J. Tuculina²

¹University of Medicine and Pharmacy, Faculty of Dentistry, ²University of Medicine and Pharmacy, Department of Odontology, Faculty of Dentistry, ³University of Medicine and Pharmacy Craiova, Faculty of Dentistry, Department of Odontology, ⁴University of Medicine and Pharmacy Craiova, Faculty of Dentistry. Department of Pedodontics, ⁵University of Medicine and Pharmacy Craiova, Faculty of Dentistry, Department of Orthodontics, ⁶University of Medicine and Pharmacy, Department of Radiology, Craiova, Romania

Objectives: Cervical dental erosion is a lesion of undamaged etiology, which is formed on the vestibular, oral or occlusal surfaces of the teeth. Erosion lesions appear at patients who consume acidic drinks, have acidic gastric regurgitation, or have a medication that causes an oral acid pH. The study was to identify cervical dental erosion on a group of patients diagnosed with osteoporosis, following the appropriate treatment for the disease.

Method: A total of 32 patients diagnosed with osteoporosis participated in the study. The patients were followed for 6 months, both in terms of the occurrence and clinical evolution of erosion lesions, but also of the diet. The treatment of dental erosion injuries includes general and local measures. General treatment - calcium, phosphorus, microelements, vitamin complex lasting one month (calcium gluconate, lithium, vitamin C, B1, etc.). The following treatment methods were applied locally: the use of toothpastes that reduce the effects of dental hyperextension and the modification of dental brushing techniques¹, local application of various preparations (lacquer, gel, remineralization solutions) for the purpose of diminishing the dental sensitivity, obturation of the lack of enamel by using composite materials, compomere, glass ionomer, prosthetic restoration of teeth with extensive odontal lesions².

Conclusions: Osteoporosis generally appears at elderly patients with hormonal problems 3,4,5,6,7. Treatment of osteoporosis includes a medication which induce an oral acid pH. All patients have positive treatment results. Monitoring the dental erosion damage at patients with osteoporosis is mandatory.

References:

1. Răescu M et al . Environmental Engineering Manag J 2010;9:1521
2. Dăguci C et al. Rom J of Morphol Embryol 2014;55:401
3. Albulescu DM et al. Rev Chim 2018;9:2438
4. Popescu M et al. Rev Chim 2018;8:2089
5. Radu L et al. Rev Chim 2018;10:2754
6. Albulescu DM et al. Rev Chim 2018;12:3683
7. Radu L et al. Rev Chim 2018;12:3483

P841

EFFICIENCY OF THERAPEUTIC MEANS IN OSTEOPOROSIS INDUCED BY GONADIC HORMONES

S.- A. Preda¹, M. Popescu², A. Predescu³, M. Cojocar⁴, M. Raescu⁵, A. Camen⁶, M. J. Tuculina⁴

¹University of Medicine and Pharmacy, Faculty of Dentistry, Craiova, ²University of Medicine and Pharmacy, Department of Endocrinology, Craiova, ³University of Medicine and Pharmacy of Craiova, Research Center for Microscopic Morphology and Immunology, Craiova, ⁴University of Medicine and Pharmacy, Department of Odontology, Faculty of Dentistry, Craiova, ⁵Titu Maiorescu University, Dental Medicine Faculty, Bucharest, ⁶University of Medicine and Pharmacy Craiova, Faculty of Dentistry, Craiova, Romania

Objectives: There are multiple therapeutic options in osteoporosis induced by gonadal insufficiency (ovarian or testicular), and the choice of the appropriate therapy should be based on the following principles: comorbidity, extraskelatal effects, cost-benefit report 1,2,3,4,5. For cases with premature ovarian failure, we followed the evaluation of patients with high risk of osteoporosis, exclusion of secondary causes of osteoporosis, the selection of appropriate treatment.

Methods: The study was performed on 24 cases of premature ovarian failure with age between 19-34 y. The therapeutic options include the non-pharmacological approach, the therapeutic intervention with pharmacological agents in relation to the pathogenic mechanism of hypogonadal osteoporosis. Estro-progestative substitution is the first-line therapeutic attitude in premature ovarian failure to prevent osteoporosis, metabolic and visceral complications. Curative treatment was given with the following

Objectives: growth or at least bone stabilization; assurance of bone quantity and quality; fracture prevention; therapy of fracture complications; maintaining an optimal physical state.

Results: Requires curative therapy: patients with sexoid osteoporosis with a T-score below -1.5 DS; patients with sexoidopathy osteopenia that associate fractures of fragility; patients with hypogonadal osteoporosis with a T-score below -2.5 DS.

Conclusions: Several therapeutic agents are currently available that stop or slow down bone loss, reduce bone remodeling rate, and reduce the risk of fracture. In the current context of modern medicine, the prevention of osteoporosis aims the removing risk of first fracture and as such, the same drugs can be used both for the prevention and treatment of osteoporosis.

References:

1. Popescu M et al. Rev Chim 2018;8:2089
2. Radu L et al. Rev Chim 2018;10:2754
3. Albulescu DM et al. Rev Chim 2018;9:2438
4. Albulescu DM et al. Rev Chim 2018;12:3683
5. Radu L et al. Rev Chim 2018;12:3483

P842

BONE TURNOVER IN DIABETIC OSTEOPOROSIS PATIENTS

J. S. Hwang¹, J. F. Chen²

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Linkou, ²Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, Taiwan

Objective: Diabetes mellitus is associated with an increased risk of fractures, which is not explained by BMD. Furthermore, in the fracture risk assessment tool (FRAX) model, common risk factors and BMD were underestimated the fracture risk in type 2 diabetes patients. Although, glycemic control condition, the duration of disease, hypoglycemia, risk of falling, and adverse effects of medication, which could lead to higher fractures in diabetic patients, and many studies have investigated biochemical bone turnover rate in diabetes patients, no definite inferences can be made, but bone turnover markers have useful in fracture risk assessment and monitoring treatment efficacy in postmenopausal osteoporosis. The aim of this study is to evaluate the bone turnover and fracture risk in postmenopausal osteoporosis women with diabetes.

Methods: This cross-sectional study investigated patients who were postmenopausal osteoporosis women with diabetes at endocrine clinic. In this study, country-specific fracture risk for 10-y probability of a hip or major osteoporotic fracture, were calculated by the WHO Collaborating Center, using the FRAX algorithm. The FRAX algorithm includes femoral neck BMD, age, sex, BMI, previous history of fracture, parental history of hip fracture, current smoking, recent use of corticosteroids, presence of rheumatoid arthritis, and at least 3 alcoholic beverages per day. A single, fasting blood sample to assess bone markers, and other biochemical tests were performed in the study visit. Patients were measure the bone specific alkaline phosphatase for formation, and β -CrossLaps for resorption were analyzed the bone turnover rate.

Results: In this cross-sectional study, we investigated 52 Taiwanese postmenopausal women, with 30 subjects diabetes and 32 nondiabetes at osteoporosis clinic, aged between 50-77 y, have high risk for fractures by FRAX, defined as 10-y major osteoporotic fracture probability ($\geq 20\%$) or hip fracture probability ($\geq 3\%$), and found both bone formation and resorption markers were elevated.

Conclusions: Our findings suggest that in diabetes osteoporosis women have high risk for fractures by FRAX, with 10-y major osteoporotic fracture probability or hip fracture probability and high bone markers, but no significant difference bone markers in diabetes and nondiabetes osteoporosis women.

Acknowledgement: Taiwanese Osteoporosis Association

P843

USE OF BONE MASS DENSITY ASSESSMENT IN FRAGILITY FRACTURE PATIENTS IN MALAYSIAN TERTIARY HOSPITAL

J. F. Leong¹, M. A. Sharkawi¹, K. B. Levin¹, M. A. Mohd-Ariff¹, M. K. Yin², A. M. Sabarul¹

¹Department of Orthopaedic and Traumatology, Faculty of Medicine, University Kebangsaan Malaysia, ²Department of Pharmacy, University Kebangsaan Malaysia, Wilayah Persekutuan Kuala Lumpur, Malaysia

Objective: Principal part of all clinical practice guidelines recommended that adults who sustained a fracture above the age of 50 should have BMD. Low BMD is associated with increased risk of fracture. We did a study to look at patients with fragility fractures who had their bone mass density using DXA in tertiary university hospital.

Methods: Patient admitted to the hospital with fragility fractures were identified from the admission registry from January 2017 to December 2017. BMD was checked from the hospital computer system if patients attended their DXA appointment within 6 months since their admission.

Results: A total of 219 patients (68, 31% male and 151, 69% female) were identified with fragility fractures. Majority sustained hip fractures followed by other lower limb fracture, upper limb fracture and vertebrae fracture. From this study, only 36 (18.6%) of patients had their BMD.

Conclusion: Multiple studies reported a wide range of 1% to 32% of patients had their BMD scans following fragility fracture (1). Another similar study by Kung *et al.* that looks at postmenopausal women in Asian countries who had fragility fracture reported that only 28.2% of them had BMD measurements (2). Internationally FRAX assessment tool is the most commonly used to estimate 10 years risk of major osteoporotic fracture and hip fracture. It can calculate with or without BMD but will give refined estimation with BMD result. Another assessment tool, the Canadian association of radiologist and osteoporosis Canada (CAROC) tool and Garvan in Australia will require BMD result to assess patients risk of osteoporotic fracture. Compared to international recommendation and the numbers of subjects at high risk of osteoporotic fracture, BMD testing through DXA scan are still underutilized in our center. More awareness needed to be emphasized among the clinician and patients to assess and guide the management of their osteoporosis.

References:

1. Giangregorio L et al. Semin Arthritis Rheum 2006;35:293.
2. Kung AW et al. BMC Women's Health 2013;13:7.

P844

ROLES AND LIMITS OF OSTEODENSITOMETRY WITH ULTRASOUND

S.-A. Preda¹, M. Popescu², A. Predescu³, M. Cojocaru⁴, M. Raescu⁵, A. Camen⁶, M. J. Tuculina⁴, D. M. Albuлесcu⁷

¹University of Medicine and Pharmacy, Faculty of Dentistry, Craiova, ²University of Medicine and Pharmacy, Department of Endocrinology, Craiova, ³University of Medicine and Pharmacy of Craiova, Research Center for Microscopic Morphology and Immunology, Craiova, ⁴University of Medicine and Pharmacy, Department of Odontology, Faculty of Dentistry, Craiova, ⁵Titu Maiorescu University, Dental Medicine Faculty, Bucharest, ⁶University of Medicine and Pharmacy Craiova, Faculty of Dentistry, Craiova, ⁷University of Medicine and Pharmacy, Department of Radiology, Craiova, Romania

Ultrasound densitometry through attenuation of the ultrasonic band in the calcaneus is the most used method of determining the direct measurement of bone mass and density for establishing the paraclinic osteoporosis diagnosis in our country ^{1,2,3,4}. Taking into account the recent use, most frequently, of DXA in measuring bone mass and density, we have proposed in our study to make a comparison of the two methods. The study covered 140 patients with osteoporosis diagnosed through ultrasound densitometry in the Endocrinology Clinic between January and March 2016, whose T-score ranged between -2.5 and -5. Then we determined at these patients T-score by the DXA technique and the results were compared. It was found that 105 patients were confirmed with osteoporosis by DXA technique, 34 patients with osteopenia (T-score between -1 and -2.5) and one patient presented the T-score within the normal range. Advantages of ultrasound osteodensitometry would be low cost, lack of exposure to irradiation, and as disadvantages consisted in the limitation of bone mass determination only at the calcaneus level and accuracy of the inferior outcome of the DXA technique. In conclusion ultrasonic osteodensitometry can be used as initial screening test, as an initial diagnosis of osteoporosis and DXA is recommended to confirm the diagnosis, both techniques suggesting the risk of pathological bone fracture⁵.

References:

1. Popescu M et al. Rev Chim 2018;8:2089
2. Radu L et al. Rev Chim 2018;10:2754
3. Albuлесcu DM et al. Rev Chim 2018;9:2438
4. Albuлесcu DM et al. Rev Chim 2018;12:3683
5. Radu L et al. Rev Chim 2018;12:3483

P845

BONE CHARACTERISTICS AND OBESITY PHENOTYPES IN AN IRANIAN ELDERLY POPULATION: BUSHEHR ELDERLY HEALTH PROGRAM (BEHP)

F. Amininezhad¹, F. Sharifi², M. Ebrahimput¹, M. Payab³, A. Ostovar⁴, I. Nabipour⁵, B. Larijani¹

¹Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Science Institute, Tehran University of Medical Sciences, Tehran, ²Elderly Health Research Center, Endocrinology and Metabolism Population Science Institute, Tehran University of Medical Sciences, Tehran, ³Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular Cellular Science Institute, Tehran University of Medical Science, Tehran, ⁴Osteoporosis Research Center, Endocrinology and Metabolism Clinical Science Institute, Tehran University of Medical Sciences, Tehran, ⁵The Persian Gulf Biomedical Science Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran

Objectives: Obesity and osteoporosis are two major health problems with high impact on the morbidity and mortality of population worldwide. BMI is usually used to indicate the amount of obesity, but it cannot distinguish fat from lean body mass. Obesity phenotypes (OPh) are defined based on obesity and metabolic syndrome (MetS) criteria. Although, association between BMI and bone density was known, effects on complex of obesity and metabolic components on bone health particularly bone quality has not been revealed. The objectives of this study was determination of relationship between bone health with different phenotype of obesity in a representative older population in Iran.

Methods: results of this study was a cross-sectional view to Bushehr Elderly Health Program (BEHP) data. Sampling of the BEHP is a multistage stratified method from residents ≥ 60 y in Bushehr. Demographic and lifestyle information were collected using standard questionnaires. Weight, height, and waist circumference of the participants were measured. BMI was calculated by dividing weight by square of height. Definition of obesity was based on WHO definition. The BMD of lumbar spine (L1-L4) and neck of femurs also trabecular bone score were measured by DXA (using a software for calculation of TBS). Osteoporosis was defined as T-score ≥ -2.5 in each of mentioned sites. Low bone quality was defined as TBS <1.3 . The participants were classified in four different obesity phenotypes according to general obesity and MetS (metabolic healthy obese, metabolic nonhealthy non-obese, metabolic no-healthy obese, metabolic healthy nonobese). Associations between osteoporosis and TBS of lumbar spines and with OPh were assessed using univariate and multiple variable logistic regression models.

Results: Totally, 2262 people (1171 women) were considered for analyses. The prevalence of MHNO, MHO, MNHNO, and MNHO were 902 (39.9%), 138 (6.1%), 758 (33.5%), and 464 (20.5%), respectively. In final multivariate logistic regression models those who had MHO (OR: 0.22; 95%CI: 0.12-0.36), MNHNO (OR: 0.52; 95%CI: 0.4-0.66) and MNHO (OR: 0.22; 95%CI: 0.16-0.3) pheno-

types had a significant lower risk of cumulative osteoporosis and who had MHO (OR: 2.38; 95%CI: 1.51-3.76), MNHNO (OR: 1.49; 95%CI: 1.11-2) and MNHO (OR: 2.5; 95%CI: 1.82-3.42) phenotypes (in compared to the MHNO group) had a significant higher risk of low bone quality based on TBS cutoff (adjusted for sex, age, physical activity, and smoking).

Conclusion: It seems that despite the BMD is higher in different phenotypes of obesity, the bone quality is lower in these groups in compared to nonobese subjects.

P846

THE ROLE OF COMPLEX THERAPY IN FIGHT WITH PAIN AND SLEEP DISORDERS IN FIBROMYALGIA PATIENTS

M. Borcan¹, A. M. Bumbea², I. C. Resceanu³, O. Rogoveanu², G. Radoi⁴, C. Albu⁵, D. V. Caimac², B. S. Bumbea⁶

¹Neuropsychiatry Hospital, Craiova, ²University of Medicine, Craiova ³University of Craiova, Craiova, ⁴Deliamed Srl, Poiana Mare, ⁵University of Medicine and Pharmacy, Craiova, ⁶Emergency County Hospital, Craiova, Romania

Objectives: Usually people how suffer from fibromyalgia are fatigue and have sleep disorders and the risk for fibromyalgia is increase if the patient is suffering from a rheumatic disease.

Methods: We observed a group of 60 patients with fibromyalgia (according to the criteria of the American College of Rheumatology) that we followed for 4 weeks and were divided into two equal lots: the study group - 30 patients and control group - 30 patients. All patients age is between 40-60 y. They all followed specific and appropriate drug treatment. Patients in the study group next to drug therapy followed 30 min of physical therapy (thermotherapy and physiotherapy). Patients in the control group followed only medical treatment. The assessment was made initially at admission and 4 weeks later (at discharge), following the VAS of pain and sleep disorders questionnaire SDQ.

Results: The control group presented a minimal reduction of pain from a VAS of 6.4 to 3.5 and the study group managed to significantly improve their status starting from a pain with a score on VAS of 7.1 and reaching 3.2. the sleep disorders were improved in study group with 23.5% compared with control group.

Conclusions: Physical therapy demonstrates its utility in combating pain and sleep disorders in fibromyalgia patients. Combining physical therapy with specific drug therapy also improves the functional status and quality of life.

P847

CURRENT CONCEPTS IN THE THERAPY OF HYPOGONADAL OSTEOPOROSIS

S.- A. Preda¹, M. Popescu², A. Predescu³, M. Cojocaru⁴, M. Raescu⁵, A. Camen⁶, M. J. Tuculina⁴, D. M. Albulescu⁷

¹University of Medicine and Pharmacy, Faculty of Dentistry, Craiova, ²University of Medicine and Pharmacy, Department of Endocrinology, Craiova, ³University of Medicine and Pharmacy of Craiova, Research Center for Microscopic Morphology and Immunology, Craiova, ⁴University of Medicine and Pharmacy, Department of Odontology, Faculty of Dentistry, Craiova, ⁵Titu Maiorescu University, Dental Medicine Faculty, Bucharest, ⁶University of Medicine and Pharmacy Craiova, Faculty of Dentistry, Craiova, ⁷University of Medicine and Pharmacy, Department of Radiology, Craiova, Romania

Objectives: In modern therapy of hypogonadal osteoporosis is discussing two distinct aspects: prevention of osteoporosis, osteoporosis treatment. For the cases with late puberty -hypergonadotropic hypogonadism (gonadal dysgenesis) and hypogonadotropic hypogonadism - the major objectives of hypogonadic osteoporosis prophylaxis were ensuring the conducting of sexualization process, maintaining the stability of the bone mass during ontogenesis, fighting the factors that cause osteoporosis and its consequences (osteoporotic fractures) 1,2,3,4,5.

Methods: The study was performed on 36 cases with hypogonadal osteoporosis from which: pubertal tardive 18 cases with age between 11-26 y - gonadal dysgenesis -11 cases (feminine Turner phenotype syndrome 8, Klinefelter syndrome-3), hypogonadotropic hypogonadism 7 cases (pituitary dwarfism with infantile sexuality -2, adipose genital syndrome 5 case. Therapeutics options - the therapeutic solution associates estroprogestative/ androgenic substitution with antiresorbent medications (bisphosphonate) or proformate.

Results: Requires curative therapy: patients with osteopenia/osteoporosis, with T-score under -1.5 DS; patients with osteopenia / osteoporosis, with T-score under -2.5 DS and having fractures

Conclusions: Modern osteoporosis therapy divides the pharmacological agents into two major classes: antiresorbptive agents (bone resorption inhibitors), proformators (stimulators of bone formation)

References:

1. Popescu M et al. Rev Chim 2018; 8:2089
2. Radu L et al. Rev Chim 2018;10:2754
3. Albulescu DM et al. Rev Chim 2018;9:2438

4. Albulescu DM et al. Rev Chim 2018;12:3683

5. Radu L et al. Rev Chim 2018;12:3483

P848

INITIATION TIMING OF ANTIOSTEOPOROSIS MEDICATIONS THERAPY AND THE RISK OF SUBSEQUENT OSTEOPOROTIC FRACTURE: A NONLINEAR RELATIONSHIP


C.-Y. Wang¹, S.-H. Fu², R.-S. Yang³, F.-Y. Hsiao⁴

¹School of Pharmacy, College of Medicine, National Taiwan University, Taipei, ²Department of Orthopedics, National Taiwan University Hospital Yun-Lin Branch, Yunlin, ³Department of Orthopedics, National Taiwan University Hospital, Taipei, ⁴Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan

Objectives: To investigate how AOM initiation timing affects the risk of subsequent osteoporotic fractures, and what factors influence AOM prescription timing.

Methods: Women older than 50 years old with diagnostic codes indicating hospitalization for hip fracture, prescribed AOMs ≤ 1 y post index hip fracture and with AOMs medication possession ratio (MPR) between 0.8-1.2 within 1 y were sampled from the Taiwan National Health Insurance Research Database. Associations between different AOMs initiation timing with subsequent fracture-related hospitalizations were analyzed. Established evidence has shown the critical role of adherence of AOMs on patient's clinical outcomes. Therefore, in this study, we condition on patients with good adherence to illustrate the crucial influence of properly initiation timing of AOMs therapy on the antifracture benefit of AOMs therapy. The medication possession ratio is a measure for patient's adherence and defined as the proportion of days on AOM treatment. Multiple generalized additive models (GAMs) were fitted to detect nonlinear effects of different initiating time of AOMs. Factors influencing AOM initiation timing were elucidated using multivariate logistic regression analyses.

Results: There were 1887 hip fracture patients with a MPR between 0.8-1.2 within 1 y after initiating AOMs. AOM initiation timing was significantly associated with age, index year, index hospitalization duration, and geographic region; adherence, with index fracture after 2010, medical center vs. local hospital admission; adherence decreased with age. The GAMs analysis revealed the relationship between different initiation timing and risk of subsequent osteoporotic fractures was nonlinear. And patients initiated AOMs between 1 to 5 months post index fracture showed optimal results. (Figure 1)



Conclusion: In addition to good adherence, the antifracture benefit of AOMs depends crucially on properly initiation timing.

P849

OSTEOGENESIS IMPERFECTA: EVOLUTION OF THE BONE MINERAL DENSITY AND EVALUATION OF FRACTURE RISK UNDER BISPHOSPHONATES

M. A. El Achek¹, A. Farhat¹, S. Zrour¹, I. Bejia¹, M. Touzi¹, M. Jguirim¹, N. Bergaoui¹

¹Rheumatology Department Fattouma Bourguiba University Hospital, Monastir, Tunisia

Objective: Osteogenesis imperfecta (OI), or Lobstein’s disease, also known as ‘glass bone disease’ is a rare genetic disorder predisposing to low bone mass with impaired bone microarchitecture and abnormal quality of bone material, causing fracture susceptibility and bone deformities. The main objectives of our work was to study the clinical and paraclinical characteristics, and global management, of adult patients and children with OI in a rheumatology department by comparing them with data from the literature. Then to study the evolution of the BMD and to evaluate the fracture incidence under treatment by bisphosphonates.

Methods: This is a cross-sectional, observational, descriptive, analytical and monocentric study of subject with OI followed at Fattouma Bourguiba University Hospital in Monastir, Tunisia

Results: We collected 13 patients with OI, including 5 children and 8 adults. Seven patients were female and 6 were male, including 12 patients with type IB and one with type IIIB. Three adult patients had a family history of OI. For children, it was sporadic and the genetic survey did not reveal similar cases in the family. The mean age of clinical onset of the disease was 9 y and 3 months [0-33 y] with a mean age at diagnosis of 15 y and 7 months [14 months- 40 y]. The clinical manifestations were dominated by osteo-articular symptoms. Chronic mechanical bone pain related to fractures was present in eight patients. Twelve patients

had a history of fracture. These were repeated fractures without trauma or minimal trauma in the majority of cases mainly in the lower limbs. The first fracture site was the femur associated with other fracture sites (there were no fractures in the pelvis, hands and skull). Deformities were observed in 7 patients, mainly in the limbs (6 patients), in the spine (2 patients) and in the thorax (1 patient). In our study the frequency of osteoporosis and/or osteopenia regardless of the measured site and using the T-score value for women ≤ -2.5 and the Z-score ≤ -2 for children and men was 84.62%. All patients received Pamidronate treatment according to Glorieux’s protocol with calcium and vitamin D supplementation. The treatment was also multidisciplinary. Bisphosphonate treatment was well tolerated for the majority of patients. There was a decrease in the number of fractures and also a densitometric gain objectivized for the majority of patients.

Conclusion: Our results confirm the efficacy of BP in patients with OI regardless of age group. Short-term adverse effects are rare and transient.

P850

SEXOIDOPATHY HYPOGONADIC OSTEOPOROSISS.- A. Preda¹, M. Popescu², A. Predescu³, D. M. Albulescu⁴, M. Cojocaru⁵, M. Raescu⁶, M. J. Tuculina⁵, A. Camen⁷

¹University of Medicine and Pharmacy, Faculty of Dentistry, Craiova, ²University of Medicine and Pharmacy, Department of Endocrinology, Craiova, ³University of Medicine and Pharmacy of Craiova, Research Center for Microscopic Morphology and Immunology, Craiova, ⁴University of Medicine and Pharmacy, Department of Radiology, Craiova, ⁵University of Medicine and Pharmacy, Department of Odontology, Faculty of Dentistry, Craiova, ⁶Titu Maiorescu University, Dental Medicine Faculty, Bucharest, ⁷University of Medicine and Pharmacy Craiova, Faculty of Dentistry, Craiova, Romania

The bone is a dynamic connective tissue whose structure has been developed to perform three major functions: it is the most important organ for maintaining calcium homeostasis and a significant deposit of phosphates, magnesium, potassium and bicarbonates; provides the mechanic support of soft tissues, being an important lever for the action of the muscles; is the major headquarters of hematopoiesis at the adult human. Consequently, osteoporosis is defined as a systemic disease of the skeleton, characterized by loss of bone mass, damage the bone tissue microarchitecture, increased bone fragility, exaggeration of fracture risk. Hypogonadal sexoidopathy osteoporosis take in to discussion the absence or deficiency of estrogen, progesterone and androgen, singularly or in combination. It has been shown that estrogen deficiency induces an accelerated and irreversible bone mass, predominantly trabecular through increasing the frequency of activation of new remodeling units, accelerating bone turnover; excessive supplementation of osteoclastic resorption activity; reducing the intestinal calcium absorption by inducing a decrease of the concentration of active vitamin D3 (calcitriol). Progesterone deficiency at women with anovulatory cycles leads to decreased bone mass, especially trabecular. Gonadal androgenic output produces the reduction of cortical and trabecular bone through bone resorption and mineralization reduction; low calcitriol plasma levels and calcium malabsorption; reduction of circulating concentrations of estradiol and calcitonin 1,2,3. From the above mentioned Results: hypogonadal osteoporosis can be prematurely installed, is asymptomatic for a long time and the etiological diagnosis is sometimes laborious; early diagnosis of gonadal insufficiency requires the adoption of prophylactic measures, bone changes from prepubertal, pubertal or postpubertal stage to ensure a maximum bone mass corresponding to sex and age 5,6 .

References:

1. Popescu M et al. Rev Chim 2018;8:2089
2. Radu L et al. Rev Chim 2018;10:2754
3. Albulescu DM et al. Rev Chim 2018;9:2438
4. Albulescu DM et al. Rev Chim 2018;12:3683
5. Radu L et al. Rev Chim 2018;12:3483

P851

EFFICIENCY OF LASER THERAPY IN COMPLEX TREATMENT OF RHEUMATOID ARTHRITISE. Guryanova¹, Y. Polyakova², E. Shamitova¹

¹Chuvash State University, Cheboksary, ²Volgogradski Centre Rheumatology, Volgograd, Russia

Objective: Rheumatoid arthritis (RA) affects about 0.4-1% of the population, in Chuvashia - 0.34%. Laser therapy is successfully used to reduce the immune-inflammatory reactions of the body. The purpose of the study is to increase the effectiveness of pathogenetic treatment using laser therapy in a complex of patients with RA.

Methods: Surveyed 112 patients with RA with a duration of 3 to 10 y or more (men-30, women-100). The age of patients ranged from 27-61 y. The minimum degree of activity was in 52 (47.7%), the average - in 50 (38.5%), high - in 10 (13.8%) patients. Stage I is observed in 30 (26.9%), II - in 50 (41.5%), III - in 20 - (23.9%), IV - in 12 (7.7%) patients with RA. The patients were divided into groups: Group I - 90 patients who received complex treatment with the use of low-intensity laser therapy according to the method of supervision and Group II - 30 patients who did not receive laser therapy. The control group consists of 22 healthy individuals identified by sex and age of patients with RA. Examinations do not have corticosteroid therapy for at least 3 months prior to the time of the survey. The technique of laser therapy includes cutaneous laser irradiation of the joints in the projection of the joint space. For gluing with a wavelength of 0.89 microns. The pulse frequency is 80-1500 Hz, the pulse power is 5 W, the duration of exposure to the field is 1-2 min, the total radiation time does not exceed 10 min. The course is 10-15 procedures.

Results: Pain on a scale VAS in group 1 decreased by 16% compared with the control group. Morning stiffness decreased by 29%, fatigue by 26%. Improved sleep quality was recorded in 19% of patients in group 1 and 5% in the control group. Reduced dependence on the use of NSAIDs in 28%, although the dose of drugs has not decreased. Normalized clinical and laboratory indicators of the activity of the process with a minimum, medium and high degree of activity of the process, stages I and II and the duration of the disease up to 3 y.

Conclusions: It is recommended to use laser therapy in patients with rheumatoid arthritis at the second radiological stage in addition to the basic therapy.

P852

HYPOPARATHYROIDISM: EVALUATION AND TREATMENTS.- A. Preda¹, M. Popescu², A. Predescu³, D. M. Albuiescu⁴, M. Cojocaru⁵, M. Raescu⁶, M. J. Tuculina⁵, A. Camen⁷

¹University of Medicine and Pharmacy, Faculty of Dentistry, Craiova, ²University of Medicine and Pharmacy, Department of Endocrinology, Craiova, ³University of Medicine and Pharmacy of Craiova, Research Center for Microscopic Morphology and Immunology, Craiova, ⁴University of Medicine and Pharmacy, Department of Radiology, Craiova, ⁵University of Medicine and Pharmacy, Department of Odontology, Faculty of Dentistry, Craiova, ⁶Titu Maiorescu University, Dental Medicine Faculty, Bucharest, ⁷University of Medicine and Pharmacy Craiova, Faculty of Dentistry, Craiova, Romania

Hypocalcemia is one of the most common endocrine disorders. It is caused by low PTH secretion, absence of its receptors, insufficient vitamin D intake or resistance to vitamin D. Clinically, occur acroparastesis. muscle cramps at both the striated and smooth muscles. Other complications are represented by premature cataracts, calcification of the core at the base of the skull, cardiac manifestations, psychic changes ^{1,2,3,4}. The diagnosis is based on anamnesis, clinical examination and laboratory dosing: total calcium and calcium ionic. serum albumin, magnesium, creatine, serum PTH, vitamin D ⁵. The treatment is achieved with intravenous calcium preparations for severe. decompensated cases followed by the administration of oral calcium preparation. Vitamin D preparations are also associated with the recommendation to avoid overdosing. The treatment should be adjusted according to serum levels of calcium, phosphorus and creatinine to avoid precipitation in the tissues of the phosphoalkalic salts

References:

1. Popescu M et al. Rev Chim 2018;8:2089
2. Radu L et al. Rev Chim 2018;10:2754
3. Albuiescu DM et al. Rev Chim 2018;9:2438
4. Albuiescu DM et al. Rev Chim 2018;12:3683
5. Radu L et al. Rev Chim 2018;12:3483

P853

OSTEOPOROSIS MANAGEMENT IN A FRAGILITY FRACTURE PATIENTS AT TERTIARY REFERRAL CENTER, MALAYSIAJ. F. Leong¹, M. A. Sharkawi¹, K. B. Levin¹, M. A. Mohd-Arif¹, M. K. Yin², A. M. Sabarul¹

¹Department of Orthopaedic and Traumatology, Faculty of Medicine, University Kebangsaan Malaysia, ²Department of Pharmacy, University Kebangsaan Malaysia, Wilayah Persekutuan Kuala Lumpur, Malaysia

Objective: Osteoporosis is defined as deterioration in bone and architecture resulting in weakness of the bone. The major complication is fragility fracture, which occur after a simple fall from standing height. Patients who sustain fragility fracture are at

increased risk of sustaining another fracture hence efforts are directed towards secondary fracture prevention. The aim of this study was to identify osteoporosis management in patients admitted with fragility fractures in tertiary university hospital.

Method: It is a prospective study. Patient admitted to a university teaching hospital with fragility fractures were identified from the admission registry from January 2017 to December 2017. The demographic data and drug prescriptions related to osteoporosis treatment were obtained upon discharged and within 6 months since diagnosed with fragility fractures.

Results: A total of 219 patients (68, 31% male and 151, 69% female) were identified. Mean age was 73.8 years old. Majority of patient sustained hip fracture (n=144, 65.8%) followed by lower limb fracture (n=46, 21%) then upper limb fracture (n=24, 11%) and vertebrae fracture (n=16, 7.3%). 70% of patients were prescribed with calcium and 68% were given vitamin D within 6 months since admission. Only about 39% of patients were given antiosteoporotic drugs.

Conclusion: Many studies have shown, only about 20% of osteoporotic fracture patients receive an assessment and treatment for osteoporosis (1). Study from Korea has shown 39% of their patients with hip fracture were prescribed with antiosteoporotic medication and this corresponds with our finding (2). A multi-disciplinary team approach is recommended to manage patients with fragility fracture thus the implementation of fracture liaison service (FLS), which has shown better follow-up and improved treatment. Persistent care gap exists for people suffering fragility fractures caused by osteoporosis. Improvement in after fracture care can be achieved by implementing a FLS program in the hospital setting.

References:

1. Friedlaender GE. J Am Acad Orthop Surg 2010;18:278.
2. Kim SC et al. Am J Med 2015;128:519e26.

P854

TEN YEARS OF EXPERIENCE IN FIGHTING OSTEOPOROSIS WITH THE ESCEO-IOF-SONG POWERED BY JOHANN SEBASTIAN BACHC. Günther¹

¹Orthopädische Fachlinik Schwarzach/Dept Osteology, Schwarzach, Germany

Objective: In order to increase public awareness and knowledge about the osteoporosis, novel measures are necessary. I use the "ESCEO-IOF Song" for many years in the fight against osteoporosis. On its tenth anniversary, I would like to put a spot on my experiences with it.

Methods:

- In front of the J.S. Bach memorial in Leipzig I had an idea on October 25, 1992, which I shortly presented in a one minute presentation at the Osteoporosis World Congress 1993 in Hong Kong and named it "J.S. Bach Rule of Osteoporosis Prevention".

- At the World Osteoporosis Day in 2007, I presented an "IOF-Osteoporosis-Song" in a German version which was using the IOF topics of the World Osteoporosis Days from 2004 to 2008. These topics were converted into lyrics and music, arranged by Gert Fischer (Leipzig) and musically accompanied by the brass ensemble of the world famous "Leipziger Gewandhausorchester" in Bad Füssing/ Germany.

Results: After agreement of the "Neue Bach-Gesellschaft Leipzig (NBG)" and the choirmaster of the "Leipziger Thomanerchor" Prof. Georg Christoph Biller, I used the "Bach Rule" in over 1800 osteoporosis lectures. The NBG published this rule for its 3800 members worldwide. In a pilot survey of 350 listeners to this osteoporosis lecture, 349 (99%) liked this "Bach Rule". The German version of IOF-Song 2007 has been published in the magazine "Mobiles Leben" (4/2007) of the "Kuratorium Knochengesundheit", a former member of the IOF. The song was also presented at the 2nd International Educational Symposium in Bratislava/Slovakia on September 30, 2008 and the English version had its world premiere at ECCEO 9 in Athens, Greece on March 18, 2009. The song was also translated into Chinese at the 18th International Osteoporosis Symposium in Beijing/China at April 17, 2010. Meanwhile I used the "ESCEO-IOF-Song against Osteoporosis" in the last ten years since 18th March 2009 in over 200 lectures with a total of more than 50 000 listeners.

Conclusions:

- The "J.S. Bach Rule for Osteoporosis Prevention" has proved itself in almost two thousand lectures and therefore, hopefully increased the public awareness of the disease.
- The German version of the "IOF-song 2007" shows a very good acceptance, and many osteoporosis support groups have asked for the text and tune, using it for education and raising public awareness.
- The English version of the "ESCEO-IOF-Song against Osteoporosis" at ECCEO 9 in Athens experienced a good acceptance and was published on the website of IOF and ESCEO (see: *Google*: ESCEO – IOF Song Part 2).
- Last but not least, I hope, that the songs "BACH-Rule of Osteoporosis Prevention" and the "ESCEO-IOF Song against Osteoporosis" can remember my honoured surgical colleagues from all over the world: "Don't forget the prevention of osteoporosis!"

P855

STUDIES ON DIFFERENT MODELS OF INFLAMMATION AND INFLAMMATORY PAIN IN DIABETIC AND NONDIABETIC RATS: EFFECT OF IBUPROFEN

K. Koleva¹, S. Marchev¹, R. Nikolov¹, M. Vlaskovska¹, S. Surcheva¹

¹Department of Pharmacology and Toxicology, Faculty of Medicine, Medical University – Sofia, Sofia, Bulgaria

Objective: Clinical analysis showed that compared with people without diabetes, those with diabetes were 70 percent more likely to have rheumatoid arthritis, 33 percent more likely to suffer from osteoarthritis, and 29% more likely to have osteoporosis. (Molsted et al., 2018) People with diabetes are at increased risk of developing musculoskeletal complications, but the relationship between these complications and the diabetic control is not clear. Our aim was to compare the models of carrageenan and complete Freund's adjuvant (CFA)-induced inflammation and inflammatory pain in diabetic and nondiabetic rats. The effects of ibuprofen on these two models have been also compared.

Methods: Male Wistar rats were used for the experiments in accordance with the procedure approved by the Ethics Committee of the Medical University – Sofia. Diabetes was induced in rats by a single application of streptozotocin (STZ, 75 mg/kg, i.p.) and confirmed by blood glucose monitoring 3 d afterwards. Inflammatory hyperalgesia was induced by intraplantar injection of carrageenan. Adjuvant arthritis was induced by intraplantar injection of CFA. Hind paw volume (swelling) was determined by plethysmometry. Mechanical hyperalgesia was measured by paw pressure test (PPT). Rats were treated with ibuprofen 20 and 40 mg/kg i.p.

Results: It was found that the late phase of adjuvant arthritis was more pronounced in the diabetic rats. PPT showed a significant decrease in the paw withdrawal threshold in the diabetic rats. No significant difference was found in swelling and hyperalgesia between diabetic and nondiabetic rats in carrageenan-induced inflammation. Ibuprofen dose-dependently reduced paw volume in carrageenan-induced inflammation and in the early phase of CFA-induced arthritis.

Conclusion: Symptoms of CFA-induced arthritis in diabetic rats are more severe compared with those in nondiabetic rats. Ibuprofen by dose-dependent manner reduces paw volume and inflammatory hyperalgesia with no significant difference in the effect in diabetic and nondiabetic rats.

Reference: Molsted S et al. Diabetes is associated with elevated risks of osteoarthritis, osteoporosis, and rheumatoid arthritis. Presented at: 2018 European Association for the Study of Diabetes Annual Meeting; October 1-5, 2018; Berlin, Germany. Abstract 1112.

P856

MORPHOLOGICAL CHANGES OF THE SPINE IN ELDERLY PATIENTS WITH OSTEOPOROSISD. V. Caimac¹, M. Borcan², C. Albu³, A. M. Bumbea¹, O. Rogoveanu¹, R. Traistaru³, A. Bighea³, C. Bostina⁴¹University of Medicine, Craiova, Romania, ²Neuropsychiatry Hospital, Craiova, ³University of Medicine and Pharmacy, Craiova, ⁴Emergency County Hospital, Craiova, Romania**Objectives:** The study objective was to highlight the morphological changes of the spine during the evolution of primary osteoporosis in a target group of patients who received antiresorptive therapy with biphosphates in comparison with the ones who did not receive this treatment.**Method:** In the retrospective study were included 144 female (70 and 80 years old) with primary osteoporosis and scoliosis divided in two subgroups: the first subgroup 62 patients that had biphosphate treatment for 5 y and the second subgroup 52 patients that did not receive antiresorptive treatment. The spine status was evaluated by measuring the patient's waist and determining the Cobb angle of scoliosis, and also using the T-score determined by the DXA scan. For these three parameters was made an initial evaluation (T0) followed by two measurements done at 2.5 y (T1) and 5 y (T2).**Results:** The bisphosphonate group, T-score showed an improvement from -3.9 (T0) to -3.5 (T1) and to -3.3 (T2). The average value of Cobb angle has changed from 12.5° (T0) to 14.3° (T1) and to 16.3 (T2). The mean height of the female patients in the treated group showed a decrease from 163.5 cm (T0) to 162.2 cm (T1) and to 160.1 cm (T2). The group without bisphosphonate treatment, the mean values of T-score depreciation were from -3.8 (T0) to -4.01 (T1) and to -4.2 (T2). The average Cobb angle value has modified from 12.9° (T0) to 14.8° (T1) and to 17.2° (T2). The average height changed from 164.6 cm (T0) to 162.3 cm (T1) and to 160.2 cm(T2).**Conclusions:** Osteoporosis decreases BMD, with consequences on spine morphology, translated by alignment changes and compression of the vertebrae. The administration of bisphosphonates has the effect of slowing the progression of structural changes induced in the spine by the development of osteoporosis.

P857

EFFECT OF HORMONE TREATMENT ON BONE HEALTH IN TRANSGENDER MALES: A SYSTEMATIC REVIEWA. Varghese¹, M. Bourque², N. Nigil Haroon¹¹NOSM, Sudbury, Canada, ²UCC, Dublin, Ireland**Objective:** Not much data exists on the effect of transgender hormone treatment on bone health. We conducted a systematic review of studies to examine the effect of hormone treatment on BMD in transgender males.**Methods:** Two authors independently searched Embase and Medline for studies.**Results:** 15 studies (8 cohort and 7 cross-sectional, N=607 subjects) were eligible. Subjects were aged between 18-47 y. Duration of hormone treatment ranged from 12 months to 12 y. Three studies reported lower BMD at the lumbar spine and hip at baseline compared to controls. Out of the eight longitudinal studies analyzing BMD, three reported significant increase in lumbar spine and others documented maintenance of BMD at spine and hip. Among the 5 studies analyzing BMD at 24 months, significant increase was noted by 3 studies at the lumbar spine and at the femoral neck by one study. Stable trends were noted by two studies at both hip and spine. Data from cross-sectional studies mostly suggested maintenance of BMD at one year. One study documented stabilization up to 10 y.**Conclusion:** Hormone treatment in transgender males either increases or maintains BMD. Available evidence is weak as most studies have smaller sample size, shorter follow-up and lack control groups. Fracture outcomes have not been reported.

Table. Study characteristics and change in BMD (reported by longitudinal studies)

	Author	Country	Year	N	Age (years)	Change in BMD
1	Meriggiola	Italy	2008	15	18-45*	Spine 0.98±0.06 vs. 1.01 0.08
2	Van Caenegem	Belgium	2015	23	27 (7)	Spine 1.029 ±0.085 vs. 1.028 ±0.084 Femoral neck 0.861 ±0.101 vs. 0.862 ±0.102 Total hip 0.861 ±0.101 vs. 0.861 ±0.101
3	Wiepjes	Belgium, Netherlands	2017	199	24 (21-31)†	Spine 1.028 ±0.121 vs. 1.037± 0.122 Total hip 0.951 ±0.116 vs. 0.962± 0.117 Femoral neck 0.836± 0.115 vs. 0.832±0.1
4	Pelusi	Italy	2014	15	30.9 (27.9-33.9)‡	Spine 1.07 (0.96-1.19) vs. 1.03 (0.94-1.13)
				15	29.4 (26.6-32.1)‡	Total hip 1.13 (1.07-1.19) vs. 1.13 (1.05-1.19)
				15	28.2 (25.6-30.8)‡	
5	Haraldsen	Norway	2007	21	25.1 (4.8)	Mean change at the lumbar spine: 0.01 Mean change at the total hip: -0.002
6	Turner	USA	2004	15	37.0 (3.0)‡	*7.8% increase in hip BMD at two years 0.984 ±0.05 g /cm ² -1.060 ± 0.04 g /cm ² ; 3.1% increase in spine BMD at two years
7	Van Kesteren	Netherlands	1998	19	25.0 (16-39)‡	1.04 ±0.12 vs. 1.08 ±0.12 at one year
8	Mueller	Germany	2010	45	30.4 (9.1)	Hip 1.07 (0.12) vs. 1.08 (0.12)* Spine 1.22 (0.14) vs. 1.23 (0.13)*
9	Broulik	Czech Republic	2018	35	47 (4) vs 48.2 (4)	No data
10	Reutsche	Switzerland	2005	15	34.3 (5.6)‡	No data
11	Van Caenegem	Belgium	2012	50	37 (8)	No data
12	Miyajima	Japan	2012	18	33.4 (5.3)	No data
				32	33.7 (5.5)	No data
13	Schlatterer	Germany	1998	10	39.9	No data
14	Goh & Ratnam	Singapore	1997	5	22-37*	No data
				27	25-39*	No data
				32	NS	No data
15	Lips	Netherlands	1996	15	30 (6.1)	No data

*Statistically significant. BMD is expressed as g/cm²
 **0 to indicate at time of study (not before start of treatment). †Data presented as range only. ‡Data presented as median (IQR). §Data presented as mean (95% CI)
 ¶Data presented as mean (SEM) ††Data presented as mean (range) †††Data presented as median and median absolute deviation (MAD) ††††Data presented as median only.
 Abbreviations: CHT – cross-sex hormone treatment (ie. testosterone) SARI – 5-alpha reductase inhibitor AI – aromatase inhibitor
 LS – lumbar spine HIP – total hip WB – whole body R – radius TG – transgender TS – transsexual

P858 INCIDENCE OF HIP FRACTURE IN A TERTIARY REFERRAL CENTER, MALAYSIA

J. F. Leong¹, M. A. Sharkawi¹, K. B. Levin¹, M. A. Mohd-Ariff¹, M. K. Yin², A. M. Sabarul¹

¹Department of Orthopaedic and Traumatology, Faculty of Medicine, University Kebangsaan Malaysia, ²Department of Pharmacy, University Kebangsaan Malaysia, Wilayah Persekutuan Kuala Lumpur, Malaysia

Objective: Hip fracture is an osteoporosis related fracture with significant consequences for the individual and the society. There is a wide variation in the incidence of hip fracture in the different regions of the world. Aim of the study was to identify incidence of hip fracture and management in our tertiary university hospital, Malaysia

Method: It is a prospective study from 1 January 2017 to 31 December 2017. Patients admitted to our tertiary care hospital with hip fracture were identified from the admission registry. The diagnosis and demographics data were recorded. Patients who had fracture following severe trauma or known to have malignancy and atypical fracture were excluded from the study.

Results: A total of 144 (45 male and 99 female) were identified with hip fracture. Majorities were from Chinese ethnicity of 95 (66%) patients followed by Malay 42 (29%) patients and Indian 7 (5%) patients. There were 71 patients sustained extracapsular hip fracture and 73 intracapsular hip fractures. 91 patients (63%) had

surgical intervention and 53 (37%) were treated conservatively. The average number of days from admission to surgery was 8 d and average length of stay was 15 d. There were 4 (3%) inpatient mortality before operation.

Conclusion: Most reliable hip data incidence in Malaysia are from 1996 and 1997, where those over 50 y was 90 per 100,000 individuals per year (1). The inpatient hospital cost for hip fractures in 1997 was estimated to be 6.8 million USD (RM 22 million), not including rehabilitation or nursing care costs. With an ageing population, hip fracture numbers and cost are expected to increase. Hip fractures registries are a good way to improve knowledge about this condition and its quality of cares. It also can provide a unique opportunity to compare how healthcare systems of different countries are responding to the same clinical challenge.

Reference: 1. Lee J-K and Khir ASM. *Int J Rheum Dis* 2007;10:300.

P859

ROLE OF SHOCKWAVE THERAPY IN IMPROVING JOINT FUNCTION IN PATIENTS WITH SPASTICITY

C. Bostina¹, D. V. Caimac², A. M. Bumbea², M. Borcan³, B. S. Bumbea¹, A. Mustescu², A. Florescu¹, C. Albu⁴, I. C. Resceanu⁵, R. Traistaru⁴, A. Bighea⁴

¹Emergency County Hospital, Craiova, ²University of Medicine, Craiova, ³Neuropsychiatry Hospital, Craiova, ⁴University of Medicine and Pharmacy, Craiova, ⁵University of Craiova, Craiova, Romania

Objectives: Extracorporeal shock wave therapy is a noninvasive method of treatment which consists in applying shock waves directly to the affected area, thus an acceleration of tissue regeneration is achieved with an improvement of circulation through muscles and tendons and reducing the tissue tension. The aim of the study is to highlight the role of extracorporeal shock wave therapy in patients with varying degrees of spasticity after stroke by restoring the correct posture of affected limbs and improving the joint function.

Method: The study included 50 patients. All of them presented on admission a 3rd grade spasticity on the Ashworth scale. Patients were divided into two groups: group A patients followed treatment with central myorelaxants and group B patients received, additional to the drug therapy, shockwave therapy aiming towards spastic muscles. The patients were evaluated, initially and after 3 weeks, with VAS scale of limb pain, Ashworth spasticity scale and 6MWD scale.

Results: The evaluations revealed that the pain was decreased by 25.2% more at the patients from B group comparing with the first group. Spasticity remained unchanged in the first week, and at the final assessment we observed an improvement of 32.4% at the patients from group B. The walking distance measured by 6MWD scale also had an improvement of 13.4 more meters at patients from group B who received shockwave therapy

Conclusions: Shockwave therapy has been proved to be beneficial in reducing spasticity in patients with stroke in combination with drug therapy. In addition to therapeutic use, we must highlight that it is a noninvasive, easy to use method with insignificant side effects.

P860

BODY MASS INDEX IS ASSOCIATED WITH IMPROVED BONE MINERAL DENSITY: EVIDENCE FROM AN IRISH POPULATION

R. Sullivan¹, S. Khan¹, M. Rafferty¹, N. Fallon¹, G. Steen¹, C. O'Carroll¹, N. Maher¹, R. Lannon¹, J. B. Walsh¹, K. McCarroll¹

¹Mercer's Institute For Successful Ageing (MISA), Department Of Medicine for the Elderly, St James Hospital, Dublin, Ireland

Objectives: Recent studies have challenged the traditional view that high BMI is protective against osteoporosis, particularly in people with a BMI ≥ 40 kg/m² (1). Our aim was to establish the relationship between BMI and BMD in patients attending a Bone Health Clinic and to explore the association in the very obese.

Methods: Data was obtained from a database of patients attending a tertiary Bone Health Clinic from 2003-2018. We analysed the relationship between BMI and BMD at AP spine, total hip and neck of femur and in a subgroup with BMI > 40 kg/m². We also looked at the relationship between vertebral fractures and BMI.

Results: We identified 4740 patients; mean age was 66.97 years and 1319 (27.8%) had ≥ 1 vertebral fractures. There was a positive correlation between BMI and BMD at all sites: total hip ($r=0.44$, $p<0.0001$), AP Spine ($r=0.128$, $p<0.0001$), femoral neck ($r=0.291$, $p<0.0001$), independent of age. In those with BMI > 40 kg/m², there was a negative trend between BMI and BMD at all sites ($r=-0.266$, $p=0.155$). In addition, patients with vertebral fractures were more likely to have a higher BMI ($p=0.01$).

Conclusions: This study confirmed that BMI is associated with greater BMD. This effect was particularly pronounced in total hip BMD, possibly reflecting the protective effect of weight-bearing. This protective effect of BMI may be lost in those who were very obese. Higher BMI was associated with a greater prevalence of vertebral fractures, a relationship previously noted in a number of small studies (2), but not before demonstrated in a study of this size (3).

References:

1. Oldroyd A et al. *Int J Clin Pract* 2014;68:771.
2. Pirro M et al. *J Bone Miner Metab* 2010;28:88.
3. Compston JE et al. *Am J Med* 2011;124:1043.

P861

NEUROLOGICAL EVENTS POSTSYNTHETIC REMISSION THERAPY AND BIOLOGICAL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS

M. Borcan¹, D. V. Caimac², C. Bostina³, B. S. Bumbea³, A. Mustescu², A. Florescu³, I. C. Resceanu⁴

¹Neuropsychiatry Hospital, Craiova, ²University of Medicine, Craiova, ³Emergency County Hospital, Craiova, ⁴University of Craiova, Craiova, Romania

Objectives: Rheumatoid arthritis benefits from modern therapies that have greatly reduced disease progression. Of these, the most important are biological therapies. We aim to assess neurological risk in a cohort of patients with rheumatoid arthritis over 2 y in DMARDs therapy and biological therapy.

Method: 95 patients were enrolled in the study who were in 2-y treatment, 50 patients with biological therapy and were initially evaluated neurologically at 1 y and 2 y, and the group of patients with remission therapy, 45 patients: 23 patients treated with leflunomide and 22 patients treated with methotrexate. The biological therapies used included chimeric anti-TNF α 5 antibodies, partially humanized anti-TNF receptor α 23 antibodies, fully immunized anti-TNF α 12 antibodies and anti-CD4-10 antibodies. Patients were clinically evaluated, imaging skull and electrophysiological electromyography.

Results: Clinical evaluation revealed 23 neurological clinical events in group with DMARDs (paraesthesia-6, dizziness-9, headache-5, superficial sensitivity-3, sensory-motor-2 neuropathy). The group of patients in biological therapy presented only 12 clinical events (paraesthesia-2, headache-4, dizziness-6, visual disturbances -4 disorders, superficial sensitivity disorders-1, deep-sensitivity disorders-1). MRI imaging has evolved into the group in biological therapy 9 cases with nonactive demyelinating lesions, 5 cases with mild cortical atrophy. The DMARDs treatment group presented only 1 cases of cortical atrophy without demyelinating lesions. The electrophysiological evaluation revealed 11 cases of changes in sensory nerve speed in patients with remission therapy and 2 cases of reduction of nerve speed motors. The biological treatment group had only 2 cases of sensory nerve speed reduction.

Conclusions: Although neurological manifestations have existed in both groups, a profile of neuropathic affections in patients with synthetic remission therapy DMARDs is configured, and in those who undergo biological treatment, the prevalence of central lesions but without clinical expression is established.

P862

OSTEOPOROSIS AND OSTEOPOROTIC BONE FRACTURES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

V. Zivkovic¹, B. Stamenkovic¹, S. Stojanovic¹, B. Radovanovic Dinic²

¹Institute for Treatment and Rehabilitation "Niska Banja", ²Clinical Centre Nis, Clinic of Gastroenterology and Hepatology, Nis, Serbia

Objective: Osteoporosis and osteoporotic bone fractures significantly contribute to the morbidity and mortality in patients with systemic lupus erythematosus (SLE). It is thought that inflammation is an important predictor of increased bone fragility due to the action of inflammatory mediators, factors involved in a disturbed immune system, and bone remodeling. The activity of a chronic inflammatory disease could be one of the principal factors of osteoporosis in SLE patients, and suppression of the inflammation and disease remission is important for the prevention of osteoporosis, among other things. Our aim was to examine BMD in SLE patients, prevalence of osteoporotic fractures and association of BMD with disease activity, organ damage and quality of life.

Methods: The study involved 105 SLE patients, hospitalized at the Clinic of Rheumatology, Institute Niška Banja, in whom the diagnosis was made based on the revised ACR criteria (1997 update). In addition to a clinical examination, in all enrolled patients the disease activity was evaluated using the *Systemic Lupus Erythematosus Disease Activity Index* (SLEDAI), organ damage was evaluated using the SLICC/ACR damage index (SDI), quality of life using the *Medical Outcome Survey Short Form 36* (SF-36). The measurement of BMD of the lumbar vertebrae L1-L4 and the hip was performed using DXA on the Hologic x-ray system. Osteoporosis and osteopenia were determined based on the 1994 definition by the WHO.

Results: The studied group involved 94 women (89.52%) and 11 men (10.48%) aged on the average 45.04 ± 10.49 y. Their average disease duration was 10.26 ± 8.34 y. Normal bone density was found in 27 patients (25.71%), osteopenia in 66 (62.86%), and osteoporosis in 12 patients (11.43%). Fifteen patients (15.29%) had osteoporotic fractures, out of which 12 (80%) had BMD values corresponding to osteopenia, and 3 (20%) patients the values corresponding to osteoporosis. The subgroups with osteopenia and osteoporosis had significantly longer disease duration compared to those with normal BMD ($p < 0.05$). The patients from the group with osteoporosis had significantly higher prednisolone doses in their therapy ($p < 0.05$) compared to the subgroup with normal BMD. There were no significant differences in the activity of their disease measured by SLEDAI between the studied subgroups, nor between the patients with osteoporotic fractures and those without osteoporotic fractures. There was a negative correlation between BMD values at the level of L1-L4 vertebrae and damage index ($r = -0.236$, $p < 0.05$), and positive correlation with quality of life: physical health ($r = 0.224$, $p < 0.05$), mental health ($r = 0.208$,

$p < 0.005$), and general health ($r = 0.209$, $p < 0.05$). BMD at the level of the hip did not demonstrate correlation with any of the studied parameters.

Conclusion: Lower BMD values in SLE patients are associated with longer disease duration, higher doses of prednisolone, higher organ damage index and poor quality of life. The SLEDAI activity index in this studied group did not show any correlation with BMD. Spine BMD measurement in SLE patients is a better indicator of bone changes and bone fragility compared to hip BMD measurement.

P863

TWO CASES OF OSTEOPETROSIS: PRESENTED WITH AND WITHOUT FRACTURE

D. Gogas Yavuz¹, O. Elbasan¹

¹Marmara University School of Medicine, Istanbul, Turkey

Objective: Osteopetrosis is a very rare metabolic bone disease usually is not associated with fracture. Here we report two consequent osteopetrosis cases one presented with fracture the other with loss of hear.

Case 1: 28 years old male patient diagnosed osteopetrosis during childhood with bone biopsy, no mental disorder and fracture history. He complains bilateral progressive hear loss for the last 3 y. He referred to our endocrinology clinic to rule out Paget disease of bone. His physical examination reveals large head appearance. There was no feature and family history of bone disease His bone scintigraphy reported diffuse osteoblastic activity increased in scalp and bilateral extremity periosteal reaction associated with hypertrophic osteoarthropathy. Mix type hear loss was detected. Biochemistry test results were calcium (Ca) 9.7 mg/dL (N:8.8-10.6), phosphor (P) 2.6 mg/dL (N:2.4-4.4), 25(OH)vitamin D 20.94 ng/mL (N:30-100), PTH 42.1 pg/mL (N:15-65), alkaline phosphatase (ALP) 99 U/L (N:30-120), C-telopeptide (CTx) 0.73 ng/mL (N:0.12-0.95) and osteocalcin 0.48 ng/mL (N:0.4-8.2). DXA showed that increased BMD levels (L1-L4 BMD 2.778 g/cm². Z-score 13.6; femur neck BMD 2.779 g/cm². Z-score 13.6).

Case 2: 52 years old women diagnosed osteopetrosis by genetic testing during childhood . She has a history of multiple hip, arm fractures for the last 15 y and a recent mandible fracture after teeth extraction. Her aunt and cousin had a clinical diagnosis of osteopetrosis. She complained purulent secretion from skin fistula on left mandibular area after teeth extraction. Plastic surgery refer to our endocrinology clinic for the further evaluation. She was on armchair due to the defects of left arm and leg. Mandibular asymmetry and left mandibular skin fistula was observed. Biochemistry exam was in normal range except elevated alkaline phosphatase level. (Ca 10.2 mg/dL, P 4.7 mg/dL, PTH 34 pg/mL, ALP 168 U/L, CTx 0.19 ng/mL, osteocalcin 5.45 ng/mL). Bone scintigraphy reported increased osteoblastic activity in cranium, bilateral proximal humerus and left femur right 9. costa and 11.costa. DXA showed showed that increased BMD levels (L1-L4 BMD 2.758 g/cm² T-score 13.0. Z-score 14.0; femur neck BMD 2.109 g/cm², T-score 9.7 Z-score 10.4). Antibiotic treatment was modified for mandibular osteomyelitis.

Conclusion: Although osteopetrosis known as a stable disease osteopetrosis patients need lifelong follow-up for complications including fracture and osteomyelitis.

P864

VITAMIN D AND CALCIUM LEVELS IN SARAJEVO CANTON CHILDREN FROM 8-12 YEARS OF AGE WITH VERIFIED SPINE DEFORMITIES

S. S. Saric¹, Z. A. Zubovic²

¹Canton Sarajevo Health Institute - CBR Saraj Polje, ²Canton Sarajevo Health Institution - CBR Saraj Polje, Sarajevo, Bosnia-Herzegovina

Objective: Vitamin D and calcium play an important role in the formation of bone tissue inciting osteoblasts to develop increased quantities of osteocalcin – bone proteins and alkaline phosphatases. Optimum vitamin D and calcium levels, especially during the stage of fast growth and development of children, play a decisive role in the proper mineralization, maturation, bone tissue formation and in the reduction of risk factors concerning bone tissue deformities. Our aim was to establish serum vitamin D and calcium levels in the Sarajevo Canton area children from 8-12 y of age with diagnosed spine deformities.

Method: The research involved 121 children, their age ranging from 8-12 y. They were diagnosed some of the spine deformities, verified both clinically and by x-ray images. as well as treated in CBR Saraj Polje within the period from 1 October 2017 to 1 October 2018. To all the patients total serum vitamin D and calcium concentration as well as body weight index were verified.

Results: The research group covered 121 children, of which 56% (68) were girls and 44% (53) were boys of 10.3 average age. Average D vitamin level in the quoted group amounted to 28.5 ng/ml, with the variable ranging from 11.2-51.2 ng/ml, whereas the average level of BMI amounted to 18.02 kg/m², the variable ranging from 14.0-25.4 kg/m². Insufficient D vitamin level was registered in 56.4 (68) children. Average D vitamin level in the quoted group amounted to 21.7 ng/ml, the variables ranging from 11.2-29.8 ng/ml. Average BMI level of the group amounted to 17.14 kg/m². The group of children consisted of 77.3% (53) girls, with the average D vitamin level of 20.8 ng/ml, and of 22.7% (15) boys with the average D vitamin level of 24.9 ng/ml. The most frequent spine deformity in the group was scoliosis vertebrae lumbalis sinistroconvexa, diagnosed in 41% (28) children of the group. Calcium serum levels in all the patients were within referential levels, with variables ranging from 2.20-2.51 mmol/L, the average amounting to 2.34 mmo/L.

Conclusion: The above research showed that the children between 8-12 y of age with diagnosed spine deformities exhibit insufficient D vitamin levels, 56.4% of them requiring therapeutic intervention, adjusted to their exclusive individual needs and strict follow-up. Also, the above results require serum vitamin D follow-up in the fast growing and development stage of the children in order to prevent vitamin D insufficiency in the children of the quoted ages.

P865

EPIDEMIOLOGY OF RHEUMATIC DISEASES IN KAZAKHSTAN

B. Issayeva¹, M. Saparbayeva¹, S. Issayeva¹, G. Dalibayeva¹

¹Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan

Objective: Diseases of the musculoskeletal system and connective tissue (DMSCT) are on the leading position on the negative impact on society. The aim of this study was to analyze the number of cases and prevalence of major rheumatic diseases (RD) in Kazakhstan.

Methods: The incidence and prevalence of RD according to the official medical statistical report (form No.12, Medinform) of Kazakhstan for 2012-2017 was analyzed.

Results: The proportion of DMSCT in the overall morbidity structure of the country's population was 4.9% (2017). The total number of patients with DMSCT in 2017 was 941,629, of which 364,762 were first identified (5220.4 and 2022.2 per 100,000 of the whole population, acc.). The increase rate was 33.1%. The greatest proportion (19.2%) in the structure of RD had osteoarthritis (OA). The prevalence of OA increased 2.7 times for this period from 365.4 per 100,000 (61,355 cases) to 1002.6 per 100,000 population (180,849 cases). 70.2% of patients with OA were women (2017). The number of patients with rheumatoid arthritis was increased 1.8 times: in 2012 – 40,158 (239.2 per 100,000 of population), in 2017 – 73,826 cases (409.3/100,000). 76.2% of patients were women (2017). The number of patients with systemic pathology of connective tissue was increased 1.3 times during the analyzed period: in 2012 – 7,421 (44.2 per 100,000 population), in 2017 – 9,661 cases (53.6/100,000), of which 81% were women. From this group, patients with systemic lupus erythematosus (SLE) are distinguished. In 2012 - 2,732 (16.3 per 100,000 population), in 2017 - 4,448 patients (24.7/100,000) with SLE were identified and the number was increased 1.5 times for this period. Patients with osteoporosis in the adult population have been registered only in recent years: in 2012 – 1,129 patients (9.6 per 100,000 of adult population), of which first diagnosed - 307 cases (2.6/100,000 of adult population), in 2017 – 1,526 patients (12.4/100,000) and 456 cases (3.7/100,000), acc. The prevalence of acute rheumatic fever decreased 4.8 times for the analyzed period: in 2012 – 5,245 cases (31.2 per 100 thousand of population), in 2017 – 1,181 (6.5/100,000) were identified, of which the diagnosis was first established in 1,035 (6.2/100,000) and 645 patients (3.6/100,000, respectively). The number of patients with rheumatic heart disease was decreased 1.6 times: in 2012 – 33,361 (198.7/100,000), in 2017 – 22,422 cases (124.3 per 100,000 population), but the incidence was still high - 15.3 per 100,000 population (2017).

Conclusion: The analysis of the incidence and prevalence rates of rheumatic diseases suggests that the social significance of the problem remains. High growth rates of major rheumatic diseases may be associated with improved diagnostics, but require further improvement of specialized care, the use of innovative technologies in the early diagnosis and treatment of patients.

P866

HUMOR AS PSYCHOLOGICAL STRENGTH IS ASSOCIATED WITH LESS PAIN INTENSITY INDEPENDENT OF CLINICAL AND RADIOLOGICAL SEVERITY OF KNEE OSTEOARTHRITIS

C. M. L. Lau¹, C. K. J. Cheng², C. H. J. Fan³, H. W. Lau², S. H. P. Yung¹, Y. H. Hung³, W. K. J. Chan², K. W. K. Ho¹

¹Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, ²Department of Psychology, The University of Hong Kong, ³Department of Orthopaedics & Traumatology, Alice Ho Miu Ling Nethersole Hospital, Hong Kong, China

Objective: Positive psychology interventions have been shown to be effective in improving psychological and physical wellbeing in general populations and patients with chronic pain. The goal of the current exploratory cross-sectional study is to identify psychological strengths that can be targeted in patient with osteoarthritis (OA) for subsequent development of positive psychology interventions.

Methods: A consecutive 147 OA patients referred to a joint replacement center participated in this study. They complete a questionnaire measuring their psychological strengths and emotional experience. Radiographs of knee were taken and physical examination of the knee were performed and also quantified with Knee Society Score and Oxford Knee Score.

Results: Correlational analysis revealed that humour, a psychological strength, is significantly correlated with both psychological (increased positive emotional experience, $r=.31$, $p<.01$) and medical (decreased perceived pain intensity, $r=-.29$, $p<.01$) outcomes. In subsequent hierarchical regression analyses, we found that humour has significant incremental predictability even after controlling for the disease severity (radiographic Kellgren-Lawrence grading, range of movement, alignment, and knee scores), emotional experience, and demographical measurements ($r^2=.09$, $p<.01$).

Conclusion: Our results are the first to show that people with higher humour have less pain intensity, independent of clinical and radiological severity of knee osteoarthritis. This study suggests that humor could be a potential therapeutic target for chronic pain associated with knee osteoarthritis and further studies to investigate its biological pathway (like change in endorphins level) and using positive psychology interventions to cultivate humor in OA patients for pain relief are warranted.

P867

IS CALF CIRCUMFERENCE A VALID CLINICAL MEASURE FOR EVALUATING MUSCLE MASS IN THE ELDERLY?

M. Tsekoura¹, E. Billis¹, E. Tsepis¹, C. Matzaroglou¹, M. Tyllianakis², E. Panagiotopoulos², J. Gliatis²

¹Technological Educational Institute of Western Greece, Physiotherapy Department, Aigio, ²University Hospital of Patras, Department of Orthopaedics Surgery, Rio, Greece

Objective: Sarcopenia, resulting from reduced skeletal muscle mass is associated with aging and is a major public health consideration for its functional consequences. Calf circumference (CC) measurements, which are simple to obtain and noninvasive, have been used as a tool for assessing nutritional status and muscle mass in general population. The aim of this study was to explore whether calf circumference and its cutoff values are a valid tool for assessing muscle mass in the elderly.

Methods: The study's cohort consisted of community-dwelling Greek elderly recruited from two sites; the University Hospital of Rio, Greece and the laboratory of Technological Educational Institute of Western Greece. Muscle mass was assessed using bioelectrical impedance (BIA) analysis. Calf circumference was measured with inelastic tape with the elderly participants in the upright position, with feet 20 cm apart. CC was measured at the calf's greatest girth. The receiver operating curve (ROC) analysis was performed to determine cutoffs of CC.

Results: A total of 331 adults (females 248; males 83) aged 60-95 y (71.55±7.49) participated in the present cross-sectional study. Testing the validity of CC as a proxy marker for low muscle mass, an area under the curve (AUC) of 0.82 for males and 0.84 for females were found and their optimal cutoff values of CC were 34.5 cm for males and 33 cm for females. Skeletal muscle mass index (SMMI) were positively correlated with CC (males $r=0.53$; females $r=0.49$).

Conclusion: CC can be used as a measure for identification of muscle mass decrease in routine evaluations of the elderly in primary care. The suggested cutoff values of calf circumference for predicting low muscle mass are <34 cm in men and <33 cm in women.

P868

PREVALENCE OF VITAMIN D DEFICIENCY AND ITS DETERMINANTS IN PREDEFINED MYANMAR HEALTHCARE-USER POPULATIONS

M. W. Aung¹, Z. C. Pyone¹, T. Hlaing², E. Mitchell³, M. Aye⁴

¹Department of Endocrinology, University of Medicine 1, Yangon General Hospital, Yangon, Myanmar, ²Department of Chemical Pathology, University of Medicine 1, Yangon General Hospital, Yangon, Myanmar, ³Improving Global Health Fellow, Thames Valley & Wessex Leadership Academy, London, UK, ⁴Department of Endocrinology, Hull Royal Infirmary, Hull, UK

Objective: To determine the prevalence of vitamin D insufficiency (21-29 ng/ml) and deficiency (≤ 20 ng/ml), in at-risk groups compared to healthy volunteers in Myanmar.

Methods: We recruited 181 participants (age ≥ 45 y) in this cross-sectional study: Group 1 (n=60) with acute osteoporotic fragility fractures; Group 2 (n=60) outpatients who had prior fragility fractures (>6 weeks) and/or had clinical risk factors; Group 3 (n=61) age-matched healthy volunteers. Comparison is made for vitamin D (25OHD), calcium, phosphate, alkaline phosphatase, PTH after capturing demographic, dietary and lifestyle factors.

Results: Mean 25OHD concentrations were 19.83, 24.69 and 16.40 ng/mL for groups 1, 2 and 3. Group 2 (at-risk outpatients) had higher 25OHD compared to group 1 ($P=0.012$) and group 3 ($P=0.00$). Vitamin D deficiency (≤ 20 ng/mL) was found in 51.7%, 31.7% and 81.6% and insufficiency (21-29 ng/mL) in 40%, 46.6%, 11.7% for groups 1 to 3. Multiple logistic regression analysis after adjusting for covariates (age, sex, diet, exercise, smoking, alcohol) showed adjusted OR of 0.36 in group 2, 3.51 in group 3 compared to group 1 ($p<0.05$).

Conclusion: Vitamin D deficiency and insufficiency is common in Myanmar. Age, BMI and activity levels did not affect 25OHD in this study. Our findings mirror previous literature showing low 25OHD in Asian populations. Skin pigmentation, dietary choices and traditional clothing may be contributory. Healthy controls (group 3) were health professionals: their indoor urbanised work pattern may be relevant. More research is needed to inform strategies to optimise vitamin D status in Myanmar population.

P869

STANDARDIZED INCIDENCE OF OSTEOPOROTIC FRACTURES IN THE REPUBLIC OF KAZAKHSTAN

S. Issayeva¹, O. Lesnyak², B. Issayeva¹, A. Zakroyeva³, D. Dilmanova¹

¹Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan, ²Mechnikov North West State Medical University, St. Petersburg, Russia, ³Ural State Medical University, Yekaterinburg, Russia

Objective: There is scant information on the epidemiology of fracture in Kazakhstan. The aim is to determine the incidence of osteoporotic non-vertebral fractures in women and men aged 50 y and over in Kazakhstan based on regional data.

Methods: This study is the component of the international multi-center “Epidemiology of osteoporotic fractures in Eurasian counties” study (EVA). We carried out a population-based survey in Taldykorgan, which is representative to the entire country in terms of ethnicity, gender and age distribution. The low-energy nonvertebral fractures, in 2015-2016, retrospectively from hospital registers and in 2017 prospectively with the inclusion of information from primary care sources were identified.

Results: The annual age-standardized hip fracture incidence among people of 50 y and older was 338/100,000 for women and 226/100,000 for men, the distal forearm fracture rate reached 755/100,000 for women and 201/100,000 for men, humerus fracture incidence was 242/100,000 for women and 114/100,000 for men. These epidemiological data allow attributing Kazakhstan to high rank countries of osteoporotic fractures for men and women.

Conclusion: The Republic of Kazakhstan is in dire need in programs aimed at prevention, early detection and treatment of osteoporosis. These age- and sex-specific osteoporotic fracture incidences is going to incorporate into the ‘authentic’ FRAX model for Kazakhstan.

P870
VALIDATION OF THE FRACTURE RISK ASSESSMENT TOOL (FRAX) CALCULATOR IN TAIWAN: TWO COHORTS STUDY

C. H. Wu¹, F. W. Liang², I. T. Liu³, Y. F. Chang¹, L. C. Ou⁴, C. S. Chang¹, T. H. Lu⁵

¹Department of Family Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, ²Department of Public Health, College of Health Science, Kaohsiung Medical University, Kaohsiung, ³Department of Family Medicine, E-Da Hospital/I-Shou University, Kaohsiung, ⁴College of Education, National Kaohsiung Normal University, Kaohsiung, ⁵Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Objectives: In 2030, the aging population will reach to 20% in Taiwan. The incidence of osteoporotic hip fracture in Taiwan was 9th ranking in Worldwide and top one ranking in Asia-Pacific regions.

Taiwan FRAX® calculator was launched in 2010, but the appropriateness had never been validated by the long-term follow-up cohort.

Methods: The two cohorts including 776 (M/F=408/468) subjects aged 65 from Tianliao district in 2009-2010 and 1200 (M/F=524/676) subjects aged 40 and over from Douliou district in 2009-2010 were follow-up. The clinical risk factors (CRFs) for osteoporotic fracture were assessed along with DXA derived BMD to generate the baseline FRAX (with or without BMD) either major osteoporotic fracture (MOF) or hip fracture (HF) scores accordingly. We identified all claims records of outpatient clinic/emergency room visits or hospital admissions of patients from 2009-2016 in the Taiwan National Health Insurance Research Database (NHIRD). The primary outcomes were the rate of major fractures (vertebral, hip, upper arm, or wrist), hip fracture and non-hip fracture according to ICD 9.0 code. Pathological fractures and high-energy fractures were excluded.

Results: Of the 1573 subjects with completed data, the fracture rate of major fracture is 1.843% (1843/100,000 population) during 2009-2016. Using the cutoffs by MOF FRAX score ≥20% or HF FRAX score ≥3%, the fracture rate were significantly higher in high score group (either with or without BMD, MOF or HF) (The ratio of fracture rate between high and low score group were shown in Table).

	FRAX HF Score (without BMD) At 3%	FRAX HF Score (with BMD) At 3%	FRAX MOF Score (without BMD) At 20%	FRAX MOF Score (with BMD) At 20%
Hip Fracture	15.94	15.42	9.51	4.99
Non-Hip Fracture	2.91	4.03	1.85	7.22
Major Fracture	4.02	5.18	4.26	6.91

Conclusions: The 2010 Taiwan FRAX is preliminarily validated and the cutoffs of MOF at 20% and HF at 3% are acceptable. However, the different cutoffs might be needed to provide better discrimination of high risk patients in advance.

P871

APPLICATION OF FRAX® FOR THE DEVELOPMENT OF SPECIFIC INTERVENTION THRESHOLDS IN OSTEOPOROSIS TREATMENT IN RUSSIAN FEDERATION

E. N. Gladkova¹, O. M. Lesnyak², O. N. Anoshenkova³, V. A. Tavlujev³, K. Y. Belova⁴, I. B. Belousova⁵, O. B. Ershova⁶, B. V. Zavodovky⁷, I. V. Kryukova⁸, A. A. Latfullin⁹, N. V. Leonova¹⁰, I. A. Skripnikova¹¹

¹Mechnikov North-Western State Medical University, St. Petersburg, ²Mechnikov North-Western State Medical University, St. Petersburg, ³Medical Center Health Maximum, Tomsk, ⁴Federal State Budgetary Educational Institution of Higher Education "Yaroslavl State Medical University", Yaroslavl, ⁵Clinical Hospital 101 FMBA Russia in Lermontov, Lermontov, ⁶Federal State Budgetary Educational Institution of Higher Education "Yaroslavl State Medical University", Yaroslavl, ⁷Research Institute of Clinical and Experimental Rheumatology, Volgograd, ⁸Moscow Regional Research and Clinical Institute named M.F. Vladimirovskiy, Moscow, ⁹Medical center BarsMed, Kazan, Russia, ¹⁰Multidisciplinary Medical Clinic "Anturium", Barnaul, ¹¹National Medical Research Center Preventive Medicine, Moscow, Russia

Objective: To determine the reasonable treatment threshold for Russian Federation (RF).

Methods: The FRAX-based probabilities using Russian FRAX model were calculated in 3866 unselected postmenopausal women aged 50 y or more from 6 DXA centers from different parts of RF. Different intervention thresholds including a fixed threshold irrespective of age (20% for major osteoporotic fractures [MOF] and 3% for hip fracture [HF]), age-dependent (AD) thresholds (European and Russian thresholds based on the probabilities of MOF) and hybrid threshold (AD threshold with a transition to fixed thresholds of 20% for MOF and 4% for HF at 70 years and older) were tested. The proportion of women eligible for treatment using different intervention thresholds was calculated.

Results: In the sample tested the mean 10-y probability of MOF was 13.8%, HF - 2.4%. For fixed threshold 26.8% women aged 50 y or more were eligible for treatment, for Russian AD threshold (for MOF and HF) - 27.4%, for European AD threshold - 53.6%. For hybrid threshold (for MOF and HF) 31.8% women aged 50 y or more were eligible for treatment. The fixed thresholds (20% for MOF and 3% for HF) identified for treatment 12% of women aged 50-54 y and 72% in age group of 80 y and older. The use of AD thresholds identified very low proportion of women aged 80 y and older eligible for treatment: the European threshold found 5% and the Russian threshold - 18%. In contrast, in women aged 50-54 y 90% were eligible for treatment using the European threshold and 28.3% - using Russian threshold. The use of both Russian hybrid thresholds (MOF and HF) identified 28.3% of women aged 50-54 y and 64% in older age groups (85 y and older).

Conclusion: In Russian sample, combination of intervention hybrid thresholds for MOF and HF identified the most reasonable proportions of women in different age groups.

P872

COMPARISON OF JAW OSTEONECROSIS OCCURRENCE AFTER TOOTH EXTRACTION IN PATIENTS WITH AND WITHOUT BISPHOSPHONATE TREATMENT

V. Vyskocil¹, D. Hrusak², J. Jambura², L. Hauer², P. Posta²

¹Charles University Hospital Osteocentre Department of Medicine II, ²Charles University Hospital Department of Oral and Maxillofacial Surgery, Plzen, Czech Republic

The objective of the observation was to evaluate occurrence of the jaw osteonecrosis (ONJ) in osteoporotic patients in the Czech population. 75 patients mean age 62.67±8.66 with antiresorptive treatment longer than 3 y were observed. The patients were split according the type of medication: alendronate, ibandronate, risendronate, denosumab and combined antiresorptive treatment. Number of extracted tooth, severity of osteoporosis as a T-score in LS spine and hip and in case of longer therapy also the length of drug holiday in months was evaluated. Number of vertebral, hip and nonvertebral fractures before and during antiresorptive treatment, concomitant treatment with proton pump inhibitors or corticoids, occurrence of diabetes as a risk factor and atypical fractures as a treatment complication were also evaluated. The authors observed a frequency of OPG scans of jaw before beginning of treatment. There was no ONJ found. The set of 10.000 osteoporotic patients with tooth extraction and antiresorptive therapy shorter than 3 y or calcium and vitamin D supplementation was used as a control group. The set of 5.000 oncology patients after tooth extraction was used as the second control group.

The authors compared the incidence with own ONJ database, 24 women osteoporotic patients and 49 men oncology patients. The authors found no case of osteonecrosis when the patients were treated in University Clinic of Stomatology. All patients with ONJ were treated in other institutions and the University Clinic was involved in complication treatment after tooth extraction in non-university institutions. The most significant values of the statistical evaluation; age (mean 62.67, median 8.53) and duration of treatment completed (mean 9.17, median 8.53), reveal the "Most at risk patient". aged in the 7th decade with 10 y of treatment. The situation in oncology patients group was different. The preventive stomatology examination with antibiotic prophylaxis was not standardly used in patients with highly dosed short term antiresorptive therapy and concomitant antiangiogenic treatment.

P873

RESULTS OF TECAR THERAPY IN PATIENTS WITH ACUTE OR CHRONIC SHOULDER PAIN

I. R. Marcu¹, S. Patru¹, D. Matei¹, A. C. Bighea¹

¹University of Medicine and Pharmacy, Craiova, Romania

Objective: To investigate the effect of Tecar therapy on patients with shoulder pain. The device used is composed of a generator that distributes signals at a frequency 0.5 MHz at a maximum power of 300 W.

Methods: A total of 40 patients who applied to our clinic with acute or chronic shoulder pain and complied with the selection criteria were included in the study. The patients were randomly assigned into Group I ($n=20$, Tecar treatment) and Group II ($n=20$, control). In Group I, patients were given Tecar treatment and an exercise protocol for 10 sessions during a period of 2 weeks. The sessions were started with resistive treatment with an electrode positioned on the area to be treated for 10 min, followed by another 10 min with a capacitive electrode applied. In Group II, placebo Tecar therapy and the same exercise protocol was given for the same period. Patients were evaluated according to the parameters of pain, palpation sensitivity, algometric sensitivity and shoulder joint range of motion before and after treatment.

Results: Analysis of measurement results within each group showed a significant posttreatment improvement for some active and passive movements in both groups, and also for algometric sensitivity in Group I ($p<0.05-0.01$). Posttreatment palpation sensitivity values showed improvement in 17 patients (85%) for Group I and six patients (30%) for Group II. The majority of the patients in Group I expressed a reduction in pain evaluated on a visual analogue scale (VAS) and the changes were statistically significant in acute and chronic cases. Comparison between two groups showed superior results ($p<0.01$ and $p<0.001$) in Group I for the parameters of pain, passive extension and palpation sensitivity but no significant difference for other parameters.

Conclusions: The results of our study have shown better results in pain, palpation sensitivity and passive extension, but no significant improvement active range and algometric sensitivity in Tecar treatment group compared to the control group in the patients with shoulder pain.

P874

RAPAMYCIN IMPROVES BONE MASS IN HIGH-TURNOVER OSTEOPOROSIS WITH IRON ACCUMULATION THROUGH POSITIVE EFFECTS ON OSTEOGENESIS AND ANGIOGENESIS

A. F. W. Wang¹, J. D. W. Wu¹, Y. J. X. Xu¹

¹Department of Orthopedics, Second Affiliated Hospital of Soochow University, Suzhou, China

Objective: Iron accumulation is an independent risk factors of I type osteoporosis, and mTOR plays an important role on the crosstalk between osteogenesis and angiogenesis. Our aim was to identify the role of mTOR in the high-turnover osteoporosis with iron accumulation, the underlying molecular mechanism, and whether rapamycin can target at mTOR treating I type osteoporosis with iron accumulation effectively.

Methods: We establish mouse models of iron accumulation and transgenic mouse models (Hepc^{-/-}) of high-turnover type osteoporosis with iron accumulation to observe the variety of mTOR in these mice, and treat osteoblasts with FAC to watch mTOR in vitro. Then we injected rapamycin to mouse models of high-turnover osteoporosis with iron accumulation, transfected the FAC treated osteoblasts with mTOR relative siRNA and cultured HUVECs with

CM extracted from osteoblasts, to detect indexes of bone, osteogenesis and angiogenesis in bone and in vitro. Finally, relative biomarkers of cell signaling pathways were measured.

Results: We found the osteoblastic mTOR was activated both in mouse models of iron accumulation and high-turnover osteoporosis with iron accumulation, and the deteriorative bone, osteogenesis and angiogenesis induced by iron accumulation were improved by suppressing mTOR with rapamycin in mice and siRNA transfection in vitro. The mTOR/STAT1/Cxcl9 pathway signals were stimulated by iron accumulation in osteoblasts.

Conclusion: Our study shows that iron accumulation impairs the bone regeneration of osteoporosis via osteoblastic mTOR/STAT1/Cxcl9 pathway, and rapamycin can target at mTOR improving osteogenesis and angiogenesis in bone of high-turnover type osteoporosis with iron accumulation to increase bone mass.

P875

MATERNAL FOKL VDR POLYMORPHISM IS A DETERMINANT OF BOTH MATERNAL AND NEONATAL 25(OH)D STATUS AT BIRTH: A VALIDATION COHORT FROM NORTHERN GREECE

S. Karras¹, T. Koufakis¹, D. Goulis², C. Annweiler³, E. Dursun⁴, D. Gezen-Ak⁴, M. Grammatiki¹, E. Manthou¹, X. Tsekmekidou¹, P. Zebekakis¹, K. Kotsa¹

¹Aristotle University of Thessaloniki, Medical School, First Department of Internal Medicine, Division of Endocrinology and Metabolism, AHEPA University Hospital, Thessaloniki, Greece,

²Aristotle University of Thessaloniki, Medical School, First Department of Obstetrics and Gynecology, Unit of Reproductive Endocrinology, Thessaloniki, Greece, ³Angers University Hospital, Department of Neuroscience, Division of Geriatric Medicine, Angers, France, ⁴Istanbul University, Cerrahpasa Faculty of Medicine, Department of Medical Biology, Istanbul, Turkey

Objective: Accumulating evidence underlines the relationship between optimal 25-hydroxyvitamin D [25(OH)D] concentrations during pregnancy and normal fetal growth and development. We aimed to assess the role of VDR FokI (rs10735810) gene polymorphism as a determinant of maternal and neonatal 25(OH)D status in a Greek cohort of mothers and their children.

Methods: We studied 70 pairs of newly delivered neonates and their mothers at birth. Only healthy mothers with full-term, uncomplicated births were included in the study. VDR FokI polymorphism was assessed in mothers and children using polymerase chain reaction and restriction fragment length polymorphism analysis. Maternal and neonatal 25(OH)D levels were determined at the time of birth.

Results: Mothers' mean age, term BMI and gestational age were 31.9 ± 0.7 y, 29.6 ± 0.7 kg/m² and 38.8 ± 0.2 weeks, respectively. Both mothers and children were found to be vitamin D deficient [25(OH)D concentrations 45.6 ± 3.1 and 40.6 ± 2.6 nmol/l, respectively]. Maternal 25(OH)D concentrations were found to be positively correlated with neonatal 25(OH)D status ($p<0.001$). Maternal heterozygosity (Ff genotype) was significantly related to lower maternal and neonatal 25(OH)D concentrations ($p=0.02$

and $p=0.003$, respectively). In contrast, no significant association between neonatal VDR FokI status and neonatal 25(OH)D concentrations was observed.

Conclusions: Results from a vitamin D deficient maternal–neonatal cohort from Northern Greece, indicate a strong impact of maternal vitamin D status during pregnancy on neonatal 25(OH)D concentrations and suggest that this relationship is mediated by maternal polymorphisms in vitamin D regulatory genes. Further trials with larger sample sizes are needed in order to validate our findings, from this region.

P876

EFFECT OF ZOLEDRONIC ACID ON TRABECULAR BONE SCORE AND OTHER MARKERS OF BONE HEALTH IN HEART TRANSPLANTED PATIENTS

M. Rakusa¹, B. Vrtovec², G. Poglajen², M. Jensterle Sever¹

¹Department of Endocrinology, Diabetes and Metabolic Disease, University Medical Centre Ljubljana, ²Advanced Heart Failure and Transplantation Programme, Department of Cardiology, University Medical Centre Ljubljana, Ljubljana, Slovenia

Objective: Trabecular bone score (TBS) is understudied as a marker of bone health in heart transplanted patients. The aim of our pilot study was to evaluate the effects of zoledronic acid (ZA) on bone health including TBS in this population.

Methods: We included 13 treatment naïve (TN) patients (9 men, 4 women) and 9 patients (8 men, 1 woman) who already received at least one application of ZA (TR). All patients received cholecalciferol, alfalcidol and calcium supplements. We measured TBS, BMD, corrigated calcium (cCa), estimated glomerular filtration (eGF), c-terminal telopeptide (CTX), procollagen type I N propeptide (PINP), intact PTH (iPTH).

Results: Time from transplantation was 6.2 ± 5.4 months for TN and 76.1 ± 66.1 month for TR. In TR compared to TN, there were lower CTX 1151.9 ± 557.7 pmol/L; 2936.6 ± 1763.0 pmol/L; $p<0.009$), lower Ca (2.11 ± 1.0 mmol/L; 2.24 ± 0.7 mmol/L; $p<0.002$), and higher iPTH (83.6 ± 46.1 ng/L; 44.8 ± 18.9 ng/L; $p<0.017$). There were no significant difference in TBS (1.285 ± 0.08 ; 1.274 ± 0.13), lumbar BMD (0.935 ± 0.08 g/cm²; 0.901 ± 0.19 g/cm²), neck BMD (0.681 ± 0.09 g/cm²; 0.731 ± 0.14 g/cm²), hip BMD (0.846 ± 0.12 g/cm²; 0.893 ± 0.16 g/cm²), T-score on lumbar (-1.4 ± 0.7 SD; -1.6 ± 1.8 SD), neck (-1.7 ± 0.6 SD; -1.4 ± 1.0 SD) and hip (-1.0 ± 0.8 SD; -0.8 ± 1.0 SD), PINP (39.39 ± 13.53 ; 52.64 ± 44.33), and eGF (76 ± 14 mL/min/1.73 m²; 70 ± 18 mL/min/1.73 m²), between TR and TN. No patients had fractures in the time of observation.

Conclusions: CTX was significantly lower in TR than in TN. Lack of difference in TBS and BMD despite the longer exposure to corticosteroid and immunosuppressive treatment in TR compared to TN also implied a protective role of ZA on bone health after heart transplant. Our results indicated that treatment with vitamin D and calcium should be more intensively tailored when patients receive ZA to prevent secondary hyperparathyroidism. The role of TBS in this population needs further investigation.

P877

HOME TRAINING KINETIC PROGRAM FOR SECONDARY KNEE OSTEOARTHRITIS AFTER STROKE

A. M. Bumbea¹, M. Borcan², B. S. Bumbea³, R. Traistaru⁴, O. Rogoveanu¹, A. Mustescu¹, A. Florescu³, D. V. Caimac¹, C. Bostina³

¹University of Medicine, Craiova, ²Neuropsychiatry Hospital, Craiova, ³Emergency County Hospital, Craiova, ⁴University of Medicine and Pharmacy, Craiova, Romania

Objectives: Knee osteoarthritis is a common disease determinate by spasticity on the side of hemiparesis in patients with stroke.

Method: There were enrolled 58 patients with at least 2 y after onset of stroke and spasticity quantified by Ashworth scale in grade 2-3. The patients were divided into two groups. The first, control group, received myorelaxant and painkiller treatment, and the study group also received the same medication and a home training kinetic program for two months. The evaluations were made at enrolment point and after two months. The following parameters were evaluated: visual analogue scale (VAS), Ashworth scale, and WOMAC.

Results: There have been noticed significant changes in knee functionality in the study group. The pain assessed for the VAS was reduced in study group from 6.5 to 3.2, compared to the control group starting at 6.8 and reaching 5.4. Spasticity was reduced in the study group by 23.4% compared to the control group. The WOMAC score showed an improvement in the study group starting from a composite score of 127.3 and reaching 76.7, and the control group remained at values close to initial score, from 132.4 to 121.3.

Conclusions: It is proven that medication therapy to combat spasticity and pain, improves joint function, but the results are far superior if a sustained kinetic program is added.

P878

FRAILTY SYNDROME AND BONE HEALTH PARAMETERS IN OLDER ADULTS: RESULTS FROM BUSHEHR ELDERLY HEALTH PROGRAM (BEHP)

F. Sharifi¹, Z. Madadi¹, H. Fakhrzadeh¹, M. Arzaghi¹, G. Shafiee², R. Heshmat², A. Ostovar³, N. Mehrdad⁴, Z. Badrkhahan⁵, I. Nabipour⁶, B. Larijani⁴

¹Tehran University of Medical Sciences/Endocrinology and Metabolism Population Sciences Institute/Elderly Health Research Center, Tehran, ²Tehran University of Medical Sciences/Endocrinology and Metabolism Population Sciences Institute/Chronic Diseases Research Center, Tehran, ³Tehran University of Medical Sciences/Endocrinology and Metabolism Clinical Sciences Institute/Osteoporosis Research Center, Tehran, ⁴Tehran University of Medical Sciences/Endocrinology and Metabolism Clinical Sciences Institute/Endocrinology and Metabolism Research Center, Tehran, ⁵Tehran University of Medical Sciences, School of Medicine, Tehran, ⁶Bushehr University of Medical Sciences/The Persian Gulf Biomedical Sciences Research Institute/The Persian Gulf Marine Biotechnology Research Center, Bushehr, Iran

Objectives: frailty is a chronic condition was accompanied by several health conditions such as mortality and hospital admission. The association between frailty and bone health included osteoporosis and low trabecular bone score (TBS) has not been cleared yet. Our objective was to assess the association between frailty and bone health in the elderly.

Methods: The sample of this cross-sectional study was elderly ≥ 60 y that was selected from a city in the south of Iran, using a multistage stratified cluster random method. Demographic and medical history data were gathered using expert approved questionnaires. Anthropometric indices were standardly measured. BMI calculated by dividing of weight by square of height. Two times systolic and diastolic blood pressure were measured according to guidelines. Bone densitometry and TBS were assessed by a DXA device on lumbar spines and neck of femurs. Osteoporosis was defined as T-score ≤ -2.5 in each of the mentioned sites. Fasted blood sample was collected and fasting blood sugar, HbA1C were measured by auto-analyzer. Diabetic Mellitus and hypertension were defined using standard guidelines. Univariate and multivariable logistic and linear regression models were used to evaluate the associations.

Result: After removed the missing data of 2233 subjects were analyzed. The mean age of the participants was 69.2 (69.0 - 69.5) y and 51.5% of them were female. The prevalence of osteoporosis was 30.5% (28.6% - 32.5%). that more common in elderly women than men [44.4% (41.5% - 47.3%) in women vs. 15.9% (13.8% - 18.2%) in men]. The mean of TBS had a decreasing trend from non-frails to frails subjects. In the univariate model, there is a strong association between frailty and osteoporosis [odds ratio (OR) 4.57; 3.29 - 6.36]. The relationship between frailty and osteoporosis remind significant after adjustment for age, gender, BMI, smoking, and alcohol consumption (OR of prefrailty=1.33;

1.05 - 1.68, OR frailty: 1.67; 1.08 - 2.58). Moreover, prefrailty and frailty had a negative association with TBS in multivariable linear models ($\beta = -0.06$, $P = 0.002$ and $\beta = -0.08$, $P < 0.001$, respectively).

Conclusion: The frailty syndrome is a predisposing factor for several health outcomes. Moreover, it may accompany by the worse bone health parameters in elderly.

P879

HEPCIDIN IMPROVES POSTMENOPAUSAL BONE LOSS BY INHIBITING OSTEOCLAST FUNCTION

H. Zhang¹, Y.-J. Xu²

¹Department of Orthopaedics, The Second Affiliated Hospital of Soochow University, ²Department of Orthopaedics, The Second Affiliated Hospital of Soochow University, Suzhou, China

Objective: To explore the effect of hepcidin on bone mass in postmenopausal osteoporosis.

Methods: The study consisted of two stages. In the first, collecting the data of physical examination population (all female) age from 55-74 y and serum samples which were used to examine hepcidin PINP and β -CTX by ELISA. In the second, 8-week-old female mice were divided into Sham operation (Sham), ovariectomized (OVX) and ovariectomized + hepcidin overexpression group (OVX+Hamp). The OVX+Hamp group mice were hepcidin conditional overexpression. Both OVX and OVX+Hamp mice had bilateral ovaries removed to establish postmenopausal osteoporosis mice model. The three group mice received intraperitoneal injection of tamoxifen after 1 week of surgery to induce hepcidin overexpression. Another 8 weeks later, levels of hepcidin, serum ferritin, and CTX were detected by ELISA. MicroCT was used to detect bone microstructure; Prussian blue staining to observe liver and bone iron deposition; TRAP staining to observe osteoclasts; bone pits experiment to evaluate osteoclast capacity of bone resorption; q-PCR to test the expression levels of osteoclast associated genes.

Results: Physical examination data shows a linear correlation between hepcidin and BMD ($r = 0.45658$, $p = 0.0058$), a linear correlation between hepcidin and β -CTX ($r = -0.35244$, $p = 0.0479$), but no linear correlation between hepcidin and PINP ($p = 0.8776$). BMD in OVX+Hamp mice improved compare to OVX group. Serum hepcidin and liver iron in OVX+Hamp group were higher than those in other two groups, but serum ferritin, bone iron deposition and CTX were decreased. Next, we turned to cells committed to the osteoclast phenotype, we found the number of TRAP-positive osteoclasts derived from bone marrow and in the distal femur and bone resorption area proportion were significantly increased in OVX group while suppressed in OVX+Hamp group. In vitro experiments revealed that hepcidin overexpression significantly inhibited osteoclastogenesis by inhibiting cell metabolism and regulation of osteoclasts, such as MMP9, CTSK, and TRAP, mRNA expression.

Conclusions: Hepcidin slows bone loss and improve bone metabolism in postmenopausal women or ovariectomized mice by suppressing the differentiation and resorption capacity of hyperactive osteoclasts.

P880

PERSPECTIVES OF WOMEN WITH EXPERIENCE OF A FRAGILITY FRACTURE IN EUROPE: ATTITUDES TOWARDS FUTURE FRACTURE RISK, OSTEOPOROSIS AND PHARMACOTHERAPY

C. Chaine¹, P. Ray¹, J. Timoshanko²

¹AplusA, London, ²UCB Pharma, Slough, UK

Objective: Fragility fractures (FF) are common in women >50 y, with 1 in 3 experiencing a fracture (Fx).¹ However, the cause of these Fx is poorly recognised and measures taken to prevent future Fx are often inadequate. Recent US patient (pt) survey data suggest that awareness of osteoporosis (OP) and its contribution to Fx risk, appreciation of the benefits of OP pharmacotherapy (Rx), and discussion about OP with healthcare professionals (HCPs) are limited.² This study gained insight into the attitudes and experiences of post-FF women in Europe regarding future Fx risk management.


Methods: Women ≥51 y from Germany (DE), Spain (ES), UK, France (FR) and Italy (IT) (EU5) with self-reported experience of a FF completed a 30min online survey (AplusA; 13–20 Feb 2018). Data are reported for EU5 pts who had their first Fx at ≥50 y; pts whose first Fx was a hand/finger or ankle/foot/toe Fx were excluded.

Results: 199 women participated (DE: 38; ES: 36; UK: 41; FR: 34; IT: 50). The most commonly experienced Fx was of the lower arm/wrist (43%). 43% reported >1 Fx (any type). Most women discussed bone health with an HCP within 6 months (mo) (70%; 42% with a GP) and HCPs were their primary source of information on OP (85%). Around a third reported taking a DXA test within 6 mo of their first FF (37%). Advice from HCPs to prevent Fx focused on calcium/vitamin D supplements (74%) and diet/exercise changes (54%); 46% were prescribed OP-Rx. After having a FF, around half worried about future Fx (51%) and 39% voiced concerns about their general health (Figure). A third of pts thought that OP had caused their Fx (33%), most were likely to attribute it to a fall (67%). Only 18% felt empowered to manage their bone health; 61% did not think OP-Rx reduces risk of Fx or were unsure. 97% had never joined a support group.


Conclusions: These results indicate that pts discuss future Fx risk with an HCP soon after having a FF and are concerned about future Fx. However, low levels of DXA testing and OP-Rx, and poor awareness of the link between OP and Fx risk remain. Better education to empower women at risk of FF is critical.

Figure: Women in Europe [a] who have experienced a FF [b] are concerned about future Fx and their long-term health (n=199)

A) Perceived greater likelihood of another Fx if already experienced one



B) Feelings experienced since first Fx



[a] Countries included: Germany, Spain, UK, France and Italy; [b] Fx included: lower arm/wrist (43%), rib (21%), upper arm/shoulder/clavicle (19%), hip/pelvis (14%), lower leg (14%), spine/vertebrae (14%), other (14%). FF: fragility fracture; Fx: fracture.

References:

- Hernlund E. Arch Osteoporos 2013;8:136
- Boudreau D. J Am Geriatr Soc 2017;65:1829

Acknowledgements: The study was funded by UCB Pharma and Amgen, conducted by AplusA, medical writing by Costello Medical.

Disclosures: CC and PR: Employees of AplusA; JT: Employee of UCB Pharma

P881

DOES A TREAT-TO-TARGET STRATEGY APPLY IN THE MANAGEMENT OF PATIENTS WITH FRAGILITY FRACTURES? A EUROPEAN OVERVIEW

T. Thomas¹, E. Casado², P. Geusens³, W. Lems⁴, C. Hofbauer⁵

¹CHU de St-Etienne, INSERM U1059, Université de Lyon, St-Etienne, France, ²University Hospital Parc Taulí, Sabadell, Barcelona, Spain, ³Maastricht University, Maastricht, Netherlands and Hasselt University, Hasselt, Belgium, ⁴Amsterdam University Medical Center, VUmc, Amsterdam, The Netherlands, ⁵Technische Universität Dresden, Dresden, Germany

Objectives: To develop an international consensus on best practice management of fragility fracture (Fx), with a specific focus on the applicability of a treat-to-target (T2T) strategy for prevention of subsequent Fxs.

Methods: 12 experts (5 rheumatologists, 5 endocrinologists, 2 orthopedic surgeons) from 8 European countries used a modified Delphi approach to reach consensus on statements pertaining to aspects of Fx management. Panelists reported their level of agreement with a series of statements ("strongly disagree", "disagree", "agree" or "strongly agree"). Consensus was defined as $\geq 75\%$ agreement with a statement, with refinement and revoting until consensus was reached. All voting was electronic and blind.

Results: All panelists answered every survey question; consensus was reached for 21/22 (95.5%) items. The main management goals for patients (pts) with Fx are to maximise and preserve pt independence and to prevent new Fx, and the best approach to achieve such goals is to set a treatment target with pts, and make therapeutic decisions based on the probability of reaching that target. Treatment adherence is thus an important means to achieving treatment goals.

BMD, assessed via DXA scan, is the best available surrogate of Fx risk, albeit with some limitations, and is therefore the most clinically appropriate target. Experts suggest the target T-score should be a level associated with no increase in Fx risk (e.g., -2.5 to -1.0 at the total hip) dependent on what is feasible for the pt to achieve; whilst a single overarching treatment target can be established for most post-Fx pts, some require a personalized target. The timepoint for assessment of whether the treatment target has been met will also vary, with frequency of monitoring dependent on the type of treatment.

Conclusions: This expert consensus supports the value of a T2T strategy in osteoporosis and establishes key principles for goal-directed therapy. Importantly, the study aligns with other European workgroups. Further work should focus on recommendations for the sequence of specific osteoporosis treatments in pts at varying levels of risk of fragility Fx.

References: 1. Nogués X. Osteoporos Int 2018;29:489.

Acknowledgements: The study was designed and overseen by Jen Timoshanko (UCB Pharma) and Daniella Taylor (Ogilvy Healthworld) with Thierry Thomas and Lorenz Hofbauer as the chairs of

the panel. The study was funded by UCB Pharma and Amgen. Editorial services for the abstract were provided by Costello Medical. The authorship would like to thank those that participated in the expert panel.

P882

THE EFFECTIVENESS OF CHOLECALCIFEROL FOR THE TREATMENT OF HYPOVITAMINOSIS D

A. Rudenka¹, T. D. Barysenka²

¹Belarusian Medical Academy of Postgraduate Education, ²Minsk City Clinical Hospital No. 1, Minsk, Belarus

Objective: To evaluate the effectiveness of different doses of cholecalciferol for treatment of vitamin D deficiency in menopausal women.

Methods: 67 women with serum 25(OH)D values below 20 ng/ml were enrolled in the study (mean age 61.3 \pm 8.5 y). Enrolled subjects were randomized into two groups. Group I - treatment group of cholecalciferol at dose of 50,000 IU orally - 1 tablet once a week; patients of group II received 7000 IU of cholecalciferol daily as an oil solution in drops. Level of total vitamin D (25(OH)D), PTH in serum was determined by the method of electrochemiluminescence (Cobas e411, Roche Diagnostic, Germany). Quantitative measurement of total calcium, inorganic phosphorus, alkaline phosphatase in serum was performed on a Beckman Coulter analyzer of the AU series. Laboratory testing was performed at baseline and after 8 weeks of treatment. Significance was assessed by parametric statistics using analysis of variances and the criterion of least significance in the ANOVA module. The differences were considered significant at $P < 0.05$.

Results: Statistically significant increase in total vitamin D concentration was observed in patients of group I: in 32 out of 32 (100%) patients taking 50,000 IU of cholecalciferol once a week 25(OH)D levels exceeded 30 ng/ml and reached target values, the average content of 25(OH)D was 39.93 ng/ml. In group II, the average concentration of 25(OH)D after 8 weeks of treatment was 30.21 ng/ml, while 27 patients (71.4%) reached the target serum hydroxyvitamin D level. During the study, no adverse events were observed in both groups, no deviations in laboratory parameters of calcium, phosphorus, alkaline phosphatase, PTH were detected at baseline and during follow-up.

Conclusion: The results of our study indicate the efficacy and safety of weekly administration of 50,000 IU of cholecalciferol to achieve target levels of 25(OH)D in menopausal women with vitamin D deficiency.

P883

FREQUENCY OF LOW BONE MINERAL DENSITY AND ANDROGENIC STATUS IN PATIENTS WITH PSORIATIC ARTHRITIS

O. Samokhovec¹, E. Rudenka², A. Buhlova³, A. Rudenka³, S. Kryvashei¹, L. Alehnovich³, T. D. Barysenka¹

¹Minsk City Clinical Hospital No. 1, ²Belarusian State Medical University, ³Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus

Objective: To study BMD and androgenic status in men with psoriatic arthritis (PsA).

Methods: 50 men with PsA were examined (mean age 46.5 (10.7) y) and 30 men of the control group (CG) (mean age 45.6 (7.5) y). Exclusion criteria were glucocorticoid treatment, endocrinopathy, systemic connective tissue diseases, malabsorption syndrome, malignant neoplasms. Determination of levels of total testosterone (TS) and sex hormone-binding globulin (SHBG) was performed by electrochemiluminescence method (Cobas e411, Roche Diagnostic, Roche Diagnostics GmbH, Germany). The level of free TS was calculated based on the levels of albumin total TS, SHBG using electronic calculator (www.issam.ch/freetesto.htm). BMD was measured by DXA. Statistical analysis was performed using parametric and nonparametric statistics. The differences were considered significant at $P < 0.05$.

Results: 29 (59%) patients with PsA had low BMD (osteopenia and osteoporosis). Levels of TS in patients with PsA corresponded to reference values, median was 4.82 [3.55; 5.34] ng/ml and was not significantly different from the CG (4.12 [2.68; 5.50] ng/ml), p 0.419. Median level of SHBG was 38.67 [22.96; 48.30] nmol/L in patients with PsA and 38.51 [22.88; 45.33] nmol/L in CG, p 0.930. Estimated level of free TS in the group of patients with psoriatic lesions was 0.0989 ng/ml (or 2.05%), in CG 0.0946 ng/ml (or 1.96%), which corresponds to physiological values.

Conclusion: The absence of androgen deficiency in men with psoriatic lesions of the skin and joints necessitates further study of factors affecting BMD. The study is ongoing.

P884

DIAGNOSIS OF PSEUDOPSEUDOHYPOPARATHYROIDISM IN A PATIENT ON A RHEUMATOLOGY CONSULT

L. Vega¹, I. Calvo¹, O. Iburguenoitia¹, D. Montero¹, M. L. Garcia Vivar¹, E. Ruiz¹, I. Torre¹, O. Fernandez¹, C. Perez¹, J. M. Blanco¹, A. R. Intxaurbe¹, E. Cuende¹, N. Rivera¹, M. J. Allande¹, E. Galindez¹

¹Hospital Universitario Basurto, Bilbao, Spain

Objective: Pseudopseudohypoparathyroidism is an autosomal dominant disorder with unknown prevalence. The patients presented the same phenotype as pseudohypoparathyroidism type 1A, with which the differential diagnosis should be made. Both diseases present the same genetic defect: a mutation of the GNAS 145 gene at the 20q13.325 locus.

Methods: We report the case of a 31 year old man who was diagnosed with pseudopseudohypoparathyroidism in our hospital and we describe the main epidemiological and clinical characteristics.

Results: Our patient is a 31 years old man with brachydactyly and acrodysostosis diagnosis in childhood. He also presents short stature, facial malformations and skeletal alterations in thorax.

He was admitted in our department for hands and feet arthralgias for which radiographies were performed. Hands radiographies showed shortening of the metacarpals and distal phalanges and epiphysis of the proximal phalanx of the second finger of the left hand with a conical shape could be seen and feet radiographies showed globally short bones with hypoplasia of the fourth metatarsal. Given the suspicion of pseudohypoparathyroidism a study of phosphocalcic metabolism was performed which didn't show any abnormalities. Family molecular study of the GNAS gene was requested confirming a paternal inheritance mutation leading to pseudopseudohypoparathyroidism diagnosis.

Conclusion: Pseudopseudohypoparathyroidism is a rare entity with scarcity of reported cases. In patients with Albright's hereditary osteodystrophy phenotype without hypocalcemia or hyperphosphatemia pseudopseudohypoparathyroidism should be considered as a possible cause. The confirmation of heterozygous GNAS mutations on the paternal GNAS allele will lead to definitive diagnosis.

P885

LIMITATION OF UTILITY THE LUMBAR SPINE SCAN DXA FOR WOMEN OVER 50 YEARS OLD

A. Adamenka¹, E. Rudenka², Y. Meshcharakou¹

¹Medical Academy, ²Belarusian State Medical University, Minsk, Belarus

Objective: To determine the age of limitation of utility analysis results of DXA scans and cost-effectiveness in women older than 50 y.

Methods: The BMD was assessed with DXA by Lunar Prodigy Advance, GE, USA, 2008 in the lumbar spine (LS) (assessment of BMD L1-L4, g/cm²; Z-score L1-L4, SD; T-score L1-L4, standard deviation (SD)) and femoral neck (FN) (BMD region total, g/cm²; Z-score region total, SD; T-score region total, SD). Standard radiography of the LS in the lateral projection carried out as necessary. Statistical processing was performed using the program MedCalc Software reg. number is BE 0809344640. Win pro №X18-45392. Work order №162000450.

Results: There were examined 365 women aged over 50 y ($n=365$, mean age in the examining group was 77 [73:81] y). Vertebra's deformities of the lumbar spine, based on the standard radiography scans or vertebral morphometry scans, were detected in 103 (28.2%) women; degenerative and focal changes processes lead to additional pathological ossification – diffuse idiopathic skeletal hyperostosis (DISH or Forestier's disease), osteochondrosis of the lumbar spine, spondyloarthropathy) were detected in 120 (32.8%) women. The quantity of artifacts (osteoarthritis, congenital or acquired hip dislocation, aseptic necrosis of the femoral head) in the DXA scans of the femoral neck was significantly less

and was diagnosed in 10 (2.7%) women. With the help of ROC analysis, there was determined the age of limitation of using LS DXA: associated criterion 72,14, +PV (Positive Predicted Values) 97,4; -PV 12,9.

Conclusion: Femoral neck DXA is more preferable and reliable for women over 72 y than lumbar spine DXA. DXA of the lumbar spine is recommended to complement vertebral morphometry or standard radiography in order to visualize artifacts and improve the reliability of the analysis. Carrying out DXA of the femoral neck allows you to more accurately interpreting the results of the measurement of BMD in women over 72 y for the verification of osteoporosis. The presence of artifacts is not allowed to exactly estimate the BMD's changes in time and reduce cost-effectiveness for clinical screening and BMD testing.

P886

PROBLEM OF DEFICIENCY OF VITAMIN D AT ADULTS AND THEIR CHILDREN

M. Fominykh¹, O. Khromtsova¹, K. Dorochina¹, A. Popov¹

¹FSBEI HE "Ural State Medical University" of the Ministry of Health of the Russian Federation, Yekaterinburg, Russia

Objective: Vitamin D deficiency is associated with an increased risk of developing cardiovascular, endocrine, autoimmune and neoplastic diseases, a decrease in the body's immune defense and an increase in mortality. Vitamin D deficiency is registered in half of the world's population. Ekaterinburg is located at 56 degrees north latitude, i.e. in the zone of insufficient insolation. Our aim was to assess the level of knowledge about vitamin D and the lifestyle of students and their parents.

Methods: A one-stage survey was conducted among students of the 3rd class of the School No. 99 of Ekaterinburg and their mothers. 30 pupils and 30 mothers took part in the review from September to October. All participants completed an anonymous questionnaire to study the risk factors for vitamin D deficiency, which took into account: age, gender, frequency of eating food containing vitamin D (milk and dairy products, fish, eggs), insolation regimen, bone fractures, and the frequency of cold, level of awareness of vitamin D.

Results: The average age of children was 8.6 y. The ratio of boys and girls is 1:1. The average age of parents was 35.6 y (from 28-49 y), 87% had a higher education, the rest had a secondary special education. Half of the mothers had low physical activity. Most children (84%) regularly received milk (50%), hard cheese (80%), yogurt (30%) and cottage cheese (10%). But 35% of children don't eat fish, 76% liver. The rest get the fish no more than 1 time per week. All children receive butter 3 times a week. Among parents, 60% consume daily dairy products, oily fish on average 1 time per week. Eggs are eaten 3 times a week by 80% of mothers, 60% by liver <1 time per week, 90% of parents consume butter 3 times a week. The walking time in 65% of children was 30-60 min. 70% of mothers give walks 30-60 min, <30 min - 20%, 1-2 h - 10%. They have a cold more than 3 times a year, 66% of children, 70% of parents have a cold once a year, and the rest more often. The daily intake of vitamin D was considered important by 43% of children,

31% were not very important, and 26% found it difficult to answer. 70% of parents considered daily intake of vitamin D important for their health and claimed that they received adequate amounts of vitamin D with meals. Only 20% of children did not hear about the existence of vitamin D. They received information on the Internet (16%), in the media (30%), from parents (13%) and from the attending physician (41%). All parents knew about vitamin D: from information in school 10%, in the media and on the Internet - 60%, from the attending physician - 30%. Vitamin D received 10 children (30%): 5 - as part of a multivitamin complex, 3 people - in capsules and 2 - in drops. A direct correlation ($p < 0.05$) between the risk factors of mothers and their children was revealed.

Conclusions:

1. The lack of awareness of children and their parents about vitamin D and the need for its supplementation was revealed.
2. Most children and one third of their mothers are often ill, which also requires the elimination of vitamin D deficiency.
3. It is necessary to inform children and their parents about vitamin D and the principles of a healthy lifestyle more and more access.

P887

DXA AND QCT DENSITOMETRY IN LATVIA: 10-YEAR DATA QUALITATIVE AND QUANTITATIVE ANALYSIS

R. Engels¹, S. Upmale², I. Rasa², M. Mukane³

¹Riga East Clinical University; Hospital Riga Stradins University; Latvian Osteoporosis and Bone Metabolic Disease Association; Hospital of Traumatology and Orthopedics; Latvian University, ²Riga East Clinical University Hospital; Riga Stradins University; Latvian Osteoporosis and Bone Metabolic Disease Association, ³Riga East Clinical University Hospital; Riga Stradins University; Latvian Osteoporosis and Bone Metabolic Disease Association, Riga, Latvia

Objective: Osteoporosis (OP) is the leading cause of low energy trauma fractures which often lead to severe disability and death. In 2017, there were 8094 registered fractures in Latvia. 37.2% of these fractures were acquired by patients in the age group 65 y and older, 78.4% of which were women. The main aim of this study was to analyse the availability of diagnostic tools for OP and osteopenia in Latvia and improve the national management of patients with decreased BMD. Improving OP diagnostics with DXA and QCT could improve its treatment and reduce fracture rates among Latvia's population.

Methods: In 2009 Latvian Osteoporosis and Bone Metabolic Disease Association made a united register for all the Latvia's DXA and QCT units which was based on the EU OP Consultation Panel Questionnaire (2008). For the last 10 y starting from 2009 data have been collected and analysed in this cross-sectional study.

Results: As of 2019 there is a total of 25 DXA and 3 QCT units in Latvia. 13 DXA units are located in the capital city Riga, and 12 are located in different regional towns. EU has recommended a DXA unit count of 10.6 per 1 million citizens, which Latvia ful-

files with 25 DXA units per 1.93 million citizens. Despite a steady increase of DXA units from the 1st unit in 1989, 17 in 2009 to 25 in 2017, the amount of DXA measurements carried out has decreased from 32677 in 2009 to 29148 in 2017. Nonetheless, the number of patients diagnosed with OP has increased from 10035/year (30.7%) in 2009 to 11876/y (40.7%) in 2017. Since 2009 QCT unit count has remained the same but the amount of scans done has decreased from 1206 to 573 in 2017. The waiting time has increased from 6.1 d in 2009 to 18.3 d in 2017 for DXA and 0 d to 3.8 d for QCT accordingly.

Conclusions: We conclude that better patient selection has been made since 2009 as fewer DXA scans have been performed, nevertheless more patients have been diagnosed with OP. Further data collection is needed, and reorganisation of unit localisation must be done to reduce the increasing waiting lines for DXA which could also increase the total number of DXA scans done.

P888

DYSLIPIDAEMIA: DOES IT ACCELERATE THE ONSET OF OSTEOPOROSIS IN SPONDYLOARTHRITIS?

O.-R. Predescu¹, C. Palici¹, C. Criveanu², L. Suiu¹, A. E. Musetescu², A. F. Vreju², P. Ciurea²

¹Department of Rheumatology County Emergency Hospital Craiova, ²University of Medicine and Pharmacy of Craiova, Craiova, Romania

Objectives: Dyslipidaemia is associated not only with atherosclerosis process, but also with bone remodeling. Elevated LDL serum levels and low HDL were linked to decreased BMD. Inflammation plays a similar role in these two processes previously mentioned. Recent studies reported a decline of BMD in patients diagnosed with spondyloarthritis, the prevalence of osteoporosis varying between 3-47% (depending on selection process and diagnosis tools) and osteopenia 88% of cases. This study is aimed at establishing a correlation between dyslipidaemia and the increased fracture risk in spondyloarthritis patients.

Methods: In this case-control study we have included patients diagnosed with spondyloarthritis between 2010-2018, according to modified New York criteria for ankylosing spondylitis and CASPAR for psoriatic arthritis involving the axial segment. In all patients we determined cholesterol serum levels including its fractions (HDL and LDL), triglycerides, BMD being measured using DXA (total hip). The fracture risk was established using FRAX calculator.

Results: 91 patients have met the criteria: 31 cases with psoriatic arthritis and axial involvement, and 60 ankylosing spondylitis cases. After we determined BMD, we identified 21 osteoporosis cases (11 ankylosing spondylitis cases, 10 psoriatic arthritis) the average age was 57.55 y, and 70 control cases (normal BMD), average age 51.27 y. In the first group total cholesterol values ranged between 169-284 mg/dl, and 72-208 mg/dl in the second group. We observed the fact that in osteoporosis group LDL serum level had a 28% higher mean value as compared to the control group and a 26% higher value for triglycerides. The average

risk fracture in patients with low BMD was 5.9% as compared to 2.2% in patients with normal BMD. In both groups the average period for the disease evolution was 14 y.

Conclusion: Dyslipidaemia can play a significant role in BMD decrease, causing an increased fracture risk in spondyloarthritis patients. In this case statin use could have two beneficial effects: correction of dyslipidaemia and possibly increasing BMD.

P889

SEARCH FOR CLINICAL AND GENETIC MARKERS OF OSTEOARTHRITIS AND CONNECTIVE TISSUE DYSPLASIA DEVELOPMENT IN AN ISOLATED AND COMORBID STATE

A. Tyurin¹, D. Shapovalova², L. Lukmanova³, R. Khusainova²

¹Bashkir State Medical University, ²Institute of Biochemistry and Genetics, ³Bashkir State Medical University, Ufa, Russia

Objective: A clinical and genetic assessment of the presence of osteoarthritis (OA) with various localizations, undifferentiated connective tissue dysplasia (uCTD) and joint hypermobility (JHM) in 484 individuals of both sexes of different age groups was carried out. The main task was to identify risk markers and build prognostic models of the pathology development.

Methods: We searched for associations of 4 polymorphic variants of matrix metalloproteinase genes (rs35068180 (MMP3), rs2252070 (MMP13), rs226794 and rs2830585 (ADAMTS5)) with the development of osteoarthritis as a whole, taking into account the localization of the pathological process, and the presence of uCTD as a whole and its individual phenotypic markers, as well as in the comorbid state with OA was carried out. 158 patients had osteoarthritis, 252 had a symptom complex of uCTD, 92 of them were in the comorbid state with OA. Intergroup comparison of the data obtained was carried out taking into account the sample size and the distribution of data using nonparametric criteria (χ^2). Pathology risk prediction models were constructed using the method of multivariate logistic regression, with ROC analysis and calculation of the area under the curve (AUC).

Results: The significance of the polymorphic loci of MMP3, MMP13, ADAMTS5 genes in the formation of the symptom complex of uCTD in general and its individual phenotypes was detected. The polymorphic locus of MMP3 gene was associated with OA in the comorbid state with uCTD. Statistically significant models based on clinical-genetic data using the method of multiple logistic regression, that allow predicting the development of osteoarthritis of knee, hip joints and polyosteoarthritis were calculated with only one gene involved (rs226794 ADAMTS5).

Conclusion: Matrix metalloproteinases are involved both in the formation of phenotypic signs of uCTD, and in the development of OA. This indicates the general genetic links of the pathogenesis of these conditions and the possibility of genetic testing for pre-clinical assessment of the risk of pathology developing.

Acknowledgement: The research was supported by the Russian Foundation for Basic Research (Grant No. 17-44-020913 p_a)

P890

HIGH PREVALENCE OF ABNORMAL STRENGTH AND PHYSICAL PERFORMANCE TESTS IN ROMANIAN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS USING REGIONAL REFERENCE DATA

D. Grigorie¹, A. Stancu², M. Alexe², A. Sucaliuc³

¹National Institute of Endocrinology, Carol Davila University of Medicine, ²Carol Davila University of Medicine, ³National Institute of Endocrinology, Bucharest, Romania

Objectives: EWGSOP2 recommends the use of regional normative references, with cutoff points usually set at -2 SD compared to the mean reference value. Our aim was to define the cutoff points of a reference Romanian population and to assess the prevalence of abnormal tests in a cohort of older patients with postmenopausal osteoporosis.

Methods: 88 healthy subjects (43.2% females), with ages between 18-62 y and normal mean BMI (24.7 kg/m²) were used to calculate reference cutoffs for our population (set at -2 SD) of the following tests: grip strength (GS) (Jamar dynamometer); gait speed (GSp); chair rise test (CRT); time to climb a flight of stairs (CFS). The cutoffs were then used to assess the prevalence of abnormal tests in a group of 64 female patients over 65 y (72±5.89), 90% had osteoporosis by DXA (39% at the femoral neck), 58% with prevalent fractures, 16% with at least one fall in the previous year (11% with at least 2 falls).

Results: We calculated and used the following cutoffs: GS of the nondominant hand 19.3 kg, GSp 0.95 m/s, CRT 16.7 s and CFS 0.35 m/s. The prevalence of abnormal tests results was: GS of the nondominant hand 33.8%, GSp 46.9%, CRT 59.7% and CFS 59.7%, respectively. Results of all tests depended on age and BMI and correlated significantly between them and were significantly different from the reference population. GS correlated significantly with FN BMD ($r=0.353$; $p=0.008$). Subjects with abnormal balance were significantly more likely to have low performance by GS (45.5% vs. 11.9%; $p=0.03$), GSp (36.7% vs. 9.1%; $p=0.009$) and CFS (36.8% vs. 10.3%; $p=0.015$). Subjects with at least 2 falls were significantly more likely to have low GS than those with either no or one fall (22.7% vs. 4.8%; $p=0.029$). For the other tests, there were numerically more falls in subjects with lower physical performance.

Conclusions: We found a high prevalence of abnormal strength and physical performance tests in patients with postmenopausal osteoporosis, using calculated cutoffs from a regional reference population.

P891

FRAILITY AND CHRONIC PAIN

P. Kucukdagli¹, G. Bahat¹, T. Erdogan¹, O. Yilmaz¹, B. Turkmen¹, C. Kilic¹, M. A. Karan¹

¹Istanbul University/Istanbul Faculty of Medicine/Internal Medicine/Division of Geriatrics, İstanbul, Turkey

Objective: Frailty is most often defined as a syndrome of physiological decline in late life, characterized by marked vulnerability to adverse health outcomes. Frail older adults are less able to adapt to stressors such as acute illness or trauma than younger or nonfrail older adults. This increased vulnerability contributes to increased risk for multiple adverse outcomes, including procedural complications, falls, institutionalization, disability, and death. We aimed to assess prevalence of frailty in elder people and its relationship with other conditions in this study.

Methods: 1107 individuals ≥ 60 y of age admitted to Istanbul Medical School Geriatrics outpatient clinic for the first time the period between 2013-2016 were enrolled to study. We used The International Association of Nutrition and Aging's FRAIL scale contains 5 simple questions to define frailty. Frail person was accepted as who gets ≥ 3 points in scale. Patients were asked about their fallings, urinary incontinence, chronic pain, sleep disorders, activities of daily living (ADL), instrumental activities of daily living (IADL), cognitive status, number of illness and medication, postural instability and assessed about their nutritional status by Mini Nutritional Assessment (MNA).

Results: 1107 patients were analyzed with a geriatric assessment. The sample was composed of women (66.8%) and men (33.2%) with mean age of 78.5 ± 5.7 y. Prevalence of frailty was 16% ($n=179$). Correlation analyses and multivariate regression analysis were performed to investigate the association between frailty and other factors. In multivariable analysis frailty was found independently associated with age ($p=0.041$), chronic pain ($p=0.021$), usual walking speed ($p<0.01$), malnutrition ($p<0.01$), instrumental activities of daily living (IADL) ($p=0.024$) respectively.

Conclusion: Frailty is a common clinical syndrome in older adults, which carries an increased risk for poor health outcomes, including falls, incident disability, hospitalization, and mortality. Elucidating its etiology and natural history is therefore critical for identifying high-risk subsets and new arenas for frailty prevention and treatment. An important strength of our study is assessment of chronic pain which is a new area of research in frailty concept. Our findings provide data on the significance of chronic pain and its association with frailty.

P892

RISK FACTORS OF OSTEOPOROSIS IN WOMEN WITH ARTERIAL HYPERTENSION OF DIFFERENT AGES

L. Kezhun¹, L. Yakubova¹¹Grodno State Medical University, Grodno, Belarus

Objective: To assess the incidence of clinical factors (CF) and the risk of osteoporosis (OP) in women with arterial hypertension (AH) of different ages.

Methods: We have investigated 76 postmenopausal women with AH who were divided into 2 age groups: group I – women aged 45-55 (n=37), group II – aged 56-65 (n=39). The groups were comparable by systolic and diastolic blood pressure (SBP and DBP) and by the heredity of cardiovascular diseases (CVD). Several anthropometric parameters and BMI have been evaluated. By means of questionnaire survey using the Adapted International *Osteoporosis Risk Test* (IOF) CF and OP risks in the assessed females have been analyzed.

Results: Women in both groups had I-II stage AH and showed no statistically significant difference in SBP, DBP and BMI as well. Hereditarily tainted by CVD were 78.3% respondents in group I and 64.1% – in group II. Regression analysis did not show any statistically significant differences between hereditarily tainted subjects in CVD or OP parameters. Assessment of CF of OP incidence in both groups showed the following differences: group II showed higher incidence (17.9% vs. 2.7% in group I; $p < 0.03$) of OP heredity (fractures or diagnosed OP in parents); lower dairy products intake (15.7% vs. 2.7% respectively; $p < 0.04$); visual disturbances (71.8% and 32.4% ($p < 0.001$); backache (92.3% vs. 63.2%; $p < 0.003$), these were the factor contributing to the increased amount of medications taken by females in group II – 2.6 ± 1.6 as compared to group I – 1.8 ± 1.2 ($p < 0.004$). The fact is proved by the established moderate correlation ($r = 0.34$; $p < 0.05$) between visual analog pain scale and the amount of taken medications in group II only. Psychotropic drugs were taken only by group II respondents – 5.3%. High incidence accompanied by secondary OP was marked in both groups (27% and 30.8% respectively). High OP risk (more than 3 CF) had 24.6% of the respondents, moderate risk – 37.7% (2–3 CF), low risk – 24.6% (1CF); differences in both groups were not found. History of fractures in minor traumas had 7.9% of postmenopausal women.

Conclusion: In postmenopausal women with AH under 56 years of age the incidence of certain CF is not age-dependent. With older age females show lower dairy products intake, visual disturbances, backache, OP heredity (fractures or diagnosed OP in parents) and increased medications intake. Postmenopausal women with AH having high OP risk (32.5%) require prophylactic OP medications.

P893

IDENTIFICATION OF PATIENTS AT HIGH RISK FOR OSTEOPOROTIC FRACTURES THROUGH RADIOFREQUENCY ECHOGRAPHIC MULTISPECTROMETRY (REMS): RESULTS OF A 5-YEAR FOLLOW-UP STUDY

S. Gonnelli¹, G. Bianchi ^{*2}, M. L. Brandi ^{*3}, C. Caffarelli ^{*1}, S. Casciaro ^{*4}, L. Cavalli ^{*5}, L. Cianferotti ^{*5}, F. Conversano ^{*4}, A. Fassio ^{*6}, G. Girasole ^{*2}, A. Grimaldi ^{*7}, F. A. Lombardi ^{*4}, M. Muratore ^{*8}, P. Pisani ^{*4}, L. Quarta ^{*8}, D. Gatti⁹

¹Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, ²SC Rheumatology, ASL 3 Genovese, Genoa, ³Department of Surgery and Translational Medicine, University of Florence, Metabolic Bone Diseases Unit, University Hospital of Florence, Florence, ⁴National Research Council, Institute of Clinical Physiology, Lecce, ⁵Department of Surgery and Translational Medicine, University of Florence, Metabolic Bone Diseases Unit, University Hospital of Florence, Florence, ⁶Rheumatology Unit, Department of Medicine, University of Verona, Verona, ⁷O.U. of Rheumatology, "Galateo" Hospital, San Cesario di Lecce, ASL-LE, Lecce, ⁸O.U. of Rheumatology, "Galateo" Hospital, San Cesario di Lecce, ASL-LE, Lecce, ⁹Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy

*Equal contributors listed in alphabetical order

Objective: To investigate the ability of the BMD values provided by the innovative technology called REMS [1] in the identification of patients at risk for osteoporotic fractures.

Methods: 1272 women (30-90 y, BMI ≤ 35 kg/m²) underwent both DXA and REMS investigations on lumbar spine and a follow-up period up to 5 y to assess the incidence of osteoporotic fractures. The enrolled subjects were then divided into 2 groups: those who suffered an osteoporotic fracture during the follow-up period and those who did not. Among the nonfractured subjects, we selected the oldest ones in order to have a group of nonfractured subjects being equal in number to the fractured ones and with a similar age range. The performance of REMS and DXA in fracture prediction was comparatively assessed by determining sensitivity and specificity in the identification of fractured patients when the typical BMD threshold for the diagnosis of osteoporosis (i.e., T-score ≤ -2.5) was employed.

Results: After a mean of 3.5 ± 0.7 y of follow-up, the incidence of osteoporotic fractures was 14.2% (180 out of 1272 subjects). The selection of the 180 oldest patients among the nonfractured ones (controls) allowed the comparison of two number- and age-matched groups (67.2 ± 7.6 y for fracture group vs. 66.9 ± 7.2 y for controls, $p = 0.62$). The two groups were also reasonably homogeneous regarding height ($p = 0.28$), weight ($p = 0.62$) and BMI ($p = 0.33$). The only significant differences were shown for the T-score values: REMS provided -1.96 ± 1.27 for controls and -2.68 ± 1.28 for fractured subjects ($p < 0.001$), whereas DXA scans resulted in -1.94 ± 1.21 for controls and -2.52 ± 1.20 for fracture group ($p < 0.001$). Employing T-score ≤ -2.5 as the cutoff value,

REMS identified the fractured subjects with sensitivity=65.0% and specificity=59.4% (OR=2.7). By employing the same cutoff, DXA identified the fractured subjects with sensitivity=56.7% and specificity=59.4% (OR=1.9).

Conclusions: REMS investigations on lumbar scans showed a good performance in the identification of patients at risk for incident osteoporotic fractures. This confirms the potential of this nonionizing approach for early diagnosis of osteoporosis.

References: [1] Di Paola et al. Osteoporos Int 2019 (in press, online available)

P894

RADIOFREQUENCY ECHOGRAPHIC MULTISPECTROMETRY (REMS): CLINICAL EXPERIENCE

M. D. Tomai Pitinca¹, C. Caffarelli², S. Gonnelli²

¹National Council of Research, Institute of Clinical Physiology, Lecce, ²Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy

Objective: To illustrate the clinical experience on the use of a nonionizing technique for BMD assessment at the Internal Medicine Department in Siena (Italy).

Methods: REMS is a new approach for the assessment of BMD. This technology was clinically validated through single centre and multicentre studies [1]. By using this method daily, at the department of Internal Medicine in Siena (Italy,) we drew some preliminary clinical considerations.

Results: REMS can be performed on almost the entire population unless there are serious physical impediments. It is easy and fast. It is feasible in populations that are not normally assessable (i.e., pregnant women) or difficult to assess by DXA [2] (children, subjects with psychomotor delays). It is feasible in many different settings: In the Emergency Departments to make early diagnosis in subjects with low intensity trauma fracture. In orthopaedics departments to assess treatment in subjects diagnosis with hip fractures or to assess the best pharmacological treatment before vertebroplasty in patients with vertebral fracture. REMS can assess the quality of bone revealing the presence of many false negatives in particular among patients with lumbar osteoarthritis or vertebral fracture. If this is confirmed, we could explain why osteopenic, or even patients with a normal BMD, present fragility fracture.

Conclusion: Fragility fractures weigh on health expenditure in every European country. It is important to have methods and paths to make an early diagnosis. A recent multicentre clinical study showed that REMS is an accurate technology to osteoporosis diagnosis in lumbar spine and femoral neck [1]. If these observations are confirmed, REMS could be a valid diagnostic tool to investigate the disease that induce bone fragility.

References:

- [1] Di Paola et al. Osteoporos Int 2018
- [2] Caffarelli C et al. CCMBM 2018

P895

PREVALENT AND INCIDENT MORPHOMETRIC VERTEBRAL FRACTURES IN ADULTS WITH REFRACTORY EPILEPSY AND INTELLECTUAL DISABILITY

J. J. L. Berkvens¹, H. J. M. Majoie¹, K. Beerhorst², S. Mergler³, P. Verschuure¹, I. Y. Tan¹, J. P. W. van den Bergh⁴

¹Epilepsy Center Kempenhaeghe, Heeze, ²Zuyderland Medical Center, Heerlen, ³ASVZ, Care and Service Center for People with Intellectual Disabilities, Sliedrecht, ⁴VieCuri Medical Center, Venlo, The Netherlands

Objective: To determine prevalent and incident morphometric vertebral fractures (VF) in adults with refractory epilepsy and intellectual disability residing at a long-stay care facility.

Methods: In 2009, all institutionalized patients aged 18 y or older (n=261) were invited to undergo a DXA measurement and a vertebral fracture assessment (VFA). In 2016, DXA and VFA were repeated. If evaluable, vertebrae T4-L4 were assessed using quantitative morphometry. VFs were graded as mild (20-25% reduction in height), moderate (25-40% reduction) or severe (>40% reduction) according to the method described by Genant. Prevalent VFs were analyzed at baseline. A VF present in 2016, but not in 2009, was considered an incident VF. Worsening VFs were defined as prevalent VFs with at least one grade deterioration at follow-up.

Results: A total of 141 patients (87 male, 61.7%) aged between 18-79 years old (44.8±15.7) at cohort entry could be studied. In 2009, 56 patients (39.7%) had one or more prevalent VFs (Table 1), 40 (28.4%) had at least one mild VF, 34 (24.1%) at least one moderate and 3 patients (2.1%) had a severe VF. For follow-up, 23 vertebrae (in 19 patients) with a prevalent VF could not be evaluated at follow-up and 4 vertebrae (in 3 patients) with a fracture at follow-up were not evaluable at baseline. During 7-y follow-up, 39 new VFs occurred in 29 patients (20.6%) and 15 patients (10.6%) had a worsening VF. The combined incidence of new and worsening VFs was 27.7%.

Conclusion: In adults with refractory epilepsy VFA is challenging, due to physical and behavioral aspects, resulting in a substantial proportion of unevaluable vertebrae. Nevertheless, 40% had a VF at baseline and after 7-y follow-up, 28% had at least one new and/or worsening VF.

Table 1

Nr of VFs	2009 N (%)	2016 N (%)
0	85 (60.3)	80 (56.7)
1	27 (19.1)	26 (18.4)
2	14 (9.9)	19 (13.5)
3	14 (9.9)	8 (5.7)
4	1 (0.7)	7 (5.0)
5	0	1 (0.7)

P896

LOW TRAUMA BONE FRACTURES AND MAGNESIUM DEFICIENCY TEST RESULTS IN YOUNG MALE ADULTS WITH BENIGN JOINT HYPERMOBILITY SYNDROME

A. V. Akimova¹, P. A. Palabugina¹, A. A. Popov¹¹The Urals State Medical University, Ekaterinburg, Russia

Objective: The frequency of monogenic hereditary connective tissue disorders (Marfan syndrome, Ehlers-Danlos syndrome, etc.) being low, benign joint hypermobility syndrome (BJHS) is reported to occur quite often in young adults. Muscle and joint pain as well as low traumatic bone fractures are the most obvious phenotypic features of BJHS. Magnesium deficiency clinical presentation also include twitches, tremors, muscle weakness, cramps and other locomotor system symptoms. Our aim was to assess frequency of BJHS, bone fractures and magnesium deficiency in a sampling of healthy young males.

Methods: 143 young male adults aged from 18-25 (median age 23) consented to take part in a cross sectional study. Inclusion criteria were the following: signed informed consent, absence of known rheumatologic or metabolic diseases. Exclusion criteria: monogenic hereditary connective tissue disorders, professional sports activities, history of severe trauma, any chronic disease or long term medication. Evaluation of clinical signs of hereditary connective tissue disorders, assessment of Beighton score, BJHS Brighton criteria (1990) and Russian Satellite Center "Trace Element Institute for UNESCO" Magnesium deficiency self-assessment test were performed. History of bone fractures was registered.

Results: 62 (43.4%) of the sampling had BJHS, while 51 males (35.7%) had a history of low traumatic fractures: there were 24 cases of a single fracture, and 27 cases of multiple bone fractures. BJHS increased fractures risk OR=5.89 (95%CI 2.83-12.26), $\chi^2=24.66$; $P<0.001$. A weak positive correlation was found between the number of fractures and Beighton score value (Spearman $R=0.258$; $p=0.018$) and scores of magnesium deficiency test (0.28 ; $p=0.047$).

Conclusion: low traumatic peripheral bones fractures in a sampling of young healthy males were associated with BJHS. The role of magnesium deficiency in propensity to bone fractures in young males require more profound studies with laboratory confirmation.

P897

SYSTEM OF SECONDARY PREVENTION OF RECURRENT OSTEOPOROTIC BONE FRACTURES IN VOLGOGRAD

V. Polyakov¹, G. Kravtsov¹, V. Dorochin², J. Polyakova³¹Volgograd State Medical University, ²Emergency Hospital 25, ³Federal State Budgetary Institution "Zborovsky Research Institute of Clinical and Experimental Rheumatology", Volgograd, Russia

Objective: In Russia, fracture liaison services (FLS) was introduced several years ago. Our aim was to estimate the number of patients with low-energy fracture (LEF) in the Traumatology. Rate the participation of the traumatologist in the efficiency of the FLS.

Materials: a sample of patients with LEF (gr. I) was taken from the register of patients in the Trauma. Gr. II of the recommendations of the traumatologist. These are patients with a high energy trauma, but with a history LEF. Risk factors for fractures of all patients were assessed.

Results. 69 patients (69.66 ± 12.06 y, $M\pm\sigma$) - I gr, 17 patients (75.4 ± 4.005) - II gr. In gr I, fractures of the bones of the lower leg - 33.3%, neck of the femur - 24.6%, proximal femur - 15.9%, humerus - 11.5%, forearm bones - 10.1% and vertebrae - 4, 3%. In gr II - 52.9% of fractures of the bones of the leg, 23.5% of the humerus, 17.6% of the forearm and 5.9% of the vertebrae. The high risk of major fractures for FRAX in gr I was 40.6%, the high risk of hip fractures was 52.2%, DXA was required to clarify the risk for 26.1% of patients, in gr II there was a high risk in 100% of patients. In gr I, 66% of patients knew about osteoporosis, 20% had previously passed DXA, 23% followed prevention guidelines, and 0% took antiosteoporotic drugs. In gr II, they knew about the disease "osteoporosis" - 94% of patients, 17% were examined, 26% followed the prevention recommendations, and 0% took antiosteoporotic drugs. After interacting with the staff of the FLS, 56% of patients in gr II and 58% of gr II began specific therapy.

Conclusions: A high percentage of patients in the Traumatology after a minimal injury. There is a high awareness of the presence of the disease "osteoporosis" and the complete absence of treatment of this disease. Some patients (24.7%) are not in the field of view of the FLS coordinator. The recommendations of the traumatologist increase the compliance therapy of osteoporosis.

P898

MORPHOLOGICAL FEATURES OF SYNOVIAL MEMBRANE REMODELING IN HIP OSTEOARTHRITIS

S. Smiyan¹, R. Bodnar¹, Y. Bodnar¹¹I. Horbachevsky Ternopil State Medical University, Ternopil, Ukraine

Objective: Existing publications on pathomorphology of osteoarthritis (OA) are mostly limited to cartilage and subchondral bone studies. Despite its crucial role, to date, synovial membrane remodeling in OA has not been sufficiently investigated. Our aim was to assess structural changes of synovial membrane in hip OA.

Methods: In 20 patients undergoing hip replacement surgery for OA, a light optical study of synovial membrane specimens was performed. Articular damage was staged according to modified Bandi classification: stage I - chondromalacia, stage II - up to 50% of cartilage thickness damage, stage III - >50% of cartilage thickness damage, stage IV - whole thickness cartilage loss with bone exposure. Hematoxylin - eosin, Mallory's trichrome, Weigert's resorcin fuchsin, and periodic acid - Schiff reaction stains were used to study the tissue sections.

Results: Stage I-II hip OA was diagnosed in 8 patients, stage III-IV hip OA was found in 12 patients undergoing hip replacement surgery. In stages I-II of OA, plethoric capillaries and venules were seen. Dilated lymphatic capillaries were filled with homogeneous eosinophilic fluid and occasional red blood cells. Arterioles were dilated and plethoric with marked wall edema and subendothelial layer fibrosis. Scarce lymphohistiocytic infiltration and compact arrangement of fuchsinophilic fibers was noted in superficial collagen-elastic layers. Diffuse lymphohistiocytic and fibroblastic infiltration, fuchsinophilia of collagen fibers, interstitial edema, thickening, disarray and fragmentation of elastic fibers was observed in the deep layer.

Stages III-IV of OA were characterized by predominant destructive changes of synoviocytes and villi. Plethoric venules, constricted arterioles with perivascular sclerosis and lymphohistiocytic infiltration, dilated lymphatic vessels were seen. Collagen-elastic layers were thickened due to sclerosis, edema and lymphohistiocytic infiltration. The collagen fibers were fuchsinophilic and chaotically arranged. The elastic fibers were disarrayed and fragmented.

Conclusion: Marked synovial remodeling is seen in stages III-IV of hip OA. It is characterized by villous disorganization, degenerative lesions of fibers of both superficial and deep layers, and impaired microcirculation.

P899

ROLE OF VITAMIN D IN THE TREATMENT OF PARATHYROID ADENOMA

M. Ghasaboghlyan¹, V. Vardanyan², G. Hovhannisyan¹, V. Mukuchyan³

¹Vardanants Center of Innovative Medicine, ²Yerevan State Medical University, ³Erebuni Medical Center, Yerevan, Armenia

Objective: Primary hyperparathyroidism is a rather frequent disorder characterized by high plasma PTH and calcium. Vitamin D deficiency is prevalent in all areas of the world. Vitamin D deficiency has been described in patients with primary hyperparathyroidism. When present, vitamin D deficiency may be associated with large size parathyroid adenomas and musculoskeletal pain. Our aim was to evaluate the efficacy of vitamin D in the treatment of adenoma of the parathyroid glands and primary hyperparathyroidism.

Methods: 41 patients (age 25-60, 9 males and 32 females) with parathyroid adenoma where enrolled in the study. All of them were in the stage of primary hyperparathyroidism. The patients were treated with vitamin D (6000 IU/d) and calcium (1000 mg/d) for a follow-up period of 6 months. No surgical intervention was performed. The determination of serum levels of PTH, calcium, vi-

tamin D, as well as neck CT scan and ultrasound were performed twice – at baseline and at the end of follow-up period. All patients were informed about the potential aim of the study and expectations from the treatment with vitamin D.

Results: Eventually, follow-up was complete in all patients. The treatment was well tolerated, no serious adverse effects occurred. In 13 patients out of 41 we determined significant ($p < 0.05$) reduction of the sizes of adenoma as well as normalization of laboratory parameters.

Conclusion: Taking into account all above mentioned, it can be concluded that vitamin D and calcium can be considered as a treatment modality of parathyroid adenoma and primary hyperparathyroidism.

P900

VITAMIN D DEFICIENCY AND AUTOIMMUNE MARKERS: WHICH IS A KEY PLAYER?

O. Derevyanko¹, L. Ibragimova², E. Pekareva², M. Ragimov², T. Nikonova², L. Nikankina²

¹Lechebnyi Tsentr Ltd, ²Endocrinology Research Centre, Moscow, Russia

Objective: Vitamin D is a neuro-hormone regulating calcium-phosphate homeostasis. However, vitamin D deficiency has been reported in several chronic conditions associated with increased inflammation and dysregulation of the immune system such as type 1 diabetes (T1D), Hashimoto's thyroiditis, autoimmune gastritis. The role of autoimmune gastritis in the pathogenesis of nutritional deficiencies has been reported therefore we assumed a possible association between gastric parietal cells autoantibodies (PCA) which often appear in T1D and 25(OH)D deficiency. The aim of this study was to evaluate the prevalence of 25(OH)D deficiency in patients with T1D and vitamin D status association with PCA. We also assessed the prevalence of thyroid peroxidase autoantibodies (TPOAb) in T1D patients and its potential influence on vitamin D status.

Methods: 68 T1D patients (42 females; mean age 43.5 ± 12.8 y) were followed up in Endocrinology Research Centre from December 2017 to November 2018. 25(OH)D, parathormone, calcium, PCA, TPOAb were measured in all T1D patients. We also evaluated autoantibodies to glutamic acid decarboxylase (GAD), islet antigen 2 (IA2) and zinc transporter isoform-8 (Znt8) to confirm autoimmune genesis of diabetes. The results were compared with a control group of 42 healthy subjects.

Results: In T1D group (n=68) 25(OH)D levels were significantly lower than in the control group $14.6 [9.1; 23.0]$ vs. $27.0 [22.1; 34.7]$ ng/ml, $p < 0.0001$. 23 out of 68 patients with T1D were positive to PCA and 45 patients were negative to PCA. Vitamin D values in these groups were $17.3 [9.9; 23.6]$ and $12.4 [7.1; 23.0]$ respectively. Only 3 out of 42 patients (7%) were positive to PCA in control group without autoimmune diseases. It is noteworthy that T1D patients with TPOAb (30 out of 68 patients) had lower 25(OH)D values as compared to those without TPOAb (38 patients) - $11.8 [6.8; 22.1]$ vs. $20 [11.1; 26.7]$ ng/ml; $p = 0.0047$.

Conclusion: Data from the present study showed a significant reduction of 25(OH)D levels in T1D patients. No meaningful difference in Vitamin D status was found in patients with and without PCA. Possible impairment of vitamin D absorption in autoimmune gastritis may be caused by mucosal atrophy which may appear years after PCA start to be detectable in blood. TPOAb in T1D patients may play a role in Vitamin D deficiency in such patients.

Acknowledgement: This research was supported by Grant № 17-75-30035 by Russian Science Foundation.

P901

LATVIAN VALIDATION OF SARQOL®: A QUALITY OF LIFE QUESTIONNAIRE SPECIFIC FOR SARCOPENIA

S. Upmale¹, M. Mukane¹, D. R. Engels², I. Leite³, I. Rasa¹

¹Riga Stradins University, Riga East Clinical University Hospital, Latvian Osteoporosis and Bone Metabolic Disease Association,

²Riga Stradins University, Riga East Clinical University Hospital, Latvian Osteoporosis and Bone Metabolic Disease Association, Hospital of Traumatology and Orthopedics, Latvian University,

³Pauls Stradins Clinical University Hospital, Latvian Osteoporosis and Bone Metabolic Disease Association, Riga, Latvia

Objective: Translate and adapt the SarQoL (quality of life questionnaire specific for sarcopenia) into Latvian and assess the psychometric performances of the translated questionnaire.

Methods: The English version was used. The translation was performed according to the standard guidelines. No difficulties were faced in the translation process. A total of 45 Caucasian subjects were enrolled in the study. The questionnaire form was filled, grip strength was measured using a hand dynamometer Jamar Plus Digital. According to the criteria suggested by the EWGSOP, only 3 participants were sarcopenic; therefore we divided the participants into 2 groups with low and normal muscle mass. To test the psychometric performance, we assessed the discriminative power, internal consistency, test-retest reliability, floor-ceiling effects, and constructed validity. Data were analysed according to the SarQoL standards.

Results: A total of 45 participants (39 female, mean age 58.9 (CI 95% 46.3–71.7) (min 27; max 84) were included. Mean BMI was 25.4 kg/m² (CI 95% 21.4–29.5). Mean SarQoL result was 77.8 (CI 95% 65.1–90.4). Mean hand grip strength was 30.2 kg (CI 95% 22.7–37.6). All subjects were divided into 2 groups depending on the average grip strength between both hands (Group 1 <30 kg, n=26 and Group 2 ≥30 kg, n=19). The results indicated good discriminative power – Group 1 mean SarQoL 74.41 (CI 95% 61.11–87.71) vs. Group 2 mean SarQoL 82.4 (CI 95% 72.1–93.6) [p=0.035]. Cronbach's α between SarQoL domains was 0.84 indicating excellent internal consistency. We found a good positive correlation between SarQoL and SF-36 (Spearman's Correlation test $r=0.84$; $p<0.0001$). There was an excellent agreement between the test-retest reliability with an ICC of 0.98 (CI 95% 0.92–0.99). No floor nor ceiling results were detected.

Conclusion: Our results show that the Latvian version of the SarQoL questionnaire could be a useful instrument in assessing the quality of life in patients with sarcopenia.

P902

DETERMINANTS OF NEONATAL 25(OH)D STATUS IN A GREEK POPULATION COHORT

S. Karras¹, T. Koufakis¹, D. Goulis², C. Annweiler³, E. Dursun⁴, D. Gezen-Ak⁴, P. Mourampetzis¹, D. Dina¹, E. Zisimopoulou¹, V. Antonopoulou¹, E. Manthou¹, K. Kotsa¹

¹Aristotle University of Thessaloniki, Medical School, First Department of Internal Medicine, Division of Endocrinology and Metabolism, AHEPA University Hospital, Thessaloniki, Greece,

²Aristotle University of Thessaloniki, Medical School, First Department of Obstetrics and Gynecology, Unit of Reproductive Endocrinology, Thessaloniki, Greece, ³Angers University Hospital, Department of Neuroscience, Division of Geriatric Medicine, Angers, France, ⁴Istanbul University, Cerrahpasa Faculty of Medicine, Department of Medical Biology, Istanbul, Turkey

Objective: Accumulating evidence highlights the relationship between optimal 25-hydroxyvitamin D [25(OH)D] concentrations during the first months of life and normal growth and development. We aimed to assess maternal and neonatal determinants of neonatal 25(OH)D concentrations in a Greek cohort of mothers and their children.

Methods: We studied 70 pairs of newly delivered neonates and their mothers. Only healthy mothers with full-term, uncomplicated births were included in the trial. Biochemical, demographic and anthropometric parameters were recorded in both groups. Stepwise linear regression analysis was performed to identify factors associated with neonatal 25(OH)D status.

Results: Mothers' mean age, term BMI and gestational age were 31.9±0.7 y, 29.6±0.7 kg/m² and 38.8±0.2 weeks, respectively. 71.2% of mothers were receiving calcium supplementation. Both mothers and children were found to be vitamin D deficient [25(OH)D levels 45.6±3.1 and 40.6±2.6 nmol/l, respectively]. Maternal 25(OH)D concentrations and BMI at term were found to be positively correlated with neonatal 25(OH)D status ($p<0.001$ and $p=0.009$, respectively). In contrast, mothers' calcium serum concentrations and daily calcium supplementation were inversely related to neonatal 25(OH)D concentrations ($p<0.001$ and $p=0.023$, respectively). In terms of neonatal characteristics, a positive correlation was detected between upper arm length ($p<0.001$) and abdominal skin fold ($p=0.002$) and a negative association between height ($p=0.037$), PTH levels ($p=0.004$) and neck-rump length ($p=0.036$) and 25(OH)D status.

Conclusions: Results from a vitamin D deficient maternal–neonatal cohort from Northern Greece, indicate that in addition to maternal vitamin D status, maternal anthropometry might affect neonatal vitamin D concentrations at birth. Additional trials are needed in order to further elucidate the aforementioned associations and translate the findings into daily clinical benefit.

P903

INFLUENCE OF CHRONIC PROTEIN-ENERGY MALNUTRITION ON BONE MINERAL DENSITY IN CHILDREN WITH SEVERE SOMATIC DISEASES

U. Arisah¹, H. Z. Mosbah¹, N. Balatska¹, V. Povoroznyuk², I. Gedeon³, A. Musienko², K. Volotsuha⁴

¹Kyiv Medical University, Kyiv, Ukraine ²State Institution "D. F. Chebotarev Institute of Gerontology NAMS Ukraine, Kyiv, Ukraine ³Okhmatdyt National Children's Specialized Hospital, Kyiv, Ukraine ⁴State Institution "Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine"

Objective: To evaluate the peculiarities of BMD in children with chronic protein-energy malnutrition (CPEM) due to severe somatic diseases.

Methods: 45 patients aged from 5 to 20 years old (62% female) with chronic somatic diseases were examined. CPEM was found in 31.1%. BMD was measured by "Discovery wi". Short stature was diagnosed in 24% of the examined. Height adjustment formula was used for recalculating BMD Z-score.

Results: Low BMD was registered in 40% of children; three of them (0.07%) had osteoporosis with multiple vertebral fractures. The average age of children with CPEM was the same as in those who did not have malnutrition (12.64±3.67 vs. 12.01±4.60 yrs.). Children with CPEM had significantly lower Z-score at total body (-2.65±0.93 vs. 1.02±0.90 SD, p<0.001) and L1-L4 (-2.73±1.53 vs. -0.95±1.12 SD, p<0.001). Furthermore, low BMD was found in 86% in group with CPEM while in group without malnutrition it was registered only in 16%. Also, we found significant correlation between BMI and Z-score at the level L1-L4 (r=0.40, p<0.01) and total body (r=0.55, p<0.001). Likewise, BMI influenced on trabecular bone score (r=0.48, p<0.025).

Conclusion: Chronic protein-energy malnutrition is one of the important factors which could influence on BMD in children with severe somatic diseases. It is important to use effective nutritional screening tools for early CPEM diagnosis and intervention and permit the child to reach the optimal peak bone mass.

P904

METABOLIC BONE DISEASE IN PATIENTS WITH THORACIC TUBERCULOUS SPONDYLITIS AND HIV INFECTION

P. Yablonskiy¹, M. Serdobintsev¹, E. Sokolovich¹, K. Sazonov¹, V. Novikov¹, T. Chernovol¹, M. Diakova¹, E. Shuvalova¹, A. Vishnevskii¹, V. Oleinik¹, A. Cherkasov¹, D. Esmeldiaeva¹

¹Saint-Petersburg State Research Institute of Physiopulmonology, Saint-Petersburg, Russia

Objective: To determine the frequency of metabolic bone disease in HIV infected patients with thoracic tuberculous spondylitis and its connection with the degree of immunodeficiency.

Methods: We analyzed the results of the IOF one-minute osteoporosis risk test, DXA and biochemical bone turnover markers in 40 adult patients aged 18-45 with verified thoracic tuberculous spon-

dylitis who underwent radical reconstructive spine surgeries in our clinic. Patients were divided into two groups. 20 patients with HIV infection and thoracic tuberculous spondylitis (group 1) and 20 patients with thoracic tuberculous spondylitis and HIV-negative status (group 2).

Results: The IOF test results showed a higher risk of bone fracture due to osteoporosis in group 1 patients. The combination of HIV infection and spinal tuberculosis contributes to a 3-fold decreased BMD compared to patients with tuberculous spondylitis without HIV infection. Bone turnover markers and results of BMD measurements in patients with HIV infection and spinal tuberculosis do not depend on the degree of immunodeficiency according to the CD4+ T-cell count.

Conclusions: HIV infection causes the higher risk of bone fracture due to osteoporosis in patients with thoracic tuberculous spondylitis. There is no connection of bone turnover markers and BMD with the degree of immunodeficiency according to the CD4+ T-cell count.

P905

BONE MINERAL DENSITY MEASURED BY THE RADIOFREQUENCY ECHOGRAPHIC MULTISPECTROMETRY (REMS) TECHNIQUE IN PATIENTS IN LONG TERM STEROID TREATMENT WITH AND WITHOUT FRACTURE

M. D. Tomai Pitinca¹, C. Caffarelli², S. Gonnelli²

¹National Council of Research, Institute of Clinical Physiology, Lecce, ²Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy

Objective: Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis. The diagnosis of osteoporosis is currently established by measurements of BMD. DXA of proximal femur and lumbar spine is the reference technology used to establish or confirm a diagnosis of osteoporosis. The innovative REMS approach, clinically validated for osteoporosis diagnosis, allows to measure the densitometric parameters BMD, T-score and Z-score directly on lumbar vertebrae and proximal femur. The present work is focused on the use of the REMS approach [1] in women taking long-term corticosteroids therapy with and without fracture.

Methods: 30 female patients in chronic treatment with corticosteroids, referred to a South-Central Osteoporosis clinic, were recruited (mean age 65.4±10.6 y). Fifteen showed fragility fractures while the remaining patients did not have a fracture history. Patients were submitted to an ultrasound scan of the lumbar spine and proximal femur by using the REMS technique.

Results: Femoral and lumbar BMD values measured by REMS technology resulted more reduced in patients in steroid treatment who presented fractures than those not fractured (p<0.05).

Conclusions: These preliminary results show that REMS technology can discriminate patients with and without fractures even during corticosteroid therapy. Bone loss in these patients occurs early after initiation of steroid therapy and is related to dose and

treatment duration. The extent of bone loss is variable and not clearly determinable. If these data are confirmed in larger studies, REMS technology could become a valid method for assessing and monitoring patients taking long term steroid therapy to establish the most effective and safe therapeutic approaches.

References: [1] Di Paola et al. Osteoporos Int 2018

P906

MICROCIRCULATION IMPROVEMENT AS A RESULT OF BIOFEEDBACK TRAINING IN PATIENTS WITH SYSTEMIC SCLEROSIS

R. Grekhoff¹, A. Aleksandrov¹

¹Zborovsky Research Institute for Clinical and Experimental Rheumatology, Volgograd, Russia

Objective: Microcirculatory disorders are the most important clinical symptoms in patients suffering from systemic sclerosis (SS), therefore we found it feasible to evaluate the clinical efficacy of biofeedback (BFB) in the complex therapy of SS patients based on analysis of nailfold capillaroscopy. Our aim was to study the impact of biofeedback on microcirculation disturbances in patients with SSc.

Methods: We observed 50 patients with SS Among the patients examined, 94% were women and 6% were men. The average age of the patients was 38 ± 3.6 y, duration of illness – 14 ± 3.7 y. Raynaud's phenomenon (RP) was noted in all SS patients. A severe form of RP was seen in 80% of the patients. The effectiveness of biofeedback was analyzed by studying dynamics of the measures from the nailfold capillaroscopy and comparing the data obtained of patients from the main and control groups.

Results: It was found that SS patients who were under biofeedback training, showed significant positive dynamics in the following signs of capillaroscopic picture: dilation of the capillaries ($\chi^2=9.646$ $p=0.026$), morphological changes of the capillaries ($\chi^2=4.89$ $p=0.027$), and hemorrhage ($\chi^2=4.521$ $p=0.034$). In the control group of patients, in only one indicator of capillaroscopy that a significant change was noted, particularly by the presence of dilated capillaries ($\chi^2=5.834$ with $p=0.016$). These findings suggest that treatment results were significantly better in the main study group of patients with SS.

Conclusions: The biofeedback implementation favors a decrease in reflex muscular tonic syndromes, improvement of microcirculation and peripheral blood flow and significantly allows an amelioration in the results of SS therapy.

P907

USE OF TERIPARATIDE IN NONUNION HEALING: BRIEF REPORT

R. Z. Hussain¹, J. Palencia¹, F. Serra¹, J. Fakeeha¹

¹Department of Orthopaedics, King Saud Medical City, Riyadh, Saudi Arabia

5-10% of bone fractures do not heal spontaneously and need treatment. The nonhealing (27-34%) of segmental fractures leads to high rates of disability (40-50%). Allograft healing procedures

for fractures are associated with high complications rate namely late graft fracture (24%–27%), and infection (9%–16%). Human PTH stimulates osteoblasts and reduces osteoblast apoptosis. Intermittent administration of human PTH increases callus formation and improves mechanical strength. It has proven to increase skeletal bone mass in osteoporotic patients.

Research on human PTH is conducted mainly on animal models. A recent study from the USA has reported that delayed short treatment with teriparatide in rats enhances intramembranous bone formation at the graft-host junction and therefore improves femoral allograft healing.

There are several case reports among humans. A study from Japan has reported 2 cases of ulnar fracture in smokers who had nonunion after ulnar shortening osteotomy. Both were treated with teriparatide in addition to low intensity pulsed ultrasound. At follow-up after 10 and 6 months of treatment with teriparatide, both patients had successful bone healing without additional surgical interventions. teriparatide and low intensity pulsed ultrasound are presented as a possible alternative to surgical intervention particularly among smokers who have a higher incidence of nonunion (30%).

Another report from the UK in a 21-year-old female with extended oligoarticular juvenile idiopathic arthritis diagnosed at age of 8 y who also sustained a low-impact short oblique closed fracture of her right lower tibia. She was treated with teriparatide and later zoledronic acid. She started showing signs of healing within a 12 months' period. But authors have advised interpreting the results with caution.

A case series from Italy reports successful callus formation and healing of traumatic fractures of the lower limb with Teriparatide in 4 patients who had undergone open fixation.

Summary: The effect of human PTH on callus formation and its potential role in the nonunion of fractures cannot be doubted. But we have to interpret data from animal models with great caution. We need RCT comparing gold standard procedures before we can replace surgical options in the treatment of a fracture with teriparatide.

P908

ASSOCIATION BETWEEN PLASMA CHERMERIN CONCENTRATION AND BONE MINERAL DENSITY IN POSTMENOPAUSAL OSTEOPOROTIC FEMALES

S. T. Tariq^{1,2}, M. T. Shahzad³

¹University Medical and Dental College, The University of Faisalabad/ Pharmacology and Therapeutics, Faisalabad,

²University Medical and Dental College, The University of Faisalabad/ Physiology, Faisalabad, ³University of Health Sciences Lahore/ Pharmacology and Therapeutics, Lahore, Pakistan

Objective: Chemerin is a novel adipokine associated with bone erosion in small observational studies. The objective of this study was to explore relationship of serum chemerin with BMD in postmenopausal osteoporotic females.

Methods: In this study, 150 postmenopausal females were recruited. BMD assessment was done through DXA Scan and according to the criteria of WHO, females having T-score ≤ -2.5 and below were defined as osteoporotic and women with T-score -1 or above was selected as control group. Serum chemerin levels were determined by commercially available ELISA kit.

Results: The median age in postmenopausal control group (n=60) was 54 (50-57) y and in postmenopausal osteoporotic group (n=90) was 60 (55-66) y. Serum chemerin levels were significantly increased 0.128 ng/ml (0.144-0.574) vs. 0.270 ng/ml (0.079-0.261) in osteoporotic group as compared to control group ($p < 0.001$). In postmenopausal females serum chemerin levels were significantly correlated with BMD at lumbar spine ($r = 0.28$, $p < 0.001$), right femoral neck ($r = -0.29$, $p < 0.001$), right hip ($r = 0.25$, $p = 0.002$), left femoral neck ($r = -0.31$, $p < 0.001$) and left hip ($r = -0.25$, $p = 0.002$). Linear regression analysis of serum chemerin revealed its significant association with BMD at right femoral neck ($r^2 = 0.028$, $p < 0.05$) and left femoral neck ($r^2 = 0.037$, $p < 0.05$)

Conclusion: This study indicates that serum chemerin levels were significantly higher in osteoporotic group as compared to control group. Chemerin clearly assumes a negative role in connection with BMD. Further investigations are expected to show whether chemerin assumes a job in the pathophysiology of osteoporosis and whether chemerin is qualified as a marker or indicator of osteoporosis.

P909

CLINICAL PROFILE OF PATIENTS WITH OSTEOPOROSIS TREATED WITH ZOLEDRONIC ACID

E. Tabti¹, Z. Drici², S. Chiali¹, H. Bestaoui¹, A. Lounici³

¹Centre Hospitalo-universitaire de Tlemcen, ²Centre Hospitalo-universitaire de Tlemcen, ³Université Aboubekr Belkaid Tlemcen, Tlemcen, Algeria

Objective: Zoledronic acid is an intravenous, highly potent aminobisphosphonate and the first once yearly treatment to have been approved for use in patients with postmenopausal osteoporosis or at high risk of fracture. The aim of this work is to study the clinical profile of patients with osteoporosis treated with zoledronic acid.

Methods: 10-month prospective study including patients with osteoporosis treated with zoledronic acid. Indications for treatment are postmenopausal osteoporosis (PMO), corticoid-induced osteoporosis (CIO), severe osteoporosis with or without hip fracture. Osteoporosis is defined by a femoral neck T-score and/or lumbar spine ≤ -2.5 by DXA. Zoledronic acid is administered as an annual infusion of 5 mg. A pre-treatment assessment including serum creatinine and serum calcium and oral assessment was performed prior to infusion of zoledronic acid.

Results: We collected 11 patients treated with zoledronic acid including 9 women; the average age is 65 y. Among women, there were 3 cases of PMO, 1 case of hyperparathyroidism and 5 cases of CIO: the underlying pathologies were rheumatoid arthritis (RA) in 3 patients, one case of Gougerot-Sjogren syndrome and a case

of sarcoidosis. Both men had CIO: a 23-year-old man with lupus and a 74-year-old man with RA. 6 patients had a T-score ≤ -3 and 7 patients had at least one fracture.

Conclusion: The majority of our patients treated with zoledronic acid have severe osteoporosis complicated with fractures. Intravenous zoledronic acid 5 mg once a year is a convenient and effective treatment option especially in our patients at high risk of fracture.

P910

TERIPARATIDE AND DENOSUMAB COMBINATION THERAPY: PATIENT CHARACTERISTICS AND OUTCOMES IN AN IRISH BONE HEALTH AND OSTEOPOROSIS UNIT

K. Jusmanova¹, M. Rafferty¹, L. Fennelly¹, G. Steen², N. Maher², R. Lannon¹, K. McCarroll¹

¹Medicine for The Elderly Department, MISA, St. James's Hospital, ²Medicine for The Elderly Department, MISA, Bone Health Unit, St. James's Hospital, Dublin, Ireland

Objective: Recent studies show that dual therapy with denosumab and teriparatide is superior to teriparatide alone in improving BMD at the lumbar spine and total hip. [1] We aimed to identify patients at a bone health clinic where dual therapy was used, profiling their characteristics as well as biochemical and BMD response to treatment.

Methods: Patients commenced on dual therapy between 2015-2018 were identified from a Bone Health Clinic database. Data were collected for age, gender, baseline BMD (as assessed by DXA) and baseline bone markers (CTX and PINP). In addition, follow-up bone markers and BMD assessments (where available) were recorded.

Results: 17 patients were identified, 14 (82%) were female and mean age was 77.2 (range 61-92). Mean baseline T-score at hip was -3.7 and at spine -4.7 . Treatment was tolerated well with no side effect reported. CTX was significantly suppressed from baseline to 14 months 0.288 to 0.165 ($p < 0.05$) with nonsignificant changes in PINP ($p > 0.05$). In three patients where DXA was completed at 2-y follow-up, there was a significant improvement in mean BMD at the hip by 10.7%. and spine by 16.4%.

Conclusion: Dual therapy was reserved for patients at our clinic with severe osteoporosis of hip (T-score typically -3.0 or below) and spine. Treatment resulted in a very substantial improvement in hip BMD. Bone marker changes in CTX were similar to previously reported though there was less change in PINP which may reflect the differential effect on bone remodelling vs. new modelling.

Reference: 1. [Lou S et al. Osteoporos Int 2019;30:59](#)

P911

CLINICAL CONSIDERATIONS IN PREMENOPAUSAL BONE HEALTH THROUGH A GYNECOLOGICAL ROUTINE ASSISTANCE

A. O. Pedro¹, A. V. Gueldini de Moraes¹, C. L. Benetti-Pinto¹

¹Department of Obstetrics and Gynecology - University of Campinas, Campinas, São Paulo State, Brazil

Brazil has an aging population, with an associated increase in the prevalence of chronic diseases. Osteoporosis is of particular concern because it leads to an increased risk of fractures, with subsequent negative impacts on women's health. From a gynecological perspective, bone health should be addressed during all women's life span and not only to postmenopausal period of life. The Women's Health Hospital (tertiary university hospital) from State University of Campinas – UNICAMP has a established assistance routine in most of the outpatient clinics to prevent osteoporosis during a routine gynecological and obstetrics consultation. The routine assistance in selected ambulatories has the objective to address high risk patients for bone loss on special clinical conditions during adolescence and puberty, women with gynecological endocrinological morbidities (primary amenorrhea, premature ovarian failure, hypothalamic amenorrhea), surgical induced-menopause, during pregnancy and lactation period and in breast and gynecological cancer survivors. The assistance to bone healthcare is based on nutrition orientation, adequate physical activity to specific age groups, call attention to lifestyle habits, fall prevention and when necessary provide hormonal and antiresorptive pharmacological treatment. The gynecological involvement to prevent osteoporosis and fragility fracture during women's life span will have an important impact in high risk patients and it will create a better understand and consciousness of this silence epidemic.

P912

PREVALENCE OF LOW BONE MASS IN BREAST CANCER PATIENTS ON ENDOCRINE THERAPY WITH AROMATASE INHIBITORS USING T-SCORE, FRAX AND TBS-ADJUSTED INTERVENTION THRESHOLDS

M. Punda¹, T. Jukic¹, D. Vidovic², M. Bosak Butkovic¹, R. Granic¹, M. Franceschi¹

¹UHC "Sestre Milosrdnice", Department of Oncology and Nuclear Medicine, ²UHC "Sestre Milosrdnice", Clinic of Traumatology, Zagreb, Croatia

Objectives: The bone health guidelines for hormone responsive breast cancer (HRBC) patients treated with aromatase inhibitors (AIs) recommend the management of low bone mass based on BMD testing using DXA and according to the fracture risk assessment (FRAX) tool. The trabecular bone score (TBS)-adjusted FRAX incorporates TBS as a surrogate measure of bone microarchitecture. The aim of the study was to determine the prevalence of low bone mass in HRBC patients based on T-score, FRAX and FRAX-TBS criteria and its impact on treatment decision.

Methods: 69 HRBC postmenopausal patients treated with AIs, not previously receiving bone-modifying agents, were examined. Spine and hip BMD were measured using DXA, and TBS was calculated from L1-L4 spine BMD. The FRAX tool was calculated in two ways manner: as authentic (FRAX, FRAX-TBS) and by selecting glucocorticoids (GCs) as a counterpart for AIs (FRAX-GC, FRAX-TBS-GC). FRAX thresholds of MOF >20% and HF >3% were used.

Results: The patients aged 60.72±9.29 (mean, SD) years while the BMD evaluation was performed 15.34±15.08 months after starting AI treatment; in 23.2% out of them after 24 months. The mean BMI was 26.69±3.69 kg/m², and patients were menopausal for 13.53±11.65 years. A low bone mass was detected in 42% and 58% of patients using T-score ≤-2.5 and T-score <-2.0 threshold, respectively. A mean TBS was 1.382±0.08 (range 1.172- 1.543). Applying the FRAX-TBS tool among 28 patients with a T-score ≥-2.4, the high fracture risk was observed in 5 patients: according to HF >3% in both FRAX-GC and FRAX-TBS-GC and one patient out of them had MOF >20% in FRAX-GC model.

Conclusions: Applying the T-score ≤-2.5 and T-score <-2.0 thresholds we observed a low bone mass in half of our patients, and in almost a quarter of them DXA was performed more than two years after starting AI treatment. The application of the FRAX-GC and FRAX-TBS-GC tools among patients in osteopenic range additionally increased the number of patients requiring treatment. A longer follow-up is needed to determine if FRAX-TBS-GC tool could be routinely used among HRBC patients receiving AIs.

P913

FRAX ESTIMATED FRACTURE RISK MIGHT BE A GOOD MAJOR OSTEOPOROTIC FRACTURE PREDICTOR IN TYPE 2 DIABETIC FEMALES WITH OSTEOPOROSIS

A. Tabain¹, K. Blaslov², D. Tabak³, I. Glavinić⁴, I. Dumić-Čule⁵, A. Balenović⁴, S. Vukičević⁵

¹Polyclinic Medikol, ²University Clinical Hospital Center "Sestre Milosrdnice", ³Health Center Zagreb West, ⁴Health Center Zagreb, Zagreb, Croatia, ⁵Laboratory for mineralized Tissue, Zagreb, Croatia

Objective: Diabetes is an important risk factor for bone fragility. However, the 10-y probability risk of major osteoporotic fracture (MOF) and hip fracture (HF), calculated with fracture risk assessment tool (FRAX) is often underestimated in diabetic patients, mostly due to higher BMI as one of the variables included in FRAX calculation. Thus, we aimed to investigate the association in FRAX calculated risk in BMI matched, postmenopausal, osteoporotic females, with and without type 2 diabetes mellitus (T2DM).

Methods: This cross-sectional study included 63 age and BMI matched postmenopausal women. They were divided in two groups, according to T2DM presence. FRAX probabilities were calculated and T-score measurements were obtained with DXA. We compared FRAX MOF and HF risk between groups. In addition, we did an intra group differences in T2DM according to osteoporosis presence, detected by DXA.

Results: The study population was 66.8 years old, with BMI mean value of 27.89 kg/m².

There were 33 (52.4%) T2DM females, and 30 (47.6%) controls. We detected 12 osteoporotic patients, 8 in T2DM, and 4 in control group. There were no significant differences in age (mean, median 72.1, 74.0 vs. 64.7, 63.0), BMI status (mean, median 29.0, 28.6 vs. 26.8, 26.4) and T-score values in femoral neck area (mean, median -0.951, -0.700 vs. -0.989, -1.3), as expected.

There was no significant difference between T2DM females and controls in FRAX estimated MOF risk (p=0.094), as well as in HF risk (p=0.077). However, T2DM females with osteoporosis revealed significant higher FRAX MOF risk in comparison to T2DM females without osteoporosis (p=0.044 assessed with Mann-Whitney U test). Hip fracture risk in osteoporotic and nonosteoporotic T2DM patients wasn't significantly different (p=0.098).

Conclusion: Our results indicate that T2DM patients might be disposed to higher frequency of fractures. This might be due to the metabolic disbalance as a natural core of the disease, which is in accordance to the FRAX calculation. Further study investigation are required in order to elucidate the contribution of BMI and other risk factors that affect the FRAX calculation in diabetic patients.

P914

APPRECIATION OF OSTEOPOROTIC TREATMENT COMPLIANCE WITH ALENDRONATE 70 MG ORALLY

B. Bengana¹, A. Boukabous¹, N. Bahaz¹, S. Lefkir¹

¹University Hospital of Benimessous, Algiers, Algeria

Objective: Patients suffering from osteoporosis (OP) have not the opportunity to enjoy from an accurate and concrete parameters response to OP treatment. They therefore have no palpable evidence of the favorable effect generated by antiosteoporotic treatment (AOT). given the silent nature of the pathology. That is way we see the noncompliance with treatment in some patients.

It was imperative to estimate the extent of the lack of compliance with AOT in order to deduce the factors related to this deficiency in order to reduce the size of the problem.

Methods: It is a descriptive cross study performed in all patients over 38 y for both sexes and that exhibit postmenopausal or corticosteroid-induced OP justifying AOT orally (alendronate 70 mg orally per week) observed over a period of at least 6 months.

Methods: We collected data of 153 patients. in 9 out of 10 cases this was a woman, the mean age was 59.3±8.1 y, the average duration of gain of treatment was 32.2±18.2 months, 3 of 5 patients believe that treatment is for musculoskeletal pains. 1/3 of respondents confess not to take their weekly treatment regularly. regular physical activity was performed by only 21% of patients. the factors related to noncompliance were lack of education (p=0.032) and sedentary lifestyle (p=0.044).

Conclusion: OP is unfortunately underestimated by both patients and physicians, and its short- and long-term repercussions are often minimized. Our study has shown that the various measures required in its management are poorly followed by patients

despite their proven effectiveness in reducing fractures. One in three patients in our sample do not follow their treatment properly. Therapeutic education seems to be the answer to overcome this lack of adhesion.

P915

EFFECT OF IGF-1 GENE POLYMORPHISM ON BONE MINERAL DENSITY IN OSTEOPOROTIC POSTMENOPAUSAL SUDANESE WOMEN

H. Mohamed¹, A. Ismail², K. Braima³

¹Karary University, Khartoum, Saudi Arabia, ²Neelain University, Khartoum, Saudi Arabia, ³Murdoch University, Perth, Australia

Objective: BMD is the hallmark of OP and exhibits high heritability; efforts to understand OP genetic determinants have therefore been increased. In this study a polymorphism of IGF-I gene was examined in Sudanese postmenopausal women to analyse the genetic background for osteoporosis.

Method: A cross-sectional study conducted during the period of 2014-2015. We studied 836 women referred to our hospital. Based on the DXA results and inclusion criteria 121 postmenopause women (45-80 years old) were selected. Classified into three groups, osteoporotic, T-score (≥ -2.5), osteopenia, T-score (-1 to -2.5) and normal, T-score (≤ -1) as the control group. A most common single nucleotide polymorphisms (SNP) in (IGF-1) gene (rs35767) were measured using RT-PCR TaqMan. Serum concentration of IGF-1 was measured by ADVIA (Siemens Healthcare Diagnostics Inc., Deerfield, IL, USA).

Results: The IGF-I SNP (rs11568820) CC genotype was found to be associated with osteoporosis and BMD at the total hip (not lumbar spine (L1-L4) under recessive and additive genetic model (AOR (95%CI)=2.0(1.0-8); p=0.0) and (OR (95%CI)=1.5 (0.1-7); p=0.02) respectively. Serum level of IGF-I was strongly associated with decreased BMD with level significantly decreasing ($P < 0.01$).

Conclusions: We found significant associations between CC genotype of IGF-1 rs35767, BMD and osteoporosis risk, suggesting that IGF-1 rs35767 can be used as a predictive factor for determining the risk of osteoporosis. Serum IGF-1 can be used as predictor marker for determine early decreased BMD. Further study with large sample size are needed to confirm the results of our study.

P916

PARATHYROID ADENOMA AS A PREDICTOR OF SEVERITY OF OSTEOPOROSIS IN HYPERPARATHYROIDISM

O. Hannigan¹, S.-A. Lynch², E. Hurley¹, M. Rafferty¹, R. Lannon¹, N. Fallon¹, J. B. Walsh¹, B. McCarthy¹, M. C. Casey¹, K. McCarroll¹

¹Mercers Institute for Research on Ageing, St James's Hospital,

²Mercers Institute for Research on Ageing, St James's Hospital, Dublin, Ireland

Objective: Hyperparathyroidism is a known cause of bone disease (1), and its management and treatment are an important factor in the prevention and treatment of osteopaenia and osteoporosis. This study aimed to evaluate the significance of the presence of a parathyroid adenoma in the severity of osteoporosis in a cohort with primary hyperparathyroidism.

Methods: We identified patients from our tertiary referral, bone health clinic who had a biochemical diagnosis of primary hyperparathyroidism and had both a DXA and Sestimibi scan (\pm ultrasound parathyroid). We used regression models to explore for associations between the presence of parathyroid adenoma and age, gender and severity of osteoporosis/osteopaenia (as assessed by BMD).

Results: 100 subjects were identified: 81 were female and mean age was 67.5 ± 13.3 (range 37-94). 79% were osteopenic and 33% had osteoporosis as defined by WHO criteria. 12 had vertebral fractures on VFA and six had fractures at multiple sites. 60 had a parathyroid adenoma confirmed on Sestimibi scan \pm ultrasound parathyroid. Age or gender did not predict the presence of parathyroid adenoma on imaging ($P > 0.05$). In addition, no relationship was found between the presence of parathyroid adenoma and the severity of osteoporosis ($P > 0.05$).

Conclusion: In our cohort, a significant proportion of patients with primary hyperparathyroidism had negative imaging. However, in those found to have a parathyroid adenoma, there was no difference in the severity of osteoporosis. Primary hyperparathyroidism is an important risk factor irrespective of imaging results and requires close follow-up. Repeat imaging including with the use of MRI should be considered in patients with negative scans who are candidates for surgery.

Reference: Fraser WD. Lancet 2009;374:145.

P917

UTILITY OF FOREARM DXA AT IDENTIFYING OSTEOPOROSIS IN AN IRISH COHORT WITH PRIMARY HYPERPARATHYROIDISM

S.-A. Lynch¹, O. Hannigan², T. McNicholas³, M. Gallagher², G. Steen², K. McCarroll², B. McCarthy², J. B. Walsh², M. C. Casey², R. Lannon²

¹Mercers Institute for Research on Ageing, St James's Hospital,

²Mercers Institute for Research on Ageing, St James's Hospital,

³The Irish Longitudinal Study on Ageing, Trinity College Dublin, Dublin, Ireland

Objective: Hyperparathyroidism is a known cause of severe bone disease(1), and its management and treatment are an important factor in the prevention and treatment of osteopaenia and osteoporosis. It has been increasingly recognised that primary hyperparathyroidism has a more profound effect on the bone of the distal forearm due to its relatively high rate of cortical bone(2). Our study aimed to investigate the utility of forearm DXA at identifying osteoporosis in an Irish population with primary hyperparathyroidism vs. traditional DXA (AP spine, femoral neck and total hip) as measured by T-score.

Methods: Chart review was performed on patients attending a bone health clinic in a large tertiary referral centre. 32 subjects were identified as having a biochemical diagnosis of primary hyperparathyroidism and DXA of forearm (total) and AP-spine/total hip/femoral neck. Analysis was then performed using a discrete statistical analysis software, STATA.

Results: Of the 32 subjects 7 were men, 25 women. 17 had a diagnosis of osteoporosis by T-score identified at any site. 5 had a diagnosis of osteoporosis as measured by T-score identified on forearm DXA which was not picked up on AP spine, total hip or femoral neck DXA. This was a statistically significant result on chi-squared test, $p = .001$. Those subjects who had osteoporosis identified at AP spine/total hip/femoral neck had a tendency towards a worse T-score in their forearm, however this was not statistically significant (mean -3.8, range:-7.3 to -2.1).

Conclusion: Forearm DXA is an important modality in diagnosing osteoporosis in the context of primary hyperparathyroidism. All patients with a diagnosis of primary hyperparathyroidism should be referred for DXA with a forearm DXA as standard.

References:

1. Fraser WD. Lancet 2009;374:145.
2. Wood K et al. Oncologist 2012;17:322.

P918

OSTEOPOROTIC FRACTURES IN THE ELDERLY: IS HYPONATREMIA PLAYER OR BYSTANDER?

L. A. M. Schiara¹, E. Grosso², L. Richiardi³, G. Moirano³, M. Tibaldi³, E. Spertino³, C. Vezza³, G. C. Isaia³, P. D'Amelio³

¹Department of Medical Science, City of Health and Science Hospitals, ²Department of Orthopaedics, Traumatology, City of Health and Science Hospitals, ³Department of Medical Science, City of Health and Science Hospital, Turin, Italy

Objective: To evaluate the role of hyponatremia in fragility fractures and mortality in elderly.

Variable	Normonatremic (234) Median (IQR)	Hyponatremic (50) Median (IQR)	p
MMSE	24.8 (22.2-26.7)	24.6 (22.2-26.3)	0.503
MNA	21.5 (18.5-24.5)	20.0 (17.0-22.5)	0.005
BMI (kg/m ²)	25.3 (22.7-29.0)	22.6 (20.9-24.6)	0.000
Force to the dynamometer (Kgp)	20.0 (14.0-28.0)	18.0 (12.0-24.0)	0.099
Tinetti score	17.0 (12.0-23.0)	18.0 (12.0-24.0)	0.556
Previous fragility fractures (%)	22 (44.0%)	59 (25.2%)	0.008

Survival analysis showed that hyponatremia at baseline was associated with higher mortality rate (p=0.005), hazard ratio (HR) crude=1.80 (95%CI 1.19-2.71), HR adjusted for comorbidities, sex, age=1.75 (1.16-2.65).

Conclusions: Our result shows that hyponatremic patients are generally more affected by malnutrition; our results highlight the roles of hyponatremia as worse prognosis indicator and risk for fragility fractures regardless to other important variables as age, sex and co-morbidities. Serum sodium is an easily available and affordable biochemical measurement in clinical practice; hence, the assessment of hyponatremia could be used as an index of worse outcome in old patients, supplementing the patient assessment clinical scales.

P919

UTILITY OF FOREARM DXA IN THE EVALUATION AND MANAGEMENT OF PATIENTS ATTENDING A SPECIALIST OSTEOPOROSIS AND BONE HEALTH CLINIC

E. Gannon¹, M. Rafferty¹, N. Fallon¹, C. O'Connell¹, E. Hendy¹, R. Lannon¹, K. McCarroll¹

¹St James Hospital, Dublin, Ireland

Objective: To review the utility of forearm DXA in the evaluation of patients attending a specialist osteoporosis and bone health clinic, the indications for its use, and to assess if forearm DXA provided any change in diagnosis of osteoporosis when compared to results in DXA from the spine.

Method: 284 hospitalized geriatric patients without secondary causes of hyponatremia or osteoporosis were recruited in the study. Age, sex, comorbidities, drugs and previous fragility fractures were recorded. Blood levels of sodium, potassium, phosphate and calcium were measured. Cognitive function, nutrition, muscular strength and balance were evaluated by standard tests. Normo- and hypo-natremic patients were compared for the analysed variables. The mortality rate of the patients was recorded with a follow-up after hospital discharge. The ethics committee of our hospital approved the study.

Results Hyponatremic patients were more malnourished (BMI, MNA score), without significant differences in cognitive performance (MMSE), in risk of falls (Tinetti scale) nor in muscle strength. Interestingly, hyponatremic patients reported higher prevalence of fragility fractures (Table 1).

Methods: Data was retrospectively extracted from a bone database of patients who had undergone forearm DXA in a tertiary referral centre for Osteoporosis and Bone Health, from 2003-2018. The results were analysed using SPSS.

Results: Forearm DXA was carried out in 339 of 8000 patients included in the database from 2003-2018. The mean age of patients was 73.17, 269 (79%) were female. Hyperparathyroidism was an indication for forearm DXA in 49 patients, 160 patients did not have a corresponding spine measurement and the assumption was made spinal DXA was not tolerated in these patients and thus an indication for forearm DXA. Of those that did have comparative spine T-scores measured (n=180), osteoporosis was diagnosed in 112 (62.2%) of patients with forearm DXA, and 84 (46.6%) on spinal DXA. A chi-square test was conducted to assess whether the proportion diagnosed with osteoporosis on DXA forearm significantly differed to DXA spine, the results were found to be significant X²=15.397, p<0.01. Forearm DXA upgraded the diagnosis from osteopenia or normal to osteoporosis in 47 patients (26.1%).

Conclusions: Forearm DXA is recommended and used in our unit for patients with hyperparathyroidism. It is also helpful in the evaluation of BMD if patients in who spinal imaging is not possible. There was a significant difference in those identified with T-scores in the osteoporotic range on forearm DXA compared with AP Spine DXA. Therefore, its use may be considered in patients undergoing evaluation for osteoporosis and the result, where available, considered in the evaluation of fracture risk and treatment thresholds.

P920

INCIDENCE OF OSTEOPOROSIS IN WOMEN WITH RHEUMATOID ARTHRITIS RELATED TO ACTIVITY OF THE DISEASE

L. I. Suiu¹, C. Criveanu², A. F. Vreju², A. E. Musetescu², O. R. Predescu¹, P. L. Ciurea²

¹County Clinical Emergency Hospital Craiova, ²University of Medicine and Pharmacy Craiova, Craiova, Romania

Objective: Osteoporosis, a condition with a great socioeconomic impact, is a systemic skeletal disease characterized by reduced bone mass and microarchitectural damage to bone tissue resulting in increased bone fragility and, implicitly, fracture risk. It is known to be common in patients with rheumatoid arthritis. This study follows the evaluation of osteoporosis in women with rheumatoid arthritis depending on postmenopausal status, disability and activity of the disease.

Methods: We analyzed a group of 47 female patients diagnosed with rheumatoid arthritis who fulfills the 2010 revised criteria of ACR/EULAR. The BMD measurements were performed using DXA in the hip (total hip) or in the lumbar spine. Patients are aged between 40-70 y. We excluded from this study patients who received glucocorticoid therapy.

Results: Of the 47 patients, 9 of these (19.14%) had a DAS28CRP of <2.69 (disease remission), 5 (55.55%) aged over 50 and 4 (44.44%) of these under the age of 50. 60% of those over 50 years old had a T-score < -2.5 SD and the remaining 40% had osteopenia (T-score < -1 > -2.5SD) or normal BMD. Of those under the age of 50 years 1 (20%) had a T-score -2.7 SD and the remaining 3 (80%) had a T-score value between 0.4 -1 SD. Related to low disease activity, of all patients, 13 (27.65%) had a DAS28CRP >2.6 <3.0 and of those, 8 (61.53%) were over 50 y of age, 7 (87.5%) with a T-score ranging from 0.8 SD to -2 SD and one patient (12.5%) with T-score - 2.5 SD; 5 (38.41%) under 50 y of age, all with a T-score > - 2.4 SD. Moderate disease activity was found at 16 patients (34.04%) who had a DAS28CRP value of between 3.1 and 4.0. 9 were under 50 years old and T-score < -2.5 SD - 55.5%, higher than -2.4 SD - 44.4%, and 7 were over 50 years old with T-score < -2.5 SD percent of 71.4% and >- 2.5 SD percent of 28.57%. 9 of the 47 patients(19%) had a DAS28CRP > 5 value (high disease activity) and 6 of them (67%)were aged over 50 y, 4(67%) of which had a T-score <-2.5 SD and 3 (33%) aged under 50 years had a T-score > -2 SD. 57.4% of female patients which we analyzed had postmenopausal status and 22.2% of them were diagnosed with osteoporosis.

Conclusions: Osteoporosis is a disease commonly seen in postmenopausal women with rheumatoid arthritis, and is also influenced by increased activity of the disease.

P921

SEASONALLY DEPENDENT DECREASE OF THE NUMBER OF FRACTURES IN POLAND IN THE YEARS 2010-2015

K. Jedynasty¹, M. Zięba², P. Głuszko³, W. Grzeszak⁴, A. Szypowska⁵, A. Śliwczyński⁶, M. Walicka¹, E. Franek⁷


¹Department of Internal Diseases, Endocrinology and Diabetology/Central Clinical Hospital MSWiA, Warsaw, ²Analyses and Strategies Department/Ministry of Health, Warsaw, ³Department of Rheumatology/National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, ⁴Department of Internal Medicine, Diabetology and Nephrology/Medical University of Silesia, Zabrze, ⁵Department of Paediatrics/Warsaw Medical University, Warsaw, ⁶University of Humanities and Economics in Lodz/Satellite Campus in Warsaw, Warsaw, ⁷Department of Human Epigenetics/Mossakowski Medical Research Centre, Warsaw, Poland

Objective: Falls are the main risk factors of extravertebral fractures. The risk of slip and fall injuries is highest in winter. However, the number of cold and snowy days decreases with the climate changes. The study aimed to examine trends in fracture incidence in the last years and their correlation with temperature and number of snowy days.

Methods: A database of the National Health Fund, covering almost all fractures in Poland in the years between 2010-2015, was analyzed. Only patients older than 50 y were included.

Results: In the examined period there was a significant decrease of the yearly incidence of the forearm (from 71907 to 54169) and femur (from 27291 to 25002) fractures that was dependent mainly on the decrease during winter months (Figure 1). From the other side a statistically significant increase of incidence of the humerus and lumbar spine fractures, whereas the incidence of thoracic spine fractures was stable. The differences in the incidence of the latter three types of fractures were not seasonally dependent.

Figure 1. Number of fractures in November-March and April-October



The number of fractures was related to the weather. Table 1 shows Pearson's correlation coefficients between weather variables (based on meteorological station in Warsaw) and number of fractures (for period November-March).

Table 1. Pearson's correlation coefficients between weather variables and number of fractures.

	humerus	femur	lumbar spine/ vertebra	thoracic spine/ vertebra	forearm
Mean temperature in December	0.389	-0.838*	0.599	0.158	-0.813*
6789 Mean temperature in January	0.311	-0.870*	0.495	0.096	-0.888*
Mean temperature in February	0.512	-0.429	0.678	0.401	-0.357
Number of days with snow (per year)	-0.176	0.698	-0.544	-0.131	0.823*
Mean annual temperature	0.554	-0.949*	0.829*	0.332	-0.930*

Conclusion: Even in a short-time observation period (2010-2015) a climate-dependent decrease of the incidence of forearm and femur fractures can be observed

P922
BONE MINERAL DENSITY IN MEN WITH CRURIS FRACTURE

R. Filipov¹, K. Markovic¹, I. Dimitrijevic¹, S. Kozomara¹, M. Stoickov¹

¹Institute Niska Banja, Nis, Serbia

Objective: Today osteoporosis is one of the biggest health problems of civilisation. It has a significant role in the etiology of fractures in elder population. Osteoporosis in men, although of significantly lower frequency, in comparison to women, is not only a growing health but also a socioeconomic problem. Our aim was to establish the frequency of osteoporosis in men who had cruris fracture.

Methods: 456 male patients were examined. Out of them, 256 were in the investigated group (IG), they were the patients who had cruris fracture, while 200 out of them were without fracture and they were included in the control group (CG). Measuring of BMD was performed on the DXA Hologic apparatus, on both lumbar vertebra L1-L4 and on the left hip.

Results: Average BMD value on the lumbar spine in the investigated group was 0.845±0.12 g/cm² (T-score -1.8±0.89), and on the hip 0.801±0.112 g/cm² (T-score -1.9±0.82). Average BMD value on the lumbar spine in the control group was 0.965±0.121 g/cm² (T-score -1.23±0.91) and on the hip it was 0.824±0.145 g/cm² (T-score -1.37±0.82). Statistically significant difference was not found between absolute values of BMD as on the lumbar spine (p>0.01), as on the hip (p>0.5), between the investigated and control group. There is no statistically significant difference between average T-score values on the lumbar spine or on the hip in the investigated and control group.

Conclusion: Cruris fracture in men are not associated with the presence of osteoporosis.

P923
PREDICTORS OF POOR RESPONSE TO TNFα INHIBITORS IN PATIENTS WITH ANKYLOSING SPONDYLITIS

A. Boukabous¹, B. Bengana¹, N. Bahaz¹, S. Debbah¹, S. Lefkir¹

¹University Hospital of Benimessous, Algiers, Algeria

Objective: TNFα inhibitors represent a major advance in the treatment of certain refractory forms of ankylosing spondylitis (AS). Unfortunately, some patients have failures despite these therapies, apart from their undesirable effects and cost, which must be taken into account. Defining immediately patients likely to be good or bad responders would be of great help. The objective of our work was to try to assess the failure rate of these treatments but also to identify possible predictors of nonresponse to anti-TNFα in an Algerian population of AS.

Method: It is a prospective study of a cohort of AS meeting New York criteria, recruited between June 2009 and June 2017 subjected to a treatment with anti-TNFα with evaluation before and after 6 months of treatment, we have evaluated the demographic, clinical, biological data of the sample.

Results: We selected 74 patients for the analysis (etanercept=35, adalimumab=31, infliximab=8), the mean age is 34.6 y ±9.6, the sex ratio is 3.62. the mean duration of the disease is 12.1 y ±8.2, the mean duration of treatment is 33.9 months ±21.1. After 6 months of treatment we noted 77% of good responders having completed a BASDAI 50, against 23% nonresponders. Factors associated with poor response to TNFα antagonists were smoking (p=0.025) and high BMI (p=0.0001).

Conclusion: In our study more than ¾ of patients still respond well to anti-TNFα after 6 months of treatment against 23% who admit a failure, the elements in favor of a bad response to anti-TNFα are patients who smoke and those with a high BMI. This work is expected to be continued on a larger sample and in the longer term to better understand the predictors of nonresponse to these molecules.

P924

WALKING ABILITY BY 6 MONTHS POSTFRACTURE DETERMINES ONE-YEAR MORTALITY OF FRACTURES OF THE PROXIMAL FEMUR: A STUDY FROM A PORTUGUESE HOSPITAL CENTER

R. Prado Costa¹, S. Ganhão², F. Aguiar², H. Tavares¹, L. Brito²

¹Department of Physical and Rehabilitation Medicine of Centro Hospitalar Universitário de São João, ²Department of Rheumatology of Centro Hospitalar Universitário de São João, Porto, Portugal

Objective: Fragility fractures of the proximal femur (FFPF) are associated with significant morbidity, mortality, loss of independence, and financial burden. The first year after a hip fracture appears to be the most critical time. The aim of the present study was the determination of factors associated with greater mortality after a FFPF in a Portuguese hospital center.

Methods: Retrospective study comprising patients admitted to Centro Hospitalar Universitário de São João with FFPF from 2015 to 2017. Data were collected from electronic medical records. Kaplan-Meier analysis with log-rank test was calculated to compare the differences of mean survival time. A Cox proportional-hazard models for survival time was performed to determine factors that were associated with 1-y survival. The studied factors were the age, gender, type of fracture, type of surgery, Charlson comorbidity index (CCI), length of stay in orthopedic ward, previous walking ability and walking ability by 6 month post fracture.

Results: Data from 522 patients were used for analysis. The mean age was 83±7.6 years old and 416 patients were women. The mean length of stay was 21.0 d (interquartile range of 17 d). Around 4.8%, 13.0% and 18.4% died, respectively, within 1, 6 and 12 month after the fracture. The mean survival time was significantly lower for greater age ($p=0.009$), for femoral neck fracture ($p=0.006$), for surgery with arthroplasty ($p=0.01$), for greater length of stay ($p=0.008$) and for patients unable to walk by 6 month post fracture ($p=0.004$). The hazard ratio (HR) of mortality were significantly higher for surgery with arthroplasty (HR: 3.4; $p=0.003$) and inability of walk by 6 month post-fracture (HR: 3.1; $p=0.009$).

Conclusion: The mortality at one year in our medical center is in accordance with the literature. It is known that immobilization during inpatient hospital is associated with sarcopenia, loss of strength and function. This can lead to inability to walk leading to further increase in likelihood of death as demonstrated. Unfortunately, those patients were not integrated earlier in multidisciplinary rehabilitation/geriatric facilities which, in part, may negatively influence the functional and vital prognosis in FFPF.

P925

DETECTION OF SUBLESIONAL OSTEOPOROSIS IN PATIENTS AT RISK

M. L. Cevei¹, B.-M. Muscalau², D. Stoicanescu³

¹University of Oradea, Faculty of Medicine and Pharmacie, Oradea, ²Spitalul Clinic de Recuperare Medicala Baile Felix, Oradea, ³University of Medicine and Pharmacie, Victor Babes, Timisoara, Timisoara. Romania

We performed a prospective study on 138 patients hospitalized in Medical Rehabilitation Clinical Hospital Baile Felix, Romania, 95 men, diagnosed with tetra, para or hemiparesis due to vertebro-medullary trauma (51.44%), stroke (18.11%), craniocerebral trauma (5.07%), tumors, cerebral abscess, encephalitis a.o. (25.36%). Their mean age was 45.30. Mean age in the group with vertebromedullary trauma was 39.1 y, 58.8 y in the group with stroke, 30.42 y in patients with craniocerebral trauma and 47.82 y in the others. Osteoporosis was detected using DXA investigation in 77.53% cases. Osteoporosis was present in 77.46% of patients with vertebromedullary trauma, 76% of those with stroke, 85.71% of cases with craniocerebral trauma and 77.14% in the remaining cases. According to ASIA classification 35.21% of patients with vertebromedullary trauma had ASIA-A impairment, 26.76% ASIA-B, 22.53% ASIA-C and 12.67% had ASIA-D. Osteoporosis was present in 76% of cases with ASIA-A, 94.73% patients with B, 68.75% with C and 66.6% with D. Quantification of spasticity using the modified Ashwort scale showed that 73.23% of the cases had spasticity. Out of these 14.08% had grade 1, 32.39% had grade 2, 18.3% had 3 and 8.45% had 4. Osteoporosis was present in 76.68% of cases with grade 0, 70% patients with 1, 73.91% with 2, 92.4% with grade 3 and 66.6% with 4. The mean duration from the moment of the motor deficit causal event until DXA investigation was 33.7 months for vertebromedullary trauma, 33.43 months for stroke, 60 months for craniocerebral trauma, 26.7 months for other etiologies. Within 24 months from the causal event, osteoporosis was present in 71.87% of cases, mean age 45.47 y, distributed as follows: 60% of patients with vertebromedullary trauma, mean age 48.11 y; 81.81% of cases with stroke, mean age 50.77 y; 14.28% of those with craniocerebral trauma, mean age 34 y and 80% of patients with other etiologies, mean age 49.

Conclusion: Bone loss is mainly due to reduced mobility and traction forces on the bone, but also to other complex processes. Sublesional osteoporosis detection is important because bone loss is partially reversible, thus initiation of antiosteoporotic therapy is beneficial.

P926

ANALYSIS OF BONE MASS MEASUREMENT REQUESTS BY ALGERIAN PHYSICIANS: ARE THEY COMPLYING WITH THE INDICATIONS OF THE INTERNATIONAL SOCIETY OF CLINICAL DENSITOMETRY (ISCD)?

B. Bengana¹, A. Boukabous¹, N. Bahaz¹, S. Lefkir¹

¹University Hospital of Benmessous, Algiers, Algeria

Objective: Bone strength and the risk of fracture depend on bone mineral content or BMD. DXA is the gold standard and key examination for measuring BMD. Its indications are clearly known. This exam is not reimbursed by Algerian social insurance. Indeed, measuring BMD is helpful in some people with risk factors of osteoporosis. The ISCD has produced some indications for the measure of bone density. We also wanted to appreciate the profile of BMD prescriptions of Algerian physicians. Are they meet the ISCD recommendations?

Methods: It is a descriptive study of a survey in different municipalities of Algiers, we analysed all the prescriptions for BMD measurement during 6 months from December 2017 to May 2018, with assessment of complete patient and physician profile. We also examined the various indications justified by the requests. We appreciated whether or not they matched the indications of BMD measurement according to the ISCD.

Results: Altogether 551 requests were received, of which 62% came from rheumatologists (8/10 of them from the private sector), 16% were oncologists and 12% were general practitioners; most of the prescriptions concerned women of menopausal age. In 1/5 the cases the requests were not meeting indications of BMD measurement according to the ISCD (2 of 3 were general practitioners).

Conclusion: The BMD measurement prescriptions come from the rheumatologists in 2/3 of the cases and remain insufficient from the general practitioners, in most cases their requests are not complying with the indications of the ISCD. Indications to men are exceptional.

P927

PATIENT AND SERVICE-LEVEL PREDICTORS OF BONE TREATMENT RECOMMENDATION POST-FRACTURE: RESULTS FROM THE UK NATIONAL FRACTURE LIAISON SERVICE (FLS) DATABASE

S. Hawley¹, N. Vasilakis², B. Wiles², C. L. Gregson³, N. Gittoes⁴, G. Clunie⁵, C. Cockill⁶, I. Price⁷, A. Judge³, A. Smith², M. K. Javaid¹


¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, ²Care Quality Improvement Department, Royal College of Physicians, London, ³University of Bristol, Bristol, ⁴Department of Endocrinology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, ⁵British Society for Rheumatology, Cambridge, ⁶Yeovil District Hospital NHS Foundation Trust, Yeovil, ⁷Patient and Carer Network, Royal College of Physicians, London, UK

Objective: To describe antiosteoporosis treatment recommendations postfracture and identify patient and organisational predictors of: decision to treat (including oral bisphosphonate, parenteral therapy or clinical/GP referral for consideration of treatment) vs. decision not to treat; and oral bisphosphonate vs. parenteral therapy recommendations.

Methods: Patients with fragility fracture diagnosed in England between 01/01/2017-31/12/2017 were identified from the Royal College of Physicians national FLS database. Patients diagnosed within centres achieving <50% case finding or with ≥50% unknown/missing treatment information were excluded. Descriptive statistics outlined treatment recommendations, with stratification by FLS. Patient and FLS-level factors (highest nurse band; nurse & administrator whole time equivalent per 1000 admissions (</> median)) were identified by complete case analysis using multilevel multivariable logistic regression.

Results: Of 19,217 eligible patients (mean age 73 y; 77% female) from 15 FLS centres, 24% were recommended an oral bisphosphonate, 6% denosumab, 5% zoledronic acid, 25% were referred and 40% were neither referred nor recommended treatment. There was marked variation in these outcomes by FLS. Patient-level characteristics and odds ratios (OR) for appropriate treatment recommendation/referral are shown in the figure; adjustment for FLS-level factors (which were nonpredictive) did not attenuate these associations. Predictors of parenteral (vs. oral bisphosphonate) therapy were age ≥75 y (OR: 2.03 [95%CI: 1.64–2.51]), smoking (OR: 1.39 [0.99–1.95]), living in a residential home (OR: 2.81 [1.95–4.04]), hip (OR: 1.37 [1.10–1.71]) or spine (OR: 1.83 [1.34–2.50]) fracture, previous fracture (OR: 2.03 [1.66–2.48]) and previous bone treatment (OR: 2.86 [2.24–3.65]). At the FLS level, the number of full-time nurses per 1000 admissions (above and below median of 0.46 whole time equivalents) was also predictive of parenteral therapy (OR: 6.50 [1.16–36.48]).

Figure: mutually adjusted patient-level predictors of being recommended bone treatment in the FLS setting



Conclusion: Multiple factors are associated with treatment recommendations made postfracture, including greater intensity of nurse time. These results provide clinicians and service managers with insights towards standardising and improving services.

Acknowledgments: The Fracture Liaison Service Database is commissioned by the UK Healthcare Quality Improvement Partnership (HQIP)

P928
PHYSICAL PERFORMANCE IN OLDEST OLD COMMUNITY-LIVING DURING A 3- YEAR FOLLOW-UP: LOCOMOV PROJECT

S. N. Carmo¹, M. C. F. Arbex¹, J. E. F. Okazaki¹, D. R. B. Tavares¹, J. C. Galiano¹, J. A. P. Alves¹, F. C. Santos¹

¹Federal University of São Paulo, São Paulo, Brazil

Objective: To evaluate the physical performance in the community-living elderly aged 80 y or more with or without locomotive syndrome (LS), comparing both groups.

Methods: This is an analysis of 3 years follow-up of the prospective cohort - LOCOMOV Project. The individuals were evaluated using the questionnaires related to LS diagnostic (geriatric locomotive function scale-25), basic and instrumental daily living activities (Katz and Lawton, respectively) and physical performance tests (4-meter gait speed - 4mGS, 5 times sit-to-stand test - 5xSST, two-step-test - TST and hand grip - HG). For the statistical analysis, the data collected was submitted to the following tests: McNemar, T-Student, chi-square, Wilcoxon and analysis of variance (ANOVA). The global significance level was set at 0.05 (5%).

Results: At baseline, there were 102 participants, but we considered the data from 87 individuals (missing data: 4 dropouts, 5 deaths and 6 participants who developed moderate to severe dementia). The mean age was 87.3 years. There were 24 male and 63 female; 48 individuals were LS carriers and 39 were not. We did not observe interactions between time and group for all variables. The participants with LS presented themselves evolutionarily worst in TST (p<0.001), as well as in 5xSST (p<0.001). Also, 4mGS and HG were worse (p<0.001 and p<0.004, respectively) in LS carriers. For basic activities of daily living, the decline was higher in those with LS than in those without it, 20.0% and 4.8%, respectively (p=0.035).

Conclusion: Those oldest old community-dwelling with LS, presented worse physical performance and also decline in functionality in the 3-y follow-up.

P929

TRABECULAR BONE SCORE IN ADDITION TO BONE MINERAL DENSITY IN FEMALE PATIENTS WITH PSORIATIC ARTHRITIS

M. Punda¹, F. Grubisic², R. Vukojevic³, M. Bosak Butkovic⁴, I. Blazekovic⁴, S. Grazio²

¹UHC "Sestre Milosrdnice", Department of Oncology and Nuclear Medicine, ²UHC Sestre Milosrdnice, Department of Rheumatology, Physical Medicine and Rehabilitation, ³UHC Sestre Milosrdnice, Division for Diagnostic and Interventional Radiology, ⁴UHC Sestre Milosrdnice, Department of Oncology and Nuclear Medicine, Zagreb, Croatia

Objectives: In patients with psoriatic arthritis (PsA) the studies evaluating BMD using DXA provide inconsistent and conflicting results, and there are a limited number of studies that evaluated bone microarchitecture. The aims of the study were to assess the bone microarchitecture by trabecular bone score (TBS) using DXA in addition to BMD in PsA patients and controls and to investigate the determinants of a low TBS among patients.

Methods: The study included 60 female PsA patients aged 61.85±8.43 (mean, SD) y and 107 age-matched female controls. Spine and hip BMD were assessed by DXA. TBS was calculated from the anteroposterior image of the spine BMD.

Results: The prevalence of osteoporosis (T-score ≤ -2.5) in PsA patients was similar to controls (23.3% and 21.5%, respectively). However, a significantly higher proportion of controls had a T-score between -2.4 and -1.0, compared to patients (61.7% vs. 43.3%, p=0.032). There were no significant between-group differences in TBS and BMD at the lumbar spine, while significantly higher BMD at the femoral neck was detected in patients (p=0.017). Patients had significantly higher weight (mean 77.13±13.45 kg) and higher BMI (28.45±4.99 kg/m²) compared to controls, all p<0.05. According to TBS results (1.36±0.09) the patients with a TBS in the lowest tertile (TBS ≤ 1.33, n=20) were compared to patients with a TBS value in the 2 upper tertiles (TBS > 1.34, n=40). In univariate analysis low TBS showed trends of association toward higher BMI, to higher prevalence of low T-score (< -1.0) and to a lower lumbar spine BMD, however the results did not reach significance. No association was observed between low TBS and age, duration of the disease, previous non-traumatic fractures, menopause duration, or use of GCs.

Conclusions: Our results show no significant differences in the prevalence of osteoporosis and in TBS values between PsA patients and controls. Surprisingly, we observed significantly higher femoral neck BMD in patients compared to controls, which might be explained by significantly higher weight and BMI among patients. We found no predictors of low TBS related to parameters of the disease.

P930

INFECTIONS WITH ANTI-TNFα: PROSPECTIVE STUDY OVER 12 YEARS

B. Bengana¹, A. Boukabous¹, N. Bahaz¹, S. Debbah¹, M. Djekoune¹, S. Lefkir¹

¹University Hospital of Benimessous, Algiers, Algeria

Objective: Anti-TNFα has significantly improved the prognosis of some chronic inflammatory diseases (CID). Nevertheless, they carry with them a significant risk of opportunistic infections, imposing a rigorous surveillance and an adequate education of the patients. In a context of endemic tuberculosis, it is imperative to take the appropriate precautions to detect this kind of infection in rheumatismers under anti-TNFα. The aim of our work was to study the profile of infectious incidents in patients treated with anti-TNFα.

Methods: This is a prospective and descriptive study in patients treated with anti-TNFα over a 12-y period (2006-2018). We examined all infectious complications for each patient who received an anti-TNFα for with CID while assessing the level of severity, the type of infection and the risk factors that may be related to this type of incident.

Results: During the study period, 134 patients were identified, these patients were followed for ankylosing spondylitis (AS) for 58 cases, 36 for enteric rheumatism, 23 for psoriatic arthritis and 17 for rheumatoid arthritis. The mean age was 46.3 y (19-64 y), the mean age of the disease was 44.2 months (8-140). The molecules used were: infliximab, etanercept, adalimumab with a respective number n (%)=29 (21), 44 (33), 61 (46). Of the 134 patients evaluated, 71 were diagnosed and treated by a physician (in 47 patients), only 5 were serious: 2 cases of tuberculosis were reported (intestinal and ganglionic tuberculosis), 1 case of chickenpox of the adult, 1 case with perianal abscess, 1 case of erysipelas of the lower limb. The infection was bacterial, viral or mycotic [n (%)=38 (53), 61 (86), 7 (8)]. A large proportion of the patients were on conventional immunosuppressive therapy. The factors related to the occurrence of infectious incidents were use of corticosteroids p<0.0001, habitat in rural areas p=0.042.

Conclusion: More than a third of patients have infectious complications after TNFα treatment in our study sometimes with serious issue. Thus, with the emergence of these accidents, the physician has to be very vigilant when instituting this biotherapy, and secondly, a rigorous and prolonged monitoring of the patients.

P931

PREVALENCE OF FRACTURE RISK BY FRAX TOOL AMONGST ELDERLY INPATIENTS AT INCREASED RISK OF FALLS

A. Nandi¹, N. Obeichina¹, S. Johal¹, A. Jayakumar¹, S. Zaheer¹, R. Adlakha¹, S. Rehman¹, H. Yasmeen², D. Al-Rubaye¹

¹University Hospitals of Derby and Burton NHS Foundation Trust,

²University Hospitals of Derby and Burton NHS Foundation Trust, Burton-on Trent, UK

Objective: Elderly inpatients have a significant risk of falls and fracture. The Inpatient Falls Strategy¹ highlighted the need for screening all patients 65 y and above for fracture risk. The NICE has identified these patients at increased risk of falls². The latest NOGG guidelines³ recommends using FRAX Tool⁴ which predicts the absolute 10-y risk of sustaining a major osteoporotic and hip fracture. Its value has not been well assessed in elderly inpatients. Our aim was to determine prevalence of fracture risk in elderly in-patients at risk of falls by FRAX- tool and identify patients who need treatment.

Methods: Retrospective analysis of eligible inpatients aged 65-90 y at risk of falls (according to NICE CG 146)² over 3 weeks in January 2019. Data extracted from electronic patient records and history taking. The FRAX⁴ Tool was applied to predict 10-y major osteoporotic and hip fracture risk. Data analysed by StatsDirect.

Results: 100 eligible patients were analysed. Mean age was 81.2±6.3 y and BMI 25.4±6.2 kg/m²; 51% patients were female. 41 patients had previous fractures; 15% had history of parental hip fracture. 8 patients were current smokers, 9 consumed >3 units of alcohol. 20 were on glucocorticoids while 19 patients had secondary osteoporosis. The absolute 10-y risk of major osteoporosis and hip fracture, according to FRAX were 21.4±14.4 and 13.8±12.9 respectively. 35 patients needed bone protection: but only 16 patients were on treatment. Our study findings were similar to the Irish study⁵ with absolute risk scores of 15±12 and 7.6±11 for osteoporotic and hip fracture respectively.

Conclusions: The 35% prevalence of elderly inpatients at risk fracture and falls calls for routine screening of this population by FRAX- tool and subsequent initiation of treatment. Our findings support the only available study on FRAX scoring in elderly patients.

References:

1. National Audit of Inpatient Falls, 2015
2. NICE, CG146, 2012
3. NOGG, University of Sheffield, 2017
4. FRAX: Fracture Risk Assessment Tool, 2008

5. Haroon M et al. Ir J Med Sci 2018; doi: 10.1007/s11845-018-1882-2

P932

PREVALENCE OF SARCOPENIA IN INDIAN MEN AND WOMEN VARIES ACCORDING TO THE DEFINITION USED

A. Zengin¹, B. Kulkarni², A. V. Khadiilkar³, V. Ekbote³, N. Kajale³, N. Tandon⁴, S. K. Bhargava⁵, H. P. S. Sachdev⁶, S. Sinha⁶, C. H. D. Fall⁷, P. R. Ebeling¹

¹Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia, ²Clinical Division, National Institute of Nutrition, Jamai Osmania PO, Hyderabad, India, ³Hirabai Cowasji Jehangir Medical Research Institute, Pune, India, ⁴Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, India, ⁵Department of Paediatrics, Sunder Lal Jain Hospital, New Delhi, India, ⁶Department of Paediatrics and Clinical Epidemiology, Sitaram Bhartia Institute of Science and Research, New Delhi, India, ⁷MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK

Objective: India has over one third of the world's population aged >60, which is estimated to rise to over 38% by 2050 – equal to 494 million people. Prevention of sarcopenia is critical to ensure healthy independent ageing in India. The prevalence of sarcopenia in India is unknown, as is whether the existing definitions, mainly developed in Caucasian populations (FNIH and EWGSOP2), are vigorous in this population. Our aim was to identify whether: (1) existing definitions are able to determine the prevalence of sarcopenia in India; (2) either the lowest 20th percentile of an older population, or 2SDs below a young Indian reference population is a more robust criterion for predicting sarcopenia in this population.

Methods: Cohort studies across different regions of India were used to compare appendicular lean mass index (ALMI, kg/m²), by DXA, and grip strength (GS, kg). The young Indian (YI) group (aged 20-35yrs) consisted of men (M) and women (W) (n=1070): from New Delhi Birth Cohort, Andhra Pradesh Children and Parents Study (APCAPS), Indian Migration Study (IMS) and the Pune Pregnancy Study; the older Indian (OI) population (>45 y) comprised 1764 participants from: APCAPS and IMS. Two SD below the mean of the YI, and the lowest 20th percentile of OI identified Indian specific cut-points for GS and ALMI. Receiver operating characteristic (ROC) analyses were used to determine the area under the curve, and sensitivity and specificity to discriminate between sarcopenic individuals who had low vs. normal GS across the 4 definitions.

Results:

Developed cut-points					Prevalence of sarcopenia			
		n	GS	ALMI	EWGSOP2	FNIH	YI	OI
Men	YI	602	15.4	6.0	35%	42%	8%	8%
	OI	1014	15.9	6.2				
Women	YI	468	9.9	4.5	28%	35%	1%	6%
	OI	750	11.3	5.2				

GS	MEN				WOMEN			
	Sensitivity (%)	Specificity (%)	AUC	OR (95%CI)	Sensitivity (%)	Specificity (%)	AUC	OR (95%CI)
EWGSOP 2	68	69.1	0.686	4.8 (3.7, 6.2)	78.6	47.5	0.630	3.3 (2.4, 4.7)
FNIH	84.2	51.1	0.676	5.6 (4.1, 7.5)	89.8	27.3	0.586	3.3 (2.1, 5.2)
Young Indian	28.3	93.2	0.607	5.4 (3.7, 7.9)	5.1	98	0.515	2.6 (0.8, 8.7)
Older Indian	43.4	86.9	0.651	5.1 (3.6, 7.2)	42.3	80.8	0.615	3.1 (2.0, 4.7)

Conclusion: EWGSOP2 was most robust at detecting low GS, more so in men than women. The variation in the prevalence of sarcopenia depends on the definition used and highlights the importance of measuring functional capability across ethnic populations.

P933
EVALUATION OF LOW LEVEL LASER THERAPY IN THE TREATMENT OF COMPLEX REGIONAL PAIN SYNDROME AFTER ANKLE FRACTURE

I. Dimitrijevic¹, M. Kocic², M. Lazovic³, D. Mancic⁴, R. Filipov¹

¹Institute For Treatment and Rehabilitation "Niška Banja", Nis, ²Clinic for Physical Medicine and Rehabilitation, Clinical Center Niš, Faculty of Medicine, Nis, ³Institute for Rehabilitation Belgrade, Belgrade, Serbia and Faculty of Medicine, University of Belgrade, Belgrade, ⁴Department of Electronics, Faculty of Electronic Engineering, University of Niš, Nis, Serbia

Objective: In complex regional pain syndrome (CRPS), sympathetic dysfunction in addition to being responsible for hyperthermia and pain, also increase demineralization of the bone. The aim of this study was to evaluate, the effects low level laser therapy (LLLT) in the treatment patients with CRPS type I after ankle fracture.

Methods: The prospective randomized study included 13 patients with unilateral CRPS type I after ankle fracture, that had been diagnosed clinically on the basis of the modified research diagnostic criteria defined by the Budapest consensus group. In all patients, radiographic findings were shown a localised demineral-

ization of the bone in the affected extremity. Patients were treated with LLLT and kinesitherapy at the Clinic of Physical Medicine and Rehabilitation of the Clinical Center Nis (Serbia). Low level laser therapy (power of 70 mW, wavelength of 810nm, modulated mode frequency of 70 and 5000 Hz) was applied on eight points along joint line and painful zone of the affected area with 1.5 J/cm². The following parameters were assessed before and after the 20 therapeutic procedures had been applied: a) temperature asymmetry between the symmetrical regions of interest (ROIs) by using infrared thermography (Varioscan high resolution 3021) b) pain intensity. Temperature asymmetry was calculated as the temperature difference in maximal temperature values, between ROIs of unaffected and affected lower extremity (ΔT_{max}). b) Intensity of pain was measured by visual analog scale (VAS).

Results: The quantitative analysis of the thermograms, before the applied therapy, was measured the mean ΔT_{max} 1.86±1.09°C, which after the applied therapy was statistically significant reduced to 0.81±1.01°C ($t=4.891$; $p<0.001$). Before the applied therapy was measured the mean VAS 6.23±1.09, which after the applied therapy was statistically significant reduced to 4.0±1.35 ($t=9.667$; $p<0,001$).

Conclusion: Low level laser therapy might be effective in the treatment of post-traumatic CRPS type I.

P934
IS OSTEOPOROSIS SELF-ASSESSMENT TOOL A GOOD SCREENING TOOL FOR ASIAN MALE OSTEOPOROSIS?

P.-C. Wu¹, D.-H. Liu²

¹Department of Chinese medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City,
²Department of Physical Medicine and Rehabilitation, Shin Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan

Objectives: Validation and comparison of Osteoporosis Self-assessment Tool (OST) in Asian male races.

Methods: We collected all researches about OST in Asian men from Medline/PubMed. Finally, 4 articles were included and summarized in Table 1. The OST was calculated based on age and body weight using the following formula: [body weight (kg) – age (y)] × 0.2.

Results: In Table 1, the OST has acceptable sensitivity (64.0-87.3%), fair specificity (41.0-65.7%) and high negative predictive value (83.0-97.5%) in Asian male races. The high negative predictive value can screen out men with low risk of osteoporosis. The area under the receiver operating characteristic curve (AUC) over 0.7 with p<0.05 was noted in Chinese in Hong Kong, but the AUC was unknown in China. The screening tool is poor and not acceptable if its AUC is under 0.7.

Table 1. Validation of Osteoporosis Self-assessment Tool in Asian male races

Ethnicity	Indonesia	Taiwan	Chinese in Hong Kong	China
Age	≥50 y/o		≥65 y/o	≥50 y/o
Osteoporosis Definition	WHO criteria: T-score ≤ -2.5 at any one site of femoral neck, total hip, or lumbar spine			
Total male subjects	113	2290	1914	1488
Cutoff value	2	-2	-2	-1
AUC	0.574	0.697	0.759	NA
Sensitivity	0.74	0.640	0.818	0.873
Specificity	0.41	0.657	0.562	0.562
PPV	0.28	0.269	0.225	0.183
NPV	0.83	0.902	0.952	0.975

NA: not available; AUC: area under the receiver operating characteristic curve;

PPV: positive predictive value; NPV: negative predictive value

Conclusions: OST may be a simple tool with fair sensitivity/specificity and high negative predictive value. And it also could be a suitable screening tool to identify Asian men at risk of osteoporosis, especially in Chinese in Hong Kong.

P935
STAGED SURGICAL TREATMENT FOR TUBERCULOUS ARTHRITIS

M. Serdobintsev¹, A. Berdes¹, A. Cherkasov¹, B. Babkov¹

¹Saint-Petersburg State Research Institute of Physiopulmonology, Saint-Petersburg, Russia

Objective: To evaluate the results of total hip arthroplasty (THA) and total knee arthroplasty (TKA) in the staged surgical treatment of patients with tuberculous arthritis.

Methods: We analyzed the results of complex treatment of 153 patients (age range 18-79 years old) with tuberculous coxitis (117) and gonitis (36) in the period from 2016-2018. The first stage of the treatment after confirming the diagnosis was the antituberculosis therapy for 1-2 months as a preoperative preparation. At the second stage the radical surgical debridement was performed. In 101 cases of coxitis and 34 cases of gonitis the op-

eration was ended with implantation of an antibiotic-impregnated cement spacer. At the third stage (4-8 months) patients received antituberculosis therapy in accordance with an antibiotic sensitivity analysis. At the fourth stage patients underwent a complex clinic, instrumental (biopsy of the joint tissues) and laboratory examination. If there were no signs of activity of the tuberculosis THA or TKA was performed. The fifth stage was functional rehabilitation and the continuation of antituberculosis drug therapy for 4-6 months. Each patient gave responses to the Harris Hip Score (HHS) or the Knee Society Score (KSS) before total arthroplasty and a year later.

Results: The average results of HHS before and after the operation were 32.7±4.3 points and 88.7±6.4 points respectively (statistically significant difference, p=0.001). The average results of the KSS before and after the operation were 41.5±6.8 points and 82.1±7.3 points respectively (statistically significant difference, p<0.05). No tuberculous arthritis occurred during the observation period.

Conclusion: The staged surgical treatment with the inclusion of THA or TKA after radical surgical debridement with implantation of an antibiotic impregnated cement spacer with intensive anti-tuberculosis therapy has high functional outcomes and significantly improves the quality of life in patients with tuberculous arthritis.

P936

CUTANEOUS ADVERSE EFFECTS WITH BIOLOGIC AGENTS

B. Bengana¹, A. Boukabous¹, N. Bahaz¹, S. Lefkir¹

¹University Hospital of Benmessous, Algiers, Algeria

Objective: Biologic agents (BA) are designed to treat chronic inflammatory diseases (CID), however, the adverse effects inherent with these drugs are more and more encountered. Among them are dermatological manifestations: infections, allergic reactions or even skin cancers, which sometimes require stopping treatment temporarily or permanently. The goal of this work consists to identify the cutaneous manifestations (CA) that have been reported to the most commonly used biologics in CID.

Methods: It is a prospective study in patients received in day hospital and treated with BA for CID during a period of 9 months (October 2017 - June 2018), we recorded all the data on CA after a complete dermatological examination, nor forgetting that we appreciated the phototype of the patients, the level of exposure to the sun and means of photoprotection.

Results: We collected the data of 68 patients under BA for the study (adalimumab=21, etanercept=17, tocilizumab=12, infliximab=7, rituximab=11) with a clear female predominance 59.4%, the mean age was 39 y. 37 (54%) had cutaneous manifestations. The main CA occurred with TNF α inhibitors 21/68 (30%), with more often skin infections. The other CA encountered were cutaneous rashes and allergic reactions, appearance of psoriasis or eczema and injection site reactions. we did not cross any skin cancer.

Conclusion: Cutaneous manifestations remain frequent and relatively benign with BA. This work confirms the importance of education and dermatological monitoring of patients treated with biologic drugs in the CID. This prospective study needs to be completed over a longer period especially to screen any skin cancer.

P937

STUDY REGARDING PAIN ASSESSMENT AND MANAGEMENT AFTER ROTATOR CUFF INJURIES COMBINING OSTEOARTHRITIS OF THE SHOULDER

I. Mitoiu¹, D. Clantau¹, R. Nartea¹, L. Gheorghievici¹, A. Nica¹

¹Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

Objective: Rotator cuff injury is a common pathology in a rehabilitation service as it has a big impact in patient private, social and professional life. Pain and mobility restriction are important, difficult to bear and hard to treat. In order to find better and faster

ways for our patients to recover and trying to build up specific rehabilitation protocols it is important to note a combined experience of a team for a longer time.

Methods: The study follows a yearlong experience in a rehabilitation clinic working to improve the clinical and functional aspects of the shoulder pain and limitations in patients after different types of rotator cuff injuries on an osteoarthritic field. An X-ray and ultrasound exam were needed for the selection of the patients. Being divided in recent and old, associating or not adhesive capsulitis, our in or day patients had a pain and functional assessment before and after a personalized rehabilitation program. We used the goniometer, the MRC scale, the SST scale and the NRS scale. The patients have had a complex program including physical and manual therapy with a proper immobilization and mobilization balance helped by electrotherapy (TENS, cryoultrasound, laser therapy, shockwave). Different types of NSAIDs associating capsaicin patches have also been used.

Results: The data show a pain improvement of almost 3 of 10 points, a muscle force improvement of approx. 1 of 5 points and a better range of motion (internal and external rotation, abduction) especially for the patients after a recent trauma.

Conclusion: Our results underline the importance of a well designed recovery program performed in a rehabilitation facility not very far from the time of injury.

P938

STRUCTURE OF PROXIMAL EPIPHYSEAL CARTILAGE OF THE TIBIA IN OLD RATS UNDER EFFECTS OF EXCESSIVE DIETARY CHOLESTEROL AND CORRECTION DRUGS AGAINST ITS ADVERSE EFFECTS ON BONE

R. Lopak¹, V. Luzin², N. Zaboltnaya², A. Samokish²

¹FSBEI HE "Rostov State Medical University", Rostov-on-Don, Russia, ²SE "St. Luke Lugansk State Medical University", Lugansk, Ukraine

Objectives: investigation of effects of excessive dietary cholesterol on structure of the proximal growth plate of the tibia in old female rats and considering efficacy of Osteocare, Calcemin, and Calcemin Advance as correction drugs against adverse effects of cholesterol on bone formation.

Methods: for the experiment purposes we selected 175 female rats with body weight of 330-345 grams. Animals of the group 1 received standard food, animals of the group 2 received 2.5% of pure cholesterol and 10% of lard as the replacement of removed carbohydrates. In the groups 3 through 5 animals on the same cholesterol diet received per os Osteocare, Calcemin, and Calcemin Advance in therapeutic dosage calculated for a rat basing on human dose. Animals were withdrawn from the experiment upon expiration of observation terms (the 7th, the 15th, the 30th, the 60th, the 90th, and the 180th day). HE stained frontal sections of the proximal epiphyses of tibiae were photographed in light microscope for further morphometry.

Results: cholesterol excess led to derangement of growth plate structure and thus functioning of it. Alterations became evident beginning from the 15th day and progressed throughout the experiment. By the 180th day, proliferation and osteogenic zones in the group 2 were narrower than those of the group 1 by 9.22% and 11.60%. Spongiosa amount and osteoblasts quantity decreased by 9.89% and 9.81%. Calcium drugs we used reduced adverse effects of cholesterol on growth plate – osteogenic zone width, spongiosa amount and osteoblasts quantity in the group 3 increased by 4.66%, 4.61%, and 5.18%, in the group 4 – by 6.88%, 5.87%, and 5.28% and in the group 5 – by 8.22%, 6.01%, and 6.53% (all in comparison with the group 2).

Conclusions: dietary cholesterol excess produces marked adverse effects on bone formation. These effects grow with time in absence of treatment. Third generation calcium drugs reduce adverse effect of cholesterol on bone formation. Calcemin Advance appeared to be the most effective medication among those we considered.

P939

DIAGNOSING OSTEOPOROSIS IN HOSPITALISED PATIENTS: CAN WE IMPROVE?

L. Chicea¹

¹Universitatea Lucian Blaga of Sibiu, Sibiu, Romania

Objective: Osteoporosis (OP) patients may be hospitalised for different conditions connected with OP. Accurate history and examination, together with awareness of OP should lead to an accurate diagnosis and better management of OP in all hospital departments. The objectives of this study were to identify the hospital departments with the highest prevalence of OP patients; to identify the most frequent comorbidities, and to identify the most frequent symptoms in patients with OP as a principal diagnosis.

Methods: We conducted a retrospective 3 y (2014-2016) observational study using the Academic District Emergency Hospital of Sibiu database and records. Medical conditions were found using the diagnosis related groups (DRG). All records of patients with OP as a principal diagnosis were examined for presenting symptoms and signs.

Results: 2510 OP patients were admitted during 3 y. We found 2197 (87.5%) patients with no fracture mentioned in the diagnosis. Most of the patients were admitted in the Rehabilitation Department (832 – 33.14%), followed by the Endocrinology Dept. (30.13% - 378), Internal Medicine (11.6%-291) and Orthopedic surgery (198-7.88%). More than one-third of patients (35.18%) had postmenopause OP, while few cases (<5%) were diagnosed with secondary OP. Most frequent comorbidities were cardiovascular diseases, (43% hypertension and 26% coronary artery disease) and endocrine and metabolic diseases (40%). Musculoskeletal diseases were present in 37% of OP patients. Vertebral fractures were clinically identified (pain, vertebral tenderness, kyphosis) in about 65% cases.

Conclusions: Orthopedic surgeons, diabetologists, internal medicine and rehabilitation specialists, who are involved with OP patients should raise awareness and become more specific in

diagnosing and managing or referring OP patients. Internal hospital protocols and common projects with Endocrinologists and Rheumatologists may lead to better hospitalized OP patients' outcome.

Disclosures: Liana Chicea received consultant fees from Abbvie, Zentiva, Pfizer, MSD Romania.

P940

CORRELATION BETWEEN BODY MASS INDEX AND RADIOLOGICAL STAGE OF KNEE OSTEOARTHRITIS: A SERIES OF 73 CASES

M. A. El Achek¹, K. Baccouche¹, H. Zeglaoui¹, N. El Amri¹, E. Bouajina¹

¹Rheumatology Department Farhat Hached Sousse, Sousse, Tunisia

Objective: Knee osteoarthritis is a common condition and a real public health problem. Its origin is multifactorial but the disease is strongly linked to age and weight. In this series, an attempt has been made to correlate the severity of the radiological stage of knee osteoarthritis with the BMI.

Methods: This is a prospective study that gathered 73 patients followed in our consultation of Rheumatology at Farhat Hached university hospital in Sousse presenting mechanical gonalgia. All patients benefitted of x-rays radiography of both knees face and profile. Patients followed for chronic inflammatory rheumatism or microcrystalline arthropathy are excluded from this work.

Results: They were 91.8% women and 8.2% men with an average age of 61.75 y [42-85 y]. Patients had bilateral gonalgia in 75% of cases. The average BMI was 32.3 kg/m² [19-43 kg/m²]. X-rays showed Kellgren-Lawrence stage 1 knee osteoarthritis in 12% of cases, stage 2 in 29.43% of cases, stage 3 in 30.79% of cases and stage 4 in 27.78% of cases. A positive but not statistically significant association was found between advanced stages of knee osteoarthritis (stage 3 and 4) and obesity (BMI> 30 kg/m²) (p=0.06).

Conclusion: Overweight appears to be a major risk factor not only for the occurrence of knee osteoarthritis but also for the severity of its radiological progression. A wider study is still needed to better study this correlation.

P941

EFFECT OF AGE, WEIGHT AND CARTILAGE SCORE ON BIOMECHANICAL PROPERTIES OF THE PATELLAR TENDON IN SHEEP

F. Kayser¹, E. Bori², B. Innocenti², F. Hontoir³, V. Simon³, J.-M. Vandeweerdt³

¹Centre Hospitalier Universitaire-Catholic University of Leuven-Namur, Yvoir, ²BEAMS-University of Brussels, Brussels, ³NaRiLiS-IRVU-University of Namur, Namur, Belgium

Objective: To assess the eventual correlation between biomechanical characteristics of healthy ovine patellar tendon and age, weight and cartilage score.

Methods: 40 matched ovine cadaveric stifles were dissected to isolate the patellar tendon, after scoring the gross cartilage appearance. After 10 preconditioning tests (to get fiber alignment), the biomechanical tests were performed: the uniaxial test was performed independently for each ligament on a standard 1 kN tensile testing machine (accuracy 0.3%). Load to failure, stiffness and modulus of elasticity were calculated for each specimen and correlated among age, weight and cartilage lesion of the specimen.

Results: The patellar ligament has a typical nonlinear behavior with a cutoff value at 150 N. We found no statistical difference in tendon stiffness between young and old specimens. However, we found a positive correlation ($r=0.7$) between the tendon stiffness and cartilage score ($p<0.05$) and between the tendon stiffness and the sheep weight ($p<0.05$). Repeatability was high for every limb, ensuring robustness of the results.

Conclusion: These biomechanical tests provide essential objective and quantitative information on the elastic properties of patellar tendon in sheep often used as animal model in research. Our study showed no correlation between tendon stiffness and age. In human, tendon stiffness changes with age. In opposition to our results, previous animal studies showed increase of tendon stiffness with age. We demonstrated a positive correlation between tendon stiffness and weight. In human, obesity is associated to higher tendon injury incidence. The current study demonstrated positive correlation between tendon stiffness and cartilage score. This correlation is known in human, in whom an association between osteoarthritis and tendinopathy has already been described. These results are reasonable because in specimen with heavy weight or degenerative disease, the muscle needs to apply more force for a certain activity and tendon stiffness has to be higher.

P942

ASSOCIATIONS BETWEEN CARDIAC WORKLOAD AND BONE MINERAL DENSITY IN GAMBIAN MEN AND WOMEN

A. Zengin¹, A. Prentice², R. Janha³, L. M. Jarjou³, P. R. Ebeling¹, K. A. Ward⁴

¹Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia, ²MRC Elsie Widdowson Laboratory, University of Cambridge, Cambridge, UK, ³MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Keneba, The Gambia, UK, ⁴MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK

Objective: Eighty percent of global cardiovascular disease (CVD) mortality occurs in low-middle-income countries. Evidence shows an increased rate of fracture following major cardiovascular events and elevated blood pressure. This study aimed to investigate the associations between cardiac workload and bone outcomes in adult Gambians.

Methods: The Gambian Bone and Muscle Ageing Study recruited 249 women and 239 men ([mean±SD] 61.1±12.5 and 60.8±12.3 y). Blood pressure and heart rate were measured with the OMRON705IT. Rate pressure product (RPP), an indicator of cardiac workload, was calculated as heart rate*systolic blood pressure (bpm*mmHg). DXA was used to measure aBMD and bone mineral content (BMC) at the wholebody, total hip, femoral neck, lumbar spine and radius. Linear regressions explored the relationship between RPP and bone outcomes, adjusting for age, weight, height; including a sex-RPP interaction. Results are expressed as β -coefficients [95%CI] of percentage unit change in bone outcomes and sex-RPP interaction p-values (p-int).

Results: BMI was greater in women (22±4) than men (21±3), $p=0.001$; blood pressure differences were similar. With greater age, RPP was higher in women than men ($p<0.0001$). In unadjusted analyses, RPP was negatively associated with all bone outcomes in women but not in men. Following adjustments, every 1% increase in RPP was negatively associated in women with: wholebody aBMD (-0.08%[-0.12,-0.03], p-int=0.007), wholebody BMC (-0.12%[-0.19,-0.05], p-int=0.02), femoral neck BMC (0.19%[-0.31,-0.07], p-int 0.05), radius aBMD (-0.2%[-0.28,-0.11], p-int<0.0001) and radius BMC (-0.19%[-0.28,-0.10], p-int=0.008). No such associations were found in men.

Conclusion: There are negative associations between RPP and aBMD in Gambian women and not men. Sex-specific and timely osteoporosis and CVD prevention will help to reduce fracture risk.

P943

AN INVESTIGATION OF CHANGE IN MATERNAL VOLUMETRIC BONE MINERAL DENSITY (VBMD) AND BONE MICROARCHITECTURE AT THE DISTAL TIBIA AND RADIUS DURING PREGNANCY

M. Ó Breasail¹, A. Prentice¹, K. A. Ward²

¹Medical Research Council Nutrition and Bone Health Research Group, Cambridge, ²Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

Objectives: To determine whether pregnancy induces changes in maternal vBMD and bone microarchitecture.

Methods: The study included healthy premenopausal Cambridge women (53 pregnant (P), 37 non-pregnant nonlactating (NPNL)) aged 30-45 y (mean 35.4±3.8 y). Single-slice pQCT (XCT 2000L) and HR-pQCT (XTremeCTI) scans at the distal tibia and radius were obtained twice (14-16 and 34-36 weeks pregnancy, similar scan interval for NPNL). Outcomes were pQCT total and trabecular vBMD; HR-pQCT total and trabecular vBMD, trabecular microarchitecture (number (Tb.N), thickness (Tb.Th), separation (Tb.Sp)), cortical vBMD, cortical thickness (Ct.Th), and cortical porosity (Ct.Po). Within-group changes were tested (t-tests vs. no change). Standardised residuals of between-visit change were computed and linear regression models with covariates of group, height, baseline weight, and age, parity, smoking history and previous contraception use were fitted. Model of best fit was select-

ed by backwards stepwise regression. Results are presented as the difference P vs. NPNL expressed relative to SD of within individual change ($Z\text{-score} \pm \text{SEM}$), significance $p < 0.05$.

Results: Significant P vs. NPNL baseline differences were only found in Tb.N (P lower) and Tb.Th (P higher). Within-group changes were found in both groups suggesting bone mobilisation/loss, though greater in P. No significant P vs. NPNL differences in change were detected at the radius. P vs. NPNL differences in pQCT total -0.65 ± 0.22 and trabecular vBMD -0.50 ± 0.23 were found at the distal tibia. Change in HR-pQCT trabecular vBMD did not differ between groups. P vs. NPNL significantly differed for Tb.N 0.47 ± 0.23 , Tb.Sp -0.54 ± 0.24 , total -0.49 ± 0.24 and cortical vBMD -0.67 ± 0.23 , and Ct.Th -1.01 ± 0.21 and Ct.Po 0.78 ± 0.23 .

Conclusion: Pregnancy-induced bone mineral mobilisation exceeding natural age-related change was observed through decreases in total (pQCT and HR-pQCT), trabecular (pQCT) and cortical (HR-pQCT) vBMD vs. NPNL. In the absence of a decrease in HRpQCT trabecular vBMD, changes in Tb.N and Tb.Sp may need to be considered in the context of cortical compartment change. No evidence of bone mineral mobilisation was found at the distal radius. The implications of these changes on future maternal skeletal health require further investigation.

P944

BONE QUALITY IN ELDERLY PATIENTS WITH CHRONIC VENOUS INSUFFICIENCY

M. A. Farago¹, V. Huplea²

¹University of Oradea, Faculty of Medicine and Pharmacy,

²University of Oradea, Pharmacy and Medicine Faculty, Romania

Objective: Demonstrate the bone quality in patients with limited mobility caused by medium and severe chronic venous insufficiency.

Methods: An observational study of 64 patients, average age of 69, presenting chronic venous insufficiency, CEAP class ≥ 4 . We observed musculoskeletal pain localization, level of joint mobility muscular strength, mineral bone density, registered through DXA and ADLs dependence, level of needed care. We identified comorbidities and their severity, and established a correlation between bone mass and present level of function.

Results: Associated with chronic venous insufficiency, 60 patients (86, 95%) presented arthralgia in the spinal cord area and supporting joints, especially knee and lumbar areas. Joint mobility was limited in both vertebral and weight bearing joints in all patients. Walking distance capacity is limited to below 500 m in most of the patients, due to joint pain and/or venous claudication. Muscular strength is low in stabilizing muscles of the supporting joints as well as in dorsal and lumbar paravertebral muscles. Comorbidities: HTA and coronary disease in 55 patients (79.71%), type 2 diabetes in 23 patients (33.33%), gastric ulcer in 3 patients (4.34%), overweight and obesity in 42 patients (60.86%). DXA indicated osteoporosis in 36 patients (52.17%), osteopenia in 19 patients (27.53%) and no modifications in 9 patients (13.04%). No endocrine conditions were identified. Significant care aid is needed in 41 cases.

Conclusions: Low BMD might be linked to multiple factors, limited motion and level of activity due to multiple and severe comorbidities or secondary to menopause, or even aspects of atherosclerosis. Appears a high risk of falling and fractures due to alteration of proprioception, limited joint mobility and low muscle strength in the stabilizing muscles of the weight bearing joints. Low bone density associated with atherosclerosis increase the risk of heart attack, stroke, pulmonary thromboembolism, thus significantly decreasing the life expectancy.

P945

BONE DISEASE AFTER LUNG TRANSPLANTATION: OSTEOPOROSIS AND FRACTURES

S. Mészáros¹, E. Hosszú², V. Müller³, Z. Süttő³, A. Bohács³, Z. Kovács³, E. Csizsér³, C. Horváth¹

¹1st Department of Internal Medicine, Semmelweis University,

²2nd Department of Pediatric Semmelweis University,

³Department of Pulmonology, Semmelweis University, Budapest, Hungary

Objectives: Post-transplantation bone disease is a major complication in most of patients, with lowered BMD, increased fracture risk and consequently, increased mortality and reduced quality of life. Many factors contribute to the pathogenesis of osteoporosis after organ transplantation, such as immunosuppressive medications, nutritional and lifestyle factors. This study aimed to assess BMD and incidence of fractures after lung transplantation.

Methods: This observational study analysed the medical records of 19 patients who underwent lung transplantation (male/female 9/10, aged 42.8 ± 10.5 y). Demography, clinical parameters of lung disease, laboratory data, and osteoporosis risk factors were analysed. BMD of the lumbar spine and hip were measured by DXA (GE Lunar Prodigy, WI, USA) and evaluated by T-score.

Results: Osteoporosis (T-score < -2.5) was found in 20% the study population, and osteopenia (T-score from -1.0 to -2.5) in approximately 60%. Only 20% of our lung transplant patients presented normal bone mass density. In our study population the most affected bone was the lumbar spine. Patients with pulmonary hypertension and with lowest BMI had the highest decrease in BMD. Fractures were present in 15,8% of subjects (3/19) after the lung transplantation, and did not correlate with BMD or the diagnosis of osteoporosis.

Conclusions: Bone loss and bone fractures are common complications after lung transplantation. Therefore, early diagnosis and prevention of osteoporosis in lung transplant candidates should receive high priority.

P946

EFFICIENCY OF APPLICATION OF "HUBER" APPARATUS IN COMPLEX TREATMENT OF OSTEOPOROSIS

A. M. Ignatyev¹, T. A. Ermolenko¹, N. I. Turchin¹, T. L. Prutiian¹

¹Odessa National Medical University, Odessa, Ukraine

Objective: To study the effectiveness of the use of the multifunctional apparatus "Huber" in the complex treatment of osteoporosis (OP).

Methods: 120 patients aged from 48 to 62 years were treated (mean age - 56.7 ± 2.3 y) with OP. The study of BMD was performed using ultrasound densitometry (AOS-100NW, Aloka (Japan)). The functional state in the musculoskeletal system was assessed using the "Insight TM" biosignal recording and processing device. Depending on the method of treatment, the patients were divided into 3 groups: Group 1 (n=40) - standard osteotropic therapy and the "Huber" hardware complex were used; 2nd group (n=40) - standard osteotropic therapy and kinesitherapy were used; Group 3 (n=40) - only standard osteotropic therapy was performed. Treatment efficacy was assessed after 6 and 12 months.

Results: Initially, by the T-score of OSI, the groups were comparable, and it was: in the 1st group - -2.89 ± 0.31 SD, ($p > 0.05$), in the 2nd group - -2.73 ± 0.25 SD, ($p > 0.05$), in the 3rd group - -2.71 ± 0.21 SD, ($p > 0.05$). After 6 months and 12 months therapy showed an increase in BMD in all groups, in the 1st group was higher ($p < 0.05$) compared with the 2nd and 3rd groups. T-score of OSI in the 1st group was -1.84 ± 0.2 SD and -1.14 ± 0.12 SD, ($p < 0.05$), in the 2nd group - -2.04 ± 0.18 SD and -1.39 ± 0.17 SD, group 3 - -2.24 ± 0.17 SD and -1.53 ± 0.13 SD, respectively.

The index of neurospinal function (NSF index) before treatment in all study groups was "problematic" and was in the 1st group - $63.4 \pm 2.23\%$, in the 2nd group - $64.3 \pm 2.19\%$ in the 3rd group - $63.2 \pm 2.24\%$ ($p > 0.05$). After 6 months therapy in the 1st group of NSF index was $78.4 \pm 3.4\%$, in the 2nd group - $74.2 \pm 2.5\%$, which corresponded to the "average" mark, in the 3rd group of NSF index was $68.3 \pm 1.9\%$ - "problematic". After 12 months NSF Index therapy of the 1st group amounted to $94.3 \pm 2.8\%$, in the 2nd group - $85.1 \pm 3.2\%$, in the 3rd group - $75.9 \pm 2.3\%$. On the "Insight TM" scale, NSF index reached the values "excellent" only in patients of the 1st group, in the 2nd group it was at the level of "good", in the 3rd group - "averaged".

Conclusions: The use of multifunctional apparatus "Huber" in the complex therapy of OP contributes to a greater increase in BMD ($p < 0.05$) and improvement of the functional state in the musculoskeletal system ($p < 0.05$).

P947

PRIMARY HYPERPARATHYROIDISM IN SARAWAK: CLINICAL PROFILE AND COMPLICATION BURDEN

Y. C. Kuan¹, F. Tan¹

¹Sarawak General Hospital, Kuching, Sarawak, Malaysia

Objective: Although primary hyperparathyroidism (PHPT) is increasingly reported to present as asymptomatic hypercalcemia, symptomatic disease is still common in developing country. Described herein the clinical profile and complication burden of PHPT in a single tertiary referral centre in Malaysia.

Method: A retrospective review of medical records of patients with PHPT, in Sarawak General Hospital from May 2005 to January 2018.

Results: 34 patients were identified. Mean age at diagnosis was 54.7 ± 14 y. 61.6%, were women. There were 41.2% Chinese, 26.5% Malay and 20.6% Sarawak natives. Mean serum calcium was 3.13 mmol/L (range: 2.48-4.85 mmol/L). 41% had elevated alkaline phosphatase level and 40.9% had serum creatinine > 100 μ mol/L. 26.5% had asymptomatic hypercalcaemia but classical complication was still prevalent. 47.1% of patients had nephrolithiasis, 35.3% had peptic ulcer disease and 4 patients (11.7%) had mental changes. For patients 60 y and above (n=14), three patients presented with fracture; 5 of the remaining 11 patients showed osteoporosis on BMD.

The cohort also showed high cardiovascular burden with 64.7% having hypertension; 14.7% and 11.8% suffered from stroke and ischemic heart disease respectively. Two patients died, secondary to hypercalcemia crisis before parathyroidectomy could be performed due to delay in presentation and diagnosis. Both recorded very high calcium level above 4.50 mmol/L.

Conclusion: PHPT is still associated with high morbidity and mortality in our setting where serum calcium is not routinely measured especially in the rural areas. Greater awareness and better screening strategies seems warranted to improve outcome.

P948

ROWELL SYNDROME

V. Huplea¹, C. Turda¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objective: We have a case report of a young woman presented to Dermatology Department for cutaneous lesions of erythema multiforme associated with arthralgias of small joints of hands, myalgias, no signs of acute inflammation. A young woman with musculoskeletal symptoms and cutaneous lesions should be checked for collagenosis. Rowell syndrome is characterized by presentation of lupus erythematosus with erythema multiforme-like lesions (with absence of any known precipitating factors) associated with antinuclear, anti-La (SS-B)/anti-Ro (SS-A) antibodies and rheumatoid factor (RF) positivity. It is a rare presentation considered to be more common among females.

Methods: A woman aged 44 years old presented for typical concentric “target” lesions localized on the acral extensor surfaces of the extremities symmetrical, abdomen and back, onset 3 days ago. Dermatological diagnosis is erythema multiforme. Etiology of erythema multiforme is very large: infectious agents, medications, other etiology factors as hormonal, malignancies; about 50% of cases are idiopathic.

Results: In our case no mycoplasma species, no viral infections as herpes simplex type 1 or 2, adenovirus, coxsackievirus B5, cytomegalovirus, echoviruses, enterovirus, Epstein-Barr, hepatitis A/B/C viruses was detected. Throat culture for group A streptococcal infection – negative, antistreptolysin O antibodies– negative exclude streptococcal infection, acute rheumatic fever respectively; X-rays for small joints of hands is negative for acute rheumatoid osteoarthritis. No medication intake as anticonvulsants as well as immunologic disorders, malignancies, hormonal diseases or therapy was involved. Antinuclear antibodies, anti-La, anti-Ro, antibodies are positive, confirming collagenosis: subacute lupus erythematosus; positive rheumatoid factor is a major criteria besides the other ones named for Rowell syndrome. Rheumatoid factor is the autoantibody that was first found in rheumatoid arthritis but can also indicate the occurrence of autoimmune activity unrelated to rheumatoid arthritis.

Conclusions: We underline the importance of immunological tests in young females with dermatological manifestations of erythema multiforme-like lesions associated with arthralgias and myalgias as first sign for lupus erythematosus a severe disease which requires special attention and monitoring. Less than 100 cases of Rowell syndrome have been described in literature.

P949

PERSISTENCE REGARDING OSTEOPOROSIS TREATMENT IN SECONDARY PREVENTION OF OSTEOPOROTIC FRACTURES IN REHABILITATION CONSULTATION

C. Parra Soto¹, E. García Álvarez², J. Acosta Rueda², R. Espada Zaragoza², E. González Navarro², C. González-King Garibotti², G. Cuko²

¹Hospital Reina Sofia, Tudela, ²Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

Objective: To determine persistence to osteoporosis pharmacotherapy after osteoporotic fracture.

Methods: Retrospective observational study of patients treated in a rehabilitation consultation from March 2014 to December 2017. The pharmacy dispensaries of the treatment prescribed in a Rehabilitation consultation were evaluated monthly, according to recommendations of SEIOM (Spanish Society of Bone Research) and patient preferences. Persistence was defined as continuation of treatment without a >30-d gap in prescription refills.

Results: 53 patients (82.6% women). Mean age, 68 (±9.12 y). Derivatives from Traumatology (52.2%), Primary Care and Rheumatology (13% respectively). The most frequent reason for consultation was fracture (52.2%). 39.1% of patients had secondary osteoporosis and 47.8% had previous fracture. 30.4% had pre-

viously received pharmacological treatment of osteoporosis. Pharmacological treatment were prescribed: oral bisphosphonates 39.1%, teriparatide 39.1%, denosumab 21.8%. As a complementary treatment: 43.5% were prescribed cholecalciferol and 30.4% cholecalciferol + calcium. In 30.4% of the patients it was necessary to change medication mainly due to side effects or difficulty in administering the drug. The average treatment time was 29.78 months (±14.44). 75.62% persisted with osteoporosis pharmacotherapy regimen and 65.62% with complementary treatment. Treatment with teriparatide presented the highest persistence rate (96.78%). Of 21 patients prescribed oral bisphosphonates, 72.37% persisted with treatment; and of 12 patients prescribed denosumab, 68.81% persisted with treatment.

Conclusion: Persistence among patients attending our rehabilitation consultation was higher than that reported in the literature. This could be due to the fact that it includes patients with the intention of secondary prevention, sensitized with the complications of osteoporotic fractures and with outpatient follow-up.

P950

THE UTILITY OF AN ONLINE VIRTUAL CONSULTATION IN A FRACTURE LIAISON SERVICE

E. Trujillo¹, H. Sanchez¹, A. Aznar¹, M. Garcia¹, I. Ferraz¹, B. Rodriguez-Lozano¹, S. Bustabad¹

¹Servicio de Reumatología. HUC-Fractura osteoporótica. Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

In October 2017, a fracture liaison service (FLS) was set up by the Rheumatology Service of the Hospital Universitario de Canarias, which was accredited by the IOF (International Osteoporosis Foundation, Capture the Fracture Programme) in 2018. One of the essential aspects of an FLS is to establish case detection systems for patients with fractures. In our unit we have a virtual online consultation for Primary Care and the rest of the specialties of our reference area. Family doctors and other specialists generate a virtual appointment with the rheumatologist, who accesses the patient's entire clinical history and assesses the case. According to their assessment, there are three possibilities for action:

1. Resolution of the remote inter-consultation from FLS, proposing action guidelines, advising or establishing treatments.
2. Appointment at FLS. In order to try to ensure that the majority of patients who come to the consultation receive high resolution care, the help of the family doctor is requested in order to request complementary tests to help in the diagnosis and decision making process.
3. Direct communication between both professionals to exchange opinions and doubts.

The objective of this study is to analyze the usefulness of the virtual online consultation in our FLS unit.

Methods: A descriptive study that retrospectively reviews the virtual appointments of patients consulted for possible fracture due to fragility performed from January 15, 2018 to January 15, 2019. We analyzed the profile of the patients (age, sex), the specialist who consults, the type of fractures, whether it is the first fracture

or has other previous fractures, whether it had previous diagnosis and/or treatment for osteoporosis, and the need or not for face-to-face visit.

Results: 113 virtual online consultations were performed on patients with possible fragility fracture from January 15, 2018 to January 15, 2019. 88% were women and the mean age was 74 y. The attached table summarizes the analysis of the data.

Doctor making the consultation (%)	Primary Care Physician	67
	Traumatologist	21
	Neurosurgeon	10
	Others: pulmonologist, hematologist, rehab, endocrinologist. Digestologist,	2
Fracture type%	Colles	8
	Vertebra	71
	Femur	18
	Other	3
¿Previous diagnosis of osteoporosis? (%)	yes	26
	No	74
¿pre-treatment for osteoporosis? (%)	yes	28
	No	72
¿Other fragility fractures? (%)	yes	28
	No	72
Consultation decision (%)	Resolution of the remote interconsultation	17
	Appointment at FLS	70
	Exchange of doubts	13

Conclusion: According to the results of our study, in a Fracture Coordination Unit (FLS), virtual online consultation with primary care and other specialties of the reference area is useful in the recruitment of patients with fragility fractures; it resolves one out of every four assessments, avoiding unnecessary appointments in the Unit; it allows patients who are cited to receive high resolution care by previously coordinating with; their doctor the necessary complementary tests; and it allows good communication to exchange opinions or doubts.

P951

BACK PAIN IN PREGNANCY OR IN THE POSTPARTUM PERIOD

A. V. Gueldini de Moraes¹, F. Garanhani de Castro Surita¹, A. Orcesi Pedro¹

¹Department of Obstetrics and Gynecology, School of Medical Sciences

University of Campinas, UNICAMP, Campinas, Brazil

Pregnancy- and lactation-associated osteoporosis (PLO) is a rare syndrome affecting women during late pregnancy and the early postpartum period, which can lead to vertebral fractures in women of reproductive age. It is possible that there is underdiagnosis as a result of the overlapping symptomatology with the frequent aches affecting normal pregnancies. There are no established diagnostic criteria for PLO. However, a diagnosis can be easily ob-

tained by an accurate medical interview, physical examination, imaging studies, and laboratory data, including BMD measurement after childbirth. This disease should be suspected when a woman presents with severe back pain in the late stages of pregnancy or the early postpartum period. An accurate and prompt diagnosis helps with appropriate treatment and prevents the progression of the disease. Clinical judgment must be used to balance the potential benefit and risks of treatment that is being considered. Due to the low incidence, no treatment strategy has been yet established. Bisphosphonates (BPs) have been used, but these are known to have a strong binding affinity to bone, and the accumulated BPs are released after treatment. The fetus of a subsequent pregnancy may be exposed to BPs even long after the discontinuation of therapy, and the potential risk is unclear. There have been some reports of PLO treated with teriparatide. It has also been reported that switching from teriparatide to denosumab leads to better therapeutic effects in postmenopausal patients. The suggested treatment strategy includes optimize calcium and vitamin D intake, load reduction and analgesia. Cessation of lactation seems to be the major classical treatment in the reports. Women who present with back pain in late pregnancy or the post-partum period should always be evaluated for pregnancy-related osteoporosis. Traditional risk factors associated with osteoporosis should be assessed as they may be contributory, and other differential diagnoses (such as na underlying genetic disorder) should be considered. The use of bisphosphonates to treat these patients

needs to be carefully considered, balancing the intended benefits of preventing subsequent fractures and disability against the potential risks of side effects and harm to future pregnancies.

P952

COGNITIVE DYSFUNCTION RESPONSIBLE FOR LOCOMOTOR DECONDITIONING

V. Huplea¹, C. Turda¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objective: To identify the causes of locomotor deconditioning in an elderly patient without life threatening illnesses.

Methods: We present the case of a 74 years old female patient, with musculoskeletal pain and consecutive dysfunction with care aid need. She was in negative mood. We followed the clinical evaluation protocol, starting with medical history, physical examination and laboratory diagnostic tests and imaging tests. For diagnostic purpose we considered multidisciplinary evaluations (psychiatrically and neurological exam) as well as psychological exam to identify the level of anxiety, depression and cognitive function.

Results: Subjective complaints: low back pain and right knee pain, alteration of posture and walk, vertigo and fear of falling. Objective findings: dorsolumbar scoliosis, lumbar hyperlordosis, lumbar paravertebral muscle contracture, Schober +2 cm, with no radicular pain, limited right hip and right knee mobility. Also, difficulty in maintaining standing position and limping while walking. Imaging tests findings: spinal compression L2-L3, osteoporosis, mild right hip osteoarthritis and mild bilateral knee osteoarthritis, spondylarthritis. Clinical exam and imaging evaluation for the vertigo syndrome and anxiety revealed vertebrobasilar circulatory insufficiency, cerebral atrophy, anxiety disorder, depression and mild cognitive dysfunction. DXA scan – osteopenia.

Conclusions: With a psychological background of anxiety and depression and the installation of cognitive dysfunction, the patient lost the capacity to manage locomotor pain symptoms, reaching the need for care assistance. Elderly patients would benefit from complex psychological, emotional and cognitive evaluations and established rehabilitation treatments that could slow down the complex functional and psychological deterioration.

P953

IMPACT OF OSTEOPENIA IN FRACTURE RISK AND IN RISK ASSESSMENT CALCULATED BY FRAX

C. Horvath¹, E. Hosszu², M. Svebis¹, A. Tabak¹, K. Bors³, E. Csupor⁴, S. Meszaros¹

¹1st Department of Internal Medicine, Semmelweis University,

²2nd Department of Pediatrics, Semmelweis University,

³Rehabilitation Hospital, Visegrad, Hungary, ⁴Budavar Endocrine Center, Budapest, Hungary

Objective: It is widely accepted that the majority of low trauma fractures occur in patients with BMD better than -2.5 T-score. However, only a few data are available concerning the fracture

risk caused directly by osteopenia. Aims of the study: 1, Assessing the frequency of osteopenia among patients referred for bone densitometry with suspected osteoporosis. 2, Estimating for how much of fractures occur in charge of osteopenia. 3, Calculating FRAX probabilities in osteopenic patients compared to the osteoporotic group.

Methods: Data of 11807 women were analyzed who have been referred for bone densitometry in 2008-2014. 2986 patients (26%) had previous fracture. BMD was measured by a Prodigy densitometer (GE Lunar, WI, USA) at lumbar spine, hip and forearm. Osteopenia and osteoporosis were categorized according to the T-scores. Fracture probabilities were calculated using the Hungarian FRAX model. Data analysis was done by SPSS.

Results: Normal BMD was found in 18.3% of the patients while in 46% osteopenia and in 36% osteoporosis was detected, with fractures in 14.8, 22.9 and 35.7% of cases, respectively. Only 49.1% of previous fractures occurred in osteoporotic patients, however, 10.4% of fractured patients had normal density and 40.5% had osteopenia. The FRAX probabilities for hip and major fractures increased step-by-step in groups of normal BMD, osteopenia in one bone, osteopenia in all three bones, osteoporosis in one bone and osteoporosis in all three bones ($p < 0.0001$ among all groups). Compared to normal bone density, osteopenia increased the fracture risk of hip by 6-fold and of major fractures by 2-fold ($p < 0.0001$). Osteoporosis resulted in a 4-fold hip fracture risk and 2-fold major fracture risk than osteopenia did ($p < 0.0001$). The major fracture probability in patients with osteopenia and previous fracture was 12.34% (CI: 11.82-12.85), what is more than that of osteoporotic patients without previous fracture: 10.69% (CI: 10.46-10.92), $p < 0.001$.

Conclusion: Osteopenia seems to be responsible for a similar or greater fracture risk than osteoporosis, so intervention and reimbursement should be fracture risk based rather than BMD. Osteopenia needs much more interest in the future.

P954

PRO-INFLAMMATORY EFFECTS OF ENDOGENOUS CALCITONIN GENE-RELATED PEPTIDE IN ACUTE RHEUMATOID ARTHRITIS

T. Maleitzke¹, A. Hildebrandt¹, J. Weber¹, A. Kienzle¹, C. Carsten¹, G. Duda², S. Tsitsilonis¹, J. Keller¹

¹Center for Muskuloskeletal Surgery, Charité -

Universitätsmedizin Berlin, ²Julius Wolff Institute for

Biomechanics and Muskuloskeletal Regeneration, Charité - Universitätsmedizin Berlin, Berlin, Germany

Objective: 1% of today's population suffer from rheumatoid arthritis (RA), the most common inflammatory joint disease worldwide with a quarter of patients requiring a total joint arthroplasty (TJA) during their life. An imbalance of bone formation and bone resorption is in part responsible for bone erosions, subsequent joint deformities, and chronic pain in RA. Compromised bone quality is a fundamental surgical challenge during TJA in patients with RA, accompanied by an increased risk of periprosthetic fractures and infections. To battle these clinical challenges, we studied the role

of calcitonin gene-related peptide (CGRP), a member of the calcitonin family of peptides, in experimental RA. We were previously able to show an osteoanabolic effect of CGRP in healthy bone metabolism. Here we report for the first time, the pro-inflammatory effects of endogenous CGRP signaling in an *in vivo* mouse model of RA.

Methods: Collagen antibody-induced arthritis (CAIA) was induced in global CGRP-deficient mice (n=14) and wildtype (WT) littermates (n=13). Controls were treated with PBS accordingly (n=8 CGRP-deficient and n=8 WT mice). Arthritis was monitored over a time course of 10 d. Daily clinical assessments and measurements of ankle swelling were performed. On day 10, samples were harvested and stored for further histological, radiological and molecular analysis.

Results: Disease manifestation peaked between day seven and nine in all mice receiving the collagen antibody cocktail. Arthritis was significantly less pronounced in CGRP-deficient mice compared to WT littermates, indicated by a lower semi-quantitative arthritis score with reduced swelling and redness for all paws. Congruently, ankle size of CGRP-deficient mice was significantly smaller when compared to WT mice during the acute phase of arthritis.

Conclusion: Here we show for the first time, the pro-inflammatory effects of CGRP on the acute manifestation of RA in an experimental *in vivo* study. These findings point towards a pivotal role of endogenous CGRP, controlling inflammatory processes in RA. Our current histologic, radiologic and molecular analyses will allow to further decipher the role of CGRP in bone erosions and autoimmunity in RA. We aim to translate our findings to significantly increase bone quality in RA patients, eligible for TJA surgery.

P955

CALCIUM AND VITAMIN D INTAKE AMONG BRAZILIAN PREGNANT ADOLESCENTS

M. Pinho-Pompeu¹, D. S. Morais Paulino¹, A. V. Gueldini de Moraes¹, A. Orcesi Pedro¹, F. Garanhani de Castro Surita¹

¹ Department of Obstetrics and Gynecology, School of Medical Sciences University of Campinas, UNICAMP, Campinas, Brazil

Objective: To know the dietary calcium (Ca) and vitamin D (VitD) intake by pregnant adolescents and the association with sociodemographic factors and perinatal outcomes.

Methods: Cohort study among primiparas under 19 years of age at the Women's Hospital (CAISM), University of Campinas (UNICAMP), Brazil. Sociodemographic variables, obstetric history and anthropometric measures were collected. To calculate dietary Ca and VitD intake, a 24-h dietary recall (24HRec) was applied in three moments during pregnancy and one at postpartum visit. All 24HRec was analyzed by the program Nutrition Data System for Research (NDSR)[®] in order to provide the intake of Ca and VitD. Chi-square test and Fisher's exact test were used to analyze continuous variables.

Results: 150 adolescents were included. Mean age±SD was 15.4±1.3 y, 55.9% (81) were white and 83.8% (124), live with partners. Mean±SD self-reported prepregnancy weight was 55.9±11.0

kg, with a prevalence of overweight and obesity of 17.3%. Mean±SD intake of Ca was 659.9±335 mg, (minimum 179.2 and maximum of 2017.4 mg). The mean±SD intake of Vit D was 4.1±1.3 µg (minimum 0.04 and maximum 12.5 µg). Only 4% adolescents presented Ca intake above the recommendation (1300 mg) and 24.7% presented VitD intake above the recommendation (5 µg). Ca and/or VitD supplementation was not observed among pregnant adolescents, however, the intake of multivitamins was observed in 6% adolescents. Cesarean section rate was 36.9%. Among newborns, 9.7% presented gestational age under of 37 weeks and 9.7% weighed <2500 g at birth. No statistical significance association were found between Ca/VitD intake and sociodemographic factors, anthropometric measures and perinatal outcomes.

Conclusion: Ca and VitD daily intake among pregnant adolescents were low. Adolescents should be advised to adjust the intake of Ca and VitD through diet, once these nutrients are related to the development of bones, and a low intake of these nutrients during pregnancy could be related with osteoporosis in the adulthood. Therefore, the use of multivitamins requires careful assessment, because formulas may not provide adequate intake for pregnant adolescents.

P956

DEVELOPMENT AND VALIDATION OF THE TOOL FOR ASSESSING SOCIAL PARTICIPATION IN THE ELDERLY (IAPSI): LOCOMOV PROJECT

J. C. Galiano¹, M. C. F. Arbex¹, J. E. F. Okazaki¹, D. R. B. Tavares¹, J. A. P. Alves¹, S. N. Carmo¹, F. C. Santos¹

¹Federal University of São Paulo, São Paulo, Brazil

Objectives: To develop and validate a tool for assessing social participation of the elderly (IAPSI) and verify whether there is a correlation with locomotive syndrome (SLo).

Methods: We first based theoretical foundation to conceptualize social participation (SP). In order to select the items with best potential to represent SP, questions exalting psychological perspectives and the satisfaction with SP were selected. The instrument's content validity were examined. Items were analyzed by a committee of gerontologists experts (specialists in Nursing, Social Assistance, Psychology, Psychiatry and Geriatrics). Criterion validity was examined between IAPSI and WHO Quality of Life instruments (WHOQOL-bref and WHOQOL-old social participation domain). Additionally, we analyzed sociodemographic data, functionality (Katz and Lawton), comorbidities, self-perception of life and locomotion (25-question Geriatric Locomotive Function Scale, Brazilian validated version – (GLFS 25P)). The psychometric properties of IAPSI were studied in community-dwelling elders of the Locomov Project, a longitudinal cohort focused on locomotion of old individuals in Brazil. Internal consistency was confirmed by Cronbach's α . Pearson correlation coefficient was analyzed between the IAPSI and WHOQOL-bref and WHOQOL-old (SP domain). The significance level was set at $p < 0.05$. The final tool contained 6 items distributed into 5 domains: domestic life, community life, interpersonal relation, recreation, time spent.

Results: 102 elderly were analyzed, mean age 87.29 y. The Cronbach's reliability coefficient was 0.63. Pearson's correlation coefficient between IAPSI and WHOQOL-bref and WHOQOL-old (SP domain) was 0.54 and 0.64 respectively ($p < 0.001$), showing excellent concurrent validity of IAPSI. The association between IAPSI and SLo was significant ($p = 0.0321$).

Conclusion: The IAPSI offers a valid and reliable instrument for assessing SP of elderly. In this study, the SLo was associated with lower scores in social participation.

P957

CONSEQUENCES OF CHRONIC VENOUS DISEASE ON LOWER LIMBS FUNCTION

V. Huplea¹, M. A. Farago¹

¹University of Oradea, Faculty of Medicine and Pharmacy, Oradea, Romania

Objectives: To investigate the lower limbs joint pain, the lower limbs kinematics in patients with chronic venous disease.

Methods: A prospective studies of 14 in patients with chronic venous disease and lower limbs joint pain and dysfunction. Venous disease was classified according to the CEAP classification (International Consensus Committee reporting standards on venous disease). Lower limbs joints were evaluated for pain (visual analogue scale, VAS 0-10), for range of motion - goniometry, muscle forces (0-5 scale), function WOMAC score, the gait, body alignment.

Results: Most of patients with moderate or severe chronic venous disease. Joint pain was mostly present at ankle and knee level with mean VAS of 6.2. Other site of pain, low back in most of the patients. Body alignment hyperlordosis, genu valgum and pronated feet in most of the patients. Joints ROM: limited ankle movements, particularly dorsiflexion, limited patella movements and limited knee flexion in 8 patients, limited spine movement in most of the patients. Muscle imbalances particularly lower crossed syndrome was presents in 12 patients (85.75%). Muscle insufficiency in hip and knee stabilizers. Alteration of the gait in most of the patients particularly to the heel strike and mid swing. Because of joints pain we couldn't perform balance testing.

Conclusions: Calf muscle pump dysfunction is responsible for sustained elevation of venous pressure at the ankle and is correlated with limited range of movement of the ankle joint, particularly dorsiflexion. Knee pain and dysfunction might be secondary to ankle dysfunction. Foot pronation might be the consequence to intrinsic foot muscle hypotrophy, secondary to ankle pain and dysfunction. For limiting joint pain and dysfunction appears the importance of regular kinetic training in early stages of chronic venous insufficiency.

P958

CALCIUM AND VITAMIN D INTAKE IN BRAZILIAN PREGNANT WOMEN

D. S. Morais Paulino¹, M. Pinho-Pompeu¹, A. V. Gueldini de Moraes¹, A. Orcesi Pedro¹, F. Garanhani de Castro Surita¹

¹ Department of Obstetrics and Gynecology, School of Medical Sciences University of Campinas, UNICAMP, Campinas, Brazil

Objective: Investigate the intake of calcium (Ca) and vitamin D (VitD) during the third trimester of gestation among Brazilian pregnant women.

Methods: Cross-section study conducted with 49 adult pregnant women from Woman's Hospital (CAISM), University of Campinas (UNICAMP), during the third trimester of high-risk pregnancy. Ca and Vit. D intake by food were investigated through three 24-h dietary recall. The food data were transformed from domestic measures to grams or milliliters and then analyzed through the program Nutrition Data System for Research (NDSR)® in order to provide the quantity of Ca and VitD. Sociodemographic factors and obstetric history were collected from medical record. Descriptive statistics analysis were performed.

Results: Mean±SD gestation age was 32.27±1.84 weeks and the mean±SD age of women was 30±6 y. The majority of women were nonwhite (57.2%), live with partner (91.8%) and were multiparous (83.7%). The mean±SD Ca and vitD intake was 700.7±319.5 mg and 5.2±4.5 µg, respectively. The lowest quartile of Ca intake was 354.7 mg and the highest quartile 1510.9 mg, however only 2 pregnant women presented calcium intake above the recommendation of 1500 mg/d. The lowest quartile of vit. D intake was 2.2 µg and the highest quartile 31.6 µg. VitD intake above the recommendation (15 µg/d) was showed by 75.5% of pregnant women.

Conclusion: The intake of Ca is less adequate than VitD among adult pregnant women. Pregnant women should be advised to adjust the intake of Ca through food or specific supplementation. Low intake of these nutrients during pregnancy could be related with osteoporosis and bone fractures in the future.

P959

CLIMACTERIC AND LOW BACK PAIN: WHAT CAN GYNECOLOGISTS DO ABOUT IT?

A. V. Gueldini de Moraes¹, A. Bonacin Neto², A. Orcesi Pedro¹

¹Department of Obstetrics and Gynecology, School of Medical Sciences, University of Campinas, UNICAMP, Campinas,

²Orthopaedic Surgeon, Hospital Santa Casa de Misericordia de Araras, Araras, Brazil

Low back pain (LBP) affects large numbers of women, especially those aged 45-60. Postmenopausal women shows accelerated disc degeneration due to estrogen deficiency, resulting in narrower intervertebral disc space, increased prevalence of spondylolisthesis, and increased prevalence of facet joint osteoarthritis and higher osteoporosis related spine fracture rate. Vertebral compression fractures (VCFs) are the most common complication of osteoporosis. The higher LBP prevalence in women is due to

many factors: perimenopausal abdominal weight gain, genetics, estrogen deficiency, smoking, history of fragility fractures, previous falls, parental history of fragility fractures, premature menopause, sarcopenia, poor neuromuscular function, malnutrition, alcohol intake and medications that promote bone loss.

Clinical presentation: More than two-thirds of patients with VCFs are asymptomatic. Symptomatic patients may present with back pain and fracture demonstrated on radiography. Patients with an acute fracture may report abrupt onset of pain with position changes. Physical examination findings are often normal, but may demonstrate kyphosis and midline spine tenderness. Chronic VCF may present with loss of height in addition to kyphosis. Compression fractures are typically diagnosed by lateral radiography of the vertebral spine, with or without anteroposterior views. Radiographic criteria for VCFs include a decrease in vertebral body height of at least 20% or a 4-mm reduction from baseline height. MRI can help distinguish benign from malignant fractures and determine the timing of the fracture (edema). MRI or computed tomography should be considered in patients who do not improve with conservative care and in those with progressive symptoms.

Conclusion: Goals of treatment include pain relief, restoration of function, and prevention of future fractures. Gynecologists must access benefits and risks of hormone replacement therapy in order to prevent early postmenopausal bone loss and augment bone mass in late postmenopause. This measure may also be protective for recurring LBP. Additionally, gynecologists can encourage weight-bearing and muscle-strengthening exercise, smoking cessation, and adequate intake of calcium and vitamin D. Consider reassess imaging if patients have no improvement after 6 weeks.

P960

IMPACT OF MUSCLE MASS ON THE BONE RESORPTION MARKERS URINE NTX AND PLASMA CTX

J. Blennerhassett¹, P. Chubb¹, S. Vasikaran¹, M. Gillett¹

¹Clinical Biochemistry, PathWest-Fiona Stanley Hospital, Murdoch, Australia

Objectives: Bone turnover marker (BTM) levels in blood and urine are thought to reflect bone turnover rate. Whilst BTM in blood is reported as an absolute value, spot urine BTM levels are reported as a ratio to creatinine concentration to correct for the impact of hydration on their urine concentration. However, when renal function is normal, creatinine concentrations in serum and in urine are impacted significantly by muscle mass since it is a catabolic product of muscle. Therefore, we sought to examine the impact of muscle mass on urine creatinine concentration and urine NTX/creatinine ratio using plasma CTX as control.

Methods: We studied plasma CTX and urine NTX/creatinine ratio measured in 975 consecutive patients over 50 y of age with normal renal function (glomerular filtration rate >60 mL/min/1.73m²) in our laboratory. Of these, 798 were females and 177 males. The association of serum and urine creatinine was assessed by Spearman correlation. Relationships between plasma CTX and

urine NTX/creatinine respectively with quintiles of serum creatinine were studied by Kruskal-Wallis test. P-values <0.05 were considered significant. Statistics were performed on MedCalc, version 18.10.

Results: Plasma CTX ranged from 40 ng/L to 1669 ng/L and there was no difference in median CTX between the serum creatinine quintiles (p=0.65). Urine and serum creatinine concentrations were significantly associated (p<0.001). NTX/Cr ranged from 3 nmol BCE/mmol Cr to 375 nmol BCE/mmol Cr. There were significant differences in NTX/Cr between quintiles of serum creatinine (p<0.001). In post hoc testing, the median NTX/Cr in serum creatinine quintile 1 (35 nmol BCE/mmol Cr) was higher than that in quintiles 3-5 (medians of 28, 29 and 29 nmol BCE/mmol Cr respectively); NTX/Cr in quintile 2 (median 21 nmol BCE/mmol Cr) was significantly greater than that in quintiles 4 and 5.

Conclusions: A low serum creatinine (<66 umol/L in our study) is associated with lower urine creatinine excretion and may lead to a significant increase in the calculated urine NTX/creatinine ratio. Urine NTX results should be treated with caution in patients with low muscle mass.

P961

DYSPNEA IN SYSTEMIC SCLEROSIS: SARCOPENIA IS MORE RELEVANT THAN INTERSTITIAL LUNG DISEASE


A. Ariani¹, L. Barone¹, A. Barbieri¹, L. Monica¹, F. Magalini¹, M. Riva¹

¹Internal Medicine and Rheumatology Day Hospital, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

Objectives: Systemic sclerosis (SSc) is an autoimmune disease characterized by both visceral and muscle impairment. Dyspnea (DYS) is the most important symptom related to SSc interstitial lung disease (ILD), but it is not correlated with its extension nor severity. The main aim of this study is to investigate if sarcopenia has a pivotal role in dyspnea onset of patients affected by SSc.

Methods: We enrolled consecutive SSc patients who underwent a chest computed tomography (CT) and completed the SarQoL questionnaire (1) within 3 months. Clinical data and dyspnea presence at the time of CT were recorded. Patients were clustered in four groups according to the presence/absence of ILD and DYS: A) no ILD and DYS; B) only ILD; C) only DYS; D) both DYS and ILD. The Kruskal-Wallis test assessed the differences of SarQoL score distributions between the above mentioned subgroups. A logarithmic regression stepwise analysis assessed the association of dyspnea with SarQoL score, disease duration, age, sex, autoimmune profile and presence/absence of ILD. A p-value <0.05 was considered statistically significant.

Results: 41 SSc patients were divided in four subgroup. SarQoL scores in patients without dyspnea (groups B and C) were higher than in groups B and D (respectively 76.3, 80.5, 57.0, and 52.1; p=0.003) (see Figure). In the multivariate logistic regression analysis, only SarQoL score was significant when tested with dyspnea (OR 0.90, CI 95%: 0.84-0.96; p=0.001).



Conclusions: The observed data support the hypothesis that sarcopenia is the main reason why a SSC-ILD patient has dyspnoea. Moreover, sarcopenia appears to be related to dyspnea even in patients without ILD.

Reference: (1) Beudart C et al. Age Ageing 2015;44:960

P962

A DESCRIPTIVE ANALYSIS OF A CARE SERVICE FOR OSTEOPOROTIC PATIENTS IN BRAZIL

F. Gazoni¹, K. Tutiya², D. R. Tavares², A. Meneses³

¹Sao Paulo Federal University, ²Sao Paulo Feral University, ³Prevent Senior, Sao Paulo, Brazil

Objectives: To describe a population of osteoporotic patients referred to an outpatient during a four year period.

Method: This study is a descriptive and observational analysis of patients referred to an outpatient called Health of Bones in São Paulo/Brazil from 2015-2018. The service began in January 2015 with the objective of diagnosing, treating and accompanying patients with osteoporosis or at high risk of fracture. All patients were followed up by a physician and a gerontologist. In 2017 the service became a FLS (fracture liaison service) with the objective of capturing all the fractures treated in a referred hospital or those diagnosed in other specialties clinics. The data were summarized through descriptive statistics. For numerical variables we used mean and standard deviation and for categorical data, absolute and relative frequencies.

Results: From January 2015 to September 2018 10,693 patients were evaluated, being 92% women, with mean age of 75 years old (from 41-103 years old; SD: 9.5), 9799 people had a diagnosis of osteoporosis (91.6%) being mostly primary osteoporosis (22.1% with secondary osteoporosis). The majority was eutrophics, 21.9% had low and 19.9% high BMI. Few patients had vitamin D levels below 30 ng/ml (38.3% in 2015 vs. 19.3% in 2018). Related to fractures, we evaluated along the 4-y period 5016 patients with fractures (i.e., 47% of our population had a fragility fracture (FF)). In 2015, 32.5% had a diagnosis of at least one fracture, 40.9% in 2016, 43.2% in 2017 and 79.1% in 2018. From all fractures, 37% were vertebral fracture, 36% hip fracture and 48% other fragility

fractures and most of them had only one FF (65%, n=3250). All patients with osteoporosis were instructed to start treatment: 72% with oral bisphosphonate, 17% with denosumab, 3.7% with zoledronate 3.7% with raloxifene and 2.2% with teriparatide.

Conclusion: The population on this 4-y period was predominantly women, elderly, with primary osteoporosis. After implementing measures for capturing the fractures, we were able to increase the reference of fractured patients after the first fracture episode and to institute drug treatment. Treatment was predominantly with oral bisphosphonates.

P963

APPLYING OF NEXT-GENERATION SEQUENCE FOR PATIENTS WITH EARLY-ONSET CHRONIC NONBACTERIAL OSTEOMYELITIS FROM NORTH CAUCASIAN REGION OF RUSSIA

M. Kostik¹, M. Makhova¹, E. Suspitsin¹, A. Sokolenko¹, V. Zorin², E. Isupova¹, S. Magomedova³, I. Kostik⁴, H. Takayanagi⁵, A. Mushkin², E. Imyanitov¹

¹Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, ²Science research Institute of Physiopulmonology, Saint-Petersburg, ³Republican Children's Clinical Hospital, Makhachkala, ⁴Children's Rehabilitation Center "Detskye Duni", Saint-Petersburg, ⁵The University of Tokyo, Tokyo, Japan

Objective: Chronic nonbacterial osteomyelitis (CNO) is a heterogeneous group of immune-mediated inflammatory bone diseases with unclear pathogenesis. At present, only a few genes associated with this condition have identified. The aim of the study was to evaluate the spectrum of mutations in genes associated with primary immunodeficiency syndromes (PIDs) and autoinflammatory diseases (AIDs) in the cohort of patients with early onset CNO from North Caucasus (Dagestan and Chechnya).

Methods: We selected a subgroup of the CNO patients (n=22) having the following features: 1) early disease onset (<5 y); 2) all children were initially diagnosed as having tuberculosis (TB) due to bone morphology findings (granulomatous, e.g., tuberculosis-like inflammation), but had a negative TB culture test; 3) initial treatment with a combination of 3-4 anti-MBT drugs during 1-2 y was ineffective, and the patient continued to develop new inflammatory bone foci; 4) patients had very severe clinical and radiological signs of disease; 5) all patients were from areas with traditionally high prevalence of consanguinity. Targeted next generation sequencing analysis of 302 genes related to PIDs and AIDs was performed.

Results: Rare variants of PID genes were detected in 7/22 (32%) patients. Mutations affecting the genes previously associated with CNO were found only in two patients: one of them carried heterozygous variant IL1RN c.170G>T (p.C57F) and another had IL1RN c.512T>C (p.V171A). No mutation of LPIN2 was revealed. Other detected variants included one pathogenic MEFV p.M694V mutation in the heterozygous state and a number of VUS in CD40LG, NLRP12, CR2, NLRP3, IL12B, PLCG2, SH3BP2, CARD14, IRF8, CASP10, and NFKB1A genes.

Conclusion: Mutations in known genes were detected only in a minor fraction of CNO patients from Dagestan and Chechnya.

Acknowledgement: This work supported by the Russian Foundation for Basic Research (grant № 18-515-57001) and by Japan Medical Research Foundation (grant № 18jmr001).

P964

ANALYSIS OF RISK FACTORS ASSOCIATED TO REFRACTURES IN AN OSTEOPOROTIC POPULATION

K. Tutiya¹, F. Gazoni², D. R. Tavares¹, A. Meneses³

¹Sao Paulo Feral University, ²Sao Paulo Federal University,

³Prevent Senior, Sao Paulo, Brazil

Objectives: To predict the risk factors associated to refractures in an elderly fractured population using a logistic regression modeling approach.

Methods: This study is a longitudinal and observational analysis of a sample of patients referred to an outpatient called Health of Bones in São Paulo/Brazil during the year of 2015. We included the referred patients who had a previous fragility fracture and were adherent to the implemented treatment with physician and gerontologist. Retrospectively, we analyzed records to assess refractures during the first year of follow-up. We performed a multivariate logistic regression using the stepwise method. All the variables that had a p-value of 0.2 in the univariate analysis were included. The analysis was performed using Stata/IC 15.1.

Results: A sample of 263 patients were analyzed, most of them women (92%), with mean age of 80.5 years old (SD: 8.5). The majority (81%) had primary osteoporosis, mean vitamin D 32.1ng/ml (SD: 10.8), T-score lumbar spine -2.5 (SD: 1.5), femoral neck -2.5 (SD:0.81), total hip -2.3 (SD: -0.9). 50.9% were treating osteoporosis, 86.6% were with oral bisphosphonate. After physician first assessment, 100% received treatment, 64% oral bisphosphonate, 11.1% denosumab, 6.6% teriparatide and 4.5% zoledronate. In the univariate analysis, age was statistically significant associated with refracture (p-value 0.03). The logistic model included age (OR 1.21, 95%CI 0.99-1.48), femoral neck T-score (OR 2.42, 95%CI 0.83-7.08), vitamin D (OR 0.96, 95%CI 0.86-1.08), number of gerontologist appointments (OR 0.37, 95%CI 0.09-1.49) and number of chronic previous fractures (OR 1.49, 95%CI 0.52-4.31). The model R squared was 0.3 and final p-value 0.04.

Conclusion: Despite the small sample, it seems that age alone is a risk factor for refracturing in an osteoporotic elderly female population. Vitamin D level, femoral neck T-score, number of gerontologist appointments and number of chronic previous fractures seems to contribute for it.

P965

MOOD DISORDERS AND ANTIDEPRESSANT USE ARE ASSOCIATED WITH TRABECULAR BONE SCORE IN WOMEN

K. Anderson¹, K. Holloway-Kew¹, L. Williams¹, J. Pasco¹

¹Deakin University, Geelong, Australia

Objective: Mood disorders and antidepressants, in particular selective serotonin reuptake inhibitors (SSRIs) have been associated with lower BMD and increased fracture risk. This study aims to assess if trabecular bone score (TBS), a tool for indirectly assessing bone microarchitecture at the lumbar spine, is similarly associated with SSRIs, antidepressants, and current mood disorders.

Methods: This study included 682 women (aged 28-94 y) enrolled in the Geelong Osteoporosis Study. TBS was determined from lumbar spine DXA scans (Lunar Prodigy) using TBS iNsite software (Version 2.2). Current use of antidepressant medications was self-reported. Current mood disorder was determined using the Structured Clinical Interview for Diagnosis (SCID-I/NP). Multivariable linear regression models were used to assess associations between mood disorders, antidepressants and TBS, adjusting for potential covariates including age, height, weight and lifestyle factors (alcohol consumption, physical activity, smoking and other medication use).

Results: 60 women (9%) met criteria for a current mood disorder and 111 (16%) reported current antidepressant use, of which 84 (12%) were using an SSRI. Current mood disorder was associated with lower TBS, before (p=0.055) and after adjustments (p<0.001). Similarly, use of any antidepressant and SSRIs were associated with 5.42% and 5.13% lower TBS (both p<0.001), respectively, which persisted in the adjusted models. A combined model including current mood disorder and use of antidepressants found their effects on TBS to be independent (β =-0.048, p=0.009 and β =-0.038, p=0.008 respectively).

Conclusion: Both current mood disorder and antidepressant use were independently associated with lower TBS in a population-based sample of Australian women. This confirms the previous research showing negative effects on bone health, and presents new data indicating that bone microarchitecture, not just bone quantity, is affected.

P966

LEVELS OF ALBUMIN AND VITAMIN D IN PATIENTS WITH EPILEPSY

A. Pinzón¹, G. Gonzalez¹, C. Salcedo¹, J. Dominguez¹, M. Puentes¹, K. Claros¹

¹University Surcolombiana, Neiva, Colombia

Objective: Anticonvulsants have been described as causing low levels of vitamin D with a negative impact on bone health. There are few data that assess albumin levels and their relationship with vitamin D. Our aim was to evaluate the ratio of serum albumin and vitamin D levels in patients with anticonvulsant consumption.

Methods: A descriptive, cross-sectional study in outpatient of the University Hospital of Neiva with diagnosis of epilepsy and age >18 y. A sample of 90 patients was calculated, excluding those who had stage 3, 4, 5 chronic kidney disease, child Pugh grade A, B or C liver cirrhosis, neoplasms, pregnant or lactating. Vitamin D 25-OH, PTH, serum albumin and serum calcium were measured.

Results: 90 patients were studied. The median age was 36.5 y, 46.7% men and 53.3% women. The average vitamin D was 31.1 ng/ml with a standard deviation of 10.0, 51.1% (n=46) had low levels of vitamin D, 38.8% with insufficiency (20-30 ng/dl) and 12, 2% with deficiency (<20 ng/dl). Patients with vitamin D deficiency had

lower albumin levels and higher levels of PTH, being statistically significant, without alterations in BMI, serum calcium or corrected calcium. Table 1.

Conclusions: Chronic renal failure is related to low serum albumin levels and also urinary loss of vitamin D transporter protein affecting bone health. In our study we found a relationship between vitamin D deficiency and a lower serum albumin level without affecting the calcium level. It should be clarified if patients with low albumin levels associated with vitamin D deficiency present an early or greater bone involvement.

Table 1. Blood studies associated with vitamin D insufficiency and deficit in patients with anticonvulsant treatment.

Data	Normal N=43	Insufficiency N=35	P	Deficit N=11	p
Anthropometric					
BMI median (ranges)	24.0 (19.7–35.3)	24.1 (18.0–33.8)	0.87	23.3 (21.6–33.2)	0,68
PTH pg/ml					
Median (ranges)	43.3 (22.1–86.4)	49.1 (18.4–132.7)	0.21	103.9 (30.7–182.9)	<0,01
Calcium serum mg/dl					
Mean (SD)	9.2 (0.7)	9.05 (0.5)	0.33	8.9 (0.6)	0,23
Albumin serum g/dl					
Mean (SD)	4.0 (0.4)	3.9 (0.3)	0.20	3.7 (0.3)	0,02
Corrected calcium mg/dl					
Mean (SD)	9.2 (0.7)	9.12 (0.5)	0.68	9.1 (0.7)	0,84

P967
THE REGULATORY MECHANISM SIRT-1 ON NFG EXPRESSION IN SYNOVIUM OF OSTEOARTHRITIS

S. P. So Youn¹, Y. L. Yi Sle¹, C. K. Chi Dae²

¹Department of Pharmacology, School of Medicine, Pusan National University, ²Department of Pharmacology, School of Medicine, Pusan National University, Yongsan-si, South Korea

Nerve growth factor (NGF) is widely known pain mediator and the regulation of NGF with tanezumab has robust analgesic effect on knee osteoarthritis (OA) pain but, inflammation aggravate OA synovitis and get worse OA pain. Although the important function of IL-1β on inducing NGF expression is well established, the regulatory mechanisms of NGF expression are poorly defined. SIRT1 has been shown to play a critical role in cellular inflammation. The present study investigated the role of SIRT1 as a regulator of NGF in inflammation of OA. Synoviocytes were isolated from knee synovium of OA patients. NGF mRNA were measured by qRT-PCR. NGF protein were detected by immunoblot. IL-1β and NGF were detected in synovium of OA patients by immunohistochemistry. Using immunohistochemistry, we examined the expressions of NGF and IL-1β in synovial tissue sections from OA patients. NLRP inflammasome and IL-1β were found abundantly expressed in OA tissues. IL-1β stimulat-

ed the expression of NGF mRNA and protein in OA synoviocytes. SRT1720, a SIRT1 activator, increased SIRT1 activity in OA synoviocytes. Additionally, Pretreatment with SRT1720 suppressed IL-1β- induced NGF mRNA and protein. Blocking SIRT1 activity by EX527 (an inhibitor of SIRT1) failed that SRT1720 reduces IL-1β-induced NGF mRNA and protein. This study provides the showing that SIRT1 plays critical role in regulating NGF in synovium of OA, suggesting that SIRT1 may be a potential therapeutic target to reduce OA pain.

P968
DEVELOPMENT OF RAT MODEL OF NEUROLOGICAL HETEROTOPIC OSSIFICATION

R. Brady¹, P. Casillas-Espinosa¹, S. McDonald¹, T. O'Brien¹, S. Shultz¹

¹Monash University, Department of Neuroscience, Melbourne, Australia

Objectives: Neurological heterotopic ossification (NHO) occurs in approximately 20% of traumatic brain injury (TBI) patients and is characterised by the formation of bone (up to 1.5 kg) in soft tissue. NHO typically forms in muscle and around joints, causing pain, nerve entrapment, soft tissue catabolism, and joint deformation. There are no predictive markers for NHO, therefore NHO

can only be identified after the lesion has mineralised. Though the identification of predictive biomarkers would greatly improve the clinical management of this condition. The lack of biomarkers is in large part due to the challenges and limitations involved in studying this condition in humans, however, animal models allow for the control of these confounds. Here we aimed to develop a novel rat model of TBI-induced NHO that closely mirrors the injury mechanics and post-injury sequelae of NHO observed in humans and to identify plasma-based markers that predict the development of NHO.

Methods: 8-week-old male rats were given a moderate-severe TBI, induced via lateral fluid percussion injury, a femoral fracture and a muscle crush injury (n=12). Blood was collected at 2, 7, 21 and 42 d postinjury and analysed using reverse phase protein microarray (RPPM). Rats were euthanized at 6 weeks postinjury and the formation of NHO was assessed via microCT.

Results: MicroCT analysis revealed that six of 12 rats given a TBI, muscle injury and fracture went on to develop NHO, while the other six did not. Rats that developed NHO had significantly reduced plasma levels of IL-6 when compared to rats that did not develop.

Conclusion: In this study we have developed a novel rat model of NHO that features injury combinations NHO patients commonly present with. In addition, our finding that rats that went on to develop NHO had reduced circulating levels of IL-6, suggests that plasma levels of IL-6 may serve as a predictive biomarker of the formation of NHO.

P969

FREQUENCY OF SKULL BASE PATHOLOGY IN BELARUSIAN CHILDREN WITH OSTEOGENESIS IMPERFECTA

A. Pachkaila¹, D. Chapurok², E. Rudenka³

¹Belarusian Medical Academy of Postgraduate Education, ²Minsk Regional Children's Clinical Hospital, ³Belarusian State Medical University, Minsk, Belarus

Objective: To analyze the frequency of craniovertebral junction pathology (basilar impression/invasion, platybasia) in children with osteogenesis imperfecta (OI).

Methods: We analyzed the skull base morphology from lateral skull radiographs, obtained between the ages of 3-17 y in 31 bisphosphonate-treated (pamidronate) and 6 nontreated OI boys (22) and girls (15). They represented OI types I, III, IV. They were examined by a pediatrician, geneticist, radiologist, ophthalmologist, neurologist. Possible neurological symptoms typical for the skull base abnormalities (double vision, nystagmus, imbalance and incoordination, increased intracranial pressure, headache/neck pain, etc.) had been looked for in clinical examinations. We used the definitions and criteria established by O. Kovero et al. (2006) to classify the skull base abnormalities.

Results: We found that 62% (23/37) of patients had a normal craniovertebral junction structure, 38% (14/37) had the skull base abnormalities. Isolated platybasia occurred in 11 children, basilar invagination in - 1 child, combination of basilar invagination with platybasia - in 1 child, combination of basilar impression with plat-

ibasia - in 1 child. Abnormalities were detected in 5 of 9 patients with severe OI, in 7 of 21 - with moderate OI, in 2 of 7 - with mild OI. They were revealed in 6 of 7 children with most severe OI type (III). The most severe types of abnormalities (basilar impression or invagination) were detected in patients with severe OI (and were not detected in mild OI). However, there were no significant differences in the frequency of abnormalities between patients with mild, moderate and severe OI, bisphosphonate treated and nontreated patients. All the examined patients did not reveal neurological symptoms typical for skull base abnormalities.

Conclusion: Skull base abnormalities are a frequent complication of OI in children. Their early detection is important for the subsequent patient management.

P970

MULTIDISCIPLINARY APPROACH OF GERIATRIC PATIENTS AFTER HIP TRAUMA

S. I. Stanciugelu¹, C. R. Homorogan¹, A. Lazarescu¹, J. M. Patrascu¹

¹Victor Babes University of Medicine and Pharmacy, Timisoara, Romania

Objective: To identify a model for multidisciplinary approach in hip trauma patients.

Methods: In the first part of our study, we performed a retrospective study, using the medical data of 55 patients, over 65 years old, which underwent a proximal femur fracture. We noted all associated chronic pathologies in four major categories: cardiovascular disease, neurological pathology, psychiatric disorders and others, and the number of interdisciplinary consultations they had. In the second part of our study, we included 32 medical doctors of from different fields. Were collected sociodemographic data and was applied a questionnaire that contained 3 simple yes/no questions, to evaluate their availability to work in a multidisciplinary team.

Results: 23.5% of the patients needed pre-intervention interdisciplinary consultation, out of which 12% needed cardiologic consult, 7% neurological evaluation, and 3.5% others. 91.7% of the patients have associated a cardiovascular disease, the most frequent disease being hypertension. Neurological comorbidities were present in 21% of the patients, including pathologies like history of stroke, hemiplegia, cerebral ischemia or different types of paresis.

10% of the patients had history of psychiatric pathology, including depression, anxiety, and other disorders. The results for the second part of the study, were 100% affirmative answers for the first two questions, while the last question revealed that only 70% of doctors would sacrifice their time to be part of such a multidisciplinary team. The doctors who would not participate in such teams were younger than 40 years old.

Conclusions: Multidisciplinary approach is vital not only in the successful reintegration of the elderly patient, but also in correct perioperative management, taking into consideration that the great majority associate complex chronic pathology. Regarding the age of the doctors, older doctors would sacrifice more of their time because they understand that such an approach would make

a better outcome for the patients. If doctors would collaborate, the multidisciplinary team would work better, making the process easier and building professional relationships, which are proven to be more effective.

P971

BONE MINERAL DENSITY IS ASSOCIATED WITH OVARIAN VOLUME IN POSTMENOPAUSAL WOMEN

E. Armeni¹, L. Aravantinos¹, P. Vakas¹, A. Augoulea¹, D. Rizos², A. Antoniou¹, A. Alexandrou¹, E. Deligeoroglou¹, I. Lambrinouadaki¹

¹2nd Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Aretaieio Hospital, ²Hormonal and Biochemical Laboratory, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece

Objectives: To evaluate the potential link between ovarian volume, anthropometric and demographic parameters as well as BMD and hormonal status in women after the menopausal transition.

Methods: This cross-sectional study included a total of 161 healthy postmenopausal women, retrieved from the Menopause Clinic of the 2nd Department of Obstetrics and Gynecology, Aretaieio Hospital, Athens, Greece. We evaluated anthropometric parameters, including body mass including BMI and waist to hip ratio (WHR). Sonographical assessment included estimation of the average ovarian volume for each participant. DXA was used to measure bone density in the femoral neck (FN) and the lumbar spine (LS).

Results: The average values of ovarian volume increased stepwise with increasing BMI quartiles (Q1:0.985±0.25, Q2: 1.11±0.29, Q3: 1.07±0.28, Q4: 1.19±0.38, p-value for linear trend 0.013). Moreover, the average ovarian volume correlated positively with BMI values (r=0.128, p-value=0.038), FN BMD (r=0.233, p-value=0.003), FN T-score (r=0.223, p-value=0.004) and FN Z-score (r=0.171, p-value=0.027). Multivariate analysis showed that FN BMD was predicted by ovarian volume, independently of age, menopausal age and BMI. Finally, ovarian volume was predicted by WHR (b-coefficient=0.157, p-value=0.047) and SHBG (b-coefficient=-0.160, p-value=0.042), independently of age and BMI.

Conclusion: The results of the present study indicate that the average ovarian volume was positively and independently associated with femoral BMD and adiposity indexes in postmenopausal women. Lower SHBG levels were associated with higher ovarian volume. Insulin resistance may mediate these results. The significance of these findings should be assessed in larger prospective studies.

P972

NECK PAIN: THE RELATIONSHIP BETWEEN CERVICAL SPINE MRI AND ELECTRODIAGNOSTIC FINDINGS USING SEVERITY GRADING SCORE

M. O. Kim¹, H. S. Kim¹

¹Department of Physical & Rehabilitation Medicine, Inha Univ. Hospital, Incheon, South Korea

Objective: In patients with neck pain, cervical spine MRI and electrodiagnostic (EDX) study are commonly performed examinations. Many researchers studied that cervical spine MRI and EDX study allows us to know useful information of cervical pain source. However, few studies have been preceded the relation of severity between EDX and MRI. This research is about the relationship of cervical spinal findings on EDX and MRI study in patients with neck pain.

Method: Authors retrospectively reviewed 50 patients with a neck pain who evaluated with both an EDX study and a cervical spine MRI within 1 month of each other. One radiologist assessed cervical MRI imaging and experienced physiatrists performed nerve conduction study and needle electromyography (NCV + EMG). We devised the '00 severity grading score' of EDX study and cervical spine MRI through comprehensive literature reviews. In addition, we investigated (1) correlation of total score of the MRI abnormalities with EDX findings, (2) correlation of each subscore of the EDX findings (NCV, abnormal spontaneous activity, motor unit potentials) with subscores of MRI findings. The correlations among the subscores analyzed by Pearson correlation coefficient.

Results: The total score of MRI abnormalities had strong correlation (r=0.767) with total score of EDX findings (p<0.05). The abnormal spontaneous activity showed higher correlation with total score of MRI abnormalities (r=0.868) than the findings of NCV (r=0.452), motor unit potentials (r=0.785) (p<0.05). The subscore of the MRI findings including bilateral involvement (r=0.708), cord compression (0.604) showed correlation with total scores of EDX findings (p<0.05). However, other subscores of MRI including multilevel disc herniation, unilateral root compression showed no correlation with total scores of EDX findings (p>0.05).

Conclusion: There were strong correlations between total score of EDX and cervical spine MRI findings. However, we must not ignore that each subscore of radiologic finding significantly not correlated with EDX scores. It showed that the severity of cervical spine MRI should not exaggerate the process of EDX findings.

P973

CALCIUM INTAKE IN BOGOTA, COLOMBIA: AN UPDATE

P. E. Sanchez Marquez¹, A. F. Coy Barrera¹, A. Medina Orjuela², M. A. Rivera

¹Fundacion Universitaria de Ciencias de la Salud, ²Hospital de San Jose, Bogota. Colombia

Objective: Determine daily calcium intake in a random population of Bogota, Colombia.

Methods: Observational descriptive study of a transverse cohort with a prospective collection of information. The sample was obtained by convenience, of volunteers over 18 years old, in Bogota, Colombia who answered the calcium intake questionnaire from the international osteoporosis foundation, from different socioeconomic level given by the place of residency, between June and December 2018. People with calcium supplements were excluded.

Results: 450 volunteers participated. 296 (65.8%) were women. The median age was 34.5 (interquartile range IQR of 21-55) and 30 y (IQR 21-51) for women and males respectively.

The mean calcium intake was 724.5 mg/d, 731.5 mg/d (IQR 533-1032 mg) for women, being 776 mg/d (IQR of 545-1107 mg), 629 mg/d (IQR of 489-838 mg) and 769 mg/d (IQR 568-1042 mg) in women age range of 18-30, 31-50 and over 50 y. The median calcium intake for men was 717.5 mg/d (IQR 536-1012), being 778 mg/d (IQR 570-1142 mg), 634.5 mg/d (IQR 396-891 mg) and 751 mg/d (IQR 497-892) for man of age range between 18-30, 30-50 and over 50 y respectively. The median calcium intake in lower socioeconomic level was 566 mg/d (IQR 426-916.5), 83% had a consumption lower than 1000 mg/d, 4.4% between 1000-1200 mg/d and 14.89% higher than 1200 mg/d. In the middle class, the intake was 715 mg/d (IQR 547-1033), 71.5% of the group with a lower consumption of 1000 mg, 13.59% consuming 1000-1200 mg and 14.89% consumed over 1200 mg/d. In the highest class the median was of 892 mg/d (IQR 668-1103 mg), 58.9% had a day intake lower than 1000 mg, 23.29% consumed between 1000-1200 mg and 17.8% over 1200 mg/d. The main cause of low intake in women and men was unawareness of requirements in 92.4% and 88.1%, followed by gastrointestinal intolerance. This was observed independently of the socioeconomic level and age.

Conclusions: The calcium intake of Colombia is 724.5 mg/d, the highest in South America considering the calcium map, however, it is still below the recommended requirements. Unawareness is the first cause independent of age and socioeconomic level. The highest income volunteers had a higher intake without differences by age or gender.

P974

CLINICAL AND DEMOGRAPHIC PROFILE OF PATIENTS CONSULTING FOR FRAGILITY FRACTURES IN A HOSPITAL IN COLOMBIA DURING THE YEARS 2015-2017: IMAGE OF THE COLOMBIAN HEALTH SYSTEM

D. G. Fernández-Ávila¹, D. Rincón², D. Pinzón¹, J. Gutiérrez¹

¹Hospital Universitario San Ignacio - Pontificia Universidad Javeriana / Departamento de Medicina Interna, ²Universidad Militar Nueva Granada / Servicio de Reumatología, Bogotá, Colombia

Objectives: To describe the clinical and demographic characteristics of patients with fragility fractures seen in our hospital. To describe the risk factors for fragility fractures. To inquire about the patient's knowledge about osteoporosis. To follow each case

establishing whether after presenting the complication (fracture), the patient would receive an ambulatory treatment covered by the health insurance.

Methods: Cross-sectional descriptive study

Results: 111 patients mean age of 74.4 y (± 11.3), 84 (75.6%) were women. All consulted for osteoporotic fracture. The most frequent type of fracture was hip (51.4%), followed by vertebra (23.4%), wrist (22.5%) and humerus (4.5%). 87.4% (n=97) had no personal history of fracture and only 1% had a history of frailty fracture in a first-degree relative. Risk factors: 7.2% (n=8) used glucocorticoids, 3.6% (n=4) antiepileptics and 3.6% (n=4), warfarin 21.6% (n=24) were smokers. 77.5% (n=86) had never previously undergone a densitometry despite the fact that, because of their age, they had indicated that this study had previously been performed. Knowledge of osteoporosis by patients: 49.5% (n=55) did not know that osteoporosis was present, 58.6% (n=65) did not know that fracture was the main complication of this disease and 62.2% (n=69) does not relate to fractures with osteoporosis. All patients were educated and sensitized about osteoporosis and the importance of diagnosis and treatment and they were given an order to perform densitometry at discharge, despite the above 24.3% (n=27) densitometry was performed in the next year of the fracture. As for treatment, 33.3% (n=37) received calcium plus vitamin D. Only 9.9% (n=11) received treatment for osteoporosis (7 patients with bisphosphonate and 4 with denosumab), none received teriparatide osteoformer therapy.

Conclusions: The present study demonstrates the lack of understanding by the Colombian patients about osteoporosis. Despite of clear indications described international guidelines, we have found a lack of densitometry measurements on our follow-up patients. More serious, only 10% of the patients received treatment for osteoporosis and none of them used an osteoformer therapy. This proves the suboptimal follow-up made by the health insurance companies of our country. Urgent educational and public health policies are needed.

P975

SOCIAL NETWORKS AS INFORMATION SOURCES FOR PATIENTS WITH OSTEOPOROSIS

D. G. Fernández-Ávila¹, D. M. Romero-Alvernia¹, J. Barahona-Correa¹, A. García¹, O. Muñoz¹, O. Rosero²

¹Hospital Universitario San Ignacio - Pontificia Universidad Javeriana / Departamento de Medicina Interna, Bogotá, ²Instituto de Osteoporosis de Los Llanos, Osteollanos, Villavicencio, Colombia

Objective: To establish quantitative and qualitative data on osteoporosis treatment published in social networks for Spanish speaking patients.

Methods: Facebook (FB) and YouTube (YT) accounts were created. A convenience sampling was performed in each network based on most viewed videos. Data were obtained during January 2019 using the terms "osteoporosis treatment", only videos in

Spanish were included. Two independent reviewers assessed the reliability of the information. Retrieved variables were: Time on the internet (TI, d), # views, # likes, # shared, duration (s).

Results: 50 videos were selected in each platform, only 36% (FB) and 54% (YT) presented reliable information. The most viewed video on FB was "Tratamiento para dolores articulares" (479.826 views), whereas on YT was "Jugo verde para la osteoporosis, anemia y caída del cabello" (2'426.582 views). Most videos offered treatment with unknown compounds, nonapproved by regulatory agencies, or natural therapies (sesame, vegetables, moringa, coconut oil, curcumin, etc.). 4 offered a cure, including stem cells.

Dairy products and pH alterations were considered as the cause of osteoporosis in 2 videos, thus alkalinizing diets were treatment options. Acupuncture was offered. Table 1 summarizes quantitative data. No differences were detected between reliable and false multimedia in FB, however the latter presented more views and likes in YT. No correlations between TI and # views were observed.

Conclusions: Social networks are an increasing source of health information for patients. False information on osteoporosis treatment is common and appears to be more frequently viewed, particularly on YT. Regulatory policies should be considered.

	Facebook			Youtube		
	F (n=32)	R (n=18)	p ^a	F (n=23)	R (n=27)	p ^a
TI	105 (26-250)	143 (102-486)	0.3746	1391 (906-2005)	1871 (1267-2506)	0.2131
# Views	642 (119-6499)	382 (182-3720)	0.9037	80825 (29796-266708)	22491 (8736-68191)	0.0031**
# Likes	11 (3-139)	19 (11-73)	0.5435	2000 (395-4200)	100 (37-806)	0.0002**
# Shared	7 (2-90)	10 (1-57)	0.8138	-	-	-
# Duration	169 (53-440)	143 (104-288)	0.8375	433 (211-1860)	334 (197-478)	0.1761

F False; R Reliable; ^a Mann-Whitney

P976
EFFECT OF TERIPARATIDE ON BONE MINERAL DENSITY AND BONE MARKERS IN REAL LIFE: ARGENTINE EXPERIENCE

R. Guelman¹, A. Sánchez², M. Varsavsky¹, M. L. García³, M. Sarli⁴, P. Rey⁴, V. Farias⁴, M. B. Zanchetta⁴, E. Giacoia⁵, H. Salerni⁶, L. Maffei⁷, V. Premrou⁷, B. Oliveri⁸, M. Pavlove⁹, S. Karlsbrum⁹, M. S. Larroudé¹⁰, L. Brun¹¹, P. R. Costanzo⁶

¹Servicio de Endocrinología y Medicina Nuclear, Hospital Italiano de Buenos Aires. Ciudad Autónoma de Buenos Aires, ²Centro de Endocrinología, Rosario, ³Sanatorio Julio Méndez, Ciudad Autónoma de Buenos Aires, ⁴Instituto de Investigaciones Metabólicas, Ciudad Autónoma de Buenos Aires, ⁵Servicio de Endocrinología y Metabolismo Hospital Posadas, Ciudad Autónoma de Buenos Aires, ⁶Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo (CICEMO), Ciudad Autónoma de Buenos Aires, ⁷Consultorios Asociados de Endocrinología Dra. Laura Maffei, Ciudad Autónoma de Buenos Aires, ⁸Mautalen Salud e Investigación, Ciudad Autónoma de Buenos Aires, ⁹Hospital Durand, Buenos Aires, Ciudad Autónoma de Buenos Aires, ¹⁰Centro Rossi, Ciudad Autónoma de Buenos Aires, ¹¹Laboratorio de Biología Ósea, Fac Cs Médicas, UNR, Ciudad Autónoma de Buenos Aires, Argentina

Objective: Evaluate the effect of teriparatide (TPTD) on MD and bone markers under clinical practice conditions in specialized centers.

Methods: Cross-sectional study of 257 postmenopausal women treated with TPTD for at least 12 months. We considered serum calcium, PTH, 25OHD, alkaline phosphatase (AP), bone AP (bAP), osteocalcin (BPG), C-terminal telopeptide (CTX) and urinary deoxypyridinoline (Dpyr). In addition, lumbar spine (LS), femoral neck (FN) and total hip (TH) BMD (g/cm²) was evaluated by DXA (Lunar Prodigy). Data were expressed as mean±SD and were analyzed with Wilcoxon test vs. basal (*p<0.05 vs. basal).

Results: 257 patients who completed 12 months of treatment were included (100 completed 18 m and 76 completed 24 m). Main characteristics: age 68.6±10.1 y (range: 43-101), age of menopause 48.0±4.7 y, previous fractures: 54.1% (median of vertebral fractures 2 [range 1-9] and nonvertebral fractures 1 [range=1-5]), previous use of bisphosphonates (BP) 79% (6.0±3.6 y). Bone formation and bone resorption markers significantly increased from 6 m returning to basal values at 18 m (AP, bAP) or 24 m (Dpyr). CTX and BPG remained increased to 24 m. PTH decreased significantly at 6 m and returned to baseline values at 18 m, inverse to calcemia behavior. No changes in 25OHD were observed. There was a significant increase in LS BMD from 6 m (+6.2%*) with a maximum at 24 m (+13.0%*). FN and TH BMD showed a significant increase from 12 m (FN 12 m: +2.5%* and 24 m: +7.9%*; TH 12 m: +1%* and 24 m: +5.5%*). According to the previous use (n=203) of BP or not (n=54), a significant increase in LS BMD was found from 6 m to 24 m compared to basal in both groups (+13.4%* and +11.3%*, respectively) and no differences were observed in FN and TH BMD in these groups.

Conclusions: As reported in clinical studies, treatment of osteoporotic postmenopausal women with TPTD in routine clinical practice induced a significant increase in bone formation and resorption markers from 6 months onwards and an increase in BMD from 6-12 m with continuous gain up to 24 m. In addition, TPTD induced an increase in BMD regardless of the previous use of BP.

P977

PREDICTORS OF TENDENCY TO LOCOMOTIVE SYNDROME AMONG THE OLDEST OLD DURING A 3-YEAR FOLLOW-UP

M. C. F. Arbex¹, S. N. Carmo², J. E. F. Okazaki², D. R. B. Tavares², J. C. Galiano, J. A. P. Alves, F. C. Santos

¹Federal University of São Paulo (UNIFESP), Discipline of Geriatrics and Gerontology, Pain and Osteoarticular Diseases Group, SP, Araraquara, ²Federal University of São Paulo (UNIFESP), Discipline of Geriatrics and Gerontology, Pain and Osteoarticular Diseases Group, São Paulo, Brazil

Objective: Identify the predictors for worse scores associated with locomotive syndrome (LS) in community-dwelling elderlies with 80 y or more.

Methods: This is a first analysis of a prospective cohort study - LOCOMOV Project, with a 3 y follow-up. At baseline 102 people (mean age 87.2 y, 73.5% female) were evaluated using questionnaires related to LS diagnostic (GLFS 25-p), basic and instrumental daily living activities (Katz and Lawton, respectively), quality of life (WHOQOL-Bref), social participation (social dimension of WHOQOL-OLD) and physical performance tests (4m gait speed-GS4m, 5-sit and stand test - SS5x, two-step-test -TSS and hand grip-HG). The data collected were submitted to the t-Student test, variance analysis (ANOVA), Pearson correlation coefficient and multiple logistic regression (stepwise) for statistical analysis. The significance level was set at 0.05 (5%).

Results: During the period, we lost 4 patients, 5 died and we excluded 6 patients that developed dementia. Therefore, we analyzed data of 87 patients with a mean age of 87.3 y. Linear regression models showed significant predictors for worse values of GLFS25-p (adjusted R²=29.9): (1) female (b=5.7, P=0.021); (2) osteoporosis (b=9.6, P<0.001); (3) osteoarthritis (b=4.2, P=0.018); (4) gait speed <0.8 m/s (b=7.2, P=0.001) and (5) increase IMC (b=0.9, P<0.001). In addition, individuals with LS also had a higher prevalence of chronic pain and worse quality of life in univariate analysis during the 3-y interval (P<0.001).

Conclusion: Our logistic model showed that oldest old community-dwelling women who has osteoporosis, osteoarthritis, worse gait speed or increase IMC are strongly associated with worse predictors of tendency to SL.

P978

USE AND IMPACT ON SOCIAL NETWORKS BY OSTEOPOROSIS JOURNALS

D. G. Fernández-Ávila¹, V. Avila¹, O. Muñoz¹, A. García¹, O. Rosero²

¹Hospital Universitario San Ignacio - Pontificia Universidad Javeriana / Departamento de Medicina Interna, Bogotá, ²Instituto de Osteoporosis de Los Llanos, Osteollanos, Villavicencio, Colombia

Objective: To evaluate the presence, number of followers and activity of the osteoporosis journals in the main social networks.

Methods: The platform of scientific journals Scopus was consulted, selecting the journals located under the terms "osteoporosis" and "bone". The Scimago Journal Rank (SRJ) of the year 2017 was taken as an approximation to the impact of the magazine. The social networks Facebook, Twitter and YouTube were consulted, searching for the journals found in the Scopus search. Date of consultation: 01-20-2019.

Results: In SCOPUS, 7 journals were found with the search term "osteoporosis" and 21 journals with the term "bone", of which only 8 (28.5%) had an active account in at least one of the social networks consulted (Facebook, Twitter and YouTube). On Facebook, the most active journals with the largest number of followers were J Bone Joint Surg, Bone Joint J and Osteoporos Int. On Twitter, the journals with the most followers are Bone Joint J, Bone Joint Res and Osteoporos Int. The activity on Twitter, measured as number of twits, had the same behavior according to the number of followers. The magazines with YouTube channel are J Bone Joint Surg (2193 subscribers, 271 videos, most viewed video 40215 views), Osteoporos Int (387 subscribers, 210 videos, most viewed video 30485 views), and Bone Joint J (33 subscribers, 6 videos, most viewed video 1300 views).

Conclusion: In the era of the digital world, social networks have become a new form of interaction between scientific publications and their readers. In spite of the above, very few osteoporosis journals have an active account in social networks and journals with active accounts have low activity rates in the network. It opens an opportunity for osteoporosis journals to venture into social networks to improve their visibility and impact in the scientific world.

Table 1: Characterization of scientific journals in social networks of the osteoporosis area.

Journal	SRJ	Facebook	Twitter	Twits
J Bone Joint Surg (Q1). USA	2.72	18609	NA	NA
Bone Joint J (Q1). UK	2.04	10930	21213	1683
Osteoporos Int (Q1). Germany	1.52	9798	5260	2800
Bone Joint Res (Q1). UK	1.19	5871	10600	3866
Bone Res (Q1). UK	1.12	NA	1545	1834
Arch Bone Joint Surg (Q2). Iran	0.63	38	NA	NA
J Osteoporos (Q3). USA	0.64	NA	130	184
Revista de Osteoporosis y Metabolismo Mineral (Q4). Spain	0.12	2	11	2

SJR: Scimago Journal Rank. Facebook: Number of followers. Twitter: Number of followers. Twits: Number of twits reported on the platform. NA: Not applicable.

P979

REFERENCE VALUES FOR BODY COMPOSITION IN MEXICAN CHILDREN AND ADOLESCENTS

D. Lopez-Gonzalez¹, J. Wells², M. Cortina Borja³, P. Clark

¹hospital Infantil de Mexico Federico Gomez/Clinical Epidemiology Research Unit, Mexico City, Mexico, ²UCL Institute of Child Health/Childhood Nutrition Research Centre, London, UK, ³University College London/Faculty of Population Health Sciences, London, UK

Objective: The assessment of growth and development in children has been made by anthropometric measurements such as weight, height and BMI. Although very practical, BMI has the limitation to group the different compartments of body composition (BC) as the same, wrongly classifying subjects with high lean-mass (LM) as overweight/obese, or individuals with high fat-mass (FM) as healthy. The recognition of the importance of the different body components during childhood is being recognized lately since they can have an impact in the development of chronic diseases as osteoporosis, sarcopenia and others in the adulthood.

Reference values for body composition must be developed in every population of children and adolescents in order to implement preventive or treatment strategies with a long term view. Our aim was to determine reference values of BC by DXA for healthy Mexican children and adolescents.

Methods: We carried a population based cross-sectional study in healthy Mexican children aged 5-20 years. We carried clinical history and examination, anthropometric measurements, blood sample for glucose and lipid profile; BC by DXA iDXA GE. We used descriptive statistics to report demographic and clinical data. We report BC by FM, LM, bone mineral content (BMC), FM index (FMI). We developed age- and gender-specific smoothed percentile curves for LM, FM and BMC by means of gamlss method, R statistics.

Results: We have assessed 1885 children and adolescents (990 males and 895 females). Nutritional status according to BMI classified 64% of subjects as normal weight, 16% overweight, 15% obese, and 5% underweight. We excluded subjects with obese, underweight and metabolic alterations for the construction of the graphs; we included 1332 children/adolescents for the construction of the graphs. Noteworthy 8% of subjects classified by BMI as normal weight had fat percentage mean value (36%) similar than overweight group, similar in 15% of the adolescents. In 3% of children, and 5% of the adolescents classified as normal weight has mean fat percentage (41%) similar than obese group.

We present the smooth curves for total lean mass, by gender.

Figure 1. Lean mass in female.




Figure 2. Lean mass in male.




Figure 3. Fat mass in female.





Figure 4. Fat mass in male.



Conclusions: Ethnic-specific reference values and risk cutoff points must be generated to improve health-status classification of children. We have developed such values for our population that will allow us to implement strategies of nutrition and physical activity in vulnerable groups.

**P980
OSTEOPOROSIS DIAGNOSIS KNOWLEDGE
ASSESSMENT AND BONE DENSITOMETRY
INTERPRETATIONS OF PHYSICIANS IN COLOMBIA**

D. G. Fernández-Ávila¹, K. Álvarez-Raigoza¹, J. Gutiérrez¹

¹Hospital Universitario San Ignacio - Pontificia Universidad Javeriana / Departamento de Medicina Interna, Bogotá, Colombia

Objectives: Assessment and description of knowledge and main concepts of osteoporosis and bone densitometry (DXA) interpretations of a physicians group in Colombia.

Methods: Cross-sectional descriptive study. Two professors from the Department of Rheumatology, both experts in osteoporosis designed a survey with 36 questions in four scopes of osteoporosis knowledge including: indications of DXA scan, readings of the bone densitometry, evaluation of images, the entire questions are based on clinical scenarios.

Results: 41 residents of the internal medicine program, answered the survey. 58.8% were woman, average age 27.7 years old (± 2 y). The 90.3%, 80.2% and 76.8% defined properly T-score, Z-score and BMD, respectively, despite this applying those terms in clinical

context the correct term for Z-score was found in 63.4% and BMD in 78.8%. The DXA analyze was 58.5% in osteopenia and 74.1% in osteoporosis accurately. The accepted meaning of severe osteoporosis was found in only 13.5% of the total population. There were 5 clinical cases representing examples in where DXA scan was indicated and 82.9% corrects, in contrast 4 cases with DXA scan not indicated and 65.2% answer correctly. Four images of femoral neck, two of them in right position and two of them non-interpretable with the following correct answers 62.3% and 47.1% respectively. Same situation presenting lumbar spine 2 images right position with 74.2% right identified and 55.1% in noninterpretable images. The cutoff established to consider a physician to pass the test answering accurately at least 11 of the 18 clinical cases representing the 63.4% of the group, although only 24.9% choose poorly the correct segment in densitometry of the lumbar spine, femur and forearm. The 71.1% of the physicians recognize the vertebral fracture as the most prevalent in osteoporosis. In addition with a visual analogue scale from 0 to 100, evaluates the interest in osteoporosis the 55.2% indicate 80 or even higher interested, 32.8% between 50-80, and 12% <50.

Conclusions: Data exhibit low level of knowledge in osteoporosis diagnosis and assessment of densitometry in a physician group from Colombia.

P981

EFFICACY AND SAFETY OF DENOSUMAB IN HEMODIALYSIS PATIENTSH. Tanigawa¹, Y. Tamagawa², M. Tanemura¹, R. Nakajima¹, S. Imai³¹Department of Orthopaedic Surgery, JCHO Shiga Hospital, Otsu, ²Department of General Medicine, Kusatsu General Hospital, Kusatsu, ³Department of Orthopaedic Surgery, Shiga University of Medical Science, Otsu, Japan

Objective: The number of patients with end-stage renal disease (ESRD) undergoing hemodialysis is increasing worldwide. The age of these patients is also increasing because of improvements in long-term prognosis with hemodialysis. This has also led to an increasing number of hemodialysis patients with osteoporosis. Hemodialysis patients with osteoporosis experience degrading bone quality and decreasing bone mass. Compared to osteoporotic patients without renal dysfunction, hemodialysis patients with osteoporosis have an extremely high risk of fracture. A safe and effective treatment for osteoporosis in hemodialysis patients has not been established. Selective estrogen receptor modulators (SERMs) like denosumab (DMAB), as well as teriparatide (TPTD), provide options for treating osteoporosis in patients with ESRD. Although SERMs can be used safely in women, they have little effect on increasing BMD. Many hemodialysis patients have hyperparathyroidism, which is a contraindication for TPTD. DMAB is considered a safe and effective treatment for osteoporosis if hypocalcemia is strictly controlled. However, few studies have described the efficacy of DMAB administration in hemodialysis patients. Herein, we report the safety and efficacy of DMAB in hemodialysis patients with osteoporosis.

Methods: DMAB was administered to 25 patients (12 men, 13 women) with osteoporosis who were undergoing hemodialysis at our hospital. The mean patient age was 70.6±11.0 y. The average hemodialysis period at initial DMAB administration was 131.7 months and the average follow-up period was 13 months. An active vitamin D formulation was administered to all patients, and calcium carbonate supplements were also administered. Serum Ca values were evaluated at 1, 2, 3, 4, 6, and 8 weeks after initial administration and every 4 weeks thereafter. DMAB effects were assessed using BMD and bone metabolism markers (PINP and TRACP-5b, respectively) at 6 months after initial administration.

Results: BMD increased by 2.3% in the lumbar spine and 2.1% in the femoral neck at 6 months after DMAB administration. PINP levels decreased by 23.8% and TRACP-5b levels by 34.6% in the 6 months after initial administration. Serum Ca levels decreased in almost all patients, and the average rate of reduction compared to that at pre-DMAB administration was 16.8%. Serum Ca levels tended to decrease the most at 4–6 weeks after DMAB administration. No symptomatic hypocalcemia was observed.

Conclusion: We believe that among patients with ESRD and osteoporosis, DMAB should be the first choice for effective and safe osteoporosis treatment.

P982

BONE MASS IN WOMEN WITH PREMATURE OVARIAN INSUFFICIENCY: A COMPARATIVE STUDY BETWEEN ESTROPROGESTATIVE HORMONE THERAPY AND COMBINED ORAL CONTRACEPTIVESL. B. Carvalho¹, C. L. Bonacordi¹, D. A. Yela¹, A. O. Pedro¹, C. L. Benetti-Pinto¹¹Department of Obstetrics and Gynecology - University of Campinas, Campinas, Brazil

Objective: To evaluate the effect of combined oral contraceptive (COC) on BMD in women with premature ovarian insufficiency (POI).

Methods: A retrospective study of women with POI was carried out. Bone densitometry were analyzed at two or more moments (2±1-year interval). The difference between final and initial (delta) BMD values was calculated for lumbar spine (LS), total femur (TF) and femoral neck (FN). The women were divided into four groups: The COC group (ethinylestradiol 30 µg associated with levonorgestrel, continuously use), smaller dose group (conjugated estrogen (CE) 0.625 mg continuous plus medroxyprogesterone OR 17β-estradiol (E2) 1mg continuous plus norethisterone), higher dose group (CE 1.25 mg continuous plus medroxyprogesterone OR E2 2 mg continuous plus norethisterone), tibolone 2.5 mg group and group without HT (hormonal therapy). For the analysis of the effect of treatments over time, we used generalized estimating equations, with variables without normal distribution transformed into ranks.

Results: A total of 173 women with 210 delta densitometries were included. The mean (SD) age was 30.5 (9.27) y and the HT was started at 29.67 (9.46) y, BMI was 24.9 (5.02). The COC group presented improvement in BMD in LS and TF over time, similar to the high dose group. In LS, there was loss of BMD in the group without HT, lower dose and tibolone group. For FN, BMD reduced in all groups. For TF, there was reduction in the lower dose group. Comparing the deltas between two densitometries, considering the COC Group as a reference, it was observed loss of BMD in LS in the group without HT (p<0.001), lower dose (p<0.001) and tibolone group (p=0.026). For TF, the reduction occurred in the group without HT (p=0.014), lower dose (p<0.001) and higher dose (p=0.038). For FN there was no difference between these groups.

Conclusions: For the BMD of POI women, continuous administration of COC was shown to be superior to the lowest dose HT, similar outcomes to that of higher dose of estrogen. Thus, COC can be considered as an alternative treatment for hormone replacement in women with POI.

P983

PLACENTAL GENE EXPRESSION OF VITAMIN D METABOLIC COMPONENTS AND CALCIUM TRANSPORTERS IN GESTATIONAL DIABETES AND PRE-ECLAMPSIA CASES

S. V. Varshney¹, G. K. Kachhawa¹, R. D. Dada¹, V. K. Kulshreshtha¹, R. K. Kumari¹, R. A. Agarwal¹, T. G. Gupta¹, R. K. Khadgawat¹

¹All India Institute of Medical Sciences, New Delhi, India

Objective: Bone mass acquired during neonatal stage is an important determinant of risk of bone disease through the rest of life. Gestational diabetes (GDM) and pre-eclampsia (PE) represents the unrecognized risk factors for reduced bone mineral content in neonates. As vitamin D and calcium influence fetal bone development, our aim was to explore the components of vitamin D metabolism and calcium transport in the placenta of GDM and PE cases and its effect on neonatal bone mass determination.

Methods: The gene expression of the vitamin D metabolic components (CYP2R1, CYP27B1, CYP24A1 and VDR) and calcium transporters (TRPV5/6, CaBP-9k/28k, PMCA 1/2/3/4, IP3R1/2/3 and RyR1/2/3) and a marker of oxidative stress hOGG1 were quantified by real time PCR in placental samples of 63 women with GDM (n=21), PE (n=22), and healthy pregnancies (n=20). Serum calcium and 25(OH)D levels were estimated in maternal and cord blood samples collected immediately after delivery. Neonatal wholebody BMD, BMC and bone area were measured within 2 d postbirth using DXA.

Results: In this study, 52% subjects were vitamin D deficient. CYP2R1 and VDR mRNA expression were significantly down regulated in contrast to upregulation of CYP27B1 and CYP24A1 mRNA expressions in GDM and PE compared with healthy cases. Calcium transporters- TRPV5/6, CaBP-9K/28K, IP3R1/2/3, RyR1/2/3, PMCA1/2/3/4 were downregulated in GDM and PE placentas. The hOGG1 mRNA expression was upregulated in both GDM and PE groups. Gestational period affected CYP24A1, VDR and PMCA3 mRNA expression in all the cases. Further, CYP24A1, VDR and PMCA3 mRNA expression was correlated with BMD/BMC of neonates at birth in all the cases.

Conclusion: Oxidative stress may cause disrupted vitamin D homeostasis and calcium transport in the placenta of GDM and PE cases. Serum 25(OH)D reduction may be due to increased expression of CYP24A1 and reduced expression of VDR gene. In calcium transport pathway, ATP depletion affected PMCA's expression and subsequently CaBP's and TRPV's. Reduced BMD/BMC in the neonates of these cases may be as consequences of altered CYP24A1, VDR and PMCA3 mRNA expression.

P984

A RISK ASSESSMENT STUDY ON WORK-RELATED MUSCULOSKELETAL DISORDERS AMONG DENTISTS IN MANGALORE, INDIA

A. Ss¹

¹Eids, Malappuram, India

Objective: Work-related musculoskeletal disorders (WMSDs) are responsible for morbidity in many working populations, which are of multifactorial in origin and of global concern due to industrialization. Dentists as one of the healthcare professionals are prone to develop these WMSDs. The study aims to determine the prevalence of WMSDs among dentists in Mangalore region and explores the various risk factors for the development of MSDs and WMSDs.

Methods: This proposed study is a cross-sectional study conducted among dentists of two randomly selected dental colleges of Mangalore, India. A structured questionnaire was used to collect the demographic information, occupational history, risk factors, and ergonomic awareness with job task details. Prevalidated standardized tools such as quick exposure check list, rapid entire body assessment score sheet, and Nordic Musculoskeletal Questionnaire were also used. Data were entered in MS Excel and analyzed through SPSS version 22.

Results: More than 92% of the participants reported pain and discomfort in at least one part of their body. The major affected body part is neck, followed by the lower back and wrist. More than half of the orthodontists and oral surgeons reported that their MSDs are work-related origin. Pearson's correlation test indicated that there is a positive correlation between the current exposure and risk ($r=0.613$). Multivariate regression analysis found that younger participants, male (OR=4.1), involved physical activity (OR=1.04), dentists not taught about ergonomics in their dental school (OR=1.69) or never attended any workshops (OR=1.38), who reported task involving sustained muscle contraction (OR=1.12) or task with repetitive movements (OR=1.11) are the major risk factors for the development of MSDs among the dentists.

Conclusions: This risk assessment study found that there is a high prevalence of MSDs and WMSDs among dentists. Ergonomic awareness and health promotion need to be integrated with the professional practice for dentists.

P985

POTENTIAL AUTOCRINE ROLE FOR SEROTONIN IN HUMAN OSTEOCLASTOGENESISJ. Cleminson¹, J. M. Hodge², J. A. Pasco³, F. Collier², R. Samarasinghe⁴, L. J. Williams⁴¹Deakin University, Geelong, ²Geelong Centre for Emerging Infectious Diseases, Barwon Health, Geelong, ³Melbourne Medical School-Western Precinct, The University of Melbourne, St Albans, ⁴School of Medicine, Deakin University, Geelong, Australia

Objectives: Mood disorders and selective serotonin reuptake inhibitors are implicated in bone loss and fracture risk. Serotonin acts centrally to regulate mood, and peripherally to control gut and cardiovascular function. Additionally, a role for peripheral serotonin in bone homeostasis has been proposed. Transcription of genes for serotonin receptors and tryptophan hydroxylase (TPH1), a rate-limiting enzyme in serotonin biosynthesis, have been reported in both osteoblasts and osteoclasts (OC). This study investigated the transcription profile of serotonin receptor-2B (5-HTR2B) and TPH1 in human osteoclastogenesis and the impact of blocking serotonin biosynthesis using a chemical inhibitor of TPH1.

Methods: Human osteoclasts were generated from umbilical cord blood. CFU-GM-derived OC precursors were cultured in serotonin-depleted media containing RANKL and M-CSF for up to 21 days. Gene transcription of 5-HTR2B and TPH1 was assessed by real-time PCR. In addition, OC precursors were cultured on dentine slices in the presence of TPH1 inhibitor (LP533401-HCl); n=4 slices per treatment. Data from a representative experiment were analysed using one-way ANOVA and Tukey's Pairwise Comparisons.

Results: Multinucleated OCs were observed from day-6 of culture. Transcription of both 5-HTR2B and TPH1 peaked at day-14 (>7404-fold and >3.6-fold, respectively) and dropped to baseline levels by day-18. Co-treatment with LP533401-HCl dose-dependently decreased OC number and resorption, with maximum reductions of 59.7% (p=0.0001) and 40.9% (p=0.003), respectively, at 10 mM, whereas OC size dramatically increased (+135.4%; p=0.0001).

Conclusion: These data indicate that human OCs express serotonin receptor 2B and possess the ability to synthesise serotonin. The observed increase in OC fusion and reduction in resorption following chemical blockade of TPH1 point to a possible auto-crine regulatory role for serotonin within the bone microenvironment.

P986

HIGH ANTIBODY TITERS TO CYCLIC CITRULLINATED VIMENTIN PROMOTE THE DEVELOPMENT OF PERIARTICULAR OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITISA. V. Aleksandrov¹, I. Y. Alekhina², N. V. Aleksandrova¹, L. N. Shilova³, V. A. Aleksandrov³¹Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky, Volgograd, ²Stavropol State Medical University, the Department of Hospital Therapy, Stavropol, ³Volgograd State Medical University, the Department of Hospital Therapy, Volgograd, Russia

Objective: Evaluation of the effect of antibodies to cyclic citrullinated vimentin (anti-MCV) on the risk of osteoporosis in patients with rheumatoid arthritis (RA).

Methods: 57 RA patients were examined (mean age 50.5±10.1 y). The patients with the developed stage of the disease (47.4%) prevailed, the average activity (DAS28=3.2-5.1) of the pathological process (86%); with the second radiographic stage (42%) and functional class 2 (77%). Osteodensitometry was performed on a X-ray densitometer Lunar DPX, GE (USA). In accordance with the WHO recommendations, the assessment of the bone tissue of the proximal femur condition was carried out according to the T-criterion, the decrease of which from -1.0 to -2.5 was regarded as osteopenia, a value below -2.5 was considered as a diagnostic sign of osteoporosis. IgM-rheumatoid factor (IgM-RF) was determined using the latex agglutination method (normal up to 20 IU/ml) and antibodies to cyclic citrullinated vimentin (anti-MCV) (normal up to 20 U/ml) using ELISA test.

Results: 61.4% of RA patients were positive for anti-MCV. Rheumatoid factor (RF) was determined in the blood in 47.3% of patients with RA. A positive correlation was found between anti-MCV and disease activity (r=0.48), as well as a negative correlation between increased diagnostic anti-MCV titers and low T-criterion (r=-0.673). In the subgroup of patients with RA with a high content of anti-MCV (with values >65 units/ml), a significantly more pronounced decrease in BMD was observed according to the results of the T-criterion (p=0.026) and high disease activity (p=0.047). Anti-MCV are able to induce the differentiation and activation of osteoclasts. It can lead to decrease in the mineral density of the periarticular bone and increase the risk of fractures in patients with RA. The average titers of anti-MCV (67.6±42.5 U/ml) in RA patients with osteopenia were lower than in the group of RA patients with osteoporosis (102.8±74.0 U/ml) (p=0.09). No significant relationship was found between the T-criterion and age, the presence of RF and the duration of RA (p>0.1).

Conclusions: All anti-MCV-positive patients with RA (especially with high antibody titers) should be examined for signs of osteoporosis.

P987

ASSOCIATION BETWEEN SEVERITY OF ANKLE FRACTURE, BMI AND OSTEOPOROSIS

A. Myhre Hjelle¹, P. Mielnik¹, A. Lober², G. Tell³

¹Departement of Rheumatology, District General Hospital of Førde, Førde, ²Departement of Radiology, District General Hospital of Førde, Førde, ³Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway

Objective: Ankle fractures are among the most prevalent fractures in patients over 50 y, and the prevalence is rising [1]. Ankle fractures have not been considered to be related to osteoporosis, however some studies suggest otherwise [2, 3]. Some studies

observe that low energy ankle fractures predict future fractures at other sites. King et al [4] concluded that osteoporosis/osteopenia was not associated with severity of ankle fracture using the Weber classification. Our aim was to investigate if patients with ankle fracture are more likely to have osteoporosis than controls, and to see if the severity of ankle fracture is correlated to osteoporosis or BMI.

Methods: 105 consecutive patients over the age of 40 with acute ankle fracture involving the lateral malleolus were included in this case-control study. BMD of the hips and spine was measured and history of previous fracture, comorbidities, medication, physical activity, smoking habits, BMI and nutritional factors were registered.

Results:

Table 1

	Ankle fracture	Weber A	Weber B	Weber C	Controls
N	105	18	70	17	197
Age mean	57.1 (SD ¹ 9.9)	56.0 (SD 8.9)	57.0 (SD 9.8)	58.2 (SD 12.1)	60.3 (SD 10.6)
Gender					
Female	69.2% *	55.0% **	75.7%	58.8% *	82.7%
Male	30.8%	45.0%	24.3%	41.2%	17.3%
BMD ² (DXA ³)					
Osteoporosis ⁴	23.4%	38.8% *	22.8%	5.8%	22.3%
Osteopenia ⁵	47.7%	44.4%	34.2%	41.1%	51.8%
Normal BMD ⁶	29.9%	16.6%	42.8%	52.9%	25.9%
BMI ⁷ (kg/m ²)					
Mean	28.6 (SD 4.9) *	25.8 (SD 3.4)	28.8 (SD 4.8) *	30.7 (SD 5.7) *	27.3 (SD 5.2)
Overweight ⁸	39.2%	11.1%	37.1%	41.1%	35.6%
Obesity ⁹	33.6%	44.4%	37.1% *	47.0% *	25.1%

¹Standard deviation ²BMD ³ DXA of hips and spine

⁴T-score ≤ -2,5 ⁵T-score -1.0 - -2.5 ⁶T-score ≥ -1.0

⁷BMI body mass index

BMI categories according to The International Classification of adult overweight and obesity:

⁸BMI 25-29.55 ⁹BMI ≥30.0

p values are presented as: * < 0.05 ** < 0.01

Conclusions: The prevalence of osteoporosis was 23.4% in patients with ankle fracture. The OR for ankle fracture was not significantly higher among those with osteoporosis (OR 1.5, p=0.3). Osteoporosis or osteopenia adjusted for age, gender and BMI was not a risk factor for increasing severity of the ankle fracture, but being overweight or obese significantly increased the risk of sustaining a more complex fracture (Weber B or C).

References:

1. Kannus P et al. Bone 2002;31:430

2. Giannini S et al. Aging Clin Exp Res 2013;25 (Suppl 1):S77
 3. Lee KM et al. Osteoporos Int 2013;24:2819
 4. King CM et al. J Foot Ankle Surg 2012;51:543.

P988

CLINICAL CASE OF A NONVISUAL GIANT PARATHYROID ADENOMAN. Romanova¹, T. Grebennikova¹¹The National Medical Research Center for Endocrinology, Moscow, Russia

Solitary parathyroid adenomas are the leading cause of primary hyperparathyroidism in 0% to 85% of cases. The presentation of a parathyroid adenoma in a supernumerary gland is a challenge for the surgeon. The high sensitivity having different imaging techniques has been a key to locate preoperatively the pathological parathyroid gland. The purpose of this article is to present the diagnostic and therapeutic approach used for a 68-year-old female patient with non-visual ectopic location gland using MIBI scintigraphy with 99mTechnetium.

A 68-year-old female was admitted to our Centre with the diagnosis of primary hyperparathyroidism. The patient suffered from typical symptoms of hypercalcemia such as weakness, osteoporosis and recurrent nephrolithiasis. Primary hyperparathyroidism was confirmed based on the patient's biochemical profile, which showed increased levels of serum calcium (Ca^{2+} 1.43 mmol/L (1.03-1.29), Ca 2.94 mmol/L (2.10-2.55)); the PTH level was 277 pg/mL (15-65). Ultrasonography revealed a nodule at the superior pole of the left lobe of the thyroid gland, 9x6x3 mm in size and a large nodule with cystic component at the inferior pole of the right lobe of the thyroid gland, 37x28x28 mm in size (that was diagnosed as thyroid nodule). MIBI scintigraphy with 99mTechnetium showed positivity at the superior pole of the left lobe of the thyroid gland. Intraoperatively, a superior left parathyroid adenoma was found and excised. Further, during revision at the lower pole of the right lobe on the spine, partly extending beyond the sternum was determined by a giant parathyroid adenoma, 55x35x30 mm in size, without connection with the thyroid gland. Additionally, levels of intact PTH were determined intraoperatively and a reduction was found, 20 min after the removal of the adenoma. After the excision, the levels of serum calcium and PTH were normalized. Histopathology: the tissue of the parathyroid gland with a usual histological structure and a parathyroid adenoma with cystic degeneration.

Conclusion: This is a rare case of a giant nonvisual ectopic location parathyroid adenoma. All of the ectopic location nodules with cystic degeneration should be fine-needle aspiration washout on PTH in primary hyperparathyroidism.

P989

EFFECTS OF EXERCISE WITH AND WITHOUT A MULTINUTRIENT FORTIFIED DAIRY PRODUCT ON MARKERS OF BONE AND CARTILAGE METABOLISM IN SEDENTARY MIDDLE AGED WOMEN: SECONDARY ANALYSIS OF A 4-MONTH DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED TRIALR. M. Daly¹, J. Gianoudis¹, B. De Ross¹, S. O'Connell¹, M. Kruger², L. Schollum³, C. Gunn³

¹Deakin University, Institute for Physical Activity and Nutrition, Melbourne, Australia, ²Massey University, Massey Institute of Food Science and Technology, Palmerston North, New Zealand, ³Fonterra Co-operative Group Ltd, Palmerston North, New Zealand

Objective: To investigate the effects of exercise with and without a multinutrient fortified dairy product (FDP) on markers of bone turnover and cartilage metabolism in sedentary middle-aged women.

Methods: In this secondary analysis of a 4-month double-blind, placebo RCT, 244 sedentary women (45-65 y) participated in a multicomponent exercise (Ex) program including high-velocity resistance and challenging balance training 3 d/week with random allocation to twice daily low fat FDP (2x150 ml) with added protein, calcium, vitamin D and other micronutrients or an energy matched placebo. Bone turnover was assessed via plasma C-terminal crosslinking telopeptide of type I collagen (β -CTX) and plasma procollagen type I N-terminal peptide (PINP). Urinary levels of C-terminal crosslinked telopeptide type II collagen (CTX-II) were assessed as a marker of cartilage turnover. Serum intact PTH and serum 25-hydroxyvitamin D [25(OH)D] were also evaluated.

Results: A total of 216 women (89%) completed the study. Adherence was 90% and 92% for FDP and placebo, respectively, and 78-79% for Ex. Mean baseline calcium intake was 808 mg/d and serum 25(OH)D was 63 nmol/L in all women. After 4 months, mean serum 25(OH)D increased in FDP (+9 nmol/L) and decreased in placebo (-12 nmol/L) (interaction, $P < 0.001$). There was also a significant between group difference for the change in serum PTH (11%, $P < 0.01$), due to a decrease in placebo. For both β -CTx and PINP there was a significant net 16% and 17% reduction in FDP compared to placebo (interaction, both $P < 0.001$). In contrast, there were no changes in urinary CTX-II in either group after 4 months.

Conclusion: Daily consumption of a multi-nutrient fortified dairy product with exercise training for 4 months was associated with a reduction in bone turnover markers, but no change in cartilage metabolism, in middle-aged sedentary women, when compared to exercise alone.

Disclosures: L.S. and C.G. are employees of Fonterra Co-operative Group Ltd. This study was funded by a Primary Growth Partnership grant via the Ministry of Primary Industries in New Zealand with Fonterra Co-operative Group Ltd.

P990

ABNORMAL BONE STRUCTURE, MECHANICAL PROPERTIES AND COMPOSITION ARE ASSOCIATED WITH IMPAIRED BONE QUALITY & QUANTITY IN PATIENTS OF T2DM COMPARE TO NONDIABETIC OSTEOPOROTIC INDIVIDUALS

P. Sihota¹, N. Kumar², R. N. Yadav², V. Mehandia², S. K. Bhadada³, V. Dhiman³, J. C. Bose⁴, D. Neradi⁵, S. Aggarwal⁵, S. Sharma⁵, V. G. Goni⁵, R. Dhaliwal⁶

¹Department of Mechanical Engineering, Indian Institute of Technology Ropar, Ropar, India, ²Department of Mechanical Engineering, Indian Institute of Technology (IIT), Ropar, India, ³Department of Endocrinology, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India, ⁴Department of Internal Medicine, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India, ⁵Department of Orthopedics, Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India, ⁶Department of Endocrinology, Diabetes & Metabolism, State University of New York Upstate, Medical University, Syracuse, New York, USA

Objective: Individuals with T2DM are predisposed for increased bone fragility compared to nondiabetic individuals, despite comparable or higher areal BMD. Accumulation of advance glycation endproducts into the bone alters the intrinsic material properties and structural integrity of bone tissue and leads to impaired bone quality and composition. Our aim was to compare the bone quality (bone mechanical properties) and structural parameters in bone tissue of diabetic (DM) and nondiabetic (NDM) osteoporosis patients.

Methods: Trabecular bone quality, structure parameters and composition of NDM (n=30) and DM (n=15) individuals with osteoporosis are compared in patients undergoing total hip replacement surgery. Age, serum calcium, phosphorus, alkaline phosphatase, PTH, 25(OH)D and BMD are comparable between groups. Values are expressed in mean (SD).

Results: Structural parameters (μ -CT) shows the low values of BV/TV (NDM: 23.15 \pm 6.49; DM 18.23 \pm 5.89, p=0.019), Tb. Th (mm) (NDM: 0.173 \pm 0.028; DM 0.153 \pm 0.028, p=0.043) and Tb. N (1/mm) (NDM: 1.46 \pm 0.35; DM 1.16 \pm 0.27, p=0.007) in DM group compare to NDM group. However, there is significantly increase in Tb.Sp (mm) (NDM: 0.548 \pm 0.145; DM 0.773 \pm 0.306, p=0.029) and Structural Model Index (NDM: 0.95 \pm 1.57; DM 1.79 \pm 0.93, p=0.04) in DM individuals. Tissue mechanical properties shows significant reduction in modulus, yield stress and ultimate stress (NDM: 424.05 \pm 139.74; DM 265.45 \pm 114.92, p=0.018), (NDM: 6.68 \pm 3.20; DM 4.12 \pm 2.13, p=0.004) and (NDM: 8.54 \pm 3.88; DM 5.28 \pm 2.82, p=0.004) respectively in DM group. Nanoindentation finding suggest that modulus and hardness (NDM: 9.347 \pm 0.403; DM 8.001 \pm 0.482, p=0.04) and (NDM: 0.498 \pm 0.045; DM 0.297 \pm 0.029, p=0.01) are respectively reduced in DM group as compared to NDM. Mean mineral crystal size (PXRD) shows low mean crystal length (NDM: 22.195 \pm 0.343; DM 21.705 \pm 0.494, p=0.421) and increase in mean crystal width (NDM: 6.009 \pm 0.168; DM 7.225 \pm 0.307,

p=0.003) in DM group. On macromolecular vibrations (FTIR) protein structure was comparable between groups; however protein content was significantly low in T2DM individuals.

Conclusion: The T2DM alters the bone ultrastructural arrangement, material properties, volume fraction and finally the overall bone strength. In this study, we have investigated the wide range of DM bone quality parameters and the possible mechanism is explored to understand the DM bone quality degradation.

P991

THREE YEARS PERSISTENCE WITH DENOSUMAB AS OSTEOPOROSIS THERAPY IN A LARGE HEALTHCARE ORGANIZATION IN ISRAEL

N. Fund¹, I. Goldshtein¹, V. Rouach², G. Chodick³, V. Shalev³

¹Institute of Research and Innovation, Maccabi Healthcare Services, ²Institute of Research and Innovation, Maccabi Healthcare Services. Institute of Endocrinology, Tel Aviv Sourasky Medical Center, ³Institute of Research and Innovation, Maccabi Healthcare Services, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Objectives: To assess the long term persistence for 12-36 months with denosumab in a large, unselected population using validated clinical patient data including dispenses.

Methods: This retrospective study utilized the computerized database of Maccabi healthcare services, a payer-provider insuring over 2 million individuals in Israel. Data were collected for new denosumab initiators from January 2012 to June 2016 with at least two dispenses, followed until December 31, 2017 for 12-36 months. We excluded patients with malignancies, chronic kidney disease, previous anabolic therapy and chronic glucocorticoid treatment. Discontinuation was defined as a gap of at least 3 months without filling a new prescription, and persistence \geq 70% coverage. The comparison group was new oral bisphosphonates initiators during the same period.

Results: A total of 1277 eligible denosumab initiators were identified, 96% of which were women, with a mean age of 70.8 \pm 8.8 years old. Most of the patients (78%) had 2 y of follow-up, and 43% had three years. A total of 86.8% of them received a second denosumab injection in the first year, almost 2-fold compared with 48.2% persistence with oral bisphosphonates. After two years, denosumab persistence rates decreased to 64.4%, still significantly higher than oral bisphosphonates (39.6%). However, in the third year of follow-up denosumab persistence rates dropped to 38.4%, similar to oral bisphosphonates persistence with 32.7% in the third year.

Conclusions: In this real-world, population-based study, patients treated with denosumab exhibited excellent persistence in the first year, which dramatically deteriorated in the third year of follow-up. Further research is needed to explore the barriers for long term persistence with denosumab, and assistive tools may be in order to help physicians and patients in maintaining treatment continuity after the first and second years of treatment.

Disclosures: The study was funded by Medison pharma. The funders had no role in study design, data collection and analysis, or the preparation of this abstract.

P992

EFFECT OF DYSLIPIDEMIA ON BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN WITH METABOLIC SYNDROME

V. Povoroznyuk¹, P. Larysa², P. Liliya²

¹D.F. Chebotarev Institute of Gerontology NAMS Ukraine, Kyiv, ²I. Hobachevsky Ternopil State Medical University, Ternopil, Ukraine

Objective: One of the important medical problems in postmenopausal women, along with cardiovascular diseases include osteoporosis, which contribute to a significant decrease in quality and life expectancy due to the development of complications: cardiovascular catastrophes in the first case and fractures in the other. The analysis of the literature reveals contradictory data on the relationship between the level of lipids and the bone tissue. The aim of this study was to determine relationship between serum level of lipids and BMD in postmenopausal women with obesity and (MS) metabolic syndrome.

Methods: 333 women aged 50-79 years old (mean duration of menopause period – 12.38±8.05 y) were examined and shared into three groups of 111 women in the same age (62.19±7.57 y) and height (1.60±0.04 sm): A - group included female without obesity (BMI ≤29.9 kg/m²), B – women with obesity (BMI >29.9 kg/m²) and C – female with MS (diagnosis according to IDF criteria, 2005). It was used DXA (Prodigy, GE Medical systems, Lunar, Madison, WI, USA, 2005) for measuring of lumbar spine (L1-L4), femoral neck, total body and forearm BMD and bone quality indexes (last according to Med-Imaps installation). Data were analyzed using Statistical Package 6.0.

Results: A significant higher BMD of all examined sites was found in women with obesity and MS (p<0.001) compared to A group ones. Analysis showed that waist circumference has significant negative correlation with HDL serum level and positive correlation with BMD of lumbar spine and femur. Significant negative association between waist circumference and cholesterol and LDL serum levels in female without obesity were present. It was established negative correlation between serum HDL level and BMD of lumbar spine (L1-L4) and ultradistal radius BMD. The TBS (L1-L4) indexes positively correlated with HDL level and negatively with triglycerides serum level in patients of A group.

Conclusion: Menopausal women with obesity and metabolic syndrome have a significantly higher BMD at all measured sites compared to females without obesity. There is a link between the state of BMD and lipid metabolism in the postmenopausal period, which is more pronounced in women without obesity.

P993

THE ROLE OF CORRECTION OF BIOMECHANICAL DISORDERS IN THE TREATMENT OF CERVICOGENIC HEADACHE

A. Barulin¹, O. Kurushina¹, A. Drushlyakova¹

¹Volgograd state medical university, Volgograd, Russia

Objective: Determine the effectiveness of training on the stabilometric platform in the correction of clinical signs of cervicogenic headache .

Methods: 64 patients with cervicogenic headache (CH) were examined. CH was diagnosed using criteria of ICHD-3 and the author's questionnaire developed by us for this research. The average age is 31.7±3.4 y. Patients are divided into two groups. The first group: pharmacotherapy+physiotherapy. The second group: pharmacotherapy+stabilometric platforms training. The clinical neurological examination was performed. Biomechanical parameters (biauricular, biacromial lines) were assessed by visual-optical analysis (VOA). Stabilometric parameters were studied: the statokinesiogram area, displacement of the center of pressure, energy spent.

Results: The method of correction of biomechanical disorders in CH based on the principle of biological feedback has been developed and tested. After treatment: 62.5% of patients relapse of CH occurred a month later after pharmacological treatment, 43.8% - after pharmacological treatment and treatment on the stabilometric platform (p<0.05). The parameter 'statokinesiogram area': the best dynamics of return to the norm of the second group was 105±10.2 mm², while in the first only 148±10.4 mm². The degree of displacement of the center of pressure in the first group decreased by 13.7%, in the second group by 46.3%. The parameter 'energy spent' demonstrated the same direction of the changes and made a decrease in the first group of 18.4%, while in the second group it was 29.6%. Analysis VOA showed a significant approximation of the degree of deviation of biauricular, biacromial lines to the norm o in the second group of participants.

Conclusions: The use of the biofeedback method on the stabilometric platform for the correction of biomechanical disorders improves the results of treatment of CH. Correcting the general biomechanics, we correct the biomechanics of the cervical spine.

P994

INCIDENT FRACTURES UNDER ORAL BIPHOSPHONATES TREATMENT IN A LARGE HEALTHCARE ORGANIZATION IN ISRAEL

N. Fund¹, I. Goldshtein¹, V. Rouach², G. Chodick³, V. Shalev³

¹Institute of Research and Innovation, Maccabi Healthcare Services, ²Institute of Research and Innovation, Maccabi Healthcare Services, Institute of Endocrinology, Tel Aviv Sourasky Medical Center, ³Institute of Research and Innovation, Maccabi Healthcare Services, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Objectives: To characterize and estimate the proportion of patients with incident fractures despite high adherence to oral bisphosphonates, in a real-world setting.

Methods: This retrospective study utilized the computerized database of Maccabi healthcare services, a payer-provider insuring over 2 million individuals in Israel. Data were collected from January 1998 to December 2017 for primary prevention patients treated with oral bisphosphonates with high adherence during at least 3 y. A fracture event was considered as under treatment if it occurred following at least 3 y of adherent treatment ($\geq 70\%$ coverage) with oral bisphosphonates and within one year after treatment cessation. We excluded patients with chronic kidney disease, previous anabolic therapy and chronic glucocorticoid treatment.

Results: Out of 27,009 primary prevention patients treated with oral bisphosphonates for at least 3 y with adherence $\geq 70\%$, 3105 (11.5%) sustained a first fracture under treatment. Among those patients with fracture, 95.3% were women, with a mean age of 72.1 years old (SD=9). Most of these patients had a nonhip non-vertebral fracture (53.5%), 26.2% vertebral, and 19.8% hip. Among patients with T-score measurements before this fracture under treatment (n=1347), 57.7% had osteopenia and 35.6% had osteoporosis.

Conclusions: Despite high adherence to oral bisphosphonates 11.5% of patients sustain incident fractures. Further studies are required to identify as early as possible which patients will benefit from alternate treatment to minimize their risk.

Disclosures: The study was funded by Medison pharma. The funders had no role in study design, data collection and analysis, or the preparation of this abstract.

P995

AGE EFFECTS OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN RHEUMATOID ARTHRITIS

I. Golovach¹, I. Semeniv¹, I. Zazirniy¹

¹Clinical Hospital Feofania, Kyiv, Ukraine

Objective: It is well known that age, glucocorticoid intake and activity of the rheumatoid process are the main factors affecting the state of bone tissue, bone metabolism and the rate of bone loss. The aim of the study is to determine the structural and functional

state of bone tissue in patients of different ages suffering from rheumatoid arthritis, who have been taking glucocorticoids for a long time.

Methods: There were 223 patients with rheumatoid arthritis who took glucocorticoids under observation. Patients were divided into groups according to their age: young (20-44 y) - 75 patients (33.6%), middle-aged (45-59 y) - 79 (35.4%), and elderly (60-74 y) - 69 (30.9%) patients. The drug of choice was prednisone. The receiving of glucocorticoids period ranged from 6 months to 23 y, with an average of 4.7 ± 2.9 y. The dose varied for each patient from 2.5 mg/d to 40 mg/d depending on the degree of disease activity. To assess the impact of the time period of glucocorticoid therapy on the state of bone tissue, 237 patients with rheumatoid arthritis who did not take glucocorticoid were examined. Evaluation of bone tissue and the presence of osteoporosis was performed using DXA using a Hologic Discovery apparatus. The history of bone fractures was also evaluated. Spinal radiography was performed in lateral projection to visualize possible spinal deformities.

Results: Studies have proved significant changes in the state of bone tissue when taking glucocorticoids. The age of patients is an important factor in determining the rate of bone loss and the formation of glucocorticoid-induced osteoporosis. Systemic glucocorticoid therapy causes the development of osteoporosis and osteopenic syndrome in patients. Thus, the osteopenic syndrome was diagnosed in 45.74% of patients, and osteoporosis in 59.67% of patients who have continuously taken glucocorticoids for more than 1 y. The most significant changes in bone tissue were found in the age group of 20-44 y. Systemic administration of glucocorticoids led to the formation of osteoporosis in 45.2% of patients in that age group.

Conclusion: The young patients' bone tissue damage characteristics caused by systemic glucocorticoid therapy should be taken into account when planning preventive measures in case of long-term hormonal therapy.

P996

ASSOCIATION OF BONE METABOLISM GENE VARIANTS WITH BONE MINERAL DENSITY IN POSTMENOPAUSAL OSTEOPOROTIC WOMEN

K. Kobets¹, E. Rudenko², I. Mosse¹, A. Rudenka³, V. Samokhovec³, P. Marozik¹

¹Institute of Genetics and Cytology of the National Academy of Sciences of Belarus, ²Belarusian State Medical University, ³Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus

Objective: Postmenopausal osteoporosis (PMO) is a common, multifactorial disease with a pronounced genetic predisposition. This skeletal disease is characterized by loss of BMD with increased susceptibility to fractures. The aim of this study was to evaluate the association of genes, involved in bone metabolism, with the BMD level in patients with PMO.

Methods: A total of 123 women with severe PMO (age 64.0±3.2, spine BMD 0.851±0.121 g/cm²; femur neck BMD 0.762±0.134 g/cm²) were genotyped for *SOST* (sclerostin, rs1234612), *PTH* (rs7125774), *MTHFR* (methylenetetrahydrofolate, rs1801131, rs1801133), *MTR* (methyltransferase, rs1805087), *MTRR* (methyltransferase reductase, rs1801394), *RANKL* (rs9594738, rs9594759) genes using PCR analysis. BMD was measured by DXA. Significance was assessed using χ^2 test. The differences were considered significant at P<0.05.

Results: We found a statistically significant association of the average spine BMD level with *SOST*, *PTH*, *MTHFR* rs1801133, and *RANKL* rs9594759 genes (P<0.05) and analogical tendency for *MTRR* rs1801394 (P=0.059, Table 1). It is important that for rs1801133, the average spine BMD level in the careers of unfavorable homozygous variants was lower compared to alternative genotypes, heterozygotes had intermediate BMD level.

Table 1. The association study of bone metabolism markers with spine BMD level

Gene variants	Genotype	n	Spine BMD, g/cm ²	P	Model
rs1234612	T/T	61	0.823±0.022	0.049	dominant
	C/T+C/C	61	0.877±0.019		
rs7125774	T/T	55	0.816±0.023	0.03	dominant
	C/T+C/C	68	0.877±0.018		
rs1801133	C/C	53	0.883±0.019	0.044	
	C/T	58	0.839±0.022		
	T/T	12	0.767±0.032		
rs1801394	G/G+A/G	78	0.916±0.035	0.059	recessive
	A/A	45	0.811±0.032		
rs9594759	T/T	68	0.814±0.021	0.049	dominant
	C/T+C/C	55	0.868±0.020		

Conclusion: Our findings highlight the importance of gene polymorphisms analysis to reveal the genetic mechanisms, determining decrease of BMD and fracture risk. Complex screening of these markers can be used to implement personalized prevention, treatment and rehabilitation programs.

Acknowledgements: This work was funded by Union State program "DNA Identification", grant №6.3.

P997

OSTEOPOROSIS (OP) DIAGNOSIS AND TREATMENT OF WOMEN AGED ≥70 YEARS IN PRIMARY CARE: RESULTS FROM A LARGE EUROPEAN CROSS-SECTIONAL STUDY

E. V. McCloskey¹, J. Rathi², S. Heijmans³, M. Blagden⁴, R. Koukakis⁵, R. Stad⁶, J. O’Kelly⁵, S. Papapoulos⁷

¹University of Sheffield, Sheffield, UK, ²Carrig Medical Centre, Cork, Ireland, ³ResearchLink, Linkebeek, Belgium, ⁴Ashgate Medical Practice, Chesterfield, UK, ⁵Amgen Ltd, Uxbridge, UK, ⁶Amgen GmbH, Rotkreuz, Switzerland, ⁷Leiden University Medical Center, Leiden, The Netherlands

Objective: To assess patterns of real-world OP diagnosis and medical treatment in European primary care.


Methods: Eligible patients were community-dwelling women aged ≥70 who visited their primary care physician for any reason and provided consent. Patient demographics, treatment history and

clinical risk factors were collected via self-reported questionnaires and medical records. The primary objective was to assess the proportion of women aged ≥70 y at increased risk of fragility fracture and not receiving OP medication. Increased risk of fragility fracture was defined as at least one of (1) history of fracture, (2) 10-y probability of both hip and major OP fracture above country-specific FRAX thresholds, (3) T-score ≤ -2.5.

Results: 3798 patients (median age 77 y) were enrolled between Mar-Oct 2018 from 8 countries (Belgium, France, Germany, Ireland, Poland, Slovakia, Switzerland, UK). Visits were mainly for existing conditions (follow-up for known disease 52.1%, medication refill 20.6%, new symptoms 21.7%). Prevalence of FRAX risk factors ranged from 1% (alcohol ≥3 units/d) to 32% (prior fracture). 2077 women (54.7%, median age 80 y) were determined to be at increased fracture risk, but only 30.9% of these had a recorded diagnosis of OP. For the primary outcome, 74.6% (95%CI: 72.7-76.5%) of women at increased risk of fragility fracture were not receiving any OP medication; this treatment gap was much lower in those with a recorded diagnosis of OP than in those without a recorded diagnosis (Figure). A small proportion of patients who did not meet the definition of increased risk for fragility fracture were diagnosed with OP (9.5%).

Conclusions: This real-world study of OP management in European primary care found that three-quarters of women aged ≥70 y at increased risk of fragility fracture were medically untreated for OP. Insufficient OP diagnosis appears to be an important barrier

to treatment; future strategies need to increase awareness and facilitate the diagnosis of increased fracture risk to improve primary care management of OP.



Acknowledgements: Study sponsored by Amgen

Disclosures: Eugene McCloskey: Grants/research support from ActiveSignal, Amgen, AR UK, AstraZeneca, Consilient Healthcare, GSK, Hologic, I3 Innovus, Internis, IOF, Lilly, Medtronic, Merck, MRC, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Synexus, Te-thys, UCB, Unilever, and Warner Chilcott. Consultant for ActiveSignal, Amgen, Consilient Healthcare, Fresenius Kabi, GSK, Synexus, and UCB. Speaking fees from Agnovos, Amgen, AstraZeneca, Consilient Healthcare, GSK, Hologic, Internis, Lilly, Pfizer, Roche, Servier, and UCB. Reija Koukakis, Robert Stad, James O’Kelly: Amgen employment and stock ownership. Socrates Papapoulos: Consulting/speaking fees Amgen, Axsome, Gador, Radius Health, UCB.

P998
BURDEN OF FRAGILITY FRACTURES IN 6 EUROPEAN COUNTRIES

F. Borgström¹, N. Norton¹, L. Karlsson¹, G. Ortsäter¹, N. C. Harvey², E. V. McCloskey³, J. A. Kanis³

¹Quantify Research, Stockholm, Sweden, ²MRC Life course Epidemiology Unit; NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK, ³University of Sheffield, Sheffield, UK

Objectives: To estimate current and projected societal burden related to fragility fracture in France, Germany, Italy, Spain, Sweden and the UK (EU6).


Methods: A previously published model used to estimate the burden of osteoporosis in Europe was updated to reflect the most recent data. The model estimates the annual burden-related fragility fractures where the health impact is measured using Quality Adjusted Life Years (QALYs). Fracture-related costs, risks and mortality after fracture in each country were retrieved from the literature. Quality of life values for the general population were

combined with fracture-related disability multipliers to estimate the total QALY loss in each country. Burden projections up to 2030 were based on projected demographic changes.

Results: The total monetary cost in EU6 was estimated at €37.5 billion in 2017 and projected to increase to €47.4 billion in year 2030. On a per capita basis, Sweden (€199) ranked first and the UK (€79) last. The total health burden in 2017 was estimated at 1.0 million QALYs and is expected to increase by 25.6% in the year 2030. On a per capita basis, Sweden had the largest burden (4.22 QALYs per 1 000) and France the lowest (2.11 per 1 000).

Conclusions: The societal burden related to fragility fractures is high and is expected to increase by more than 25% by 2030.

Figure: Estimated annual fracture-related costs in EU6 (billion euro) by fracture site in 2017 and 2030



P999
HEALTH LITERACY AND APPROPRIATE USE OF CALCIUM SUPPLEMENTS IN A POPULATION-BASED SAMPLE OF AUSTRALIAN WOMEN

S. M. Hosking¹, K. L. Holloway-Kew¹, L. J. Williams¹, A. Page², S. L. Brennan-Olsen³, A. Beauchamp³, R. Buchbinder⁴, J. A. Pasco¹

¹Deakin University, Geelong, ²Alfred Health, Melbourne, ³The University of Melbourne, St Albans, ⁴Monash University, Melbourne, Australia

Objectives: Low health literacy is associated with inadequate dietary calcium in women. We investigated associations between health literacy and appropriate use of calcium supplements in Australian women.

Methods: Data were utilised from women (n=652, median age 59.3 y [range 29-92 y]) participating in the Geelong Osteoporosis Study (GOS), a population-based cohort in south-eastern Australia. Health literacy was ascertained using the Health Literacy Questionnaire (HLQ), a multidimensional tool that generates scores across nine scales. Dietary calcium intake was ascertained using the Food Frequency Questionnaire, developed by the Victorian Cancer Council, and categorised as sufficient/insufficient using age specific estimated average requirements. Calcium supplementation was self-reported and defined as appropriate if used where dietary intake was insufficient or not used where dietary intake was sufficient. One-way analysis of variance (ANOVA) and Cohen’s d effect sizes (ES [95%CI]) (categorised; small >0.2-0.5,

moderate >0.5-0.8, large >0.8) were calculated for differences in mean HLQ scale scores between participants who did vs. did not self-report taking supplements.

Results: Among participants, 395 (60.6%) had insufficient dietary calcium but did not take a calcium supplement. A further 21 (3.2%) of women with adequate dietary intake also used calcium supplements. Women with inadequate dietary calcium who did not take supplements demonstrated lower mean scores for the HLQ scale 'Ability to find good health information' compared to other participants (mean 4.1 SD0.6 vs. mean 4.2 SD0.5; *p*-value <0.01). Small effect sizes were also observed for this scale (ES 0.20 [95%CI 0.04, 0.36]). No differences in HLQ scores were seen for the remaining scales or for women overusing calcium supplements.

Conclusions: These data suggest, for women with inadequate dietary calcium, targeted information regarding calcium supplementation needs to be made accessible.

P1000

STRONTIUM TREATMENT HAS SYNERGISTIC EFFECTS WITH PTH AS EVALUATED IN OVX RATS

P. Ammann¹, I. Badoud²

¹Division of Bone Diseases, Department of Medicine, University Hospital Geneva, ²Division of Bone Diseases, Department of Medicine, University Hospital Geneva, Geneva, Switzerland

Most of the antifracture efficacy of strontium treatment is related to an improvement of bone material level properties. Strontium is also known to stimulate bone formation during skeletal growth and bone healing process. An obvious question is to understand if strontium could improve bone material level properties under PTH treatment and influence the PTH stimulating effect on bone formation.

The aims of this study are to evaluate whether the association of strontium with PTH can be synergistic influencing both bone tissue quality and the bone formation induced by PTH. OVX rats were treated with strontium ranelate (Strontium, 625 mg/kg day po) alone, with a stimulator of bone formation (PTH 8 µg/kg*day SC) with or without strontium ranelate. Five groups of 12 rats (SHAM, OVX, Strontium, PTH, PTH+Strontium) received treatments or respective vehicles for 8 weeks. At the end of the experiment, vertebrae and tibia were removed for biomechanics, microCT and nanoindentation testing. Values are mean±SEM. Significant of differences are evaluated by ANOVA (*vs. OVX, #vs. Strontium and °vs. PTH)

	SHAM	OVX	Strontium	PTH	PTH+Strontium
Bone strength (N)	322.97±32.91*°	240.03±14.93°	254.91±15.03°	405.70±20.55*#	473.55±22.88*#°
Nano-hardness (mPa)	389.45±12.9°	369.57±15.72	400.67±12.48*°	344.79±13.58#	418.54±12.77*°
Trabecular thickness (mm)	0.098±0.001*°	0.090±0.002°	0.097±0.002*°	0.129±0.003*#	0.135±0.002*#°
Cortical volume (mm ³)	5.425±0.115°	5.455±0.363°	5.708±0.147°	6.198±0.118*#	6.591±0.199*#°

PTH but not strontium, fully prevents the deleterious effect of OVX on bone strength; values obtained under PTH are significantly higher as compared to SHAM. Combined therapy with strontium resulted in a further significant increase of bone strength as compared with PTH treatment alone. The addition of strontium improved intrinsic bone tissue quality in PTH+Strontium treated rats and corrected the impaired intrinsic tissue quality observed under PTH treatment. Furthermore, the addition of strontium to PTH resulted in a significant increment of trabecular thickness and tibia cortical volume as compared to PTH alone; reflecting its positive influence on bone formation induced by PTH.

Together, these data suggest that strontium treatment maximizes the in vivo effect of PTH by improving the intrinsic bone tissue quality of the new formed bone and by a synergistic effect on bone formation.

P1001

SERUM IRISIN LEVEL FORECASTS OSTEOPOROTIC FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS

D. Lavrova¹, B. Zavodovsky², Y. Akhverdyan², L. Sivordova², Y. Polyakova², T. Kvlividze¹, E. Zagorodneva¹

¹Volgograd State Medical University, ²Federal State Budgetary Institution "Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovskiy", Volgograd, Russia

Objectives: It is known that increased irisin (IR) level is associated with in osteoporotic fractures in postmenopausal osteoporosis regardless of BMD. IR can protect osteocytes from apoptosis, promote differentiation of osteoblasts, induce the expression of a key regulator of bone remodeling in vivo – sclerostin. Our aim was to study the serum IR level in rheumatoid arthritis (RA) patients with OP.

Methods: Our study included 170 patients: 110 RA patients (mean age 53.58±12.32; hereinafter M±SD) and 60 healthy controls. All RA patients were examined using DXA using Lunar DPX-Pro densitometer. All patients underwent the complex clinical and laboratory examination using standard methods. Serum IR level was measured by indirect solid-phase enzyme immunoassay using the commercial test system Irisin ELISA (BioVender, Cat No. RA-G018R) according to the instructions attached to the kit. Eight people out of 110 patients with RA had fractures over the next 3 y and 6 months.

Results: We revealed that mean concentration of IR in RA group was 14.48±7.07 ug/ml, which was significantly lower than of healthy controls - 20.49±4.82 ug/ml (p<0.001). We divided the RA patients into two groups: the first group (n=44) included patients with reduced serum IR levels (<10.85 ug/mL), the second group (n=66) consisted of patients with normal IR level (>10.85 ug/ml). We did not note any significant relationships between serum IR level and BMD at any site and between IR with either lean or fat mass. We did not find any difference of bone turnover markers between the first and the second group. However, in 1st group we revealed lower level of 25(OH)- vitamin D (p=0.044). We observed higher incidence of pathological bone fractures in this group too (p=0.047).

Conclusions: Thus, we noted relationship between decreased serum IR level, 25(OH)-vitamin D concentration and higher incidence of pathological bone fractures in RA patients.

We believe that the level of IR serum can be used to predict the occurrence of osteoporotic fractures.

P1002

PTH TREATMENT MODULATES CARTILAGE QUALITY

P. Ammann¹, I. Badoud²

¹Division of Bone Diseases, Department of Medicine, University Hospital Geneva, ²Division of Bone Diseases, Department of Medicine, University Hospital Geneva, Geneva, Switzerland

PTH has demonstrated bone anabolic effects and PTH receptors are present in chondrocytes. By acting on the entire osteochondral plate, PTH could prevent the development of osteoarthritis as suggested by preclinical studies.

The objective of this study is to demonstrate the modulatory effect of systemic PTH administration on cartilage quality and subchondral bone, using an ovariectomized (OVX) mouse model with impaired cartilage quality and subchondral bone loss. PTH was injected at a dose of 80 mg/kg /d for 8 weeks. A bio-indentation test (PIUMA, OPTICS) was performed at both condyles. The elastic modulus (MPa) and the force (mN) were recorded by fixing a depth of indentation that affects the upper third of the cartilage. The cartilage thickness and bone microarchitecture were evaluated by computed tomography (Scanco 40) using an ionic contrast agent (Hexabrix).

	SHAM (n=6)	OVX (n=5)	OVX+PTH (n=7)
Modulus (MPa)	3.88±0.32	1.77±0.27*°	4.00±0.45
Force (mN)	828±25	460±37*°	848±21
Hyalin cartilage (mm)	0.017±0.001	0.022±0.006	0.017±0.001
Mineralised cartilage (mm)	0.047±0.002	0.050±0.007	0.042±0.003
BV/TV (%)	32.5±3.0	20.1±5.4*	32.4±4.6

* vs. SHAM, ° vs. OVX+PTH (ANOVA)

PTH treatment fully prevented the decrease in modulus and indentation force induced by OVX at the level of the cartilage. Cartilage thickness did not change after OVX or after PTH administration. Administration of PTH prevented OVX induced alteration of the subchondral bone microarchitecture.

Ovariectomy induces an alteration in the cartilage quality (without modifying its mass) and in subchondral bone, both resembling early osteoarthritis. The administration of PTH totally prevents these deleterious effects on the osteochondral plate. PTH treatment could represent a potential therapeutic intervention for osteoarthritis.

P1003

THE REFERENCE VALUES OF BONE TURNOVER MARKER PINP, AND THE EFFECT OF CIRCADIAN RHYTHM ON ITS VALUE IN HEALTHY ELDERLY POPULATION: A SYSTEMATIC REVIEW AND META-ANALYSIS

N. Fahimfar¹, A. Fatahi², Z. Cheraghi³, S. Gharibzadeh⁴, P. Khashayar⁵, N. Mehrdad⁶, B. Larijani⁷, A. Ostovar¹

¹Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ²Department of Medical Surgical Nursing, School of Nursing and Midwifery, e, Hamadan University of Medical Sciences, Hamadan, Iran, ³Modeling of Noncommunicable Disease Research Center, Hamadan University of Medical Science, Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran, ⁴Department of Epidemiology and Biostatistics, Pasteur Institute of Iran, Tehran, Iran, ⁵Center for Microsystems Technology, Imec and Ghent University, Ghent, Belgium, ⁶Elderly Health Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, ⁷Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Objective: BTMs, as surrogates for bone metabolism, are suggested to be advantageous to assess the fracture risk and also to monitor the treatment response; however, extensive use of BTMs are still limited due to their variability, and uncertain biological significance. Serum type 1 procollagen (PINP) is a marker of bone formation. In this meta-analysis we aimed to determine the reference values of PINP in population aged ≥ 50 y and also to estimate the effect of circadian rhythm on the values.

Methods: A comprehensive search in the international databases including PubMed, EMBASE, Web of Science, Scopus and also google and google scholar was undertaken to find related articles up to October 2018. The search strategy included the keywords as "bone turnover marker" "BTMs" "PINP" "procollagen type I N-terminal peptide" for the reference values and "circadian rhythm/s" "twenty-four hour rhythm/s" "nyctohemeral rhythm/s" "diurnal rhythms" for the effect of circadian on the values of PINP. The random effects model was used to report the results at 95%CI. In some studies of diurnal rhythms, the PINP values were not reported for the all measurements; so the numbers corresponding to each measurement were extracted from the reported graphs. All analysis was conducted via Stata 11.

Results: In all, 9 studies were included to estimate the mean values of PINP and three studies on 5 different countries were used to identify the effect of circadian rhythms. The pooled mean of PINP concentration in population aged ≥ 50 y was 42.60 (95%CI: 41.19, 44.01). The reference value of PINP were 37.06 (95%CI: 33.35, 40.78) in men and 44.32 (95%CI: 43.05, 45.60) in women.

As Figure 1 shows, there was no significant diurnal rhythms of PINP. It exhibited an early morning peak and lower concentrations during daytime.

Conclusion: The results showed no severe variation of PINP, with a peak value in early morning. To identify the role of PINP in the prediction of bone changes, complementary studies are needed.




Figure 1: Diurnal time trend of the values of PINP (ng/ml)
Solid line shows the real values and dotted line depicts the moving average

P1004

OSTEOCALCIN/OXYTOCIN/IL-6 AND NGF/BDNF MRNA LEVELS IN BONE MEDIATE MUSCLE PHENOTYPE DEPENDENT RESPONSE TO COLD STRESS CHALLENGE IN MICE

C. Camerino¹, E. Conte², M. R. Carratu¹, D. Tricarico²

¹Department of Biomedical Sciences and Human Oncology (Section of Pharmacology), School of Medicine, University of Bari, ²Department of Pharmacy-Drug Sciences, University of Bari, Bari, Italy

Oxytocin (Oxt), osteocalcin (Ost) and NGF/BDNF pleiotropic functions on bone, reproduction and cognition. Oxt/Ost are required for muscle regeneration. Here, we explored the signaling regulating bone and muscle response to cold stress (CS). The mRNA levels of *Ngf*, *Bdnf*, *Ost*, *Oxt* and their receptors (*p75ntr*, *Ntrk1*, *Ntrk2*, *Gprc6a*, *Oxtr*), *Ucp1* and *Il-6* in bone, soleus (SOL) and tibialis (TA) muscles from 3 months-old mice exposed to CS were investigated. The expression of different Myosin heavy chain: *Mhc2b* (fast-glycolytic), *Mhc1* (slow-oxidative) were also investigated. Mice (n=15) were divided into: controls maintained at room temperature (RT=23°C), exposed to CS at T=4°C for 6 h and 5 d. CS exposure for 5 d enhanced *Ngf*, but not its receptors, and *Ucp1* genes in bone. *Ucp1* and *Ngf* genes were upregulated by 2- and 1.5-fold respectively in TA after 6 h CS. *Ntrk1* was upregulated by 4- and 22-fold respectively in SOL after 6 h and 5 d CS, while *p75Ntr* was downregulated in both muscles after 6 h CS. *Bdnf* increased by 9.5-fold in bone after 5 d CS while it was not affected in muscle. *Ntrk2* was upregulated after 5 d CS in TA. *Oxt* was upregulated by 5-fold following 5 d CS in bone. *Oxtr* and *Il-6* genes were upregulated respectively by 1- and 1.5-fold after 5 d CS in SOL. *Ost* increased by 16-fold in bone after 5 d while decreases in

Sol by 0.9 fold. *Gprc6a* was unaffected. *Mhc2b* was downregulated respectively by 0.96- and 0.88-fold after 6 h and 5 d CS in SOL. *Mhc2a* was significantly downregulated by 0.88-fold after 5 d CS in TA. Our study confirms that *Ngf* and *Ucp1* are activated in bone as well as in muscle. *Oxt* and *Ost* are highly expressed in bone. *Oxy* exerts phenotype-dependent protective effects towards slow-twitch muscle through up-regulation of its receptor. *Ost* may use BDNF receptor to exert its action in muscle. CS induced a marked shift of SOL toward the slow-twitch phenotype. CS induced a mild shift of the TA toward the fast-twitch phenotype. IL-6 up-regulation in muscle after CS is consistent with the concept of a coordinated axis between bone and muscle.

P1005

OBES, PHYSICALLY INACTIVE POSTMENOPAUSAL WOMEN WITH LOW WALKING SPEED SHOW ACCELERATED PERIPROSTHETIC BONE LOSS IN THE TROCHANTERIC REGIONS OF THE PROXIMAL FEMUR

E. J. Aro¹, A. Myllymäki¹, E. Svedström², H. T. Aro¹

¹Department of Orthopaedic Surgery and Traumatology, University of Turku, ²Department of Diagnostic Imaging, Turku University Hospital, Turku, Finland

Objective: Postmenopausal women undergoing cementless total hip replacement (THR) are at an increased risk for late periprosthetic bone resorption. Strain-adaptive bone remodeling is a positive sign of femoral stem osseointegration but inevitably carries well known risks of bone fragility. The bone resorption process has been linked with female sex, aging, low preoperative BMD and mismatched in size between the stem and femoral bone. The latter may occur in aging women due to intramedullary widening of the proximal femur. Periprosthetic bone resorption does not develop in all subjects and the prediction of this adverse event is difficult. Probably there are still unknown patient-related risk factors. At best, these factors could be modifiable. We hypothesized that a patient's impaired functional capacity and low activity level could elicit accelerated periprosthetic bone loss. Our prospective 9-y study delineated the functional recovery and the progress of periprosthetic bone loss in a cohort of postmenopausal women. The subjects had experienced an uncomplicated surgical recovery from cementless THR with stable osseointegrated femoral stems verified on a prior 9-y follow-up with radiostereometric analysis¹.

Methods: The cohort consisted of 35 women (mean age, 62±8.4 y at the time of surgery), who underwent cementless THR for primary hip osteoarthritis with a proximal hydroxyapatite-coated anatomic femoral stem with ceramic-ceramic bearings. At baseline screening, 43% of the subjects were obese (class 1-3, BMI >30.0), 43% had one or more comorbidities (ASA 3), 55% had Dorr B or Dorr C femur morphology. Based on T-scores of preoperative DXA screening, 31% had normal BMD, 49% had osteopenia, and 11% had osteoporosis. Evaluation of functional recovery included the measurements of walking speed (GAITRite®). According to the recommendation², subjects were asked to walk at a self-selected comfortable walking speed along a 10-m walkway. The mean coefficient of variation of the repeated measurements was 4.7%.

Aside with registering UCLA activity score, assessment of inter-individual differences in daily walking activity was performed by means of digital pedometers for periods of 14 d at defined periods up to 2 ys. DXA measurement for periprosthetic BMD (Hologic®) was performed for seven Gruen zones of the proximal femur, and the measured precision was 1.5–3.4% depending on the zone. The baseline measurements were before surgery and repeated at 3 months, 6 months, 1 y, 2 y and 9 y. The baseline measurement of periprosthetic BMD was performed within 5 d after surgery.

Results: The preoperative walking speed (mean±SD; 1.04±0.21 m/s) improved by 29.0% (95%CI 18.9 to 39.0) within 1 y after surgery (1.23±0.22 m/s), but declined again by 9 y (1.01±0.27 m/s). Compared with baseline, periprosthetic BMD decreased by 13.8% (95%CI, 8.4 to 19.2) in the greater trochanteric region (zone 1), by 9.0% (95%CI 3.3 to 14.7) in the lesser trochanteric region (zone 6) and by 40.4% (95%CI, 33.5 to 47.2) in the medial femoral neck region (zone 7) by 9 y. In univariate regression analysis, the measured walking speed at 9 y was a significant predictor of periprosthetic bone loss in the trochanteric regions (zone 1 and 6) and in the medial femoral neck (zone 7). Subsequently, the subjects were divided into two groups based on the median walking speed measured 1 y after surgery (1.25 m/s), representing the time-point of maximal walking speed. The subjects walking at the slower speed (<1.25 m/s) (n=17) had higher BMI (p<0.001), less walking steps per day before and after surgery (p<0.001), and lower UCLA activity scores preoperatively (p=0.034) and at 2 y (p=0.049) compared with the subjects with the walking speed of ≥1.25 m/s (n=18). Periprosthetic bone loss started faster in the subjects with low walking speed. At 9 y, the bone loss in the greater trochanteric region was higher (-19.0%, 95%CI -11.6 to -26.4) in the subjects with low walking speed compared with those with higher walking speed (-8.6%, 95%CI -0.7 to -16.4, respectively) (p=0.048). The bone loss was greater in the subjects with low walking speed also in the lesser trochanteric region (-15.0%, 95%CI -8.0 to -21.9) compared with those with higher walking speed (-3.0%, 95%CI -11.8 to -3.0) (p=0.030). The difference of bone loss in the medial femoral neck was not significant (-44.5% vs. -36.2%).

Conclusion: Postmenopausal women with high BMI walked at a slower speed and were physically inactive before and after total hip replacement. They experienced an accelerated loss of periprosthetic bone in the muscle insertion regions of the greater and lesser trochanters of the proximal femur. This result suggests that not only the stress-shielding effect of an osseointegrated hip prosthesis but also a decreased functional loading of the operated hip may contribute to periprosthetic bone loss.

References:

¹Aro E et al. *Acta Orthop* 2018;89:490.

²Foucher KC. *J Orthop Res* 2016;34:88.

P1006

COMPARISON OF LUMBAR SPINE BONE MINERAL DENSITY VALUES BY DXA WITH QUANTITATIVE COMPUTED TOMOGRAPHY (QCT): PRELIMINARY RESULTS

L. Sconfienza¹, S. Faenza², D. Albano¹, S. Gitto², A. Corazza¹, C. Messina¹

¹IRCCS Istituto Ortopedico Galeazzi, ²Università degli Studi di Milano, Milano, Italy

Objective: QCT may represent an opportunity for BMD screening in patients performing computed tomography of the abdomen. We retrospectively compared lumbar spine QCT BMD values to BMD by DXA using a retrospective asynchronous calibration of QCT scans.

Methods: We retrospectively selected a cohort of 15 subjects that performed a CT of the abdomen for various reasons and a lumbar spine DXA during the previous year. CT exams were performed using a Siemens Somatom Definition AS scanner; DXA exams were performed using an Hologic QDR-Discovery W densitometer. Volumetric BMD (vBMD) were measured from lumbar spine using Mindways QCT Pro software with asynchronous calibration, without the subject present. The analysis included the first three lumbar vertebrae. T-score values were used for DXA diagnosis according to the WHO criteria. For QCT, the American College of Radiology ranges for trabecular spine BMD was used as follows: BMD >120 mg/cm³=normal; 80 mg/cm³ ≤ BMD ≤120 mg/cm³=osteopenia; BMD <80 mg/cm³=osteoporosis.

Results: Among the selected patients we included 12 females and 3 males, age 75±10 y (mean±SD). QCT diagnosis was as follows: osteoporosis=8; osteopenia=4; normal status=2. DXA diagnosis was as follows: osteoporosis=5; osteopenia=1; normal status=9. All subjects classified as osteoporotic at DXA were correctly classified at QCT, with the exception of one case in which QCT showed osteopenic values (vBMD=81.42 mg/cm³). In 5 cases DXA was normal but QCT showed vBMD in the range of osteoporosis, and this was due to severe osteoarthrosis at lumbar spine leading to fictitious increase of DXA BMD values.

Conclusion: Our preliminary results showed that QCT with asynchronous calibration is able to provide vBMD values that are comparable to that of DXA in osteoporotic patient, thus offering the possibility for opportunistic identification of these subject. In addition, QCT showed the capability to diagnose osteoporosis in subject in which DXA was limited by the presence of osteoarthrosis.

P1007

LOW OSTEOCALCIN CONCENTRATION IS ASSOCIATED WITH HIGHER RISK OF TYPE 2 DIABETES IN THE 5-YEAR PROSPECTIVE COHORT ITDIAB

C. Confavreux¹, P. Szulc², M. Wargny³, M.-C. Carlier⁴, E. Sornay-Rendu¹, M. Pichelin⁵, B. Cariou³

¹Université de Lyon - INSERM UMR1033 Lyon - Service de Rhumatologie des Hospices Civils de Lyon, Lyon, ²Université de Lyon - INSERM UMR1033 Lyon, Lyon, ³Endocrinologie, Institut du Thorax, INSERM UMR 1087/CNRS UMR 6291/CIC1413- Université de Nantes- CHU de Nantes, Nantes, ⁴Département de Biochimie des Hospices Civils de Lyon, Lyon, ⁵Centre Investigation Clinique, Institut du Thorax, INSERM UMR 1087/ CNRS UMR 6291/CIC1413- Université de Nantes- CHU de Nantes, Nantes, France

Objective: In vivo mice experiments and human cross-sectional or retrospective studies suggest that bone is an endocrine organ active on energy metabolism through at least one hormone: osteocalcin. Since there was no prospective data, we aimed to assess the association between baseline osteocalcin serum level and the risk of mellitus diabetes.

Methods: IT-DIAB is a 5-y single center prospective cohort of men and women followed annually for diabetes onset. Included patients were prediabetic with an elevated FINDRISC, a score risk to predict diabetes and a fasting blood glucose between 1.1-1.26 g/L. At baseline, patients underwent a clinical examination and a morning fast blood withdrawal. Total serum osteocalcin was assessed using ELECSYS-Roche diagnosis kit. Primary endpoint was the onset of diabetes based on abnormal fasting blood glucose >1.26 g/L or positive oral glucose tolerance test. We performed a Cox multivariate survival analysis, a Youden analysis and a quartile analysis to analyze the link between osteocalcin and diabetes onset.

Results: Among 365 prediabetic individuals, 297 have been followed-up during 5 y. 103 patients became diabetic. Median time to diabetes onset was 24.7 months [interquartile range 13.1-38.9 months]. Lower total serum osteocalcin was significantly associated with an increased risk of diabetes onset (HR=1.56 per 1SD decrease [95%CI: 1.23-1.98; p<0.005]). This association persists even after adjustment on age, familial history of diabetes, glycated hemoglobin A1c (HbA1c), fasting blood glucose (HR=1.44 [1.13-1.83] p<0.01). The risk was notably increased (HR=2.54 [1.53-4.22] p<0.001) when osteocalcin was below the cutoff value of 0.2 SD (<17.4 ng/mL in men and <18.2 ng/mL in women) by comparison with patients over the cutoff. In addition, low osteocalcin was associated with diabetes onset even when the other classical risk factors (high FINDRISC score, hyperglycemia, family history of diabetes) were absent (HR=3.69 per 1 SD decrease [1.06 - 12.85] p<0.05).

Conclusion: We present here a prospective study where low serum osteocalcin in prediabetic patients is strongly associated with an increased risk of mellitus diabetes. We observe that os-

teocalcin brings an additive value to the usual risk factors of diabetes. Altogether, these data support the osteocalcin function on energy metabolism in humans.

P1008

REHABILITATION ENGAGEMENT LEVEL IN PATIENTS WITH OSTEOARTHRITIS

V. Salaru¹, A. Vizdoaga¹, L. Mazur-Nicorici¹, N. Loghin-Oprea¹, V. Sadovici-Bobeica¹, T. Rotaru¹, M. Mazur¹

¹State University of Medicine and Pharmacy "Nicolae Testemițanu", Chisinau, Moldova

Objective: Kinetotherapy is a nonpharmacological treatment that is recommended in clinical guidelines for the management of osteoarthritis (OA) and should be considered prior to pharmacological interventions. However, the participation levels of the patients in the therapy session are different and could influence the treatment outcomes. The aim of this study was to evaluate the engagement of patients with osteoarthritis in rehabilitation kinetotherapy programs in clinical practice in the Republic of Moldova.

Methods: A structured interviews were conducted with patients with osteoarthritis and were admitted to outpatient rehabilitation facilities associated with a university medical center.

By interviewing the patients, this study evaluates their opinion and engagement to kinetotherapy programs. The Hopkins Rehabilitation Engagement Rating Scale (HRERS) was used to measure engagement and was completed by five clinicians. The HRERS items rate the following: the level of attendance at therapy sessions, the attitude expressed by the patient toward his/her therapy, the need for verbal or physical prompts to facilitate initiation or maintenance of engagement within the therapy session, the patient's acknowledgment of the need for therapy, and the patient's level of active participation in the therapy.

Results: There were 78 patients enrolled in the study including 49 females (62, 8%), mean age \pm SD 56.7 \pm 14.7 (range 41-74) and the disease duration was 9.9 \pm 6.97 (range 2-24) y. Knee pain was present in 68 (87. 1%) of patients, the level of pain according to VAS was 56.7 \pm 11.5 mm. The radiographic characteristics: KL II-41 (52.6%) patients, KL III- 29 (37.2%) and the most severe form KLIV - 8 (10.2%) cases. The level of engagement and participation of patients in rehabilitation program varied from: 2 persons who needed clinical intervention to improve the patient's engagement (HRERS <20), 10 persons (12.8%) were "at risk" for greater absenteeism from therapy (score range, 20-25), and 66 patients (84.6%), had the score >25, that could be considered as fully engaged in their rehabilitation therapies. The degree of involvement was strongly dependent on the pain intensity and functional limitations of the knee ($r=0.47$, $p<0.05$). From patient's perspective, the most frequently cited reasons for low engagement level was interference with the patient's work schedule (64.1%), inconvenient sessions appointments (76.9%), and the long way to the rehabilitation center (43.5%).

Conclusion: The engagement level in outpatient rehabilitation programs in patients with knee osteoarthritis is high and it is determined by the pain intensity and functional limitation of the joint, also could be negatively influenced by personal and organizational factors.

P1009

PREDICTIVE FACTORS FOR FUNCTIONAL DISABILITY IN FEMALE PATIENTS WITH RHEUMATOID ARTHRITIS

D. Matei¹, D.-M. Viezuina², I.-R. Marcu¹, A. Bighea¹, S. Patru¹

¹UMF Craiova, rehabilitation Department, ²Emergency Hospital Craiova, Craiova, Romania

Objective: Various factors responsible for disability (pain, the activity of disease and The Stanford Health Assessment Questionnaire (HAQ)) were used to investigate the functional course of the rheumatoid arthritis disease.

Methods: A total of 61 female patients with rheumatoid arthritis (RA) (according to American College of Rheumatology criteria) were followed prospectively for 1 y. At baseline and at endpoint, HAQ scores, the activity of disease (DAS28), the level of pain (VAS10cm) and biological assessment were performed.

Results: Correlations between baseline data and HAQ or SF-36 scores at endpoint were analyzed, using nonparametric tests. A multilinear regression model was performed to select independent prognostic factors of disability for RA female patients. The mean HAQ decreased from 1.4(\pm 0.35) to 0.4(\pm 0.61) and the final HAQ disability was associated with baseline values of pain, DAS28 and C-reactive protein values but not with the level of anti-CCP antibodies. Age and rheumatoid factor did not contribute to prediction of the disability after 1 y follow-up.

Conclusion: The functional disability in female patients with rheumatoid arthritis reflects the cumulative effects of the disease evolution and can be an important outcome measure.

P1010

BONE MINERAL DENSITY AND BONE TURNOVER MAKERS IN DIFFERENTIATED THYROID CANCER PATIENTS

D. Gogas Yavuz¹, C. Dincer¹, O. Elbasan¹, T. Apaydin¹

¹Marmara University School of medicine, Istanbul, Turkey

Objective: Suppression of thyroid stimulating hormone (TSH) with levothyroxine (LT4) is long term management strategy aims to reduce recurrence and metastasis. Supraphysiologic doses of levothyroxine may have adverse effects on cardiovascular system and bone. The aim of this study was to investigate the BMD and bone turnover markers of the differentiated thyroid cancer patients who were under TSH suppression treatment with levothyroxine at least 1 y period in our endocrinology clinic.

Methods: Differentiated thyroid cancer who were followed at least a year under LT4 suppression treatment included in this cross-sectional study. BMD was measured by DXA at the lum-

bar spine and femoral neck. Serum calcium (Ca), parathormone (iPTH), 25OH vitamin D, osteocalcin (OC) and c-telopeptide (CTx) levels were evaluated.

Results: A total of 185 patients with of the patients (F/M: 154/31, 50.7±11.3 y) included in the study. Duration of disease was 6.2±4.6 y. The mean daily dose of levothyroxine was 129±42.4 µg/d and 1.85±2.05 µg/kg body weight. TSH level was suppressed (0.001±0.04 mIU/L). 25(OH)D levels were 27.9±11.7 ng/ml. Serum calcium, PTH,OC and CTx were in normal range. The mean femur neck BMD was 0.97±0.17 g/cm² and L1-4 BMD was 1.14±0.20 g/cm². There was a weak positive correlation between total daily levothyroxine dose and femur BMD (r=0.23, p:0.01) and L1-4 BMD (r=0.21, p:0.01). Duration of disease and femur neck BMD shown a significant negative correlation (r=-0.16, p=0.02) but not with lumbar BMD. There was a negative correlation between femur (r:-0.22, p:0.01) and L1-4 BMD (r:-0.31, p:0.0004) and serum osteocalcin levels.

Conclusion: Duration of TSH suppression can be predictor for bone lose in TSH suppressed thyroid carcinoma patients. Patients need be monitored regularly for osteoporosis and unnecessary excessive TSH suppression should be avoided.

P1011
3D ANALYSIS OF LOCAL BONE DENSITY DEFECTS IN PATIENTS WITH FEMORAL NECK FRACTURE

S. Di Gregorio¹, S. Martinez², L. Brance¹, L. Humbert³, P. Sanchez⁴, L. Del Rio¹

¹CETIR Centre Medic, Barcelona, Spain, ²Servei Reumatologia, Hospital Mutua de Terrassa, ³Galgo Medical, Barcelona, Spain, ⁴Centre Tecnologia Diagnostica, Terrassa, Spain

Objective: To assess the anatomical distribution of bone density defects in patients with femoral neck fracture using a DXA-based 3D modelling technique.

Methods: 106 patients who recently suffered a femoral neck fracture and 106 sex- and age-matched (±5 y) subjects without hip fracture were included in this study (77 females and 29 males in

each group). Mean age of patients was 79.9 (7.7) y and mean age of controls was 80.0 (7.8) (p=0.996). DXA scans (contralateral hip for patients) were performed using a Prodigy (GE Healthcare) scanner. DXA scans were performed on average 13 days after the fracture (range: 2-60 d). Areal BMD (aBMD) was calculated. The 3D-SHAPER software (v2.9, Galgo Medical) was used to model the femoral shape and volumetric BMD (vBMD) distribution from hip DXA scans. Trabecular vBMD and cortical surface BMD (sBMD) were calculated. DXA and DXA-derived 3D measurements calculated for each group were compared using Student's t-test. Area under the receiver operating curve (AUC) was computed.

Results: aBMD was found to be 5.0% lower at total femur (p=0.044) and 7.5% lower at neck (p<0.001) in the fracture group, compared to controls. aBMD at neck was shown to better discriminate between fracture and control groups, with an AUC of 0.642, compared to total hip aBMD (AUC of 0.580). Trabecular neck vBMD was 14.8% lower and cortical neck sBMD 6.3% lower in the fracture group, compared to controls (p<0.001). AUC was 0.668 for trabecular neck vBMD, and 0.618 for cortical neck sBMD (p<0.001). vBMD values obtained at each voxel of the patient-specific 3D models were compared between groups. Figure 1 (left) shows that vBMD values in the superior aspect of the femoral neck were associated with the highest AUCs (range: 0.667 – 0.759). When using the average vBMD in the superior aspect of the femoral neck (i.e., in the region highlighted in Figure 1, left) to discriminate between groups, an AUC of 0.748 was found (Figure 1, right).

Conclusion: Patients with neck fracture showed local defects in vBMD in the superior aspect of the femoral neck, which is consistent with findings of biomechanical studies testing sideways fall configuration. vBMD calculated in this region of interest using a DXA-based 3D modelling technique was found to better discriminate between patients with neck fracture and controls, compared to standard aBMD measurements at neck. Advanced assessment of local defects in vBMD could potentially improve fracture prevention.





Figure 1: AUC obtained using vBMD values at each voxel (left). Comparison of ROC curves (right). The "superior Neck vBMD" curve was computed using the average vBMD calculated over the region highlighted in the left image.

P1012

ADIPOKINES AND VASCULAR MARKERS IN BONE REMODELING IN IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION

A. Kochetkova¹, G. Ugai¹, V. Maistrovskaia¹

¹Pacific State Medical University, Vladivostok, Russia

Objective: Osteoporosis is a major comorbidity of cardio-respiratory diseases, but the mechanistic links between pulmonary arterial hypertension and bone remain elusive. The purpose of the study was to evaluate serum adipokines and endothelin-1 (ET-1) levels in the patients with idiopathic pulmonary arterial hypertension (IPAH) NYHA class III-IV and to determine its associations with BMD.

Methods: Pulmonary and hemodynamic parameters, BMD Z-scores at the lumbar spine (LS) and femoral neck (FN), serum leptin, adiponectin, visfatin, ghrelin and endothelin-1 (ET-1), were evaluated in 32 patients with IPAH NYHA class III-IV and 30 healthy volunteers.

Results: Leptin, adiponectin and ET-1 were higher in the patients with IPAH than in healthy subjects. Visfatin and ghrelin levels showed a tendency to increase compared to that of healthy subjects. The univariate analysis revealed a positive correlation between BMD Z-scores at both sites and 6-min walk test, and inverse relation with pulmonary vascular resistance (PVR) and mean pulmonary arterial pressure (mPAP). Adiponectin and visfatin showed positive correlations with PVR ($p=0.009$ and $p=0.006$) while ghrelin correlated with mPAP ($p=0.012$). Serum adiponectin, visfatin, ghrelin and leptin were inversely associated with Z-scores. After adjusting for BMI and FMI, such associations persisted between visfatin and adiponectin levels and Z-scores at both sites. ET-1 related to mPAP, cardiac index and PVR. Negative correlation was observed between ET-1 and FN BMD ($p=0.01$). Positive correlations have revealed between ET-1 and adiponectin ($p=0.02$), visfatin ($p=0.004$) in IPAH patients.

Conclusion: These results provide further evidence that adipokine and endothelial dysregulation may cause not only a decrease in BMD, but also an increase in hemodynamic disorders of IPAH.

P1013

ANALYSIS OF BONE MINERAL DENSITY AND TRABECULAR BONE SCORE IN MEN WITH ANKYLOSING SPONDYLITIS: RESULTS OF CROSS-SECTIONAL ANALYSIS

Z. Killinger¹, M. Kužma¹, M. Adamcová¹, P. Jackuliak¹, S. Tomková², J. Payer¹

¹Comenius University Faculty of Medicine, 5th department of Internal Medicine, University hospital, Bratislava, Slovakia, Bratislava, ²Internal Department of 1st Private Hospital, Šaca, Košice, Košice, Slovakia

Objective: Ankylosing spondylitis (AS) is characterized by pathologic new bone formation in the cortical bone of the spine and impairment and loss of trabecular bone mass of the vertebral body leading to osteoporosis with prevalent vertebral fractures (VF). Our aim was comparison of noninvasive bone parameters – BMD and trabecular bone score (TBS) of AS males with healthy controls.

Methods: A pilot cross-sectional study of AS males and healthy age, BMI- matched controls was performed. In all subjects, single measurements of BMD of total hip (TH) and lumbar spine (LS), femoral neck (FN), and trabecular bone score (TBS) was performed. N-terminal type 1 procollagen (PINP) and C-terminal telopeptide (CTx).

Results: We present a preliminary data from multicentric study currently ongoing in Slovakia. 38 male patients with AS and 32 healthy males without difference in age and BMI were included in the study. AS patients had significantly greater PINP ($<.0001$) and lower FN BMD ($<.0001$) in comparison to healthy controls. There was no difference in LS BMD, TBS and CTx observed between groups.

Conclusion: This analysis shows that AS men, had lower BMD at femoral neck and higher and PINP levels, but no difference in LS BMD compared to healthy controls. No difference in LS BMD in males along with activated bone formation may be associated with more active disease and advanced syndesmophytes formation. TBS differences between groups did not reach statistical significance, however, this study has some limitations such is small sample size, cross-sectional design and lack of data on VFs. Additional new tools, better reflecting bone quality and thus predicting VFs, are needed.

P1014

CLINICAL ASSESSMENTS AND BONE CHANGES IN ELDERLY PATIENTS WITH HIP ARTHROPLASTY DUE TO FEMORAL NECK FRACTURE

D. Matei¹, A. Bighea¹, I.-R. Marcu¹, S. Patru¹¹UMF Craiova, Rehabilitation Department, Craiova, Romania

Objective: To emphasize correlations between clinical manifestations and the morphological changes in femoral bone.

Methods: 39 patients were enrolled in the study (27 females and 12 males). Of these patients, 35 patients received cementless implants, while 4 received cemented implants. All the patients needed a complex rehabilitation programme. The indication of arthroplasty enabled specialists to obtain biological material needed for the histological study.

Results: The patients' ages were between 68-92 (with an average of 76); hip fractures are due to a loss in bone resistance by the appearance of osteoporosis, especially after the age of 75. The study established that most of the fractures took place after the patients falling usually while standing while the trauma intensity was small in 88% of cases. We may say that in women the hip fracture incidence is more frequent than in men.

Conclusions: After the age of 75, the number of femoral fractures shows an increase because of osteoporosis, the constant increase of the median life expectation, the presence of other comorbidities (such as cardiopathy, diabetes, dementing illnesses); the most frequent cause that led to fracture was falling from one's height.

P1015

HUMAN ALLOGENEIC CELL THERAPY AFTER MUSCLE TRAUMA IN HIP ARTHROPLASTY PATIENTS INCREASES FUNCTIONAL REGENERATION

T. Winkler¹, T. Maleitzke¹, A. Agres², P. Reinke³, R. Ofir⁴, C. Perka⁵, H.-D. Volk⁶, G. Duda⁷

¹CMSC, JWI, BCRT, BIH, Charité - Universitaetsmedizin Berlin, Berlin, Germany, ²JWI, Charité - Universitaetsmedizin Berlin, Berlin, Germany, ³BCRT, BIH, Charité - Universitaetsmedizin Berlin, Berlin, Germany, ⁴Pluristem Therapeutics, Haifa, Israel, ⁵CMSC, Charité - Universitaetsmedizin Berlin, Berlin, Germany, ⁶IMI, BCRT, BIH, Charité - Universitaetsmedizin Berlin, Berlin, Germany, ⁷JWI, BCRT, BIH, Charité - Universitaetsmedizin Berlin, Berlin, Germany

Objectives: Insufficient muscle regeneration following trauma represents an unaddressed clinical need, above all in elderly patients. On the basis of promising preclinical data, we evaluated safety and functional outcome following local placenta-derived mesenchymal like adherent stromal cell (PLX-PAD) transplantation using acute iatrogenic muscle damage after total hip arthroplasty (THA) as a model system.

Methods: We conducted a randomized, double blind, placebo-controlled phase I/II study. 20 patients undergoing THA via lateral approach received transplantation (TX) of 300x106 (n=6),

150x106 (n=7) PLX-PAD or placebo (n=7) into the injured gluteus medius muscle (GM). Follow-up included safety, function, MRI and muscle biopsies.

Results: The cell therapy could be shown to be save with no relevant AEs having been observed until 2 y follow-up. Primary efficacy endpoint, change of GM contraction moment after 26 weeks, showed a significant increase in the 150M group (+31.2±7.0 Nm, p=0.0067) compared to placebo (+5.4±6.5 Nm) accompanied by an increase in muscle volume (+24.4±4.2 cm³, p=0.004). Change of contraction force and muscle volume in the 300M group showed a similar pattern as in the 150M group but was not statistically significant. Change of mean fiber diameters and regenerating myofiber count demonstrated a faster healing after cell TX. Surprisingly, placenta cell therapy resulted in a reduction of the postoperative stress reaction.

Conclusions: This is data from the first clinical study investigating allogeneic cell therapy for acute skeletal muscle injury. Although a limited number of patients were included in this trial, our results indicate a safe therapy with improved functional and structural outcome. Our data is the basis for the phase III study HIPGEN, which is supported by a Horizon 2020 grant, investigating the effect of this cell therapy on mobility and mortality of elderly hip fracture patients undergoing arthroplasty.

P1016

USE OF HIGH DOSES OF CHOLECALCIFEROL FOR THE TREATMENT OF HYPOVITAMINOSIS D IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS

O. Samokhovec¹, A. Rudenka², E. Rudenka³, T. D. Barysenka¹, S. Kryvashei¹, L. Alehnovich²

¹Minsk City Clinical Hospital No. 1, ²Belarusian Medical Academy of Postgraduate Education, ³Belarusian State Medical University, Minsk, Belarus

Objective: To assess the level of vitamin D in women with postmenopausal osteoporosis and to evaluate the effectiveness of treatment of hypovitaminosis D with high doses of cholecalciferol for 3 months.

Methods: 80 female patients with postmenopausal osteoporosis who were examined in Minsk city center of osteoporosis and diseases of the musculoskeletal system were enrolled in the study (mean age 66.4 (8.7) y). Serum concentration of 25(OH)D was determined by electrochemiluminescence (Cobas e411, Roche Diagnostic). Levels of 25(OH)D <30 ng/ml were considered as vitamin D insufficiency, <20 ng/ml - as vitamin D deficiency.

Results: Hypovitaminosis D was observed in 86% of patients. Median content of 25 (OH) D at baseline was 16.74 [7.42; 24.58] ng/ml. For the purpose of drug therapy, cholecalciferol was administered in a dose of 50,000 IU once every 2 weeks for 3 months. A repeated study of the level of vitamin D performed after 3 months of therapy showed a positive trend in the level of 25(OH)D in all subjects: median level 35.99 [32.11; 43.66] ng/ml, with p<0.001.

Conclusions: The doses of cholecalciferol used in the study (50,000 IU once in 2 weeks) can eliminate vitamin D deficiency and allow achieve optimal level of more than 30 ng/ml for 3 months in elderly female patients.

P1017

RELATIONSHIPS BETWEEN FUNCTIONAL PARAMETERS AND QUALITY OF LIFE IN KNEE OSTEOARTHRITIS PATIENTS

D. Matei¹, A. Bighea¹, I.-R. Marcu¹, S. Patru¹

¹UMF Craiova, rehabilitation Department, Craiova, Romania

Objective: To evaluate the impact of the functional status on the quality of life in patients with knee osteoarthritis (OA).

Methods: we included 81 patients diagnosed with knee OA (ACR criteria). All the patients were evaluated Modified Health Assessment Questionnaire (MHAQ) and WOMAC questionnaire.

Results: Pain (VAS100mm scale) was significantly higher in the elderly male patients ($p < 0.05$) being strongly correlated with WOMAC value ($r^2 = 0.611$). The WOMAC values varied significantly for the 2 residing areas ($p < 0.05$). Correlations were found for all functional parameters according to BMI but the most significant being for the physical function subscale of WOMAC ($r^2 = 0.431$).

Conclusions: Trying to investigate the functional disabilities and how they affect the patient's perception of their condition, we found female gender, residing in urban areas and obesity were all linked with higher WOMAC scores and were strongly correlated with MHAQ.

P1018

VALIDATING THE ACTIVITIES-SPECIFIC BALANCE CONFIDENCE (ABC) SCALE IN GREEK ELDERLY POPULATION

E. Makri¹, S. Lampropoulou², G. P. Euthimiou³, C. Matzaroglou², S. Mavromoustakos¹

¹Department of Physical Therapy, Alexander Technological Educational Institute of Thessaloniki, Thessaloniki,

²Physiotherapy Department, Technological Educational Institute of Western Greece, Aigio, ³Rehabilitation Center LYDIA Euromedica, Kavala, Greece

Objectives: Fear of falling and balance disorders are closely related to the risk for falling and risk for fractures. Thus, evaluating the fear of falling is extremely important for falls prevention. The Activities-Specific Balance Confidence (ABC) Scale is a questionnaire that very well documents the fear of falling, during 16 functional tasks in- and outdoors, and has good psychometric properties. However, it has not been adapted or validated into Greek. The objectives of the present study, therefore, are i) to cross culturally adapt the ABC scale into Greek and ii) to evaluate its psychometric properties in Greek elderly participants.

Methods: Cross cultural adaptation with forward and backward translation by 6 bilingual translators was conducted according to international guidelines and following permission by the instructor of the scale. The final Greek version of the scale (ABCGR) was

piloted to 30 healthy Greek elderly (13 males and 17 females, 66 ± 6 years old) for testing its psychometric characteristics. The ABCGR was correlated with the Confidence Balance questionnaire (CONFbal), the Fall Efficacy Scale - International (FES-I) and the observational measure of the Functional Reach Test (FRT), for testing the convergent validity. Test-retest Reliability of the ABCGR questionnaire was assessed with repeated measure in 10-d period.

Results: Translation process completed with no particular difficulties. The content was clear and comprehensible to the participants and this led to the Greek version of the ABC (ABCGR). The ABCGR yielded weak to strong correlations with the FES-I ($r = -0.654$, $p < 0.001$), the CONFbal ($r = -0.368$, $p < 0.05$), and the FRT ($r = 0.500$, $p < 0.05$). The test-retest reliability of the ABCGR was found to be excellent ($ICC_{1,1} = 0.911$).

Conclusions: The ABCGR scale, is clear and comprehensible to the Greek population tested. The first results also indicate a valid and reliable tool for assessing the balance confidence in functional tasks. Further testing in a larger sample is required in order to obtain more representative results.

P1019

EFFECT OF EXERCISE GUIDANCE REGARDING ITS DELIVERY TIME ON FALLS REDUCTION AND THE IMPROVEMENT OF BALANCE AND PHYSICAL FUNCTIONING IN THE ELDERLY

A. Kellari¹, S. Lampropoulou², C. Matzaroglou³, V. Sakellari⁴

¹Physiotherapy Program, Life and Health Sciences Department, University of Nicosia, Cyprus and MSc in Advance Physiotherapy Program; Technological Educational Institute of Sterea Ellada, Lamia, Greece, Nicosia, Cyprus, ²Physiotherapy Program, Life and Health Sciences Department, University of Nicosia, Cyprus and Physiotherapy Department, Technological Educational Institute of Western Greece, Aigio, Greece, ³Physiotherapy Department, Technological Educational Institute of Western Greece, Aigio, Greece, ⁴MSc in Advance Physiotherapy Program; Technological Educational Institute of Sterea Ellada, Lamia, Greece and Physiotherapy Department, University of West Attika, Athens, Greece

Objectives: Balance and strength group exercise-based intervention with verbal and visual guidance reduces falls and improve balance in the elderly. However, the efficacy of the timing that this visual and verbal guidance is given by the group leader has not been investigated. Thus, the objectives of this study are to evaluate the effects of guidance delivery time on falls related confidence, balance, gait and cognitive functions.

Methods: 24 community Cypriot elderly (aged 74 ± 6 SD) participated in a single-blind clinical control trial. Being separated in 2 age matched groups, they received individually tailored progressive 12 weeks-Otago Exercise Program (OEP) for strength and balance, in two ways of delivery. Group 1 received visual and verbal additional guidance before the performance of the exercise while group 2 received the guidance by the exercise instructor only in

parallel with the exercise. Fear of falling (Falls Efficacy Scale-International (FES-I), balance (mini-Balance Evaluation Systems Test (mini-BESTest), gait (Functional Gait Assessment (FGA) and cognitive function (Montreal Cognitive Assessment (MoCA) were evaluated at baseline, 6 and 12 weeks of the program. Ethics approval was given by the Cyprus National Bioethics Committee.

Results: In average, falls reduced by 11% and the participants reported less fear of falling (2 points reduction in the total FES-I score from 24 to 22/64, $p < 0.05$). The gait performance improved by 2 points on the FGA scale (from 23 to 25/30, $p < 0.05$). Balance was also improved by 3 points on the mini-BESTest scale (from 19 to 22/28, $p < 0.05$). In addition, the cognitive performance was improved as indicated by a 3-points increase of the MoCA test scoring (from 22 to 25/30, $p < 0.05$). The timing of visual feedback and previous exercise verbal explanation did not have any significant main effect ($p > 0.05$) on physical functioning and on the assessed scores, FES-I: ($F(1, 17)=1, r=.24$), mini-BESTest: ($F(1, 16) < 1, r=.23$), FGA ($F(1, 17) < 1, r=.08$) or mental activities ($F(1, 16) < 1, r=.05$).

Conclusions: OEP reduced the incidents of falls, improved significantly balance, gait and cognitive functions of community older adults, regardless the delivery time of the verbal exercise explanation and the visual exercise demonstration provided.

Acknowledgements: Erasmus plus, Student Mobility for Studies.

P1020

EPIDEMIOLOGY OF HIP FRACTURES IN IRELAND: A SYSTEMATIC REVIEW

A. Ibrahim¹, C. Armstrong², F. Heaney², E. McCabe¹, R. Singh¹, J. J. Carey¹

¹Department of Medicine, National University of Ireland (Galway)/ Rheumatology Department, Galway University Hospitals, ²Rheumatology Department, Galway University Hospitals, Galway, Ireland


Objective: To perform a systematic review of published studies on hip fractures in Ireland.

Methods: A recent IOF report states Ireland has the 6th highest rate of hip fracture, but published data are limited. We performed a comprehensive systematic search of published Irish hip fracture literature from 1950-July 2018. No studies were found between 1950-1959 and 1970-1979. Screening, data extraction, and risk of bias assessment was done in duplicate. A qualitative overview, along with quantitative secular trend analyses of demographics, inpatient length of stay (LOS), inpatient (IMR) and 1-y mortality rates (1YMR) was performed. We summarized demographics. LOS and mortality rates were assessed by decade utilizing central tendency measures (means/medians) with 95%CI, using the one sample t-test or sign test as appropriate.

Results: 110 studies were included for qualitative analysis and 60 for quantitative data synthesis. Overall, there was considerable clinical & methodologic heterogeneity amongst studies, few interventional trials and none prior to 1960. Age remained stable: 79.2 to 80.7, but the proportion of males increased from 15.6% in 1960s to 26.16% after 2010. LOS, IMR, and 1YMR declined markedly from 1960 to 2018, in a similar pattern to other EU countries.

Conclusions: A 60-y literature on fragility hip fractures in Ireland is characterized by considerable variation in methods and outcomes. There has been a marked decline in LOS, IMR and 1YMR.

Figure 1: Decline in inpatient mortality over the past 60 y in Ireland



P1021

PREVALENCE OF SARCOPENIA USING SARC-F IN THE ELDERLY PATIENTS: CORRELATION BETWEEN BODY COMPOSITION, FUNCTIONAL STATUS AND PHYSICAL PERFORMANCE-A PRELIMINARY STUDY

P. Borman¹, Y. Dogan², P. Bilgic³, O. Sümeýra⁴, Y. Gökçe-Kutsal⁵, S. Karahan⁶

¹University of Hacettepe Faculty of Medicine Department of PMR, ²University of Hacettepe Faculty of Medicine Dept of PMR, ³University of Hacettepe Faculty of Health Sciences Dept of Nutrition and Dietetics, ⁴University of Hacettepe Faculty of Health Sciences Dept of Nutrition and Dietetics, ⁵University of Hacettepe Faculty of Medicine Dept of PMR, ⁶University of Hacettepe Faculty of Medicine Dept of Biostatistics, Ankara, Turkey

Objectives: Sarcopenia is the age-dependent loss of skeletal muscle mass and strength which causes disability, falls and hospitalizations in the elderly. A definite consensus on the diagnosis of sarcopenia has not been reached yet (2). The aim of this study was to assess the prevalence of sarcopenia by SARC-F -a simple clinical symptom index (1) and to investigate the relationship between SARC-F scores and body composition parameters, muscle strength, functional status and physical performance scores in a group of geriatric patients.

Methods: 60 patients from the outpatient clinics of Physical Medicine and Rehabilitation department were recruited according to the eligibility criteria. The demographical and clinical characteristics were recorded. Body composition comprising BMI, body fat, fat-free mass; muscle strength assessed by grip strength measurement and functional status assessed by short physical performance battery (SPPB) were determined. 4m gait speed, chair stand and balance tests were performed. The nutritional status assessed by mini nutritional assessment (MNA), and physical activity status assessed by Physical Activity Scale for the Elderly (PASE) were also recorded.

Results: 9 male and 51 female patients with a mean age of 66+4.8 y were included to the study. The mean BMI was 30.2±5.4 kg/m². 13.3% of patients had falls, 75% of them were nonsmokers, 92% nonalcoholic and 76% of them had more than two chronic diseases. 18% of the patients had sarcopenia. The demographical and clinical parameters except BMI, number of falls and the scores of chair stand and balance tests, were similar between patients with and without sarcopenia (Table 1). There were negative correlations between the scores of SARC-F and the grip strength (p:0.002,r:-0.39) chair stand (p:0.000, r:-0.44, balance test (p:0.033, r:-0.28)and SBBP total scores (p:0.011,r:-0.33).

Conclusion: Nearly 20% of the elderly had sarcopenia, in whom obesity and falls were common. Sarcopenia screened using SARC-F was associated with decreased muscle strength, balance and increased functional disability. We suggest the use of SARC-F as an easy, quick and practical screening tool for the diagnosis of sarcopenic elderly in the routine clinical practice.

References:

1. Malmstrom TK and Morley JE. J Am Med Dir Assoc 2013;14:531.
2. McLean RR and Kiel DP. J Bone Mineral Res 2015;30:588.

Table 1: The demographic and clinical characteristics according to the presence of sarcopenia.

	SARCF<4 n=49	SARCF≥4 n=11	P
BMI (kg/m ²)	29.5±5.3	34.3±5.6	0.047*
Body fat (%)	35.1±7.5	36.8±6.7	0.408
Fat-free mass (kg)	45.6±7.1	49.9±45.6	0.228
Grip strength (kg)	21.9±6.6	20.9±8.8	0.546
MNA	24.5±3.0	25.1±4.3	0.643
Falls (n)	1.3±0.8	1.5±0.7	0.023*
PASE score	68.7±30.2	74.4±38.8	0.876
4m gait speed test (min)	2.5±1.1	2.1±1.4	0.459
Chair stand test (min)	1.9±1.1	0.9±0.9	0.005*
Balance test	3.8±0.5	3.4±0.9	0.000*
SBBP total score	8.2±1.9	6.4±2.1	0.074
Comorbidity (n)	1.8±1.6	2.9±1.4	0.938

P1022

RISK FACTORS FOR NEW AND PERSISTENT CHRONIC OPIOID USE AFTER HIP FRACTURE SURGERY: A DANISH NATIONWIDE COHORT STUDY FROM 2005 TO 2016

N. M. Edwards¹, C. Varnum², S. Overgaard³, L. Nikolajsen⁴, A. B. Pedersen¹

¹Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus N, ²Department of Orthopaedic Surgery, Vejle Hospital, Denmark, Vejle, ³Department of Orthopaedic Surgery and Traumatology, Odense University Hospital, Odense, ⁴Department of Anesthesiology and Intensive Care, Aarhus University Hospital, Aarhus, Denmark

Objectives: Opioids are commonly prescribed for acute pain treatment in hip fracture (HF) patients. However, 80% of patients taking opioids will experience an adverse effect and some patients might develop a chronic use of opioids after surgery. We examined risk factors for new and persistent chronic opioid use after HF surgery.

Methods: Using Danish nationwide health registries, we identified all HF surgery patients ≥65 y of age (n=69,456). Among nonusers before surgery, we defined new chronic opioid use as at least two dispensing within 1 y after surgery. Persistent chronic opioid use was defined as at least one dispensing of opioids 6 months before and two dispensing within 1 y after surgery. We calculated adjusted odds ratios (aOR) with 95%CIs to explore following risk factors: age, sex, surgical indications, preoperative medications,

and comorbidities defined through Charlson Comorbidity Index (CCI low, medium and high) and a number of individual comorbidities.

Results: A total of 9% patients were new users, whereas 13% were persistent users. The aORs for being a new user were 1.39 (1.28-1.50) and 1.23 (1.15-1.32) for age groups 65-74 and 75-84 y, (ref=85+) 1.09 (1.02-1.16) for female (ref=male), 1.02 (0.96-1.09) and 0.93 (0.86-1.02) for medium and high CCI (ref=low, no known comorbidity), 1.20 (1.12-1.29) and 1.53 (1.38-1.70) for overweight and obese patients (ref=normal BMI), and 1.26 (1.15-1.37) for preoperative use of NSAID. The aORs for being a persistent user were 1.45 (1.35-1.55) and 1.25 (1.18-1.33) for age groups 65-74 and 75-84 y, 1.83 (1.72-1.95) for female, 1.59 (1.50-1.69) and 2.07 (1.93-2.22) for medium and high CCI, 1.19 (1.10-1.1.29) and 1.35 (1.23-1.48) for underweight and obese patients, and 1.75 (1.63-1.88) for preoperative use of NSAID. There was no association between other potential risk factors and chronic opioid use.

Conclusion: We identified several risk factors associated with new and persistent chronic opioid use, including high age, female sex, comorbidity and preoperative NSAID use. This is clinically relevant in order to identify and develop more effective and targeted preventive intervention strategies to reduce opioid use and thereby the associated adverse events among elderly patients.

P1023

INFLUENCE OF HIGHEST AND LOWEST BODY MASS INDEX HISTORY IN BONE MINERAL DENSITY AMONG WOMEN WITH ANOREXIA NERVOSA AND BULIMIA NERVOSA

M. A. P. Lopes¹, M. P. Silva¹, T. C. Correia¹, M. S. Alvarenga², L. A. Martini¹

¹Department of Nutrition of the Faculty of Public Health of the University of São Paulo, ²Eating Disorder Program of the Institute of Psychiatry of the Faculty of Medicine of the University of São Paulo (AMBULIM), São Paulo, Brazil

Objective: To evaluate BMD among women with anorexia nervosa (AN) or bulimia nervosa (BN).

Methods: It is a cross-sectional study with female patients from the Eating Disorder Program of University of São Paulo, Brazil. DXA was performed to access total, femoral neck and lumbar-spine BMD. Body weight and height were measured and eating disorder history was evaluated by standardized questionnaire. Independent T-Test and Pearson's correlations were performed at a significance level of 0.05.

Results: 29 patients, mean age 32.2 years old (SD=9.67), were evaluated. Mean illness duration was 13.0 y (SD=9.2) and 40% have menses interrupted throughout life. BMI did not differ between AN (n=19) and BN (n=10) patients (23.5 kg/m², SD=9.97 vs. 31.8 kg/m², SD=26.0; respectively); and 16.7% of the patients were underweight, 53.3% normal weight, 16.7% overweight and 6.7% class III obesity. No differences were observed in total BMD (1.123 g/cm³, SD=0.103), lumbar spine BMD (1.157 g/cm³, SD=0.136) and femoral neck BMD (0.976 g/cm³, SD=0.150)

between AN and BN. According to z-score, 1 BN (BMI=27.2 kg/m²) and 1 AN (BMI=14.3 Kg/m²) patient presented lumbar spine BMD below the expected range for age and another 1 from BN (BMI=23.6 kg/m²) presented femoral neck BMD below the expected range for age. History of lowest weight for actual height (39.5 kg, SD=6.8 vs. 51.4 kg SD=18.3; p=0.016) and highest weight for actual height (62.3 kg, SD=9.7 vs. 73.3, SD=19.1; p=0.008) differed between AN and BN, respectively. History of highest BMI correlated with total BMD (r=0.431, p=0.02) and of lowest BMI correlated with total BMD (r=0.439, p=0.017) and lumbar spine BMD (r=0.393, p=0.035). Actual BMI presented positive correlation with total BMD (r=0.694, p=0.001) and lumbar-spine BMD (r=0.414, r=0.029). Amenorrhea length (mean 2.38 months; SD=5.3) correlated negatively with lumbar-spine BMD (r=-0.397, p=0.033).

Conclusions: No significant differences were observed in BMD among AN and BN patients. However, the history of amenorrhea and weight variation throughout adult life may explain BMD alterations. Future analysis should include the measurement of biochemical parameters in order to clarify the influence of body weight variations in BMD in this population.

P1024

PSYCHOLOGICAL IMPLICATIONS OF AESTHETIC FUNCTION RESTAURATION IN PATIENTS WITH DENTOMAXILLARY DISHARMONS ASSOCIATED WITH POSTURAL IMBALANCES

L. Todor¹, L. Liana¹, G. Gabriela¹, A. Adriana¹, G. Ciavoi¹, A. Porumb¹, A. Cuc¹, A. Tent¹

¹University of Oradea, Oradea, Romania

Objective: To study the changes that occur psychologically in the patient with dentomaxillary disharmons that frequently associate with postural imbalances. Research that has taken place over the past 20 y has shown that the entire musculoskeletal apparatus together with the skull and the mandible is a unique anatomic-functional system. When only one component of this system works generates negative repercussions on the whole organism.

Method: The study took place between 2015-2018. I studied 54 patients (25 women and 29 men) diagnosed with dental-associated jawbone disharmonies postural imbalances evaluated before and after 6 months after recovery treatment . The treatment was performed in collaboration with a dentist - kinetherapist specialist. The patients were evaluated by a psychologist before, 6 months after the beginning of the treatment and at the end of it. The psychological reports were centralized and processed.

Results: 81.72% of the self-esteem of the patient increased the self-esteem of the patient and 79.6% of the males and the social relations improved to 78, 56% of the barabati and 86.7% of the women. The motivation also increased to 65.4% of women and 61.3% of men.

Conclusion: The restoration of aesthetic function in a patient leads to the growth of psychic attributes such as self-esteem, motivation, also anxiety decreases. We can also conclude that in the results we did not notice significant differences between the sexes.

P1025

ASSOCIATION BETWEEN DYSPHAGIA AND FRAILITY IN COMMUNITY DWELLING OLDER ADULTS

G. Bahat¹, O. Yilmaz¹, S. Durmazoglu¹, C. Kilic¹, M. B. Aykent², P. Kucukdagli¹, D. Erbas Sacar¹, M. A. Karan¹

¹Istanbul Medical Faculty Internal Medicine Department Geriatrics Division, ²Marmara Medical Faculty Internal Medicine Department Nephrology Division, Istanbul, Turkey

Objective: Dysphagia is described as a geriatric syndrome that occurs more frequently with aging. It is associated with deterioration in functionality but usually ignored. Frailty is a geriatric syndrome that is recognized more with its well known adverse consequences. Frailty can be related falls and osteoporotic fractures Very recently, dysphagia has been suggested to accompany frailty in older adults. We aimed to investigate the association between dysphagia and frailty in the community dwelling older adults.

Method: Design: prospective, cross-sectional study. Setting: geriatric outpatient clinic. Participants: older adults aged ≥ 60 y. Measurements: Dysphagia was evaluated by EAT-10 questionnaire and frailty by FRAIL scale. Handgrip strength (HGS) was evaluated by hand-dynamometer. Gait speed was evaluated by 4-m usual gait speed (UGS). Nutritional status was assessed by mininutritional assessment-short form (MNA-SF).

Results: 1138 patients were enrolled. Mean age was 74.1 ± 7.3 y. EAT 10 questionnaire was answered by all and FRAIL-scale by 851 subjects. EAT 10 score >15 points was regarded as significant dysphagia risk. EAT-10 score >15 points was associated with older age ($p=0.002$), female gender ($p<0.001$), neurodegenerative diseases ($p=0.002$), higher number of chronic diseases ($p=0.001$) and regular drugs ($p=0.001$), higher FRAIL score ($p=0.001$), lower HGS ($p=0.002$), UGS ($p=0.01$) and MNA-SF scores ($p<0.001$). In multivariate analyses, the factors independently associated with presence of EAT-10 score >15 were FRAIL score and the number of drugs.

Conclusion: Dysphagia is associated with frailty irrespective to age, presence of neurodegenerative diseases, number of chronic diseases and drugs. To our knowledge, this is the largest series in the literature providing data on independent association of dysphagia with frailty. Frailty and dysphagia may reflect fall risk and osteoporotic fractures indirectly. These patients should be considered in terms of fall because of the increased risk of fracture in the frail elderly who have dysphagia.

P1026

INCIDENCE AND RELATED FACTORS FOR INPATIENT FALLS IN THE DEPARTMENT OF INTERNAL MEDICINE

O. Yilmaz¹, N. Guder², P. Kucukdagli¹, C. Kilic¹, G. Bahat¹, D. Erbas Sacar¹, M. A. Karan¹, S. Palanduz²

¹Istanbul Medical Faculty Internal Medicine Department Geriatrics Division, ²Istanbul Medical Faculty Internal Medicine Department, Istanbul, Turkey

Objective: Prevention of in-hospital falls and injuries are possible if enough awareness is constituted. Falls are common problems in hospital and associated with serious morbidity and mortality. There are many scales used in clinical practice to determine the factors that increase the risk of falling in inpatients and to take measures if possible. 'Itaki the fall Scale' developed for this purpose in Turkey and is a scale commonly used in hospitalized patients for risk assessment of falling The aim of this study was to assess the prevalence of fall-related factors in patients admitted to the Internal Medicine Clinic of the Istanbul Faculty of Medicine and the possible relationship with the clinics, and to determine whether the risk score in these patients predictive for falling by national scale of Itaki.

Method: We examined the results of Itaki scale risk scores, possible risk factors, total number of diseases, current medication and falling outcomes of >18 y patients hospitalized in Istanbul Medical Faculty Internal Medicine Clinics between 2012-2016.

Results: In a 5-y follow-up period, 5598 patients (women $n=2665$; men $n=2933$) and total 8337 hospitalizations were evaluated retrospectively. The mean age of all patients was 56.9 ± 17.7 and the mean age of the fallen patients was 59.5 ± 18 . It was observed that 2.2% ($n=121$) of the inpatients had fallen. In fallen patients, 6.6% ($n=8$) had a recurrent fall. The mean risk of falling in all patients was 10 ± 4.4 ; (9.8 ± 4.3 in males and 10.1 ± 4.5 in females). The risk of falling in women was higher ($p<0.005$). ($P<0.001$). The fall risk scores was significantly increased with age ($p<0.001$) The Itaki fall risk score in patients in the faller group was significantly higher ($p<0.001$) than the non-faller group ($p<0.001$). Most of the faller patients was observed in hematology clinic ($n=32$) Repeated falls was associated with bone marrow deficiency ($P<0.005$), such as MDS and aplastic anemia ($p<0.005$). ($p<0.005$, $p<0.005$, $p<0.001$, respectively).

Conclusion: In-hospital falls is a clinical problem requiring adequate awareness and related to significant morbidity and mortality. Fall risk identification of inpatients is important to take preventing measures, enhance the quality of patients life and preclude new comorbidities increasing mortality. According to our study, the Itaki Falling Risk Scale seems to be predictive for falling. According to our hospital's 5-y data, the average falling rate is 2.2%, which seems to be in accordance with the literature (0.5% to 3.5%). In addition, since there is no previous study in the literature studied Falling Risk Scale. our study is important to increase the awareness of this scale outside our country. Due to longness of hospitalization, falling rates was observed most common in the hematology clinic among all internal medicine clinics. According

to our study, female gender and older age was associated with more falls. High Itaki risk scores seems to be predictive for falls so that the more falls were seen in patients with higher risk score

P1027

FSH ROLE IN LOW BONE DENSITY IN PRIMARY OVARIAN INSUFFICIENCY

R. Abdala¹, M. B. Zanchetta, M. Guilligan²

¹IDIM (Instituto de Diagnostico e Investigaciones Metabolicas),

²Instituto de Diagnostico e Investigaciones Metabolicas, Buenos Aires, Argentina

Objective: Primary ovarian insufficiency (POI) is the cessation of menses before age 40 y, associated with estrogen decrease and gonadotropins increased. It is associated with loss bone mass, osteoporosis and risk of fracture. The FSH has been studied as the possible cause, although its full role is not clear. It could be related with activity and differentiation of the osteoclast.

Methods: retrospective analytical and descriptive study. POI patients with <5 y of amenorrhea were evaluated. Our aim was to evaluate the relationship between FSH, LH and E2 with BMD of LS and FN. 41 women with POI confirmed were included in this study. Women with secondary causes of low bone mass and with hormonal replacement therapy were exclude. For the statistical analysis the infostat statistic package was used, the relationship between the variables was determined by Pearson's linear correlation and the calculation of the coefficient of determination by linear regression.

Results: The values are expressed as means. The age of consultation was 36.4 y while the age of amenorrhea was 35 y. The FSH LH E2 and vitamin D values were 80.2 mIU/ml, 40.12 mIU/ml, 34.06 pg/ml and 23.6 ng/ml respectively. No differences were observed between vitamin D levels and seasons (21 ng/mL winter, 22 ng/mL autumn and 21 ng/mL spring). More than 50% of the patients had T-score <-1 in any of the 2 regions. Patients with low bone mass had higher FSH levels than patients with normal BMD 66 vs. 84 mIU/mL. A negative linear correlation was observed between FSH and BMD CL $r = -0.48$ and a coefficient of determination $r^2 = 0.24$ $p = 0.02$.

Conclusion: A negative correlation was observed between FSH levels and BMD. This demonstrates the influence of FSH and its receptors on osteoclastic activity and bone resorption. Maybe it explains a part of the physiopathogenesis of the low bone mass of these patients that apparently does not only depend on estradiol levels

P1028

SARCOPENIA AND TYPE 2 DIABETES MELLITUS

Y. Dionyssiotis¹, P. Athanassiou², J. Papathanasiou³, G. Trovas⁴, I. Kostoglou-Athanassiou⁵

¹University Hospital Ioannina, Ioannina, Greece, ²Rheumatology Department, General Hospital Aghios Pavlos, Thessaloniki, Greece, ³Department of Kinesitherapy, Faculty of Public Health, Medical University of Sofia, Sofia, Bulgaria, ⁴Laboratory for Research of the Musculoskeletal System, University of Athens, Kifissia, Greece, ⁵Endocrinology Department, General Hospital Asklepieio Voulas, Athens, Greece

Objective: The analysis of body composition for assessing the health and nutrition of the individual is a useful test. Diseases such as diabetes mellitus may be associated with adverse changes in body composition. Sarcopenia is characterized by a progressive and generalized loss of skeletal muscle mass and functionality. However, there is a lack of studies that examine the association of sarcopenia in patients with type 2 diabetes mellitus (T2DM).

Methods: In this retrospective, non-randomized study, we studied 35 individuals who visited endocrinological outpatient clinics, aged 20-80 years, to assess the presence of sarcopenia in T2DM in comparison with 16 controls. Sarcopenia was defined using the European Working Group on Sarcopenia in Elderly, EWGOSP that includes both muscle mass (skeletal muscle index, SMI) and muscle function/physical activity (walking speed as a measure of physical performance). Appendicular skeletal mass (ASM) and other parameters such as total fat and total muscle mass (in kg) were calculated. The skeletal muscle index (SMI) was calculated as ASM divided by the square of the body height in meters. Low muscle mass is defined as SMI <7.0 kg/m² in males and SMI <5.7 kg/m² in females. Low physical performance was defined as a walking speed of <0.8 m/s.

Results: The incidence of sarcopenia was significantly higher in patients with T2DM than in healthy subjects (27% vs. 20%, $p = 0.01$ for sarcopenia) and higher in elderly participants (70 y and over) vs. younger (40% vs. 12%, $p < 0.001$). Walking velocity was significantly lower in patients with T2DM than in controls men and women (1.02 ± 0.34 vs. 1.25 ± 0.15 , $p < 0.001$) and (1.01 ± 0.22 vs. 1.27 ± 0.12 , $p < 0.001$), respectively.

Conclusions: The prevalence of sarcopenia in patients with T2DM is moderate and gradually increases significantly in older men.

P1029

REAL-WORLD EFFECTIVENESS OF OSTEOPOROSIS (OP) TREATMENT IN THE OLDEST OLDO. E. Ström¹, R. Lauppe¹, O. Ljunggren², A. Spångéus³, G. Ortsäter¹, J. O'Kelly⁴, K. Åkesson⁵¹Quantify Research, Stockholm, Sweden, ²Uppsala university hospital, Uppsala, Sweden, ³Linköping University Hospital, Linköping, Sweden, ⁴Amgen Inc., Uxbridge, UK, ⁵Skåne University Hospital, Malmö, Sweden**Objectives:** To study real-world effectiveness of OP treatment in oldest old women (≥ 80 y) compared with younger women (65-79 y) in the clinical setting using Swedish health register data. A secondary objective was to estimate the health benefit of treatment in this elderly population.**Methods:** National registers and data from DXA machines were used to study effectiveness of all available OP treatments in women 60-79 and ≥ 80 y using three different Methods: 1) BMD change up to 8 y after treatment start; 2) fracture incidence where patients served as their own controls, comparing the first 3 months after treatment start (proxy for no treatment) with the subsequent 12 months; and 3) fracture incidence postfracture in women ≥ 80 y treated with either OP treatment or Ca/Vit-D monotherapy. QALYs from treating women who received Ca/Vit-D for 3 y after a fracture were estimated with the IOF reference model using effectiveness results from this study.**Results:** Analysis 1 (n=2161): Total hip BMD increased by up to 6.7% and 7.7% in women 60-79 and ≥ 80 years old, respectively. Increase in BMD was 1.1% per year in both age groups. Analysis 2 (n=116,581): Relative to the 3-month baseline, fracture incidence was lower in the subsequent 12 months of treatment. Incidence rate ratios were estimated at 0.65, 0.74, 0.29, and 0.81 for any, hip, vertebral and nonhip-nonvertebral fractures respectively ($p < 0.05$), with no statistical differences between age groups. Analysis 3 (n=25,805): Incidence over 24 months of any fracture in women ≥ 80 y on OP treatment (21%) was lower than women given Ca/vit-D (15%) (adjusted HR=0.78, $p < 0.05$). Treatment allocation was not random, with higher mortality (HR=2.0) and fewer prior vertebral fractures (14% vs. 32%), but more hip fractures (43% vs. 31%), in patients on Ca/vit-D. QALYs gained from treatment was estimated at 0.101, 0.046, 0.035 in women 65, 80, and 85 y.**Conclusions:** Treatment effect on fracture risk and BMD was similar in the oldest old and younger women. Treatment decisions after fracture in women ≥ 80 y appears to be influenced by health status and prior fracture type over other risk factors. Health benefits in older patients are attenuated by shorter life expectancy but still tangible and warrant treatment consideration.

P1030

MIDTERM RESULTS OF MINIMALLY INVASIVE ANTEROLATERAL THA USING A SHORT FEMORAL STEMT. Sasaki¹, T. Kodama²¹Department of Orthopedic Surgery, Tokyo Metropolitan Health and Medical Treatment Corporation Ohkubo Hospital, Tokyo, ²Department of Orthopedic Surgery, JCHO Saitama Medical Center, Saitama, Japan**Objective:** Short femoral stems became available in Japan in 2012. The objective of this study is to evaluate the outcome of THA using short femoral stem (Taperloc Micropasty) in Japanese patients.**Methods:** We retrospectively reviewed all 60 THA between July 2013 and December 2015 at our institute, and 32 THA (53%) were done with short femoral stems. A single orthopedic surgeon performed all THA procedures. The surgical approach was antero-lateral in the lateral position in all cases. The mean age of patients at the time of surgery was 66.7 y. The original diseases were 29 osteoarthritis and 3 osteonecrosis.**Results:** There was no revision, infection, deep vein thrombosis, nor dislocation. One patient had femoral fracture during the surgery, we had to switch the stem to the standard one in this case. The average surgery time was 108 min (range, 80-168 min); the average blood loss during surgery was 282 g (range, 95-720 g). The cup we used was Regenerex M2a Taper (Zimmer Biomet). Median cup size was 52 mm (range, 48-60 mm); median stem size was 8 and 9 (range, 4-13). The bearing surfaces were all ceramic on highly crosslinked polyethylene. Radiological findings showed stem subsidence (within 5 mm) in 2 patients; one had severe osteoporosis, while the other had leg length discrepancy.**Conclusions:** THA using a short femoral stem has satisfactory clinical and radiological results in Japanese patients.

P1031

SARCOPENIA AND RELATED FACTORS IN HOSPITALIZED PATIENTSO. Yilmaz¹, G. Bahat¹, P. Kucukdagli¹, D. Erbas Sacar¹, M. A. Karan¹¹Istanbul Medical Faculty Internal Medicine Department Geriatrics Division, Istanbul, Turkey**Objective:** Patients admitted to the hospital due to an acute illness may develop sarcopenia due to the acute illness itself or previous chronic diseases, decreased physical activity and nutrition and appetite problems. We aimed to investigate sarcopenia and associated factors in patients admitted to our inpatient clinic.**Methods:** Between April 2017–December 2017, prospectively with patients admitted to the study. Patients were evaluated with bioimpedance analysis (BIA), normal gait speed (NGS) and hand grip strength (HGS) within the first 48 h after admission and BIA, NGS and HGS measurements were repeated during discharging. Age, height, weight and gender data were also recorded.

Results: A total of 143 patients admitted to the study were included. The mean age of the patients was 62.3 ± 17.6 . The prevalence of sarcopenia was 24%. There was a significant difference the HGS (21.8 ± 11.4 at the time of admission and 23.9 ± 10.4 at the discharge) between admission and discharge. The difference between the mean values of the BIA muscle analysis (47 ± 9.2 on admission and 44.8 ± 7.4 on exit) between admission and discharge was found to be statistically significant ($p=0.02$). There was a significant positive correlation between hand grip strength and BIA muscle analysis at admission and discharge. This suggests that patients recovering from acute illness may have improved muscle function, although there is no increase in muscle mass.

Conclusion: In the study, it was determined that muscle function measured by HGS and NGS was better at the discharge. This suggests that recovery of acute disease can improve muscle function without changing muscle mass.

P1032

ANALYSIS OF FACTORS AFFECTING BONE MINERAL DENSITY IN AN INDIAN ADULT POPULATION

K. V. Acharya¹, S. Aier¹

¹Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India

Objective: As the age advances the plethora of chronic diseases does too. Comorbidities often adversely affect the management of osteoporosis. There is a need for detailed information on the comorbidities that may alter the course of osteoporosis by reducing the BMD. The T-scoring system is based on females, male remain under diagnosed or undertreated. We aimed to determine the factors affecting BMD.

Methods: The height and weight indexing was done at the time of visit, and the BMI calculated accordingly. Brief history (including comorbidities and time since menopause) taken and documented. The BMD was measured using Sunlight mini omni machine, which is an ultrasound based scan. The software (provided by the company) computed the T-score. All the patients were prescribed standard calcium and vitamin D preparation. And was followed up for a minimum of 6 weeks. Two consecutive follow-up was taken. The follow-up (response to treatment) was done on the basis of T-score.

Results: 542 cases were included of which 445 were females and 97 were males. The BMI calculated showed significant difference between the groups ($p=0.035$). There was significant difference between overweight and obese ($p=0.047$). On assessment of T-score on the first visit males had a mean of -1.25 ± 1.40 and the females had a mean of -1.66 ± 1.31 . On follow-up both the groups had a positive response to treatment. But males had a slower response to treatment ($p=0.005$). The menopausal women ($n=311$) had a negative relationship between BMD and duration of menopause. There was positive trend in the response to treatment in diabetics and hypertensives, but there was no statistical difference between cases with diabetes and hypertension and those without.

Conclusion: Contrary to the current literature, high BMI can be associated with lower levels of BMD. Response to treatment is slower in male in comparison to females. There is an inverse relationship between BMD and duration of menopause. There is a positive response to treatment even with patients with comorbidities.

P1033

PTH TYPE-1 RECEPTOR GENE EXPRESSION ANALYSIS DURING IN VITRO MYOGENESIS OF HUMAN SKELETAL MUSCLE SATELLITE CELLS

P. Sharma¹, C. Romagnoli¹, R. Zonefrati¹, S. Fabbri¹, E. Lucattelli², M. Innocenti³, L. Cianferotti¹, M. L. Brandi¹

¹Department of Experimental and Clinical Biomedical Sciences, University of Florence, ²Azienda Ospedaliero Universitaria Careggi, ³Department of Health Sciences, University of Florence, Firenze, Italy

Objective: The skeletal muscle function is severely impaired in hypoparathyroidism. The direct effect of PTH deficiency in skeletal muscle regeneration has not been fully elucidated. Satellite cells are the stem cells of the skeletal muscle, responsible for skeletal muscle regeneration. The aim of this work is to analyze the expression of PTH type-1 receptor (PTH1R) during *in vitro* myogenesis of human satellite cells (hSCs).

Methods: The hSCs were isolated from healthy human skeletal muscle biopsies and characterized by analysing the presence of gene and protein of the main nuclear transcription factor PAX7, by PCR and flow cytometry (FACS), respectively. To establish a model of *in vitro* myogenesis, hSCs were grown in differentiation medium for 7 days and we have characterized the myogenic phenotype, by verifying the presence of multinucleated cells by microscopy and the expression of terminal differentiation marker Myosin Heavy Chain (MHC) by qPCR. To detect variation in expression of PTH1R gene during *in vitro* myogenesis, the hSCs were grown for T0-3-6-9 days in myogenic differentiation medium and qPCR was performed.

Results: We have isolated and established the primary culture of hSCs. The results of PCR and FACS analysis in cultured hSCs have shown the presence of the gene and the protein (98%) of PAX7, respectively. We have confirmed the myogenic phenotype during differentiation by detection of multinucleated cells and by a significant increase in expression of MHC gene vs. control group T0 ($p<0.05$). The obtained results show the suitability of the *in vitro* myogenesis model, for further studies. The results of PTH1R gene expression analysis have shown a significant increase of this receptor after 6 days of *in vitro* myogenesis vs. control group T0 ($p<0.05$).

Conclusion: The results have shown the successful isolation and characterization of cultured hSCs and the establishment of an *in vitro* myogenesis model, used for the PTH1R expression analysis. The major finding of the studies is detection of increase in expression of the PTH1R gene during myogenic differentiation, suggesting the possible involvement of PTH1R in myopathies related to hypoparathyroidism.

Acknowledgement: Marie Skłodowska-Curie Innovative Training Networks CaSR Biomedicine, Project n.675228.

P1034

STATIN EFFECTS ON THE BMD FOR DYSLIPIDEMIC SMOKING PATIENTS VS. NONSMOKING ONES

C. F. Palici¹, P. L. Ciurea², A. F. Vreju³, A. E. Musetescu³, O.-R. Predescu⁴, C. Criveanu³

¹Department of Rheumatology County Emergency Hospital, ²Department Of Rheumatology, University of Medicine and Pharmacy of Craiova, ³Department Of Rheumatology, University Of Medicine and Pharmacy Of Craiova, ⁴Department of Rheumatology County Emergency Hospital Craiova, Craiova, Romania

Objective: The prevalence of osteoporosis depends on the risk of bone mass loss, as well on the risk factors that accelerate this process. Statins are widely used as lipid-lowering medicines; however other beneficial effects have been observed. some of which have an impact on the bone metabolism. This study aims at establishing if statins have the same beneficial effects on osteoporosis smoking patients.

Methods: There have been included in the study a number of 63 smoking patients (42 men, 21 women) with high values of total cholesterol and triglycerides. 17 of whom follow a statin cure. We have excluded subjects with autoimmune and inflammatory chronic diseases as well as those with corticotherapy and those who have followed of are currently following bisphosphonate treatment. The study was carried on between 2016-2018 and included patients aged between 53-68. For the patients' evaluation we have applied a survey referring to the number of smoked cigarettes a day, the duration of smoking and the dose of statins administered per day. For measuring BMD, we have used the DXA lumbar spine.

Results: In the studied groups, BMI averaged 20.7 kg/m², the duration of smoking was on average 10 y (±2), and the average number of cigarettes per day was 18. The doses of statins administered did not exceed 40 mg/d, the drugs used were atorvastatin (80%) and simvastatin (20%). BMD measurements have shown higher T-score values in the lumbar spine DXA for statin treated smoking patients as compared with the statin nontreated smoking patients considering the number of smoked cigarettes a day; thus, according to the number of cigarettes per day we recorded the following T-score values: for smokers of between 1-10 cigarettes/d (-0.21, - 0.71) with statins vs. (-0.7, -1.3) for those without statins, for those with 11-20 cigarettes/d a T-score (-0.43-0.98) with statins vs. (-0.87, -1.8) for those without treatment and for smokers of over 20 cigarettes/d a T-score (-0.49, -1.3) with statins vs. (-1.3, -2.1) for the nonstatin ones.

Conclusions: Our study has demonstrated the potential beneficial role of statin use in dyslipidemic patients, even in the presence of additional risk factors such as smoking, in increasing or maintaining the BMD, through stimulation of bone formation, biochemical mechanisms of cholesterol synthesis and osteoclastogenesis being similar.

P1035

OSTEOPOROTIC HIP FRACTURES IN THE WEST OF IRELAND: A SECULAR TREND ANALYSIS (2005-2015)

A. Ibrahim¹, C. Armstrong², F. Heaney², J. McCabe³, S. Kearns⁴, C. Murphy⁴, R. Singh¹, E. McCabe¹, J. J. Carey¹


¹Department of Medicine, National University of Ireland (Galway)/ Rheumatology Department, Galway University Hospitals, ²Rheumatology Department, Galway University Hospitals, ³Department of Medicine, National University of Ireland (Galway)/ Orthopaedic Department, Galway University Hospitals, ⁴Department of Medicine, National University of Ireland (Galway)/ Orthopaedic Department, Galway University Hospitals, Galway, Ireland

Objective: Review trends of demographics, hospital length of stay (LOS), inpatient and 1-y mortality rates (1YMR) among West of Ireland hip fragility fracture patients between 2005-2015.

Methods: A recent IOF report states Ireland has the 6th highest rate of hip fracture, but published data are limited. As part of our hospitals' FLS programme, The HOOFF Project, data were cleaned, validated and summarised for admissions from 2005-2015. Analytical statistical methods were used to summarize inpatient (IMR) and 1YMR using the one sample proportion statistical test. Subgroup analyses included age and gender specific mortality rates.

Results: 4792 patients were identified, and some missing data especially 2008 and 2009. 2899, 2307, 1705, and 1680 patients had validated data for analysis of demographics, LOS, inpatient and 1-y mortality respectively. Median age was 80 y (IQR: 80-87), and increased from 79 in 2005 to 83 in 2015. 71% were female (range: 61-79), and remained stable. Median inpatient length of stay was 13 d (IQR: 9-21); a slight decline was noted. IMR and 1YMR increased, average rates: 6.6% (95%CI: 5-8), and 16% (95%CI: 14-18) respectively.

Conclusions: Our analysis is in keeping with prior Irish studies. Despite an overall decline in LOS, IMR and 1YMR fragility remain high in Irish hip fracture patients.



P1036

TREATMENT OF AN ADULT PATIENT WITH HYPOPHOSPHATASIA WITH ASFOTASE ALFAS. H. Scharla¹, U. G. Lempert¹¹Practice Endocrinology & Diabetes, Bad Reichenhall, Germany

Hypophosphatasia is a rare condition in osteomalacia and is due to a mutation in the TNSALP (tissue-nonspecific alkaline phosphatase) gene. Clinically, it may present as osteoporosis. Therefore, if a patient with osteoporosis also shows low level of alkaline phosphatase the diagnosis of hypophosphatasia has to be considered. Therapy of hypophosphatasia is challenging. The following case report demonstrates the course of treatment in an adult patient.

Patient history: The female patient, born in 1963, presented herself for the first time in 2010. She suffered within a short time interval fractures of both ankles without adequate trauma. Fracture healing was delayed, so that the patient was immobilized and unable to walk. The patient was premenopausal. Risk factors for osteoporosis were a mild diabetes mellitus, lactose intolerance and familial osteoporosis disposition. DXA bone densitometry yielded a femoral neck T-score of -2.0. Differential diagnosis of hypophosphatasia was discarded despite low alkaline phosphatase levels because pyridoxal phosphate levels (vitamin B6) as an additional hypophosphatasia marker were normal. After approval by the health insurance company, osteoanabole treatment with teriparatide (in premenopausal women off label) was performed over 18 months. With this therapy, the ankle fractures healed and the patient was able to walk again. Consecutively, alendronate was given as sequential therapy. After 3 y of alendronate therapy the patient suffered fractures of the feet and was again immobilized. Therefore, differential diagnosis of hypophosphatasia was considered again and molecular genetic analysis was performed. Two mutations in the TNSALP -Gen were detected: c.787>C: T/C het and c.1565>C: T/C het, thus confirming the diagnosis of hypophosphatasia. An enzyme replacement therapy with Asfotase Alfa (Alexion Inc.) was started. No further fractures occurred, the patient remained mobile and her quality of life was markedly increased.

Conclusions: In patients with low levels of alkaline phosphatase and an unusual course of osteoporosis hypophosphatasia should be considered even if pyridoxal phosphate levels are normal. Nowadays, the confirmation of diagnosis of hypophosphatasia by molecular genetic analyzes is possible. Enzyme replacement therapy with Asfotase Alfa is successful in adult patients, too.

P1037

ULTRASOUND, DYNAMOMETRY AND ELASTOGRAPHY: A PILOT STUDY OF THE CLINICAL FEASIBILITY OF DIFFERENT DIAGNOSTIC TECHNIQUES IN THE MUSCLE EVALUATIONV. Bojnec¹, L. Sosic¹, B. Jesensek Papez¹, M. Kljaic Dujic¹¹University Medical Centre Maribor, Maribor, Slovenia

Objectives: This pilot study was to assess the clinical feasibility of the ultrasound in evaluating muscle function, if it is possible to obtain accurate information in everyday practice with an ultrasound and how the sonographically obtained parameters correlate with muscle strength assessed with a dynamometer.

Methods: Measurements were performed on a homogenous cohort of 9 healthy volunteers (4 of them female) aged 26-34 y (mean 29). Rectus femoris (RF) was evaluated with the ultrasound in its middle third during muscle relaxation and maximum voluntary isometric contraction of the knee extensors of the dominant leg. Parameters measured with the ultrasound with the knee at 90° angle and the patient seated over the edge of the table were: muscle thickness (MTr - relaxed, MTc - contracted), pennation angle (PAr - relaxed, PAc - contracted) and muscle cross-sectional area in the relaxed (CSAr) and contracted state (CSAc). RF muscle stiffness was evaluated with shear-wave elastography in the longitudinal plane in the relaxed and contracted muscle (SWEr - relaxed, SWEc - contracted). The isometric extensor knee torque was tested with isokinetic dynamometer at 90° knee angle.

Results: Statistically significant differences were found between MTr and MTc ($p=0.015$) as well as SWEr and SWEc ($p=0.008$). The differences between CSAr - CSAc and PAr - PAc were not statistically significant ($p=0.260$ and $p=0.671$, respectively). A strong correlation was found between extensor knee torque and SWEc using the Spearman correlation coefficient ($R=0.683$; $p=0.042$). Change in CSA and MT also statistically significantly correlated with knee extensor torque ($R=0.667$, $p=0.05$; $R=0.678$, $p=0.045$, respectively) but change in PA did not ($R=-0.294$, $p=0.442$).

Conclusion: The results of our pilot study show that SWE strongly correlates with muscle strength; however, the sample size was too small to draw firm conclusions. According to changes in muscle thickness and cross-sectional area of the muscle in our sample, these parameters could also predict muscle strength but this was not the case with changes in pennation angle in our study.

P1038

SEX HORMONES INTERACTION WITH TRABECULAR BONE SCORE AND MINERAL DENSITY IN MENV. Povoroznyuk¹, A. Musiienko¹¹D. F. Chebotarev Institute of Gerontology NAMS Ukraine, Kyiv, Ukraine

Objective: To evaluate the relationship of sex hormones with bone quality and mineral density in men.

Methods: We examined 72 men aged 40-87 y. Depending on their BMI, all the subjects were divided into 2 groups: Group I - 19 men with obesity whose BMI was ≥ 30 kg/m² (mean age

60.3±10.8 years, height – 177.3±5.8 cm, weight – 102.5±7.6 kg, BMI 32.6±1.9 kg/m²), and Group II – 53 men without obesity and BMI of <30 kg/m² (mean age – 60.5±13.5 y, height – 174.6±6.9 cm, weight – 79.2±10.3 kg, BMI – 25.9±2.4 kg/m²). The BMD of lumbar spine at the site L1-L4 and femoral neck were measured by DXA (Prodigy, GEHC Lunar, Madison, WI, USA). The TBS of L1-L4 was assessed by means of TBS iNsight® software installed on our DXA machine (product of Med-Imaps, Pessac, France). Total testosterone and SHBG were measured in all the subjects using an enzyme immunoassay method. The level of free testosterone was calculated using the ISSAM website calculator.

Results: In general, we found that obese men have a significantly higher BMD at the level of lumbar spine (group I – 1.402±0.232 g/cm², group II – 1.203±0.245 g/cm², F=9.08, p=0.004) and femoral neck (I group – 1.050±0.141 g/cm², group II – 0.925±0.164 g/cm², F=8.80, p=0.004) in comparison with men of no obesity. Significant differences between the groups for the TBS were not found. When assessing the hormonal status in men, it was revealed that obese men have a significantly lower total testosterone (group I – 12.55±3.48, group II – 17.64±6.10, F=11.74, p=0.001) and SHBG (group I – 43.03±20.27, group II – 58.15±25.39, F=5.46, p=0.02). However, the probable differences in the levels of free and bioavailable testosterone were not found. The level of SHBG increased with age and there was a probable negative correlation with BMD of femoral neck (r=-0.39; p<0.001). There was no significant correlation between total testosterone and BMD of femoral neck in men with a normal body weight (r=-0.19, p=0.2) and an obesity (r=0.02, p=0.93). Significant association between TBS and sex hormones in men was not revealed.

Conclusions: Men with obesity have a significantly lower total testosterone and SHBG, but their BMD is significantly higher than the one of men with a normal weight.

P1039

PREVALENCE OF GASTROINTESTINAL EFFECTS IN OSTEOPOROSIS PATIENTS WITH BISPHOSPHONATES

C. Criveanu¹, P. L. Ciurea¹, A. Rosu¹, A. F. Vreju¹, A. E. Musetescu¹, S. C. Dinescu¹, A. Barbulescu², C. S. Firulescu¹, B. A. Chisalau¹, C. F. Palici¹

¹Department of Rheumatology, University of Medicine and Pharmacy of Craiova, ²Department of Pharmacology, University of Medicine and Pharmacy of Craiova, Craiova, Romania

Objective: Bisphosphonates, such as alendronate, risedronate, ibandronate and zoledronate, are the leading drugs that have been used in the treatment of osteoporosis. Usually, they are well tolerated and safe, however side effects have been observed, such as gastrointestinal and kidney consequences, osteonecrosis of the jaw, atrial fibrillation and esophageal cancer. We have considered 40 women patients with osteoporosis following bisphosphonates treatment in which we assessed the prevalence of gastrointestinal effects.

Methods: 40 postmenopausal women prescribed with osteoporosis medication were enrolled in the study. The average age of the study-group was 62.5 y (58-73) and the average duration of the treatment lasted for a period between 3 months and 4 y.

Results: Of the total number of subjects, 8 (20%) patients presented at least one gastrointestinal side-effect. In 37,5% of the cases, heartburn and indigestion were the dominant consequences, 12.5% complained of vomiting and nausea, 25% had an aggravated pre-existent gastroesophageal reflux. 15% of the patients already had preexistent risk factors of gastrointestinal comorbidities such corticosteroids treatment, alcohol consumption or smoking.

Conclusions: Gastrointestinal side effects of oral bisphosphonate consumption are often observed in postmenopausal women with osteoporosis, but these effects can be minimized in the case of patients taking oral bisphosphonates on an empty stomach, with plain water, while remaining in an upright position without eating or drinking for at least 30-60 min.

P1040

GENDER FEATURES OF BONE MINERAL DENSITY IN THE UKRAINIAN PATIENTS WITH NEUROLOGICAL DISORDERS

V. Povoroznyuk¹, N. Grygorieva¹, M. Bystrytska¹

¹D. F. Chebotarev Institute of gerontology NAMS Ukraine, Kyiv, Ukraine

Objective: Stroke, Parkinson's disease and systemic osteoporosis are important age-related diseases which are associated with an increased disability. Each of them has own prevalence, risk factors and clinical features; however, their combination is life threatening for older age patients. Furthermore, gender is a common crucial risk factor for both pathologies. The aim of this research was to study the gender features of BMD and body composition indexes in patients with stroke and Parkinson's disease.

Methods: We performed a cross-sectional case-control research design and examined 295 patients aged 50-80 years old, who were divided into three groups: the first group – patients without PD and any other illnesses and conditions which may influence the bone state and turnover (control group, n=126 (66 women and 60 men)), the second group – patients with PD (n=85 (47 women and 38 men)), the third group - patients after stroke (n=84, 40 men and 44 women). BMD was measured using the DXA method (Prodigy, GEHC Lunar, Madison, WI, USA).

Result: Our study showed an increased incidence of osteoporosis in patients with neurological disorders in comparison with the control group. Males after stroke had a significantly lower total body, upper extremity and trunk BMDs compared to indexes of control group without any differences in lower extremity BMDs in contrast to the women after stroke who had lower BMDs of total body, trunk and upper/lower extremities in comparison with parameters of the control group. The results of our study indicated significant difference between the BMD values in PD patients compared to controls in women at lumbar spine, femoral

neck and proximal femur, distal radius and total body in contrast to men, who demonstrated lower BMD indexes of femoral neck, distal radius and total body compared with control group.

Conclusion: BMDs in patients with neurological disorders have their own national and gender particularities that should be taken into account during their assessment and development of rehabilitation programs.

P1041

CAN WE AVOID THE LOSS OF BONE MINERAL DENSITY ONE YEAR AFTER DENOSUMAB DISCONTINUATION? THE REOLAUS BONE PROJECT

G. Liebich¹, D. Stoll¹, E. Gonzalez-Rodriguez¹, D. Hans¹, O. Lamy¹, B. Aubry-Rozier¹

¹Lausanne University Hospital, Lausanne, Switzerland

Objectives: Denosumab discontinuation (DD) induces bone turnover markers (BTMs) increase, BMD decrease, and increased risk of spontaneous vertebral fractures. Prescribing a bisphosphonate after DD could avoid this rebound effect. The objective of the ReoLaus (Rebound Effect Observatory in Lausanne) Bone Project is to follow bone parameters after DD. We report the determinants associated to BMD loss 1 year after DD.

Methods: 170 patients are followed in ReoLaus. Patients with a BMD follow-up >1 y after DD with a standardized management were included. We defined as significant a lumbar spine BMD loss (Losers group) over 3.96% at one year after DD as compared with values at the end of the denosumab treatment 18 months after last injection.

Results: 71 postmenopausal women stopped denosumab after 7.7±2.2 injections: age 63.8±8.1 years, BMI 23.8±4.5, 0.96 prevalent fractures/patient, 8.45% previously exposed to corticoids, 22.54% to anti-aromatases. 17.25 months after last denosumab injection 30 patients were classified as Losers and 41 as Stable. At denosumab introduction Losers were younger (61.4±7.3 vs. 65.5±8.2 y, p=0.034) with higher sCTX level (644.7 vs. 474.1 ng/ml, p=0.005). The rate of BP given <2 y before denosumab was not different, but none of the Losers had received zoledronate vs. 12% of the Stable (p=0.047). Other pre-denosumab characteristics were not different. Number of denosumab injections, BTMs and BMD values were comparable in both groups during denosumab treatment. First BTMs values measured 7.5 months (median) after last denosumab injection and before bisphosphonates were not different (sCTX: Losers, 592 ng/ml; Stable, 379 ng/ml, p=0.06). At DD 59% received zoledronate, 24% alendronate, 3% others, and 14% nothing (p=0.39 between groups). BTMs 12.8 months post-BP were higher in Losers as compared to Stable (sCTX 537 vs. 336 ng/ml, p=0.009). Incidence of new fractures was low (0.18/patient) without between group's difference.

Conclusion: In our subcohort, being younger, having high BTMs and not having received zoledronate before denosumab introduction increases the risk of a BMD loss, even if a bisphosphonate is prescribed at DD. Our results support the use of denosumab after a bisphosphonate to restrain the BMD loss at its discontinuation.

P1042

RELATIONSHIP BETWEEN DIABETES AND HANDGRIP STRENGTH AMONG KOREANS AGED MORE THAN 20 YEARS

E. Y. Choj¹

¹Dankook University, Cheonan City, South Korea

Objective: Handgrip strength (HGS) is simple, quick, and inexpensive method to measure muscle strength. Few studies investigated the relationship between the diabetes and handgrip strength, but their results are conflicting. This study assessed the association of relative handgrip strength with the diabetes in the Korean adult population.

Methods: Data from 7644 Korean adults aged ≥20 y (3,377 men and 4,276 women) who participated Korea National Health and Nutrition Examination Survey (KNHANES) 2014 to 2015 were analyzed.

Results: The increasing quartiles of relative HGS (defined as the sum of both hands' HGS divided by BMI) were inversely associated with the risk of diabetes in both men and women (OR, 0.74; 95%CI, 0.65-0.85, vs. OR, 0.66; 95%CI, 0.55-0.79, respectively) after multivariable adjustment for age, smoking status, monthly alcohol consumption, regular aerobic exercise, and education level. On multivariable logistic regression analyses, participants with the highest relative HGS had a significant decrease in relative risk of diabetes, compared with those with the lowest relative HGS. The multivariable adjusted ORs (with 95%CI) for Diabetes in quartiles 1, 2, 3, and 4 were 1.00, 0.73 (0.51-1.04), 0.71 (0.48-1.05), and 0.34(0.21-0.55) in men and 1.00, 0.80 (0.55-1.17), 0.56 (0.34-0.93), and 0.22 (0.11-0.42) in women, respectively.

Conclusions: Relative HGS, which is which is an indicator of muscle strength, was inversely associated with the risk of diabetes in Korean adults. Top of form longitudinal studies are required to investigate the association between muscle strength and diabetes.

Bottom of Form

P1043

INTERNALIZATION OF THE SUBSTANCE P RECEPTOR FOLLOWING TREADMILL EXERCISE IN AN ANKLE JOINT MODEL OF OSTEOARTHRITIS

V. Bourassa¹, H. Deamond¹, A. Ribeiro-da-Silva¹

¹McGill University, Montreal, Canada

Objective: The internalization of the receptor for substance P, the neurokinin-1 receptor (NK-1r) on lamina I projection neurons of the spinal dorsal horn has been used as a marker of nociceptive responses. Lamina I is an important centre for the modulation and forwarding to the brain of pain-related information. Therefore, changes in the properties of lamina I projection neurons may be important for pain. Previous work from our lab has shown de novo expression of NK-1r on lamina I pyramidal neurons in both neuropathic pain and inflammatory arthritis models. In addition to this, we have shown that forced movement of an inflamed joint or intradermal injection of capsaicin leads to NK-1r internalization.

This project aims to investigate whether internalization of the receptor on NK-1r positive neurons will occur in a rat ankle joint model of osteoarthritis (OA) after a treadmill exercise.

Methods: Using rats of both sexes, OA was induced using an injection of the glycolytic inhibitor mono-iodoacetate (MIA) into the right tibio-talar joint. At 8 weeks post MIA injection, a time where OA-related pain is consistent and irreversible, animals were forced to run for 10 min at a speed of 15 m/min on a treadmill and immediately perfused. NK-1r internalization was then analyzed using immunocytochemistry and confocal microscopy.

Results: Qualitative analysis of our results shows that running MIA animals underwent significant internalization of the NK-1r as compared to nonrunning MIA animals and vehicle-injected controls. This indicates that movement during a treadmill exercise results in pain, which is of significance as pain during movement is a major complaint of osteoarthritis patients.

Acknowledgments: Valerie Bourassa is a recipient of a Louise and Alan Edwards Foundation Doctoral Studentships. Haley Deamond is a recipient of studentship from the McGill University Faculty of Medicine. This work was funded by Canadian Institutes of Health Research Operating Grant MOP-136903

P1044

IMPACT OF HYPOGONADISM ON BOTH CORTICAL AND TRABECULAR COMPARTMENTS AT THE PROXIMAL FEMUR USING 3D DXA MODELING APPROACH

M. R. Mascarenhas¹, R. Winzenrieth², I. Fortes³, A. Tirado⁴, J. Monteiro⁴, F. Sampaio⁵, A. P. Barbosa⁶

¹Endocrinology & Metabolic Diseases, Faculty Medicine, Fracture Osteoporosis Outpatient Clinic - Endocrinology, Diabetes & Metabolism Department, HSM-CHULN, EPE, Lisboa, Portugal, ²Galgo Medical SL, Barcelona, Spain, ³Fracturary Osteoporosis Outpatient Clinic - Endocrinology, Diabetes and Metabolism Department, Santa University Maria Hospital-CHULN, EPE, Lisbon, Portugal, ⁴Fracturary Osteoporosis Outpatient Clinic Orthopedics Department, HSM-CHULN, EPE, Lisbon, Portugal, ⁵Fracturary Osteoporosis Outpatient Clinic - Physical & Rehabilitation Department, HSM-CHULN, EPE, Lisbon, Portugal, ⁶Endocrinology & Metabolic Diseases, Faculty Medicine, Fracturary Osteoporosis Outpatient Clinic - Endocrinology, Diabetes & Metabolism Department, HSM-CHULN, EPE, Lisbon, Portugal

Objective: In men may lead to an overall bone loss and thus, one of the major causes of secondary osteoporosis in men. The aim of this study was to evaluate the effect of

hypogonadism on the cortical and femoral bones.

Methods: The BMD of the lumbar spine and hip by DXA (QDR4500 Acclaim and Discovery W, Hologic, USA) in 60 hypogonadal [(HYP+), mean age=51.4±16.2 years] and in 70 normal (HYP-) men; 3D DXA modeling was performed using a software algorithm (3D-SHAPER® v2.9, Galgo Medical, Spain) in order to derive QCT-like subject-specific 3D models from the hip DXA scans. The

following 3D measurements were extracted: the trabecular and cortical volumetric BMD (Trabecular/cortical vBMD), the cortical thickness (Cth) and the cortical surface BMD (Cortical sBMD) as well as neck cross-sectional moment of inertia (CSMI) and Z modulus. In addition, appendicular fat and lean mass were assessed using dedicated DXA acquisition. Adequate statistical tests were used depending on parameter normality distribution (statistical significance $P < 0.05$).

Results: The mean age, height, weight and BMI were identical. HYP+ had lower BMD at both lumbar spine ($p=0.003$) and total femur ($p=0.0001$), lower lean mass than HYP- (54 vs. 58 kg, $p < 0.01$), but higher fat content (26 vs. 21 kg, $p < 0.01$). Univariate 3D analysis showed impairment of both compartments in HYP+ (all $p < 0.01$). Among all 3D measurements, Cth was the best discriminant between HYP+ and HYP- ($p=0.0004$). Further, HYP+ had lower CSMI and Z modulus ($p < 0.0001$). Multivariate analysis showed that, among all studied parameters (2D and 3D), femoral neck CSMI was the best to discriminate the presence of hypogonadism ($p < 0.0001$) with an AUC of 0.72 [0.64-0.8].

Conclusion: In this first study, several bone parameters, measured either by conventional 2D DXA or using 3D DXA-based modeling, were impaired in hypogonadism. 3D analysis highlighted a more prominent negative effect of hypogonadism on the cortical thickness and CSMI. These results suggest a possible major involvement of the cortical compartment in such condition and a bone more likely to sustain a fracture.

P1045

MUSCLE ASSESSMENT IN PATIENTS WITH ANKYLOSING SPONDYLITIS: ARE THEY AT RISK OF SARCOPENIA?

O.-E. Branea¹, O. Nechifor¹, M. Copotioiu¹

¹University of Medicine, Pharmacy, Sciences and Technology of Târgu Mureș, Târgu Mureș, Romania

Objective: Ankylosing spondylitis (AS) is an impairing chronic condition associated with pain and rigidity. The main aim of this study was to assess sarcopenia and muscular inflammation in progress in this pathology.

Methods: A prospective noninterventional study was performed on 73 patients. Definition of European Working Group on Sarcopenia in Older People, classifying patients with sarcopenia was used. Ultrasound examinations (US) of scapulo-humeral and coxo-femoral joints assessed muscular inflammation. Moreover, muscle strength was estimated by using handgrip dynamometer test (low muscle strength < 20 kg in women and < 30 kg in men) [1] and muscle mass as in Landi's formula: $MAC = \text{mid-arm circumference} - (3.14 \times \text{triceps skinfold thickness})$ (low muscle mass as $MAC < 21.1$ cm in men and $MAC < 19.2$ cm in women) [2].

Results: Two-thirds were men, diagnosed in their early 30s, with more than 15% having family antecedents and hip replacement surgery. Only 60 patients were fully examined. The majority of them was hyperstenic (BMI=28.44 kg/m²), meanwhile more than half of them hypertensive and 1/3 had diabetes. Inflammatory markers were elevated in more than 15% patients, respectively

typical joints alterations were present (40% osteophytes, 23% entesophytes, 19% calcifications). MAC proved that more than 15% of patients have a low muscle mass and dynamometer tests pointed out that more than 25% of men and 75% of women had low muscle strength, both decreasing by age. An association between visual analogue scale and muscular strength was observed ($p=0.003$; $p=0.002$). Also, US could play a role in diagnosing protocol of sarcopenia as associations between US and MAC (for osteophytes $p=0.015$), respectively US and muscle strength (for entesophytes $p=0.005$) were proven.

Conclusion: The muscle performance of the patients with AS is severely affected, particularly in women. A muscle strength decrease, by ageing could have a toll on life quality.

References:

- [1] Cruz-Jentoft AJ et al. Age Ageing 2010;39:412.
[2] Landi F et al. Clin Nutr 2012;31:652.

P1046

MYELITIS AS A BEHCET DISEASE MANIFESTATION

C. D. Parvanescu¹, B. A. Chisalau¹, S. C. Firulescu¹, S. C. Dinescu¹, R. M. Dumitrascu², C. Criveanu¹, A. L. Barbulescu¹, A. Rosu¹, P. L. Ciurea¹, L. Streba³, A. F. Vreju¹, A. E. Musetescu¹

¹Rheumatology Department, University of Medicine and Pharmacy Craiova, ²Rheumatology Department, Emergency County Hospital Craiova, ³University of Medicine and Pharmacy, Craiova, Romania

Objective: Behcet disease is a multisystemic vasculitis, of unknown cause, that typically runs a relapsing and remitting course, with recurrent bipolar aphthosis and eye, skin, nerve, vessel or joint involvement. Central nervous system is involved in <5% of the cases, especially in men. Most frequently involved segment is cerebral trunk with pyramidal tracts, III, IV and VI cranial nerves.

Methods: We present the case of a 50 yo male, with the onset of the disease 10 y before presentation. He was then suspect for having a seronegative spondyloarthritis on inflammatory back pain, MRI, with bilateral sacroiliac bones STIR hypersignal, but with negative result for HLA-B27) and he started treatment with 2 g of sulphasalazine, for 2 y, with no improvement and more than that, he started to feel numbness in hands and feet. He was referred to a neurologist, that recommended electromyography, and cervical MRI that showed myelitis at the level of C3-T9. Laboratory tests revealed ANA negative, rheumatoid factor absent, HLA B51-positiv, HLA DR 17-positiv.

Results: Based on HLA B51 positivity, nervous system involvement, mouth and genital aphthosis and specific eye involvement, he was diagnosed with Behcet disease and the treatment with cyclophosphamide 600 mg per months, for 6 months, was started, followed by Azathioprine with a good outcome. Later assessment included MRI of the lumbar spine and sacroiliac joints, that showed no bone marrow involvement progression.

Conclusion: Imaging methods, as MRI a musculoskeletal ultrasonography gained more and more importance lately, due to quick and accurate diagnosis and to the possibility of dynamic evaluation of the patient's response to treatment.

P1047

THE ROLE OF MUSCULOSKELETAL ULTRASONOGRAPHY IN THE EVALUATION OF CONJUNCTIVE TISSUE DISEASES PATIENTS WITH HAND TENDONS INVOLVEMENT

R. M. Dumitrascu¹, S. C. Dinescu², S. C. Firulescu², C. D. Parvanescu², B. A. Chisalau², D. Popa³, C. Criveanu², A. L. Barbulescu², A. E. Musetescu², A. Rosu², P. L. Ciurea², A. F. Vreju²


¹Rheumatology Department, Emergency County Hospital Craiova, ²Rheumatology Department, University of Medicine and Pharmacy Craiova, ³Plastic Surgery Department, University of Medicine and Pharmacy Craiova, Craiova, Romania

Infections are frequent in patients with autoimmune diseases, sometimes promoting autoinflammatory process and sometimes secondary to immune system dysfunction or to immunosuppressant therapies. Our aim was to prove the role of musculoskeletal ultrasonography in evaluation of conjunctive tissue diseases patients with hand tendons involvement

Methods: We present the case of a female 40 yo patient, former smoker, known with an overlap syndrome, SLE with hematologic, joint, kidney and serositis involvement and systemic scleroderma, with limited skin involvement. Autoimmune status was confirmed by the presence of anti dsDNA, anti-Sm, antihistone, antiribosomal p protein, anti-SCL 70 antibodies. At admission time, the patient status was influenced, with specific facies, digital ulcers, telangiectasia on the face and thorax, and active/late capillaroscopic pattern. Blood tests showed increased inflammation markers and complement consumption. Kidney tests showed a proteinuria of 1317.50 mg/24h. Computer tomography (CT) of the thorax initially revealed basal opacity, that was interpreted as bacterial pneumonia and was treated with macrolide and quinolones antibiotics, with good outcome. Control CT showed basal and apical fibrotic lesions. The patient remained on 20 mg/d prednisone, 50 mg/d azathioprine and peripheric vasodilators and after 2 months, she presented with no skin ulcers, clinical status improved, except pain, fusiform swelling, flexed resting position and local celsian signs present at the level of the third right finger.

Results: Ultrasonography of the hand showed dactylitis of the 3rd right finger, with tenosynovitis of the flexor tendons, synovitis of the metacarpophalangeal (MCP) and proximal interphalangeal joints. Despite empirical antibiotic treatment, with a 2nd generation cephalosporin, there was no improvement in the finger symptoms after 2 weeks and the patient was sent to Plastic surgery Department. The infectious tenosynovitis was confirmed and after surgical drainage was tried with no results, finger amputation was decided, at the level of MCP joint with respect to the systemic scleroderma disease, with favorable outcome.

Conclusion: Ultrasonography permitted fast and accurate diagnosis of the tendon involvement and although tenosynovitis is a common finding in patients with systemic scleroderma, the glucocorticoids and immunosuppressant therapies favored infection at the tendon sheath level.



P1048
CASE REPORT: TIBIAL NERVE DAMAGE DUE TO BAKER'S CYST ASPIRATION

M. Sahin¹

¹Istanbul Medipol University/ School of Medicine/ Department of Orthopedics and Traumatology, Istanbul, Turkey

Objectives: Baker's cyst is one of the most common masses of popliteal fossa, which is caused by swelling of the gastrocnemius-semimembranosus bursa filled with joint fluid. Although most Baker cysts commonly present as an asymptomatic mass, they

may cause clinical problems such as thrombophlebitis, compartment syndrome, and entrapment neuropathy. Among those, neuropathy can occur either from the cyst itself or after cyst rupture. Treatment options include medication, cyst aspiration and surgical removal.

Methods: We introduce a case of tibial nerve injury due to aspiration of Baker's cyst. For this case report, we tested MRI of knee and needle EMG.

Results: A 53 years old man presented with pain, burning and numbness started from the left popliteal region radiating down through the posterior thigh, calf and dorsolateral of foot. These symptoms had been started suddenly about 1 month before the cyst aspirated by the doctor. Hypoesthesia was seen in the dorsolateral of the foot and no motor losses. MRI revealed a baker's cyst of approximately 2.8 cm away from the tibial nerve with a diameter of 2 cm. Knee joint was in a normal form. The EMG revealed that the motor parts of tibial and sural nerve were not affected, sensation branches were affected. Physical therapy and rehabilitation started Gabapentin and vitamin B complex were added to the treatment. At the end of the 4th month clinical improvement was observed.

Conclusions: Although Baker's cyst is frequently seen as asymptomatic, patients with local pain, tenderness and neural compression due to rupture of baker cysts have been reported in the literature. No cases were reported due to aspiration. In our patient, it was not decided whether the damage in the nerve was due to the contact of the needle to the nerve during aspiration or the chemical reaction due to the rupture of the cyst during that time. As a result, aspiration of baker's cyst should not be preferred because of the possibility of recurrence and complication. We believe that aspiration should be performed on the threshold of USG to avoid complications in cases where the patient is not suitable for surgery and cannot respond to conservative treatment in rare cases.

P1049
RISK FACTORS ASSOCIATED WITH LOW BONE DENSITY AND FRACTURE RISK IN ADULTS WITH INTELLECTUAL DISABILITY

M. -H. Hsieh¹, J.-T. Chien², H.-R. Chang³

¹Fracture Liaison Service, Department of Orthopedics, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Institute of Medicine, Chung Shan Medical University, Chia-Yi, ²Department of Orthopedics, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, ³Institute of Medicine, Ching Shang Medical University, Taichung, Taiwan

Objectives: The population of people with intellectual disabilities (ID) is underprivileged and their health needs impact on primary and secondary healthcare specialties. One important aspect of their physical health is bone health as people with ID have increased risk factors associated with osteoporosis. It has been identified that this population has an increased prevalence of low BMD and osteoporosis. The aim of this study was screening of the risk factors.

Methods: This study was conducted in a national education and nursing institution in Yunlin, Taiwan. 200 female adults with moderate to severe ID underwent blood test, BMD and detailed questionnaires. Their basic characters were recorded. Statistical analyses used to evaluate the association included chi-squared tests, ANOVA, and logistic regression. $p < 0.05$ was considered as significant.

Results: Of these participants, 81% had abnormal BMD, and 43% met the criteria for osteoporosis. After adjusting for potential confounding variables, the determinant risk factors for low BMD were age ($\beta = 0.242, p = 0.001$), lower body weight ($\beta = 0.326, p = 0.016$), menopause ($\beta = 0.239, p = 0.001$) and the scale of falling risk ($\beta = 0.121, p = 0.04$). The risk factors for high fracture risk were age ($\beta = 0.105, p < 0.001$), level of ambulation ($\beta = 1.777, p = 0.009$), and without osteoporosis medication ($\beta = 1.925, p < 0.001$). Though the majority of participants with osteoporosis were under medication treatment, only 29% of participants with osteopenia had received treatment.

Conclusion: This study identified a high prevalence of low BMD among adults with ID, even they were in pre-menopause status. We conclude that we should be screening for the risk factors associated with low BMD in adults with ID. These ID adults who are at high risk of fracture need early treatment to prevent morbidity and improve their quality of life.

P1050

OSTEOCALCIN SERUM LEVEL IN PATIENTS WITH NONTRAUMATIC AVASCULAR NECROSIS (AVN) OF THE FEMORAL HEAD

E. Rapushi¹, T. Backa¹, A. Zoto¹, L. Nuhaj¹, E. Zicishti¹, V. Salko¹, I. Xhemali², I. Kola¹

¹UHC "Mother Theresa", Department of Internal Medicine, Rheumatology Service, ²German Polyclinic, Tirana, Albania

Objective: Osteocalcin is a protein (noncollagenous) that can be found in the bones extracellular matrix, as well as in the circulating blood serum. It is produced by osteoblasts and chondrocytes and stimulated by vitamin K. This protein is a marker of bone formation and turnover. Nontraumatic AVN is a situation that develops during bone cells blood flow interruption. Etiology and pathophysiology of nontraumatic AVN has multiple factors. We aimed in evaluating osteocalcin serum level in patients with nontraumatic AVN of the femoral head in different stages.

Methods: We examined 84 patients diagnosed with non-traumatic AVN of the femoral head (48 males, aged 34 ± 6.7 years old and 36 females, aged 29 ± 5.4 years old). AVN diagnosis was established after performing hips MRI. To all the patients osteocalcin serum level was measured using the ELISA-OSTEO kit (13-46 ng/ml). Patients were divided in three groups according to the MRI findings: AVN stage I, II-III, IV (based on AVN classification according to Ficat and Arlet).

Results: Osteocalcin serum levels in the three groups of patients in our study represented significant differences. Patients with AVN stage I (20 patients), osteocalcin serum level was low 6 ± 1.09 ng/ml; in the second group with AVN stage II-III (36 patients) os-

teocalcin serum level was elevated 43 ± 6.4 ng/ml and in the third group with 28 patients osteocalcin serum level was low or near the normal values 13.3 ± 4.5 ng/ml. If we compare the osteocalcin serum levels between the patients with AVN group one and two we can see the high serum levels of osteocalcin indicating that in stage II and III of AVN, bone remodeling is remarkably significant ($p < 0.001$); in the third group, AVN stage IV, bone remodeling lowers its intensity and osteocalcin serum level tends to be closer to the normal values.

Conclusion: This study results emphasize the role of osteocalcin in non-traumatic AVN. In patients with non-traumatic AVN of the femoral head stage II and III where the bone remodeling process is remarkably significant, the osteocalcin serum level is higher; in patients stage I osteocalcin serum level is lower and it can probably be considered a risk factor for AVN but this issue requires another detailed study; in patients with AVN stage IV where bone remodeling is expected to be lower, osteocalcin serum levels are close to normal.

P1051

INCIDENT FRACTURE AND OSTEOPOROSIS RISK IN MIDDLE-AGED WOMEN WITH TYPE 1 DIABETES: A 15-YEAR LONGITUDINAL STUDY

E. P. Thong¹, F. Milat², A. E. Joham¹, S. Ranasinha¹, P. R. Ebeling³, G. D. Mishra⁴, H. J. Teede¹

¹Monash Centre for Health Research and Implementation, Monash University, Clayton, ²Hudson Institute of Medical Research, Clayton, ³Department of Medicine, School of Clinical Sciences, Monash University, Clayton, ⁴Centre for Longitudinal and Life Course Research, School of Public Health, University of Queensland, St Lucia, Australia

Objectives: To determine the relative risk of incident fracture and osteoporosis diagnoses in middle-aged women with Type 1 diabetes (T1D), compared to age-matched controls, and to examine baseline risk factors for fracture and osteoporosis in this group.

Methods: Longitudinal observational study using data from the Australian Longitudinal Study in Women's Health, of 106 women with self-reported T1D and 11,761 age-matched controls. Women were followed for up to 15 y over 6 questionnaires. The main outcomes of interest were self-reported incident fracture and osteoporosis diagnoses. Women with type 2 diabetes were excluded from the study.

Results: No differences between mean age at baseline (47.4 ± 1.5 vs. 47.1 ± 1.5 years, $p = 0.08$) or BMI (25.4 ± 5.0 vs. 25.8 ± 5.0 kg/m², $p = 0.57$) were observed between women with T1D or controls. Mean age at menopause was lower (47.7 ± 3.4 vs. 50.3 ± 3.7 y, $p < 0.001$) in women with T1D. 1180 fractures and 1013 new diagnoses of osteoporosis occurred in the control group, compared to 16 fractures and 18 new diagnoses of osteoporosis in the group with T1D, over 155,328 person-years of follow-up. Incidence rate ratios for fracture and osteoporosis in women with type 1 diabetes vs. controls, were 1.44 (95%CI 0.76 – 2.47, $p = 0.21$) and 2.02 (95%CI 1.17 – 3.24, $p = 0.001$), respectively. The mean time to fracture (7.2 ± 4.3 vs. 9.8 ± 4.3 years, $p = 0.03$) and new osteopo-

rosis diagnoses (6.7 ± 4.6 vs. 8.8 ± 4.0 years, $p=0.02$) was shorter in women with T1D. Among women with T1D, those with a new diagnosis of osteoporosis had lower BMI (22.9 ± 2.7 vs. 26.0 ± 5.2 kg/m², $p=0.04$) and underwent menopause earlier (45.8 ± 4.2 vs. 48.1 ± 3.1 years, $p=0.04$). No differences in characteristics were observed between women with T1D with or without incident fracture.

Conclusions: The incidence rate of self-reported osteoporosis is two-fold greater in women with T1D compared to controls. While incident fracture rates were not different, time to fracture was shorter in women with T1D. Women with T1D reach menopause at a younger age than controls, and the perimenopausal period provides an important opportunity for bone health assessment in this cohort.

P1052

ADDRESSING PITFALLS AND CHALLENGES IN THE EVALUATION AND MANAGEMENT OF BONE FRAGILITY IN FD/MAS

N. A. T. Hamdy¹

¹Leiden University Medical Center, Department of Medicine, Division of Endocrinology & Center for Bone Quality, Leiden, The Netherlands

Objective: To address pitfalls and challenges encountered in the evaluation and management of bone fragility in FD/MAS.

Methods: Reviewing factors contributing to poor bone quality, decreased bone strength and increased bone fragility in FD/MAS and addressing difficulties and controversies faced by multidisciplinary teams of healthcare professionals engaged in its evaluation and management.

Results: Skeletal manifestations of FD/MAS are due to post-somatic activating *GNSa* mutations in cells of the osteogenic lineage, leading to replacement of normal bone by disorganized and poorly mineralized fibro-osseous tissue at one or more skeletal site. Local overexpression of RANKL and IL-6 increases the number and activity of osteoclasts, FGF23-mediated renal phosphate wasting and hypophosphatemia further disturb mineralisation, and FD-associated endocrinopathies may worsen bone remodeling. All these factors may variably decrease bone strength by locally disrupting bone microarchitecture and mineralisation, leading to increased morbidity due to pain, deformities and fractures, curtailing patient autonomy and impairing quality of life. There are still controversies on how best to evaluate bone fragility in FD/MAS. The value of bone markers and of current imaging techniques in evaluating determinants of bone fragility such as FD activity, the relationship of these markers with pain, and their value in the evaluation of clinical outcome of treatment remain to be established. Whereas it is essential to correct vitamin deficiency, hypophosphatemia and hyperfunctioning endocrinopathies in all cases, a prerequisite before considering treatment with antiresorptives, opinions are still divided on the beneficial effects of bisphosphonates in FD/MAS and data about other antiresorptives are scarce in this disorder.

Conclusion: Identifying difficulties, controversies and remaining knowledge gaps in the complex evaluation and management of the patient with FD/MAS, has led our FD/MAS international consortium to develop consensus best clinical practice guidelines, which are currently being finalised, aiming at informing and improving care for all patients with this complex and fascinating rare bone disease.

Acknowledgments: Members of the FD/MAS International consortium and involved PAGs

P1053

OUTCOMES OF TOTAL HIP REPLACEMENT IN PATIENTS WITH ANKYLOSIS OF THE HIP JOINT

D. Markov¹, K. Zvereva¹, P. Chernov¹

¹Saratov State Medical University, Saratov, Russia

Objective: Ankylosis of the hip joint is one of the most difficult pathologies of the hip joint which leads to a significant reduction of the patient's life quality. The most recognized method of treatment is a total hip replacement (THR). The aim of the study was to evaluate the results of total arthroplasty in patients with ankylosis of the hip joint.

Methods. We analyzed the results of total hip replacement in 65 patients with ankylosis of the hip joint who were operated from January 1, 2012 to December 31, 2017. Gender distribution: 28 women and 37 men. The mean age of patients was 67 ± 5.9 y. Surgical approach - anterolateral. All patients were implanted of Double Mobility Cup System. Surgery was performed under endotracheal anesthesia in combination with neuroleptanalgesia. All patients received standard treatment in the postoperative period. Results of surgical treatment were evaluated using a Harris Hip Score (HHS), Oxford Hip Score (OHS) and a VAS scale after 1 y. Statistical processing of data was carried out using Microsoft Excel AtteStat 12.0.5.

Results: The average values on the HHS scale were 71 ± 3.6 points. The distribution of outcomes was 34% (22 patients) poor, 47% (31 patient) fair, 19% (12 patients) good. Excellent results were not obtained in any patient. The average value on the OHS scale was 29 ± 2.7 points. A full recovery of the hip joint function in any case was not noted. The average value on the VAS scale was 4.9 ± 1.1 points. The most common complications were recurrent dislocations of the prosthetic head, aseptic loosening of the components.

Conclusion: THR associated with a high percentage of poor results and complications in patients with ankylosis of the hip joint. It could be treat using THR only if muscle component of gluteal region and lower extremity is in action, and ankylosis is not too much old.

P1054

RELATIONSHIP BETWEEN OSTEOPOROSIS VERTEBRAL COMPRESSION FRACTURE PATIENTS AND THE RISK OF VENOUS THROMBOEMBOLISM: A NATIONWIDE, POPULATION-BASED CASE-CONTROL STUDY

W.-H. Wang¹

¹Changhua Christian Hospital Orthopaedic Department/ Kaohsiung Medical University Medical Department, Taichung, Taiwan

Objective: Percutaneous vertebroplasty (PV) is a therapeutic procedure for vertebral compression fracture. Venous thromboembolisms (VTE) have been reported as procedure complications. The relationship between PV and the risk of VTE is unclear.

Methods: We conducted a retrospective, population-based case-control study using the National Health Insurance Research Database (NHIRD) to investigate the relationship between vertebral compression fracture patients receiving PV and risk of VTE.

We identified 1639 patients with receiving PV and 14,887 subjects without receiving PV from 2000-2013. After development of 1:1 propensity score-matched cohort study, 1639 PV patients and 1639 control patients were followed up for more than 12 y. Using the application of PV as the exposure factor, cause-specified Cox's proportional hazard model was performed to examine the association between PV and VTE. We used three different adjusted models, including covariate adjustment using the propensity score, traditional measured confounders and confounder selection model using backward elimination procedure.

Results: The incidence and risk of VTE between patients receiving PV and matched participants were insignificantly different after propensity matching and using three different adjusted models. In the subgroup analyses, age, sex, comorbidity and cancer were not to increase the risk of VTE between the two cohorts. However, vertebral compression fracture patients with the history of heart failure, arrhythmia, cancer, with using antihypertension medications, and aged were significantly increase the risk of VTE regardless receiving PV or not, and patients receiving analgesic drugs decreased the risk of VTE.

Table 1: Demographic

	Before propensity score matching			After propensity score matching		
	Percutaneous vertebroplasty=0	Percutaneous vertebroplasty=1	P-value	Percutaneous vertebroplasty=0	Percutaneous vertebroplasty=1	P-value
	N=14887	N=1639		N=1639	N=1639	
Age	65.97±16.86	74.99±10.38	<0.001	75.39±10.65	74.99±10.38	0.277
Gender	5235(35.16%)	416(25.38%)	<0.001	409(24.95%)	416(25.38%)	0.778
Geographic location						
Northern Taiwan	6167(41.43%)	659(40.21%)	0.356	661(40.33%)	659(40.21%)	0.972
Central Taiwan	2885(19.38%)	313(19.1%)	<0.001	325(19.83%)	313(19.1%)	0.628
Southern Taiwan	5407(36.32%)	626(38.19%)	0.038	608(37.1%)	626(38.19%)	0.540
Eastern Taiwan and Islands	428(2.87%)	41(2.5%)	0.047	45(2.75%)	41(2.5%)	0.743
Monthly Income	12253.7±11731.64	11054.81±9944.2	<0.001	10862.96±11287.37	11054.81±9944.2	0.606
Charlson Comorbidity Index	2.51±2.4	3.54±2.66	<0.001	3.47±2.63	3.54±2.66	0.4633
Hypertension	7093(47.65%)	1120(68.33%)	<0.001	1145(69.86%)	1120(68.33%)	0.345
Hyperlipidemia	2704(18.16%)	427(26.05%)	<0.001	415(25.32%)	427(26.05%)	0.631
Diabetes Mellitus	3105(20.86%)	508(30.99%)	<0.001	502(30.63%)	508(30.99%)	0.820
Coronary Artery Disease	3043(20.44%)	474(28.92%)	<0.001	474(28.92%)	474(28.92%)	1.000
Congestive Heart Failure	1346(9.04%)	277(16.9%)	<0.001	247(15.07%)	277(16.9%)	0.153
Chronic kidney disease	1318(8.85%)	250(15.25%)	<0.001	233(14.22%)	250(15.25%)	0.402
Stroke	2264(15.21%)	371(22.64%)	<0.001	382(23.31%)	371(22.64%)	0.648
COPD	3001(20.16%)	463(28.25%)	<0.001	460(28.07%)	463(28.25%)	0.907
PAOD	252(1.69%)	38(2.32%)	0.067	36(2.2%)	38(2.32%)	0.814
Dysarrhythmia	1507(10.12%)	284(17.33%)	<0.001	258(15.74%)	284(17.33%)	0.222

Figure 1: Kaplan-Meier estimation for PE/DVT risk among patients with (solid line) and without (dashed line) percutaneous vertebroplasty before and after propensity score matching

Figure 1: Kaplan-Meier estimation for PE/DVT risk among patients with (solid line) and without (dashed line) percutaneous vertebroplasty before and after propensity score matching




Figure 1: Kaplan-Meier estimation for PE/DVT risk among patients with (solid line) and without (dashed line) percutaneous vertebroplasty before and after propensity score matching




Table 2. Incidence and risk of PE/DVT in patients with percutaneous vertebroplasty and without percutaneous vertebroplasty or matched participants.

Table 2. Incidence and risk of PE/DVT in patients with percutaneous vertebroplasty and without percutaneous vertebroplasty or matched participants.

	Events	PY	Incidence ^a	Model 1 ^b		Model 2 ^c		Model 3 ^d		Model 4 ^e	
				cHR (95% CI)	P Value	aHR (95% CI)	P Value	aHR (95% CI)	P Value	aHR (95% CI)	P Value
Before propensity score matching											
Control cohort	204	77136	2.64 (2.28,3.01)	Reference	-	Reference	-	Reference	-	Reference	-
Percutaneous vertebroplasty	23	4502	5.11 (3.02,7.20)	1.684 (1.09,2.60)	0.0191	1.079 (0.70,1.68)	0.734	1.088 (0.69,1.72)	0.7196	1.084 (0.68,1.72)	0.7321
After propensity score matching											
Control cohort	28	4411	6.35 (4.00,8.7)	Reference	-	Reference	-	Reference	-	Reference	-
Percutaneous vertebroplasty	23	4502	5.11 (3.02,7.20)	0.804 (0.46,1.40)	0.4379	0.775 (0.45,1.35)	0.3678	0.807 (0.47,1.40)	0.4455	0.798 (0.46,1.40)	0.4301

Abbreviations: aHR, adjusted hazard ratio; cHR, crude hazard ratio; CI, confidence interval; CKD, chronic kidney disease; PY, person-years.

^aIncidence rate, per 1,000 person-years.

^bModel 1: cHR for crude hazard ratio.

^cModel 2: Adjusted for all variables listed in Table 1 and Cox regression model with backward elimination procedure was carried out.

^dModel 3: Adjusted for propensity score.

^eModel 4: Adjusted for propensity score and percutaneous vertebroplasty was performed in time-varying variable.

Table 3. Subgroup analyses of the risk of CKD in patients with percutaneous vertebroplasty and matched participants.

Table 3. Subgroup analyses of the risk of CKD in patients with percutaneous vertebroplasty and matched participants.

Subgroup	Subjects without percutaneous vertebroplasty		Subjects with percutaneous vertebroplasty		Compared to control group					
	n	Event	n	Event	aHR (95% CI) [§]	P-value	P _{interaction}	aHR (95% CI) [‡]	P-value	P _{interaction}
Before propensity score matching										
Gender							0.4616			0.9190
Female	9652	140	1223	18	1.19(0.718,1.973)	0.5005		1.136(0.674,1.915)	0.6314	
Male	5235	64	416	5	0.927(0.362,2.376)	0.8751		0.931(0.354,2.447)	0.884	
Age, years							0.6754			0.4158
<75	9420	98	665	7	1.165(0.534,2.542)	0.7017		1.079(0.479,2.428)	0.855	
≥75	5467	106	974	16	1.141(0.668,1.951)	0.6287		1.049(0.604,1.822)	0.8637	
Comorbidity							0.2878			0.5508
<3	10401	100	853	5	0.681(0.274,1.69)	0.407		0.704(0.276,1.795)	0.4621	
≥3	4486	65	489	13	1.314(0.788,2.188)	0.2949		1.247(0.735,2.117)	0.4126	
Cancer										
Yes	201	5	35	0	--	--	--	--	--	--
No	14686	199	1604	23	1.145(0.737,1.779)	0.5479		1.119(0.707,1.773)	0.6309	
Anticoagulant drug used within 1 month after the index-date							0.8579			0.8687
Yes	216	8	27	1	1.305(0.151,11.283)	0.809		1.95(0.208,18.312)	0.559	
No	14671	196	1612	22	1.089(0.694,1.709)	0.7099		1.088(0.682,1.735)	0.7231	
After propensity score matching										
Gender							0.8905			0.8920
Female	1253	23	1223	18	0.808(0.435,1.503)	0.5007		0.788(0.425,1.461)	0.4502	
Male	386	5	416	5	0.89(0.255,3.11)	0.8554		0.828(0.239,2.876)	0.7668	
Age, years							0.6760			0.7183

Table 3. Subgroup analyses of the risk of CKD in patients with percutaneous vertebroplasty and matched participants.

Table 3. Subgroup analyses of the risk of CKD in patients with percutaneous vertebroplasty and matched participants.

Subgroup	Subjects without percutaneous vertebroplasty		Subjects with percutaneous vertebroplasty		Compared to control group					
	n	Event	n	Event	aHR (95% CI) [§]	P-value	P _{interaction}	aHR (95% CI) [‡]	P-value	P _{interaction}
<75	657	7	665	7	0.973(0.324,2.919)	0.9608		0.947(0.332,2.703)	0.919	
≥75	982	21	974	16	0.795(0.413,1.529)	0.4913		0.759(0.396,1.455)	0.4064	
Comorbidity							0.8066			0.7975
≤=3	1175	12	1142	10	0.985(0.416,2.332)	0.9734		0.847(0.366,1.961)	0.6982	
>3	464	16	497	13	0.855(0.404,1.808)	0.6813		0.721(0.347,1.5)	0.382	
Cancer										
Yes	42	2	35	0	--	--	--	--	--	--
No	1597	26	1604	23	0.875(0.497,1.539)	0.6423		0.864(0.493,1.513)	0.6084	
Anticoagulant drug used within 3 month after the index-date										
Yes	30	0	27	1	--	--	--	--	--	--
No	1609	28	1612	22	0.778(0.444,1.364)	0.3803		0.767(0.439,1.341)	0.3526	

[§]Model was adjusted for all variables listed in Table 1.

[‡] Model Adjusted for propensity score.

Table . The short term risk of PE/DVT in patients with percutaneous vertebroplasty and matched participants.

Table ?. The short term risk of PE/DVT in patients with percutaneous vertebroplasty and matched participants.

	Events	PY	Incidence ^a	Model 1 ^b		Model 2 ^c		Model 3 ^d	
				cHR (95% CI)	P Value	aHR (95% CI)	P Value	aHR (95% CI)	P Value
Within 6 month risk of PE/DVT									
Control cohort	9	755.27	11.92 (4.13,19.7)	Reference	-	Reference	-	Reference	-
Percutaneous vertebroplasty	10	757.18	13.21 (5.02,21.39)	1.11 (0.45,2.72)	0.825	1.08 (0.44,2.67)	0.871	1.11 (0.45,2.72)	0.829
Within 12 month risk of PE/DVT									
Control cohort	12	1398	8.58 (3.73,13.44)	Reference	-	Reference	-	Reference	-
Percutaneous vertebroplasty	13	1405.69	9.25 (4.22,14.28)	1.08 (0.49,2.36)	0.850	1.05 (0.48,2.30)	0.903	1.08 (0.49,2.37)	0.847

Abbreviations: aHR, adjusted hazard ratio; cHR, crude hazard ratio; CI, confidence interval, CKD, chronic kidney disease; PY, person-years.

^aIncidence rate, per 1,000 person-years.

^bModel 1: cHR for crude hazard ratio.

^cModel 2: Adjusted for all variables listed in Table 1 and Cox regression model with backward elimination procedure was carried out.

^dModel 3: Adjusted for propensity score.

The propensity-score model results of probability of percutaneous vertebroplasty

Supplementary table: The propensity-score model results of probability of percutaneous vertebroplasty

Variables	Estimate	Odds ratio	95% CI		P value
			Lower	Upper	
Age	0.0312	1.032	1.027	1.037	<.0001
Gender	-0.3027	0.739	0.652	0.837	<.0001
Index-year	0.2597	1.296	1.272	1.321	<.0001
Geographic location					
Northern Taiwan	1	--	--	--	--
Central Taiwan	0.011	1.011	0.870	1.175	0.887
Southern Taiwan	0.144	1.155	1.021	1.306	0.022
Eastern Taiwan and Islands	0.083	1.087	0.765	1.544	0.642
Comorbidity diseases at baseline					
Hypertension	0.1652	1.18	1.04	1.338	0.0101
Congestive Heart Failure	0.1875	1.206	1.027	1.417	0.0224
COPD	0.1613	1.175	1.033	1.337	0.0142
Dysrhythmia	0.153	1.165	0.997	1.363	0.0552
Medication					
Anti-diabetic agents	0.1827	1.201	1.049	1.374	0.0081
Analgesic drugs	0.4709	1.601	1.419	1.807	<.0001

Abbreviations: PAOD, peripheral artery occlusive disease; CI, confidence interval.

Table 3: The significant risk factor of PE/DVT

Table 3: The significant risk factor of PE/DVT

	Before propensity score matching		After propensity score matching	
	aHR (95% CI)	P Value	aHR (95% CI)	P Value
Age	1.033(1.021,1.046)	<.0001		
Coronary Artery Disease			2.126(1.166,3.877)	0.0139
Congestive Heart Failure	2.152(1.552,2.984)	<.0001	2.24(1.221,4.111)	0.0092
Dysrhythmia	1.473(1.053,2.062)	0.0239		
Cancer	2.799(1.152,6.803)	0.0231		
Antihypertension drug	1.878(1.396,2.526)	<.0001	2.73(1.237,6.025)	0.0129
Analgesic drugs			0.5(0.26,0.962)	0.038

The results showed that LA could inhibit the activation, migration, and formation of osteoclastogenesis of macrophages in a dose-dependent manner. In RA-bearing mice, the expressions of inflammation-related cytokines were suppressed, and clinical symptoms and bone erosion were ameliorated by LA. The accumulation of 18F-FDG in the joints of RA-bearing mice was also significantly decreased by LA. The results indicate that LA significantly improves the symptoms of RA by down-regulating expressions of inflammatory cytokines and osteoclastogenesis.

Conclusions: Vertebral compression fracture patients who received PV seems not to increase the risk of VTE, but should be monitored cautiously in subgroup prone to developing VTE.

Acknowledgement We thank the grant support from the Taiwanese Osteoporosis Association.

P1055

EFFECTS OF EARLY PHYSICAL EXERCISE PROGRAM IN PATIENTS WITH RECENT HIP ARTHROPLASTY FOR OSTEOARTHRITIS

I. R. Marcu¹, S. Patru¹, D. Matei¹, A. C. Bighea¹

¹University of Medicine and Pharmacy, Craiova, Romania

Objective: To examine the effects of a two weeks kinetic program on pain and functional status in patients with recent hip arthroplasty for osteoarthritis.

Methods: We conducted an observational, prospective, randomized study on a sample of 47 patients with recent hip arthroplasty for osteoarthritis. Patients were transferred from the Traumatology and Orthopedics Clinic to the Physical Medicine and Rehabilitation Clinic from 7 to 10 d after undergoing surgery and were randomly assigned to a control group (23 patients) who received only analgesics and NSAID's when needed (group 1) and a study group (24 patients) whose therapeutic program included daily physical exercise (group 2). Patients were initially evaluated and after two weeks of rehabilitation treatment. The clinical and functional parameters assessed were pain on a visual analogue scale (100 mmVAS), physical impairments (muscular strength, mobility of hip joint) and disabilities (Tinetti Gait Scale, D'Aubigné Scale and movement capacity).

Results: The scores for functional parameters improved: pain- 42.6% (group 2) and 33.4% (group 1) ($p=0.000054$); physical impairments: muscular strength- 8.3% (group 2), without improving by group 1, mobility: 41.8% (group2) and 21.4% (group 1); disabilities: Tinetti Gait Scale- 33.6% (group 2) and 22.1% (group 1), D'Aubigné Scale- 35.8% (group 2) and 22.4% (group 1), movement capacity- 55.8% (group2) and 31.9% (group 1). The results were statistic significant ($p<0.05$).

Conclusions: Improvement of pain, physical impairments and disabilities for the study group certifies the efficacy of the early rehabilitation program including physical exercise in patients with hip arthroplasty for osteoarthritis and motivates the continuation of the study on a longer period of time and on a larger number of patients. Rehabilitation program must begin right after patients underwent surgery for hip replacement.

P1056

THE FRACTURE PREDICTIVE ABILITY OF LUMBAR SPINE BMD AND TBS AS CALCULATED BASED ON DIFFERENT COMBINATIONS OF THE LUMBAR SPINE VERTEBRAE: THE OSTEOLAUS STUDY

E. Shevroja¹, F. Mo Costabella¹, B. Aubry-Rozier¹, E. Gonzalez Rodriguez¹, O. Lamy¹, D. Hans¹

¹Lausanne University Hospital, Lausanne, Switzerland, Lausanne, Switzerland

Objective: Trabecular bone score (TBS), a surrogate of bone microarchitecture, is an independent predictor of osteoporotic fractures. It is measured in the lumbar spine (LS) DXA scans in the same regions of interest as BMD, L1-L4. We aimed to study whether different combinations of the lumbar vertebrae in the calculations of LS TBS and BMD perform differently in major osteoporotic fractures (MOF) prediction.

Methods: Study comprised 1475 postmenopausal women (mean age=64.5 y) of the OsteoLaus Study, a Swiss population-based cohort, who had undergone questionnaires, vertebral fracture assessments, LS DXA scans (Hologic) and TBS (Medimaps, v4.0) measurements. T-tests were run to test the differences in general characteristics between women who fractured and those who did not; binary logistic regressions adjusted for age+BMI or for age+BMI+LS BMD were performed to study the odds ratios per one SD decrease in LS BMD or TBS, respectively; the areas under the curve (AUC) were then calculated for each model.

Results: During the 5 y of follow-up, 125 women had a fracture. Fractured women were older, had higher BMI, and lower LS BMD and TBS. TBS was an independent predictor of MOF. The best lumbar vertebrae combination for TBS was L1-L2 (OR(95%CI): 1.81(1.35-2.44); AUC (95%CI): 0.716(0.654-0.778)), whereas the poorest combination was L3-L4 (OR(95%CI): 1.24(0.92-1.68); AUC (95%CI): 0.686(0.621-0.751)). Similarly, for BMD the L1-L2 combination also had the best performance in MOF prediction (OR(95%CI): 1.47(1.21-1.78); AUC (95%CI): 0.689(0.625-0.753)), whereas the L2-L4 had the poorest performance (OR(95%CI): 1.27(1.10-1.46); AUC (95%CI): 0.673(0.608-0.738)). Compared to the current used combination (L1-L4), L1-L2 and L1-L3 performed better for both BMD and TBS.

Conclusion: Excluding L4 seemed to improve the fracture risk prediction in overall. L4 might be affected by spine lordosis, thus its accuracy is questionable. Nevertheless, further investigation is needed to clarify the possible causes for the differences in performance among the LS vertebrae combinations.

Disclosures: Didier Hans holds stock in Medimaps Group, the makers of the Trabecular Bone Score software.

P1057

VERTEBRAL PAIN AND PHYSICAL PERFORMANCE INDICES IN POSTMENOPAUSAL WOMEN WITH VERTEBRAL FRACTURES DEPENDING ON BONE MINERAL DENSITY PARAMETERS

N. Grygorieva¹, V. Povoroznyuk¹, O. Rybina¹

¹Institute of Gerontology named after D. F. Chebotareva NAMS of Ukraine, Kyiv, Ukraine

Vertebral fractures (VFs) are amongst one of the most crucial osteoporotic fractures which manifest increased morbidity and mortality; however, their clinical features usually differ. BMD is one of the important parameters of bone strength and risk of osteoporotic fractures. The aim of the research was to study the indices of vertebral pain (VP) and physical performance (PP) in postmenopausal women with VFs depending on BMD parameters. We examined 89 females aged 50-89 years old with VFs in thoracic and/or lumbar spine which were divided into 3 groups: I – patients with osteoporosis (OP), according to WHO criteria for DXA, n=41; II – women with osteopenia (OPN), n=26; III – females with normal BMDs (NB), n=22. The parameters of VP in thoracic and/or lumbar spine were measured by 11-component visual analog scale (VAS), the indices of PP using static and dynamic functional tests (Thomayer, Schober tests, chest excursion, lateral trunk lean, 3-, 4-, 15-meter tests, “stand up from the chair”, static balancing). BMD was measured by DXA (Lunar, Prodigy). We have found the significantly lower parameters of weight and height in women with VFs and OP or OPN compared to females with NB. However, we did not establish any reliable differences of VP neither in thoracic nor in lumbar spine depending on BMD state. Also, we did not reveal the significant differences of most parameters of PP, except for the indices of chest excursion (mean parameter, of the inhalation and exhalation) which were reliably lower in patients with OP.

In conclusion, the indices of VP and PP do not differ in postmenopausal women depending on BMD parameters, except for chest excursion that should be taken into account in rehabilitation programs for females with VFs.

P1058

QUETIAPINE AMELIORATES BONE RESORPTION IN COLLAGEN-INDUCED ARTHRITIS IN MICE VIA SUPPRESSIONS OF THE AKT AND ERK SIGNALING PATHWAYS

W.-H. Wang¹

¹Changhua Christian Hospital Orthopaedic Department/ Kaohsiung Medical University Medical Department, Taichung, Taiwan


Objective: Quetiapine, an atypical antipsychotic drug, shows anti-inflammatory effects; however, its underlying mechanism during collagen-induced arthritis (CIA) remains ambiguous. IL-6,

TNF α and IL-1 β were reduced by quetiapine via an inhibition of ERK and AKT phosphorylation and this was followed by a subsequent effect on the NF- κ B and CREB signaling pathways. The therapeutic efficacy of quetiapine in CIA mouse model was also explored. Pro-inflammatory cytokines IL-17, IL-6 and IL-1 β were decreased, while the immunosuppressive factors TGF β and IL-10 were increased when CIA mice were treated with quetiapine. 18F-FDG/microPET was used to monitor the inflammation status of the CIA mouse's joints. The severity of bone resorption was also evaluated by microCT and H&E staining. Bone resorption and the uptake of 18F-FDG were absent in the quetiapine-treated group, which had PET images similar to the control mice. On the other hand, uptake of 18F-FDG was observed in the celecoxib-treated group on days 32 and 43. These findings suggest that quetiapine is a potential anti-inflammatory drug and may be useful as an adjuvant treatment for rheumatoid arthritis.


Methods: Inhibition by quetiapine of various proinflammatory cytokines, namely IL-6, TNF α and IL-1 β , using lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophage model was investigated. The therapeutic efficacy of quetiapine in CIA mouse model was also explored. CIA mice were treated with quetiapine. 18F-FDG/microPET was used to monitor the inflammation status of the CIA mouse's joints. The severity of bone erosion was also evaluated by microCT and H&E staining. Uptake of 18F-FDG was observed in the celecoxib-treated group on days 32 and 43.

Results: IL-6, TNF α and IL-1 β cytokines were reduced by quetiapine via an inhibition of ERK and AKT phosphorylation and this was followed by a subsequent effect on the NF- κ B and CREB signaling pathways. The therapeutic efficacy of quetiapine in CIA mouse model was also explored. Pro-inflammatory cytokines IL-17, IL-6 and IL-1 β were decreased, while the immunosuppressive factors TGF β and IL-10 were increased when CIA mice were treated with quetiapine. 18F-FDG/microPET was used to monitor the inflammation status of the CIA mouse's joints. The severity of bone resorption was also evaluated by microCT and H&E staining. Bone resorption and the uptake of 18F-FDG were absent in the quetiapine-treated group, which had PET images similar to the control mice. On the other hand, uptake of 18F-FDG was observed in the celecoxib-treated group on days 32 and 43. Similar results were obtained by ex vivo autoradiography.


Quetiapine treatment inhibits LPS-induced macrophage activation



Quetiapine diminishes the migration ability of RAW 264.7 cells




Anti-inflammatory effects of quetiapine on LPS-stimulated RAW 264.7 cells




The lysates of RAW 264.7 cells were analyzed with Western blot.

Quetiapine inhibits NF-κB and CREB signaling pathways *via* suppressions of ERK and AKT phosphorylation




Nuclear proteins and whole cell lysate from the RAW 264.7 cells were analyzed with Western blot.

The levels of serum IL-6, IL-17, IL-1 β , TNF- α and BAFF are decreased by quetiapine in CIA mice




*** $P < 0.001$, ** $P < 0.01$, * $P < 0.05$ vs. CIA mice, #### $P < 0.001$, ## $P < 0.01$, # $P < 0.05$ compares between different experimental group.

Quetiapine suppresses arthritis-related proteins and promotes the immunosuppressive factors in CIA mice treated with quetiapine




Quetiapine decreases the uptake of ¹⁸F-FDG in the joints of CIA mice



Each group of mice were i.v. injected with 18.5 MBq/0.1 ml of ¹⁸F-FDG on day 20, 32 and 43 for micro-PET imaging. For each hind leg, a region of interest (ROI) was drawn on the summed ¹⁸F-FDG image and standardized uptake value (SUV) was calculated from knee to paw. ****P < 0.01, *P < 0.05** versus normal mice, **##P < 0.01, #P < 0.05**.

Quetiapine decreases the uptake of ¹⁸F-FDG in the joints of CIA mice



Each groups of mice were i.v. injected with 18.5 MBq/0.1 ml of ¹⁸F-FDG on day 32 for *ex-vivo* autoradiography.

The results showed that quetiapine could inhibit the activation, migration, and formation of osteoclastogenesis of macrophages in a dose-dependent manner. In RA-bearing mice, the expressions of inflammation-related cytokines were suppressed, and clinical symptoms and bone erosion were ameliorated by quetiapine. The accumulation of ¹⁸F-FDG in the joints of RA-bearing mice was also significantly decreased by quetiapine. The results indicate that quetiapine significantly improves the symptoms of RA by downregulating expressions of inflammatory cytokines and osteoclastogenesis.

Conclusions: These findings suggest that quetiapine is a potential anti-inflammatory drug and may be useful as an adjuvant treatment for rheumatoid arthritis.

Acknowledgement: We thank the grant support from the Taiwanese Osteoporosis Association.

P1059

TRABECULAR BONE SCORE AND LIFE EXPECTANCY WITH AND WITHOUT OSTEOPOROTIC FRACTURE: THE ROTTERDAM STUDY

E. Shevroja¹, E. Asllanaj², F. Koromani², T. Muka², O. H. Franco³, C. Zilikens⁴, A. G. Uitterlinden⁴, D. Hans¹, F. Rivadeneira⁴


¹Lausanne University Hospital, Lausanne, Switzerland, Lausanne, Switzerland, ²Department of Epidemiology, Erasmus University Medical Centre, Rotterdam, Netherlands, Rotterdam, The Netherlands, ³Institute of Social and Preventive Medicine, Bern, Switzerland, Bern, Switzerland, ⁴Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, Netherlands, Rotterdam, The Netherlands

Objective: Trabecular bone score (TBS), a texture analysis of lumbar spine (LS) DXA scans, predicts major osteoporotic fractures (MOF) independently of BMD. We aimed to study the association of TBS with overall life expectancy (LE), and when considering MOF.

Methods: Study comprised 6849 individuals (3,982 women) with a mean age of 65 y from the Dutch population-based Rotterdam Study. We developed a multistate life table to calculate LE for individuals who had low, moderate and high TBS values; considering difference in years lived with and without MOF. Calculations employed prevalence, incidence rate, and hazard ratios (HRs) for three transitions (healthy to MOF, healthy to death, and MOF to death), categorized by baseline TBS tertiles adjusted for BMI, LS-BMD and cohort.

Results: During 7.2 y, 306 incident MOF and 522 deaths were observed in women; and 114 MOF and 558 deaths in men. Individuals with the lowest (HR: 1.25(0.92-1.71) in women and 1.91(1.08-3.40) in men) and mid (HR:1.12(0.82-1.52) in women and 1.75(1.01-3.02) in men) tertiles of TBS had a higher MOF risk as compared to the highest. Mortality of nonfractured individuals was also higher in the lowest and mid TBS tertiles. Fractured individuals with the lowest (HR:2.34(1.34-4.07) in women and 5.87(2.80-12.29) in men) and mid (HR: 1.81(1.02-3.22) in women and 2.80(1.33-5.88) in men) tertiles of TBS had higher risk of death as compared to the highest. Total LE was higher in women (39.7 y) than in men (35.3 y).

Conclusion: Women and men have an increased mortality risk after suffering a MOF. The risk is higher among those with lower TBS, and among men.



[Figure 1. Life expectancy with and without fracture in women of each TBS category]

P1060

BMD, TBS AND FRAX INDICES IN POSTMENOPAUSAL WOMEN WITH DIFFERENT TYPES OF OSTEOPOROTIC FRACTURES

V. Povoroznyuk¹, N. Grygorieva¹

¹Institute of Gerontology named after D. F. Chebotarev NAMS of Ukraine, Kyiv, Ukraine

BMD and Trabecular bone score (TBS) are independent parameters of bone strength which effectively predict osteoporotic fractures risk. FRAX and adjusted FRAX by TBS are simple calculators which assess 10-years probability of major osteoporotic fractures (MOFs) and hip fracture (HF). Their significance was confirmed in various studies; however, information depending on type of osteoporotic fractures is limited. The purpose was to study the indices of BMD, TBS, FRAX and adjusted FRAX by TBS in postmenopausal women with different types of osteoporotic fractures. We examined 275 women aged 50 years and older, which were divided into two groups depending on previous fractures (PFs) presence. The females with fractures also were divided according to fracture localization: vertebral fractures (VFs), humerus fractures (HFs), ulna/radius fractures (URFs) and wrist fractures (WFs). BMD and TBS were measured by X-ray absorptiometry (Lunar, Prodigy), assessment of risk factors was performed by FRAX and adjusted FRAX by TBS. FRAX scores with BMI, BMD and TBS were calculated. It was established that BMD of lumbar spine and total body and TBS indices were significantly lower only in patients with VFs compared to women without previous fractures (PFs) in contrast to patients with other fractures. BMD of femoral neck and total hip did not differ in any group with fractures compared to control. In addition, indices of FRAX/BMI-MOFs were significantly higher for women independently of type of fractures, however, FRAX/BMI-HF were reliably higher only at women with VFs and URFs compared to parameters of women without PFs. FRAX/BMD-MOFs and FRAX/TBS-MOFs indices were significantly higher in females independently from type of fractures, except the women with HFs. Parameters of FRAX/BMD-HF and FRAX/TBS-HF were higher only in patients with VFs. In conclusion, BMD of lumbar spine and total body, but not in femoral neck, TBS indices are reliably lower only in patients with VFs compared to women with other osteoporotic fractures. FRAX and adjusted FRAX by TBS are important indices for fractures risk assessment in postmenopausal women with previous fractures which propose additional information without BMD measurement.

P1061

ASSOCIATION BETWEEN POLYPHARMACY AND SARCOPENIA DIAGNOSED ACCORDING TO DIFFERENT DEFINITIONS

A. Mastavičiūtė¹, G. Sadauskaitė¹, J. Kilaitė¹, M. Tamulaitienė¹, V. Alekna¹

¹Faculty of Medicine, Vilnius University, Vilnius, Lithuania

Objective: To investigate the association between polypharmacy and sarcopenia diagnosed using three different definitions.

Methods: A cross-sectional study was performed in National Osteoporosis Center based in Vilnius, Lithuania. Inclusion criteria were: age 60 or more years, unrestricted mobility, MMSE score ≥ 21 . Number of medications taken was evaluated by total count of prescribed, over-the-counter and supplemental medicines. Polypharmacy was defined as regular use of 5 or more medications. Sarcopenia was defined according to 1) European Working Group on Sarcopenia in Older People criteria made in 2018 (EWGSOP2), 2) International Working Group on Sarcopenia (IWGS) and 3) Foundation for the National Institutes of Health (FNIH) criteria. Muscle mass was measured by DXA (iDXA, GE Lunar, USA), muscle strength was evaluated measuring handgrip strength (JAMAR, Patterson Medical, UK), and physical performance was evaluated by the Short Physical Performance Battery (SPPB) test or gait speed, where appropriate. Relationship between polypharmacy and sarcopenia was assessed using binary logistic regression.

Results: The study was performed on 246 subjects: 87 (35.4%) men and 159 (64.6%) women. Mean age was 79.27 ± 6.48 y, ranging from 62.8-94.7 years. Mean number of medications taken was 3.76 ± 1.82 . Polypharmacy was prevalent in 49 (19.9%) subjects. Sarcopenia was defined in 79 (32.1%), 82 (33.3%) and 23 (9.3%) subjects according to EWGSOP2, IWGS and FNIH criteria, respectively. Logistic regression analysis confirmed that polypharmacy was associated with sarcopenia diagnosed using EWGSOP2 and IWGS definitions (OR: 0.27 (0.11-0.66) and 0.29 (0.12-0.71), respectively). There was no association between polypharmacy and sarcopenia diagnosed according to FNIH criteria (OR: 0.47 (0.14-1.65)). Number of medications taken was associated with sarcopenia diagnosed using criteria of all three operational definitions: EWGSOP2 (OR: 1.86 (1.41-2.44)), IWGS (OR: 1.81 (1.38-2.37)) and FNIH (OR: 1.57 (1.05-2.35)).

Conclusion: Results of our study shows that number of medications taken was associated with sarcopenia despite the diagnostic criteria used. Polypharmacy was associated with sarcopenia diagnosed according to EWGSOP2 and IWGS criteria.

P1062

PROTON PUMP INHIBITORS: A RISK FACTOR FOR OSTEOPOROSIS?

C. Criveanu¹, P. L. Ciurea¹, A. F. Vreju¹, A. E. Musetescu¹, A. Barbulescu², S. C. Dinescu¹, C. S. Firulescu¹, O. R. Predescu³, A. Rosu¹, C. F. Palici¹

¹Department of Rheumatology, University of Medicine and Pharmacy of Craiova, ²Department of Pharmacology, University of Medicine and Pharmacy of Craiova, ³Department of Rheumatology, County Emergency Clinical Hospital of Craiova, Craiova, Romania

Objectives: Recent data in the specialty literature have shown that proton pump inhibitors (PPI) can interfere with calcium absorption by inducing hypochlorhydria. These agents are widely used both for gastrointestinal disorders and in combination with anti-inflammatory drugs. This study is aimed at analyzing long-term effects of PPI on serum calcium and BMD variations in patients with PPI treatment.

Methods: Two groups of patients, menopausal women in particular, 78 subjects with a daily 40 mg omeprazole or pantoprazole administration, for gastroesophageal reflux and gastritis and 62 patients in the control group (without PPI treatment). Patients who had previously received calcium and vitamin D3 supplements, as well as those with bisphosphonate treatment, those with malabsorption syndrome and those with an operated stomach were not included in the study. Patients were evaluated twice a year between 2016-2018. Reference serum calcium values were between 8.6-10 mg/dl. The BMD was assessed using the DXA at the lumbar spine level.

Results: In the group of patients with PPI treatment, the registered serum calcium values were between 7.6-8.9 mg/dl as compared to the control group where the serum calcium values were between 8.1-9 mg/dl. The initial T-score in the first group varied between -1 and -2.8 SD as compared to the patients without PPI treatment where T-score values were between 0.6 and -1.4 SD. On the final assessment, there was a decrease in the BMD by approximately 1.7% in the study group, compared to vs. the control group where the measured BMD did not record significant variations. **Conclusions:** The long-term use of PPI seems to have an unfavorable impact on the BMD by achieving a negative balance of calcium. This effect could be fought against with citrate calcium supplements whose absorption is not influenced by a decrease in gastric acidity.

P1063

CONSISTENT IMPLANT RESORPTION AND BONE FORMATION IN THREE SPECIES WITH AND WITHOUT ANTIRESORPTIVE THERAPY FOLLOWING TREATMENT WITH A TRIPHASIC CALCIUM-BASED IMPLANT MATERIAL

R. Hill¹, J. Shaul¹, J. Howe¹, D. Burr², D. Hall³, T. Turner³, R. Urban³, B. Huber⁴, K. Engelke⁵, H. Genant⁶

¹AgNovos Healthcare, Rockville, ²Indiana University School of Medicine, Indianapolis, ³Rush University Medical Center, Chicago, ⁴Copley Hospital, Morrisville, ⁵Bioclinica Inc, Princeton, ⁶University of California San Francisco, San Francisco, USA

Objective: The study compared implant resorption and bone formation in 3 species with and without antiresorptive therapy following triphasic calcium-based implant material (AGN1) implantation.

Methods: Three species were studied, each with subgroups receiving either antiresorptive treatment or none: drill hole defects in OVX rat proximal femurs (N=6/group) and dog humeri (N=10/group), and proximal femurs in 12 osteoporotic women. Patients had one proximal femur injected with AGN1 as part of a local osteo-enhancement procedure (LOEP); the other was an untreated control. Half were prescribed antiresorptives. Analyses included μ CT/histopathology (rat/dog), biomechanics (dog) and DXA/CT (patients). Follow-up timepoints for rats, dogs, and patients were 18, 26, and 25 weeks.

Results: More than 95% of AGN1 was resorbed by 26 weeks in all species; resorption was not significantly affected by antiresorptive treatment. AGN1 was replaced by normal bone in rats as assessed by histology/ μ CT and in dogs by histology/ μ CT/biomechanical testing. In patients, AGN1 increased bone in the proximal femur as assessed by CT and femoral neck aBMD (0.917 ± 0.140 vs. control 0.530 ± 0.045 g/cm², $p < 0.001$). In rats, alendronate (15 μ g/kg 2x wk) increased percent bone ($26.4 \pm 14.0\%$ vs. $13.4 \pm 6.0\%$, $p = 0.012$). In dogs, alendronate (0.2mg/kg/d) had minimal impact on percent bone ($22.0 \pm 5.2\%$ vs. $19.0 \pm 3.4\%$, $p = 0.147$). In patients, antiresorptives did not significantly impact aBMD (0.938 ± 0.152 vs. 0.897 ± 0.139 g/cm², $p = 0.636$).

Conclusions: The study showed antiresorptives had no significant effect on AGN1 resorption across species. Normal bone formed in rat and dog implanted defects regardless of antiresorptive treatment. The good bone quality in the preclinical models and similar patient results suggest that new patient bone would also be healthy and metabolically active. These results demonstrate that the effectiveness of AGN1 LOEP as a treatment for local osteoporotic bone loss is not compromised by antiresorptive treatment.

P1064

STUDY OF PREVALENCE OF OSTEOPOROSIS AND VITAMIN D DEFICIENCY IN ELDERLY PATIENTS WITH HIP FRACTURES

U. C. Saini¹, S. Aggarwal¹, S. Bhadada¹, A. Dadra¹, P. Kumar¹, V. Kumar¹

¹Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India

Objective: Osteoporosis is a major public health problem worldwide. Concomitant vitamin D deficiency increases the risk of fractures secondary to low bone mass and muscle imbalance leading to frequent falls. Vitamin D deficiency is often under-recognized, especially in the elderly.

Methods: Prospective cohort study between January 2013 and December 2013. Consecutive elderly patients (aged >60 y) with proximal femur fractures were enrolled. Patients with malignancy, significant trauma or fractures of additional bones were excluded. Osteoporosis was identified by DXA scan of nonfractured hip and lumbar spine. Metabolic tests including serum calcium, renal functions, parathormone and vitamin D levels were done.

Results: 66 patients were included over 1 y. Majority were females (n=37, 56%). Mean age at presentation was 64.1 ± 13.8 in males and 70.3 ± 12.1 y in females. Common fracture sites were inter-trochanteric (53%; N=35), neck of femur (37.9%; N=25) and subtrochanteric fractures (9.1%; N=6). Majority of fractures were sustained at home (N=49; 74.2%), after a fall in bathroom/wet floor. Vitamin D was deficient in 74.2% (N=49) patients (72.4% men, 75.7% women). Mean serum vitamin levels were 10.1 ± 9.5 ng/ml in men and 9.7 ± 9.1 ng/ml in women. Mean parathormone levels were 67.4 ± 37.8 pg/ml in men and 106.2 ± 150.2 pg/ml in women. Secondary hyperparathyroidism was observed in 27 patients (40.9%). Mean BMD of hip was 0.62 ± 0.1 g/cm² and of spine was 0.848 ± 0.2 g/cm². Prevalence of osteopenia, osteoporosis and severe osteoporosis was 15.2%, 62.1% and 18.2% respectively. BMD was similar in men and women for hip (0.620 ± 0.2 g/cm² vs. 0.624 ± 0.1 g/cm²), whereas lower in women for spine (0.892 ± 0.3 g/cm² vs. 0.815 ± 0.2 g/cm² respectively). Other risk factors included smoking (N=14, 21.2%), alcoholism (N=12, 18.2%) and inadequate sun exposure (60%). Family history of fragile fractures was present in 8%; past history was noted in 18%. No significant difference was observed in the BMD of patients with or without adequate sunlight exposure, calcium and vitamin D supplementation at the time of fracture.

Conclusion: Prevalence of osteoporosis and vitamin D deficiency is very high in elderly patients with hip fractures. It is an under-recognized cause of morbidity and mortality in the elderly population and needs timely intervention.

P1065

VALIDATION OF THE LITHUANIAN VERSION OF SARCOPENIA SPECIFIC QUALITY OF LIFE QUESTIONNAIRE (SARQOL®)

V. Alekna¹, J. Kilaitė¹, A. Mastavičiūtė¹, M. Tamulaitienė¹, C. Beaudart²

¹Faculty of Medicine, Vilnius University, Vilnius, Lithuania,

²Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium

Objective: To translate and validate the SarQoL questionnaire into Lithuanian language.

Methods: A cross-sectional study was performed on community-dwelling Lithuanian people aged ≥ 60 y. European Working Group on Sarcopenia in Older People criteria were used for diagnosis of sarcopenia. Muscle mass was evaluated by DXA. Muscle strength was assessed measuring handgrip strength with hydraulic dynamometer. Physical performance was evaluated by short physical performance battery. Primary translation from French to Lithuanian, backward translation to French, expert committee review, pre-test of final version of the Lithuanian SarQoL was performed. Subjects also completed quality of life questionnaires SF-36 and EQ-5D. To analyse the test-retest reliability, sarcopenic subjects again filled the SarQoL questionnaire after two weeks. Validity of the Lithuanian SarQoL was assessed by discriminative power and construct validity, reliability was evaluated by internal consistency and test-retest reliability. Adjusted logistic regression analysis was used to compare sarcopenic and non-sarcopenic subjects. Internal consistency was determined using Cronbach's alpha coefficient. The correlation of each domain of the SarQoL and SF-36, EQ-5D questionnaires with the score of the whole SarQoL was measured using Spearman's correlations. Test-retest reliability was measured by the intraclass coefficient correlation.

Results: The study was performed on 166 subjects: 99 women (59.6%) and 67 men (40.4%). Median age of subjects was 78 (62.8–94.7) y. Sarcopenia was diagnosed in sixty three subjects. After adjustment for confounders, the total score of the SarQoL questionnaire was significantly lower for sarcopenic than for non-sarcopenic subjects: 77.55 ± 9.8 vs. 49.16 ± 7.46 , OR 0.802 (95%CI 0.68–0.945). Cronbach's alpha coefficient was 0.96 for internal consistency. The SarQoL questionnaire revealed good correlation with some domains of the SF-36 and EQ-5D questionnaires for convergent validity and weak correlation with some domains of the EQ-5D for divergent validity. An excellent agreement between test and retest was found with an ICC of 0.99 (95%CI 0.98–1).

Conclusions: Lithuanian version of the SarQoL is valid, reliable and consistent and could be used to assess quality of life in sarcopenic population.

P1066

BONE TEXTURE ASSESSMENT ON VFA LATERAL SPINE IMAGES BY USING THE TEXTURE RESEARCH INVESTIGATIONAL PLATFORM (TRIP) AND ITS FRACTURE DISCRIMINATION ABILITY: THE OSTEOLAUS STUDY.

E. Shevroja¹, B. Aubry-Rozier¹, E. Gonzalez Rodriguez¹, O. Lamy¹, D. Hans¹

¹Lausanne University Hospital, Lausanne, Switzerland, Lausanne, Switzerland

Trabecular bone score (TBS) is a grey-level texture score, which is shown to be a surrogate for trabecular bone microarchitecture. TBS is measured from the antero-posterior (AP) spine DXA images. A recently developed tool, Texture Research Investigational Platform (TRIP), can assess bone texture scores (BTS) based on a derived approach of the TBS algorithm on any skeletal site besides spine and any image type besides AP spine DXA. Lateral view of the spine has the advantage to enable the exclusion of the posterior elements from the region of analysis.

Objectives: We aimed to measure BTS on the lateral spine VFA images, to study its correlation with spine bone mineral density (BMD) and TBS, and to see how it differs between fractured and non-fractured individuals.

Material and methods: We evaluated 90 women from the OsteoLaus study (45 fractured and 45 non-fractured, age-matched), with a mean age of 72.3(7.7) years and mean BMI 25.9(4.1) kg/m². All women had AP lumbar DXA scans and lateral VFAs performed using Lunar iDXA (GE Healthcare, Madison, WI, USA) and TBS measured using v3.03. BTS was assessed using TRIP v1.0 (Medimaps, France) by manually employing 8-points on each L1-L4 vertebrae (see image). Vertebral fractures were assessed in VFA images based on the Genant's method. The correlations of BTS with spine BMD and TBS were assessed by using Pearson's correlation coefficient and the differences between the fractured and non-fractured women were assessed by independent samples t-tests.

Results: In general, fractured women had a higher BMI and were shorter. Spine BMD was significantly correlated with TBS ($r=0.56$, $p<0.001$) and BTS ($r=0.38$, $p<0.001$); BTS was non significantly correlated with TBS ($r=0.14$, $p=0.20$). Those who fractured had a significantly lower spine BMD T-score (-1.15 vs -0.02 , $p<0.05$), and TBS (1.24 vs 1.33 , $p<0.001$). BTS was also lower among the fractured women (0.52 vs 0.54).

Conclusion: In conclusion, this study showed that BTS as measured on the lateral spine VFA images had indeed lower values among the fractured individuals. Nevertheless, our study sample was small and further investigations in larger studies are needed to confirm the ability of BTS from VFA image in fracture discrimination or prediction.



P1067
FAMILY HISTORY INFLUENCES FRACTURE RISK
BMD INDEPENDENTLY

A. Gasparik¹, M. Cevei², D. Stoicanescu³, T. Szocs¹

¹University of Medicine and Pharmacy (UMFST) Tirgu Mures, Tirgu Mures, ²University of Oradea, Oradea, ³University of Medicine and Pharmacy V. Babes, Timisoara, Romania

Osteoporosis, a major public health issue has been associated with a positive family history. We aimed to evaluate how family history of osteoporotic fractures influences: 1. fracture rate, 2. BMD levels, 3 BMD levels when the fractures occurred compared to negative history. We included 541 patients, with an average age of 55 years. Our study confirms that a positive family history significantly increase fracture prevalence (37 vs. 17%, $p < 0.001$), decreases BMD scores and: fractures occurred at higher (better) T and Z-scores. As a conclusion we can affirm that family history increases the probability of a fracture also independently of the BMD scores.

P1068
PREDICTORS OF OSTEOPOROTIC HIP FRACTURE
BEYOND FRAX

P. Xenophontos¹, G. Lavranos¹, P. Manolopoulos¹, K. Tsioutis¹, T. Dardavessis²

¹European University Cyprus, Nicosia, Cyprus, ²Aristotle University of Thessaloniki, Thessaloniki, Greece

Objective: Osteoporotic hip fractures remain a major cause of mortality and morbidity in individuals above 65 years of age. The aim of this study was to determine causative agents other than those included in the FRAX model contributing to the development of such incidents.

Methods: All patients over 65 admitted in a secondary general hospital for a period of 1 y due to osteoporotic risk fractures were included in a cohort trial, recording their demographics, quality of life, main health indicators and comorbidities and surgical outcome up to 3 months post admission. The study was approved by the Institutional and the National Bioethics Committee and the Personal Data Protection Commissioner. All data was pseudonymized and analyzed via the SPSS 20 Statistical Package.

Results: In total, 206 patients were enrolled in the trial, of which 128 female and 78 male, with a mean age of 81.1 y. No correlation was detected between incidence of osteoporotic fracture and increasing age, sex or the prevalence of comorbidities such as cancer (any site), hypertension or chronic heart/renal failure. On the contrary, an increased risk was observed for patients with diabetes type 2 (prevalence 27.7% vs. 22% in the general population, $p = 0.045$) and atrial fibrillation (prevalence 13.6% vs. 5.9% in the general population, $p < 0.001$).

Conclusion: Apart from the FRAX score, additional factors, such as atrial fibrillation and diabetes mellitus also contribute to the incidence of major osteoporotic fractures. In patients over 65, such comorbidities enhance the clinical indication for osteoporosis screening and prevention.

P1069
ARE ORTHOPEDIC DOCTORS SUFFICIENTLY
CONCERNED WITH VITAMIN D?

M. Sahin¹

¹Istanbul Medipol University/ School of Medicine/ Department of Orthopedics and Traumatology, Istanbul, Turkey

Objectives: Vitamin D is synthesized in the skin under the influence of ultraviolet lights coming from the sun or is obtained from food and it is known that it has a very important place for the skeletal structure. Studies stated that the deficiency clinically causes deformations such as joint swelling, rickets, muscle weakness, fractures, bone loss, chronic fatigue, pain and falls, and increases the risk of falling and fractures. Regular intake of vitamin D is very important to decreasing the risk of falling by increasing the protein synthesis, which enables the growth of muscle cells with vitamin D receptor mechanism. The aim of our study was to

emphasize the importance of investigating vitamin D levels affecting the musculoskeletal system and to reduce the risks as an orthopedists.

Methods: In the last 2 y, 50.453 (17.022M, 33.431 F) vitamin D (25 (OH) D) examination was performed. After 12 h fasting, the test was performed before 10:00 am. The insufficiency limit was determined <20 ng/ml, the deficiency values were between 20-30 ng/ml and the normal value was 30-80 ng/ml. The results were classified according to the gender and department that ordered and were grouped for age range as <18, 18-45, 46-65 and >65 y.

Results: Vitamin D level of individuals with a mean age of 33.71 was 26.31. When the results of vitamin D were measured, 24138 (47%) were insufficiency, 9251 (18%) were deficient and 17064 (35%) were within normal limits. According to age groups, under the age of 18, 46.47%, between the age of 18-45, 74.68%, and between the age of 45-65, 72.43% found to be deficient and incomplete in the individuals. When the results were evaluated according to the ordering departments 342 (0.67%) of 50453 tests were ordered by the orthopedics and traumatology department.

Conclusions: In our study, a high rate of vitamin D insufficiency and deficiency was determined and this rate was found to be around 70% in the adult age group. It is noteworthy that orthopedics and traumatology doctors are not interested in vitamin D great lack of deficiency which affects negative the musculoskeletal system. These doctors, who deal with pain, falls and fractures, need to increase their interest in vitamin D metabolism, measurement, evaluation and treatment.

P1070

SUCCESSFUL TREATMENT OF RHEUMATOID ARTHRITIS WITH TOCILIZUMAB AND ITS EFFECT ON METHOTREXATE AND CORTICOSTEROID DOSING SCHEDULE

P. Athanassiou¹, M. Gatsiou¹, L. Athanassiou², P. Tsakiridis¹, A. Tzanavari¹, E. Devetzi¹, C. Katsavouni¹, I. Kostoglou-Athanassiou³

¹Department of Rheumatology, St. Paul's Hospital, Thessaloniki,

²First Department of Internal Medicine, Asclepeion Hospital,

Voula, Athens, ³Department of Endocrinology, Asclepeion Hospital, Voula, Athens, Greece

Objective: Successful management of rheumatoid arthritis (RA) depends on the early administration of DMARDs and biologic DMARDs. The biologic agent tocilizumab, an interleukin-6 receptor inhibitor, has been used for the management of RA. The aim was to describe a cohort of RA patients treated with tocilizumab and the effect of this treatment on the other DMARDs used, namely methotrexate and corticosteroids.

Methods: In a cohort of 80 patients with rheumatoid arthritis the biologic agent tocilizumab was administered in combination with methotrexate administered sc and 10 mg prednisolone. Within this cohort, 26 patients were on tocilizumab administered iv 8 mg/kg/4wks (maximum dose 800 mg) and 54 were on tocilizumab administered sc 162 mg/wk. As corticosteroid administration is characterized by adverse effects, such as osteoporosis and

diabetes mellitus, in the course of the disease, in all patients an effort was made to reduce and, if possible, withdraw corticosteroids. An effort was also made to reduce methotrexate dosage. After a year, prednisolone was either significantly reduced or withdrawn. The final dosage of prednisolone was either 2.5-5 mg or complete withdrawal. The successful reduction of methotrexate dosing schedule was also achieved. The final methotrexate dose was either 12.5 mg sc or complete withdrawal. After a period of 52 weeks in this cohort 42 of 80 patients (52.5%) were on monotherapy with tocilizumab.

Results: In a cohort of 80 patients with RA the administrations of tocilizumab, either iv or sc, proved safe and effective. Remission or low disease activity of RA was achieved. Corticosteroid dosage was reduced. Methotrexate dosage was also reduced. After 52 weeks within the group of RA patients on treatment with tocilizumab, in 42 complete withdrawal of corticosteroids and methotrexate proved feasible. Patients on tocilizumab monotherapy remained in remission.

Conclusions: It appears that tocilizumab is safe and effective for the treatment of RA. Tocilizumab treatment may permit withdrawal of both corticosteroids and methotrexate in patients with RA. The management of active RA initially with low dose corticosteroids in combination with methotrexate sc and, in the case of failure to achieve remission, with the addition of the biologic agent tocilizumab had as a result either significant corticosteroid reduction or complete withdrawal and reduction of methotrexate dosage, the disease remaining in remission.

P1071

ASSOCIATION OF ESSENTIAL MINERALS WITH CONCENTRATIONS OF 25-HYDROXYVITAMIN D AND 1,25-DIHYDROXYVITAMIN D AMONG SAUDI PATIENTS

H. Sulaiman Alfadul¹, N. Al-Daghari¹, S. Yakout¹

¹Prince Mutaib Chair for Biomarkers on Osteoporosis, King Saud University, Riyadh, Saudi Arabia

Objective: To determine the patterns of essential minerals in Saudi patients with and without vitamin D deficiency and explore known associations between essential minerals with 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D among Saudi patients.

Method: A convenience sample case-control study involving (N=199) Saudi patients, with vitamin D deficiency (N=87) (35male/52female), and vitamin D sufficiency (N=112) (66male/46female), were included in this study. Calcium, phosphate, magnesium, copper, iron, total iron binding capacity (TIBC), lipid profile, 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were measured.

Results: Results showed a significant difference (P<0.05) in plasma glucose (P=0.053), TIBC (P=0.015) and transferrin saturation (P=0.004) and no significant difference in calcium, phosphate, magnesium, copper and iron concentration between the vitamin D deficient and the vitamin D sufficient group. High levels of 25-hydroxyvitamin D in the vitamin D sufficient group was found to be significantly associated with high levels of HDL cholesterol,

and low levels of calcium and magnesium. High levels of 25-hydroxyvitamin D in the vitamin D deficient group was found to be significantly associated with low levels of copper and glucose.

High levels of 1,25-dihydroxyvitamin D in the vitamin D deficient group was found to be significantly associated with low levels of magnesium.

Conclusion: In conclusion, association between vitamin D and various essential minerals varies considerably.

Table: Associations between bone strength and its changes at the distal radius and tibia and the risk of incident major osteoporotic fractures in women.

Multivariate cox regression	RADIUS (n=514)		TIBIA (n=556)	
	HR (95%CI)	P-value	HR (95%CI)	P-value
Failure load (baseline) ↘SD	1.81 (1.06, 3.10)	0.030	1.63 (1.01, 2.61)	0.045
Failure load (change) ↗SD	0.80 (0.52, 1.23)	0.310	1.33 (0.94, 1.89)	0.106
Age ↗SD	0.92 (0.58, 1.46)	0.736	0.94 (0.63, 1.42)	0.782

Data are hazard ratio associated with one standard deviation change of each parameter, obtained from Cox's proportional hazard models.

P1072
COMPARATIVE STUDY OF WEEKLY ALENDRONATE VS. YEARLY ZOLEDRONIC ACID INJECTION IN TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS IN TERMS OF EFFICACY, COMPLIANCE AND BONE MARKERS ESTIMATION

R. Malhotra¹, L. Chawla¹

¹All India Institute of Medical Sciences, New Delhi, India

Objectives: To compare the efficacy and compliance of alendronate vs. zoledronic acid in treatment of postmenopausal osteoporosis with calculation of bone turnover markers level in serum and urine.

Methods: A total of 122 postmenopausal women with osteoporosis were included followed by written consent. Diagnosis of osteoporosis was made by DXA scan (T-score <-2.5 or below). Patients were categorized in two treatment groups (group 1 & 2) by random allocation methods. Group 1 and 2 were designated as alendronate (AL) arm zoledronic acid (ZA) arm respectively. The changes recorded in patients were observed at baseline, 3 and 12 months of therapy either with AL or ZA. Compliance for the drug AL was assessed by asking the patient to return the empty packets of medicines consumed by them. Efficacy of treatment was assessed by calculating bone turnover markers for bone resorption such as urine NTx, BCTx and bone formation markers such as BSAP and PINP. Two-sample Wilcoxon rank-sum (Mann-Whitney) test was used. Data are represented in median (min-max) values and p value was considered significant as <0.05.

Results: The mean age, height and weight of patients were 60.40±6.98 y, 147.56±6.55, and 58.45±8.58 respectively. The median baseline BMD, PTH, vitamin D, calcium, ALP and phosphorous were -3.7 g/cm³, 46.27 pg/ml, 33.60, 9.33, 180.88 Ka/IU and 3.94 mg/dl respectively. While comparing the data in alendronate and zoledronic acid arms, we analysed values in between groups

at baseline, and at 3 months and 1 y follow-up. The value of different bone markers were statistically compared between the two groups. The bone resorption markers, B-CTx shows p value of 0.4296 and 0.5208 between the two groups at 3 months and 1 year follow-up respectively, and NTx shows p value of 0.9206 and 0.1580 between two groups at 3 months and 1 y respectively. Additionally, the bone formation markers, PINP and BSAP shows p values of 0.6988 and 0.4227, 0.9174 and 0.5028 at 3 months and 1 year between two groups respectively.

Conclusion: As seen from the final statistical analysis, it is clear that there is no difference between the 2 groups in terms of efficacy of treatment. It may be noted that the compliance rate in treatment with zoledronic acid group was 100% as the injection was only given once under supervision, making it a superior drug in terms of convenience. However, oral bisphosphonate (alendronate) being effective and affordable may remain a first line of therapy for the treatment of osteoporosis. A longer term follow-up, however, is desired to adequately compare the difference in outcomes between these two drug groups.

P1073
ARE THYROID HORMONES IN THE NORMAL RANGES ASSOCIATED WITH BONE MINERAL DENSITY, TBS, OR INCIDENT FRACTURES IN POSTMENOPAUSAL WOMEN? THE 5-YEAR FOLLOW-UP COLAUS/OSTEOLAUS COHORT

C. Vendrami¹, P. Marques-Vidal¹, E. Gonzalez Rodriguez¹, D. Hans¹, G. Waeber¹, O. Lamy¹

¹Lausanne University Hospital/Internal Medicine, Lausanne, Switzerland

Objective: Several studies found that subclinical hyperthyroidism is associated with low BMD and increased fracture risk. In healthy postmenopausal women, results regarding an association between TSH levels in the normal range and BMD are contradictory.

Trabecular bone score (TBS) is often decreased in secondary osteoporosis. The aim of this study was to determine the association between thyroid hormones (TSH, fT4) in the normal range and BMD, TBS, and incident fractures at 5 y.

Method: We assessed 1475 women aged 50-80 y following in the CoLaus/OsteoLaus cohort. Exclusion criteria were treatment for OP, diabetes, hypo/hyperthyroidism, with hormonal replacement therapy or prednisone, and TSH or fT4 outside the normal ranges. We evaluated BMD at lumbar spine, femoral neck and total hip, TBS, and vertebral fracture with DXA. Incident major OP fractures were evaluated 5-years later by questionnaire and DXA.

Results: 710 women (age 68.7±7.5 y, BMI 25.9±4.6 kg/m², TSH 2.31±1.34 mU/l, fT4 15.45±2.00 pmol/l) met the inclusion criteria. There was no significant association between TSH or fT4 and BMD measures at any site. A positive correlation was found between TSH and TBS (p<0.001), even after correction for tissue thickness (p<0.001). This correlation was no more significant after multiple adjustments for age, BMI, renal function, and smoking history. There was no significant association between fT4 and TBS. Mean TSH (2.32±0.53 vs. 2.15±0.18 mU/l) and mean fT4 (15.47±0.79 vs. 15.18±0.24 pmol/l) were similar in women without or with major OP fracture 5 years later.

Conclusion: In postmenopausal women with TSH or fT4 in the normal ranges, neither BMD, nor major OP fractures incidence were associated with TSH or fT4 values. This is the first study showing a correlation between TSH and TBS. Lower TSH may lead to a weaker bone structure without affecting BMD, but further studies are needed to evaluate the influence of thyroid hormones on TBS.

P1074

THE EVALUATION OF BONE MINERAL DENSITY AND VERTEBRAL FRACTURE FREQUENCY IN PATIENTS WITH PROLACTIN SECRETING PITUITARY ADENOMA

E. Imre¹, D. Gogas Yavuz¹

¹Marmara University School of Medicine, Istanbul, Turkey

Objective: An increased prevalence of radiological vertebral fractures was observed in women with prolactin (PRL)-secreting pituitary adenoma. The aim of this study was to evaluate BMD, bone turnover markers and vertebral fracture frequency in patients admitted a tertiary endocrine clinic

Methods: 230 patients diagnosed prolactinoma over a year and 46 controls were in this cross-sectional study. Vertebral fractures assessment done on lateral X-ray examinations of the thoracic and lumbar spine according to Genant's classification. BMD was measured at the lumbar spine and femoral neck by DXA. The levels of prolactin, calcium, PTH, 25 OH vit D, osteocalcin, C telopeptide levels were evaluated. BMI was calculated.

Results: Vertebral fractures were observed in 106(46%) patients with prolactinoma and in 13 (20.3%) of controls (P<0.001). vertebral Fracture detected. Clinical and laboratory results of the vertebral fracture positive and negative prolactinoma patients was shown in Table 1. Vertebral fracture detected prolactinoma patients have lower BMD measurements compared to patients without vertebral fracture (p<0.001). Fractured patients with prolactinoma were older than nonfractured patients (p=0.006) but there was not a difference in the duration of the disease (p 0.88). The serum prolactin level at the follow-up wasn't statistically different between two groups (p=0.96).

Conclusion: This cross-sectional study shows that radiological vertebral fractures occurred more in patients with PRL-secreting pituitary adenomas according to the controls. Vertebral fractures were significantly correlated with BMD.

Table 1: Clinical and laboratory parameters of vertebral fracture positive and negative prolactinoma patients

	Vertebral Fracture + (n:106)	Vertebral fracture - (n:124)	P-values
Age (years)	44,43 ± 12,46	38,45 ± 9,79	0,006
Duration of disease (years)	6,434 ± 6,035	6,355 ± 5,541	0,88
BMI (kg/m ²)	29,47 ± 7,674	29,94 ± 6,600	0,75
L1-L4 BMD (g/cm ²)	1,114 ± 0,1869	1,196 ± 0,1808	0,0008
Femur neck BMD (g/cm ²)	0,9589 ± 0,1848	0,9935 ± 0,1415	0,07
Serum Prolactine (ng/ml)	128 ± 346,5	261,3 ± 17,54	0,96
25-OH-D (ng/dl)	22,4 ± 11,38	20,09 ± 10,63	0,14

P1075

THE BIOLOGIC AGENT SB4 ETANERCEPT BIOSIMILAR IN THE TREATMENT OF AUTOIMMUNE RHEUMATIC DISORDERS: REMISSION OF MUSCULOSKELETAL AND OTHER MANIFESTATIONS

P. Athanassiou¹, E. Devetzi¹, L. Athanassiou², P. Tsakiridis¹, A. Tzanavari¹, M. Gatsiou¹, C. Katsavouni¹, I. Kostoglou-Athanassiou³

¹Department of Rheumatology, St. Paul's Hospital, Thessaloniki,

²First Department of Internal Medicine, Asclepeion Hospital, Voula, Athens, ³Department of Endocrinology, Asclepeion Hospital, Voula, Athens, Greece

Objective: The etanercept biosimilar SB4 has entered the market recently and is being evaluated for its safety and efficacy in the treatment of autoimmune rheumatic disorders. The aim of the study was to describe the efficacy and safety of the etanercept biosimilar SB4 in the treatment of autoimmune rheumatic disorders. In particular, the efficacy of the etanercept biosimilar SB4 in the treatment of the musculoskeletal manifestations of autoimmune rheumatic disorders was evaluated.

Methods: The etanercept biosimilar SB4 was administered in 50 patients with autoimmune rheumatic disorders, 16 with rheumatoid arthritis, 14 with ankylosing spondylitis and 20 with psoriatic arthritis. Patients were previously on treatment with various agents, DMARDs and biologic agents. In particular, within the group of 16 patients with rheumatoid arthritis, 10 were on treatment with various anti-TNF agents and methotrexate, while 6 were on treatment with methotrexate and corticosteroids. Thus, within this group of 16 patients with rheumatoid arthritis in 6 the SB4 etanercept biosimilar was administered as a first line biologic treatment. Within the group of 14 patients with ankylosing spondylitis 11 were on treatment with anti-TNF agents and were switched to SB4. Within this group of 14 patients with ankylosing spondylitis in 3 biologic treatment was initiated with SB4. Within the group of 20 patients with psoriatic arthritis 12 were on treatment with anti-TNF agents and were switched to SB4, 4 were on treatment with an interleukin-17 inhibitor and were switched to SB4, 1 was on treatment with the IL-12/23 inhibitor ustekinumab and was switched to SB4 and in 3 biologic treatment was initiated with SB4.

Results: All 16 patients with rheumatoid arthritis achieved remission of the disease and tolerated the agent well. All 14 patients with ankylosing spondylitis achieved remission of the disease with SB4 and tolerated the agent very well. All 20 patients with psoriatic arthritis achieved remission of the disease as far as arthritis and dermatologic manifestations and tolerated the agent very well. No adverse reactions were observed. Additionally, patients reported being satisfied with the use of the SB4 method of administration.

Conclusions: The SB4 etanercept biosimilar appears to be safe and effective for the treatment of autoimmune rheumatic disorders. In particular, remission was achieved in rheumatoid arthritis patients and ankylosing spondylitis patients. In psoriatic arthritis

both articular and skin manifestations responded to the treatment. The agent was equally effective either after switch from another biologic agent or as initial treatment.

P1076

DIAGNOSTIC PERFORMANCE OF PINP IN IDENTIFYING CUSHING'S DISEASE

T. Tsoriev¹, Z. Belaya¹, T. Grebennikova¹, L. Nikankina¹, A. Ilyin¹, G. Melnichenko¹, I. Dedov¹

¹The National Medical Research Centre for Endocrinology, Moscow, Russia

Objective: N-terminal propeptide of type I procollagen (PINP) is a bone formation marker which was recommended by the IOF and IFCC for use in clinical trials for monitoring the efficacy of osteoporosis treatment. Patients with Cushing's disease (CD) have suppressed bone formation and osteocalcin can be used as a diagnostic biomarker to differentiate endogenous hypercortisolism from healthy controls and postmenopausal osteoporosis [1]. The goal of this study was to evaluate whether PINP can be used to diagnose CD.

Methods: We enrolled subjects with CD confirmed by routine testing (late-night salivary cortisol; 24h urinary free cortisol) and healthy controls. Fasting serum samples were taken from patients with CD and stored at -40°C. Commercially available kits ECLIA Cobas e601 Roche were used to estimate both PINP and osteocalcin values. ROC-analysis was used to determinate the diagnostic accuracy and the threshold for PINP to differentiate CD.

Results: The study included 29 patients with CD (39.93 years old, 95%CI 34.07-45.79) and 26 controls (34.69 years old, 95%CI 30.32-39.07) matched by sex, age and BMI (p=0.257, 0.155 and 0.771 between groups, respectively). Both bone formation markers, osteocalcin and PINP, were markedly decreased in patients with CD. PINP levels negatively correlated with late-night salivary cortisol: $\rho=-0.651$ (p<0.001). The area under the curve (AUC) for PINP - 0.808 (95%CI 0.693-0.924) was significantly lower compared to the AUC for osteocalcin - 0.925 (95%CI 0.857-0.992). The threshold for PINP at 53.4 ng/ml yielded a sensitivity of 96.55% and a specificity of 57.69% to diagnose CD among healthy subjects. At the same time the threshold for osteocalcin at 15.2 ng/ml yielded a sensitivity of 92.59% and a specificity of 77.78%.

Conclusions: PINP has less diagnostic accuracy vs. osteocalcin in identifying Cushing's disease. However, it can be useful as a complementary diagnostic test in CD diagnosis.

Reference: 1. Belaya ZE et al. Bonekey Rep 2016;5:815.

P1077

MUSCLE ASSESSMENT WITH DYNAMIC 2D SHEAR WAVE ELASTOGRAPHY: PITFALLS AND LIMITATIONS

M. Kljaic Dujic¹, V. Bojnec¹

¹University Medical Centre Maribor, Maribor, Slovenia

Objectives: Recently, many studies have been published on muscle ultrasound dynamic shear wave elastography (dSWE). However, most of them deliver very heterogeneous findings, which make them less comparable and the results less informative. Therefore, it is nearly impossible to use meta-analyses as a reliable statistical approach. The lack of standardized protocols and a very high inter- and intraobserver variability remain a diagnostic problem. How to avoid typical procedural mistakes and to deal with pitfalls and limitations of the SWE technique remains an important issue.

Methods: Over the past 2 y, 161 papers on muscle SWE have been publicized (PubMed). SWE still has a major variation in repeatability, especially in different muscle groups and contraction evaluation. The main reason for the variety in results is discussed in this literature review.

Results: Muscle architecture and force loading can be very complex. Each muscle is composed of grouped fascicles, which attach to aponeuroses and form a pennation angle. Fibre direction changes in unipennate, bipennate or multipennate muscles and muscle anatomy knowledge can be helpful. Stiffness measurements and visualization were better in longitudinal fibre and probe orientation. Stiffness values were higher in nearby arteries and deeper tissue layers, in particular over the bone. During muscle contractions, heterogeneous elastogram patterns appeared often due to force orientation and specific biomechanics, therefore inconsistencies might be expected. It might be challenging to achieve complete relaxation or to repeat the exact rate of muscle contraction. Muscle fatigue, temperature, previous physical therapy, higher probe pressure, joint and even patient position can significantly affect stiffness values. Higher measurements were also a result of many technical factors, such as larger ROI, linear probe and ultrasound presets. Measurements obtained on two separate ultrasound machines are difficult to compare. Caution is needed due to artefacts: attenuation effect (deeper structures), reflections (bone, fascia), signal void (fluid), mirrored elastogram, and movement artefact.

Conclusion: As an emerging noninvasive technology, dynamic SWE of muscle is being investigated and despite numerous studies, this technique alone is still not reliable and accurate enough for routine clinical use. With the technological progress and considering muscle peculiarities, it has the potential for a good additional diagnostic tool.

P1078

RADIAL EXTRACORPOREAL SHOCKWAVE THERAPY IN REHABILITATION OF CALCIFIC TENDINOPATHY OF THE ROTATOR CUFF

M. Manoleva¹, E. Nikolikj Dimitrova¹, B. Kalcovska Ivanovska¹, M. Gocevska¹, L. Malinovska Nikolovska², V. Koevska¹, C. Gjerakaroska Savevska¹, B. Mitrevska¹

¹Institute of Physical Medicine and Rehabilitation, Medical Faculty, "Ss Cyril and Methodius" University, ²GOB "8mi Septemvri", Skopje, Macedonia

Objective: The most common cause of shoulder pain is calcific tendinopathy of the rotator cuff. The clinical assessment of the disease is dominated by pain and limited range of movement in the shoulder. Treatment of calcific tendinopathy of the rotator cuff can be conservative and operative. In a conservative approach in the acute phase, NSAIDs and local application of corticosteroids, cryotherapy and positioning of the shoulder joint in mild abduction are provided. In the subacute and chronic phase of the disease, physical agents and exercises are used. Radial extracorporeal shockwave therapy is newer form of nonsurgical treatment with physical modalities. The aim of this presentation is to evaluate the effects of the radial extracorporeal shockwave therapy (RESWT) in rehabilitation of calcific tendinopathy of the rotator cuff.

Materials and Methods: A 42-year-old woman comes for examination due to pain and limited range of movement in the right shoulder. The patient was treated with medication and conventional physical treatment two months before. Plain radiography of the right shoulder revealed presence of calcific rounded masses in the attachment of tendons within the rotator cuff. VAS score on the day of admission was 8. Range of movement was: elevation 85°, retroflexion 20°, abduction 40°, adduction 10°, internal rotation 30°, external rotation 40°. The patient was on RESWT treatment, number of strokes was 2000, duration of treatment - 7 min (determined by an application protocol), 5 treatments applied once a week in one session, local in the area of the right shoulder.

Results: 3 months after RESWT treatment VAS score was 1; range of movement was: elevation 165°, retroflexion 30°, abduction 90°, adduction 25°, internal rotation 70°, external rotation 80°; control plain radiography of the right shoulder showed completely disintegrated and resolved calcification.

Conclusion: RESWT is an effective alternative compared to other conservative and operative treatments of calcific tendinopathy of the rotator cuff. This treatment shows better efficiency in terms of pain relief, improved shoulder joint function, disintegration of calcification, safety, noninvasiveness and cost-effectiveness. Therefore RESWT should be the treatment of choice in this pathology.

P1079

EFFECTS OF ANGIOPOIETIN-LIKE PROTEINS TYPES 3 AND 4 ON ANGIOGENESIS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOPOROSIS

V. A. Aleksandrov¹, L. N. Shilova², N. V. Aleksandrova¹, N. V. Nikitina¹, A. V. Aleksandrov²

¹Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky, ²Volgograd State Medical University, the Department of Hospital Therapy, Volgograd, Russia

Objective: The family of angiopoietin-like proteins actively participates in both physiological and pathophysiological, primarily inflammatory processes. The angiopoietin-like protein 3 (ANGPTL3) and the angiopoietin-like protein 4 (ANGPTL4) are of interest due to their contribution to the processes of angiogenesis and lipid metabolism. Periarticular osteoporosis (OP) in rheumatoid arthritis (RA) is accompanied by systemic bone loss and a high risk of osteoporotic fractures. The purpose is to study the influence of ANGPTL3 and ANGPTL4 on the peculiarities of angiogenesis in patients with RA and OP.

Methods: The study included 36 RA patients (aged from 33-64 years old, women – 100%). A control group (12 people) comprised healthy individuals aged 28-52 years old. Levels of ANGPTL3 and ANGPTL4 in serum were determined by the enzyme immunoassay using the commercial test systems from “Bio Vendor”. Ultrasound examination of the wrist joints was carried out according to the standard procedure using a linear sensor with a frequency of 5-12 MHz on the ultrasound diagnostic system Accuvix V10. The features of the blood flow were studied by color and energy dopplerography (the number of color locus was visually assessed). Osteodensitometry was performed on a X-ray densitometer Lunar DPX. The assessment of the bone tissue of the proximal femur condition was carried out according to the T-criterion.

Results: The level of ANGPTL3 and ANGPTL4 was significantly higher in patients with RA ($p=0.043$ and $p=0.038$, respectively), than in the control group. Hypervascularization rates were significantly correlated with ANGPTL4 in patients with RA ($r=0.38$, $p=0.002$) according to Doppler data. A positive correlation was found between the level of ANGPTL4 and low T-criterion ($r=-0.842$). It has been proved that ANGPTL3 and ANGPTL4 has a pro-angiogenic activity. Apparently, ANGPTL4 can activate proliferation processes in the synovial membrane, by binding to integrin- $\alpha v \beta 3$. Besides, the concentration of mast cells is increased in the synovium of affected joints. Mast cells significantly influence angiogenesis through the production of proangiogenic cytokines, including ANGPTL4.

Conclusions: The search for new serological markers that can serve as objective indicators of various pathological processes, such as neovascularization, developing in inflammatory joint diseases, is an important stage in clinical trials in RA with osteoporosis. The connection between ANGPTL4 and OP in women with RA requires further research.

P1080

EFFECT OF TREATMENT ON FUNCTION, MOBILITY AND LIPID PROFILE IN ANKYLOSING SPONDYLITIS

A. Tzanavari¹, I. Kostoglou-Athanassiou², L. Athanassiou³, T. Dardavesis⁴, P. Athanassiou¹

¹Department of Rheumatology, St. Paul's Hospital, Thessaloniki,

²Department of Endocrinology, Asclepeion Hospital, Voula, Athens, ³First Department of Internal Medicine, Asclepeion Hospital, Voula, Athens, ⁴Department of Hygiene and Social Medicine, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

Objective: Ankylosing spondylitis (AS) is a chronic systemic inflammatory disorder which affects the sacroiliac joints, the axial skeleton, peripheral joints as well as other organs. It develops in young adults causing significant mobility and functional disorders, with associated severe dysfunction or disability. Ankylosing spondylitis has serious adverse effects on the ability to work and quality of life. The aim was to follow-up a group of AS patients as far as their mobility and functional ability, as well as to evaluate comorbidities, lipid profile and cardiovascular risk and to evaluate the effect of treatment on these parameters.

Methods: Questionnaires were used for the estimation of function and mobility, namely BASDAI, BASFI, BASMI, health indices, namely BAS-G, ASAS-Health Index and a questionnaire of productivity and work-related productivity, namely WPAI:GH was utilized. The inflammation indices ESR and CRP were measured, as well as blood total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. The 10-y cardiovascular risk was evaluated using SCORE.

Results: BASDAI index decreased from 3.91 ± 0.67 before to 2.51 ± 0.47 (mean \pm SEM) after treatment in AS patients ($p < 0.001$, Student's t-test), BASFI from 4.05 ± 0.68 to 3.17 ± 0.61 ($p < 0.001$), BAS-G from 4.25 ± 0.69 to 3.29 ± 0.57 ($p < 0.001$), ASAS-Health Index from 7.29 ± 1.23 to 5.23 ± 0.93 ($p < 0.001$) and ESR from 16.12 ± 3.4 mm/h to 12.41 ± 2.9 mm/h ($p < 0.001$). Total cholesterol increased from 113.52 ± 20.26 mg/dl before to 193.41 ± 8.81 mg/dl ($p < 0.001$) after treatment, HDL cholesterol from 25.37 ± 4.64 mg/dl to 54.06 ± 4.74 mg/dl ($p < 0.001$), LDL cholesterol from 69.52 ± 13.02 mg/dl to 112.5 ± 8.67 mg/dl ($p < 0.001$) and triglycerides from 86.97 ± 22.21 mg/dl to 138.65 ± 23.91 mg/dl ($p < 0.001$).

Conclusions: It appears that in AS indices of function and mobility as well as health indices improve after treatment, whereas the lipid profile is altered, without, however, an adverse effect on atherogenesis.

Acknowledgements: Dr. Tzanavari Aikaterini was supported by a fellowship from the Hellenic Society for Rheumatology.

P1081

RELATIONSHIPS BETWEEN CLINICAL PHENOTYPE AND PROFILE OF AUTOANTIBODIES IN RHEUMATOID ARTHRITIS

M. V. Volkava¹, A. V. Kundzer¹¹Belorussian medical Academy of Postgraduate Education, Minsk, Belarus

Objective: The concept of rheumatoid arthritis (RA) as a heterogeneous disease with a variety of immunological options and a variety of clinical phenotype is gaining popularity. Heterogeneity of RA may explain why the similar treatment strategies do not lead to the same results in all patients with RA. The term "endotype" - a subtype of the disease, determined by a set of individual clinical and molecular biological, including immunological signs can be useful for the development of a personalized approach in the treatment of RA. The aim of the work was to study the relationship between the presence of certain autoantibodies in the patient with RA and the clinical phenotype of RA.

Methods: The study were included 182 patients (23 men (12.64%) and 159 women (87.36%), who fulfilled the EULAR/ACR 2010 classification criteria for RA. The mean age of patients was 52.50±14.01 y. The median age of RA onset (first symptoms) was 46 y (95%CI: 41,724 - 49,213). The disease duration in the examined patients was 48.00 months (95%CI: 36.00 - 69.05). Levels of rheumatoid factor (RF), antibodies to cyclic citrullinated peptide (anti-CCP), antibodies to Sa-antigen (anti-Sa) and antibodies to heterogeneous nuclear protein K (anti-gnpK) were evaluated by ELISA method according to the instructions of test system manufacturers. The presence of antinuclear antibodies (ANA) was determined by IIF on an automated digital system AKLIDES using appropriate reagents.

Results: The several clinical phenotypes of RA were distinguished. The group of the typical variant of RA without systemic manifestations included 123 patients who had a typical articular syndrome and had no systemic or spondylarthritis (SpA) signs. The typical variant of RA with systemic manifestations was determined in 40 patients who, in addition to the typical signs, had systemic manifestations. The group of RA with signs of SpA included 19 patients who, in addition to typical signs, have atypical for RA, but specific for SpA manifestations (HLA-B27-allele, axial, non-axial and extraskelatal signs of SpA). RA activity levels according to indices DAS28, CDAI, SDAI did not differ in patients depending on clinical phenotype ($p < 0,05$).

The frequency of occurrence of anti-CCP and RF in typical RA with systemic manifestations (95.20% and 89.70%, respectively) was higher than in typical RA ($p = 0.03$ and $p = 0.003$, respectively) and RA with signs of SpA ($p = 0.003$ and $p = 0.03$, respectively). There were no differences between the frequency of anti-Sa and anti-gnpK antibodies between clinical phenotypes ($p < 0.05$). The frequency of ANA occurrence was highest in the systemic variant of RA (65.00%) and significantly exceeded the frequency of ANA occurrence in the typical variant of RA ($p = 0.007$). The levels of anti-CCP ($p = 0.003$), RF ($p = 0.004$), ANA ($p = 0.003$) and anti-Sa ($p = 0.02$) antibodies were significantly higher in the systemic vari-

ant of RA compared to the typical variant of RA. Anti-CCP and RF levels were higher in the systemic variant of RA than in RA with signs of SpA ($p = 0.0005$ and $p = 0.005$, respectively).

Conclusions: Thus, anti-CCP, RF and ANA are not only significant diagnostic biomarkers of RA, but also can be useful for stratification of patients and isolation of individual clinical and immunological variants of the disease. The highest incidence of anti-CCP, RF and ANA, as well as higher levels of autoantibodies in RA with systemic manifestations corresponds to the idea of the predominance of B-cell autoimmunity over T-cell in this group of patients.

P1082

RELATIONSHIP BETWEEN SARCOPENIA AND URINARY INCONTINENCE

T. Erdogan¹, G. Bahat¹, C. Kilic¹, P. Kucukdagli¹, M. M. Oren², O. Erdogan³, O. Yilmaz¹, D. Erbas Sacar¹, M. A. Karan¹¹Istanbul Medical Faculty Internal Medicine Department Geriatrics Division, ²Istanbul Medical Faculty Public Health Department, ³Istinye State Hospital, Istanbul, Turkey

Objective: Urinary incontinence (UI) and sarcopenia are common geriatric syndromes. They both increase the risk of falls and fractures in older adults. Identification of factors associated with UI is necessary to identify risky individuals, to take preventive measures and to recognize commonly associated comorbidities. We suggest that sarcopenia and/or its components may be associated with stress and urgency UI through decrease in muscle mass/strength. In this study, we aimed to investigate the relationship between UI (stress and/or urgency) and sarcopenia.

Methods: Female older adults ≥ 60 y that applied to geriatric outpatient clinic were analyzed cross-sectionally. Demographic data, clinical data including the presence of UI, UI types fecal incontinence, constipation were obtained. Functional status was assessed by basic and instrumental activities of daily living (ADL and IADL), nutrition by mini-nutritional assessment-short form (MNA-SF). Total muscle mass was measured by bioimpedance analysis and adjusted by three different methods (by height², BMI or weight). Hand grip strength and walking speed were assessed. The factors found significantly associated with UI in univariate analysis were further evaluated by logistic regression analysis.

Results: A total of 802 female adults were included. The prevalence of UI was 48.9%. Associated factors with presence of UI were higher age and BMI, presence of fecal incontinence, constipation, lower activities of ADL and IADL scores, lower grip strength, lower skeletal muscle mass adjusted by weight and BMI and presence of sarcopenia adjusted by weight and BMI in univariate analyses. In regression analysis independent factors related with UI were presence of fecal incontinence, constipation, IADL dependency, low muscle mass adjusted by weight and BMI and sarcopenia adjusted by weight.

Conclusion: The results of our study suggest that UI is independently associated with sarcopenia when muscle mass was adjusted by weight and also with presence of low muscle mass when muscle mass was adjusted by weight or BMI. Sarcopenia

and urinary incontinence are related and both increase the risk of falls and fracture. The primary aim should be the prevention of sarcopenia in order to decrease the risk of falls.

P1083

HIP FRACTURES IN THE ELDERLY: OSTEOMALACIA IS AN UNDER RECOGNIZED CAUSE

U. C. Saini¹, K. Kumar¹, R. K. Kanojia¹, D. K. Chouhan¹, K. Vaiphei¹, A. Bal¹, M. Prakash¹, S. Bhadada¹

¹Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India

Objective: To assess the prevalence of osteomalacia in osteoporotic hip fractures and correlate biochemical markers of osteomalacia to the histopathology.

Methods: Prospective cohort study between July 2015 and June 2016. Consecutive elderly patients (aged >50 y) with proximal femur fractures were enrolled. Patients with malignancy, significant trauma or fractures of additional bones were excluded. Osteoporosis was identified by DXA scan of nonfractured hip and lumbar spine. Metabolic tests including serum calcium, phosphorous, alkaline phosphate, renal and liver functions, parathormone and vitamin D levels were done. During surgery, bony tissues was taken from a site adjacent to the fracture. Histological examination was performed on nondecalcified paraffin sections using H&E, toluidine blue, elastic von Gieson, Masson's trichrome and solochrome cyanine stains.

Results: Out of total 45 cases, 25 were female and 20 were male patients. Mean age of patients was 68.7 y [53-85 y]. Abnormal values of serum calcium were noted in 20 patients [44.4%], serum phosphorus in 10 patients [22.2%], serum ALP in 24 patients [53.3%] and serum vitamin D in 22 patients [48.9%]. In histopathology, 30 patients out of 41 patients [73.17%] showed Osteomalacia; for the rest of 4 patients, histopathology not representative and showed dead or fibrous tissue. 3 patients (6.7%) had mild, 8 patients (17.8%) had moderate and 19 patients (42.2%) had severe osteomalacia. Histopathological grade and prevalence of osteomalacia neither correlated well with vitamin D levels nor with any other metabolic marker such as serum calcium, serum phosphorus, alkaline phosphate.

Conclusion: In the majority of elderly osteoporotic hip fracture patients, osteomalacia is the cause of bone weakness and fractures occur due to minor trauma. Abnormal biochemical values may not be significantly associated with osteomalacia; hence, histopathology remains the gold standard for diagnosis of osteomalacia.

P1084

INCIDENCE AND RISK FACTORS INVOLVED IN THE DEVELOPMENT OF COMPLEX REGIONAL SYNDROME

C. E. Gofită¹, A. E. Mușetescu¹, F. A. Vreju¹, A. Florescu¹, O. C. Rogoveanu¹, P. L. Ciurea¹

¹Emergency County Hospital of Craiova, Craiova, Romania

Objectives: The complex regional pain syndrome (CRPS) is a neuropathic disorder that involves regional disabling pain with severity that is disproportionate to an inciting event. It is usually accompanied by swelling, impaired motor function and sympathetic dysfunction (sudomotor abnormality). CRPS has three evolutionary stages acute, dystrophic and atrophic and it is classified in two types depending on the existence of nerve damage. In this study we evaluated the patient's history prior to the onset of CRPS, which might give clues to the potentially shared pathogenic or etiologic factors, as well as the risk factors for CRPS.

Methods: A total of 45 cases diagnosed with CRPS were assessed based on the clinical presentation (Budapest criteria 2010). Anamnestic data regarding demographics, age, sex, clinical criteria and biological samples were collected from the investigated patients, after signing the informed consent. Moreover, the visual analogue scale was used for the evaluation of pain.

Results: In this study, we systematically investigated the associations between medical history and CRPS occurrence with the purpose to find potential risk factors and leads towards CRPS underlying mechanisms. The mean age for CRPS onset in the study population was 50 y, its incidence increasing with age. Sex distribution was favorable to females in a ratio of 4:1. The fracture was the most common precipitating injury in 27 (60%) of the cases, while for the rest, other initiating events were incriminated, including soft tissue and tendon injuries, strokes, sprains, malignancies and postherpetic neuralgia. The role of inflammation is endorsed by the demonstration of inflammatory mediators in serum from patients with CRPS. Additionally, the sympathetic nervous system dysfunction led to mixed dyslipidemia, hyperglycemia and hyperuricemia.

Conclusion: This observational study revealed the predisposition of some patients to develop CRPS and are susceptible to generate abnormal reactions to painful stimuli. Early recognition of risk factors and diagnosis of CRPS, followed by occupational and physical therapies could result in decreased pain symptomatology and improved outcome.

P1085

THE USE OF DRUG THERAPY FOR OBESITY IN THE TREATMENT OF PATIENTS WITH THE METABOLIC PHENOTYPE OF KNEE OSTEOARTHRITIS

E. Strebkova¹, L. Alekseeva¹

¹Nasonova Research Institute of Rheumatology, Moscow, Russia

Objective: Currently in the world there is a pandemic of obesity, which leads to an increase in diseases associated with overweight. Obesity is an important factor in the development and

progression of osteoarthritis (OA). The metabolic phenotype of OA, which is directly associated with obesity, is highlighted. Due to the growing number of patients with obesity and OA, a high level of comorbidity and the lack of effectiveness of non-drug therapy, the problem of the effectiveness and safety of the therapy of obesity is very relevant. Our aim was to evaluate the efficacy and safety of drug therapy for obesity in patients with knee OA.

Methods: 50 female patients (45-65 y.o.) with Kellgren-Lawrence stage II-III knee OA and obesity (BMI >30 kg/m²). Patients in Group 1 (n=25) took 120 mg of orlistat 3 times a day in combination with a low-calorie diet and exercise for 6 months. Patients in Group 2 (n=25) were on a low-calorie diet combined with exercise for 6 months. All patients initially received various nonsteroidal anti-inflammatory drugs (NSAIDs) in tablet form. All patients were assessed for body mass, parameters of the WOMAC index, EQ-5D quality of life index, NSAID consumption, and orlistat therapy safety assessment.

Results: After 6 months of drug therapy for obesity, patients from Group 1 achieved a significant weight loss by 10.07% (p<0.05) (Figure 1). Patients from Group 2 the use of nonpharmacological methods of treating obesity reduced body weight by 0.84% (p>0.05). Patients from Group 1 improved the WOMAC index (Figure 2): pain decreased by 52.5% (p<0.05), stiffness by 47.98% (p<0.05), and functional insufficiency by 51.55% (p<0.05). Patients from Group 2 also showed a decrease in the WOMAC index, but these changes were worse than in patients with greater weight loss. Patients from Group 1 showed a significant improvement in the quality of life for the EQ-5D index by 52.27% (p<0.05). Patients from Group 2 against the background of insignificant changes in body weight, the quality of life index EQ-5D did not change. The need to take NSAIDs on the background of drug therapy for obesity and weight loss decreased by 4.6 times. On the contrary, in Group 2 of patients on the background of non-pharmacological treatment of obesity after 3 months of observation, the need for NSAIDs was maintained in 76%. The need for NSAIDs in patients of Group 2 decreased 1.3 times. In general, the tolerability of orlistat in patients of Group 1 was good. Adverse reactions were observed in two patients in the form of steatorrhea. The appearance of an undesirable reaction was associated with errors in nutrition (eating food saturated with animal fats), which did not require discontinuation of the drug. After correcting the diet, no adverse reactions were noted in patients.

Conclusion: The results of our study showed a significant decrease in body weight by more than 10% in the group of patients with OA while receiving orlistat. Significant weight loss helps reduce pain intensity, improve joint function, improves the quality of life of patients with OA, reduces the need for NSAIDs, which can help stabilize other comorbid diseases in patients with OA and obesity. The study noted good safety of therapy with orlistat; no serious adverse reactions were reported. Thus, drug therapy for obesity using orlistat can be included in the management of patients with OA and obesity, who cannot achieve weight loss using non-drug methods.

Figure 1. Body mass dynamics during the study





Figure 2. Dynamics of changes in the total WOMAC during the study



P1086

VITAMIN D DEFICIENCY IN PATIENTS WITH LOW-ENERGY HIP FRACTURES

G. L. Sorokina¹, V. Y. Murylev², E. V. Kurilina³, L. R. Ivanenko², G. A. Kukovenko¹, Y. R. Goncharuk²

¹Botkin Hospital, ²I.M. Sechenov First Moscow State Medical University (Sechenov University), ³Burdenko Main Military Clinical Hospital, Moscow, Russia

Objective: Since the end of the last century, due to a high diagnostic level of osteoporosis using X-ray absorptiometry, there has been a decrease in interest in other metabolic bone diseases, such as osteomalacia. Pseudo-fractures, or Looser zones, are characteristic manifestations of osteomalacia as a result of vitamin D deficiency. According to statistics, the prevalence of vitamin D deficiency in patients aged 60 y and older with low-energy fractures can reach 69%, and the insufficiency rates can be as high as 98%. It is known that the appointment of specific anti-osteoporotic therapy during osteomalacia can lead to severe adverse effects. The objective was to assess the prevalence and study the peculiarities of vitamin D associated osteomalacia in patients with low-energy hip fractures.

Methods: 12 patients with low-energy hip fractures at the average age of 71 y (from 56-92 y) were examined. 10 of them were women (83%). Risk factors for osteoporosis and osteomalacia, symptoms of osteomalacia, history of injuries, biochemical blood tests (calcium, phosphorus, alkaline phosphatase, urea, creatinine, PTH, 25 (OH)vitamin D) were evaluated. All patients underwent hip arthroplasty. Removed bone fragments were examined histologically for signs of osteomalacia.

Results: In 11 cases (92%), clinical and biochemical changes characteristic of osteomalacia were found, which was confirmed by histological examination of resected bones. In 3 cases (25%) pseudofractures of other localization were found. Vitamin D deficiency was noted in 83% of cases, severe deficiency in 2 cases (17%).

Conclusions: Osteomalacia is a common problem especially in patients with low-energy hip fractures. Screening for vitamin D deficiency is indicated for all patients at risk. Prophylactic vitamin D supplementation will probably reduce the risk of fractures.

P1087

VALIDATION STUDY OF THE BERG BALANCE SCALE AS A CLINICAL TOOL TO PREDICT FALL RISK IN NEUROLOGICAL PATIENTS IN RUSSIA

A. Zimin¹, G. Yusupova¹

¹Research center of Neurology, Moscow, Russia

Objective: Balance disorders are the significant symptoms of many neurological diseases (Parkinson's disease, multiple sclerosis, stroke, etc.). There is a need for the standardized objective clinical tool to predict fall risk in neurological patients (NP) in Russia and Russian-speaking countries as there is not validated scale for this purpose. Meanwhile in Europe and USA Berg Balance Scale (BBS) is widely used for assessment of NP stability (Lima C. et al., 2018). The aim was to perform a validation study of Russian version of BBS.

Methods: 58 neurological patients included in the study had mild to moderate disability and could walk unassisted. The entire BBS validation procedure included translation by two independent medical translators and back translation by a native English speaker with fluent Russian, cultural adaptation and finally, assessment of psychometric parameters: internal and test-retest consistency, Inter-rater reliability, concurrent validity, and sensitivity. To test concurrent validity of the translated scale, Romberg Balance Test was performed in stabilometric platform Stablan-01-2 (JSC Rhythm, Russia).

Results: Internal consistency of Russian version of the BBS assessed by Cronbach's alpha was 0.84 ($p < 0.01$) that was higher than critical threshold (0.80). Inter-rater reliability of the scale evaluated by the Cohen's kappa was 0.92 ($p < 0.001$). Test-retest consistency was also high with the Pearson's correlation coefficient $r = 0.96$ ($p < 0.001$), indicating the stability of patient's assessment during the observation period. The BBS scores correlated significantly ($r = 0.79$, $p < 0.05$) with Romberg Balance Test, indicating acceptable concurrent validity. Finally, it was revealed high

enough level of sensitivity as Student's t-test showed a significant difference ($p = 0.047$) between scores before and after rehabilitation treatment.

Conclusions: Russian version of the BBS is a valid and sensitive tool to assess fall risk in neurological patients. It is also a useful scale for entire clinical examination of NP.

P1088

DIABETES, URINE INFECTIONS AND CANCER PREDICT POSTOPERATIVE OSTEOPOROTIC HIP FRACTURE MORTALITY

P. Xenophonos¹, P. Manolopoulos¹, K. Tsioutis¹, T. Dardavessis²

¹European University Cyprus, Nicosia, Cyprus, ²Aristotle University of Thessaloniki, Thessaloniki, Greece

Objective: Osteoporotic hip fractures remain a major cause of mortality and morbidity in individuals above 65 y of age. The aim of this study was to determine the predictors of outcome in patients submitted to surgery for osteoporotic hip fracture.

Methods: All patients over 65 admitted in a secondary general hospital for a period of 1 y due to osteoporotic risk fractures were included in a cohort trial, recording their demographics, quality of life, main health indicators and comorbidities and surgical outcome up to 3 months post admission. The study was approved by the Institutional and the National Bioethics Committee and the Personal Data Protection Commissioner. All data was pseudonymized and analyzed via the SPSS 20 Statistical Package.

Results: In total, 206 patients were enrolled in the trial, of which 128 female and 78 male, with a mean age of 81.1 y. Overall fatality for the three month follow-up was 4.4% (9/206). Among the population, only 10 individuals were already on treatment for osteoporosis, of which none died (0% fatality, $p < 0.0001$). On the other hand, fatality was increased among patients with diabetes (4/57 or 7% vs. 3.36%, $p < 0.001$), history of cancer (4/17 or 23.5% vs. 2.65%, $p < 0.0001$) and recent urinary tract infection (1/10 or 10% vs. 4%, $p < 0.001$).

Conclusion: A number of comorbidities, including diabetes and urinary tract infections negatively predict the outcome of major osteoporotic fractures. Early osteoporosis diagnosis and treatment seems to improve survival even among a very high risk population group for fractures.

P1089

LEVELS OF IMPROVEMENTS IN BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS TREATED WITH ROMOSUZUMAB: A POST HOC ANALYSIS OF THE ARCH PHASE 3 TRIAL

F. Cosman¹, E. M. Lewiecki², P. R. Ebeling³, E. Hesse⁴, N. Napoli⁵, T. Matsumoto⁶, M. Rojeski⁷, W. Yang⁷, C. Libanati⁸, S. L. Ferrari⁹

¹Columbia University, New York, USA, ²New Mexico Clinical Research & Osteoporosis Center, Albuquerque, USA, ³Monash University, Melbourne, Australia, ⁴University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁵Campus Bio-Medico University of Rome, Rome, Italy, ⁶Fujii Memorial Institute of Medical Sciences, University of Tokushima, Tokushima, Japan, ⁷Amgen Inc., Thousand Oaks, USA, ⁸UCB Pharma, Brussels, Belgium, ⁹Geneva University Hospital, Geneva, Switzerland

Objectives: To quantify the percentage of patients (pts) achieving improvements in BMD of different magnitudes with romosozumab (Romo) followed by alendronate (ALN) vs. ALN alone in the ARCH trial (NCT01631214).¹

Methods: Pts with osteoporosis and fragility fractures (Fx) were randomized to receive 210 mg subcutaneous Romo monthly or 70 mg oral ALN weekly for 12 months, followed by open-label ALN. Post hoc analyses assessed proportions of pts with ≥3%, ≥5% and ≥10% BMD improvements from baseline (BL) at lumbar spine (LS), total hip (TH) or femoral neck (FN) at Months 12 and 24. Included pts had a BL BMD and ≥1 post-BL BMD. Missing values were imputed by carrying forward the last non-missing observation in the treatment period; p-values were based on a logistic regression model adjusting for treatment, age, presence of severe vertebral Fx at BL, BL BMD, DXA manufacturer and BL BMD-by-DXA manufacturer interaction.

Results: 3679 pts were included in the analysis. Demographics and BL T-scores were similar between groups. At Month 12, a greater proportion of Romo pts achieved ≥3%, ≥5% and ≥10% improvements in BMD compared to ALN pts at all sites measured (all p<0.001) (Table). At 12 months, ≥5% gain at LS was seen in 91% of Romo vs. 48% ALN pts; at TH in 56% Romo vs. 26% of ALN pts; and at FN in 50% Romo vs. 21% ALN pts. At Month 24, after pts had transitioned to (or continued) ALN for 1 year, responder rates remained higher in Romo-to-ALN vs. ALN alone at all sites (all p<0.001) (Table).

Table. Patients meeting BMD improvement thresholds

BMD change from BL	Month	ALN, % (n=1577-1781) ^a			Romo, % (n=1571-1781) ^a		
		LS	TH	FN	LS	TH	FN
≥3%	12	67.2	47.2	37.6	95.1	74.1	65.6
	24	78.1	56.4	44.6	94.1	78.9	73.5
≥5%	12	47.7	25.9	21.3	91.2	55.9	49.6
	24	65.9	34.4	26.6	91.2	63.6	56.2
≥10%	12	14.4	3.1	4.3	68.2	18.0	16.7
	24	29.0	6.7	5.4	74.5	26.9	21.6

^aN numbers varied between BMD site and time period

Conclusions: After 1 year of Romo treatment, a significantly greater proportion of pts achieved high BMD gains at all skeletal sites compared with those seen on ALN therapy alone; these gains were maintained over 1 year of follow-up ALN therapy.

Reference: 1. Saag K. NEJM 2017;377:1417.

Acknowledgements: This study was funded by UCB Pharma and Amgen. Editorial services were provided by Costello Medical.

Disclosures: FC: Consultant/speaker (Amgen, Radius Health); consultant (Tarsa); former consultant/speaker (Eli Lilly). EL: Consultant (Amgen, Radius Health); speaker (Radius Health); research support (Amgen, Radius Health). PE: Research support (Amgen, Eli-Lilly); honoraria for speaker fees/advisory board (Amgen, UCB, Alexion). TM: Advisor (Amgen, Chugai, Daiichi Sankyo, Teijin). MR and WY: Employees and stockholders (Amgen).

P1090

HOW ARE PATIENTS MONITORED FOLLOWING ASSESSMENT BY FRACTURE LIAISON SERVICES: A GLOBAL AUDIT OF CURRENT PRACTICES

M. Fujita¹, K. Åkesson², T. Thomas³, W. F. Lems⁴, S. L. Ferrari⁵, C. Cooper⁶, M. K. Javaid⁷, D. O'Gradaigh⁸, P. Mitchell⁹

¹International Osteoporosis Foundation, Nyon, Switzerland, ²Department of Orthopaedics, Malmo Skane University Hospital, Malmo, Sweden, ³Rheumatology Department, University Hospital of St-Etienne, St Etienne, France, ⁴Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands, ⁵Faculty of Medicine, University of Geneva, Geneva, Switzerland, ⁶MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK, ⁷NDORMS, University of Oxford, Oxford, UK, ⁸Department of Rheumatology, Waterford Regional Hospital, Waterford, Ireland, ⁹Osteoporosis New Zealand, Auckland, New Zealand

Objectives: Despite robust evidence for the effectiveness of secondary fracture prevention, uptake in the real-world setting remains disappointing. One barrier to implementation is the effectiveness of monitoring strategies. There are few guidelines for this, and we here describe the current methods used to monitor patients by an FLS to inform a minimal global set of monitoring questions.

Methods: We used organisation audit returns from FLSs to the Capture the Fracture programme, International Osteoporosis Foundation. For every FLS that apply to join the CTF programme, a Best Practice Framework questionnaire is completed. In this questionnaire, questions on 13 standards, including patient monitoring (or "long-term management") standard are posed. The long term management standard consists of 8 items that assess how an FLS follows up with their patients in the short and long term.

Results: 323 FLSs from 41 countries completed this standard. 278/323 (86%) reported a pathway for evaluating patients. Of those FLS with a monitoring pathway, 74% were delivered by FLS, 4% by primary care and 22% by other clinical services. The content of the monitoring evaluation differed between FLSs: 96% included a measure of adherence, 89% asked about unwanted medication effects, 90% further fractures, 84% further falls and 77% risk factors for fracture. 66% of FLSs included all of the above components. Other components included DXA (6%), nutritional assessment (4%), function (4%) and turnover markers (3%). The timing of the monitoring visits varied. 62% of FLSs re-evaluated patients within 6 months, 46% between 6 and 12 months, 22% between 1 and 2 years and 18% after 2 years. 71% of services only re-evaluated patients once, 12% twice, 10% three times and 5% four times. 16% of services included re-evaluation before and after 6 months. Where the FLS conducted the monitoring, 96% of services used more than one method, with 81% used the clinic setting, 53% prescription records, 51% telephone calls and 6% postal questionnaires.

Conclusion: FLSs use a variety of content and methods for monitoring assessments. Further work is needed to link the observed variation in monitoring pathways to the effectiveness, efficiency and improved patient experience of FLSs to close the secondary fracture prevention care gap.

P1091

BONE DENSITOMETRY BY REMS TECHNIQUE REDUCES THE RISK OF BONE DENSITY OVERESTIMATION IN SUBJECTS AFFECTED BY OSTEOARTHRITIS

L. Cavalli¹, F. Lombardi², D. Perrone², M. L. Brandi¹

¹SOD Diseases of Mineral and Bone Metabolism, CTO, AOU-Careggi, Florence, ²Institute of Clinical Physiology - National Research Council, IFC-CNR, Lecce, Italy

Objective: To evaluate the predictive value of the radiofrequency echographic multispectrometry (REMS) [1] technique in detecting bone fragility in patients affected by osteoarthritis.

Methods: The lumbar and femoral T-score values of postmenopausal women (mean age 70.6 y, range 50-90 y, average BMI 24.2) measured by DXA were compared with those obtained by REMS technique, performed in the same anatomical sites within a month from DXA examination.

Results: In 30 subjects with clinical-radiological signs of osteoarthritis of the spine, lumbar (LS) T-score obtained with DXA were significantly higher than that measured at the femoral neck (FN). In the same subjects, REMS outcomes in femur and spine were more similar to each other (average T-score LS: -2.6±1.6 vs. T-score FN: -2.4±0.6), and significantly lower than the corresponding DXA measurement (significant difference between DXA and REMS T-score for both LS (p=0.006) and FN (p=0.010).

Conclusions: Osteoarthritis of the spine may reduce the accuracy of lumbar DXA examination, resulting in an overestimation of LS T-score with respect to FN one [2]. The densitometric parameters detected in the same subjects on spine and femur by REMS technique are more similar each other, than as results by DXA. REMS, which showed a strong correlation with DXA in a multicentric comparison study [1], is not affected by the presence of altered soft tissues composition. These data suggest a major predictive value of REMS in detecting osteoporosis in presence of osteoarthritis.

References:

1. Di Paola M et al. *Ost Int* 2018; doi:10.1007/s00198-018-4686-3
2. Blake GM and Fogelman I. *J Bone Min Res* 2008;23:457

P1092

PREDICTING PERSISTENT PAIN TWO YEARS AFTER WHIPLASH INJURIESC. Matzaroglou¹, K. Kafchitsas², P. Diaremes², I. Gelalis³, V. Angelopoulos¹, P. Gkrilias¹, J. Gliatis⁴, M. Tyllianakis⁴¹Technological University of Western Greece, Human Assessment and Rehabilitation Lab, Aigio, Greece, ²Asklepios Orthopaedic Clinic, Lindelohe, Schwandorf, Germany, ³University of Ioannina, Department of Orthopaedics, Spinal Surgery and Adult Reconstructive Surgery, Ioannina, Greece, ⁴University Hospital of Patras, University of Patras, Patras, Greece**Objectives:** The aim of this population cohort study is to determine the 2-y persistence of neck pain after whiplash injuries in Greece and Germany and to explore socio-demographic, health-related, occupational, physical, and lifestyle factors that might be linked to such persistence.**Methods:** Details of age and gender, questions relating to psychosocial, health-related, occupational, physical, and lifestyle factors estimated. Sociodemographic factors included social class, which was categorized according to the Standard Occupational Classification, marital status (married/partner or other) and number of children. Other health-related factors included current and past smoking status and daily alcohol intake. The measure of psychological distress was version of the HADS and BECK scales, which has been validated in general population samples. Finally, physical and lifestyle factors included SF-36 quality of life related scale, were measured. All that questionnaires used in 6, 12 months and 2 y after injury.**Results:** There were 344 responders to the baseline questionnaires. There were 254 replies to the 2-y follow-up, a response of 73.83%. A total of 16.6% reported having neck pain in 6 months after injury. 12.7% reported neck pain 12 months after injury and 9.6% reported neck pain 2 y after injury. Mean age was 35 y in nonresponders, mean age 54 years in responders. There were statistically significant differences in the reporting of persistent neck pain across different age categories with the highest likelihood of pain being among those 40-59 y of age. Sociodemographic and health-related factors: social class, marital status, BMI, smoking status, and number of children were not linked to the likelihood of chronic neck pain. Health-related factors were significant risk factors for persistence: poor general health (SF-36), poor psycho-

logical health (HADS, BECK). Among the occupational, physical activity, and lifestyle factors investigated, there were few predictors of persistent neck pain. The significant predictors included employment status and physical activity.

Conclusion: The message is to achieve a secondary prevention which focus more on treating in those at elevated risk of persistent pain

P1093

MAJOR RISK FACTORS OF POSTMENOPAUSAL WOMEN OSTEOPOROSIS IN TAIWAND.-H. Liu¹¹Department of Physical Medicine and Rehabilitation, Shin Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan**Objective:** To detect the major risk factors of postmenopausal women osteoporosis in Taiwan.**Methods:** A bus, equipped with DXA, serving for Taiwan country-wide BMD test was available between 2008-2011. Participants must complete a questionnaire regarding risk factors of osteoporotic fracture in FRAX® tool before BMD test. The risk variables comprised age, body height, body weight, postmenopausal age, previous fragility fracture, parent fractured hip, current smoking, alcohol consumption, glucocorticoids use, rheumatoid arthritis, and secondary osteoporosis. The participants are postmenopausal women. Osteoporosis was defined as lowest T-score ≤ -2.5 at any sites, including lumbar spine (L1 ~ L4), total hip, femoral neck. We performed regression coefficients through the univariate and multivariable analysis to detect the major risk factors of postmenopausal women osteoporosis.**Results:** A total of 12175 postmenopausal women (mean age: 66.0 \pm 9.6 y) were enrolled in this study. Of the study subjects, 5027 met the WHO definition of osteoporosis (41.3%). Through the univariate and multivariable analysis, we identified 7 major risk factors of osteoporosis, including age, body height, body weight, postmenopausal age, previous fracture, current smoking, and glucocorticoids use ($p < 0.05$), especially in age, body weight and smoking. The index weights of the final 7 variables which derived from multiple variable regression are listed in Table 1. The regression coefficients for the univariate and multivariable analysis of postmenopausal women osteoporosis risk factors are showed in Table 1.**Table 1. The regression coefficients for the univariate and multivariable analysis of postmenopausal women osteoporosis risk factors**

Variable	Univariate analysis			Multivariable analysis			Index weight
	β	SE [±]	P	β	SE [±]	P	
Age (vs.10 y younger)	-0.433	0.009	<0.001	-0.364	0.011	<0.001	-2
Height (vs.10 cm shorter)	0.573	0.016	<0.001	0.175	0.019	<0.001	1
Weight (vs.10 kg lighter)	0.439	0.010	<0.001	0.343	0.012	<0.001	2
Postmenopausal age (vs.10 y younger)	0.145	0.021	<0.001	0.161	0.022	<0.001	1
Previous fracture (vs. no)	-0.464	0.032	<0.001	-0.228	0.028	<0.001	-1
Smoking (vs. no)	-0.227	0.102	0.026	-0.293	0.090	0.001	-2
Glucocorticoids (vs. no)	-0.122	0.046	0.008	-0.198	0.039	<0.001	-1
Parent hip fracture (vs. no)	0.018	0.039	0.634	-	-	-	
Rheumatoid arthritis (vs. no)	-0.026	0.044	0.552	-	-	-	
Secondary osteoporosis (vs.no)	0.064	0.041	0.124	-	-	-	
Alcohol (vs. no)	-0.002	0.140	0.987	-	-	-	

*SE: standard error

Conclusion: Under the WHO definition of osteoporosis, this study revealed that the major risk factors of postmenopausal women osteoporosis in Taiwan are age, body height, body weight, postmenopausal age, previous fracture, current smoking, and glucocorticoids use, especially in age, body weight and smoking.

Acknowledgements: The authors would like to thank Taiwan Osteoporosis Association for offering the data and authorizing the data management.

P1094

TREATMENT METHODS AND OUTCOMES OF HIP FRACTURE IN LITHUANIAN HOSPITALS

M. Tamulaitiene¹, E. Antropik¹, M. Kvedaraitė¹, A. Mastaviciute¹, J. Jaramavicius¹, V. Alekna¹

¹Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Vilnius, Lithuania

Objective: To analyze the inpatient treatment methods and outcomes of hip fractures in Lithuania during 2001-2010.

Methods: This is a retrospective study of patients aged 60 and over, hospitalized with primary hip fracture. Data was collected from 47 orthopedic-traumatology inpatient departments. Treatment was categorized as: 1) surgical (including screws, plates, DHS – dynamic hip screws, DCS – dynamic condylar screws and intramedullary nails); 2) arthroplasty; 3) conservative. The outcomes were rehabilitation, long-term care hospital, discharge home, and death.

Results: Overall, 20368 patients over 60 y with hip fracture were hospitalized during 2001-2010. Mean hospitalization duration was 12 d. Strong correlation between age and the duration of hospitalization was found (r=0.997; p<0.05). During hospitalisation, 72.8% of patients were treated surgically (95%CI:72.1–73.3%), arthroplasty was used in 19.9% (95%CI:18.9-20.1%), conservative treatment in 7.3% (95%CI:6.9–7.6%) of patients. The vast majority of the patients have been discharged home: 78.8% of patients

after surgical treatment (95%CI:77.9–79.7%), 11.7% after arthroplasty (95%CI:11–12.4%), and 9.5% after conservative treatment (95%CI:8.9–10.1%). Inpatient rehabilitation has been performed (95%CI: 45.3–48%) in 46.7% of patients after surgical treatment and in 52% of cases after arthroplasty (95%CI:50.6–53.4%). After surgical treatment, 80.8% of patients were sent to the facility of outpatient rehabilitation (95%CI: 79.4–82.2%); outpatient rehabilitation was received by 13.3% of patients after arthroplasty (95%CI:12.2–14.5%) and 5.9% patients after conservative treatment (95%CI:5.1–6.7%). More patients (78.3%) were moved to long-term care hospital after surgery (95%CI:76.7–79.9%), than after arthroplasty (9,1%; 95%CI:7.9–10.2%). Strong correlation between method of treatment and the duration of hospitalization has been found (r=1; p<0.05) suggesting that the more invasive and aggressive treatment is applied, the time of hospitalization is longer. Patient gender was not related to the hospitalization duration.

Conclusions: In patients with hip fracture, the duration of hospitalization was mostly dependent on age and the treatment method applied. The most common treatment method was surgery, the vast majority of patients have been discharged home despite the treatment method applied.

P1095
VITAMIN D-PTH STATUS AND BMD ADJUSTED FOR TRABECULAR BONE SCORE (TBS) IN TYPE 2 DIABETIC PATIENTS

A. T. Andreeva¹, D. A. Burmistrova¹, A. L. Grigorieva², T. L. Karonova¹

¹V.A.Almazov National Medical Research Centre, ²St. Petersburg City Rheumatology Centre, St. Petersburg, Russia

Objectives: Recent studies showed that TBS has advantages over BMD to assess bone quality for type 2 diabetic patients. We examined patients with type 2 diabetes and calculated 10-y probability of fracture using standard FRAX® tool and FRAX tool adjusted for TBS.

Methods: A total of 252 type 2 diabetic patients aged 36 to 86 years (mean 61.0±8.8, 172 females) were examined. DXA (Lunar Prodigy, USA) was performed in 124 subjects (110 females). Serum 25(OH)D (AbbottArchitect 8000) and iPTH (Biomerica, USA) levels were performed in 70 pts, HbA1c was determined by standard method.

Results: The study results showed that only 20 (7.9%) subjects had normal BMI, while 232 (92.1%) subjects were overweight or obese. Mean HbA1c was 8.8±1.7%, diabetes duration was 1-30 years (13.1±6.4). Approximately 50% of diabetic subjects were treated by insulin only or in combination with antihyperglycemic drugs. Serum 25(OH)D level was between 7.5 and 44.5 ng/ml (22.7±9.4). Only 22.9% had normal vitamin D status and 77.1% were insufficient or deficient. We found negative correlation between 25(OH)D and iPTH (r=-0.37, p=0.002). We did not find association between 25(OH)D and HbA1c level in study population. Twenty four (9.5%) patients had fractures in their medical history. DXA results showed low BMD in 39 (31.5%) diabetic female. BMD in patients with or without fractures was the same. Results of 10-y probability of fractures showed major osteoporotic fracture risk was from 0.4 to 24.0% (6.9±3.8) and hip fracture risk - from 0 to 15.0% (0.9±1.5). Fracture risk was associated with age (r=0.40, p=0.0001) and BMI (r=0.20, p=0.001), and did not associate with diabetes duration, HbA1c, 25(OH)D or iPTH levels. BMD adjusted for TBS was performed in 33 (10 male) diabetic patients. TBS was from 1.02 to 1.53 (mean 1.28±0.1). 22 (66.7%) patients, including 5 men, had BMD lower then 1.35 g/cm². Hence, two-thirds of diabetic pts had impaired bone quality. However, 10-y probability of

hip fracture or major osteoporotic fracture risks did not clinically differ when we used or did not use TBS for these patients (0.8% & 0.6%; 8.5% & 7.4%).

Conclusion: Our results showed that patients with type 2 diabetes have low serum 25(OH)D level and normal BMD, according to DXA results, in most cases. Using BMD adjusted for TBS identified 67% of type 2 diabetic patients with decreased bone quality.

P1096
TIBOLONE EFFECT ON BONE COMPONENTS USING 3D SHAPER TECHNOLOGY COMPARED TO HORMONE REPLACEMENT THERAPY AND PLACEBO IN POSTMENOPAUSAL WOMEN

M. A. Guagnelli¹, P. Clark¹, L. Castrejón-Delgado², M. A. Sánchez-Rodríguez², V. M. Mendoza-Núñez²

¹Unidad de Epidemiología Clínica, Hospital Infantil de México Federico Gómez, ²Facultad de Estudios Superiores Zaragoza, Universidad Nacional Autónoma de México, Mexico City, Mexico

Objective: Tibolone, a selective estrogen receptor modulator, has been used for the management of postmenopausal symptoms and protect BMD. Yet, the effect on separate components of bone (i.e., trabecular and cortical) has not been widely analyzed. 3D Shaper, a software algorithm that assesses the proximal femur in 3D from a standard hip DXA scan provides an advanced characterization of cortical and trabecular structures. Our objective was to analyze the effect of tibolone on bone at 6, 12 and 18 months of treatment compared to estrogens and placebo using 3D Shaper.

Methods: 90 postmenopausal women aged 45-59 diagnosed based on FSH and LH levels were randomized to receive either 1) tibolone 2.5 mg/d, 2) conjugated estrogens 0.625 mg + medroxyprogesterone 5 mg or 3) placebo (30 per group). DXA scans were performed at recruitment, 6, 12 and 18 months. For the purpose of this preliminary analysis 56 women were included (18 tibolone, 23 estrogens, 15 placebo).

Results: Three main results were obtained: Cortical surface BMD (cortical sBMD), in mg/cm²: calculated as cortical thickness (in cm) multiplied by the cortical volumetric density, associated with cortex strength. Trabecular volumetric BMD (trabecular vBMD), in mg/cm³, a measure of the mean density in the trabecular compartment. And Integral volumetric BMD (integral vBMD), in mg/cm³, a measure of mean density in the integral (cortical and trabecular) compartment.

Relevant differences among groups were only detected by 18 months:

	Cortical sBMD (mg/cm ²)	Trabecular vBMD (mg/cm ³)	Integral vBMD (mg/cm ³)
Tibolone	182.39±22.6	200.89±36.4	387.99±48.1
Estrogens	167.51±20.0	187.52±34.1	362.97±49.3
Placebo	172.64±20.4	192.84±41.8	370.27±49.3

Differences were not statistically significant, however.

Conclusions: Tibolone seems to have a more significant effect on cortical sBMD and integral vBMD, although at this moment of the study the data results are to be confirmed by expanding the number of measurements.

P1097

IS DIABETES AT RISK OF DEVELOPING OSTEOPOROSIS?

A. Mocian¹, A. Şulea¹, M. Copotoiu¹

¹Emergency Clinical County Hospital of Targu-Mures, Targu-Mures, Romania

Objective: Inflammation is an important part of the pathogenesis of diabetes and osteoporosis. Diabetes might be a risk factor for the development of osteoporosis due to its pathogenesis. The study is aiming to seek if diabetes is a prone condition for osteoporosis.

Methods: The study, a prospective one, is focusing on two groups: patients with diabetes and osteoporosis and patients with diabetes without osteoporosis, which were included in the study. We monitored the following variables: bone densitometry at the lumbar and both femoral neck site, the treatment (corticotherapy, antiosteoporotic drugs, classical DMARDs) and the subclinical activity of the disease (ultrasound evaluation of the small joints – the wrist, the MCPs and PIPs).

Results: A total of 30 diabetic patients were included in the study. 60% (n=18) out of 30 patients diagnosed with diabetes were diagnosed with osteopenia and 40% (n=12) out of 30 with osteoporosis. Patients with classical DMARDs developed less osteoporosis (p<0.05), r: 0.56. The group of patients diagnosed with diabetes presented an increased prevalence of the synovitis at the level of the small joints of the hand. The presence of tenosynovitis was noted at the level of the radiocarpal joints. A surprise reveals us the group of patients with diabetes on antiosteoporotic treatment: they presented synovitis at the level of the radiocarpal joints which is associated with osteoporosis.

Conclusion: Due to their mechanism of action classical DMARDs might protect patients with diabetes from osteoporosis.

P1098

FALLS PREDICT OSTEOSARCOPENIA IN CHILEAN OLDER PEOPLE

C. Albala¹, L. Lera¹, C. Marquez¹, B. Angel¹, R. Saguez¹, P. Arroyo²

¹INTA, Universidad de Chile, ²Clinic Hospital Universidad de Chile, Santiago de Chile, Chile

Objective: Fear of falling is an important cause of physical inactivity in older people, leading to sarcopenia and osteoporosis. The objective of this study is to determine if falls predict osteosarcopenia in older people

Methods: Follow-up of ALEXANDROS cohorts designed to study disability associated with obesity in community-dwelling people 60 y and older living in Santiago, Chile. At baseline 1123 (68.5% women, mean age 72y±6.7) had DXA scan and the measurements

for the diagnosis of sarcopenia. WHO standards for BMD classified them in normal, osteopenia and osteoporosis. Sarcopenia was identified using the algorithm from the EWGS validated for Chile. Osteosarcopenia was defined as having sarcopenia plus osteoporosis. Report of last year falls, history of chronic diseases self-reported disability/functional limitations, ability to walk was registered. Anthropometric measurements were performed. Logistic regression models for osteosarcopenia according to baseline falls were built.

Results: At baseline 23.2% of the sample had osteoporosis, 19.5% had sarcopenia and 8% osteosarcopenia. Osteosarcopenia was found in 34.4% of osteoporotic people and 40.8% of the people with sarcopenia. From the total sample, 65.6% were free of both conditions. Osteopenia was found in 49.8% of the total sample. After a median follow-up of 4.5 y (RIQ 4.0-4.8 y) a second evaluation was done in 410 people. The adjusted OR of osteosarcopenia according to baseline falls was 2.39 (95%CI:1.02-5.58).

Conclusions: Besides fractures, falls pose an important risk for future osteosarcopenia. The prevention of sarcopenia and osteoporosis is compulsory in people experiencing falls.

Acknowledgement: Research related to this abstract was funded by Fondecyt grants 1080589 & 1130947

P1099

QUALITY OF LIFE AND GERIATRIC SYNDROMES IN ELDERLY PEOPLE IN THE REPUBLIC OF MOLDOVA

E. Deseatnicova¹, G. Soric¹, S. Agachi¹, A. Negara¹, L. Groppa¹

¹State Medical and Pharmaceutical University Nicolae Testemitanu, Chisinau, Moldova

Objective: Recent demographic trends in the Republic of Moldova are characterized by increased life expectancy. The phenomenon requires concrete medical and social actions increasing autonomy of the elderly and ensuring appropriate quality of life. We aimed at establishing the frequency and types of geriatric syndromes in elderly and assessing their quality of life.

Methods: 1158 patients aged 65 y and over were included in the study. All the patients were examined consecutively as they were admitted to geriatric department during 2017-2018. The research included investigation, clinical and paraclinical examination, geriatric scores (Katz, Lawton, Tinetti, MMSE, Nottingham). All the data were processed using Statistics 7.

Results: The average age of the patients was 71.64±0.17 y, men 41.45% and women 58.54%. 56.3% of the surveyed lived in the rural area and 43.7% lived in the city. 32.38% of people live alone, 50.77% with their spouse, 1.12% with older parents, and 15.71% with children. Most of people are retired 1007 (86.96%) and their average monthly income is 1460±21.86 lei (appr. €75). 95.76% (F - 59.06% and M - 40.93%) had one or more geriatric syndromes. They were: falls 33.63%, frailty 28.4%, urinary incontinence 20.82%, constipation 15.68%, dehydration 7.12%, malnutrition 3.33%, depression 7.12%, pain 90.8% and cognitive disorders 23.62%. According to geriatric evaluation results Katz-score constituted 11.37±0.04, Lawton score – 14.62±0.07, Tinetti score –

22.89±0.13 and MMSE score – 24.65±0.09. The results of quality of life evaluation showed reduction of energy value 59.99±1.09, of emotional reaction – 36.50±0.82, increase of pain – 53.74±0.88, impaired sleep – 54.37±1.06, social isolation - 29,58±0.88, and reduction of physical abilities – 47.96±0.82.

Conclusions: Geriatric syndromes were diagnosed in 95.76% of patients, predominantly women 59.06% vs. 40.93% men. Out of the total geriatric syndromes determined in the elderly patients in the study pain syndrome prevailed - 90.80% followed by the fall syndrome - 33.63%, the fragility syndrome - 28.40%, mild cognitive impairments - 23.62% and depression syndrome - 22.36% of cases. Elderly patients with geriatric syndromes have a poor quality of life. The most affected items were social isolation, emotional reaction and physical ability.

P1100

FRAILITY IN ELDERLY MAINTENANCE HEMODIALYSIS PATIENTS

Z. Amreyeva¹, G. Chingayeva¹, A. Kanatbayeva¹, A. Shepetov¹, M. Kulkayeva¹, E. Alimzhanova¹

¹JSC National Medical University, Department of Nephrology, Almaty, Kazakhstan

Objective: The population in Kazakhstan is rapidly aging, as a result the number of geriatric patients on maintenance hemodialysis (MHD) has been increasing. Frailty is prevalent in dialysis patients and is one of the common factors that can lead to increased morbidity and mortality. The primary objectives of this study were to evaluate the prevalence of frailty in elderly patients on MHD by using Edmonton Frailty Scale and assess their association with clinical and laboratory measurements. A secondary objective was to investigate the relationship between nutritional status and frailty.

Methods: From July to September 2018, a total of 65 elderly patients undergoing HD in 7 dialysis facilities in Almaty, Kazakhstan were enrolled in this cross-sectional study. All participants were evaluated for the cognitive status through Mini-Mental State Examination (MMSE), nutritional status by using Mini Nutritional Assessment (MNA), Malnutrition-Inflammation Score (MIS), and anthropometric measurements (BMI, triceps skinfold (TSF), midarm muscle circumference (MAMC)), functionality (Handgrip strength), as well biochemical data were collected from medical records. Frailty was defined in accordance with the Edmonton Frail scale (EFS).

Results: The study participants' median age was 69 (range: 65-88) years old, and median dialysis vintage was 36 (IQR 15–60) months, 53.8% were female. The main comorbidities were hypertension (69.2%) and diabetes (35.4%). The prevalence of frailty assessed by the EFS was 23.1% (men: 13.3%; women: 86.7%), 43.1% patients were nonfrail (men: 64.3%; women: 35.7%), 33.8% patients were vulnerable (men: 45.5%; women: 54.5%). Based on MIS the prevalence of PEW was 73.8% and, according to MNA, the risk of malnutrition was detected in 47.7%, and 9.2% had malnutrition. No significant difference was observed between genders in the frequency of PEW. Mean body weight was 69.1±11.3 kg, the

mean BMI was slightly overweight 25.6±4.29 kg/m², while hand-grip strength was 21.33±3.36 in men and 15.5±5.51 in women, p=0.008, and it is lower than the normal population standard values. The frail patients group had a higher proportion of women 86.7% (p=0.001), worse nutritional status (93.3% and 86.7% had PEW evaluated by MIS (p=0.018) and MNA (p=0.035), respectively), more frequency of falls (p=0.01), anemia (p=0.038) when compared to group of non-frail and vulnerable patients. 66.7% of frail patients were widowed (p=0.005). The mean MMSE in this group of patients was 26.7±1.9.

Conclusion: The prevalence of frailty among elderly hemodialysis patients in this study was 23.1%, and we detected that 86.7% of them were female, as well PEW increased in frail patients. Also the study showed that protein-energy wasting is common among elderly hemodialysis patients. Its prevalence varies between 73.8% and 56.9% depending on the measurement tool used to evaluate the nutritional status. In our country with limited resources, EFS, MIS and MNA could help to follow elderly hemodialysis patients.

P1101

DISCREPANCIES IN TRABECULAR BONE SCORE AND BONE MINERAL DENSITY IN PATIENTS WITH T2DM

T. Grebennikova¹, N. Sasonova¹, T. Tsoriev¹, T. Chernova¹, L. Rozhinskaya¹, M. Shestakova¹, G. Melnichenko¹, Z. Belaya¹

¹The National Medical Research Centre for Endocrinology, Moscow, Russia

Objective: The enormous prevalence and heterogeneity of subjects with T2DM suggest different mechanisms of bone fragility in a various T2DM patient groups. Patients can have ordinary postmenopausal osteoporosis with coexisting T2DM or conditions when bone quality changes greater than BMD – diabetosteoporosis, or independent alteration of bone by diabetes – diabetic bone disease [1]. In order to investigate whether this concept can be supported using routine DXA, we evaluated BMD and trabecular bone score (TBS) values in subjects with T2DM.

Methods: We enrolled 126 consecutive patients (91 women and 35 men) with T2DM who were routinely referred for BMD measurements. All enrolled patients were without known history of osteoporosis and its treatment. BMD and TBS measurements were done on iDXA (GE) with TBS iNsign software v2.1 (Medimaps, Merignac, France). The data on diabetes complications and known medical history of fracture was taken from the electronic database of our clinic.

Results: The median age (Q25-Q75); of enrolled subjects was 71 (62-77) years; BMI – 30.2 kg/m² (28.5-35.6). Vertebral fracture were found in 7 cases; nonvertebral in 14 cases. Among the 126 enrolled patients, in 15 (11.9%) cases (11 female and 4 male) the T-score at the L1-L4 and/or femoral neck was <-2.5. In this group of patients the median L1-L4 T-score was -1.7 (-2.7 - -0.7); neck T-score was -2.9 (-3.6 - -2.7). These patients also had degraded TBS – 1.24 (1.11-1.39) with a TBS T-score of -2.4 (-4.0 - -0.9) and lower BMI compared to other patients p=0.009; in 3 cases they

had nonvertebral fractures, but there were no cases of vertebral fractures. In 26 (20.6%) subjects (23 female and 3 male) there was degraded TBS (1.20 (1.17-1.22); TBS T-score -2.9 (-3.3- -2.5) without osteoporosis as measured by BMD (L1-L4 T-score -0.5 (-1.0 - 1.2); neck T-score -1.4 (-1.9 - 0.1); total hip -0.5 (-0.8 - 0.75). Patients with discrepancies between TBS and BMD values had higher HbA1c 8.4% (7.6-10.0) vs. other subjects 7.7 (6.15-8.65%) $p=0.009$ and had significantly higher prevalence of vertebral fracture ($n=4$) including multiple vertebral fractures ($n=2$) $p=0.028$ vs. other subjects. In this group nonvertebral fractures were found in 5 patients, in 2 cases multiple. In one male patient there were vertebral and multiple nonvertebral fractures, without evidence of low BMD (neck -1.4 T-score) or TBS - 1.422. This subject suffered from diabetes for 13 y and had diabetic retinopathy which may explain microvascular complications in other organs including bone and his predisposition to fall.

Conclusion: A discrepancy between BMD and TBS seems to be evident in patients with T2DM and this is associated with an increased rate of vertebral fractures and higher HbA1c. However the number of these patients is relatively small and may be diluted in the epidemiological studies.

Reference: 1. Ferrari S. *Calcif Tissue Int* 2017;100:107

P1102

OLDER WOMEN WITH REDUCED KIDNEY FUNCTION ARE AT INCREASED RISK OF FRACTURE

L. Malmgren¹, F. McGuigan², A. Christensson³, K. Åkesson²

¹Lund University, Clinical Sciences, Malmö, and Department of Geriatrics Skåne University Hospital, ²Lund University, Clinical Sciences and Department of Orthopedics, Skåne University Hospital, ³Department of Nephrology, Skåne University Hospital, Malmö, Sweden

Objective: The extent to which the typical age-related functional decline of kidney function contributes to fracture risk is unclear. In a longitudinal study of older community dwelling women, we investigated the association between kidney function and fracture.

Methods: In the OPRA (Osteoporosis Risk Assessment) cohort cystatin C based estimations of kidney function were available at age 75 ($n=981$), 80 ($n=685$) and 85 ($n=365$). Kidney function was categorized as normal (CKD stage 1-2), mild-moderate (stage 3a), poor (stage 3b-5) and association with imminent, short and long term fracture risk investigated (adjusted for weight, smoking, vitamin D). Women were also categorized by both kidney function (stage 3-5) and osteoporosis (T-score ≤ -2.5), and fracture risk assessed.

Results: Mild-moderate kidney dysfunction was associated with increased risk of hip fracture (HRadj 2.00, 95%CI 1.00-3.98) and osteoporotic fractures (HRadj 1.51, 1.04-2.18) over 5 y between 75-80 y. Risk attenuated with increasing age and over a 10-y time frame. Fracture risk was not increased among women with the worst kidney function. Even without osteoporosis, reduced kidney function was associated with higher osteoporotic fracture risk

between age 75-80 (HRadj 1.66, 95%CI 1.08-2.54). Having both osteoporosis and reduced kidney function conferred an additional risk increase (HRadj 2.53 (95%CI 1.52-4.23).

Conclusion: Older women with even mild-moderate reduction of kidney function are at increased fracture risk and DXA measurement is clinically valuable for risk assessment.

Disclosures: KÅ – lecture fees, MSD and Eli Lilly.

P1103

ATHEROSCLEROTIC DISEASE IN SYSTEMIC SCLEROSIS: A CASE REPORT

P.-A. Sulea¹, I. Tilea², A. Varga³, D. Butilca¹, C. Suciuc⁴

¹Emergency Clinical County Hospital Tirgu Mures, Romania, ²Emergency Clinical County Hospital Tirgu Mures, Romania, Family Medicine Discipline, Department M3, Faculty of Medicine, University of Medicine and Pharmacy Tirgu Mures, ³Family Medicine Discipline, Department M3, Faculty of Medicine, University of Medicine and Pharmacy Tirgu Mures, Romania, ⁴Family Medicine Discipline, Department M3, Faculty of Medicine, University of Medicine and Pharmacy Tirgu Mures, Targu Mures, Romania

Objectives: Scleroderma is an autoimmune, connective tissue disease of unknown cause, characterized by excessive tissue fibrosis with typical skin distribution and multisystemic involvement. Progressive vascular fibrosis leads towards chronic ischemia particularly in the peripheral tissues. Macrovascular changes tend to occur often in scleroderma patients, however, coronary artery disease (CAD) and important generalised atherosclerosis have a scarce occurrence, as inflammation in scleroderma tends to be less important when compared to other connective tissue diseases. Our case report aims to present a possible association between atherosclerosis and scleroderma.

Methods: We report the case of a 60 years old woman with basal cell carcinoma, hypertension, left ventricular failure NYHA II, important CAD, generalised atherosclerosis with carotid artery stenosis, atherosclerosis of the abdominal aorta, chronic obliterating diseases of lower limb arteries and an unremarkable dyslipidemic profile. At presentation. the patient had xerostomia, dysphagia, pyrosis, asthenia, inflammatory arthralgia of the small joints of the hands, extensive skin fibrosis, hyperpigmentation areas alternating with depigmentation over the entire skin surface and Raynaud's phenomenon. She was evaluated by spirometry, capillaroscopy, computed tomography scan, echocardiography, upper gastrointestinal series and gastroscopy. Laboratory tests were positive for antinuclear antibodies and negative for specific scleroderma and other rheumatic disease antibodies. Nonetheless, she did present important inflammatory markers.

Results: The investigations lead to the suspicion of scleroderma with Raynaud's phenomenon, interstitial lung disease and esophageal dysmotility.

Conclusions: Our case report emphasises on the involvement of scleroderma spectrum of diseases on atherosclerosis progression, particularly in patients lacking notable traditional risk factors. Scleroderma is not recognised as an important atheroscle-

rotic risk factor, however macrovascular disease and peripheral tissue necrosis are frequently reported in association with this pathology. The underlying mechanism is suspected to be fibrosis however little emphasis has been placed on a possible contribution from atherosclerotic disease.

P1104
10-YEAR EXPERIENCE OF ACUTE ARTICULAR SYNDROME MANAGEMENT SYSTEM

A. Povzun¹, K. Povzun¹

¹Scientific Research Institute of Emergency Care n.a. I.I. Dzhanlidze, Saint-Petersburg, Russia

Objective: 10 y ago we established acute articular syndrome (AAS) management system in Saint-Petersburg. We use possibility of one of the leading emergency care hospitals to provide emergency hospitalization of AAS patients instead planned one with waiting period. AAS is a heterogeneous group of diseases, common to which is the articular apparatus involvement into the pathological process. Saint-Petersburg Scientific Research Institute of Emergency Care named after I.I. Dzhanlidze in 2008 began to be on duty 24/7 for AAS patients. There was developed and implemented a special program of AAS management. Emergency indications patients with preliminary AAS diagnosis are admitted to began diagnostic and treatment processes simultaneously.

Methods: The performance of this project at the 24/7 on duty multidisciplinary emergency medicine hospital allows using all diagnostic capabilities of the emergency department, to ensure the consultation of different medical specialists. We realize the possibility of patient hospitalization with AAS diagnosis as a preliminary one, not with the specific nosological diagnosis. This approach provides a purposeful route for these patients from outpatient centers and ambulances directly to the Institute of Emergency Care with a goal to their concentration in the multispecialty hospital for differential diagnostics procedures with simultaneous beginning of symptomatic and pathogenetic therapy. There were two different groups of patients: naïve AAS patient with unknown rheumatological diagnosis and previously examined patients with known diagnosis, but having AAS as a worsening or relapse of their disease.

Results: Recommendations on optimizing the algorithm of examination of patients were revealed. The main principles of differential diagnostics of AAS and groups of nosological forms were presented. Initial symptomatic therapy purpose was to speedy pain relief. This approach greatly improves the compliance of patients, so subsequently assigned pathogenetic therapy to be more effective. The main groups of medications and key features of their usage were considered. The stages of pathogenetic therapy, the most commonly occurring drug interactions and side effects were reflected. We summarized the 1874 rheumatic patients' treatment experience in our Institute from a cohort of AAS patients. The distribution features of the patients with recurrence of articular syndrome Main features in previously verified diagnosis and newly diagnosed disease patients were described. The most frequent diagnosis was osteoarthritis, rheumatoid arthritis and goat attack.

Conclusion: We recommend widespread introduction of our successful experience of such medical care system for AAS patients.

P1105
SEPTIC OR ASEPTIC THE OSTEITIS FROM SAPHO SYNDROME?

C. Matzaroglou¹, K. Kafchitsas², P. Diaremes², A. Spyridonidis³, D. Papachristou³, E. Billis¹, S. Lampropoulou¹, M. Tyllianakis³

¹Technological University of Western Greece, Human Assessment and Rehabilitation Lab, Aigio, Greece, ²Asklepios Orthopaedic Clinic, Lindelohe, Schwandorf, Germany, ³Department of Medicine, University of Patras, Patras, Greece

Objective: The SAPHO syndrome "Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis" is a term, include a variety of musculoskeletal disorders associated with skin conditions, mainly palmoplantar pustulosis and acne. Osteitis typically is the most prominent skeletal lesion seen in this syndrome and the most authors consider this osteitis as aseptic. Our purpose was to present the physical history of the patients and our experience in treatment of SAPHO syndrome.

Methods: We present 18 patients from 3 different orthopaedic centers with femoral osteitis and sternocostal hyperostosis. The classic clinical, radiographic, and histologic features of this syndrome and physical history of our patients are described. Two patients had no past or current history of skin disease, although they met the criteria for the SAPHO syndrome.

Results: The mean interval between the onset of cutaneous or musculoskeletal symptoms and the final diagnosis of SAPHO syndrome was 9.2 y. This interval was not influenced by patient age. The skin manifestation following the skeletal manifestation in all cases. Diagnosis of SAPHO syndrome is difficult. The lesion often confused with suppurative osteomyelitis because of similar clinicopathologic findings. The diagnosis is more difficult if atypical sites are involved and there is no skin disease {Table-1}.

Conclusion: Although the optimal treatment is unclear and the most authors consider the osteitis as aseptic, it is important in our cases with SAPHO syndrome, long-term antibiotic therapy with clindamycin.

Table 1. Diagnostic criteria proposed by Kahn for SAPHO syndrome diagnosis, 1994

1. Chronic recurrent multifocal sterile and axial osteomyelitis, with or without dermatosis
2. Acute, subacute, or chronic arthritis associated with palmoplantar pustulosis, pustulous psoriasis, or severe acne
3. Any sterile osteitis associated with palmoplantar pustulosis, pustulous psoriasis, or severe acne

P1106
EFFECTS OF COMBINED CRYO-ULTRASOUND THERAPY IN PATIENTS WITH MUSCULOSKELETAL CONDITIONS

A. S. Nica¹, B. Mitoiu¹, D. M. Clantau¹, G. Mologhianu¹, M. I. Constantinovici¹

¹"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania

Objective: Therapeutical ultrasound is a physical therapy modality commonly used in the rehabilitation of different musculoskeletal conditions for its important physiological and therapeutical effects. In the acute and early post-acute phase of musculoskeletal conditions, especially posttraumatic or in inflammatory osteoarthritis, the thermal effect of the therapeutical ultrasound may increase inflammation or the risk of other adverse effects in these patients. Combining the benefits of ultrasound with cryotherapy may be helpful in these patients, preventing thermal complications. We want to analyze the effects of cryo-ultrasound therapy in a group of patients with different musculoskeletal conditions.

Methods: In our study we included 117 patients with different musculoskeletal conditions, such as posttraumatic hand dysfunction, shoulder pain with inflammatory reaction, posttraumatic lower limb, posttraumatic muscle spasms and gonarthrosis in inflammatory phase. 51.3% of patients experienced nociceptive pain, 20.5% had neuropathic pain and 28.2% had mixed pain. All patients were included in a rehabilitation program in our clinic for functional improvement. For the control of musculoskeletal symptoms the patients were treated with cryo-ultrasound therapy. The patients were evaluated from clinical point of view, analyzing the evolution of pain, inflammation (thermography) and oedema at the admission, after one week of therapy and at the end of the two weeks rehabilitation program. Also, they were evaluated from functional point of view.

Results: Our patients showed good results in improving pain and inflammation after one week as well as after two weeks of therapy. The improvement was better in the group of patients with nociceptive pain. Also, cryo-ultrasound therapy helped improving soft-tissue oedema, thus increasing mobility and patient's participation in daily living activities. The improvement of symptoms correlated with the functional improvement.

Conclusion: Combining therapeutical ultrasound with cryotherapy may be helpful in posttraumatic patients and in patients with osteoarthritis in the inflammatory acute phase, preventing the inconvenience of the thermal effect of ultrasound. Also it may enhance the therapeutical benefits of ultrasound related to the improvement of pain and inflammation and the control of soft-tissue oedema. For a better control of the symptomatology and functional improvement, cryo-ultrasound should be associated with other proper physical therapy modalities.

P1107
USE OF PROXIMAL FIBULAR OSTEOTOMY WITH PLATELET RICH PLASMA FOR THE MANAGEMENT OF GRADE 3 OA KNEE

V. Khanna¹

¹Ranjana Hospital, Allahabad, India

Objective: Total knee replacement (TKR) has become the dictum of management of advanced osteoarthritis (OA) of knee. New procedures like proximal fibular osteotomy (PFO) and the use of platelet rich plasma (PRP) have gained popularity in recent years for OA management. This study was done to see the effect of PRP combined with PFO for the management of Grade 3 OA knee. This combined therapy may prove to be a good alternative line of management to TKR which should be restricted to Grade 4 OA knee.

Methods: A total of 100 patients were included in this prospective study. Post-traumatic or secondary OA cases were excluded from the study. Only cases of Grade 3 OA (Kellgren-Lawrence grading) were included in the study. After an informed consent and preoperative evaluation 40 ml of the patients' blood was taken and PRP was processed (nonleucocyte reduced). Preoperative functional evaluation was done by VAS scoring and WOMAC scoring system. Following this, all the patients underwent PFO and intra-articular injection of PRP injection. Standard postoperative care was given. Patient was allowed standing and walking from the next day onwards. Postoperative functional scoring was assessed by VAS and WOMAC scoring on 2nd, 10th, 30th and 180th postoperative day (POD) and compared.

Results: Out of the 100 patients included in the study 62 were females and 38 were males. Mean age was 62.3+3.5 y. The preoperative and postoperative mean VAS and WOMAC score are given in Table 1.

Table 1: Preoperative and Postoperative functional assessment of OA patients.

	VAS	WOMAC	p value
Preoperative	4.5 ± 1.2	81.2 ± 5.1	
2 nd POD	5.3 ± 0.9	83.5 ± 3.2	
10 th POD	2.3 ± 1.7	52.5 ± 7.2	p<0.05
30 th POD	1.1 ± 0.5	28.9 ± 5.1	p<0.05
180 th POD	0.4 ± 0.2	17.4 ± 3.2	p<0.05

Conclusion: The result of this study clearly indicates that this combined therapy maybe of use in Grade 3 OA knee however, larger studies with longer follow-up period are required.

P1108

EFFICIENCY OF TOTAL HIP ARTHROPLASTY FOR PATIENTS WITH TUBERCULOUS COXITISM. Serdobintsev¹, A. Berdes¹, A. Cherkasov¹, B. Babkov¹¹Saint-Petersburg State Research Institute of Physiopulmonology, Saint-Petersburg, Russia

Objective: Total hip arthroplasty (THA) is quite widespread operation in general orthopedics, but it has not been studied enough in the treatment of tuberculous coxitis. Some authors point to the complete safety of the operation in combination with antituberculosis drug therapy (ADT), others say that the operation can be performed only 10 y after the last exacerbation of the tuberculous infection in the joint. The aim of the work was to evaluate the effectiveness of THA in the surgical treatment of advanced active tuberculosis of the hip joint.

Methods: We analyzed the results of the complex treatment of 103 patients (44 men and 59 women, age range 19-74 years old) who underwent THA in our clinic. Verification of the diagnosis was based on the results of histological and bacteriological examinations of surgical specimens. Group 1 consisted of 24 patients with advanced active tuberculous coxitis who underwent ADT for 1 month before and 8-12 months after the radical surgical debridement. Only then the patients underwent THA with ADT for 4-6 months. Group 2 consisted of 37 patients with healed tuberculosis of the hip who underwent THA. 42 patients with advanced active tuberculosis of the hip joint (group 3) underwent bone plastic operations using autobonegraft from iliac crest. Based on gender, age, comorbidity, the groups were comparable for analysis. The results of surgical treatment were traced from 3 to 94 months (the average was 57 months).

Results: The most severe bone defects of the hip joint (type 2C and 3A) by Paprosky W.G. and types II and III of congenital hip dislocations by Hartofilakidis G. were diagnosed by 17.9% and 39.5% respectively frequently in patients with healed tuberculosis of the hip compared in comparison to the patients with advanced active tuberculous coxitis. Before the surgery the average results of Harris Hip Score in group 1, 2 and 3 were 34, 47 and 42 points respectively. The ratio of good and excellent results of Harris Hip Score after THA in group 1, 2 and 3 were 79.2%, 51.4% and 28.6% respectively. The inclusion of THA in the surgical treatment of advanced active tuberculosis of the hip joint reduces the period of complete restoration of joint function by 9.8 months and reduces the treatment time of the diseased by 1.5 times.

Conclusions: Severe bone defects of the hip joint in patients with healed tuberculosis cause high anatomical and functional impairment of the affected joint and make the operation more difficult. Surgical treatment with the inclusion of THA of patients with advanced active tuberculous coxitis in comparison to the bone plastic operations using autobonegraft from iliac crest is characterized by shorter period of functional rehabilitation and better social adaptation of patients.

P1109

OSTEOPOROSIS AND SARCOPENIA IN PATIENTS WITH LIVER CIRRHOSISF. Marc¹, D. M. Farcas¹, A. Pallag¹, D. Galusca¹, A. Hoza¹, C. Moldovan¹¹Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania

Objective: In an internal medicine department, there are many patients with liver cirrhosis of different etiologies. It would very important to evaluate them for the presence of osteoporosis and/or sarcopenia, in order to improve their survival rates and to decrease the risk of complications.

Methods: Our study included 42 patients admitted in Internal medicine department over a period of 6 months diagnosed with liver cirrhosis, either of alcoholic or viral (B or C) etiology. They have been evaluated for osteoporosis with DXA and for sarcopenia with handgrip test - Jamar dynamometer, measurement of arm circumference and timed up and go test. We also measured the levels of 25-hydroxyvitamin D.

Results: From the 42 patients, 18 (42.8%) were female and 24 (57.2%) male. From the women group, 38.8% were of alcoholic. 61.2% of viral etiology and from the male group, 58.3% were alcoholic, 41.7% of viral etiology. The T-score <-2.5 (osteoporosis) was identified predominantly in postmenopausal women with alcoholic cirrhosis. sarcopenia was diagnosed predominantly in men aged between 60-70 y who had alcoholic cirrhosis. We found both osteoporosis and sarcopenia (osteosarcopenia) in 23.8% (10) patients, mostly in patients with advanced liver cirrhosis (Child C). Vitamin D deficiency and insufficiency was found in 78.5% of all patients.

Conclusions: It is very important to diagnose the presence of osteoporosis and/or sarcopenia in patients with liver cirrhosis, because early intervention may prevent further muscle loss and bone fractures, for a better quality of life and survival rate.

P1110

ASSOCIATION BETWEEN BONE MINERAL DENSITY AND INCIDENCE OF BREAST CANCER: A POPULATION BASED STUDY

M. Fraenkel¹, Y. Mizrakli², M. Koretz³, L. Norton⁴, T. Shafat², V. Medvedovsky⁵, D. B. Geffen⁶, V. Novack², E. Siris⁷

¹Endocrinology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel, ²Clinical Research Center, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel, ³Breast Health Center, Soroka University Medical Center and the Faculty of Health Science, Ben Gurion University of the Negev, Beer-Sheva, Israel, ⁴Breast Center, Memorial Sloan Kettering Cancer Center, New York, USA, ⁵Endocrinology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁶Department of Oncology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel, ⁷Division of Endocrinology, Columbia University Medical Center, New York, USA

Objectives: Estrogen may have contrasting effects in postmenopausal women on breast cancer incidence (increasing risk) and on bone health (higher BMD). The objective of this study was to assess DXA- BMD in the female population of southern Israel treated at Soroka University Medical Center (SUMC); comparing women with new diagnosis of breast cancer and matched controls without breast cancer.

Methods: Women with new diagnosis of breast cancer treated at SUMC between 4/2012 and 10/2017 were prospectively enrolled in the study. Women who received radiotherapy or chemotherapy prior to screening were excluded. Controls were recruited at the mammography unit following a breast mammography or breast ultrasound that were reported as normal. Patients and controls were excluded if they had other oncologic, hematologic, autoimmune, other bone disease or if they were on chronic steroid therapy. Cases and controls were matched 1:1 by age, BMI, Parity and use of HRT. All study population had DXA BMD (GE Lunar Prodigy) and lab assessment at baseline.

Results: Of 869 women with newly diagnosed breast cancer 464 signed informed consent; 387 completed study protocol, of these 284 were matched to controls. Mean age of cases and controls was 58 y. At baseline breast cancer patients had lower vitamin D levels compared to controls (48.9 ± 19 and 53.8 ± 24.8 nmol/L $p=0.016$). Total hip BMD was significantly higher in breast cancer patients compared to controls (0.95 ± 0.14 and 0.92 ± 0.12 $p=0.002$ g/cm²; T-score 0.32 ± 1.09 and 0.01 ± 0.88 $p<0.001$ and Z-score 0.32 ± 1.09 and 0.01 ± 0.88 $p<0.001$). Among breast cancer patients, no correlation was found between baseline BMD and tumor size, grade, nodal involvement or stage.

Conclusions: Women with newly diagnosed breast cancer have higher BMD than controls, this may imply that BMD can serve as a surrogate for breast cancer risk.

P1111

SARCOPENIA IN DIALYSIS PATIENTS

R. Abdala¹, A. L. Negri¹, E. Del Valle¹, M. M. Sesta¹, J. Dalto¹, M. B. Zanchetta¹

¹IDIM (Instituto de Diagnostico e Investigaciones Metabolicas), Buenos Aires, Argentina

Objectives: Sarcopenia is the loss of skeletal muscle mass and its function that occurs with aging. These modifications lead to greater morbidity and mortality as a result of falls, hospitalization, depression and dependence among others. Chronic kidney disease (CKD) and hemodialysis (HD) produce a favorable environment for the development of sarcopenia. Our aim was to describe the prevalence of sarcopenia and determine the degree of commitment of each component (muscle mass, strength and physical performance).

Methods: Cross-sectional study. A total of 100 HD adult patients were evaluated. The criteria proposed by EWGSOP 2018 were used. The samples with normal distribution were evaluated by Student's Test and Wilcoxon for independent samples. Correlation analysis and multiple linear regression were used to evaluate associations. Statistical significance was considered with $p<0.05$.

Results: 59 male (M) and 41 female (F). The prevalence of sarcopenia was 10% in M and 20% in F. Patients with lower muscle strength had a higher prevalence of falls in the last year (40% two or more falls) $p<0.05$. The average age of the M were 54 y and F 58 y. 35% of M showed low grip strength (GP) and 25% low appendicular lean mass (ALM). In M the ALM correlated with weight r 0.75, height r 0.64 and GS r 0.46 ($p<0.05$). The regressor variables (M) that were associated with GS: ALM, Albumin and weight R 20.41 ($p<0.05$). 54% of F had low ALM, 27% low GS and 17% poor physical performance. ALM in F correlated positively with weight r 0.78, height r 0.66, GS r 0.59 and sit-stand r 0.40 ($p<0.05$). GS correlated positively with ALM in M and F. The time of dialysis adjusted was associated with measures of physical performance.

Conclusion: We observe the important compromise of muscle mass and its function in this population. Understanding their pathophysiology and recognizing those patients at risk would allow us to develop strategies to prevent this condition and its complications

P1112

CHOOSING THE OPTIMAL TREATMENT OF OSTEOPOROSIS IN A PATIENT WITH OSTEOGENESIS IMPERFECTA WHICH ASSOCIATES AGGRAVANTS RISK FACTORS FOR BONE DEMINERALIZATION

B. I. Gavrilă¹, C. Ciofu¹, V. Stoica¹, I. Ancuta¹, M. Bojinca¹

¹Department of Internal Medicine and Rheumatology, Dr. I. Cantacuzino' Clinal Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania

Objective: We present the case of a female patient, 57 year old, who is hospitalized in the rheumatology clinic in February 2018 for tenderness and swollen joints.

Methods: This is the first presentation in our clinic and from patient history we note osteogenesis imperfecta (diagnosed in childhood), seropositive rheumatoid arthritis (2007), osteoporosis with multiple vertebral compressions, repeated episodes of fracture (in 2015 right ankle and right hip fractures). From the time of diagnosis with rheumatoid arthritis she followed initial treatment with leflunomide, then associated methotrexate and adalimumab from 2010. In the 2010-2014 period, there were no pain or swollen joints. After 4 y, symptoms reappeared and she switched adalimumab treatment with rituximab. Also, in 2014 her physician started treatment with corticosteroids (methylprednisolone 8 mg/d) and introduced bisphosphonate therapy, along with calcium and alpha D3. On this background, joint symptoms are controlled, but the patient had 2 episodes of spontaneous fractures (right ankle, then right hip). We recommend stopping methylprednisolone and changing biological treatment, but the patient refused.

Results: At this patient, there are multiple causes of osteoporosis: postmenopausal osteoporosis, osteogenesis imperfecta, prolonged immobilization due to fractures, rheumatoid arthritis, corticosteroids treatment.

Conclusion: In a case of noncompliant patient, who refuse stopping corticosteroids, under important immunosuppressive therapy (leflunomide, methotrexate and mabthera), denosumab represents a safe alternative? Do we have other therapeutic options?

P1113

ONE-YEAR RETROSPECTIVE STUDY OF HOSPITALISED PATIENTS ON PARENTERAL THERAPY WITH BISPHOSPHONATES AT THE UNIVERSITY CLINIC OF ENDOCRINOLOGY IN SKOPJE, MACEDONIA

A. Mucha¹, V. Limani¹, S. Markovikj¹

¹University Clinic of Endocrinology, Diabetes and Metabolic Diseases, Skopje, Macedonia

Objective: To evaluate hospitalised patients with diagnosed osteoporosis for a 1-y period at the university clinic of endocrinology, diabetes and metabolic diseases in Skopje, Macedonia.

Methods: National electronic database was searched during the

period January-December 2018. The retrospective study was performed including all hospitalised patients on parenteral form of bisphosphonates addressing gender, age, duration of disease, risk factors as well as other comorbidities.

Results: A total of 59 patients were analysed. 54 were females (91,5%) and only 5 were males (8,5%). The average age of hospitalised patients was 65.13 y; only 2 of analysed patients were below 40 y of age (females, 34 years old and 25 y respectively). 6 of patients were having familiar anamnesis for osteoporosis (10.15%). Study shows that 17 of patients are smokers (28.8%). All 59 patients have other comorbidities, mostly with hypertension, gastrointestinal problems and diabetes. 31 patients who were hospitalised had bone fractures (52.54%). The cause for osteoporosis in 43 of 59 patients (72,88%) was early menopause. Other cause was primary hyperparathyroidism and use of corticosteroids.

Conclusions: Most of the patients in our country (around 74%) who are on parenteral therapy with bisphosphonates are treated at university clinic of endocrinology, diabetes and metabolic diseases. This retrospective study shows that more than 90% of patients are females, every second patient had a bone fracture and almost every third patient is a smoker. In every 10 patients, 7 of them had an early menopause as a main cause for osteoporosis.

P1114

INFLUENCE OF REHABILITATION THERAPY ON EVOLUTION IN PATIENTS WITH FIBROMYALGIA

D. M. Farcas¹, F. Marc², C. Suteu³, I. Gasparik⁴, L. Sachelarie⁵

¹Faculty of Medicine and Pharmacy Oradea, Oradea, ²Faculty of Medicine and Pharmacy Oradea, Oradea, ³Faculty of Medicine and Pharmacy, Oradea, ⁴ASPOR, Targu Mures, ⁵University Apollonia, Iasi, Romania

Objective: To evaluate a group of patients with fibromyalgia for wellbeing and quality of life.

Method: We assessed a group of 52 patients with fibromyalgia. The patients were divided in two groups. The first group included a number of in 26 patients who underwent a physical rehabilitation program three times per week for 12 months and the second group consisted in 26 sedentary patients. All the patients from the study were evaluated with Fibromyalgia Impact Questionnaire Index for fibromyalgia, Short Form 36 for quality of life, Hamilton Anxiety Rating Scale for anxiety. Patients were recruited from ambulatory system Bihor county, Romania. The mean age in the first group was 58.19±2.54, and in the control group of 57.93±4.32. We found BMI and educational level almost similar in both groups. The inclusion criteria were: age over 18, fulfilling the ACR criteria for fibromyalgia, possibility of evaluation and reevaluation at 6, 12 month, complying with the principles of medical ethics. The exclusion criteria were: age under 18, severe diseases, noncompliance.

Results: We noticed a small improvement for Fibromyalgia Impact Questionnaire Index in the group who underwent physical rehabilitation program at six months, and a mild improvement

at 12 months, vs. the sedentary group with no improvement at all. Quality of life improved also in the active group at six and at 12 months, than in the sedentary group where we noticed no improvement. Anxiety, rated with Hamilton Anxiety Rating Scale, proved a mild diminishing in anxiety score at six and at 12 months in the group with therapy than in the sedentary group with the same grade of anxiety till the end of the study. We also noticed correlation between Fibromyalgia Impact Questionnaire Index and Short Form 36 for quality of life and Hamilton Anxiety Rating Scale for anxiety.

Conclusion: Even if fibromyalgia is a chronic syndrome, a proper management and follow-up could improve its evolution and also improve patients quality of life.

P1115

ACUTE NONGONOCOCCAL SEPTIC ARTHRITIS OF THE ANKLE IN HIGH RISK PATIENT WITH DIABETIC FOOT AND RHEUMATOID ARTHRITIS

S. C. Dinescu¹, R. M. Dumitrascu², S. C. Firulescu¹, D. C. Parvanescu¹, A. B. Chisalau¹, C. Criveanu¹, A. L. Barbulescu³, A. E. Musetescu¹, A. Rosu¹, P. Ciurea¹, F. A. Vreju¹

¹Rheumatology Department, University of Medicine and Pharmacy, ²Rheumatology Department, Emergency County Hospital, ³Pharmacology Department, University of Medicine and Pharmacy, Craiova, Romania

Patient history: A 70-year-old male patient, with congestive heart disease, recent diagnosis of seropositive rheumatoid arthritis (RA) and long-standing diabetes mellitus with multiple vascular and neurologic complications, is admitted for acute pain and swelling in the left ankle. The ankle joint is enlarged on both anterior and retromaleolar aspects, with local tenderness and erythema. He reports the occurrence of infected mal perforans ulceration 6 month prior, positive for *Staphylococcus aureus*, with unsuccessful surgical interventions, and poor outcome with persistent open plantar lesion evident on present examination.

Investigations: On admission, blood work shows increased acute-phase reactants, normocytic anaemia, increased ferritin, normal liver and kidney function tests. He does not display fever or shivers and has a normal bowel habits. Imaging tests for the affected ankle include musculoskeletal ultrasonography (US), x-ray and MRI. US evaluation showed features of tibiotarsal synovitis with overall inhomogeneous joint effusion, peroneus tenosynovitis and marked irregularities of distal tibial and fibular bone cortical. Synovial fluid drawn through US guided arthrocentesis had purulent features and was sent for bacteriology tests. Structural changes seen on x-ray and MRI support a possible underlying Charcot arthropathy.

Outcome: Fluid samples yielded positive results for *Staphylococcus aureus* infection which could have been linked to the previous infection site on the plantar surface. He underwent an initial 2 weeks intravenous antibiotic course with fluoroquinolones, to whom, the pathogen showed sensitivity on antibiogram, which was then continued orally. Drainage through a surgical approach

was postponed at that point. Initially, the patient reports a slight recovery in joint mobility and stability, with relative reduction in pain. Although swelling of the ankle displays a small improvement, US follow-up exams detected the persistence of infiltrate in joint space and peroneus peritendinous sheet. Outcome after one week was unfavourable, with acute bladder globe and acute decompensated heart failure with massive pleural effusion. The patient was referred on discharge to an orthopaedist to assess the opportunity for surgery.

P1116

CIRCULATING MIRNAS MIR-31-5P AND MIR-203A PREDICT INCIDENT FRAGILITY FRACTURES INDEPENDENTLY OF FRAX IN TYPE 2 DIABETIC POSTMENOPAUSAL WOMEN AND SIGNIFICANTLY IMPROVE FRAX'S ACCURACY FOR FRACTURE RISK PREDICTION IN DIABETIC BONE DISEASE

U. Heilmeyer¹, M. Hackl², F. Schroeder³, S. Torabi⁴, S. Skalicky⁵, E. Geiger⁵, K. Vierlinger⁶, G. Eiriksdottir⁷, E. F. Gudmundsson⁸, T. H. Aspelund⁸, T. B. Harris⁹, V. Gudnason⁸, T. M. Link⁴, J. Grillari⁵, A. V. Schwartz¹⁰

¹Department of Geriatrics and Center for Aging and Mobility, University Hospital Zürich and University of Zürich, Department of Radiology and Biomedical Imaging, UCSF, San Francisco, USA, ²TAmiRNA GmbH, Vienna, Austria, ³Institute for Computational Statistics, Technical University Vienna, Vienna, Austria, ⁴Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, USA, ⁵Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria, ⁶Department of Molecular Diagnostics, Austrian Institute of Technology, AIT, Vienna, Austria, ⁷Icelandic Heart Association, Kopavogur, Iceland, ⁸The Icelandic Heart Association, Kopavogur, Iceland, ⁹National Institute on Aging, Laboratory of Epidemiology and Population Sciences, Bethesda, USA, ¹⁰Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, USA

Objective: Type 2 diabetes mellitus (T2D) is characterized by an increased skeletal fracture risk which is only incompletely captured by standard tools such as the FRAX. Novel, ubiquitously available biomarkers are therefore needed that can improve FRAX's accuracy of fracture prediction in diabetics. MicroRNAs (miRNAs) have emerged as key players in bone health and disease including osteoporosis. They are easily accessible via blood draw as they are released into the blood stream from cells of various tissues proportional to local disease severity. Recently, serum miRNA classifiers including miR-203a were found to discriminate T2D women with and without prevalent fragility fractures with high accuracy (AUC>0.90). However, to date, it is unknown if such serum miRNAs can predict fracture independent of FRAX and if they can be used to improve FRAX' accuracy for diabetic patients.

Methods: The AGES-Reykjavik cohort encompasses 330 T2D postmenopausal women. After excluding all women with bone-impacting medications/conditions, 171 remained for analysis. Thereof, 71 women sustained an incident fragility fracture during the 10-y

follow-up. Baseline serum miR-31-5p and miR-203a levels were measured by qPCR-arrays in all 171 participants. Cox proportional hazard models, ROC Analysis and DeLong's AUC comparisons were used for statistical analysis.

Results: Baseline serum miR-31-5p and miR-203a were each significantly associated with a higher risk of incident fragility fractures (miR-31-5p: HR 1.29 (95%CI 1.12 to 1.49), miR-203a: HR 1.28 (95%CI 1.08 to 1.53). HRs remained significant after adjustments for total femoral vBMD or/and clinical FRAX. We next created a 4-feature diabetic fragility signature (consisting of miR-203a, miR-31-5p, clinical FRAX and femoral integral vBMD). This combined signature performed with an AUC of 0.87 (95%CI 0.81 to 0.92) significantly better than clinical FRAX (AUC 0.77, $p < 0.01$) or vBMD alone (AUC 0.72, $p < 0.001$), or than both combined (AUC 0.82, $p = 0.032$).

Conclusion: Our results show that serum microRNAs can be used to predict fracture risk independently of clinical FRAX and/or vBMD in T2D women and may significantly improve fracture risk prediction in diabetics once added to the traditional fracture risk prediction tools such as clinical FRAX and femoral vBMD.

Acknowledgements: NIH N01-AG-12100, NIH RC1 AR058405, AWS Seedgrant (P1405046), EU-FP7 Frailomic (305483) and SY-BIL (602300)

Disclosures: AVS reports a research grant from Hologic Inc. MH serves as CEO for TamiRNA and JG as TamiRNA advisor.

P1117

ONSET SYMPTOMS OF PRIMARY MALIGNANT BONE TUMORS: A RETROSPECTIVE STUDY

A. D. Bilous¹, D. Oltean-Dan², G. Tomoaia², I. Cozma¹, I. C. Filipescu¹

¹Department of Rheumatology, "Iuliu Hatieganu" University of Medicine and Pharmacy, ²Department of Orthopedics and Traumatology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania

Objective: Primary malignant bone tumors cause remarkable morbidity and mortality in both children and adults, even if it is a rare type of neoplasm. The primary symptom that occurs in a patient with malignant primary bone tumor is pain. Other symptoms that can appear are pathological fractures, joint swelling, bone swelling or systemic symptoms like fever or weight loss.

Methods: We retrospectively evaluated the patients charts from the Department of Orthopedics and Traumatology of Emergency Clinical County Hospital of Cluj-Napoca, Romania, for a period of 6 y, from June 2012 until May 2018. Charts were reviewed to collect data on patient's demographics, diagnosis of primary malignant bone tumor, type of tumor, localization and clinical symptoms. There were excluded from our study the cases with metastatic or benign bone tumors. The onset symptoms were divided into 7 groups: pathological fractures, pain, swelling, arthritis, osteomyelitis, incidental finding and unknown onset symptoms.

Results: Out of the 37 patients with malignant primary bone tumor, 20 were female and 17 were male, with a mean age of 46.95 ± 17.45 y [16-78]. The most frequent onset symptom was pain in 37.83%, followed by pathological fractures in 27.02%, arthritis in 10.81%, swelling and unknown onset symptoms in 8.10%, incidental finding in 5.40% and osteomyelitis in 2.70% cases. Moreover, the patients with pathological fracture onset were older than the other group of patients (51.73 vs. 44.26 y, $p = 0.23$). Most pathological fractures were localized in the femur (70%), followed by the tibia (20%) and the radius (10%).

Conclusions: Due to the high morbidity and mortality of the primary malignant bone tumors, even if they represent a rare encountered pathology, it is important to suspect this pathology in patients of all ages with progressive bone pain that gets worse during night or with fractures after low energy trauma.

P1118

NEUROPATHIC COMPONENT OF PAIN IN PATIENTS AFTER SURGICALLY TREATED OSTEOPOROTIC HIP FRACTURE

K. Bošković¹, S. Tomašević-Todorović¹, S. Kević¹, A. Knežević¹, S. Pantelinac¹, D. Simić-Panić¹, J. Ivačić²

¹Clinical Center of Vojvodina, Clinic for medical rehabilitation, Novi Sad, ²General Hospital, Senta, Serbia

Objective: Pain in patients after surgically treated osteoporotic hip fracture is a consequence of the lesion of somatosensory structures and contains nociceptive and neuropathic components. The study was to determine the neuropathic component of pain in patients who had an osteoporotic fracture of the hip joint and who are surgically treated.

Methods: This study covered 60 male and female patients, aged 32-81 y, with osteoporotic fracture of the hip joint, who were treated at the Clinic for Medical Rehabilitation of the Clinical Center of Vojvodina. For each patient a pain intensity was investigated, a neuropathic pain component, quality of life and functional recovery with PainDETECT questionnaire, visual analog scale (VAS), Harris hip score (HHS), WOMAC scale and SF-36 questionnaires.

Results: In our study of 60 patients, 27% is male and 73% female. The average age is 65 y. The average value of VAS is statistically significant, $p < 0.001$ Based on HHS, 76% of the respondents had a low level of disability, 20% were regular functional findings, and 4% had a good level of functioning. Using the PainDETECT questionnaire, following results were obtained: 26% of the patients had a little chance of developing neuropathic pain, with 26% requiring additional testing to determine the exact neuropathic pain component, 46.8% of the subjects had the basis for neuropathic pain. Based on the WOMAC scale, 54.4% of respondents had higher functional limitations, 46.6% had less functional constraints. Based on the overall health assessment with the help of the SF-36 questionnaires, 46.6% had poorer results, 54.4% of the respondents had better results. There is a correlation between the age variables and SF scale of SF-36 questionnaires, and ages with total SF-36 questionnaires.

Conclusion: Identification and adequate treatment of neuropathic pain components are essential to a functional recovery and quality of life in patients after surgically treated osteoporotic hip fracture were better.

P1119

IGG4 RELATED DISEASE: A RARE ENTITY WITH MULTIPLE SHAPES

R.-I. Gutiu¹, D. Fodor², M. Badarinza³, I. K. Papp¹, B. Balan¹

¹County Clinical Emergency Hospital of Cluj-Napoca/ Rheumatology/Medical Clinic II, ²Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca/Internal Medicine/County Clinical Emergency Hospital of Cluj-Napoca/Medical Clinic II, ³Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca/County Clinical Emergency Hospital of Cluj-Napoca/ Medical Clinic II, Cluj-Napoca, Romania

Objective: Hyper IgG4 syndrome is a rare immune fibro-inflammatory condition, first discussed in 2001, which can involve basically any organ. The most common clinical presentation is the enlargement of one (40% of the cases) or multiple organs caused by masses of IgG4 infiltrates, that produce plasma cells, lymphocytes and fibrosis. In most of the cases the differential diagnosis with malignancies is necessary. Ocular involvement is identified in a small amount of cases, leading to usually bilateral exophthalmia.

Method: We present the case of a 32-year-old male patient, with diamine oxidase deficiency, and severe bilateral exophthalmia for the past 3 y, unaccompanied by pain and normal visual acuity. Previous investigations excluded hypothyroidism or any other form of cancer and the response to low doses of glucocorticoids was insufficient. In the process of establishing the etiology, the patient has been investigated echographically, which has revealed enlarged, inhomogeneous lacrimal glands, with no involvement of the salivary glands and local lymph nodes, and an imagistically normal thyroid gland. An orbital angio-RM has been performed showing an orbital idiopathic inflammatory process involving both orbits. The blood tests showed no significant modifications. The clinical presentation, the negative cancer screening and the normal biological results conducted to the suspicion of an autoimmune disease, the IgG4 related disease being the pathology that causes orbitopathy the most frequent. Seric IgG4 was >135 mg/dl.

Results: Despite the patient's medical history, we decided to start the treatment with a methylprednisolone pulse therapy and to continue with a higher dose of prednisone (40 mg/d), as it is considered the first line of therapy. The response was only partial once again, concluding that the patient was corticoreistant. Taking this into consideration, rituximab was the next best choice of therapy. The patient followed two doses of rituximab (2000 mg), concomitant with GCs with a good result.

Conclusion: The IgG4 related disease is an under recognized condition, which affects males more than females. It has a variety of clinical implications and there is no reliable biomarker for its diagnosis. Careful investigation and monitoring of the patient are the only certain path for a correct diagnosis.

P1120

INVOLVEMENT OF THE MAP KINASE PATHWAY IN OSTEOBLASTS AND OSTEOCLASTS GENE EXPRESSION UNDER DIFFERENT GRAVITATIONAL CONDITIONS

V. Chatziravdeli¹, A. N. Tsartsalis², G. Katsaras³, G. Lambrou³

¹8th Orthopaedic Department, General Hospital " Asklepieio", ²Naval Hospital of Athens, Department of Endocrinology Diabetes and Metabolism, ³First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece

Objectives: Presentation of osteoblast and osteoclast gene expression alterations in the MAP kinase (MAPKs) pathway under microgravity (0g) and hypergravity (2g) conditions compared to normal gravity (1g).

Methods: We retrieved raw genomic data from the Gene Expression Omnibus (GEO) Database, regarding gene expression of stromal cells, osteoblastic (2T3 mouse preosteoblasts, MLO-Y4 osteocytes, osteoblasts) and cells of the macrophage lineage (RAW264.7) under different gravitational conditions and performed bioinformatics analysis. Genes whose expression levels showed statistical significance ($p < 0.05$) were analyzed using the KEGG Pathway Analysis in order to identify signaling pathways that they were involved in.

Results: Our study revealed a cluster of genes related to the MAP-kinases pathway that showed significant difference in expression levels ($p = 2.26 \times 10^{-7}$). MAPK8IP3 was upregulated in microgravity (0g) compared to normal gravity in all cell types. The difference in expression levels was even greater when compared with hypergravity (2g) conditions, where overexpression was noted ($p = 0.0158$ / false discovery rate = 0.073).

Conclusions: The family of MAPKs (ERK, JNK, p38) consists of signal molecules that respond rapidly to cellular stress and alter gene expression in the cell's nucleus. They regulate cellular proliferation, differentiation and apoptosis via intricate and complex pathways. Changes in gravitational conditions are perceived by cells of the osteoblastic/ osteoclastic lineage and respond rapidly by altering gene expression in the nucleus. Part of this process is mediated by the MAPK pathway. Both in 0g and 2g cells upregulated MAPK8IP3, with hypergravity having a greater impact, thus suggesting a significant involvement of the MAPK family early in the process of achieving homeostasis in the cellular level, when exposed to different gravitational forces.

P1121

VITAMIN D REGULATES NF- κ B DEPENDENT SIGNALING IN EXPERIMENTAL OSTEOPOROSIS ASSOCIATED WITH TYPE 1 DIABETES

I. Shymanskyi¹, A. Mazanova¹, O. Lisakovska¹, M. Veliky¹¹O.V. Palladin Institute of biochemistry of NAS of Ukraine, Kyiv, Ukraine

Objective: Secondary osteoporosis is a common clinical complication related to type 1 diabetes mellitus (DM1), however precise cellular and molecular mechanisms are not fully clarified. Proinflammatory processes and deregulation of the vitamin D-endocrine system in diabetes can lead to an abnormal transactivation of the nuclear factor κ B (NF- κ B) and cause unbalanced bone formation and resorption. The study was performed to find out the role of NF- κ B in the development of secondary osteoporosis associated with experimental DM1 and to assess the potential of vitamin D3 (VD3) for the treatment of diabetes induced bone loss.

Methods: DM1 was induced in male Wistar rats by single i.p. injection of STZ (55 mg/kg b.w.). Two weeks later, diabetic rats were treated with or without selective NF- κ B inhibitor BAY 11-7082 (1 mg/kg b.w., i.p for 10 d) or 100 IU of vitamin D3 (orally, for 30 d). The protein levels of RANK, RANKL, osteoprotegerin (OPG), total and phosphorylated at Ser 311 p65 subunit of NF- κ B, vitamin D receptor (VDR) and 25-hydroxyvitamin D 1 α -hydroxylase (CYP27B1) were assayed by western blot analysis. Changes in the mRNA levels of VDR and CYP27B1 were measured by real-time quantitative PCR. 25OHD content was assayed by ELISA.

Results: DM1 induced elevation of RANK and RANKL protein levels in bone tissue with a significant decrease in the OPG expression, indicating an intensification of bone resorption. Diabetes also led to 25OHD deficiency and insufficient VDR expression in bone tissue, while CYP27B1 mRNA level was elevated. DM1 was accompanied by an increase in total and phosphorylated NF- κ B/p65. BAY 11-7082 treatment resulted in partial normalization of bone remodeling, 25OHD and CYP27B1 levels. It also blocked NF- κ B/p65 phosphorylation in bone tissue of diabetic animals but increased the level of total NF- κ B. VD3 treatment restored parameters of RANKL/RANK/OPG axis as well as mRNA and protein levels of VDR and CYP27B1. Significant decrease in both total and phosphorylated NF- κ B/p65 was also seen after VD3 treatment.

Conclusion: Selective NF- κ B inhibition and VD3 treatment partially reversed DM1-associated impairments of bone remodeling, which highlights the role of vitamin D-deficiency and NF- κ B transcriptional activation in elevated bone tissue resorption.

P1122

PATTERNS OF CLINICAL MANIFESTATIONS INVOLVEMENT IN PATIENTS WITH OVERLAP SYNDROME

S. C. Firulescu¹, C. D. Parvanescu¹, B. A. Chisalau¹, C. Criveanu¹, S. C. Dinescu¹, R. M. Dumitrascu², H. V. Popoviciu³, R. A. Ionescu⁴, A. L. Barbulescu¹, A. Rosu¹, P. L. Ciurea¹, A. F. Vreju¹

¹Rheumatology Department, University of Medicine and Pharmacy Craiova, Craiova, ²Rheumatology Department, Emergency County Hospital Craiova, Craiova, ³Department of Rheumatology, University of Medicine and Pharmacy Targu Mures, Targu Mures, ⁴Department of Rheumatology, University of Medicine and Pharmacy Carol Davila Bucharest, Bucharest, Romania

Objective: Overlap syndrome (OS) is a clinical condition that meets the criteria for diagnosis of at least two connective tissue diseases that occur at the same time or at different times in the same patient. It may include systemic sclerosis (SSc), dermatomyositis or poly/dermatomyositis, (PM/DM), Sjögren's syndrome (SS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Any association between diseases may be possible, with certain associations being encountered more frequently. The clinical picture is often complex, often making the diagnosis and treatment difficult. The combined pathology of these conditions has a major impact on clinical development, diagnosis and treatment. Clinical manifestations depend on affected organs, degree of inflammation and disease progression. The study proposed the evaluation of clinical and biological correlations, with the identification of frequent associations in overlap syndrome, compared to SLE patients.

Methods: The study included 20 patients with SLE and 18 patients with OS (different overlapping between systemic lupus erythematosus, systemic scleroderma, RA, mixed connective tissue disease, or dermatomyositis), which were clinically and paraclinically evaluated. The clinical information included type of systemic involvement, such as kidney or hematological (anemia, leukopenia, thrombocytopenia) involvement and serositis. The inflammation markers and immunological changes (rheumatoid factor, antibodies profiles) were noted too.

Results: The most important finding was that in the OS of SLE with any other disease, compared to SLE patients, was reducing to approximately half of the renal manifestations in patients with OS (SLE-RA) compared to the latter ones (27% vs. 50%) ($p < 0.05$), while cytopenia and serositis are more common in patients with RA-SLE (63.64% vs. 55% and 45% vs. 35%) ($p < 0.05$). Patients with OS (SLE-BMTC) had renal manifestations and cytopenia in the same percentage as SLE patients but did not have serositis. Patients with OS (SLE-SSc) had only cytopenia in the same percentage as SLE patients but did not have serositis and kidney involvement.

Conclusions: This study demonstrated that there is a different pattern of involvement in patients with overlapping syndromes, according to compounding diseases, suggesting that carefully assessment of all systems and structures could lead to accurate diagnosis, optimal treatment and prevention of complications.

P1123

METABOLIC SYNDROME IN PATIENTS WITH GOUT ATTENDED IN A SPECIALIZED OUTPATIENT UNIT IN SPAIN: COMPARISON WITH GENERAL POPULATION AND CARDIOVASCULAR IMPLICATIONS

E. Calvo Aranda¹, F. M. Sanchez Aranda¹

¹Rheumatology Department, Hospital Universitario Infanta Leonor, Madrid, Spain

Objective: Metabolic syndrome (MS) is a cluster of interrelated components: central adiposity or higher waist circumference, high values of triglycerides (TG), elevated blood pressure (BP), impaired fasting glucose and decreased HDL-cholesterol (HDL-c). It is associated with a higher incidence of developing diabetes (DM), as well as with other cardiovascular diseases (CVD). A direct relationship between serum uric acid (sUA) and the risk of develop MS has been reported in several studies of patients with hyperuricemia and gout. Our aim was to study the prevalence of MS and associated CVD in patients with gout attended in a specialized outpatient unit, comparing with other local and national studies.

Methods: Retrospective observational study with consecutive patients diagnosed with gout according to EULAR/ACR criteria between August and December 2018. We analyzed the presence of MS according to the 2015 International Diabetes Federation (IDF) criteria (central obesity as BMI ≥ 30 kg/m² or BP ≥ 94 cm (≥ 80 in women), with ≥ 2 of the following: TG ≥ 150 mg/dl, HDL-c < 40 mg/dl (< 50 in women), hyperglycemia ≥ 100 mg/dl (or T2DM previously diagnosed or hypoglycaemic treatment), arterial hypertension (HT; $\geq 130/85$ mmHg or use of antihypertensive drugs). Treatments received and family history (FH) of gout an CVD were recorded. Demographic, anthropometric, clinical and analytical variables were analyzed. All data were compared with those obtained in three Spanish studies of the general population: DARIOS 2012, ENRICA 2014, SIMETAP 2018.

Results: 57 patients with gout were included. Average age 62 y (39-90), 48 y (18-90) at the time of gout onset. 94.7% males. 40.3% with FH of gout, tophi in 52.6%. Clinical pattern: monoarticular 15.8%, oligoarticular 56.1%, polyarticular 28.1%. 68.4% received urate-lowering therapy: 45.6% allopurinol, 22.8% febuxostat. SUA at the time of inclusion 6.7 mg/dl (2.6-11.3). Total cholesterol 186 mg/dl (96-350). TG 185 mg/dl (68-742). BMI 31.8 kg/m² (24-58.1). MS was found in 66.7% and pMS (MS without DM or CVD) in 26.3%. Obesity 57.9% and overweight 38.6%. HT 80.7%; 10.5% diagnosed in our unit. DM 22.8%. Dyslipidemia (DL: hypercholesterolemia and/or high levels of TG) 64.9%; 14% diagnosed in our unit. 29.8% smokers, 49.1% formers. Alcohol consumers 54.4%. Chronic kidney disease (CKD) 42.1%; 12.3% diagnosed

in our unit. Ischemic heart disease (IHD) 14%. Stroke 24.6%. FH of CVD 24.6%. Comparing with the general population the prevalence of MS and pMS was higher (DARIOS 2012: 31% and 24%, respectively; ENRICA 2014: 22.7% and 16.9%; SIMETAP 2018: 41% and 25%), as well as with the presence of CKD (11.5% in SIMETAP) and CVD (SIMETAP: HT 38%, T2DM 16%, obesity 28%, IHD 4.8% and stroke 3.8%).

Conclusions: There is a very significant percentage of MS and pMS in patients with gout compared to the general population, with important presence of CKD and CVD, sometimes underdiagnosed. Nursing guidelines were established healthy lifestyle and periodic controls directed at all patients, with special emphasis on those newly diagnosed of HT or DL, as well as those of higher cardiovascular risk.

P1124

MUSCULOSKELETAL DISORDERS AMONG ELITE GREEK YOUTH SOCCER PLAYERS.

A. Zavvos¹, P. Gkriilas², D. Stergiopoulos¹, C. Matzaroglou²

¹National and Kapodistrian University of Athens, Greece, Athens, ²Technological Educational Institute (TEI) of Western Greece, School of Health and Welfare, Department of Physical Therapy, Aigio Achaia, Greece

Objectives: Participation in soccer practice and games has been shown to favor the development of asymmetries. Youth players had a higher incidence of training injuries than professionals. The purpose of this study was to record the musculoskeletal symptoms per anatomical body region in adult Greek elite youth soccer players.

Methods: The Greek version of Nordic Musculoskeletal Questionnaire (NMQ)³, was given to participants during the 2017-2018 soccer season. Participants in NMQ were asked whether they had pain/discomfort in 9 different anatomical regions (neck, shoulders, elbow, wrists/hands, upper back, lower back, hips/thighs, knees and ankles/feet) during the preceding 12 months and if those symptoms prevented their normal activity during the last year as well as the 7 previous days. Analysis consisted of descriptive statistics.

Results: 51 (19 in U-15, 15 in U-17 and 17 in U-20) elite Greek youth soccer players (age: 16.8 \pm 1.6 y, height: 1.75 \pm 0.07 m, weight: 64.6 \pm 12.4 kg, BMI: 21.0 \pm 3.6 kg/m², training age: 10.3 \pm 3.0 y, training h/week: 9.9 \pm 2.5 h) completed the NMQ. The 12-month prevalence rate of pain/discomfort was 17.6% in ankles/feet, followed by the knees (15.7%), wrists/hands (9.8%), shoulders (9.8%), the neck (7.8%), lower back (7.8%) and hips/thighs (7.8%), elbows and upper back (0%). Those symptoms prevented athlete's normal activity (functionally) during the last 12 months with different prevalence rate per anatomical body region (ankles/feet: 13.7%, shoulders: 9.8%, knees: 9.8%, lower back: 7.8%, hips/thighs: 5.9%, wrists/hands: 2.0%, neck: 0.0%, elbows: 0.0% and upper back: 0.0%).

Conclusion: The incidence rates of musculoskeletal pain/discomfort in elite Greek youth soccer players, highlights the need for specific injury prevention programs.

References:

1. Gkrilias P et al. J Phys Ther Sci 2018;30:1141
2. Pfirrmann D et al. J Athl Train 2016;51:410
3. Antonopoulou M et al. Eur J Gen Practice 2004;10:35

P1125**DECREASE RISK OF FALLS AFTER THE BALANCE TRAINING ON A STABILOMETRIC PLATFORM IN NEUROLOGICAL PATIENTS**A. Zimin¹, G. Yusupova¹¹Research Center of Neurology, Moscow, Russia

Objective: Balance is an essential skill for everyday life. Patients with many different neurological diseases (Parkinson's disease, multiple sclerosis, stroke, etc.) suffer from balance disorders what leads to increase risk of falls and fractures. Moreover corticosteroids what are widely applied in neurological clinical practice effecting on induce bone loss and immobility determine the importance of balance training in prevention of fall risk in neurological patients (NP) The aim was to assess the effectiveness of the stabilometric platform training via Russian version Berg Balance Scale (BBS).

Methods: 58 neurological patients (stroke n=18, multiple sclerosis n=14, Parkinson's disease n=14, syndrome Guillain-Barré n=10) included in the study had mild to moderate disability and could walk unassisted. All of them had the balance training on the stabilometric platform (Stabilan-01-2, JSC Rhythm, Russia; duration 30 min, n=20 procedures). Romberg Balance Test and BBS were performed before and after treatment.

Results: After 20 trainings on a stabilometric platform BBS scores and Romberg Balance Test results increased significantly in all groups (p<0.05). The BBS scores correlated significantly (r=0.79, p<0.05) with the Romberg Balance Test. The best results had Stroke patients (+6.3 scores, p<0.01), least multiple sclerosis patients (+2.4 scores, p=0.048) after rehabilitation treatment.

Conclusions: Balance training on a stabilometric platform in neurological patients is effective for decrease risk of falls.

P1126**PRIMARY HYPERPARATHYROIDISM COMPLICATED WITH SEVERE OSTEOPOROSIS AND RENAL FAILURE**A. Hritiuc¹, C. Moldovan¹, M. Carsote², I. F. Turturea³, C. E. Georgescu⁴, A. Valea⁴¹Clinical County Hospital, Cluj-Napoca, ²UMPh C. Davila, Bucharest, ³Clinical County Hospital, Dej, ⁴UMPh I. Hatieganu & Clinical County Hospital, Cluj-Napoca, Romania

Objective: Osteoporosis is a common complication of primary hyperparathyroidism (PHPT) along with kidney stones and nephrocalcinosis. Severe osteoporosis associated with multiple vertebral and nonvertebral fractures is relatively rare in elderly females patients with primary PTHP.

Method: We aim to present a case of an elderly woman diagnosed with PTHP and renal failure. Endocrine assessment related to PHPT is provided. The patient was followed in different tertiary centres of endocrinology. The informed consent was obtained.

Case report: A 71-year woman diagnosed 6 y ago with chronic renal failure of unspecified etiology, currently in G4 KDIGO stage, was admitted for diffuse osteoarticular pain, moderate difficulty in walking and high blood pressure. She has medical history of posttraumatic fracture of straight lamb four years ago and straight hip fracture one year ago. Phosphocalcic metabolism assessment showed elevated PTH of 1072.7 pg/mL (normal: 12-88 pg/mL), hypercalcemia: ionic calcium of 6.31 mg/dL (normal: 4.4-5.4 mg/dL), total calcium of 11.36 mg/dL (normal: 8.8-10.6 mg/dL) with low urinary calcium of 59 mg/24h (normal:100-300 mg/24h), normal serum phosphorus of 4.21 mg/dL (normal: 2.5-4.5 mg/dL) with low urinary phosphorus of 0.23 g/24h (normal: 400-1300 mg/24h), low 25-hydroxyvitamin D(25OHD) of 8.76 ng/mL (normal >30 ng/mL). Ultrasound suggest an inferior left mass of 14 mm confirmed at computed tomography. Osteoporosis was highlighted at lumbar DXA: BMD of 0.72 g/cm², T-score of -3.9SD, Z-score of -2.3 SD, total hip BMD of 0.7 g/cm², T-score of -2.4 SD, Z-score of -1.1 SD. Radiographs revealed thinning of bone cortices and a cystic lesions of the left humeral head of 25/28 mm and bilateral distal clavicular erosions. She received vitamin D and parathyroidectomy was indicated.

Conclusion: Parathyroidectomy is indicated in all forms of PHPT associated with renal failure due to increased risk of morbidity and mortality. The choice of medical treatment for osteoporosis is difficult for patients with advanced renal failure stages.

P1127**ASSOCIATION OF CLINICAL PARAMETERS AND FEATURES OF ULTRASOUND OF THE KNEE IN A CONSECUTIVE GROUP OF PATIENTS**N. Martusevich¹, K. Gudkevich², A. Aleshkevich¹, T. Bondar³¹Belarusian State Medical University, ²Minsk City Clinical Hospital No.6, ³Minsk Regional Clinical Hospital, Minsk, Belarus

Objective: To determine the relationships between clinical parameters and features of ultrasound (US) of the knee.

Methods: This was a cross-sectional study, recruiting 47 consecutive patients aged 47 (36-54), 60.42% (n=29) were female. Those with recent trauma, rheumatic diseases were excluded from the study. Patients underwent assessment for knee pain (visual analog scale (VAS)), US examination of the knee joints according to the 4-point scale (synovial proliferation, joint effusion, power Doppler signal (PD), patellofemoral joint cartilage (PFJ), medial femoral cartilage (MF), medial (MM) and lateral meniscus (LM), osteophytes, Baker cysts). US staging of knee OA was also performed.

Results: Patients were divided into 2 groups: those with knee pain (n=28) and asymptomatic patients (n=19). Pathological US features were found in both groups (Table). In 5 out of 19 asymptomatic patients, degenerative changes of different degree of the

joint structures were identified (PFJ, MF, osteophytes, MM, LM), in 4 patients – joint effusion. Prevalence of PFJ, MF, MM, LM changes, osteophytes and Baker cysts did not differ between groups. Groups differed in PD signal expression in the synovia (p=0.07). Functional association between VAS score and PD expression (R=1.0, p<0.05) was revealed; moderate correlation between VAS score and joint effusion (R=0.47, p<0.05), PFJ (R=0.58, p<0.05), osteophytes (R=0.66, p<0.001), OA US stage (R=0.58, p<0.001) was observed.

Conclusion: In the patients under study, degenerative and inflammatory findings were common in the symptomatic group, but were also identified in the asymptomatic patients. Clinical parameters were more strongly associated with active inflammation (as verified by US) rather than with degenerative changes.

Parameter	Prevalence in patients with knee pain, n=28	Prevalence in asymptomatic patients, n=19	P
Synovial proliferation	0 (0%)	0 (0%)	1,0
Joint effusion	10 (35,71%)	4 (21,05%)	0,34
Power Doppler signal	5 (3,57%)	0 (0%)	0,07
Patellofemoral joint cartilage	5 (17,86%)	1 (5,26%)	0,38
Medial femoral cartilage	3 (10,71%)	2 (10,53%)	1,0
Osteophytes	9 (32,14%)	3 (15,79%)	0,31
Medial meniscus	9 (32,14%)	5 (26,32%)	0,75
Lateral meniscus	2 (7,14%)	2 (10,53%)	1,0
Baker cysts	6 (21,43%)	4 (21,05%)	1,0

P1128

TERIPARATIDE: THE FIRST THERAPEUTIC OPTION FOR SEVERE POSTMENOPAUSAL OSTEOPOROSIS

S. Naumescu¹, A. Hritiuc¹, C. Moldovan¹, M. Carsote², C. E. Georgescu³, A. Valea³

¹Clinical County Hospital, Cluj-Napoca, ²UMPh C. Davila, Bucharest, ³UMPh I. Hatieganu & Clinical County Hospital, Cluj-Napoca, Romania

Objective: Severe osteoporosis with multiple fractures are common in postmenopausal women leading to high morbidity and mortality. For patients with very low BMD associated with multiple spine fractures teriparatide may be the first therapeutic approach.

Methods: A case of severe postmenopausal osteoporosis associated with multiple vertebral fractures is introduced. Bone was evaluated by central DXA, bone scintigraphy and bone radiography. Phosphocalcic metabolism assay including the bone turnover was performed. The informed consent was obtained.

Case report: A 58-year-old female with no prior significant medical history is admitted for further investigation after multiple vertebral fractures located at L2-L5 level have been revealed at the radiological examination performed for diffuse vertebral pain associated with walking difficulties. The biochemical parameters revealed: alkaline phosphatase of 119 U/L (normal: 35-104 U/L), normal levels of ionized calcium, normal blood phosphorus and decreased levels of circulating osteocalcin of 9.66 ng/mL (nor-

mal: 15-46 ng/mL) with normal β-CrossLaps of 0.075 ng/mL (normal:0.104-1.008 ng/mL). Hormonal profile showed normal PTH of 40.8 pg/mL (normal: 15-65 pg/mL) and 25OH D (25-hydroxyvitamin D) values of 37 ng/mL (normal >30). Wholebody scintigraphy revealed no metastasis. DXA showed decreased BMD of 0.52 g/cm², T-score of -5.6SD, Z-score of -4.8 SD, total hip BMD of 0.760 g/cm², T-score of -1.7 SD, Z-score of -1 SD. The normal value of serum cortisol and thyroid hormones have excluded another endocrine pathology as the cause of osteoporosis. Teriparatide in a once daily dose of 20 µg subcutaneous was initiated in combination with orally vitamin D. A slight improvement of BMD (of 0.66 g/cm²) and T-score (of -4.4 SD) was obtained after 2 y of treatment, which is why risedronate 75 mg, 2 doses per month was introduced.

Conclusion: Treatment of severe osteoporosis with multiple vertebral fractures is still a challenge for clinical practice. Because there is insufficient data regarding the risk of fracture in severe osteoporosis, bisphosphonates or denosumab remain the therapeutic alternatives at the end of teriparatide treatment.

P1129

RELIABILITY OF SOFT TISSUE ULTRASONOGRAPHY IN IDENTIFYING AN INFECTIOUS THIGH MASS

S. C. Dinescu¹, R. M. Dumitrascu², S. C. Firulescu¹, D. L. Sandulescu³, E. M. Vintila³, A. M. Nasarimba⁴, C. Criveanu¹, L. Streba⁵, A. Rosu¹, P. Ciurea¹, F. A. Vreju¹

¹Rheumatology Department, University of Medicine and Pharmacy, ²Rheumatology Department, Emergency County Hospital, ³Gastroenterology Department, Emergency County Hospital, ⁴Internal Medicine Department, Emergency County Hospital, ⁵Oncology Department, University of Medicine and Pharmacy, Craiova, Romania

Objective: Imaging methods are lately gaining more and more importance in the diagnosis and management of inflammatory joint diseases, but sometimes, their role in the differential with septic causes of the illness is crucial. Our aim was to underline the usefulness of soft tissue ultrasonography (US) in septic patients with localized purulent mass.

Patient history: A 58-year-old male patient presented to the emergency room in a general poor state, with fever, fatigue and intense pain in the right upper thigh. He is diabetic and has a history of viral liver cirrhosis with a current decompensated status. On clinical examination, the patient displayed a very tender upper right thigh, on the medial aspect, with evident swelling of the right lower leg. An US examination was prompted in order to get some insight into the etiology of the present symptoms. Ultrasound evaluation showed an inhomogeneous hypoechoic fluctuant well delineated mass, that was localized between the pectineus and adductor longus muscles. An aspiration manoeuvre was considered necessary for diagnostic purpose. We used an ultrasound guided spinal 18G needle and 10ml of brown, purulent fluid was withdrawn and sent to bacteriology test, which came positive for Staphylococcus aureus.

Outcome: The patient was referred to the surgery department. Diagnosis of infectious etiology was confirmed, with successful evacuation of 300 ml of purulent fluid. Samples obtained both from US-guided aspiration and during surgery yielded positive results for *Staphylococcus aureus* infection. Postoperative tomography confirmed the absence of residual infectious infiltrate in the affected thigh. US evaluation was a reliable tool with significant aid in initial diagnosis, as it can help the clinician in differentiating between an infectious and a lymphatic mass, and also provides precise anatomical references for a guided fluid sample aspiration or eventual surgical approach.

P1130
SEVERE OSTEOPOROSIS COMPLICATED WITH RADIOULNAR FRACTURE IN A TYPE 2 DIABETES MELLITUS PATIENTS

C. Moldovan¹, R. Turturea², M. Carsote³, A. Hritiuc¹, C. E. Georgescu⁴, A. Valea⁴

¹Clinical County Hospital, Cluj-Napoca, ²Clinical County Hospital, Dej, ³UMPh C. Davila, Bucharest, ⁴UMPh I. Hatieganu & Clinical County Hospital, Cluj-Napoca, Romania

Objective: Like type 2 mellitus diabetes, osteoporosis is a silent condition associated with increased morbidity and mortality. The relationship between these two entities is still controversial. Although hyperinsulinemia and obesity seem to have a beneficial effect on bone mass, persistent hyperglycemia decreases bone formation and interferes negatively with calcium and vitamin D metabolism.

Method: A case report is introduced regarding a female patient with type 2 mellitus diabetes and nodular goiter. Endocrine evaluation performed in different departments included thyroid stimulating hormone (TSH), free thyroxine (FT4), anti-thyroglobulin (TGAb) and anti-thyroid peroxidase antibodies (TPOAb), calcitonin, parathormone(PTH) and 25-hydroxyvitamin D (25OHD), biochemical tests like total calcium, ionic calcium (Cat/i), β -Cross-Laps (β -CTx), osteocalcin, glycated haemoglobin (HbA1c) and imagery assessment: thyroid ultrasound (TUS), central DXA.

Case report: A 68-year patient diagnoses with osteoporosis 5 y ago after radioulnar fracture by falling from the same level is admitted for further assessment with market asthenia, fatigue and multiple joints pain. In the last 3 y the patient has been treated with bisphosphonates and vitamin D. Biochemical tests revealed normal Cat/i, low osteocalcin (of 8.8 ng/mL, normal 15-46 ng/mL), normal β -CTx, hyperglycemia (of 131 mg/dL, normal of 74-106 mg/dL) and high HbA1c (of 7.29%, normal 4-6%). The endocrine assays highlighted normal PTH with slightly decreased 25OHD (of 29.7 ng/mL, normal 30-100ng/mL), normal TSH, FT4, calcitonin, and negative TgAb, TPOAb in addition to a TUS finding of a large parenchymal nodule without intra and perinodular vascular signal. DXA showed still decreased BMD of 0.683 g/cm², T-score of -3.9 SD and Z-score of 2.7 SD, total hip BMD of 0.576 g/cm², T-score of -2 SD, Z-score of -1.6 SD. Monthly bisphosphonates was recommended together with vitamin D. Also, the patient continued oral antidiabetic therapy for prevention of additional metabolic complications.

Conclusions: The radioulnar fracture may be the first manifestation of osteoporosis in a patient with type 2 mellitus diabetes. Microvascular events, peripheral neuropathy and metabolic complications associated with inadequate glycemic control are the main factors involved in increasing the risk of fracture in the diabetic patient.

P1131
ATYPICAL FEMORAL FRACTURE: THE PRICE FOR LONG TERM BIPHOSPHONATES ADHERENCE?

E.-T. Oprea¹, C. G. Barbu², S. V. Fica²

¹ELIAS University Hospital, ²Carol Davila University of Medicine, Bucharest, Romania

Bisphosphonates are the most widely prescribed drug therapy for osteoporotic fracture prevention, often considered, first line therapy for postmenopausal osteoporosis. The association between atypical femoral fractures and bisphosphonate therapy is complex and controversial; bisphosphonate therapy appears to increase risk of atypical fractures, with greater risk associated with longer durations of treatment. Suppression of bone turnover with long durations of bisphosphonate treatment could cause a loss of material toughness or microdamage accumulation, but the pathophysiology of atypical femoral fracture is not completely understood. Although atypical femoral fractures in bisphosphonate-treated patients is a rare complication, the case reports over the last years have raised concerns about long-term safety of antiresorptive therapy.

We report the case of a 66-year-old woman, who was referred to our clinic by the orthopedic service, for a nontraumatic right femoral diaphysis fracture, intramedullary full length nail reconstructed. The patient had a medical history of type 2 diabetes mellitus treated with oral antidiabetic agents, and with an osteoporosis diagnosis established 13 y ago, for whom oral bisphosphonates treatment was recommended, she states that the bisphosphonates therapy has gone uninterrupted for the last 13 y. No significant abnormalities were observed at clinical exam, lab tests suggested a well controlled diabetes mellitus with no other notable changes, but, the osteoresorption markers were highly suggestive for decreased bone remodeling (osteocalcin=9.2 ng/ml); DXA: L1-L4 T-score=-1.9(BMD=0.955); left hip T-score=-2.6 BMD=0.683; the comparison with previous DXAs suggested that BMD was rather stationary CT scan revealed, besides the right femoral diaphysis fracture, a small, incomplete fracture at the side wall of the left femoral diaphysis. As a therapeutic approach, we recommended the replacement of antiresorptive treatment with anabolic therapy, with VitD supplementation, aiming to restart the bone remodeling process, and to decrease the risk of further nontraumatic fractures.

Although bisphosphonates are generally considered safe, long term therapy should be monitored with biochemical markers of bone turnover and should be discontinued in patients without a clear indication for antiresorptive therapy. It is necessary to follow-up the patients who have suffered an atypical fracture of the femur because an incipient stress fractures in the contralateral limb may propagate when weight bearing is reduced in the frac-

tured limb. Given the previous case reports and rat models, teriparatide appears to be the appropriate postoperative treatment for healing atypical femoral fractures, future research into the pharmacological treatment of atypical femoral fractures being needed.

P1132

FALLS AND RELATED FACTORS IN DIABETIC ELDERLY PEOPLE

O. Yilmaz¹, C. Idiz², P. Kucukdagli¹, D. Erbas Sacar¹, I. Satman², G. Bahat¹

¹Istanbul Medical Faculty Internal Medicine Department Geriatrics Division, ²Istanbul Medical Faculty Internal Medicine Department Division of Endocrinology, Istanbul, Turkey

Objective: Diabetics develop the conditions necessary for sarcopenia and falls earlier than other aging individuals. Falls are an important health problem in the elderly population. Being diabetic and sarcopenic is even more risky for falls. In this study, we aimed to investigate the relationship between sarcopenia and fall in the elderly who admitted to the diabetes outpatient clinic.

Methods: Design: prospective, cross-sectional study. Setting: diabetes outpatient clinic (August- December 2018). Participants: Older adults aged ≥ 60 y. Measurements: Sarcopenia was evaluated by SARC F questionnaire. Patients' data about number of chronic diseases and prescribed drugs, falls (in the preceding year), BMI were recorded. SPSS (statistical package for social sciences) v21 program was used for statistical analysis.

Results: 164 patients were enrolled. Mean age was 72.1 ± 7.3 y and 110 (66%) were women and 54 (34%) were men. SARC F questionnaire was answered by all. SARC F score >4 points was regarded as sarcopenia. 32.9% of men and 67.1% of women were sarcopenic. The nonsarcopenic group experienced a 25.7% falling, while the sarcopenic group had a 62.5% falling. There was a statistically significant difference about falls and falling fear between this two groups ($p < 0.001$). The total number of diseases and medications was higher in sarcopenic and falling group (respectively $p = 0.009$ and $p = 0.017$). In logistic regression analyses, recurrent falls were found to increase sarcopenia 3.9 times.

Conclusion: Falls is associated with sarcopenia in the diabetic elderly population. These patients should be considered in terms of fall because of the increased risk of fracture in the diabetic elderly. In the routine evaluation, the falls should be questioned because the falls is very frequent in diabetic elderly people.

P1133

FOLLOW-UP AFTER 2 YEARS OF DAILY TERIPARATIDE IN DIABETIC PATIENT

M. Carsote¹, A. Dumitrascu², A. Valea³, A. Ghemigian⁴, C. Dumitrache⁵

¹UMPh C. Davila & C.I. Parhon National Institute of Endocrinology, Bucharest, ²C.I. Parhon National Institute of Endocrinology, Bucharest, ³UMPh I. Hatieganu & Clinical County Hospital, Cluj-Napoca, ⁴UMPh C. Davila & C.I. Parhon National Institute of Endocrinology, Bucharest, ⁵UMPh C. Davila, Bucharest, Romania

Teriparatide represents an anabolic therapy for bone status with a single life time administration for 2 years. Despite daily injections, a patient may also have daily insulin therapy for diabetes. This is a case report of a menopausal female with severe osteoporosis and type 1 diabetes mellitus. DXA T-score is provided (GE Lunar Prodigy device).

Case data: This is a 73-year-old female with more than 2 decades in menopause, also diagnosed with insulin dependent diabetes mellitus, mild arterial hypertension and bilateral coxarthrosis. She was diagnosed with osteoporosis and weekly alendronate was offered to her for 3 y. Lumbar L1-4 T-score was stationary of -3.1 SD but she suffered a spontaneous vertebral fracture at low thoracic level. Bisphosphates were switched to daily 20 μ g of subcutaneous teriparatide which she followed for 2 y. By the end of the first year lumbar T-score reached -2.1 SD and after the second -1.9 SD. No new fracture was detected and soon after she had two times bilateral hip prosthesis surgery because of arthrosis. After Teriparatide she started subcutaneous denosumab every 6 months. After one more year T-score was -1.9 SD, and after another -1.3 SD.

Conclusion: BMD increase at lumbar spine under Teriparatide continues after the drug is stopped in addition to antiresorptive treatment that follows bone building medication.

P1134

DOES THE GAIT PATTERN IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AT EARLY STAGES OF DISEASE DIFFER FROM HEALTHY CONTROLS? A CROSS-SECTIONAL STUDY

L. Domingues¹, C. S. Mendes¹, R. Matias², S. R. Manica¹, C. L. Crespo¹, J. C. Branco¹, F. M. Pimentel-Santos¹

¹CEDOC-Chronic Diseases Research Center - Nova Medical School|Faculdade de Ciências Médicas, ²Champalimaud Research - Champalimaud Centre for the Unknown, Lisbon, Portugal

Objective: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease characterized by a progressive mobility reduction of the rachis. The postural changes associated may cause balance problems in advanced stages with gait repercussions. However, although we have a detailed picture of the disease at later stages, we lack an in-depth description of the early stages of the disease, which can impact the understanding of the

mechanisms generating movement impairment. This study aimed to evaluate the progressive movement decay in young patients in early stages of axSpA based on 3D gait kinematics.

Methods: A cross-sectional study was conducted on 46 participants (18-50 years old), 23 patients with axSpA (according to ASAS criteria, with <10 y since symptoms onset) and 23 healthy controls, matched by gender and age. Subjects' movement was reconstructed using a 3D full-body kinematic model fed by 15 inertial sensors placed in the head, arms, trunk, pelvis, thighs, shanks and feet. The primary outcomes comprise the general gait parameters regarding gait deviation index, speed, cadence, stance duration, body vertical regularity (sample entropy), step length, range of movement and peak velocity of the different joints. Physical activity was controlled by the international physical activity questionnaire (IPAQ).

Results: A total of 23 patients and 23 controls were included with a mean age of 37 ± 7.5 y, predominantly males (60%). The patients with axSpA had 5 ± 3.2 y of disease duration, with BASDAI and BASFI of 3 ± 2.2 and 2 ± 2.9 , respectively. No statistically significant differences between groups were found for physical activity. However, gait analysis showed statistically significant differences between axSpA and healthy controls on gait deviation index (median 83 vs. 87%, $p=0.022$, with higher score values representing similar performance to normal movement), speed (median 0.79 vs. 0.85 m/s, $p=0.015$), stance duration at the left side (median 68 vs. 67 s, $p=0.027$), left step length (median 0.47 vs. 0.49 m, $p=0.008$), and vertical regularity (median 0.39 vs. 0.33, $p=0.029$, with higher values representing a less regular and predictable movement pattern). At the sagittal plane, patients showed higher values of left arm maximum flexion (median 14 vs. 10°, $p=0.011$), lower lumbar extension peak velocity (median 45 vs. 60°/s, $p=0.016$) and higher ankle angular peak velocity on right side (median 330 vs. 299°/s, $p=0.020$).

Conclusion: These results provide evidence for a particular gait pattern in young axSpA patients at early stages of disease progression, consistent with a gingerly pattern. The observed speed reduction and increased time in stance phase and in vertical regularity could result in a compensatory mechanism leading to an increase in the maximum flexion of the arm and in the ankle angular peak in order to achieve a more stable and balanced locomotion. A better understanding of the gait features may allow the development in the future of a specific rehabilitation and intervention approaches to the impairment of movement.

P1135

TERIPARATIDE-RELATED TRANSITORY HYPERCALCEMIA

M. Carsote¹, D. Terzea², A. Valea³, D. Paun¹, C. Dumitrache⁴

¹UMPh C. Davila & C.I. Parhon National Institute of Endocrinology, Bucharest, ²C.I. Parhon National Institute of Endocrinology, Bucharest, ³UMPh I. Hatieganu & Clinical County Hospital, Cluj-Napoca, ⁴UMPh C. Davila, Bucharest, Romania

Teriparatide is an option for severe osteoporosis. Hypercalcemia is reported in some cases especially after the first few weeks of therapy. This is a case report of two menopausal female diagnosed with severe menopausal osteoporosis and treated with Teriparatide. We analysed the patients' profile while developing transitory hypercalcemia. GE Lunar Prodigy provided BMD and associated T-score.

Cases data: This is a 64-year-old female who was treated for 8 y with oral bisphosphonates and teriparatide was introduced because of her lumbar T-score (of -2.9 SD). After 12 months of therapy, the yearly assessment as required by National Protocol revealed a valued of total calcium of 10.4 mg/dL (normal levels between 8.5-10.2 mg/dL) and a confirmation based on ionic calcium. At that time she was under calcium supplements of 500 mg/d in addition to 1000 UI of cholecalciferol every day. The calcium supplements were stopped. Adequate oral hydration was also recommended. Within one month the total calcium decreased to 10.18 mg/dL.

This is an 80-year old female with a history of 7 y of therapy with oral bisphosphonates. At the end of this period of time, lumbar T-score was -3.9 SD and Teriparatide was recommended. After first year of daily injections the total calcium was 10.4 mg/dL (the same normal values as above) with a confirmation based on ionic calcium. Supplements with calcium were stopped (but not the daily dose of 1000 UI/d of vitamin D) and after two months total calcium was high normal (of 10.2 mg/dL).

Conclusion: Transitory hypercalcemia introduced in these cases did not require teriparatide stop and lifestyle intervention seemed enough to control it.

P1136

RISK OF CANCER INCIDENCE AMONG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

A. M. Abdalla¹, F. I. Abdelrahman²

¹Rheumatology and Rehabilitation Department, Aswan University, Benha, ²Rheumatology Department, Zagazig University, Zagazig, Egypt

Objective: Cancer is considered a major cause of morbidity and mortality in SLE patients(1). Several studies recently reported a higher prevalence of malignancy in SLE patients compared to the general population. Our aim was to determine the incidence of different types of cancer in SLE patients and to identify the associated risk factors.

Methods: The study was conducted on a cohort of SLE patients, diagnosed according to the updated American College of Rheumatology classification criteria(2), who attending the Rheumatology and Rehabilitation department, Zagazig University in the period between January 2018 and July 2018. We used a screening questionnaire to screen patients who were diagnosed with cancer. We collected demographic and laboratory data on all screened patients and their disease activity using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). For the patients with cancer, we recorded the age at onset of lupus, the age at diagnosis of cancer, the type of cancer, treatment received, immunosuppressive regimen (dose and duration) and cancer outcomes.

Results: We recruited 118 patients (97 female, 21 male), mean age (25.7±7.5) y with mean SLE duration of (7.28±6.26) y with a mean SLEDAI score (8.93±8.94). Most of them (86.4%) had lupus nephritis, (72.4%) had hematological abnormalities and (17.8%) had neuropsychiatric lupus. Majority (91%) were on corticosteroid with either a steroid sparing agent like mycophenolate mofetil (33.1%), azathioprine (43.2%) or cyclosporin (14.4%). 67 of them (56.8%) were either receiving or had received intravenous cyclophosphamide with mean cumulative dose of (7.5±4.7) gm. 18(15.3%) patients(14 female and 4 males) were diagnosed with cancer during the course of their SLE with mean age at onset (31±3.7), mean age at diagnosis of cancer (39.28±10.77). SLE duration (18.17±6.02) and mean SLEDAI (7.39±4.19). Majority of patients with cancer had lupus nephritis (88.9%) and all cancer patients were on a median dose of prednisolone 10 (2.5- 20) mg daily with median of 10 (4-24) years of steroids. Four patients (22.2%) had a family history of cancer with majority developing cancer after the diagnosis of SLE. 15(83.3%) of them had received intravenous cyclophosphamide prior to the development of cancer with mean total dose of 6.7±4.6, 12(66.7%) had received MMF, 6 (33.3%) had received cyclosporine and 9(50%) had received azathioprine. Four patients had lymphoma (22.2%), 3 had cervical cancer (16.7%), 3 had cancer breast (16.7%), 2 had colorectal cancer (11.1%), 2 had squamous cell carcinoma(11.1%), 1 had leukemia (5.6%), 1 had bronchogenic carcinoma (5.6%), 1 had prostate cancer(5.6) and one had cancer thyroid (5.6%). 12 (66.7%) of them had been treated and improved, 5 (27.8%) of them had metastasis, 1 (5.6%) died from serious infection. There is no significant difference in SLEDAI between patients with malignancy and patient without. We found that malignancy is correlated to longer disease duration and older age at onset of disease with significant difference (p value=0.01. 0.001 respectively).

Conclusion: We found an increasing incidence of cancer in SLE patients (15.3%) with high risk of cervical cancer in comparison to normal population. The risk of cancer in SLE patients is higher with older age at onset of SLE and longer disease duration with no risk of higher disease activity by SLEDAI. Up to the best of our knowledge, our study is the first study to concentrate on the risk of cancer in Egyptian SLE patients.

References:

1. Tessier-Cloutier B et al. Lupus 2015;1:1
2. Hochberg MC. Arthritis Rheum 1997;40:1725

P1137

VITAMIN D (25OHD) IN PATIENTS WITH CHRONIC RHEUMATIC DISEASES RECEIVING TREATMENT WITH ADALIMUMAB: DESCRIPTIVE STUDY OF A COHORT

B. A. Blanco Cáceres¹, P. García Escudero¹, M. González Fernández¹

¹Hospital Universitario Cruces, Bizkaia, Spain

Objective Patients with chronic rheumatic diseases (CRD) have lower levels of 25OHD, inverse correlation has been described and greater severity between the different CRD with 25OHD deficit. Most scientific societies recommend levels >30 ng/mL. Patients with refractory disease to conventional therapy have a higher inflammatory load, require optimal levels of 25OHD and often needs biological disease-modifying antirheumatic drugs (bDMARD) in order to prevent structural damage. The aim of this study was to describe the epidemiological, clinical and therapeutic characteristics of patients receiving adalimumab (ADL) in which 25OHD levels were determined in 2018.

Methods: Transversal, retrospective study in a hospital setting. We analyzed data from patients included in a study to determine levels of ADL at Hospital Universitario Cruces, in whom the serum level of 25OHD was determined at least once during the last year. Among 104 patients, 74 with 25OHD determination were included.

Results: 74 patients selected, 45.9% were men and 54.1% women. The mean age was 54.9 y (SD±13.6). 41.9% (31) had rheumatoid arthritis, 36.5% (27) spondyloarthritis, 17.6% (13) psoriatic arthritis and 4.1% (3) juvenile idiopathic arthritis. 35.1% (26) had deficit (<20 ng/mL) of 25OHD, 31.1% (23) insufficiency (20-30 ng/mL) and only 33.8% (25) optimal levels (>30 ng/mL). The 62.2% (46) of the patients received oral supplementation, of these 67.4% maintained levels >20 ng/mL and 32.6% <20 ng/mL. 37.8% (28) did not receive supplementation, despite this 60.7% within this group had levels >20 ng/mL. No statistical differences were found regarding vitamin D deficit and oral supplementation (p>0.05).

13.5% (10) of the patients also had osteoporosis (OP); in this group 6 had deficit of 25OHD, 1 insufficiency and only 3 optimal levels, all of them received 25OHD supplementation. Without differences between the groups in relation to the DMARD treatment.

Conclusions: Vitamin D levels were determined in 71.2% of patients and not in all of them as it would be advisable. Among the patients with 25OHD determination, 62.2% received oral supplementation, however only 33.8% of the patients reached optimal levels (>30 ng/mL) without statistical differences regarding supplementation. 13.5% of the patients who received supplementation also had OP. Despite the weakness of the study in terms of design and sample, we can assume that it is necessary to obtain levels of 25OHD >30 ng/mL with adequate supplementation, if necessary, due to the positive effects known in CRD.

P1138

THE ORTHOGERIATRIC PREVENTION SERVICE IMPROVES AUTOMATIC CAPTURE AND OUTCOMES AMONG FUNCTIONALLY RESILIENT OLDER PERSONS

V. Prenni¹, M. Baroni¹, L. Parretti¹, V. Bubba¹, C. Comanducci¹, G. Caironi¹, A. Caraffa², P. Mecocci¹, P. L. Antinolfi², G. Giuseppe², V. Boccardi¹, C. Ruggiero¹

¹Orthogeriatric Service, Geriatric Unit, S.M. della Misericordia Hospital, University of Perugia, ²Orthopaedics and Traumatology ward, S.M. della Misericordia Hospital, University of Perugia, Perugia, Italy

Objective: Hip fractures are associated with high mortality (20-25% by the year), severe and permanent disability (80% of survivors are dependent on at least one basic activity of daily life). The prevention of re-fractures in high-risk individuals, such as patients with a previous femur fracture, may help to improve the functional recovery process and, by reducing the recurrence of falls and fractures, promotes the maintenance of the maximum level of functional autonomy. Numerous organizational models have been developed in order to offer the most appropriate diagnostic and therapeutic pathway to such high risk persons. The aim of this study is to evaluate the effectiveness of an orthogeriatric outpatient service in the prevention of refracture and health-related outcomes.

Methods: Observational study conducted on 762 over-65 persons with hip fracture between February 2016 and February 2017. All patients received at discharge an outpatient visit at the orthogeriatric outpatient service. The visit was scheduled via a centralized server and carried out within 30-40 d after the hip fracture. 271 persons reached the orthogeriatric service (cases) and 283 received usual care (controls). Cases received pharmacological and non-pharmacological therapeutic indications. A 3, 6 and 12 months from outpatient visits, a telephone follow-up was conducted for both groups. The percentage of patients who receive therapeutic indications aimed at preventing falls and refractures, those who adhere to these indications at follow-up and those who develop complications, including falls, refractures and use of social and health services were estimated.

Results: 79% women and 21% men, with a mean age of 84 y, which preserved a good level of functional autonomy before the fracture (71% ADL>4), despite of previous falls and fractures (42%). Compared to controls, 97% of cases started vitamin D and diet integration of calcium, while 66% were on the most suitable drugs for fracture prevention. Cases were more likely to be disabled at three months, while less likely at 12 months, with mortality reduced by almost half, lower rate of refractures and lower use of health-care services. Cases were more adherent to calcium/vitamin D supplementation and antifracture therapy than controls at 3, 6 and 12 months. Cases received more appropriate prescriptions of antifractures treatments than controls, with persons functionally independent showing a high rate of adherence.

Conclusions: The orthogeriatric outpatient service has the potential to identify and manage clinical and care needs of frail older adults at high risk of falls, fractures, and adverse events. It is necessary to better validate this model of care and verify its effectiveness for fracture prevention.

P1139

RAMAN SPECTROSCOPY DETECTION OF COLLAGEN TYPE I PRODUCTION IN HUMAN OSTEOBLAST-LIKE CELLS INDUCED WITH INTERLEUKIN 1 β PRO-INFLAMMATORY CYTOKINE

N. A. Che Ahmad Tantowi¹, J. Kerns¹

¹Lancaster Medical School, Lancaster University, Lancaster, UK

Objective: IL-1 β is one of the major pro-inflammatory cytokines implicated in the pathogenesis of inflammatory bone loss through altered bone homeostasis. Raman spectroscopy is an emerging non-invasive diagnostic tool that can provide useful information on key biochemical markers within cells and tissues for monitoring diseases. The aims of this study were i) to evaluate the effect of IL-1 β pro-inflammatory cytokine on collagen type I production in osteoblast-like cells and ii) to determine Raman spectroscopy chemical fingerprint of collagen type I produced.

Methods: Osteoblast-like MG63 cells were grown on osteogenic media in the absence (control) or presence of the recombinant human IL-1 β (1 ng/ml or 10 ng/ml) for 48 h. Cell viability was assessed by PrestoBlue while collagen type I production was evaluated by Picro-sirius red assays. Immunofluorescence staining was performed using antibody against collagen I α 1 (COL1A1). Raman spectroscopy was used to determine collagen type I biochemical fingerprints.

Results: Within 48 h exposure, IL-1 β significantly ($p < 0.05$) reduced collagen type I production in the MG63 *in vitro* culture, in dose-dependent manner. The suppression of collagen type I in the IL-1 β stimulated cells did not statistically affect changes in cell viability. Immunofluorescence of COL1A1 antibody confirmed the dose-dependent effect of IL-1 β in collagen type I production in MG63. Raman spectra showed changes in collagen intensity represented by amide I, amide III, C-C stretching, CH₂ deformation and CH₂ wagging peaks in IL-1 β treated cells compared to control. Hydroxyproline band did not change relative to control suggesting that decreased in collagen production resulted from less synthesis rather than increased degradation.

Conclusions: These results highlight that one of the mechanisms by which IL-1 β inhibits bone formation in inflammatory bone diseases is by suppressing production of collagen type I in bone matrix. Raman spectroscopy is capable of recognizing changes in collagen type I produced by osteoblasts and represents a promising nondestructive tool to study chemical changes in the bone extracellular matrix observed in inflammatory bone loss.

P1140

TERIPARATIDE-RELATED TBS CHANGES

M. Carsote¹, A. A. Gheorghisan-Galateanu¹, A. Valea², D. Paun¹, E. Petrova¹, C. Dumitrache³

¹UMPh C. Davila & C.I. Parhon National Institute of Endocrinology, Bucharest, ²UMPh I. Hatieganu & Clinical County Hospital, Cluj-Napoca, ³UMPh C. Davila, Bucharest, Romania

Objective: Teriparatide works as a BMD increaser and new data suggest a TBS (trabecular bone score) improvement. Type 2 diabetic females represent a particular group of patients to whom TBS is a useful tool. Nevertheless, the data of teriparatide dependent TBS values represents a relatively new topic.

Method: This is a case report regarding TBS in a female with severe osteoporosis treated with daily 20 µg teriparatide by self-administration through subcutaneous route. We introduce lumbar T-score in association with TBS under therapy (GE Lunar Prodigy device and TBS Insight software).

Case data: This is a 61-year-old female known with type 2 diabetes mellitus (treated with both oral medication and insulin) and high blood pressure. She had noncomplicated osteoporosis and weekly alendronate was offered to her for 3 y reaching a lumbar L1-4 T-score of -2.3 SD. Drug holiday was started but after 1 y she had thoracic T6 and T12 vertebrae fractures while T-score decreased to -2.7 SD. After 2 y of teriparatide the value become -1.9. TBS at the baseline teriparatide therapy was 1203 and at the end 1303.

Conclusion: More data are necessary to use the initiation of osteoanabolic therapy based on TBS in cases when BMD does not adequately reflect fracture risk as seen in type 2 diabetic postmenopausal women.

P1141

EFFECT OF TREATMENT ON DISEASE ACTIVITY, MUSCULOSKELETAL MANIFESTATIONS, SKIN MANIFESTATIONS AND LIPID PROFILE IN PSORIATIC ARTHRITIS

M. Kostopoulos¹, I. Kostoglou-Athanassiou², L. Athanassiou³, P. Tsakiridis¹, P. Athanassiou¹

¹Department of Rheumatology, St. Paul's Hospital, Thessaloniki, Greece, ²Department of Endocrinology, Asclepeion Hospital, Voula, Athens, Greece, ³First Department of Internal Medicine, Asclepeion Hospital, Voula, Athens, Greece

Objective: Psoriatic arthritis (PsA) is a chronic systemic autoimmune disorder affecting the joints and the skin. It develops in patients of all age groups and it has significant adverse effects on quality of life. Currently, various biologic agents are administered in PsA patients, improving significantly the musculoskeletal and skin manifestations of the disease as well as quality of life. The aim was to follow-up a group of PsA patients as far as disease activity, musculoskeletal manifestations, skin manifestations and to evaluate comorbidities, lipid profile and cardiovascular risk and the effect of treatment with biologic agents on these parameters.

Methods: The BMI of the patients was calculated at baseline before treatment and after treatment over the course of 9 months at 3-month intervals. Disease activity was estimated using the DAPSA before and after treatment over the course of 9 months, at 3-month intervals. Blood total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were measured at baseline and after treatment at 3, 6 and 9 months. The 10-y cardiovascular risk was evaluated using the Heart score Greece, at baseline and after 3, 6 and 9 months on treatment with biologic agents.

Results: The BMI of the patients was 29.01±0.65 before treatment and 28.63±0.6, 28.37±0.6 and 29.39±0.87 after treatment at 3, 6 and 9 months, respectively. Disease activity decreased very significantly after treatment with biologic agents in PsA patients, the DAPSA score decreasing from 27.56±0.65 (mean±SEM) before treatment to 12.56±0.40, 5.76±0.38 and 4.43±0.57 at 3, 6, and 9 months after treatment, respectively (p<0.001, Student's t-test). Musculoskeletal manifestations improved significantly after treatment in PsA patients. Total cholesterol decreased from 231.56±6.23 mg/dl before treatment to 202.91±3.96 mg/dl, 188.38±4.48 mg/dl and 171.29±6.89 mg/dl after treatment at 3, 6 and 9 months, respectively (p<0.001). HDL cholesterol increased from 50.62±2.07 mg/dl before treatment to 55.26±1.09 mg/dl, 56.03±0.98 mg/dl and 57.57±1.04 mg/dl after treatment, at 3, 6 and 9 months, respectively (p<0.001). LDL cholesterol decreased from 154.47±5.74 mg/dl before treatment to 139.61±4.90 mg/dl, 128.21±5.15 mg/dl and 92.71±5.96 mg/dl after treatment at 3, 6 and 9 months, respectively (p<0.001). Triglycerides were 152.03±9.26 mg/dl before treatment and decreased to 132.32±5.42 mg/dl, 121.05±4.52 mg/dl and 95.65±8.14 mg/dl after treatment at 3, 6 and 9 months, respectively (p<0.001). The Heart score Greece decreased from 4.35±0.006% before treatment, to 3.71±0.005%, 3.5±0.004% and 2.8±0.005% after treatment, at 3, 6 and 9 months, respectively (p<0.001).

Conclusions: It appears that in PsA disease activity decreases very significantly after treatment with biologic agents, whereas the lipid profile and the heart disease risk is significantly improved.

Acknowledgements: Dr. Kostopoulos Markos was supported by a fellowship from the Hellenic Society for Rheumatology.

P1142

FRACTURES RELATED TO OSTEOPOROSIS IN UMBRIA REGION: THE FROST- UMBRIA STUDY

M. Lapenna¹, L. Parretti¹, M. Baroni¹, V. Bubba¹, A. R. Bogini², G. Duranti², G. Baglioni², V. Boccardi¹, P. Mecocci¹, C. Ruggiero¹

¹Orthogeriatric Service, Geriatric Unit, S.M. della Misericordia Hospital, University of Perugia, ²General Practitioners, ASL Umbria 1, Umbria Region, Perugia, Italy

Objective: Several validated algorithms, based on clinical risk factors and BMD, have been developed to identify people at high risk of fracture. They have been developed in a subgroup of the population and often they show low sensibility and specificity in the general population. In addition, they remain unknown to gen-

eral practitioners (GPs), who consider these tools far from their clinical practice and hard to apply. Therefore, this study aims to describe the prevalence of low BMD, major fragility fractures and clinical risk factors in the general population visiting the GPs in the main district of the Umbria region. In addition, the issue of prescription of antifracture treatments is investigated.

Methods: This is a prospective observational study conducted in persons aged 30 or more years, visiting the outpatient GP setting. Participants were randomly selected from the database of GPs, at the time of GP visit they underwent comprehensive evaluation including fracture risk, fracture history, diseases, drugs, functional status, and lifestyle.

Results: A sample of 1356 participants has been recruited, mainly women (n=756, 55%) with 63% (n=847) of them with more than 50 years old. A diagnosis of low BMD was detected in 10% of the sample (n=139), and history of fragility fractures in 9% (n=109). Of note, 56% (n=62) of persons with previous fragility fractures missed the diagnosis of low bone strength because BMD was not over the WHO threshold. Major clinical risk factors in both groups were: female gender (95% and 72%, respectively), family history of osteoporosis (22% and 21%), gait disorders (14% and 26%) and falls (14% and 25%). Disease-causing bone disorders were detected in 5% (n=7) and 9% (n=10), while drug affecting bone metabolism in 9% (n=13) and 9% (n=10) of persons with low bone density and previous fragility fractures, respectively. Antifracture drugs and vitamin D are prescribed to 34% and 43% of persons with low BMD, but to 24% and 22% of those with previous fragility fractures. A combination therapy is prescribed in 14% of persons with BMD and 9% of those who sustained a fragility fracture.

Conclusions: Older adults are confirmed as high risk of fractures in the general population, with only 9% of persons being affected by diseases and taking drugs with deleterious effects on bone. The GPs should start identifying persons at high risk of fractures based on validated algorithm, the evidence of previous fragility fractures, limiting the exclusive use of the BMD.

P1143

1° COLOMBIAN CONSENSUS OF OSTEONECROSIS OF THE JAW (ONJ) ASSOCIATED WITH DRUGS

M. Chalem¹, A. Medina², A. K. Sarmiento¹

¹Fundacion Santa Fe, ²Asociacion Colombiana de Osteoporosis y Metabolismo Mineral, Bogota, Colombia

Objectives: To provide management guidelines using algorithms that guide health professionals (dentists and doctors) to prevent, diagnose and treat ONJ in the different clinical scenarios.

Methods: It was selected a technical team with specialists from multiple areas and extensive experience in bone health from Healthy Bone Group of the Fundación Santa Fe in Bogotá city, and the Colombian Association of Osteoporosis and Mineral Metabolism (ACOMM), divided into work groups. The development of each theme was based on the posing of questions. After a review of the scientific literature in working meetings, the definitions and recommendations were generated and presented in this document, focused in doctors and dentists by using algorithms.

Results: The incidence of ONJ in patients treated with bisphosphonates (BP) is 0.01- 0.04% and 0.8-11% for osteoporosis and cancer respectively. The risk of ONJ induced by BP increases with the use of powerful antiresorptives (zoledronate and denosumab), high doses and higher frequencies, and duration of therapy >4 y. This consensus includes physiopathology and risk factors like infection in mouth, comorbidities, genetic mutations, type of dental procedures and medications as BP, denosumab and antiangiogenic agents. The use of bone biomarkers and their relation with ONJ in subjects with osteoporosis is controversial. This document allows give a guideline in different clinical scenarios of prevention and treatment of ONJ.

Conclusions: Although the risk of ONJ associated with drugs is very low in the patients with osteoporosis, this Consensus of ONJ allows guide the dentist and the physician in different scenarios in the context of dental procedures in patients receiving antiresorptives for osteoporosis or cancer to obtain the benefit in prevention of fragility fractures. The algorithms for prevention or treatment for ONJ could be multidisciplinary, taking in to account the risk-benefit balance in each situation.

P1144

TERIPARATIDE: BETWEEN YES AND NO

M. Carsote¹, S. Albu¹, A. Valea², C. Vasiliu³, C. Dumitrache⁴

¹UMPh C. Davila & C.I. Parhon National Institute of Endocrinology, Bucharest, ²UMPh I. Hatieganu & Clinical County Hospital, Cluj-Napoca, ³UMPh C. Davila & C.I. Parhon National Institute of Endocrinology, Bucharest, ⁴UMPh C. Davila, Bucharest, Romania

Teriparatide is recommended based on national protocols in cases with severe osteoporosis and low T-score at the end with at least 3-5 y of bisphosphonates. However, the new fracture or BMD low may in fact be associated with secondary causes of osteoporosis which actually do not indicate osteoanabolic medication.

Case data: This is a 77-year-old female known with type 2 diabetes mellitus, chronic heart angina, high blood pressure, atrial fibrillation and polynodular goiter. She had been treated for a decade with oral bisphosphonates (alendronate and risedronate). She did not develop secondary negative effects but T-score remained low. She associated a forearm fracture. So her GP referred the patient for teriparatide. The clinical evaluation indicates a mammary tumour which was confirmed as carcinoma. Mammogram showed an infiltrative left breast neoplasia of 7 cm with a solid part of 3.5 cm. The patient refused surgery, chemotherapy was started in addition to intravenous zoledronic acid.

Conclusion: In severe cases of osteoporosis, menopausal screening of breast cancer is useful to exclude secondary caused of bone loss

P1145

THE COST OF HIP FRACTURE IN ELDERLY: TIME SERIES ANALYSIS ON THE ECONOMIC IMPACT OF THE PUBLIC HEALTH SYSTEM

V. C. U. Peterle¹, P. E. Bezerra Junior², J. C. Geber Junior³, L. B. Bezerra³, W. H. S. Martins⁴, W. Darwin Junior⁵, C. D. Maciel⁶, M. R. C. Garbi Novaes⁷

¹University of Brasília / Faculty of Health Sciences / Postgraduation in Health Sciences, Brasília, ²Department of Health of the Federal District / School of Health Sciences / Medical Residency, Brasília, ³Department of Health of the Federal District / School of Health Sciences, Brasília, ⁴University Center of Brasilia (UNICEUB) / Medical School, Brasília, ⁵University of São Paulo (USP) / School of Engineering of São Carlos (EESC), São Paulo, ⁶University of São Paulo (USP) / School of Engineering of São Carlos (EESC), São Paulo, ⁷Department of Health of the Federal District / School of Health Sciences / Postgraduation and Extension, Brasília, Brazil

Objective: To identify the profile of costs related to hip fracture in patients over 60 y hospitalized in public hospitals in Brasília, Brazil.

Methods: Ecological study, in a time series (2008-2016), population-based (Brasília is the capital of Brazil and seat of government of the Federal District). Data from hospital morbidity of hip fractures (ICD-10 S72 code) were collected through the Hospital Information System of the Brazilian National Health System (SIH-SUS), and the population measured/estimated through the Brazilian Institute of Geography and Statistics (IBGE).

Results: Between 2008-2016, 3721 hospitalizations for hip fracture in the elderly were registered in the public health services of the Federal District. It was observed an ascending pattern, with a 42% increase in minimum trauma fractures, between 2008-2016, in agreement with a growth of 81.52% referring to the population over 60 y in the Federal District (2008=184.423 vs 2016=334.772), representing a geometric mean annual growth rate of 7.74%. The total cost in the period was R\$ 8,180,600.70 mi, which represented about 2.15% of the total cost in the Federal District with hospitalizations of elderly patients (R\$ 378,780,084.82); Average of R\$ 908,955.63/y for this pathology only. Average value for hospitalization of R\$ 2,198.50*. The mean number of hospitalized days was 18.2 and the mean duration of other pathologies in FD in the elderly was 10.3 d. 2428 cases were female (65%) with cost of R\$ 5,428,512.20 mi; The age group above 80 y was the most affected age group, with 41% of hospitalizations.

Conclusion: Population projections indicate a considerable increase in the cost related to hip fracture in the elderly, whose attention of the health authorities due to individual and governmental losses should be to invest in the prevention of this type of fracture and in the early diagnosis of osteoporosis.

P1146

ADULT ONSET STILL'S DISEASE – DIAGNOSTIC AND THERAPEUTIC APPROACH: LONG-TERM FOLLOW-UP

P. Athanassiou¹, A. Tzanavari¹, L. Athanassiou², P. Tsakiridis¹, E. Devetzi¹, M. Gatsiou¹, D. Pantelidis¹, I. Kostoglou-Athanassiou³

¹Department of Rheumatology, St. Paul's Hospital, Thessaloniki, ²First Department of Internal Medicine, Asclepeion Hospital, Voula, Athens, ³Department of Endocrinology, Asclepeion Hospital, Voula, Athens, Greece

Adult onset Still's disease is a systemic autoinflammatory disorder characterized by fever, arthritis and a characteristic skin eruption. The etiology of the disease remains unknown, genetic and infectious causes being discussed. The course of the disease may be monophasic, intermittent or chronic. The aim was to describe a cohort of patients with adult onset Still's disease, including course of the disease, therapeutic approach as well as long term follow-up.

Cases description: The cases of 3 patients with adult onset Still's disease are described. The first was a female patient, aged 40, who presented 7 y ago with fever, arthralgias, bilateral pleural effusion, splenomegaly, lymphadenitis, a salmon like rash and a sore throat. Laboratory investigations revealed elevated liver function tests, leukocytosis (WBC 20.500/mm³, poly 77.1%), thrombocytosis (PLT 608.000/mm³), ESR 83mm/1h, CRP 19.8 mg/dl (normal values <0.5 mg/dl), ferritin >1.000 ng/dl, ANA (-), and RF (-). The diagnosis of adult onset Still's disease was made and methylprednisolone 32 mg/d was administered, which was tapered, methotrexate and later on anakinra (an IL-1 receptor antagonist) with partial response. Two years later canakinumab was introduced (a fully human monoclonal antibody to IL-1b). After three years of successful treatment with canakinumab, the drug was withdrawn. However, 5 months later the disease recurred. Thereafter, canakinumab was administered again successfully. The second case was a male patient, aged 23 with juvenile idiopathic systemic arthritis, [ANA(-) and RF(-)], diagnosed at age 6.5 y. At the age of 21 the patient developed fever, leukocytosis (WBC 15.400/mm³, poly 83.3%), ESR 82 mm/1h, CRP 20 mg/dl, anemia, ferritin 1.313 ng/dl, chest pain, arthralgias and serositis affecting multiple organs. Pulse methylprednisolone was administered being followed by the successful administration of canakinumab. The third patient was a male patient, aged 15 y, who was hospitalized with fever 39°C, arthritis of the right ankle and both knees, a sore throat, WBC 26.400/mm³ (poly 86,6%), ESR 90mm/1h, CRP 14.9 mg/dl and ferritin 1.027 ng/dl. The diagnosis of Still's disease was made and methylprednisolone, followed by canakinumab were administered successfully.

Conclusions: A cohort of patients with adult onset Still's disease is described. The disease responded to canakinumab and long-term remission was induced. In conclusion, the systemic characteristics and chronicity of adult onset Still's disease as well as the response of the disease to agents suppressing the activity of autoinflammatory disorders is described.

P1147

LEVELS OF FOLLICULAR STIMULATING HORMONE ARE ASSOCIATED WITH BONE MINERAL DENSITY AND BONE TURNOVER IN POSTMENOPAUSAL WOMEN

E. Armeni¹, A. Augoulea¹, D. Rizos², G. Kaparos², A. Antoniou³, K. Panoulis¹, I. Lambrinou¹

¹2nd Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Aretaieio Hospital, ²Hormonal and Biochemical Laboratory, National and Kapodistrian University of Athens, Aretaieio Hospital, ³1st Department of Radiology, National and Kapodistrian University of Athens, Aretaieio Hospital, Athens, Greece

Objectives: To explore the association between follicle stimulating hormone (FSH) and BMD as well as markers of bone turnover, in a large sample of postmenopausal women, not on antiosteoporosis treatment. **Materials and Methods:** This cross-sectional study evaluated a total of 2576 postmenopausal women, aged 56±6.4 y (range 34-80 y, menopausal age 1-39 y). Blood samples were obtained for hormonal assessment as well as for determination of serum levels of markers of bone formation (e.g., osteocalcin; serum type 1 procollagen (PINP)) and bone resorption (e.g., C-telopeptide (CTX)). BMD was evaluated using DXA, at both the lumbar spine (LS) and femoral neck (FN).

Results: Serum levels of FSH correlated with values of bone turnover at lumbar spine (BMD, $r=-0.128$, $p\text{-value}<0.001$; T-score, $r=-0.116$, $p\text{-value}<0.001$; Z-score, $r=-0.128$, $p\text{-value}<0.001$) and at the femoral neck (BMD, $r=-0.121$, $p\text{-value}<0.001$; T-score, $r=-0.105$, $p\text{-value}=0.001$; Z-score, $r=-0.120$, $p\text{-value}<0.001$). Women with osteopenia/osteoporosis had significantly higher levels of FSH compared with women presenting with normal BMD values (LS: 75.8 ± 30.7 mU/mL vs. 67.1 ± 28.8 mU/mL, $p\text{-value}<0.001$; FN: 73.1 ± 29.1 mU/mL vs. 68.1 ± 28.4 mU/mL, $p\text{-value}=0.008$). Multivariate analysis confirmed that LS-BMD values were predicted by FSH (b-coefficient=-0.105, $p\text{-value}=0.006$), in combination with age, YSM and BMI. Similar results were observed for LS T-score and Z-score values. Logistic regression analysis showed that FSH levels predicted LS osteopenia/osteoporosis (OR 1.011, $p\text{-value}<0.001$), in models adjusted for age, BMI and YSM. On the other hand, FSH values did not predict FN-BMD or FN-osteopenia/osteoporosis. Finally, the multivariate analysis confirmed a direct association between FSH levels and markers of bone formation as well as bone resorption (FSH levels, osteocalcin: b-coefficient=0.278, $p\text{-value}=0.001$; CTX, b-coefficient=0.271, $p\text{-value}=0.003$; PINP, b-coefficient=0.264, $p\text{-value}=0.003$), adjusting for age and YSM.

Conclusions: Higher levels of FSH are associated with lower BMD, an effect particularly pronounced in the lumbar spine, and which was independent of age, BMI and YSM. Moreover, FSH is affecting both bone formation and bone resorption. Further studies are required to estimate the precise mechanisms mediating the observed associations.

P1148

VITAMIN D LEVELS IN PATIENTS WITH OSTEOPOROSIS IN NEIVA, COLOMBIA

A. Pinzón¹, N. Vasquez¹, C. Celemin²

¹University Surcolombiana, ²University of Tolima, Neiva, Colombia

Objective: The city of Neiva in Colombia is located in the torrid zone, 600 m above sea level, with an average temperature of 35°C/d and with solar exposure 365 d a year. Under these conditions it is important to know the status of vitamin D levels in patients with osteoporosis. Our aim was to determine the prevalence of vitamin D levels in patients diagnosed by bone densitometry for osteoporosis in Neiva, Huila-Colombia.

Methods: Patients older than 50 y were included for a period of one year, with a diagnosis of osteoporosis by densitometry and reporting of 25-OH vitamin D by chemiluminescence, who attended the university hospital Neiva. Measures possible association between qualitative variables (odds ratio) is established and a linear regression model in which the independent variable that best predicts the outcome of the dependent variable, and observe the correlation was determined. Statistical analysis was performed on SPSS version 19 package.

Results: Hypovitaminosis D is a very common disorder in the study population (89%) and in 55% of cases is associated with secondary hyperparathyroidism. Prevalence of deficiency levels of 35.5% (n=20), insufficiency of 53.5% (n=30) and optimal 11% (n=6) were found. When performing a bivariate analysis of the levels of BMD and vitamin D levels, we found that BMD down simultaneously with the fall in serum levels of vitamin D. This association was statistically significant at the level of lumbar spine $p=0.0063$.

Conclusion: Insufficiency and deficiency of vitamin D is very common even in areas where sun exposure is daily throughout the year, making it necessary to perform testing in all patients with osteoporosis.

P1149

IMPACT OF GASTROINTESTINAL DISORDERS ON BONE QUALITY: DESCRIPTION OF TWO CASES

I. Kostoglou-Athanassiou¹, C. Samaras², L. Athanassiou², A. Fabri², O. Spyropoulou², D. Fasfali², E. Siarkos², I. Giagtzoglou², P. Athanassiou³, P. Potamou²

¹Department of Endocrinology, Asclepeion Hospital, Voula, Athens, ²First Department of Internal Medicine, Asclepeion Hospital, Voula, Athens, ³Department of Rheumatology, St. Paul's Hospital, Thessaloniki, Greece

Disorders of the gastrointestinal tract may have an impact on bone quality which may manifest as either osteomalacia or osteoporosis. Gastritis may have an impact on the bone as it demands the chronic administration of proton pump inhibitors. Malignant neoplasms of the gastrointestinal tract may be accompanied by malabsorption of nutrients and micronutrients. The aforementioned disorders may also be related to vitamin D deficiency.

With the abovementioned mechanisms gastrointestinal disorders may cause either osteomalacia or osteoporosis. The aim was to describe two cases of patients with gastrointestinal disorders, namely, chronic gastritis and cancer of the large intestine who developed osteoporosis.

Cases description: The cases of two patients with gastrointestinal disorders who developed vitamin D deficiency and osteoporosis are described. The first patient was female, aged 84 and presented with gastric pain. Gastroscopy was performed and chronic gastritis was diagnosed. Laboratory investigations revealed 25(OH)D₃ levels of 15 ng/ml and bone density of the left femur showed a T-score of -3.9. The second patient aged 85 y presented with pain in the left loin. Laboratory investigations revealed severe anemia. Gastroscopy revealed chronic gastritis. Abdominal radiology revealed a large malignant neoplasm in the area of the sigmoid colon. Bone density measurement in the area of the left femur showed a T-score of -3.1. In the first case gastritis was managed with proton pump inhibitors. Vitamin D along with drugs for the treatment of osteoporosis were also administered. In the second case the neoplasm was surgically excised and treatment for osteoporosis was initiated.

Conclusions: The cases of two patients with gastrointestinal disorders who developed vitamin D deficiency and osteoporosis are described. Gastrointestinal disorders have an impact on bone quality. They may be accompanied by vitamin D deficiency, malabsorption of nutrients and may demand long-term treatment with proton pump inhibitors, known for an adverse effect on bone density. Additionally, the management of osteoporosis in such patients should be carefully planned as medications used for osteoporosis may be accompanied by gastrointestinal adverse effects, such as gastritis. In conclusion, in patients with gastrointestinal disorders bone density should be measured and if osteoporosis is revealed, it should be accordingly treated.

P1150
DIAGNOSIS OF MCCUNE ALBRIGHT SYNDROME IN A PATIENT FOLLOWED ON A RHEUMATOLOGY CONSULT OF OSTEOPOROSIS


D. Montero¹, E. Cuende¹, E. Galindez¹, E. Ruiz¹, I. Torre¹, A. R. Intxaurbe¹, O. B. Fernández², J. M. Blanco², C. E. Pérez², I. Calvo¹, O. Ibarquengoitia², L. Vega², M. L. García-Vivar²

¹Universitary Hospital of Basurto, ²Univeristary Hospital of Basurto, Bilbao, Spain

The follow-up of patients in an osteoporosis unit treated with antiresorptive treatment is, on occasion, cause for surprise. Bone fibrous dysplasia is a metabolic bone disease that requires treatment with bisphosphonates for pain relief and reduction of disease outbreaks. This disease is associated with numerous syndromes, among which is that of McCune Albright.

We report a case of a 36-year-old woman under treatment with bisphosphonates, who had a history of precocious puberty and skin changes, and finally diagnosed of McCune Albright syndrome in our rheumatology department.

Conclusions: Clinicians should be aware of this and other types of atypical and serious syndromes associated with bone dysplasia and other bone metabolic disorders.



P1151
PERIOPERATIVE MORTALITY FOLLOWING FEMORAL NECK FRACTURES: THE EFFECT OF IMPROVEMENTS IN MULTIDISCIPLINARY CARE OVER TWO DECADES

M. J. Best¹, K. T. Aziz¹, R. S. Sterling¹, H. S. Khanuja¹

¹Johns Hopkins Hospital, Department of Orthopaedic Surgery, Baltimore, USA

Objective: This study aims to analyze changes in perioperative mortality and length of hospital stay in patients with femoral neck fractures over two decades in the USA (US): a time during which multidisciplinary perioperative fracture care became a standard across the US.

Material and Methods: The National Hospital Discharge Survey was used to identify all patients who were admitted to US hospitals with femoral neck fractures from 1990 to 2010. A cohort of 1,891,857 patients was identified over the study period. Trends in and mortality and length of hospital stay over the 20 year period were analyzed and logistic regression was used to isolate independent variables associated with mortality.

Results: Perioperative mortality decreased from 3.0% in 1990 to 1.2% in 2010 (P<0.001). When comparing the study group by decade, mortality decreased from 2.9% in the 1990-1999 group, to 2.1% in 2000-2010 group (P<0.001), despite an increase in comorbidities in the latter group (53.7% in 1990-1999 vs. 68.9% in 2000-2010). Length of hospital stay decreased from 14.4 d in 1990 to 5.3 d in 2010 (P<0.001), (8.9 d in 1990-1999 to 6.2 d in 2000-2010, P<0.001). When controlling for confounders, multi-variable logistic regression showed that patients with COPD, CHF and those undergoing dialysis were at greatest odds for mortality. Pulmonary embolism and acute myocardial infarction were complications associated with the highest odds of mortality.

Conclusions: Perioperative mortality and length of hospital stay for patients with femoral neck fractures has decreased over the study period despite an overall increase in comorbidities. During the 20 years of this study, multidisciplinary perioperative fracture care was implemented and became widespread. This study highlights the importance of multidisciplinary care, both preoperatively with risk stratification and medical optimization, and postoperatively with improved therapy and pain management protocols for patients with femoral neck fractures.

P1152

QUANTIFYING MUSCLE FATTY INFILTRATE IN PEOPLE WITH OR AT RISK OF HAVING KNEE OSTEOARTHRITIS

D. Januszyk¹, J. De Jesus¹, B. S. Jang¹, J. Krok¹, J. Elliott², K. Blount³, M. Hoggarth¹, D. Pinto⁴

¹Northwestern University/Department of Physical Therapy, Chicago, USA, ²Faculty of Health Sciences, The University of Sydney, Northern Sydney Local Health District, Sydney, Australia, ³Northwestern Medical Faculty Foundation, Chicago, USA, ⁴Marquette University/Department of Physical Therapy, Milwaukee, USA

Objective: Osteoarthritis (OA) affects 35 million people in the US. Muscle characteristics have been identified as possible contributors to the development and progression of OA. There has been some exploration of the relationship between muscle fat infiltrate (MFI) and OA but most studies are limited by sample size. We aimed to investigate the methods of quantifying MFI in the muscles of the thigh using conventional MRI available from the Osteoarthritis Initiative (OAI) dataset.

Methods: MR imaging of adults from the Osteoarthritis Initiative cohort. MFI was calculated as the proportion of mean signal intensity value of each muscle to fat signal intensity. Fat signal intensity was captured in 3 ways: MFI V1 used mean fat signal intensity from a standardized location, V2 used max signal intensity from a standardized location, V3 used max signal intensity from entire image.

Results: MRI data of 49 adults, 13 males and 39 females with mean age 70 (range 49-81). Comparing MFI calculations for each of the measurement methodologies resulted in ICC values indicating good to excellent levels of reliability between four investigators. The ICC for using mean FSI from standardized location (SL) ranged from 0.88-0.96 (95%CI). The ICC for using maximum FSI from SL ranged from 0.82-0.98 (95%CI). The ICC for maximum FSI of entire image ranged from 0.95-1.00 (95%CI). The V2 and V3-based MFI estimates of recuts femoris were correlated with the Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP) score for constant knee pain.

Conclusion: MFI may provide useful insight into the presentation of patients with knee OA, such as those with high levels of constant pain. Choice of fat signal intensity values in the MFI calculation results in significantly different fat values. This study provides evidence that further investigation into the use of fat intensities in MFI calculation is warranted in order to produce

consistent estimations of MFI in patients. Continued research on the relationship between MFI and progression of knee OA is warranted with larger sample sizes and inclusion of other disease-modifying variables.

P1153

SECONDARY OSTEOPOROSIS SCREENING IN FRACTURE LIAISON SERVICE: IS IT NECESSARY?

E. Abate¹

¹Mayo Clinic Florida, Jacksonville, USA

Objective: Fracture liaison service (FLS) is a secondary fracture prevention program implemented to provide screening and treatment for post fragility fracture care. We reviewed labs performed at the time of FLS enrollment and evaluation at mayo clinic Florida to determine if workup for secondary causes of osteoporosis is of any utility in post fracture care.

Methods: Mayo clinic Florida FLS protocol consist of a Cerner data base registry, that registers patients with a diagnosis of fracture coming to the emergency room or admitted to the hospital. FLS nurse will review each chart and include and exclude patients into FLS program based on criteria's. Inclusion criteria is age >50, GFR>35, fractures occurring from a standing position. Exclusion criteria is fracture of face, fingers, toes and non-fragility fractures, hospice patients and severe dementia. Patients are contacted within 90 d of post discharge from hospital or emergency department by phone call. If a patient agrees to participate in the program, then appropriate labs and imaging consisting of BMD spine, hip and or distal radius, 24-h urine calcium, 24-h urine creatinine, total 25 hydroxyvitamin D, TSH, PTH, calcium, phosphorus, tissue transglutaminase, serum electrophoresis and alkaline phosphorus will be obtained.

Results: 175/343 patients met criteria to be included in Mayo Clinic Florida FLS program 1/2017-1/2018. 52/175 patients chose not to follow-up with mayo clinic. 19 could not be reached by phone. 104/343 were agreeable to be evaluated at mayo clinic. 50/104 seen by endocrinology, 25/104 seen by primary care physician at mayo clinic, and 24/104 did not show up, or canceled their appointments. The remaining were seen by other specialties rheumatology, oncology, orthopedics. 2/50 patients have low vitamin D (<20 ng/dl) with elevated PTH consistent with secondary hyperparathyroidism. One patient had primary hyperparathyroidism with kidney stones and hypercalciuria which was not previously recognized. Few had mild abnormality of TSH which was mildly elevated and not of significance. Only 6/50 had total 25-hydroxyvitamin D level <20 ng/dl. No other significant abnormality was detected.

Conclusion: Implementing and sustaining a successful FLS program is challenging due to a high level of time and funding required to sustain such a program. In addition, many of these tests and imaging for workup of osteoporosis are not reimbursed at a high rate; therefore brings another challenge to the healthcare system. Therefore, simplifying osteoporosis care and evaluation is important. Our data shows serum PTH, serum calcium, serum

phosphorus, creatinine and 25-hydroxyvitamin D are the most essential diagnostic tests needed for evaluation and treatment of these patients.

P1154

OSTEOSARCOMA SURVEILLANCE PROGRAM ESTIMATING THE INCIDENCE OF OSTEOSARCOMA AMONG TERIPARATIDE USERS BY LINKING STATE CANCER REGISTRY DATA TO PHARMACY DATABASE DATA (USA)

N. Kellier-Steele¹, A. Anderson², D. Casso², S. Oliveria², A. Gilsean³, K. Midkiff³, D. Harris³, E. Andrews³

¹Eli Lilly and Company, Indianapolis, USA, ²IQVIA, Durham, USA, ³RTI-HS, Raleigh, USA

Objective: To estimate the incidence of osteosarcoma (OS) among teriparatide patients and unexposed matched comparator patients.

Methods: Data from IQVIA LRx, a commercial pharmacy database (aged 18+), or the Medicare Part D database (aged 65+) were used to create teriparatide-exposed cohorts and unexposed comparator cohorts (general population (GP) and osteoporosis (LRx only)). These cohorts were then linked with state cancer registry (SCR) data containing OS diagnosis information. Patients were followed from their index date to the earliest of either OS diagnosis, death (Medicare only), or the end of study period. Primary analysis included estimation of incidence rate ratio with an adjustment to the person-time of observation using a coverage fraction (70% for LRx and 68% for Medicare).

Results: In the LRx database, 335,191 teriparatide patients matched to 637,387 unexposed osteoporosis patients and 379,283 teriparatide patients matched to 1,428,943 unexposed GP patients. A total of 29 SCRs participated, covering 70% of all expected US OS cases aged 20+ during the study period. A total of 18 OS cases were observed, the same 3 in both teriparatide cohorts, 6 in the osteoporosis cohort, and 9 in the GP cohort. In the main analysis, the IRR (per 1,000,000 person-years) was 1.0 (95%CI: 0.2, 4.5) for the teriparatide osteoporosis comparison and 1.3 (95%CI: 0.2, 5.1) for the teriparatide GP comparison. In the Medicare Part D database, 153,316 teriparatide patients matched to 613,247 unexposed general population patients. A total of 26 SCRs participated, covering 68% of all expected US OS cases aged 65+ during the study period. There were no cases of OS observed in the teriparatide cohort and the rate observed in the GP cohort was consistent with the expected rate in the background population (exact rate not reported due to privacy policy of CMS). In the main analysis, the IRR (per 1,000,000 person-years) was 0.0 (95%CI: 0.0, 3.2) for the teriparatide GP comparison.

Conclusions: The findings from this study suggest that the point estimates for OS among teriparatide-exposed patients is consistent with what is expected in the background population though the confidence intervals are wide.

P1155

DALBERGIA SISSOO LEAF EXTRACT ATTENUATES FURTHER PROGRESSION OF MIA INDUCED OSTEOARTHRITIS IN RAT MODEL

P. K. Kothari¹, R. T. Trivedi²

¹Csir cdri lucknow, Lucknow, India, ²Csir-cdri lucknow, Lucknow, India

Objective: To check effect of *Dalbergia sissoo* leaf extract (DSLE) on MIA induced model of Osteoarthritis. Previously our study reported the positive effects of the leaves Extract of *Dalbergia sissoo* (DSE) on cartilaginous cells to enhance the fracture healing in rats however its positive effects on MIA induced osteoarthritis model remains unknown. The purpose of this study was to evaluate its anti-osteoarthritic and Chondro-protective effects in MIA induced OA model.

Material and Methods: Histology and staining, ELISA, u-CT, H&E, Toluidine blue, CTX-II and COMP ELISA.

Introduction: Osteoarthritis (OA) is highly prevalent and debilitating disorder of the joints. OA surgery model in rats were developed by injecting MIA (Inhibitor of glycolysis pathway) in knee joint by fine syringe. *In-vivo* doses of DSLE 250 mg.kg⁻¹day⁻¹ and 500 mg.kg⁻¹day⁻¹ were given orally for 28 days daily. We assessed the chondro-protective effect of DSLE by micro-CT analysis of knee joint, gross appearance of knee joint, Histology of tibia sections and their staining by H&E and Toluidine blue.

Result: Serum analysis indicated that DSLE down regulated cartilage oligomeric matrix protein (COMP), and CTX-II expression which were increased in MIA model of osteoarthritis. DSLE prevented further progression of osteoarthritis in MIA model.

Discussion: Data showed that DSLE acts as a strong anti-oxidant and an anti-inflammatory. MIA induced loss of articular cartilage and changes in thickness of calcified cartilage and loss in sub-chondral bone were significantly prevented by DSLE.

Key Words: Osteoarthritis (OA), *Dalbergia sissoo* leaf extract (DSLE), Micro-CT (u-CT), Mono-sodium Iodoacetate (MIA).

Statistics: One way ANOVA test done between all the group Control, MIA, MIA +DSLE 250 mg.kg⁻¹day⁻¹ and MIA +500 mg.kg⁻¹day⁻¹

References:

1. Khedgikar V, Kushwaha P, Ahmad N, et al Ethanol extract of *Dalbergia sissoo* promotes rapid regeneration of cortical bone in drill-hole defect model of rat. *Biomed Pharmacother.* 2017 Feb; 86:16-22.
2. Kumar P, Kushwaha P, Ahmad N, et al Design and synthesis of dalbergin analogues and evaluation of anti-osteoporotic activity. *Bioorg Med Chem Lett.* 2017 Apr 15;27(8):1765-1775.

P1156

HYPERURICEMIA AND GOUT IN PATIENTS WITH PAGET'S DISEASE OF BONEM. A. Teran¹, C. Pijoan¹, J. Quiñones¹, J. Bachiller¹, M. Vázquez¹¹Ramon y Cajal University Hospital, Madrid, Spain

Objective: To analyze the frequency of hyperuricemia and gout in patients with a diagnosis of Paget's disease of bone (PD) and to establish the correlation between the activity of Paget's disease and its treatment in the fluctuations of uric acid levels.

Methods: Patients with Paget's disease and with scintigraphic uptake suggestive of activity were included. A database was created including demographic information, the presence of symptoms associated with PD, its type (monostotic or polyostotic), alkaline phosphatase (AP) and uric acid (UA) levels at diagnosis and the treatment received. AP and UA levels after treatment were also collected as well as the presence of possible hyperuricemic risk factors (HRF), history of gout and levels of AP and UA during gout attacks, if any. Finally data was analyzed using SPSS v21.

Results: A total of 95 patients were included with a mean age of 70.59 years (range 45-89), with 56% of them being women. The mean values of AP and UA at diagnosis were 178.05 mg/dL \pm 82.81 and 5.84 mg/dL \pm 1.74 respectively. 58.9% of the patients had monostotic involvement (56/95) and only 53.12% had associated symptoms (51/95), whereas in the rest of the patients PD was an incidental finding. 70.83% did not present HRF and 56 patients (58.9%) had received treatment for their PD (41% of them with zoledronic acid). Pearson correlation between PA and UA levels was found moderately positive (0.710 with $p < 0.0005$) and 50.52% of the patients (48/95) had UA levels above 6mg/dL at the time of diagnosis, with a mean of 7.10 mg/dl \pm 1.74. In 93.5% of the cases there was a decrease in UA levels after the treatment for PD, with a mean decrease of 0.78 mg/dL \pm 1.3 over the baseline value at one year of follow-up. Only 11.57% of the patients in our cohort presented gout symptoms during their follow-up, with an increase in AP levels at the time of the attack in 63.63% of the cases. CONCLUSIONS: In our cohort, there was a moderate positive correlation between the elevation of AP and UA in patients with active Paget's disease. Treatment for PD produced a decrease in UA levels from baseline in most patients. Similarly, during gout attacks, an increase in AP levels could be detected but, although there may be an association between flares and the activity of Paget's disease, no correlation was found in our study.

P1157

IN VIVO ASSESSMENT OF THE ANTIRESORPTIVE ACTIONS OF RESOLVIN D1: RELEVANCE TO OSTEOPOROSISH. B. Benabdoun¹, P. E. R. Rondon¹, J. F. Fernandes¹, H. F. Fahmi², F. Vallières¹, M. Benderdour¹¹Research Centre, Hôpital du Sacré-Coeur de Montreal, Montreal, Canada, ²Osteoarthritis Research Unit, Centre Hospitalier de l'Université de Montréal, Montreal, Canada

Objective: Resolvin D1 (RvD1), an important member of resolvins, exerts a *wide* spectrum of biological effects, including resolution of inflammation, tissue repair and preservation of cell viability. The aim of the present study is to investigate the bone protective actions of RvD1 *in vivo* using an experimental model of osteoporosis.

Methods: Fifteen days after bilateral ovariectomy (OVX) or sham surgery, 4-months old mice were randomly separated into 4 groups: Group 1: sham mice; Group 2: OVX + vehicle, Groups 3 and 4 OVX mice received a daily i.p. injection of 100 and 500 since day 1, respectively. Animals were sacrificed after 3-months post-treatment and biomarkers related to bone resorption were determined in serum. Bone density and microarchitecture were evaluated by microcomputed tomography (micro-CT) 3D.

Results: After 3-months post-treatment, we showed that RvD1 reduced significantly the serum levels of parameters related to bone resorption, such as tartrate-resistant acid phosphatase (TRAP), receptor activator of NF-KB ligand (RANKL), and C-terminal peptides of type I collagen (CTX-1). The activity of alkaline phosphatase was also normalized by RvD1 and reached control levels. In contrast to the serum biomarkers, we observed no changes in micro-CT 3D bone parameters.

Conclusion: Our preliminary data suggest a promising novel therapy for osteoporosis treatment and prevention through reducing the early changes in bone resorption. These changes precede those of bone microarchitecture and density.

P1158

RATES OF FRACTURES IN ADULTS OVER 50 YEARS OF AGE IN BRAZIL: A RETROSPECTIVE ANALYSIS OF THE HOSPITAL ADMISSION DATABASE FROM 2004 TO 2012L. C. Martinez¹, M. M. Pinheiro¹, A. R. B. Silva¹, A. C. Guersoni¹, V. L. Szejnfeld¹¹UNIFESP, São Paulo, Brazil

Introduction: Epidemiological studies in Brazil on fragility fractures are scarce. Most of them were done in specific population. Few were done considering all Brazilian population. Until now, there is no data concerning the secular trend of fractures in Brazil. To evaluate the rate of hospitalization related to major and hip fractures in individuals aged over 50 years, according to Brazilian public health system hospitalization database.

Methods: This is an ecological study with a temporal tendency including men and women enrolled from 2004 to 2012, according to their ICDs. It was included only those with low trauma fracture. All of them were classified concerning fracture type and by age and the data were calculated per 100,000 inhabitants.

Results: Hospitalization rate for major fractures was stable from 2004 to 2009 in both sex. However, there was an increase after 2010, especially in women after 60 years (44/100.000 population). Regarding hip fractures, women had higher rate, especially in those aged over 80 years (463/100.000 population). In both men and women, there was a slight reduction of hip fractures absolute number from 2004 to 2012. Major and hip fractures were more frequently observed in the South and Southeast region, showing some epidemiological differences.

Conclusions: Although the rate of hospitalization for hip fracture has been 5 times higher than major fractures from 2004 to 2012, there was slight decline of hip fractures and an increase of major fractures, highlighting secular trends differences between them, as well among Brazilian regions.

Keywords: osteoporosis, secular trends, fragility fractures, hip fractures, major fractures

P1159

PULSED ELECTROMAGNETIC FIELD IN REHABILITATION OF PROXIMAL HUMERAL OSTEOPOROTIC FRACTURES

I. M. Borda¹, L. Irsay¹, V. Ciorcea¹, I. Onac¹, R. Ungur¹

¹University of Medicine and Pharmacy Iuliu Hatieganu, Rehabilitation Hospital, Rehabilitation Department, Cluj-Napoca, Romania

Objective: The aim of the study was to assess the effects of Pulsed Electromagnetic Field (PEMF) on pain, range of movement and functional performance in patients with proximal humeral osteoporotic fractures.

Material and Methods: 62 women (68.7 ± 6.3 years) with proximal humeral osteoporotic fractures, conservatory treated by reduction and immobilization, were included (after the end of immobilization) in a prospective randomized controlled study. Osteoporosis was confirmed by dual-energy X-ray absorptiometry (DXA) method. Patients were randomly assigned to either PEMF (36 patients) or control group (26 patients). PEMF therapy or sham therapy (in the control group) was applied 10 minutes / day, for 10 days. Patients from both groups received a standard exercise programme. Parameters assessed on the first and on the last day of treatment were: pain (visual analogue scale - VAS), range of motion (goniometry), function (Disabilities of the Arm, Shoulder and Hand score - DASH).

Results: After the rehabilitation programme, improvement of all measured parameters was recorded in both groups, but with constant significant differences in favour of PEMF group: pain (p<0.01), range of motion (p<0.05), function (p<0.05).

Conclusion: PEMF provided important additional benefits in rehabilitation of patients with proximal humeral osteoporotic fractures.

P1160

MANDIBULAR BONE MINERAL DENSITY IN PATIENTS WITH EHLERS-DANLOS SYNDROME

S. M. Eshaghi¹, A. Shirvani²

¹Gilan University, Rasht, Iran, ²Boston University/Endocrinology, Boston, United States

The Ehlers-Danlos syndrome (EDS) is a hereditary disorder with several types that affect the connective tissue and collagen structures in the body. EDS patients are high risk for oral and mandibular disorders include implant failure. There is some evidence of peri-implant bone loss in EDS patients and its relationship with implant treatment failure. Here we report that implant treatment failed in six EDS patients which were predictable only based on mandibular bone mineral densitometry (BMD).

Longitudinal data before and after implant treatment were examined for 10 healthy (mean age 45.8±6.2 years) and 10 patients with EDS (mean age 42.9±7.1 years). All subjects had BMD measurements by dual energy X-ray absorptiometry (DEXA) at lumbar spine and hip as well as mandibular BMD by image processing of preapical radiography.

Although there was no statistically significant difference in central BMD between EDS patients and healthy controls, mean mandibular body BMD values in the EDS patients were lower than control group. The lower mandibular BMD in EDS patients was associated with implant treatment failure.

This is the first report on low mandibular BMD in EDS patients and its potential relationship with implant treatment failure in this patients. Further evaluation of mandibular BMD in individuals with EDS is needed to confirm the predictable value of mandibular BMD in implant treatment failure.

P1161

VIBRATION THERAPY AS AN INTERVENTION FOR POSTURAL TRAINING AND FALL PREVENTION AFTER DISTAL RADIUS FRACTURE IN ELDERLY PATIENTS: A RANDOMIZED CONTROLLED TRIAL

R. M. Y. Wong¹, W. T. Ho¹, C. Y. Tso¹, W. K. R. Ng¹, S. K. H. Chow¹, T. N. Tang¹, W. H. Cheung¹

¹The Chinese University of Hong Kong, Hong Kong, China

Introduction: Distal radius fracture is a sentinel event associated with postural instability and risk of subsequent hip fracture. The latest Cochrane systematic review shows a lack of effectiveness of current rehabilitation interventions. Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation to improve muscle strength and balancing abilities. The primary objective is to apply LMHFV to improve postural stability and prevent falls in distal radius fracture elderly patients.

Materials and Methods: A randomized controlled trial was conducted to investigate the effect of 3 months LMHFV on postural stability and fall rates after a distal radius fracture. 120 patients will be recruited based on inclusion and exclusion criteria. Inclusion criteria: 1) aged 60 or above 2) fracture distal radius 6 weeks to 3 months 3) injury due to unintentional fall. Randomization to control or LMHFV (n=60 per group) was performed. LMHFV was provided with vertical vibration at 35Hz, 0.3g, for 20 min/day, 5 days/week for 3 months. Assessments include postural stability by Biodex Balance System SD (Overall Stability Index (OSI), Anteroposterior Stability Index (APSI), Medial/Lateral Stability Index (MLSI), Limits of Stability (LOS)), fall occurrence, timed up-and-go test (TUG), compliance and adverse events.

Results: There were no significant differences between baseline characteristics. Currently 90 patients recruited and preliminary results have been generated. 2 patients dropped out (1 lost contact, 1 refused continuation) from control group and 3 patients dropped out (1 lost contact, 1 refused continuation, 1 died from medical disease) from LMHFV group. There were no significant differences between baseline characteristics. 96% and 93% compliance of control and LMHFV was documented.

There was significant improvement with LMHFV compared to control at 3 months for OSI ($p=0.049$), MLSI ($p=0.046$), LOS ($p=0.049$) and TUG ($p=0.038$). Falls occurred significantly less in LMHFV group with 2 times compared to 9 times in control group at 3 months ($p=0.026$). No adverse events were recorded.

Conclusion: Our results showed improved postural stability and decreased falls. Future clinical practice may adopt the use of LMHFV in distal radius fracture elderly patients.

Acknowledgement: The authors would like to thank the community centers and collaboration

P1164

THE EFFICACY OF COMPLEX KINESIOTHERAPY IN WEIGHT LOSS AND MUSCLE FUNCTION IMPROVING IN OBESITY PATIENTS

V. Vasileva¹, L. Marchenkova¹, M. Eryomushkin¹

¹FSBI National Medical Research Center for Rehabilitation and Balneology of the Ministry of Health of Russia, Moscow, Russia

Aim of the study: was to estimate the effect of complex 3-week treatment with 4 kinesiotherapy methods on body weight loss and muscle function in patients with obesity.

Material and methods: 80 men and women aged 21-69 years old with alimentary obesity were enrolled in the study (mean age 52.4±11 years, weight 111.3±24.5 kg, BMI 40.3±8.1 kg/m², waist circumference WC 113.4±16 cm, hip circumference HC 124.2±16 cm). The complex kinesiotherapy administered daily for 3 week and included interactive sensorimotor trainings on double unstable platform, kinesiotherapy in a pool, special complex of physical exercises in a gym and ergocycle trainings. Weight, WC, HC, fall number for last 3 weeks were measured at baseline and after the treatment was completed. Muscle strength and walking speed functional tests results assessment (10-meters-walk test,

Up-and-go test, 4 special tests for back and abdomen muscle endurance to static and dynamic loading) were performed at baseline and in 3 weeks.

Results: There was a significant reduction in body weight (111.3±24.4 kg at baseline vs 107.9±23.1 kg in 3 weeks; $p=0.000$), in BMI (40.3±8.1 vs 39.1±7.7 kg/m²; $p=0.000$), in WC (113.4±15.9 vs 109.2±15.1 cm; $p=0.000$) and in HC (124.1±15.5 vs 119.7±14.1cm; $p=0.000$) in treated obese patients. 10-meters-walk speed increased from 0.84±0.15 m/sec at baseline to 0.88±0.17 m/sec in 3 weeks ($p=0.000$). Up-and-go test results improved from 8.4±2.1 to 7.9±2.09 sec ($p=0.000$). We registered statistically significant elevation of the endurance to static loading in abdomen muscles from 13.1±9.7 to 16.49±12.8 sec ($p=0.000$) and in back muscles from 14.8±11.9 sec to 18.6±14.9 sec ($p=0.000$). The endurance to dynamic loading increased in abdomen muscles from 29.9±11.2 to 34.84±11.93 times ($p=0.000$) and also in back muscles from 9.1±7.4 to 12.2±9.2 times ($p=0.000$). Fall number markedly decreased from 0.14 ±0.34 at baseline to 0.0 (95%CI: 0.02; 0.25) after completion of treatment.

Conclusions: Investigated complex treatment with 4 kinesiotherapy methods promotes body weight loss, WC and HC reduction in obesity. 3-week special training of obese patients is associated with increasing in gate speed and lower extremities muscle strength, and it also causes improvement in static and dynamic loading endurance of back and abdomen muscles. Those changes may probably improve balance function and decrease risk of falling in obese patients.

P1162

AWARENESS OF OSTEOPOROSIS AND USE OF DXA AMONG NURSES

N. R. Njeze¹, S. N. Ezeofor¹, O. R. Agwu- Umahi², D. U. Akpagbula³, N. C. Njeze³

¹Department of Radiation Medicine, University of Nigeria Medical School, Nsukka, Nigeria, ²Department of Community Medicine, University of Nigeria Medical School, Nsukka, Nigeria, ³Department of Radiation Medicine, University of Nigeria Teaching Hospital, Ituku- Ozalla, Enugu, Nigeria

Introduction: Nurses play a major role in management of osteoporosis and so should be versed in this subject matter. It is also common knowledge that this disease though prevalent is not popular in developing countries. Nurses play a role in mgt of patients to ensure success of multidisciplinary modality of treatment of osteoporosis. The nurse is the patient informant in knowledge and education so as to assist their patients in their lifestyle changes. It is also expected that adequate knowledge may be lacking in this useful group of health personnel so it is important that the nurse is adequately exposed to osteoporosis in order to improve the quality of life of patients, avoid fractures and reduce mortality. It is observed that there is reduced evidence of osteoporosis awareness in Africa and level of knowledge in South East Nigeria is also minimal. Health care givers sometimes do not appreciate presence of osteoporosis even when a fracture has occurred. These patients are therefore left untreated. Osteoporosis is a common metabolic disease which occurs in 200 million

worldwide and about 33.6 million Americans have low bone density at the hip. Osteoporosis is associated with loss of bone substance and many people are not aware they are at risk of it or they have it already. It is therefore important that people are alerted by various arms of health personnel who will educate them about preventive measures and methods that will make them prevent falls especially the preventable ones. Fractures are known to occur more in individuals who have osteopenia than those who have osteoporosis. The bone is a vital organ in the body and comprises mainly collagen and calcium phosphate. Collagen is responsible for the flexible framework while the calcium phosphate provides the strength and therefore hardens the bone. Bone density depends on peak bone mass and amount of bone lost. Peak bone mass occurs before 30 years of age. At this time bones are larger and bigger. After 30 years bone formation slows down and bone resorption increases. Bone mineral density accounts for about 70% of bone strength. T-score is an index of BMD and represents the standard deviation from the normal value of that of a healthy young adult. The values of T-score and Z-score according to WHO are used for assessment. This results in low bone density with resultant increase in fragility fracture. Hip fractures have high morbidity and mortality rate. Fractures of the spine reflects mostly as loss in height. Osteoporosis is associated with loss of bone substance and many people are not aware they are at risk of it or they have it already. Osteoporosis can occur in younger people especially those that did not attain optimal bone mass as a result of poor nutrition. Underlying disease, extreme exercise and early amenorrhoea can also predispose one to osteoporosis. Low levels of estrogen that occur at menopause(especially when it occurs before 45 years of age) contributes immensely to occurrence of osteoporosis in women 14. When osteoporosis occurs in males, the mortality rates are double the values in females. It is important that nurses who form a significant part of health professionals should be well versed in the subject of osteoporosis and its management.

Methodology: About 500 questionnaires were distributed during a nurses workshop but 305 nurses accepted to participate in the awareness study. Most people had heard of osteoporosis.

Result: A total of 305 respondents (nurses) were in this study. Most of the respondents (290) had heard about osteoporosis. Nearly half (141) know that osteoporosis is caused by reduction in bone density but failed to realise that the DXA is the best imaging modality for diagnosing osteoporosis. About 75% (228) of the nurses know that rheumatoid arthritis is a risk factor of osteoporosis. It is imperative that nurses have adequate knowledge of osteoporosis so that they can form a significant part of the clinical team.

P1163

COMMON RADIOLOGIC FINDINGS IN KNEE OSTEOARTHROSIS

N. R. Njeze¹, S. N. Ezeofor¹, A. U. Katchy², N. C. Njeze³

¹Department of Radiation Medicine, University of Nigeria Medical School, Nsukka, Nigeria, ²Department of Surgery, University of Nigeria Medical School, Nsukka, Nigeria, ³Department of Radiation Medicine, University of Nigeria Teaching Hospital, Ituku- Ozalla, Enugu, Nigeria

Aim To identify the commonest radiological features of osteoarthrosis in this environment, attempt to form an indigenous classification with a view to adding more value to management especially prior to knee replacement therapy and ultimately correlate these findings with gender. **Methodology** This is a retrospective study which involved collecting all the knee joint radiographs of patients who presented at the radiology department to have radiographs of their knee joints as a result of pain of osteoarthritis. The radiologic features were recorded with a template recorded during routine reporting. **Introduction** Osteoarthrosis(OA) is a degenerative joint disease in which the cartilage breaks down resulting in swelling, pain and difficulty in moving the affected joint and resultant low self esteem. There is usually functional and structural collapse of the synovial joint. OA occurs when there is an imbalance between the breakdown and repair of joints so much so that there is an overwhelming increase in breakdown. It is an active disease in which mechanical factors have enormous influence in its initial process. Other less influential factors include genetic, metabolic and vascular factors. Osteoarthritis is the commonest type of arthritis. It is expected that its prevalence will increase with worldwide increase in obesity. OA is a major cause of morbidity in people 45 years and above. The plain radiograph of the knee is an informative initial imaging modality in diagnosis of OA and its follow up in order to monitor progress of disease. There is a view that there is unequal correlation between plain film findings and clinical symptoms. Radiologic signs of primary OA include asymmetrical narrowing of joint space commonly seen in the medial tibiofemoral compartment and or patello femoral knee compartment, osteophyte formation, subchondral cysts, subchondral sclerosis. Osteophytes develop earlier than joint space narrowing(JSN). This means that osteophytes are used to diagnose OA while assessment of severity depends on narrowing of joint space and concomitant subchondral bony abnormalities. Weight bearing radiographs are generally preferred as they show more JSN than nonweight- bearing knee joint radiograph because they will show evidence of radiographic severity subchondral cysts (geode) alteration in shape of the femoral condyles and the tibial plateau. There are many ways of grading the radiological findings of OA. The most popular plain radiograph classification of OA is Kellgren Lawrence grading. This method was initially proposed by Kellgren and his group in 1957. It was later accepted by World health organization(WHO) in 1961. This grading starts from 0 to IV and is determined solely by plain film features of osteoarthritis in the knee. Grade 0 = No radiological features of OA present; grade 1= Doubtful joint space narrowing(JSN) with possible osteophytic lipping; grade 2 is definite osteophytes and

possible JSN on AP weight bearing radiograph; grade 3 is presence of multiple osteophytes definite JSN, sclerosis with possible bony deformity; grade 4 is presence of large osteophytes, marked JSN, severe sclerosis and definite bony deformity. Another classification is Ahlback classification. It was proposed by Ahlback et al. in 1968. There are five grades: Grade 1 has JSN 10mm. Results A total number of 322 knee joint radiographs were reported and their findings recorded in a template which contained the plain film findings commonly seen in patients suffering from osteoarthritis; These included osteophytes, joint space narrowing, sclerotic changes, erosions etc There were 232 females and 90 males.

Knee pain was commoner in females. Most of the patients had history of previous injury. Both knees were involved but right was more affected than the left. The tibia was most affected followed by patella and then the femur. The 3 bones were equally affected by osteophytes. The intertibial spiking affected the right knee more than the left. The tibia had more sclerosis in both knees than other bones. Tibia had more subchondral cysts than femur and patella.

References 1. org .Henry Knipe and Vivek Pai et al. Kellgren and Lawrence system for classification of OA of the knee 2. Advances and Imaging of OA and Cartilage. Roemer FW, Crema MD, Trattnig S, Guermazi ALI. RSNA. 2011

P1165

A DIET HIGH IN FAT AND FRUCTOSE NEGATIVELY AFFECTS OSSEOINTEGRATION AND BONE METABOLISM IN FEMALE RATS

S. King¹, C. Baptiston Tanaka², D. Ross³, J. J. Kruzic², I. Levinger⁴, I. Klineberg¹, T. C. Brennan Speranza³

¹School of Dentistry, Faculty of Medicine and Health, University of Sydney, Sydney, Australia, ²School of Mechanical and Manufacturing Engineering, UNSW Sydney, Sydney, Australia, ³Department of Physiology; Bosch Institute for Medical Research, University of Sydney, Sydney, Australia, ⁴Institute of Health and Sport (IHES), Victoria University, Melbourne, Australia

Purpose: To test the hypothesis that diet induced metabolic changes adversely affect peri-implant bone microstructure, implant osseointegration and are associated with altered activity and formation of osteoblasts.

Materials and Methods: Thirty female Sprague Dawley rats were divided into three groups of (n=10), control group (normal chow), and 2 intervention groups on a high-fat (60%) high-fructose (20%) diet. Titanium implants were placed in the proximal tibial metaphyses in all groups either before commencing the diet (dHFHF) or 6 weeks after commencing the diet (HFHF) and observed for an 8 week healing period. Metabolic changes were measured by insulin tolerance and oral glucose tolerance tests at regular intervals along with weekly fasting blood glucose levels (fBGLs). Structural and functional features of the peri-implant bone, including bone-to-implant contact (BIC), were analysed post-euthanasia using microcomputed tomography, and dynamic histo-

morphometry. Expression of the master osteoblast transcription factor, runt related transcription factor (RUNX2) was measured ex vivo by extraction of RNA from the right humerus.

Results: The fBGLs were unchanged across all groups. Reduced sensitivity to insulin was noted in the dHFHF group at the final time point but not in the HFHF group. There were no changes to glucose tolerance in either of the intervention groups. Peri-implant trabecular bone volume was significantly reduced in the HFHF group compared to the control group ($p=0.02$) and BIC was significantly reduced in both the HFHF (25.42 ± 3.61) and dHFHF (28.56 ± 4.07) groups compared to control group (43.26 ± 3.58 , $p<0.05$). Osteoblast activity and Runx2 expression were significantly reduced in both intervention groups ($p<0.05$).

Conclusions: Osseointegration is compromised regardless of whether the implant is placed before or after the onset of the diet, indicating that changes in bone cell function affect both the initiation and maintenance of osseointegration. Bone structure and function are adversely affected and these changes occur despite the absence of changes to blood glucose levels and insulin and glucose tolerance suggesting that the changes in bone cell function are independent of diet related metabolic changes to blood glucose levels or insulin resistance.

P1166

SYMPTOMATIC EFFECTS OF LONG-TERM CRYSTALLINE GLUCOSAMINE SULPHATE THERAPY IN HAND OSTEOARHRITIS

A. Fioravanti¹, S. Tenti¹, N. Mondanelli², N. Giordano³, I. Gallo¹, S. Giannotti²

¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ²Section of Orthopedics and Traumatology, Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Le Scotte, Siena, Italy, ³Scleroderma Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Policlinico Le Scotte, Siena, Italy

Objective: According to Guidelines, the optimal management of HOA requires a combination of nonpharmacological (such as local application of heat, exercise, ultrasound and splints for thumb base OA) and pharmacological treatments. Aim of this retrospective observational study is to evaluate the efficacy of a therapeutic strategy -including the use of prescription crystalline glucosamine sulfate (GS) at daily dose of 1500 mg- for HOA in reducing hand pain and improving hand function.

Material and Methods: This is a 6-months observational study with retrospective review of medical records, conducted at the Center for the diagnosis and the management of Hand Osteoarthritis, Rheumatology Unit of Azienda Ospedaliera Universitaria Senese (Italy). 108 patients of both sexes, with concomitant knee osteoarthritis and primary HOA, aged between 40 and 85 years who had clinical symptoms of HOA for at least 3 months (defined as global hand pain score superior to 40 mm on a 0-100 Visual Analogue Scale (VAS) and Functional Index for Hand Osteoarthritis (FIHOA) score of at least 6, met the eligibility. Primary outcome

was to evaluate the symptomatic effects of GS treatment in addition to conventional therapy (i.e. exercise, acetaminophen and/or NSAIDs), compared to the efficacy of conventional therapy alone. Secondary outcomes were health assessment questionnaire (HAQ), medical outcomes study 36-item short form (SF-36), duration of morning stiffness and symptomatic drugs consumption. Patients were examined at baseline and after 3 and 6 months.

Results: Out of 108 subjects included in the study, 55 patients undergoing GS therapy presented a significant decrease in the VAS pain score and in the FIHOA score ($p < 0.001$) compared to the control group (53 patients). Moreover, the therapeutic strategy including GS administration, presented association to a significant decrease in morning stiffness at 6 months follow-up ($p < 0.01$), with a significant reduction of HAQ score ($p < 0.001$). Besides, drug consumption in the GS group, was reduced at 3 and 6 months ($p < 0.05$ and $p < 0.001$, respectively). The control group didn't present any significant change of all the analyzed parameters throughout the follow-up period.

Conclusions: This retrospective study highlighted that the use of GS with the usual care is more effective in improving hand OA related symptoms than the conventional OA therapy alone. GS might be considered as potential effective treatment for primary hand OA.

P1167

PLATELET-RICH PLASMA ADVANCED FROM ARTERIAL BLOOD ACHIEVES A BETTER THERAPEUTIC RESULT IN TREATMENT FOR KNEE OSTEOARTHRITIS

J. S. Nurković¹

¹Center for regeneration and rehabilitation Nurković, Novi Pazar, Serbia

Objective: In recent years, platelet-rich plasma advanced (PRP) is a new therapeutic approach for knee osteoarthritis (KOA). PRP advanced is autologous concentration of a high number of cytokines growth factors from platelets in a small volume of plasma, previously stimulated by a low-level laser (LLL) and electromagnetic field (EMF). We wanted to examine whether the isolation of the growth factor from arterial blood further enhances the therapeutic effects of the procedure.

Material and Methods: PRP was isolated from peripheral blood of 100 persons ranging in age from 18 to 65 years, during the first half of 2018. PRP samples are divided into two groups: arterial blood (50 patients) and venous blood (50 patients). Arterial blood sample is collected from brachial artery, venous from cephalic vein, both controlled by ultrasound. All samples were LLL- and EMF-treated, as in our earlier scientific papers. After that instillation of PRP-a were done. Patients were examined for range of motion, improvements in VAS scale, WOMAC score, Lequesne index (LI), ambulation speed, and medical outcomes study 36 short-form health survey (SF-36) seven, thirty, three and six months after intraarticular application of PRP-a.

Results: Both groups showed a significant improvement in all parameters compared to the period before the application ($p < 0.05$). Changes in range of motion, ambulation speed, and the SF-36 in both groups were recorder after three and six months of procedure. Compared with those in group of patients receiving PRP-a from venous blood, patients treated PRP-a from arterial blood showed significant improvements in VAS, WOMAC and LI. There were no PRP-a-related adverse events during and after the interventions.

Conclusion: PRP-a from arterial blood achieves a better therapeutic result in treatment for knee osteoarthritis, compared to PRP-a isolated from venous blood.

P1168

THE IMPACT OF LOW-LEVEL LASER AND ELECTROMAGNETIC FIELD ON OSTEOGENIC DIFFERENTIATION AND AGING OF HUMAN MESENCHYMAL STEM CELLS ISOLATED FROM ADIPOSE TISSUE

J. S. Nurković¹

¹Center for regeneration and rehabilitation Nurković, Novi Pazar, Serbia

Objective: In recent years, electromagnetic field (EMF) and low-level laser (LLL) have been found to affect various biological processes, the growth and proliferation of cells, and especially that of stem cells. The aim of this study was to investigate the effects of EMF and LLL on the characteristics and abilities of human adipose tissue-derived mesenchymal stem cells (hATMSCs) and thus to examine the impact of these therapeutic physical modalities on stem cell engraftment.

Material and Methods: hAT-MSCs were isolated from subcutaneous adipose tissue of 12 persons ranging in age from 18 to 65 years. LLL was applied also for 7 days, for varying periods of time, at different radiation energies of 1 J/cm², 3 J/cm², 5 J/cm² and 10 J/cm², with a wavelength of 808 nm, power output of 200 mW, and power density of 0.2 W/cm². EMF was applied for a period of 7 days, once a day for varying periods of time, via a magnetic cushion surface at a frequency of 50 Hz and an different intensity of 1 mT, 3 mT, 5 mT and 10 mT. Nonexposed cells (control) were cultivated under the same culture conditions. Seven days after treatment, optimum doses of LLL and EMF are determined, and the cells were examined for cell viability, morphology, osteogenic proliferation, differentiation, aging and oxidative stress.

Results: We found that after 7 days, the number of EMF-treated hATMSCs was significantly higher than the number of the untreated cells, LLL-treated hAT-MSCs were more numerous than EMF-treated cells, and hATMSCs that were treated with the combination of EMF and LLL were the most numerous. EMF and/or LLL treatment did not significantly affect hAT-MSC viability by itself. The same positive effects were registered also when osteogenic differentiation was examined. LLL and/or EMF treatment did not affect aging and oxidative stress of hAT-MSCs. Changes

in cell morphology were also observed, in terms of an increase in cell surface area and fractal dimension in hAT-MSCs treated with EMF and the combination of EMF and LLL.

Conclusion: LLL and/or EMF treatment accelerated the proliferation and enhance osteogenic differentiation of hAT-MSCs without compromising their viability, without affecting aging and oxidative stress, and therefore, they may be used in stem cell tissue engineering.

P1169

OSTEOCALCIN AND BODY MASS INDEX: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES

X. Liu¹, Y. Liu², J. Mathers¹, I. Levinger^{3,4}, B. B. Yeap^{5,6}, J. R. Lewis^{5,7,8}, K. E. Brock¹, T. C. Brennan Speranza^{1,2}

¹Department of Physiology, Sydney Medical School, The University of Sydney, Sydney, Australia, ²School of Public Health, Sydney Medical School, The University of Sydney, Sydney, Australia, ³Institute of Health and Sport (IHES), Victoria University, Melbourne, Australia, ⁴Australian Institute for Musculoskeletal Science (AIMSS), Department of Medicine-Western Health, Melbourne Medical School, The University of Melbourne, Melbourne, Australia, ⁵Medical School, University of Western Australia, Perth, Australia, ⁶Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, Australia, ⁷Centre for Kidney Research, Children's Hospital at Westmead, School of Public Health, Sydney Medical School, The University of Sydney, Sydney, Australia, ⁸School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia

Objective: Rodent studies have suggested that the bone-derived protein osteocalcin (OC), may have role in energy metabolism. Given obesity is a major risk factor for metabolic disorders, a meta-analysis of observational studies was conducted to investigate whether total serum osteocalcin (TOC) and ucOC levels are associated with BMI in adult general populations.

Methods: Literature search up to 15 Jan 2019 were conducted in MedLine, Embase and PubMed to identify relevant studies. Pooled correlation coefficients were derived with 95% confidence intervals (CIs) using random-effects models. Between-study heterogeneity was assessed and explored using sub-group analyses and meta-regressions. Publication bias was assessed by Egger's test.

Results: We identified 52 correlation coefficients for TOC (n=24336 participants) and 14 correlation coefficients for ucOC (n=8059 participants) in the meta-analysis. Both lower TOC (r=-0.151, 95% CI -0.171 to -0.130, p<0.001) and ucOC levels (r=-0.060, 95% CI -0.103 to -0.016, p=0.01) were correlated with increased BMI in overall analysis, with moderate heterogeneity (I²=52% for TOC and I²=54% for ucOC) and evidence of publication bias were detected (Egger's regression p<0.05). Sub-group analysis indicated the correlation between TOC and BMI was modified by ethnicity, with a stronger pooled correlation in studies from Caucasians and other regions (r=-0.187) compared to studies from East Asian populations (r=-0.126; intra-group

p-value=0.002). However, this trend was not found in studies of ucOC. The correlation between ucOC and BMI was modified by the mean/median BMI of study populations (R²=77%), where the correlation coefficient tended to decrease with increased BMI of the study populations.

Conclusion: Previous meta-analyses have reported an association between measures of glucose metabolism and OC, although it has not been clear whether the association is due to glucose handling or measures of body composition. Here we show that both TOC and ucOC were negatively correlated with BMI, raising the question of which function of energy metabolism is driving this relationship. The association between OC and BMI may be affected by ethnicity and presence of metabolic disorders. Further investigations comparing different ethnic populations and individual participant data meta-analysis would elucidate the veracity of the associations between osteocalcin and obesity in humans.

P1170

DIFFERENCES IN HIP GEOMETRY BETWEEN FEMALE SUBJECTS WITH AND WITHOUT ACUTE HIP FRACTURE

L. Wang¹, Y. Su², X. Cheng², X. Wu², M. Yang², R. Yang², K. Engelke³

¹Beijing Jishuitan Hospital, Peking University, Beijing, China, ²Beijing Jishuitan Hospital, Peking University, Beijing, China, ³Institute of Medical Physics, University of Erlangen, Erlangen, Germany

Objective: While it is well known that hip BMD is reduced in patients with hip fracture, differences in geometrical parameters such as cortical volume and thickness between subjects with and without hip fracture are well less known,

Methods: CT scans from 421 independently community-dwelling elderly women, enrolled in the China Action on Spine and Hip Status (CASH) study (NTC 01758770) between March 2016 and May 2017, were included in the study. 230 of the women had acute hip fractures. CT scans were taken within 48 h after fracture to minimize changes in vBMD and body composition. 191 age matched women served as controls. CT scans were analyzed with MIAF - femur. For the purpose of this analysis integral and cortical volumes of total hip, head, neck, trochanter and intertrochanter were analyzed. In the head and neck the volumes were further subdivided into superior anterior (SA) and posterior (SP) as well as inferior anterior (IA) and posterior (IP) quadrants. In addition cortical thickness was determined for all sub VOIs listed above. Differences between fractured and unfractured females were compared by Ancova, using age, height and weight, CT pixel size and slice thickness as covariates.

Results: Results of the univariable analysis are shown in the Table for those variables that remained significant after adjustments. Integral volume of the total femur, neck and intertrochanter did not significantly differ between groups. Cortical volume and thickness were significantly lower in the fractured subjects with exception of the trochanter where cortical thickness was slightly higher in the fractured subjects and cortical volume did

not change. In unfractured subjects, the ratio of cortical to total volume was significantly greater for total femur, neck, trochanter and intertrochanter but differences in the trochanter were small. A closer inspection of the quadrants (details omitted) showed that at the neck, in the fractured subjects, cortical thickness was significantly lower in all quadrants whereas cortical volume was

significantly higher (n.s. in quadrant SA). Femoral head volume of all quadrants was higher ($p < 0.05$ for quadrants SP and SA) higher in fracture subjects. Total neck volume of IP and IA quadrants was numerically higher and of SP and SA quadrants numerically lower than in fractured patients ($p < 0.05$ for SA).

Variable/VOI	SubVOI	Mean ± SD unfractured	Mean ± SD fractured	p
Age		70.8 ± 6.8	71.3 ± 7.8	n.s.
Height		157.9 ± 5.7	159.0 ± 5.7	n.s.
Weight		62.7 ± 9.8	60.1 ± 9.9	0.008
Total Femur	cort vol	15.8 ± 3.7	15.1 ± 2.9	<0.001
	cort thick.	1.84 ± 0.25	1.76 ± 0.23	<0.001
Head	int vol	35.5 ± 5.3	38.0 ± 5.9	<0.001
	cort vol	4.15 ± 1.0	4.07 ± 1.3	0.001
Neck	cort thick.	1.74 ± 0.25	1.63 ± 0.35	<0.001
	int vol	24.7 ± 4.3	26.5 ± 5.2	<0.01
Trochanter	cort thick.	1.71 ± 0.21	1.73 ± 0.24	<0.001
	cort vol	5.9 ± 2.9	4.9 ± 1.4	<0.001
Intertroch.	cort thick.	2.07 ± 0.37	1.90 ± 0.24	<0.001

Conclusion: Differences in total and cortical volume as well as cortical thickness between fractured and unfractured females vary substantially across the proximal femur.

P1171

ASSESSMENT OF FUNCTIONAL STATUS OF CONSERVATIVE TREATMENT FRACTURE OF THE WRIST – PATIENTS WITH AND WITHOUT REDUCED BONE DENSITY

K. Markovic¹, S. Bacevic², L. J. Milasinovic-Stanojevic³, R. Filipov¹

¹Institute for Treatment and Rehabilitation “Niska Banja”, Nis, Serbia, ²General Hospital, Prokuplje, Serbia, ³Private polyclinic - Latrija, Novi Sad, Serbia

Introduction: More than 10% of all human skeletal fractures, make up fractures of distal radial bone. A typical break (fractura radii loco typico) is localized to 1.5-2.5cm above the wrist. There is a Colles-type fracture (where the proximal fragment goes forward and medially and distal backward and dorsal) and Smith's fracture (the proximal fragment moves backward and dorsally and the distal forward and the medial). Only 5% of these fractures require surgical treatment-these are most patients, with reduced bone density.

Aim: Assessment of functional status of conservative treatment fracture of the wrist, using the Gartland-Werley (G-W) score system, as well as its elements (residual deformities, complications, subjective and objective discomfort). Measuring of bone mineral density was performed on Hologic Discovery densitometer, anteroposterior scan of lumbal vertebrae L1-L4 by the method of two energetic absorptiometry by X-rays (DXA) was performed.

Method: It was tested 102 patients with fractures of distal radial bone, which were treated non-operatively with a minimum follow-up period of six months. In the age of life between 21 and 84 years - average 62.9,SD±10,5. The left wrist was injured in 64 (62.7%) patients and right at 38 (37.3%). There were 82 women (80.4%) of average BMD=0.778gr/sm², T-scor=-2.2 and 20 men (19.6%) of average BMD =0.889gr/sm²,T-scor=-1.6

Results: The results, when applying the G-W score, were excellent in 37.1%(BMD=0.848gr/sm²,T-scor=-1.6), good in 43.3% (BMD=0.960gr/sm²,T-scor=-1.4), satisfactory in 15.8%(BMD=0.772gr/sm²,T-scor=-2.1), and poor in 3.8% patients(BMD=0.694gr/sm²,T-scor=-2.5) at the end of the assessment. The G-W score elements had the following percentages in the scoring results: residual and subjective discomfort equally by 15 patients, objective discomfort (functional results) 41 and complications 23. The correlation analysis showed a statistically significant correlation of the residual deformities and the total G-W score ($p < 0.01$) and between objective discomfort and total G-W score at the same level.

Conclusion: Fractures of distal radial bone, require a special approach and adequate assessment of final treatment results, because inadequate treatment results in the reduction of patients daily activities and their ability to work - especially when we have reduced bone density.

Keywords: Fracture of the Wrist, Reduced bone density, Functional Assessment, Scoring System

P1172

EPIDURAL INJECTIONS ON LUMBAR SPONDYLOSIS PATIENTS MAY BE ASSOCIATED WITH THE RISK OF OSTEOPOROSIS: A NATIONWIDE POPULATION-BASED COHORT STUDYH. W. Chen¹, I. H. Chen¹, T. C. Yu¹, W. T. Wu¹, K. T. Yeh¹¹Hualien Tzu Chi Hospital, Hualien city, Taiwan

Objective: Epidural injections (EI) involve the administration of local anesthetic, steroids, or both into the spinal epidural space. The procedure was regarded as a reasonable approach for lumbosacral radiculopathy. The refractory period may prolong over 6 weeks, which makes an option of nonsurgical management. However, recent studies have revealed the negative effect on BMD. The main purpose of this study is to illustrate the association between EI and the following risk of osteoporosis based on the nationwide population database.

Methods: 5253 patients with spondylosis have received EI between 2000-2013 were identified from the National Health Insurance Research Database. Each was randomly selected and frequency-matched with an individual without EI by age, sex, and the index year. Furthermore, the risk factors of osteoporosis were stratified by gender, age, urbanization level, income level, and comorbidity.

Results: The incidence rates of osteoporosis in the EIs group and the non-EI group were 8.42 and 7.30 per 1,000 person-years respectively. The EIs group had a higher risk of osteoporosis [adjusted hazard ratio (aHR)=1.21, 95%CI=1.03-1.42]. Correlated risk factors included male (adjusted subhazard ratio aSHR=1.33, 95%CI=1.00-1.77), lowest urbanization level (aSHR=1.42, 95%CI=1.07-1.89), low income populations.(aSHR=1.86, 95%CI=1.14-3.06) and without comorbidity (aSHR=1.58, 95%CI=1.08-2.32)

Conclusion: According to previous literature, anti-osteoporotic prescription following EIs may achieve better prognosis. The lowest urbanization level and lower income level may decrease the accessibility to further follow-up and anti-osteoporotic agent. While patient without comorbidity may lack in motivation to further follow-up after the symptom relief by the procedure successfully. EIs on lumbar spondylosis are related to higher risks of osteoporosis. The therapy should be recommended with caution, especially in patients with correlated risk factors.



2019 PARIS

WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES

PARIS, France | 2019

Abstract Book

**Satellite Symposia
Abstracts**

SY1

VITAMIN D AND BONE HEALTH: PRACTICAL MANAGEMENT

R. Rizzoli¹¹Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

Vitamin D is an important regulator of calcium and phosphorus homeostasis. By promoting optimal extra-cellular calcium and phosphorus concentrations, it ensures mineralization of newly deposited bone and/or cartilage matrix. Its role in preventing rickets in childhood and osteomalacia in adults is well established. The elderly are at high risk of vitamin D insufficiency, because they have less sunshine exposure and their skin capacity to produce vitamin D₃ decreases with age. Patients with serum 25-hydroxyvitamin D (25-(OH)D) levels <50 nmol/L have increased bone turnover and bone loss, as compared with patients with levels >50 nmol/L. Vitamin D deficiency is very frequent in hip fractured patients. Combined to calcium, vitamin D decreases fracture risk, particularly in vitamin D insufficient patients. In contrast, an increased risk of fracture and falls is observed with the yearly administration of large doses of vitamin D (corresponding however to a mean daily dose of 1350 IU). Several factors can explain the lack of vitamin efficacy on clinical outcomes in recent large studies and meta-analyses. Low doses as well as high doses may be inefficient in vitamin D replete healthy subjects, with a U-shape relationship between for instance fall risk or mortality and vitamin D supplements. Therefore, non-intermittent schedule should be privileged with doses correcting vitamin D insufficiency. Because of its low cost and very high safety, it is logical to correct vitamin D insufficiency in order to protect bone health in elderly subjects.

SY2

VITAMIN D AND MUSCLE

B. Dawson-Hughes¹¹Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, United States

Vitamin D deficiency mimics several of the age-related changes that occur in muscle. In vitamin D deficiency, there is a preferential loss of type 2 muscle fibers, fewer intramuscular vitamin D receptors, and reduced balance. A recent meta-analysis of 29 randomized placebo-controlled intervention trials revealed that vitamin D supplementation improved muscle strength. Vitamin D supplementation has also improved balance in older adults, as measured by reduced sway. The evidence that vitamin D supplementation will lower risk of falling is decidedly mixed. This is not surprising because falls are complex events that often involve multiple deficits. A 2011 meta-analysis concluded that a dose of 700 to 800 IU was required to lower risk of falls and that with optimal dosing, the risk reduction was on the order of 15%. Several subsequent trials tested 800 IU per day. In one conducted in postmenopausal women, neither 800 IU per day (nor 50,000 IU twice monthly) influenced risk of falling. A similar null result was observed in another 800 IU trial in over 400 postmenopausal women age 70 to 80 years. Trials testing high infrequent doses of

vitamin D have found that supplementation had either no effect or actually increased risk of falling. A factor that may affect efficacy of supplementation is the vitamin status of the study population. Many of the trials cited above involved participants who were vitamin D replete or only mildly insufficient at baseline. Additional trials in adults with low 25(OH)D levels (<50 nmol/L) are needed to clarify this. In conclusion, supplemental vitamin D is not effective in reducing falls in adults who are replete or mildly insufficient. In the few available studies in vitamin D deficient adults, daily supplementation with a moderate dose of vitamin D appears to improve muscle performance and lower risk of falling.

SY3

TREATING TO TARGET – A REALITY ON THE HORIZON?

UCB¹¹UCB, Brussels, Belgium

We hope you can participate in this exciting symposium, as our distinguished faculty explore the ‘why, what and how?’ of using a targeted approach when managing patients with fragility fractures.

Most of us would agree that the ultimate goal of treating osteoporosis is to prevent fractures and reduce the associated mortality and morbidity that impacts our patients’ independence. In this symposium, we will take a critical look at the current landscape and approach to managing patients with fragility fractures and ask **why** it could be time to consider a more targeted approach to guide management decisions. As this ‘treat-to-target’ strategy is well established in several chronic diseases, we will invite perspectives from a leading expert in type 2 diabetes. We will discuss **what** learnings can be gleaned from this area, consider which clinical targets could be useful when treating patients with fragility fractures and review the supporting evidence.

Using illustrative clinical cases, we will also reflect on **how** this evidence can be applied to our patients in the clinic, considering the variety of factors that impact patients’ risk of fracture and their need to reach an agreed treatment target. Together with our audience, we will brainstorm and review the considerations for a treat-to-target approach in patients with fragility fractures, and question how the strategy could become a clinical reality.

We hope that after participating in this symposium, you will be able to answer the following questions:

1. Why might you consider a different approach for patients with fragility fractures?
2. What potential targets would you consider for a treat-to-target approach in patients with fragility fracture?
3. Which patient groups could be prioritised for a treat-to-target approach?

This symposium is sponsored by UCB.

SY4

ESCEO RECOMMENDATIONS FOR CLINICAL TRIALS FOR HAND OSTEOARTHRITIS

J.-Y. Reginster^{1,2}, on behalf of the ESCEO Working Group on Hand Osteoarthritis

¹Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ²Chair for Biomarkers and Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia

Objective: To provide guidance on the methodology for performing clinical trials in hand osteoarthritis (hOA)

Material and methods: The ESCEO working Group consisted of clinical scientists, experts in the field of hOA and representatives of national or European licensing authorities giving their contribution on a personal basis

Results: The consensus guideline is intended to provide a reference tool for practice, and should allow for a better standardization of the conduct of clinical trials in hOA. hOA is a heterogeneous disease affecting different and often multiple, joints of the thumb and fingers. It is recognized that the various phenotypes and limitations of diagnostic criteria may make the results of hOA trials difficult to interpret. Nonetheless, practical recommendations for the conduct of clinical trials of both symptom and structure-modifying drugs are outlined, included guidance on study design, execution and analysis.

Conclusion: The Working Group acknowledges that the methodology for performing clinical trials in hOA will evolve as the knowledge of the disease increases.

The ESCEO Working Group on hOA was constituted by Jean-Yves Reginster, Nigel K. Arden, Ida K. Haugen, François Rannou, Etienne Cavalier, Olivier Bruyère, Jaime Branco, Roland Chapurlat, Sabine Collaud Basset, Nasser Al Daghri, Elaine Dennison, Gabriel Hertero-Beaumont, Andrea Laslop, Burkhard F. Leeb, Stefania Maggi, Ouafa Mkinsi, Anton S. Povzun, Daniel Prieto-Alhambra, Thierry Thomas, Daniel Uebelhart, Nicola Veronese, Cyrus Cooper.

SY5

HAND OSTEOARTHRITIS: SPECIFICITIES AND SIMILARITIES WITH KNEE OSTEOARTHRITIS - A SHORT OVERVIEW

E. Maheu¹

¹Rheumatology Department, Hôpital Saint-Antoine, APHP, and private office, Paris, France

Hand and knee osteoarthritis (OA) are the most frequent locations of OA, which is the first arthritic disease in the world by frequency. They are responsible for a very heavy human and social burden, with pain, functional impairment leading to a loss of autonomy and ability to move, and work loss. OA is associated to an excess mortality rate by 1.55.

OA prevalence grows dramatically with aging (in all populations) and the increasing epidemic of obesity/overweight affecting all countries in the world.

Radiologic hand OA (Kellgren-Lawrence grade \geq II) is present in 67% of women and 55% of men aged 55 years and over, which represents at least a 100 million of Europeans, among whom 20% will have a symptomatic disease.

There is currently no specific cure targeting OA. Treatments are, therefore, aimed at reducing symptoms (pain, stiffness, functional impairment and mobility limitations). International treatment guidelines recommend for both sites non-pharmacologic treatments (exercise, weight loss for the knee, splints and orthoses, education) and pharmacologic options including paracetamol, Non Steroidal Anti-inflammatory drugs, opioids, intra-articular steroids for flares and, for some groups, symptomatic slow-acting drugs. If this medical treatment fails, surgical options may be considered.

Despite its frequency, few clinical trials have been conducted in hand OA, unlike knee OA, though guidelines for the conduct of hand OA have been recently published (1, 2).

As in knee OA, there are OA phenotypes in hand OA, such as metabolic and inflammatory phenotypes.

Hand OA has been shown to be twice more frequent in overweight. Its prevalence also grows with comorbidities, such as hypertension and diabetes all together. Weight and metabolic syndrome are also associated with risk of knee OA and more symptoms. Inflammatory phenotype is also associated with both diseases, joint effusion and synovitis being responsible for more pain and severe disease, which may lead to an accelerated joint degradation, in both cases, as shown by longitudinal studies using ultrasounds.

However, the main difference is that hand OA is a polyarticular disease, affecting up to 32 joints, each of which able to be radiologically or clinically affected and to progress on its own. Patients have to be assessed and followed up at joint' and patient's levels, which complicates hand OA management. Synovitis and flares have to be treated quickly, as in rheumatoid arthritis, in order to prevent further severity and destructions, responsible for deformities, a major concern for many patients. At patient level, oral treatments and exercises must be proposed, on the short and long term.

There is certainly a room in hand OA for treatments proven to be effective in knee OA. Trials and further studies are mandatory to assess efficacy of these treatments in hand OA. Hand OA remains, by far, an orphan field with many patients waiting for a better management and treatments meeting their expectations.

1. Kloppenburg M, Maheu E, et al. Osteoarthritis Cartilage 2015.
2. Reginster JY et al. Seminars Arthritis Rheum 2018.

SY6

A NEW OPPORTUNITY TO TREAT HAND OSTEOARTHRITIS: THE ROLE OF CRYSTALLINE GLUCOSAMINE SULPHATE

S. Tenti¹, S. Giannotti², N. Mondanelli², N. Giordano³, I. Gallo¹, A. Fioravanti¹

¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ²Section of Orthopedics and Traumatology, Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Le Scotte, Siena, Italy, ³Scleroderma Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Policlinico Le Scotte, Siena, Italy

Objective: To retrospectively evaluate the symptomatic effects of crystalline glucosamine sulfate (GS) treatment in addition to conventional therapy, in comparison to the conventional therapy alone in patients with primary hand osteoarthritis (HOA).

Material and Methods: This is a 6-months retrospective comparative study including 108 patients with concomitant knee and primary HOA, according to the ACR criteria. To be eligible the patients had to present clinical symptoms of hand OA for at least 3 months, defined as global hand pain score superior to 40 mm on a 0–100 Visual Analogue Scale (VAS) and a Functional Index for Hand Osteoarthritis (FIHOA) score of at least 6. The participants were stratified into two groups based on whether or not crystalline GS treatment at the daily dose of 1500 mg was added to the conventional therapy for HOA (including exercise, analgesics and NSAIDs). According to our standard of care, the patients were evaluated at baseline and after 3 and 6 months. Primary outcome measures were the change in the patient's assessment of global hand pain on a 0-100 VAS and in the FIHOA score; secondary outcomes were health assessment questionnaire (HAQ), duration of morning stiffness, medical outcomes study 36-item short form (SF-36) and symptomatic drugs consumption.

Results: A total of 108 patients were included, of whom 55 were treated with GS in addition to conventional therapy (GS group) and 53 with conventional therapy (control group), alone. The patients who received GS therapy presented a more pronounced decrease in the VAS pain score and in the FIHOA score ($p < 0.001$) compared to the control group. Furthermore, GS treatment was associated with a significant decrease in the duration of morning stiffness at 6 months follow-up ($p < 0.01$) and with a significant reduction of HAQ score ($p < 0.001$) and drug consumption at 3 and 6 months ($p < 0.05$ and $p < 0.001$, respectively). There were no significant modifications of all the analyzed parameters throughout the follow-up in the control group. Differences between the two groups were significant for all parameters at 3 and 6 months of follow-up. No serious adverse event was recorded in both group.

Conclusions: This study demonstrated that the combination of crystalline GS with the usual care is more effective in improving hand pain and function than the conventional OA therapy alone. Thus, GS could represent a potential successful therapy for primary hand OA.

SY7

THE CHALLENGE OF EARLY SYMPTOMATIC KNEE OSTEOARTHRITIS (ESKOA)

A. Migliore¹

¹Rheumatology Unit, Department of Internal Medicine, San Pietro Fatebenefratelli Hospital, Rome, Italy

An international panel of experts in the field of OA has provided a potential clinical definition for early symptomatic knee osteoarthritis (ESKOA) and its related criteria to diagnose. Knee Osteoarthritis (KOA) is one of the leading cause of morbidity and disability in the world and its economic burden is continuously increasing. The KOA management should be improved because, more and more often, Doctors (HCPs) visit KOA patients in a late-stage, when surgery is the last option available. Therefore, it is important to define a useful tool for early identification and consequently early treatment strategies which might reduce KOA patient morbidity and related costs.

Often patients do not consider OA as a “real” disease and therefore they do not approach the HCP during an early stage, while they frequently favor a “self-medication” approach. Only when symptoms keep worsening and the clinical scenario is more complicate, patients refer to the specialists: this is the reason why preventive care is rarely performed. The challenge is, for the HCPs, to be allowed to manage patients' clinical conditions and structural characteristics before the onset of established radiographic KOA, since radiographic signs become evident only in an advanced stage of the disease.

Risk factors for OA (e.g. family history, obesity, strong sport activity, post-trauma joint surgery, congenital malformation) should be taken into account when trying to circumscribe the early phase of the disease. ESKOA can thus be defined when two mandatory symptoms are present, even in the absence of risk factors: knee pain -in the absence of any recent trauma- and very short joint stiffness -less than 10 min when starting movement. Otherwise, ESKOA is defined when 1 or 2 risk factors are present with concomitant knee pain; or 3 or more risk factors are present with at least one of the mandatory symptom described above, and with symptoms lasting less than 6 months. These criteria are applicable in the absence of active inflammatory arthritis, generalized pain, Kellgren-Lawrence grade > 0 , any recent knee trauma or injury, and age lower than 40 years.

Migliore A, et al. The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology. Rheumatol Int (2017) 37:1227–1236

SY8

SERUM KINETICS OF CARTILAGE BIOLOGICAL MARKERS IN RESPONSE TO IMMOBILIZATION AND PHYSICAL EXERCISE, AND THE POTENTIAL ROLE OF CGS IN THIS CONTEXT

A.-M. Liphardt^{1,2}, A. Mündermann^{3,4,5}

¹Dept. of Int. Medicine 3 - Rheumatology and Immunology, University Hospital Erlangen, Friedrich-Alexander-University (FAU) Erlangen, Erlangen, Germany, ²German Sport University Cologne, Institute of Biomechanics and Orthopedics, Cologne, Germany, ³Dept. of Orthopedics and Traumatology, University Hospital Basel, Basel, Switzerland, ⁴Dept. of Biomed. Engineering, University of Basel, Basel, Switzerland, ⁵Dept. of Clin. Research, University of Basel, Basel, Switzerland

The mechanical environment plays an important role in the maintenance of cartilage health. Biological markers of cartilage metabolism allow to investigate the effect of chronic or acute changes to the mechanical environment of articular cartilage. Biological markers of cartilage metabolism have already been shown to play an important role in the assessment of progression of osteoarthritis. Their measurement and monitoring might therefore be a helpful tool in disease management.

Various experiments in recent years have shown the mechano-sensitivity of cartilage oligomeric matrix protein (COMP) to loading and immobilization. A recent study tested the acute response of cartilage biomarkers to a 30-minute walking-stress-test with reduced (80% body weight (BW)), normal (100% BW) or additional (120% BW) load. Blood samples taken before and after the walking-stress-test were assessed on COMP, ADAMTS-4, PRG-4, MMP3, MMP-9, and IL-6. Results show that COMP and MMP-3 both increased immediately after the 30-minute walking-stress-test with significant differences between the loading conditions (COMP: 26.8±12.8%, 28.0±13.3% and 37.3±18.3% (P<0.001), MMP-3: 20.4±10.9%, 23.1±11.8% and 36.5±18.5% (P<0.001) for the reduced, normal or increased load condition, respectively). PRG-4, ADAMTS-4, IL-6, and MMP-9 did not show consistent response to acute loading.

In previous investigations, COMP and MMP-3 have already been shown to be sensitive to intensive sports activity such as running a marathon. Faster marathon times corresponded with greater increase in MMP-3 levels,¹ and shorter recovery periods for COMP levels.²

MMP-3 and COMP have also shown a dose-dependent response to prescription crystalline glucosamine sulfate (pCGS) in a non-clinical setting. ³Glucosamine is a biologically active molecule that is substrate for proteoglycan, an important constituent of the extracellular cartilage matrix. Evidence supports long-term clinical use of pCGS as SYSADOA in OA to reduce symptoms and improve function. Based on these previous results, the substance may therefore have positive effects on the levels of relevant biological markers for cartilage health. Considering what is known from the mentioned stress test experiments and the *in vitro* test-

ing of pCGS, this interesting concept should now be verified in a clinical surrounding, e.g. by assessing biomarker levels of athletes treated with pCGS during periods of high training intensity.

References

1. Vuolteenaho K, et al. Running a Marathon Induces Changes in Adipokine Levels and in Markers of Cartilage Degradation – Novel Role for Resistin. *PLoS ONE* 2014; 9(10): e110481 (page 1-7)
2. Mündermann A et al. Marathon performance but not BMI affects post-marathon pro-inflammatory and cartilage biomarkers. *Journal of Sports Sciences* 2017; 35:7, 711-718
3. Chiuseroli R, et al. Experimental pharmacology of glucosamine sulfate. *Int J Rheumatol.* 2011; 2011: Article ID 939265, 8 pages

SY9

THE MANY FACES OF RARE BONE DISEASE

C. Cooper¹, C. Roux², M. L. Brandi³, K. Briot⁴, S. Minisola⁵, L. Rejnmark⁶

¹MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ²Paris Descartes University, Paris, France, ³Department of Surgery and Translational Medicine, University of Florence, Florence, Italy, ⁴Department of Rheumatology, Cochin Hospital, Assistance Publique- Hôpitaux de Paris, Paris, France, ⁵Department of Internal Medicine and Medical Disciplines, Sapienza University, Rome, Italy, ⁶Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark

The aim of this interactive, expert-led symposium is for attendees to have an improved knowledge of the role of phosphate wasting in rare bone diseases and an increased confidence in identifying and managing the clinical symptoms of different rare bone diseases.

Early recognition and treatment of rare bone diseases offers the opportunity to improve clinical outcomes and prevent lifelong complications for patients^{1,2}. Although our knowledge of the mechanisms of phosphate wasting disorders causing hypophosphataemia has increased in recent years, recognising the key symptoms of these rare bone diseases remains a challenge in clinical practice³.

During this interactive symposium, a panel of experts will discuss:

- The main regulators of phosphate metabolism, including FGF23, and their role in phosphate wasting disorders
- The key challenges relating to the early recognition, differential diagnosis and treatment options of phosphate wasting disorders
- Presentation of interactive case reports that use examples from clinical practice to illustrate these challenges and approaches to address them

Interactive keypad voting will provide an opportunity for attendees to discuss patient diagnosis and share their opinion on appropriate treatment and management options for different rare bone

diseases. Attendees will also have the chance to engage with the expert faculty in Q&A sessions throughout the symposium and hear leading specialist advice on the optimal management of patients with bone diseases associated with phosphate wasting disorders.

This symposium is sponsored by Kyowa Kirin International plc.

References:

1. Linglart A, et al. *Endocr Connect*. 2014;3:R13–30.
2. Minisola S, et al. *Nat Rev Dis Primers*. 2017;3:17044.
3. Marcucci G, et al. *Osteoporos Int*. 2018;29:2369–87.

SY10

EFFICACY AND TOLERANCE OF PHARMACEUTICAL-GRADE CHONDROITIN SULFATE: WHAT DOES EVIDENCE-BASED MEDICINE SAY?

J.-Y. Reginster^{1,2}, G. Honvo¹, A. Geerinck¹, O. Bruyère¹

¹Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium, ²Chair for Biomarkers and Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia

Objective: To re-assess through systematic reviews and meta-analyses the efficacy and safety of pharmaceutical-grade Chondroitin Sulfate (CS) for the management of osteoarthritis. **Material and methods:** Systematic reviews and meta-analyses where conducted under the auspices of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, to assess the efficacy (746 records identified through database searching) and safety (3815 records identified through database searching) of CS in the management of osteoarthritis. Studies were carefully assessed to identify high risk of bias.

Results: When including all clinical trials, CS showed a significant beneficial effect ($p < 0.001$) for pain and Lequesne index improvement. This effect was confirmed, for both outcomes, when only including studies with low risk of bias ($p < 0.001$). However, when analysing the studies with low risk of bias, based on the CS manufacturer, only pharmaceutical-grade CS showed a beneficial effect on pain (SMD: -0.25; 95% CI: -0.34 - -0.16) and Lequesne index (SMD: -0.33; 95% CI: -0.47 - -0.20) whereas other CS (non-pharmaceutical GRADE) did not show any significant effect on pain or on the Lequesne index. CS was not associated with an increase in the incidence of any adverse event or severe adverse events. When looking at different organ classes, no increase in adverse event was recorded following the intake of CS.

Conclusions: Pharmaceutical-grade CS is a safe and effective medication for the treatment of osteoarthritis. This cannot be extrapolated to other CS (non-pharmaceutical-grade products).

SY11

IS THERE A RESPONDER PROFILE TO PHARMACEUTICAL-GRADE CHONDROITIN SULFATE? AN ANALYSIS OF THE CONCEPT STUDY

O. Bruyère¹

¹Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium

In the CONCEPT study (Reginster J-Y, Dudler J, Blicharski T, et al. *Ann Rheum Dis* 2017;76:1537–1543) 800 mg/day of pharmaceutical-grade Chondroitin Sulfate (CS) was shown to be superior to placebo and similar to celecoxib in reducing pain and improving function over 6 months in patients with symptomatic knee osteoarthritis (OA). We investigate, in the present study, whether a responder profile to CS could be defined, i.e. to determine a patient's profile with the best response to the treatment. Subjects from the CS group of the CONCEPT study were included in the present analysis. Within the CS group, various groups were created based on different categories of age, sex, BMI, Kellgren & Laurence severity, age since OA and baseline level of pain/function. The non-parametric Kruskal-Wallis (KW) test was applied to compare the VAS Pain/Lequesne Index evolutions between groups and the Dwass, Steel, Crichlow-Flinger (DSCF) procedure was used to compute multiple comparisons. The impact of various covariates on the VAS Pain/Lequesne Index evolution was assessed by means of a multiple regression. The probability to respond to CS treatment was significantly associated with the duration between the date of diagnostic and the initiation of the treatment: higher the duration, lower the response both for pain and function, particularly for patients with duration > 10 years as compared to patients with duration < 5 years. A significant effect of the baseline function on the improvement of the Lequesne Index is also observed, with a highest response in patients with the lowest function at baseline. No other criteria have been found to be associated with the response to CS treatment in the CONCEPT study.

SY12

CS PHARMACEUTICAL GRADE AND CS NUTRACEUTICALS HOW FAR ARE THEY?

O. F. Restaino¹, R. Finamore¹, A. Stellavato¹, M. De Rosa², C. Schiraldi¹

¹Department of Experimental Medicine, Section of Biotechnology and Molecular Biology, University of Campania "Luigi Vanvitelli", Napoli, Italy, ²Bioteknet Scpa, Napoli, Italy

Objectives: Chondroitin sulfate is a symptomatic slow-acting molecule recommended by ESCEO for the treatment of osteoarthritis. It is commercialized as pharmaceutical grade product and as food supplement in combination with other components (e.g. methylsulfonylmethane, plant extracts, vitamins, collagen etc.). Food supplements do not need to undergo the strict regulatory controls of pharma grade products, thus composition and the eventual presence of contaminants may not be evidenced before commercialization. Concerns should rise on the biological efficacy of these formulations. In this research a systematic multi-an-

alytical approach was designed to analyse over 25 different food supplements from 8 diverse European countries, in comparison to pharmaceutical grade samples.

Methods: Strong anion exchange chromatography, high performance capillary electrophoresis, size exclusion chromatography coupled to laser scattering detector and finally heterocorrelated NMR technique were used to evaluate: a) content and purity of CS b) presence of Keratan Sulfate (KS) as contaminant c) CS extractive source.

In vitro model based on human chondrocytes and synoviocytes were set up for bioactivity comparison, using time lapse video microscopy, and biomarkers quantifications via western blotting and ELISA assays.

Results: The analytical approach helped in assessing that the CS content in food supplements was lower than expected/declared. In addition KS accounted for up to 30% contamination of CS in food supplements. After the structural analysis, the biological efficacy of 5 food supplements was tested in comparison to pharmaceutical products. The results of an in vitro model on synoviocytes and chondrocytes cells, proved higher cell viability, proliferation and inflammation reduction (NF-kb mediated pathway) by the pharmaceutical products while the food supplements tested were not as effective. A couple of those appeared also cytotoxic.

Conclusions: Assessment of quality and purity of CS, beside the dosage is of key importance to find a robust correlation between treatment and clinical outcomes in OA patients.

References:

- Chevalier X. and Conrozier T. MA@PoC. (2017); 1(1), 134-144.
- Da Cunha A. L., et al. Carbohydr. Polym. (2015); 134, 300-308.
- Restaino O.F., et al. Analytica Chimica Acta (2017); 958:59-70. doi: 10.1016/j.aca.2016.12.005.
- Volpi N. and Maccari F. Quantifood Analytical Methods. (2008); 1(3): 195-204.

Acknowledgments: Bioteknet was supporting the research work, the methods were developed in the framework of PON03PE_00060_3 funded by MiMIUR, Italy.

SY13

NEW INSIGHTS INTO THE MECHANISM OF ACTION OF TERIPARATIDE

E. Eriksen¹

¹Department of Clinical Endocrinology, Morbid Obesity and Preventive Medicine, University Hospital, Oslo, Norway

The current gold-standard for the diagnosis of osteoporosis, dual x-ray absorptiometry (DXA), measures areal projected bone mineral density (aBMD). Besides including projection artifacts, DXA does not allow assessment of the spatial distribution of BMD within the bone or aspects of bone quality, such as trabecular microstructure and matrix mineralization. Although BMD has been shown to be correlated with bone strength, structural and material properties of bone matrix are important factors in determining the mechanical competence of bone. Teriparatide increases bone

mass primarily by increasing bone turnover with greater stimulation of formation than resorption, increases bone modeling on trabecular and cortical surfaces, and improves bone microarchitecture, quality, and strength¹. Studies with teriparatide have shown relatively greater increases in bone formation and bone mass based on biopsies than based on BMD. This observation is especially notable in subjects switched from potent antiresorptive drugs to teriparatide. With removal of old, highly mineralized bone, and replacement with new less fully mineralized bone, transient reductions followed by a delayed increase of aBMD at skeletal sites with predominantly cortical bone have been reported after Teriparatide. We recently carried out an analysis to investigate whether assessment of aBMD adequately reflects changes of mineral and organic matrix content in cortical and trabecular bone determined by Fourier transform infrared imaging (FTIRI), BMD, and quantitative computed tomography following 2 years of teriparatide treatment in postmenopausal women who were previously treatment-naïve or on long-term alendronate therapy². Paired biopsies and aBMD measurements were obtained before and at end of teriparatide treatment from postmenopausal women with osteoporosis who were either alendronate pretreated (mean, 57.5 months) or osteoporosis-treatment naïve.

Micro-computed tomography derived cortical width (Ct.Wi) and trabecular bone volume fraction (BV/TV) increased, accompanied by similar increases in the overall mineral content of their respective bone compartments. Mineral density did not change. Marked increases in the total content of both mineral and organic matrix associated with volumetric growth in both compartments consistently exceeded those of aBMD. Our data indicate that 2 years of teriparatide treatment leads to increased bone organic matrix and mineral content in the iliac crest. The magnitude of these increases in the iliac crest were not, however, detected with conventional aBMD measurements at other skeletal sites. Thus early assessment of aBMD during the early phases of teriparatide therapy will lead to underestimation of bone accrual.

1. Dempster DW et al. J Bone Miner Res (2016); 31:1527-35.
2. Paschalis EP et al. J Bone Miner Res (2018); 33:2230–35. PP-TE-FR-0206 January 2019

SY14

NEW RESULTS OF TERIPARATIDE IN THE TREATMENT OF SEVERE OSTEOPOROSIS

A. Diez-Perez¹

¹Musculoskeletal Research Unit, Hospital del Mar Institute of Medical Research, Barcelona, Spain

Teriparatide, recombinant human parathyroid hormone (1-34), is indicated for treatment of male and postmenopausal severe osteoporosis and for treatment of glucocorticoid-induced osteoporosis patients at high risk for fracture. Clinical trials have demonstrated that teriparatide increases bone mineral density (BMD) and reduces vertebral fracture risk by 65% to 84% and non-vertebral fractures by 53% in postmenopausal women with established osteoporosis.

A recent head-to-head study of postmenopausal women with osteoporosis and spine fractures (VERO trial) showed fewer incident spine and clinical fractures with 20 µg of teriparatide once daily versus 35 mg of oral risedronate¹. During 24 months new vertebral fractures occurred in 28/680 (5.4%) of patients in the teriparatide group and 64/680 (12.0%) patients in the risedronate group (risk ratio 0.44, 95% CI 0.29–0.68; $p < 0.0001$). Clinical fractures occurred in 4.8% in the teriparatide group and 9.8% in the risedronate group (hazard ratio 0.48, 95% CI 0.32–0.74; $p = 0.0009$). Non-vertebral fragility fractures occurred in 4.0% patients in the teriparatide group and 6.1% in the risedronate group (hazard ratio 0.66; 95% CI 0.39–1.10; $p = 0.10$). In a preplanned subgroup analysis of fracture data across subgroups (age, number and severity of prevalent vertebral fractures, prevalent non-vertebral fractures, glucocorticoid use, prior osteoporosis drugs, recent bisphosphonate use), the risk reduction of teriparatide versus risedronate did not significantly differ in any of the subgroup analyzed².

A recent systematic review and individual-level meta-analyses of 23 randomized clinical trials comparing teriparatide to placebo or other anti-osteoporosis drugs in a total of 8644 subjects with osteoporosis in the approved indications for its clinical use, indicate that there is a significant reduction of hip fracture (odds ratio: 0.448, 95% CI 0.22–0.87; $p = 0.019$), and a neutral effect on the pooled upper limb fractures reported³. These results are consistent with the reduction in hip fracture risk with continuous therapy observed in a pool analysis of four real world observational studies in subjects treated with teriparatide⁴.

Collectively, these recent results indicate additional fracture benefit of using an anabolic as compared to an anti-resorptive drug, and they support consideration of teriparatide for the treatment of osteoporosis as a first-line therapy in patients at high risk for osteoporotic fractures.

1. Kendler DL et al. *Lancet* (2018); 391:230–40.
2. Geusens P et al. *J Bone Miner Res* (2018); 33:783–94.
3. Díez-Pérez A et al. *Bone* (2019); 120:1–8.
4. Silverman S et al. *Calcif Tissue Int* (2018); <https://doi.org/10.1007/s00223-018-0485-2> PP-TE-FR-0206 January 2019

SY15 IMPROVING OSTEOPOROSIS CARE – GETTING CLOSER TO THE PATIENT

E. V. McCloskey¹, C. Roux², S. Papapoulos³, L. Borgermans⁴

¹University of Sheffield, Sheffield, United Kingdom, ²Paris Descartes University, Paris, France, ³Leiden University Medical Center, Leiden, The Netherlands, ⁴University of Ghent, Ghent, Belgium

Faculty:

- Professor Eugene McCloskey (University of Sheffield, UK)
- Professor Christian Roux (Paris Descartes University, France)

- Professor Socrates Papapoulos (Leiden University Medical Center, The Netherlands)
- Professor Liesbeth Borgermans (University of Ghent, Belgium)

This educational symposium will be chaired by Professor Eugene McCloskey and Professor Christian Roux.

Professor Socrates Papapoulos will discuss the latest developments in identifying the osteoporosis treatment gaps in elderly women. Information from a recently conducted cross-sectional osteoporosis primary care observational study will be presented.

Professor Eugene McCloskey will explore the utilisation of fracture risk assessments in primary care to optimise identification of the right patient and address the treatment gaps in osteoporosis. Ultimately, this presentation will delve into ways of improving management and treatment of osteoporosis in elderly women.

Professor Liesbeth Borgermans will provide an overview of the current challenges and opportunities faced by primary care physicians in osteoporosis management, with a focus on how to improve patient care. Experience from an osteoporosis treatment protocol currently used in Belgium will be presented.

The symposium will include open discussion time and the audience will be able to ask questions and participate in interactive voting.

Disclosures:

- Eugene McCloskey: Consultant/advisor/speaker fees and research support from AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Servier, Synexus, UCB, Warner Chilcott. Additional research support from ARUK, I3 Innovus, MRC, IOF, Unilever.
- Christian Roux: Speaker fees and/or research grants from Alexion, Amgen, UCB, Ultragenyx.
- Socrates Papapoulos: Consultant/speaker fees from Amgen, Axsome, Gador, Radius Health, UCB.
- Liesbeth Borgermans: Speaker fees from Amgen.



SAVE THE DATE!

14TH INTERNATIONAL CONFERENCE
ON OSTEOGENESIS IMPERFECTA

OI2020

5-8 SEPTEMBER 2020

SHEFFIELD, UK

For further information contact

Nick Bishop (Sheffield, UK)

Local Organising Committee Chair

Email: iccbh@ectsoc.org

Website: www.iccbh.org

www.iccbh.org

bisphosphonates2019

CELEBRATING **50** YEARS

15-17 JULY 2019 • SHEFFIELD, UK



SHEFFIELD TOWN HALL

Dear Colleagues

The year 2019 will mark 50 years since the first publications on the biological effects of the bisphosphonates. Since then more than 27,000 papers have appeared on PubMed! We invite you to join us in Sheffield as we celebrate this golden anniversary. The meeting will review developments over the past 50 years, discuss our current understanding and look at what the future may hold.

The discovery that bisphosphonates could inhibit bone resorption led very quickly to their clinical use in Paget's disease and in patients with skeletal complications of cancer and later in osteoporosis. They remain the major drugs used for these conditions and their use in clinical therapeutics is likely to continue well into the future.


Sheffield is England's 5th largest city, and with its two universities has been voted the UK's most popular student destination. It has a vibrant and diverse social scene, and at the same time is one of the UK's greenest cities, with one third of the city lying within the Peak District National Park. Transport links are good and there is a choice of international airports within an hour of the city.

We hope to welcome you to Sheffield in July

Richard Eastell & Graham Russell (*Meeting Chairs*)

Register now at www.bisphosphonates2019.org

For more information contact Janet Crompton, *Meeting Organiser*,
info@bisphosphonates2019.org



Organising Committee

CO-CHAIRS:

Richard Eastell (*Sheffield, UK*)

Graham Russell (*Oxford and Sheffield, UK*)

Nick Bishop (*Sheffield, UK*)

Janet Brown (*Sheffield, UK*)

Philippe Clézardin (*Lyon, France & Sheffield, UK*)

Rob Coleman (*Sheffield, UK*)

Steve Cummings (*San Francisco, USA*)

Hal Ebetino (*Rochester, USA*)

Erik Eriksen (*Oslo, Norway*)

Allie Gartland (*Sheffield, UK*)

Peyman Hadji (*Frankfurt, Germany*)

Ingunn Holen (*Sheffield, UK*)

Bente Langdahl (*Aarhus, Denmark*)

Shelly Lawson (*Sheffield, UK*)

Eugene McCloskey (*Sheffield, UK*)

Socrates Papapoulos (*Leiden, The Netherlands*)

Stuart Ralston (*Edinburgh, UK*)

Ian Reid (*Auckland, New Zealand*)

Mike Rogers (*Sydney, Australia*)

bisphosphonates2019

in association with
the Mellanby Centre,
University of Sheffield





2019 PARIS

WORLD CONGRESS ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL DISEASES

PARIS, France | 2019

Abstract Book

Author Index

Abarca B.	P684	Ahn Y.	P295
Abate E.	P1153	Aier S.	P1032
Abaza N.	P164	Aikten D.	P823
Abdala R.	P1027, P1111	Aitken A. D.	P172
Abdalla A. M.	P1136	Aitken D.	OC32, P117, P179, P820
Abdel Hamid A. I.	P158	Aitken D. A.	P815
Abdelrahman F.	P773	Aivaliotis I.	P560
Abdelrahman F. I.	P1136	Akarirmak U.	P447, P451
Abdi S.	P218, P220, P395, P491	Åkesson K.	P1029, P1090, P1102
Abdulatif S. A.	P503	Akhtyamov I.	P749
Abdulbari A.	P402	Akhtyamov I. F.	P354
Abdulsattar A.	P773	Akhverdyan Y.	P210, P384, P424, P1001
Abo Elmagd A.	P158	Akhverdyan Y. R.	P371, P566
Abrahamsen B.	NS1, OC6, OC8, ESCEO-IOF-WHOCC1, P586	Akimova A. V.	P896
Abutiban F.	P325	Akpagbula D.	P207
Acharya K. V.	P1032	Akpagbula D. U.	P1162
Acosta Rueda J.	P949	Aksenova T.	P634, P656, P771
Adachi J. D.	MTE4, NS35, P249, P409, P441, P548	Al Attia H. M.	P109, P152, P204
Adamcová M.	P1013	Al Jarallah K.	P230
Adamenka A.	P885	Al Saedi A. A.	P308
Adamkovicova M.	P662	Al-Ali N.	P325
Adarnli S.	P600	Al-Amro A.	P395
Adib G.	P590	Al-Ashkar A.	P216
Adil M.	P760	Al-Daghri N.	NS8, P218, P219, P220, P491, P523
Adlakha R.	P931	Al-Disi D.	P218
Adriana A.	P1024	Al-Enezi S.	P325
Afonso M. P.	P495	Al-Jarki F.	P325
Agachev Y. U.	P592	Al-Kandari S.	P325
Agachi S.	P1099	Al-Obaid A.	P325
Agarkova O.	NS25	Al-Rubaye D.	P931
Agarwal R. A.	P983	Al-Saleh Y.	NS10
Aggarwal S.	P990, P1064	Alaa Eldin Ahmed Saad A.	P216
Aghi A.	P594	Alalawi Y. A.	P649
Agnusdei D.	P573	Alaskar A.	P491
Agostino R. M.	P713	Albala C.	P1098
Agrawal S.	OC13	Albanell J.	P521
Agres A.	P1015	Albano D.	P129, P1006
Agrhum A.	NS30	Albergaria B.-H.	NS46
Agrhum Working Group A.	NS32, NS33	Albu C.	P846, P856, P859
Agricola R.	P777, P780	Albu S.	P1144
Aguiar F.	P924	Albuisson E.	P277
Aguilar A.	P121	Albulescu D. M.	P7829, P831, P834, P835, P836, P838, P840, P844, P847, P850, P852
Aguilar G.	P775	Aldaghri N.	P395
Aguirre Etxebarria A.	P114, P241	Aldinucci A.	P700
Agwu- Umahi O. R.	P1162	Alehnovich L.	P883, P1016
Agwu-Umahi O.	P207	Alekhina I. Y.	P732, P986
Ahedi H.	P777, P780	Alekna V.	P806, P811, P1061, P1065, P1094
Ahijado Guzmán M. D. P.	P284, P362	Aleksandrov A.	P906
Ahmaidi S.	P558	Aleksandrov A. V.	P732, P738, P740, P986, P1079
Ahmed F.	P585		
Ahmed M. K.	P402		

Aleksandrov N. O.	P796	Andriopoulos I.	P556
Aleksandrov V. A.	P732, P738, P740, P986, P1079	Andrusha A. B.	P346
Aleksandrova N. V.	P732, P738, P740, P986, P1079	Angel B.	P1098
Alekseeva L.	P403, P1085	Angelopoulos V.	P406, P438, P696, P1092
Alekseeva L. I.	P741, P750	Anghel D.	P410
Aleksic I.	P502	Angulo Tabernero M.	P135
Aleksic J.	P209, P304, P533	Anikin S. G.	P741
Aleshkevich A.	P1127	Annar D.	P257, P258, P692
Alessa T.	P325	Annweiler C.	P875, P902
Alexandre dos Santos E.	P588	Anoshenkova O. N.	P871
Alexandrou A.	P971	Ansari M. G.	P218, P220
Alexandru D. O.	P265, P286	Anthony P.	P428
Alexe M.	P890	Antinolfi P. L.	P1138
Algun C.	P273	Antón Torres A.	P504
Alharbi F.	P395	Antonic B.	P322
Alhijili F. A. A.	P329	Antoniou A.	P971, P1147
Ali A. M.	P248, P364, P398	Antonopoulos D.	P302
Alimzhanova E.	P1100	Antonopoulou V.	P902
Aljohani N.	P218, P220	Antony B.	P429, P430
Allande M. J.	P884	Antony B. E.	P820
Alliot-Launois F.	P515	Antoun A.	P450
Almohaya M.	P415	Antropik E.	P1094
Almstedt H. C.	P744, P747	Aouinti S.	P575
Alnaami A.	P219	Apaydin T.	P1010
Alokail M.	NS9, P219, P220	Appannah G.	P297, P299, P729
Aloumanis K.	P165	Arab F.	P476
Alpantaki K.	P176, P177	Aramburu F.	P367, P516
Altuntaş Y.	P753	Arapova S.	P746
Alvarenga M. S.	P1023	Araújo Martini L.	P588
Alvarez M.	P489	Aravantinos L.	P971
Álvarez-Raigoza K.	P980	Arbex M. C. F.	P928, P956, P977
Alves J. A. P.	P928, P956, P977	Arbiv M.	P291
Alzahrani J.	P548	Archana A.	P631
Amer O.	P218, P220	Ardashev S.	P749
Amin R. M.	P709	Arden N.	PL3, P180, P754
Amin S.	P674	Arden N. K.	P376
Amininezhad F.	P845	Aref'Eva L.	P425
Amir R.	P236, P262	Ariani A.	P961
Ammann P.	P1000, P1002	Arinze-Onyia S.	P207
Amreyeva Z.	P1100	Arioli G.	P812
An Ki Yong K. Y.	P374	Arisah U.	P903
An W.	P253	Armeni E.	P971, P1147
Anastasilakis A.	P243	Armstrong C.	P1020, P1035
Ancuta I.	P1112	Aro E. J.	P1005
Anderson A.	P1154	Aro H. T.	P1005
Anderson K.	P965	Arroyo P.	P1098
Anderson K. B.	P671	Arzaghi M.	P724, P878
Anderson S.	P226	Asada Y.	P577, P624
Ando-Kondo M.	P283	Asao Y.	P244
Andreeva A.	P703	Asllanaj E.	P1059
Andreeva A. T.	P381, P1095	Aspelund T. H.	P1116
Andrews E.	P1154	Astrakhantsev D.	P803

Astrup A.	SL1	Bajuifer S. J. B.	P329
Atamanova E.	P215	Bakhtin V. M.	P752, OCs6
Athanassiou L.	P1070, P1075, P1080, P1141, P1146, P1149	Bakhtiyarova A.	P703
Athanassiou P.	P1028, P1070, P1075, P1080, P1141, P1146, P1149	Bakos B.	P162
Atkinson E. J.	P674	Bal A.	P1083
Au I. L. Y.	P490	Balan B.	P1119
Aubertin-Leheudre M.	MTE14, NS66	Baleanu B.	P365
Aubry-Rozier B.	P1041, P1056, P1066	Balenović A.	P913
Augoulea A.	P971, P1147	Ball P.	P608, P722
Aung M. W.	P868	Balogun S.	OC32
Aurelian J.	P271	Balseanu A.	P484
Aurelian S. M.	P271	Baltin M.	P734, P736
Avdeeva K.	P187	Baltina T.	P592, P734, P736
Avdic D.	P678	Bancsik K.	P313, P315, P316
Averkiewa J.	P828	Banfi G.	P580
Avila V.	P978	Banica T.	P419
Avouac B.	P180	Bannuru R.	P651
Aye M.	P868	Bannuru R. R.	P754
Aykent M. B.	P1025	Bansal A.	P709
Ayumu K.	P555	Bansal B.	P477
Azharuddin M.	P760	Bansback N.	P774
Aziz K. T.	P709, P710, P712, P716, P1151	Bañuelos Díaz A. B. D.	P246
Azizieh F.	P230	Baptiston Tanaka C.	P1165
Aznar A.	P950	Baraf L.	P759
Babak G.	P681	Barahona-Correa J.	P975
Babalyan V.	P764	Barakat E. B.	P503
Babkov B.	P935, P1108	Baranov A.	P735
Babosova R.	P641	Baranova I.	P568, P571, P661
Babykina G.	OC16	Barbarash O.	P819, P824, P832
Baccouche K.	P940	Barbieri A.	P961
Bacevic S.	P1171	Barbosa A. P.	P1044
Bachiller J.	P1156	Barbu C.	P762
Backa T.	P1050	Barbu C. G.	P1131
Badarinza M.	P1119	Barbulescu A.	P1039, P1062
Badea I.-A.	P225	Barbulescu A. L.	P1046, P1047, P1115, P1122
Badokin V. V.	P354	Barceló-Bru M.	P526
Badoud I.	P1000, P1002	Bardesono F.	P630, P636
Badrkhahan Z.	P724, P878	Barışık C. C.	P274
Bae K. H.	P537	Barker K.	P376
Bagcaci S.	P140	Baron E.	P413
Baghdasaryan S.	P764	Barone L.	P961
Bagher L.	P724	Baroni M.	P1138, P1142
Baglioni G.	P1142	Barral M.	P670
Bahat G.	P348, P660, P663, P891, P1025, P1026, P1031, P1082, P1132	Barroga C.	P226
Bahat Ozturk G.	P408	Bartlett J.	P351
Bahaz N.	P914, P923, P926, P930, P936	Barulin A.	NS23, P993
Baird J.	ESCE04	Barysenka T. D.	P882, P883, P1016
Bajaj D. R.	P787	Basaric M.	P287, P485
Bajalska A.	P231, P238, P239	Baselga S.	P296
Bajraktarova Prosheva T. B. P.	P510	Baskakova R.	P789
		Bassam R.	P219
		Bat-El B.	P174, P181, P183

Bataille S.	P141	Bernetti A.	P512
Bataiosu M.	P838, P840	Berro A.-J.	P558
Batalov A.	P331	Bertalan Z.	P587, P673
Bauer D.	P323	Bertholon D. R.	P515
Bauer E.	P277	Besli O.	P447, P451
Bauer J.	P539, EUGMS-ESCEO-IOF3, ESCEO9, ESCEO10, ESCEO-WHOCC1, ESCEO-WHOCC2	Best M. J.	P709, P710, P712, P716, P1151
Beattie R.	P160	Bestaoui H.	P909
Beauchamp A.	P534, P999	Betancourt J.	P576
Beaudart C.	MTE14, OC24, OC28, P153, P154, P201, P542, P688, P693, P1065, ESCEO9, ESCEO10, OCs1	Bevilacqua G.	P439
Becerra-Fernandez E.	P367	Bezerra Junior P. E.	P772, P1145
Becker C.	P539	Bezerra L. B.	P1145
Bedina S.	P544, P794	Bezrudnaya N. V.	P796
Bedina S. A.	P479, P617, P621	Bhadada S.	P1064, P1083
Beek K. J.	P543	Bhadada S. K.	P990
Beerhorst K.	P895	Bhargava S. K.	P932, OCs9
Behets C.	P669	Bhattoa H. P.	NS17
Bejia I.	P849	Bianchi G.	P812, P893
Bekele D. I.	P674	Bibas M.	P625, P679, P684
Belaya Z.	P294, P559, P1076, P1101	Bieber B.	P594
Belaya Z. E.	P796	Bierma-Zeinstra S.	P777, P780
Belinski Opris D.	P394	Bighea A.	P856, P859, P1009, P1014, P1017
Bell J.	OC25	Bighea A. C.	P448, P449, P809, P873, P1055
Bellone F.	P713, P715, P717	Bijedić A.	P531
Belousova I. B.	P871	Bilen H.	P753
Belousova L. V.	P381	Bilezikian J. P.	OC4
Belova K.	P723, P733, P735	Bilezikian P.	P764
Belova K. Y.	P796, P871	Bilgic P.	P1021
Beltrami G.	P700	Billis E.	P506, P867, P1105
Beltsevich D.	P743	Bilous A. D.	P1117
Ben Bouallègue F.	P575	Binkley N.	OC18, P252
Ben-Shlomo N.	P332, P464	Bintas S.	P165
Benabdoun H. B.	P1157	Bitzidis A.	P380, P388, P399, P603
Benamara S.	P473	Bitzidou C.	P388, P399
Benderdour M.	P1157	Biver E.	MTE12, OC22, ESCEO10, ESCEO-IOF-SFR-GRIO1
Benetti-Pinto C. L.	P911, P982	Bjelobrck M.	P122
Bengana B.	P914, P923, P926, P930, P936	Blagden M.	P997
Benoit B.	P557	Blain H.	P515
Benzinger P.	P539	Blanco Cáceres B. A.	P1137
Berdes A.	P935, P1108	Blanco J. A.	P132
Berg G.	P676	Blanco J. M.	P440, P508, P884, P1150
Bergaoui N.	P849	Blank L. M.	P813
Berghea F.	P394	Blaslov K.	P913
Bergmann B.	P365	Blazekovic I.	P929
Bergthaler M.	P685	Blennerhassett J.	P960
Beringer T. R. O.	P349	Blizzard L.	P777, P780
Berkvens J. J. L.	P895	Blizzrad B. L.	P172
Bermejo-Bescós P.	P561	Blount K.	P1152
		Bludov A. B.	P813
		Bobak M.	P469
		Boccardi V.	P1138, P1142
		Bochis C.	P635, P642

Bodnar R.	P898	Bowe S. J.	OC13
Bodnar Y.	P898	Boyadzhieva V.	P805, P821
Body B.	P365	Boyd R.	P573
Body J. -J.	P173	Bozilov S.	P763
Bodzsar E.	P257, P258, P692	Bradács A.	P379
Böezennec B.	P579	Brady R.	P968
Bogaerts S.	NS5	Braga M.	P649
Bogdanovic B. G.	P444	Braganca Rodrigues I.	OC15
Bogini A. R.	P1142	Braima K.	P915
Bohács A.	P945	Bramble L. F.	P747
Bojinca M.	P394, P1112	Brance L.	P1011
Bojnec V.	P1037, P1077	Brance M. L.	P646, P647, P648
Bokan Mirković V.	P549	Branco J. C.	P1134
Bokan-Mirkovic V.	P602	Brandi M. L.	MTE6, P182, P294, P594, P700, P812, P893, P1033, P1091, SY9
BoľShakov P.	P734	Branea O.-E.	P1045
Bolognese M. A.	OC3	Brennan-Olsen S.	
Bonacin Neto A.	P959	Brennan-Olsen S. L.	OC13, P534, P650, P999
Bonacordi C. L.	P982	Brennan-Speranza T. C.	P1165, P1169
Bondar T.	P1127	Breville P.	NS31
Bondarenko E. A.	P609	Briganti S. I.	P432
Bonnet C.	P515	Briones-Figueroa A.	P766
Boonen A.	P697	Briot K.	SY9
Borcan M.	P846, P856, P859, P861, P877	Brito I.	P924
Borda I. M.	P1159	Brito N. L. R.	P768
Borgermans L.	SY15	Brkljacic B.	P150
Borges J.	P303, P306	Brock K.	P416
Borges J. B.	P300	Brock K. E.	P1169
Borgström F.	P998	Brodie E.	P527
Bori E.	P941	Broseta J. J.	P358
Boriskova M.	P703	Brown J. P.	OC3
Borman P.	P1021	Brun L.	P775, P976
Borovskikh M. D.	P638	Brunetti G.	P123
Bors K.	P953	Brunova J.	P589
Bortolasci C. C.	P650	Brutskaya-Stempkovskaya E. V.	P341
Bosak Butkovic M.	P912, P929	Bruyère O.	MTE14, NS12, OC21, OC24, OC26, OC28, OC33, P141, P153, P154, P180, P201, P470, P517, P542, P688, P689, P693, P754, SY10, SY11, ESCE04, ESCE06, ESCE09, ESCE010, OCs1
Bosco D.	P186	Bubba V.	P1138, P1142
Bose J. C.	P990	Buchbinder R.	P999
Bosic M.	P748	Büchele G.	P539
Boskovic K.	P335, P436, P583	Buchon D.	P515
Bošković K.	P1118	Buckinx F.	NS67, OC26, P141, P470, P542
Bossard C.	P226	Buehring B.	NS63, P252
Bostina C.	P856, P859, P861, P877	Buhas C.	P480
Botto-Van Bemden A.	P625, P679	Buhlova A.	P883
Bouajina E.	P940	Buksman S.	P730
Bouchonville I. M.	P527	Bumbea A. M.	P387, P389, P391, P392, P446, P846, P856, P859, P877
Bouhedja N.	P532		
Boukabous A.	P914, P923, P926, P930, P936		
Boulenouar H.	P206		
Bourassa V.	P1043		
Bourke A.	OC27		
Bourque M.	P778, P857		
Bours S.	P697		

Bumbea B. S.	P846, P859, P861, P877	Capanna R.	P700
Bungau S.	P635, P642	Caparbo V.	P426
Buonomenna C.	P129	Capisizu A.	P271
Burada F.	P484	Capus A. M.	P312, P317, P318
Burianov O.	P298	Caraffa A.	P1138
Burkard T.	P701	Cardinal M.	P669
Burkard T. S.	OC27	Carey J. J.	P1020, P1035
Burmistrova D. A.	P1095	Cariou B.	P1007
Burn E.	OC27	Carlier M.-C.	P1007
Burr D.	P1063	Carmo S. N.	P928, P956, P977
Bursuc R.	P410	Carné X.	P684
Burtey S.	P141	Caron V.	P705
Burton S.	P443	Carpenter T.	OC5
Bustabad S.	P950	Carr A.	P376
Busuioc E.	P410	Carr W.	NS19
Butilca D.	P1103	Carratu' M. R.	P1004
Butler K.	P127	Carrera D.	P342
Butler P. W.	OC18, P409	Carsote M.	P1126, P1128, P1130, P1133, P1135, P1140, P1144
Buturoiu M.	P762	Carsten C.	P954
Butvyn S. M.	P454	Carter S.	P433
Bycova S.	P187	Cartocci M.	P303
Bystrytska M.	P1040	Cartucci M. C.	P300
Byun S.-E.	P195	Carvalho A.	P300, P303, P306
C. Thambiah S.	P729	Carvalho L. B.	P982
Cabello Santos C.	NS16	Casademont J.	P576
Cabrera-Alarcon J. L.	P281, P516	Casado E.	P881
Cadet C.	NS30	Casajoana A.	P551
Caffarelli C.	P812, P893, P894, P905	Casciaro S.	P893
Cahiwat J.	P226	Casey M. C.	P916, P917
Cai G.	P427	Casillas-Espinosa P.	P968
Caimac D. V.	P846, P856, P859, P861, P877	Casini A.	P432
Caironi G.	P1138	Casso D.	P1154
Calders P.	P419	Castagné B.	P670
Calina D.	P484, P494	Castellitto D.	P432
Calis F.	NS55	Castiglioni C.	P630, P636
Callaghan P.	P785, P788	Castrejón-Delgado L.	P1096
Calvo Aranda E.	P1123	Castro Sauras A.	P133, P134, P197
Calvo E.	P516	Catalano A.	P713, P715, P717
Calvo I.	P440, P508, P884, P1150	Cauley J.	P783
Camargos B.	P185	Cauley J. A.	OC38
Camarillo Romero E.	P242	Cavalier E.	NS18, P141, P201, P675, P677, P680, ESCEO-IOF-SFR-GRIO4
Camarillo Romero M.	P242	Cavalli L.	P812, P893
Camén A.	P841, P844, P847, P850, P852	Cavalli L.	P1091
Camerino C.	P1004	Cawthon P. M.	OC23
Cameron I.	P548	Cazac V.	P498, P513
Campanacci D. A.	P700	Cazares Montiel D.	P721
Campesino Nieto S. C. N.	P786	Celemin C.	P1148
Campillo F.	P597	Celestino Zanabria C.	P242
Cantalejo Moreira M.	P284	Center J.	P654
Cantrell D. C.	P309	Center J. R.	P217
Canturk Z.	P753	Cerdà D.	P576
Capan N.	P348		

Cerinic M. M.	P812	Chen Y.-T.	P500
Cernovas A.	P806	Cheng C. K. J.	P866
Cervo M. M.	OC32	Cheng Q.	P361
Cesareo R.	P123, P186, P432	Cheng X.	P213, P221, P1170
Cesari M.	P542	Cheong H.	P428
Cevei M.	OCs11, P666, P1067	Chepesiuk R.	OC15
Cevei M. L.	P711, P714, P765, P925	Cheraghi Z.	P1003
Chaine C.	P880	Cherkashina I. V.	P732
Chakhtoura M.	P783	Cherkasov A.	P904, P935, P1108
Chalem M.	NS60, P1143	Chernov P.	P1053
Chalès G.	P515	Chernova T.	P1101
Chamoun N.	P783	Chernovol T.	P904
Chan A. C. M.	P490	Chesnikova E. I.	P507
Chan D.-C.	P355, P658	Cheung M. Y.	P155
Chan W. K. J.	P866	Cheung P. C.	P423
Chan W. L. D.	P490	Cheung W. H.	P1161
Chan Y. L.	P324	Cheverda A.	P372
Chandran M.	P554, OCs3	Chi Dae C. K.	P967
Chang C.	P151	Chi P. J.	P478
Chang C. S.	P870, OCs8	Chiali S.	P909
Chang C.-H.	P536	Chicea L.	P939
Chang H.-R.	P782, P1049	Chien J.-T.	P782, P1049
Chang J.	P345	Chien L.-N.	P658
Chang J.-K.	P497	Chin W.-L.	P437
Chang L.-H.	P497	Chines A.	P411
Chang Y.	P536	Chingayeva G.	P1100
Chang Y. F.	P870, OCs8	Chisalau A. B.	P1115
Chanpoo M.	P788	Chisalau B. A.	P1039, P1046, P1047, P1122
Chantelot C.	P632	Chislari L.	P498, P513
Chapurlat R.	MTE10, P229, P639, P689, P670	Chiu K.	P226
Chapurok D.	P969	Cho D. H.	P501
Charles A.	OC26, P180, P470	Chodick G.	OC10, P991, P994
Charlez Marco A.	P135	Choi E. Y.	P1042
Chary-Valckenaere I.	P277	Choi K. H.	P359
Chatzellis E.	P626	Choi S.-H.	P193
Chatziravdeli V.	P1120	Choi Y. J.	P200
Chau C.	P515	Chotiyarnwong P.	P356
Chau Y. T.	P115	Chou L.-Y.	P637
Chaves P.	P306	Chou Y.	P637
Chawla L.	P1072	Chouhan D. K.	P1083
Che Ahmad Tantowi N. A.	P1139	Chow S. K. H.	P1161
Chen B.	P163	Christensson A.	P1102
Chen C. Y.	P324	Chrousos G.	P270
Chen C.-H.	P497, P500, P637	Chrysanthakopoulou D.	P599
Chen C.-Y.	P428	Chua D.	P293
Chen F.-H.	P360	Chubb P.	P960
Chen H. W.	P1172	Chui K. H. T.	P178
Chen I. H.	P1172	Chung C. P.	P799
Chen J. F.	P842	Chung D. J.	P501
Chen L.-K.	NS64	Chung J. O.	P501
Chen M.	P217	Chung K. Y.	P728, P739
Chen M.-F.	P536	Chung Y. S.	P200

Chung Y. W.	P374	Confavreux C.	P1007
Churilov I.	P416	Connacher S.	P466
Churilov L.	P416	Connaughton C.	P534
Cianferotti * L.	P812, P893	Constantinovici M. I.	P1106
Cianferotti L.	P1033	Conte E.	P1004
Ciavoi G.	P1024	Conversano F.	P812, P893
Cibere J.	P774	Conviser J.	P142
Čičkušić A.	P531	Cook M. M.	P747
Ciccuttini C. F.	P172	Cooper C.	SL2, OC6, OC14, OC23, OC25, OC30, OC38, PL8, P127, P180, P320, P363, P376, P422, P433, P439, P452, P455, P471, P523, P546, P586, P601, P677, P689, P698, P754, P801, P1090, SY9, ESCEO3, ESCEO4, ESCEO7, ESCEO9, OCs4
Ciccuttini F.	P429, P430, P777, P780, P823, P826, P839	Copotoiu M.	P1045, P1097
Cimms T.	OC5	Coppola C.	P573
Cioara F.	P261, P310, P311, P312, P313, P314, P315, P316, P317, P318, P353, P379, P480, P499, P635, P642, P666, P711	Corazza A.	P1006
Ciofu C.	P1112	Corbetta S.	P580
Ciortea V.	P1159	Corcoran P.	P778
Cisari C.	P342	Corella E.	P121
Ciurea P.	P888, P1115, P1129	Cornelissen D.	P697
Ciurea P. L.	P387, P389, P390, P391, P392, P393, P492, P494, P920, P1034, P1039, P1046, P1047, P1062, P1084, P1122	Corominas H.	P576
Cladovan C.	P379	Coronel P.	P208
Clantau D.	P937	Corp N.	ESCEO4
Clantau D. M.	P1106	Correia T. C.	P1023
Clantau M. D.	P540	Cortet B.	OC16, P515, P579, P632, P798, ESCEO-IOF-SFR-GRIO6
Clapauch R.	P730	Cortina Borja M.	P979
Clark P.	P411, P767, P979, P1096	Cosman F.	OC9, P1089
Claros K.	P966	Costa M.	NS39
Claustrat B.	P229	Costanzo P. R.	P976
Clegg P.	P640	Coste J.	P615
Cleminson J.	P985	Costello R. E.	OC27
Cleva R.	P426	Cotrau P.	P311, P312, P314
Clunie G.	P927	Courtney C.	P548
Clynes M.	P601, OCs4	Coussens M.	P419
Clynes M. A.	P439, P452, P455	Covei A.	P829, P831, P834, P835, P836
Cochet C.	P515	Cowdery S.	P652
Cockill C.	P927	Coy Barrera A. F.	P973
Codreanu C.	P394	Cozma I.	P1117
Cohen S.	P731	Crandall C.	P320
Cojocar M.	P829, P841, P844, P847, P850, P852	Crandall J.	OC1
Čokolič M.	P366	Crespo C. L.	P1134
Colaanni G.	P123	Crittenden D. B.	OC9, OC18, P411
Cole B.	P651	Criveanu C.	P390, P391, P392, P393, P888, P920, P1034, P1039, P1046, P1047, P1062, P1115, P1122, P1129
Cole Z. A.	P546	Croisier J.-L.	NS6, P153, OCs1
Collier F.	P985	Cross M.	P429, P430
Colucci S.	P123	Crozier S. R.	P546, P801
Comanducci C.	P1138		
Comisel S.	P829, P831, P834, P835, P836		
Conaghan P. G.	P754, ESCEO4		

Cruz-Jentoft A. J.	P561, P567, EUGMS-ESCEO-IOF1, ESCEO9, ESCEO10, ESCEO-WHOCC2	De Camargo O. P.	P768, P769, P770
Cruz-Medina E.	P761	De Farias F. E. S.	P770
Csiszér E.	P945	De França N.	P535, P737
Csupor E.	P953	De Jesus J.	P1152
Cuc A.	P1024	De Rezende M. U.	P768, P769, P770
Cuende E.	P440, P508, P884, P1150	De Rosa M.	SY12
Cueva Tovar K.	P719	De Ross B.	OC20, P989
Cuko G.	P949	De Sire A.	P342
Culliford D. J.	OC27	De Vil J.	P496
Cummings S. R.	OC29	De Vries F.	P128
Curtis E. M.	OC25, P180, P455, P546, ESCEO4	De Wandele I.	P419
D'Amelio P.	P918	Deamond H.	P1043
D'Andrea F.	P342	Debbah S.	P923, P930
D'Angelo S.	P546	Dedeyne L.	P686, P687, P690
D'Antico S.	P792	Dedov I.	P1076
D'Arrigo G.	P594	Deev A.	P407
D'Este C.	OC13	Degtiarev V. K.	P738
D'Onofrio L.	P432	Deinite G.	P396
Da Silva C. A. C.	P770	Del Río Barquero L.	P646, P647, P648
Dabir D. V.	P747	Del Rio L.	P1011
Dada R. D.	P983	Del Valle E.	P1111
Dadra A.	P1064	Delabrière I.	P632
Dagher H.	P783	Delalić A.	P531
Daina C. M.	P310, P312, P315, P316, P317, P318, P480	Delanaye P.	P141
Daina L. G.	P261, P310, P311, P312, P313, P314, P315, P316, P317, P318, P379, P480	Deligeoroglou E.	P971
Dalibayeva G.	P865	Delisle J.	P557
Dalto J.	P1111	Dellamary L.	P226
Daly R. M.	OC20, P989	Delmestri A.	OC6, OC27, P422, P586, P698
Damjanov N.	P287	Demin N.	P582
Damner A.	P642	Demyan Y.	P372
Danilowicz K.	P699	Denderen J. C.	P543
Dantas W. S.	P426	Deniz F. D.	P169
Dardavesis T.	P1080	Dennison E. M.	OC14, OC30, OC38, P363, P433, P439, P452, P455, P471, P546, P601, ESCEO1, ESCEO4, OCs4
Dardavessis T.	P1068, P1088	Derevyanko O.	P900
Dardenne N.	P688	Deseatnicova E.	P1099
Darvishian N.	P476	Deshmukh V.	P226
Darwin Junior W.	P1145	Detilleux J.	OC33
Dascalu I. T.	P835, P838, P840	Devanne H.	P563
Davidson A.	P181	Devetzi E.	P1070, P1075, P1146
Davie P.	P443	Dhaliwal R.	P990
Davtyan D.	P559	Dharancy S.	P798
Dawson-Hughes B.	P567, PL9, SY2	Dhiman V.	P990
Dayana D.	P759	Di Gregorio S.	P646, P647, P648, P1011
Dazai M.	P119	Di Monaco M.	P630, P636
De Abajo F.	P625, P679	Di Paola * M.	P812
De Blas I. D. B.	P246	Di Tommaso A. M.	P186
De Bont J.	P127	Diakova M.	P904
		Diaremes P.	P1092, P1105
		Diaz A.	P343
		Díaz A. G.	P699
		Diaz-Curiel M.	P296

Diaz-Escobar L.	P767	Duarte-Salles T.	OC27, P127
Didier H.	P775	Duda G.	P954, P1015
Dies Perez A.	P521	Dudkina A. A.	P623
Diez-Perez A.	P518, P653, P671, P795, SY14	Dumić-Čule I.	P150, P282, P913
Difrancesco A.	OC37	Dumitrache C.	P1133, P1135, P1140, P1144
Dilmanova D.	P305, P869	Dumitrascu A.	P1133
Dimai H. P.	P587, P673, P685	Dumitrascu R. M.	P1046, P1047, P1115, P1122, P1129
Dimitreva A. E.	P813	Dupont J.	P686, P687, P690
Dimitriadis Z.	P506	Dupuy C.	ESCEO9
Dimitrijevic I.	P922, P933	Duque G.	NS62, P534
Dina D.	P902	Duque G. D.	P308
Dinavahi R.	P659	Duranti G.	P1142
Dincer C.	P1010	Durieux N.	OC24
Dincer F.	ESPRM-ESCEO-IOF1	Durmazoglu S.	P1025
Dinescu S. C.	P1039, P1046, P1047, P1062, P1115, P1122, P1129	Dursun E.	P875, P902
Ding C.	P345, P429, P430	Dutta D.	P553
Ding D. C.-H.	P172	Dwyer T.	P429, P430
Ding J. M.	P417, P418, P607	Dydykina I.	P633
Dionysiotis Y.	P1028	Dydykina I. S.	P750
Dirksen C.	P697	Dydyshka Y.	P357, P725, P827
Ditto M. C.	P792	Dydyshka Y. V.	P341
Dixit V.	P475	Dyomin N. V.	P750
Djekic-Ivankovic M.	OC15	Dzeranova L.	P745, P746
Djekoune M.	P930	Dzubur-Aganovic M.	P678
Djennane M.	P191, P192	Eakin G.	P625, P679
Dobre R.	P529	Eastell R.	OC29, P677
Dobрева E.	P435	Ebeling P. R.	OC9, OC12, OC32, PL2, P411, P657, P932, P942, P1051, P1089, OCs9
Dobrovol'skaya O.	P633	Ebrahimput M.	P845
Dobrovol'skaya O. V.	P796	Eckert R.	P466
Docea A. O.	P484	Eckstein F.	P429, P815
Dogan Y.	P1021	Edwards M. H.	OC14, P452
Dolidze N.	P202, P235	Edwards N. M.	P1022
Dolzhenkova E. A.	P813	Eftimov M.	P541, P578, P616
Domingues L.	P1134	Eick G.	OC13
Dominguez J.	P966	Eiki S.	P555
Dominguez Pascual I.	P462, P463	Einbinder Y.	P528
Dong S. S.	P417, P418, P607	Eiriksdottir G.	P1116
Doori P.	P301	Eisman J.	P654
Dorochin V.	P897	Eisman J. A.	P217
Dorochina K.	P886	Eissa M.	P742
Doskaliuk B.	P275, P276	Ekbote V.	P932, OCs9
Douglas I.	P698	Ekinci E. I.	P416
Dreiser R.-L.	P837	El Achek M. A.	P849, P940
Drelichman G.	P775	El Amri N.	P940
Dresner-Pollak R.	P825	El Gaafary M.	P742
Dreval A. V.	P796	El Hage R.	P450, P558, P563
Drici Z.	P909	El Hajj Fuleihan G.	P783
Driessen J. H.	P128	El Miedany Y.	P742
Drossinos V.	P165	El O.	NS53
Drushlyakova A.	P993	El-Shafei T. M.	P472
Du Souich P.	P625, P679		
Duarte J. A.	P234		

El-Werfalli R.	P649	Evdokimova A. M.	P695
Elaroussy N.	P742	Evensen E.	P505
Elashmawey A.	P326	Evers S.	P697
Elbasan O.	P863, P1010	Eymard F.	ESCEO-IOF-SFR-GRIO3
Elbeialy A.	P254	Ezeofor S.	P207
Elderiny G.	P742	Ezeofor S. N.	P1162, P1163
Eldesouky H.	P254	Fabbri A.	P432
Elez J.	P209, P304	Fabbri S.	P1033
Elfayoumi G. E.	P503	Fabre B.	P699
Elganzoury A.	P164	Fabri A.	P1149
Elhadary H. M.	P138, P266	Fabris F.	P594
Elkabalawy T.	P398	Fadil M.	P131
Elkasabi M.	P130	Faenza S.	P1006
Elli F. M.	P528	Fahim A. E.	P472
Elliott J.	P1152	Fahimfar N.	P613, P628, P629, P726, P727, P797, P1003, OCs5
Elsalmawy A. H. A.	P329	Fahmi H. F.	P1157
Emaus N.	P505	Fahmy A.	P216
Emelyanov N. I.	P190	Fahrleitner-Pammer A.	P587, P685
Emelyanova O. I.	P190	Faisal F.	P545
Emmelot - Vonk M. H.	P128	Fakeeha J.	P907
Endo K.	P244	Fakhrzadeh H.	P724, P878
Engelke K.	NS36, P1063, P1170	Falcone S.	P432
Engels D. R.	P901	Fall C. H. D.	P932, OCs9
Engels R.	P887	Fallon N.	P860, P916, P919
English S.	P349	Fan C. H. J.	P728, P739, P866
Enkin A. A.	P644	Fanaskov V.	P832
Ensrud K.	OC23	Fang T.-J.	P500
Erbas Sacar D.	P408, P1025, P1026, P1031, P1082, P1132	Fang Y.	P264
Erdeljan B.	P519, P522	Farafonova U.	P703
Erdogan O.	P1082	Farag Y.	P742
Erdogan T.	P660, P663, P891, P1082	Farago M. A.	P944, P957
Eremeev A.	P736	Farahmand P.	P404
Ergezen G.	P273, P565	Farcas D. M.	P1109, P1114
Eriksen E.	SY13	Fardellone P.	P126, P579
Ermolaeva L. G.	P644	Farhat A.	P849
Ermolenko T. A.	P946	Farias V.	P976
Ernst M. T.	OC6	Farouk H.	P164
Erra A.	P526	Fascio E.	P580
Ershova O.	P723, P733, P735	Fasfali D.	P1149
Ershova O. B.	P796, P871	Fassio A.	P893
Ersoy R.	P753	Fatahi A.	P1003
Eryomushkin M.	P456, P509, P1164	Fattal C.	P575
Eryomushkin M. A.	P507	Fauny M.	P277
Escudero Marcos R. E. M.	P246, P786	Fechtenbaum J.	MTE13
Esdaille J. M.	P774	Fedkov D.	P321
Eshaghi S. M.	P1160	Fedyanin A.	P734, P736
Esmeldiaeva D.	P904	Feher P.	P257, P258, P692
Espada Zaragoza R.	P949	Feldman S.	OC15
Espallargas Doñate T.	P133	Feng J. C.	P417, P418, P607
Espallargas M. T.	P132	Fennelly L.	P910
Espinete C.	P526	Fernandes J. C.	P557
Euthimiou G. P.	P1018	Fernandes J. F.	P1157

Fernandez Cortes A.	P721	Frolova T. V.	P215
Fernández Díaz D. F. D.	P246	Frost S.	P654
Fernandez J.	P604	Fu S.-H.	P781, P816, P818, P848
Fernandez N.	OC36	Fuggle N. R.	OC14, P180, P471, ESCEO4
Fernandez O.	P440, P508, P884	Fujii T.	P577
Fernández O. B.	P1150	Fujimaki H.	P584
Fernandez Tormos E.	P256	Fujita M.	P1090
Fernández-Ávila D. G.	P974, P975, P978, P980	Fund N.	OC10, P991, P994
Féron J. M.	P515	Funnell L.	OC15
Ferrari S. L.	MTE5, OC9, OC18, OC22, P1089, P1090	Furniss D.	P127
Ferraz I.	P950	Fusaro E.	P792
Ferreira R. M.	P234	Fusaro M.	P594
Fica S.	P453, P762	Gabriela G.	P1024
Fica S. V.	P1131	Gabruskaya T.	P808
Ficheur G.	OC16	Gadermaier E.	P676
Fielding R.	PL6	Gadisseur R.	P680
Figueiredo C.	NS36	Galbusera F.	P580
Filipescu I. C.	P1117	Galesanu C.	P397
Filipov R.	P922, P933, P1171	Galesanu M. R.	P397
Filipovic K.	P533, P570	Galiano J. C.	P928, P956, P977
Finamore R.	SY12	Galich A.	P343
Finianos B.	P563	Galindez E.	P440, P508, P884, P1150
Fioravanti A.	P1166, SY6	Gallagher M.	P917
Firulescu C. S.	P1039, P1062	Gallaher C.	P137
Firulescu S. C.	P1046, P1047, P1115, P1122, P1129	Galli G.	P182, P700
Fistonic I.	P414	Gallieni M.	P594
Fitzpatrick L. A.	P622	Gallo I.	P1166, SY6
Fitzpatrick R.	P376	Galusca D.	P1109
Florescu A.	P387, P389, P390, P391, P392, P393, P481, P482, P492, P494, P859, P861, P877, P1084	Gama A.	P588
Florescu L. M.	P387, P389, P481, P482	Ganhão S.	P924
Fodor D.	P1119	Gani L.	P293
Foe C.	P696	Gannon E.	P919
Fominykh M.	P886	Gao R.	P334
Fong L.	P457	Gao X.	P221
Formicki G.	P641	Gao Y.	P327, P328, P785
Fortes I.	P1044	Gapon L.	P187
Fougère B.	NS65	Garanhani de Castro Surita F.	NS14, P951, P955, P958
Fousekis K.	P560	Garbi Novaes M. R. C.	P772, P1145
Fraenkel M.	P759, P1110	García A.	P975, P978
Fraga G.	P576	García Alonso M. G. A.	P246, P786
Franceschi M.	P912	García Álvarez E.	P949
Franchi A.	P700	García Escudero P.	P1137
Franco O. H.	P1059	García Fuentes J.	P197
Franek E.	P921	García J.	P131, P132
Franekova L.	P751	García M.	P950
Freemantle N.	P411	García M. L.	P440, P508, P976
Friesenbichler J.	P105	García Melendez G.	P198
Frigeri A.	P343	García Vivar M. L.	P884
Frisoli A.	P300, P303, P306	García-Giralt N.	P521
		García-Vivar M. L.	P1150
		Garduno García J. J.	P242
		Garg B.	P475

Garibay-Nieto N.	P767	Ghosh P.	P760
Garnero P.	P575	Giacoia E.	P343, P976
Garriga C.	P376	Giagtzoglou I.	P1149
Gaskin J.	OC13	Giangregorio L.	OC15, P441
Gasparik A.	OCs11, P1067	Giannini S.	P594
Gasparik I.	P765, P1114	Giannotti S.	P1166, SY6
Gat R.	P759	Gianoudis J.	OC20, P989
Gatsiou M.	P1070, P1075, P1146	Giarola I. C.	P769
Gatti D.	P812, P893	Gibofsky A.	OC37
Gaudin J.	P654	Gielen E.	MTE1, P686, P687, P690
Gaudio A.	P713, P715	Gil E.	P184
Gavrila B. I.	P1112	Gil J.	P597
Gayko O.	P372	Gil S.	P426, P535
Gazar Y.	P157, P158, P344	Gillett M.	P960
Gazi S.	P530	Gilmutdinov I.	P749
Gazoni F.	P962, P964	Gilsenan A.	P1154
Geber Junior J. C.	P772, P1145	Gilson M.	P680
Gecevska D.	P239	Giménez S.	P684
Gee A. H.	OC3	Gimeno M.	P208
Geerinck A.	OC21, OC28, P180, P517, P688, SY10	Giordano N.	P1166, SY6
Geffen D. B.	P1110	Giorgadze E.	P235
Geiger E.	P1116	Girasole G.	P812, P893
Gelalis I.	P696, P1092	Giraud J.	P515
Gelis A.	P575	Gitto S.	P129, P1006
Gen I.	P555	Gittoes N.	P267, P927
Genant H.	P1063	Giuseppe G.	P1138
Geneva- Popova M.	P331	Giusti A.	P812
Genovesi E.	P699	Gjerakaroska Savevska C.	P1078
Georgescu C. E.	P1126, P1128, P1130	Gjerakarovska Saveska C.	P238, P239
Georgieva A.	P541, P578, P616	Gjerakarovska-Savevska C.	P231
Gerakaroska-Savevska C.	P412	Gkouvas G.	P165
Gerami H.	P476	Gkrilias P.	P406, P438, P556, P560, P599, P696, P1092, P1124
Gerasimov O.	P734, P736	Gladkova E. N.	P796, P871
Gerganova A.	P618, P619, P664, P665, P810, OCs7	Glanz V.	P667
Gesmundo A.	ESCE010	Glavinić I.	P913
Geusens P.	P173, P409, P881	Gliatis J.	P438, P506, P867, P1092
Gevers S.	P128	Glorieux F.	P428
Gezen-Ak D.	P875, P902	Gluszeko P.	P921
Ghaly M. S.	P472	Goc Z.	P641
Gharibzadeh S.	P613, P628, P629, P726, P727, P797, P1003, OCs5	Gocevska M.	P231, P412, P683, P1078
Ghasaboghlyan M.	P899	Godfrey K.	P801
Ghate N.	P253	Godfrey K. M.	P546
Ghemigian A.	P1133	Goemaere S.	OC3, P419
Gheonea D.	P394	Goetz C.	P587
Gheorghievici G.	P540	Gofita C.	P492, P494
Gheorghievici L.	P937	Gofiță C. E.	P1084
Gheorghisan-Galateanu A. A.	P1140	Gogas Yavuz D.	P753, P863, P1010, P1074
Gherghina F.	P483	Goh K. H.	P115
Ghias A.	P226	Goisser S.	ESCE010
Ghit M.	P344	Gojkovic F.	P209, P304
		Gokce Kutsal Y.	NS54
		Gökçe- Kutsal Y.	P1021

Gokmen G.	P140	Gregson C. L.	P927
Gold G.	OC36	Grekhoff A.	P620
Goldshtein I.	OC10, P382, P991, P994	Grekhoff R.	P906
Golovach I.	P995	Gren A.	P641
Gómez A.	P121	Griffin J.	NS21
Gómez J.	P184	Grigoreva I.	P819, P824, P828
Gómez-Bori A.	P358	Grigorie D.	P833, P890
Gomez-Gomez A.	P281	Grigorieva A. L.	P1095
Gomez-Vaquero C.	P551	Grillari J.	P1116
Gonçalves R. S.	P234	Grillasca J.	P450
Goncharuk Y. R.	P1086	Grimaldi A.	P893
Goni V. G.	P990	Grkova-Miskovska E.	P412
Gonnelli S.	P812, P893, P894, P905	Gronskaya S.	P294
Gontar I. P.	P190	Groppa L.	P498, P513, P1099
Gonzalez A. P.	P259	Grosman A.	P382
Gonzalez Buesa E.	P114, P241	Grosso E.	P918
Gonzalez D.	P699	Groti Antonic K.	P322
González Fernández M.	P1137	Groupe Agrhum A.	NS31
Gonzalez G.	P966	Grubisic F.	P929
González Navarro E.	P949	Grujic Z.	P830
Gonzalez Rodriguez E.	P691, P1056, P1066, P1073	Gruslin B.	OC26, P470
González S.	P184	Gruzmanov A.	P790
Gonzalez-Fernandez C.-M.	P367	Grygorieva N.	P1040, P1057, P1060, OCs10
González-King Garibotti C.	P949	Grzeszak W.	P921
Gonzalez-Rodriguez E.	P1041	Gu Y.	P604
Goodman C. G.	P308	Gu Y. D.	P334
Goodpaster B. H.	OC38	Guagnelli M. A.	P1096
Gorbunov V.	P634, P656, P771	Gualano B.	P426, P535
Gorbunova T.	P771	Guan J.	P659
Gordzheladze K.	P723	Guan M.	P401
Goulis D.	P875, P902	Guder N.	P1026
Gournay A.	P632	Gudkevich K.	P1127
Grafe J.	P756	Gudmundsson E. F.	P1116
Graham S.	P375	Gudnason V.	OC7, P1116
Gram J.	OC19	Gueldini de Moraes A. V.	NS14, P911, P951, P955, P958, P959
Grammatiki M.	P875	Guelman R.	P976
Grande Cabrerizo C.	P462, P463	Guerrero F.	P551
Grandjean A.	P798	Guerrero R.	P199
Grandjean M.	P343	Guerrero Riscos M. A.	P462, P463
Grange L.	P515	Guersoni A. C.	P1158
Granic R.	P912	Guggenbuhl P.	P515
Grano M.	P123	Guglielmi G.	NS11, P523, P524
Grapton X.	P532	Guillemin F.	OC11, P615
Gratal P.	P682	Guillén E.	P358
Grauer A.	OC3	Guillen-Astete A.	P569
Graves S. E.	P820	Guilligan M.	P1027
Gray A.	NS38	Guindy M.	P382
Grazio S.	P929	Guiot A.	P639
Grbovic V.	P800	Guk I.	P372
Grebennikova T.	P294, P988, P1076, P1101	Gungor F.	P348
Grebennikova T. A.	P796	Gunn C.	OC20, P989
Green D.	P534	Günther C.	P854

Guo Y.	P417, P418, P607	Hebert J.	OC32
Gupta A.	P146, P147, P148, P149, P370, P377, P467, P468	Heijmans S.	P997
Gupta R.	P230, P272	Heilmeier U.	P1116
Gupta T. G.	P983	Hend H.	P1071
Gurler M.	P171	Hendy E.	P919
Gurt I.	P825	Hernández-Jaras J.	P358
Guryanova E.	P851	Herrera S.	P576
Gutiérrez J.	P974, P980	Herrero-Beaumont G.	P208, P682, P754
Gutiu R.-I.	P1119	Herrmann F.	OC36
Hackl M.	P1116	Heshmat R.	P613, P628, P629, P724, P726, P727, P797, P878, OCs5
Hagino H.	OC17, P244, P283, P340, P488	Hesse E.	OC9, P1089
Hajaoui M.	P693	Hew F. L.	P297, P299, P729
Hakami Y. H.	P649	Hildebrandt A.	P954
Halıcı M.	P368	Hilgsmann M.	OC34, P622, P697, ESCEO2, ESCEO9, ESCEO10, ESCEO-IOFUSA1, ESCEO-IOF-WHOCC1
Hall D.	P1063	Hill R.	OC35, P1063
Halliday A.	P179	Hillier L.	P441
Hamdy N.	NS27	Himmler G.	P676
Hamdy N. A. T.	P1052	Hindi S.	P323
Hamidi Z.	P476	Hiraku K.	P611, P612
Hamoud H.	P344	Hirano F.	P233
Han W.	P345	Hirdes J.	P441
Hanley D. A.	OC3	Hisako F.	P555
Hanna F.	P436	Hlaing T.	P868
Hannigan O.	P916, P917	Hlapovic D.	P335
Hans D.	OC35, P691, P1041, P1056, P1059, P1066, P1073	Ho A. W. H.	P155
Hansen S.	OC19	Ho K. W. K.	P728, P739, P866
Hao Y.	P554, OCs3	Ho M.-L.	P497
Harada K.	P119	Ho W. T.	P1161
Harb M.	P344	Hochberg M.	OC37, P651
Hardie S. L.	P146, P147, P148, P149	Hochberg-Klein S.	P825
Harfouche L.	P473	Hodge J. M.	P985
Harhaji V.	P591	Hodgkins B.	P464
Harris D.	P1154	Hodgkins J.	P464
Harris R.	P226	Hodosan V.	P311, P312, P317
Harris T. B.	OC38, P1116	Hofbauer C.	P881
Hars M.	OC22, OC36	Hoggarth M.	P1152
Harvey N. C.	MTE3, OC1, OC2, OC7, OC23, OC25, P319, P320, P513, P546, P590, P591, P593, P801, P998	Högler W.	P428
Hashimoto J.	P244	Holloway-Kew K.	P653, P965
Haskovic E.	P678	Holloway-Kew K. L.	P650, P652, P655, P671, P999
Hassab Elnaby M.	P164	Holroyd C. R.	P801
Hassan M.	P164, P742	Holub A.	P103, P104, P110, P111
Hassett G.	P654	Holzer L. A.	P105
Hattenbach J.	P332	Homorogan C. R.	P970
Hauer L.	P872	Hong S.	P352
Hawa G.	P243	Hong Y. S.	P720
Hawley S.	P422, P927	Hontoir F.	P640, P941
He S.	P361	Honvo G.	OC21, P180, P517, P754, SY10, ESCEO4
He Y.	OC27	Hood J.	P226
Heaney F.	P1020, P1035		

Horii C.	P804	Idiz C.	P1132
Horst-Bruinsma I. E.	P543	Iervasi G.	P594
Horvath C.	P953	Ignatyev A. M.	P946
Horváth C.	P945	Iidaka T.	P363, P804
Hosking S. M.	P999	Ikeda S.	P283
Hosszu E.	P953	Ilea C. D. N.	P310, P314, P315
Hosszú E.	P945	Ilhan B.	P348
Hou H.	P250	Ilijamakova N.	P771
Hovhannisyán G.	P899	Ilundain A.	P224
Howe J.	OC35, P1063	Ilundain A. I.	P223
Howe T. S.	P461	Ilyin A.	P1076
Hoza A.	P1109	Ilyin M.	P735
Hozan C.	P316	Imai S.	P981
Hrdý H. P.	P460	Imel A.	P428
Hritiuc A.	P1126, P1128, P1130	Imre E.	P1074
Hrusak D.	P872	Imyanitov E.	P963
Hsiao F.-Y.	P781, P816, P818, P848	Inchaurre A. R.	P440
Hsieh M. -H.	P782, P1049	Ing How M.	P143, P144, P145
Hsu B. G.	P478	Innocenti B.	P941
Hsu H.	P500	Innocenti M.	P1033
Hsu Y.-H.	P360	Inose H.	P240
Huang C.-C.	P781, P816, P818	Inoue G.	P584
Huang S.	OC18, P411	Inskip H.	P689
Huang T.	P401	Inskip H. M.	P546, P801
Huang W.-J.	P355, P658	Insogna K.	OC5, P442
Huang Z.	P260	Intxaurbe A. R.	P508, P884, P1150
Huber B.	OC35, P1063	Invernizzi M.	P342
Huertas J. A.	P386	Ioannidis G.	P441
Hughebaert L.	P675	Iolascon G.	P342
Hughes L.	P293	Ionescu R.	P394
Huish E.	P709	Ionescu R. A.	P1122
Humbert L.	P521, P551, P597, P1011	Iovan C.	P635
Humphries T.	P443	Iovanovici D. C.	P642
Hung C.-C.	P781, P816, P818	Irina Alexandrovna S.	P156
Hung S. Y.	P478	Irsay L.	P1159
Hung W.-C.	P437	Isaenkova D.	P789
Hung Y. H.	P728, P739, P866	Isaia G. C.	P918
Hunter D.	P345	Ishibashi H.	P283
Huplea V.	P944, P948, P952, P957	Ismail A.	P915
Hurley E.	P916	Ismail N.	P742
Hussain R. Z.	P907	Ismailov H. G.	P813
Hussain S. D.	P218	Issayeva B.	P305, P865, P869
Hutchings N.	P764	Issayeva S.	P305, P865, P869
Hwang D. W.	P161	Isupova E.	P963
Hwang J. S.	P842	Ito N.	P442
Hyde N. K.	P652, P655, P671	Ito S.	P545
Iarenenko O.	P321	Iuhas-Ienciu C.	P379
Ibanez M.	P226	Ivacic J.	P335
Ibarguengoitia O.	P440, P508, P884, P1150	Ivačić J.	P1118
Ibragimova L.	P900	Ivanac G.	P150
Ibrahim A.	P1020, P1035	Ivanenko L. R.	P1086
Iconaru I.	P365	Ivanov A.	P331

Ivanov S. N.	P354, P421	Johansson H.	OC1, OC2, OC7, OC23, P319, P320, P513, P590, P591, P593, P596
Ivanova E.	P703	Johansson J.	OC12
Izmozherova N. V.	P752, OCs6	Johansson P.	P596
Jackuliak P.	P1013	John L. H.	OC27
Jagus D.	P147, P148, P149	Jomkoh M. S.	P493
Jambura J.	P872	Jones G.	OC32, P117, P179, P429, P430, P610, P777, P780, P820, P823, P826, P839
Jameson K.	OC25, P363, P601, OCs4	Jones J. G.	P172
Jameson K. A.	OC14, P439, P452, P455, P471	Jones T.	NS20
Jan de Beur S.	OC5	Jordanova S. J.	P510
Jandric S.	P718	Jordhani M.	P707
Jang B. S.	P1152	Jorgensen N.	P677
Janha R.	P942	Jørgensen N. R.	OC19
Jankovic T.	P519, P533, P645	Jovanovic A.	P830
Janković T.	P522	Jovanovic J.	P763
Janta I.	P516	Jovanovic V.	P763
Janto M.	P310, P317, P318	Ju J. H.	P720
Jantzi M.	P441	Judea C.	P635, P642
Januszyk D.	P1152	Judge A.	P376, P689, P698, P927
Jaramavicius J.	P1094	Jukic T.	P912
Jarjou L. M.	P942	Julien C.	P670
Jassim N. A.	P402	Jung I.	P295
Javaid K.	MTE8, NS29, NS40	Jung J. Y.	P200
Javaid M. A.	OC6, P586	Jung J.-Y.	P720
Javaid M. K.	P127, P422, P466, P698, P927, P1090	Jung K. H.	P538
Javier J. L. S.	P786	Jung M. H.	P124
Jayakumar A.	P931	Jurca C.	P353
Jedynasty K.	P921	Jurca T.	P353
Jeiranashvili N.	P235	Jurcut C.	P410
Jensen M. H.	OC8	Jurisc Skevin A.	P800
Jensterle Sever M.	P876	Jusmanova K.	P910
Jeon S. R.	P359	Jwad K.	P188
Jeong J. H.	P359	Kachhawa G. K.	P983
Jepsen D. B.	OC19	Kadić A.	P791
Jeremic I.	P748	Kafadar H. I.	P368
Jeremic-Knezevic M.	P335	Kafchitsas K.	P1092, P1105
Jerkovich F.	P699	Kajale N.	P932, OCs9
Jesensek Papez B.	P1037	Kakita A.	P624
Jguirim M.	P849	Kalcovska Ivanovska B.	P239, P683, P1078
Ji Y. I.	P124	Kalcovska-Ivanovska B.	P231, P412
Jiang Y.	P361	Kalentzos V.	P302
Jick S. S.	P701	Kalinchenko B.	NS24
Jin E. S.	P359	Kallsbrum S.	P343
Jin Hee P.	P301	Kalmar A.	P496
Jin N.	P611, P612	Kaloudis A.	P556
Jin X.	P361	Kaltenegger H.	P667
Jingjing L.	P301	Kamal C.	P445, P446
Jo B. S.	P799	Kamal D.	P265, P286, P445, P446
Joel J.	OC11	Kamal K. C.	P265, P286
Johal S.	P931	Kamenický P.	P442
Joham A. E.	P1051		

Kanaka-Gantenbein C.	P270	Kearns S.	P1035
Kanatbayeva A.	P1100	Keen H.	P117
Kang K. Y.	P720	Keerthanaa B.	P156
Kanis J. A.	SL2, OC1, OC2, OC7, OC23, PL7, P319, P320, P513, P590, P591, P593, P677, P998	Kellari A.	P1019
Kanojia R. K.	P1083	Keller J.	P954
Kaparos G.	P1147	Kellier-Steele N.	P1154
Kapetanios G.	P165	Kelly A.	P654
Kapusta E.	P641	Kendler D.	P411, P415
Karadzic M.	P763	Kendler D. L.	OC18, P173
Karagozoglou Coskunsu D.	P431	Kennedy S.	P226, P651
Karahan A. Y.	P140	Kentaro U.	P555
Karahan S.	P1021	Kerns J.	P1139
Karakoyun A.	P140	Keshavarz S. A.	P338, OCs2
Karamitros A.	P369	Ketenci S.	P140
Karan A.	P348	Kevic S.	P335, P436, P583
Karan M. A.	P348, P408, P660, P663, P891, P1025, P1026, P1031, P1082	Kević S.	P1118
Kardalas E.	P414	Kezhun L.	P892
Karlsbrum S.	P976	Khachidze N.	P235
Karlsson L.	P998	Khadgawat R. K.	P983
Karlsson M. K.	OC23	Khadilkar A. V.	P932, OCs9
Karmali K.	P365	Khakimov U. R.	P459
Karnwal B.	P552	Khalid S.	OC6, P586
Karonova T.	P672, P703	Khaliq S.	P704
Karonova T. L.	P381, P1095	Khan A.	P649
Karras S.	P875, P902	Khan S.	P860
Karytska N.	P725, P827	Khan T.	P649
Karytska N. S.	P802, P807	Khanna V.	P1107
Kashevarova N.	P403	Khanuja H. S.	P716, P1151
Kashevarova N. G.	P741	Kharin N.	P592, P734, P736
Katchy A. U.	P1163	Kharnas S.	P435
Kato T.	P240	Khashayar P.	P613, P628, P797, P1003, OCs5
Katogi T.	P283	Khattak M.	P219
Katpattil S. K. P.	P175	Khromtsova O.	P886
Katsaras G.	P1120	Khusainova R.	P889
Katsavouni C.	P1070, P1075	Kienzle A.	P954
Katsumata K.	P244	Kilaité J.	P1061, P1065
Kattamis A.	P270	Kilasonia L.	P202
Kaufman J.-M.	MTE11	Kilic C.	P348, P891, P1025, P1026, P1082
Kaul A.	P137	Killinger Z.	P1013
Kaux J.-F.	NS7	Kim D.	P295
Kawakami T.	P624	Kim E. H.	P537
Kawakubo A.	P584	Kim H.	P102
Kawamoto Y.	P119	Kim H. A.	P200
Kaydok E.	P140	Kim H. S.	P972
Kayser F.	P941	Kim J.	P212, P295
Kazantsev D. I.	P574	Kim J. W.	P161, P268
Kazuhide I.	P555	Kim J. Y.	P359
Kazwini S.	P558	Kim M. O.	P972
Kc S.	P226	Kim S.	OC15
Kearns A. E.	P674	Kim S. M.	P336, P337, P339
		Kim Y.	P255
		Kinchaya-Polishchuk T.	P372

King S.	P1165	Kostoglou-Athanassiou I.	P1028, P1070, P1075, P1080, P1141, P1146, P1149
Kinnard K.	P365	Kostopoulos M.	P1141
Kirazli Y.	NS52	Kothari P. K.	P1155
Kirilov N.	P486, P487	Kotowicz M.	P653
Kirilova E.	P486, P487	Kotowicz M. A.	P650, P671
Kirsch A.	P685	Kotsa K.	P875, P902
Kirschvink N.	P640	Koufakis T.	P875, P902
Kirvalidze N.	P202	Koukakis R.	P997
Kirwan J.	P426	Koutserimpas C.	P176, P177, P302
Kitaigrodsky A.	P343	Kovac A.	P678
Kleyer A.	NS36	Kovach C.	P252
Kline G.	OC15	Kovacova V.	P662
Klineberg I.	P1165	Kovacs S.	P680
Kljaic Dujic M.	P1037, P1077	Kovalenko P.	P633
Knezevic A.	P335, P436, P583	Kovalyova O. N.	P346
Knežević A.	P1118	Kováts Z.	P945
Ko H. -J.	P295	Kowal P.	OC13
Kobayashi T.	P361	Koyama T.	P584
Kobayashi Y.	P119	Kozlova V.	P681
Kobets K.	P806, P811, P996	Kozomara S.	P922
Koch'Jan A.	P803	Kraev K.	P331
Kochetkova A.	P1012	Krasimirova-Kurteva E.	P805
Kochish A. U.	P421	Kratochvilova S.	P589
Kocic M.	P933	Kratschmann C.	P667
Kodama T.	P285, P1030	Kravtsov G.	P425, P897
Koehler J.	P142	Kravtsov V.	P425
Koevska V.	P231, P238, P239, P412, P683, P1078	Krisper P.	P685
Kogan E.	P743	Krivorotko M. S.	P459
Koh J. S. B.	P461	Krok J.	P1152
Kokkoris P.	P626	Krueger D.	P252
Kokov A.	P819, P824	Kruger M.	P989
Kola I.	P1050	Krutko D.	P789, P790
Kolesarova A.	P662	Kruzic J. J.	P1165
Koleushko K. G.	P215	Krylov A. S.	P813
Koleva K.	P855	Krylov V.	P434, P435
Kolovos S.	OC27	Kryukova I. V.	P796, P871
Komatsu Y.	P119	Kryvashei S.	P883, P1016
Kondo-Ando M.	P577, P624	Krzesinski J. -M.	P141
Konsta M.	P543	Kšela U.	P366
Konstantinidis D.	P380	Kuan Y. C.	P947
Kontopoulou E.	NS45	Kubota T.	P442
Kontoudis A.	P380	Kuchina A. S.	P623
Kopaliani M.	P202	Kucukdagli P.	P660, P663, P891, P1025, P1026, P1031, P1082, P1132
Kopec J. A.	P774	Kucukdagli P.	P408
Koppo K.	P686, P687, P690	Kudinskiy D. M.	P813
Koren S. K.	P309	Kukovenko G. A.	P1086
Korenskaya E. G.	P232, P562, P609	Kulkarni B.	P932, OCs9
Koretz M.	P1110	Kulkayeva M.	P1100
Koromani F.	P1059	Kullich W.	P667
Kostik I.	P963	Kulshreshtha V. K.	P983
Kostik M.	P808, P963	Kumar E. K.	P309
Kostik M. M.	P702		

Kumar K.	P1083	Langdah B.	P409
Kumar M.	P553, P631	Lannon R.	P860, P910, P916, P917, P919
Kumar N.	P990	Lanyan A.	P691
Kumar P.	P1064	Lapauw B.	P419
Kumar R.	OC5, P475	Lapenna M.	P1142
Kumar V.	P1064	Lapshina S.	P749
Kumari R. K.	P983	Largo R.	P208, P682
Kundzer A. V.	P1081	Larijani B.	P476, P613, P628, P629, P726, P727, P797, P845, P878, P1003, OCs5
Kurabayashi T.	P283	Larrainzar Garijo R.	P256
Kuran B.	P140	Larroude M.	P775
Kurilina E. V.	P1086	Larroudé M. S.	P976
Kurth A.	P587	Larysa P.	P992
Kurth A. A.	MTE9	Lasco A.	P713, P715
Kurushina O.	NS22, P993	Lasco C.	P717
Kuzin A. V.	P813	Laslett L.	P117, P179, P429, P430
Kužma M.	P1013	Latfullin A. A.	P871
Kuzmanov A.	P541, P578, P616	Lattafi R.	P473
Kuzmanov K.	P541, P578, P616	Lattermann C.	OC37
Kuzmanova V.	P541, P578, P616	Lau C. K. J.	P178
Kuznetsov N.	P435	Lau C. M. L.	P728, P739, P866
Kvedaraite M.	P1094	Lau E. M. C.	P659
Kvlividze T.	P384, P1001	Lau H. W.	P866
Kvlividze T. Z.	P566	Lau J. C. K.	P490
Kwoh K.	P345	Lauppe R.	P1029
Kwok K. B.	P728, P739	Laursen H. V. B.	OC8
Kwok T.	OC23	Lavranos G.	P1068
Kwon S. R.	P538	Lavrov I.	P736
La Tegola L.	P524	Lavrova D.	P1001
Labashova L.	P357, P595	Law S. C.	P115
Labrie J. W.	P744, P747	Lazar L.	P499, P635, P642
Ladang A.	P201, P675	Lazarescu A.	P970
Lafarge D.	P515	Lazovic M.	P933
Lafamme G. Y.	P557	Lazurenko L. L.	P215
Lafont S.	P669	Le Goff C.	P675
Laga Cuen A. C.	P114, P241	Le Quintrec J. L.	NS32
Laganà A.	P792	Leach S.	P652
Lagvilava L.	P202	Leal J.	P376
Lai C.	P226	Lebbah S.	P192
Lai Y. Y.	P729	Leduc S.	P557
Lakatos P.	P162	Lee C. K.	P352
Lakhani A.	P657	Lee D. W.	P799
Lamangan L.	P226	Lee H. Y.	P200
Lambrinouadaki I.	P971, P1147	Lee J.	P255, P550
Lambrou G.	P270, P1120	Lee J. S.	P352
Lamp K.	OC5	Lee J. Y.	P799
Lampropoulou S.	P1018, P1019, P1105	Lee K. B.	P178, P423, P490
Lamuedra A.	P682	Lee M.	P203
Lamy O.	P691, P1041, P1056, P1066, P1073	Lee S. K.	P720
Landi F.	ESCE09, ESCE010	Lee S. Y.	P538
Lane J.	P127	Lee S.-J.	P295
Lane N.	OC37	Lee W.	P295
Lane N. E.	OC4		

Lee Y. K.	P161	Libanati, C.	P586
Lefkir S.	P914, P923, P926, P930, P936	Libber J.	P252
Legroux-Gérot I.	P798	Liebich G.	P1041
Lei K.	P219	Lila A.	P403
Leitão Y. M.	P237	Liliya P.	P992
Leite I.	P901	Lillo Adan M.	P113, P136
Leithner A.	P105, P667	Lim D. H.	P352
Lejniaks A.	P758	Lim K. K.	P461
Lekamwasam H. B.	P280	Lim M. J.	P538
Lekamwasam S.	P280, P608, P722	Lim P. C.	P333
Lelli D.	P123, P186	Lim S. J.	P336, P337, P339
Lelong C.	OC35	Lim S.-J.	P193, P194, P195
Lemac D.	P150	Lima A. V.	P772
Lemesle P.	P532	Lima M.	P737
Lempert U. G.	P1036	Limani V.	P1113
Lems W.	NS34, P409, P881	Limousin Aranzabal B.	P256
Lems W. F.	P128, P543, P1090	Lin C. F.	P324
Leonardi M. H.	P705	Lin H.	P361
Leoncini G.	P700	Lin S.-Y.	P497, P500, P637
Leong J. F.	P843, P853, P858	Lin Y.-H.	P637
Leonova N. V.	P871	Lin Y.-S.	P497, P637
Lepore F.	P573	Lindsay J. R.	P349
Lera L.	P1098	Link T. M.	P1116
Lerena V.	P699	Liou H. H.	P478
Lerner U.	P382	Liphardt A.-M.	SY8
Leslie W.	P249	Lisakovska O.	P1121
Leslie W. D.	OC15	Lisenkov D.	P592
Lesnyak O.	P305, P661, P764, P869	Lisnic N.	P397
Lesnyak O. M.	P513, P796, P871	Liu C.	P290
Lespessailles E.	OC16, P173, P409	Liu D.-H.	P934, P1093
Letaeva M.	P832	Liu E.	OC1, OC7, P319, P320, P590, P591, P593
Levin K. B.	P843, P853, P858	Liu G.	P163
Levine M.	P249	Liu I. T.	P870, OCs8
Levinger I.	P1165, P1169	Liu J. K. H.	OC25
Levy D.	P382	Liu X.	P1169
Lewerin C.	P596	Liu Y.	P1169
Lewiecki E.	P527	Ljuhar D.	P587
Lewiecki E. M.	OC9, OC18, P1089	Ljuhar R.	P587, P673
Lewis J. R.	P1169	Ljunggren O.	P1029
Li C.-H.	P605, P606	Lobanov M. N.	P574
Li C.-Y.	P605, P606, P781, P816, P818	Lober A.	P987
Li G.	P249, P260, P290	Locatelli F.	P594
Li K.	P213	Locquet M.	OC24, OC26, P153, P154, P201, P693, ESCEO9, ESCEO10, OCs1
Li L. C.	P774	Loeuille D.	P277
Li S. D.	P334	Lofty H.	P742
Li S.-S.	P637	Loghin-Oprea N.	P1008
Li W. Y.	P178, P423	Logue J.	P127
Li Y.-F.	P658	Loh W. J.	P293
Li Z. Y.	P514	Lohberger B.	P667
Liana L.	P1024	Lombardi * F. A.	P893
Liang F. W.	P870, OCs8	Lombardi F.	P1091
Libanati C.	OC3, OC6, OC9, P1089		

Lombardi G.	P580	Maher N.	P860, P910
Lone K. P.	P704	Maheu E.	NS30, NS33, P837, SY5
Lootens T.	P496	Mahfoud Z.	P783
Lopak R.	P938	Mahmood Z. A.	P402
Lopes M. A. P.	P1023	Mahon P. A.	P546
Lopez Gavilanez E.	P593	Maïmoun L.	P575
López L. C.	P358	Maisarahmattap S.	P826
López Sánchez J. L. S.	P246	Maistrovskaia I.	P784
Lopez Subias J.	P113	Maistrovskaia V.	P1012
Lopez Subías J.	P136	Majoie H. J. M.	P895
López- Corbeto M.	P576	Makarova E.	P456, P509
Lopez-Gonzalez D.	P767, P979	Makarova E. V.	P507
Lopez-Longo J.	P367	Makhova M.	P963
Lopez-Reyes A. G.	P208	Makino M.	P624
López-Romero P.	P173	Makkaveeva O.	P656
Lorentzon M.	OC1, OC2, OC7, OC23, P319, P320, P590, P591, P593	Maklakova M. D.	P623
Lorimer H.	P443	Makras P.	P243, P369, P373
Lorimer M.	P820	Makri E.	P1018
Lorinczova Z.	P420	Makris K.	P677
Loste Ramos A.	P135	Maksimovic-Simovic M.	P519
Lounici A.	P909	Maksoud C.	P237
Loutsidi N.-E.	P222	Maldonado G.	P199, P245
Lovy M.	P332, P464	Maldonado L. M.	P386
Lu T. H.	P870, OCs8	Maleitzke T.	P954, P1015
Lu Y.-M.	P500	Málek M. Z.	P460
Luca D.	OC5	Malevich E. E.	P807
Lucas S.	P343	Malfait F.	P419
Lucas S. P.	P699	Malhotra R.	P475, P1072
Lucattelli E.	P1033	Malinovska Nikolovska L.	P1078
Lucisano M. P.	P572	Malle O.	P685
Lukmanova L.	P889	Malmgren L.	P1102
Luong S.-N.	P179	Malo M.	P557
Luque-Alarcon M.	P569	Malouf J.	P576
Luzin V.	P803, P822, P938	Malouf-Serra J.	P409
Luzo M. C. M.	P770	Malyshenko O.	P828
Lynch S.-A.	P916, P917	Malyutina S.	P469
Ma X.	P361	Mamedova E.	P559
Machado-Rodrigues A.	P588	Mamus M.	P544, P794
Macías-Hernández S.-I.	P761, P776	Mamus M. A.	P479, P617, P621
Maciel C. D.	P1145	Man L. C.	P155
Macisaac R. J.	P416	Mancic D.	P933
Madadi Z.	P878	Manfredini M.	P812
Maddox J.	P659	Manfrini S.	P123, P186, P432
Maes D.	P496	Manica S. R.	P1134
Maffei L.	P976	Manicourt D.	P669
Magalhães R. T.	P772	Manolache A.	P410
Magalini F.	P961	Manoleva M.	P231, P412, P683, P1078
Magallares B.	P576	Manolopoulos P.	P1068, P1088
Maggi D.	P186, P432	Mansour R.	P466
Maggi S.	OC31, P523, P524, P525, ESCEO4, ESCEO9, ESCEO10	Manthou E.	P875, P902
Magomedova S.	P963	Mantovani G.	P528
		Mao M.	P428

Marante Fuertes J.	P103, P104, P110, P111	Masato K.	P611, P612
Marc F.	P353, P666, P1109, P1114	Masayuki M.	P555
March L.	P429, P430	Mascarenhas M. R.	P1044
Marchand P.	P226	Masenko V.	P819, P824
Marchenkova L.	P456, P509, P1164	Masi L.	NS26
Marchenkova L. A.	P507	Massazza G.	P630, P636
Marchev S.	P541, P616, P855	Mastaviciute A.	P806, P1094
Marcu I. R.	P448, P449, P809, P873, P1055	Mastavičiutė A.	P1061, P1065
Marcu I.-R.	P1009, P1014, P1017	Masud T.	OC19
Mari A.	P176, P177, P302	Mata L.	P599
Mariano-Goulart D.	P575	Matchar D. B.	P461
Marín A. M.	P576	Mateescu B. R.	P453
Marín D.	P167, P168	Matei D.	P448, P449, P809, P873, P1009, P1014, P1017, P1055
Marin F.	P173	Matejevic T.	P602
Marin Ossa D.	P699	Mathers J.	P1169
Marin Peña O.	P256	Mathurin P.	P798
Marin-Huertas C.	P367	Matias R.	P1134
Marini F.	P182, P700	Matijevic R.	P591
Marinkovic S.	P269	Matsumoto R.	P244
Markov D.	P1053	Matsumoto T.	P361, P1089
Markovic K.	P922, P1171	Mattap S. M.	P117, P179
Markovich S.	P598	Matucci M.	P625, P679
Markovikj S.	P1113	Matzaroglou C.	P406, P438, P506, P556, P560, P599, P696, P867, P1018, P1019, P1092, P1105, P1124
Marmara N.	P626	Maurer-Ertl W.	P105
Marozik P.	P806, P811, P996	Mautalen C.	OC3
Marques-Vidal P.	P691, P1073	Mavromoustakos S.	P1018
Marquez C.	P1098	Mazanko K.	P321
Marrero T.	P495	Mazanova A.	P1121
Martel-Pelletier J.	P170, P820	Mazur M.	P1008
Martignène N.	OC16	Mazur-Nicorici L.	P1008
Martín Fuentes M.	P405	Mazurenko E.	P469
Martin J.	P670	Mazurenko O. G.	P644
Martin N.	P495	Mazurenko S.	P789, P790
Martin S.	P762	Mazurenko S. O.	P644, P796
Martín-Aragón S.	P561	McAlindon T.	MTE7, OC37, P180, P651, P754, ESCE05
Martinez L. C.	P1158	McArthur C.	P441
Martinez Martinez M.	P242	McCabe E.	P378, P1020, P1035
Martinez S.	P648, P1011	McCabe J.	P1035
Martínez Trufero J.	P504	McCarroll K.	P860, P910, P916, P917, P919
Martínez-García M.	P521	McCarthy B.	P916, P917
Martinez-Laguna D.	OC6, P127, P518, P586	McCloskey E. V.	OC1, OC2, OC7, OC23, OC29, PL1, P319, P320, P356, P513, P590, P591, P593, P997, P998, SY15
Martinez-Morales G. M.	P776	McClung M.	OC29, P411
Martini L.	P535, P737	McCormack W. P.	P744
Martini L. A.	P1023	McCullogh K.	P594
Martiniakova M.	P641, P662	McDonald S.	P968
Martino G.	P715, P717	McDonald-Blumer H.	OC15
Martins W. H. S.	P1145		
Martos T.	P521		
Martusevich N.	P1127		
Martynyuk L. P.	P454		
Marusina A.	P723		
Masashi T.	P555		

McGowan D. P.	P215	Michelle D.	P250
McGowan K. A.	P215	Midkiff K.	P1154
McGuigan F.	P1102	Mielnik P.	P987
McKenna M. J.	P458	Migliaccio S.	P342
McMillan L.	OC12	Miglinas M.	NS50
McNicholas T.	P917	Migliore A.	P208, SY7
Md Said S.	P729	Mihalache R.	P271
Md-Said S.	P297, P299	Mikhailov A. N.	P807
Mealiffe M.	P442	Miladinovic K.	P678, P814
Mecocci P.	P1138, P1142	Miladinović K.	P791
Mediene Benchekor S.	P206	Milankov M.	P122
Mediero A.	P682	Milano E.	P630, P636
Medina A.	P1143	Milasinovic-Stanojevic L. J.	P436, P1171
Medina A. M.	P259	Milat F.	P657, P1051
Medina J. P.	P208	Milenkovic R.	P214, P748
Medina Orjuela A.	NS59, P973	Milicic T.	P748
Medioli A.	P474	Millar A.	P649
Medvedeva E.	P215	Millar L.	P534
Medvedovsky V.	P759, P1110	Miller P.	OC5
Megas P.	P406, P438	Milosevic J.	P800
Mehandia V.	P990	Min H. K.	P720
Mehrdad N.	P628, P724, P797, P878, P1003, OCs5	Min J. M.	P359
Mei Q.	P604	Min Y.-K.	P193
Meier C. R.	P701	Minamizaki T.	P545, P585
Mekawy D.	P742	Mine Y.	P585
Melchior B.	P226	Minisola S.	P173, SY9
Meléndez Laborda A.	P385	Minoves M.	P646
Mellström D.	OC23, P596	Mirovsky Y.	P309
Melnichenko G.	P294, P743, P1076, P1101	Mirzaei A.	P118, OCs2
Mendes C. S.	P1134	Mirzaei D. R.	P330
Mendieta Zeron H.	P242	Mirzaei K.	P338, P350
Mendizábal S.	P358	Mishevskaja Jovanovska S.	P598
Mendoza-Nuñez V. M.	P1096	Mishra G. D.	P1051
Meneses A.	P962, P964	Mitchell E.	P868
Meng L.	P227	Mitchell P.	P1090
Meng T.	P429, P430	Mithal A.	P477
Meng Y.	P334	Mitlak B.	OC4
Menos Aikateriniadis C.	P438	Mitoiu B.	P1106
Mentaverri R.	P126	Mitoiu B. I.	P540
Merege-Filho C. A.	P426	Mitoiu I.	P937
Merello-Miguel A.	P561	Mitrevska B.	P231, P238, P239, P412, P683, P1078
Mergler S.	P895	Miyagi M.	P584
Meriuts O.	P822	Miyagishima T.	P119
Mescheryakov J.	P885	Mizrakli Y.	P1110
Messina C.	P129, P580, P1006	Mo Costabella F.	P1056
Messina O. D.	SL3	Mo'Ezz M.	P254
Meszaros S.	P953	Mocian A.	P1097
Mészáros S.	P945	Moga I.	P480
Meyer R.	P689	Moghtit F.-Z.	P206
Meza García J. D. D.	P721	Mohajeri-Tehrani M. R.	P476
Miagkova M.	P407	Mohamad-Ismuddin S.	P297, P299
Michael A.	P267, P307	Mohamed H.	P915

Mohamed S.	P457	Mukhopadhyay S.	P553
Mohammed A.	P218, P220	Mukuchyan V.	P899
Mohd-Ariff M. A.	P843, P853, P858	Müller C.	P685
Mohseni F.	P476	Müller V.	P945
Moirano G.	P918	Mündermann A.	SY8
Moldovan C.	P1109, P1126, P1128, P1130	Muniesa Herrero A.	P197
Mole E.	P530	Muniesa Herrero M. P.	P134, P197
Mole I.	P530	Muniesa Herrero P.	P133
Molina A.	P495	Munns C.	P428
Molinedo M.	P167, P168	Muñoz Gomez M. D. M.	P385
Moller I.	P679	Muñoz O.	P975, P978
Möller I.	P625, P684	Muñoz-Lasa S.	ESPRM-ESCEO-IOF3
Mologhianu G.	P540, P1106	Munugoda I. P.	P815, P820
Mondal S.	P553	Mura T.	P575
Mondanelli N.	P1166, SY6	Murai I. H.	P426
Mondockova V.	P662	Muranaka T.	P119
Monfort J.	P625, P679, P684	Murata K.	P584
Monica L.	P961	Muratore * M.	P812, P893
Monod P.	P515	Muresan M.	P666
Monov S.	P288	Murphy C.	P1035
Monova D.	P288	Murphy D.	P416
Montandon S.	P443	Murylev V. Y.	P813, P1086
Montañez Ruiz M.	P198	Muscalau B.-M.	P925
Monteiro J.	P1044	Musetescu A. E.	P387, P389, P390, P391, P392, P393, P483, P492, P494, P888, P920, P1034, P1039, P1047, P1062, P1115
Montero D.	P440, P508, P884, P1150	Muşetescu A. E.	P1084
Morabito N.	P713, P715, P717	Mushkin A.	P963
Morais Paulino D. S.	P955, P958	Musiienko A.	P1038
Morales D. R.	OC27	Musikhina N.	P187
Morales Olazabal R.	P719	Mustafina S.	P469
Morales-García M.	P776	Mustescu A.	P859, P861, P877
Moraru I. A.	P829, P831, P838, P840	Muzsnai A.	P258, P692
Moreau M.	P365	Muzzammil M.	P247, P564, P643
Morell-Hita J. L.	P766	Muzzi Camargos B.	NS48, NS58
Mori G.	P123	Myasoutova L.	P749
Mori S.	P488	Myers D. M.	P308
Morin S.	P557	Myhre Hjelle A.	P987
Morin S. N.	OC15	Myllymäki A.	P1005
Moriwaki K.	P340	Nabipour I.	P613, P628, P629, P724, P726, P727, P797, P845, P878, OCs5
Morones-Alba J. D.	P776	Naciu A. M.	P123, P186, P432
Morris H.	P677	Naidoo N.	OC13
Morrissey H.	P608, P722	Nakajima R.	P981
Mortada M.	P742, P773	Nakamura A.	P442
Moschou D.	P530	Nakamura M.	P119
Mosse I.	P996	Nakamura T.	P488
Mosyagina N.	P803	Nakura Y.	P577
Mourampetzi P.	P902	Namba N.	P428
Mouton A.	P470	Namkuntze M. R.	P493
Mozgovaya E. E.	P479, P617, P621	Nandi A.	P931
Mucha A.	P1113		
Muftic M.	P678		
Muka T.	P1059		
Mukane M.	P887, P901		

Napoli N.	OC9, OC18, P123, P186, P432, P1089	Nistal Rodríguez F. J. N.	P246, P786
Naraen S.	P375, P443	Nistor Cseppento C. D.	P635, P642
Naranjo A.	P495	Nistor-Cseppento C. D.	P499
Narihiro O.	P611, P612	Njeze N.	P207
Narita R.	OC17	Njeze N. C.	P1162, P1163
Nartea R.	P540, P937	Njeze N. R.	P1162, P1163
Nasarimba A. M.	P1129	Nofal K.	P157
Nasef S. I.	P472	Nogueira H.	P588
Nashi N.	P115	Nogues Solan X.	P521
Nasonov E.	P633	Nogues X.	P795
Naumescu S.	P1128	Nogues-Solan X.	P518
Nava-Bringas T. I.	P761, P776	Nordstrom A.	OC12
Navarro Grijalva M.	P593	Nordstrom P.	OC12
Nawara M.	P158	Norton L.	P1110
Nechifor O.	P1045	Norton N.	P998
Negara A.	P1099	Novack V.	P759, P1110
Negm A.	P548	Novella Navarro M.	P385
Negri A. L.	P1111	Novella-Navarro M.	P281, P516
Negru M. M.	P410	Novikov V.	P904
Nehrer S.	P587	Novikova I.	P735
Neji N.	P248, P364	Novkovic S.	P287, P485
Nejkov S.	P549, P602	Novosad P. N.	P460
Nelson-Filho P.	P572	Ntanil G.	ESCE04
Neradi D.	P990	Nuhaj L.	P1050
Nestorova R.	P708	Nuño Alves A.	P504
Newman A. B.	OC38	Nurković J. S.	P1167, P1168
Ng W. K. R.	P1161	Nurmohamed M. T.	P543
Nguyen H.	P557, P657	Nurullaev I.	P790
Nguyen S.	P716	Nushrat N.	P545
Nguyen T.	P654	Nuti * R.	P812
Nguyen T. V.	P217	Ó Breasail M.	P943
Nica A.	P937	O'Brien T.	P968
Nica A. S.	P1106	O'Carroll C.	P860
Nica S. A.	P540	O'Connell C.	P919
Niculescu D.	P529	O'Connell S.	OC20, P989
Nieto J.-C.	P367	O'Gradaigh D.	P1090
Nigil Haroon N.	P778, P857	O'Green A.	P226
Nikankina L.	P745, P900, P1076	O'Kelly J.	P997
Nikitin M. V.	P732, P738	O'Gradaigh D.	NS41
Nikitina E.	P758	O'Kelly J.	P1029
Nikitina N. V.	P738, P740, P1079	O'Leary C.	OC27
Nikitinskaya O.	P582, P633	Obeichina N.	P931
Nikolajsen L.	P1022	Obermayer-Pietsch B.	P685
Nikolic-Dimitrova E.	P231	Obradović M.	P122
Nikolik- Dimitrova E.	P412	Ocampos G. P.	P768, P769, P770
Nikolikj Dimitrova E.	P1078	Oddy W.	OC32
Nikolikj-Dimitrova E.	P683	Odén A.	OC23
Nikolov R.	P855	Ofir R.	P1015
Nikomarov D.	P413	Oh C.	P550
Nikonova T.	P900	Ohlsson C.	OC23
Nilsson O.	P428	Ohta H.	P283, P488
Nishimura H.	P233	Ojeda S.	P495

Okamura N.	P119	Paixao T.	P587, P673
Okawa A.	P240	Palabugina P. A.	P896
Okazaki J. E. F.	P928, P956, P977	Palanduz S.	P1026
Olçar H. A.	P368	Palencia J.	P907
Oleinik V.	P904	Palermo A.	P123, P186, P432
Olivares A.	P495	Palici C.	P888
Oliveira M. L.	P112	Palici C. F.	P1034, P1039, P1062
Oliveri B.	P343, P699, P976	Pallag A.	P353, P1109
Oliveria S.	P1154	Pallares N.	P518
Oltean-Dan D.	P1117	Palmer A. J.	P217
Omelka R.	P641, P662	Palmini G.	P182, P700
Onac I.	P1159	Pan F.	P117, P823, P826, P839
Onita P.	P817	Panagiotopoulos E.	P506, P867
Oprea E.-T.	P1131	Panagiotopoulou A.	P626
Or K.	P309	Panahi N.	P613
Orcesi Pedro A.	NS15, NS16, NS47, P951, P955, P958, P959	Panisello Sebastia J. J.	P113
Ordahan B.	P140	Pankiv I.	P706
Oren M. M.	P1082	Panko N. O.	P211
Orimo H.	P488	Pannacciulli N.	OC18, OC29, P409
Orlov A. V.	P702	Panoulis K.	P1147
Ortega Izquierdo M. E.	P504	Pantelidis D.	P1146
Ortsäter G.	P998, P1029	Pantelinac S.	P436, P1118
Orwoll E.	OC23	Pantis C.	P311, P312
Osani M.	MTE7, ESCE05	Papachristou D.	P696, P1105
Osca Guadalajara M.	P139	Papadopoulos E. C.	NS44
Osmanov Y.	P743	Papadopoulou E.	P599
Østbye T.	P461	Papaioannou A.	P249, P441, P548
Ostojic P.	P214	Papapoulos S.	P997, SY15
Ostovar A.	P613, P628, P629, P724, P726, P727, P797, P845, P878, P1003, OCs5	Papassotiriou I.	P270
Oswald E.	P625	Papathanasiou J.	P1028
Oswald I.	P480	Papatheodorou A.	P626
Otahal P.	P117, P820	Papichev E.	P210, P384, P424
Otlocan L.	P410	Papichev E. V.	P371
Otteva E. N.	P741	Papoulidis N.	P205
Ou L. C.	P870, OCs8	Papp I. K.	P1119
Ovejero Crespo D.	P795	Paramonova O. V.	P232, P562
Overgaard S.	P1022	Pardaens L.	P793
Özbek E. A.	P368	Pardina Lanuza N.	P114, P241
Ozkaraoğlu B.	P431	Pardo N.	P576
Ozkaraoğlu D.	P431	Parida G.	P475
Ozkuk K.	P140	Parisi S.	P792
Ozsari L.	P171	Park C.-W.	P193, P194
Ozsari L. O.	P169	Park I.	P550
Paccou J.	OC16, P632	Park J. S.	P212
Pachkaila A.	P969	Park K. S.	P799
Padez C.	P588	Park S.-H.	P194, P195, P720
Padidela R.	P428	Park W.	P538
Paesmans P.	P365	Park Y. J.	P799
Page A.	P999	Park Y. S.	P212, P799
Paiement P.	P170	Park Y.-S.	P193, P194
		Parra Soto C.	P949
		Parretti L.	P1138, P1142

Parsons C.	P433, ESCE04	Peterle V. C. U.	P772, P1145
Parsons C. M.	OC30, P689	Petermans J.	OC26, P154, P542, P693
Parvanescu C. D.	P1046, P1047, P1122	Peters B.	P737
Parvanescu D. C.	P1115	Petersen S.	OC25
Parvu M.	P394	Petit Dop F.	P689
Pasapera Alban N.	P719	Petranova T. Z.	P708
Pascariu I.	P397	Petropoulou M.	P548
Pasco J.	P653, P965	Petrova E.	P1140
Pasco J. A.	P650, P652, P655, P671, P985, P999	Petrushkina A.	P743, P745, P746
Pashkevich A. A.	P702	Petrusic T.	P755
Pasiyeshvili L. M.	P346	Peyser A.	P174, P181, P183
Patrascu J. M.	P970	Pflimlin A.	P632
Patru S.	P448, P449, P809, P873, P1009, P1014, P1017, P1055	Philibert P.	P575
Paula-Silva F. W. G.	P572	Phruetthiphat D. R.	P779, P785, P788
Paulina C.	P394	Pichelin M.	P1007
Paun D.	P1135, P1140	Pieber T.	P685
Pavlov-Dolijanovic S.	P214, P748	Pigarova E.	P294, P743, P745, P746
Pavlove M.	P976	Pijoan C.	P1156
Pavlovic D.	P800	Pijoan Moratalla C.	P278
Paxinos O.	P369	Piketky M.	P575
Payab M.	P845	Pimentel-Santos F. M.	P1134
Payer J.	P1013	Pineda-Moncusí M.	P521
Peacock M.	OC5	Pinedo-Villanueva R.	NS3, OC27, P422
Pearson R. A.	OC3	Pinheiro M. M.	P1158
Peat G. M.	P376	Pinho-Pompeu M.	P955, P958
Pedersen A.	NS4	Pinto A. L.	P535
Pedersen A. B.	P1022	Pinto D.	P1152
Pedone C.	P123, P186, P432	Pinzón A.	P966, P1148
Pedraza M.	P226	Pinzón D.	P974
Pedro A. O.	P911, P982	Piot A.	P229
Pejovic-Milic A.	P756	Pisani * P.	P812, P893
Pekareva E.	P900	Pisano P. G.	P263, P347
Peker O.	NS56	Pitino A.	P594
Peleganchuk V. A.	P574	Plapler P. G.	P769
Pelletier J.-P.	P170, P820	Plebani M.	P594
Peña Jimenez D.	P135	Podnar G.	P209
Pereira R. M.	P426	Pogljajen G.	P876
Pérez Alcántara A.	P104, P110, P111	Pogodina M. A.	P354
Perez B.	P343	Pogosyan K.	P703
Perez C.	P508, P884	Poiana C.	P529
Pérez C. E.	P440, P1150	Poletto G.	P705
Pérez-Castrillón J. L.	P597	Pollard C.	P443
Pérez-Coto I.	P757	Polyakov V.	P425, P897
Perka C.	P1015	Polyakova J.	P210, P424, P897
Peroni C. L.	P792	Polyakova J. V.	P371, P566
Perovic M.	P214	Polyakova Y.	P384, P851, P1001
Perrier-Cornet J.	P277	Polyzos S.	P243
Perrone D.	P1091	Ponce A.	P646
Persil Ozkan O.	P348	Pons J.	P223
Petcu C.	P838, P840	Poole K. E. S.	OC3
Petelina T.	P187	Popa A. R.	P314
		Popa D.	P1047

Popa M.	P762	Priymak D. V.	P796
Popescu M.	P829, P831, P834, P835, P836, P841, P844, P847, P850, P852	Prodanovic S.	P748
Popescu M. F.	P318	Protsenko V.	P298
Popivanov P.	P618, P619, P664, P665, P810, OCs7	Prutiian T. L.	P946
Popov A.	P886	Przhialkovskaya E.	P294, P559
Popov A. A.	P752, P896, OCs6	Puentes M.	P966
Popova S. T.	P331	Puisieux F.	P632
Popova V.	P331	Punda M.	P912, P929
Popovici Mut A. M.	P313, P318	Punj V.	P253
Popovici Mut E. D.	P313, P316, P318	Punthakee Z.	P649
Popoviciu H. V.	P1122	Punzi L.	P523
Popovtseva A. V.	P574	Puyuelo Jarne I.	P114, P241
Porrero Carro J. L.	P405	Pyone Z. C.	P868
Portale A.	P442	Qadir A. Q.	P106, P107, P108
Portela R. C.	P772	Qaffaf M.	P443
Portier A.	NS31	Qassem S.	P189
Portinho P. C.	P520	Qefoyan M.	P764
Porumb A.	P1024	Quarta * E.	P812
Posta P.	P872	Quarta * L.	P893
Potamoussi P.	P1149	Quashie T.	OC13
Pottel H.	P141, P677	Quesada-Masachs E.	P576
Pouchot J.	P615	Quiñones J.	P1156
Poveda J.	P127	Quiñones Torres J. R.	P278
Povoroznyuk V.	P992, P1038, P1040, P1057, P1060, OCs10	Quinonez K.	P141
Povzun A.	P1104	Quintanilla A. Q.	P786
Povzun K.	P1104	Quintero M.	P625, P679
Pozzilli P.	P186, P432	Quiroz Reyes A.	P242
Prada A.	P516	Quittan M.	ESPRM-ESCEO-IOF2
Prado C.	P296	Rabenda V.	P180
Prado Costa R.	P924	Radoi G.	P846
Prakash M.	P1083	Radomir M.	P122
Prats-Urbe A.	OC27	Radovanovic Dinic B.	P862
Preda S.- A.	P829, P831, P834, P835, P836, P838, P840, P841, P844, P847, P850, P852	Raeisi A.	P726, P727
Predescu A.	P829, P831, P834, P835, P836, P841, P844, P847, P850, P852	Raescu M.	P841, P844, P847, P850, P852
Predescu O. R.	P920, P1062	Rafferty M.	P860, P910, P916, P919
Predescu O.-R.	P888, P1034	Raghupathy R.	P230
Predko N.	P581	Ragimov M.	P900
Premrou V.	P976	Ragusa O. L. F.	P396
Prenni V.	P1138	Raiesi A.	P628, P629, P797, OCs5
Prentice A.	P942, P943	Raisi-Estabragh Z.	OC25
Price A.	P376	Rakusa M.	P876
Price I.	P927	Ramanau H.	P581
Prieto-Alhambra D.	NS2, OC6, OC27, P127, P376, P422, P518, P586, P698, P701	Ramkhelawon B.	P620
Prieto-Potin I.	P682	Ranasinha S.	P1051
Prikhodchenko I.	P822	Ranera M.	P131
Priora M.	P792	Rangan A.	P376
		Ranger P.	P557
		Rannou F.	MTE2, P180, P754, ESCEO-IOF-SFR-GRIO5
		Rapp K.	P539
		Raptis K.	P176, P177, P205, P302, P369
		Rapushi E.	P1050
		Rasa I.	P887, P901

Rasaei N.	P338, P350, OCs2	Rizzoli R.	SL2, OC22, OC36, PL10, P523, P542, P567, SY1, ESCE010
Rashidbeygi M. S.	P330	Robbiani D.	P343
Raskina T.	P741, P819, P824, P828, P832	Robinson B.	P594
Rat A. C.	OC11	Robinson D.	OC27
Rat A.-C.	P615	Robinson D. E.	P698
Rathi J.	P997	Robinson S.	P433
Rauch M.	P701	Rochelle R.	P527
Ray P.	P880	Rodionova S.	P279
Raymuyev K. V.	P354	Rodionova S. S.	P459
Raynauld J.-P.	P170	Rodríguez Morera R.	P521
Razi F.	P613, P628, P797, OCs5	Rodríguez R.	P521
Razvalayeva D. V.	P507	Rodríguez Vela J.	P135
Rebollo S.	P167, P168	Rodríguez-Lozano B.	P950
Recknor C.	OC3	Rodríguez-Lozano C.	P495
Reginster J.-Y.	SL2, OC21, OC24, OC26, OC28, OC33, OC34, PL4, P153, P180, P201, P218, P219, P220, P470, P517, P523, P542, P622, P688, P689, P693, P754, SY4, SY10, ESCE04, ESCE09, ESCE010, OCs1	Rodríguez-Sanz M.	P521
Rehman S.	P931	Roels T.	P669
Reinke P.	P1015	Roganovic N.	P125
Rejnmark L.	SY9	Rogatkina T.	P425
René R.	ESCE09	Rogoveanu I.	P483
Renò F.	P342	Rogoveanu O.	P445, P446, P846, P856, P877
Reps J.	OC27	Rogoveanu O. C.	P265, P286, P387, P389, P390, P391, P392, P481, P482, P483, P484, P492, P494, P1084
Resceanu I. C.	P846, P859, P861	Roguin Maor N.	P413
Restaino O. F.	SY12	Rojas R. W.	P259
Rey P.	P976	Rojas Vilca J.	P719
Reyes C.	P127	Rojeski M.	OC9, P1089
Reyes-Delpech P.	P767	Rolland C.	P515
Rhee Y.	P411	Rolland Y.	P542, EUGMS-ESCEO-IOF2, ESCE09, ESCE010
Ribeiro-da-Silva A.	P1043	Romagnoli C.	P182, P700, P1033
Ribom E.	OC23	Romanova N.	P988
Richardson J.	P548	Rombaut L.	P419
Richiardi L.	P918	Romera M.	P684
Ridout R.	OC15	Romero Escribano E.	P198
Rik L.	P250	Romero M. C.	P386
Rillo A.	P131, P132	Romero-Alvernia D. M.	P975
Rillo Lazaro A.	P133, P139	Romualdo P. C.	P572
Rillo Lázaro A.	P134, P197	Roncero-González S.	P757
Rincón D.	P974	Rondon P. E. R.	P1157
Rincon O.	P489	Roques C.	P515
Ringe J. D.	P404	Rosado-Marques V.	P588
Rios C.	P199, P245	Roschel H.	P426
Ristanovic V.	P269	Rosen E.	P825
Riva M.	P961	Rosenblum R. C.	P528
Rivadeneira F.	P1059	Rosengren B. E.	OC23
Rivera M. A.	P973	Rosenkranz A.	P685
Rivera N.	P884	Rosero O.	P975, P978
Rizos D.	P971, P1147	Rosero Olarte O.	NS57
		Ross D.	P1165
		Rossi I.	P775
		Rossini M.	P812

Rosu A.	P1039, P1046, P1047, P1062, P1115, P1122, P1129	Sachenkov O.	P592, P734, P736
Rotaru L.	P498, P513	Sadauskaitė G.	P1061
Rotaru T.	P1008	Sadovici-Bobeica V.	P1008
Rotman Pikielny P.	P528	Safianik E. A.	P752, OCs6
Rotonda C.	P615	Safonova Y.	P661
Rouach V.	OC10, P291, P382, P991, P994	Saguez R.	P1098
Roubille C.	OC11	Sahin M.	P140, P273, P274, P565, P1048, P1069
Roux C.	MTE13, NS28, OC11, P515, SY9, SY15	Sahin N.	P140
Royo Agustin M.	P133, P134, P139, P197	Saini U. C.	P1064, P1083
Royo M.	P131, P132	Saito H.	P233
Rozhinskaya L.	P294, P743, P746, P1101	Sajjad M. A.	P652
Rozhinskaya L. Y.	P796	Sajjadi S. F.	P338, OCs2
Rubiño F.	P495	Sakellari V.	P1019
Ruci D.	P707	Sala L.	P516
Rudenska A.	P681, P806, P811, P882, P883, P996, P1016	Salah W.	P742
Rudenska E.	P581, P681, P883, P885, P969, P1016	Salaru V.	P1008
Rudenska E. V.	P695	Salbas E.	P140
Rudenko E.	P806, P811, P996	Salcedo C.	P966
Rufus-Membere P.	P653	Saleh A.	P130
Rufus-Membere P. G.	P652, P671	Salemkar S.	P476
Ruggiero C.	P1138, P1142	Salerni H.	P343, P976
Ruiz Barrera L.	P242	Salko V.	P1050
Ruiz de Temiño A.	P597	Salman S.	P188, P189
Ruiz E.	P508, P884, P1150	Samaras C.	P1149
Ruiz M. E.	P440	Samaras N.	P380, P603
Ruiz Ruiz J.	P284	Samarasinghe R.	P985
Rukhadze T.	P202	Samartzi A.	P270
Rumyantsev P.	P743	Sami N.	P415
Rusanova O. A.	P190	Samigullina R. R.	P796
Rusman T.	P543	Samokhovec O.	P883, P1016
Russo G. T.	P715	Samokhovec V.	P806, P811, P996
Russu E.	P498, P513	Samokish A.	P938
Ryan P.	OC27	Samoutis G.	NS43
Rybina O.	P1057, OCs10	Sampaio F.	P1044
Ryg J.	OC19	Samsudin I. N.	P297, P299, P729
Rygaert X.	P180	San Martin J.	OC5, P428, P442
Rymar O.	P469	Sanagustin M.	P167, P168
Ryzhkov A. D.	P813	Sánchez A.	P976
Ryzhkova D. V.	P381	Sánchez Almaraz R.	P405
Sá-Pinto A. L.	P426	Sanchez Aranda F. M.	P1123
Saag K.	P409	Sanchez H.	P950
Saavedra A.	P495	Sanchez Marquez P. E.	P973
Sabapathipillai S.	P280	Sánchez Ortuño P.	P648
Sabarul A. M.	P843, P853, P858	Sanchez P.	P1011
Sabati Rajic A.	P322	Sánchez-Castellano C.	P561
Sabau A. M.	P635, P642	Sánchez-Rodríguez M. A.	P1096
Sabico S.	P219	Sancho M.	P167, P168
Sachdev H. P. S.	P932, OCs9	Sanders K.	P534, P567
Sachelarie L.	P1114	Sanders K. M.	P217
		Sandoval-García M. A.	P757
		Sandulescu D. L.	P1129
		Sanesi L.	P123

Santesso N.	OC15	Sekiya T.	P577
Santilli V.	P512	Sellam J.	ESCEO-IOF-SFR-GRIO2
Santo M. A.	P426	Sellam S.	OC11
Santonati A.	P186, P432	Semeniv I.	P995
Santos E.	P737	Semenova E.	P592
Santos F. C.	P928, P956, P977	Sen S.	P475
Santos P.	P737	Sena A. G.	OC27
Sanz A. S.	P786	Senbel E.	P515
Saparbayeva M.	P865	Seo H. A.	P537
Saraux A.	P615	Seo J. W.	P374
Sardella A.	P715, P717	Seo T.	P226
Saric S. S.	P864	Sepulveda C.	P495
Saridogan M.	P447, P451	Serdobintsev M.	P904, P935, P1108
Sarifakioglu B.	P140	Serra F.	P907
Sarli M.	P976	Serrier H.	P670
Sarmiento A. K.	P1143	Sert O.	P140
Sarmiento Lievano A. K.	NS61	Servitja S.	P521
Sarocka A.	P641, P662	Sesta M. M.	P1111
Sas L. M.	P481, P482	Sevcik T.	P420
Sas T. N.	P481, P482	Sevinc B.	P140
Sasaki T.	P1030	Seymour H.	P146, P147, P148, P149
Sasonova N.	P1101	Shafat T.	P1110
Sati H.	P475	Shafiee G.	P613, P628, P629, P724, P726, P727, P797, P878, OCs5
Satman I.	P1132	Shah S.	P477
Sava C.	P635	Shahifar N.	P297, P299, P729
Savas S.	P140	Shahzad M. T.	P908
Sayre E. C.	P774	Shakurova L.	P456, P509
Sazonov K.	P904	Shakurova L. R.	P507
Scaglia L.	P474	Shalev V.	OC10, P382, P991, P994
Scarcella C.	P715	Shalnova S.	P407
Schafer A.	P323	Shamai-Lubovitz O.	P382
Scharla S. H.	P1036	Shambatov M. A.	P752, OCs6
Schett G.	NS36	Shamitova E.	P851
Schiara L. A. M.	P918	Shanmugaraj K.	P156
Schiraldi C.	SY12	Shao S. R.	P514
Scholler G.	P105	Shapovalova D.	P889
Schollum L.	OC20, P989	Sharapova E.	P403
Schott A.-M.	P670	Sharapova E. P.	P741
Schrank Y.	P730	Sharara S.	P783
Schroeder F.	P1116	Shargorodsky M. S.	P120
Schwartz A. V.	P1116	Sharifi F.	P724, P726, P727, P845, P878
Sciortino R. M.	P625, P679	Sharkawi M. A.	P843, P853, P858
Scofiienza L. M.	P129	Sharma J. P.	P477
Sconfienza L.	P580, P1006	Sharma M.	P760
Scott D.	OC12, OC32, P567	Sharma P.	P1033
Scotton D.	P679	Sharma S.	P990
Seetharaman S. K.	P115	Shaul J.	P1063
Seewordova L.	P210	Shaw N. J.	P422
Sei M.	P611, P612	Shaw S.	ESCEO4
Seiji O.	P555	Shehab D.	P230
Seino Y.	P624	Shepelkevich A.	P357, P595, P725, P827
Sekiguchi-Ueda S.	P624	Shepelkevich A. P.	P341, P802, P807

Shepetov A.	P1100	Sinha S.	P932, OCs9
Shere C.	P471	Sinyaeva I. R.	P215
Shestakova M.	P1101	Siraj N.	P649
Shevchenko N. S.	P211	Sirakova K.	P618, P619, P664, P665, P810, OCs7
Shevroja E.	P1056, P1059, P1066	Sirbu A.	P762
Shibata M.	P577, P624	Sirbu A. E.	P453
Shih H.-N.	P536	Sirbu A. M.	P833
Shilova L.	P544, P794	Siris E.	OC18, P759, P1110
Shilova L. N.	P232, P562, P609, P732, P738, P740, P986, P1079	Sivordova L.	P384, P424, P425, P1001
Shin C. S.	P659	Sivordova L. E.	P371, P566
Shin Y.	P253	Skalicky S.	P1116
Shiraki M.	P488	Škarić Karanikić Z.	P549
Shiroma E. J.	OC38	Skaric-Karanikic Z.	P602
Shirvani A.	P1160	Skarpas G.	NS42
Shivappa N.	OC32	Skjødt M. K.	OC8
Shmilovitz S.	P382	Skrepnik N.	OC37
Shoepe T. C.	P744	Skrinar A.	P428
Shore-Lorenti C.	P657	Skripnikova I.	P407
Shubeska Stratrova S.	P598	Skripnikova I. A.	P871
Shukla H.	P370, P377, P467, P468	Skrynnik L.	P681
Shukla R.	P370, P377, P467, P468	Skuratov O.	P372
Shultz S.	P968	Slaidina A.	P758
Shumnalieva R.	P288	Slashuk K.	P743
Shuvalova E.	P904	Sleptsov I.	P703
Shymanskyi I.	P1121	Śliwczyński A.	P921
Shynkaruk I.	P321	Smedescu V.	P410
Si L.	P217	Smirnov A. V.	P750, P813
Siarkos E.	P1149	Smith A.	P927
Sierra A. S.	P259	Smith L.	OC31, P523
Sierra-Pereira A.	P757	Smiyan S.	P898
Sifuentes-Giraldo W. A.	P766	Snodgrass J.	OC13
Siggeirsdottir K.	OC7	So Youn S. P.	P967
Siglinsky E.	P252	Soare I.	P762
Sigurdsson G.	OC7	Soare I. S.	P453
Sihota P.	P990	Sobhy Abdulhameed Abdulkhaliq M.	P216
Silva A. R. B.	P1158	Soboleva U.	P758
Silva Junior J. B.	P772	Soen S.	P283, P488
Silva L. A. B.	P572	Sogabe S.	P119
Silva M. P.	P1023	Soin A. S.	P477
Silva M.-R.	P588	Sokolenko A.	P963
Silva R. A. B.	P572	Sokolovic S.	NS51
Silverman S.	P622, ESCEO-IOFUSA2	Sokolovich E.	P904
Simić-Panić D.	P1118	Solehah S.	P457
Simmons H.	P428	Soltani A.	P613
Simon D.	NS36	Sone T.	P488
Simon V.	P640, P941	Songpatanasilp P.	P779
Sinaki M.	P203	Soo Young L.	P301
Sindhupakorn D. R.	P493	Soric G.	P1099
Singh D.	P166	Sornay-Rendu E.	P1007
Singh P.	P166	Sorokina G. L.	P1086
Singh R.	P1020, P1035	Sosic L.	P1037
Sinha M.	P307		

Souberbielle J.	P192	Stroncek J.	OC35
Souberbielle J. C.	P126	Stuart A. L.	P655
Sousa C.	P112	Stuart Silverman S.	P323
Soysal P.	OC31, P525	Styazhkina E. M.	P507
Spângéus A.	P1029	Su Y.	P1170
Spanou S.	P388, P399, P603	Subasinghe H.	P608, P722
Spertino E.	P918	Subin-Teodosijevic S.	P519, P533
Spitsina S.	P544, P794	Subin-Teodosijević S.	P522
Spitsina S. S.	P479, P617, P621	Sucaliuc A.	P833, P890
Spoendlin J.	P701	Suciu C.	P1103
Spooner L.	ESCE04	Suciu N. R.	P353, P666
Springe B.	P758	Suciu R. N.	P642, P711
Sproviero W.	OC27	Sudoruk E.	P749
Spyridonidis A.	P696, P1105	Sugimoto T.	P283
Spyropoulou O.	P1149	Suh C. H.	P200
Squibb K.	P117, P179	Suh J.	P295
Sranko P.	P662	Sui S. X.	P650, P652, P655
Srikumaran U.	P709, P710, P712	Suiu L.	P888
Srouf F.	P515	Suiu L. I.	P920
Ss A.	P984	Şulea A.	P1097
Stad R.	P997	Sulea P.-A.	P1103
Stambolova M.	P288	Suleymanova A.	P568, P571, P661
Stamenkovic B.	P502, P862	Sulikashvili T.	P235
Stanciugelu S. I.	P970	Suliman Y.	P742
Stancu A.	P890	Sullivan R.	P860
Stanisavljevic S. N.	P444	Sümeýra O.	P1021
Stathi D.	P373	Sun K.-T.	P605, P606
Steen G.	P860, P910, P917	Suñen Sanchez E.	P135
Steinecker-Frohnwieser B.	P667	Surcheva S.	P855
Stellavato A.	SY12	Suspitsin E.	P963
Stenkova N. F.	P215	Suteu C.	P1114
Stepanova A.	P672	Süttő Z.	P945
Stergiopoulos D.	P1124	Suzuki A.	P283, P577, P624
Sterling R. S.	P716, P1151	Svebis M.	P953
Stern N.	P291	Svedström E.	P1005
Stewart D.	P372	Swearingen C.	OC37, P226, P651
Stoica V.	P1112	Syddall H. E.	OC14, OC38
Stoicanescu D.	OCs11, P711, P714, P765, P925, P1067	Sylvetsky N.	P174, P183
Stoickov M.	P922	Symeonidis N.	P373
Stoilov N.	P805, P821	Szabo B.	P162
Stojanoska Matjanoska L.	P238, P239	Szejnfeld V. L.	P1158
Stojanovic S.	P502, P862	Szili B.	P162
Stojanovic S. L. J.	P444	Szocs T.	OCs11, P1067
Stoll D.	P1041	Szulc P.	P229, P639, P1007
Stolnicki B.	P547	Szypowska A.	P921
Strakhov M. A.	P354	Taani M.	P252
Strand V.	P651	Tabacco G.	P123, P186, P432
Strauss V. Y.	OC27, P698	Tabain A.	P913
Streba L.	P1046, P1129	Tabak A.	P953
Strebkova E.	P1085	Tabak D.	P913
Strebkova E. A.	P741	Tabti E.	P909
Ström O. E.	P1029	Tabuena Sanchez A.	P135

Tabushi F.	P705	Teran Tinedo M. A.	P278
Tai T.	P151	Tereshenkova I. I.	P215
Tai T. W.	P324	Terpos E.	P243
Tai Y. T.	P292	Terzea D.	P1135
Takacs I.	P162	Thabane L.	P249, P548
Takaso M.	P584	Thambiah S. C.	P297, P299
Takasoe A.	P233	Theocharatos S.	P165
Takayama L.	P426	Theodorakopoulos S.	P530
Takayanagi H.	P963	Thibaud G.	P515
Takayanagi T.	P577, P624	Thomas T.	NS37, P515, P754, P881, P1090
Takayuki I.	P555	Thomsen Ernst M.	P586
Talevski J.	P534	Thong E. P.	P1051
Tam B.	P226	Tian J.	P427, P823, P826, P839
Tam S. M.	P178	Tian W.	P213
Tamagawa Y.	P981	Tibaldi M.	P918
Tamar T.	P759	Tibiche A.	P191
Tambiah J.	OC37, P226, P651	Tikhomirova E.	P544, P794
Tamulaitiene M.	P806, P811, P1094	Tikhomirova E. A.	P479, P617, P621
Tamulaitienė M.	P1061, P1065	Tilea I.	P1103
Tan C. S.	P461	Timoshanko J.	P880
Tan F.	P947	Tirado A.	P1044
Tan G. D.	P698	Tirosh A.	P731
Tan I. Y.	P895	Tit D. M.	P635, P642
Tanaka S.	P283, P363, P804	Tiu K. L.	P178, P423, P490
Tandon N.	P932, OCs9	Tiulpakov A.	P559
Tanemura M.	P981	To K.	P351
Tang H.	P361	Tobias J.	OC30
Tang T. N.	P1161	Todor L.	P1024
Tanigawa H.	P981	Todorov P.	P708
Tanimoto K.	P545	Todorova M.	P541, P578, P616
Taosuwan S.	P788	Tofiloska Josifoska S. T. J.	P510
Tariq S.	P704	Tolentino- Bazan K.	P776
Tariq S. T.	P908	Tolis K.	P205
Taskina E.	P403	Tolman C.	P659
Taskina E. A.	P741, P750	Toloumis G.	P626
Tavares D. R.	P962, P964	Tomai Pitinca M. D.	P894, P905
Tavares D. R. B.	P928, P956, P977	Tomasevic-Todorovic S.	P335, P436, P583
Tavares H.	P924	Tomašević-Todorović S.	P1118
Tavluev V. A.	P871	Tomatsu E.	P577, P624
Tchetina E.	P403	Tomic T.	P830
Tebe C.	P518	Tomkova S.	P420
Teede H. J.	P1051	Tomková S.	P1013
Tell G.	P987	Tomoaia G.	P1117
Tembo M. C.	P650, P652, P655	Tomomitsu M.	OC17
Temelkova K.	P664, P665, P810, OCs7	Tong C. V.	P159, P292
Temelkova N.	P618, P619, P664, P665, P810, OCs7	Torabi S.	P1116
Tent A.	P1024	Torgashin A.	P279
Tenti S.	P1166, SY6	Torgashina A.	P279
Tentori F.	P594	Tormo S.	P343
Teodosijevic Subin S.	P645	Toro Prieto F. J.	P462, P463
Teplyakova O. V.	P638	Toroptsova N.	P582, P633
Teran M. A.	P1156	Toroptsova N. V.	P796

Torre I.	P440, P508, P884, P1150	Turturea I. F.	P1126
Torrent M.	P576	Turturea R.	P1130
Torres Naranjo J. F.	P721	Turvida S. G.	P753
Toshishige M.	P585	Tusquets I.	P521
Toshiyuki N.	P555	Tutiya K.	P962, P964
Toth E.	OC6, P586	Tuzun S.	NS49
Tournis S.	P176, P177, P205, P302, P677	Twito O.	P528
Tournoy J.	P686, P687, P690	Tyllianakis M.	P438, P506, P867, P1092, P1105
Touzi M.	P849	Tyurin A.	P889
Towler M.	P160	Tzanavari A.	P1070, P1075, P1080, P1146
Trăistaru M. R.	P265, P286	Ucb U.	SY3
Traistaru R.	P445, P446, P483, P492, P856, P859, P877	Uchida K.	P584
Treece G. M.	OC3	Uebelhart D.	P754, ESCE04, ESCEO-WHOCC4
Trejos J. A.	P386	Uehara S.	P361
Tremollières F.	P515	Uemura Y.	P488
Triantafylopoulos I.	P205	Ueng S. W. N.	P536
Tricarico D.	P1004	Ugai G.	P1012
Tripepi G.	P594	Uitterlinden A. G.	P1059
Tripto-Shkolnik L.	OC10, P731	Ulivieri F. M.	P129
Trivedi R. T.	P1155	Ulmer T.	P253
Trofimenko A.	P544, P794	Ungur R.	P1159
Trofimenko A. S.	P479, P609, P617, P621, P623	Upmale S.	P887, P901
Trombetti A.	OC36	Urban R.	P1063
Troshin P.	P592	Urgel A. C.	P131, P132
Trovias G.	P1028	Urgel Granados A.	P133, P504
Trujillo E.	P950	Urgel Granados A. C.	P134, P197
Trushyna A. S.	P695	Urgel Granados A. J.	P139
Tsagareli M.	P235	Usategui R.	P597
Tsai H.-Y.	P658	Uysal B.	P140
Tsai J. P.	P478	Vadzianava V.	P725
Tsakiridis P.	P1070, P1075, P1141, P1146	Vadzianava V. V.	P802, P807
Tsarenok S.	P634, P656, P771	Vagic K.	P287, P485
Tsartsalis A. N.	P270, P1120	Vahdat K.	P629
Tsartsalis D.	P270	Vaiphei K.	P1083
Tsekmekidou X.	P875	Vakas P.	P971
Tsekoura M.	P506, P867	Valcheva-Kuzmanova S.	P541, P578, P616
Tsepis E.	P406, P506, P560, P867	Valea A.	P1126, P1128, P1130, P1133, P1135, P1140, P1144
Tsezou A.	P373	Valenzuela G. J.	OC4
Tsioutis K.	P1068, P1088	Valero-Alcaide R.	ESPRM-ESCEO-IOF3
Tsitsilonis S.	P954	Vallières F.	P1157
Tso C. Y.	P1161	Van de Laarschot D. M.	P458
Tsoriev T.	P1076, P1101	Van de Wijdeven K.	P128
Tsourdi E.	P243	Van den Bergh J. P.	P128
Tsuji Y.	P119	Van den Bergh J. P. W.	P895
Tuculina M. J.	P829, P831, P834, P835, P836, P838, P840, P841, P844, P847, P850, P852	Van Maren M.	P128
Turchin N. I.	P946	Van Middelkoop M.	P777, P780
Turda C.	P948, P952	Van'T Hof R.	P640
Turkic E.	P678	Vandeweerd J.-M.	P640, P941
Turkmen B.	P660, P663, P891	Vanhaverbeke T.	P793
Turner T.	P1063	Vaquero N.	ESCEO9, ESCEO10
		Vaquero T.	P296

Vaquero-Pinto M. N.	P561	Vidican D.	P833
Varas de Dios B.	P405	Vidovic D.	P912
Vardanyan V.	P899	Vierlinger K.	P1116
Varga A.	P1103	Viezuina D.-M.	P1009
Varghese A.	P778, P857	Vikhareva A. A.	P752, OCs6
Varnum C.	P1022	Vilarrasa N.	P551
Varsavsky M.	P976	Villacorta Linaza B.	P463
Varshney S. V.	P983	Villalvilla A.	P682
Vasikaran S.	P677, P960	Vincent A.	P657
Vasilakis N.	P927	Vintila E. M.	P1129
Vasileva E.	P672	Viprey M.	P670
Vasileva V.	P509, P1164	Vishnevskii A.	P904
Vasilieva N.	P827	Visman I.	P543
Vasilieva N. A.	P341	Visser J. V.	P128
Vasiliu C.	P1144	Vitale J.	P580
Vasilyev E.	P559	Vitaloni M.	P625, P679, P684
Vasilyeva N.	P725	Vittinghof E.	P323
Vasilyeva N. A.	P802, P807	Viun T. I.	P116
Vasquez N.	P1148	Vizdoaga A.	P1008
Vassallo K.	P649	Vlachou E.	P270
Vavra- Hadžiahmetović N.	P791	Vladu A.	P311, P315, P316
Vazhev Z.	P331	Vlaskovska M.	P541, P578, P616, P855
Vázquez Díaz M.	P278, P766	Vohora D.	P166, P196
Vázquez M.	P1156	Volk H.-D.	P1015
Vega L.	P440, P508, P884, P1150	Volkava M. V.	P1081
Veiga Cabello R. M.	P284, P362	Voronkina A.	P832
Velaiutham S.	P333	Vorotnikova S.	P745
Veliky M.	P1121	Vrána V. R.	P460
Vendrami C.	P1073	Vranješ M.	P122
Venidiktova Y. U.	P822	Vreju A. F.	P888, P920, P1034, P1039, P1046, P1047, P1062, P1122
Venn A.	P429, P430	Vreju F. A.	P1084, P1115, P1129
Venter A.	P480	Vrijens B.	ESCEO-IOF-WHOCC1
Vered I.	P731	Vrtovec B.	P876
Verges J.	P625, P679, P684	Vucic Z.	P533, P570
Verkhoturova S.	P634, P656, P771	Vuilleumier P.	OC36
Verlhac B.	NS33	Vujasinovic Stupar N.	P214, P748
Veronese N.	NS13, OC21, OC31, P517, P523, P524, P525, ESCEO8, ESCEO-WHOCC3	Vukicevic S.	P282
Veroniki A.	P548	Vukičević S.	P913
Verroken C.	P419	Vukojevic R.	P929
Verschueren S.	P686, P687, P690	Vukovic M.	P602
Verschuure P.	P895	Vuković M.	P549
Vesa C. M.	P261, P310, P313, P314	Vyskocil V.	P872
Veselinovic M.	P800	Waarsing J. H.	P777, P780
Vestergaard P.	OC8	Wadhwa R.	P196
Veza C.	P918	Waeber G.	P1073
Viapiana * O.	P812	Waidyaratne E. I.	P608, P722
Vicas L.	P499, P635, P642	Waldbillig A.	P649
Vicente P.	P167, P168	Walicka M.	P921
Vico L.	PL5	Wallwitz J.	P676
Vidal Neira L. F.	P719	Walsh C.	P443
Vidal Wilman M.	P719	Walsh J. B.	P860, P916, P917
		Wan C. W. R.	P739

Wang A. F. W.	P874	Wu C. H.	P870, OCs8
Wang C.	OC29	Wu C.-H.	P437, P659
Wang C.-Y.	P781, P816, P818, P848	Wu F.	OC32, P427
Wang C.-Z.	P637	Wu F. T.	P610
Wang H.	P250	Wu H.	P417
Wang J.	P264	Wu J. D. W.	P874
Wang L.	P213, P221, P1170	Wu P.-C.	P383, P934
Wang W.-H.	P1054, P1058	Wu W. F.	P172
Wang Y.	OC4	Wu W. T.	P1172
Wanting J.	P465	Wu X.	P1170
Ward K.	OC30	Wyers C. E.	P128
Ward K. A.	OC14, OC25, P471, P942, P943	Xammar C.	P551
Ward L.	P428	Xavier R. M.	P769
Ward W. E.	OC15	Xenophontos P.	P1068, P1088
Wargny M.	P1007	Xhemali I.	P1050
Warling X.	P141	Xia W.	P361
Watanabe M.	OC17	Xiang L.	P604
Watar F.	P680	Xiaxia X.	P627
Wataru S.	P555, P611, P612	Xu X.	P264
Watelain E.	P450	Xu Y.	P163, P290
Weber J.	P954	Xu Y. J.	P327, P328
Weber T.	OC5	Xu Y. J. X.	P874
Weigl L.	P667	Xu Y.-J.	P879
Weiguo B.	P101, P400	Xuezhe H.	P251
Weijden M. A. C.	P543	Yablonskiy P.	P904
Weiler-Sagie M.	P413	Yadav R. N.	P990
Weiss R.	OC4, P622	Yagisawa M.	P119
Wells J.	P979	Yaish I.	P291
Wenchen J.	P101	Yakout S.	P395, P491
Westbury L. D.	OC14, OC38	Yakovlev A. T.	P566
Whallett A. J.	P307	Yakubova L.	P892
White C.	P654	Yamamoto G. J.	P770
Whitmarsh T.	OC3	Yamamoto M.	P244
Whyte P.	P428	Yanevskaya L.	P703
Wieczorek M.	P615	Yang C.-H.	P437
Wiles B.	P927	Yang M.	P401, P1170
Williams L.	P965	Yang R.	P1170
Williams L. J.	P650, P652, P655, P985, P999	Yang R.-S.	P355, P500, P658, P781, P816, P818, P848
Williams R. D.	OC27	Yang T. L.	P417, P418, P607
Williams S. A.	P622	Yang T.-H.	P355, P658
Wills K.	P117, P179	Yang W.	OC9, P659, P1089
Winkler T.	P1015	Yang Y.	P610
Winther A.	P505	Yang Y. C.	OC3
Winzenberg T.	OC32, P117, P217, P427, P610, P777, P780	Yao S.	P417, P418, P607
Winzenberg W. T.	P172	Yasa C.	P348
Winzenrieth R.	OC22, P415, P521, P551, P1044	Yasmeen H.	P931
Wirth W. W.	P815	Yasuoka H.	P283
Wittoek R.	P627, P793	Yatsyshyn R.	P275, P276
Wluka W. A.	P172	Yavropoulou M.	P243
Wong H.	P774	Yay A. Y.	P169
Wong R. M. Y.	P1161	Yazici Y.	OC37, P226, P651
Woo Y. C.	P659	Yeap B. B.	P1169

Yeap S. S.	P297, P299, P729	Zanchetta M. B.	P343, P976, P1027, P1111
Yeh K. T.	P1172	Zapatero Gaviria A.	P284
Yela D. A.	P982	Zariffeh H.	P649
Yeo W.	P461	Zavodovky B. V.	P871
Yeu J.	P295	Zavodovsky B.	P210, P384, P424, P1001
Yi S.-M.	P194, P195	Zavodovsky B. V.	P371, P566
Yi Sle Y. L.	P967	Zavratnik A.	P366
Yidirim C. Y.	P169	Zavvos A.	P1124
Yildirim P.	P140	Zaytseva E. M.	P813
Yilmaz O.	P660, P663, P891, P1025, P1026, P1031, P1082, P1132	Zazirniy I.	P995
Yimer B. B.	OC27	Zborovskaya I.	P384
Yin L.	P213	Zborovskaya I. A.	P617, P621, P732, P738, P740
Yin M. K.	P843, P853, P858	Zebekakis P.	P875
Yin X.	P409	Zeglaoui H.	P940
Ying-Hung L.	P614	Zeljko S.	P214
Yoel U.	P759	Zemánek Z. M.	P460
Yokoyama Y.	OC17	Zeng J.	P249, P260
Yonem A. Y.	P169	Zengin A.	P932, P942, OCs9
Yong E.	P511	Zenkova T.	P746
Yoon B.-K.	P193	Zepeda-Mora R.	P761, P776
Yoon J. Y.	P161, P268	Zha Z.	P250
Yoshiko Y.	P545, P585	Zhang H.	P879
Yoshimura N.	P363, P804	Zhang J.	P601, OCs4
Yoshino Y.	P283, P577, P624	Zhang K.	P417, P418, P607
Yoshioka H.	P585	Zhang R.	P221
Young J.	P649	Zhang Y. J.	P418
Yu D.	OC27	Zhang Z.	P361
Yu T. C.	P1172	Zhang Z. L.	P289
Yu W.	P361	Zhao C.	P250
Yuan Y.	P264	Zhao Y.	P345
Yue H.	P289	Zhao Z.	P658
Yue S.	OC29	Zhelenina L. A.	P702
Yuki S.	P119	Zheng X.	P250
Yung S. H. P.	P866	Zheng Z. S.	P172
Yusupova G.	P1087, P1125	Zhu Z.	P345
Zabihyeganeh M.	P118	Zhukouskaya V.	P725, P827
Zaboltnaya N.	P938	Zhukov A.	P743, P745
Zacay G.	P731	Zicishti E.	P1050
Zaghloul M. Z.	P503	Zięba M.	P921
Zagorodneva E.	P1001	Zilikens C.	P1059
Zagoudinos D.	P380	Zillikens M. C.	P458
Zaha D.	P261, P310, P312, P314, P666	Zimin A.	P1087, P1125
Zahari Sham S. Y.	P729	Zinger G.	P174, P181, P183
Zahari-Sham S. Y.	P297, P299	Zisimopoulou E.	P902
Zaheer S.	P931	Zivkovic V.	P862
Zahid A.	P649	Zmierczak H. G.	P419
Zaina A.	P413	Zonefrati R.	P182, P700, P1033
Zainuddin N.	P297, P299, P729	Zonić-Imamović M.	P531
Zaki K.	P157	Zonova E. V.	P741
Zakroyeva A.	P305, P869	Zorin V.	P963
Zakroyeva A. G.	P513	Zotkin E.	P661
Zamfirescu A.	P271	Zoto A.	P707, P1050

Zoupidou K.	P530
Zrour S.	P849
Zsakai A.	P257, P258, P692
Zubovic Z. A.	P864
Zueva E.	P187
Zunquin G.	P563
Zvekic Svorcan J.	P304, P645
Zvekic-Svorcan J.	P533, P570
Zvekić-Svorcan J.	P522
Zvereva K.	P1053
Zyangirov R.	P694
Zyma A.	P372

PRACTICAL ARTICLES
EXPERT INTERVIEWS
NEWS AND INSIGHTS
PEER REVIEWED | OPEN ACCESS
CONCISE | MULTIMEDIA



VIEW – DOWNLOAD – SUBSCRIBE
FREE

touch **ENDOCRINOLOGY**.com

Bone Research Society Events

BONE RESEARCH SOCIETY CLINICAL TRAINING COURSE

OSTEOPOROSIS

& OTHER METABOLIC BONE DISEASES

This annual 3-day residential training course provides trainees in medical specialties such as rheumatology, endocrinology, care of the elderly, gastroenterology, orthopaedics, respiratory medicine and clinical chemistry with the knowledge and understanding to manage patients with osteoporosis and other metabolic bone diseases.

The course focuses on practical issues relating to patient management and is strongly recommended for any trainee who foresees that patients with these disorders will form a significant part of their workload in future.

Specialist nurses in osteoporosis and falls will also find this course valuable, as well as newly qualified consultants or others wishing to update their knowledge.

See the Bone Research Society website for details of the 2019 course.



SOME COMMENTS FROM THOSE WHO ATTENDED PREVIOUS COURSES:

“Fantastic course, probably the best I have ever been on”

“Brilliant course set at the right level, knowledgeable speakers, will definitely recommend it”

“Excellent, relevant course – I have already started recommending it to my peers”

BRS/BORS 5TH JOINT MEETING

4-6 SEPTEMBER 2019, CARDIFF, UK



VENUE:

Sir Martin Evans Building
School of Biosciences, Cardiff University

ORGANISING COMMITTEE:

CO-CHAIRS:

Bronwen Evans (Cardiff University)
Tel: 029 2074 3135 | Email: evansba@cardiff.ac.uk

Richie Gill (University of Bath)
Tel: 01225 383627 | Email: r.gill@bath.ac.uk

Jim Gallagher (University of Liverpool)

Kassim Javaid (University of Oxford)

Deborah Mason (Cardiff University)

Ines Reichert (Kings College London)

Mike Stone (Cardiff & Vale UHB/University of South Wales)

Mark Wilkinson (University of Sheffield)



Bone Research Society
www.boneresearchsociety.org



British Orthopaedic Research Society
www.borsoc.org.uk


For more information please visit our website or email events@boneresearchsociety.org



Bone Research Society
www.boneresearchsociety.org



Both events endorsed by
**International Osteoporosis
Foundation**



ICCBH

9TH INTERNATIONAL CONFERENCE
ON CHILDREN'S BONE HEALTH

22-25 June 2019

SALZBURG, AUSTRIA



Scientific Programme

The aim of this Conference is to bring together scientists and clinicians from a wide range of disciplines and from across the globe to gain a better understanding of the growing skeleton in health and disease. Attendees will have an interest in rare and inherited bone disorders, general aspects of bone health and bone disease in children, adolescents and young adults.

KEY TOPICS

- Bone development
- Bone health in chronic and rare diseases
- Nutrition and rickets
- Bone fragility and metabolism
- Epidemiology
- Orthopaedics
- Bone diagnostics
- Novel drug targets and medical therapies
- Physical activity and biomechanics

Comments from previous ICCBH attendees:

"I spent four wonderful, inspiring, exciting days"


"One of the friendliest and best organised conferences I have ever attended"

"This conference was amazing, both in terms of speakers and organisation"

DEADLINE FOR LATE BREAKING ABSTRACTS: 22 April 2019



WORLD CONGRESS
ON OSTEOPOROSIS,
OSTEOARTHRITIS AND
MUSCULOSKELETAL
DISEASES



WCO
IOF-ESCEO

2020 BARCELONA

April 2-5, 2020

Barcelona | Spain
CCIB Congress Center



WORLD'S LEADING CLINICAL CONFERENCE ON BONE, JOINT AND MUSCLE HEALTH
Congress Organizer Sinklar Congress Management B.V. | Congress Secretariat www.humacom.com

www.WCO-IOF-ESCEO.org